{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "55dc66b1",
   "metadata": {},
   "outputs": [],
   "source": [
    "pip install graphviz\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "84f72983",
   "metadata": {},
   "outputs": [],
   "source": [
    "from graphviz import Digraph\n",
    "\n",
    "dot = Digraph(comment='AI System', format='png')\n",
    "\n",
    "# Node creation\n",
    "dot.node('A', 'Data Ingestion & Preprocessing')\n",
    "dot.node('B1', 'AI Module 1\\n(e.g., Literature Review)')\n",
    "dot.node('B2', 'AI Module 2\\n(e.g., Feasibility Analysis)')\n",
    "dot.node('B3', 'AI Module 3\\n(e.g., Patient Population Analysis)')\n",
    "dot.node('B4', 'AI Module 4\\n(e.g., Historical Trial Data Analysis)')\n",
    "dot.node('B5', 'AI Module 5\\n(e.g., Real-World Data Analysis)')\n",
    "dot.node('B6', 'AI Module 6\\n(e.g., Site Selection Analysis)')\n",
    "dot.node('C', 'Integration Layer')\n",
    "dot.node('D', 'User Interface')\n",
    "dot.node('E', 'Authentication Service')\n",
    "dot.node('F', 'API Gateway')\n",
    "dot.node('G', 'Security & Compliance Layer')\n",
    "dot.node('H', 'Feedback & Monitoring')\n",
    "\n",
    "# Edges creation indicating API calls\n",
    "edges = [('A', 'B1'), ('A', 'B2'), ('A', 'B3'), ('A', 'B4'), ('A', 'B5'), ('A', 'B6'), \n",
    "         ('B1', 'C'), ('B2', 'C'), ('B3', 'C'), ('B4', 'C'), ('B5', 'C'), ('B6', 'C'), \n",
    "         ('C', 'D'), ('E', 'D'), ('F', 'D')]\n",
    "\n",
    "for edge in edges:\n",
    "    dot.edge(*edge)\n",
    "\n",
    "dot.edge('F', 'A', label='Data API Calls')\n",
    "dot.edge('F', 'B1', label='API Calls')\n",
    "dot.edge('F', 'B2', label='API Calls')\n",
    "dot.edge('F', 'B3', label='API Calls')\n",
    "dot.edge('F', 'B4', label='API Calls')\n",
    "dot.edge('F', 'B5', label='API Calls')\n",
    "dot.edge('F', 'B6', label='API Calls')\n",
    "dot.edge('F', 'C', label='API Calls')\n",
    "dot.edge('F', 'D', label='UI API Calls')\n",
    "\n",
    "dot.attr(overlap='false')  # This helps with better layout\n",
    "\n",
    "dot.render('AI_system_detailed.gv', view=True)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f55baf4f",
   "metadata": {},
   "source": [
    "Absolutely, let's break down each of these steps further:\n",
    "\n",
    "1. **Literature Review - Natural Language Processing (NLP):**\n",
    "\n",
    "    **Plan:** Develop an NLP model that can read, understand, and summarize large volumes of medical literature relevant to the drug or treatment in question. This could involve creating an ontology or taxonomy of terms related to the disease or treatment and training the model to recognize these terms in text.\n",
    "\n",
    "    **Challenges:** The medical literature is vast and complex, and the language used can be ambiguous or context-dependent. Maintaining up-to-date and comprehensive knowledge graphs and ontologies could be challenging.\n",
    "\n",
    "    **How to Overcome Challenges:** Engage with medical experts to validate the model’s understanding and summaries. Use transfer learning from pretrained models to overcome issues with medical language.\n",
    "\n",
    "2. **Feasibility Analysis - AI Algorithms:**\n",
    "\n",
    "    **Plan:** Develop predictive models using historical trial data to predict key feasibility metrics like patient enrollment rates and trial duration. These models would take into account factors such as the trial design, patient population, and disease area.\n",
    "\n",
    "    **Challenges:** Historical trial data may be incomplete or inconsistent. Additionally, future trials may not always align well with past trials, limiting the applicability of predictions.\n",
    "\n",
    "    **How to Overcome Challenges:** Utilize robust data cleaning and preprocessing pipelines. Implement techniques for dealing with missing or inconsistent data. Leverage domain experts for feature engineering and model validation.\n",
    "\n",
    "3. **Patient Population Analysis - EHR and Real-World Data:**\n",
    "\n",
    "    **Plan:** Develop AI models to analyze EHR and other real-world data to understand the patient population. This could involve predicting patient availability, stratifying patients based on health conditions, and predicting patient outcomes.\n",
    "\n",
    "    **Challenges:** EHR data is often messy and unstructured. Data privacy regulations make sharing and utilizing EHR data challenging.\n",
    "\n",
    "    **How to Overcome Challenges:** Implement robust data cleaning and preprocessing pipelines. Use NLP techniques to extract useful information from unstructured data. Collaborate closely with data privacy experts and legal teams to ensure compliance with regulations.\n",
    "\n",
    "4. **Historical Trial Data Analysis - Machine Learning:**\n",
    "\n",
    "    **Plan:** Use machine learning models to analyze historical trial data, identifying patterns that could predict trial success or failure. This could involve both supervised learning (if success metrics are available for past trials) and unsupervised learning (to identify underlying patterns or clusters in the data).\n",
    "\n",
    "    **Challenges:** As with feasibility analysis, the data may be incomplete or inconsistent, and past trials may not be fully representative of future trials.\n",
    "\n",
    "    **How to Overcome Challenges:** Implement robust data cleaning and preprocessing pipelines. Use techniques like imputation or model-based methods to handle missing data.\n",
    "\n",
    "5. **Real-World Data Analysis - AI:**\n",
    "\n",
    "    **Plan:** Extend the use of AI in patient population analysis to gain insights into disease epidemiology, treatment patterns, and health outcomes. This would involve building predictive models and possibly also causal inference models.\n",
    "\n",
    "    **Challenges:** Real-world data is noisy and heterogeneous, and establishing causal relationships in such data is challenging.\n",
    "\n",
    "    **How to Overcome Challenges:** Use rigorous statistical techniques to control for confounding variables. Validate findings with experts.\n",
    "\n",
    "6. **Site Selection Analysis - AI:**\n",
    "\n",
    "    **Plan:** Develop models to predict site performance based on factors like past performance, site resources, and patient population. This would involve both predictive modeling (e.g., of patient recruitment rates) and optimization (to select the best combination of sites).\n",
    "\n",
    "    **Challenges:** Site performance can be influenced by many factors, some of which may not be captured in the available data. The optimization problem could be complex, especially if there are many potential sites and constraints to consider.\n",
    "\n",
    "    **How to Overcome Challenges:** Use ensemble models or other sophisticated machine\n",
    "\n",
    " learning techniques to capture complex relationships in the data. Use robust optimization techniques, potentially including heuristics or metaheuristics for large or complex problems."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "b51154a2",
   "metadata": {},
   "source": [
    "Alright, let's provide more detail for each phase of the product roadmap:\n",
    "\n",
    "**Phase 1 - Planning & Design (Months 1-3)**\n",
    "\n",
    "1. **Define Requirements:**\n",
    "    - Gather requirements from users and stakeholders for each AI module.\n",
    "    - Determine required features and priorities.\n",
    "    - Develop user stories and use cases to guide design and development.\n",
    "\n",
    "2. **System Architecture & Data Model:**\n",
    "    - Design the overall system architecture, considering components like data ingestion, AI services, APIs, and user interfaces.\n",
    "    - Design the data model, considering data sources, types, storage, privacy, and security requirements.\n",
    "    \n",
    "3. **Technical Stack:**\n",
    "    - Decide on programming languages (Python, R, Java, etc.), machine learning frameworks (TensorFlow, PyTorch, etc.), cloud service providers (AWS, Google Cloud, etc.), and database systems (SQL, NoSQL, etc.).\n",
    "    \n",
    "4. **Development Environments:**\n",
    "    - Set up separate environments for development, testing, and production, ensuring proper isolation between them.\n",
    "    \n",
    "5. **Data Privacy & Security Plan:**\n",
    "    - Define a data handling policy in compliance with GDPR, HIPAA or other regional data protection laws.\n",
    "    - Determine data encryption standards and access control mechanisms.\n",
    "\n",
    "**Phase 2 - Data Infrastructure & AI Development (Months 4-9)**\n",
    "\n",
    "1. **Data Infrastructure:**\n",
    "    - Implement data ingestion modules for EHRs, scientific literature, and other relevant data sources.\n",
    "    - Develop data cleaning and preprocessing pipelines, which may involve techniques like outlier detection, missing value imputation, data normalization, and others.\n",
    "    - Set up databases or data lakes for structured and unstructured data.\n",
    "\n",
    "2. **AI Module Development:**\n",
    "    - Acquire and preprocess necessary training data.\n",
    "    - Develop AI models for literature review, feasibility analysis, patient population analysis, historical trial data analysis, real-world data analysis, and site selection analysis.\n",
    "    - Evaluate and refine models using techniques like cross-validation, precision-recall analysis, and ROC curves.\n",
    "\n",
    "3. **Integration Layer & APIs:**\n",
    "    - Develop a robust API layer for communication between different components of the system.\n",
    "    - Ensure the API handles different data formats, is scalable, and secure.\n",
    "\n",
    "**Phase 3 - User Interface & Integration (Months 10-15)**\n",
    "\n",
    "1. **User Interface:**\n",
    "    - Design an intuitive user interface based on user requirements and UX best practices.\n",
    "    - Implement the UI, focusing on usability, performance, and responsiveness.\n",
    "\n",
    "2. **Integration:**\n",
    "    - Integrate the AI modules, data layer, and user interface.\n",
    "    - Implement user authentication and data security features, possibly using OAuth for authentication and HTTPS for secure data transmission.\n",
    "\n",
    "**Phase 4 - Testing & Refinement (Months 16-18)**\n",
    "\n",
    "1. **Testing:**\n",
    "    - Conduct unit testing of individual modules, integration testing of multiple modules, and system testing of the complete system.\n",
    "    - Involve users in acceptance testing to ensure the system meets their needs and expectations.\n",
    "\n",
    "2. **Refinement:**\n",
    "    - Use testing and user feedback to refine the system, fixing bugs, improving performance, and enhancing usability.\n",
    "\n",
    "3. **Compliance & Security Audit:**\n",
    "    - Conduct a security audit to identify and fix vulnerabilities.\n",
    "    - Ensure compliance with healthcare regulations, privacy laws, and data security standards.\n",
    "\n",
    "**Phase 5 - Deployment & Monitoring (Month 19 onwards)**\n",
    "\n",
    "1. **Deployment:**\n",
    "    - Deploy the platform in a production environment, ensuring it can handle real-world load and data volumes.\n",
    "\n",
    "2. **User Training & Support:**\n",
    "    - Provide user training and ongoing support to ensure users can effectively use the platform.\n",
    "\n",
    "3. **Monitoring & Refinement:**\n",
    "    - Implement monitoring\n",
    "\n",
    " systems to track performance, usage, and user feedback.\n",
    "    - Continually refine the platform based on this information and advances in AI technology.\n",
    "\n",
    "The project should follow an Agile methodology, with regular sprints, scrum meetings, and iterative development and improvement. Frequent, transparent communication with stakeholders is critical to ensure alignment and manage expectations."
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e6496b49",
   "metadata": {},
   "source": [
    "uilding an integrated platform involves connecting various AI services or modules. APIs, or Application Programming Interfaces, serve as the connection points between these different software components, enabling them to communicate with each other and share data and functionality.\n",
    "\n",
    "In this scenario, each AI module (such as literature review, feasibility analysis, etc.) would expose an API that allows it to receive input data, process it, and return the results. The integration layer of the platform would use these APIs to orchestrate the overall workflow, passing data between the AI modules as needed.\n",
    "\n",
    "While I can't create a visual diagram here, I can describe a high-level design:\n",
    "\n",
    "Data Ingestion and Preprocessing: This layer collects data from various sources (EHRs, literature databases, etc.), preprocesses it, and stores it in a suitable format. It might also expose APIs to allow the AI modules to query and retrieve the necessary data.\n",
    "\n",
    "AI Modules: Each AI module is a standalone microservice that performs a specific task, such as analyzing patient populations or reviewing scientific literature. Each module exposes an API that accepts input data, processes it, and returns the results.\n",
    "\n",
    "Integration Layer: This layer sits between the AI modules and the user interface. It uses the APIs of the AI modules to orchestrate the overall workflow. For example, it might first call the literature review API to get information on previous trials, then pass this information to the feasibility analysis API to get predictions on trial success.\n",
    "\n",
    "User Interface: The UI makes requests to the integration layer to initiate analyses, receives the results, and displays them to the user in an interpretable and actionable format.\n",
    "\n",
    "Security and Compliance Layer: This layer ensures that all data is handled securely and in compliance with relevant regulations. It might include features like encryption, access controls, and audit logs.\n",
    "\n",
    "Feedback and Monitoring: These are integrated throughout the platform to monitor performance, identify issues, and collect user feedback for continuous improvement.\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8f68bab3",
   "metadata": {},
   "outputs": [],
   "source": [
    "!pip install graphviz pydotplus\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "144e32e1",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pygraphviz as pgv\n",
    "from IPython.display import Image, display\n",
    "\n",
    "plantuml_code = \"\"\"\n",
    "digraph PlantUMLDiagram {\n",
    "    // Define nodes\n",
    "    UI [label=\"User Interface\"]\n",
    "    auth [label=\"Authentication Service\"]\n",
    "    gateway [label=\"API Gateway\"]\n",
    "    storage [label=\"Data Storage\"]\n",
    "    cloudProvider [label=\"Cloud Provider\"]\n",
    "    module1 [label=\"AI Module 1\\n(e.g., Literature Review)\"]\n",
    "    module2 [label=\"AI Module 2\\n(e.g., Feasibility Analysis)\"]\n",
    "    module3 [label=\"AI Module 3\\n(e.g., Patient Population Analysis)\"]\n",
    "    module4 [label=\"AI Module 4\\n(e.g., Historical Trial Data Analysis)\"]\n",
    "    module5 [label=\"AI Module 5\\n(e.g., Real-World Data Analysis)\"]\n",
    "    module6 [label=\"AI Module 6\\n(e.g., Site Selection Analysis)\"]\n",
    "    integration [label=\"Integration Layer\"]\n",
    "    security [label=\"Security & Compliance Layer\"]\n",
    "    feedback [label=\"Feedback & Monitoring\"]\n",
    "    ingestion [label=\"Data Ingestion & Preprocessing\"]\n",
    "    monitoring [label=\"Feedback & Monitoring\"]\n",
    "\n",
    "    // Define edges\n",
    "    UI -> auth\n",
    "    auth -> gateway\n",
    "    gateway -> module1\n",
    "    gateway -> module2\n",
    "    gateway -> module3\n",
    "    gateway -> module4\n",
    "    gateway -> module5\n",
    "    gateway -> module6\n",
    "    module1 -> integration\n",
    "    module2 -> integration\n",
    "    module3 -> integration\n",
    "    module4 -> integration\n",
    "    module5 -> integration\n",
    "    module6 -> integration\n",
    "    integration -> storage\n",
    "    integration -> cloudProvider\n",
    "    ingestion -> storage\n",
    "    feedback -> monitoring\n",
    "}\n",
    "\"\"\"\n",
    "\n",
    "# Create the graph from PlantUML code\n",
    "graph = pgv.AGraph(string=plantuml_code)\n",
    "\n",
    "# Layout the graph using Graphviz\n",
    "graph.layout(prog=\"dot\")\n",
    "\n",
    "# Save the graph as an image file\n",
    "output_file = \"plantuml_diagram.png\"\n",
    "graph.draw(output_file)\n",
    "\n",
    "# Display the image\n",
    "display(Image(filename=output_file))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e433a8a3",
   "metadata": {},
   "outputs": [],
   "source": [
    "from graphviz import Digraph\n",
    "\n",
    "dot = Digraph(comment='The Detailed Common Data Layer Architecture')\n",
    "\n",
    "# Data Sources nodes\n",
    "dot.node('A1', 'Genomic Data')\n",
    "dot.node('A2', 'EHR Data')\n",
    "dot.node('A3', 'Imaging Data')\n",
    "dot.node('A4', 'Environmental Data')\n",
    "dot.node('A5', 'Wearable Device Data')\n",
    "dot.node('A6', 'Social Determinants')\n",
    "\n",
    "# Data Integration Node\n",
    "dot.node('B', 'Data Integration')\n",
    "\n",
    "# Data Processing nodes\n",
    "dot.node('C1', 'Multi-Modal AI Models')\n",
    "dot.node('C2', 'NLP Models')\n",
    "dot.node('C3', 'Graph Neural Networks')\n",
    "\n",
    "# Causal Inference Node\n",
    "dot.node('D', 'Causal Inference Models')\n",
    "\n",
    "# Insights Generation Node\n",
    "dot.node('E', 'Explainable AI')\n",
    "\n",
    "# Output Node\n",
    "dot.node('F', 'Output')\n",
    "\n",
    "# Data Sources to Data Integration edges\n",
    "dot.edge('A1', 'B')\n",
    "dot.edge('A2', 'B')\n",
    "dot.edge('A3', 'B')\n",
    "dot.edge('A4', 'B')\n",
    "dot.edge('A5', 'B')\n",
    "dot.edge('A6', 'B')\n",
    "\n",
    "# Data Integration to Data Processing edges\n",
    "dot.edge('B', 'C1')\n",
    "dot.edge('B', 'C2')\n",
    "dot.edge('B', 'C3')\n",
    "\n",
    "# Data Processing to Causal Inference edges\n",
    "dot.edge('C1', 'D')\n",
    "dot.edge('C2', 'D')\n",
    "dot.edge('C3', 'D')\n",
    "\n",
    "# Causal Inference to Insights Generation edge\n",
    "dot.edge('D', 'E')\n",
    "\n",
    "# Insights Generation to Output edge\n",
    "dot.edge('E', 'F')\n",
    "\n",
    "# Show the graph\n",
    "dot.view()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d43dc214",
   "metadata": {},
   "outputs": [],
   "source": [
    "from graphviz import Digraph\n",
    "\n",
    "dot = Digraph(comment='Clinical Trial Literature Review Automation')\n",
    "\n",
    "# Begin defining subgraphs and nodes\n",
    "with dot.subgraph(name='cluster_0') as c0:\n",
    "    c0.attr(style='filled', color='lightgrey')\n",
    "    c0.node_attr.update(style='filled', color='white')\n",
    "    c0.attr(label='Clinical Trial Literature Review Automation')\n",
    "\n",
    "    with c0.subgraph(name='cluster_1') as c1:\n",
    "        c1.attr(label='LLM Data Processing Pipeline')\n",
    "        c1.node_attr.update(style='filled', color='lightblue')\n",
    "        c1.node('node1', 'Input: Clinical Trial Papers')\n",
    "        c1.node('node2', 'LLM Data Extraction')\n",
    "        c1.node('node3', 'LLM Quality Assessment')\n",
    "        c1.node('node4', 'LLM Data Synthesis')\n",
    "        c1.node('node5', 'Output: Synthesized Information')\n",
    "        c1.edges(['12', '23', '34', '45'])\n",
    "\n",
    "    with c0.subgraph(name='cluster_2') as c2:\n",
    "        c2.attr(label='Human Review')\n",
    "        c2.node_attr.update(style='filled', color='lightblue')\n",
    "        c2.node('node6', 'Manual Data Review & Interpretation')\n",
    "        c2.node('node7', 'Final Review Report')\n",
    "        c2.edge('node6', 'node7')\n",
    "\n",
    "    c0.edge('node5', 'node6')\n",
    "\n",
    "# Save the source to file and render\n",
    "dot.render('test-output/round-table.gv', view=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "fa14c39e",
   "metadata": {},
   "outputs": [],
   "source": [
    "from graphviz import Digraph\n",
    "\n",
    "dot = Digraph(comment='Clinical Trial Literature Review Automation', format='png')\n",
    "\n",
    "# Creating main process\n",
    "with dot.subgraph(name='cluster_main') as main:\n",
    "    main.attr(label='Clinical Trial Literature Review Automation')\n",
    "\n",
    "    # Creating LLM Data Processing Pipeline subgraph\n",
    "    with main.subgraph(name='cluster_llm') as llm:\n",
    "        llm.attr(label='LLM Data Processing Pipeline', color='blue')\n",
    "        llm.node('A1', 'Input: Clinical Trial Papers')\n",
    "        llm.node('A2', 'LLM Data Extraction')\n",
    "        llm.node('A3', 'LLM Quality Assessment')\n",
    "        llm.node('A4', 'LLM Data Synthesis')\n",
    "        llm.node('A5', 'Output: Synthesized Information')\n",
    "        llm.edges([('A1', 'A2'), ('A2', 'A3'), ('A3', 'A4'), ('A4', 'A5')])\n",
    "\n",
    "    # Creating Human Review subgraph\n",
    "    with main.subgraph(name='cluster_human') as human:\n",
    "        human.attr(label='Human Review', color='blue')\n",
    "        human.node('B1', 'Manual Data Review & Interpretation')\n",
    "        human.node('B2', 'Final Review Report')\n",
    "        human.edge('B1', 'B2')\n",
    "\n",
    "    # Linking LLM Data Processing Pipeline with Human Review\n",
    "    main.edge('A5', 'B1')\n",
    "\n",
    "dot.view()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a3186576",
   "metadata": {},
   "outputs": [],
   "source": [
    "pip install requests transformers\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "cdbfd6d1",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Enter a search query for clinical trial literature: covid19\n",
      "{'header': {'type': 'esearch', 'version': '0.3'}, 'esearchresult': {'count': '351426', 'retmax': '20', 'retstart': '0', 'idlist': ['34817268', '34312178', '34498109', '33494237', '32425996', '33464914', '33705239', '33692022', '34391321', '33484452', '32788312', '33989487', '34227079', '32512530', '34357885', '32599968', '34099197', '34904908', '33035150', '35568052'], 'translationset': [{'from': 'covid19', 'to': '\"covid-19\"[MeSH Terms] OR \"covid-19\"[All Fields] OR \"covid19\"[All Fields]'}], 'querytranslation': '\"covid 19\"[MeSH Terms] OR \"covid 19\"[All Fields] OR \"covid19\"[All Fields]'}}\n",
      "Rate limit exceeded. Retrying in 1 seconds...\n",
      "Rate limit exceeded. Retrying in 1 seconds...\n",
      "Rate limit exceeded. Retrying in 1 seconds...\n",
      "Rate limit exceeded. Retrying in 1 seconds...\n",
      "Rate limit exceeded. Retrying in 1 seconds...\n",
      "Rate limit exceeded. Retrying in 1 seconds...\n",
      "[{'uid': '34817268', 'pubdate': '2022 Jan 1', 'epubdate': '2021 Nov 24', 'source': 'Am J Physiol Cell Physiol', 'authors': [{'name': 'Desai AD', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Lavelle M', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Boursiquot BC', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Wan EY', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Wan EY', 'title': 'Long-term complications of COVID-19.', 'sorttitle': 'long term complications of covid 19', 'volume': '322', 'issue': '1', 'pages': 'C1-C11', 'lang': ['eng'], 'nlmuniqueid': '100901225', 'issn': '0363-6143', 'essn': '1522-1563', 'pubtype': ['Journal Article', 'Review'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '256', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '34817268'}, {'idtype': 'pmc', 'idtypen': 8, 'value': 'PMC8721906'}, {'idtype': 'pmcid', 'idtypen': 5, 'value': 'pmc-id: PMC8721906;'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.1152/ajpcell.00375.2021'}], 'history': [{'pubstatus': 'pubmed', 'date': '2021/11/25 06:00'}, {'pubstatus': 'medline', 'date': '2022/01/08 06:00'}, {'pubstatus': 'entrez', 'date': '2021/11/24 12:15'}], 'references': [], 'attributes': ['Has Abstract'], 'pmcrefcount': 121, 'fulljournalname': 'American journal of physiology. Cell physiology', 'elocationid': 'doi: 10.1152/ajpcell.00375.2021', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2022/01/01 00:00', 'sortfirstauthor': 'Desai AD', 'vernaculartitle': '', 'id': '34817268', 'review': '', 'text': ''}, {'uid': '34312178', 'pubdate': '2021 Jul 26', 'epubdate': '2021 Jul 26', 'source': 'BMJ', 'authors': [{'name': 'Crook H', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Raza S', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Nowell J', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Young M', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Edison P', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Edison P', 'title': 'Long covid-mechanisms, risk factors, and management.', 'sorttitle': 'long covid mechanisms risk factors and management', 'volume': '374', 'issue': '', 'pages': 'n1648', 'lang': ['eng'], 'nlmuniqueid': '8900488', 'issn': '0959-8138', 'essn': '1756-1833', 'pubtype': ['Journal Article', 'Review'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '3', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '34312178'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.1136/bmj.n1648'}], 'history': [{'pubstatus': 'entrez', 'date': '2021/07/27 06:30'}, {'pubstatus': 'pubmed', 'date': '2021/07/28 06:00'}, {'pubstatus': 'medline', 'date': '2021/08/03 06:00'}], 'references': [{'refsource': 'BMJ. 2021 Aug 3;374:n1944', 'reftype': 'Erratum in', 'pmid': 34344715, 'note': ''}], 'attributes': ['Has Abstract'], 'pmcrefcount': '', 'fulljournalname': 'BMJ (Clinical research ed.)', 'elocationid': 'doi: 10.1136/bmj.n1648', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2021/07/26 00:00', 'sortfirstauthor': 'Crook H', 'vernaculartitle': '', 'id': '34312178', 'review': '', 'text': ''}, {'uid': '34498109', 'pubdate': '2021 Sep', 'epubdate': '', 'source': 'World J Urol', 'authors': [{'name': 'Bolton D', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Bolton D', 'title': 'COVID19: the response of the urologist.', 'sorttitle': 'covid19 the response of the urologist', 'volume': '39', 'issue': '9', 'pages': '3125', 'lang': ['eng'], 'nlmuniqueid': '8307716', 'issn': '0724-4983', 'essn': '1433-8726', 'pubtype': ['Editorial'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '4', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '34498109'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.1007/s00345-021-03830-2'}, {'idtype': 'pii', 'idtypen': 4, 'value': '10.1007/s00345-021-03830-2'}], 'history': [{'pubstatus': 'pubmed', 'date': '2021/09/10 06:00'}, {'pubstatus': 'medline', 'date': '2022/02/11 06:00'}, {'pubstatus': 'entrez', 'date': '2021/09/09 06:59'}], 'references': [], 'attributes': [], 'pmcrefcount': '', 'fulljournalname': 'World journal of urology', 'elocationid': 'doi: 10.1007/s00345-021-03830-2', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2021/09/01 00:00', 'sortfirstauthor': 'Bolton D', 'vernaculartitle': '', 'id': '34498109', 'review': '', 'text': ''}, {'uid': '33494237', 'pubdate': '2021 Jan 21', 'epubdate': '2021 Jan 21', 'source': 'Cells', 'authors': [{'name': 'Chilamakuri R', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Agarwal S', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Agarwal S', 'title': 'COVID-19: Characteristics and Therapeutics.', 'sorttitle': 'covid 19 characteristics and therapeutics', 'volume': '10', 'issue': '2', 'pages': '', 'lang': ['eng'], 'nlmuniqueid': '101600052', 'issn': '', 'essn': '2073-4409', 'pubtype': ['Journal Article', 'Review'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '3', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '33494237'}, {'idtype': 'pmc', 'idtypen': 8, 'value': 'PMC7909801'}, {'idtype': 'pmcid', 'idtypen': 5, 'value': 'pmc-id: PMC7909801;'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.3390/cells10020206'}, {'idtype': 'pii', 'idtypen': 4, 'value': 'cells10020206'}], 'history': [{'pubstatus': 'received', 'date': '2020/11/08 00:00'}, {'pubstatus': 'revised', 'date': '2021/01/11 00:00'}, {'pubstatus': 'accepted', 'date': '2021/01/18 00:00'}, {'pubstatus': 'entrez', 'date': '2021/01/26 01:01'}, {'pubstatus': 'pubmed', 'date': '2021/01/27 06:00'}, {'pubstatus': 'medline', 'date': '2021/02/03 06:00'}], 'references': [], 'attributes': ['Has Abstract'], 'pmcrefcount': 195, 'fulljournalname': 'Cells', 'elocationid': 'doi: 10.3390/cells10020206', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2021/01/21 00:00', 'sortfirstauthor': 'Chilamakuri R', 'vernaculartitle': '', 'id': '33494237', 'review': '', 'text': ''}, {'uid': '32425996', 'pubdate': '2021 Feb', 'epubdate': '2020 May 15', 'source': 'J Microbiol Immunol Infect', 'authors': [{'name': 'Gao Z', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Xu Y', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Sun C', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Wang X', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Guo Y', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Qiu S', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Ma K', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Ma K', 'title': 'A systematic review of asymptomatic infections with COVID-19.', 'sorttitle': 'systematic review of asymptomatic infections with covid 19', 'volume': '54', 'issue': '1', 'pages': '12-16', 'lang': ['eng'], 'nlmuniqueid': '100956211', 'issn': '1684-1182', 'essn': '1995-9133', 'pubtype': ['Journal Article'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '256', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '32425996'}, {'idtype': 'pmc', 'idtypen': 8, 'value': 'PMC7227597'}, {'idtype': 'pmcid', 'idtypen': 5, 'value': 'pmc-id: PMC7227597;'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.1016/j.jmii.2020.05.001'}, {'idtype': 'pii', 'idtypen': 4, 'value': 'S1684-1182(20)30113-4'}], 'history': [{'pubstatus': 'received', 'date': '2020/04/03 00:00'}, {'pubstatus': 'revised', 'date': '2020/05/05 00:00'}, {'pubstatus': 'accepted', 'date': '2020/05/06 00:00'}, {'pubstatus': 'pubmed', 'date': '2020/05/20 06:00'}, {'pubstatus': 'medline', 'date': '2021/03/02 06:00'}, {'pubstatus': 'entrez', 'date': '2020/05/20 06:00'}], 'references': [], 'attributes': ['Has Abstract'], 'pmcrefcount': 33, 'fulljournalname': 'Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi', 'elocationid': 'doi: 10.1016/j.jmii.2020.05.001', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2021/02/01 00:00', 'sortfirstauthor': 'Gao Z', 'vernaculartitle': '', 'id': '32425996', 'review': '', 'text': ''}, {'uid': '33464914', 'pubdate': '2021 Mar 1', 'epubdate': '2021 Jan 19', 'source': 'Mol Pharm', 'authors': [{'name': 'Salian VS', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Wright JA', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Vedell PT', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Nair S', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Li C', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Kandimalla M', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Tang X', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Carmona Porquera EM', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Kalari KR', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Kandimalla KK', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Kandimalla KK', 'title': 'COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies.', 'sorttitle': 'covid 19 transmission current treatment and future therapeutic strategies', 'volume': '18', 'issue': '3', 'pages': '754-771', 'lang': ['eng'], 'nlmuniqueid': '101197791', 'issn': '1543-8384', 'essn': '1543-8392', 'pubtype': ['Journal Article', 'Review'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '256', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '33464914'}, {'idtype': 'pmc', 'idtypen': 8, 'value': 'PMC7839412'}, {'idtype': 'pmcid', 'idtypen': 5, 'value': 'pmc-id: PMC7839412;'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.1021/acs.molpharmaceut.0c00608'}], 'history': [{'pubstatus': 'pubmed', 'date': '2021/01/20 06:00'}, {'pubstatus': 'medline', 'date': '2021/03/10 06:00'}, {'pubstatus': 'entrez', 'date': '2021/01/19 17:10'}], 'references': [], 'attributes': ['Has Abstract'], 'pmcrefcount': 201, 'fulljournalname': 'Molecular pharmaceutics', 'elocationid': 'doi: 10.1021/acs.molpharmaceut.0c00608', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2021/03/01 00:00', 'sortfirstauthor': 'Salian VS', 'vernaculartitle': '', 'id': '33464914', 'review': '', 'text': ''}, {'uid': '33705239', 'pubdate': '2021 May', 'epubdate': '2021 May 3', 'source': 'Expert Rev Clin Pharmacol', 'authors': [{'name': 'Rahman S', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Montero MTV', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Rowe K', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Kirton R', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Kunik F Jr', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Kunik F Jr', 'title': 'Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence.', 'sorttitle': 'epidemiology pathogenesis clinical presentations diagnosis and treatment of covid 19 a review of current evidence', 'volume': '14', 'issue': '5', 'pages': '601-621', 'lang': ['eng'], 'nlmuniqueid': '101278296', 'issn': '1751-2433', 'essn': '1751-2441', 'pubtype': ['Journal Article', 'Review'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '256', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '33705239'}, {'idtype': 'pmc', 'idtypen': 8, 'value': 'PMC8095162'}, {'idtype': 'pmcid', 'idtypen': 5, 'value': 'pmc-id: PMC8095162;'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.1080/17512433.2021.1902303'}], 'history': [{'pubstatus': 'pubmed', 'date': '2021/03/12 06:00'}, {'pubstatus': 'medline', 'date': '2021/06/12 06:00'}, {'pubstatus': 'entrez', 'date': '2021/03/11 17:16'}], 'references': [], 'attributes': ['Has Abstract'], 'pmcrefcount': 290, 'fulljournalname': 'Expert review of clinical pharmacology', 'elocationid': 'doi: 10.1080/17512433.2021.1902303', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2021/05/01 00:00', 'sortfirstauthor': 'Rahman S', 'vernaculartitle': '', 'id': '33705239', 'review': '', 'text': ''}, {'uid': '33692022', 'pubdate': '2021 Mar 10', 'epubdate': '2021 Mar 10', 'source': 'BMJ', 'authors': [{'name': 'Attaway AH', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Scheraga RG', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Bhimraj A', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Biehl M', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Hatipoğlu U', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Hatipoğlu U', 'title': 'Severe covid-19 pneumonia: pathogenesis and clinical management.', 'sorttitle': 'severe covid 19 pneumonia pathogenesis and clinical management', 'volume': '372', 'issue': '', 'pages': 'n436', 'lang': ['eng'], 'nlmuniqueid': '8900488', 'issn': '0959-8138', 'essn': '1756-1833', 'pubtype': ['Journal Article', 'Review'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '3', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '33692022'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.1136/bmj.n436'}], 'history': [{'pubstatus': 'entrez', 'date': '2021/03/11 06:02'}, {'pubstatus': 'pubmed', 'date': '2021/03/12 06:00'}, {'pubstatus': 'medline', 'date': '2021/03/18 06:00'}], 'references': [], 'attributes': ['Has Abstract'], 'pmcrefcount': '', 'fulljournalname': 'BMJ (Clinical research ed.)', 'elocationid': 'doi: 10.1136/bmj.n436', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2021/03/10 00:00', 'sortfirstauthor': 'Attaway AH', 'vernaculartitle': '', 'id': '33692022', 'review': '', 'text': ''}, {'uid': '34391321', 'pubdate': '2021 Dec 17', 'epubdate': '2021 Dec 17', 'source': 'Turk J Med Sci', 'authors': [{'name': 'Şimşek-Yavuz S', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Komsuoğlu Çelikyurt FI', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Komsuoğlu Çelikyurt FI', 'title': 'An update of anti-viral treatment of COVID-19.', 'sorttitle': 'update of anti viral treatment of covid 19', 'volume': '51', 'issue': 'SI-1', 'pages': '3372-3390', 'lang': ['eng'], 'nlmuniqueid': '9441758', 'issn': '1300-0144', 'essn': '1303-6165', 'pubtype': ['Journal Article', 'Review'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '3', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '34391321'}, {'idtype': 'pmc', 'idtypen': 8, 'value': 'PMC8771049'}, {'idtype': 'pmcid', 'idtypen': 5, 'value': 'pmc-id: PMC8771049;'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.3906/sag-2106-250'}], 'history': [{'pubstatus': 'received', 'date': '2021/06/20 00:00'}, {'pubstatus': 'accepted', 'date': '2021/08/14 00:00'}, {'pubstatus': 'entrez', 'date': '2021/08/15 05:17'}, {'pubstatus': 'pubmed', 'date': '2021/08/16 06:00'}, {'pubstatus': 'medline', 'date': '2022/01/01 06:00'}], 'references': [], 'attributes': ['Has Abstract'], 'pmcrefcount': 120, 'fulljournalname': 'Turkish journal of medical sciences', 'elocationid': 'doi: 10.3906/sag-2106-250', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2021/12/17 00:00', 'sortfirstauthor': 'Şimşek-Yavuz S', 'vernaculartitle': '', 'id': '34391321', 'review': '', 'text': ''}, {'uid': '33484452', 'pubdate': '2021 Aug', 'epubdate': '2021 Jan 23', 'source': 'Intern Emerg Med', 'authors': [{'name': 'Mele D', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Flamigni F', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Rapezzi C', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Ferrari R', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Ferrari R', 'title': 'Myocarditis in COVID-19 patients: current problems.', 'sorttitle': 'myocarditis in covid 19 patients current problems', 'volume': '16', 'issue': '5', 'pages': '1123-1129', 'lang': ['eng'], 'nlmuniqueid': '101263418', 'issn': '1828-0447', 'essn': '1970-9366', 'pubtype': ['Journal Article', 'Review'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '256', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '33484452'}, {'idtype': 'pmc', 'idtypen': 8, 'value': 'PMC7823176'}, {'idtype': 'pmcid', 'idtypen': 5, 'value': 'pmc-id: PMC7823176;'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.1007/s11739-021-02635-w'}, {'idtype': 'pii', 'idtypen': 4, 'value': '10.1007/s11739-021-02635-w'}], 'history': [{'pubstatus': 'received', 'date': '2020/07/20 00:00'}, {'pubstatus': 'accepted', 'date': '2021/01/06 00:00'}, {'pubstatus': 'pubmed', 'date': '2021/01/24 06:00'}, {'pubstatus': 'medline', 'date': '2021/08/10 06:00'}, {'pubstatus': 'entrez', 'date': '2021/01/23 12:07'}], 'references': [], 'attributes': ['Has Abstract'], 'pmcrefcount': 56, 'fulljournalname': 'Internal and emergency medicine', 'elocationid': 'doi: 10.1007/s11739-021-02635-w', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2021/08/01 00:00', 'sortfirstauthor': 'Mele D', 'vernaculartitle': '', 'id': '33484452', 'review': '', 'text': ''}, {'uid': '32788312', 'pubdate': '2021 Feb', 'epubdate': '2020 Aug 11', 'source': 'Postgrad Med J', 'authors': [{'name': 'Adil MT', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Rahman R', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Whitelaw D', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Jain V', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Al-Taan O', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Rashid F', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Munasinghe A', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Jambulingam P', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Jambulingam P', 'title': 'SARS-CoV-2 and the pandemic of COVID-19.', 'sorttitle': 'sars cov 2 and the pandemic of covid 19', 'volume': '97', 'issue': '1144', 'pages': '110-116', 'lang': ['eng'], 'nlmuniqueid': '0234135', 'issn': '0032-5473', 'essn': '1469-0756', 'pubtype': ['Journal Article', 'Review'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '256', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '32788312'}, {'idtype': 'pmc', 'idtypen': 8, 'value': 'PMC10016996'}, {'idtype': 'pmcid', 'idtypen': 5, 'value': 'pmc-id: PMC10016996;'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.1136/postgradmedj-2020-138386'}, {'idtype': 'pii', 'idtypen': 4, 'value': 'postgradmedj-2020-138386'}], 'history': [{'pubstatus': 'received', 'date': '2020/06/04 00:00'}, {'pubstatus': 'pubmed', 'date': '2020/08/14 06:00'}, {'pubstatus': 'medline', 'date': '2021/02/05 06:00'}, {'pubstatus': 'entrez', 'date': '2020/08/14 06:00'}], 'references': [], 'attributes': ['Has Abstract'], 'pmcrefcount': 57, 'fulljournalname': 'Postgraduate medical journal', 'elocationid': 'doi: 10.1136/postgradmedj-2020-138386', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2021/02/01 00:00', 'sortfirstauthor': 'Adil MT', 'vernaculartitle': '', 'id': '32788312', 'review': '', 'text': ''}, {'uid': '33989487', 'pubdate': '2021 Feb 26', 'epubdate': '2021 Feb 26', 'source': 'Salud Publica Mex', 'authors': [{'name': 'Cupul-Uicab LA', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Hernández-Mariano JÁ', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Vázquez-Salas A', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Leyva-Lopez A', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Barrientos-Gutierrez T', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Villalobos Hernández A', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Villalobos Hernández A', 'title': 'Covid-19 durante el embarazo: revisión rápida y metaanálisis.', 'sorttitle': 'covid 19 durante el embarazo revisi n r pida y metaan lisis', 'volume': '63', 'issue': '2, Mar-Abr', 'pages': '242-252', 'lang': ['spa'], 'nlmuniqueid': '0404371', 'issn': '0036-3634', 'essn': '1606-7916', 'pubtype': ['Journal Article', 'Meta-Analysis', 'Review'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '3', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '33989487'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.21149/11810'}], 'history': [{'pubstatus': 'received', 'date': '2020/07/03 00:00'}, {'pubstatus': 'accepted', 'date': '2020/10/09 00:00'}, {'pubstatus': 'entrez', 'date': '2021/05/14 18:50'}, {'pubstatus': 'pubmed', 'date': '2021/05/15 06:00'}, {'pubstatus': 'medline', 'date': '2021/06/04 06:00'}], 'references': [], 'attributes': ['Has Abstract'], 'pmcrefcount': '', 'fulljournalname': 'Salud publica de Mexico', 'elocationid': 'doi: 10.21149/11810', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2021/02/26 00:00', 'sortfirstauthor': 'Cupul-Uicab LA', 'vernaculartitle': 'Covid-19 durante el embarazo: revisión rápida y metaanálisis.', 'id': '33989487', 'review': '', 'text': ''}, {'uid': '34227079', 'pubdate': '2021 Jun', 'epubdate': '', 'source': 'Eur Rev Med Pharmacol Sci', 'authors': [{'name': 'Tirelli U', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Taibi R', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Chirumbolo S', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Chirumbolo S', 'title': 'Post COVID syndrome: a new challenge for medicine.', 'sorttitle': 'post covid syndrome a new challenge for medicine', 'volume': '25', 'issue': '12', 'pages': '4422-4425', 'lang': ['eng'], 'nlmuniqueid': '9717360', 'issn': '1128-3602', 'essn': '2284-0729', 'pubtype': ['Journal Article', 'Review'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '4', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '34227079'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.26355/eurrev_202106_26154'}, {'idtype': 'pii', 'idtypen': 4, 'value': '26154'}], 'history': [{'pubstatus': 'entrez', 'date': '2021/07/06 06:45'}, {'pubstatus': 'pubmed', 'date': '2021/07/07 06:00'}, {'pubstatus': 'medline', 'date': '2021/07/15 06:00'}], 'references': [], 'attributes': ['Has Abstract'], 'pmcrefcount': '', 'fulljournalname': 'European review for medical and pharmacological sciences', 'elocationid': 'doi: 10.26355/eurrev_202106_26154', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2021/06/01 00:00', 'sortfirstauthor': 'Tirelli U', 'vernaculartitle': '', 'id': '34227079', 'review': '', 'text': ''}, {'uid': '32512530', 'pubdate': '2020 Oct', 'epubdate': '2020 May 30', 'source': 'Asian J Psychiatr', 'authors': [{'name': 'Dinakaran D', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Manjunatha N', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Naveen Kumar C', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Suresh BM', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Suresh BM', 'title': 'Neuropsychiatric aspects of COVID-19 pandemic: A selective review.', 'sorttitle': 'neuropsychiatric aspects of covid 19 pandemic a selective review', 'volume': '53', 'issue': '', 'pages': '102188', 'lang': ['eng'], 'nlmuniqueid': '101517820', 'issn': '1876-2018', 'essn': '1876-2026', 'pubtype': ['Journal Article', 'Review'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '256', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '32512530'}, {'idtype': 'pmc', 'idtypen': 8, 'value': 'PMC7261092'}, {'idtype': 'pmcid', 'idtypen': 5, 'value': 'pmc-id: PMC7261092;'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.1016/j.ajp.2020.102188'}, {'idtype': 'pii', 'idtypen': 4, 'value': 'S1876-2018(20)30300-2'}], 'history': [{'pubstatus': 'received', 'date': '2020/04/06 00:00'}, {'pubstatus': 'revised', 'date': '2020/05/27 00:00'}, {'pubstatus': 'accepted', 'date': '2020/05/28 00:00'}, {'pubstatus': 'pubmed', 'date': '2020/06/09 06:00'}, {'pubstatus': 'medline', 'date': '2020/12/15 06:00'}, {'pubstatus': 'entrez', 'date': '2020/06/09 06:00'}], 'references': [], 'attributes': ['Has Abstract'], 'pmcrefcount': 64, 'fulljournalname': 'Asian journal of psychiatry', 'elocationid': 'doi: 10.1016/j.ajp.2020.102188', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2020/10/01 00:00', 'sortfirstauthor': 'Dinakaran D', 'vernaculartitle': '', 'id': '32512530', 'review': '', 'text': ''}, {'uid': '34357885', 'pubdate': '2021 Aug 1', 'epubdate': '', 'source': 'Curr Sports Med Rep', 'authors': [{'name': 'Nieman DC', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Nieman DC', 'title': 'Exercise Is Medicine for Immune Function: Implication for COVID-19.', 'sorttitle': 'exercise is medicine for immune function implication for covid 19', 'volume': '20', 'issue': '8', 'pages': '395-401', 'lang': ['eng'], 'nlmuniqueid': '101134380', 'issn': '1537-890X', 'essn': '1537-8918', 'pubtype': ['Journal Article', 'Review'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '4', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '34357885'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.1249/JSR.0000000000000867'}, {'idtype': 'pii', 'idtypen': 4, 'value': '00149619-202108000-00004'}], 'history': [{'pubstatus': 'entrez', 'date': '2021/08/06 17:17'}, {'pubstatus': 'pubmed', 'date': '2021/08/07 06:00'}, {'pubstatus': 'medline', 'date': '2021/08/13 06:00'}], 'references': [], 'attributes': ['Has Abstract'], 'pmcrefcount': '', 'fulljournalname': 'Current sports medicine reports', 'elocationid': 'doi: 10.1249/JSR.0000000000000867', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2021/08/01 00:00', 'sortfirstauthor': 'Nieman DC', 'vernaculartitle': '', 'id': '34357885', 'review': '', 'text': ''}, {'uid': '32599968', 'pubdate': '2020 Dec 17', 'epubdate': '2020 Dec 17', 'source': 'Turk J Med Sci', 'authors': [{'name': 'Gül Ü', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Gül Ü', 'title': 'COVID-19 and dermatology.', 'sorttitle': 'covid 19 and dermatology', 'volume': '50', 'issue': '8', 'pages': '1751-1759', 'lang': ['eng'], 'nlmuniqueid': '9441758', 'issn': '1300-0144', 'essn': '1303-6165', 'pubtype': ['Journal Article', 'Review'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '3', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '32599968'}, {'idtype': 'pmc', 'idtypen': 8, 'value': 'PMC7775718'}, {'idtype': 'pmcid', 'idtypen': 5, 'value': 'pmc-id: PMC7775718;'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.3906/sag-2005-182'}], 'history': [{'pubstatus': 'received', 'date': '2020/05/14 00:00'}, {'pubstatus': 'accepted', 'date': '2020/06/25 00:00'}, {'pubstatus': 'entrez', 'date': '2020/07/01 06:00'}, {'pubstatus': 'pubmed', 'date': '2020/07/01 06:00'}, {'pubstatus': 'medline', 'date': '2020/12/31 06:00'}], 'references': [], 'attributes': ['Has Abstract'], 'pmcrefcount': 88, 'fulljournalname': 'Turkish journal of medical sciences', 'elocationid': 'doi: 10.3906/sag-2005-182', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2020/12/17 00:00', 'sortfirstauthor': 'Gül Ü', 'vernaculartitle': '', 'id': '32599968', 'review': '', 'text': ''}, {'uid': '34099197', 'pubdate': '2021 Jul', 'epubdate': '2020 Nov 10', 'source': 'Indian J Tuberc', 'authors': [{'name': 'Rai DK', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Sharma P', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Kumar R', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Kumar R', 'title': 'Post covid 19 pulmonary fibrosis. Is it real threat?', 'sorttitle': 'post covid 19 pulmonary fibrosis is it real threat', 'volume': '68', 'issue': '3', 'pages': '330-333', 'lang': ['eng'], 'nlmuniqueid': '0373027', 'issn': '0019-5707', 'essn': '0019-5707', 'pubtype': ['Journal Article', 'Review'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '256', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '34099197'}, {'idtype': 'pmc', 'idtypen': 8, 'value': 'PMC7654356'}, {'idtype': 'pmcid', 'idtypen': 5, 'value': 'pmc-id: PMC7654356;'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.1016/j.ijtb.2020.11.003'}, {'idtype': 'pii', 'idtypen': 4, 'value': 'S0019-5707(20)30213-4'}], 'history': [{'pubstatus': 'received', 'date': '2020/10/12 00:00'}, {'pubstatus': 'accepted', 'date': '2020/11/05 00:00'}, {'pubstatus': 'entrez', 'date': '2021/06/08 05:47'}, {'pubstatus': 'pubmed', 'date': '2021/06/09 06:00'}, {'pubstatus': 'medline', 'date': '2021/06/17 06:00'}], 'references': [], 'attributes': ['Has Abstract'], 'pmcrefcount': 28, 'fulljournalname': 'The Indian journal of tuberculosis', 'elocationid': 'doi: 10.1016/j.ijtb.2020.11.003', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2021/07/01 00:00', 'sortfirstauthor': 'Rai DK', 'vernaculartitle': '', 'id': '34099197', 'review': '', 'text': ''}, {'uid': '34904908', 'pubdate': '2022 Feb', 'epubdate': '2021 Dec 14', 'source': 'Ann Intern Med', 'authors': [{'name': 'Laine C', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Moyer DV', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Cotton D', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Cotton D', 'title': 'COVID-19: Challenging Clinical Questions.', 'sorttitle': 'covid 19 challenging clinical questions', 'volume': '175', 'issue': '2', 'pages': '276-277', 'lang': ['eng'], 'nlmuniqueid': '0372351', 'issn': '0003-4819', 'essn': '1539-3704', 'pubtype': ['Journal Article'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '256', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '34904908'}, {'idtype': 'pmc', 'idtypen': 8, 'value': 'PMC8722698'}, {'idtype': 'pmcid', 'idtypen': 5, 'value': 'pmc-id: PMC8722698;'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.7326/M21-4611'}], 'history': [{'pubstatus': 'pubmed', 'date': '2021/12/15 06:00'}, {'pubstatus': 'medline', 'date': '2022/02/23 06:00'}, {'pubstatus': 'entrez', 'date': '2021/12/14 12:14'}], 'references': [{'refsource': 'doi: 10.7326/M21-3840', 'reftype': 'Comment in', 'pmid': '', 'note': ''}, {'refsource': 'doi: 10.7326/M21-2342', 'reftype': 'Comment in', 'pmid': '', 'note': ''}, {'refsource': 'doi: 10.7326/M21-1260', 'reftype': 'Comment in', 'pmid': '', 'note': ''}, {'refsource': 'doi: 10.7326/M21-0331', 'reftype': 'Comment in', 'pmid': '', 'note': ''}, {'refsource': 'doi: 10.7326/M20-8008', 'reftype': 'Comment in', 'pmid': '', 'note': ''}, {'refsource': 'doi: 10.7326/M20-6841', 'reftype': 'Comment in', 'pmid': '', 'note': ''}], 'attributes': ['Has Abstract'], 'pmcrefcount': 6, 'fulljournalname': 'Annals of internal medicine', 'elocationid': 'doi: 10.7326/M21-4611', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2022/02/01 00:00', 'sortfirstauthor': 'Laine C', 'vernaculartitle': '', 'id': '34904908', 'review': '', 'text': ''}, {'uid': '33035150', 'pubdate': '2021 Feb', 'epubdate': '2020 Oct 19', 'source': 'Adv Wound Care (New Rochelle)', 'authors': [{'name': 'Singh H', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Kaur H', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Singh K', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Sen CK', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Sen CK', 'title': 'Cutaneous Manifestations of COVID-19: A Systematic Review.', 'sorttitle': 'cutaneous manifestations of covid 19 a systematic review', 'volume': '10', 'issue': '2', 'pages': '51-80', 'lang': ['eng'], 'nlmuniqueid': '101590593', 'issn': '2162-1918', 'essn': '2162-1934', 'pubtype': ['Journal Article'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '256', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '33035150'}, {'idtype': 'pmc', 'idtypen': 8, 'value': 'PMC8020517'}, {'idtype': 'pmcid', 'idtypen': 5, 'value': 'pmc-id: PMC8020517;'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.1089/wound.2020.1309'}], 'history': [{'pubstatus': 'pubmed', 'date': '2020/10/10 06:00'}, {'pubstatus': 'medline', 'date': '2021/01/12 06:00'}, {'pubstatus': 'entrez', 'date': '2020/10/09 17:07'}], 'references': [], 'attributes': ['Has Abstract'], 'pmcrefcount': 97, 'fulljournalname': 'Advances in wound care', 'elocationid': 'doi: 10.1089/wound.2020.1309', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2021/02/01 00:00', 'sortfirstauthor': 'Singh H', 'vernaculartitle': '', 'id': '33035150', 'review': '', 'text': ''}, {'uid': '35568052', 'pubdate': '2022 Sep', 'epubdate': '2022 May 11', 'source': 'Lancet Respir Med', 'authors': [{'name': 'Huang L', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Li X', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Gu X', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Zhang H', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Ren L', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Guo L', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Liu M', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Wang Y', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Cui D', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Wang Y', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Zhang X', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Shang L', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Zhong J', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Wang X', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Wang J', 'authtype': 'Author', 'clusterid': ''}, {'name': 'Cao B', 'authtype': 'Author', 'clusterid': ''}], 'lastauthor': 'Cao B', 'title': 'Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study.', 'sorttitle': 'health outcomes in people 2 years after surviving hospitalisation with covid 19 a longitudinal cohort study', 'volume': '10', 'issue': '9', 'pages': '863-876', 'lang': ['eng'], 'nlmuniqueid': '101605555', 'issn': '2213-2600', 'essn': '2213-2619', 'pubtype': ['Journal Article'], 'recordstatus': 'PubMed - indexed for MEDLINE', 'pubstatus': '256', 'articleids': [{'idtype': 'pubmed', 'idtypen': 1, 'value': '35568052'}, {'idtype': 'pmc', 'idtypen': 8, 'value': 'PMC9094732'}, {'idtype': 'pmcid', 'idtypen': 5, 'value': 'pmc-id: PMC9094732;'}, {'idtype': 'doi', 'idtypen': 3, 'value': '10.1016/S2213-2600(22)00126-6'}, {'idtype': 'pii', 'idtypen': 4, 'value': 'S2213-2600(22)00126-6'}], 'history': [{'pubstatus': 'received', 'date': '2022/03/09 00:00'}, {'pubstatus': 'revised', 'date': '2022/03/25 00:00'}, {'pubstatus': 'accepted', 'date': '2022/03/31 00:00'}, {'pubstatus': 'pubmed', 'date': '2022/05/15 06:00'}, {'pubstatus': 'medline', 'date': '2022/09/09 06:00'}, {'pubstatus': 'entrez', 'date': '2022/05/14 19:07'}], 'references': [{'refsource': 'Lancet Respir Med. 2022 Sep;10(9):e82', 'reftype': 'Comment in', 'pmid': 35697052, 'note': ''}, {'refsource': 'Lancet Respir Med. 2022 Sep;10(9):e81', 'reftype': 'Comment in', 'pmid': 35697054, 'note': ''}], 'attributes': ['Has Abstract'], 'pmcrefcount': 44, 'fulljournalname': 'The Lancet. Respiratory medicine', 'elocationid': 'doi: 10.1016/S2213-2600(22)00126-6', 'doctype': 'citation', 'srccontriblist': [], 'booktitle': '', 'medium': '', 'edition': '', 'publisherlocation': '', 'publishername': '', 'srcdate': '', 'reportnumber': '', 'availablefromurl': '', 'locationlabel': '', 'doccontriblist': [], 'docdate': '', 'bookname': '', 'chapter': '', 'sortpubdate': '2022/09/01 00:00', 'sortfirstauthor': 'Huang L', 'vernaculartitle': '', 'id': '35568052', 'review': '', 'text': ''}]\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Some weights of the model checkpoint at bert-base-uncased were not used when initializing BertForSequenceClassification: ['cls.seq_relationship.weight', 'cls.predictions.transform.LayerNorm.weight', 'cls.predictions.transform.dense.weight', 'cls.seq_relationship.bias', 'cls.predictions.bias', 'cls.predictions.transform.LayerNorm.bias', 'cls.predictions.transform.dense.bias']\n",
      "- This IS expected if you are initializing BertForSequenceClassification from the checkpoint of a model trained on another task or with another architecture (e.g. initializing a BertForSequenceClassification model from a BertForPreTraining model).\n",
      "- This IS NOT expected if you are initializing BertForSequenceClassification from the checkpoint of a model that you expect to be exactly identical (initializing a BertForSequenceClassification model from a BertForSequenceClassification model).\n",
      "Some weights of BertForSequenceClassification were not initialized from the model checkpoint at bert-base-uncased and are newly initialized: ['classifier.bias', 'classifier.weight']\n",
      "You should probably TRAIN this model on a down-stream task to be able to use it for predictions and inference.\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "import torch\n",
    "import transformers\n",
    "import urllib\n",
    "import time\n",
    "\n",
    "\n",
    "def get_literature(query, api_key):\n",
    "    \"\"\"Fetches relevant clinical trial literature from PubMed.\"\"\"\n",
    "    query = urllib.parse.quote(query)\n",
    "    url = f\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&retmode=json&retmax=20&sort=relevance&term={query}&api_key={api_key}\"\n",
    "    response = make_request_with_retry(url)\n",
    "\n",
    "    if response.status_code == 200:\n",
    "        literature = response.json()\n",
    "        #print(literature)  # Print the fetched literature\n",
    "        return literature\n",
    "    else:\n",
    "        raise Exception(f\"Error fetching literature: {response.status_code}\")\n",
    "\n",
    "\n",
    "\n",
    "def preprocess_literature(literature):\n",
    "    \"\"\"Converts the collected data into a format suitable for the LLM.\"\"\"\n",
    "    processed_literature = []\n",
    "    for study_id in literature[\"esearchresult\"][\"idlist\"]:\n",
    "        study = get_study_details(study_id)\n",
    "        study[\"text\"] = study.get(\"abstract\", \"\")  # Update this line\n",
    "        processed_literature.append(study)\n",
    "    print(processed_literature)\n",
    "    return processed_literature\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "def get_study_details(study_id):\n",
    "    \"\"\"Fetches detailed information for a specific study from PubMed.\"\"\"\n",
    "    url = f\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id={study_id}\"\n",
    "    response = make_request_with_retry(url)\n",
    "\n",
    "    if response.status_code == 200:\n",
    "        study = response.json()\n",
    "        study_details = study[\"result\"][study_id]\n",
    "        study_details[\"id\"] = study_id\n",
    "        study_details[\"review\"] = study_details.get(\"abstract\", \"\")  # Update this line\n",
    "        \n",
    "        return study_details\n",
    "    else:\n",
    "        raise Exception(f\"Error fetching study details: {response.status_code}\")\n",
    "\n",
    "\n",
    "\n",
    "def make_request_with_retry(url, max_retries=3):\n",
    "    \"\"\"Makes a request with retry and exponential backoff.\"\"\"\n",
    "    retry_delay = 1\n",
    "    for attempt in range(1, max_retries + 1):\n",
    "        try:\n",
    "            response = requests.get(url)\n",
    "            if response.status_code == 200:\n",
    "                return response\n",
    "            elif response.status_code == 429:\n",
    "                print(f\"Rate limit exceeded. Retrying in {retry_delay} seconds...\")\n",
    "                time.sleep(retry_delay)\n",
    "                retry_delay *= 2\n",
    "                continue\n",
    "            else:\n",
    "                response.raise_for_status()\n",
    "        except Exception as e:\n",
    "            print(f\"Request failed. Retrying in {retry_delay} seconds...\")\n",
    "            time.sleep(retry_delay)\n",
    "            retry_delay *= 2\n",
    "    raise Exception(\"Max retries exceeded. Unable to complete the request.\")\n",
    "\n",
    "\n",
    "def train_llm(literature):\n",
    "    \"\"\"Fine-tunes a pre-trained LLM on a specialized corpus of clinical trial literature.\"\"\"\n",
    "    model = transformers.AutoModelForSequenceClassification.from_pretrained(\"bert-base-uncased\")\n",
    "    # Training code for LLM\n",
    "    return model\n",
    "\n",
    "\n",
    "def extract_data(llm, literature, tokenizer):\n",
    "    \"\"\"Uses the trained LLM to extract relevant data from the literature.\"\"\"\n",
    "    for study in literature:\n",
    "        inputs = tokenizer.encode_plus(\n",
    "            study[\"text\"],\n",
    "            add_special_tokens=True,\n",
    "            truncation=True,\n",
    "            max_length=512,\n",
    "            padding=\"max_length\",\n",
    "            return_tensors=\"pt\"\n",
    "        )\n",
    "        outputs = llm(**inputs)\n",
    "        logits = outputs.logits\n",
    "        predicted_label = torch.argmax(logits, dim=1)\n",
    "        \n",
    "        study[\"study_design\"] = predicted_label.item()\n",
    "        study[\"sample_size\"] = int(study[\"study_design\"])\n",
    "        study[\"interventions\"] = study.get(\"interventions\", [])\n",
    "        study[\"outcome_measures\"] = study.get(\"outcome_measures\", [])\n",
    "        study[\"main_findings\"] = study.get(\"main_findings\", \"\")\n",
    "    #print(literature)\n",
    "    return literature\n",
    "\n",
    "\n",
    "def generate_report(literature):\n",
    "    \"\"\"Generates a comprehensive review report.\"\"\"\n",
    "    report = \"\"\n",
    "    for study in literature:\n",
    "        study_id = study.get(\"id\")\n",
    "        review = study.get(\"review\")\n",
    "        #print(f\"Study ID: {study_id}\")  # Print the study ID for debugging purposes\n",
    "        #print(f\"Review: {review}\")  # Print the review for debugging purposes\n",
    "        if study_id and review:\n",
    "            report += f\"Study {study_id}: {review}\\n\"\n",
    "    \n",
    "    #print(report)  # Print the generated report for debugging purposes\n",
    "    \n",
    "    return report\n",
    "\n",
    "\n",
    "\n",
    "if __name__ == \"__main__\":\n",
    "    query = input(\"Enter a search query for clinical trial literature: \")\n",
    "    api_key = 'dcbe9b28ab11329579a3694164c127836807'\n",
    "    literature = get_literature(query, api_key)\n",
    "    processed_literature = preprocess_literature(literature)  # Add this line\n",
    "    llm = train_llm(processed_literature)  # Pass the processed literature\n",
    "    tokenizer = transformers.AutoTokenizer.from_pretrained(\"bert-base-uncased\")\n",
    "    literature = extract_data(llm, processed_literature, tokenizer)  # Pass the processed literature\n",
    "    report = generate_report(literature)\n",
    "    #print(report)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "7c5f70f7",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a6aa9103",
   "metadata": {},
   "outputs": [],
   "source": [
    "!pip install torch torchvision\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "9a8aabd6",
   "metadata": {},
   "outputs": [],
   "source": [
    "dcbe9b28ab11329579a3694164c127836807"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d405d665",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "dd48c0aa",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "id": "26704f33",
   "metadata": {},
   "source": [
    "## V2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "21693e03",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Enter a search query for clinical trial literature: covid 19\n",
      "Request failed. Retrying in 1 seconds...\n",
      "Request failed. Retrying in 2 seconds...\n",
      "Request failed. Retrying in 4 seconds...\n",
      "Failed to retrieve full text for PMID: 33664170\n",
      "Request failed. Retrying in 1 seconds...\n",
      "Request failed. Retrying in 2 seconds...\n",
      "Request failed. Retrying in 4 seconds...\n",
      "Failed to retrieve full text for PMID: 34355645\n",
      "Request failed. Retrying in 1 seconds...\n",
      "Request failed. Retrying in 2 seconds...\n",
      "Request failed. Retrying in 4 seconds...\n",
      "Failed to retrieve full text for PMID: 32749914\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Some weights of the model checkpoint at bert-base-uncased were not used when initializing BertForSequenceClassification: ['cls.seq_relationship.weight', 'cls.predictions.transform.LayerNorm.weight', 'cls.predictions.transform.dense.weight', 'cls.seq_relationship.bias', 'cls.predictions.bias', 'cls.predictions.transform.LayerNorm.bias', 'cls.predictions.transform.dense.bias']\n",
      "- This IS expected if you are initializing BertForSequenceClassification from the checkpoint of a model trained on another task or with another architecture (e.g. initializing a BertForSequenceClassification model from a BertForPreTraining model).\n",
      "- This IS NOT expected if you are initializing BertForSequenceClassification from the checkpoint of a model that you expect to be exactly identical (initializing a BertForSequenceClassification model from a BertForSequenceClassification model).\n",
      "Some weights of BertForSequenceClassification were not initialized from the model checkpoint at bert-base-uncased and are newly initialized: ['classifier.bias', 'classifier.weight']\n",
      "You should probably TRAIN this model on a down-stream task to be able to use it for predictions and inference.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Study 33400058: <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n",
      "<!DOCTYPE collection SYSTEM \"BioC.dtd\">\n",
      "<collection><source>PMC</source><date>20210914</date><key>pmc.key</key><document><id>7784226</id><infon key=\"license\">CC BY</infon><passage><infon key=\"article-id_doi\">10.1208/s12248-020-00532-2</infon><infon key=\"article-id_pmc\">7784226</infon><infon key=\"article-id_pmid\">33400058</infon><infon key=\"article-id_publisher-id\">532</infon><infon key=\"elocation-id\">14</infon><infon key=\"issue\">1</infon><infon key=\"kwd\">antiviral drugs anti-SARS-CoV-2 antibody antiviral vaccines ARDS convalescent plasma therapy immunotherapy nanotherapeutics</infon><infon key=\"license\">Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.</infon><infon key=\"name_0\">surname:Majumder;given-names:Joydeb</infon><infon key=\"name_1\">surname:Minko;given-names:Tamara</infon><infon key=\"section_type\">TITLE</infon><infon key=\"title\">KEY WORDS</infon><infon key=\"type\">front</infon><infon key=\"volume\">23</infon><infon key=\"year\">2021</infon><offset>0</offset><text>Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>74</offset><text>The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a serious public health threat worldwide with millions of people at risk in a growing number of countries. Though there are no clinically approved antiviral drugs and vaccines for COVID-19, attempts are ongoing for clinical trials of several known antiviral drugs, their combination, as well as development of vaccines in patients with confirmed COVID-19. This review focuses on the latest approaches to diagnostics and therapy of COVID-19. We have summarized recent progress on the conventional therapeutics such as antiviral drugs, vaccines, anti-SARS-CoV-2 antibody treatments, and convalescent plasma therapy which are currently under extensive research and clinical trials for the treatment of COVID-19. The developments of nanoparticle-based therapeutic and diagnostic approaches have been also discussed for COVID-19. We have assessed recent literature data on this topic and made a summary of current development and future perspectives.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>1164</offset><text>INTRODUCTION</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>1177</offset><text>Newly emerging virus diseases have become a major public health threat around the world in recent years. During the last two decades, outbreaks of several viral diseases have been reported including the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002, H1N1 influenza in 2009, the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, Ebola virus disease (EVD) in 2013, and Zika virus in 2015. The most recent and ongoing viral disease caused by the novel coronavirus has severely threatened public health worldwide. The outbreak of novel coronavirus was initially reported to the World Health Organization (WHO) on December 31, 2019. On January 12, 2020, WHO designated this virus as novel coronavirus â2019-nCoVâ, and later, it was termed as the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses (ICTV) because of its similarity with the previous SARS-CoV. On January 30, 2020, WHO declared this viral outbreak as a public health emergency of international concern. Later on February 11, 2020, WHO termed this disease as coronavirus disease 2019 (COVID-19) and, subsequently on March 11, 2020, WHO declared COVID-19 as a global pandemic since the SARS-CoV-2 viral infection has spread rapidly in a growing number of countries. As of October 31, 2020, more than 45Â million people were infected with the COVID-19 disease, and 1.2Â million deaths have been reported globally. While human-to-human transmission rate is higher for SARS-CoV-2 than that of SARS-CoV virus, the mortality rate of COVID-19 disease is much lower than that of SARS-CoV infection. While all coronaviruses distress the respiratory tract, SARS-CoV-2 virus additionally also affects the heart, gastrointestinal system, liver, kidney, and the central nervous system eventually leading to multi-organ failure.</text></passage><passage><infon key=\"file\">12248_2020_532_Fig1_HTML.jpg</infon><infon key=\"id\">Fig1</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>3052</offset><text>Human coronavirus. a Schematic structure of SARS-CoV-2 virus. b A transmission electron microscope image of SARS-CoV-2 spherical viral particles in cell. The virus is colorized in blue. Adapted from the US Centers for Disease Control. Reproduced with permission from </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>3320</offset><text>SARS-CoV-2 genome contains single-stranded positive-sense RNA encapsulated within a membrane envelop with an average diameter of 75â150Â nm. The envelope is covered with glycoprotein spikes giving coronaviruses their crown-like appearance (corona is the Latin term for crown or garland). The genome of SARS-CoV-2 has a length of about 30Â K nucleotides. Almost 85% homology of this virus is also similar to the SARS-CoV. Four main structural proteins are encoded in SARS-CoV-2 viral genome, namely, spike (S) surface glycoprotein, membrane (M) protein, envelope (E) protein, and nucleocapsid (N) protein (Fig.Â 1a). Several other nonstructural proteins are also encoded by the viral genome (RNA polymerase, RdRp; papain-like protease, PLpro; coronavirus main protease, 3CLpro). A representative transmission electron microscope (TEM) image of SARS-CoV-2 viruses in host cells is shown in Fig. 1b, where the SARS-CoV-2 viruses have been colorized in blue color.</text></passage><passage><infon key=\"file\">12248_2020_532_Fig2_HTML.jpg</infon><infon key=\"id\">Fig2</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>4283</offset><text>Overview of the coronavirus replication cycle (simplified, not to scale). The figure depicts viral development from initial binding and release of viral genome to eventual exocytosis of the mature virion. ERGIC, endoplasmic reticulum-Golgi intermediate compartment (also referred to as vesicular-tubular cluster). Drawn using a template retrieved from </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>4636</offset><text>The replication of COVID-19 as any other virus requires a host cell and normally includes attachment, penetration, uncoating, replication, assembly, and release steps. A schematic representation of cellular uptake and replication of SARS-CoV-2 virus is shown in Fig.Â 2. Spike glycoprotein on the surface of the COVID-19 binds to angiotensin-converting enzyme 2 (ACE2) receptor protein located on the host cell plasma membrane and facilitates the host cell invasion. Serine protease TMPRSS211 produced by a host cell facilitates the process of this invasion. After receptor-mediated endocytosis of the virus into the host cells, it releases viral genome (single-stranded positive RNA), and using host ribosome translates into viral polyproteins. Viral proteinases 3CLpro and PLpro cleave viral polyproteins into effector proteins. RNA-dependent RNA polymerase in turn synthesizes a full-length negative-strand RNA template which is used to make more viral genomic RNA. Viral genome then is synthesized by genomic replication, and four essential structural viral proteins (N, S, M, and E) are produced by transcription then translation. N protein binds genomic RNA while S, M, and E proteins are integrated into the membrane of the endoplasmic reticulum (ER) forming ERGICâendoplasmic reticulum-Golgi intermediate compartment (also referred to as vesicular-tubular cluster). Assembled nucleocapsid with helical twisted RNA is encapsulated into the ER lumen, viral progeny is transported by the ERGIC toward the plasma membrane of the host cell, and finally, daughter virus is released by exocytosis.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>6237</offset><text>In general, antiviral treatment and prevention approaches are based on the (a) inhibition of the replication of the viral genome by either preventing virus entering host cells or suppression of one or more steps in its replication, (b) priming the immune system and creating a form of memory against the virus by the vaccination, (c) injection of the antiviral antibodies produced in the plasma from the recovered patient to the infected patient, and (d) treatment of lung damage and respiratory distress syndrome accompanied the viral infection. In this review, we have summarized the ongoing developments of therapeutic and diagnostic approaches based on the conventional methodologies for COVID-19. Besides the conventional methods, we have presented recent developments of various nanocarrier-based therapeutic and diagnostic approaches for COVID-19.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>7092</offset><text>Coronavirus disease 2019 (COVID-19) is defined as a disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The signs and symptoms of COVID-19 disease are different from patient to patient, but most common clinical symptoms include fever, fatigue, cough, expectoration, anorexia, sputum production, shortness of breath, etc. during various stages of this disease. Besides, less common symptoms such as sore throat, headache, confusion, hemoptysis, shortness of breath, and chest tightness have been also observed as well as minor symptoms such as nausea, vomiting, diarrhea, and gastrointestinal complication were also reported. Similar signs and symptoms of COVID-19 were observed in children like the adults, but those symptoms were usually milder as compared with the adult patients. However, there were patients not yet symptomatic (presymptomatic) as well as there were patients (asymptomatic) with no typical symptoms of COVID-19 disease as revealed in many reports. Several asymptomatically infected COVID-19 patients were found to be asymptomatic throughout the period of the infection. A recent study also revealed that the rate of human-to-human transmission of SARS-CoV-2 virus is higher than that of the previous two coronaviruses SARS-CoV and MERS-CoV infections.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>8397</offset><text>To date, there is no effective therapy for COVID-19. Therefore, the key management of COVID-19 patients included early diagnosis, immediate patient isolation, and protective conditions to prevent the infection. Typical treatment for COVID-19 disease included general supportive care, respiratory support, as well as nutritional support.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>8734</offset><text>COVID-19: THERAPEUTIC APPROACHES</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>8767</offset><text>Currently, there are no clinically approved drugs or therapeutics by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19. Traditional drug discovery approaches are time-consuming, and trial-and-error methods are often ineffective. Because of regulatory requirements to assess safety and efficacy of drug, the time required to develop a new drug takes average one to two decades. A rational approach to overcome the sustained high failure rates and the time and costs involved in the research and development to bring a new drug in the market is to repurpose existing drugs based on similarity of disease mechanisms for the targeted drugs. Moreover, repurposed drugs have the advantage of less development costs and time because of their previously available pharmacokinetic, toxicology, and safety data. Taking repurposing as a primary strategy, many randomized controlled trials of known drugs are ongoing in patients with COVID-19. Recently, both researchers and clinicians have been paid significant attention for developing vaccines and antiviral therapeutics. On August 2020, more than 350 COVID-19 therapeutic drugs (mostly repurposed) are investigated with more than 75% of them entered in human clinical trials, and more than 150 repurposed and original vaccines are under study with about 25% of them on the various phases of human trials.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>10138</offset><text>Antiviral Drugs</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_3</infon><offset>10154</offset><text>Treatment Mechanisms</text></passage><passage><infon key=\"file\">12248_2020_532_Fig3_HTML.jpg</infon><infon key=\"id\">Fig3</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>10175</offset><text>Proposed therapeutic treatments for COVID-19. a, b Targeting viral entry mechanism. a Viral entry mechanism of SARS-CoV-2. b Possible approaches for blocking ACE2 receptors. c Antiviral drugs targeting the coronavirus replication cycle (simplified). Abbreviations: ACE2, angiotensin-converting enzyme 2; scFvs, recombinant human single-chain variable region fragments against the S1 domain of spike (S) protein of the SARS-CoV; ACE2-Fc, immunoglobulin fragment (Fc)-ACE2 fusion protein</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>10661</offset><text>In general, two distinct approaches are being explored for repurposing of conventional drugs and development of novel therapeutic drugs: prevention of virus entry into the host cells and suppression of various steps in virus replication inside the cells (Fig.Â 3).</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_3</infon><offset>10926</offset><text>Blocking Viral Entry</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>10947</offset><text>COVID-19 viruses target angiotensin-converting enzyme (ACE) 2 receptors overexpressed in the cells of lung and gastrointestinal tissues in the human body (Fig. 3a). The receptor-binding domain (RBD) of spike protein on the surface of the coronavirus binds to ACE2 on the plasma membrane of infected cells, initiating receptor-mediated endocytosis. Three strategies are currently investigating in order to block this interaction and abrogate infection. First, a high number of soluble RBD mimetics can be administered to bind ACE2 receptors and saturate available sites, preventing virus binding and entering host cells (Fig. 3b (1)). Second, antibodies or single-chain antibody fragments (scFv) against ACE2 receptors can also be administered to accomplish a similar task. Third strategy targets the coronavirus RBDs directly by using the ACE2 extracellular domain in order to bind to the spike protein. A fragment crystallizable (Fc) region (the tail fragment of an antibody) that interacts with ACE2 cell surface receptors bonded directly to RBDs of the virus again can prevent its interaction with the host cells and preventing infection. Despite extensive research for developing various antiviral therapeutics that are capable to prevent or at least limit binding of SARS-CoV-2 virus to ACE2 receptors, certain aspects of these approaches may potentially limit their efficacy. First, native mimetics, antibody, and their fragments possess a relatively low stability in the blood stream and may drop their specific activity during their transfer to their primary targets (ACE2 receptors in lung cells and RBDs in the virus). On our opinion, the most effective ways to protect therapeutic payload from the degradation in the blood stream include their conjugation to nanoparticles and delivery specifically to the site of action. In the case of COVID-19 and other SARS viruses, inhalation delivery of ACE2 antibodies by nanoparticles specifically to the lungs is capable not only to deliver them as close as possible to the targeted cellular receptors and preserve their specific activity but also substantially limit the inactivation of ACE2 receptors in other non-targeted organs limiting possible adverse side effects of the treatment. Currently, we are carrying out the experiments for delivering of ACE2-targeted antibodies using lipid nanoparticles by inhalation. Other limitations include possible binding of remedies to sites on the ACE2 receptors or RBDs that do not compete or interfere with viral entry. The potency of such therapeutics can be improved by enhancing their binding affinity against the epitope of the RBD.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_3</infon><offset>13582</offset><text>Targeting the Coronavirus Replication</text></passage><passage><infon key=\"file\">Tab1.xml</infon><infon key=\"id\">Tab1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>13620</offset><text>List of Drugs Repurposed in Clinical Trials for COVID-19. Modified From </text></passage><passage><infon key=\"file\">Tab1.xml</infon><infon key=\"id\">Tab1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th&gt;Drugs&lt;/th&gt;&lt;th&gt;Applications&lt;/th&gt;&lt;th&gt;Targets&lt;/th&gt;&lt;th&gt;Mechanism of action against life cycle of SARS-CoV-2 virus&lt;/th&gt;&lt;th&gt;References&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;Favipiravir&lt;/td&gt;&lt;td&gt;Viral diseases&lt;/td&gt;&lt;td&gt;RNA-dependent RNA polymerase (RdRp)&lt;/td&gt;&lt;td&gt;Inhibits viral RNA polymerase and RNA replicase activity&lt;/td&gt;&lt;td&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR41&quot;&gt;41&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Remdesivir&lt;/td&gt;&lt;td&gt;Ebola virus diseases (EVD)&lt;/td&gt;&lt;td&gt;Viral proteases, RdRp&lt;/td&gt;&lt;td&gt;Interferes with viral RNA polymerase activity and reduces viral RNA synthesis to arrest viral replication&lt;/td&gt;&lt;td&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR8&quot;&gt;8&lt;/xref&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR42&quot;&gt;42&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Lopinavir&lt;/td&gt;&lt;td&gt;HIV infections&lt;/td&gt;&lt;td&gt;Viral proteases&lt;/td&gt;&lt;td&gt;Inhibits the viral proteases activity&lt;/td&gt;&lt;td&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR9&quot;&gt;9&lt;/xref&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR10&quot;&gt;10&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Ritonavir&lt;/td&gt;&lt;td&gt;HIV infections&lt;/td&gt;&lt;td&gt;Viral proteases&lt;/td&gt;&lt;td&gt;Inhibits the viral proteases activity&lt;/td&gt;&lt;td&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR9&quot;&gt;9&lt;/xref&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR10&quot;&gt;10&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Chloroquine&lt;/td&gt;&lt;td&gt;Malarial&lt;/td&gt;&lt;td&gt;Angiotensin Converting Enzyme-2 (ACE2)&lt;/td&gt;&lt;td&gt;Interferes with glycosylation of ACE2&lt;/td&gt;&lt;td&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR43&quot;&gt;43&lt;/xref&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR44&quot;&gt;44&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Ribavirin&lt;/td&gt;&lt;td&gt;Respiratory syncytial virus (RSV) infection&lt;/td&gt;&lt;td&gt;RdRp&lt;/td&gt;&lt;td&gt;Inhibits viral RNA polymerase activity&lt;/td&gt;&lt;td&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR45&quot;&gt;45&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Umifenovir (Arbidol)&lt;/td&gt;&lt;td&gt;Influenza&lt;/td&gt;&lt;td&gt;S-spike glycoprotein&lt;/td&gt;&lt;td&gt;Inhibits membrane fusion and prevent viral entry into the host cells&lt;/td&gt;&lt;td&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR46&quot;&gt;46&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>13693</offset><text>Drugs\tApplications\tTargets\tMechanism of action against life cycle of SARS-CoV-2 virus\tReferences\t \tFavipiravir\tViral diseases\tRNA-dependent RNA polymerase (RdRp)\tInhibits viral RNA polymerase and RNA replicase activity\t\t \tRemdesivir\tEbola virus diseases (EVD)\tViral proteases, RdRp\tInterferes with viral RNA polymerase activity and reduces viral RNA synthesis to arrest viral replication\t\t \tLopinavir\tHIV infections\tViral proteases\tInhibits the viral proteases activity\t\t \tRitonavir\tHIV infections\tViral proteases\tInhibits the viral proteases activity\t\t \tChloroquine\tMalarial\tAngiotensin Converting Enzyme-2 (ACE2)\tInterferes with glycosylation of ACE2\t\t \tRibavirin\tRespiratory syncytial virus (RSV) infection\tRdRp\tInhibits viral RNA polymerase activity\t\t \tUmifenovir (Arbidol)\tInfluenza\tS-spike glycoprotein\tInhibits membrane fusion and prevent viral entry into the host cells\t\t \t</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>14575</offset><text>In contrast to ACE2 receptor blockers, the most part of repurposed anti-COVID-19 drugs do not interact with the viral entry to the host cells. Instead, drugs block one or several steps of virus replication inside the cell (Fig. 3c). Drugs may prevent endocytosis (e.g., chloroquine, nafamostat, griffithsin), inhibit endosome maturation (e.g., hydroxychloroquine, apilimod, colchicine, vinorelbine), and release of viral genome (e.g., cinanserin, disulfiram) and virus replication, transcription, and translation of viral proteins (e.g., bananin, 5-hydroxychromone, remdesivir, favipiravir, ribavirin). siRNA-based therapeutics and some repurposing drugs can also be employed to prevent the formation of daughter virion and its release from the host cell by exocytosis. A summary of various repurposed drugs in clinical trials for treatment of COVID-19 with original application, targeted molecules, and brief description of a major mechanism of action with references are shown in Table I. Below, we provide brief information of several repurposed and original antiviral drugs, antibodies, and vaccines proposed and tested for the treatment of COVID-19 infection.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_3</infon><offset>15740</offset><text>Remdesivir</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>15751</offset><text>Remdesivir, a recently discovered novel antiviral drug in the class of nucleotide analogs, has shown potent effect in treating Ebola virus and Marburg virus infections. Remdesivir was developed by Gilead Sciences for the treatment of viral diseases caused by various RNA viruses. The drug displayed antiviral activity against various single-stranded RNA viruses such as Nipah virus, Hendra virus, and coronaviruses (including MERS and SARS-CoV viruses). More recently, remdesivir is being studied for the treatment of COVID-19 infections. On May 1, 2020, the US-FDA approved an emergency use authorization (EUA) for remdesivir based on the preliminary clinical data indicating quick recovery of the COVID-19 patients. In a recent clinical trial study, patients with confirmed COVID-19 infection were treated with compassionate use of remdesivir for 10Â days. On day 1, patients were treated intravenously with 200Â mg dose. Then, treatment with 100-mg intravenous daily dose was continued for another 9Â days. The results showed clinical improvements for 36 of 53 patients (ca. 68%). In a recent study, Spinner et al. conducted a randomized and open-label phase 3 clinical trial of remdesivir in total 584 patients with moderate COVID-19 disease (ClinicalTrials.gov Identifier: NCT04292730). All the patients were randomized in three groups: 197 patients in 10-day course of remdesivir treatment, 199 patients in 5-day course of remdesivir treatment, and 200 patients in standard care treatment only. Remdesivir was injected intravenously at a dose of 200Â mg on day 1 followed by daily treatment of 100Â mg for an entire treatment course. Initial results revealed that clinical status distribution was better in the group of patients randomized to a 5-day course of remdesivir treatment when compared with that of the standard care group. More recently, the FDA has approved the antiviral drug Veklury (remdesivir) which inhibits replication of SARS-CoV-2 virus for the treatment of patients with COVID-19 requiring hospitalization.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_3</infon><offset>17785</offset><text>Umifenovir</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>17796</offset><text>Umifenovir is an indole-based antiviral agent, which is mainly used for the treatment of influenza and other respiratory diseases in Russia and China. Umifenovir was found to show activity against other type of RNA and DNA viruses such as Zika virus, Lassa virus, and Ebola virus Antiviral activity of umifenovir may be attributed to interactions of its aromatic residues with the viral glycoproteins, which is involved in viral fusion through the cell membrane. Currently, this drug is being investigated for the treatment of COVID-19 infection. In an early report, Lian et al. performed a retrospective study of umifenovir in 81 COVID-19 patients. All the patients were divided into control group (nÂ =â36) and umifenovir treatment group (nÂ =â45). After 7Â days of post-treatment, no deaths were reported in both groups; however, 28 out of 36 (78%) patients in the control group tested negative for SARS-CoV-2 infection, whereas similar numbers (33 out of 45 or 73% patients) were obtained in the umifenovir treatment group. Thus, the initial results revealed that umifenovir treatment did not improve outcomes in COVID-19 patients. Recently, Chen et al. performed a retrospective cohort study in 200 patients with COVID-19 to see the effect of umifenovir (Arbidol) in combination with Shufeng Jiedu Capsules for 2Â weeks. The control group patients were treated with Arbidol hydrochloride capsules, and the experimental group patients were treated with combination of Arbidol hydrochloride capsules and Shufeng Jiedu Capsules. The subsidence of a fever was observed more rapidly in the experimental group of participants. The chest CT scan also showed better resolution of pneumonia symptoms in the experimental group than that in the control group.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_3</infon><offset>19554</offset><text>Favipiravir</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>19566</offset><text>Favipiravir is a pyrazine class antiviral drug, which was mainly used for the treatment of influenza in Japan. It works by inhibiting the function of RNA-dependent RNA polymerase (RdRp) enzymes, the protein which is involved in the transcription and replication of viral genomes. Besides influenza, it was also investigated for the treatment of Ebola virus, and recently, it has been evaluated for the treatment of COVID-19.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_3</infon><offset>19991</offset><text>Chloroquine</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>20003</offset><text>Chloroquine is an aminoquinoline class small molecule drug, which is used for the treatment of malaria. Chloroquine was also repurposed for the treatment of other diseases such as HIV and rheumatoid arthritis. This drug potentially can have a wide spectrum of antiviral action on all steps of the viral entry and replication. Latest studies revealed that chloroquine inhibits the process of glycosylation of angiotensin-converting enzyme 2 (ACE2), an enzyme which is present on the cell membranes of cells in the lungs, arteries, heart, kidney, etc. and found to involve in the mechanism of cellular entry of SARS-CoV and SARS-CoV-2 viruses. Recently, the FDA has issued an emergency use authorization for chloroquine for the treatment of COVID-19.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_3</infon><offset>20752</offset><text>Clinical Trials of Antiviral Drugs</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>20787</offset><text>Currently, there are a number of drug candidates in various stages of clinical trials for the treatment of COVID-19. On the end of September 2020, 322 out of total 409 drug candidates are tested in human trials, with 119 of them entered phase III and 46âphase IV. Here, we have summarized results from few clinical trials of antiviral therapeutics for COVID-19. Remdesivir is a broad-spectrum antiviral agent which works by inhibiting the viral RNA-dependent RNA polymerase activity. Remdesivir has been found to show activity against the previous SARS-CoV and MERS-CoV infections. Recently, Beigel et al. conducted intravenous treatment of remdesivir in a clinical trial of total 1063 adult patients with COVID-19 disease. All patients were randomly divided into two groups, namely, remdesivir and placebo groups. Patients in remdesivir group received 200Â mg dose on day 1, followed by 100Â mg daily dose for additional 9Â days. Preliminary results revealed that patients of remdesivir group had average recovery time of 11Â days as compared with 15Â days of the patients who received placebo. Thus, remdesivir treatment demonstrated better clinical benefit than placebo in shortening the recovery time of adult patients with COVID-19. Another randomized clinical trial also revealed that remdesivir treatment reduced the recovery time from the SARS-CoV-2 infection. On May 1, 2020, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization of remdesivir for the treatment of patients with severe condition of COVID-19. Currently, remdesivir is under clinical trial at the phase III level for the treatment of COVID-19. Further clinical studies of remdesivir are ongoing to evaluate its safety and efficacy in more patients with SARS-CoV-2 infection. Favipiravirâan antiviral drug used to treat influenzaâwas investigated in a phase II clinical trial in China at the early days of the outbreak of SARS-CoV-2 infection for its efficacy and safety in COVID-19 patients. Later, favipiravir in combination with other antiviral drugs were also investigated in clinical trials for COVID-19. However, no significant therapeutic outcome was observed from these clinical studies of favipiravir for COVID-19 (Chinese Clinical Trial Registry Identifiers: ChiCTR2000030987, ChiCTR2000029600). Lopinavir/ritonavir is an FDA-approved combination agent for HIV treatment. Lopinavir/ritonavir combination agent is currently being studied in clinical trial for COVID-19. Recently, Cao et al. performed a randomized controlled trial of lopinavir/ritonavir in 199 patients with COVID-19 disease. The efficacy of lopinavir/ritonavir treatment was compared with the standard care and management for COVID-19 patients. However, no significant difference was observed in terms of viral clearance or mortality rates in both the treated and standard care group of patients. Chloroquine, an antimalarial drug was also evaluated in clinical trials for COVID-19. In March 2020, Gautret and co-authors performed an open-label randomized controlled trial of hydroxychloroquine (HCQ) in COVID-19 patients. All the treated patients received 200Â mg of HCQ for 10Â days with 3 doses per day, while the control group received usual care for COVID-19. Results revealed that, at day 6 post-inclusion, 70% of hydroxychloroquine-treated patients were virologically cured (had negative PCR results in nasopharyngeal samples) compared with 12.5% in the control group (pÂ =â0.001). Other antiviral drugs such as ribavirin were also investigated in a randomized controlled trial in COVID-19 patients, but the results showed mixed success. More recently, glucocorticoids as dexamethasone were investigated in clinical trial of patients with severe COVID-19. Initial results revealed that dexamethasone treatment reduced death rate of the COVID-19 patients by one-third as compared with the COVID-19 patients who received only standard supportive care treatment.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>24738</offset><text>While promising preliminary results were observed from few of the ongoing clinical trials, still many concerns related to safety and toxicity of the repurposed drugs limited their further clinical studies. For example, based on the results of recent clinical trials, the US FDA revoked its Emergency Use Authorization (EUA) for both chloroquine and hydroxychloroquine (HCQ) for the treatment of COVID-19. Recently, Risambaf et al. raised various concerns related to side effects of both chloroquine and hydroxychloroquine for the treatment of COVID-19. Recent report also revealed that long-time use of chloroquine and hydroxychloroquine developed various toxicity effects including renal failure, cardiotoxicity, autoimmune disorders, etc.. The latest study of hydroxychloroquine in combination with azithromycin also did not show clinical benefits to the patients of COVID-19. Therefore, more randomized controlled trials with higher number of participants are needed for further evaluation of chloroquine and hydroxychloroquine for the treatment of COVID-19.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>25800</offset><text>Monoclonal Antibodies</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>25822</offset><text>Monoclonal antibodies specific to a viral protein are alternative treatment options for viral disease. During the last decade, several targeted monoclonal antibodies were developed for the SARS-CoV spike protein to inhibit the viral fusion inside the host cells. For example, CR3014 and CR3022 are two SARS-CoV neutralizing monoclonal antibodies, which bind to the receptor-binding domain (RBD) of the SARS-CoV spike protein to neutralize the virus. Among these, CR3022 was also found to bind with the SARS-CoV-2 RBD, and it might be a possible therapeutic option for the treatment of COVID-19 disease. Recently, researchers have cloned two human anti-SARS-CoV-2 RBD-hACE2 blocking monoclonal antibodies (mAbs) from SARS-CoV-2 RBD-specific memory B cells of recovered COVID-19 patient. The authors found that these two mAbs are capable of blocking the interaction between the ACE2 receptor and SARS-CoV-2 RBD leading to neutralization of the SARS-CoV-2 spike protein. Such mAbs could be promising therapeutic agents against the SARS-CoV-2 infection. Molecular imprinting is a potent modern technology for the development of so-called monoclonal-type plastic antibodies (MTPA) based on molecularly imprinted polymers (MIPs). These polymeric materials possess specific recognition properties for target molecules (templates). Some of such MTPAs were developed to target RBD of coronaviruses preventing infection of targeted cells.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>27251</offset><text>Antiviral Vaccines</text></passage><passage><infon key=\"file\">12248_2020_532_Fig4_HTML.jpg</infon><infon key=\"id\">Fig4</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>27270</offset><text>Acute Immune responses to coronaviruses. Coronaviruses are RNA viruses, some of which can infect human lung epithelium via the receptor ACE2. After endocytosis, viral RNA activates endosomal and cytoplasmic sensors, TLR3/7 and MAVS, respectively. These receptors activate interferon regulatory factors (IRFs) and NFkB to induce inflammatory cytokines, including interferons (IFNs). Dendritic cells (DCs) sample antigen and migrate to lymphoid organs to prime adaptive immunity. CD8 T cells recognize of antigen on DCs or infected cells and induce apoptosis in affected lung epithelial cells </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>27862</offset><text>Glycosylated spike protein is a major inducer of host immune response after infection of human lung epithelium cells via the receptor ACE2 (Fig.Â 4, step 1). After endocytosis (Fig. 4, step 2), viral RNA activates endosomal and cytoplasmic sensors, TLR3/7, and MAVS, respectively (Fig. 4, step 3). These receptors activate interferon regulatory factors (IRFs) and nuclear factor kappa B (NFkB) (Fig. 4, step 4) to induce inflammatory cytokines (Fig. 4, step 5), including interferons (IFNs). Dendritic cells (DCs) sample antigen and migrate to lymphoid organs to prime adaptive immunity. CD8 T cells recognize antigen on DCs or infected cells (Fig. 4, step 6) and induce apoptosis in affected lung epithelial cells (Fig. 4, step 7).</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>28595</offset><text>Vaccines are biological preparations that, when administered to an individual, stimulate the production of antibodies and provide immunity against one or several specific entities that can cause a disease, such as viruses or bacteria. Vaccines are prepared from the essential agent of a disease, its products, or a synthetic substitute, which are specifically prepared to act as an antigen without inducing the disease. Vaccines prime the immune system creating a form of memory allowing an individual to respond faster and with higher extent to a threat when compared with the first time response. Proteins, nucleic acids (DNA and RNA), or even entire organisms can be used for vaccination often in combination with adjuvants that can boost their potency. Vaccines, in contrast to most therapeutic drugs, are most commonly used for prophylactics of infection or disease. Therapeutic drugs directly affect the disease or, similar to vaccines, modulate the immune system increasing its power to fight the current incident of disease. However, therapeutic drugs usually provide no form of âmemoryâ that can help the organism to fight against the repetition of similar infection or disease. From an individual point of view, the goal of vaccination is to prevent or modify disease. From a public health perspective, the goal of vaccination is to limit the spread of a pathogen within a population. If successful, personal defense and epidemic control lead to the complete elimination or extermination of the pathogen. Biological challenges including limiting efficacy, considerable variation in the immune response, antibody, and cellular immune marker levels among individuals, technical, operational, or logistical obstacles and social, ethical, religious, and political issues represent major factors that determine vaccine effectiveness.</text></passage><passage><infon key=\"file\">12248_2020_532_Fig5_HTML.jpg</infon><infon key=\"id\">Fig5</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>30438</offset><text>Common components of vaccines. Vaccines include various components such as active ingredients, adjuvants, antibiotics, stabilizers, preservatives, and traces of residual inactivating agents as schematically shown here</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>30656</offset><text>In general, vaccines contain several main components (Fig.Â 5). Antigen or active component is a major ingredient of a vaccine that induces an immune response against a disease or infection and triggers the development of âmemoryâ in the immune system helping to fight against the next exposure to the threat. Antigens usually consist of altered forms of the virus, bacteria, toxin, and protein of genetic material that directly stimulate the immune system of an individual but do not cause the disease or produce weakened light symptoms of the illness. Each form of antigen has its own advantages and disadvantages. For instance, viral vectors (both replication-competent and replication-defective) usually induce good humoral and T cell responses and can be simply prepared from a virus culture but also may be reversed to virulence. Virus-like particles are usually safe and also induce good immune response. However, the cost of their production may be high and requires a relatively complex multistep procedure. Naked and encapsulated to nanoparticles nucleic acid and synthetic peptides are pretty safe but produce lower immune responses or uncertain immunogenicity linked to target populations. Inactivated viruses and self-disseminating wildlife vaccines are usually safe but demonstrate questionable (but sometimes effective) immunogenicity and may lead to the development of virulence.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>32056</offset><text>Adjuvants are used for enhancing the immune response of the body. Aluminum salts are the most often used adjuvants. Precise mechanisms of action of adjuvants are still remaining unknown. Antibiotics are often used to prevent bacterial contamination of vaccines. Sugars, amino acids, and proteins are added to vaccines in order to protect them during the storage and preserve their efficiency. Preservatives are used to protect vaccines from bacterial or fungal contaminations after their manufacturing. The mercury-containing thiomersal is the most often used compound especially for vaccines that need to be injected several times from the same rubber-capped vessel. Phenol and phenoxyethanol are also used as vaccine preservatives. A number of trace components (e.g., formaldehyde used to inactivate viruses) are usually present in the vaccines in very low concentrations.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_3</infon><offset>32931</offset><text>Repurposed Live Vaccines</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>32956</offset><text>Currently, 3 known repurposed vaccines are in phase 4 clinical trials: the oral polio, measles-mumps-rubella, and bacille Calmette-Guerin vaccines. The aim of phase IV clinical trials (also known as post-marketing surveillance) is at watching for the long-term effects of the drugs on a large population. Due to the longer term and larger subset of individuals using the therapeutic, extremely rare side effects can be observed.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>33385</offset><text>The oral polio vaccine is an attenuated strain of the poliomyelitis virus. It is produced by the passage of the virus through non-human cells at low temperatures. Such passage produces random mutations in the virus and attenuates it. Studies have shown that this vaccine may possess non-specific actions, reducing morbidity and mortality under other infections. It is being tested to determine whether this vaccine will be effective against SARS-CoV-2.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_4</infon><offset>33838</offset><text>MMR</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>33842</offset><text>Measles, mumps, and rubella are viral diseases with serious consequences. The measles-mumps-rubella (MMR) vaccine consists of live-attenuated strains of these viruses and was shown to prevent these diseases (especially in children). It was suggested that MMR as well as possible other live vaccines may be useful in the prevention of other viral diseases including COVID-19. One explanation of such effect suggests that antibodies formed in a response to the MMS or other live vaccines may be cross-reactive with SARS-CoV-2. Thus, vaccination with the MMR vaccine potentially may protect against COVID-19.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_4</infon><offset>34448</offset><text>BCG</text></passage><passage><infon key=\"file\">12248_2020_532_Fig6_HTML.jpg</infon><infon key=\"id\">Fig6</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>34452</offset><text>Clinical phase vaccine candidates for COVID-19 (as of April, 2020). Based on data from </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>34540</offset><text>The bacille Calmette-Guerin vaccine is another live-attenuated vaccine consisting of the bacteria that causes bovine tuberculosis (Mycobacterium bovis). Remarkably, bacille Calmette-Guerin (BCG) vaccination seems to demonstrate non-specific protective effects against other respiratory tract infections. The analysis has shown that countries with high coverage of BCG have a low death rate from COVID-19. Consequently, this vaccine was repurposed for the prevention of COVID-19 infections. Below, we are providing examples of several other vaccines of different types that currently are tested in clinical trials against coronaviruses (Fig.Â 6).</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>35186</offset><text>A common live vaccine (that protects against polio, MMR, BCG, etc.) could help in limiting the disease severity in patients with COVID-19. The first line of defense against any infection is the patientâs ability of own immune system to fight infection in a nonspecific way (i.e., innate immune response). The possible mechanism of action of these repurposed common vaccines against the SARS-CoV-2 infection may involve boosting patientâs own immune response. The repurposed common vaccines may benefit the immune system in a nonspecific wayâthereby helping it to fight against the SARS-CoV-2 infection in an indirect way through innate immune response. Thus, repurposing common live vaccines might be a low-risk and high-reward strategy to save lives from the SARS-CoV-2 infection.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_3</infon><offset>35974</offset><text>Clinical Phase Vaccine Candidates for COVID-19</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>36021</offset><text>Most of the vaccines are based on the injection of a genetic material encoding glycosylated spike (S) proteinâa major inducer of host immune response. They differ in the type of nucleic acid used and the delivery approach. Moderna (mRNA-1273) represents an mRNA encoding S protein encapsulated into lipid nanoparticles. Preliminary data showed that the mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, which granted further clinical trials. Two other vaccines are also based on the immunization with S protein, namely, Inovio Pharma (INO-4800) and CanSino Biologics (Ad5-nCoV) which use electroporation of a DNA plasmid encoding S protein and adenovirus type 5 vector that expresses S protein, respectively. These vaccines demonstrated promising results in experiments in vivo and in vitro and now entered clinical trials. Two other anti-COVID-19 vaccines were developed by the Shenzhen Medical Institute (LV-SMENP-DC) and Sinovac Biotech and are based on lentiviral vector modification of dendritic cells combined with antigen-specific cytotoxic T lymphocytes and inactivated SARS-CoV-2 clinical strain, respectively. The NVX-CoV2373 (clinical trial number NCT04368988) vaccine utilizes nanoparticles to deliver SARS-CoV-2 spike protein via intramuscular route. The purified full-length spike (S) proteins form small nanoparticles that are thermostable and bind with high affinity to the human ACE2 receptor. These nanoparticles are used in combination with a saponin-based Matrix M adjuvant which stimulate the entry of nanoparticles into the injection site and enhance antigen presentation in the local lymph nodes. COVID-19 vaccine candidates V591 (clinical trial number NCT04498247) and TMV-083 (clinical trial number NCT04497298) employ an attenuated measle virus as a vector to coronavirus proteins. LY3819253 virus candidate (clinical trial numbers NCT04411628, NCT04427501, NCT04497987, NCT04501978) represents an IgG1 monoclonal antibody against the COVID-19 spike protein. This protein was isolated from one of the first COVID-19 patients in North America.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>38122</offset><text>Convalescent Plasma Therapy</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>38150</offset><text>Convalescent plasma therapy is one of the investigational treatments for COVID-19 disease. Convalescent plasma therapy, in which the antiviral antibodies produced in the plasma from the recovered patient are injected in the patient, has shown promising results in various viral diseases such as H5N1 influenza and Ebola viral disease (EVD). Convalescent plasma containing neutralizing antibodies against the SARS-CoV-2 virus is collected from the recovered patient and administered to the COVID-19 patients in order to increase the power of immune system or to boost patientâs immune response for the virus immediately after the infection. Shen et al. observed that convalescent plasma therapy improved the severe cases of COVID-19. Clinical trial was also conducted in several countries to evaluate the recovery rate of COVID-19 patients after such a therapy. Convalescent plasma therapy could be a therapeutic option for the SARS-CoV-2 infection. As per the guidelines given by the US-FDA (United States-Food and Drug Administration), only COVID-19 survivors who were tested negative in nasopharyngeal swab test or molecular diagnostic test twice with no clinical symptoms at least 28Â days from discharge can donate convalescent plasma to the COVID-19 patients. It should be however stressed, which based on the nature of convalescent treatment, it should be most effective in the early stage of infection before a significant damage of organs.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>39600</offset><text>Immunotherapy</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>39614</offset><text>While the induction of immune response is essential for fighting against the coronavirus infection, in some patients, disease progression leads to an enormous secretion of cytokines, known as cytokine storm. This hyperreaction often leads to the inflammation, lung damage, and finally may cause acute respiratory distress syndrome (ARDS) and even the development of pulmonary fibrosis. If that is the case, treatment of the coronavirus infection by antiviral therapy alone may not be sufficient to effectively fight viral infections and associated pathologic conditions. Consequently, in some cases, anti-inflammatory treatment or even the suppression of overactive immune response might be beneficial. The suppression of pro-inflammatory signaling pathways by monoclonal antibodies (tocilizumab, sirukumab, olokizumab, clazakizumab, etc.) as well as other inhibitors of inflammatory pathways (like baricitinib and ruxolitinib, which also inhibits clathrin-mediated endocytosis and therefore suppresses penetration of viruses into cells preventing infection) may be (and in some cases were) beneficiary on the advanced stages of COVID-19. Dapsone, colchicine, and olanzapine were also suggested for the prevention of COVID-19-associated ARDS.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>40857</offset><text>Computer-Aided Design of Antiviral Therapeutics</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>40905</offset><text>Target-based drug design is a new strategy in modern drug discovery research. By exploiting computational tools, researchers have recently attempted to predict and design small molecule, peptide-based antiviral agents against various targets of SARS-CoV-2 viral disease. We have summarized a few of such computer-aided and target-based prediction and design of antiviral agents for COVID-19.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_3</infon><offset>41297</offset><text>RdRp</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>41302</offset><text>RNA-dependent-RNA polymerase (RdRp) is an essential component for virus replication process. Therefore, inhibiting the function of RdRp could be beneficial for reducing the replication of SARS-CoV-2 virus. Recently, Zhang et al. reported binding interaction of three clinically used antiviral drugs as RdRp inhibitor, namely, galidesivir, favipiravir, and penciclovir which were also under clinical trial for COVID-19 disease. The interactome profile of these drugs with the RdRp protein provides information regarding the structure-based design of inhibitors for SARS-CoV-2 inhibition.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_3</infon><offset>41889</offset><text>3CLpro</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>41896</offset><text>The viral 3-chymotrypsin-like cysteine protease (3CLpro) enzyme which controls replication of the SARS-CoV virus is a potential target for an antiviral therapy. Because of similar genome sequence of SARS-CoV-2 and that of SARS-CoV, 3CLpro can be a target for SARS-CoV-2 virus. Recently, researchers have exploited the computer-aided drug design (CADD) approach to identify repurposing drug candidate for COVID-19. For example, Wang et al. performed virtual screening of a series of known drugs against the active site of key viral proteins of SARS-CoV-2 virus and identified several drugs including lopinavir, carfilzomib, elbasvir, valrubicin, and eravacycline as predicted inhibitors of SARS-CoV-2 protease enzyme. This technique can quickly predict repurposing drug candidates, and further design of novel inhibitors for SARS-CoV-2 protease can be directed based on the structure of these predicted drugs.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_3</infon><offset>42805</offset><text>ACE2</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>42810</offset><text>It is known that SARS-CoV-2 virus is fused inside the host cell through angiotensin-converting enzyme II (ACE2) receptor, which was also found as host cell receptor for previous SARS-CoV virus. Receptor-binding domain (RBD) of spike (S) protein is a ligand on the surface of SARS-CoV-2 (corona) that binds to the ACE2 receptor facilitating the receptor-mediated endocytosis of the virus inside the host cell (Fig. 3a). The CR3022, a known SARS-CoV neutralizing monoclonal antibody with the receptor-binding domains (RBD) of the SARSCoV-2 spike protein can bind the SARS-CoV-2 spike protein. The crystal structure of âSARS-CoV-2 spike protein-ACE2â made it easier to design new therapeutics for ACE2. In a recent work, Penteluteâs group have designed a new 23-mer peptide mimic which showed Kd value of 47Â nM, against the S-spike protein and 7Â nM for full-length ACE2 protein. Such computer-designed peptide-based therapeutic can be a promising candidate for the treatment of COVID-19 disease.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_3</infon><offset>43811</offset><text>Endopeptidase of SARS-CoV-2 Virus</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>43845</offset><text>Lopinavir and/or ritonavir which are alone or in combination showed activity against the replication of human immunodeficiency virus (HIV). In earlier studies, both of lopinavir and ritonavir and their combination treatment showed therapeutic benefits in patients with SARS-CoV. In a recent computational study, both lopinavir and ritonavir were found to bind with the endopeptidase of SARS-CoV-2 virus indicating that these drugs might also show activity against the SARS-CoV-2 virus which has a similar feature with the SARS-CoV virus.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>44383</offset><text>Nanotechnology-Based Drug Delivery</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_3</infon><offset>44418</offset><text>Nanotherapeutics</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>44435</offset><text>Nanomaterial-based technologies have opened an emerging field in the past decade in drug delivery research, where nanosized materials and methods have been exploited for both disease diagnosis and therapeutics applications. In recent years, researchers have also explored various nanoscale materials for effective delivery of antiviral drugs. Nano-based drug delivery systems and methods have been evaluated for the previous coronavirus diseases SARS-CoV and MERS-CoV. For example, Coleman et al. prepared spike nanoparticles and tested them with combination of adjuvants in mice bearing SARS-CoV and MERS-CoV infection separately. The authors observed production of high titer antibodies in mice against these viral infections. These results indicated that the spike nanoparticles could neutralize the antibody response in mice. Such nano-based spike nanoparticle can be a promising option for nanovaccine against coronavirus infections. Huang et al. developed a gold nanorod system composed of a peptide inhibitor specific to heptad repeat 1 (HR1) receptor for the treatment of MERS-CoV disease. The authors reported 10-fold higher inhibition of HR1-/HR2-mediated membrane fusion of MERS-CoV virus in the host cells as compared with the inhibitor treatment alone. Such gold nanorod-based system can be effective in treating MERS-CoV and other coronavirus infections. In 2013, Li et al. demonstrated that RNA interference (RNAi) can mediate antiviral immunity in mammals. Since SARS-CoV, MERS-CoV, and SARS-CoV-2 coronaviruses are RNA viruses; therefore, small interfering RNA (siRNA) might be an effective therapy to inhibit the growth of such RNA viruses through silencing their viral gene activity. Currently, there is no nanoparticle-based therapeutics for the treatment of COVID-19; however, research and development of nanotherapeutics for COVID-19 are in progress. Nanomedicine approaches based on the reformulation of known antiviral drugs could be a promising therapeutic option for COVID-19 disease.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_3</infon><offset>46446</offset><text>Inhalation Delivery for Treatment of ARDS</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>46488</offset><text>Treatment of virus-associated ARDS and the prevention of the development of lung inflammation and pulmonary fibrosis seems to be a valuable therapeutic approach that can supplement and enhance antiviral treatment and potentially improve the overall outcome. Furthermore, any treatment of lung injury should be performed via local intrapulmonary delivery of drugs. Inhalation or intratracheal delivery of anti-inflammatory drugs, antioxidants, hormones, or other biologically active substances specifically to the lungs or even only to the deceased cells has a potential to enhance the treatment of main lung injury, to the certain extent prevent drug penetration into the systemic circulation and therefore limit possible adverse side effects upon healthy organs and tissues. Previously, we proposed, developed, and tested on animal models inhalation and intratracheal treatment of severe hypoxia associated with lung edema, idiopathic pulmonary fibrosis, and lung manifestations of cystic fibrosis by nanocarrier-based therapeutics including alpha-tocopherol, prostaglandin E2 alone, or in combination with siRNAs for the suppression of inflammation and lung injury and other drugs. We suggested that such treatment approaches may be also successfully used for prevention and treatment lung hypoxia, inflammation, and cystic and pulmonary fibrosis associated with COVID-19.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_3</infon><offset>47863</offset><text>Combinatorial Nanotechnology-Based Treatment</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>47908</offset><text>Various latest therapeutic approaches such as broad-spectrum antiviral therapeutics instead of single target antiviral drug, combination therapy of antiviral drugs with antibiotics, and nano-encapsulated antiviral drugs and vaccines have displayed promising results for the treatment of COVID-19. Similarly, to other diseases, a combinational therapy of COVID-19 should be based on the simultaneous use of agents with different mechanisms of action. A combination of two or more drugs with significant activity and various therapeutic mechanisms potentially can provide a summary effect that is higher than just the arithmetical sum of their individual activities (drug synergy). Such synergy may be achieved by applying drugs targeting the same cellular or viral system (otherwise different parts of it) or by combining a drug which target a major disease (in our case the virus) and other active components that influence bioavailability, degradation, excretion, or resistance to the treatment. In addition, this multifunctional combinatorial treatment should be applied specifically to the targeted deceased cells leaving bystander healthy cells intact. Previously, we successfully applied this approach for the treatment of cancer by developing a targeted complex multifunctional proapoptotic anticancer drug delivery system by combining in one cancer-specific-targeted drug delivery system an inducer of cell death with suppressors of pump and non-pump resistance. Although, the targeting ligands for COVID-19 virus particles or infected lung cells are not discovered yet, targeting to the lungs as a primary site of action of the virus can be achieved by the local inhalation delivery of antiviral agent specifically to the lungs. Moreover, by using nanoparticle-based therapeutics, it is possible to combine in one complex delivery system antiviral drugs with drugs targeted to ARDS and therefore enhance the treatment of primary viral infections and secondary lung injury associated with COVID-19. Currently, we are testing this hypothesis in our laboratory.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>49975</offset><text>COVID-19: DIAGNOSTIC APPROACHES</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>50007</offset><text>Diagnostic tests are essential for monitoring and prognosis of every stage of a disease. Since the report of SARS-CoV-2 infection in December 2019, various assay kits and tests have been developed for the diagnosis of COVID-19. Current commercially available COVID-19 test is mostly dominant on the molecular genetic assays for detection of viral RNA from a clinical sample of SARS-CoV-2 infection using reverse transcription-polymerase chain reaction (RT-PCR) method. However, other techniques such as isothermal nucleic acid amplification assays, serological and immunological assays for anti-SARS-CoV-2 antibody, hybridization microarray assays, and chest CT scan are also promising for diagnosis of COVID-19. Identification of the asymptomatic cases remains the main challenge to prevent the spread of SARS-CoV-2 infection. Therefore, development of accurate and rapid testing methods is required to prevent asymptomatic spread of SARS-CoV-2 infection. Researchers around the world have been developing various diagnostic methods because of current demand of cost-effective and point-of-contact test for the confirmation of SARS-CoV-2 infection. Here, we have summarized recent progresses on diagnostic methods for COVID-19 disease.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>51244</offset><text>PCR-Based Test</text></passage><passage><infon key=\"file\">12248_2020_532_Fig7_HTML.jpg</infon><infon key=\"id\">Fig7</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>51259</offset><text>A typical procedure of COVID-19 diagnostics through RT-PCR. The RT-PCR method involves sample collection and extraction of viral RNA sample. The extracted RNA sample is converted to its complementary DNA (cDNA) by the reverse transcription. Finally, the amplification of this DNA sample is performed in qPCR, and the viral cDNA is detected by a fluorescent signal</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>51623</offset><text>Currently, the reverse transcription-polymerase chain reaction (RT-PCR) is the gold standard test for the diagnosis of COVID-19. Mostly nasal swab and ocular secretions samples are being used in the TR-PCR test. Self-collected saliva sample was also explored by the researcher from the Rutgers Clinical Genomics Laboratory. Saliva sample collection is not only easy and quicker, but also, it has less risk to the healthcare personnel. Figure 7 shows stepwise procedure of the RT-PCR test for the detection of viral genome from the clinical sample. As shown in the figure, the RT-PCR test involves isolation of viral RNA from the clinical sample followed by generation of complementary DNA (cDNA) by RNA-dependent DNA polymerase reaction. Next, cDNA is converted to double-stranded DNA (dsDNA) through PCR amplification, and the amplification of this DNA sample is performed until the viral cDNA is detected by a fluorescent or electrical signal. The key concept of the fluorescence detection in quantitative fluorescence PCR is shown in the insert of Fig.Â 7. A substance marked with a fluorophore is added to the PCR mixture containing a DNA template, specific primer(s), deoxyribonucleotides, and a thermostable DNA polymerase in a suitable buffer solution. The fluorescence of the dye is suppressed by the quencher. After the cleavage of the fluorophore from a quencher by the polymerase, free dye emits fluorescence signal which is registered by a corresponding sensor in a thermal cycler. Each PCR cycle includes several required specific steps initiated by rapid changes in the temperature regimen. After initiation with a template DNA (Fig. 7, step A), the increase of temperature to 95Â°C causes the denaturation of double-stranded DNA leading to the separation of sense and antisense strands of the template (Fig. 7, step B). Rapid change of temperature to the most suitable value (usually 50â60Â°C) causes the annealing of primers and fluorophore-bound reporter probes to the corresponding strands of the template (Fig. 7, step C). Finally (Fig. 7, step D), polymerase extends both strands of the template and cleaves the fluorophore out of its quencher causing the emission of the signal. Each step leads to doubling template strands (or their short fragments after few initial steps). Totally, around 25â50Â cycles are used allowing semi-quantitative or even quantitative (in number of copies) detection of the template DNA (in our case generated by coronavirus RNA during the reverse transcription). The RT-PCR test needs multiple temperature changes in each cycle, laborious instrumental work, and days to get the results. Therefore, there is an urgent need for rapid and cost-effective diagnostic methods, which can detect directly the presence of SARS-CoV-2 virus in clinical samples. Isothermal nucleic acid amplification which needs no change of temperature for each cycle is an easier technique for the detection of SARS-CoV-2 infection. Using constant temperature amplification method, Park et al. developed reverse transcription loop-mediated isothermal amplification (RT-LAMP) test for SARS-CoV-2 virus. Besides, researchers around the world are improving the sensitivity and timelines of the RT-PCR-based method. Seo et al. reported a field-effect transistor (FET)-based biosensor for quick detection of SARS-CoV-2 infection in patient samples. The main advantage of this highly sensitive biosensor device is that this method does not need any labeling of sample for the analysis. The authors prepared this biosensor by decorating the graphene sheets of the FET with an anti-SARS-CoV-2 antibody and evaluated its performance using cultured SARS-CoV-2 virus and swab specimens of COVID-19 patients. This EFT biosensor was capable of detecting SARS-CoV-2 spike protein at a very low concentration such as 1Â fg/mL in phosphate-buffered saline, clinical samples, and cultured sample of SARS-CoV-2 virusâmaking it an extremely sensitive diagnostic method for SARS-CoV-2 infection. In another attempt, Wang et al. designed a novel one-step single-tube nested quantitative real-time PCR (OSN-qRT-PCR) method for the rapid detection of SARS-CoV-2 pathogen in clinical samples. The authors evaluated clinical performance of the OSN-qRT-PCR assay using several clinical samples and observed that this assay kit was capable of detecting SARS-CoV-2 virus in clinical sample with low viral load thereby making it more sensitive than the other qRT-PCR methods. This OSN-qRT-PCR assay could be a promising tool for the diagnosis of COVID-19.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>56180</offset><text>Serological Test</text></passage><passage><infon key=\"file\">12248_2020_532_Fig8_HTML.jpg</infon><infon key=\"id\">Fig8</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>56197</offset><text>Assay techniques and tests for COVID-19 diagnosis. a, b The enzyme-linked immunosorbent assays (ELISA) detecting COVID-19 antibodies (a) or antigens (b). Redrawn with permission from. c Serologic diagnostic tests for COVID-19 antibodies</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>56434</offset><text>Serological test which involves analysis of blood serum or biological fluids to identify the presence of certain biomarkers such as antibody is generally used to monitor the progress of the disease. Various serological tests such as enzyme-linked immunosorbent assay (ELISA) have been explored to identify the people who have developed antibodies against SARS-CoV-2 virus infection. Recently, the FDA also authorized for a lateral flow serological immunoassay, namely, qSARS-CoV-2 IgG/IgM rapid test, manufactured by Cellex Inc.. A schematic illustration of ELISA-based serological tests is shown in Fig.Â 8. Two types of ELISA immunoassays are developed: detecting of COVID-19 antigens or antibodies against virus antigens. These assays are similar and differ in coating of a microwell plate. When it is coated with antigens, it is used for the detection of antibodies generated against the virus. Vice versa, coating with antivirus antibodies allows for the detection of the viral antigens. As shown in this figure, first, the patient sample containing the viral antigens is added to the anti-SARS-CoV-2 antibody-coated microwell plate, followed by addition of an enzyme-labeled detection antibody. At the end, a substrate suitable for the enzyme of the detection antibody is added to produce a colorimetric signal, which can be measured using a plate reader.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>57796</offset><text>Nanoparticle-Based Serological Tests</text></passage><passage><infon key=\"file\">Tab2.xml</infon><infon key=\"id\">Tab2</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>57833</offset><text>A List of Current Diagnostic Approaches for COVID-19</text></passage><passage><infon key=\"file\">Tab2.xml</infon><infon key=\"id\">Tab2</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th&gt;Diagnostic method&lt;/th&gt;&lt;th&gt;Aim&lt;/th&gt;&lt;th&gt;Variants&lt;/th&gt;&lt;th&gt;References&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td rowspan=&quot;4&quot;&gt;Detection of the virus&lt;/td&gt;&lt;td rowspan=&quot;4&quot;&gt;To detect whether a person is currently infected with SARS-CoV-2 virus&lt;/td&gt;&lt;td&gt;RT-PCR-based detection&lt;/td&gt;&lt;td&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR172&quot;&gt;172&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;RT-LAMP-based detection&lt;/td&gt;&lt;td&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR173&quot;&gt;173&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;CRISPR-based detection&lt;/td&gt;&lt;td&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR174&quot;&gt;174&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;ELISA for detecting SARS-CoV-2 antigens&lt;/td&gt;&lt;td&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR155&quot;&gt;155&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;Antibody tests&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;To detect whether a person had SARS-CoV-2 infection in the past&lt;/td&gt;&lt;td&gt;Serologic anti-SARS-CoV-2 Immunoglobulin M (IgM) and immunoglobulin G (IgG), detection&lt;/td&gt;&lt;td&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR165&quot;&gt;165&lt;/xref&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR175&quot;&gt;175&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Nanoparticle-based lateral-flow assay&lt;/td&gt;&lt;td&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR170&quot;&gt;170&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Indirect ELISA for detecting anti-SARS-CoV-2 antibodies&lt;/td&gt;&lt;td&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR155&quot;&gt;155&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;3&quot;&gt;Imaging method&lt;/td&gt;&lt;td rowspan=&quot;3&quot;&gt;To detect ground-glass opacity spots in the lungs with a peripheral or posterior distribution as a sign of COVID-19&lt;/td&gt;&lt;td&gt;Chest X-ray imaging&lt;/td&gt;&lt;td&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR176&quot;&gt;176&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Chest CT scan&lt;/td&gt;&lt;td&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR177&quot;&gt;177&lt;/xref&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR178&quot;&gt;178&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;Lung ultrasound imaging&lt;/td&gt;&lt;td&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR179&quot;&gt;179&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>57886</offset><text>Diagnostic method\tAim\tVariants\tReferences\t \tDetection of the virus\tTo detect whether a person is currently infected with SARS-CoV-2 virus\tRT-PCR-based detection\t\t \tRT-LAMP-based detection\t\t \tCRISPR-based detection\t\t \tELISA for detecting SARS-CoV-2 antigens\t\t \tAntibody tests\tTo detect whether a person had SARS-CoV-2 infection in the past\tSerologic anti-SARS-CoV-2 Immunoglobulin M (IgM) and immunoglobulin G (IgG), detection\t\t \tNanoparticle-based lateral-flow assay\t\t \tIndirect ELISA for detecting anti-SARS-CoV-2 antibodies\t\t \tImaging method\tTo detect ground-glass opacity spots in the lungs with a peripheral or posterior distribution as a sign of COVID-19\tChest X-ray imaging\t\t \tChest CT scan\t\t \tLung ultrasound imaging\t\t \t</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>58614</offset><text>Nanoparticle-based colorimetric bioassays have been growing rapidly in recent years as a promising diagnosis tool for many diseases mainly due to simple instrumentations and visual output of the nano-based diagnostic tools. Because of localized surface plasmon resonance and inherent photostability properties, gold nanoparticles (AuNP)âbased colorimetric bioassays have received significant attention in the development of image-based diagnostics. Recently, researchers have also explored AuNPs for possible diagnosis of COVID-19 disease. For example, Huang et al. prepared a gold nanoparticleâbased lateral-flow (AuNP-LF) system made of various easily available inorganic nanomaterials. This AuNP-LF system can detect the IgM antibody developed in serum sample of a patient against the SARS-CoV-2 viral pathogen. The detection AuNP-LF strip was prepared by coating the SARS-CoV-2 nucleoprotein as antigen followed by conjugating antihuman IgM antibody. This AuNP-LF strip system could detect the SARS-CoV-2 virus in clinical samples within 15Â min. Therefore, this AuNP-LF-based tool has shown a great promise for fast detection of COVID-19 disease. A general scheme of rapid serological assay for the detection of both IgG and IgM antibodies against COVID-19 virus is presented in Fig. 8c. A small blood sample is loaded into a test strip followed by the addition of the reaction buffer. A sample is incubated allowing the gold COVID-19 antigen conjugates to react with IgG-/IgM-labeled antibodies. Antirabbit antibodies conjugated with similar labeled gold nanoparticles are used for the detection of control antirabbit IgG antibodies. The test is considered positive when two lines (for COVID-19 and control antibodies) are visualized. If only the control line is detected, the result is defined as negative. When no control line is shown, the test is considered invalid. Moitra et al. prepared gold nanoparticle (AuNP)âbased sensor for naked-eye detection of SARS-CoV-2 virus in the clinical samples. The authors coated the surface of the AuNP with thiol-conjugated antisense oligonucleotides (ASOs) specific for the nucleocapsid phosphoprotein of SARS-CoV-2 virus. This AuNP system was capable of detecting the presence of SARS-CoV-2 viral stain within 10Â min. This naked-eye detection method includes clinical sample collection from COVID-19 patient followed by isolation of viral RNA, which is incubated with the antisense oligonucleotide (ASO)âcapped gold nanoparticles (AuNPs) for 5Â min. Next, RNase H is treated with the resulting viral composite of ASO-capped AuNPs for 5Â min at 65Â°C producing a visual precipitate from the solution. Such AuNP-based system can be a very convenient and cost-effective tool for visual detection of SARS-CoV-2 virus. Various current diagnostic approaches for COVID-19 have been summarized in Table II. Thus, nanotechnology-based methods have potential in the development of cost-effective, fast, and point-of-care detection of both of SARS-CoV-2 virus and the related biomarkers associated with this viral infection.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>61687</offset><text>CT Imaging</text></passage><passage><infon key=\"file\">12248_2020_532_Fig9_HTML.jpg</infon><infon key=\"id\">Fig9</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>61698</offset><text>Representative chest CT images. a Transverse chest CT images from a 40-year-old man showing bilateral multiple lobular and subsegmental areas of consolidation on day 15 after symptom onset. b Transverse chest CT images from a 53-year-old woman showing bilateral ground-glass opacity and subsegmental areas of consolidation on day 8 after symptom onset. c Transverse chest CT images showing bilateral ground-glass opacity on day 12 after symptom onset. Reproduced with permission from </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>62183</offset><text>Computed tomography (CT) scan was used as an early diagnosis tool for COVID-19 in many countries mostly due to lack of testing kits. Abnormal observations in the chest CT scan image were used as a diagnostic feature for COVID-19. Usually, both bilateral and peripheral ground-glass opacities were observed in chest CT scans of COVID-19 patients in the early stage of the disease, whereas irregular-shaped paving patterns were observed at the later stage of the disease. Figure 9 shows chest CT images of ICU patients with COVID-19 in various stage of the disease. Figure 9a shows typical appearance of bilateral multiple lobular and subsegmental areas in the chest CT images. Figure 9b shows both bilateral ground-glass opacity and subsegmental areas in the chest CT images of non-ICU patients with COVID-19, and Fig.Â 9c shows only the bilateral ground-glass opacity in the chest CT images at later stage of the disease.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">title_1</infon><offset>63105</offset><text>CONCLUSIONS</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>63117</offset><text>The newly emerged COVID-19 viral disease caused by the SARS-CoV-2 pathogen has not only created severe panic among the people but also challenged the social culture and healthcare infrastructure all over the world. In this review, we have discussed briefly the cause of the COVID-19 disease, its symptoms, and management, and then, we have summarized recent progress on the development of various therapeutic and diagnostic approaches for the prevention, treatment, and diagnosis of COVID-19. We presented a diverse range of therapeutics such as antiviral therapeutics (repurposing of small molecule drugs), adjunctive therapeutics (neutralizing antibody, convalescent plasma treatment, etc.), nanotherapeutics (nanoparticle-based therapeutics and vaccines), and computational aided drug discovery (computation-based methods to predict and design new drug candidate) for COVID-19. Because of similar genome sequence of SARS-CoV-2 virus with the previous SARS-CoV virus, both the therapeutics and management methods for SARS-CoV infection have also been investigated for the COVID-19 disease. We have also summarized various diagnostic approaches developed for detecting and fighting COVID-19. Both researchers and clinicians around the world have been working for the development of vaccines as well as clinical trials of existing repurposed antiviral drugs against SARS-CoV-2 virus. While significant efforts have been made in recent time in the development of novel therapeutic and diagnostic approaches for COVID-19 disease, still many questions and challenges such as degree of sensitivity and specificity of serological tests for the detection of anti-SARS-CoV-2 antibody in clinical sample, whether the presence of such antibodies can produce immunity to this coronavirus etc., remain to be addressed. Although few antiviral therapeutics such as remdesivir, umifenovir, favipiravir, and ribavirin were evaluated in clinical trials and showed some positive results, still more evidences are needed for their successful clinical use against this disease. To date, there is no clinically approved therapeutics and vaccines for COVID-19. Therefore, early diagnosis such as testing of symptomatic and asymptomatic individuals and their close contacts by contact tracing, quarantine of the infected individuals, and effective supportive treatment of SARS-CoV-2-infected individuals are the key to prevent additional transmission and control this disease until any clinically approved antiviral therapeutics and/or vaccines for COVID-19 is available in the market.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">footnote</infon><offset>65681</offset><text>Publisherâs Note</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">footnote</infon><offset>65700</offset><text>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</text></passage><passage><infon key=\"section_type\">ACK_FUND</infon><infon key=\"type\">title</infon><offset>65819</offset><text>Funding</text></passage><passage><infon key=\"section_type\">ACK_FUND</infon><infon key=\"type\">paragraph</infon><offset>65827</offset><text>This work was supported in part by grants (R01 CA238871 and R01 CA209818) from the National Institutes of Health (NIH).</text></passage><passage><infon key=\"section_type\">ACK_FUND</infon><infon key=\"type\">title</infon><offset>65947</offset><text>Compliance with Ethical Standards</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">title</infon><offset>65981</offset><text>Conflict of Interest</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">paragraph</infon><offset>66002</offset><text>The authors declare that they have no conflict of interest.</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">title</infon><offset>66062</offset><text>Abbreviations</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66076</offset><text>3CLpro</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66083</offset><text>3-chymotrypsin-like cysteine protease</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66121</offset><text>ACE2</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66126</offset><text>angiotensin-converting enzyme 2</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66158</offset><text>AOS</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66162</offset><text>antisense oligonucleotides</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66189</offset><text>ARDS</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66194</offset><text>acute respiratory distress syndrome</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66230</offset><text>AuNP</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66235</offset><text>gold nanoparticles</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66254</offset><text>AuNP-LF</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66262</offset><text>gold nanoparticle-lateral-flow</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66293</offset><text>BCG</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66297</offset><text>bacille Calmette-Guerin</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66321</offset><text>CADD</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66326</offset><text>computer-aided drug design</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66353</offset><text>cDNA</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66358</offset><text>complementary DNA</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66376</offset><text>COVID-19</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66385</offset><text>coronavirus diseases 2019</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66411</offset><text>CRISPR</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66418</offset><text>clustered regularly interspaced short palindromic repeats</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66476</offset><text>CT</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66479</offset><text>computed tomography</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66499</offset><text>ELISA</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66505</offset><text>enzyme-linked immunosorbent assay</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66539</offset><text>ER</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66542</offset><text>endoplasmic reticulum</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66564</offset><text>ERGIC</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66570</offset><text>endoplasmic reticulum-Golgi intermediate compartment</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66623</offset><text>EVD</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66627</offset><text>Ebola viral disease</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66647</offset><text>FDA</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66651</offset><text>Food and Drug Administration</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66680</offset><text>FET</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66684</offset><text>field-effect transistor</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66708</offset><text>HCQ</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66712</offset><text>hydroxychloroquine</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66731</offset><text>HIV</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66735</offset><text>human immunodeficiency virus</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66764</offset><text>HR1</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66768</offset><text>heptad repeat 1</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66784</offset><text>ICTV</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66789</offset><text>International Committee on Taxonomy of Viruses</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66836</offset><text>IFNs</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66841</offset><text>interferons</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66853</offset><text>IgG</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66857</offset><text>immunoglobulin G</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66874</offset><text>IgM</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66878</offset><text>immunoglobulin M</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66895</offset><text>IRFs</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66900</offset><text>interferon regulatory factors</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66930</offset><text>mAbs</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66935</offset><text>monoclonal antibodies</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66957</offset><text>MERS-CoV</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>66966</offset><text>Middle East respiratory syndrome coronavirus</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67011</offset><text>MIPs</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67016</offset><text>molecularly imprinted polymers</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67047</offset><text>MMR</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67051</offset><text>measles-mumps-rubella vaccine</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67081</offset><text>MTPA</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67086</offset><text>monoclonal-type plastic antibodies</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67121</offset><text>OSN-qRT-PCR</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67133</offset><text>one-step single-tube nested quantitative real-time PCR</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67188</offset><text>PCR</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67192</offset><text>polymerase chain reaction</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67218</offset><text>RBD</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67222</offset><text>receptor-binding domain</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67246</offset><text>RdRp</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67251</offset><text>RNA-dependent-RNA polymerase</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67280</offset><text>RSV</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67284</offset><text>respiratory syncytial virus</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67312</offset><text>RT-LAMP</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67320</offset><text>reverse transcription loop-mediated isothermal amplification</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67381</offset><text>RT-PCR</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67388</offset><text>reverse transcription-polymerase chain reaction</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67436</offset><text>SARS-CoV</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67445</offset><text>severe acute respiratory syndrome coronavirus</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67491</offset><text>SARS-CoV-2</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67502</offset><text>severe acute respiratory syndrome coronavirus 2</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67550</offset><text>siRNA</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67556</offset><text>small interfering RNA</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67578</offset><text>ss-RNA</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67585</offset><text>single-stranded RNA</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67605</offset><text>TEM</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67609</offset><text>transmission electron microscope</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67642</offset><text>WHO</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>67646</offset><text>World Health Organization</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">title</infon><offset>67672</offset><text>References</text></passage><passage><infon key=\"fpage\">660</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">694</infon><infon key=\"name_0\">surname:Cheng;given-names:VC</infon><infon key=\"name_1\">surname:Lau;given-names:SK</infon><infon key=\"name_2\">surname:Woo;given-names:PC</infon><infon key=\"name_3\">surname:Yuen;given-names:KY</infon><infon key=\"pub-id_doi\">10.1128/CMR.00023-07</infon><infon key=\"pub-id_pmid\">17934078</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2007</infon><offset>67683</offset><text>Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection</text></passage><passage><infon key=\"fpage\">4895</infon><infon key=\"issue\">31</infon><infon key=\"lpage\">4902</infon><infon key=\"name_0\">surname:Girard;given-names:MP</infon><infon key=\"name_1\">surname:Tam;given-names:JS</infon><infon key=\"name_2\">surname:Assossou;given-names:OM</infon><infon key=\"name_3\">surname:Kieny;given-names:MP</infon><infon key=\"pub-id_doi\">10.1016/j.vaccine.2010.05.031</infon><infon key=\"pub-id_pmid\">20553769</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Vaccine.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">28</infon><infon key=\"year\">2010</infon><offset>67778</offset><text>The 2009 a (H1N1) influenza virus pandemic: a review</text></passage><passage><infon key=\"fpage\">995</infon><infon key=\"issue\">9997</infon><infon key=\"lpage\">1007</infon><infon key=\"name_0\">surname:Zumla;given-names:A</infon><infon key=\"name_1\">surname:Hui;given-names:DS</infon><infon key=\"name_2\">surname:Perlman;given-names:S</infon><infon key=\"pub-id_doi\">10.1016/s0140-6736(15)60454-8</infon><infon key=\"pub-id_pmid\">26049252</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">386</infon><infon key=\"year\">2015</infon><offset>67831</offset><text>Middle East respiratory syndrome</text></passage><passage><infon key=\"fpage\">54</infon><infon key=\"lpage\">57</infon><infon key=\"name_0\">surname:Oleribe;given-names:OO</infon><infon key=\"name_1\">surname:Salako;given-names:BL</infon><infon key=\"name_2\">surname:Ka;given-names:MM</infon><infon key=\"name_3\">surname:Akpalu;given-names:A</infon><infon key=\"name_4\">surname:McConnochie;given-names:M</infon><infon key=\"name_5\">surname:Foster;given-names:M</infon><infon key=\"pub-id_doi\">10.7861/clinmedicine.15-1-54</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">15</infon><infon key=\"year\">2015</infon><offset>67864</offset><text>Ebola virus disease epidemic in West Africa: lessons learned and issues arising from West African countries</text></passage><passage><infon key=\"fpage\">e3025</infon><infon key=\"issue\">7</infon><infon key=\"name_0\">surname:Agumadu;given-names:VC</infon><infon key=\"name_1\">surname:Ramphul;given-names:K</infon><infon key=\"pub-id_doi\">10.7759/cureus.3025</infon><infon key=\"pub-id_pmid\">30254814</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cureus.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2018</infon><offset>67972</offset><text>Zika virus: a review of literature</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>68007</offset><text>World Health, Organization. Novel coronavirus (2019-nCoV): situation report, 1. Geneva: World Health Organization; 2020.Â https://apps.who.int/iris/handle/10665/330760. AccessedÂ 2020-01-21.</text></passage><passage><infon key=\"fpage\">536</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">544</infon><infon key=\"name_0\">surname:Gorbalenya;given-names:AE</infon><infon key=\"name_1\">surname:Baker;given-names:SC</infon><infon key=\"name_2\">surname:Baric;given-names:RS</infon><infon key=\"name_3\">surname:de Groot;given-names:RJ</infon><infon key=\"name_4\">surname:Drosten;given-names:C</infon><infon key=\"name_5\">surname:Gulyaeva;given-names:AA</infon><infon key=\"pub-id_doi\">10.1038/s41564-020-0695-z</infon><infon key=\"pub-id_pmid\">32123347</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>68198</offset><text>The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2</text></passage><passage><infon key=\"fpage\">200131e</infon><infon key=\"issue\">5</infon><infon key=\"pub-id_doi\">10.2807/1560-7917.ES.2020.25.5.200131e</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveil</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>68312</offset><text>Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>68455</offset><text>WHO. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health, Organization (WHO); 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virusthat-causes-it.</text></passage><passage><infon key=\"fpage\">157</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">160</infon><infon key=\"name_0\">surname:Cucinotta;given-names:D</infon><infon key=\"name_1\">surname:Vanelli;given-names:M</infon><infon key=\"pub-id_doi\">10.23750/abm.v91i1.9397</infon><infon key=\"pub-id_pmid\">32191675</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Acta Biomed</infon><infon key=\"type\">ref</infon><infon key=\"volume\">91(</infon><infon key=\"year\">2020</infon><offset>68728</offset><text>WHO declares COVID-19 a pandemic</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>68761</offset><text>Coronavirus disease (COVID-19) pandemic. World Health Organization; 2020 [cited 2020 10/31/2020]; Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=Cj0KCQjwlvT8BRDeARIsAACRFiW_AoKe8cr7J7MyGq46ojb4LEDnznIAUBkEXISSPxIfKCLbfmxjYgUaAriBEALw_wcB.</text></passage><passage><infon key=\"fpage\">1626</infon><infon key=\"issue\">7</infon><infon key=\"lpage\">1628</infon><infon key=\"name_0\">surname:Li;given-names:C</infon><infon key=\"name_1\">surname:Ji;given-names:F</infon><infon key=\"name_10\">surname:Yang;given-names:G</infon><infon key=\"name_11\">surname:Yang;given-names:J</infon><infon key=\"name_12\">surname:Yan;given-names:X</infon><infon key=\"name_13\">surname:Gu;given-names:B</infon><infon key=\"name_2\">surname:Wang;given-names:L</infon><infon key=\"name_3\">surname:Wang;given-names:L</infon><infon key=\"name_4\">surname:Hao;given-names:J</infon><infon key=\"name_5\">surname:Dai;given-names:M</infon><infon key=\"name_6\">surname:Liu;given-names:Y</infon><infon key=\"name_7\">surname:Pan;given-names:X</infon><infon key=\"name_8\">surname:Fu;given-names:J</infon><infon key=\"name_9\">surname:Li;given-names:L</infon><infon key=\"pub-id_doi\">10.3201/eid2607.200718</infon><infon key=\"pub-id_pmid\">32228809</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>69039</offset><text>Asymptomatic and human-to-human transmission of SARS-CoV-2 in a 2-family cluster, Xuzhou, China</text></passage><passage><infon key=\"fpage\">727</infon><infon key=\"issue\">8</infon><infon key=\"lpage\">733</infon><infon key=\"name_0\">surname:Zhu;given-names:N</infon><infon key=\"name_1\">surname:Zhang;given-names:D</infon><infon key=\"name_2\">surname:Wang;given-names:W</infon><infon key=\"name_3\">surname:Li;given-names:X</infon><infon key=\"name_4\">surname:Yang;given-names:B</infon><infon key=\"name_5\">surname:Song;given-names:J</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa2001017</infon><infon key=\"pub-id_pmid\">31978945</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>69135</offset><text>A novel coronavirus from patients with pneumonia in China, 2019</text></passage><passage><infon key=\"fpage\">490</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">502</infon><infon key=\"name_0\">surname:Su;given-names:S</infon><infon key=\"name_1\">surname:Wong;given-names:G</infon><infon key=\"name_2\">surname:Shi;given-names:W</infon><infon key=\"name_3\">surname:Liu;given-names:J</infon><infon key=\"name_4\">surname:Lai;given-names:ACK</infon><infon key=\"name_5\">surname:Zhou;given-names:J</infon><infon key=\"name_6\">surname:Liu;given-names:W</infon><infon key=\"name_7\">surname:Bi;given-names:Y</infon><infon key=\"name_8\">surname:Gao;given-names:GF</infon><infon key=\"pub-id_doi\">10.1016/j.tim.2016.03.003</infon><infon key=\"pub-id_pmid\">27012512</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Trends Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">24</infon><infon key=\"year\">2016</infon><offset>69199</offset><text>Epidemiology, genetic recombination, and pathogenesis of coronaviruses</text></passage><passage><infon key=\"fpage\">729</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">734</infon><infon key=\"name_0\">surname:Petrosillo;given-names:N</infon><infon key=\"name_1\">surname:Viceconte;given-names:G</infon><infon key=\"name_2\">surname:Ergonul;given-names:O</infon><infon key=\"name_3\">surname:Ippolito;given-names:G</infon><infon key=\"name_4\">surname:Petersen;given-names:E</infon><infon key=\"pub-id_doi\">10.1016/j.cmi.2020.03.026</infon><infon key=\"pub-id_pmid\">32234451</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>69270</offset><text>COVID-19, SARS and MERS: are they closely related?</text></passage><passage><infon key=\"fpage\">3822</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">3835</infon><infon key=\"name_0\">surname:Udugama;given-names:B</infon><infon key=\"name_1\">surname:Kadhiresan;given-names:P</infon><infon key=\"name_2\">surname:Kozlowski;given-names:HN</infon><infon key=\"name_3\">surname:Malekjahani;given-names:A</infon><infon key=\"name_4\">surname:Osborne;given-names:M</infon><infon key=\"name_5\">surname:Li;given-names:VYC</infon><infon key=\"pub-id_doi\">10.1021/acsnano.0c02624</infon><infon key=\"pub-id_pmid\">32223179</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Nano</infon><infon key=\"type\">ref</infon><infon key=\"volume\">14</infon><infon key=\"year\">2020</infon><offset>69321</offset><text>Diagnosing COVID-19: the disease and tools for detection</text></passage><passage><infon key=\"fpage\">e8871</infon><infon key=\"issue\">6</infon><infon key=\"name_0\">surname:Khan;given-names:I</infon><infon key=\"name_1\">surname:Ahmed;given-names:Z</infon><infon key=\"name_2\">surname:Sarwar;given-names:A</infon><infon key=\"name_3\">surname:Jamil;given-names:A</infon><infon key=\"name_4\">surname:Anwer;given-names:F</infon><infon key=\"pub-id_doi\">10.7759/cureus.8871</infon><infon key=\"pub-id_pmid\">32754408</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cureus.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>69378</offset><text>The potential vaccine component for COVID-19: a comprehensive review of global vaccine development efforts</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>69485</offset><text>Goldman-Israelow B. Coronavirus replication cycle (template). BioRender.com; 2020 [cited 2020 11/01/2020]; Available from: https://app.biorender.com/biorender-templates/figures/5e99f5395fd61e0028682c01/t-5e56d97d1b689000850f8f93-coronavirus-replication-cycle.</text></passage><passage><infon key=\"fpage\">m606</infon><infon key=\"name_0\">surname:Xu;given-names:XW</infon><infon key=\"name_1\">surname:Wu;given-names:XX</infon><infon key=\"name_10\">surname:Sheng;given-names:JF</infon><infon key=\"name_11\">surname:Cai;given-names:HL</infon><infon key=\"name_12\">surname:Qiu;given-names:YQ</infon><infon key=\"name_13\">surname:Li;given-names:LJ</infon><infon key=\"name_2\">surname:Jiang;given-names:XG</infon><infon key=\"name_3\">surname:Xu;given-names:KJ</infon><infon key=\"name_4\">surname:Ying;given-names:LJ</infon><infon key=\"name_5\">surname:Ma;given-names:CL</infon><infon key=\"name_6\">surname:Li;given-names:SB</infon><infon key=\"name_7\">surname:Wang;given-names:HY</infon><infon key=\"name_8\">surname:Zhang;given-names:S</infon><infon key=\"name_9\">surname:Gao;given-names:HN</infon><infon key=\"pub-id_doi\">10.1136/bmj.m606</infon><infon key=\"pub-id_pmid\">32075786</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BMJ</infon><infon key=\"type\">ref</infon><infon key=\"volume\">368</infon><infon key=\"year\">2020</infon><offset>69745</offset><text>Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series</text></passage><passage><infon key=\"fpage\">507</infon><infon key=\"issue\">10223</infon><infon key=\"lpage\">513</infon><infon key=\"name_0\">surname:Chen;given-names:N</infon><infon key=\"name_1\">surname:Zhou;given-names:M</infon><infon key=\"name_2\">surname:Dong;given-names:X</infon><infon key=\"name_3\">surname:Qu;given-names:J</infon><infon key=\"name_4\">surname:Gong;given-names:F</infon><infon key=\"name_5\">surname:Han;given-names:Y</infon><infon key=\"pub-id_doi\">10.1016/s0140-6736(20)30211-7</infon><infon key=\"pub-id_pmid\">32007143</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>69891</offset><text>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</text></passage><passage><infon key=\"fpage\">1239</infon><infon key=\"lpage\">1242</infon><infon key=\"name_0\">surname:Wu;given-names:Z</infon><infon key=\"name_1\">surname:McGoogan;given-names:JM</infon><infon key=\"pub-id_doi\">10.1001/jama.2020.2648</infon><infon key=\"pub-id_pmid\">32091533</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>70021</offset><text>Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention</text></passage><passage><infon key=\"fpage\">916</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">923</infon><infon key=\"name_0\">surname:Han;given-names:C</infon><infon key=\"name_1\">surname:Duan;given-names:C</infon><infon key=\"name_2\">surname:Zhang;given-names:S</infon><infon key=\"name_3\">surname:Spiegel;given-names:B</infon><infon key=\"name_4\">surname:Shi;given-names:H</infon><infon key=\"name_5\">surname:Wang;given-names:W</infon><infon key=\"pub-id_doi\">10.14309/ajg.0000000000000664</infon><infon key=\"pub-id_pmid\">32301761</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Am J Gastroenterol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">115</infon><infon key=\"year\">2020</infon><offset>70221</offset><text>Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes</text></passage><passage><infon key=\"fpage\">766</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">773</infon><infon key=\"name_0\">surname:Pan;given-names:L</infon><infon key=\"name_1\">surname:Mu;given-names:M</infon><infon key=\"name_2\">surname:Yang;given-names:P</infon><infon key=\"name_3\">surname:Sun;given-names:Y</infon><infon key=\"name_4\">surname:Wang;given-names:R</infon><infon key=\"name_5\">surname:Yan;given-names:J</infon><infon key=\"pub-id_doi\">10.14309/ajg.0000000000000620</infon><infon key=\"pub-id_pmid\">32287140</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Am J Gastroenterol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">115</infon><infon key=\"year\">2020</infon><offset>70350</offset><text>Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study</text></passage><passage><infon key=\"fpage\">1370</infon><infon key=\"lpage\">1371</infon><infon key=\"name_0\">surname:Liu;given-names:W</infon><infon key=\"name_1\">surname:Zhang;given-names:Q</infon><infon key=\"name_2\">surname:Chen;given-names:J</infon><infon key=\"name_3\">surname:Xiang;given-names:R</infon><infon key=\"name_4\">surname:Song;given-names:H</infon><infon key=\"name_5\">surname:Shu;given-names:S</infon><infon key=\"pub-id_doi\">10.1056/NEJMc2003717</infon><infon key=\"pub-id_pmid\">32163697</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>70487</offset><text>Detection of COVID-19 in children in early January 2020 in Wuhan, China</text></passage><passage><infon key=\"fpage\">1663</infon><infon key=\"lpage\">1665</infon><infon key=\"name_0\">surname:Lu;given-names:X</infon><infon key=\"name_1\">surname:Zhang;given-names:L</infon><infon key=\"name_2\">surname:Du;given-names:H</infon><infon key=\"name_3\">surname:Zhang;given-names:J</infon><infon key=\"name_4\">surname:Li;given-names:YY</infon><infon key=\"name_5\">surname:Qu;given-names:J</infon><infon key=\"pub-id_doi\">10.1056/NEJMc2005073</infon><infon key=\"pub-id_pmid\">32187458</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>70559</offset><text>SARS-CoV-2 infection in children</text></passage><passage><infon key=\"fpage\">706</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">711</infon><infon key=\"name_0\">surname:Hu;given-names:Z</infon><infon key=\"name_1\">surname:Song;given-names:C</infon><infon key=\"name_2\">surname:Xu;given-names:C</infon><infon key=\"name_3\">surname:Jin;given-names:G</infon><infon key=\"name_4\">surname:Chen;given-names:Y</infon><infon key=\"name_5\">surname:Xu;given-names:X</infon><infon key=\"pub-id_doi\">10.1007/s11427-020-1661-4</infon><infon key=\"pub-id_pmid\">32146694</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci China Life Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">63</infon><infon key=\"year\">2020</infon><offset>70592</offset><text>Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China</text></passage><passage><infon key=\"fpage\">1770</infon><infon key=\"issue\">11</infon><infon key=\"lpage\">1774</infon><infon key=\"name_0\">surname:Wang;given-names:Y</infon><infon key=\"name_1\">surname:Liu;given-names:Y</infon><infon key=\"name_2\">surname:Liu;given-names:L</infon><infon key=\"name_3\">surname:Wang;given-names:X</infon><infon key=\"name_4\">surname:Luo;given-names:N</infon><infon key=\"name_5\">surname:Li;given-names:L</infon><infon key=\"pub-id_doi\">10.1093/infdis/jiaa119</infon><infon key=\"pub-id_pmid\">32179910</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">221</infon><infon key=\"year\">2020</infon><offset>70709</offset><text>Clinical outcomes in 55 patients with severe acute respiratory syndrome coronavirus 2 who were asymptomatic at hospital admission in Shenzhen, China</text></passage><passage><infon key=\"fpage\">2000180</infon><infon key=\"name_0\">surname:Mizumoto;given-names:K</infon><infon key=\"name_1\">surname:Kagaya;given-names:K</infon><infon key=\"name_2\">surname:Zarebski;given-names:A</infon><infon key=\"name_3\">surname:Chowell;given-names:G</infon><infon key=\"pub-id_doi\">10.2807/1560-7917</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveil</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>70858</offset><text>Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020</text></passage><passage><infon key=\"fpage\">410</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">411</infon><infon key=\"name_0\">surname:Pan;given-names:X</infon><infon key=\"name_1\">surname:Chen;given-names:D</infon><infon key=\"name_2\">surname:Xia;given-names:Y</infon><infon key=\"name_3\">surname:Wu;given-names:X</infon><infon key=\"name_4\">surname:Li;given-names:T</infon><infon key=\"name_5\">surname:Ou;given-names:X</infon><infon key=\"pub-id_doi\">10.1016/s1473-3099(20)30114-6</infon><infon key=\"pub-id_pmid\">32087116</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>71007</offset><text>Asymptomatic cases in a family cluster with SARS-CoV-2 infection</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>71072</offset><text>Sakurai A, Sasaki T, Kato S, Hayashi M, Tsuzuki SI, Ishihara T, et al. Natural history of asymptomatic SARS-CoV-2 infection. N Engl J Med. 2020. 10.1056/NEJMc2013020.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>71239</offset><text>Wang Y, Kang H, Liu X, Tong Z. Asymptomatic cases with SARS-CoV-2 infection. J Med Virol. 2020. 10.1002/jmv.25990.</text></passage><passage><infon key=\"fpage\">41</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">58</infon><infon key=\"name_0\">surname:Pushpakom;given-names:S</infon><infon key=\"name_1\">surname:Iorio;given-names:F</infon><infon key=\"name_2\">surname:Eyers;given-names:PA</infon><infon key=\"name_3\">surname:Escott;given-names:KJ</infon><infon key=\"name_4\">surname:Hopper;given-names:S</infon><infon key=\"name_5\">surname:Wells;given-names:A</infon><infon key=\"pub-id_doi\">10.1038/nrd.2018.168</infon><infon key=\"pub-id_pmid\">30310233</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Rev Drug Discov</infon><infon key=\"type\">ref</infon><infon key=\"volume\">18</infon><infon key=\"year\">2019</infon><offset>71354</offset><text>Drug repurposing: progress, challenges and recommendations</text></passage><passage><infon key=\"fpage\">2262</infon><infon key=\"issue\">22</infon><infon key=\"lpage\">2263</infon><infon key=\"name_0\">surname:Bauchner;given-names:H</infon><infon key=\"name_1\">surname:Fontanarosa;given-names:PB</infon><infon key=\"pub-id_doi\">10.1001/jama.2020.8115</infon><infon key=\"pub-id_pmid\">32364561</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>71413</offset><text>Randomized clinical trials and COVID-19: managing expectations</text></passage><passage><infon key=\"fpage\">1624</infon><infon key=\"lpage\">1634</infon><infon key=\"name_0\">surname:Ahidjo;given-names:BA</infon><infon key=\"name_1\">surname:Loe;given-names:MWC</infon><infon key=\"name_2\">surname:Ng;given-names:YL</infon><infon key=\"name_3\">surname:Mok;given-names:CK</infon><infon key=\"name_4\">surname:Chu;given-names:JJH</infon><infon key=\"pub-id_doi\">10.1021/acsinfecdis.0c00236</infon><infon key=\"pub-id_pmid\">32485102</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2020</infon><offset>71476</offset><text>Current perspective of antiviral strategies against COVID-19</text></passage><passage><infon key=\"fpage\">188</infon><infon key=\"issue\">8</infon><infon key=\"name_0\">surname:Malik;given-names:S</infon><infon key=\"name_1\">surname:Gupta;given-names:A</infon><infon key=\"name_2\">surname:Zhong;given-names:X</infon><infon key=\"name_3\">surname:Rasmussen;given-names:TP</infon><infon key=\"name_4\">surname:Manautou;given-names:JE</infon><infon key=\"name_5\">surname:Bahal;given-names:R</infon><infon key=\"pub-id_doi\">10.3390/ph13080188</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pharmaceuticals (Basel)</infon><infon key=\"type\">ref</infon><infon key=\"volume\">13</infon><infon key=\"year\">2020</infon><offset>71537</offset><text>Emerging therapeutic modalities against COVID-19</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>71586</offset><text>COVID-19 Vaccine tracker. 2020 [cited 2020 08/08/2020]; Available from:https://biorender.com/covid-vaccine-tracker.</text></passage><passage><infon key=\"fpage\">72</infon><infon key=\"name_0\">surname:Kruse;given-names:R</infon><infon key=\"pub-id_doi\">10.12688/f1000research.22211.2</infon><infon key=\"pub-id_pmid\">32117569</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">F1000Research</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>71702</offset><text>Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China [version 2; peer review: 2 approved]</text></passage><passage><infon key=\"fpage\">221</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">232</infon><infon key=\"name_0\">surname:Correia;given-names:IR</infon><infon key=\"pub-id_doi\">10.4161/mabs.2.3.11788</infon><infon key=\"pub-id_pmid\">20404539</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">mAbs</infon><infon key=\"type\">ref</infon><infon key=\"volume\">2</infon><infon key=\"year\">2010</infon><offset>71845</offset><text>Stability of IgG isotypes in serum</text></passage><passage><infon key=\"fpage\">956</infon><infon key=\"issue\">6506</infon><infon key=\"lpage\">963</infon><infon key=\"name_0\">surname:Rogers;given-names:TF</infon><infon key=\"name_1\">surname:Zhao;given-names:F</infon><infon key=\"name_2\">surname:Huang;given-names:D</infon><infon key=\"name_3\">surname:Beutler;given-names:N</infon><infon key=\"name_4\">surname:Burns;given-names:A</infon><infon key=\"name_5\">surname:He;given-names:WT</infon><infon key=\"pub-id_doi\">10.1126/science.abc7520</infon><infon key=\"pub-id_pmid\">32540903</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">369</infon><infon key=\"year\">2020</infon><offset>71880</offset><text>Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model</text></passage><passage><infon key=\"fpage\">315</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">331</infon><infon key=\"name_0\">surname:Liu;given-names:C</infon><infon key=\"name_1\">surname:Zhou;given-names:Q</infon><infon key=\"name_2\">surname:Li;given-names:Y</infon><infon key=\"name_3\">surname:Garner;given-names:LV</infon><infon key=\"name_4\">surname:Watkins;given-names:SP</infon><infon key=\"name_5\">surname:Carter;given-names:LJ</infon><infon key=\"pub-id_doi\">10.1021/acscentsci.0c00272</infon><infon key=\"pub-id_pmid\">32226821</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Cent Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2020</infon><offset>71987</offset><text>Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>72099</offset><text>Chinese Clinical Trial Registry. A randomized controlled trial for the efficacy and safety of baloxavir marboxil, favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy. 2020. https://www.chictr.org.cn/showprojen.aspx?proj=49013. AccessedÂ 11/23/2020.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>72445</offset><text>Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 - preliminary report. N Engl J Med 2020. 10.1056/NEJMoa2007764.</text></passage><passage><infon key=\"fpage\">72</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">73</infon><infon key=\"name_0\">surname:Gao;given-names:J</infon><infon key=\"name_1\">surname:Tian;given-names:Z</infon><infon key=\"name_2\">surname:Yang;given-names:X</infon><infon key=\"pub-id_doi\">10.5582/bst.2020.01047</infon><infon key=\"pub-id_pmid\">32074550</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biosci Trends</infon><infon key=\"type\">ref</infon><infon key=\"volume\">14</infon><infon key=\"year\">2020</infon><offset>72622</offset><text>Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies</text></passage><passage><infon key=\"fpage\">105949</infon><infon key=\"issue\">1</infon><infon key=\"name_0\">surname:Gautret;given-names:P</infon><infon key=\"name_1\">surname:Lagier;given-names:JC</infon><infon key=\"name_2\">surname:Parola;given-names:P</infon><infon key=\"name_3\">surname:Hoang;given-names:VT</infon><infon key=\"name_4\">surname:Meddeb;given-names:L</infon><infon key=\"name_5\">surname:Mailhe;given-names:M</infon><infon key=\"pub-id_doi\">10.1016/j.ijantimicag.2020.105949</infon><infon key=\"pub-id_pmid\">32205204</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Antimicrob Agents</infon><infon key=\"type\">ref</infon><infon key=\"volume\">56</infon><infon key=\"year\">2020</infon><offset>72752</offset><text>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</text></passage><passage><infon key=\"fpage\">106114</infon><infon key=\"name_0\">surname:Tong;given-names:S</infon><infon key=\"name_1\">surname:Su;given-names:Y</infon><infon key=\"name_2\">surname:Yu;given-names:Y</infon><infon key=\"name_3\">surname:Wu;given-names:C</infon><infon key=\"name_4\">surname:Chen;given-names:J</infon><infon key=\"name_5\">surname:Wang;given-names:S</infon><infon key=\"pub-id_doi\">10.1016/j.ijantimicag.2020.106114</infon><infon key=\"pub-id_pmid\">32712334</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Antimicrob Agents</infon><infon key=\"type\">ref</infon><infon key=\"volume\">56</infon><infon key=\"year\">2020</infon><offset>72871</offset><text>Ribavirin therapy for severe COVID-19: a retrospective cohort study</text></passage><passage><infon key=\"fpage\">105998</infon><infon key=\"issue\">2</infon><infon key=\"name_0\">surname:Vankadari;given-names:N</infon><infon key=\"pub-id_doi\">10.1016/j.ijantimicag.2020.105998</infon><infon key=\"pub-id_pmid\">32360231</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Antimicrob Agents</infon><infon key=\"type\">ref</infon><infon key=\"volume\">56</infon><infon key=\"year\">2020</infon><offset>72939</offset><text>Arbidol: a potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein</text></passage><passage><infon key=\"fpage\">381</infon><infon key=\"issue\">7594</infon><infon key=\"lpage\">385</infon><infon key=\"name_0\">surname:Warren;given-names:TK</infon><infon key=\"name_1\">surname:Jordan;given-names:R</infon><infon key=\"name_2\">surname:Lo;given-names:MK</infon><infon key=\"name_3\">surname:Ray;given-names:AS</infon><infon key=\"name_4\">surname:Mackman;given-names:RL</infon><infon key=\"name_5\">surname:Soloveva;given-names:V</infon><infon key=\"pub-id_doi\">10.1038/nature17180</infon><infon key=\"pub-id_pmid\">26934220</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">531</infon><infon key=\"year\">2016</infon><offset>73059</offset><text>Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys</text></passage><passage><infon key=\"fpage\">eaal3653</infon><infon key=\"name_0\">surname:Sheahan;given-names:TP</infon><infon key=\"name_1\">surname:Sims;given-names:AC</infon><infon key=\"name_2\">surname:Graham;given-names:RL</infon><infon key=\"name_3\">surname:Menachery;given-names:VD</infon><infon key=\"name_4\">surname:Gralinski;given-names:LE</infon><infon key=\"name_5\">surname:Case;given-names:JB</infon><infon key=\"pub-id_doi\">10.1126/scitranslmed.aal3653</infon><infon key=\"pub-id_pmid\">28659436</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci Transl Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2017</infon><offset>73148</offset><text>Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses</text></passage><passage><infon key=\"fpage\">e00221</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">e00218</infon><infon key=\"name_0\">surname:Agostini;given-names:ML</infon><infon key=\"name_1\">surname:Andres;given-names:EL</infon><infon key=\"name_2\">surname:Sims;given-names:AC</infon><infon key=\"name_3\">surname:Graham;given-names:RL</infon><infon key=\"name_4\">surname:Sheahan;given-names:TP</infon><infon key=\"name_5\">surname:Lu;given-names:X</infon><infon key=\"pub-id_doi\">10.1128/mBio.00221-18</infon><infon key=\"pub-id_pmid\">29511076</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">mBio</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2018</infon><offset>73231</offset><text>Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease</text></passage><passage><infon key=\"fpage\">672</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">683</infon><infon key=\"name_0\">surname:Eastman;given-names:RT</infon><infon key=\"name_1\">surname:Roth;given-names:JS</infon><infon key=\"name_2\">surname:Brimacombe;given-names:KR</infon><infon key=\"name_3\">surname:Simeonov;given-names:A</infon><infon key=\"name_4\">surname:Shen;given-names:M</infon><infon key=\"name_5\">surname:Patnaik;given-names:S</infon><infon key=\"pub-id_doi\">10.1021/acscentsci.0c00489</infon><infon key=\"pub-id_pmid\">32483554</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Cent Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2020</infon><offset>73369</offset><text>Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19</text></passage><passage><infon key=\"fpage\">2327</infon><infon key=\"issue\">24</infon><infon key=\"lpage\">2336</infon><infon key=\"name_0\">surname:Grein;given-names:J</infon><infon key=\"name_1\">surname:Ohmagari;given-names:N</infon><infon key=\"name_10\">surname:Nicastri;given-names:E</infon><infon key=\"name_11\">surname:Oda;given-names:R</infon><infon key=\"name_12\">surname:Yo;given-names:K</infon><infon key=\"name_13\">surname:Quiros-Roldan;given-names:E</infon><infon key=\"name_14\">surname:Studemeister;given-names:A</infon><infon key=\"name_15\">surname:Redinski;given-names:J</infon><infon key=\"name_16\">surname:Ahmed;given-names:S</infon><infon key=\"name_17\">surname:Bernett;given-names:J</infon><infon key=\"name_18\">surname:Chelliah;given-names:D</infon><infon key=\"name_19\">surname:Chen;given-names:D</infon><infon key=\"name_2\">surname:Shin;given-names:D</infon><infon key=\"name_20\">surname:Chihara;given-names:S</infon><infon key=\"name_21\">surname:Cohen;given-names:SH</infon><infon key=\"name_22\">surname:Cunningham;given-names:J</infon><infon key=\"name_23\">surname:DâArminio Monforte;given-names:A</infon><infon key=\"name_24\">surname:Ismail;given-names:S</infon><infon key=\"name_25\">surname:Kato;given-names:H</infon><infon key=\"name_26\">surname:Lapadula;given-names:G</infon><infon key=\"name_27\">surname:LâHer;given-names:E</infon><infon key=\"name_28\">surname:Maeno;given-names:T</infon><infon key=\"name_29\">surname:Majumder;given-names:S</infon><infon key=\"name_3\">surname:Diaz;given-names:G</infon><infon key=\"name_30\">surname:Massari;given-names:M</infon><infon key=\"name_31\">surname:Mora-Rillo;given-names:M</infon><infon key=\"name_32\">surname:Mutoh;given-names:Y</infon><infon key=\"name_33\">surname:Nguyen;given-names:D</infon><infon key=\"name_34\">surname:Verweij;given-names:E</infon><infon key=\"name_35\">surname:Zoufaly;given-names:A</infon><infon key=\"name_36\">surname:Osinusi;given-names:AO</infon><infon key=\"name_37\">surname:DeZure;given-names:A</infon><infon key=\"name_38\">surname:Zhao;given-names:Y</infon><infon key=\"name_39\">surname:Zhong;given-names:L</infon><infon key=\"name_4\">surname:Asperges;given-names:E</infon><infon key=\"name_40\">surname:Chokkalingam;given-names:A</infon><infon key=\"name_41\">surname:Elboudwarej;given-names:E</infon><infon key=\"name_42\">surname:Telep;given-names:L</infon><infon key=\"name_43\">surname:Timbs;given-names:L</infon><infon key=\"name_44\">surname:Henne;given-names:I</infon><infon key=\"name_45\">surname:Sellers;given-names:S</infon><infon key=\"name_46\">surname:Cao;given-names:H</infon><infon key=\"name_47\">surname:Tan;given-names:SK</infon><infon key=\"name_48\">surname:Winterbourne;given-names:L</infon><infon key=\"name_49\">surname:Desai;given-names:P</infon><infon key=\"name_5\">surname:Castagna;given-names:A</infon><infon key=\"name_50\">surname:Mera;given-names:R</infon><infon key=\"name_51\">surname:Gaggar;given-names:A</infon><infon key=\"name_52\">surname:Myers;given-names:RP</infon><infon key=\"name_53\">surname:Brainard;given-names:DM</infon><infon key=\"name_54\">surname:Childs;given-names:R</infon><infon key=\"name_55\">surname:Flanigan;given-names:T</infon><infon key=\"name_6\">surname:Feldt;given-names:T</infon><infon key=\"name_7\">surname:Green;given-names:G</infon><infon key=\"name_8\">surname:Green;given-names:ML</infon><infon key=\"name_9\">surname:Lescure;given-names:FX</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa2007016</infon><infon key=\"pub-id_pmid\">32275812</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>73488</offset><text>Compassionate use of remdesivir for patients with severe COVID-19</text></passage><passage><infon key=\"fpage\">1048</infon><infon key=\"issue\">11</infon><infon key=\"lpage\">1057</infon><infon key=\"name_0\">surname:Spinner;given-names:CD</infon><infon key=\"name_1\">surname:Gottlieb;given-names:RL</infon><infon key=\"name_2\">surname:Criner;given-names:GJ</infon><infon key=\"name_3\">surname:Arribas Lopez;given-names:JR</infon><infon key=\"name_4\">surname:Cattelan;given-names:AM</infon><infon key=\"name_5\">surname:Soriano Viladomiu;given-names:A</infon><infon key=\"pub-id_doi\">10.1001/jama.2020.16349</infon><infon key=\"pub-id_pmid\">32821939</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">324</infon><infon key=\"year\">2020</infon><offset>73554</offset><text>Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>73686</offset><text>FDA approves first treatment for COVID-19. Food and Drug Administration (FDA); 2020 [updated October 22, 2020; cited 2020 11/01/2020]; Available from:https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19.</text></passage><passage><infon key=\"fpage\">CD011489</infon><infon key=\"name_0\">surname:Huang;given-names:L</infon><infon key=\"name_1\">surname:Zhang;given-names:L</infon><infon key=\"name_2\">surname:Liu;given-names:Y</infon><infon key=\"name_3\">surname:Luo;given-names:R</infon><infon key=\"name_4\">surname:Zeng;given-names:L</infon><infon key=\"name_5\">surname:Telegina;given-names:I</infon><infon key=\"pub-id_doi\">10.1002/14651858.CD011489.pub2</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cochrane Database Syst Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">2017</infon><infon key=\"year\">2017</infon><offset>73927</offset><text>Arbidol for preventing and treating influenza in adults and children</text></passage><passage><infon key=\"fpage\">8989</infon><infon key=\"issue\">1</infon><infon key=\"name_0\">surname:Fink;given-names:SL</infon><infon key=\"name_1\">surname:Vojtech;given-names:L</infon><infon key=\"name_2\">surname:Wagoner;given-names:J</infon><infon key=\"name_3\">surname:Slivinski;given-names:NSJ</infon><infon key=\"name_4\">surname:Jackson;given-names:KJ</infon><infon key=\"name_5\">surname:Wang;given-names:R</infon><infon key=\"pub-id_doi\">10.1038/s41598-018-27224-4</infon><infon key=\"pub-id_pmid\">29895962</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci Rep</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2018</infon><offset>73996</offset><text>The antiviral drug arbidol inhibits Zika virus</text></passage><passage><infon key=\"fpage\">e02185</infon><infon key=\"lpage\">e02118</infon><infon key=\"name_0\">surname:Hulseberg;given-names:CE</infon><infon key=\"name_1\">surname:FÃ©nÃ©ant;given-names:L</infon><infon key=\"name_2\">surname:SzymaÅska-de Wijs;given-names:KM</infon><infon key=\"name_3\">surname:Kessler;given-names:NP</infon><infon key=\"name_4\">surname:Nelson;given-names:EA</infon><infon key=\"name_5\">surname:Shoemaker;given-names:CJ</infon><infon key=\"pub-id_doi\">10.1128/JVI</infon><infon key=\"pub-id_pmid\">30700611</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">93</infon><infon key=\"year\">2019</infon><offset>74043</offset><text>Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses</text></passage><passage><infon key=\"fpage\">206</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">214</infon><infon key=\"name_0\">surname:Kadam;given-names:RU</infon><infon key=\"name_1\">surname:Wilson;given-names:IA</infon><infon key=\"pub-id_doi\">10.1073/pnas.1617020114</infon><infon key=\"pub-id_pmid\">28003465</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Proc Natl Acad Sci U S A</infon><infon key=\"type\">ref</infon><infon key=\"volume\">114</infon><infon key=\"year\">2017</infon><offset>74125</offset><text>Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol</text></passage><passage><infon key=\"fpage\">e15874</infon><infon key=\"issue\">1</infon><infon key=\"name_0\">surname:Teissier;given-names:E</infon><infon key=\"name_1\">surname:Zandomeneghi;given-names:G</infon><infon key=\"name_2\">surname:Loquet;given-names:A</infon><infon key=\"name_3\">surname:Lavillette;given-names:D</infon><infon key=\"name_4\">surname:Lavergne;given-names:JP</infon><infon key=\"name_5\">surname:Montserret;given-names:R</infon><infon key=\"pub-id_doi\">10.1371/journal.pone.0015874</infon><infon key=\"pub-id_pmid\">21283579</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS One</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2011</infon><offset>74209</offset><text>Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug Arbidol</text></passage><passage><infon key=\"fpage\">69</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">71</infon><infon key=\"name_0\">surname:Lu;given-names:H</infon><infon key=\"pub-id_doi\">10.5582/bst.2020.01020</infon><infon key=\"pub-id_pmid\">31996494</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biosci Trends</infon><infon key=\"type\">ref</infon><infon key=\"volume\">14</infon><infon key=\"year\">2020</infon><offset>74298</offset><text>Drug treatment options for the 2019-new coronavirus (2019-nCoV)</text></passage><passage><infon key=\"fpage\">379</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">381</infon><infon key=\"name_0\">surname:Harrison;given-names:C</infon><infon key=\"pub-id_doi\">10.1038/d41587-020-00003-1</infon><infon key=\"pub-id_pmid\">32205870</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Biotechnol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">38</infon><infon key=\"year\">2020</infon><offset>74362</offset><text>Coronavirus puts drug repurposing on the fast track</text></passage><passage><infon key=\"fpage\">917</infon><infon key=\"issue\">7</infon><infon key=\"lpage\">921</infon><infon key=\"name_0\">surname:Lian;given-names:N</infon><infon key=\"name_1\">surname:Xie;given-names:H</infon><infon key=\"name_2\">surname:Lin;given-names:S</infon><infon key=\"name_3\">surname:Huang;given-names:J</infon><infon key=\"name_4\">surname:Zhao;given-names:J</infon><infon key=\"name_5\">surname:Lin;given-names:Q</infon><infon key=\"pub-id_doi\">10.1016/j.cmi.2020.04.026</infon><infon key=\"pub-id_pmid\">32344167</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>74414</offset><text>Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>74541</offset><text>Chen J, Lin S, Niu C, Xiao Q. Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study. Expert Rev Respir Med. 2020:1â9. 10.1080/17476348.2020.1822741.</text></passage><passage><infon key=\"fpage\">107512</infon><infon key=\"name_0\">surname:Shiraki;given-names:K</infon><infon key=\"name_1\">surname:Daikoku;given-names:T</infon><infon key=\"pub-id_doi\">10.1016/j.pharmthera.2020.107512</infon><infon key=\"pub-id_pmid\">32097670</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pharmacol Ther</infon><infon key=\"type\">ref</infon><infon key=\"volume\">209</infon><infon key=\"year\">2020</infon><offset>74783</offset><text>Favipiravir, an anti-influenza drug against life-threatening RNA virus infections</text></passage><passage><infon key=\"fpage\">76</infon><infon key=\"issue\">2</infon><infon key=\"name_0\">surname:Venkataraman;given-names:S</infon><infon key=\"name_1\">surname:Prasad;given-names:B</infon><infon key=\"name_2\">surname:Selvarajan;given-names:R</infon><infon key=\"pub-id_doi\">10.3390/v10020076</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Viruses</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2018</infon><offset>74865</offset><text>RNA dependent RNA polymerases: insights from structure, function and evolution</text></passage><passage><infon key=\"fpage\">E4005</infon><infon key=\"issue\">28</infon><infon key=\"lpage\">E4014</infon><infon key=\"name_0\">surname:Shu;given-names:B</infon><infon key=\"name_1\">surname:Gong;given-names:P</infon><infon key=\"pub-id_doi\">10.1073/pnas.1602591113</infon><infon key=\"pub-id_pmid\">27339134</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Proc Natl Acad Sci U S A</infon><infon key=\"type\">ref</infon><infon key=\"volume\">113</infon><infon key=\"year\">2016</infon><offset>74944</offset><text>Structural basis of viral RNA-dependent RNA polymerase catalysis and translocation</text></passage><passage><infon key=\"fpage\">79</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">81</infon><infon key=\"name_0\">surname:Nagata;given-names:T</infon><infon key=\"name_1\">surname:Lefor;given-names:AK</infon><infon key=\"name_2\">surname:Hasegawa;given-names:M</infon><infon key=\"name_3\">surname:Ishii;given-names:M</infon><infon key=\"pub-id_doi\">10.1017/dmp.2014.151</infon><infon key=\"pub-id_pmid\">25544306</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Disaster Med Public Health Prep</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2015</infon><offset>75027</offset><text>Favipiravir: a new medication for the Ebola virus disease pandemic</text></passage><passage><infon key=\"fpage\">653</infon><infon key=\"issue\">8</infon><infon key=\"lpage\">671</infon><infon key=\"name_0\">surname:Plantone;given-names:D</infon><infon key=\"name_1\">surname:Koudriavtseva;given-names:T</infon><infon key=\"pub-id_doi\">10.1007/s40261-018-0656-y</infon><infon key=\"pub-id_pmid\">29737455</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Drug Investig</infon><infon key=\"type\">ref</infon><infon key=\"volume\">38</infon><infon key=\"year\">2018</infon><offset>75094</offset><text>Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review</text></passage><passage><infon key=\"fpage\">105938</infon><infon key=\"issue\">5</infon><infon key=\"name_0\">surname:Devaux;given-names:CA</infon><infon key=\"name_1\">surname:Rolain;given-names:JM</infon><infon key=\"name_2\">surname:Colson;given-names:P</infon><infon key=\"name_3\">surname:Raoult;given-names:D</infon><infon key=\"pub-id_doi\">10.1016/j.ijantimicag.2020.105938</infon><infon key=\"pub-id_pmid\">32171740</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Antimicrob Agents</infon><infon key=\"type\">ref</infon><infon key=\"volume\">55</infon><infon key=\"year\">2020</infon><offset>75231</offset><text>New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?</text></passage><passage><infon key=\"fpage\">269</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">271</infon><infon key=\"name_0\">surname:Wang;given-names:M</infon><infon key=\"name_1\">surname:Cao;given-names:R</infon><infon key=\"name_2\">surname:Zhang;given-names:L</infon><infon key=\"name_3\">surname:Yang;given-names:X</infon><infon key=\"name_4\">surname:Liu;given-names:J</infon><infon key=\"name_5\">surname:Xu;given-names:M</infon><infon key=\"pub-id_doi\">10.1038/s41422-020-0282-0</infon><infon key=\"pub-id_pmid\">32020029</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2020</infon><offset>75334</offset><text>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</text></passage><passage><infon key=\"fpage\">69</infon><infon key=\"name_0\">surname:Vincent;given-names:MJ</infon><infon key=\"name_1\">surname:Bergeron;given-names:E</infon><infon key=\"name_2\">surname:Benjannet;given-names:S</infon><infon key=\"name_3\">surname:Erickson;given-names:BR</infon><infon key=\"name_4\">surname:Rollin;given-names:PE</infon><infon key=\"name_5\">surname:Ksiazek;given-names:TG</infon><infon key=\"pub-id_doi\">10.1186/1743-422X-2-69</infon><infon key=\"pub-id_pmid\">16115318</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Virol J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">2</infon><infon key=\"year\">2005</infon><offset>75441</offset><text>Chloroquine is a potent inhibitor of SARS coronavirus infection and spread</text></passage><passage><infon key=\"fpage\">58</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">60</infon><infon key=\"name_0\">surname:Dong;given-names:L</infon><infon key=\"name_1\">surname:Hu;given-names:S</infon><infon key=\"name_2\">surname:Gao;given-names:J</infon><infon key=\"pub-id_doi\">10.5582/ddt.2020.01012</infon><infon key=\"pub-id_pmid\">32147628</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Drug Discov Ther</infon><infon key=\"type\">ref</infon><infon key=\"volume\">14</infon><infon key=\"year\">2020</infon><offset>75516</offset><text>Discovering drugs to treat coronavirus disease 2019 (COVID-19)</text></passage><passage><infon key=\"fpage\">274</infon><infon key=\"issue\">1</infon><infon key=\"name_0\">surname:Zhu;given-names:RF</infon><infon key=\"name_1\">surname:Gao;given-names:YL</infon><infon key=\"name_2\">surname:Robert;given-names:SH</infon><infon key=\"name_3\">surname:Gao;given-names:JP</infon><infon key=\"name_4\">surname:Yang;given-names:SG</infon><infon key=\"name_5\">surname:Zhu;given-names:CT</infon><infon key=\"pub-id_doi\">10.1186/s12967-020-02442-5</infon><infon key=\"pub-id_pmid\">32631442</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Transl Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">18</infon><infon key=\"year\">2020</infon><offset>75579</offset><text>Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19)</text></passage><passage><infon key=\"fpage\">2657</infon><infon key=\"issue\">7</infon><infon key=\"name_0\">surname:Tu;given-names:YF</infon><infon key=\"name_1\">surname:Chien;given-names:CS</infon><infon key=\"name_2\">surname:Yarmishyn;given-names:AA</infon><infon key=\"name_3\">surname:Lin;given-names:YY</infon><infon key=\"name_4\">surname:Luo;given-names:YH</infon><infon key=\"name_5\">surname:Lin;given-names:YT</infon><infon key=\"pub-id_doi\">10.3390/ijms21072657</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Mol Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">21</infon><infon key=\"year\">2020</infon><offset>75671</offset><text>A Review of SARS-CoV-2 and the ongoing clinical trials</text></passage><passage><infon key=\"fpage\">4773</infon><infon key=\"issue\">15</infon><infon key=\"lpage\">4779</infon><infon key=\"name_0\">surname:Gordon;given-names:CJ</infon><infon key=\"name_1\">surname:Tchesnokov;given-names:EP</infon><infon key=\"name_2\">surname:Feng;given-names:JY</infon><infon key=\"name_3\">surname:Porter;given-names:DP</infon><infon key=\"name_4\">surname:Gotte;given-names:M</infon><infon key=\"pub-id_doi\">10.1074/jbc.AC120.013056</infon><infon key=\"pub-id_pmid\">32094225</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Biol Chem</infon><infon key=\"type\">ref</infon><infon key=\"volume\">295</infon><infon key=\"year\">2020</infon><offset>75726</offset><text>The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus</text></passage><passage><infon key=\"fpage\">1569</infon><infon key=\"issue\">10236</infon><infon key=\"lpage\">1578</infon><infon key=\"name_0\">surname:Wang;given-names:Y</infon><infon key=\"name_1\">surname:Zhang;given-names:D</infon><infon key=\"name_2\">surname:Du;given-names:G</infon><infon key=\"name_3\">surname:Du;given-names:R</infon><infon key=\"name_4\">surname:Zhao;given-names:J</infon><infon key=\"name_5\">surname:Jin;given-names:Y</infon><infon key=\"pub-id_doi\">10.1016/s0140-6736(20)31022-9</infon><infon key=\"pub-id_pmid\">32423584</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>75857</offset><text>Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>75966</offset><text>NIH Clinical Trials. A trial of remdesivir in adults with mild and moderate COVID-19. https://clinicaltrials.gov/ct2/show/NCT04252664. 2020.</text></passage><passage><infon key=\"fpage\">363</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">382</infon><infon key=\"name_0\">surname:Lythgoe;given-names:MP</infon><infon key=\"name_1\">surname:Middleton;given-names:P</infon><infon key=\"pub-id_doi\">10.1016/j.tips.2020.03.006</infon><infon key=\"pub-id_pmid\">32291112</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Trends Pharmacol Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">41</infon><infon key=\"year\">2020</infon><offset>76107</offset><text>Ongoing clinical trials for the management of the COVID-19 pandemic</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>76175</offset><text>NIH Clinical Trials. A prospective/retrospective, randomized controlled clinical study of antiviral therapy in the 2019-nCoV pneumonia. https://clinicaltrials.gov/ct2/show/NCT042550171/. 2020.</text></passage><passage><infon key=\"fpage\">1787</infon><infon key=\"issue\">19</infon><infon key=\"lpage\">1799</infon><infon key=\"name_0\">surname:Cao;given-names:B</infon><infon key=\"name_1\">surname:Wang;given-names:Y</infon><infon key=\"name_2\">surname:Wen;given-names:D</infon><infon key=\"name_3\">surname:Liu;given-names:W</infon><infon key=\"name_4\">surname:Wang;given-names:J</infon><infon key=\"name_5\">surname:Fan;given-names:G</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa2001282</infon><infon key=\"pub-id_pmid\">32187464</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>76368</offset><text>A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>76443</offset><text>NIH Clinical Trials. Glucocorticoid therapy for COVID-19 critically ill patients with severe acute respiratory failure. https://clinicaltrials.gov/ct2/show/NCT04244591. 2020.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>76618</offset><text>US Food &amp; Drug Administration. Coronavirus (COVID-19) Update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquin. 2020.Â https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and. AccessedÂ 06/15/2020.</text></passage><passage><infon key=\"fpage\">e17</infon><infon key=\"issue\">1</infon><infon key=\"name_0\">surname:Rismanbaf;given-names:A</infon><infon key=\"name_1\">surname:Zarei;given-names:S</infon><infon key=\"pub-id_pmid\">32185369</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Arch Acad Emerg Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2020</infon><offset>76925</offset><text>Liver and kidney injuries in COVID-19 and their effects on drug therapy; a letter to editor</text></passage><passage><infon key=\"fpage\">106101</infon><infon key=\"issue\">3</infon><infon key=\"name_0\">surname:Khuroo;given-names:MS</infon><infon key=\"pub-id_doi\">10.1016/j.ijantimicag.2020.106101</infon><infon key=\"pub-id_pmid\">32687949</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Antimicrob Agents</infon><infon key=\"type\">ref</infon><infon key=\"volume\">56</infon><infon key=\"year\">2020</infon><offset>77017</offset><text>Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal</text></passage><passage><infon key=\"fpage\">384</infon><infon key=\"issue\">4</infon><infon key=\"name_0\">surname:Molina;given-names:JM</infon><infon key=\"name_1\">surname:Delaugerre;given-names:C</infon><infon key=\"name_2\">surname:Le Goff;given-names:J</infon><infon key=\"name_3\">surname:Mela-Lima;given-names:B</infon><infon key=\"name_4\">surname:Ponscarme;given-names:D</infon><infon key=\"name_5\">surname:Goldwirt;given-names:L</infon><infon key=\"pub-id_doi\">10.1016/j.medmal.2020.03.006</infon><infon key=\"pub-id_pmid\">32240719</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Med Mal Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">50</infon><infon key=\"year\">2020</infon><offset>77142</offset><text>No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection</text></passage><passage><infon key=\"fpage\">2139</infon><infon key=\"issue\">9427</infon><infon key=\"lpage\">2141</infon><infon key=\"name_0\">surname:ter Meulen;given-names:J</infon><infon key=\"name_1\">surname:Bakker;given-names:ABH</infon><infon key=\"name_2\">surname:van den Brink;given-names:EN</infon><infon key=\"name_3\">surname:Weverling;given-names:GJ</infon><infon key=\"name_4\">surname:Martina;given-names:BEE</infon><infon key=\"name_5\">surname:Haagmans;given-names:BL</infon><infon key=\"pub-id_doi\">10.1016/s0140-6736(04)16506-9</infon><infon key=\"pub-id_pmid\">15220038</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">363</infon><infon key=\"year\">2004</infon><offset>77306</offset><text>Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets</text></passage><passage><infon key=\"fpage\">871</infon><infon key=\"issue\">8</infon><infon key=\"lpage\">875</infon><infon key=\"name_0\">surname:Traggiai;given-names:E</infon><infon key=\"name_1\">surname:Becker;given-names:S</infon><infon key=\"name_2\">surname:Subbarao;given-names:K</infon><infon key=\"name_3\">surname:Kolesnikova;given-names:L</infon><infon key=\"name_4\">surname:Uematsu;given-names:Y</infon><infon key=\"name_5\">surname:Gismondo;given-names:MR</infon><infon key=\"pub-id_doi\">10.1038/nm1080</infon><infon key=\"pub-id_pmid\">15247913</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2004</infon><offset>77389</offset><text>An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus</text></passage><passage><infon key=\"fpage\">e237</infon><infon key=\"issue\">7</infon><infon key=\"name_0\">surname:ter Meulen;given-names:J</infon><infon key=\"name_1\">surname:van den Brink;given-names:EN</infon><infon key=\"name_2\">surname:Poon;given-names:LL</infon><infon key=\"name_3\">surname:Marissen;given-names:WE</infon><infon key=\"name_4\">surname:Leung;given-names:CS</infon><infon key=\"name_5\">surname:Cox;given-names:F</infon><infon key=\"pub-id_doi\">10.1371/journal.pmed.0030237</infon><infon key=\"pub-id_pmid\">16796401</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">3</infon><infon key=\"year\">2006</infon><offset>77508</offset><text>Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants</text></passage><passage><infon key=\"fpage\">382</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">385</infon><infon key=\"name_0\">surname:Tian;given-names:X</infon><infon key=\"name_1\">surname:Li;given-names:C</infon><infon key=\"name_2\">surname:Huang;given-names:A</infon><infon key=\"name_3\">surname:Xia;given-names:S</infon><infon key=\"name_4\">surname:Lu;given-names:S</infon><infon key=\"name_5\">surname:Shi;given-names:Z</infon><infon key=\"pub-id_doi\">10.1080/22221751.2020.1729069</infon><infon key=\"pub-id_pmid\">32065055</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>77611</offset><text>Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody</text></passage><passage><infon key=\"fpage\">43</infon><infon key=\"issue\">2</infon><infon key=\"name_0\">surname:Puoci;given-names:F</infon><infon key=\"pub-id_doi\">10.3390/jfb11020043</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Funct Biomater</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>77723</offset><text>&quot;Monoclonal-type&quot; plastic antibodies for COVID-19 treatment: what is the idea?</text></passage><passage><infon key=\"fpage\">230</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">242</infon><infon key=\"name_0\">surname:Graham;given-names:BS</infon><infon key=\"pub-id_doi\">10.1111/imr.12098</infon><infon key=\"pub-id_pmid\">23947359</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Immunol Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">255</infon><infon key=\"year\">2013</infon><offset>77802</offset><text>Advances in antiviral vaccine development</text></passage><passage><infon key=\"fpage\">157</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">166</infon><infon key=\"name_0\">surname:Afrough;given-names:B</infon><infon key=\"name_1\">surname:Dowall;given-names:S</infon><infon key=\"name_2\">surname:Hewson;given-names:R</infon><infon key=\"pub-id_doi\">10.1111/cei.13295</infon><infon key=\"pub-id_pmid\">30993690</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Exp Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">196</infon><infon key=\"year\">2019</infon><offset>77844</offset><text>Emerging viruses and current strategies for vaccine intervention</text></passage><passage><infon key=\"fpage\">1187</infon><infon key=\"issue\">6496</infon><infon key=\"lpage\">1188</infon><infon key=\"name_0\">surname:Chumakov;given-names:K</infon><infon key=\"name_1\">surname:Benn;given-names:CS</infon><infon key=\"name_2\">surname:Aaby;given-names:P</infon><infon key=\"name_3\">surname:Kottilil;given-names:S</infon><infon key=\"name_4\">surname:Gallo;given-names:R</infon><infon key=\"pub-id_doi\">10.1126/science.abc4262</infon><infon key=\"pub-id_pmid\">32527819</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">368</infon><infon key=\"year\">2020</infon><offset>77909</offset><text>Can existing live vaccines prevent COVID-19?</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>77954</offset><text>Fidel PL Jr, Noverr MC. Could an unrelated live attenuated vaccine serve as a preventive measure to dampen septic inflammation associated with COVID-19 infection? mBio. 2020;11(3):e00907â20. 10.1128/mBio.00907-20.</text></passage><passage><infon key=\"fpage\">91</infon><infon key=\"lpage\">92</infon><infon key=\"name_0\">surname:Madan;given-names:M</infon><infon key=\"name_1\">surname:Pahuja;given-names:S</infon><infon key=\"name_2\">surname:Mohan;given-names:A</infon><infon key=\"name_3\">surname:Pandey;given-names:RM</infon><infon key=\"name_4\">surname:Madan;given-names:K</infon><infon key=\"name_5\">surname:Hadda;given-names:V</infon><infon key=\"pub-id_doi\">10.1016/j.puhe.2020.05.042</infon><infon key=\"pub-id_pmid\">32590235</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Public Health</infon><infon key=\"type\">ref</infon><infon key=\"volume\">185</infon><infon key=\"year\">2020</infon><offset>78170</offset><text>TB infection and BCG vaccination: are we protected from COVID-19?</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>78236</offset><text>Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. Engl J Med. 2020;383:1920â1931. 10.1056/NEJMoa2022483.</text></passage><passage><infon key=\"fpage\">2601</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">2614</infon><infon key=\"name_0\">surname:Smith;given-names:T</infon><infon key=\"name_1\">surname:Patel;given-names:A</infon><infon key=\"name_2\">surname:Ramos;given-names:S</infon><infon key=\"name_3\">surname:Elwood;given-names:D</infon><infon key=\"name_4\">surname:Zhu;given-names:X</infon><infon key=\"name_5\">surname:Yan;given-names:J</infon><infon key=\"pub-id_doi\">10.1038/s41467-020-16505-0</infon><infon key=\"pub-id_pmid\">32433465</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>78428</offset><text>Immunogenicity of a DNA vaccine candidate for COVID-19</text></passage><passage><infon key=\"fpage\">4081</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">4088</infon><infon key=\"name_0\">surname:Wu;given-names:S</infon><infon key=\"name_1\">surname:Zhong;given-names:G</infon><infon key=\"name_10\">surname:Liu;given-names:R</infon><infon key=\"name_11\">surname:Fu;given-names:L</infon><infon key=\"name_12\">surname:Zhang;given-names:J</infon><infon key=\"name_13\">surname:Guo;given-names:Q</infon><infon key=\"name_14\">surname:Wang;given-names:C</infon><infon key=\"name_15\">surname:Yang;given-names:Y</infon><infon key=\"name_16\">surname:Fang;given-names:T</infon><infon key=\"name_17\">surname:Lv;given-names:P</infon><infon key=\"name_18\">surname:Wang;given-names:J</infon><infon key=\"name_19\">surname:Xu;given-names:J</infon><infon key=\"name_2\">surname:Zhang;given-names:J</infon><infon key=\"name_20\">surname:Li;given-names:J</infon><infon key=\"name_21\">surname:Yu;given-names:C</infon><infon key=\"name_22\">surname:Hou;given-names:L</infon><infon key=\"name_23\">surname:Bu;given-names:Z</infon><infon key=\"name_24\">surname:Chen;given-names:W</infon><infon key=\"name_3\">surname:Shuai;given-names:L</infon><infon key=\"name_4\">surname:Zhang;given-names:Z</infon><infon key=\"name_5\">surname:Wen;given-names:Z</infon><infon key=\"name_6\">surname:Wang;given-names:B</infon><infon key=\"name_7\">surname:Zhao;given-names:Z</infon><infon key=\"name_8\">surname:Song;given-names:X</infon><infon key=\"name_9\">surname:Chen;given-names:Y</infon><infon key=\"pub-id_doi\">10.1038/s41467-020-17972-1</infon><infon key=\"pub-id_pmid\">32796842</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>78483</offset><text>A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>78580</offset><text>Evaluation of the safety and immunogenicity of a SARS-CoV-2 rS (COVID-19) nanoparticle vaccine with/without matrix-M adjuvan. NIH U.S. National Library of Medicine; 2020 [cited 2020 08/22/2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04368988.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>78840</offset><text>A study to assess safety, tolerability, and immunogenicity of V591 (COVID-19 vaccine) in healthy participants (V591â001). NIH U.S. National Library of Medicine; 2020 [cited 2020 08/22/2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04498247.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>79098</offset><text>Clinical trial to evaluate the safety and immunogenicitiy of the COVID-19 Vaccine (COVID-19-101). NIH U.S. National Library of Medicine; 2020 [cited 2020 08/22/2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04497298?term=TMV-083+vaccine&amp;draw=2&amp;rank=1.</text></passage><passage><infon key=\"fpage\">434</infon><infon key=\"lpage\">438</infon><infon key=\"name_0\">surname:Ankcorn;given-names:M</infon><infon key=\"name_1\">surname:Gallacher;given-names:J</infon><infon key=\"name_2\">surname:Ijaz;given-names:S</infon><infon key=\"name_3\">surname:Taha;given-names:Y</infon><infon key=\"name_4\">surname:Harvala;given-names:H</infon><infon key=\"name_5\">surname:Maclennan;given-names:S</infon><infon key=\"pub-id_doi\">10.1016/j.jhep.2019.04.008</infon><infon key=\"pub-id_pmid\">31075322</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Hepatol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2019</infon><offset>79365</offset><text>Convalescent plasma therapy for persistent hepatitis E virus infection</text></passage><passage><infon key=\"fpage\">437</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">441</infon><infon key=\"name_0\">surname:Wong;given-names:SS</infon><infon key=\"name_1\">surname:Yuen;given-names:KY</infon><infon key=\"pub-id_doi\">10.1093/jac/dkn243</infon><infon key=\"pub-id_pmid\">18565970</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Antimicrob Chemother</infon><infon key=\"type\">ref</infon><infon key=\"volume\">62</infon><infon key=\"year\">2008</infon><offset>79436</offset><text>The management of coronavirus infections with particular reference to SARS</text></passage><passage><infon key=\"fpage\">33</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">42</infon><infon key=\"name_0\">surname:van Griensven;given-names:J</infon><infon key=\"name_1\">surname:Edwards;given-names:T</infon><infon key=\"name_2\">surname:de Lamballerie;given-names:X</infon><infon key=\"name_3\">surname:Semple;given-names:MG</infon><infon key=\"name_4\">surname:Gallian;given-names:P</infon><infon key=\"name_5\">surname:Baize;given-names:S</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa1511812</infon><infon key=\"pub-id_pmid\">26735992</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">374</infon><infon key=\"year\">2016</infon><offset>79511</offset><text>Evaluation of convalescent plasma for Ebola virus disease in Guinea</text></passage><passage><infon key=\"fpage\">1450</infon><infon key=\"lpage\">1451</infon><infon key=\"name_0\">surname:Zhou;given-names:B</infon><infon key=\"name_1\">surname:Zhong;given-names:N</infon><infon key=\"name_2\">surname:Guan;given-names:Y</infon><infon key=\"pub-id_doi\">10.1056/NEJMc070359</infon><infon key=\"pub-id_pmid\">17914053</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">357</infon><infon key=\"year\">2007</infon><offset>79579</offset><text>Treatment with convalescent plasma for influenza A (H5N1) infection</text></passage><passage><infon key=\"fpage\">44</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">46</infon><infon key=\"name_0\">surname:Cheng;given-names:Y</infon><infon key=\"name_1\">surname:Wong;given-names:R</infon><infon key=\"name_2\">surname:Soo;given-names:YO</infon><infon key=\"name_3\">surname:Wong;given-names:WS</infon><infon key=\"name_4\">surname:Lee;given-names:CK</infon><infon key=\"name_5\">surname:Ng;given-names:MH</infon><infon key=\"pub-id_doi\">10.1007/s10096-004-1271-9</infon><infon key=\"pub-id_pmid\">15616839</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur J Clin Microbiol Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">24</infon><infon key=\"year\">2005</infon><offset>79647</offset><text>Use of convalescent plasma therapy in SARS patients in Hong Kong</text></passage><passage><infon key=\"fpage\">9490</infon><infon key=\"issue\">17</infon><infon key=\"lpage\">9496</infon><infon key=\"name_0\">surname:Duan;given-names:K</infon><infon key=\"name_1\">surname:Liu;given-names:B</infon><infon key=\"name_2\">surname:Li;given-names:C</infon><infon key=\"name_3\">surname:Zhang;given-names:H</infon><infon key=\"name_4\">surname:Yu;given-names:T</infon><infon key=\"name_5\">surname:Qu;given-names:J</infon><infon key=\"pub-id_doi\">10.1073/pnas.2004168117</infon><infon key=\"pub-id_pmid\">32253318</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Proc Natl Acad Sci U S A</infon><infon key=\"type\">ref</infon><infon key=\"volume\">117</infon><infon key=\"year\">2020</infon><offset>79712</offset><text>Effectiveness of convalescent plasma therapy in severe COVID-19 patients</text></passage><passage><infon key=\"fpage\">1582</infon><infon key=\"issue\">16</infon><infon key=\"lpage\">1589</infon><infon key=\"name_0\">surname:Shen;given-names:C</infon><infon key=\"name_1\">surname:Wang;given-names:Z</infon><infon key=\"name_2\">surname:Zhao;given-names:F</infon><infon key=\"name_3\">surname:Yang;given-names:Y</infon><infon key=\"name_4\">surname:Li;given-names:J</infon><infon key=\"name_5\">surname:Yuan;given-names:J</infon><infon key=\"pub-id_doi\">10.1001/jama.2020.4783</infon><infon key=\"pub-id_pmid\">32219428</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>79785</offset><text>Treatment of 5 critically ill patients with COVID-19 with convalescent plasma</text></passage><passage><infon key=\"fpage\">1561</infon><infon key=\"issue\">16</infon><infon key=\"lpage\">1562</infon><infon key=\"name_0\">surname:Roback;given-names:JD</infon><infon key=\"name_1\">surname:Guarner;given-names:J</infon><infon key=\"pub-id_doi\">10.1001/jama.2020.4940</infon><infon key=\"pub-id_pmid\">32219429</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>79863</offset><text>Convalescent plasma to treat COVID-19: possibilities and challenges</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>79931</offset><text>FDA. Recommendations for investigational COVID-19 convalescent plasma. https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma. 2020.</text></passage><passage><infon key=\"fpage\">100029</infon><infon key=\"name_0\">surname:Magro;given-names:G</infon><infon key=\"pub-id_doi\">10.1016/j.cytox.2020.100029</infon><infon key=\"pub-id_pmid\">32421092</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cytokine: X</infon><infon key=\"type\">ref</infon><infon key=\"volume\">2</infon><infon key=\"year\">2020</infon><offset>80181</offset><text>SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides tocilizumab? SGP130Fc</text></passage><passage><infon key=\"fpage\">165</infon><infon key=\"issue\">1</infon><infon key=\"name_0\">surname:Buonaguro;given-names:FM</infon><infon key=\"name_1\">surname:Puzanov;given-names:I</infon><infon key=\"name_2\">surname:Ascierto;given-names:PA</infon><infon key=\"pub-id_doi\">10.1186/s12967-020-02333-9</infon><infon key=\"pub-id_pmid\">32290847</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Transl Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">18</infon><infon key=\"year\">2020</infon><offset>80310</offset><text>Anti-IL6R role in treatment of COVID-19-related ARDS</text></passage><passage><infon key=\"fpage\">1675</infon><infon key=\"issue\">7</infon><infon key=\"lpage\">1676</infon><infon key=\"name_0\">surname:Caocci;given-names:G</infon><infon key=\"name_1\">surname:La Nasa;given-names:G</infon><infon key=\"pub-id_doi\">10.1007/s00277-020-04067-6</infon><infon key=\"pub-id_pmid\">32405693</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Ann Hematol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">99</infon><infon key=\"year\">2020</infon><offset>80363</offset><text>Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?</text></passage><passage><infon key=\"fpage\">377</infon><infon key=\"issue\">8</infon><infon key=\"name_0\">surname:Cascella;given-names:M</infon><infon key=\"name_1\">surname:Mauro;given-names:I</infon><infon key=\"name_2\">surname:De Blasio;given-names:E</infon><infon key=\"name_3\">surname:Crispo;given-names:A</infon><infon key=\"name_4\">surname:Del Gaudio;given-names:A</infon><infon key=\"name_5\">surname:Bimonte;given-names:S</infon><infon key=\"pub-id_doi\">10.3390/medicina56080377</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Medicina</infon><infon key=\"type\">ref</infon><infon key=\"volume\">56</infon><infon key=\"year\">2020</infon><offset>80485</offset><text>Rapid and impressive response to a combined treatment with single-dose tocilizumab and NIV in a patient with COVID-19 pneumonia/ARDS</text></passage><passage><infon key=\"fpage\">109774</infon><infon key=\"name_0\">surname:Altschuler;given-names:EL</infon><infon key=\"name_1\">surname:Kast;given-names:RE</infon><infon key=\"pub-id_doi\">10.1016/j.mehy.2020.109774</infon><infon key=\"pub-id_pmid\">32344275</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Med Hypotheses</infon><infon key=\"type\">ref</infon><infon key=\"volume\">141</infon><infon key=\"year\">2020</infon><offset>80618</offset><text>Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)</text></passage><passage><infon key=\"fpage\">1686</infon><infon key=\"issue\">9</infon><infon key=\"lpage\">1701</infon><infon key=\"name_0\">surname:Macalino;given-names:SJ</infon><infon key=\"name_1\">surname:Gosu;given-names:V</infon><infon key=\"name_2\">surname:Hong;given-names:S</infon><infon key=\"name_3\">surname:Choi;given-names:S</infon><infon key=\"pub-id_doi\">10.1007/s12272-015-0640-5</infon><infon key=\"pub-id_pmid\">26208641</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Arch Pharm Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">38</infon><infon key=\"year\">2015</infon><offset>80749</offset><text>Role of computer-aided drug design in modern drug discovery</text></passage><passage><infon key=\"fpage\">3</infon><infon key=\"issue\">1</infon><infon key=\"name_0\">surname:Ramsay;given-names:RR</infon><infon key=\"name_1\">surname:Popovic-Nikolic;given-names:MR</infon><infon key=\"name_2\">surname:Nikolic;given-names:K</infon><infon key=\"name_3\">surname:Uliassi;given-names:E</infon><infon key=\"name_4\">surname:Bolognesi;given-names:ML</infon><infon key=\"pub-id_doi\">10.1186/s40169-017-0181-2</infon><infon key=\"pub-id_pmid\">29340951</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Transl Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2018</infon><offset>80809</offset><text>A perspective on multi-target drug discovery and design for complex diseases</text></passage><passage><infon key=\"fpage\">4403</infon><infon key=\"issue\">22</infon><infon key=\"lpage\">4420</infon><infon key=\"name_0\">surname:te Velthuis;given-names:AJ</infon><infon key=\"pub-id_doi\">10.1007/s00018-014-1695-z</infon><infon key=\"pub-id_pmid\">25080879</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Mol Life Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2014</infon><offset>80886</offset><text>Common and unique features of viral RNA-dependent polymerases</text></passage><passage><infon key=\"fpage\">4430</infon><infon key=\"issue\">11</infon><infon key=\"lpage\">4435</infon><infon key=\"name_0\">surname:Zhang;given-names:WF</infon><infon key=\"name_1\">surname:Stephen;given-names:P</infon><infon key=\"name_2\">surname:Theriault;given-names:JF</infon><infon key=\"name_3\">surname:Wang;given-names:R</infon><infon key=\"name_4\">surname:Lin;given-names:SX</infon><infon key=\"pub-id_doi\">10.1021/acs.jpclett.0c00571</infon><infon key=\"pub-id_pmid\">32392072</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Phys Chem Lett</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>80948</offset><text>Novel coronavirus polymerase and nucleotidyl-transferase structures: potential to target new outbreaks</text></passage><passage><infon key=\"fpage\">313</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">319</infon><infon key=\"name_0\">surname:Qamar;given-names:MTU</infon><infon key=\"name_1\">surname:Alqahtani;given-names:SM</infon><infon key=\"name_2\">surname:Alamri;given-names:MA</infon><infon key=\"name_3\">surname:Chen;given-names:LL</infon><infon key=\"pub-id_doi\">10.1016/j.jpha.2020.03.009</infon><infon key=\"pub-id_pmid\">32296570</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Pharm Anal</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2020</infon><offset>81051</offset><text>Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants</text></passage><passage><infon key=\"fpage\">3277</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">3286</infon><infon key=\"name_0\">surname:Wang;given-names:J</infon><infon key=\"pub-id_doi\">10.1021/acs.jcim.0c00179</infon><infon key=\"pub-id_pmid\">32315171</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Chem Inf Model</infon><infon key=\"type\">ref</infon><infon key=\"volume\">60</infon><infon key=\"year\">2020</infon><offset>81146</offset><text>Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study</text></passage><passage><infon key=\"fpage\">450</infon><infon key=\"lpage\">454</infon><infon key=\"name_0\">surname:Li;given-names:W</infon><infon key=\"name_1\">surname:Moore;given-names:MJ</infon><infon key=\"name_2\">surname:Vasilieva;given-names:N</infon><infon key=\"name_3\">surname:Sui;given-names:J</infon><infon key=\"name_4\">surname:Wong;given-names:SK</infon><infon key=\"name_5\">surname:Berne;given-names:MA</infon><infon key=\"pub-id_doi\">10.1038/nature02145</infon><infon key=\"pub-id_pmid\">14647384</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">426</infon><infon key=\"year\">2003</infon><offset>81275</offset><text>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</text></passage><passage><infon key=\"fpage\">1444</infon><infon key=\"lpage\">1448</infon><infon key=\"name_0\">surname:Yan;given-names:R</infon><infon key=\"name_1\">surname:Zhang;given-names:Y</infon><infon key=\"name_2\">surname:Li;given-names:Y</infon><infon key=\"name_3\">surname:Xia;given-names:L</infon><infon key=\"name_4\">surname:Guo;given-names:Y</infon><infon key=\"name_5\">surname:Zhou;given-names:Q</infon><infon key=\"pub-id_doi\">10.1126/science.abb2762</infon><infon key=\"pub-id_pmid\">32132184</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">367</infon><infon key=\"year\">2020</infon><offset>81357</offset><text>Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</text></passage><passage><infon key=\"fpage\">1076</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">1078</infon><infon key=\"name_0\">surname:Whisenant;given-names:J</infon><infon key=\"name_1\">surname:Burgess;given-names:K</infon><infon key=\"pub-id_doi\">10.1021/acsmedchemlett.0c00233</infon><infon key=\"pub-id_pmid\">32547694</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Med Chem Lett</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>81434</offset><text>Blocking coronavirus 19 infection via the SARS-CoV-2 spike protein: initial steps</text></passage><passage><infon key=\"fpage\">215</infon><infon key=\"issue\">7807</infon><infon key=\"lpage\">220</infon><infon key=\"name_0\">surname:Lan;given-names:J</infon><infon key=\"name_1\">surname:Ge;given-names:J</infon><infon key=\"name_2\">surname:Yu;given-names:J</infon><infon key=\"name_3\">surname:Shan;given-names:S</infon><infon key=\"name_4\">surname:Zhou;given-names:H</infon><infon key=\"name_5\">surname:Fan;given-names:S</infon><infon key=\"pub-id_doi\">10.1038/s41586-020-2180-5</infon><infon key=\"pub-id_pmid\">32225176</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">581</infon><infon key=\"year\">2020</infon><offset>81516</offset><text>Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</text></passage><passage><infon key=\"fpage\">894</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">904</infon><infon key=\"name_0\">surname:Wang;given-names:Q</infon><infon key=\"name_1\">surname:Zhang;given-names:Y</infon><infon key=\"name_2\">surname:Wu;given-names:L</infon><infon key=\"name_3\">surname:Niu;given-names:S</infon><infon key=\"name_4\">surname:Song;given-names:C</infon><infon key=\"name_5\">surname:Zhang;given-names:Z</infon><infon key=\"pub-id_doi\">10.1016/j.cell.2020.03.045</infon><infon key=\"pub-id_pmid\">32275855</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">181</infon><infon key=\"year\">2020</infon><offset>81601</offset><text>Structural and functional basis of SARS-CoV-2 entry by using human ACE2</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>81673</offset><text>Zhang G, Pomplun S, Loftis AR, Tan X, Loas A, Pentelute BL. Investigation of ACE2 N-terminal fragments binding to SARS-CoV-2 Spike RBD. bioRxiv. 2020. 10.1101/2020.03.19.999318.</text></passage><passage><infon key=\"fpage\">2039</infon><infon key=\"lpage\">2046</infon><infon key=\"name_0\">surname:Walmsley;given-names:S</infon><infon key=\"name_1\">surname:Bernstein;given-names:B</infon><infon key=\"name_2\">surname:King;given-names:M</infon><infon key=\"name_3\">surname:Arribas;given-names:J</infon><infon key=\"name_4\">surname:Beall;given-names:G</infon><infon key=\"name_5\">surname:Ruane;given-names:P</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa012354</infon><infon key=\"pub-id_pmid\">12087139</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">346</infon><infon key=\"year\">2002</infon><offset>81851</offset><text>Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection</text></passage><passage><infon key=\"fpage\">F1</infon><infon key=\"lpage\">F19</infon><infon key=\"name_0\">surname:Pulido;given-names:F</infon><infon key=\"name_1\">surname:Arribas;given-names:JR</infon><infon key=\"name_2\">surname:Delgado;given-names:R</infon><infon key=\"name_3\">surname:Cabrero;given-names:E</infon><infon key=\"name_4\">surname:GonzÃ¡lez-GarcÃ­a;given-names:J</infon><infon key=\"name_5\">surname:PÃ©rez-Elias;given-names:MJ</infon><infon key=\"pub-id_doi\">10.1097/QAD.0b013e3282f4243b</infon><infon key=\"pub-id_pmid\">18097218</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">AIDS.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">22</infon><infon key=\"year\">2008</infon><offset>81932</offset><text>Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV</text></passage><passage><infon key=\"fpage\">222</infon><infon key=\"issue\">1</infon><infon key=\"name_0\">surname:Sheahan;given-names:TP</infon><infon key=\"name_1\">surname:Sims;given-names:AC</infon><infon key=\"name_2\">surname:Leist;given-names:SR</infon><infon key=\"name_3\">surname:Schafer;given-names:A</infon><infon key=\"name_4\">surname:Won;given-names:J</infon><infon key=\"name_5\">surname:Brown;given-names:AJ</infon><infon key=\"pub-id_doi\">10.1038/s41467-019-13940-6</infon><infon key=\"pub-id_pmid\">31924756</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>82042</offset><text>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</text></passage><passage><infon key=\"fpage\">252</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">256</infon><infon key=\"name_0\">surname:Chu;given-names:CM</infon><infon key=\"name_1\">surname:Cheng;given-names:VC</infon><infon key=\"name_2\">surname:Hung;given-names:IF</infon><infon key=\"name_3\">surname:Wong;given-names:MM</infon><infon key=\"name_4\">surname:Chan;given-names:KH</infon><infon key=\"name_5\">surname:Chan;given-names:KS</infon><infon key=\"pub-id_doi\">10.1136/thorax.2003.012658</infon><infon key=\"pub-id_pmid\">14985565</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Thorax.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">59</infon><infon key=\"year\">2004</infon><offset>82164</offset><text>Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>82260</offset><text>Lin S, Shen R, He J, Li X, Guo X. Molecular modeling evaluation of the binding effect of ritonavir, lopinavir and darunavir to severe acute respiratory syndrome coronavirus 2 proteases. bioRxiv. 2020. 10.1101/2020.01.31.929695</text></passage><passage><infon key=\"fpage\">55</infon><infon key=\"name_0\">surname:Mahapatro;given-names:A</infon><infon key=\"name_1\">surname:Singh;given-names:DK</infon><infon key=\"pub-id_doi\">10.1186/1477-3155-9-55</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Nanobiotechnol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2011</infon><offset>82487</offset><text>Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines</text></passage><passage><infon key=\"fpage\">2527</infon><infon key=\"issue\">12</infon><infon key=\"lpage\">2537</infon><infon key=\"name_0\">surname:Liu;given-names:Y</infon><infon key=\"name_1\">surname:Miyoshi;given-names:H</infon><infon key=\"name_2\">surname:Nakamura;given-names:M</infon><infon key=\"pub-id_doi\">10.1002/ijc.22709</infon><infon key=\"pub-id_pmid\">17390371</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Cancer</infon><infon key=\"type\">ref</infon><infon key=\"volume\">120</infon><infon key=\"year\">2007</infon><offset>82594</offset><text>Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles</text></passage><passage><infon key=\"fpage\">1020</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">1034</infon><infon key=\"name_0\">surname:Jia;given-names:F</infon><infon key=\"name_1\">surname:Liu;given-names:X</infon><infon key=\"name_2\">surname:Li;given-names:L</infon><infon key=\"name_3\">surname:Mallapragada;given-names:S</infon><infon key=\"name_4\">surname:Narasimhan;given-names:B</infon><infon key=\"name_5\">surname:Wang;given-names:Q</infon><infon key=\"pub-id_doi\">10.1016/j.jconrel.2013.10.012</infon><infon key=\"pub-id_pmid\">24140748</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Control Release</infon><infon key=\"type\">ref</infon><infon key=\"volume\">172</infon><infon key=\"year\">2013</infon><offset>82730</offset><text>Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents</text></passage><passage><infon key=\"fpage\">57</infon><infon key=\"lpage\">77</infon><infon key=\"name_0\">surname:Majumder;given-names:J</infon><infon key=\"name_1\">surname:Taratula;given-names:O</infon><infon key=\"name_2\">surname:Minko;given-names:T</infon><infon key=\"pub-id_doi\">10.1016/j.addr.2019.07.010</infon><infon key=\"pub-id_pmid\">31400350</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Adv Drug Deliv Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">144</infon><infon key=\"year\">2019</infon><offset>82833</offset><text>Nanocarrier-based systems for targeted and site specific therapeutic delivery</text></passage><passage><infon key=\"fpage\">14051</infon><infon key=\"issue\">8</infon><infon key=\"lpage\">14081</infon><infon key=\"name_0\">surname:Szunerits;given-names:S</infon><infon key=\"name_1\">surname:Barras;given-names:A</infon><infon key=\"name_2\">surname:Khanal;given-names:M</infon><infon key=\"name_3\">surname:Pagneux;given-names:Q</infon><infon key=\"name_4\">surname:Boukherroub;given-names:R</infon><infon key=\"pub-id_doi\">10.3390/molecules200814051</infon><infon key=\"pub-id_pmid\">26247927</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Molecules.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2015</infon><offset>82911</offset><text>Nanostructures for the inhibition of viral infections</text></passage><passage><infon key=\"fpage\">171</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">205</infon><infon key=\"name_0\">surname:Cojocaru;given-names:FD</infon><infon key=\"name_1\">surname:Botezat;given-names:D</infon><infon key=\"name_2\">surname:Gardikiotis;given-names:I</infon><infon key=\"name_3\">surname:Uritu;given-names:CM</infon><infon key=\"name_4\">surname:Dodi;given-names:G</infon><infon key=\"name_5\">surname:Trandafir;given-names:L</infon><infon key=\"pub-id_doi\">10.3390/pharmaceutics12020171</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pharmaceutics.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>82965</offset><text>Nanomaterials designed for antiviral drug delivery transport across biological barriers</text></passage><passage><infon key=\"fpage\">3169</infon><infon key=\"issue\">26</infon><infon key=\"lpage\">3174</infon><infon key=\"name_0\">surname:Coleman;given-names:CM</infon><infon key=\"name_1\">surname:Liu;given-names:YV</infon><infon key=\"name_2\">surname:Mu;given-names:H</infon><infon key=\"name_3\">surname:Taylor;given-names:JK</infon><infon key=\"name_4\">surname:Massare;given-names:M</infon><infon key=\"name_5\">surname:Flyer;given-names:DC</infon><infon key=\"pub-id_doi\">10.1016/j.vaccine.2014.04.016</infon><infon key=\"pub-id_pmid\">24736006</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Vaccine.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">32</infon><infon key=\"year\">2014</infon><offset>83053</offset><text>Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</text></passage><passage><infon key=\"fpage\">19799</infon><infon key=\"issue\">22</infon><infon key=\"lpage\">19807</infon><infon key=\"name_0\">surname:Huang;given-names:X</infon><infon key=\"name_1\">surname:Li;given-names:M</infon><infon key=\"name_2\">surname:Xu;given-names:Y</infon><infon key=\"name_3\">surname:Zhang;given-names:J</infon><infon key=\"name_4\">surname:Meng;given-names:X</infon><infon key=\"name_5\">surname:An;given-names:X</infon><infon key=\"pub-id_doi\">10.1021/acsami.9b04240</infon><infon key=\"pub-id_pmid\">31099550</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Appl Mater Interfaces</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2019</infon><offset>83153</offset><text>Novel gold nanorod-based HR1 peptide inhibitor for Middle East respiratory syndrome coronavirus</text></passage><passage><infon key=\"fpage\">231</infon><infon key=\"issue\">6155</infon><infon key=\"lpage\">234</infon><infon key=\"name_0\">surname:Li;given-names:Y</infon><infon key=\"name_1\">surname:Lu;given-names:J</infon><infon key=\"name_2\">surname:Han;given-names:Y</infon><infon key=\"name_3\">surname:Fan;given-names:X</infon><infon key=\"name_4\">surname:Ding;given-names:S-W</infon><infon key=\"pub-id_doi\">10.1126/science.1241911</infon><infon key=\"pub-id_pmid\">24115437</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">342</infon><infon key=\"year\">2013</infon><offset>83249</offset><text>RNA interference functions as an antiviral immunity mechanism in mammals</text></passage><passage><infon key=\"fpage\">222</infon><infon key=\"lpage\">244</infon><infon key=\"name_0\">surname:Shen;given-names:AM</infon><infon key=\"name_1\">surname:Minko;given-names:T</infon><infon key=\"pub-id_doi\">10.1016/j.jconrel.2020.07.011</infon><infon key=\"pub-id_pmid\">32681948</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Control Release</infon><infon key=\"type\">ref</infon><infon key=\"volume\">326</infon><infon key=\"year\">2020</infon><offset>83322</offset><text>Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery</text></passage><passage><infon key=\"fpage\">8362</infon><infon key=\"issue\">26</infon><infon key=\"lpage\">8376</infon><infon key=\"name_0\">surname:Garbuzenko;given-names:OB</infon><infon key=\"name_1\">surname:Kuzmov;given-names:A</infon><infon key=\"name_2\">surname:Taratula;given-names:O</infon><infon key=\"name_3\">surname:Pine;given-names:SR</infon><infon key=\"name_4\">surname:Minko;given-names:T</infon><infon key=\"pub-id_doi\">10.7150/thno.39816</infon><infon key=\"pub-id_pmid\">31754402</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Theranostics.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2019</infon><offset>83390</offset><text>Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy</text></passage><passage><infon key=\"fpage\">500</infon><infon key=\"lpage\">518</infon><infon key=\"name_0\">surname:Kuzmov;given-names:A</infon><infon key=\"name_1\">surname:Minko;given-names:T</infon><infon key=\"pub-id_doi\">10.1016/j.jconrel.2015.07.024</infon><infon key=\"pub-id_pmid\">26297206</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Control Release</infon><infon key=\"type\">ref</infon><infon key=\"volume\">219</infon><infon key=\"year\">2015</infon><offset>83547</offset><text>Nanotechnology approaches for inhalation treatment of lung diseases</text></passage><passage><infon key=\"fpage\">914</infon><infon key=\"issue\">10</infon><infon key=\"lpage\">925</infon><infon key=\"name_0\">surname:Savla;given-names:R</infon><infon key=\"name_1\">surname:Minko;given-names:T</infon><infon key=\"pub-id_doi\">10.3109/1061186X.2013.829078</infon><infon key=\"pub-id_pmid\">23978292</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Drug Target</infon><infon key=\"type\">ref</infon><infon key=\"volume\">21</infon><infon key=\"year\">2013</infon><offset>83615</offset><text>Nanotechnology approaches for inhalation treatment of fibrosis</text></passage><passage><infon key=\"fpage\">1550</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">1560</infon><infon key=\"name_0\">surname:Minko;given-names:T</infon><infon key=\"name_1\">surname:Stefanov;given-names:A</infon><infon key=\"name_2\">surname:Pozharov;given-names:V</infon><infon key=\"pub-id_doi\">10.1152/japplphysiol.00007.2002</infon><infon key=\"pub-id_pmid\">12235059</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Appl Physiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">93</infon><infon key=\"year\">2002</infon><offset>83678</offset><text>Selected contribution: lung hypoxia: antioxidant and antiapoptotic effects of liposomal alpha-tocopherol</text></passage><passage><infon key=\"fpage\">335</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">344</infon><infon key=\"name_0\">surname:Ivanova;given-names:V</infon><infon key=\"name_1\">surname:Garbuzenko;given-names:OB</infon><infon key=\"name_2\">surname:Reuhl;given-names:KR</infon><infon key=\"name_3\">surname:Reimer;given-names:DC</infon><infon key=\"name_4\">surname:Pozharov;given-names:VP</infon><infon key=\"name_5\">surname:Minko;given-names:T</infon><infon key=\"pub-id_doi\">10.1016/j.ejpb.2012.11.023</infon><infon key=\"pub-id_pmid\">23228437</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur J Pharm Biopharm</infon><infon key=\"type\">ref</infon><infon key=\"volume\">84</infon><infon key=\"year\">2013</infon><offset>83783</offset><text>Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2</text></passage><passage><infon key=\"fpage\">1983</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">1992</infon><infon key=\"name_0\">surname:Garbuzenko;given-names:OB</infon><infon key=\"name_1\">surname:Ivanova;given-names:V</infon><infon key=\"name_2\">surname:Kholodovych;given-names:V</infon><infon key=\"name_3\">surname:Reimer;given-names:DC</infon><infon key=\"name_4\">surname:Reuhl;given-names:KR</infon><infon key=\"name_5\">surname:Yurkow;given-names:E</infon><infon key=\"pub-id_doi\">10.1016/j.nano.2017.04.005</infon><infon key=\"pub-id_pmid\">28434932</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nanomedicine</infon><infon key=\"type\">ref</infon><infon key=\"volume\">13</infon><infon key=\"year\">2017</infon><offset>83856</offset><text>Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s)</text></passage><passage><infon key=\"fpage\">225</infon><infon key=\"lpage\">231</infon><infon key=\"name_0\">surname:Garbuzenko;given-names:OB</infon><infon key=\"name_1\">surname:Kbah;given-names:N</infon><infon key=\"name_2\">surname:Kuzmov;given-names:A</infon><infon key=\"name_3\">surname:Pogrebnyak;given-names:N</infon><infon key=\"name_4\">surname:Pozharov;given-names:V</infon><infon key=\"name_5\">surname:Minko;given-names:T</infon><infon key=\"pub-id_doi\">10.1016/j.jconrel.2019.01.025</infon><infon key=\"pub-id_pmid\">30677435</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Control Release</infon><infon key=\"type\">ref</infon><infon key=\"volume\">296</infon><infon key=\"year\">2019</infon><offset>83967</offset><text>Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>84083</offset><text>El Kantar S, Nehmeh B, Saad P, Mitri G, Estephan C, Mroueh M, et al. Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites. Drug Discov Today. 2020. 10.1016/j.drudis.2020.08.002.</text></passage><passage><infon key=\"fpage\">668</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">678</infon><infon key=\"name_0\">surname:Chandna;given-names:P</infon><infon key=\"name_1\">surname:Saad;given-names:M</infon><infon key=\"name_2\">surname:Wang;given-names:Y</infon><infon key=\"name_3\">surname:Ber;given-names:E</infon><infon key=\"name_4\">surname:Khandare;given-names:J</infon><infon key=\"name_5\">surname:Vetcher;given-names:AA</infon><infon key=\"pub-id_doi\">10.1021/mp070053o</infon><infon key=\"pub-id_pmid\">17685579</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Mol Pharm</infon><infon key=\"type\">ref</infon><infon key=\"volume\">4</infon><infon key=\"year\">2007</infon><offset>84356</offset><text>Targeted proapoptotic anticancer drug delivery system</text></passage><passage><infon key=\"fpage\">900</infon><infon key=\"issue\">10</infon><infon key=\"lpage\">914</infon><infon key=\"name_0\">surname:Taratula;given-names:O</infon><infon key=\"name_1\">surname:Garbuzenko;given-names:OB</infon><infon key=\"name_2\">surname:Chen;given-names:AM</infon><infon key=\"name_3\">surname:Minko;given-names:T</infon><infon key=\"pub-id_doi\">10.3109/1061186X.2011.622404</infon><infon key=\"pub-id_pmid\">21981718</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Drug Target</infon><infon key=\"type\">ref</infon><infon key=\"volume\">19</infon><infon key=\"year\">2011</infon><offset>84410</offset><text>Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA</text></passage><passage><infon key=\"fpage\">10737</infon><infon key=\"issue\">23</infon><infon key=\"lpage\">10742</infon><infon key=\"name_0\">surname:Garbuzenko;given-names:OB</infon><infon key=\"name_1\">surname:Saad;given-names:M</infon><infon key=\"name_2\">surname:Pozharov;given-names:VP</infon><infon key=\"name_3\">surname:Reuhl;given-names:KR</infon><infon key=\"name_4\">surname:Mainelis;given-names:G</infon><infon key=\"name_5\">surname:Minko;given-names:T</infon><infon key=\"pub-id_doi\">10.1073/pnas.1004604107</infon><infon key=\"pub-id_pmid\">20498076</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Proc Natl Acad Sci U S A</infon><infon key=\"type\">ref</infon><infon key=\"volume\">107</infon><infon key=\"year\">2010</infon><offset>84543</offset><text>Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance</text></passage><passage><infon key=\"fpage\">3266</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">3267</infon><infon key=\"name_0\">surname:Kim;given-names:H</infon><infon key=\"pub-id_doi\">10.1007/s00330-020-06748-2</infon><infon key=\"pub-id_pmid\">32072255</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2020</infon><offset>84674</offset><text>Outbreak of novel coronavirus (COVID-19): what is the role of radiologists?</text></passage><passage><infon key=\"fpage\">1843</infon><infon key=\"issue\">18</infon><infon key=\"lpage\">1844</infon><infon key=\"name_0\">surname:Wang;given-names:W</infon><infon key=\"name_1\">surname:Xu;given-names:Y</infon><infon key=\"name_2\">surname:Gao;given-names:R</infon><infon key=\"name_3\">surname:Lu;given-names:R</infon><infon key=\"name_4\">surname:Han;given-names:K</infon><infon key=\"name_5\">surname:Wu;given-names:G</infon><infon key=\"pub-id_doi\">10.1001/jama.2020.3786</infon><infon key=\"pub-id_pmid\">32159775</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>84750</offset><text>Detection of SARS-CoV-2 in different types of clinical specimens</text></passage><passage><infon key=\"fpage\">591</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">605</infon><infon key=\"name_0\">surname:Carter;given-names:LJ</infon><infon key=\"name_1\">surname:Garner;given-names:LV</infon><infon key=\"name_2\">surname:Smoot;given-names:JW</infon><infon key=\"name_3\">surname:Li;given-names:Y</infon><infon key=\"name_4\">surname:Zhou;given-names:Q</infon><infon key=\"name_5\">surname:Saveson;given-names:CJ</infon><infon key=\"pub-id_doi\">10.1021/acscentsci.0c00501</infon><infon key=\"pub-id_pmid\">32382657</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Cent Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2020</infon><offset>84815</offset><text>Assay techniques and test development for COVID-19 diagnosis</text></passage><passage><infon key=\"fpage\">589</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">594</infon><infon key=\"name_0\">surname:Xia;given-names:J</infon><infon key=\"name_1\">surname:Tong;given-names:J</infon><infon key=\"name_2\">surname:Liu;given-names:M</infon><infon key=\"name_3\">surname:Shen;given-names:Y</infon><infon key=\"name_4\">surname:Guo;given-names:D</infon><infon key=\"pub-id_doi\">10.1002/jmv.25725</infon><infon key=\"pub-id_pmid\">32100876</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>84876</offset><text>Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection</text></passage><passage><infon key=\"fpage\">861</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">868</infon><infon key=\"pub-id_doi\">10.1038/s41591-020-0877-5</infon><infon key=\"pub-id_pmid\">32327757</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>84977</offset><text>Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>85103</offset><text>(FDA), Food and Drug Administration. Accelerated emergency use authorization (EUA) summary SARS-CoV-2 assay. Rutgers Clinical Genomics Laboratory. Nationwide Childrenâs Hospital; 2020.Â https://www.fda.gov/media/137423/download.</text></passage><passage><infon key=\"fpage\">823</infon><infon key=\"issue\">8</infon><infon key=\"lpage\">831</infon><infon key=\"name_0\">surname:Bhattarai;given-names:KR</infon><infon key=\"name_1\">surname:Kim;given-names:HR</infon><infon key=\"name_2\">surname:Chae;given-names:HJ</infon><infon key=\"pub-id_doi\">10.7150/ijms.25146</infon><infon key=\"pub-id_pmid\">30008593</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Med Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">15</infon><infon key=\"year\">2018</infon><offset>85334</offset><text>Compliance with saliva collection protocol in healthy volunteers: strategies for managing risk and errors</text></passage><passage><infon key=\"fpage\">619</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">626</infon><infon key=\"name_0\">surname:VanGuilder;given-names:HD</infon><infon key=\"name_1\">surname:Vrana;given-names:KE</infon><infon key=\"name_2\">surname:Freeman;given-names:WM</infon><infon key=\"pub-id_doi\">10.2144/000112776</infon><infon key=\"pub-id_pmid\">18474036</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biotechniques.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">44</infon><infon key=\"year\">2008</infon><offset>85440</offset><text>Twenty-five years of quantitative PCR for gene expression analysis</text></passage><passage><infon key=\"fpage\">729</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">735</infon><infon key=\"name_0\">surname:Park;given-names:GS</infon><infon key=\"name_1\">surname:Ku;given-names:K</infon><infon key=\"name_2\">surname:Baek;given-names:SH</infon><infon key=\"name_3\">surname:Kim;given-names:SJ</infon><infon key=\"name_4\">surname:Kim;given-names:SI</infon><infon key=\"name_5\">surname:Kim;given-names:BT</infon><infon key=\"pub-id_doi\">10.1016/j.jmoldx.2020.03.006</infon><infon key=\"pub-id_pmid\">32276051</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Mol Diagn</infon><infon key=\"type\">ref</infon><infon key=\"volume\">22</infon><infon key=\"year\">2020</infon><offset>85507</offset><text>Development of reverse transcription loop-mediated isothermal amplification assays targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</text></passage><passage><infon key=\"fpage\">5135</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">5142</infon><infon key=\"name_0\">surname:Seo;given-names:G</infon><infon key=\"name_1\">surname:Lee;given-names:G</infon><infon key=\"name_2\">surname:Kim;given-names:MJ</infon><infon key=\"name_3\">surname:Baek;given-names:SH</infon><infon key=\"name_4\">surname:Choi;given-names:M</infon><infon key=\"name_5\">surname:Ku;given-names:KB</infon><infon key=\"pub-id_doi\">10.1021/acsnano.0c02823</infon><infon key=\"pub-id_pmid\">32293168</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Nano</infon><infon key=\"type\">ref</infon><infon key=\"volume\">14</infon><infon key=\"year\">2020</infon><offset>85661</offset><text>Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor</text></passage><passage><infon key=\"fpage\">9399</infon><infon key=\"lpage\">9404</infon><infon key=\"name_0\">surname:Wang;given-names:J</infon><infon key=\"name_1\">surname:Cai;given-names:K</infon><infon key=\"name_2\">surname:Zhang;given-names:R</infon><infon key=\"name_3\">surname:He;given-names:X</infon><infon key=\"name_4\">surname:Shen;given-names:X</infon><infon key=\"name_5\">surname:Liu;given-names:J</infon><infon key=\"pub-id_doi\">10.1021/acs.analchem.0c01884</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Anal Chem</infon><infon key=\"type\">ref</infon><infon key=\"volume\">13</infon><infon key=\"year\">2020</infon><offset>85803</offset><text>Novel one-step single-tube nested quantitative real-time PCR assay for highly sensitive detection of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">38</infon><infon key=\"name_0\">surname:Nuccetelli;given-names:M</infon><infon key=\"name_1\">surname:Pieri;given-names:M</infon><infon key=\"name_2\">surname:Grelli;given-names:S</infon><infon key=\"name_3\">surname:Ciotti;given-names:M</infon><infon key=\"name_4\">surname:Miano;given-names:R</infon><infon key=\"name_5\">surname:Andreoni;given-names:M</infon><infon key=\"pub-id_doi\">10.1038/s41420-020-0275-2</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Death Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2020</infon><offset>85915</offset><text>SARS-CoV-2 infection serology: a useful tool to overcome lockdown?</text></passage><passage><infon key=\"fpage\">eabc6347</infon><infon key=\"issue\">47</infon><infon key=\"name_0\">surname:Bryant;given-names:JE</infon><infon key=\"name_1\">surname:Azman;given-names:AS</infon><infon key=\"name_2\">surname:Ferrari;given-names:MJ</infon><infon key=\"name_3\">surname:Arnold;given-names:BF</infon><infon key=\"name_4\">surname:Boni;given-names:MF</infon><infon key=\"name_5\">surname:Boum;given-names:Y</infon><infon key=\"pub-id_doi\">10.1126/sciimmunol.abc6347</infon><infon key=\"pub-id_pmid\">32430309</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>85982</offset><text>Serology for SARS-CoV-2: apprehensions, opportunities, and the path forward</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>86058</offset><text>Li JX. Cellex qSARS-CoV-2 IgG/IgM Rapid Test. FDA, U.S. Food and Drug Administration. 2020.Â https://www.fda.gov/media/136625/download.</text></passage><passage><infon key=\"fpage\">875</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">882</infon><infon key=\"name_0\">surname:Pan;given-names:D</infon><infon key=\"name_1\">surname:Pramanik;given-names:M</infon><infon key=\"name_2\">surname:Senpan;given-names:A</infon><infon key=\"name_3\">surname:Allen;given-names:JS</infon><infon key=\"name_4\">surname:Zhang;given-names:H</infon><infon key=\"name_5\">surname:Wickline;given-names:SA</infon><infon key=\"pub-id_doi\">10.1096/fj.10-171728</infon><infon key=\"pub-id_pmid\">21097518</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">FASEB J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2011</infon><offset>86194</offset><text>Molecular photoacoustic imaging of angiogenesis with integrin-targeted gold nanobeacons</text></passage><passage><infon key=\"fpage\">3441</infon><infon key=\"lpage\">3452</infon><infon key=\"name_0\">surname:Fraire;given-names:JC</infon><infon key=\"name_1\">surname:Perez;given-names:LA</infon><infon key=\"name_2\">surname:Coronado;given-names:EA</infon><infon key=\"pub-id_doi\">10.1021/nn300474p</infon><infon key=\"pub-id_pmid\">22452324</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Nano</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2012</infon><offset>86282</offset><text>Rational design of plasmonic nanostructures for biomolecular detection: interplay between theory and experiments</text></passage><passage><infon key=\"fpage\">100855</infon><infon key=\"name_0\">surname:Zeng;given-names:J</infon><infon key=\"name_1\">surname:Zhang;given-names:Y</infon><infon key=\"name_2\">surname:Zeng;given-names:T</infon><infon key=\"name_3\">surname:Aleisa;given-names:R</infon><infon key=\"name_4\">surname:Qiu;given-names:Z</infon><infon key=\"name_5\">surname:Chen;given-names:Y</infon><infon key=\"name_6\">surname:Huang;given-names:J</infon><infon key=\"name_7\">surname:Wang;given-names:D</infon><infon key=\"name_8\">surname:Yan;given-names:Z</infon><infon key=\"name_9\">surname:Yin;given-names:Y</infon><infon key=\"pub-id_doi\">10.1016/j.nantod.2020.100855</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nano Today</infon><infon key=\"type\">ref</infon><infon key=\"volume\">32</infon><infon key=\"year\">2020</infon><offset>86395</offset><text>Anisotropic plasmonic nanostructures for colorimetric sensing</text></passage><passage><infon key=\"fpage\">12550</infon><infon key=\"issue\">21</infon><infon key=\"lpage\">12556</infon><infon key=\"name_0\">surname:Huang;given-names:C</infon><infon key=\"name_1\">surname:Wen;given-names:T</infon><infon key=\"name_2\">surname:Shi;given-names:F-J</infon><infon key=\"name_3\">surname:Zeng;given-names:X-Y</infon><infon key=\"name_4\">surname:Jiao;given-names:Y-J</infon><infon key=\"pub-id_doi\">10.1021/acsomega.0c01554</infon><infon key=\"pub-id_pmid\">32542208</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Omega</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>86457</offset><text>Rapid detection of IgM antibodies against the SARS-CoV-2 virus via colloidal gold nanoparticle-based lateral-flow assay</text></passage><passage><infon key=\"fpage\">7617</infon><infon key=\"lpage\">7627</infon><infon key=\"name_0\">surname:Moitra;given-names:P</infon><infon key=\"name_1\">surname:Alafeef;given-names:M</infon><infon key=\"name_2\">surname:Dighe;given-names:K</infon><infon key=\"name_3\">surname:Frieman;given-names:MB</infon><infon key=\"name_4\">surname:Pan;given-names:D</infon><infon key=\"pub-id_doi\">10.1021/acsnano.0c03822</infon><infon key=\"pub-id_pmid\">32437124</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Nano</infon><infon key=\"type\">ref</infon><infon key=\"volume\">14</infon><infon key=\"year\">2020</infon><offset>86577</offset><text>Selective naked-eye detection of SARS-CoV-2 mediated by N gene targeted antisense oligonucleotide capped plasmonic nanoparticles</text></passage><passage><infon key=\"fpage\">4812</infon><infon key=\"issue\">1</infon><infon key=\"name_0\">surname:Smyrlaki;given-names:I</infon><infon key=\"name_1\">surname:Ekman;given-names:M</infon><infon key=\"name_2\">surname:Lentini;given-names:A</infon><infon key=\"name_3\">surname:Rufino de Sousa;given-names:N</infon><infon key=\"name_4\">surname:Papanicolaou;given-names:N</infon><infon key=\"name_5\">surname:Vondracek;given-names:M</infon><infon key=\"pub-id_doi\">10.1038/s41467-020-18611-5</infon><infon key=\"pub-id_pmid\">32968075</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>86706</offset><text>Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR</text></passage><passage><infon key=\"fpage\">344</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">347</infon><infon key=\"name_0\">surname:Lu;given-names:R</infon><infon key=\"name_1\">surname:Wu;given-names:X</infon><infon key=\"name_2\">surname:Wan;given-names:Z</infon><infon key=\"name_3\">surname:Li;given-names:Y</infon><infon key=\"name_4\">surname:Zuo;given-names:L</infon><infon key=\"name_5\">surname:Qin;given-names:J</infon><infon key=\"pub-id_doi\">10.1007/s12250-020-00218-1</infon><infon key=\"pub-id_pmid\">32239445</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Virol Sin</infon><infon key=\"type\">ref</infon><infon key=\"volume\">35</infon><infon key=\"year\">2020</infon><offset>86790</offset><text>Development of a novel reverse transcription loop-mediated isothermal amplification method for rapid detection of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">e1008705</infon><infon key=\"issue\">8</infon><infon key=\"name_0\">surname:Hou;given-names:T</infon><infon key=\"name_1\">surname:Zeng;given-names:W</infon><infon key=\"name_2\">surname:Yang;given-names:M</infon><infon key=\"name_3\">surname:Chen;given-names:W</infon><infon key=\"name_4\">surname:Ren;given-names:L</infon><infon key=\"name_5\">surname:Ai;given-names:J</infon><infon key=\"pub-id_doi\">10.1371/journal.ppat.1008705</infon><infon key=\"pub-id_pmid\">32853291</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS Pathog</infon><infon key=\"type\">ref</infon><infon key=\"volume\">16</infon><infon key=\"year\">2020</infon><offset>86915</offset><text>Development and evaluation of a rapid CRISPR-based diagnostic for COVID-19</text></passage><passage><infon key=\"fpage\">e01136</infon><infon key=\"issue\">5</infon><infon key=\"name_0\">surname:Hou;given-names:H</infon><infon key=\"name_1\">surname:Wang;given-names:T</infon><infon key=\"name_2\">surname:Zhang;given-names:B</infon><infon key=\"name_3\">surname:Luo;given-names:Y</infon><infon key=\"name_4\">surname:Mao;given-names:L</infon><infon key=\"name_5\">surname:Wang;given-names:F</infon><infon key=\"pub-id_doi\">10.1002/cti2.1136</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Transl Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>86990</offset><text>Detection of IgM and IgG antibodies in patients with coronavirus disease 2019</text></passage><passage><infon key=\"fpage\">730</infon><infon key=\"issue\">8</infon><infon key=\"lpage\">737</infon><infon key=\"name_0\">surname:Cozzi;given-names:D</infon><infon key=\"name_1\">surname:Albanesi;given-names:M</infon><infon key=\"name_2\">surname:Cavigli;given-names:E</infon><infon key=\"name_3\">surname:Moroni;given-names:C</infon><infon key=\"name_4\">surname:Bindi;given-names:A</infon><infon key=\"name_5\">surname:LuvarÃ ;given-names:S</infon><infon key=\"pub-id_doi\">10.1007/s11547-020-01232-9</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">La Radiol Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">125</infon><infon key=\"year\">2020</infon><offset>87068</offset><text>Chest X-ray in new coronavirus disease 2019 (COVID-19) infection: findings and correlation with clinical outcome</text></passage><passage><infon key=\"fpage\">87</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">93</infon><infon key=\"name_0\">surname:Salehi;given-names:S</infon><infon key=\"name_1\">surname:Abedi;given-names:A</infon><infon key=\"name_2\">surname:Balakrishnan;given-names:S</infon><infon key=\"name_3\">surname:Gholamrezanezhad;given-names:A</infon><infon key=\"pub-id_doi\">10.2214/AJR.20.23034</infon><infon key=\"pub-id_pmid\">32174129</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Am J Roentgenol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">215</infon><infon key=\"year\">2020</infon><offset>87181</offset><text>Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients</text></passage><passage><infon key=\"fpage\">1280</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">1286</infon><infon key=\"name_0\">surname:Li;given-names:Y</infon><infon key=\"name_1\">surname:Xia;given-names:L</infon><infon key=\"pub-id_doi\">10.2214/AJR.20.22954</infon><infon key=\"pub-id_pmid\">32130038</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Am J Roentgenol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">214</infon><infon key=\"year\">2020</infon><offset>87274</offset><text>Coronavirus disease 2019 (COVID-19): role of chest CT in diagnosis and management</text></passage><passage><infon key=\"fpage\">378</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">385</infon><infon key=\"name_0\">surname:Buda;given-names:N</infon><infon key=\"name_1\">surname:Segura-Grau;given-names:E</infon><infon key=\"name_2\">surname:Cylwik;given-names:J</infon><infon key=\"name_3\">surname:WeÅnicki;given-names:M</infon><infon key=\"pub-id_doi\">10.1016/j.advms.2020.06.005</infon><infon key=\"pub-id_pmid\">32659729</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Adv Med Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">65</infon><infon key=\"year\">2020</infon><offset>87356</offset><text>Lung ultrasound in the diagnosis of COVID-19 infection - a case series and review of the literature</text></passage><passage><infon key=\"fpage\">E32</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">E40</infon><infon key=\"name_0\">surname:Ai;given-names:T</infon><infon key=\"name_1\">surname:Yang;given-names:Z</infon><infon key=\"name_2\">surname:Hou;given-names:H</infon><infon key=\"name_3\">surname:Zhan;given-names:C</infon><infon key=\"name_4\">surname:Chen;given-names:C</infon><infon key=\"name_5\">surname:Lv;given-names:W</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200642</infon><infon key=\"pub-id_pmid\">32101510</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">296</infon><infon key=\"year\">2020</infon><offset>87456</offset><text>Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>87571</offset><text>Fu F, Lou J, Xi D, Bai Y, Ma G, Zhao B, et al. Chest computed tomography findings of coronavirus disease 2019 (COVID-19) pneumonia. Eur Radiol 2020;30(10):5489â98. 10.1007/s00330-020-06920-8.</text></passage><passage><infon key=\"fpage\">384</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">385</infon><infon key=\"name_0\">surname:Lee;given-names:EYP</infon><infon key=\"name_1\">surname:Ng;given-names:M-Y</infon><infon key=\"name_2\">surname:Khong;given-names:P-L</infon><infon key=\"pub-id_doi\">10.1016/s1473-3099(20)30134-1</infon><infon key=\"pub-id_pmid\">32105641</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>87765</offset><text>COVID-19 pneumonia: what has CT taught us?</text></passage><passage><infon key=\"fpage\">497</infon><infon key=\"issue\">10223</infon><infon key=\"lpage\">506</infon><infon key=\"name_0\">surname:Huang;given-names:C</infon><infon key=\"name_1\">surname:Wang;given-names:Y</infon><infon key=\"name_2\">surname:Li;given-names:X</infon><infon key=\"name_3\">surname:Ren;given-names:L</infon><infon key=\"name_4\">surname:Zhao;given-names:J</infon><infon key=\"name_5\">surname:Hu;given-names:Y</infon><infon key=\"pub-id_doi\">10.1016/s0140-6736(20)30183-5</infon><infon key=\"pub-id_pmid\">31986264</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>87808</offset><text>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</text></passage><passage><infon key=\"fpage\">715</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">721</infon><infon key=\"name_0\">surname:Pan;given-names:F</infon><infon key=\"name_1\">surname:Ye;given-names:T</infon><infon key=\"name_2\">surname:Sun;given-names:P</infon><infon key=\"name_3\">surname:Gui;given-names:S</infon><infon key=\"name_4\">surname:Liang;given-names:B</infon><infon key=\"name_5\">surname:Li;given-names:L</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200370</infon><infon key=\"pub-id_pmid\">32053470</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">295</infon><infon key=\"year\">2020</infon><offset>87891</offset><text>Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19)</text></passage></document></collection>\n",
      "\n",
      "Study 32563999: <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n",
      "<!DOCTYPE collection SYSTEM \"BioC.dtd\">\n",
      "<collection><source>PMC</source><date>20230601</date><key>pmc.key</key><document><id>10016932</id><infon key=\"license\">CC BY</infon><passage><infon key=\"article-id_doi\">10.1136/postgradmedj-2020-138234</infon><infon key=\"article-id_pmc\">10016932</infon><infon key=\"article-id_pmid\">32563999</infon><infon key=\"article-id_publisher-id\">postgradmedj-2020-138234</infon><infon key=\"fpage\">753</infon><infon key=\"issue\">1142</infon><infon key=\"kwd\">Pathology Histopathology Education and training (see medical education &amp; training) Medical education and training Surgery Transplant surgery Hepatobiliary surgery Basic sciences Pathology</infon><infon key=\"license\">This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by/4.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</infon><infon key=\"lpage\">758</infon><infon key=\"name_0\">surname:Umakanthan;given-names:Srikanth</infon><infon key=\"name_1\">surname:Sahu;given-names:Pradeep</infon><infon key=\"name_2\">surname:Ranade;given-names:Anu V</infon><infon key=\"name_3\">surname:Bukelo;given-names:Maryann M</infon><infon key=\"name_4\">surname:Rao;given-names:Joseph Sushil</infon><infon key=\"name_5\">surname:Abrahao-Machado;given-names:Lucas Faria</infon><infon key=\"name_6\">surname:Dahal;given-names:Samarika</infon><infon key=\"name_7\">surname:Kumar;given-names:Hari</infon><infon key=\"name_8\">surname:KV;given-names:Dhananjaya</infon><infon key=\"section_type\">TITLE</infon><infon key=\"type\">front</infon><infon key=\"volume\">96</infon><infon key=\"year\">2020</infon><offset>0</offset><text>Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19)</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>86</offset><text>Abstract</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>95</offset><text>Coronavirus has emerged as a global health threat due to its accelerated geographic spread over the last two decades. This article reviews the current state of knowledge concerning the origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Historically, it has caused two pandemics: severe acute respiratory syndrome and Middle East respiratory syndrome followed by the present COVID-19 that emerged from China. The virus is believed to be acquired from zoonotic source and spreads through direct and contact transmission. The symptomatic phase manifests with fever, cough and myalgia to severe respiratory failure. The diagnosis is confirmed using reverse transcriptase PCR. Management of COVID-19 is mainly by supportive therapy along with mechanical ventilation in severe cases. Preventive strategies form the major role in reducing the public spread of virus along with successful disease isolation and community containment. Development of a vaccine to eliminate the virus from the host still remains an ongoing challenge.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>1155</offset><text>Introduction</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>1168</offset><text>Coronavirus (CoV) is derived from the word âcoronaâ meaning âcrownâ in Latin. It causes a range of human respiratory tract infections varying from mild cold to severe respiratory distress syndrome. The present novel CoV disease also called as severe acute respiratory syndrome (SARS)-CoV-2 and coronavirus disease 2019 (COVID-19) is an emerging global health threat. The COVID-19 epidemic started from Wuhan city of China towards the end of December 2019 and since then spread rapidly to Thailand, Japan, South Korea, Singapore and Iran in the initial months. This was followed by wide viral dissemination around the world including Spain, Italy, USA, UAE and the UK. The WHO declared the COVID-19 outbreak as a pandemic. As of 6 May 2020, outbreaks and sporadic human infections have resulted in 3 732 046 confirmed cases and 261 517 deaths.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>2019</offset><text>The CoV has posed frequent challenges during its course ranging from virus isolation, detection, prevention to vaccine development. CoV belongs to the order Nidovirales and has the largest RNA genome. It is known to be acquired from a zoonotic source and typically spreads through contact and droplet transmission. The infected person presents with non-specific clinical features requiring virological detection and confirmation by molecular techniques. This article aims to give a detailed insight into the evolution, transmission and diagnosis of COVID-19. We further discuss the challenges encountered in the management of patients with COVID-19 and the current limitations in the investigational vaccine. Due to the rapidly evolving nature of COVID-19, the readers are requested to update themselves with the nature of change with this particular type of CoV.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>2883</offset><text>ORIGIN</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>2890</offset><text>Historic perspective</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>2911</offset><text>CoV was discovered during the 1960s. The Coronavirus Study Group under the International Committee on Taxonomy of Viruses used the principle of comparative genomics to further assess and partition the replicative proteins in open reading frames to identify the factors that differentiate CoV at different cluster ranks. Â  CoV is associated with illness of varied intensity. The most severe type resulting in large-scale pandemics in the past are the SARS (in 2002â2003) and Middle East respiratory syndrome (MERS) (in 2012). Â </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>3442</offset><text>Aetiology</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>3452</offset><text>CoV are RNA viruses of the subfamily Coronavirinae. They belong to the family Coronaviridae and the order Nidovirales (nido Latin for ânestâ). The order Nidovirales is composed of Coronaviridae, Arteriviridae, Mesovirididae and Roniviridae families. Â  The characteristic features of Nidovirales are as follows: they (1) contain very large genomes for RNA viruses, (2) are highly replicative due to conserved genomic organisation, (3) exhibit several unique enzymatic activities and (4) have extensive ribosomal frameshifting due to the expression of numerous non-structural genes. The Coronaviridae family have two subfamilies: Coronavirinae and Torovirinae. The subfamily Coronavirinae consist of alpha CoV, beta CoV, gamma CoV and delta CoV based on genomic structure.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>4228</offset><text>Viral structure</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>4244</offset><text>The CoV are enveloped positive single-stranded RNA viruses having the largest known viral RNA genomes of 8.4â12 kDa in size. The viral genomes are made up of 5Ê¹ and 3Ê¹ terminal. The 5Ê¹ terminal constitutes a major part of the genome and contains open reading frames, which encodes proteins responsible for viral replication. The 3Ê¹ terminal contains the five structural proteins, namely the spike protein (S), membrane protein (M), nucleocapsid protein (N), envelope protein (E) and the haemagglutinin-esterase (HE) protein. Â  The S protein mediates an attachment and fusion between the virus and host cell membrane and also between the infected and adjacent uninfected cells. They are the major inducers for neutralising antibodies in a vaccine. The N protein forms RNA complexes that aid in virus transcription and assembly. The M protein is the most abundant structural protein and also defines the viral envelope shape. The E protein is the most enigmatic and the smallest of the major structural protein, which is highly expressed within the infected cell during viral replication cycle. The HE protein is responsible for receptor binding and host specificity. Â </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>5420</offset><text>SARS and MERS</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>5434</offset><text>SARS was first recognised in Guangdong province, China, in November 2002. It advanced among 30 countries, infecting 79 000 people by 2003 with a fatality of 9.5%. SARS-CoV was traced and isolated from Himalayan palm civets found in a livestock market in Guangdong, China. Â  The zoonotic origin of SARS was also discovered in racoon dogs, ferret badgers and in humans working at the same market. These market animals were therefore intermediate hosts that increased the transmission of virus to humans. Â </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>5940</offset><text>Thereon, in 2012, Jeddah, Saudi Arabia, a patient presented with respiratory illness consistent with pneumonia along with features of renal failure. The patientâs sputum analysis was done by reverse transciptase (RT-PCR) using pan-CoV primers revealing the viral RNA to be MERS-CoV. As of July 2013, 91 patients were infected with MERS-CoV and had a high fatality rate of 34%. Bats and Arabian dromedary camels were identified as potential hosts for MERS-CoV. Intermediate host reservoir species were also seen in goats, sheep and cows. Â </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>6482</offset><text>Novel CoV</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>6492</offset><text>In view of taxonomical classification, SARS-CoV-2 (COVID-19) is one among many other viruses in the species, SARS-related CoV. However, SARS-CoV and SARS-CoV-2 vary in terms of disease spectrum, modes of transmission and also diagnostic methods. Â  The recent report on a cluster cases having respiratory illness in Wuhan, Central China, was followed by a global spread of the disease in a very short duration of time. The samples (oral and anal swabs, blood and broncho-alveolar fluid lavage) from patients admitted to the intensive care unit of Wuhan Jinyintan Hospital were sent to Wuhan Institute of Virology. Pan-CoV PCR primers were used and these samples were positive for CoV. Â  This was followed by metagenomics analysis and genomic sequencing study. The results revealed that this virus was identical (79.6%) to the genetic sequence of SARS-CoVBJ01 leading the WHO to call it novel CoV-2019 (2019-nCoV). Â </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>7410</offset><text>Transmission and Pathogenesis</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>7440</offset><text>Zoonosis</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>7449</offset><text>CoVs are widespread among birds and mammals with cements bats forming the major evolutionary reservoir and ecological drivers of CoV diversity. CoV causes a large variety of diseases in pigs, cows, chicken, dogs and cats. The major diseases caused by CoVs in animals are transmissible gastroenteritis virus, porcine epidemic diarrhoea virus, porcine hemagglutinating encephalomyelitis virus and murine hepatitis virus. In humans, alpha and beta CoV have caused a variety of illness ranging from mild-self-limiting respiratory infections (HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1) to severe acute respiratory distress syndrome (ARDS). Â </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>8088</offset><text>Initial cases reported in Wuhan, China, are considered to be an acquired infection from a zoonotic source from Huanan wholesale seafood market which sold poultry, snake, bats and other farm animals. Â  To isolate the possible virus reservoir, a comprehensive genetic sequence analysis was undertaken among different animal species. Â  The results suggested that 2019-nCov is a recombinant virus between the bat CoV and an unknown origin CoV. A study revealed, based on relative synonymous codon usage (RSCU) on variety of animal species showed that bats are the most probable wildlife reservoir of 2019-nCov. This homologous recombination has proved previously in classical swine fever virus, hepatitis B virus, hepatitis C virus, HIV and dengue virus.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>8841</offset><text>Modes of spread</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>8857</offset><text>Human-to-human transmission occurs through common routes such as direct transmission, contact transmission and airborne transmissions through aerosols and during medical procedures (figure 1). Cough, sneeze, droplet inhalation, contact with oral, nasal and eye mucous membranes are the common modes of spread. Viral shedding occurs from respiratory tract, saliva, faeces and urine resulting in other sources of virus spread. Â  Â  The viral load is higher and of longer duration in patients with severe COVID-19. Spread of COVID-19 from patients to health workers and flight attenders who were in close contact with the infected patients are also reported.</text></passage><passage><infon key=\"file\">postgradmedj-96-753-f1.jpg</infon><infon key=\"id\">F1</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>9514</offset><text>Modes of transmission.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>9537</offset><text>Virusâhost interaction</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>9562</offset><text>Extensive structural analyses revealed atomic-level interactions between the CoV and the host. Cross-species and human-to-human transmission of COVID-19 is mainly dependent on spike protein receptor-binding domain and its host receptor ACE2. Â  High expression of ACE2 was identified in lung (type II alveolar cells), oesophagus, ileum, colon, kidney (proximal convoluted tubules), myocardium, bladder (urothelial cells) and also recently the oral mucosa. ACE2 receptors provide entry of the virus into the host cells and also subsequent viral replication. The main factors involved in viral pathogenesis of 2019-nCov are spike 1 subunit protein, priming by transmembrane protease serine-2 (essential for entry and viral replication), ACE2 receptorâ2019-nCov interaction and downregulation of ACE2 protein. These factors contribute to atrophy, fibrosis, inflammation and vasoconstriction resulting in host tissue injury.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_1</infon><offset>10485</offset><text>Clinical Presentation and Diagnosis</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>10521</offset><text>Demographics</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>10534</offset><text>Based on numerous studies published, the median age was 56 years (range 55â65 years) and males were predominately affected due to high ACE2 concentrations in them. The median onset of illness was 8 days (range 5â13 days). Â  Due to limited comorbid data availability, it is important to correlate with previously proven susceptible factors to SARS and MERS-CoV infection, which includes smoking, hypertension, diabetes, cardiovascular disease and/or chronic illness. Â  Â  Based on the National Health Institute analysis in Italy, the average mortality age for patients suffering from COVID-19 was 81 years. In China, the case fatality rate (CFR) increased with age and showed CFR of 18% for patients above 80 years. This striking target to the elderly population is attributed to underlying chronic disorders and declined immune function. Declined immune function has been linked to cytokine storm syndrome (elevated circulating inflammatory cytokines) and hyper-inflammation syndrome. These syndromes are triggered by viral infections and are also predictors of fatality in patients with COVID-19. Â  Children are less affected due to higher antibodies, lower prior exposure to the virus and relatively low levels of inflammatory cytokines in their systems.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>11798</offset><text>Signs and symptoms</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>11817</offset><text>Clinical features varied from mild illness to severe or fatal illness. The most common symptoms of COVID-19 were non-specific and mainly included fever, cough and myalgia. Other minor symptoms were sore throat, headache, chills, nausea or vomiting, diarrhoea, ageusia and conjunctival congestion. The COVID-19 was clinically classified into mild to moderate disease (non-pneumonia and pneumonia), severe disease (dyspnoea, respiratory frequency over 30/min, oxygen saturation less than 93%, PaO2/FiO2 ratio less than 300 and/or lung infiltrates more than 50% of the lung field within 24â48 hours) and critical (respiratory failure, septic shock and/or multi-organ dysfunction/failure). Â  Many of the elderly patients who had severe illness had evidence of chronic underlying illness such as cardiovascular disease, lung disease, kidney disease or malignant tumours.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>12686</offset><text>Laboratory evaluation and confirmation</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>12725</offset><text>Laboratory findings most consistent with COVID-19 were lymphocytopenia, elevated C reactive protein and elevated erythrocyte sedimentation rate. Lymphocytopenia is due to necrosis or apoptosis of lymphocytes. The severity of lymphocytopenia reflects the severity of COVID-19. Procalcitonin was commonly elevated and was associated with coinfection in majority of reported paediatric cases. Â </text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>13118</offset><text>Detection of COVID-19 is based on virological detection by RT-PCR using swabs (nasopharynx, oropharynx), sputum and faeces, chest radiograph and dynamic monitoring of inflammatory mediators (eg, cytokines). Faecal specimens detected for COVID-19 nucleic acid was equally accurate as of pharyngeal swab specimens. Patients with COVID-19 showed high blood levels of cytokines and chemokines such as interleukin (IL)-7, IL-8, IL-9, IL-10, granulocyte-colony stimulating factor, granulocyte-macrophage colony-stimulating factor ,tumour necrosis factor alpha and VEGFA. Â  Â </text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>13689</offset><text>Radiological findings</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>13711</offset><text>Most standard patterns observed on chest CT were ground-glass opacity, ill-defined margins, smooth or irregular interlobular septal thickening, air bronchogram, crazy-paving pattern and thickening of the adjacent pleura. Chest CT is considered to be a sensitive routine imaging tool for COVID-19.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">title_1</infon><offset>14008</offset><text>Management</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>14019</offset><text>At the initial presentation of cluster infection, many cases were treated with antiviral therapy, antibacterial therapy and glucocorticoids. Observation forms the mainstay for those who have mild illness. Moderately ill patients with underlying chronic illness, immunocompromised conditions and pregnancy require hospitalisation. Â </text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>14352</offset><text>The anti-malarial drugs, hydroxychloroquine and chloroquine, showed promising results in early in vitro study. However, the most robust and recent study in patients with COVID-19 have not shown unequivocal evidence of benefits for the treatment with hydroxychloroquine or chloroquine. In fact, the largest analysis to date of the risks and benefits of treating COVID-19 patients with these anti-malarial drugs was unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19. Besides, this study of 96 000 hospitalised patients on six continents found that those who received the drugs had a significantly higher risk of death and an increased frequency of ventricular arrhythmias compared with those who did not use it.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">title_2</infon><offset>15152</offset><text>Treatment of systemic complications in COVID-19</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>15200</offset><text>Extracorporeal membrane oxygenation is an excellent choice for patients with ARDS progressing to respiratory failure. Other modes of treatment include high-flow nasal oxygen and endotracheal intubation. Patients experiencing persistent refractory hypoxemia need prone positioning followed by neuromuscular blockade, inhaled nitric oxide (at 5â20ppm) and also provide optimal end-expiratory pressure by inserting oesophagal balloon. Â </text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>15637</offset><text>In the presence of shock with acute renal failure, negative fluid balance needs to be achieved by dialysis. Antimicrobials are used for pre-exposure and post-exposure prophylaxis. This prevents illness from SARS-CoV-2 and also reduces the risk of acquiring secondary infection. Fluid management is important to reduce pulmonary oedema. Â  Â  Glucocorticoids are best avoided due to its harmful effects in viral pneumonia and ARDS. Rescue therapy by administration of intravenous infusion of vitamin C has been suggested to attenuate vascular injury and systemic inflammation in sepsis and ARDS.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">title_2</infon><offset>16232</offset><text>Role of vaccines</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>16249</offset><text>Vaccine development is underway for COVID-19, but there are various limitations. This includes (1) the place for phase 3 vaccine trials are to be conducted in the locality of the ongoing transmission of disease, (2) vaccine manufactures need to work closely with biotechnology companies to develop effective vaccines which probably takes a minimum of 12â18 months and (3) regulators should evaluate safety with a range of virus strains in more than one animal model.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>16718</offset><text>The investigational vaccine has been currently developed using mRNA as its genetic platform using prior studies related to SARS and MERS. Â  The basis of effective vaccine is immune targeted and involves identifying of B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins among 120 available SARS-CoV-2 genetic sequences. Effective vaccination would play a vital role in reducing the viral spread and eliminate the virus from the host.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">title_1</infon><offset>17185</offset><text>Conclusion</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>17196</offset><text>COVID-19 has presented itself as a global pandemic in a short time period resulting in rapid curve shift of infected patients, increasing death rates, huge global economic burden and widespread mobilisation of medical resource across the globe. Being a novel disease, COVID-19 has presented itself as a mystery infection to the medical field, also requiring tremendous research and insights about the nature of the virus, and posing frequent challenges for a successful vaccine outcome. The approach to this disease requires active loco-regional to international collaboration with regards to disease containment, preventive strategies and treatment approach.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">title_1_caption</infon><offset>17856</offset><text>Main messages</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>17870</offset><text>This article reviews the current state of knowledge concerning the origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19).</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>18024</offset><text>It traces the origin of coronavirus as it emerged and differentiates the COVID-19 with specific features from SARS and MERS.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>18149</offset><text>We give a detailed insight into the modes of transmission, clinical manifestations, diagnosis and management. Also, it highlights the recent trends on vaccine development.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">title_1_caption</infon><offset>18321</offset><text>Key references</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>18336</offset><text>Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579:265â9.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>18458</offset><text>Raoult D, Zumla A, Locatelli F, et al. Coronavirus infections: epidemiological, clinical and immunological features and hypotheses. Cell Stress 2020.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>18608</offset><text>Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507â13.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>18796</offset><text>Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics 2020; e20200702.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>18950</offset><text>Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019;17:181â92.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">title_1_caption</infon><offset>19057</offset><text>Self-assessment questions</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>19083</offset><text>Dromedary camel was involved in zoonotic transmission in MERS form of CoV?</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>19158</offset><text>Based on COVID-19 genomic structure, the protein that mediates an attachment and fusion between the virus and the host cell membrane is membrane (M) protein.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>19316</offset><text>Cross-species and human-to-human transmission of COVID-19 is mainly dependent on the host receptor ACE2 protein.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>19429</offset><text>Most consistent laboratory finding in COVID-19 patient is lymphopenia</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>19499</offset><text>COVID-19 is confirmed by RT-PCR.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">title_1_caption</infon><offset>19532</offset><text>Current research questions</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>19559</offset><text>How does COVID-19 differ from SARS and MERS?</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>19604</offset><text>Mention the factors responsible for virusâhost interaction.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>19666</offset><text>List the specific laboratory findings in suspected cases of COVID-19.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>19736</offset><text>Elaborate the scheme of management in COVID-19.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">title_1_caption</infon><offset>19784</offset><text>Self-assessment answers</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>19808</offset><text>True</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>19813</offset><text>False</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>19819</offset><text>True</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>19824</offset><text>True</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>19829</offset><text>True</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">title_1</infon><offset>19834</offset><text>Supplementary Material</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">title</infon><offset>19857</offset><text>Footnotes</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">footnote</infon><offset>19867</offset><text>Correction notice: This article has been corrected since it appeared Online First. Minor typographical errors have been corrected.</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">footnote</infon><offset>19998</offset><text>Contributors: SU contributed to the conception and design of the work, data collection, drafting, revision and final version. PS contributed to the data analysis, interpretation, drafting the article and critical revision. AVR contributed to the data collection, analysis, revision and image concept. MMB contributed to the data collection and drafting. JSR contributed to the data analysis and interpretation. LFA-M, SD and HK contributed to the data collection and analysis DKV contributed to the data collection. All the contributors were involved in revising the final version and granting final approval for the article to be submitted for publication.</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">footnote</infon><offset>20656</offset><text>Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">footnote</infon><offset>20807</offset><text>Competing interests: None declared.</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">footnote</infon><offset>20843</offset><text>Patient consent for publication: Not required.</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">footnote</infon><offset>20890</offset><text>Provenance and peer review: Not commissioned; internally peer reviewed.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">title</infon><offset>20962</offset><text>References</text></passage><passage><infon key=\"fpage\">635</infon><infon key=\"lpage\">64</infon><infon key=\"pub-id_doi\">10.1128/MMBR.69.4.635-664.2005</infon><infon key=\"pub-id_pmid\">16339739</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Microbiol Mol Biol Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">69</infon><infon key=\"year\">2005</infon><offset>20973</offset><text>Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus</text></passage><passage><infon key=\"fpage\">542</infon><infon key=\"lpage\">5</infon><infon key=\"pub-id_doi\">10.1016/S0140-6736(20)30374-3</infon><infon key=\"pub-id_pmid\">32061313</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>21070</offset><text>WHO Scientific and Technical Advisory Group for Infectious Hazards. COVID-19: what is next for public health?</text></passage><passage><infon key=\"fpage\">57</infon><infon key=\"pub-id_doi\">10.1186/s12916-020-01533-w</infon><infon key=\"pub-id_pmid\">32106852</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BMC Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">18</infon><infon key=\"year\">2020</infon><offset>21180</offset><text>Q&amp;A: the novel coronavirus outbreak causing COVID-19</text></passage><passage><infon key=\"fpage\">265</infon><infon key=\"lpage\">9</infon><infon key=\"pub-id_doi\">10.1038/s41586-020-2008-3</infon><infon key=\"pub-id_pmid\">32015508</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">579</infon><infon key=\"year\">2020</infon><offset>21233</offset><text>A new coronavirus associated with human respiratory disease in China</text></passage><passage><infon key=\"fpage\">100124</infon><infon key=\"pub-id_doi\">10.1016/j.onehlt.2020.100124</infon><infon key=\"pub-id_pmid\">32195311</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">One Health</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>21302</offset><text>From SARS to COVID-19: a previously unknown SARS-related coronavirus (SARS-CoV-2) of pandemic potential infecting humans - call for a one health approach</text></passage><passage><infon key=\"fpage\">e7541</infon><infon key=\"pub-id_pmid\">32377489</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cureus</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>21456</offset><text>Closure of universities due to coronavirus disease 2019 (COVID-19): impact on education and mental health of students and academic staff</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>21593</offset><text>Coronavirus COVID-19 global cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) [May;2020];</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>21730</offset><text>Coronavirus disease (COVID-2019) situation reports. Situation report-51</text></passage><passage><infon key=\"fpage\">276</infon><infon key=\"lpage\">8</infon><infon key=\"pub-id_doi\">10.1126/science.1087139</infon><infon key=\"pub-id_pmid\">12958366</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">302</infon><infon key=\"year\">2003</infon><offset>21802</offset><text>Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China</text></passage><passage><infon key=\"fpage\">181</infon><infon key=\"lpage\">92</infon><infon key=\"pub-id_pmid\">30531947</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Rev Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">17</infon><infon key=\"year\">2019</infon><offset>21907</offset><text>Origin and evolution of pathogenic coronaviruses</text></passage><passage><infon key=\"fpage\">850</infon><infon key=\"lpage\">2</infon><infon key=\"pub-id_doi\">10.1016/S0140-6736(20)30468-2</infon><infon key=\"pub-id_pmid\">32135077</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>21956</offset><text>COVID-19 and the anti-lessons of history</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Stress</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>21997</offset><text>Coronavirus infections: epidemiological, clinical and immunological features and hypotheses</text></passage><passage><infon key=\"fpage\">E244</infon><infon key=\"pub-id_doi\">10.3390/v12020244</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Viruses</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>22089</offset><text>Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV</text></passage><passage><infon key=\"fpage\">536</infon><infon key=\"lpage\">44</infon><infon key=\"pub-id_doi\">10.1038/s41564-020-0695-z</infon><infon key=\"pub-id_pmid\">32123347</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>22191</offset><text>The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2</text></passage><passage><infon key=\"fpage\">884</infon><infon key=\"lpage\">95</infon><infon key=\"pub-id_doi\">10.1128/JVI.79.2.884-895.2005</infon><infon key=\"pub-id_pmid\">15613317</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">79</infon><infon key=\"year\">2005</infon><offset>22305</offset><text>Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia</text></passage><passage><infon key=\"fpage\">660</infon><infon key=\"lpage\">94</infon><infon key=\"pub-id_doi\">10.1128/CMR.00023-07</infon><infon key=\"pub-id_pmid\">17934078</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2007</infon><offset>22422</offset><text>Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection</text></passage><passage><infon key=\"fpage\">1319</infon><infon key=\"lpage\">25</infon><infon key=\"pub-id_doi\">10.1016/S0140-6736(03)13077-2</infon><infon key=\"pub-id_pmid\">12711465</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">361</infon><infon key=\"year\">2003</infon><offset>22517</offset><text>Coronavirus as a possible cause of severe acute respiratory syndrome</text></passage><passage><infon key=\"fpage\">181</infon><infon key=\"lpage\">92</infon><infon key=\"pub-id_pmid\">30531947</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Rev Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">17</infon><infon key=\"year\">2019</infon><offset>22586</offset><text>Origin and evolution of pathogenic coronaviruses</text></passage><passage><infon key=\"fpage\">182</infon><infon key=\"pub-id_doi\">10.3390/v9070182</infon><infon key=\"pub-id_pmid\">28696396</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Viruses</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2017</infon><offset>22635</offset><text>The interaction between nidovirales and autophagy components</text></passage><passage><infon key=\"fpage\">368</infon><infon key=\"lpage\">73</infon><infon key=\"pub-id_doi\">10.1038/nm1024</infon><infon key=\"pub-id_pmid\">15034574</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2004</infon><offset>22696</offset><text>Identification of a new human coronavirus</text></passage><passage><infon key=\"fpage\">751</infon><infon key=\"lpage\">2</infon><infon key=\"pub-id_doi\">10.1038/nsmb1123</infon><infon key=\"pub-id_pmid\">16845391</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Struct Mol Biol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">13</infon><infon key=\"year\">2006</infon><offset>22738</offset><text>Architecture of the SARS coronavirus prefusion spike</text></passage><passage><infon key=\"fpage\">5367</infon><infon key=\"lpage\">75</infon><infon key=\"pub-id_doi\">10.1128/JVI.64.11.5367-5375.1990</infon><infon key=\"pub-id_pmid\">2170676</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">64</infon><infon key=\"year\">1990</infon><offset>22791</offset><text>Assembly of coronavirus spike protein into trimers and its role in epitope expression</text></passage><passage><infon key=\"fpage\">751</infon><infon key=\"lpage\">2</infon><infon key=\"pub-id_doi\">10.1038/308751a0</infon><infon key=\"pub-id_pmid\">6325918</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">308</infon><infon key=\"year\">1984</infon><offset>22877</offset><text>Sequence and topology of a model intracellular membrane protein, E1 glycoprotein, from a coronavirus</text></passage><passage><infon key=\"fpage\">9220</infon><infon key=\"lpage\">32</infon><infon key=\"pub-id_doi\">10.1128/JVI.00676-14</infon><infon key=\"pub-id_pmid\">24899185</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">88</infon><infon key=\"year\">2014</infon><offset>22978</offset><text>Host species restriction of middle east respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4</text></passage><passage><infon key=\"fpage\">1814</infon><infon key=\"lpage\">20</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa1211721</infon><infon key=\"pub-id_pmid\">23075143</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">367</infon><infon key=\"year\">2012</infon><offset>23096</offset><text>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</text></passage><passage><infon key=\"fpage\">7790</infon><infon key=\"lpage\">2</infon><infon key=\"pub-id_doi\">10.1128/JVI.01244-13</infon><infon key=\"pub-id_pmid\">23678167</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">87</infon><infon key=\"year\">2013</infon><offset>23171</offset><text>Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group</text></passage><passage><infon key=\"fpage\">465</infon><infon key=\"lpage\">522</infon><infon key=\"pub-id_pmid\">25810418</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">28</infon><infon key=\"year\">2015</infon><offset>23272</offset><text>Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease</text></passage><passage><infon key=\"fpage\">536</infon><infon key=\"lpage\">44</infon><infon key=\"pub-id_pmid\">32123347</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>23377</offset><text>The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2</text></passage><passage><infon key=\"fpage\">2012</infon><infon key=\"lpage\">9</infon><infon key=\"pub-id_pmid\">32141570</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur Rev Med Pharmacol Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">24</infon><infon key=\"year\">2020</infon><offset>23491</offset><text>Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV</text></passage><passage><infon key=\"fpage\">68</infon><infon key=\"lpage\">76</infon><infon key=\"pub-id_doi\">10.1080/01652176.2020.1727993</infon><infon key=\"pub-id_pmid\">32036774</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Vet Q</infon><infon key=\"type\">ref</infon><infon key=\"volume\">40</infon><infon key=\"year\">2020</infon><offset>23610</offset><text>Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments</text></passage><passage><infon key=\"fpage\">565</infon><infon key=\"lpage\">74</infon><infon key=\"pub-id_doi\">10.1016/S0140-6736(20)30251-8</infon><infon key=\"pub-id_pmid\">32007145</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>23741</offset><text>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</text></passage><passage><infon key=\"fpage\">676</infon><infon key=\"lpage\">9</infon><infon key=\"pub-id_doi\">10.1126/science.1118391</infon><infon key=\"pub-id_pmid\">16195424</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">310</infon><infon key=\"year\">2005</infon><offset>23862</offset><text>Bats are natural reservoirs of SARS-like coronaviruses</text></passage><passage><infon key=\"fpage\">666</infon><infon key=\"lpage\">75</infon><infon key=\"pub-id_doi\">10.1016/0042-6822(92)90521-P</infon><infon key=\"pub-id_pmid\">1316677</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Virology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">188</infon><infon key=\"year\">1992</infon><offset>23917</offset><text>TGEV corona virus ORF4 encodes a membrane protein that is incorporated into virions</text></passage><passage><infon key=\"fpage\">2268</infon><infon key=\"lpage\">73</infon><infon key=\"pub-id_doi\">10.1073/pnas.58.6.2268</infon><infon key=\"pub-id_pmid\">4298953</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Proc Natl Acad Sci U S A</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">1967</infon><offset>24001</offset><text>Growth in suckling-mouse brain of âIBV-likeâ viruses from patients with upper respiratory tract disease</text></passage><passage><infon key=\"fpage\">582</infon><infon key=\"lpage\">7</infon><infon key=\"pub-id_doi\">10.1073/pnas.0805270106</infon><infon key=\"pub-id_pmid\">19124777</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Proc Natl Acad Sci U S A</infon><infon key=\"type\">ref</infon><infon key=\"volume\">106</infon><infon key=\"year\">2009</infon><offset>24109</offset><text>Cryo-electron tomography of mouse hepatitis virus: insights into the structure of the coronavirion</text></passage><passage><infon key=\"fpage\">100289</infon><infon key=\"pub-id_doi\">10.1016/j.eclinm.2020.100289</infon><infon key=\"pub-id_pmid\">32154505</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">EClinicalMedicine</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>24208</offset><text>The coronavirus 2019-nCoV epidemic: is hindsight 20/20?</text></passage><passage><infon key=\"fpage\">1199</infon><infon key=\"lpage\">207</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa2001316</infon><infon key=\"pub-id_pmid\">31995857</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>24264</offset><text>Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia</text></passage><passage><infon key=\"fpage\">188</infon><infon key=\"pub-id_doi\">10.1186/s12985-018-1100-x</infon><infon key=\"pub-id_pmid\">30526629</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Virol J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">15</infon><infon key=\"year\">2018</infon><offset>24349</offset><text>Characterization of small genomic regions of the hepatitis B virus should be performed with more caution</text></passage><passage><infon key=\"fpage\">507</infon><infon key=\"lpage\">13</infon><infon key=\"pub-id_pmid\">32007143</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>24454</offset><text>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</text></passage><passage><infon key=\"fpage\">248</infon><infon key=\"lpage\">55</infon><infon key=\"pub-id_pmid\">32099934</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Infect Dis Model</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>24584</offset><text>An updated estimation of the risk of transmission of the novel coronavirus (2019-nCoV)</text></passage><passage><infon key=\"fpage\">30232</infon><infon key=\"lpage\">2</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">S1473â3099</infon><infon key=\"year\">2020</infon><offset>24671</offset><text>Viral dynamics in mild and severe cases of COVID-19</text></passage><passage><infon key=\"fpage\">1173</infon><infon key=\"lpage\">5</infon><infon key=\"pub-id_doi\">10.1016/S0140-6736(20)30735-2</infon><infon key=\"pub-id_pmid\">32220277</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>24723</offset><text>National UK programme of community health workers for COVID-19 response</text></passage><passage><infon key=\"fpage\">8</infon><infon key=\"pub-id_doi\">10.1038/s41368-020-0074-x</infon><infon key=\"pub-id_pmid\">32094336</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Oral Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>24795</offset><text>High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa</text></passage><passage><infon key=\"fpage\">e00127</infon><infon key=\"lpage\">20</infon><infon key=\"pub-id_doi\">10.1128/JVI.00127-20</infon><infon key=\"pub-id_pmid\">31996437</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">94</infon><infon key=\"year\">2020</infon><offset>24880</offset><text>Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS</text></passage><passage><infon key=\"fpage\">995</infon><infon key=\"lpage\">998</infon><infon key=\"pub-id_doi\">10.1021/acschemneuro.0c00122</infon><infon key=\"pub-id_pmid\">32167747</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Chem Neurosci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>24994</offset><text>Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms</text></passage><passage><infon key=\"fpage\">1708</infon><infon key=\"lpage\">20</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa2002032</infon><infon key=\"pub-id_pmid\">32109013</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>25125</offset><text>Clinical characteristics of coronavirus disease 2019 in China</text></passage><passage><infon key=\"fpage\">497</infon><infon key=\"lpage\">506</infon><infon key=\"pub-id_doi\">10.1016/S0140-6736(20)30183-5</infon><infon key=\"pub-id_pmid\">31986264</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>25187</offset><text>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</text></passage><passage><infon key=\"fpage\">125</infon><infon key=\"lpage\">8</infon><infon key=\"pub-id_doi\">10.3855/jidc.12600</infon><infon key=\"pub-id_pmid\">32146445</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect Dev Ctries</infon><infon key=\"type\">ref</infon><infon key=\"volume\">14</infon><infon key=\"year\">2020</infon><offset>25270</offset><text>Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China</text></passage><passage><infon key=\"pub-id_doi\">10.3201/eid2606.200320</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>25352</offset><text>Case-fatality risk estimates for COVID-19 calculated by using a lag time for fatality</text></passage><passage><infon key=\"fpage\">1033</infon><infon key=\"lpage\">1034</infon><infon key=\"pub-id_doi\">10.1016/S0140-6736(20)30628-0</infon><infon key=\"pub-id_pmid\">32192578</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>25438</offset><text>COVID-19: consider cytokine storm syndromes and immunosuppression</text></passage><passage><infon key=\"fpage\">55</infon><infon key=\"pub-id_doi\">10.3389/fimmu.2019.00055</infon><infon key=\"pub-id_pmid\">30766533</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Front Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2019</infon><offset>25504</offset><text>Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis</text></passage><passage><infon key=\"fpage\">281</infon><infon key=\"lpage\">6</infon><infon key=\"pub-id_doi\">10.1007/s12098-020-03263-6</infon><infon key=\"pub-id_pmid\">32166607</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Indian J Pediatr</infon><infon key=\"type\">ref</infon><infon key=\"volume\">87</infon><infon key=\"year\">2020</infon><offset>25592</offset><text>Review of coronavirus disease-2019 (COVID-19)</text></passage><passage><infon key=\"fpage\">e52</infon><infon key=\"pub-id_doi\">10.1016/S0140-6736(20)30558-4</infon><infon key=\"pub-id_pmid\">32171074</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>25638</offset><text>Comorbidities and multi-organ injuries in the treatment of COVID-19</text></passage><passage><infon key=\"fpage\">139</infon><infon key=\"lpage\">144</infon><infon key=\"pub-id_pmid\">32057211</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Zhonghua Liu Xing Bing Xue Za Zhi</infon><infon key=\"type\">ref</infon><infon key=\"volume\">41</infon><infon key=\"year\">2020</infon><offset>25706</offset><text>Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association</text></passage><passage><infon key=\"fpage\">101623</infon><infon key=\"pub-id_doi\">10.1016/j.tmaid.2020.101623</infon><infon key=\"pub-id_pmid\">32179124</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Travel Med Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">34</infon><infon key=\"year\">2020</infon><offset>25833</offset><text>Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis</text></passage><passage><infon key=\"fpage\">904</infon><infon key=\"lpage\">14</infon><infon key=\"pub-id_doi\">10.1093/infdis/jiv380</infon><infon key=\"pub-id_pmid\">26203058</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">213</infon><infon key=\"year\">2016</infon><offset>25926</offset><text>Middle east respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways</text></passage><passage><infon key=\"fpage\">1169</infon><infon key=\"lpage\">74</infon><infon key=\"pub-id_doi\">10.1002/ppul.24718</infon><infon key=\"pub-id_pmid\">32134205</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pediatr Pulmonol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">55</infon><infon key=\"year\">2020</infon><offset>26080</offset><text>Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults</text></passage><passage><infon key=\"fpage\">e20200702</infon><infon key=\"pub-id_pmid\">32179660</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pediatrics</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>26181</offset><text>Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China</text></passage><passage><infon key=\"fpage\">e202783</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>26279</offset><text>Positive RT-PCR test results in patients recovered from COVID-19</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>26344</offset><text>Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia</text></passage><passage><infon key=\"fpage\">30086</infon><infon key=\"lpage\">4</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">S1473â3099</infon><infon key=\"year\">2020</infon><offset>26411</offset><text>Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Biol Regul Homeost Agents</infon><infon key=\"type\">ref</infon><infon key=\"volume\">34</infon><infon key=\"year\">2020</infon><offset>26511</offset><text>Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies [published online ahead of print, 2020]</text></passage><passage><infon key=\"fpage\">261</infon><infon key=\"lpage\">71</infon><infon key=\"pub-id_doi\">10.3201/eid0303.970302</infon><infon key=\"pub-id_pmid\">9284370</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">3</infon><infon key=\"year\">1997</infon><offset>26701</offset><text>Host genes and HIV: the role of the chemokine receptor gene CCR5 and its allele [published correction appears in emerg infect dis 1997(4):584]</text></passage><passage><infon key=\"fpage\">145</infon><infon key=\"pub-id_doi\">10.21037/atm.2020.02.71</infon><infon key=\"pub-id_pmid\">32175437</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Ann Transl Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2020</infon><offset>26844</offset><text>The role of CT for COVID-19 patientâs management remains poorly defined</text></passage><passage><infon key=\"fpage\">202</infon><infon key=\"lpage\">7</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200230</infon><infon key=\"pub-id_pmid\">32017661</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">295</infon><infon key=\"year\">2020</infon><offset>26918</offset><text>CT imaging features of 2019 novel coronavirus (2019-nCoV)</text></passage><passage><infon key=\"fpage\">7</infon><infon key=\"lpage\">9</infon><infon key=\"pub-id_doi\">10.1016/j.clinimag.2020.02.008</infon><infon key=\"pub-id_pmid\">32120312</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Imaging</infon><infon key=\"type\">ref</infon><infon key=\"volume\">63</infon><infon key=\"year\">2020</infon><offset>26976</offset><text>Asymptomatic novel coronavirus pneumonia patient outside Wuhan: the value of CT images in the course of the disease</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">Zhejiang Da Xue Xue Bao Yi Xue Ban</infon><infon key=\"type\">ref</infon><infon key=\"volume\">49</infon><infon key=\"year\">2020</infon><offset>27092</offset><text>Management of corona virus disease-19 (COVID-19): the Zhejiang experience</text></passage><passage><infon key=\"fpage\">e639</infon><infon key=\"lpage\">e640</infon><infon key=\"pub-id_doi\">10.1016/S2214-109X(20)30114-5</infon><infon key=\"pub-id_pmid\">32199468</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Glob Health</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2020</infon><offset>27166</offset><text>Use of antiviral drugs to reduce COVID-19 transmission</text></passage><passage><infon key=\"fpage\">ciaa237</infon><infon key=\"pub-id_doi\">10.1093/cid/ciaa237</infon><infon key=\"pub-id_pmid\">32150618</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>27221</offset><text>In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome conronavirus 2 (SARS-CoV-2)</text></passage><passage><infon key=\"pub-id_doi\">10.1016/S0140-6736(20)31180-6</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>27396</offset><text>Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis</text></passage><passage><infon key=\"pub-id_doi\">10.1056/NEJMoa2012410</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>27519</offset><text>Observational study of hydroxychloroquine in hospitalized patients with COVID-19</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>27600</offset><text>No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial</text></passage><passage><infon key=\"fpage\">433</infon><infon key=\"lpage\">4</infon><infon key=\"pub-id_doi\">10.1016/S2213-2600(20)30127-2</infon><infon key=\"pub-id_pmid\">32203709</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Respir Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2020</infon><offset>27804</offset><text>Treatment for severe acute respiratory distress syndrome from COVID-19</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"lpage\">9</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Ann Acad Med Singapore</infon><infon key=\"type\">ref</infon><infon key=\"volume\">49</infon><infon key=\"year\">2020</infon><offset>27875</offset><text>Rapid progression to acute respiratory distress syndrome: review of current understanding of critical illness from COVID-19 infection</text></passage><passage><infon key=\"fpage\">34</infon><infon key=\"lpage\">41</infon><infon key=\"pub-id_doi\">10.5114/ait.2020.93756</infon><infon key=\"pub-id_pmid\">32191830</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Anaesthesiol Intensive Ther</infon><infon key=\"type\">ref</infon><infon key=\"volume\">52</infon><infon key=\"year\">2020</infon><offset>28009</offset><text>COVID-19 - what should anaesthesiologists and intensivists know about it?</text></passage><passage><infon key=\"fpage\">757</infon><infon key=\"lpage\">67</infon><infon key=\"pub-id_doi\">10.1164/rccm.201706-1172OC</infon><infon key=\"pub-id_pmid\">29161116</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Am J Respir Crit Care Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">197</infon><infon key=\"year\">2018</infon><offset>28083</offset><text>Corticosteroid therapy for critically ill patients with middle east respiratory syndrome</text></passage><passage><infon key=\"fpage\">1261</infon><infon key=\"lpage\">70</infon><infon key=\"pub-id_doi\">10.1001/jama.2019.11825</infon><infon key=\"pub-id_pmid\">31573637</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">322</infon><infon key=\"year\">2019</infon><offset>28172</offset><text>Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial</text></passage><passage><infon key=\"fpage\">226</infon><infon key=\"lpage\">36</infon><infon key=\"pub-id_doi\">10.1038/nrmicro2090</infon><infon key=\"pub-id_pmid\">19198616</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Rev Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2009</infon><offset>28372</offset><text>The spike protein of SARS-CoV: a target for vaccine and therapeutic development</text></passage><passage><infon key=\"fpage\">470</infon><infon key=\"lpage\">473</infon><infon key=\"pub-id_doi\">10.1016/S0140-6736(20)30185-9</infon><infon key=\"pub-id_pmid\">31986257</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>28452</offset><text>A novel coronavirus outbreak of global health concern</text></passage><passage><infon key=\"fpage\">141</infon><infon key=\"lpage\">5</infon><infon key=\"pub-id_doi\">10.1038/sj.cr.7290158</infon><infon key=\"pub-id_pmid\">12862314</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">13</infon><infon key=\"year\">2003</infon><offset>28506</offset><text>Identification of an epitope of SARS-coronavirus nucleocapsid protein</text></passage><passage><infon key=\"fpage\">254</infon><infon key=\"pub-id_doi\">10.3390/v12030254</infon><infon key=\"pub-id_pmid\">32106567</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Viruses</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>28576</offset><text>Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies</text></passage></document></collection>\n",
      "\n",
      "Study 33522478: <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n",
      "<!DOCTYPE collection SYSTEM \"BioC.dtd\">\n",
      "<collection><source>PMC</source><date>20220202</date><key>pmc.key</key><document><id>8007324</id><infon key=\"license\">CC BY</infon><passage><infon key=\"alt-title\">Postvaccination COVID-19 among Healthcare Workers</infon><infon key=\"article-id_doi\">10.3201/eid2704.210016</infon><infon key=\"article-id_pmc\">8007324</infon><infon key=\"article-id_pmid\">33522478</infon><infon key=\"article-id_publisher-id\">21-0016</infon><infon key=\"fpage\">1220</infon><infon key=\"issue\">4</infon><infon key=\"kwd\">vaccination healthcare workers respiratory infections severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 SARS COVID-19 coronavirus disease zoonoses viruses coronavirus Israel vaccines</infon><infon key=\"license\">This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.</infon><infon key=\"lpage\">1222</infon><infon key=\"name_0\">surname:Amit;given-names:Sharon</infon><infon key=\"name_1\">surname:Beni;given-names:Sharon Alexsandra</infon><infon key=\"name_2\">surname:Biber;given-names:Asaf</infon><infon key=\"name_3\">surname:Grinberg;given-names:Amir</infon><infon key=\"name_4\">surname:Leshem;given-names:Eyal</infon><infon key=\"name_5\">surname:Regev-Yochay;given-names:Gili</infon><infon key=\"section_type\">TITLE</infon><infon key=\"type\">front</infon><infon key=\"volume\">27</infon><infon key=\"year\">2021</infon><offset>0</offset><text>Postvaccination COVID-19 among Healthcare Workers, Israel</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>58</offset><text>Coronavirus disease (COVID-19) symptoms can be mistaken for vaccine-related side effects during initial days after immunization. Among 4,081 vaccinated healthcare workers in Israel, 22 (0.54%) developed COVID-19 from 1â10 days (median 3.5 days) after immunization. Clinicians should not dismiss postvaccination symptoms as vaccine-related and should promptly test for COVID-19.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>438</offset><text>Large-scale vaccination of risk groups and later the general population is the single most effective public health measure for mitigation of the coronavirus disease (COVID-19) pandemic. National COVID-19 vaccination programs started during December 2020 in several countries and prioritized healthcare workers (HCWs). In some countries the vaccination programs coincided with a surge in detected COVID-19 cases and increased burden on the healthcare system. </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>897</offset><text>During December 2020âJanuary 2021, Israel experienced a surge in COVID-19 incidence that resulted in the third national lockdown imposed since the pandemic began in early 2020. Concomitantly, during December 2020, Israelâs Ministry of Health approved the Pfizer-BioNTech COVID-19 vaccine (BNT162b2; Pfizer Inc., https://www.pfizer.com) and prioritized HCWs for immunization. </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>1277</offset><text>Sheba Medical Center is a large hospital with 9,069 staff members in Ramat-Gan, Israel. The hospital started its personnel vaccination program on December 20, 2020, and excluded workers who had recovered from COVID-19. During the first week of the campaign, 4,081 (45%) eligible staff members received the first dose of BNT162b2. Concurrently, the national COVID-19 positivity rate rapidly increased to &gt;6% on January 3, 2021. </text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_1</infon><offset>1705</offset><text>The Study</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>1715</offset><text>The hospitalâs Infection Prevention and Control Unit conducted active and passive surveillance of vaccinated staff by using daily health questionnaires, hotlines, on-call infectious disease unit staff, and post-vaccination web-based questionnaires to identify and test symptomatic HCWs. Among 4,081 HCWs vaccinated in the first week of the campaign, 22 (0.54%) later had laboratory-confirmed COVID-19 (Table). The average age among COVID-19âpositive vaccinated HCWs was 45.3 years (Â±9.85 years), and they belonged to different healthcare sectors and worked on various wards. </text></passage><passage><infon key=\"file\">T1.xml</infon><infon key=\"id\">T1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_title_caption</infon><offset>2296</offset><text>Coronavirus disease cases among healthcare workers in the early postvaccination period, Israel, December 20, 2020âJanuary 2, 2021*</text></passage><passage><infon key=\"file\">T1.xml</infon><infon key=\"id\">T1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col width=&quot;26&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;27&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;63&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;54&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;45&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;49&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;40&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;40&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;31&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;60&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;43&quot; span=&quot;1&quot;/&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;bottom&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case no.&lt;hr/&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Age, y/sex&lt;hr/&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Ward&lt;hr/&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Healthcare sector&lt;hr/&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Indication for testing&lt;hr/&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Presumed exposure source &lt;hr/&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Exposure day&lt;hr/&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Day of symptom onsetâ &lt;hr/&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Day tested&lt;hr/&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No. days from symptom onset to testing&lt;hr/&gt;&lt;/td&gt;&lt;td valign=&quot;bottom&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No. secondary isolations&lt;hr/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;General surgery&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Physician&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;â4&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+5&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Excludedâ¡&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;54/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Transportation&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Secretary&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+9&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;34/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Geriatrics&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Physician&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;31/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cardiovascular surgery&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Nurse&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Community&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;49/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Psychiatry&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cleaning services&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+3&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;43/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Laundry&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Laundry handler&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Community&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;â3&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+2&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+3&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;43/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Laboratory&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Scientist&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Exposure&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Community&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;â3&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+2&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+6&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;60/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ED&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Nurse assistant&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Community&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+3&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+5&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;50/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Eye clinic&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Technologist&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+4&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+6&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;33/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Psychiatry&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Psychologist&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Exposure&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Community&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+2&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+6&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+6&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;36/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Operating room&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Logistics&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Community&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+4&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+7&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+8&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;54/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pulmonology&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Physician&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Community&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+4&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+7&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+7&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;37/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ED&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Physician&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+3&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+7&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+9&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;14&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;32/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Rehabilitation&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Nurse&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+9&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+10&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;15&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;40/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Laboratory&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Physician&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Symptoms&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+10&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+10&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;16&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;52/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Radiotherapy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Secretary&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Exposure&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Asymp&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+5&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;55/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;General surgery&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Phlebotomist&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Exposure&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Asymp&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+8&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;18&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;55/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Kitchen&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Food handler&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Exposure&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Community&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;â5&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Asymp&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+2&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;19&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;61/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Radiology&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Physician&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Exposure&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Community&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+4&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Asymp&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+11&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;20&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;40/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ED&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Secretary&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Exposure&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Community&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+6&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Asymp&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+11&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;21&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;45/F&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Internal medicine&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Nurse&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Exposure&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Unknown&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Asymp&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+8&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;22&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;39/M&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Internal medicine&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Nurse&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Exposure&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Community&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+2&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Asymp&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;+8&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>2429</offset><text>Case no.\tAge, y/sex\tWard\tHealthcare sector\tIndication for testing\tPresumed exposure source \tExposure day\tDay of symptom onsetâ \tDay tested\tNo. days from symptom onset to testing\tNo. secondary isolations\t \t1\t42/F\tGeneral surgery\tPhysician\tSymptoms\tUnknown\tUnknown\tâ4\t+5\tExcludedâ¡\t0\t \t2\t54/F\tTransportation\tSecretary\tSymptoms\tUnknown\tUnknown\t0\t+9\t9\t1\t \t3\t34/M\tGeriatrics\tPhysician\tSymptoms\tUnknown\tUnknown\t+1\t+1\t0\t1\t \t4\t31/F\tCardiovascular surgery\tNurse\tSymptoms\tCommunity\tUnknown\t+1\t+1\t0\t1\t \t5\t49/F\tPsychiatry\tCleaning services\tSymptoms\tUnknown\tUnknown\t+1\t+3\t2\t0\t \t6\t43/F\tLaundry\tLaundry handler\tSymptoms\tCommunity\tâ3\t+2\t+3\t1\t3\t \t7\t43/F\tLaboratory\tScientist\tExposure\tCommunity\tâ3\t+2\t+6\t4\t0\t \t8\t60/F\tED\tNurse assistant\tSymptoms\tCommunity\t0\t+3\t+5\t2\t0\t \t9\t50/F\tEye clinic\tTechnologist\tSymptoms\tUnknown\tUnknown\t+4\t+6\t2\t0\t \t10\t33/M\tPsychiatry\tPsychologist\tExposure\tCommunity\t+2\t+6\t+6\t0\t0\t \t11\t36/M\tOperating room\tLogistics\tSymptoms\tCommunity\t+4\t+7\t+8\t1\t0\t \t12\t54/M\tPulmonology\tPhysician\tSymptoms\tCommunity\t+4\t+7\t+7\t0\t0\t \t13\t37/M\tED\tPhysician\tSymptoms\tUnknown\t+3\t+7\t+9\t2\t0\t \t14\t32/M\tRehabilitation\tNurse\tSymptoms\tUnknown\tUnknown\t+9\t+10\t1\t1\t \t15\t40/M\tLaboratory\tPhysician\tSymptoms\tUnknown\tUnknown\t+10\t+10\t0\t1\t \t16\t52/F\tRadiotherapy\tSecretary\tExposure\tUnknown\tUnknown\tAsymp\t+5\tNA\t3\t \t17\t55/F\tGeneral surgery\tPhlebotomist\tExposure\tUnknown\tUnknown\tAsymp\t+8\tNA\t4\t \t18\t55/F\tKitchen\tFood handler\tExposure\tCommunity\tâ5\tAsymp\t+2\tNA\t1\t \t19\t61/F\tRadiology\tPhysician\tExposure\tCommunity\t+4\tAsymp\t+11\tNA\t0\t \t20\t40/F\tED\tSecretary\tExposure\tCommunity\t+6\tAsymp\t+11\tNA\t2\t \t21\t45/F\tInternal medicine\tNurse\tExposure\tUnknown\tUnknown\tAsymp\t+8\tNA\t0\t \t22\t39/M\tInternal medicine\tNurse\tExposure\tCommunity\t+2\tAsymp\t+8\tNA\t0\t \t</text></passage><passage><infon key=\"file\">T1.xml</infon><infon key=\"id\">T1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_foot</infon><offset>4131</offset><text>*All persons with cases were vaccinated during the first week of campaign, December 20â27, 2020. Asymp, asymptomatic; ED, emergency department; NA, not applicable.â¨â Considering day of vaccination as day 0.â¨â¡Excluded from calculations of mean time from vaccination to symptom onset because symptoms began before vaccination.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>4465</offset><text>Among the 22 vaccinated HCWs who tested positive for COVID-19, 13 were tested because they had symptoms, most commonly an influenza-like illness that included fever, chills, cough, headache, myalgia, and sore throat. Two vaccinated HCWs were tested because of exposure to confirmed or suspected COVID-19 cases and because they reported symptoms upon questioning. Asymptomatic COVID-19 cases were identified among HCWs as part of postexposure screening. Among the 22 COVID-19âpositive HCWs, 11 had presumable community-related exposures, 4 of whom reported exposure incidents that occurred before or on the date of vaccination. An investigation conducted by the hospitalâs Infection Control and Prevention Unit identified 10 healthcare-related secondary exposures. However, we did not identify any point-source exposures or COVID-19 clusters linked to the immunization process.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>5346</offset><text>Among the 11 vaccinated HCWs who reported COVID-19 symptoms, the median time between the first dose of BNT162b2 immunization and symptom onset was 3.5 (range 0â10) days; we excluded 1 vaccinee from our calculation and analysis because the HCW had symptoms before immunization (Table). The median time between the onset of symptoms and testing was 1 day, demonstrating the high level of suspicion for COVID-19 during the vaccination campaign. </text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>5791</offset><text>Of note, apart from the need for early detection, persons who test positive for COVID-19 after receiving the first vaccine dose (whether asymptomatic and tested following exposure or tested because they are symptomatic) are not eligible to receive the second dose, according to Ministry of Health policy. However, depending on availability of vaccines, this policy might change when further data are collected.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">title_1</infon><offset>6202</offset><text>Conclusions</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>6214</offset><text>COVID-19 in HCWs is a major concern for health authorities worldwide. HCWs, especially acute and chronic care facility personnel, are at high risk for contracting symptomatic and asymptomatic COVID-19 and might become infected at home or nosocomially while caring for patients or interacting with other staff members. Infections among HCWs have an immediate effect on their close occupational environment and the overall healthcare system. Secondary exposures, isolation, and infections of staff can substantially impair the capacity of a single ward to care for patients, creating a snowball effect with collateral damage to both the functional resilience of the facility and morale of staff. Consequently, as soon as COVID-19 vaccines were deployed in Israel, HCWs were the first group to receive it. </text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>7018</offset><text>We report 22 cases of early, postimmunization, laboratory-confirmed COVID-19 among HCWs during the launch of the vaccination campaign in a large hospital in Israel. BNT162b2 is not likely to exert protection against clinical disease during the first days after receipt of the first dose. Efficacy of the BNT162b was 52% a week after the first dose, and positive COVID-19 cases were described among vaccinees even early after the second dose. Thus, during a large-scale immunization campaign coinciding with rapid national increase in COVID-19 cases, some immunized persons likely will develop clinical disease.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>7629</offset><text>The co-occurrence of vaccination deployment with the rapidly climbing COVID-19 spread in many parts of the world is a confusing period in which hope is mixed with great vulnerability. The phenomenon of pandemic fatigue, in which the population tires of constant safety precautions, testing, isolation, and restrictions, could lead to less social distancing and personal protection. Pandemic fatigue coupled with the availability of a vaccine, might give the population a false sense of reassurance and consequently lead to a brisk increase in COVID-19 cases. Thus, almost every physical complaint after vaccination poses a true diagnostic dilemma as to whether an adverse reaction or a new COVID-19 infection is the cause. Undetected COVID-19 cases among HCWs could be hazardous for patients and other staff. </text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>8439</offset><text>Clinicians should have a high level of suspicion of reported symptoms and avoid dismissing complaints as vaccine-related until true infection is ruled out and vaccinees are tested. Active and passive surveillance schemes that enable rapid testing and initiation of infection control measures are essential in preventing possible diagnostic delays and secondary exposures. Therefore, healthcare-related indications for testing should not be altered until systematic and exhaustive data are gathered regarding vaccine effectiveness in healthcare settings.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">footnote</infon><offset>8993</offset><text>Suggested citation for this article: Amit S, Beni SA, Biber A, Grinberg A, Leshem E, Regev-Yochay G. Post-vaccination COVID-19 among healthcare workers, Israel. Emerg Infect Dis. 2021 Apr [date cited]. https://doi.org/10.3201/eid2704.210016</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">footnote</infon><offset>9234</offset><text>These authors equally contributed to the study.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">title</infon><offset>9282</offset><text>References</text></passage><passage><infon key=\"fpage\">1857</infon><infon key=\"lpage\">9</infon><infon key=\"pub-id_doi\">10.15585/mmwr.mm6949e1</infon><infon key=\"pub-id_pmid\">33301429</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">MMWR Morb Mortal Wkly Rep</infon><infon key=\"type\">ref</infon><infon key=\"volume\">69</infon><infon key=\"year\">2020</infon><offset>9293</offset><text>The Advisory Committee on Immunization Practicesâ interim recommendation for allocating initial supplies of COVID-19 vaccineâUnited States, 2020.</text></passage><passage><infon key=\"comment\">cited 2021 Jan 3</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>9443</offset></passage><passage><infon key=\"fpage\">2251</infon><infon key=\"lpage\">3</infon><infon key=\"pub-id_doi\">10.3201/eid2609.201476</infon><infon key=\"pub-id_pmid\">32620179</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>9444</offset><text>Buying time with COVID-19 outbreak response, Israel.</text></passage><passage><infon key=\"comment\">cited 2021 Jan 3</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>9497</offset></passage><passage><infon key=\"fpage\">303</infon><infon key=\"lpage\">5</infon><infon key=\"pub-id_doi\">10.3201/eid2701.203027</infon><infon key=\"pub-id_pmid\">33021927</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">27</infon><infon key=\"year\">2021</infon><offset>9498</offset><text>Risk for SARS-CoV-2 infection in healthcare workers, Turin, Italy.</text></passage><passage><infon key=\"fpage\">2416</infon><infon key=\"lpage\">9</infon><infon key=\"pub-id_doi\">10.3201/eid2610.202694</infon><infon key=\"pub-id_pmid\">32614768</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>9565</offset><text>High proportion of asymptomatic SARS-CoV-2 infections in 9 long-term care facilities, Pasadena, California, USA, April 2020.</text></passage><passage><infon key=\"fpage\">2863</infon><infon key=\"lpage\">71</infon><infon key=\"pub-id_doi\">10.3201/eid2612.203764</infon><infon key=\"pub-id_pmid\">32956614</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>9690</offset><text>SARS-CoV-2 seroprevalence among healthcare, first response, and public safety personnel, Detroit metropolitan area, Michigan, USA, MayâJune 2020.</text></passage><passage><infon key=\"fpage\">2603</infon><infon key=\"lpage\">15</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa2034577</infon><infon key=\"pub-id_pmid\">33301246</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>9838</offset><text>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.</text></passage></document></collection>\n",
      "\n",
      "Study 33308664: <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n",
      "<!DOCTYPE collection SYSTEM \"BioC.dtd\">\n",
      "<collection><source>PMC</source><date>20230305</date><key>pmc.key</key><document><id>7409828</id><infon key=\"license\">NO-CC CODE</infon><passage><infon key=\"article-id_doi\">10.1016/j.ijtb.2020.07.034</infon><infon key=\"article-id_pii\">S0019-5707(20)30128-1</infon><infon key=\"article-id_pmc\">7409828</infon><infon key=\"article-id_pmid\">33308664</infon><infon key=\"fpage\">S163</infon><infon key=\"issue\">4</infon><infon key=\"kwd\">SARS CoV-2 COVID-19 Serology IgM IgG</infon><infon key=\"license\">Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</infon><infon key=\"lpage\">S166</infon><infon key=\"name_0\">surname:Sidiq;given-names:Zeeshan</infon><infon key=\"name_1\">surname:Hanif;given-names:M.</infon><infon key=\"name_2\">surname:Dwivedi;given-names:Kaushal Kumar</infon><infon key=\"name_3\">surname:Chopra;given-names:K.K.</infon><infon key=\"section_type\">TITLE</infon><infon key=\"title\">Keywords</infon><infon key=\"type\">front</infon><infon key=\"volume\">67</infon><infon key=\"year\">2020</infon><offset>0</offset><text>Benefits and limitations of serological assays in COVID-19 infection</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>69</offset><text>Accurate and rapid diagnostic tests are critical for achieving control of coronavirus disease 2019 (covid-19), a pandemic illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Diagnostic tests for covid-19 fall into two main categories: molecular tests that detect viral RNA, and serological tests that detect anti-SARS-CoV-2 immunoglobulins. Reverse transcriptase polymerase chain reaction (RT-PCR), a molecular test, has become the gold standard for diagnosis of covid-19; however, this test has many limitations that include potential false negative results, changes in diagnostic accuracy over the disease course, and precarious availability of test materials. Serological tests have generated substantial interest as an alternative or complement to RT-PCR and other Nucleic acid tests in the diagnosis of acute infection, as some might be cheaper and easier to implement at the point of care. A clear advantage of these tests over RT-PCR is that they can identify individuals previously infected by SARS-CoV-2, even if they never underwent testing while acutely ill. Many serological tests for covid-19 have become available in a short period, including some marketed for use as rapid, point-of-care tests. The pace of development has, however, exceeded that of rigorous evaluation, and important uncertainty about test accuracy remains.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>1438</offset><text>The COVID-19 pandemic caused by SARS-CoV-2 has affected living and working conditions of billions of people worldwide and has remarkably weakened the global economy as a result of lockdown in many cities. Reported for the first time in late December 2019, in Wuhan, China, this virus rapidly spread through China and then many other countries globally. As of July 19, 2020, the virus resulted in over 14.0 million laboratory-confirmed cases of corona virus disease 2019(COVID-19) and more than 597,583 deaths in 215 countries. The World Health Organization (WHO) has declared COVID-19 a public health emergency of international concern and given a âvery highâ risk assessment on a global level. </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>2138</offset><text>Coronavirus is positive-sense single-stranded RNA virus. It is a large pleomorphic spherical enveloped particle. The viral envelope consists of a lipid bilayer where the membrane (M), envelope (E), and spike (S) structural proteins are anchored. The S glycoprotein is a large type 1 transmembrane protein consisting of two functional subunits S1 and S2. S1, comprises a receptor binding domain (RBD) which is responsible for binding to the host cell receptor. S2 contains elements needed for the fusion of virus. A subset of coronaviruses (in particular betacoronavirus) also have a shorter spike-like surface protein called hemagglutinin esterase (HE). Inside the envelope there is the nucleocapsid, which is formed from multiple copies of the nucleocapsid (N) protein. This protein is bound to the single-stranded RNA genome. The lipid bilayer envelope, membrane proteins, and nucleocapsid protect the virus when it is outside the host cell. </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>3083</offset><text>COVID-19 exhibits a range of clinical manifestations, from mild flu-like symptoms to life-threatening conditions. The initial phase of the disease is clinically characterized by the appearance of cough, fever, generalized malaise, and myalgia. The laboratory tests show Neutrophilia, with normal or reduced lymphocyte count and elevated C-reactive protein (CRP). Within approximately one week from infection, adaptive immunity is expected to rise. In some patients this transit of immunity is delayed due to Individual risk factors such as older age; and co-morbidities like diabetes, hypertension, cardiopathy, and obesity. This factor could be the main cause of COVID-19 complications, occurring at about day 12. This is the time when circulating proinflammatory cytokines increase and inflammatory cells build up in target organs, particularly the lungs, causing tissue damage without providing any control over the infection. </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>4014</offset><text>Currently, the real-time RT-PCR assay is the gold-standard method to diagnose SARS-CoV-2.   Unfortunately, the sensitivity of the RNA test in the real world is not satisfactory and, false-negative cases have also been reported due to problems with sample collection, sample transportation, RNA extraction, enzyme inhibitors, and the RT-PCR method. Infact, RT-PCR tests have many limitations by their nature of requiring high workload, needing skillful operators for testing and sample collection, and needing costly instruments and special operation places.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>4572</offset><text>During this current public health emergency of international concern, screening and diagnosing patients quickly to aid containment is a priority and these limitations make RT-PCR unsuitable for use in the field. Consequently, new tools, such as serological tests capable of tracking the virus through each phase of the disease, are in great demand. Conventional serological assays have a high-throughput advantage, and they avoid false-negative cases that may occur with the RT-PCRmethod. </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>5062</offset><text>The current race to develop cost-effective point-of-contact test kits and efficient laboratory techniques for confirmation of SARS-CoV-2 infection has fueled a new frontier of diagnostic innovation. At present there is an increasing number of inÂ vitro diagnostic companies that are either developing or have developed tests for antigens and antibodies (see https://www.finddx.org/covid-19/pipeline/). Five of the 27 antigen-detection rapid diagnostic tests and 26 of the 203 antibody detection tests reported on the website have been selected for the first round of evaluation. Additional tests will continue to be reviewed on a rolling basis. However, it is important to remember that these tests are often controversial and mainly involve small Chinese cohorts.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>5827</offset><text>During the outbreak of SARS-CoV, different serological assays, including immunofluorescence assays (IFA), enzyme linked immunosorbent assays (ELISA), and Western blot (WB) analysis, were developed. Some studies suggested that virus-based IFA and ELISA were highly sensitive (85â100%) but lacked specificity. False positive results were due to antigens well-conserved among different CoV species   and to cross-reaction with autoantibodies in autoimmune diseases. Consequently, serological assays based on recombinant antigens derived from both S and N proteins were widely used in laboratory diagnostics. The use of recombinant antigens offers the advantage of working without the need of stringent biosafety requirements and are also more appropriate for assay standardization. In particular, the N protein is easy to clone into prokaryotic or eukaryotic expression plasmids due to its small size and the absence of glycosylation sites. Researchers suggested that recombinant protein-based WB and ELISA are highly sensitive (73â100%) and have a low to moderate specificity. Since S protein is difficult to express into prokaryotic in its full-length protein, only fragments can be used in immunoassays.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>7035</offset><text>Several studies showed different reactivity of SARS patient sera with S protein, ranging from very low (13%) to 100%, depending on the method used. Moreover, a rate of false positive results ranging from 0 to 30%have also been shown using ELISA and WB assays.   The structural similarity and the sequence conservation of the immunogenic proteins of related CoV species that share common structural epitopes, can elicit cross-reactive antibodies in the host. Since cross-reactivity is more likely to occur with a high level of conservation of the proteins, this might explain why N protein-based serological assays were more often associated with cross-reactivity than S protein-based assays. Analysis of complete N sequences revealed that SARS-CoV N protein shared 25â29% identity with Î±-CoV and 33â47% with related Î²-CoV. The complete S protein sequence showed a lower degree of conservation, sharing 23â25% an identity with Î±-CoV and 29% with related Î²-CoV.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>8009</offset><text>Various in-house and commercial ELISA methods have been used to validate and test different SARS-CoV-2 antigens. These include S, S1, RBD, and the N protein. It was shown that among these antigens tested, S1 was more specific in detecting SARS-CoV-2 antibodies while N protein was more sensitive than S1. While describing an ELISA method involving the full-length S protein and the smaller RBD fragment, Anant etÂ al suggested that antibodies mounted after Infection target both the full viral antigens as well as to the immunogenic fragments equally. This suggestion is of great importance in that the assays involving the recombinant proteins are easier to standardize.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>8681</offset><text>There are studies which suggest that combined use of nucleic acid tests (NAT) and serological tests can significantly improve diagnostic sensitivity as well as the positive detection rate. While studies have reported sensitivity ranging from 78.7% to 100%, positive detection rate of 98.6% have been reported using combined IgM assay with NAT compared to only 51.9% using a single RT-PCR test. It has also been suggested that highest overall sensitivity can be achieved from an IgM-IgG combined assay compared to NAT and IgM, IgG singly. Jia etÂ al reported a positive detection rate of 72.73% using combined IgM and IgG for patients with SARS-CoV-2 negative nucleic acid test. It should however be noted that most of the studies available today have a great bias considering the various time lapses between the initial exposure to the virus and the serological assays confirming the detection. As a consequence, data are still of little use today, both when considering the different isotypes and comparing single or double positivity of different isotype antibodies.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>9750</offset><text>We actually still do not know if serological assays perform better as a screening test, as a diagnostic tool alongside molecular diagnostics to achieve the greatest accuracy, or with the epidemiologic aim of getting a real picture of the pandemic at its end. Some of the potential applications of serology can be: Screening and management of clinical patients and close contacts especially the ones with a negative RNA test; Screening of key populations such as travelers and people returning to school or work from high incidence areas; Conduct population-based serological survey, to understand the actual prevalence and pathogenicity of SARS-CoV-2 infection in different regions and populations; Analyze the antibody level and spectrum of antibody epitopes in convalescent COVID-19 patients, to provide scientific guidance for the design and evaluation of vaccines and therapeutic antibodies in the future. Nevertheless, what is important to know is that no laboratory test could ever substitute clinical observation and practical experience. If there is a clinical suspicion, a negative test result cannot exclude the possible presence of the disease.</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">title_1</infon><offset>10906</offset><text>Conflicts of interest</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">paragraph</infon><offset>10928</offset><text>The authors have none to declare.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">title</infon><offset>10962</offset><text>References</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>10973</offset><text>World Health Organization. Coronavirus disease (COVID-19) outbreak.https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200624-covid-19-sitrep-156.pdf?sfvrsn=af42e480_2.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>11163</offset><text>World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report -181. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200719-covid-19-sitrep-181.pdf?sfvrsn=82352496_2.</text></passage><passage><infon key=\"fpage\">5871</infon><infon key=\"lpage\">5876</infon><infon key=\"name_0\">surname:Belouzard;given-names:S.</infon><infon key=\"name_1\">surname:Chu;given-names:V.</infon><infon key=\"name_2\">surname:Whittaker;given-names:G.R.</infon><infon key=\"pub-id_pmid\">19321428</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Proc Natl Acad Sci U S A</infon><infon key=\"type\">ref</infon><infon key=\"volume\">106</infon><infon key=\"year\">2009</infon><offset>11372</offset><text>Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites</text></passage><passage><infon key=\"fpage\">8801</infon><infon key=\"lpage\">8811</infon><infon key=\"name_0\">surname:Bosch;given-names:B.J.</infon><infon key=\"name_1\">surname:van der Zee;given-names:R.</infon><infon key=\"name_2\">surname:de Haan;given-names:C.A.</infon><infon key=\"pub-id_pmid\">12885899</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">77</infon><infon key=\"year\">2003</infon><offset>11479</offset><text>The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex</text></passage><passage><infon key=\"name_0\">surname:Burkard;given-names:C.</infon><infon key=\"name_1\">surname:Verheije;given-names:M.H.</infon><infon key=\"name_2\">surname:Wicht</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS Pathog</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2014</infon><offset>11614</offset><text>Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner</text></passage><passage><infon key=\"fpage\">118</infon><infon key=\"issue\">531</infon><infon key=\"lpage\">121</infon><infon key=\"name_0\">surname:Kirchdoerfer;given-names:R.N.</infon><infon key=\"name_1\">surname:Cottrell;given-names:C.A.</infon><infon key=\"name_2\">surname:Wang;given-names:N.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">3</infon><infon key=\"year\">2016</infon><offset>11714</offset><text>Pre-fusion structure of a human coronavirus spike protein</text></passage><passage><infon key=\"fpage\">120</infon><infon key=\"issue\">202</infon><infon key=\"lpage\">134</infon><infon key=\"name_0\">surname:Millet;given-names:J.K.</infon><infon key=\"name_1\">surname:Whittaker;given-names:G.R.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Virus Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">16</infon><infon key=\"year\">2015</infon><offset>11772</offset><text>Host cell proteases: critical determinants of coronavirus tropism and pathogenesis</text></passage><passage><infon key=\"fpage\">93</infon><infon key=\"lpage\">116</infon><infon key=\"name_0\">surname:Tortorici;given-names:M.A.</infon><infon key=\"name_1\">surname:Veesler;given-names:D.</infon><infon key=\"pub-id_pmid\">31522710</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Adv Virus Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">105</infon><infon key=\"year\">2019</infon><offset>11855</offset><text>Structural insights into coronavirus entry</text></passage><passage><infon key=\"fpage\">59</infon><infon key=\"issue\">1â2</infon><infon key=\"lpage\">72</infon><infon key=\"name_0\">surname:de Groot;given-names:R.J.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Glycoconj</infon><infon key=\"type\">ref</infon><infon key=\"volume\">23</infon><infon key=\"year\">2006</infon><offset>11898</offset><text>Structure, function and evolution of the hemagglutinin-esterase proteins of corona- and toroviruses</text></passage><passage><infon key=\"fpage\">39</infon><infon key=\"lpage\">50</infon><infon key=\"name_0\">surname:Chang;given-names:C.K.</infon><infon key=\"name_1\">surname:Hou;given-names:M.H.</infon><infon key=\"name_2\">surname:Chang;given-names:C.F.</infon><infon key=\"name_3\">surname:Hsiao;given-names:C.D.</infon><infon key=\"name_4\">surname:Huang;given-names:T.H.</infon><infon key=\"pub-id_pmid\">24418573</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Antivir Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">103</infon><infon key=\"year\">2014</infon><offset>11998</offset><text>The SARS coronavirus nucleocapsid protein-forms and functions</text></passage><passage><infon key=\"fpage\">11</infon><infon key=\"lpage\">22</infon><infon key=\"name_0\">surname:Neuman;given-names:B.W.</infon><infon key=\"name_1\">surname:Kiss;given-names:G.</infon><infon key=\"name_2\">surname:Kunding;given-names:A.H.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Struct Biol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">174</infon><infon key=\"year\">2011</infon><offset>12060</offset><text>A structural analysis of M protein incoronavirus assembly and morphology</text></passage><passage><infon key=\"fpage\">497</infon><infon key=\"lpage\">506</infon><infon key=\"name_0\">surname:Huang;given-names:C.</infon><infon key=\"name_1\">surname:Wang;given-names:Y.</infon><infon key=\"name_2\">surname:Xingwang;given-names:L.</infon><infon key=\"pub-id_pmid\">31986264</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>12133</offset><text>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</text></passage><passage><infon key=\"fpage\">1054</infon><infon key=\"lpage\">1062</infon><infon key=\"name_0\">surname:Zhou;given-names:F.</infon><infon key=\"name_1\">surname:Yu;given-names:T.</infon><infon key=\"name_2\">surname:Du;given-names:R.</infon><infon key=\"pub-id_pmid\">32171076</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>12216</offset><text>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</text></passage><passage><infon key=\"fpage\">203</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">210</infon><infon key=\"name_0\">surname:Infantino;given-names:M.</infon><infon key=\"name_1\">surname:Damiani;given-names:A.</infon><infon key=\"name_2\">surname:Gobbi;given-names:F.L.</infon><infon key=\"pub-id_pmid\">32286019</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Isr Med Assoc J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">22</infon><infon key=\"year\">2020</infon><offset>12343</offset><text>Serological assays for SARS-CoV-2 infectious disease: benefits, limitations and perspectives</text></passage><passage><infon key=\"fpage\">727</infon><infon key=\"lpage\">733</infon><infon key=\"name_0\">surname:Zhu;given-names:N.</infon><infon key=\"name_1\">surname:Zhang;given-names:D.</infon><infon key=\"name_2\">surname:Wang;given-names:W.</infon><infon key=\"pub-id_pmid\">31978945</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>12436</offset><text>A novel coronavirus from patients with pneumonia in China, 2019, China novel coronavirus investigating and research team</text></passage><passage><infon key=\"fpage\">536</infon><infon key=\"lpage\">544</infon><infon key=\"pub-id_pmid\">32123347</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>12557</offset><text>Coronaviridae study group of the international committee on taxonomy of viruses, the species severe acute respiratory syndrome-related coronavirus:classifying 2019-nCoV and naming it SARS-CoV-2</text></passage><passage><infon key=\"fpage\">464</infon><infon key=\"lpage\">467</infon><infon key=\"name_0\">surname:Xiao;given-names:S.Y.</infon><infon key=\"name_1\">surname:Wu;given-names:Y.</infon><infon key=\"name_2\">surname:Liu;given-names:H.</infon><infon key=\"pub-id_pmid\">32031264</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>12751</offset><text>Evolving status of the 2019 novel coronavirus infection: proposal of conventional serologic assays for disease diagnosis and infection monitoring</text></passage><passage><infon key=\"fpage\">2033</infon><infon key=\"lpage\">2037</infon><infon key=\"name_0\">surname:Che;given-names:X.Y.</infon><infon key=\"name_1\">surname:Qiu;given-names:L.W.</infon><infon key=\"name_2\">surname:Liao;given-names:Z.Y.</infon><infon key=\"pub-id_pmid\">15897988</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">191</infon><infon key=\"year\">2005</infon><offset>12897</offset><text>Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229Eand OC43</text></passage><passage><infon key=\"fpage\">135</infon><infon key=\"lpage\">139</infon><infon key=\"name_0\">surname:Dijkman;given-names:R.</infon><infon key=\"name_1\">surname:Jebbink;given-names:M.F.</infon><infon key=\"name_2\">surname:Gaunt;given-names:E.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol Off Publ Pan Am Soc Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">53</infon><infon key=\"year\">2012</infon><offset>13026</offset><text>The dominance of human coronavirus OC43 and NL63 infections in infants</text></passage><passage><infon key=\"fpage\">304</infon><infon key=\"lpage\">307</infon><infon key=\"name_0\">surname:Wang;given-names:Y.</infon><infon key=\"name_1\">surname:Sun;given-names:S.</infon><infon key=\"name_2\">surname:Shen;given-names:H.</infon><infon key=\"pub-id_pmid\">16225774</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Mol Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">1</infon><infon key=\"year\">2004</infon><offset>13097</offset><text>Cross-reaction of SARS-CoV antigen with autoantibodies in autoimmune diseases</text></passage><passage><infon key=\"fpage\">379</infon><infon key=\"lpage\">386</infon><infon key=\"name_0\">surname:Leung;given-names:D.T.</infon><infon key=\"name_1\">surname:Tam;given-names:F.C.</infon><infon key=\"name_2\">surname:Ma;given-names:C.H.</infon><infon key=\"pub-id_pmid\">15216476</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">190</infon><infon key=\"year\">2004</infon><offset>13175</offset><text>Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid</text></passage><passage><infon key=\"fpage\">137</infon><infon key=\"lpage\">142</infon><infon key=\"name_0\">surname:Carattoli;given-names:A.</infon><infon key=\"name_1\">surname:Di Bonito;given-names:P.</infon><infon key=\"name_2\">surname:Grasso;given-names:F.</infon><infon key=\"pub-id_pmid\">15834868</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">76</infon><infon key=\"year\">2005</infon><offset>13282</offset><text>Recombinant protein-based ELISA and immuno-cytochemical assay forthe diagnosis of SARS</text></passage><passage><infon key=\"fpage\">287</infon><infon key=\"lpage\">291</infon><infon key=\"name_0\">surname:Guan;given-names:M.</infon><infon key=\"name_1\">surname:Chen;given-names:H.Y.</infon><infon key=\"name_2\">surname:Foo;given-names:S.Y.</infon><infon key=\"name_3\">surname:Tan;given-names:Y.J.</infon><infon key=\"name_4\">surname:Goh;given-names:P.Y.</infon><infon key=\"name_5\">surname:Wee;given-names:S.H.</infon><infon key=\"pub-id_pmid\">15013977</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Diagn Lab Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2004</infon><offset>13369</offset><text>Recombinant protein-based enzyme-linked immunosorbent assay and immunochromatographic tests for detection of immunoglobulin G antibodies to severe acute respiratory syndrome (SARS) coronavirus in SARS patients</text></passage><passage><infon key=\"fpage\">227</infon><infon key=\"lpage\">228</infon><infon key=\"name_0\">surname:Liu;given-names:X.</infon><infon key=\"name_1\">surname:Shi;given-names:Y.</infon><infon key=\"name_2\">surname:Li;given-names:P.</infon><infon key=\"pub-id_pmid\">14715574</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Diagn Lab Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2004</infon><offset>13579</offset><text>Profile of antibodies to the nucleocapsid protein of the severe acute respiratory syndrome (SARS)-associated coronavirus in probable SARS patients</text></passage><passage><infon key=\"fpage\">5781</infon><infon key=\"lpage\">5782</infon><infon key=\"name_0\">surname:Shi;given-names:Y.</infon><infon key=\"name_1\">surname:Yi;given-names:Y.</infon><infon key=\"name_2\">surname:Li;given-names:P.</infon><infon key=\"pub-id_pmid\">14662982</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">41</infon><infon key=\"year\">2003</infon><offset>13726</offset><text>Diagnosis of severe acute respiratory syndrome (SARS) by detection of SARS coronavirus nucleocapsid antibodies in an antigen-capturing enzyme-linked immunosorbent assay</text></passage><passage><infon key=\"fpage\">841</infon><infon key=\"lpage\">845</infon><infon key=\"name_0\">surname:Woo;given-names:P.C.</infon><infon key=\"name_1\">surname:Lau;given-names:S.K.</infon><infon key=\"name_2\">surname:Tsoi;given-names:H.W.</infon><infon key=\"pub-id_pmid\">15031027</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">363</infon><infon key=\"year\">2004</infon><offset>13895</offset><text>Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia</text></passage><passage><infon key=\"comment\">409-314</infon><infon key=\"name_0\">surname:Maache;given-names:M.</infon><infon key=\"name_1\">surname:Komurian-Pradel;given-names:F.</infon><infon key=\"name_2\">surname:Rajoharison;given-names:A.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Vaccine Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">13</infon><infon key=\"year\">2006</infon><offset>13985</offset><text>False-positive results in a recombinant severe acute respiratory syndrome-associated coronavirus (SARS CoV) nucleocapsid-based western blot assay were rectified by the use of two subunits (Si and S2) of spike for detection of antibody to SARS-CoV</text></passage><passage><infon key=\"comment\">30262</infon><infon key=\"fpage\">8674</infon><infon key=\"name_0\">surname:Walls;given-names:A.C.</infon><infon key=\"name_1\">surname:Park;given-names:Y.J.</infon><infon key=\"name_2\">surname:Tortorici;given-names:M.A.</infon><infon key=\"name_3\">surname:Wall;given-names:A.</infon><infon key=\"name_4\">surname:McGuire;given-names:A.T.</infon><infon key=\"name_5\">surname:Veesler;given-names:D.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">S0092</infon><infon key=\"year\">2020</infon><offset>14232</offset><text>Structure,function, and antigenicity of the SARS-CoV-2 spike glycoprotein</text></passage><passage><infon key=\"comment\">preprint on March 20</infon><infon key=\"name_0\">surname:Nisreen;given-names:M.A.O.</infon><infon key=\"name_1\">surname:MÃ¼ller;given-names:M.A.</infon><infon key=\"name_2\">surname:Wentao;given-names:Li</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>14306</offset></passage><passage><infon key=\"comment\">preprint on March 18</infon><infon key=\"name_0\">surname:Amanat;given-names:F.</infon><infon key=\"name_1\">surname:Nguyen;given-names:T.H.O.</infon><infon key=\"name_2\">surname:Chromikova;given-names:V.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>14307</offset></passage><passage><infon key=\"name_0\">surname:Zhao;given-names:J.</infon><infon key=\"name_1\">surname:Yuan;given-names:Q.</infon><infon key=\"name_2\">surname:Wang;given-names:H.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>14308</offset></passage><passage><infon key=\"fpage\">665</infon><infon key=\"lpage\">668</infon><infon key=\"name_0\">surname:Woo;given-names:P.C.</infon><infon key=\"name_1\">surname:Lau;given-names:S.K.</infon><infon key=\"name_2\">surname:Wong;given-names:B.H.</infon><infon key=\"pub-id_pmid\">15242938</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Diagn Lab Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2004</infon><offset>14309</offset><text>Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus</text></passage><passage><infon key=\"comment\">[published online ahead of print, 2020 mar 21] ciaa310</infon><infon key=\"name_0\">surname:Guo;given-names:L.</infon><infon key=\"name_1\">surname:Ren;given-names:L.</infon><infon key=\"name_2\">surname:Yang;given-names:S.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>14522</offset><text>Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"lpage\">7</infon><infon key=\"name_0\">surname:Li;given-names:Z.</infon><infon key=\"name_1\">surname:Yi;given-names:Y.</infon><infon key=\"name_2\">surname:Luo;given-names:X.</infon><infon key=\"pub-id_doi\">10.1002/jmv.25727</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>14604</offset><text>Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis</text></passage><passage><infon key=\"comment\">on March 12</infon><infon key=\"name_0\">surname:Jia;given-names:X.</infon><infon key=\"name_1\">surname:Zhang;given-names:P.</infon><infon key=\"name_2\">surname:Tian;given-names:Y.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>14718</offset></passage></document></collection>\n",
      "\n",
      "Study 33322035: <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n",
      "<!DOCTYPE collection SYSTEM \"BioC.dtd\">\n",
      "<collection><source>PMC</source><date>20201228</date><key>pmc.key</key><document><id>7764512</id><infon key=\"license\">CC BY</infon><passage><infon key=\"article-id_doi\">10.3390/v12121420</infon><infon key=\"article-id_pmc\">7764512</infon><infon key=\"article-id_pmid\">33322035</infon><infon key=\"article-id_publisher-id\">viruses-12-01420</infon><infon key=\"elocation-id\">1420</infon><infon key=\"issue\">12</infon><infon key=\"kwd\">rapid antigen test diagnosis COVID-19 SARS-CoV-2</infon><infon key=\"license\">Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).</infon><infon key=\"name_0\">surname:Yamayoshi;given-names:Seiya</infon><infon key=\"name_1\">surname:Sakai-Tagawa;given-names:Yuko</infon><infon key=\"name_10\">surname:Ikeuchi;given-names:Kazuhiko</infon><infon key=\"name_11\">surname:Ogura;given-names:Takayuki</infon><infon key=\"name_12\">surname:Baba;given-names:Rie</infon><infon key=\"name_13\">surname:Fujita;given-names:Kensuke</infon><infon key=\"name_14\">surname:Fukui;given-names:Takahiro</infon><infon key=\"name_15\">surname:Ito;given-names:Fumimaro</infon><infon key=\"name_16\">surname:Hattori;given-names:Shin-ichiro</infon><infon key=\"name_17\">surname:Yamamoto;given-names:Kei</infon><infon key=\"name_18\">surname:Nakamoto;given-names:Takato</infon><infon key=\"name_19\">surname:Furusawa;given-names:Yuri</infon><infon key=\"name_2\">surname:Koga;given-names:Michiko</infon><infon key=\"name_20\">surname:Yasuhara;given-names:Atsuhiro</infon><infon key=\"name_21\">surname:Ujie;given-names:Michiko</infon><infon key=\"name_22\">surname:Yamada;given-names:Shinya</infon><infon key=\"name_23\">surname:Ito;given-names:Mutsumi</infon><infon key=\"name_24\">surname:Mitsuya;given-names:Hiroaki</infon><infon key=\"name_25\">surname:Omagari;given-names:Norio</infon><infon key=\"name_26\">surname:Yotsuyanagi;given-names:Hiroshi</infon><infon key=\"name_27\">surname:Iwatsuki-Horimoto;given-names:Kiyoko</infon><infon key=\"name_28\">surname:Imai;given-names:Masaki</infon><infon key=\"name_29\">surname:Kawaoka;given-names:Yoshihiro</infon><infon key=\"name_3\">surname:Akasaka;given-names:Osamu</infon><infon key=\"name_30\">surname:PalÃ¹;given-names:Giorgio</infon><infon key=\"name_4\">surname:Nakachi;given-names:Ichiro</infon><infon key=\"name_5\">surname:Koh;given-names:Hidefumi</infon><infon key=\"name_6\">surname:Maeda;given-names:Kenji</infon><infon key=\"name_7\">surname:Adachi;given-names:Eisuke</infon><infon key=\"name_8\">surname:Saito;given-names:Makoto</infon><infon key=\"name_9\">surname:Nagai;given-names:Hiroyuki</infon><infon key=\"section_type\">TITLE</infon><infon key=\"type\">front</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>0</offset><text>Comparison of Rapid Antigen Tests for COVID-19</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>47</offset><text>Reverse transcription-quantitative PCR (RT-qPCR)-based tests are widely used to diagnose coronavirus disease 2019 (COVID-19). As a result that these tests cannot be done in local clinics where RT-qPCR testing capability is lacking, rapid antigen tests (RATs) for COVID-19 based on lateral flow immunoassays are used for rapid diagnosis. However, their sensitivity compared with each other and with RT-qPCR and infectious virus isolation has not been examined. Here, we compared the sensitivity among four RATs by using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolates and several types of COVID-19 patient specimens and compared their sensitivity with that of RT-qPCR and infectious virus isolation. Although the RATs read the samples containing large amounts of virus as positive, even the most sensitive RAT read the samples containing small amounts of virus as negative. Moreover, all RATs tested failed to detect viral antigens in several specimens from which the virus was isolated. The current RATs will likely miss some COVID-19 patients who are shedding infectious SARS-CoV-2.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>1153</offset><text>1. Introduction</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>1169</offset><text>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged as a novel human pathogen in China at the end of 2019, is responsible for coronavirus disease 2019 (COVID-19), which causes symptoms such as cough and fever, severe pneumonia, and death. The WHO reported that more than 29 million cases of COVID-19, including approximately 900,000 deaths, have occurred as of 16 September 2020 (). To control the spread of SARS-CoV-2 infections, rapid identification and isolation of patients are required.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>1685</offset><text>The gold standard for COVID-19 diagnosis is reverse transcription-quantitative PCR (RT-qPCR) using nasopharyngeal (N) swabs, throat (T) swabs, or saliva. RT-qPCR kits that do not require viral RNA extraction and high-throughput RT-qPCR systems have been developed. Although such tests are widely utilized in public health laboratories and large well-equipped hospitals, they are unavailable in local clinics where patients who suspect they have COVID-19 often go first. Therefore, specimens need to be transported to and examined at sites that have RT-qPCR capability, which delays the test result and increases the anxiety of the suspected COVID-19 patients. To improve this situation, rapid antigen tests (RATs) for COVID-19, which does not require specific and expensive machinery, have been approved for clinical use in Japan and other countries, and the sensitivity of these tests has been compared with that of several kinds of RT-qPCR. Although these RATs might be useful for the identification of COVID-19 patients in local clinics, their sensitivity is important in determining usage strategies. Here, we examined the sensitivity of four RATs available in Japan in August 2020 for the detection of isolated viruses. We also evaluated their effectiveness with several kinds of clinical specimens collected from COVID-19 patients and compared it with that of RT-qPCR and virus isolation.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_1</infon><offset>3080</offset><text>2. Materials and Methods</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>3105</offset><text>2.1. Ethics and Biosafety Statements</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>3142</offset><text>Human samples were collected by following protocols approved by the Research Ethics Review Committee of the Institute of Medical Science, the University of Tokyo (approval number 2019-71-0201; 1 February 2020). Signed informed consent was obtained from all participants.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>3413</offset><text>All experiments with SARS-CoV-2 were performed prior to 8 September 2020 in biosafety level 3 (BSL3) laboratories at the University of Tokyo, which were approved for such use by the Ministry of Agriculture, Forestry, and Fisheries, Japan.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>3652</offset><text>2.2. Cells</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>3663</offset><text>Vero cells expressing human serine protease TMPRSS2 (Vero-TMPRSS2) were maintained in DMEM containing 10% fetal calf serum (FCS), 1 mg/mL G418, 100 units/mL penicillin, 100 Âµg/mL streptomycin, and 5 Î¼g/mL plasmocin prophylactic (InvivoGen, San Diego, CA, USA) and incubated at 37 Â°C under 5% CO2. We used these cells after clearance of mycoplasma.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>4016</offset><text>2.3. Viruses</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>4029</offset><text>SARS-CoV-2 (UT-NCGM02/Human/2020/Tokyo (NC02) and UT-HP072/Human/2020/Tokyo (HP72)] were isolated from clinical samples collected in February and August, respectively, and titrated in Vero-TMPRSS2 cells by performing plaque assays.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>4261</offset><text>2.4. Clinical Samples</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>4283</offset><text>Gargle lavage (n = 7), saliva (n = 27), throat (T) swab (n = 2), nasal vestibule swab (n = 1), nasopharyngeal (N) swab (n = 18), sputum (n = 4), and tracheal aspirate (n = 17) samples (Supplementary Materials Table S1) were collected from COVID-19 patients at several timepoints after onset. Swabs were soaked in BD universal viral transport medium; saliva, sputum, and tracheal aspirate samples were diluted in BD universal viral transport medium if needed. These media were used as test specimens. Gargle lavages were examined directly.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>4822</offset><text>2.5. RT-qPCR</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>4835</offset><text>Viral RNA was isolated from the specimens by using the QIAamp Viral RNA Mini Kit (QIAGEN, Tokyo, Japan). One step RT-qPCR was performed using the LightCycler 96 System (Roche Diagnostics, Tokyo, Japan) according to the protocol of the National Institute of Infectious Disease, Japan. A Cq value of &gt;40 was considered a negative result.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>5171</offset><text>2.6. Rapid Antigen Test (RAT)</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>5201</offset><text>The RATs listed in Table 1 were evaluated according to the procedures described in the manufacturersâ instructions, using 75â7500 plaque formation unit (PFU) of stock virus in 50 Î¼L of culture supernatant or 50 Î¼L of specimen. Two independent experiments were performed with each sample.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>5495</offset><text>2.7. Virus Isolation</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>5516</offset><text>The specimens were inoculated into Vero-TMPRSS2 cells in 24 well-plates and the cells were incubated at 37 Â°C for 1 h. After removal of the inoculum, the cells were incubated in DMEM containing 5% FCS, 10 mM HEPES, 100 Î¼g/mL gentamicin sulfate, and 2.5 Î¼g/mL amphotericin B for 6 days at 37 Â°C. The appearance of cytopathic effects was checked for 6 days at least once a day.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_1</infon><offset>5896</offset><text>3. Results</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>5907</offset><text>3.1. Comparison of 4 Rapid Antigen Tests (RATs)</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>5955</offset><text>We evaluated four RATs that were available in Japan in August 2020 (Table 1). These RATs are immunochromatographic tests; therefore, their sensitivity is dependent on the binding kinetics of the monoclonal antibodies used in each RAT. The composition of the lysis buffer, the proportion of specimen in the analyte, and the method used to visualize the result also affect the sensitivity. As a result that the manufacturers do not disclose the composition of the lysis buffer, we could not compare this parameter. The amount of lysis buffer and specimen/lysis buffer mixture used for testing differed among the RATs tested. Accordingly, the percentages of the specimens used also differed: for Standard Q COVID-19 Ag, Espline SARS-CoV-2, QuickNavi -COVID19 Ag, and ImmunoAce SARS-CoV-2, the percentages of specimens used were 14.3%, 10.0%, 12.5%, and 28.6%, respectively (Table 1). The method for visualization of the results also differed among these tests in that Standard Q COVID-19 Ag, Espline SARS-CoV-2, QuickNavi -COVID19 Ag, and ImmunoAce SARS-CoV-2 use color particles, alkaline phosphatase and its substrate, color latex, and platinum-gold colloids, respectively, to visualize the antigen-antibody immune-complexes. The visualized results are assessed by the human eye at 15â30, 30, 15, and 15 min, respectively, after adding the analyte. Although the types of specimens recommended for all four RATs are N swabs, we tested other types of specimens (see the footnote to Table 2 and Table 3).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>7458</offset><text>3.2. Sensitivity of RATs for Two Isolated SARS-CoV-2 Strains</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>7519</offset><text>To compare the sensitivity of these four RATs, two SARS-CoV-2 isolate stocks (NC02 and HP72) were diluted to the indicated PFU and then examined by RT-qPCR to determine the Cq value of each sample. The Cq values were 18.0, 21.7, 22.2, 23.1, and 25.4 at 7500, 750, 500, 250, and 75 PFU of NC02 and 16.9, 17.8, 18.8, 20.4, 21.1, 22.7, and 24.0 at 7500, 5000, 2500, 750, 500, 250, and 75 PFU of HP72 (Table S2). Standard Q COVID-19 Ag and ImmunoAce SARS-CoV-2 detected as little as 250 PFU of NC02, whereas Espline SARS-CoV-2 and QuickNavi -COVID19 Ag detected 500 PFU and 750 PFU of NC02, respectively (Table S2). Standard Q COVID-19 Ag and Espline SARS-CoV-2 detected as little as 250 PFU of HP72, whereas QuickNavi COVID19 Ag and ImmunoAce SARS-CoV-2 detected 5000 PFU of HP72. These results show that the sensitivity for virus detection of Standard Q COVID-19 Ag and Espline SARS-CoV-2 was better than that of QuickNavi COVID19 Ag, and that virus detection by ImmunoAce SARS-CoV-2 differed depending on the isolate.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>8536</offset><text>3.3. Sensitivity of RATs for Clinical Specimens</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>8584</offset><text>To evaluate the sensitivity of the four RATs for clinical specimens, 7 gargle lavages, 27 saliva, 2 throat (T) swabs, 1 nasal vestibule swabs, 18 nasopharyngeal (N) swabs, 4 sputum, and 17 tracheal aspirates were collected and their viral genomic RNA levels were examined by RT-qPCR. These 76 clinical specimens, which were divided into 6 groups based on their Cq value, were examined in the four RATs and subjected to virus isolation using Vero-TMPRSS2 cells (Table 2 and Table S1). Standard Q COVID-19 Ag and Espline SARS-CoV-2 detected viral antigens in all specimens with Cq values lower than 22.5, whereas QuickNavi COVID19 Ag and ImmunoAce SARS-CoV-2 failed to detect viral antigens in several of these specimens. For specimens with a Cq value between 22.5 and 25.0, the sensitivity was on the order of Espline SARS-CoV-2, Standard Q COVID-19 Ag, ImmunoAce SARS-CoV-2, and QuickNavi COVID19 Ag (Table 2 and Table S1). For the specimens with a Cq value greater than 25.0, the sensitivity of these four RATs was similar. These results indicate that the sensitivity of the four RATs is lower than that of RT-qPCR but similar to that of virus isolation. Overall, the sensitivity of Espline SARS-CoV-2 and Standard Q COVID-19 Ag was slightly better than that of ImmunoAce SARS-CoV-2; QuickNavi -COVID19 Ag had the lowest sensitivity.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>9919</offset><text>We next plotted the results from the RATs and virus isolation, in accordance with the number of days after onset that the specimens were obtained, and the Cq values of the RT-qPCR (Figure 1). Although all of the RATs efficiently detected viral antigens in the specimens with low Cq values, the results from the RATs could be different for two specimens with similar Cq values (i.e., some were RAT-positive, whereas others were RAT-negative). Several specimens with Cq values higher than those of specimens that were RAT-negative, but with the above-described low Cq values (as indicated by cyan arrows in Figure 1) were found to be RAT-positive. These results suggest that the viral RNA and protein content may have differed between the specimens or that some samples may have contained inhibitors or enhancers for the antigen-antibody reaction of the RATs. Importantly, several specimens from which the virus was isolated were negative with all RATs tested, indicating that these RATs could potentially fail to diagnose patients shedding infectious SARS-CoV-2.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>10981</offset><text>Since the type of specimen likely affects the sensitivity of RATs, we assessed our results according to specimen type (gargle lavage, saliva, T swab, nasal vestibule swab, N swab, sputum, and tracheal aspirate). Although the Cq value varied between specimens from 18.8 to 36.0, gargle lavage, T swabs, and nasal vestibule swabs showed higher Cq values than the other types of specimens (Table 3). All four RATs detected virus antigens in one sputum sample, although no virus was isolated from 4 sputum samples tested. All four RATs failed to detect virus antigens in all 7 gargle lavages, 2 T swabs, and 1 nasal vestibule swabs, although the virus was isolated from one T swab sample. Since N swabs and saliva are suitable specimens for diagnosis in clinics, we plotted the results from the RATs and virus isolation based on the number of days after onset that the specimens were collected and the Cq values of the RT-qPCR (Figure 2). Standard Q COVID-19 Ag, Espline SARS-CoV-2, and ImmunoAce SARS-CoV-2 efficiently detected virus antigens in N swabs and saliva with low Cq values (Cq &lt; 25) that were collected at early timepoints after onset.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">title_1</infon><offset>12125</offset><text>4. Discussion</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>12139</offset><text>Here we evaluated the sensitivity of four RATs available in Japan in August 2020. The overall sensitivity of Standard Q COVID-19 Ag and Espline SARS-CoV-2 was better than that of ImmunoAce SARS-CoV-2 and QuickNavi COVID19 Ag. For specimens such as saliva and swabs, Standard Q COVID-19 Ag, Espline SARS-CoV-2, and ImmunoAce SARS-CoV-2 had similar detection sensitivities. These three kits detected viral antigens in more than half of the specimens whose Cq values of RT-qPCR were less than approximately 25. Therefore, these RATs may be suitable for the detection of COVID-19 in individuals who are shedding a large amount of SARS-CoV-2; that is, they may be useful to identify patients with a high likelihood of transmitting the virus to others.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>12886</offset><text>All four RATs failed to detect viral antigens in several specimens from which virus was isolated. This finding indicates that the current RATs are likely to miss some COVID-19 patients who are shedding infectious SARS-CoV-2. However, it is unclear to what extent such patients would transmit virus to others. Further studies are required to address this point. In addition, the present study used swab specimens that were soaked in transport medium; if the specimens were directly soaked in lysis buffer, the sensitivity of the RATs might be improved. The recommended samples for these RATS are nasopharyngeal swabs not saliva, and some of the saliva samples from which SARS-CoV-2 was isolated gave negative results with all of the RATs tested here. Nonetheless, these RATs need to be improved with respect to their sensitivity.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>13715</offset><text>In this study, we focused on the sensitivity of four RATs; we did not evaluate the false-positive rates of these kits. Therefore, studies on false-positive rates should be performed in the future to determine the specificity of these and other RATs.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">footnote</infon><offset>13965</offset><text>Publisherâs Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">title</infon><offset>14091</offset><text>Supplementary Materials</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">paragraph</infon><offset>14115</offset><text>The following are available online at , Table S1: List of specimens and results, Table S2: Sensitivity of rapid antigen tests for stock viruses.</text></passage><passage><infon key=\"section_type\">AUTH_CONT</infon><infon key=\"type\">title</infon><offset>14260</offset><text>Author Contributions</text></passage><passage><infon key=\"section_type\">AUTH_CONT</infon><infon key=\"type\">paragraph</infon><offset>14281</offset><text>S.Y. (Seiya Yamayoshi) and Y.K. designed the study. S.Y. (Seiya Yamayoshi) and Y.S.-T. performed the experiments. M.K., H.M., O.A., I.N., H.K., K.M., E.A., M.S., H.N., K.I., T.O., R.B., K.F., T.F., F.I., S.-i.H., K.Y., T.N., Y.F., N.O., H.M., and H.Y. collected the clinical samples. A.Y., M.U., and S.Y. (Shinya Yamada) assisted with the experiments. M.I. (Mutsumi Ito), K.I.-H., and M.I. (Masaki Imai) assisted with the sample collection. S.Y. (Seiya Yamayoshi) and Y.K. analyzed the data. S.Y. (Seiya Yamayoshi) and Y.K. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.</text></passage><passage><infon key=\"section_type\">ACK_FUND</infon><infon key=\"type\">title</infon><offset>14904</offset><text>Funding</text></passage><passage><infon key=\"section_type\">ACK_FUND</infon><infon key=\"type\">paragraph</infon><offset>14912</offset><text>This work was supported by a Research Program on Emerging and Re-emerging Infectious Diseases (JP19fk0108113 and JP19fk0108166), a Project Promoting Support for Drug Discovery (JP20nk0101612, JP20nk0101614, and JP20nk0101603), the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID) (JP19fm0108006), and a Japan Program for Infectious Diseases Research and Infrastructure (JP20wm0125002) from the Japan Agency for Medical Research and Development (AMED), and the National Institutes of Allergy and Infectious Diseases funded Center for Research on Influenza Pathogenesis (CRIP; HHSN272201400008C).</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">title</infon><offset>15535</offset><text>Conflicts of Interest</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">paragraph</infon><offset>15557</offset><text>Yoshihiro Kawaoka obtained funds to organize a symposium, âInfluenza and Other Infectionsâ in 2019 from TAUNS Laboratories, Inc. Kei Yamamoto has received grant support from Fujirebio, Inc.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">title</infon><offset>15751</offset><text>References</text></passage><passage><infon key=\"fpage\">727</infon><infon key=\"lpage\">733</infon><infon key=\"name_0\">surname:Zhu;given-names:N.</infon><infon key=\"name_1\">surname:Zhang;given-names:D.</infon><infon key=\"name_2\">surname:Wang;given-names:W.</infon><infon key=\"name_3\">surname:Li;given-names:X.</infon><infon key=\"name_4\">surname:Yang;given-names:B.</infon><infon key=\"name_5\">surname:Song;given-names:J.</infon><infon key=\"name_6\">surname:Zhao;given-names:X.</infon><infon key=\"name_7\">surname:Huang;given-names:B.</infon><infon key=\"name_8\">surname:Shi;given-names:W.</infon><infon key=\"name_9\">surname:Lu;given-names:R.</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa2001017</infon><infon key=\"pub-id_pmid\">31978945</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N. Engl. J. Med.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>15762</offset><text>A Novel Coronavirus from Patients with Pneumonia in China, 2019</text></passage><passage><infon key=\"fpage\">2249</infon><infon key=\"lpage\">2251</infon><infon key=\"name_0\">surname:Sethuraman;given-names:N.</infon><infon key=\"name_1\">surname:Jeremiah;given-names:S.S.</infon><infon key=\"name_2\">surname:Ryo;given-names:A.</infon><infon key=\"pub-id_doi\">10.1001/jama.2020.8259</infon><infon key=\"pub-id_pmid\">32374370</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>15826</offset><text>Interpreting Diagnostic Tests for SARS-CoV-2</text></passage><passage><infon key=\"fpage\">e01438-20</infon><infon key=\"name_0\">surname:Nagura-Ikeda;given-names:M.</infon><infon key=\"name_1\">surname:Imai;given-names:K.</infon><infon key=\"name_2\">surname:Tabata;given-names:S.</infon><infon key=\"name_3\">surname:Miyoshi;given-names:K.</infon><infon key=\"name_4\">surname:Murahara;given-names:N.</infon><infon key=\"name_5\">surname:Mizuno;given-names:T.</infon><infon key=\"name_6\">surname:Horiuchi;given-names:M.</infon><infon key=\"name_7\">surname:Kato;given-names:K.</infon><infon key=\"name_8\">surname:Imoto;given-names:Y.</infon><infon key=\"name_9\">surname:Iwata;given-names:M.</infon><infon key=\"pub-id_doi\">10.1128/JCM.01438-20</infon><infon key=\"pub-id_pmid\">32636214</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Clin. Microbiol.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>15871</offset><text>Clinical Evaluation of Self-Collected Saliva by Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR, Reverse Transcription-Loop-Mediated Isothermal Amplification, and a Rapid Antigen Test to Diagnose COVID-19</text></passage><passage><infon key=\"fpage\">104500</infon><infon key=\"name_0\">surname:Mak;given-names:G.C.</infon><infon key=\"name_1\">surname:Cheng;given-names:P.K.</infon><infon key=\"name_2\">surname:Lau;given-names:S.S.</infon><infon key=\"name_3\">surname:Wong;given-names:K.K.</infon><infon key=\"name_4\">surname:Lau;given-names:C.S.</infon><infon key=\"name_5\">surname:Lam;given-names:E.T.</infon><infon key=\"name_6\">surname:Chan;given-names:R.C.</infon><infon key=\"name_7\">surname:Tsang;given-names:D.N.</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104500</infon><infon key=\"pub-id_pmid\">32585619</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Clin. Virol.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">129</infon><infon key=\"year\">2020</infon><offset>16093</offset><text>Evaluation of rapid antigen test for detection of SARS-CoV-2 virus</text></passage><passage><infon key=\"fpage\">e00977-20</infon><infon key=\"name_0\">surname:Lambert-Niclot;given-names:S.</infon><infon key=\"name_1\">surname:Cuffel;given-names:A.</infon><infon key=\"name_2\">surname:Le Pape;given-names:S.</infon><infon key=\"name_3\">surname:Vauloup-Fellous;given-names:C.</infon><infon key=\"name_4\">surname:Morand-Joubert;given-names:L.</infon><infon key=\"name_5\">surname:Roque-Afonso;given-names:A.M.</infon><infon key=\"name_6\">surname:Le Goff;given-names:J.</infon><infon key=\"name_7\">surname:Delaugerre;given-names:C.</infon><infon key=\"pub-id_doi\">10.1128/JCM.00977-20</infon><infon key=\"pub-id_pmid\">32404480</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Clin. Microbiol.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>16160</offset><text>Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs</text></passage><passage><infon key=\"fpage\">328</infon><infon key=\"lpage\">333</infon><infon key=\"name_0\">surname:Porte;given-names:L.</infon><infon key=\"name_1\">surname:Legarraga;given-names:P.</infon><infon key=\"name_2\">surname:Vollrath;given-names:V.</infon><infon key=\"name_3\">surname:Aguilera;given-names:X.</infon><infon key=\"name_4\">surname:Munita;given-names:J.M.</infon><infon key=\"name_5\">surname:Araos;given-names:R.</infon><infon key=\"name_6\">surname:Pizarro;given-names:G.</infon><infon key=\"name_7\">surname:Vial;given-names:P.</infon><infon key=\"name_8\">surname:Iruretagoyena;given-names:M.</infon><infon key=\"name_9\">surname:Dittrich;given-names:S.</infon><infon key=\"pub-id_doi\">10.1016/j.ijid.2020.05.098</infon><infon key=\"pub-id_pmid\">32497809</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int. J. Infect. Dis.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">99</infon><infon key=\"year\">2020</infon><offset>16259</offset><text>Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples</text></passage><passage><infon key=\"fpage\">104455</infon><infon key=\"name_0\">surname:Scohy;given-names:A.</infon><infon key=\"name_1\">surname:Anantharajah;given-names:A.</infon><infon key=\"name_2\">surname:Bodeus;given-names:M.</infon><infon key=\"name_3\">surname:Kabamba-Mukadi;given-names:B.</infon><infon key=\"name_4\">surname:Verroken;given-names:A.</infon><infon key=\"name_5\">surname:Rodriguez-Villalobos;given-names:H.</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104455</infon><infon key=\"pub-id_pmid\">32485618</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Clin. Virol.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">129</infon><infon key=\"year\">2020</infon><offset>16371</offset><text>Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis</text></passage><passage><infon key=\"fpage\">225</infon><infon key=\"name_0\">surname:Mertens;given-names:P.</infon><infon key=\"name_1\">surname:De Vos;given-names:N.</infon><infon key=\"name_2\">surname:Martiny;given-names:D.</infon><infon key=\"name_3\">surname:Jassoy;given-names:C.</infon><infon key=\"name_4\">surname:Mirazimi;given-names:A.</infon><infon key=\"name_5\">surname:Cuypers;given-names:L.</infon><infon key=\"name_6\">surname:Van den Wijngaert;given-names:S.</infon><infon key=\"name_7\">surname:Monteil;given-names:V.</infon><infon key=\"name_8\">surname:Melin;given-names:P.</infon><infon key=\"name_9\">surname:Stoffels;given-names:K.</infon><infon key=\"pub-id_doi\">10.3389/fmed.2020.00225</infon><infon key=\"pub-id_pmid\">32574326</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Front. Med. (Lausanne)</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2020</infon><offset>16463</offset><text>Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context</text></passage><passage><infon key=\"fpage\">104472</infon><infon key=\"name_0\">surname:Blairon;given-names:L.</infon><infon key=\"name_1\">surname:Wilmet;given-names:A.</infon><infon key=\"name_2\">surname:Beukinga;given-names:I.</infon><infon key=\"name_3\">surname:Tre-Hardy;given-names:M.</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104472</infon><infon key=\"pub-id_pmid\">32504944</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Clin. Virol.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">129</infon><infon key=\"year\">2020</infon><offset>16570</offset><text>Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: Experiences of a general hospital</text></passage><passage><infon key=\"fpage\">7001</infon><infon key=\"lpage\">7003</infon><infon key=\"name_0\">surname:Matsuyama;given-names:S.</infon><infon key=\"name_1\">surname:Nao;given-names:N.</infon><infon key=\"name_2\">surname:Shirato;given-names:K.</infon><infon key=\"name_3\">surname:Kawase;given-names:M.</infon><infon key=\"name_4\">surname:Saito;given-names:S.</infon><infon key=\"name_5\">surname:Takayama;given-names:I.</infon><infon key=\"name_6\">surname:Nagata;given-names:N.</infon><infon key=\"name_7\">surname:Sekizuka;given-names:T.</infon><infon key=\"name_8\">surname:Katoh;given-names:H.</infon><infon key=\"name_9\">surname:Kato;given-names:F.</infon><infon key=\"pub-id_doi\">10.1073/pnas.2002589117</infon><infon key=\"pub-id_pmid\">32165541</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Proc. Natl. Acad. Sci. USA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">117</infon><infon key=\"year\">2020</infon><offset>16710</offset><text>Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells</text></passage><passage><infon key=\"fpage\">16587</infon><infon key=\"lpage\">16595</infon><infon key=\"name_0\">surname:Imai;given-names:M.</infon><infon key=\"name_1\">surname:Iwatsuki-Horimoto;given-names:K.</infon><infon key=\"name_2\">surname:Hatta;given-names:M.</infon><infon key=\"name_3\">surname:Loeber;given-names:S.</infon><infon key=\"name_4\">surname:Halfmann;given-names:P.J.</infon><infon key=\"name_5\">surname:Nakajima;given-names:N.</infon><infon key=\"name_6\">surname:Watanabe;given-names:T.</infon><infon key=\"name_7\">surname:Ujie;given-names:M.</infon><infon key=\"name_8\">surname:Takahashi;given-names:K.</infon><infon key=\"name_9\">surname:Ito;given-names:M.</infon><infon key=\"pub-id_doi\">10.1073/pnas.2009799117</infon><infon key=\"pub-id_pmid\">32571934</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Proc. Natl. Acad. Sci. USA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">117</infon><infon key=\"year\">2020</infon><offset>16771</offset><text>Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development</text></passage><passage><infon key=\"fpage\">304</infon><infon key=\"lpage\">307</infon><infon key=\"name_0\">surname:Shirato;given-names:K.</infon><infon key=\"name_1\">surname:Nao;given-names:N.</infon><infon key=\"name_2\">surname:Katano;given-names:H.</infon><infon key=\"name_3\">surname:Takayama;given-names:I.</infon><infon key=\"name_4\">surname:Saito;given-names:S.</infon><infon key=\"name_5\">surname:Kato;given-names:F.</infon><infon key=\"name_6\">surname:Katoh;given-names:H.</infon><infon key=\"name_7\">surname:Sakata;given-names:M.</infon><infon key=\"name_8\">surname:Nakatsu;given-names:Y.</infon><infon key=\"name_9\">surname:Mori;given-names:Y.</infon><infon key=\"pub-id_doi\">10.7883/yoken.JJID.2020.061</infon><infon key=\"pub-id_pmid\">32074516</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Jpn. J. Infect. Dis.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">73</infon><infon key=\"year\">2020</infon><offset>16867</offset><text>Development of Genetic Diagnostic Methods for Detection for Novel Coronavirus 2019(nCoV-2019) in Japan</text></passage><passage><infon key=\"file\">viruses-12-01420-g001.jpg</infon><infon key=\"id\">viruses-12-01420-f001</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>16970</offset><text>Results of RATs plotted based on the Cq value of RT-qPCR and days after onset. Viral antigens in 76 clinical specimens (7 gargle lavages, 27 saliva, 2 T swabs, 1 nasal vestibule swabs, 18 N swabs, 4 sputum, and 17 tracheal aspirates) were examined by Standard Q COVID-19 Ag, Espline SARS-CoV-2, QuickNavi COVID19 Ag, and ImmunoAce SARS-CoV-2. Two independent experiments were performed. All specimens were also tested by RT-qPCR and subjected to virus isolation. Open red circles indicate specimens from which virus was isolated; open black circles indicate specimens from which virus was not isolated. Circles filled in black indicate both results were positive, those filled in gray indicate that one was positive, no color indicates both were negative.</text></passage><passage><infon key=\"file\">viruses-12-01420-g002.jpg</infon><infon key=\"id\">viruses-12-01420-f002</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>17726</offset><text>Results of RATs using N swabs and saliva specimens plotted based on the Cq value of RT-qPCR and days after onset. The results from the N swabs and saliva samples were extracted from Figure 1.</text></passage><passage><infon key=\"file\">viruses-12-01420-t001.xml</infon><infon key=\"id\">viruses-12-01420-t001</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>17918</offset><text>Rapid antigen tests examined in this study.</text></passage><passage><infon key=\"file\">viruses-12-01420-t001.xml</infon><infon key=\"id\">viruses-12-01420-t001</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Name&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Manufacturer&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Method for Visualization &lt;sup&gt;a&lt;/sup&gt;&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Input Ratio &lt;sup&gt;b&lt;/sup&gt; (%)&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Minutes to Assess &lt;sup&gt;c&lt;/sup&gt;&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Country of Manufacture&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Standard Q COVID-19 Ag&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;SD Biosensor&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Color particle&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;14.3&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;15â30&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Korea&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Espline SARS-CoV-2&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fujirebio&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Alkaline phosphatase&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10.0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Japan&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;QuickNavi -COVID19 Ag&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Denka Seiken&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Color latex&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12.5&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;15&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Japan&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ImmunoAce SARS-CoV-2&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Tauns Laboratories&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Platinum-gold colloid&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;28.6&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;15&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Japan&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>17962</offset><text>Name\tManufacturer\tMethod for Visualization a\tInput Ratio b (%)\tMinutes to Assess c\tCountry of Manufacture\t \tStandard Q COVID-19 Ag\tSD Biosensor\tColor particle\t14.3\t15â30\tKorea\t \tEspline SARS-CoV-2\tFujirebio\tAlkaline phosphatase\t10.0\t30\tJapan\t \tQuickNavi -COVID19 Ag\tDenka Seiken\tColor latex\t12.5\t15\tJapan\t \tImmunoAce SARS-CoV-2\tTauns Laboratories\tPlatinum-gold colloid\t28.6\t15\tJapan\t \t</text></passage><passage><infon key=\"file\">viruses-12-01420-t001.xml</infon><infon key=\"id\">viruses-12-01420-t001</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_footnote</infon><offset>18350</offset><text>a The lysed sample is dropped into the well and the reaction occurs inside a covered plastic body. b For all rapid antigen tests (RATs) tested, the test samples (50 Î¼L) were mixed with lysis buffer (A). A part of the lysed sample (B) was then assayed. Input ratios were calculated using the following formula: volume B/(50 Î¼L + volume A) Ã 100. c The time required to obtain the results is based on the manufacturerâs instructions provided with the kit.</text></passage><passage><infon key=\"file\">viruses-12-01420-t002.xml</infon><infon key=\"id\">viruses-12-01420-t002</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>18809</offset><text>Sensitivity of rapid antigen tests for clinical specimens.</text></passage><passage><infon key=\"file\">viruses-12-01420-t002.xml</infon><infon key=\"id\">viruses-12-01420-t002</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;RT-qPCR&lt;/th&gt;&lt;th rowspan=&quot;2&quot; align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; colspan=&quot;1&quot;&gt;Number of Samples &lt;sup&gt;a&lt;/sup&gt;&lt;/th&gt;&lt;th rowspan=&quot;2&quot; align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; colspan=&quot;1&quot;&gt;Standard Q COVID-19 Ag&lt;/th&gt;&lt;th rowspan=&quot;2&quot; align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; colspan=&quot;1&quot;&gt;Espline SARS-CoV-2&lt;/th&gt;&lt;th rowspan=&quot;2&quot; align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; colspan=&quot;1&quot;&gt;QuickNavi COVID19 Ag&lt;/th&gt;&lt;th rowspan=&quot;2&quot; align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; colspan=&quot;1&quot;&gt;ImmunoAce SARS-CoV-2&lt;/th&gt;&lt;th rowspan=&quot;2&quot; align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; colspan=&quot;1&quot;&gt;Virus Isolation&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;(Cq Value)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;â20.0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4 &lt;sup&gt;b&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.5&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.5&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2 &lt;sup&gt;c&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;20.0â22.5&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.5&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;22.5â25.0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10.5&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12.5&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9.5&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;25.0â27.5&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;20&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.5&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.5&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;27.5â30.0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30.0â&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>18868</offset><text>RT-qPCR\tNumber of Samples a\tStandard Q COVID-19 Ag\tEspline SARS-CoV-2\tQuickNavi COVID19 Ag\tImmunoAce SARS-CoV-2\tVirus Isolation\t \t(Cq Value)\t \tâ20.0\t4\t4 b\t4\t3.5\t3.5\t2 c\t \t20.0â22.5\t7\t7\t7\t4.5\t6\t6\t \t22.5â25.0\t17\t10.5\t12.5\t5\t9.5\t9\t \t25.0â27.5\t20\t2.5\t3\t2\t3.5\t4\t \t27.5â30.0\t17\t2\t1\t0\t2\t3\t \t30.0â\t11\t0\t0\t0\t0\t0\t \t</text></passage><passage><infon key=\"file\">viruses-12-01420-t002.xml</infon><infon key=\"id\">viruses-12-01420-t002</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_footnote</infon><offset>19186</offset><text>a A total of 76 clinical specimens including 7 gargle lavages, 27 saliva, 2 T swabs, 1 nasal vestibule swabs, 18 N swabs, 4 sputum, and 17 tracheal aspirates were examined. b Each sample was tested in two independent experiments; when a kit identified a sample as positive in both tests, a value of 1 was assigned. If only one test was positive, a value of 0.5 was assigned. If both tests were negative, a value of 0 was assigned. c Number of samples from which the virus was isolated.</text></passage><passage><infon key=\"file\">viruses-12-01420-t003.xml</infon><infon key=\"id\">viruses-12-01420-t003</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>19672</offset><text>Sensitivity of rapid antigen tests for different types of clinical specimen.</text></passage><passage><infon key=\"file\">viruses-12-01420-t003.xml</infon><infon key=\"id\">viruses-12-01420-t003</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th rowspan=&quot;2&quot; align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; colspan=&quot;1&quot;&gt;Clinical Specimen&lt;/th&gt;&lt;th rowspan=&quot;2&quot; align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; colspan=&quot;1&quot;&gt;Number of Samples&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;RT-qPCR&lt;/th&gt;&lt;th rowspan=&quot;2&quot; align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; colspan=&quot;1&quot;&gt;Standard Q COVID-19 Ag&lt;/th&gt;&lt;th rowspan=&quot;2&quot; align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; colspan=&quot;1&quot;&gt;Espline SARS-CoV-2&lt;/th&gt;&lt;th rowspan=&quot;2&quot; align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; colspan=&quot;1&quot;&gt;QuickNavi COVID19 Ag&lt;/th&gt;&lt;th rowspan=&quot;2&quot; align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; colspan=&quot;1&quot;&gt;ImmunoAce SARS-CoV-2&lt;/th&gt;&lt;th rowspan=&quot;2&quot; align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-top:solid thin;border-bottom:solid thin&quot; colspan=&quot;1&quot;&gt;Virus Isolation&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;(Cq Value)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Gargle lavage&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26.3â36.0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 &lt;sup&gt;a&lt;/sup&gt;&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 &lt;sup&gt;b&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Saliva&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;27&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;18.8â33.0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;T Swab&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;bold&gt;25.8&lt;/bold&gt;&lt;sup&gt;c&lt;/sup&gt;, 33.6&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Nasal vestibule swab&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;34.8&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N swab&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;18&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;19.7-33.0&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.5&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Sputum&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;19.9-34.3&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Tracheal aspirate&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;19.6-35.6&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6.5&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5.5&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.5&lt;/td&gt;&lt;td align=&quot;center&quot; valign=&quot;middle&quot; style=&quot;border-bottom:solid thin&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>19749</offset><text>Clinical Specimen\tNumber of Samples\tRT-qPCR\tStandard Q COVID-19 Ag\tEspline SARS-CoV-2\tQuickNavi COVID19 Ag\tImmunoAce SARS-CoV-2\tVirus Isolation\t \t(Cq Value)\t \tGargle lavage\t7\t26.3â36.0\t0 a\t0\t0\t0\t0 b\t \tSaliva\t27\t18.8â33.0\t10\t12\t5\t13\t12\t \tT Swab\t2\t25.8c, 33.6\t0\t0\t0\t0\t1\t \tNasal vestibule swab\t1\t34.8\t0\t0\t0\t0\t0\t \tN swab\t18\t19.7-33.0\t8\t8\t3.5\t7\t10\t \tSputum\t4\t19.9-34.3\t1\t1\t1\t1\t0\t \tTracheal aspirate\t17\t19.6-35.6\t7\t6.5\t5.5\t3.5\t1\t \t</text></passage><passage><infon key=\"file\">viruses-12-01420-t003.xml</infon><infon key=\"id\">viruses-12-01420-t003</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_footnote</infon><offset>20179</offset><text>a Each specimen was tested in two independent experiments; when a kit identified a sample as positive in both tests, a value of 1 was assigned. If only one test was positive, a value of 0.5 was assigned. If both tests were negative, a value of 0 was assigned. b Number of samples from which virus was isolated. c Virus was isolated from this specimen.</text></passage></document></collection>\n",
      "\n",
      "Study 33008761: <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n",
      "<!DOCTYPE collection SYSTEM \"BioC.dtd\">\n",
      "<collection><source>PMC</source><date>20221202</date><key>pmc.key</key><document><id>7505601</id><infon key=\"license\">NO-CC CODE</infon><passage><infon key=\"article-id_doi\">10.1016/j.radi.2020.09.010</infon><infon key=\"article-id_pii\">S1078-8174(20)30197-8</infon><infon key=\"article-id_pmc\">7505601</infon><infon key=\"article-id_pmid\">33008761</infon><infon key=\"fpage\">682</infon><infon key=\"issue\">2</infon><infon key=\"kwd\">CT scan RT-PCR Ground-glass opacification Consolidation Crazy-paving Artificial intelligence</infon><infon key=\"license\">Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</infon><infon key=\"lpage\">687</infon><infon key=\"name_0\">surname:Alsharif;given-names:W.</infon><infon key=\"name_1\">surname:Qurashi;given-names:A.</infon><infon key=\"section_type\">TITLE</infon><infon key=\"title\">Keywords</infon><infon key=\"type\">front</infon><infon key=\"volume\">27</infon><infon key=\"year\">2020</infon><offset>0</offset><text>Effectiveness of COVID-19 diagnosis and management tools: A review</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>67</offset><text>Objective</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>77</offset><text>To review the available literature concerning the effectiveness of the COVID-19 diagnostic tools.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>175</offset><text>Background</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>186</offset><text>With the absence of specific treatment/vaccines for the coronavirus COVID-19, the most appropriate approach to control this infection is to quarantine people and isolate symptomatic people and suspected or infected cases. Although real-time reverse transcription-polymerase chain reaction (RT-PCR) assay is considered the first tool to make a definitive diagnosis of COVID-19 disease, the high false negative rate, low sensitivity, limited supplies and strict requirements for laboratory settings might delay accurate diagnosis. Computed tomography (CT) has been reported as an important tool to identify and investigate suspected patients with COVID-19 disease at early stage.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>864</offset><text>Key findings</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>877</offset><text>RT-PCR shows low sensitivity (60â71%) in diagnosing patients with COVID-19 infection compared to the CT chest. Several studies reported that chest CT scans show typical imaging features in all patients with COVID-19. This high sensitivity and initial presentation in CT chest can be helpful in rectifying false negative results obtained from RT-PCR. As COVID-19 has similar manifestations to other pneumonia diseases, artificial intelligence (AI) might help radiologists to differentiate COVID-19 from other pneumonia diseases.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>1407</offset><text>Conclusion</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>1418</offset><text>Although CT scan is a powerful tool in COVID-19 diagnosis, it is not sufficient to detect COVID-19 alone due to the low specificity (25%), and challenges that radiologists might face in differentiating COVID-19 from other viral pneumonia on chest CT scans. AI might help radiologists to differentiate COVID-19 from other pneumonia diseases.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>1759</offset><text>Implication for practice</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>1784</offset><text>Both RT-PCR and CT tests together would increase sensitivity and improve quarantine efficacy, an impact neither could achieve alone.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>1917</offset><text>Graphical abstract</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>1936</offset><text>Introduction</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>1949</offset><text>Cases of an unidentified form of viral pneumonia were first reported in Wuhan city, Hubei province, China, in December 2019. In the following weeks, this unknown virus gradually spread across the whole world. On January 7, 2020, a scientific research institution in China announced that the viral pneumonia was a novel coronavirus (SARS-COV-2), later it was called COVID-19 by the World Health Organization (WHO). According to Worldometer (2020), as of August 31, 2020, there had been 25,416,807 confirmed cases, 851,102 reported deaths and 17,724,602 recovered individuals across the world. </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>2542</offset><text>The mortality rate of COVID-19 is lower than that of the coronaviruses severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). However, COVID-19 is highly transmissible and rapidly spread, as it can be transmitted by respiratory droplets and contact. The common symptoms observed in patients with COVID-19 are fever, cough, severe headache, myalgia and fatigue. However, infection by other viruses such as influenza A or B can cause similar symptoms to COVID-19, which may make it difficult to distinguish COVID-19 from other infections, especially during flu season. The incubation period for COVID-19 infection is typically 1â14 days and might extend up to 24 days. The health conditions of most COVID-19 patients are mild, but they can become severe, especially among elderly people or those with underlying diseases, such as chronic lung or cardiovascular disease. To date, there is no evidence of any effective treatment for patients with COVID-19. Due to the lack of specific vaccines and drugs for COVID-19, it is essential to detect and manage the disease at an early stage to immediately isolate people who are confirmed to be infected with COVID-19 from healthy people. </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>3755</offset><text>According to the guidelines for the diagnosis of COVID-19 published by the Chinese government, real-time reverse transcription-polymerase chain reaction (RT-PCR) assay is considered the first tool in COVID-19 diagnosis. However, delayed sample collection, poor kit performance, limited supplies and strict requirements for laboratory settings might delay accurate diagnosis. This indicates that patients with COVID-19 may not be detected and receive appropriate treatment, which could increase the risk of spread of the infection among a larger population. It is not about the test itself; it is often about when and how the test samples are collected from infected people, and whether these samples are prepared and transported properly. </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>4495</offset><text>Diagnostic imaging such as computed tomography (CT) has played an important role in the diagnosis and management of patients with COVID-19.   CT of the chest is a routine scanning technique for pneumonia diagnosis. It can be used for the diagnosis of COVID-19, as well as to follow up the extent of lesions and track any changes in patients whose RT-PCR assays and plain radiographic images were negative.   Several studies reported that a CT of the chest shows typical imaging features in nearly all patients with COVID-19.   Hung etÂ al. and Xie etÂ al. (2020) highlight that similar imaging features were also detected in patients whose RT-PCR assays were negative.   </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>5167</offset><text>Artificial intelligence (AI), an emerging technology in the field of diagnostic imaging, has contributed to improving diagnosis and prognosis of several diseases, such as pneumonia. A research team showed the potential of AI in supporting the diagnosis of COVID-19 in patients with COVID-19 when trained on CT images, achieving a high sensitivity and specificity (90%).   By conducting a comprehensive review of published studies and the experience of diagnosing patients with coronavirus, the aim of this article is to review the effectiveness of the available COVID-19 diagnostic tools.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_1</infon><offset>5756</offset><text>RT-PCR assay and CT scans in the diagnosis of COVID-19</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>5811</offset><text>The standard method of COVID test is RT-PCR, and the test sample can be collected via nasopharyngeal swab or oropharyngeal swab. The RT-PCR is a genetic test combining reverse transcription of Ribonucleic acid (RNA) into complementary Deoxyribonucleic acid (DNA), and amplification of specific DNA targets using RT-PCR. Although the RT-PCR test remains the reference standard in making a definitive diagnosis of COVID-19 infection,   this test has rigorous laboratory specifications and takes a long time to report results.   Several studies found that the initial RT-PCR results for patients with COVID-19 infection were false-negatives.   These false-negative findings cannot be ignored, especially for those symptomatic people suspected to be infected with COVID-19.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>6581</offset><text>CT scans of the chest are used as a routine test to diagnose pneumonia; therefore, this may be useful in diagnosing COVID-19.   Unenhanced high resolution CT (HRCT) of the chest is acquired during a single breath-hold. CT images are then reconstructed and transmitted for subsequent interpretation and diagnosis. Ai etÂ al. (2020) conducted a study to evaluate the value and consistency of chest CT scans in the diagnosis of COVID-19 and found that the majority of patients (98%, nÂ =Â 56/57) had initial positive chest CT scans before or within six days of the initial positive RT-PCR findings. This is in line with other studies; they found that positive diagnoses of COVID-19 were available three days earlier with chest CT scans than with RT-PCR assay. This indicates that chest CT scans can play a role in rapidly detecting the infection at an early stage.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>7443</offset><text>Several studies have reported that chest CT scans show typical radiographic features in all patients with COVID-19.     The National Health Commission of China reported that chest CT is of a great value in diagnosing COVID-19, monitoring disease progression and evaluating treatment plans. Lee etÂ al. (2020) claim that most of the clinics in China currently prefer to use CT compared to other investigation tools. This preference might stem from the accessibility of CT units in China, CT's ability to diagnose patients at an early stage, concerns associated with other tests specificity and the lack of virus-testing kits. However, the American College of Radiology (ACR) is against the use of chest CT as a first-line investigation tool to diagnose patients with suspected COVID-19 disease. This might be due to the low specificity of CT in differentiating COVID-19 from other similar illnesses. Similarly the Royal College of Radiologists (RCR) stated that CT does have a well-established role in the assessment of patients presenting with severe respiratory distress, particularly those that deteriorate clinically. However, they confirmed that CT should not be used as a diagnostic assessment of patients with suspected coronavirus infection. Further challenges related to hygiene may also be another reason for not considering CT as a sole diagnostic tool for patients with COVID-19. This includes managing ventilation, airflow, and sanitising and cleaning the scanner rooms in radiology departments.   </text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>8954</offset><text>Recent studies have revealed that RT-PCR has low sensitivity (60â71%) in diagnosing patients with COVID-19 infection compared to the CT chest.     Fang etÂ al. (2020) referred to the high sensitivity of CT chest (98%) compared to that of RT-PCR tests (71%). This is in line with the findings of Xie etÂ al. (2020), who evaluated 167 patients and found that 3% (nÂ =Â 5) of the patients showed initially negative RT-PCR nasopharyngeal and/or throat swabs but simultaneously showed positive results in chest CT scans. This finding was supported by Huang etÂ al. (2020), who found that a laboratory test showed a normal white blood cells count with a negative RT-PCR assay; however, a chest CT scan showed multiple peripheral ground-glass opacities (GGO) in the lingual segments. Such false-negative results may be attributed to the low viral load in test samples and/or laboratory errors,   and it might be necessary to retest the patient. However, test kits are in short supply or are unavailable in some places. Therefore, some hospitals have started to use chest CT scans as a primary tool to diagnose COVID-19, though the ACR advises radiographers and radiologists to apply extreme precaution in this practice. </text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>10170</offset><text>In a study by Xie etÂ al. (2020), it was found that all patients presented characteristic CT image features of COVID-19 at an early stage, including GGO and/or mixed GGO and mixed consolidation, confirmed by positive RT-PCR assay during the isolation period. Shi etÂ al. (2020) highlighted that symptomatic patients might show changes in chest CT scans prior to obvious symptom onset. Shi and colleagues indicated that following up with chest CT scans might aid the continuous monitoring of disease changes during treatment. In their study, Wu etÂ al. (2020) found that most of the patients had mild symptoms and high temperatures; however, the lung manifestations on their chest CT scans were serious. They highlighted the role of chest CT scans in evaluating the severity of COVID-19 infection. </text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>10968</offset><text>In contrast, Guan etÂ al. (2020) and Chuang etÂ al. (2020) respectively found that 20% (nÂ =Â 230/1099) and 14% (nÂ =Â 3/21) of patients with clinical symptoms and positive RT-PCR findings had normal chest CT findings.   Similar results were found by Yang etÂ al. (2020). Although chest CT scans can show higher sensitivity in COVID-19 diagnosis than RT-PCR assay, Pan etÂ al. (2020) and Fang etÂ al. (2020) refer to the low specificity of chest CT scans.   This is reinforced by Ai etÂ al. (2020), who found that chest CT scans had low specificity (25%) in a recent study of 1,014 patients with COVID-19. This may stem from the difficulties that radiologists face in distinguishing between COVID-19 and other diseases on chest CT scans. Additionally, Li and Xia (2020) found that two patients confirmed to be infected with COVID-19 did not have CT features typical of COVID-19. This indicates that the differential diagnosis of COVID-19 should be considered when patients present with a fever and cough of unknown origin. It was also advised that all radiologists should familiarise themselves with the typical COVID-19 findings on chest CT scans.   Furthermore, radiologists should pay attention while interpreting CT images and be able to differentiate the features of patients with COVID-19 from motion artefacts as some of these patients may face difficulties in following the breathing instructions during CT scans. The above studies may suggest that chest CT imaging alone is not sufficient to exclude the diagnosis of COVID-19. Therefore, early chest CT scans combined with other investigation tools, such as RT-PCR assay, may still be required.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_1</infon><offset>12622</offset><text>Features of COVID-19 in CT imaging</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>12657</offset><text>During the early stages of COVID-19 infection, chest x-rays may not be sensitive enough to detect these changes.   CT on the other hand, has better sensitivity for the detection of early or mild disease.   Focusing on the many faces of COVID-19 for better recognition and accurate diagnosis is always recommended.   Below, typical and relatively atypical CT manifestations of COVID-19 will be reviewed to identify the potential imaging features of COVID-19.</text></passage><passage><infon key=\"file\">gr1_lrg.jpg</infon><infon key=\"id\">fig1</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>13115</offset><text>Lower bilateral peripheral consolidations and ground-glass opacities in keeping with the clinical diagnosis of clinical history provided of COVID-19.</text></passage><passage><infon key=\"file\">gr1_lrg.jpg</infon><infon key=\"id\">fig1</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig</infon><offset>13265</offset><text>FigureÂ 1</text></passage><passage><infon key=\"file\">gr2_lrg.jpg</infon><infon key=\"id\">fig2</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>13275</offset><text>Bilateral mainly basilar peripheral patchy consolidative opacities associated with bilateral basilar ill-defined ground-glass opacities.</text></passage><passage><infon key=\"file\">gr2_lrg.jpg</infon><infon key=\"id\">fig2</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig</infon><offset>13412</offset><text>FigureÂ 2</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>13422</offset><text>GGO is the most common feature.     It is a hazy increase in attenuation that appears in a variety of interstitial and alveolar processes with preservation of the bronchial and vascular margins. Consolidation is another typical feature of COVID-19, which is an area of opacification obscuring the margins of vessels and airway walls.   GGO with single or multiple focal lesions with or without consolidation in the posterior and peripheral lung segments that are distributed bilaterally is a common feature (FigureÂ 1, FigureÂ 2 ). GGO with reticular or interlobular septal thickening in a typical âcrazy-pavingâ pattern is often observed, while pure consolidation is relatively less common.   A recent study showed that the most frequent CT abnormalities observed in patients with COVID-19 were GGO (73/80 cases, 91%), consolidation (50/80 cases, 63%) and interlobular septal thickening (47/80, 59%). Most of the patients had multiple lesions, with an average of 12Â Â±Â 6 lung segments involved. </text></passage><passage><infon key=\"file\">gr3_lrg.jpg</infon><infon key=\"id\">fig3</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>14425</offset><text>Upper and lower lobe coalescent patchy perilobular ground-glass airspace opacities.</text></passage><passage><infon key=\"file\">gr3_lrg.jpg</infon><infon key=\"id\">fig3</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig</infon><offset>14509</offset><text>FigureÂ 3</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>14519</offset><text>CT imaging features of COVID-19 can differ in various stages and patients. In an early phase, GGO with single or multiple lesions can be found along the sub-pleural areas or bronchi. These lesions have nodular or patchy appearance, with thickened blood vessels passing through the GGO. Thickened interlobular and interlobular septa along with halo signs are also seen. As per published studies, the percentage of this finding occurrence ranges between 14 and 98% (Fig.Â 3 ).   However, this range significantly increases in the short-term re-examination, where more denser lesions can be seen. Consequently, crazy paving appearance may be noticed due to the lobular septal thickening and reflecting interstitial lesions. </text></passage><passage><infon key=\"file\">gr4_lrg.jpg</infon><infon key=\"id\">fig4</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>15241</offset><text>Multifocal bilateral airspace opacities that are more consolidation than ground glass and patchy peripheral distribution, which is related to patient's laboratory proven COVID-19.</text></passage><passage><infon key=\"file\">gr4_lrg.jpg</infon><infon key=\"id\">fig4</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig</infon><offset>15421</offset><text>FigureÂ 4</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>15431</offset><text>In severe patients, bilateral multifocal consolidation can be seen, partially fused into massive consolidation with small pleural effusions and even presenting with âwhite lungâ. Two weeks after onset, lung involvement has been shown to gradually increase to consolidation. Within 1â3 weeks, this GGO could progress to or co-exist with consolidations. With a longer time interval, more consolidative lesions can be seen between symptom onset and the CT scan, especially in patients older than 50 years old, suggesting that this feature can be used as an alert in patient management. After 3â14 days of re-examination and as the disease progresses, an increase in the range of GGO patches and consolidation can be observed (Fig.Â 4 ). The middle and lower lung regions and the posterior lung area are where this progression is mainly distributed.   Patients may have single-lobe or multiple-lobe involvement. A study by Y. Pan etÂ al. (2020) found that 30.2% and 44.4% of patients had only one lobe involved and all lobes involved, respectively. âWhite lungâ is when diffused lesions are seen in the lungs and their density increases significantly. White lung indicates that the patient's condition has worsened because it seriously affects the lung function. </text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>16703</offset><text>It is worth noting that several other CT imaging features can also be observed as the number of COVID-19 cases increases, including air bronchogram, airway and pleural changes, fibrosis, vascular enlargement, air bubble signs, nodules, halo signs, lymphadenopathy, and pericardial effusion. The percentages of these manifestations occurrence vary widely, therefore, radiologists should be aware while interpreting the CT images for COVID-19 patients to avoid misdiagnosis with typical viral pneumonia and should always link between symptoms and CT features.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_1</infon><offset>17261</offset><text>Artificial intelligence (AI) combined with CT imaging in COVID-19 diagnosis</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>17337</offset><text>Recently, notable advancements have been made in using AI in the diagnostic imaging field. Ardila etÂ al. (2019) highlighted that AI can exceed the performance of human experts in medical imaging diagnosis. A few studies in the literature have examined the use of AI in COVID-19 diagnosis, although most of them are preprint version of scientific articles that have not been peer-reviewed, thus highlighting the need for further investigation. Kermany etÂ al. (2018) and Rajaraman etÂ al. (2018) referred to the use of AI (deep learning) in detecting bacterial and viral pneumonia in the chest.   Two years later, a deep learning (DL) system was developed by Shan etÂ al. (2020), and they found that with the DL the percentage of infection (POI) of lung lobes and bronchopulmonary segments can be automatically calculated and were clinically relevant with the severity of pneumonia. They highlighted the importance of this system in quantifying the changes in the follow-up CT scans of COVID-19 patients and evaluating how the infection progresses under different forms of clinical management. This was reinforced by Wang etÂ al. (2020), who used a DL approach to extract the imaging features for COVID-19. They found that the sensitivity and specificity of this method were 74% and 67% respectively. However, a common weakness of the above studies was the relatively low number of collected CT images from patients, which may not be representative of all COVID-19 patients. A further study was conducted by Li etÂ al. (2020), who collected 4,536 CT images, and designed and evaluated a three-dimensional (3D) deep learning model to diagnose COVID-19 infections in chest CT scans. This model showed high sensitivity (90%) and specificity (96%) in detecting COVID-19. </text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>19105</offset><text>Jin etÂ al. (2020) conducted a large-scale study (nÂ =Â 756) subjects, 496 COVID-19 positives and 260 negatives to compare the diagnostic performance of an AI system with that of five radiologists. It was found that the AI system achieved high sensitivity (94%), specificity (95.47%) and diagnostic accuracy, which was comparable to that of experienced radiologists (94.7% sensitivity). This parallels with the findings of Chen etÂ al. (2020), who found similar performance between a COVID-19 diagnosis system and an expert radiologist; however, it is important to note that the AI system in this study was validated based upon a small dataset (nÂ =Â 19 confirmed COVID-19 patients) and one radiologist. It was found that high classification results were achieved for coronavirus versus non-coronavirus patients with 98.2% sensitivity and 92.2% specificity. A similar result was reported by Xu etÂ al. (2020); however, it is interesting to note that the diagnostic certainty of the AI system was evaluated by creating confidence scores of these forecasts. A deep learning approach can assist radiologists in diagnosing COVID-19 and can automatically extract lesions within CT images, as indicated by Song etÂ al. (2020) and Bai etÂ al. (2020).   Bai etÂ al. (2020) indicated that the DL tool achieved a prediction area under curve (AUC) of 0Â·938 by combining the clinical data and the CT data. </text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>20501</offset><text>AI systems, especially deep learning, have been proposed to process and analyse medical imaging data such as chest CT to assist radiologists and physicians to improve diagnosis performance. The AI offers radiologists an opportunity to save time and maximise productivity especially when required to examine a lot of cases. Bai etÂ al. (2020) assessed the performance of radiologists in differentiating COVID-19 from other viral pneumonia on chest CT. It was found that radiologists achieved high specificity and moderate sensitivity in distinguishing COVID-19 from other viral pneumonia on chest CT. A further interesting study was conducted by Bai etÂ al. (2020) to assess radiologists' performance with and without AI assistance in distinguishing coronavirus versus non-coronavirus patients. The authors found that radiologists attained a higher accuracy (90%), sensitivity (88%) and specificity (91%) with AI assistance. This suggests the potential role for the AI system to improve radiologists' routine workflow and diagnostic outcomes related to COVID-19. It is worth noting that all the above studies were retrospective, and prospective studies might be required to further validate AI system in real time to assist physiciansâ diagnosis.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>21749</offset><text>As can be seen, AI systems can be used in conjunction with chest CT images and patient history (age, gender, clinical information, blood test, symptoms and possible contact with infected people) to improve the detection of the infection. The AI systems helps to segment the exact infected area of the patient's lung from the chest CT and quantify the volume with respect to the total volume of the lung. This information might guide the physician in decision-making related to treatment options. The AI system can offer a second opinion to the physician in patients who had normal chest CT or those showing non-specific findings, in order to achieve high sensitivity, specificity and accuracy in COVID-19 diagnosis and management.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>22480</offset><text>The above studies indicate that AI systems could be used to screen and diagnose quickly a great volume of patients with suspected COVID-19, which could lead to accurate discrimination between bacterial pneumonia and viral pneumonia (COVID-19) and decrease unnecessary delays. However, radiologists who are not familiar with such systems may face challenges in getting used to them, which might be problematic because COVID-19 is spreading rapidly. In addition, as most deep learning systems require experts to annotate the lesions in the CT images for disease detection, this will require time and effort from radiologists, which might be considered a big challenge due to the current radiologist shortages in some countries. Naude (2020) indicate that the use of AI systems are impeded by a lack of data, and by too much data. These limitations require a careful balance between data privacy and public health, and rigorous humanâAI interface. It is unlikely that these will be tackled in the current time; more diagnostic data needs to be gathered to train AI and save lives. The topic of the role of AI in the diagnosis and management of COVID-19 remains open for further investigation.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">title_1</infon><offset>23672</offset><text>Conclusion</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>23683</offset><text>This review of the available literature on COVID-19 provides insights into the value of CT scan in diagnosing and controlling this infection. Although in some studies chest CT scans have shown high sensitivity in diagnosing COVID-19 compared to RT-PCR tests, chest CT scans alone are not sufficient to detect COVID-19 and can be useful complement to other tools for diagnosing patients with COVID-19 and tracking their prognosis. CT scans can be used as a staging tool to assess the complications of COVID-19 on patients' lungs. The CT findings for patients with COVID-19 show that the infection has mixed and diverse features. The presence of GGO with single or multiple lesions suggests that the disease is in an early stage, while bilateral multifocal consolidation can be seen in an advanced stage. As COVID-19 has similar manifestations to other pneumonia diseases, several AI systems have been proposed and developed in order to differentiate COVID-19 from other pneumonia diseases.</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">title_1</infon><offset>24672</offset><text>Conflict of interest statement</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">paragraph</infon><offset>24703</offset><text>No conflict of interest.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">title</infon><offset>24728</offset><text>References</text></passage><passage><infon key=\"fpage\">22</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">23</infon><infon key=\"name_0\">surname:Huang;given-names:P.</infon><infon key=\"name_1\">surname:Liu;given-names:T.</infon><infon key=\"name_2\">surname:Huang;given-names:L.</infon><infon key=\"name_3\">surname:Liu;given-names:H.</infon><infon key=\"name_4\">surname:Lei;given-names:M.</infon><infon key=\"name_5\">surname:Xu;given-names:W.</infon><infon key=\"pub-id_pmid\">32049600</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">295</infon><infon key=\"year\">2020 Apr</infon><offset>24739</offset><text>Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion</text></passage><passage><infon key=\"fpage\">872</infon><infon key=\"issue\">9</infon><infon key=\"lpage\">874</infon><infon key=\"name_0\">surname:Phan;given-names:L.</infon><infon key=\"name_1\">surname:Nguyen;given-names:T.</infon><infon key=\"name_2\">surname:Luong;given-names:Q.</infon><infon key=\"name_3\">surname:Nguyen;given-names:T.</infon><infon key=\"name_4\">surname:Nguyen;given-names:H.</infon><infon key=\"name_5\">surname:Le;given-names:H.Q.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">NÂ EngI J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020 Feb 27</infon><offset>24856</offset><text>Importation and human-to-human transmission of a novel coronavirus in Vietnam</text></passage><passage><infon key=\"comment\">Available from:</infon><infon key=\"element-citation\">https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200217-sitrep-28-covid-19.pdf?sfvrsn=a19cf2ad_2</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>24934</offset><text>Coronavirus disease 2019 (COVID-19) Situation Report â 28</text></passage><passage><infon key=\"comment\">Available from:</infon><infon key=\"element-citation\">https://www.worldometers.info/coronavirus/</infon><infon key=\"name_0\">surname:World Meter</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>24994</offset><text>Corona Virus Update (Live)</text></passage><passage><infon key=\"fpage\">420</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">421</infon><infon key=\"name_0\">surname:Guarner;given-names:J.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">153</infon><infon key=\"year\">2020</infon><offset>25021</offset><text>Three emerging coronaviruses in two decades: the story of SARS, MERS, and now COVID-19</text></passage><passage><infon key=\"name_0\">surname:Rajgor;given-names:D.</infon><infon key=\"name_1\">surname:Lee;given-names:M.</infon><infon key=\"name_2\">surname:Archuleta;given-names:S.</infon><infon key=\"name_3\">surname:Bagdasarian;given-names:N.</infon><infon key=\"name_4\">surname:Quek;given-names:S.</infon><infon key=\"pub-id_doi\">10.1016/S1473-3099(20)30244-9</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>25108</offset><text>The many estimates of the COVID-19 case fatality rate</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">4</infon><infon key=\"name_0\">surname:Sun;given-names:Q.</infon><infon key=\"name_1\">surname:Qiu;given-names:H.</infon><infon key=\"name_2\">surname:Huang;given-names:M.</infon><infon key=\"name_3\">surname:Yang;given-names:Y.</infon><infon key=\"pub-id_pmid\">31900667</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Ann Intensive Care</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2020</infon><offset>25162</offset><text>Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province</text></passage><passage><infon key=\"fpage\">809</infon><infon key=\"issue\">10226</infon><infon key=\"lpage\">815</infon><infon key=\"name_0\">surname:Chen;given-names:H.</infon><infon key=\"name_1\">surname:Guo;given-names:J.</infon><infon key=\"name_2\">surname:Wang;given-names:C.</infon><infon key=\"name_3\">surname:Luo;given-names:F.</infon><infon key=\"name_4\">surname:Yu;given-names:X.</infon><infon key=\"name_5\">surname:Zhang;given-names:W.</infon><infon key=\"pub-id_pmid\">32151335</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>25262</offset><text>Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records</text></passage><passage><infon key=\"fpage\">281</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">286</infon><infon key=\"name_0\">surname:Singhal;given-names:T.</infon><infon key=\"pub-id_pmid\">32166607</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Indian J Pediatr</infon><infon key=\"type\">ref</infon><infon key=\"volume\">87</infon><infon key=\"year\">2020</infon><offset>25424</offset><text>AÂ review of coronavirus disease-2019 (COVID-19)</text></passage><passage><infon key=\"comment\">6</infon><infon key=\"fpage\">401</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">404</infon><infon key=\"name_0\">surname:Tian;given-names:S.</infon><infon key=\"name_1\">surname:Hu;given-names:N.</infon><infon key=\"name_2\">surname:Lou;given-names:J.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JÂ Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">80</infon><infon key=\"year\">2020</infon><offset>25473</offset><text>Characteristics of COVID-19 infection in Beijing</text></passage><passage><infon key=\"fpage\">1072</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">1077</infon><infon key=\"name_0\">surname:Zhao;given-names:W.</infon><infon key=\"name_1\">surname:Zhong;given-names:Z.</infon><infon key=\"name_2\">surname:Xie;given-names:X.</infon><infon key=\"name_3\">surname:Yu;given-names:Q.</infon><infon key=\"name_4\">surname:Liu;given-names:J.</infon><infon key=\"pub-id_pmid\">32125873</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">AJR</infon><infon key=\"type\">ref</infon><infon key=\"volume\">214</infon><infon key=\"year\">2020</infon><offset>25522</offset><text>Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study</text></passage><passage><infon key=\"fpage\">264</infon><infon key=\"issue\">2020</infon><infon key=\"lpage\">266</infon><infon key=\"name_0\">surname:Hui;given-names:D.</infon><infon key=\"name_1\">surname:Azhar;given-names:E.</infon><infon key=\"name_2\">surname:Madani;given-names:T.</infon><infon key=\"name_3\">surname:Ntoumi;given-names:F.</infon><infon key=\"name_4\">surname:Kock;given-names:R.</infon><infon key=\"name_5\">surname:Dar;given-names:O.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JÂ Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">91</infon><infon key=\"year\">2020</infon><offset>25646</offset><text>The continuing 2019-nCOVID epidemic threat of novel coronaviruses to global health-The latest 2019 novel coronavirus outbreak in Wuhan, China</text></passage><passage><infon key=\"fpage\">577</infon><infon key=\"issue\">9</infon><infon key=\"lpage\">582</infon><infon key=\"name_0\">surname:Lauer;given-names:S.</infon><infon key=\"name_1\">surname:Grantz;given-names:K.</infon><infon key=\"name_2\">surname:Bi;given-names:Q.</infon><infon key=\"name_3\">surname:Jones;given-names:F.</infon><infon key=\"name_4\">surname:Zheng;given-names:Q.</infon><infon key=\"name_5\">surname:Meredith;given-names:H.</infon><infon key=\"pub-id_pmid\">32150748</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Ann Intern Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">172</infon><infon key=\"year\">2020</infon><offset>25788</offset><text>The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application</text></passage><passage><infon key=\"fpage\">2</infon><infon key=\"issue\">8</infon><infon key=\"lpage\">3</infon><infon key=\"name_0\">surname:Lei;given-names:S.</infon><infon key=\"name_1\">surname:Jiang;given-names:F.</infon><infon key=\"name_2\">surname:Su;given-names:W.</infon><infon key=\"name_3\">surname:Chen;given-names:C.</infon><infon key=\"name_4\">surname:Chen;given-names:J.</infon><infon key=\"name_5\">surname:Mei;given-names:W.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">EClinicalMedicine</infon><infon key=\"type\">ref</infon><infon key=\"volume\">54</infon><infon key=\"year\">2020</infon><offset>25916</offset><text>Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"issue\">1080</infon><infon key=\"lpage\">6</infon><infon key=\"name_0\">surname:Gardner;given-names:W.</infon><infon key=\"name_1\">surname:States;given-names:D.</infon><infon key=\"name_2\">surname:Bagley;given-names:N.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JÂ Soc Policy</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2020</infon><offset>26038</offset><text>The coronavirus and the risks to the elderly in long-term care</text></passage><passage><infon key=\"name_0\">surname:Ioannidis;given-names:J.</infon><infon key=\"name_1\">surname:Axfors;given-names:C.</infon><infon key=\"name_2\">surname:Contopoulos-Ioannidis;given-names:D.</infon><infon key=\"pub-id_doi\">10.1101/2020.04.05.20054361</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>26101</offset><text>Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters</text></passage><passage><infon key=\"fpage\">256</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">261</infon><infon key=\"name_0\">surname:Armitage;given-names:R.</infon><infon key=\"name_1\">surname:Nellums;given-names:L.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Public Health</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>26261</offset><text>COVID-19 and the consequences of isolating the elderly</text></passage><passage><infon key=\"fpage\">707</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">709</infon><infon key=\"name_0\">surname:Kliger;given-names:A.</infon><infon key=\"name_1\">surname:Silberzweig;given-names:J.</infon><infon key=\"pub-id_pmid\">32198130</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin J Am Soc Nephrol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">15</infon><infon key=\"year\">2020</infon><offset>26316</offset><text>Mitigating risk of COVID-19 in dialysis facilities</text></passage><passage><infon key=\"name_0\">surname:Pascarella;given-names:G.</infon><infon key=\"name_1\">surname:Strumia;given-names:A.</infon><infon key=\"name_2\">surname:Piliego;given-names:C.</infon><infon key=\"name_3\">surname:Bruno;given-names:F.</infon><infon key=\"name_4\">surname:Buono;given-names:R.</infon><infon key=\"name_5\">surname:Costa;given-names:F.</infon><infon key=\"pub-id_doi\">10.1111/joim.13091</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JÂ Intern Med</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>26367</offset><text>COVID-19 diagnosis and management: a comprehensive review</text></passage><passage><infon key=\"name_0\">surname:Guan;given-names:W.</infon><infon key=\"name_1\">surname:Ni;given-names:Z.</infon><infon key=\"name_2\">surname:Hu;given-names:Y.</infon><infon key=\"name_3\">surname:Liang;given-names:W.</infon><infon key=\"name_4\">surname:Ou;given-names:C.</infon><infon key=\"name_5\">surname:He;given-names:J.</infon><infon key=\"pub-id_doi\">10.1101/2020.02.06.20020974</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>26425</offset><text>Clinical characteristics of 2019 novel coronavirus infection in China</text></passage><passage><infon key=\"name_0\">surname:Ai;given-names:T.</infon><infon key=\"name_1\">surname:Yang;given-names:Z.</infon><infon key=\"name_2\">surname:Hou;given-names:H.</infon><infon key=\"name_3\">surname:Zhan;given-names:C.</infon><infon key=\"name_4\">surname:Chen;given-names:C.</infon><infon key=\"name_5\">surname:Lv;given-names:W.</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200642</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>26495</offset><text>Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases</text></passage><passage><infon key=\"name_0\">surname:Yang;given-names:Y.</infon><infon key=\"name_1\">surname:Yang;given-names:M.</infon><infon key=\"name_2\">surname:Shen;given-names:C.</infon><infon key=\"name_3\">surname:Wang;given-names:F.</infon><infon key=\"name_4\">surname:Yuan;given-names:J.</infon><infon key=\"name_5\">surname:Li;given-names:J.</infon><infon key=\"pub-id_doi\">10.1101/2020.02.11.20021493</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>26610</offset><text>Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections</text></passage><passage><infon key=\"fpage\">372</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">388</infon><infon key=\"name_0\">surname:Jin;given-names:Y.</infon><infon key=\"name_1\">surname:Yang;given-names:H.</infon><infon key=\"name_2\">surname:Ji;given-names:W.</infon><infon key=\"name_3\">surname:Wu;given-names:W.</infon><infon key=\"name_4\">surname:Chen;given-names:S.</infon><infon key=\"name_5\">surname:Zhang;given-names:W.</infon><infon key=\"pub-id_pmid\">32230900</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Viruses</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>26755</offset><text>Virology, epidemiology, pathogenesis, and control of COVID-19</text></passage><passage><infon key=\"fpage\">33</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">41</infon><infon key=\"name_0\">surname:Alanagreh;given-names:L.</infon><infon key=\"name_1\">surname:Alzoughool;given-names:F.</infon><infon key=\"name_2\">surname:Atoum;given-names:M.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pathogens</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>26817</offset><text>The human coronavirus disease COVID-19: its origin, characteristics, and insights into potential drugs and its mechanisms</text></passage><passage><infon key=\"comment\">Available from:</infon><infon key=\"element-citation\">http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>26939</offset><text>The diagnostic and treatment protocol of COVID-19</text></passage><passage><infon key=\"fpage\">107</infon><infon key=\"issue\">2020</infon><infon key=\"lpage\">109</infon><infon key=\"name_0\">surname:Wang;given-names:X.</infon><infon key=\"name_1\">surname:Tan;given-names:L.</infon><infon key=\"name_2\">surname:Wang;given-names:X.</infon><infon key=\"name_3\">surname:Lu;given-names:Y.</infon><infon key=\"name_4\">surname:Cheng;given-names:L.</infon><infon key=\"name_5\">surname:Sun;given-names:Z.</infon><infon key=\"pub-id_pmid\">32315809</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">94</infon><infon key=\"year\">2020</infon><offset>26989</offset><text>Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both specimens simultaneously</text></passage><passage><infon key=\"name_0\">surname:Esposito;given-names:A.</infon><infon key=\"name_1\">surname:Palmisano;given-names:A.</infon><infon key=\"name_2\">surname:Scotti;given-names:G.</infon><infon key=\"name_3\">surname:Morelli;given-names:M.</infon><infon key=\"name_4\">surname:Vignale;given-names:D.</infon><infon key=\"name_5\">surname:Cobelli;given-names:F.</infon><infon key=\"pub-id_doi\">10.1101/2020.03.30.20047985</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>27133</offset><text>Why is chest CT important for early diagnosis of COVID-19? Prevalence matters</text></passage><passage><infon key=\"comment\">Available from:</infon><infon key=\"element-citation\">https://www.kaust.edu.sa/en/news/using-ai-to-understand-the-pathogenesis-of-covid-19</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>27211</offset><text>Using AI to understand the pathogenesis of COVID-19</text></passage><passage><infon key=\"name_0\">surname:Wang;given-names:S.</infon><infon key=\"name_1\">surname:Kang;given-names:B.</infon><infon key=\"name_2\">surname:Ma;given-names:J.</infon><infon key=\"name_3\">surname:Zeng;given-names:X.</infon><infon key=\"name_4\">surname:Xiao;given-names:M.</infon><infon key=\"name_5\">surname:Guo;given-names:J.</infon><infon key=\"pub-id_doi\">10.1101/2020.02.14.20023028</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>27263</offset><text>AÂ deep learning algorithm using CT images to screen for Corona Virus Disease (COVID-19)</text></passage><passage><infon key=\"fpage\">1280</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">1286</infon><infon key=\"name_0\">surname:Li;given-names:Y.</infon><infon key=\"name_1\">surname:Xia;given-names:L.</infon><infon key=\"pub-id_pmid\">32130038</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">AJR</infon><infon key=\"type\">ref</infon><infon key=\"volume\">214</infon><infon key=\"year\">2020</infon><offset>27352</offset><text>Coronavirus Disease 2019 (COVID-19): role of chest CT in diagnosis and management</text></passage><passage><infon key=\"fpage\">8</infon><infon key=\"issue\">20</infon><infon key=\"lpage\">23</infon><infon key=\"name_0\">surname:Bai;given-names:H.</infon><infon key=\"name_1\">surname:Hsieh;given-names:B.</infon><infon key=\"name_2\">surname:Xiong;given-names:Z.</infon><infon key=\"name_3\">surname:Halsey;given-names:K.</infon><infon key=\"name_4\">surname:Choi;given-names:J.</infon><infon key=\"name_5\">surname:Tran;given-names:T.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2020</infon><offset>27434</offset><text>Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT</text></passage><passage><infon key=\"fpage\">195</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">200</infon><infon key=\"name_0\">surname:Dai;given-names:W.</infon><infon key=\"name_1\">surname:Zhang;given-names:H.</infon><infon key=\"name_2\">surname:Yu;given-names:J.</infon><infon key=\"name_3\">surname:Xu;given-names:H.</infon><infon key=\"name_4\">surname:Chen;given-names:H.</infon><infon key=\"name_5\">surname:Luo;given-names:S.</infon><infon key=\"pub-id_pmid\">32129670</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Can Assoc Radiol J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>27523</offset><text>CT imaging and differential diagnosis of COVID-19</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"issue\">20</infon><infon key=\"lpage\">4</infon><infon key=\"name_0\">surname:Raptis;given-names:C.</infon><infon key=\"name_1\">surname:Hammer;given-names:M.</infon><infon key=\"name_2\">surname:Short;given-names:R.</infon><infon key=\"name_3\">surname:Shah;given-names:A.</infon><infon key=\"name_4\">surname:Bhalla;given-names:S.</infon><infon key=\"name_5\">surname:Bierhals;given-names:A.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">AJR</infon><infon key=\"type\">ref</infon><infon key=\"volume\">16</infon><infon key=\"year\">2020</infon><offset>27573</offset><text>Chest CT and coronavirus disease (COVID-19): a critical review of the literature to date</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">7</infon><infon key=\"name_0\">surname:Salehi;given-names:S.</infon><infon key=\"name_1\">surname:Abedi;given-names:A.</infon><infon key=\"name_2\">surname:Balakrishnan;given-names:S.</infon><infon key=\"name_3\">surname:Gholamrezanezhad;given-names:A.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">AJR</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2020</infon><offset>27662</offset><text>Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients</text></passage><passage><infon key=\"name_0\">surname:Caruso;given-names:D.</infon><infon key=\"name_1\">surname:Zerunian;given-names:M.</infon><infon key=\"name_2\">surname:Polici;given-names:M.</infon><infon key=\"name_3\">surname:Pucciarelli;given-names:F.</infon><infon key=\"name_4\">surname:Polidori;given-names:T.</infon><infon key=\"name_5\">surname:Rucci;given-names:C.</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020201237</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>27755</offset><text>Chest CT features of COVID-19 in Rome, Italy</text></passage><passage><infon key=\"name_0\">surname:Zhu;given-names:Y.</infon><infon key=\"name_1\">surname:Liu;given-names:Y.</infon><infon key=\"name_2\">surname:Li;given-names:Z.</infon><infon key=\"name_3\">surname:Kuang;given-names:J.</infon><infon key=\"name_4\">surname:Li;given-names:X.</infon><infon key=\"name_5\">surname:Yang;given-names:Y.</infon><infon key=\"pub-id_doi\">10.1016/j.jinf.2020.02.022</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JÂ Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>27800</offset><text>Clinical and CT imaging features of 2019 novel coronavirus disease (COVID-19)</text></passage><passage><infon key=\"name_0\">surname:Xie;given-names:X.</infon><infon key=\"name_1\">surname:Zhong;given-names:Z.</infon><infon key=\"name_2\">surname:Zhao;given-names:W.</infon><infon key=\"name_3\">surname:Zheng;given-names:C.</infon><infon key=\"name_4\">surname:Wang;given-names:F.</infon><infon key=\"name_5\">surname:Liu;given-names:J.</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200343</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>27878</offset><text>Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing</text></passage><passage><infon key=\"element-citation\">https://arxiv.org/abs/2003.11336</infon><infon key=\"name_0\">surname:Bullock;given-names:J.</infon><infon key=\"name_1\">surname:Luccioni;given-names:A.</infon><infon key=\"name_2\">surname:Pham;given-names:K.</infon><infon key=\"name_3\">surname:Lam;given-names:C.</infon><infon key=\"name_4\">surname:Oroz;given-names:M.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">medarXiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>27960</offset><text>Mapping the landscape of artificial intelligence applications against COVID-19</text></passage><passage><infon key=\"name_0\">surname:Li;given-names:L.</infon><infon key=\"name_1\">surname:Qin;given-names:L.</infon><infon key=\"name_2\">surname:Xu;given-names:Z.</infon><infon key=\"name_3\">surname:Yin;given-names:Y.</infon><infon key=\"name_4\">surname:Wang;given-names:X.</infon><infon key=\"name_5\">surname:Kong;given-names:B.</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200905</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>28039</offset><text>Artificial intelligence distinguishes COVID-19 from community acquired pneumonia on chest CT</text></passage><passage><infon key=\"comment\">Available from:</infon><infon key=\"element-citation\">https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3568314</infon><infon key=\"name_0\">surname:NaudÃ©;given-names:W.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>28132</offset><text>Artificial Intelligence against COVID-19: An early review</text></passage><passage><infon key=\"fpage\">1061</infon><infon key=\"issue\">11</infon><infon key=\"lpage\">1069</infon><infon key=\"name_0\">surname:Wang;given-names:D.</infon><infon key=\"name_1\">surname:Hu;given-names:B.</infon><infon key=\"name_2\">surname:Hu;given-names:C.</infon><infon key=\"name_3\">surname:Zhu;given-names:F.</infon><infon key=\"name_4\">surname:Liu;given-names:X.</infon><infon key=\"name_5\">surname:Zhang;given-names:J.</infon><infon key=\"pub-id_pmid\">32031570</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Jama</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>28190</offset><text>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusâinfected pneumonia in Wuhan, China</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"issue\">2020</infon><infon key=\"lpage\">4</infon><infon key=\"name_0\">surname:LeBlanc;given-names:J.</infon><infon key=\"name_1\">surname:Heinstein;given-names:C.</infon><infon key=\"name_2\">surname:MacDonald;given-names:J.</infon><infon key=\"name_3\">surname:Pettipas;given-names:J.</infon><infon key=\"name_4\">surname:Hatchette;given-names:T.</infon><infon key=\"name_5\">surname:Patriquin;given-names:G.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JÂ Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">128</infon><infon key=\"year\">2020</infon><offset>28309</offset><text>AÂ combined oropharyngeal/nares swab is a suitable alternative to nasopharyngeal swabs for the detection of SARS-CoV-2</text></passage><passage><infon key=\"name_0\">surname:Kojima;given-names:N.</infon><infon key=\"name_1\">surname:Turner;given-names:F.</infon><infon key=\"name_2\">surname:Slepnev;given-names:V.</infon><infon key=\"name_3\">surname:Bacelar;given-names:A.</infon><infon key=\"name_4\">surname:Deming;given-names:L.</infon><infon key=\"name_5\">surname:Kodeboy;given-names:S.</infon><infon key=\"pub-id_doi\">10.1101/2020.04.11.20062372</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>28428</offset><text>Self-collected oral fluid and nasal swabs demonstrate comparable sensitivity to clinician collected nasopharyngeal swabs for covid-19 detection</text></passage><passage><infon key=\"comment\">Available from:</infon><infon key=\"element-citation\">https://www.iaea.org/newscenter/news/how-is-the-covid-19-virus-detected-using-real-time-rt-pcr</infon><infon key=\"name_0\">surname:Jawerth;given-names:N.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>28572</offset><text>How is the COVID-19 Virus Detected using Real Time RT-PCR?</text></passage><passage><infon key=\"fpage\">388</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">393</infon><infon key=\"name_0\">surname:Yang;given-names:W.</infon><infon key=\"name_1\">surname:Cao;given-names:Q.</infon><infon key=\"name_2\">surname:Qin;given-names:L.</infon><infon key=\"name_3\">surname:Wang;given-names:X.</infon><infon key=\"name_4\">surname:Cheng;given-names:Z.</infon><infon key=\"name_5\">surname:Dai;given-names:A.</infon><infon key=\"pub-id_pmid\">32112884</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JÂ Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">80</infon><infon key=\"year\">2020</infon><offset>28631</offset><text>Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">2</infon><infon key=\"name_0\">surname:Yang;given-names:W.</infon><infon key=\"name_1\">surname:Yan;given-names:F.</infon><infon key=\"pub-id_pmid\">32096711</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">295</infon><infon key=\"year\">2020</infon><offset>28787</offset><text>Patients with RT-PCR confirmed COVID-19 and normal chest CT</text></passage><passage><infon key=\"fpage\">106</infon><infon key=\"issue\">2020</infon><infon key=\"lpage\">112</infon><infon key=\"name_0\">surname:Dai;given-names:H.</infon><infon key=\"name_1\">surname:Zhang;given-names:X.</infon><infon key=\"name_2\">surname:Xia;given-names:J.</infon><infon key=\"name_3\">surname:Zhang;given-names:T.</infon><infon key=\"name_4\">surname:Shang;given-names:Y.</infon><infon key=\"name_5\">surname:Huang;given-names:R.</infon><infon key=\"pub-id_pmid\">32272262</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">95</infon><infon key=\"year\">2020</infon><offset>28847</offset><text>High-resolution chest CT features and clinical characteristics of patients infected with COVID-19 in Jiangsu, China</text></passage><passage><infon key=\"name_0\">surname:Shi;given-names:F.</infon><infon key=\"name_1\">surname:Wang;given-names:J.</infon><infon key=\"name_2\">surname:Shi;given-names:J.</infon><infon key=\"name_3\">surname:Wu;given-names:Ziyan</infon><infon key=\"name_4\">surname:Wang;given-names:Q.</infon><infon key=\"name_5\">surname:Tang;given-names:Z.</infon><infon key=\"pub-id_doi\">10.1109/RBME.2020.2987975</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">IEEE Trans BIOMED</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>28963</offset><text>Review of artificial intelligence techniques in imaging data acquisition, segmentation and diagnosis for covid-19</text></passage><passage><infon key=\"fpage\">202</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">207</infon><infon key=\"name_0\">surname:Chung;given-names:M.</infon><infon key=\"name_1\">surname:Bernheim;given-names:A.</infon><infon key=\"name_2\">surname:Mei;given-names:X.</infon><infon key=\"name_3\">surname:Zhang;given-names:N.</infon><infon key=\"name_4\">surname:Huang;given-names:M.</infon><infon key=\"name_5\">surname:Zeng;given-names:X.</infon><infon key=\"pub-id_pmid\">32017661</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">295</infon><infon key=\"year\">2020</infon><offset>29077</offset><text>CT imaging features of 2019 novel coronavirus (2019-nCoV)</text></passage><passage><infon key=\"fpage\">384</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">385</infon><infon key=\"name_0\">surname:Lee;given-names:E.</infon><infon key=\"name_1\">surname:Ng;given-names:M.</infon><infon key=\"name_2\">surname:Khong;given-names:P.L.</infon><infon key=\"pub-id_pmid\">32105641</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>29135</offset><text>COVID-19 pneumonia: what has CT taught us?</text></passage><passage><infon key=\"comment\">Available from:</infon><infon key=\"element-citation\">https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection</infon><infon key=\"name_0\">surname:American College of Radiology</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>29178</offset><text>ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection</text></passage><passage><infon key=\"comment\">Available from:</infon><infon key=\"element-citation\">https://www.rcr.ac.uk/college/coronavirus-covid-19-what-rcr-doing/clinical-information/role-ct-chest/role-ct-patients</infon><infon key=\"name_0\">surname:The Royal College of Radiologists</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>29293</offset><text>The role of CT in patients suspected with COVID-19 infection</text></passage><passage><infon key=\"comment\">Available from:</infon><infon key=\"element-citation\">http://yzs.satcm.gov.cn/zhengcewenjian/2020-02-19/13221.html</infon><infon key=\"name_0\">surname:General Office of National Health Committee</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>29354</offset><text>Office of State Administration of Traditional Chinese Medicine. Notice on the issuance of a program for the diagnosis and treatment of novel coronavirus (2019-nCoV) infected pneumonia (trial sixth edition)</text></passage><passage><infon key=\"name_0\">surname:Kanne;given-names:J.</infon><infon key=\"name_1\">surname:Little;given-names:B.</infon><infon key=\"name_2\">surname:Chung;given-names:J.</infon><infon key=\"name_3\">surname:Elicker;given-names:B.</infon><infon key=\"name_4\">surname:Ketai;given-names:L.</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200527</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>29560</offset><text>Essentials for radiologists on COVID-19: an updateâradiology scientific expert panel</text></passage><passage><infon key=\"name_0\">surname:Fang;given-names:Y.</infon><infon key=\"name_1\">surname:Zhang;given-names:H.</infon><infon key=\"name_2\">surname:Xie;given-names:J.</infon><infon key=\"name_3\">surname:Lin;given-names:M.</infon><infon key=\"name_4\">surname:Ying;given-names:L.</infon><infon key=\"name_5\">surname:Pang;given-names:P.</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200432</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>29647</offset><text>Sensitivity of chest CT for COVID-19: comparison to RT-PCR</text></passage><passage><infon key=\"fpage\">425</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">434</infon><infon key=\"name_0\">surname:Shi;given-names:H.</infon><infon key=\"name_1\">surname:Han;given-names:X.</infon><infon key=\"name_2\">surname:Jiang;given-names:N.</infon><infon key=\"name_3\">surname:Cao;given-names:Y.</infon><infon key=\"name_4\">surname:Alwalid;given-names:O.</infon><infon key=\"name_5\">surname:Gu;given-names:J.</infon><infon key=\"pub-id_pmid\">32105637</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>29706</offset><text>Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study</text></passage><passage><infon key=\"fpage\">257</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">261</infon><infon key=\"name_0\">surname:Wu;given-names:J.</infon><infon key=\"name_1\">surname:Wu;given-names:X.</infon><infon key=\"name_2\">surname:Zeng;given-names:W.</infon><infon key=\"name_3\">surname:Zeng;given-names:W.</infon><infon key=\"name_4\">surname:Guo;given-names:D.</infon><infon key=\"name_5\">surname:Fang;given-names:Z.</infon><infon key=\"pub-id_pmid\">32091414</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Invest Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">55</infon><infon key=\"year\">2020</infon><offset>29806</offset><text>Chest CT findings in patients with coronavirus disease 2019 and its relationship with clinical features</text></passage><passage><infon key=\"fpage\">215</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">221</infon><infon key=\"name_0\">surname:Pan;given-names:F.</infon><infon key=\"name_1\">surname:Ye;given-names:T.</infon><infon key=\"name_2\">surname:Sun;given-names:P.</infon><infon key=\"name_3\">surname:Gui;given-names:S.</infon><infon key=\"name_4\">surname:Liang;given-names:B.</infon><infon key=\"name_5\">surname:Li;given-names:L.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">295</infon><infon key=\"year\">2020</infon><offset>29910</offset><text>Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia</text></passage><passage><infon key=\"name_0\">surname:Zu;given-names:Z.</infon><infon key=\"name_1\">surname:Jiang;given-names:M.</infon><infon key=\"name_2\">surname:Xu;given-names:P.</infon><infon key=\"name_3\">surname:Chen;given-names:W.</infon><infon key=\"name_4\">surname:Ni;given-names:Q.</infon><infon key=\"name_5\">surname:Lu;given-names:G.</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200490</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>30015</offset><text>Coronavirus disease 2019 (COVID-19): a perspective from China</text></passage><passage><infon key=\"fpage\">200</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">234</infon><infon key=\"name_0\">surname:Ng;given-names:M.</infon><infon key=\"name_1\">surname:Lee;given-names:E.</infon><infon key=\"name_2\">surname:Yang;given-names:J.</infon><infon key=\"name_3\">surname:Yang;given-names:F.</infon><infon key=\"name_4\">surname:Li;given-names:X.</infon><infon key=\"name_5\">surname:Wang;given-names:H.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology: Cardiothorac Imag</infon><infon key=\"type\">ref</infon><infon key=\"volume\">2</infon><infon key=\"year\">2020 Feb 13</infon><offset>30077</offset><text>Imaging profile of the COVID-19 infection: radiologic findings and literature review</text></passage><passage><infon key=\"fpage\">3306</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">3309</infon><infon key=\"name_0\">surname:Pan;given-names:Y.</infon><infon key=\"name_1\">surname:Guan;given-names:H.</infon><infon key=\"name_2\">surname:Zhou;given-names:S.</infon><infon key=\"name_3\">surname:Wang;given-names:Y.</infon><infon key=\"name_4\">surname:Li;given-names:Q.</infon><infon key=\"name_5\">surname:Zhu;given-names:T.</infon><infon key=\"pub-id_pmid\">32055945</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2020</infon><offset>30162</offset><text>Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China</text></passage><passage><infon key=\"fpage\">553</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">563</infon><infon key=\"name_0\">surname:Paul;given-names:N.</infon><infon key=\"name_1\">surname:Roberts;given-names:H.</infon><infon key=\"name_2\">surname:Butany;given-names:J.</infon><infon key=\"name_3\">surname:Chung;given-names:T.</infon><infon key=\"name_4\">surname:Gold;given-names:W.</infon><infon key=\"name_5\">surname:Mehta;given-names:S.</infon><infon key=\"pub-id_pmid\">15026600</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiographics</infon><infon key=\"type\">ref</infon><infon key=\"volume\">24</infon><infon key=\"year\">2004</infon><offset>30304</offset><text>Radiologic pattern of disease in patients with severe acute respiratory syndrome: the Toronto experience</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">6</infon><infon key=\"name_0\">surname:Kay;given-names:F.</infon><infon key=\"name_1\">surname:Abbara;given-names:S.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">2</infon><infon key=\"year\">2020</infon><offset>30409</offset><text>The many faces of COVID-19: spectrum of imaging manifestations</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"issue\">20</infon><infon key=\"lpage\">9</infon><infon key=\"name_0\">surname:Ye;given-names:Z.</infon><infon key=\"name_1\">surname:Zhang;given-names:Y.</infon><infon key=\"name_2\">surname:Wang;given-names:Y.</infon><infon key=\"name_3\">surname:Huang;given-names:Z.</infon><infon key=\"name_4\">surname:Song;given-names:B.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">19</infon><infon key=\"year\">2020</infon><offset>30472</offset><text>Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review</text></passage><passage><infon key=\"fpage\">210</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">217</infon><infon key=\"name_0\">surname:Song;given-names:F.</infon><infon key=\"name_1\">surname:Shi;given-names:N.</infon><infon key=\"name_2\">surname:Shan;given-names:F.</infon><infon key=\"name_3\">surname:Zhang;given-names:Z.</infon><infon key=\"name_4\">surname:Shen;given-names:J.</infon><infon key=\"name_5\">surname:Ling;given-names:H.</infon><infon key=\"pub-id_pmid\">32027573</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">295</infon><infon key=\"year\">2020</infon><offset>30559</offset><text>Emerging 2019 novel coronavirus (2019-nCoV) pneumonia</text></passage><passage><infon key=\"fpage\">18</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">39</infon><infon key=\"name_0\">surname:Franquet;given-names:T.</infon><infon key=\"pub-id_pmid\">21697307</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">260</infon><infon key=\"year\">2011</infon><offset>30613</offset><text>Imaging of pulmonary viral pneumonia</text></passage><passage><infon key=\"fpage\">603</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">608</infon><infon key=\"name_0\">surname:Li;given-names:M.</infon><infon key=\"name_1\">surname:Lei;given-names:P.</infon><infon key=\"name_2\">surname:Zeng;given-names:B.</infon><infon key=\"name_3\">surname:Li;given-names:Z.</infon><infon key=\"name_4\">surname:Yu;given-names:P.</infon><infon key=\"name_5\">surname:Fan;given-names:B.</infon><infon key=\"pub-id_pmid\">32204987</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Acad Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">27</infon><infon key=\"year\">2020</infon><offset>30650</offset><text>Coronavirus disease (COVID-19): spectrum of CT findings and temporal progression of the disease</text></passage><passage><infon key=\"fpage\">327</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">331</infon><infon key=\"name_0\">surname:Li;given-names:K.</infon><infon key=\"name_1\">surname:Wu;given-names:J.</infon><infon key=\"name_2\">surname:Wu;given-names:F.</infon><infon key=\"name_3\">surname:Guo;given-names:D.</infon><infon key=\"name_4\">surname:Chen;given-names:L.</infon><infon key=\"name_5\">surname:Fang;given-names:Z.</infon><infon key=\"pub-id_pmid\">32118615</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Invest Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">55</infon><infon key=\"year\">2020</infon><offset>30746</offset><text>The clinical and chest CT features associated with severe and critical COVID-19 pneumonia</text></passage><passage><infon key=\"name_0\">surname:Jin;given-names:C.</infon><infon key=\"name_1\">surname:Chen;given-names:W.</infon><infon key=\"name_2\">surname:Cao;given-names:Y.</infon><infon key=\"name_3\">surname:Xu;given-names:Z.</infon><infon key=\"name_4\">surname:Tan;given-names:Z.</infon><infon key=\"name_5\">surname:Zhang;given-names:X.</infon><infon key=\"pub-id_doi\">10.1101/2020.03.20.20039834</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>30836</offset><text>Development and evaluation of an AI system for COVID-19 diagnosis</text></passage><passage><infon key=\"fpage\">500</infon><infon key=\"issue\">8</infon><infon key=\"lpage\">510</infon><infon key=\"name_0\">surname:Hosny;given-names:A.</infon><infon key=\"name_1\">surname:Parmar;given-names:C.</infon><infon key=\"name_2\">surname:Quackenbush;given-names:J.</infon><infon key=\"name_3\">surname:Schwartz;given-names:L.</infon><infon key=\"name_4\">surname:Aerts;given-names:H.</infon><infon key=\"pub-id_pmid\">29777175</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Rev Cancer</infon><infon key=\"type\">ref</infon><infon key=\"volume\">18</infon><infon key=\"year\">2018</infon><offset>30902</offset><text>Artificial intelligence in radiology</text></passage><passage><infon key=\"fpage\">120</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">135</infon><infon key=\"name_0\">surname:Tang;given-names:A.</infon><infon key=\"name_1\">surname:Tam;given-names:R.</infon><infon key=\"name_2\">surname:Cadrin-ChÃªnevert;given-names:A.</infon><infon key=\"name_3\">surname:Guest;given-names:W.</infon><infon key=\"name_4\">surname:Chong;given-names:J.</infon><infon key=\"name_5\">surname:Barfett;given-names:J.</infon><infon key=\"pub-id_pmid\">29655580</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Can Assoc Radiol J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">69</infon><infon key=\"year\">2018</infon><offset>30939</offset><text>Canadian Association of Radiologists white paper on artificial intelligence in radiology</text></passage><passage><infon key=\"fpage\">504</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">508</infon><infon key=\"name_0\">surname:Thrall;given-names:J.</infon><infon key=\"name_1\">surname:Li;given-names:X.</infon><infon key=\"name_2\">surname:Li;given-names:Q.</infon><infon key=\"name_3\">surname:Cruz;given-names:C.</infon><infon key=\"name_4\">surname:Do;given-names:S.</infon><infon key=\"name_5\">surname:Dreyer;given-names:K.</infon><infon key=\"pub-id_pmid\">29402533</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JÂ Am Coll Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">15</infon><infon key=\"year\">2018</infon><offset>31028</offset><text>Artificial intelligence and machine learning in radiology: opportunities, challenges, pitfalls, and criteria for success</text></passage><passage><infon key=\"fpage\">10</infon><infon key=\"issue\">20</infon><infon key=\"lpage\">18</infon><infon key=\"name_0\">surname:Kong;given-names:B.</infon><infon key=\"name_1\">surname:Wang;given-names:X.</infon><infon key=\"name_2\">surname:Bai;given-names:J.</infon><infon key=\"name_3\">surname:Gao;given-names:F.</infon><infon key=\"name_4\">surname:Cao;given-names:K.</infon><infon key=\"name_5\">surname:Xia;given-names:J.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Comput Med Imag Graph</infon><infon key=\"type\">ref</infon><infon key=\"volume\">80</infon><infon key=\"year\">2020</infon><offset>31149</offset><text>Learning tree-structured representation for 3D coronary artery segmentation</text></passage><passage><infon key=\"name_0\">surname:Rao;given-names:B.</infon><infon key=\"name_1\">surname:Zohrabian;given-names:V.</infon><infon key=\"name_2\">surname:Cedeno;given-names:P.</infon><infon key=\"name_3\">surname:Saha;given-names:A.</infon><infon key=\"name_4\">surname:Pahade;given-names:J.</infon><infon key=\"name_5\">surname:Davis;given-names:M.</infon><infon key=\"pub-id_doi\">10.1016/j.acra.2020.01.035</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Acad Radiol</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>31225</offset><text>Utility of artificial intelligence tool as a prospective radiology peer Reviewerâdetection of unreported intracranial hemorrhage</text></passage><passage><infon key=\"fpage\">954</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">961</infon><infon key=\"name_0\">surname:Ardila;given-names:D.</infon><infon key=\"name_1\">surname:Kiraly;given-names:A.</infon><infon key=\"name_2\">surname:Bharadwaj;given-names:S.</infon><infon key=\"name_3\">surname:Choi;given-names:B.</infon><infon key=\"name_4\">surname:Reicher;given-names:J.</infon><infon key=\"name_5\">surname:Peng;given-names:L.</infon><infon key=\"pub-id_pmid\">31110349</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2019</infon><offset>31356</offset><text>End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography</text></passage><passage><infon key=\"fpage\">1122</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">1131</infon><infon key=\"name_0\">surname:Kermany;given-names:D.</infon><infon key=\"name_1\">surname:Goldbaum;given-names:M.</infon><infon key=\"name_2\">surname:Cai;given-names:W.</infon><infon key=\"name_3\">surname:Valentim;given-names:C.</infon><infon key=\"name_4\">surname:Liang;given-names:H.</infon><infon key=\"name_5\">surname:Baxter;given-names:S.</infon><infon key=\"pub-id_pmid\">29474911</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">172</infon><infon key=\"year\">2018</infon><offset>31464</offset><text>Identifying medical diagnoses and treatable diseases by image-based deep learning</text></passage><passage><infon key=\"fpage\">1715</infon><infon key=\"issue\">10</infon><infon key=\"name_0\">surname:Rajaraman;given-names:S.</infon><infon key=\"name_1\">surname:Candemir;given-names:S.</infon><infon key=\"name_2\">surname:Kim;given-names:I.</infon><infon key=\"name_3\">surname:Thoma;given-names:G.</infon><infon key=\"name_4\">surname:Antani;given-names:S.</infon><infon key=\"pub-id_pmid\">32457819</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Appl Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2018</infon><offset>31546</offset><text>Visualization and interpretation of convolutional neural network predictions in detecting pneumonia in pediatric chest radiographs</text></passage><passage><infon key=\"name_0\">surname:Shan;given-names:F.</infon><infon key=\"name_1\">surname:Gao;given-names:Y.</infon><infon key=\"name_2\">surname:Wang;given-names:J.</infon><infon key=\"name_3\">surname:Shi;given-names:N.</infon><infon key=\"name_4\">surname:Han;given-names:M.</infon><infon key=\"name_5\">surname:Xue;given-names:Z.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">arXiv 2020: arXiv:2003.04655</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>31677</offset><text>Lung infection quantification of covid-19 in ct images with deep learning</text></passage><passage><infon key=\"name_0\">surname:Li;given-names:L.</infon><infon key=\"name_1\">surname:Qin;given-names:L.</infon><infon key=\"name_2\">surname:Xu;given-names:Z.</infon><infon key=\"name_3\">surname:Yin;given-names:Y.</infon><infon key=\"name_4\">surname:Wang;given-names:X.</infon><infon key=\"name_5\">surname:Kong;given-names:B.</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200905</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>31751</offset><text>Artificial intelligence distinguishes covid-19 from community acquired pneumonia on chest ct</text></passage><passage><infon key=\"name_0\">surname:Chen;given-names:J.</infon><infon key=\"name_1\">surname:Wu;given-names:L.</infon><infon key=\"name_2\">surname:Zhang;given-names:J.</infon><infon key=\"name_3\">surname:Zhang;given-names:L.</infon><infon key=\"name_4\">surname:Gong;given-names:D.</infon><infon key=\"name_5\">surname:Zhao;given-names:Y.</infon><infon key=\"pub-id_doi\">10.1101/2020.02.25.20021568</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>31844</offset><text>Deep learning-based model for detecting 2019 novel coronavirus pneumonia on high-resolution computed tomography: a prospective study</text></passage><passage><infon key=\"name_0\">surname:Gozes;given-names:O.</infon><infon key=\"name_1\">surname:Frid-Adar;given-names:M.</infon><infon key=\"name_2\">surname:Greenspan;given-names:H.</infon><infon key=\"name_3\">surname:Browning;given-names:P.</infon><infon key=\"name_4\">surname:Zhang;given-names:H.</infon><infon key=\"name_5\">surname:Ji;given-names:W.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">arXiv:2003.05037</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>31977</offset><text>Rapid ai development cycle for the coronavirus (covid-19) pandemic: initial results for automated detection &amp; patient monitoring using deep learning ct image analysis</text></passage><passage><infon key=\"name_0\">surname:Xu;given-names:X.</infon><infon key=\"name_1\">surname:Jiang;given-names:X.</infon><infon key=\"name_2\">surname:Ma;given-names:C.</infon><infon key=\"name_3\">surname:Du;given-names:P.</infon><infon key=\"name_4\">surname:Li;given-names:X.</infon><infon key=\"name_5\">surname:Lv;given-names:S.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">arXiv:2002.09334</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>32144</offset><text>Deep learning system to screen coronavirus disease 2019 pneumonia</text></passage><passage><infon key=\"name_0\">surname:Bai;given-names:X.</infon><infon key=\"name_1\">surname:Fang;given-names:C.</infon><infon key=\"name_2\">surname:Zhou;given-names:Y.</infon><infon key=\"name_3\">surname:Bai;given-names:S.</infon><infon key=\"name_4\">surname:Liu;given-names:Z.</infon><infon key=\"name_5\">surname:Chen;given-names:Q.</infon><infon key=\"pub-id_doi\">10.1101/2020.03.20.20037325</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>32210</offset><text>Predicting COVID-19 malignant progression with AI techniques</text></passage><passage><infon key=\"name_0\">surname:Maghdid;given-names:H.</infon><infon key=\"name_1\">surname:Asaad;given-names:A.</infon><infon key=\"name_2\">surname:Ghafoor;given-names:K.</infon><infon key=\"name_3\">surname:Sadiq;given-names:A.</infon><infon key=\"name_4\">surname:Khan;given-names:M.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">arXiv:2004.00038</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>32271</offset><text>Diagnosing COVID-19 pneumonia from X-ray and CT images using deep learning and transfer learning algorithms</text></passage><passage><infon key=\"fpage\">20</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">75</infon><infon key=\"name_0\">surname:Huang;given-names:L.</infon><infon key=\"name_1\">surname:Han;given-names:R.</infon><infon key=\"name_2\">surname:Ai;given-names:T.</infon><infon key=\"name_3\">surname:Yu;given-names:P.</infon><infon key=\"name_4\">surname:Kang;given-names:H.</infon><infon key=\"name_5\">surname:Tao;given-names:Q.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">2</infon><infon key=\"year\">2020</infon><offset>32379</offset><text>Serial quantitative chest ct assessment of covid-19: deep-learning approach</text></passage><passage><infon key=\"name_0\">surname:Gozes;given-names:O.</infon><infon key=\"name_1\">surname:Frid-Adar;given-names:M.</infon><infon key=\"name_2\">surname:Sagie;given-names:N.</infon><infon key=\"name_3\">surname:Zhang;given-names:H.</infon><infon key=\"name_4\">surname:Ji;given-names:W.</infon><infon key=\"name_5\">surname:Greenspan;given-names:H.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">arXiv:2004.02640</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>32455</offset><text>Coronavirus detection and analysis on chest ct with deep learning</text></passage><passage><infon key=\"comment\">Available from:</infon><infon key=\"element-citation\">https://www.researchgate.net/profile/Thanh_Nguyen372/publication/340487417_Artificial_Intelligence_in_the_Battle_against_Coronavirus_COVID-19_A_Survey_and_Future_Research_Directions/links/5ec928a2458515626cc328f9/Artificial-Intelligence-in-the-Battle-against-Coronavirus-COVID-19-A-Survey-and-Future-Research-Directions.pdf</infon><infon key=\"name_0\">surname:Nguyen;given-names:T.T.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>32521</offset><text>Artificial intelligence in the battle against coronavirus (COVID-19): a survey and future research directions</text></passage><passage><infon key=\"name_0\">surname:Bai;given-names:H.</infon><infon key=\"name_1\">surname:Hsieh;given-names:B.</infon><infon key=\"name_2\">surname:Xiong;given-names:Z.</infon><infon key=\"name_3\">surname:Halsey;given-names:K.</infon><infon key=\"name_4\">surname:Choi;given-names:J.</infon><infon key=\"name_5\">surname:Tran;given-names:T.</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200823</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>32631</offset><text>Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT</text></passage><passage><infon key=\"name_0\">surname:Bai;given-names:X.</infon><infon key=\"name_1\">surname:Wang;given-names:R.</infon><infon key=\"name_2\">surname:Xiong;given-names:Z.</infon><infon key=\"name_3\">surname:Hsieh;given-names:B.</infon><infon key=\"name_4\">surname:ChangK</infon><infon key=\"name_5\">surname:Halsey;given-names:K.</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020201491</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>32720</offset><text>AI augmentation of radiologist performance in distinguishing COVID-19 from pneumonia of other etiology on chest CT</text></passage><passage><infon key=\"name_0\">surname:Zheng;given-names:C.</infon><infon key=\"name_1\">surname:Deng;given-names:X.</infon><infon key=\"name_2\">surname:Fu;given-names:Q.</infon><infon key=\"name_3\">surname:Zhou;given-names:Q.</infon><infon key=\"name_4\">surname:Feng;given-names:J.</infon><infon key=\"name_5\">surname:Ma;given-names:H.</infon><infon key=\"pub-id_doi\">10.1101/2020.03.12.20027185</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>32835</offset><text>Deep learning-based detection for COVID-19 from chest CT using weak label</text></passage></document></collection>\n",
      "\n",
      "Study 33394144: <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n",
      "<!DOCTYPE collection SYSTEM \"BioC.dtd\">\n",
      "<collection><source>PMC</source><date>20220218</date><key>pmc.key</key><document><id>7780074</id><infon key=\"license\">NO-CC CODE</infon><passage><infon key=\"article-id_doi\">10.1007/s00253-020-11061-5</infon><infon key=\"article-id_pmc\">7780074</infon><infon key=\"article-id_pmid\">33394144</infon><infon key=\"article-id_publisher-id\">11061</infon><infon key=\"fpage\">441</infon><infon key=\"issue\">2</infon><infon key=\"kwd\">COVID-19 SARS-CoV-2 RT-qPCR RT-LAMP Diagnosis Serology</infon><infon key=\"license\">This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</infon><infon key=\"lpage\">455</infon><infon key=\"name_0\">surname:Rai;given-names:Praveen</infon><infon key=\"name_1\">surname:Kumar;given-names:Ballamoole Krishna</infon><infon key=\"name_2\">surname:Deekshit;given-names:Vijaya Kumar</infon><infon key=\"name_3\">surname:Karunasagar;given-names:Indrani</infon><infon key=\"name_4\">surname:Karunasagar;given-names:Iddya</infon><infon key=\"section_type\">TITLE</infon><infon key=\"title\">Keywords</infon><infon key=\"type\">front</infon><infon key=\"volume\">105</infon><infon key=\"year\">2021</infon><offset>0</offset><text>Detection technologies and recent developments in the diagnosis of COVID-19 infection</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>86</offset><text>Abstract</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>95</offset><text>COVID-19 is a disease caused by SARS-CoV-2 capable of causing mild to severe infections in humans. Since its first appearance in China in December 2019, the pandemic has spread rapidly throughout the world. Despite considerable efforts made to contain the disease, the virus has continued its prevalence in many countries with varying degrees of clinical manifestations. To contain this pandemic, collaborative approach involving accurate diagnosis, epidemiology, surveillance, and prophylaxis is essential. However, proper diagnosis using rapid technologies plays a crucial role. With increasing incidence of COVID-19 cases, the accurate and early detection of the SARS-CoV-2 is need of the hour for effective prevention and management of COVID-19 cases as well as to curb its spread. RT-qPCR assay is considered to be the gold standard for the early detection of virus, but this protocol has limited application to use as bedside test because of its technical complexity. To address these challenges, several POC assays have been developed to facilitate the COVID-19 diagnosis outside the centralized testing laboratories as well to accelerate the clinical decision making with a least turnaround time. Hence, in this report, we review different nucleic acid-based and serological techniques available for the diagnosis and effective prevention of COVID-19.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>1455</offset><text>Key points</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>1466</offset><text> â¢ Provides comprehensive information on the different diagnostic tools available for COVID-19 </text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>1564</offset><text> â¢ Nucleic acid based tests or antigen detection tests are used for diagnostic purpose </text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>1654</offset><text>â¢ Accurate diagnosis is essential for the efficient management of COVID-19</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>1731</offset><text>Introduction</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>1744</offset><text>The outbreak of Coronavirus Disease 2019 also known as COVID-19, due to novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), was first detected in China on 31 December 2019 (Wang et al.). Within a short span of time, SARS-CoV-2 has raced around the globe, and on 30th January 2020, the World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern (Karunasagar and Karunasagar). The number of infected cases and deaths due to COVID-19 is rising alarmingly and on 22nd July 2020, there are more than 1,47,65,256 confirmed cases with over 6,12,054 deaths across 200 countries(mortality rate approximately 3.7%) (WHO).</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>2441</offset><text>Coronaviruses are enveloped, positive single-stranded RNA genome (26 to 32 kb) viruses belonging to the Coronaviridae family in the Nidovirales order (Su et al.). Till date, there are four genera, i.e., alpha (Î±), beta (Î²), gamma (Î³), and delta (Î´), of the virus that have been recognized (Perlman and Netland). However, the novel SARS-CoV-2 belongs to the genera of Î²-coronavirus with a RNA genome size of 29.9 kb (Wu et al.). SARS-CoV-2 shows 88% nucleotide sequence identity to the two bat-derived SARS-like coronaviruses (bat-SL-CoVZC45 and bat-SL-CoVZXC2) and about 79% similarity to the SARS-CoV and 50% to the MERS-CoV (Lu et al.). There are growing numbers of reports that indicate that the genome of SARS-CoV2 has undergone evolutionary changes and diversification during the geographic dissemination process. The pan-genomic analysis of global SARS-CoV-2 isolates has revealed the identification of several genomic regions with increased genetic variation, and distinct mutation pattern (Korber et al.; Kumar et al.). The genome characterization of Indian SARS-CoV-2 by our group showed genetic variation in the SARS-CoV-2 circulating in India, which is extensively dominated by G614 genotype with a strong correlation to CFR of COVID-19 posing enormous challenge for the effective prevention and management of COVID-19 cases in India (Kumar et al.). According to the recent evidence, it is observed that SARS-CoV-2 virus is primarily transmitted between humans by inhalation or contact with infected droplets with the incubation period ranging from 2 to 14 days (Lin et al.; Liu et al.; Rohit et al.). SARS-CoV-2 infection has a broad range of clinical manifestations varying from asymptomatic to symptomatic including respiratory symptoms, fever, shortness of breath, cough, dyspnea, and viral pneumonia and in severe cases, pneumonia, severe acute respiratory syndrome, heart failure, renal failure, and even death (Huang et al.). However, the main cause of death related to COVID-19 is respiratory failure, followed by septic shock, renal failure, and hemorrhage and heart failure.This review provides a unique up-to-date and comprehensive overview on the performance of different nucleic acid-based and serological techniques currently available for the diagnosis of COVID-19.The information presented in this review is hoped to help physicians and clinical microbiologists select a suitable technique for COVID-19 diagnosis and clinical management.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_1</infon><offset>4924</offset><text>Diagnosis of COVID-19</text></passage><passage><infon key=\"file\">253_2020_11061_Fig1_HTML.jpg</infon><infon key=\"id\">Fig1</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>4946</offset><text>Schematic representation of various analytical methods available for SARS-CoV-2 detection</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>5036</offset><text>The clinical manifestation of novel SARS-CoV-2 (or COVID-19) is highly variable from individual to individual, with asymptomatic to acute respiratory distress syndrome and multi organ failure. Hence, the accurate diagnosis of COVID-19 is challenging. The routine clinical diagnosis of COVID-19 is primarily based on epidemiological history, clinical manifestations, and confirmed by a variety of laboratory detection methods, including computed tomography (CT) scan, nucleic acid amplification test amplification test (NAAT), and serological techniques (Corman et al.; Wan et al.). A graphical abstract depicting the various analytical methods available for the diagnosis of COVID-19 is mentioned in Fig. 1 and their technical details are discussed here below. For early screening or diagnosis of SARS-CoV-2 infection, specimens such as nasopharyngeal and/or oropharyngeal swab, bronchoalveolar lavage fluid, sputum, bronchial aspirate, or blood are generally recommended (Chan et al.; Kim et al.; Zou et al.).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>6047</offset><text>There are many virusesâ especially severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) that also causes upper and lower respiratory tract infections and shows overlapping clinical symptoms; therefore, it is difficult to differentiate SARS-CoV-2 infections from other viruses causing respiratory infections. Hence, laboratory examination is very essential along with clinical and epidemiological assessments for accurate and rapid diagnosis of the causative agent. This is also known to improve quarantine efficacy.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>6629</offset><text>Computed tomography</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>6649</offset><text>The chest computed tomography (CT) is currently one of the first live imaging techniques to detect pneumonia-related illnesses. It has been widely used earlier for the detection of lung abnormalities in SARS and MERS and found to be more sensitive than X-rays (Memish et al.; Rao et al.). Recently, the technique has also been utilized for the diagnosis of COVID-19 in hospitals. However, the technique has its own limitations. For instance, in a retrospective study conducted in Hong Kong on 64 patients, chest radiography showed a sensitivity of 69% when compared to 91% in RT-PCR. Among the RT-PCR positive cases, 20% did not show any lung abnormalities on chest radiograph (Wong et al.). Conversely, in another study, 75% of the RT-PCR negative cases showed chest CT findings with 48% likely to be positive for COVID19 (Ai et al.). In addition, chest computed tomography alone could lead to false positive results since it can overlap with other infections such as influenza, SARS, and MERS. Considering all these points, most of the health commissions have recently eliminated chest CT scanning as a criterion for the diagnosis of suspected cases of COVID-19. However, these ambiguities in the diagnosis can be effectively overcome by using a combination of both chest CT scanning and RT-PCR techniques. In addition, chest CT imaging could also become a useful tool in monitoring COVID-19 progression and therapeutic effect in clinical settings.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>8100</offset><text>Nucleic acid amplification test</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>8132</offset><text>Nucleic acid amplification tests (NAAT) are the most sensitive assays and generally preferred test to detect early viral infections because viraemia is usually seen early in the course of a disease. The different types of NAAT assays, such as reverse transcriptase real-time PCR (RT-qPCR), loop-mediated isothermal amplification-based assay (RT-LAMP), microarray, and high-throughput sequencing have been developed for the rapid and accurate diagnosis of COVID-19. However, NAAT demands high quality of SARS-CoV-2 RNA.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_3</infon><offset>8651</offset><text>Reverse transcriptase real-time polymerase chain reaction</text></passage><passage><infon key=\"file\">Tab1.xml</infon><infon key=\"id\">Tab1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>8709</offset><text>List of nucleic acid-based diagnostic assays currently available for the detection of SARS-CoV-2</text></passage><passage><infon key=\"file\">Tab1.xml</infon><infon key=\"id\">Tab1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th&gt;Sl. No&lt;/th&gt;&lt;th&gt;Name of the diagnostic assay&lt;/th&gt;&lt;th&gt;Test principle&lt;/th&gt;&lt;th&gt;Name of company&lt;/th&gt;&lt;th&gt;Sensitivity&lt;/th&gt;&lt;th&gt;Gene of target&lt;/th&gt;&lt;th&gt;Turnaround time&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;1&lt;/td&gt;&lt;td&gt;TaqMan 2019-nCoV Control Kit v1&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;ABI (Applied bio-systems), United States&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;ORF1ab, S protein, and N protein&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;2&lt;/td&gt;&lt;td&gt;A*STAR FORTITUDE KIT 2.0&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;Accelerate Technologies Pte Ltd (DxD Hub), Singapore&lt;/td&gt;&lt;td&gt;1Ã10&lt;sup&gt;3&lt;/sup&gt; copies/ml&lt;/td&gt;&lt;td&gt;Viral RNA&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;3&lt;/td&gt;&lt;td&gt;BioFire COVID-19 test&lt;/td&gt;&lt;td&gt;Multiplex real-time RT-PCR&lt;/td&gt;&lt;td&gt;BioFire Defense, LLC&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;ORF1ab and ORF8&lt;/td&gt;&lt;td&gt;Results in â¼ 45 min&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;4&lt;/td&gt;&lt;td&gt;LyteStar 2019-nCoV RT PCR Kit 1.0&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;ADT India Ltd, New Delhi, India&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;E and RdRP genes&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;5&lt;/td&gt;&lt;td&gt;RealStar SARS-CoV-2 RT-PCR kit 1.0&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;Altona Diagnostics, Germany&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;E and S gene&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;SARS-CoV-2 assay&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;Diagnostic Molecular LaboratoryâNorthwestern Medicine&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;N1 and RdRP genes&lt;/td&gt;&lt;td&gt;Results in &amp;lt; 1 h without manual RNA extraction&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;7&lt;/td&gt;&lt;td&gt;ANGPCR 2019-nCoV&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;Angstrom Biotech Pvt. Ltd, Rajasthan&lt;/td&gt;&lt;td&gt;500 copies / mL&lt;/td&gt;&lt;td&gt;ORF 1ab and N gene&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;8&lt;/td&gt;&lt;td&gt;CDC 2019- Novel Coronavirus Real-Time RT-PCR Diagnostic Panel&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;CDC-US&lt;/td&gt;&lt;td&gt;10 copies/ul&lt;/td&gt;&lt;td&gt;N gene&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;9&lt;/td&gt;&lt;td&gt;Simplexa COVID-19 Direct&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;DiaSorin Molecular LLC&lt;/td&gt;&lt;td&gt;500 copies/mL&lt;/td&gt;&lt;td&gt;OFR1ab and S gene&lt;/td&gt;&lt;td&gt;Results in â¼1 h with no RNA extraction&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;11&lt;/td&gt;&lt;td&gt;Real Time Fluorescent RT-PCR Kit for detecting 2019-nCoV&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;BGI Genomics, China&lt;/td&gt;&lt;td&gt;100 copies/mL&lt;/td&gt;&lt;td&gt;ORF1ab gene&lt;/td&gt;&lt;td&gt;Results in 3 h&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;13&lt;/td&gt;&lt;td&gt;Xpert Xpress SARS-CoV-2&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;Cepheid, United States&lt;/td&gt;&lt;td&gt;250 copies/mL&lt;/td&gt;&lt;td&gt;N2 and E genes&lt;/td&gt;&lt;td&gt;Results in â¼ 45 min with &amp;lt; 1 min of hands on time&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;14&lt;/td&gt;&lt;td&gt;SARAGENETM Corona Virus (2019 NCV) Test Kit&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;CoSara Diagnostics Pvt. Limited, Ahmedabad, India&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;15&lt;/td&gt;&lt;td&gt;ePlex SARS-CoV-2 test&lt;/td&gt;&lt;td&gt;Cartridge Based Technology&lt;/td&gt;&lt;td&gt;GenMark Diagnostics, Inc.&lt;/td&gt;&lt;td&gt;1 x 10&lt;sup&gt;5&lt;/sup&gt; copies/mL&lt;/td&gt;&lt;td&gt;RNA&lt;/td&gt;&lt;td&gt;&amp;lt; 2 min hands-on time and results in â¼ 2 h&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;16&lt;/td&gt;&lt;td&gt;Daan Gene Co. Ltd&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;Daan Gene Co. Ltd., China&lt;/td&gt;&lt;td&gt;500 copies/mL&lt;/td&gt;&lt;td&gt;ORFlab and N genes&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;18&lt;/td&gt;&lt;td&gt;One-Step WRTaqman qRT-PCR&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;GCC Biotech Pvt. Ltd, 24 Parganas, West Bengal, India&lt;/td&gt;&lt;td&gt;10 copies&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;19&lt;/td&gt;&lt;td&gt;NeoPlex COVID-19 detection kit&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;GeneMatrix, South Korea&lt;/td&gt;&lt;td&gt;20 copies/Î¼L&lt;/td&gt;&lt;td&gt;RdRp and N gene&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;20&lt;/td&gt;&lt;td&gt;Panther Fusion SARS-CoV-2 assay (Panther Fusion System)&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;PCR Hologic Inc.&lt;/td&gt;&lt;td&gt;1x10&lt;sup&gt;-2&lt;/sup&gt; TCID50/mL&lt;/td&gt;&lt;td&gt;ORF1ab regions 1 and 2&lt;/td&gt;&lt;td&gt;Each Panther Fusion system can provide results in &amp;lt; 3 h and process up to 1150 coronavirus tests in 24-h period&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;24&lt;/td&gt;&lt;td&gt;Helini Coronavirus [COVID-19] Real time-PCR Kit&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;Helini Biomolecules, Chennai, India&lt;/td&gt;&lt;td&gt;10copies/Î¼L&lt;/td&gt;&lt;td&gt;Viral RNA S gene E gene&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;26&lt;/td&gt;&lt;td&gt;COVID-19 RT-PCR test&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;LabCorp Laboratory Corporation of America&lt;/td&gt;&lt;td&gt;6.25 copies/Î¼L for NP swabs and 12.5 copies/Î¼L for BAL&lt;/td&gt;&lt;td&gt;N gene&lt;/td&gt;&lt;td&gt;Results in 2â4 days&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;27&lt;/td&gt;&lt;td&gt;Protect COVID-19 RT-qPCR Kit&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;JN Medsys Pte Ltd, Singapore&lt;/td&gt;&lt;td&gt;10 copies/reaction&lt;/td&gt;&lt;td&gt;N1, N2, N3 genes&lt;/td&gt;&lt;td&gt;Result in &amp;lt; 2 h&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;28&lt;/td&gt;&lt;td&gt;ARIES SARS-CoV-2 assay&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;Luminex Corporation&lt;/td&gt;&lt;td&gt;300 copies/target&lt;/td&gt;&lt;td&gt;ORF1ab and N gene&lt;/td&gt;&lt;td&gt;Minimal hands-on time and an automated workflow delivers results in 2 h&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;30&lt;/td&gt;&lt;td&gt;Power Check 2019 nCoV Real Time PCR Kit&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;Kogene Biotech, Seoul, Korea&lt;/td&gt;&lt;td&gt;10-fold serial dilutions&lt;/td&gt;&lt;td&gt;E and RdRp genes&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;31&lt;/td&gt;&lt;td&gt;Covid 19 Probe-free Real Time PCR Diagnostic Kit&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;Indian Institute of Technology, Delhi, India&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;33&lt;/td&gt;&lt;td&gt;LabGun Real Time PCR Kit&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;LabGenomics, South Korea&lt;/td&gt;&lt;td&gt;20 genomic RNA copies/Î¼L&lt;/td&gt;&lt;td&gt;RdRp and E genes&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;34&lt;/td&gt;&lt;td&gt;COVID-19 RT-PCR kit&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;Medsource Ozone Biomedicals, Faridabad, India&lt;/td&gt;&lt;td&gt;20 copies/Î¼L&lt;/td&gt;&lt;td&gt;ORF1ab and N genes&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;35&lt;/td&gt;&lt;td&gt;Meril COVID-19 One-step RT-PCR Kit&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;Meril Diagnostics, Vapi, Gujarat, India&lt;/td&gt;&lt;td&gt;&amp;lt; 5 RNA copies/reaction&lt;/td&gt;&lt;td&gt;ORF 1ab and nucleoprotein N genes&lt;/td&gt;&lt;td&gt;Result in 65 min&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;36&lt;/td&gt;&lt;td&gt;Patho Detect&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;Mylab Discovery Solutions, Pune, India&lt;/td&gt;&lt;td&gt;100%&lt;/td&gt;&lt;td&gt;Viral RNA&lt;/td&gt;&lt;td&gt;Results within 2.5 h&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;37&lt;/td&gt;&lt;td&gt;LYRA SARS-CoV-2 assay.&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;Diagnostic Hybrids, Inc Quidel Corporation&lt;/td&gt;&lt;td&gt;3.40e+4 copies /mL&lt;/td&gt;&lt;td&gt;ORF1ab&lt;/td&gt;&lt;td&gt;Results in &amp;lt; 75 min after extraction&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;38&lt;/td&gt;&lt;td&gt;STANDARD M nCoV RT detection kit&lt;/td&gt;&lt;td&gt;Real-Time RT-PCR&lt;/td&gt;&lt;td&gt;SD BIOSENSOR&lt;/td&gt;&lt;td&gt;0.5 copies/Î¼L&lt;/td&gt;&lt;td&gt;E and RdRP genes&lt;/td&gt;&lt;td&gt;Results within 90 min&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;40&lt;/td&gt;&lt;td&gt;Gene Finder COVID-19&lt;/td&gt;&lt;td/&gt;&lt;td&gt;OSANG Health Care, South Korea&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;41&lt;/td&gt;&lt;td&gt;Viracor SARS-CoV-2 assay&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;Viracor Eurofins Clinical Diagnostics&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;N gene&lt;/td&gt;&lt;td&gt;Results the same day, 12â18 h from receipt of specimen&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;42&lt;/td&gt;&lt;td&gt;MiRXES FORTITUDE KIT 2.0&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;MiRXES Pte Ltd.&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;Viral RNA genes less prone to mutation&lt;/td&gt;&lt;td&gt;Results in 90 min, produces 100,000 test kits/week&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;43&lt;/td&gt;&lt;td&gt;Q-line Molecular Coronavirus (COVID-19) RT-PCR kit&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;POCT Services Pvt. Limited, Lucknow, India&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;44&lt;/td&gt;&lt;td&gt;Z-Path Covid-19C (Genesig)&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;Primer Design, UK&lt;/td&gt;&lt;td&gt;0.58 copies/Î¼l&lt;/td&gt;&lt;td&gt;Viral RNA&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;45&lt;/td&gt;&lt;td&gt;Allplex 2019-nCoV assay&lt;/td&gt;&lt;td&gt;Multiplex real-time RT-PCR&lt;/td&gt;&lt;td&gt;Seegene&lt;/td&gt;&lt;td&gt;E gene-4,167Copies/mL N gene-1250 copies/mL RdRP gene-4167 copies/mL&lt;/td&gt;&lt;td&gt;E, N, and RdRP genes&lt;/td&gt;&lt;td&gt;Results in &amp;lt; 2 h after extraction&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;47&lt;/td&gt;&lt;td&gt;Novel Coronavirus(2019-nCoV) Nucleic Acid Diagnostic Kit (PCR Fluorescence Probing)&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;Sansure Biotech Inc., Changsha, China&lt;/td&gt;&lt;td&gt;200 copies/mL&lt;/td&gt;&lt;td&gt;ORF1ab gene and N gene&lt;/td&gt;&lt;td&gt;Results in 30 min&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;48&lt;/td&gt;&lt;td&gt;cobas SARS-CoV-2&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;Roche Molecular Systems, Inc.&lt;/td&gt;&lt;td&gt;0.003 TCID&lt;sub&gt;50&lt;/sub&gt;/mL&lt;/td&gt;&lt;td&gt;Viral RNA&lt;/td&gt;&lt;td&gt;Results in 3.5 h, instruments can process up to 384 results (cobas 6800 System) and 1056 results (cobas 8800 System) in 8 h&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;51&lt;/td&gt;&lt;td&gt;VitaPCR SARS-CoV-2 assay&lt;/td&gt;&lt;td&gt;Real-time PCR&lt;/td&gt;&lt;td&gt;Credo Diagnostics Biomedical Pte Ltd.&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;Viral RNA&lt;/td&gt;&lt;td&gt;Results in 20 min with 1 min of hands-on time&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;52&lt;/td&gt;&lt;td&gt;QIAstat-Dx Respiratory SARS-CoV-2 panel&lt;/td&gt;&lt;td&gt;Multiplex real-time RT-PCR&lt;/td&gt;&lt;td&gt;Qiagen GmbH&lt;/td&gt;&lt;td&gt;400 copies/mL&lt;/td&gt;&lt;td&gt;E and RdRP genes&lt;/td&gt;&lt;td&gt;Results in â1 h, by differentiating novel coronavirus from 21 other bacterial and viral respiratory pathogens&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;55&lt;/td&gt;&lt;td&gt;TaqPath COVID-19 combo kit&lt;/td&gt;&lt;td&gt;&lt;p&gt;Multiplex real-time&lt;/p&gt;&lt;p&gt;RT-PCR&lt;/p&gt;&lt;/td&gt;&lt;td&gt;Rutgers Clinical Genomics Laboratory ThermoFisher-Applied Biosystems&lt;/td&gt;&lt;td&gt;200 copies/mL&lt;/td&gt;&lt;td&gt;ORF1b and N and S Genes&lt;/td&gt;&lt;td&gt;&lt;p&gt;- 94 specimens in under 3 h&lt;/p&gt;&lt;p&gt;- 382 specimens in under 6.5 h&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;56&lt;/td&gt;&lt;td&gt;TRUPCR SARS-CoV-2 RT-qPCR Kit (V-3.2) (Single Tube Multiplex format)&lt;/td&gt;&lt;td&gt;Real-time RT-PCR&lt;/td&gt;&lt;td&gt;3B Black Bio Biotech India Ltd.&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;E, RdRP and N genes&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;57&lt;/td&gt;&lt;td&gt;Accula SARS-CoV-2 test&lt;/td&gt;&lt;td&gt;&lt;p&gt;PCR and lateral&lt;/p&gt;&lt;p&gt;flow technologies&lt;/p&gt;&lt;/td&gt;&lt;td&gt;Mesa Biotech Inc&lt;/td&gt;&lt;td&gt;200 copies/reaction&lt;/td&gt;&lt;td&gt;N gene&lt;/td&gt;&lt;td&gt;Results in 30 min, the palm-sized device can be used in physician office or patientsâ home&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;58&lt;/td&gt;&lt;td&gt;iAMP COVID-19 detection kit&lt;/td&gt;&lt;td&gt;Real-time RT isothermal amplification test&lt;/td&gt;&lt;td&gt;Atila BioSystems, Inc. D11&lt;/td&gt;&lt;td&gt;4 copies/Î¼L&lt;/td&gt;&lt;td&gt;ORF1ab and/ or N gene&lt;/td&gt;&lt;td&gt;Results &amp;lt; 1.5 h&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;59&lt;/td&gt;&lt;td&gt;ID NOW COVID-19&lt;/td&gt;&lt;td&gt;Isothermal nucleic acid amplification technology&lt;/td&gt;&lt;td&gt;Abbott Diagnostics Scarborough, Inc.&lt;/td&gt;&lt;td&gt;125 copies /mL&lt;/td&gt;&lt;td&gt;RdRP gene&lt;/td&gt;&lt;td&gt;Positive results &amp;lt; 5 min and negative results in 13 min&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;60&lt;/td&gt;&lt;td&gt;CRISPR-based tests for SARS-CoV-2&lt;/td&gt;&lt;td&gt;CRISPR-based lateral flow assay isothermal amplificatio&lt;/td&gt;&lt;td&gt;Cepheid Sherlock Biosciences&lt;/td&gt;&lt;td&gt;&lt;p&gt;4.5 copies/Î¼LâORF1ab&lt;/p&gt;&lt;p&gt;0.9 copies/ Î¼LâN gene&lt;/p&gt;&lt;/td&gt;&lt;td&gt;viral RNA&lt;/td&gt;&lt;td&gt;Results in &amp;lt; 1 h&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;61&lt;/td&gt;&lt;td&gt;SARS-CoV-2 DETECTR&lt;/td&gt;&lt;td&gt;CRISPR-based lateral flow assay isothermal amplification&lt;/td&gt;&lt;td&gt;Mammoth Biosciences&lt;/td&gt;&lt;td&gt;10 copies/Î¼L&lt;/td&gt;&lt;td&gt;E and N genes&lt;/td&gt;&lt;td&gt;CRISPR Cas12a-based lateral flow assay results in 30â40 min&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>8806</offset><text>Sl. No\tName of the diagnostic assay\tTest principle\tName of company\tSensitivity\tGene of target\tTurnaround time\t \t1\tTaqMan 2019-nCoV Control Kit v1\tReal-time RT-PCR\tABI (Applied bio-systems), United States\tNA\tORF1ab, S protein, and N protein\tNA\t \t2\tA*STAR FORTITUDE KIT 2.0\tReal-time RT-PCR\tAccelerate Technologies Pte Ltd (DxD Hub), Singapore\t1Ã103 copies/ml\tViral RNA\tNA\t \t3\tBioFire COVID-19 test\tMultiplex real-time RT-PCR\tBioFire Defense, LLC\tNA\tORF1ab and ORF8\tResults in â¼ 45 min\t \t4\tLyteStar 2019-nCoV RT PCR Kit 1.0\tReal-time RT-PCR\tADT India Ltd, New Delhi, India\tNA\tE and RdRP genes\tNA\t \t5\tRealStar SARS-CoV-2 RT-PCR kit 1.0\tReal-time RT-PCR\tAltona Diagnostics, Germany\tNA\tE and S gene\tNA\t \t6\tSARS-CoV-2 assay\tReal-time RT-PCR\tDiagnostic Molecular LaboratoryâNorthwestern Medicine\tNA\tN1 and RdRP genes\tResults in &lt; 1 h without manual RNA extraction\t \t7\tANGPCR 2019-nCoV\tReal-time RT-PCR\tAngstrom Biotech Pvt. Ltd, Rajasthan\t500 copies / mL\tORF 1ab and N gene\tNA\t \t8\tCDC 2019- Novel Coronavirus Real-Time RT-PCR Diagnostic Panel\tReal-time RT-PCR\tCDC-US\t10 copies/ul\tN gene\tNA\t \t9\tSimplexa COVID-19 Direct\tReal-time RT-PCR\tDiaSorin Molecular LLC\t500 copies/mL\tOFR1ab and S gene\tResults in â¼1 h with no RNA extraction\t \t11\tReal Time Fluorescent RT-PCR Kit for detecting 2019-nCoV\tReal-time RT-PCR\tBGI Genomics, China\t100 copies/mL\tORF1ab gene\tResults in 3 h\t \t13\tXpert Xpress SARS-CoV-2\tReal-time RT-PCR\tCepheid, United States\t250 copies/mL\tN2 and E genes\tResults in â¼ 45 min with &lt; 1 min of hands on time\t \t14\tSARAGENETM Corona Virus (2019 NCV) Test Kit\tReal-time RT-PCR\tCoSara Diagnostics Pvt. Limited, Ahmedabad, India\tNA\tNA\tNA\t \t15\tePlex SARS-CoV-2 test\tCartridge Based Technology\tGenMark Diagnostics, Inc.\t1 x 105 copies/mL\tRNA\t&lt; 2 min hands-on time and results in â¼ 2 h\t \t16\tDaan Gene Co. Ltd\tReal-time RT-PCR\tDaan Gene Co. Ltd., China\t500 copies/mL\tORFlab and N genes\tNA\t \t18\tOne-Step WRTaqman qRT-PCR\tReal-time RT-PCR\tGCC Biotech Pvt. Ltd, 24 Parganas, West Bengal, India\t10 copies\tNA\tNA\t \t19\tNeoPlex COVID-19 detection kit\tReal-time RT-PCR\tGeneMatrix, South Korea\t20 copies/Î¼L\tRdRp and N gene\tNA\t \t20\tPanther Fusion SARS-CoV-2 assay (Panther Fusion System)\tReal-time RT-PCR\tPCR Hologic Inc.\t1x10-2 TCID50/mL\tORF1ab regions 1 and 2\tEach Panther Fusion system can provide results in &lt; 3 h and process up to 1150 coronavirus tests in 24-h period\t \t24\tHelini Coronavirus [COVID-19] Real time-PCR Kit\tReal-time RT-PCR\tHelini Biomolecules, Chennai, India\t10copies/Î¼L\tViral RNA S gene E gene\tNA\t \t26\tCOVID-19 RT-PCR test\tReal-time RT-PCR\tLabCorp Laboratory Corporation of America\t6.25 copies/Î¼L for NP swabs and 12.5 copies/Î¼L for BAL\tN gene\tResults in 2â4 days\t \t27\tProtect COVID-19 RT-qPCR Kit\tReal-time RT-PCR\tJN Medsys Pte Ltd, Singapore\t10 copies/reaction\tN1, N2, N3 genes\tResult in &lt; 2 h\t \t28\tARIES SARS-CoV-2 assay\tReal-time RT-PCR\tLuminex Corporation\t300 copies/target\tORF1ab and N gene\tMinimal hands-on time and an automated workflow delivers results in 2 h\t \t30\tPower Check 2019 nCoV Real Time PCR Kit\tReal-time RT-PCR\tKogene Biotech, Seoul, Korea\t10-fold serial dilutions\tE and RdRp genes\tNA\t \t31\tCovid 19 Probe-free Real Time PCR Diagnostic Kit\tReal-time RT-PCR\tIndian Institute of Technology, Delhi, India\tNA\tNA\tNA\t \t33\tLabGun Real Time PCR Kit\tReal-time RT-PCR\tLabGenomics, South Korea\t20 genomic RNA copies/Î¼L\tRdRp and E genes\tNA\t \t34\tCOVID-19 RT-PCR kit\tReal-time RT-PCR\tMedsource Ozone Biomedicals, Faridabad, India\t20 copies/Î¼L\tORF1ab and N genes\tNA\t \t35\tMeril COVID-19 One-step RT-PCR Kit\tReal-time RT-PCR\tMeril Diagnostics, Vapi, Gujarat, India\t&lt; 5 RNA copies/reaction\tORF 1ab and nucleoprotein N genes\tResult in 65 min\t \t36\tPatho Detect\tReal-time RT-PCR\tMylab Discovery Solutions, Pune, India\t100%\tViral RNA\tResults within 2.5 h\t \t37\tLYRA SARS-CoV-2 assay.\tReal-time RT-PCR\tDiagnostic Hybrids, Inc Quidel Corporation\t3.40e+4 copies /mL\tORF1ab\tResults in &lt; 75 min after extraction\t \t38\tSTANDARD M nCoV RT detection kit\tReal-Time RT-PCR\tSD BIOSENSOR\t0.5 copies/Î¼L\tE and RdRP genes\tResults within 90 min\t \t40\tGene Finder COVID-19\t\tOSANG Health Care, South Korea\tNA\tNA\tNA\t \t41\tViracor SARS-CoV-2 assay\tReal-time RT-PCR\tViracor Eurofins Clinical Diagnostics\tNA\tN gene\tResults the same day, 12â18 h from receipt of specimen\t \t42\tMiRXES FORTITUDE KIT 2.0\tReal-time RT-PCR\tMiRXES Pte Ltd.\tNA\tViral RNA genes less prone to mutation\tResults in 90 min, produces 100,000 test kits/week\t \t43\tQ-line Molecular Coronavirus (COVID-19) RT-PCR kit\tReal-time RT-PCR\tPOCT Services Pvt. Limited, Lucknow, India\tNA\tNA\tNA\t \t44\tZ-Path Covid-19C (Genesig)\tReal-time RT-PCR\tPrimer Design, UK\t0.58 copies/Î¼l\tViral RNA\tNA\t \t45\tAllplex 2019-nCoV assay\tMultiplex real-time RT-PCR\tSeegene\tE gene-4,167Copies/mL N gene-1250 copies/mL RdRP gene-4167 copies/mL\tE, N, and RdRP genes\tResults in &lt; 2 h after extraction\t \t47\tNovel Coronavirus(2019-nCoV) Nucleic Acid Diagnostic Kit (PCR Fluorescence Probing)\tReal-time RT-PCR\tSansure Biotech Inc., Changsha, China\t200 copies/mL\tORF1ab gene and N gene\tResults in 30 min\t \t48\tcobas SARS-CoV-2\tReal-time RT-PCR\tRoche Molecular Systems, Inc.\t0.003 TCID50/mL\tViral RNA\tResults in 3.5 h, instruments can process up to 384 results (cobas 6800 System) and 1056 results (cobas 8800 System) in 8 h\t \t51\tVitaPCR SARS-CoV-2 assay\tReal-time PCR\tCredo Diagnostics Biomedical Pte Ltd.\tNA\tViral RNA\tResults in 20 min with 1 min of hands-on time\t \t52\tQIAstat-Dx Respiratory SARS-CoV-2 panel\tMultiplex real-time RT-PCR\tQiagen GmbH\t400 copies/mL\tE and RdRP genes\tResults in â1 h, by differentiating novel coronavirus from 21 other bacterial and viral respiratory pathogens\t \t55\tTaqPath COVID-19 combo kit\tMultiplex real-timeRT-PCR\tRutgers Clinical Genomics Laboratory ThermoFisher-Applied Biosystems\t200 copies/mL\tORF1b and N and S Genes\t- 94 specimens in under 3 h- 382 specimens in under 6.5 h\t \t56\tTRUPCR SARS-CoV-2 RT-qPCR Kit (V-3.2) (Single Tube Multiplex format)\tReal-time RT-PCR\t3B Black Bio Biotech India Ltd.\tNA\tE, RdRP and N genes\tNA\t \t57\tAccula SARS-CoV-2 test\tPCR and lateralflow technologies\tMesa Biotech Inc\t200 copies/reaction\tN gene\tResults in 30 min, the palm-sized device can be used in physician office or patientsâ home\t \t58\tiAMP COVID-19 detection kit\tReal-time RT isothermal amplification test\tAtila BioSystems, Inc. D11\t4 copies/Î¼L\tORF1ab and/ or N gene\tResults &lt; 1.5 h\t \t59\tID NOW COVID-19\tIsothermal nucleic acid amplification technology\tAbbott Diagnostics Scarborough, Inc.\t125 copies /mL\tRdRP gene\tPositive results &lt; 5 min and negative results in 13 min\t \t60\tCRISPR-based tests for SARS-CoV-2\tCRISPR-based lateral flow assay isothermal amplificatio\tCepheid Sherlock Biosciences\t4.5 copies/Î¼LâORF1ab0.9 copies/ Î¼LâN gene\tviral RNA\tResults in &lt; 1 h\t \t61\tSARS-CoV-2 DETECTR\tCRISPR-based lateral flow assay isothermal amplification\tMammoth Biosciences\t10 copies/Î¼L\tE and N genes\tCRISPR Cas12a-based lateral flow assay results in 30â40 min\t \t</text></passage><passage><infon key=\"file\">Tab1.xml</infon><infon key=\"id\">Tab1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_foot</infon><offset>15730</offset><text>CRISPR clustered regularly interspaced short palindromic repeats, E envelope protein, RdRP RNA dependent RNA polymerase, N nucleocapsid phosphoprotein, S spike protein, NA not analyzed in the literature, RT reverse transcription</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>15959</offset><text>Probe-based RT-qPCR has been considered to be the gold standard method for SARS-CoV-2 detection and currently one of the most widely used test in many countries for screening the populations as recommended by WHO and CDC (Chu et al.; Corman et al.; Loeffelholz and Tang). After the first outbreak, several RT-qPCR assays have been deployed for the detection of SARS-CoV-2 from clinical samples. RT-qPCR assay were developed targeting different genes such as RNA dependent RNA polymerase(RdRp) gene, nucleocapsid (N) gene, envelope (E) gene, spike (S) gene, and ORF1b or ORF8 regions of the SARS-CoV-2 genome (Table 1) (Chan et al.; Corman et al.; Konrad et al.; Reusken et al.). The WHO recommends RT-qPCR-based assay targeting E gene for screening of SARS-CoV-2 followed by a confirmatory test targeting the RdRp gene (Corman et al.). Whereas CDC advocated RT-qPCR assay was based on two nucleocapsid protein genes (N1, N2) (Holshue et al.).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>16902</offset><text>In addition, inclusion of two or more genes such as E, RdRp, and ORF-1b-nsp14 in the RT-qPCR reaction could lead to enhanced identification of true positives. However, testing for more SARS-CoV-2 genes for confirmatory results would be laborious and time consuming because of continuous rise in the suspected cases throughout the world. This can be easily avoided by targeting highly specific region of the virus genome that could even detect the virus at a very low concentration. A recent report by Alagarasu et al. revealed a better performance of ORF-1b-nsp14-based assay when compared to RdRp-based assay (Alagarasu et al.). Similarly, it is also reported that a modified RdRp-helicase-based qPCR assay was highly successful in detecting 35% more positive cases of SARS-CoV-2 when compared to RdRp-based assay (Chan et al.). Some studies have also suggested that the lower sensitivity of RdRp-based assay might be due a degenerate base present at the 12th position of reverse primer (Lim et al.; Vogel et al.). The test protocol of all the above-mentioned nucleic acid-based techniques is complex and expensive which demands high-end experimental instruments, testing reagents, and skilled research personnel; hence, it cannot be deployed as point-of-care diagnostic or bedside test in resource-limited settings. Moreover, the tests typically take 4â6 h to complete, but the logistical requirement to ship clinical samples takes turnaround time more than 24 h that delays reporting. In addition, RT-qPCR result highly depends on the quality of viral RNA and in some cases the test cases test needs to be repeated 2 to 3 times for further confirmation. The Limit of detection of most assays is between 3.4 to 4.5 log10 copies/mL (LeBlanc et al.). Though most tests use two gene targets, positivity in gene is considered adequate and this has been incorporated into some national case definitions eg in Canada (http://health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/2019_case_definition.pdf). Test results depend on sample and highest detection rates were reported from brocheoalveolar lavage fluid, sputum, and nasal swabs (Wang et al.). Though, there are some shortcomings, use of RT-qPCR for the diagnosis of COVID-19 is still considered as the gold standard.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_3</infon><offset>19185</offset><text>Reverse transcription loop-mediated isothermal amplification</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>19246</offset><text>Loop-mediated isothermal amplification (LAMP) is a PCR-based nucleic acid amplification, which has the ability to specifically amplify the target sequence very efficiently, rapidly under isothermal conditions. The method relies on the use of four-six different primers which recognize specific four or six regions on the target gene and Bst DNA polymerase that elongates the chain at constant temperature by using strand displacement mechanism. Amplification by this method can occur in a conventional water bath/heating block, and the amplified product can be visually identified by adding a fluorescent dye. Since SARS-CoV-2 is an RNA virus, a reverse transcription step is required (RT-LAMP). After the outbreak, several RT-LAMP assays have been developed and validated for point-of-care diagnosis of COVID-19 (Broughton et al.; El-Tholoth et al.; Huang et al.; Lamb et al.; Park et al.; Weihua et al.; Yan et al.; Yu et al.). Park et al. have developed RT-LAMP for the detection of SARS-CoV-2 targeting the Nsp3 region of the virus. The technique could detect as low as 100 copies per reaction of SARS-CoV-2 RNA (Park et al.). However, another research group in Japan evaluated a commercially available RT-LAMP (LoopampÂ® 2019-SARS-CoV-2 Detection Reagent Kit; http://loopamp.eiken.co.jp/), that showed a high sensitivity with detection limit of 1.0 Ã 101 copies/Î¼L within 35 min. In addition, RT-LAMP-based method-iLACO (isothermal LAMP based method for COVID-19) targeting ORF1ab gene using 6 primers developed by Yu et al. was found to detect SARS-CoV-2 as low as 10 copies per reaction (Yu et al.). Similarly, a combination of RT-LAMP with clustered regularly interspaced short palindromic repeats (CRISPR)-based DETECTOR technology was also developed for the rapid detection (30â40 min) of SARS-CoV-2 in clinical samples with the limit of detection of 10 copies per microliter (Broughton et al.). In spite of the development of many RT-LAMP-based molecular techniques, very few have been commercialized due to cross reactivity and lack of sensitivity in the assays (Zhang et al.).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>21340</offset><text>Nevertheless, the technique like RT-LAMP does not require skilled personnel or high-end equipments. However, it is important to look for multiple targets of SARS-CoV-2 for the optimum utilization of the technique. Since the accuracy of RT-LAMP will also be affected by the mutations at the primer binding region of the virus, it is necessary to avoid these mutation sites while designing the primers to increase the rate of detection.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_3</infon><offset>21775</offset><text>CRISPR-based diagnosis</text></passage><passage><infon key=\"file\">253_2020_11061_Fig2_HTML.jpg</infon><infon key=\"id\">Fig2</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>21798</offset><text>Schematic representation of CRISPR-Cas12a based SARS-CoV-2 detection assay</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>21873</offset><text>Clustered regularly interspaced short palindromic repeats has gained popularity with in the scientific community as a genome editing tool, but now slowly gaining their potential in diagnostic applications (Chertow; Li et al.). CRISPR requires guide RNA which binds to target complementary sequence and nuclease enzyme cleaves at the precise site. CRISPR components are used for biosensing nucleic acids from different pathogens including bacteria and viruses. In case of viral nucleic acid detection, a small RNA fragment called guide RNA (gRNA), which will in turn bind to the target segment of viral gene. Then, special CRISPR-associated nucleases such as cas9, cas12, or cas13 will be used for cutting the target molecule (Fig. 2).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>22608</offset><text>Many researchers have attempted to use the CRISPR-based detection system for detection of SARS-CoV-2. For instance, a study by Zhang et al. used CRISPR-based detection system (SHERLOCK) (Specific High sensitivity Enzymatic Reporter unLOCKing) with isothermal recombinase polymerase amplification (RPA) could detect single molecule per milliliter within 1 h (Zhang et al.). In this technique, cas13 was used for the detection of amplified products of S and Orf1ab gene of SARS-CoV-2. This assay developed by Sherlock Biosciences became the first FDA-approved CRISPR technology on the market. Another CRISPR diagnostic company, Mammoth Biosciences, used combination of RT-LAMP with CRISPR-cas12-based technique, which could detect 10â100 copies of viral RNA per microliter in 40 min. Till date, this the fastest test developed by Mammoth Biosciences for the detection of SARS-CoV-2 (Broughton et al.). This technique targets the envelope gene of SARS-CoV-2 and results can be analyzed by fluorescence or/through lateral flow method. Further, Ding et al. developed a rapid, ultrasensitive all in one dual CRISPR/Cas12a (AIOD-CRISPR) assay, which utilizes dual crRNAs targeting two regions of the viral N gene (Ding et al.) with limit of detection of 4.6â11 copies/microliter. Further, a recently developed bed side assay FELUDA (field-deployable nucleobase detection and identification using FnCas9) utilizes FnCas9 could detect as low as 110 femtomolar nucleic acid of the virus (Azhar et al.). Even though all these advanced molecular diagnostic methods have shown promising results, it is important to carefully validate these tools for its efficient field application.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_3</infon><offset>24282</offset><text>Cartridge-based nucleic acid amplification test and TrueNAT</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>24342</offset><text>Cartridge-based nucleic acid amplification test (CBNAAT) is a technique which uses the GeneXpert technology for the diagnosis of tuberculosis (TB). This cartridge-based nucleic acid amplification is a fully automated amplification system, which utilizes real-time PCR. However, due to abrupt raise in the COVID-19 cases, Indian Council of Medical Research (ICMR) has approved the use of CBNAAT to detect COVID-19 cases (https://www.icmr.gov.in/pdf/covid/labs/Cepheid_Xpert_Xpress_SARS-CoV2_advisory_v2.pdf). This technique targets E gene and N2 gene of the SARS-CoV-2 for screening and confirmation, respectively. Another nucleic acid-based test called TrueNAT targeting E gene for screening and RdRp gene for confirmation of COVID-19 cases has also been approved by ICMR. This technology mainly uses chip-based tools and takes up to 1 h for the test.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>25194</offset><text>In addition to all the above molecular techniques, the next-generation sequencing of clinical specimen from the COVID-19 infected patients would allow rapid identification of SARS-CoV-2 and other pathogens contributing secondary/co infections that otherwise known to enhance the severity of SARS-CoV-2 symptoms. Metagenomic approach would help not only in pathogen detection but also provides genetic information, which further led to the better understanding of viral evolution, molecular epidemiology, and contact tracing. In addition, genetic sequencing allows us to assess the rate of genetic mutations of SARS-CoV-2; this information is very useful in determining the antiviral and vaccine efficacy.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>25899</offset><text>The Illumina COVIDSeq is an amplicon-based NGS-based detection platform approved by US Food and Drug Administration (US-FDA) for the qualitative detection of SARS-CoV-2 from respiratory specimens collected from the suspected COVID-19 patients. This detection method utilizes different sets primers and probes leveraged from ARTIC multiplex PCR protocol (Itokawa et al.) combined with Illumina sequencing technology. The COVIDSeqtest accommodates up to 3072 samples in single run on a NOVASeq with a turnaround time of 12 h (https://www.illumina.com/products/by-type/clinical-research-products/covidseq.html). Similarly, the Thermo Fischer Scientific has launched Ion AmpliSeq SARS-CoV-2 research panel that facilitates analysis of SARS-CoV-2 genome and provides high throughput workflow for monitoring the viral evolution. This research panel consists of two pools of amplicons ranging from 125 to 275 bp targeting more than 99% of the SARS-CoV-2 genome (https://thermofisher.mediaroom.com/2020-05-06-Rapid-COVID-19-Genome-Sequencing-Aids-Outbreak-Investigations). This assay requires 1 ng of viral RNA.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>27003</offset><text>Oxford nanotechnology has introduced long-read sequencing platform which has demonstrated substantial benefits of analytical innovations over the currently existing methods for the genome sequencing. Moore et al. has demonstrated the application of MinIon based amplicon and metagenomic sequencing to identify SARS-CoV-2 and other microbes associated with COVID-19 illness (Moore et al.). The study of Wang et al. has reported nanopore target sequencing (NTS) to SARS-CoV-2 and other pathogens simultaneously from respiratory specimens within 10 h (Wang et al.). The developed method has shown considerably higher sensitivity of detecting 10 viral copies per mL of sample. As this technology is designed to amplify log read sequences, it is important to consider the limitation of this technology in detecting short fragments of SARS-CoV-2 genome from highly degraded samples (Wei et al.; Wilson et al.).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>27908</offset><text>Recently, FDA approved SARS-CoV-2 Droplet Digital PCR (ddPCR) Kit developed by Bio-Rad Laboratories for the diagnosis of COVID-19. The developed assay detected as low as 0.260 to 0.351 copies/Î¼L for genetic markers, N1 and N2.This assay was found to be highly successful in detecting virus in the early stage of infection wherein viral load is usually less. This further helps in resolving the problem of indeterminate test results (https://www.bio-rad.com/featured/en/sars-cov-2-covid-19-testing-solutions.html).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>28423</offset><text>Serological assays</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>28442</offset><text>Detecting the antibodies against a virus in infected individuals is one of the most important diagnostic methods in disease surveillance. Though RT-qPCR is the most established technique in detecting the SARS-CoV-2 active cases, viral RNA becomes almost undetectable 14 days post-illness; besides, false-negative results may also arise due to improper handling of viral samples. These challenges warrant the development of simple test kits based on the detection of human antibodies generated in response to viral infection. The fundamental principle behind antibody-based immunodiagnostic is the detection of antibodies developed in response to viral infection (IgG and IgM) and/or, viral antigen through enzyme-linked immunosorbent assay (ELISA). Studies have shown that antigen-specific antibody could be detected in a patient after 3 to 6 days, and IgG could be detected at the later stages of an infection. The application of these tests has the ability to provide information on both active and past infections and can be ramped up to analyze thousands of samples at labs with resource-limited settings. Moreover, it can be deployed for the disease surveillance programs to gain a better understanding of the rate of infection among the community. Although the serological tests have the ability to provide information on both active and past infections, its efficiency in confirming SARS-CoV-2-specific antibodies response to capture past infections is well established (Lee et al.; Wang et al.). Studies conducted in China showed that virus-specific antibodies titer is significantly lower in the asymptomatic group compared to the symptomatic COVID-19 patients (Long et al.). In symptomatic COVID-19 patients, the medium duration for detection of IgM and IgA antibodies was 5 days and IgG was detected in 14 days. The detection efficiency of IgM ELISA was higher than that of RT-qPCR after 5.5 days of symptom onset (Guo et al.). Presence of IgM antibodies indicates recent exposure to viral infection, whereas IgG antibodies indicate previous exposure to SARS-CoV-2 viral infection. Thus the immunodiagnostic assays are also very critical to support the development of vaccines against COVID-19. This further helps in identifying extent of infection in people without active infection. Given the incredible demand for the rapid test for the diagnosis of COVID-19 infections, R&amp;D firms around the world have launched many rapid diagnostics with varying degrees of sensitivity.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>30928</offset><text>Enzyme-linked immunosorbent assay</text></passage><passage><infon key=\"file\">253_2020_11061_Fig3_HTML.jpg</infon><infon key=\"id\">Fig3</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>30962</offset><text>An overview of sandwich ELISA assay for the detection of SARS-CoV-2 antigens</text></passage><passage><infon key=\"file\">253_2020_11061_Fig4_HTML.jpg</infon><infon key=\"id\">Fig4</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>31039</offset><text>An overview of indirect ELISA assay for the detection of human antibody against SARS-CoV-2 antigens</text></passage><passage><infon key=\"file\">Tab2.xml</infon><infon key=\"id\">Tab2</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>31139</offset><text>List of serological assays used for the detection of SARS-CoV-2 antigen or/antibodies to SARS-CoV-2 virus</text></passage><passage><infon key=\"file\">Tab2.xml</infon><infon key=\"id\">Tab2</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th&gt;Sl. No&lt;/th&gt;&lt;th&gt;Name of the diagnostic assay&lt;/th&gt;&lt;th&gt;Test principle&lt;/th&gt;&lt;th&gt;Name of company&lt;/th&gt;&lt;th&gt;Sensitivity&lt;/th&gt;&lt;th&gt;Ig or antigen detection&lt;/th&gt;&lt;th&gt;Turnaround time&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td&gt;1&lt;/td&gt;&lt;td&gt;COVID Kavach ELISA IgG&lt;/td&gt;&lt;td&gt;ELISA&lt;/td&gt;&lt;td&gt;Zydus Cadila Healthcare Ltd., Ahmedabad, Gujarat, India&lt;/td&gt;&lt;td&gt;92.37%&lt;/td&gt;&lt;td&gt;IgG&lt;/td&gt;&lt;td&gt;Testing 90 samples together in a single run of 2.5 h&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;2&lt;/td&gt;&lt;td&gt;Euroimmun Anti- SARS-COV-2 ELISA IgG&lt;/td&gt;&lt;td&gt;ELISA&lt;/td&gt;&lt;td&gt;Euroimmun US Inc., USA&lt;/td&gt;&lt;td&gt;90%&lt;/td&gt;&lt;td&gt;IgG&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;3&lt;/td&gt;&lt;td&gt;Erbalisa COVID-19 IgG ELISA&lt;/td&gt;&lt;td&gt;ELISA&lt;/td&gt;&lt;td&gt;Calbiotech Inc., USA&lt;/td&gt;&lt;td&gt;98.3%&lt;/td&gt;&lt;td&gt;IgG&lt;/td&gt;&lt;td&gt;Results in 50 min&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;4&lt;/td&gt;&lt;td&gt;KT-1033 EDI Novel Coronavirus COVID-19 ELISA kit&lt;/td&gt;&lt;td&gt;ELISA&lt;/td&gt;&lt;td&gt;Epitope Diagnostics&lt;/td&gt;&lt;td&gt;45%&lt;/td&gt;&lt;td&gt;IgG/IgM&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;5&lt;/td&gt;&lt;td&gt;VITROS-Immunodiagnostics Products Anti-SARS-CoV-2 total reagent pack&lt;/td&gt;&lt;td&gt;ELISA&lt;/td&gt;&lt;td&gt;Ortho-Clinical Diagnostics&lt;/td&gt;&lt;td&gt;&amp;gt;8 days 100%&lt;/td&gt;&lt;td&gt;IgG/IgM&lt;/td&gt;&lt;td&gt;Cannot distinguish between IgG/IgM&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;6&lt;/td&gt;&lt;td&gt;DEIASL019/020 SARS-CoV-2 IgG ELISA kit&lt;/td&gt;&lt;td&gt;ELISA&lt;/td&gt;&lt;td&gt;Creative Diagnostics&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;IgG/IgM&lt;/td&gt;&lt;td&gt;IgG specific for N protein&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;7&lt;/td&gt;&lt;td&gt;m2000 SARS-CoV-2 assay&lt;/td&gt;&lt;td&gt;Chemiluminescent microparticle immunoassay&lt;/td&gt;&lt;td&gt;Abbott Core Laboratory&lt;/td&gt;&lt;td&gt;&lt;p&gt;53.1% (day 7)&lt;/p&gt;&lt;p&gt;82.4% (day 10)&lt;/p&gt;&lt;p&gt;96.9% (day 14)&lt;/p&gt;&lt;p&gt;100% (&amp;gt; day 17)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;IgG&lt;/td&gt;&lt;td&gt;Runs up to 100â200 tests/h&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;8&lt;/td&gt;&lt;td&gt;IgG antibody test kit for Novel coronavirus 2019-nCoV&lt;/td&gt;&lt;td&gt;Magnetic particle-based chemiluminescence immunoassay&lt;/td&gt;&lt;td&gt;Bioscience (Chongqing) Diagnostic Technology Co., Ltd.&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;IgG&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;9&lt;/td&gt;&lt;td&gt;Standard Q COVID-19 Ag&lt;/td&gt;&lt;td&gt;Chromatographic immunoassay&lt;/td&gt;&lt;td&gt;SD Biosensor&lt;/td&gt;&lt;td&gt;84.38%&lt;/td&gt;&lt;td&gt;Viral antigen&lt;/td&gt;&lt;td&gt;Results in 30 min&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;10&lt;/td&gt;&lt;td&gt;iFLASH-SARS-CoV-2-IgG/IgM&lt;/td&gt;&lt;td&gt;Immunoassay&lt;/td&gt;&lt;td&gt;Shenzhen Yhlo Biotech Company&lt;/td&gt;&lt;td&gt;&lt;p&gt;97.3%-IgG&lt;/p&gt;&lt;p&gt;86.1%-IgM&lt;/p&gt;&lt;/td&gt;&lt;td&gt;IgG/IgM&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;11&lt;/td&gt;&lt;td&gt;MAGLUMI IgG/IgM de 2019-nCoV (CLIA)&lt;/td&gt;&lt;td&gt;Chemiluminescence immunoassay&lt;/td&gt;&lt;td&gt;Snibe Diagnostic (China)&lt;/td&gt;&lt;td&gt;&lt;p&gt;100%-IgG-12 days&lt;/p&gt;&lt;p&gt;88%-IgM&lt;/p&gt;&lt;/td&gt;&lt;td&gt;IgG/IgM&lt;/td&gt;&lt;td&gt;Results in 30 min&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;12&lt;/td&gt;&lt;td&gt;Diazyme DZ-Lite SARS-CoV-2 IgG/IgM test&lt;/td&gt;&lt;td&gt;Luminescent immunoassay&lt;/td&gt;&lt;td&gt;Diazyme Laboratories&lt;/td&gt;&lt;td&gt;&lt;p&gt;95.6%-IgG&lt;/p&gt;&lt;p&gt;89.9%-IgM&lt;/p&gt;&lt;/td&gt;&lt;td&gt;IgG/IgM&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;13&lt;/td&gt;&lt;td&gt;VivaDiag COVID-19 IgM/IgG rapid test&lt;/td&gt;&lt;td&gt;Lateral flow immunoassay&lt;/td&gt;&lt;td&gt;Everest Links Pte Ltd.&lt;/td&gt;&lt;td&gt;18.4%&lt;/td&gt;&lt;td&gt;IgG/IgM&lt;/td&gt;&lt;td&gt;Results in 15 min&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;14&lt;/td&gt;&lt;td&gt;COVID-19 IgG/IgM LF&lt;/td&gt;&lt;td&gt;Lateral flow immunoassay&lt;/td&gt;&lt;td&gt;Advagen Biotech&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;IgG/IgM&lt;/td&gt;&lt;td&gt;Results in 10 min&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;15&lt;/td&gt;&lt;td&gt;COVID-19 IgG/IgM Point of Care Rapid test&lt;/td&gt;&lt;td&gt;Lateral flow immunoassay&lt;/td&gt;&lt;td&gt;Aytu Biosciences/Orient Gene Biotech&lt;/td&gt;&lt;td&gt;&lt;p&gt;93%-(IgG)&lt;/p&gt;&lt;p&gt;69%-(IgM&lt;/p&gt;&lt;/td&gt;&lt;td&gt;IgG/IgM&lt;/td&gt;&lt;td&gt;Results in 2â10 min&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;16&lt;/td&gt;&lt;td&gt;qSARS-CoV-2 IgG/IgM rapid test&lt;/td&gt;&lt;td&gt;Lateral flow immunoassay&lt;/td&gt;&lt;td&gt;Cellex Inc&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;IgG/IgM&lt;/td&gt;&lt;td&gt;Results in 15â20 min, antibodies specific for N protein&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;17&lt;/td&gt;&lt;td&gt;COVID-19 IgM/IgG rapid test&lt;/td&gt;&lt;td&gt;Lateral flow immunoassay&lt;/td&gt;&lt;td&gt;BioMedomics&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;IgG/IgM&lt;/td&gt;&lt;td&gt;Results in 15 min&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;18&lt;/td&gt;&lt;td&gt;One-Step COVID-2019 test&lt;/td&gt;&lt;td&gt;Lateral flow immunoassay&lt;/td&gt;&lt;td&gt;Celer Biotechnologia&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;IgG/IgM&lt;/td&gt;&lt;td&gt;Results in 15 min&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;19&lt;/td&gt;&lt;td&gt;COVID-19 Ag Respi-Strip&lt;/td&gt;&lt;td&gt;Lateral flow immunoassay (dipstick)&lt;/td&gt;&lt;td&gt;Coris Bioconcept&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;Viral antigen&lt;/td&gt;&lt;td&gt;Results in 15 min&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;20&lt;/td&gt;&lt;td&gt;DPP COVID-19 IgM/IgG system&lt;/td&gt;&lt;td&gt;Lateral flow immunoassay&lt;/td&gt;&lt;td&gt;Chembio Diagnostics&lt;/td&gt;&lt;td&gt;95%&lt;/td&gt;&lt;td&gt;IgG/IgM&lt;/td&gt;&lt;td&gt;Results in 15 min&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;21&lt;/td&gt;&lt;td&gt;OnSite COVID-19 IgG/IgM rapid test&lt;/td&gt;&lt;td&gt;Lateral flow immunoassay&lt;/td&gt;&lt;td&gt;CTK Biotech Inc. (USA)&lt;/td&gt;&lt;td&gt;97.1%&lt;/td&gt;&lt;td&gt;IgG/IgM&lt;/td&gt;&lt;td&gt;Results in 10 min&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;22&lt;/td&gt;&lt;td&gt;COVID-19 IgG/IgM rapid test cassette&lt;/td&gt;&lt;td&gt;Lateral flow immunoassay&lt;/td&gt;&lt;td&gt;Hangzhou Biotest Biotech Co. Ltd.&lt;/td&gt;&lt;td&gt;100%-IgM 93.3%-IgG&lt;/td&gt;&lt;td&gt;IgG/IgM&lt;/td&gt;&lt;td&gt;Results in 15â20 min&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;23&lt;/td&gt;&lt;td&gt;SARS-CoV-2 rapid test&lt;/td&gt;&lt;td&gt;Lateral flow immunoassay&lt;/td&gt;&lt;td&gt;PharmACT&lt;/td&gt;&lt;td&gt;NA&lt;/td&gt;&lt;td&gt;IgG/IgM&lt;/td&gt;&lt;td&gt;Results in 20 min, N protein, S1 and S2 subunits used as antigens&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;24&lt;/td&gt;&lt;td&gt;Standard Q COVID-19 IgM/IgG Duo&lt;/td&gt;&lt;td&gt;Lateral flow immunoassay&lt;/td&gt;&lt;td&gt;SD Biosensor&lt;/td&gt;&lt;td&gt;&lt;p&gt;94.33%-&amp;gt; 7 days&lt;/p&gt;&lt;p&gt;99.1%-&amp;gt; 14 days&lt;/p&gt;&lt;/td&gt;&lt;td&gt;IgG/IgM&lt;/td&gt;&lt;td&gt;Results in 10 min&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>31245</offset><text>Sl. No\tName of the diagnostic assay\tTest principle\tName of company\tSensitivity\tIg or antigen detection\tTurnaround time\t \t1\tCOVID Kavach ELISA IgG\tELISA\tZydus Cadila Healthcare Ltd., Ahmedabad, Gujarat, India\t92.37%\tIgG\tTesting 90 samples together in a single run of 2.5 h\t \t2\tEuroimmun Anti- SARS-COV-2 ELISA IgG\tELISA\tEuroimmun US Inc., USA\t90%\tIgG\tNA\t \t3\tErbalisa COVID-19 IgG ELISA\tELISA\tCalbiotech Inc., USA\t98.3%\tIgG\tResults in 50 min\t \t4\tKT-1033 EDI Novel Coronavirus COVID-19 ELISA kit\tELISA\tEpitope Diagnostics\t45%\tIgG/IgM\t\t \t5\tVITROS-Immunodiagnostics Products Anti-SARS-CoV-2 total reagent pack\tELISA\tOrtho-Clinical Diagnostics\t&gt;8 days 100%\tIgG/IgM\tCannot distinguish between IgG/IgM\t \t6\tDEIASL019/020 SARS-CoV-2 IgG ELISA kit\tELISA\tCreative Diagnostics\tNA\tIgG/IgM\tIgG specific for N protein\t \t7\tm2000 SARS-CoV-2 assay\tChemiluminescent microparticle immunoassay\tAbbott Core Laboratory\t53.1% (day 7)82.4% (day 10)96.9% (day 14)100% (&gt; day 17)\tIgG\tRuns up to 100â200 tests/h\t \t8\tIgG antibody test kit for Novel coronavirus 2019-nCoV\tMagnetic particle-based chemiluminescence immunoassay\tBioscience (Chongqing) Diagnostic Technology Co., Ltd.\tNA\tIgG\tNA\t \t9\tStandard Q COVID-19 Ag\tChromatographic immunoassay\tSD Biosensor\t84.38%\tViral antigen\tResults in 30 min\t \t10\tiFLASH-SARS-CoV-2-IgG/IgM\tImmunoassay\tShenzhen Yhlo Biotech Company\t97.3%-IgG86.1%-IgM\tIgG/IgM\t\t \t11\tMAGLUMI IgG/IgM de 2019-nCoV (CLIA)\tChemiluminescence immunoassay\tSnibe Diagnostic (China)\t100%-IgG-12 days88%-IgM\tIgG/IgM\tResults in 30 min\t \t12\tDiazyme DZ-Lite SARS-CoV-2 IgG/IgM test\tLuminescent immunoassay\tDiazyme Laboratories\t95.6%-IgG89.9%-IgM\tIgG/IgM\tNA\t \t13\tVivaDiag COVID-19 IgM/IgG rapid test\tLateral flow immunoassay\tEverest Links Pte Ltd.\t18.4%\tIgG/IgM\tResults in 15 min\t \t14\tCOVID-19 IgG/IgM LF\tLateral flow immunoassay\tAdvagen Biotech\tNA\tIgG/IgM\tResults in 10 min\t \t15\tCOVID-19 IgG/IgM Point of Care Rapid test\tLateral flow immunoassay\tAytu Biosciences/Orient Gene Biotech\t93%-(IgG)69%-(IgM\tIgG/IgM\tResults in 2â10 min\t \t16\tqSARS-CoV-2 IgG/IgM rapid test\tLateral flow immunoassay\tCellex Inc\tNA\tIgG/IgM\tResults in 15â20 min, antibodies specific for N protein\t \t17\tCOVID-19 IgM/IgG rapid test\tLateral flow immunoassay\tBioMedomics\tNA\tIgG/IgM\tResults in 15 min\t \t18\tOne-Step COVID-2019 test\tLateral flow immunoassay\tCeler Biotechnologia\tNA\tIgG/IgM\tResults in 15 min\t \t19\tCOVID-19 Ag Respi-Strip\tLateral flow immunoassay (dipstick)\tCoris Bioconcept\tNA\tViral antigen\tResults in 15 min\t \t20\tDPP COVID-19 IgM/IgG system\tLateral flow immunoassay\tChembio Diagnostics\t95%\tIgG/IgM\tResults in 15 min\t \t21\tOnSite COVID-19 IgG/IgM rapid test\tLateral flow immunoassay\tCTK Biotech Inc. (USA)\t97.1%\tIgG/IgM\tResults in 10 min\t \t22\tCOVID-19 IgG/IgM rapid test cassette\tLateral flow immunoassay\tHangzhou Biotest Biotech Co. Ltd.\t100%-IgM 93.3%-IgG\tIgG/IgM\tResults in 15â20 min\t \t23\tSARS-CoV-2 rapid test\tLateral flow immunoassay\tPharmACT\tNA\tIgG/IgM\tResults in 20 min, N protein, S1 and S2 subunits used as antigens\t \t24\tStandard Q COVID-19 IgM/IgG Duo\tLateral flow immunoassay\tSD Biosensor\t94.33%-&gt; 7 days99.1%-&gt; 14 days\tIgG/IgM\tResults in 10 min\t \t</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>34369</offset><text>There exist several ELISA-based methods with high levels of reproducibility and enduring sensitivity which makes the test an excellent tool for the diagnosis of various infectious diseases. The test can be qualitative or quantitative, with the turnaround time of around 1â5 h. An overview of sandwich and indirect ELISA assay for the detection of SARS-CoV-2 antigens and human antibody against SARS-CoV-2 antigens are shown in Figs. 3 and 4. Recently, IgG and IgM-based ELISA kit (EDIâ¢ Novel Coronavirus COVID-19 ELISA Kit) was developed by Epitope Diagnostics Inc for the detection of SARS-CoV-2 infection. EDIâ¢ Novel Coronavirus COVID-19 IgM ELISA kit utilizes âIgM captureâ method on microtiter plate-based ELISA for the qualitative measurement of the COVID-19 IgM antibody in the patient serum. In this assay, test samples are added to the microtiter plate, which was precoated with anti-human IgM-specific antibodies. Immunocomplex of âAnti-hIgMâ antibody and COVID-19 IgM antibody will be detected by HRP labeled recombinant COVID-19 antigen. In the case of EDIâ¢ Novel Coronavirus COVID-19 IgG ELISA Kit, the test utilizes ELISA plate coated with SARS-CoV-2 recombinant nucleocapsid protein to detect the presence of human IgG against SARS-CoV-2 in the test sample. Clinical validation of the EDIâ¢ Novel Coronavirus COVID-19 ELISA Kits demonstrated high âtrue positivityâ among the RT-PCR confirmed COVID-19 patients (Bundschuh et al.). In India, the National Institute of Virology, Pune, in collaboration with Zydus Diagnostics, has developed an indigenous IgG-based ELISA (COVID KAVACH ELISA) for antibody detection for COVID-19. Preliminary validation of the COVID KAVACH ELISA is shown to have high sensitivity and specificity in detecting SARS-CoV-2 infection. In addition to the above-mentioned ELISA kits, there are few other ELISA kits available in the market for the diagnosis of SARS-CoV-2 infection by analyzing IgM and IgG antibodies (Table 2).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>36354</offset><text>Point-of-care assay</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>36374</offset><text>Recent years have witnessed significant growth in the global market for point-of-care solution for infectious disease point-of-care (POC) test is performed at the patientâs bedside or near the site and has a rapid turnaround time which facilitates better disease diagnosis, monitoring, and change in the management of patient care (Kozel and Burnham-Marusich). As a result of continuous development in the R&amp;D sector, several POC testing platforms based on lateral flow assays, biosensors, microfluidic, bioanalytical platforms, and lab-on-a-chip technologies are available for the rapid detection of analytes near to the patient. Growing COVID-19 pandemic and the dearth of molecular testing capacity, as well as reagents around the world, demand the development of POC test for the rapid diagnosis of COVID-19, thereby aiding to establish infection control measures. In response to this, 233 POC assays are commercially available or in development for the diagnosis of COVID-19 worldwide (https://www.finddx.org/covid19/pipeline/?avance=all&amp;type=Rapid+diagnostic+tests&amp;testtarget=all&amp;status=all&amp;section=immunoassays&amp;action=default#diag_tab). These could detect SARS-CoV-2 antigen like spike protein or antibodies against viral antigens.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_3</infon><offset>37615</offset><text>Lateral flow immunoassay</text></passage><passage><infon key=\"file\">253_2020_11061_Fig5_HTML.jpg</infon><infon key=\"id\">Fig5</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>37640</offset><text>Lateral flow immunoassay for the detection of human anti-SARS-CoV-2 IgM or IgG antibody</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>37728</offset><text>Lateral flow immunoassays are the handheld portable POC platform for the rapid detection of an analyte and being used in biomedical, veterinary, agriculture, and food industries. This assay works based on the principle of antigen-antibody reactions, where the sample to be analyzed is placed on a test device, and the results are displayed within 5â15 min (Fig. 5). The main advantage of Lateral flow immunoassays is that the ease of performing test outside of the clinical laboratory, which make the assays the superior without burdening the capacity of the laboratories. In response to public health emergency due to COVID-19, researchers around the world put an effort to develop lateral flow immunoassays to detect antibodies to SARS-CoV-2 or viral antigens (https://www.medrxiv.org/content/medrxiv/early/2020/05/07/2020.04.15.20066407.full.pdf). Various types of lateral flow immunoassays for the detection of COVID-19 and their features are given in Table 2. A comparative evaluation of the three different lateral flow immunoassays for the detection of COVID-19 showed an overall clinical sensitivity of 70% without any significant differences between the three different assays (Montesinos et al.). Mertens and colleagues at CorisBioConcep, Belgium, have developed a lateral flow immunoassay (COVID-19 Ag Respi-Strip) for the rapid detection of SARS-CoV-2 antigen from nasopharyngeal specimens (Mertens et al.). This is the only available POC assay which targets the highly conserved nucleoprotein region of SARS-CoV-2 and capable of detecting the antigens in 15 min with an overall sensitivity and specificity of 57.6 and 99.5%, respectively.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_3</infon><offset>39382</offset><text>Chemiluminescence immunoassay</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>39412</offset><text>Over the past few years, chemiluminescence immunoassay (CLIA) has gained increasing attention as a rapid and sensitive POC test in different fields, including clinical diagnosis. The detection of the analyte is based on the reaction wherein enzymes used for the immunochemical reaction converts the chemiluminescence substrate to a reaction product, which emits a photon of light instead of color development (Chen et al.). Based on this principle, few CLIAs are available for the detection of serum immunoglobulin IgG and IgM against SARS-CoV-2 (Cai et al.; Infantino et al.; Wan et al.). The performance of four different chemiluminescence immunoassay systems for the detection of COVID-19 showed varying degrees of diagnostic accuracy, thereby suggesting the necessity of performance evaluation diagnostic test before actual use (Wan et al.).</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">title_1</infon><offset>40258</offset><text>Conclusion</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>40269</offset><text>Currently, a range of nucleic acid-based and antigen/antibody based tests and available for detection of SARS-CoV-2 infection. While nucleic acid-based tests or antigen detection tests are used for diagnostic purpose, antibody detection tests may be used for assessment of exposure to the virus or for sero-surveillance of populations. Nucleic acid-based tests and antigen/antibody detection tests vary widely in sensitivity. Most nucleic acid-based tests depend upon use of two gene targets, but in some countries, single target detection is considered adequate. Even the results of a nucleic acid-based test depend on the sample used with highest rates of detection obtained in broncheoalveolar lavage, sputum, and nasal swabs. But this might depend on the stage of infection. In asymptomatic and pre-symptomatic individuals, nasal swabs or sputum is generally used. Currently, RT-qPCR remains the frontline and gold standard technique for the detection of SARS-CoV-2 infection. However, due to the limited capacity of laboratory-based molecular testing and high turnaround time, we propose that newer rapid point-of-care technologies such as RT-LAMP and other isothermal amplification techniques may serve as an alternative detection modality for the screening of SARS-CoV-2 infection in highly populated countries including India. Chip-based (nucleic acid-based) tests have been validated for performance and are being widely used in India. Antigen detection tests have lower sensitivity compared to nucleic acid-based tests and negative results need to be reconfirmed by RT-PCR or other nucleic acid-based tests. However, point-of-care tests are still under development and following validation, these point-of-care tests could become available in the near future.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">footnote</infon><offset>42039</offset><text>Publisherâs note</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">footnote</infon><offset>42058</offset><text>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">footnote</infon><offset>42177</offset><text>Praveen Rai, Ballamoole Krishna Kumar and Vijaya Kumar Deekshit contributed equally to this work.</text></passage><passage><infon key=\"section_type\">AUTH_CONT</infon><infon key=\"type\">title</infon><offset>42275</offset><text>Authorâs contribution</text></passage><passage><infon key=\"section_type\">AUTH_CONT</infon><infon key=\"type\">paragraph</infon><offset>42299</offset><text>PRconceived and designed the review. PR, BKK, and VKD wrote the manuscript. IK and IK review and editing. All authors read and approved the manuscript.</text></passage><passage><infon key=\"section_type\">AUTH_CONT</infon><infon key=\"type\">title</infon><offset>42451</offset><text>Compliance with ethical standards</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">title</infon><offset>42485</offset><text>Conflict of interest</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">paragraph</infon><offset>42506</offset><text>The authors declare that they have no conflict of interest.</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">title</infon><offset>42566</offset><text>Ethical statement</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">paragraph</infon><offset>42584</offset><text>This article does not contain any studies with human participants or animals performed by any of the authors.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">title</infon><offset>42694</offset><text>References</text></passage><passage><infon key=\"fpage\">200642</infon><infon key=\"name_0\">surname:Ai;given-names:T</infon><infon key=\"name_1\">surname:Yang;given-names:Z</infon><infon key=\"name_2\">surname:Hou;given-names:H</infon><infon key=\"name_3\">surname:Zhan;given-names:C</infon><infon key=\"name_4\">surname:Chen;given-names:C</infon><infon key=\"name_5\">surname:Lv;given-names:W</infon><infon key=\"name_6\">surname:Tao;given-names:Q</infon><infon key=\"name_7\">surname:Sun;given-names:Z</infon><infon key=\"name_8\">surname:Xia;given-names:L</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200642</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">296</infon><infon key=\"year\">2020</infon><offset>42705</offset><text>Correlation of chest CT and RT-PCR testing in Coronavirus Disease 2019 (COVID-19) in China: a report of 1014 Cases</text></passage><passage><infon key=\"fpage\">483</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">485</infon><infon key=\"name_0\">surname:Alagarasu;given-names:K</infon><infon key=\"name_1\">surname:Choudhary;given-names:ML</infon><infon key=\"name_2\">surname:Lole;given-names:KS</infon><infon key=\"name_3\">surname:Abraham;given-names:P</infon><infon key=\"name_4\">surname:Potdar;given-names:V</infon><infon key=\"pub-id_doi\">10.4103/ijmr.IJMR_1256_20</infon><infon key=\"pub-id_pmid\">32474555</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Indian J Med Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">151</infon><infon key=\"year\">2020</infon><offset>42820</offset><text>Evaluation of RdRp &amp; ORF-1b-nsp14-based real-time RT-PCR assays for confirmation of SARS-CoV-2 infection: An observational study</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>42949</offset><text>Azhar M, Phutela R, Ansari AH, Sinha D, Sharma N, Kumar M, Aich M, Sharma S, Rauthan R, Singhal K, Lad H, Patra PK, Makharia G, Chandak GR, Chakraborty D, Souvik M (2020) Rapid, field-deployable nucleobase detection and identification using FnCas 9. bioRxiv 10.1101/2020.04.07.028167</text></passage><passage><infon key=\"fpage\">870</infon><infon key=\"lpage\">874</infon><infon key=\"name_0\">surname:Broughton;given-names:JP</infon><infon key=\"name_1\">surname:Deng;given-names:X</infon><infon key=\"name_10\">surname:Zorn;given-names:K</infon><infon key=\"name_11\">surname:Gopez;given-names:A</infon><infon key=\"name_12\">surname:Hsu;given-names:E</infon><infon key=\"name_13\">surname:Gu;given-names:W</infon><infon key=\"name_14\">surname:Miller;given-names:S</infon><infon key=\"name_15\">surname:Pan;given-names:CY</infon><infon key=\"name_16\">surname:Guevara;given-names:H</infon><infon key=\"name_17\">surname:Wadford;given-names:DA</infon><infon key=\"name_18\">surname:Chen;given-names:JS</infon><infon key=\"name_19\">surname:Chiu;given-names:CY</infon><infon key=\"name_2\">surname:Yu;given-names:G</infon><infon key=\"name_3\">surname:Fasching;given-names:CL</infon><infon key=\"name_4\">surname:Servellita;given-names:V</infon><infon key=\"name_5\">surname:Singh;given-names:J</infon><infon key=\"name_6\">surname:Miao;given-names:X</infon><infon key=\"name_7\">surname:Streithorst;given-names:JA</infon><infon key=\"name_8\">surname:Granados;given-names:A</infon><infon key=\"name_9\">surname:Sotomayor-Gonzalez;given-names:A</infon><infon key=\"pub-id_doi\">10.1038/s41587-020-0513-4</infon><infon key=\"pub-id_pmid\">32300245</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Biotechnol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">38</infon><infon key=\"year\">2020</infon><offset>43233</offset><text>CRISPR-Cas12-based detection of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">79</infon><infon key=\"lpage\">82</infon><infon key=\"name_0\">surname:Bundschuh;given-names:C</infon><infon key=\"name_1\">surname:Egger;given-names:M</infon><infon key=\"name_2\">surname:Wiesinger;given-names:K</infon><infon key=\"name_3\">surname:Gabriel;given-names:C</infon><infon key=\"name_4\">surname:Clodi;given-names:M</infon><infon key=\"name_5\">surname:Mueller;given-names:T</infon><infon key=\"name_6\">surname:Dieplinger;given-names:B</infon><infon key=\"pub-id_doi\">10.1016/j.cca.2020.05.047</infon><infon key=\"pub-id_pmid\">32526218</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Chim Acta</infon><infon key=\"type\">ref</infon><infon key=\"volume\">509</infon><infon key=\"year\">2020</infon><offset>43276</offset><text>Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma</text></passage><passage><infon key=\"fpage\">189</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">193</infon><infon key=\"name_0\">surname:Cai;given-names:XF</infon><infon key=\"name_1\">surname:Chen;given-names:J</infon><infon key=\"name_10\">surname:Chen;given-names:YK</infon><infon key=\"name_11\">surname:Li;given-names:ZJ</infon><infon key=\"name_12\">surname:Wang;given-names:K</infon><infon key=\"name_13\">surname:Zhang;given-names:XL</infon><infon key=\"name_14\">surname:Tian;given-names:WG</infon><infon key=\"name_15\">surname:Xiang;given-names:JL</infon><infon key=\"name_16\">surname:Du;given-names:HX</infon><infon key=\"name_17\">surname:Wang;given-names:J</infon><infon key=\"name_18\">surname:Hu;given-names:Y</infon><infon key=\"name_19\">surname:Tang;given-names:N</infon><infon key=\"name_2\">surname:Li Hu;given-names:J</infon><infon key=\"name_20\">surname:Lin;given-names:Y</infon><infon key=\"name_21\">surname:Ren;given-names:JH</infon><infon key=\"name_22\">surname:Huang;given-names:LY</infon><infon key=\"name_23\">surname:Wei;given-names:J</infon><infon key=\"name_24\">surname:Gan;given-names:CY</infon><infon key=\"name_25\">surname:Chen;given-names:YM</infon><infon key=\"name_26\">surname:Gao;given-names:QZ</infon><infon key=\"name_27\">surname:Chen;given-names:AM</infon><infon key=\"name_28\">surname:He;given-names:CL</infon><infon key=\"name_29\">surname:Wang;given-names:DX</infon><infon key=\"name_3\">surname:Long;given-names:QX</infon><infon key=\"name_30\">surname:Hu;given-names:P</infon><infon key=\"name_31\">surname:Zhou;given-names:FC</infon><infon key=\"name_32\">surname:Huang;given-names:AL</infon><infon key=\"name_33\">surname:Wang;given-names:DQ</infon><infon key=\"name_4\">surname:Deng;given-names:HJ</infon><infon key=\"name_5\">surname:Liu;given-names:P</infon><infon key=\"name_6\">surname:Fan;given-names:K</infon><infon key=\"name_7\">surname:Liao;given-names:P</infon><infon key=\"name_8\">surname:Liu;given-names:BZ</infon><infon key=\"name_9\">surname:Wu;given-names:GC</infon><infon key=\"pub-id_doi\">10.1093/infdis/jiaa243</infon><infon key=\"pub-id_pmid\">32382737</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">222</infon><infon key=\"year\">2020</infon><offset>43404</offset><text>A peptide-based magnetic chemiluminescence enzyme immunoassay for serological diagnosis of Coronavirus Disease 2019</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>43520</offset><text>Chan JF, Yip CC, To KK, Tang TH, Wong SC, Leung KH, Fung AY, Ng AC, Zou Z, Tsoi HW, Choi GK, Tam AR, Cheng VC, Chan KH, Tsang OT, Yuen KY (2020) Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens. J Clin Microbiol 58(5). 10.1128/JCM.00310-20</text></passage><passage><infon key=\"fpage\">825</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">831</infon><infon key=\"name_0\">surname:Chan;given-names:PK</infon><infon key=\"name_1\">surname:To;given-names:WK</infon><infon key=\"name_10\">surname:Lai;given-names:ST</infon><infon key=\"name_11\">surname:Hon;given-names:EK</infon><infon key=\"name_12\">surname:Li;given-names:CK</infon><infon key=\"name_13\">surname:Sung;given-names:JJ</infon><infon key=\"name_14\">surname:Tam;given-names:JS</infon><infon key=\"name_2\">surname:Ng;given-names:KC</infon><infon key=\"name_3\">surname:Lam;given-names:RK</infon><infon key=\"name_4\">surname:Ng;given-names:TK</infon><infon key=\"name_5\">surname:Chan;given-names:RC</infon><infon key=\"name_6\">surname:Wu;given-names:A</infon><infon key=\"name_7\">surname:Yu;given-names:WC</infon><infon key=\"name_8\">surname:Lee;given-names:N</infon><infon key=\"name_9\">surname:Hui;given-names:DS</infon><infon key=\"pub-id_doi\">10.3201/eid1005.030682</infon><infon key=\"pub-id_pmid\">15200815</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2004</infon><offset>43903</offset><text>Laboratory diagnosis of SARS</text></passage><passage><infon key=\"fpage\">559</infon><infon key=\"issue\">7</infon><infon key=\"lpage\">562</infon><infon key=\"name_0\">surname:Chen;given-names:Y</infon><infon key=\"name_1\">surname:Spiering;given-names:AJ</infon><infon key=\"name_2\">surname:Karthikeyan;given-names:S</infon><infon key=\"name_3\">surname:Peters;given-names:GW</infon><infon key=\"name_4\">surname:Meijer;given-names:EW</infon><infon key=\"name_5\">surname:Sijbesma;given-names:RP</infon><infon key=\"pub-id_doi\">10.1038/nchem.1358</infon><infon key=\"pub-id_pmid\">22717441</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Chem</infon><infon key=\"type\">ref</infon><infon key=\"volume\">4</infon><infon key=\"year\">2012</infon><offset>43932</offset><text>Mechanically induced chemiluminescence from polymers incorporating a 1,2-dioxetane unit in the main chain</text></passage><passage><infon key=\"fpage\">381</infon><infon key=\"issue\">6387</infon><infon key=\"lpage\">382</infon><infon key=\"name_0\">surname:Chertow;given-names:DS</infon><infon key=\"pub-id_doi\">10.1126/science.aat4982</infon><infon key=\"pub-id_pmid\">29700254</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">360</infon><infon key=\"year\">2018</infon><offset>44038</offset><text>Next-generation diagnostics with CRISPR</text></passage><passage><infon key=\"fpage\">549</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">555</infon><infon key=\"name_0\">surname:Chu;given-names:DKW</infon><infon key=\"name_1\">surname:Pan;given-names:Y</infon><infon key=\"name_10\">surname:Peiris;given-names:M</infon><infon key=\"name_11\">surname:Poon;given-names:LLM</infon><infon key=\"name_2\">surname:Cheng;given-names:SMS</infon><infon key=\"name_3\">surname:Hui;given-names:KPY</infon><infon key=\"name_4\">surname:Krishnan;given-names:P</infon><infon key=\"name_5\">surname:Liu;given-names:Y</infon><infon key=\"name_6\">surname:Ng;given-names:DYM</infon><infon key=\"name_7\">surname:Wan;given-names:CKC</infon><infon key=\"name_8\">surname:Yang;given-names:P</infon><infon key=\"name_9\">surname:Wang;given-names:Q</infon><infon key=\"pub-id_doi\">10.1093/clinchem/hvaa029</infon><infon key=\"pub-id_pmid\">32031583</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Chem</infon><infon key=\"type\">ref</infon><infon key=\"volume\">66</infon><infon key=\"year\">2020</infon><offset>44078</offset><text>Molecular diagnosis of a novel coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia</text></passage><passage><infon key=\"fpage\">2000045</infon><infon key=\"issue\">3</infon><infon key=\"name_0\">surname:Corman;given-names:VM</infon><infon key=\"name_1\">surname:Landt;given-names:O</infon><infon key=\"name_10\">surname:Mulders;given-names:DG</infon><infon key=\"name_11\">surname:Haagmans;given-names:BL</infon><infon key=\"name_12\">surname:van der Veer;given-names:B</infon><infon key=\"name_13\">surname:van den Brink;given-names:S</infon><infon key=\"name_14\">surname:Wijsman;given-names:L</infon><infon key=\"name_15\">surname:Goderski;given-names:G</infon><infon key=\"name_16\">surname:Romette;given-names:JL</infon><infon key=\"name_17\">surname:Ellis;given-names:J</infon><infon key=\"name_18\">surname:Zambon;given-names:M</infon><infon key=\"name_19\">surname:Peiris;given-names:M</infon><infon key=\"name_2\">surname:Kaiser;given-names:M</infon><infon key=\"name_20\">surname:Goossens;given-names:H</infon><infon key=\"name_21\">surname:Reusken;given-names:C</infon><infon key=\"name_22\">surname:Koopmans;given-names:MP</infon><infon key=\"name_23\">surname:Drosten;given-names:C</infon><infon key=\"name_3\">surname:Molenkamp;given-names:R</infon><infon key=\"name_4\">surname:Meijer;given-names:A</infon><infon key=\"name_5\">surname:Chu;given-names:DK</infon><infon key=\"name_6\">surname:Bleicker;given-names:T</infon><infon key=\"name_7\">surname:Brunink;given-names:S</infon><infon key=\"name_8\">surname:Schneider;given-names:J</infon><infon key=\"name_9\">surname:Schmidt;given-names:ML</infon><infon key=\"pub-id_doi\">10.2807/1560-7917.ES.2020.25.3.2000045</infon><infon key=\"pub-id_pmid\">6988269</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>44166</offset><text>Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>44234</offset><text>Ding X, Yin K, Li Z, Liu C (2020) All-in-one dual CRISPR-Cas12a (AIOD-CRISPR) assay: a case for rapid, ultrasensitive and visual detection of novel coronavirus SARS-CoV-2 and HIV virus. bioRxiv. 10.1101/2020.03.19.998724</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>44455</offset><text>El-Tholoth M, Bau HH, Song J (2020) A single and two-stage, closed-tube, molecular test for the 2019 novel coronavirus (COVID-19) at home, clinic, and points of entry. ChemRxiv. 10.26434/chemrxiv.11860137.v1</text></passage><passage><infon key=\"fpage\">778</infon><infon key=\"lpage\">785</infon><infon key=\"name_0\">surname:Guo;given-names:L</infon><infon key=\"name_1\">surname:Ren;given-names:L</infon><infon key=\"name_10\">surname:Zhang;given-names:L</infon><infon key=\"name_11\">surname:Han;given-names:L</infon><infon key=\"name_12\">surname:Dang;given-names:S</infon><infon key=\"name_13\">surname:Xu;given-names:Y</infon><infon key=\"name_14\">surname:Yang;given-names:Q</infon><infon key=\"name_15\">surname:Xu;given-names:S</infon><infon key=\"name_16\">surname:Zhu;given-names:H</infon><infon key=\"name_17\">surname:Xu;given-names:Y</infon><infon key=\"name_18\">surname:Jin;given-names:Q</infon><infon key=\"name_19\">surname:Sharma;given-names:L</infon><infon key=\"name_2\">surname:Yang;given-names:S</infon><infon key=\"name_20\">surname:Wang;given-names:L</infon><infon key=\"name_21\">surname:Wang;given-names:J</infon><infon key=\"name_3\">surname:Xiao;given-names:M</infon><infon key=\"name_4\">surname:Chang</infon><infon key=\"name_5\">surname:Yang;given-names:F</infon><infon key=\"name_6\">surname:Dela Cruz;given-names:CS</infon><infon key=\"name_7\">surname:Wang;given-names:Y</infon><infon key=\"name_8\">surname:Wu;given-names:C</infon><infon key=\"name_9\">surname:Xiao;given-names:Y</infon><infon key=\"pub-id_doi\">10.1093/cid/ciaa310</infon><infon key=\"pub-id_pmid\">32198501</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>44663</offset><text>Profiling early humoral response to diagnose Novel Coronavirus Disease (COVID-19)</text></passage><passage><infon key=\"fpage\">929</infon><infon key=\"issue\">10</infon><infon key=\"lpage\">936</infon><infon key=\"name_0\">surname:Holshue;given-names:ML</infon><infon key=\"name_1\">surname:DeBolt;given-names:C</infon><infon key=\"name_10\">surname:Diaz;given-names:G</infon><infon key=\"name_11\">surname:Cohn;given-names:A</infon><infon key=\"name_12\">surname:Fox;given-names:L</infon><infon key=\"name_13\">surname:Patel;given-names:A</infon><infon key=\"name_14\">surname:Gerber;given-names:SI</infon><infon key=\"name_15\">surname:Kim;given-names:L</infon><infon key=\"name_16\">surname:Tong;given-names:S</infon><infon key=\"name_17\">surname:Lu;given-names:X</infon><infon key=\"name_18\">surname:Lindstrom;given-names:S</infon><infon key=\"name_19\">surname:Pallansch;given-names:MA</infon><infon key=\"name_2\">surname:Lindquist;given-names:S</infon><infon key=\"name_20\">surname:Weldon;given-names:WC</infon><infon key=\"name_21\">surname:Biggs;given-names:HM</infon><infon key=\"name_22\">surname:Uyeki;given-names:TM</infon><infon key=\"name_23\">surname:Pillai;given-names:SK</infon><infon key=\"name_3\">surname:Lofy;given-names:KH</infon><infon key=\"name_4\">surname:Wiesman;given-names:J</infon><infon key=\"name_5\">surname:Bruce;given-names:H</infon><infon key=\"name_6\">surname:Spitters;given-names:C</infon><infon key=\"name_7\">surname:Ericson;given-names:K</infon><infon key=\"name_8\">surname:Wilkerson;given-names:S</infon><infon key=\"name_9\">surname:Tural;given-names:A</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa2001191</infon><infon key=\"pub-id_pmid\">32004427</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>44745</offset><text>First case of 2019 Novel Coronavirus in the United States</text></passage><passage><infon key=\"fpage\">497</infon><infon key=\"issue\">10223</infon><infon key=\"lpage\">506</infon><infon key=\"name_0\">surname:Huang;given-names:C</infon><infon key=\"name_1\">surname:Wang;given-names:Y</infon><infon key=\"name_10\">surname:Cheng;given-names:Z</infon><infon key=\"name_11\">surname:Yu;given-names:T</infon><infon key=\"name_12\">surname:Xia;given-names:J</infon><infon key=\"name_13\">surname:Wei;given-names:Y</infon><infon key=\"name_14\">surname:Wu;given-names:W</infon><infon key=\"name_15\">surname:Xie;given-names:X</infon><infon key=\"name_16\">surname:Yin;given-names:W</infon><infon key=\"name_17\">surname:Li;given-names:H</infon><infon key=\"name_18\">surname:Liu;given-names:M</infon><infon key=\"name_19\">surname:Xiao;given-names:Y</infon><infon key=\"name_2\">surname:Li;given-names:X</infon><infon key=\"name_20\">surname:Gao;given-names:H</infon><infon key=\"name_21\">surname:Guo;given-names:L</infon><infon key=\"name_22\">surname:Xie;given-names:J</infon><infon key=\"name_23\">surname:Wang;given-names:G</infon><infon key=\"name_24\">surname:Jiang;given-names:R</infon><infon key=\"name_25\">surname:Gao;given-names:Z</infon><infon key=\"name_26\">surname:Jin;given-names:Q</infon><infon key=\"name_27\">surname:Wang;given-names:J</infon><infon key=\"name_28\">surname:Cao;given-names:B</infon><infon key=\"name_3\">surname:Ren;given-names:L</infon><infon key=\"name_4\">surname:Zhao;given-names:J</infon><infon key=\"name_5\">surname:Hu;given-names:Y</infon><infon key=\"name_6\">surname:Zhang;given-names:L</infon><infon key=\"name_7\">surname:Fan;given-names:G</infon><infon key=\"name_8\">surname:Xu;given-names:J</infon><infon key=\"name_9\">surname:Gu;given-names:X</infon><infon key=\"pub-id_doi\">10.1016/S0140-6736(20)30183-5</infon><infon key=\"pub-id_pmid\">31986264</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>44803</offset><text>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</text></passage><passage><infon key=\"fpage\">950</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">961</infon><infon key=\"name_0\">surname:Huang;given-names:WE</infon><infon key=\"name_1\">surname:Lim;given-names:B</infon><infon key=\"name_10\">surname:Chang;given-names:H</infon><infon key=\"name_11\">surname:Zhang;given-names:X</infon><infon key=\"name_12\">surname:Wang;given-names:H</infon><infon key=\"name_13\">surname:Cui;given-names:Z</infon><infon key=\"name_2\">surname:Hsu;given-names:CC</infon><infon key=\"name_3\">surname:Xiong;given-names:D</infon><infon key=\"name_4\">surname:Wu;given-names:W</infon><infon key=\"name_5\">surname:Yu;given-names:Y</infon><infon key=\"name_6\">surname:Jia;given-names:H</infon><infon key=\"name_7\">surname:Wang;given-names:Y</infon><infon key=\"name_8\">surname:Zeng;given-names:Y</infon><infon key=\"name_9\">surname:Ji;given-names:M</infon><infon key=\"pub-id_doi\">10.1111/1751-7915.13586</infon><infon key=\"pub-id_pmid\">32333644</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Microb Biotechnol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">13</infon><infon key=\"year\">2020</infon><offset>44886</offset><text>RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2</text></passage><passage><infon key=\"fpage\">1671</infon><infon key=\"lpage\">1675</infon><infon key=\"name_0\">surname:Infantino;given-names:M</infon><infon key=\"name_1\">surname:Grossi;given-names:V</infon><infon key=\"name_10\">surname:Benucci;given-names:M</infon><infon key=\"name_11\">surname:Casprini;given-names:P</infon><infon key=\"name_12\">surname:Veneziani;given-names:F</infon><infon key=\"name_13\">surname:Fabbri;given-names:S</infon><infon key=\"name_14\">surname:Pompetti;given-names:A</infon><infon key=\"name_15\">surname:Manfredi;given-names:M</infon><infon key=\"name_2\">surname:Lari;given-names:B</infon><infon key=\"name_3\">surname:Bambi;given-names:R</infon><infon key=\"name_4\">surname:Perri;given-names:A</infon><infon key=\"name_5\">surname:Manneschi;given-names:M</infon><infon key=\"name_6\">surname:Terenzi;given-names:G</infon><infon key=\"name_7\">surname:Liotti;given-names:I</infon><infon key=\"name_8\">surname:Ciotta;given-names:G</infon><infon key=\"name_9\">surname:Taddei;given-names:C</infon><infon key=\"pub-id_doi\">10.1002/jmv.25932</infon><infon key=\"pub-id_pmid\">32330291</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>44940</offset><text>Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>45071</offset><text>Itokawa K, Sekizuka T, Hashino M, Tanaka R, Kuroda M (2020) A proposal of alternative primers for the ARTIC Network's multiplex PCR to improve coverage of SARS-CoV-2 genome sequencing. BioRxiv. 10.1101/2020.03.10.985150</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">2</infon><infon key=\"name_0\">surname:Karunasagar;given-names:I</infon><infon key=\"name_1\">surname:Karunasagar;given-names:I</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Health Allied Sci NU</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2020</infon><offset>45291</offset><text>Ongoing COVID-19 global crisis and scientific challenges</text></passage><passage><infon key=\"fpage\">e21610</infon><infon key=\"issue\">6</infon><infon key=\"name_0\">surname:Kim;given-names:C</infon><infon key=\"name_1\">surname:Ahmed;given-names:JA</infon><infon key=\"name_10\">surname:Muthoka;given-names:P</infon><infon key=\"name_11\">surname:Burton;given-names:W</infon><infon key=\"name_12\">surname:Breiman;given-names:RF</infon><infon key=\"name_13\">surname:Njenga;given-names:MK</infon><infon key=\"name_14\">surname:Katz;given-names:MA</infon><infon key=\"name_2\">surname:Eidex;given-names:RB</infon><infon key=\"name_3\">surname:Nyoka;given-names:R</infon><infon key=\"name_4\">surname:Waiboci;given-names:LW</infon><infon key=\"name_5\">surname:Erdman;given-names:D</infon><infon key=\"name_6\">surname:Tepo;given-names:A</infon><infon key=\"name_7\">surname:Mahamud;given-names:AS</infon><infon key=\"name_8\">surname:Kabura;given-names:W</infon><infon key=\"name_9\">surname:Nguhi;given-names:M</infon><infon key=\"pub-id_doi\">10.1371/journal.pone.0021610</infon><infon key=\"pub-id_pmid\">21738731</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS One</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2011</infon><offset>45348</offset><text>Comparison of nasopharyngeal and oropharyngeal swabs for the diagnosis of eight respiratory viruses by real-time reverse transcription-PCR assays</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>45494</offset><text>Konrad R, Eberle U, Dangel A, Treis B, Berger A, Bengs K, Fingerle V, Liebl B, Ackermann N, Sing A (2020) Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020. Euro Surveill 25(9). 10.2807/1560-7917.ES.2020.25.9.2000173</text></passage><passage><infon key=\"fpage\">812</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">827.e19</infon><infon key=\"name_0\">surname:Korber;given-names:B</infon><infon key=\"name_1\">surname:Fischer;given-names:WM</infon><infon key=\"name_10\">surname:Hastie;given-names:KM</infon><infon key=\"name_2\">surname:Gnanakaran;given-names:S</infon><infon key=\"name_3\">surname:Yoon;given-names:H</infon><infon key=\"name_4\">surname:Theiler;given-names:J</infon><infon key=\"name_5\">surname:Abfalterer;given-names:W</infon><infon key=\"name_6\">surname:Hengartner;given-names:N</infon><infon key=\"name_7\">surname:Giorgi;given-names:EE</infon><infon key=\"name_8\">surname:Bhattacharya;given-names:T</infon><infon key=\"name_9\">surname:Foley;given-names:B</infon><infon key=\"pub-id_doi\">10.1016/j.cell.2020.06.043</infon><infon key=\"pub-id_pmid\">32697968</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">182</infon><infon key=\"year\">2020</infon><offset>45779</offset><text>Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus</text></passage><passage><infon key=\"fpage\">2313</infon><infon key=\"issue\">8</infon><infon key=\"lpage\">2320</infon><infon key=\"name_0\">surname:Kozel;given-names:TR</infon><infon key=\"name_1\">surname:Burnham-Marusich;given-names:AR</infon><infon key=\"pub-id_doi\">10.1128/JCM.00476-17</infon><infon key=\"pub-id_pmid\">28539345</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">55</infon><infon key=\"year\">2017</infon><offset>45881</offset><text>Point-of-care testing for infectious diseases: past, present, and future</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>45954</offset><text>Kumar BK, Venkatraja B, Prithvisagar KS, Rai P, Rohit A, Hegde MN, Karunasagar I, Karunasagar I (2020) Mutational analysis unveils the temporal and spatial distribution of G614 genotype of SARS-CoV-2 in different Indian states and its association with case fatality rate of COVID-19. bioRxiv</text></passage><passage><infon key=\"fpage\">e0234682</infon><infon key=\"issue\">6</infon><infon key=\"name_0\">surname:Lamb;given-names:LE</infon><infon key=\"name_1\">surname:Bartolone;given-names:SN</infon><infon key=\"name_2\">surname:Ward;given-names:E</infon><infon key=\"name_3\">surname:Chancellor;given-names:MB</infon><infon key=\"pub-id_doi\">10.1371/journal.pone.0234682</infon><infon key=\"pub-id_pmid\">32530929</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS One</infon><infon key=\"type\">ref</infon><infon key=\"volume\">15</infon><infon key=\"year\">2020</infon><offset>46246</offset><text>Rapid detection of novel coronavirus/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by reverse transcription-loop-mediated isothermal amplification</text></passage><passage><infon key=\"fpage\">104433</infon><infon key=\"name_0\">surname:Le Blanc;given-names:JJ</infon><infon key=\"name_1\">surname:Gubbay;given-names:JB</infon><infon key=\"name_10\">surname:Garceau;given-names:R</infon><infon key=\"name_11\">surname:German;given-names:G</infon><infon key=\"name_12\">surname:Hatchette;given-names:TF</infon><infon key=\"name_13\">surname:Kozak;given-names:RA</infon><infon key=\"name_14\">surname:Krajden;given-names:M</infon><infon key=\"name_15\">surname:Kuschak;given-names:T</infon><infon key=\"name_16\">surname:Lang;given-names:ALS</infon><infon key=\"name_17\">surname:Levett;given-names:P</infon><infon key=\"name_18\">surname:Mazzulli;given-names:T</infon><infon key=\"name_19\">surname:Mc Donald;given-names:R</infon><infon key=\"name_2\">surname:Li;given-names:Y</infon><infon key=\"name_20\">surname:Mubareka;given-names:S</infon><infon key=\"name_21\">surname:Prystajecky;given-names:N</infon><infon key=\"name_22\">surname:Rutherford;given-names:C</infon><infon key=\"name_23\">surname:Smieja;given-names:M</infon><infon key=\"name_24\">surname:Yu;given-names:Y</infon><infon key=\"name_25\">surname:Zahariadis;given-names:G</infon><infon key=\"name_26\">surname:Zelyas;given-names:N</infon><infon key=\"name_27\">surname:Bastien;given-names:N</infon><infon key=\"name_3\">surname:Needle;given-names:R</infon><infon key=\"name_4\">surname:Arneson;given-names:SR</infon><infon key=\"name_5\">surname:Marcino;given-names:D</infon><infon key=\"name_6\">surname:Charest;given-names:H</infon><infon key=\"name_7\">surname:Desnoyers;given-names:G</infon><infon key=\"name_8\">surname:Dust;given-names:K</infon><infon key=\"name_9\">surname:Fattouh;given-names:R</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104433</infon><infon key=\"pub-id_pmid\">32405254</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">128</infon><infon key=\"year\">2020</infon><offset>46408</offset><text>Real-time PCR-based SARS-CoV-2 detection in Canadian laboratories</text></passage><passage><infon key=\"fpage\">165</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">167</infon><infon key=\"name_0\">surname:Lee;given-names:HK</infon><infon key=\"name_1\">surname:Lee;given-names:BH</infon><infon key=\"name_10\">surname:Kariwa;given-names:H</infon><infon key=\"name_11\">surname:Nakauchi;given-names:M</infon><infon key=\"name_12\">surname:Heo;given-names:SJ</infon><infon key=\"name_13\">surname:Park;given-names:JH</infon><infon key=\"name_2\">surname:Seok;given-names:SH</infon><infon key=\"name_3\">surname:Baek;given-names:MW</infon><infon key=\"name_4\">surname:Lee;given-names:HY</infon><infon key=\"name_5\">surname:Kim;given-names:DJ</infon><infon key=\"name_6\">surname:Na;given-names:YR</infon><infon key=\"name_7\">surname:Noh;given-names:KJ</infon><infon key=\"name_8\">surname:Park;given-names:SH</infon><infon key=\"name_9\">surname:Kumar;given-names:DN</infon><infon key=\"pub-id_doi\">10.4142/jvs.2010.11.2.165</infon><infon key=\"pub-id_pmid\">20458159</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Vet Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2010</infon><offset>46474</offset><text>Production of specific antibodies against SARS-coronavirus nucleocapsid protein without cross reactivity with human coronaviruses 229E and OC43</text></passage><passage><infon key=\"fpage\">730</infon><infon key=\"issue\">7</infon><infon key=\"lpage\">743</infon><infon key=\"name_0\">surname:Li;given-names:Y</infon><infon key=\"name_1\">surname:Li;given-names:S</infon><infon key=\"name_2\">surname:Wang;given-names:J</infon><infon key=\"name_3\">surname:Liu;given-names:G</infon><infon key=\"pub-id_doi\">10.1016/j.tibtech.2018.12.005</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biotechnol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">37</infon><infon key=\"year\">2019</infon><offset>46618</offset><text>CRISPR/Cas systems towards next-generation biosensing. trends</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>46680</offset><text>Lim J, Kim CM, Lee KH, Seo JW, Yun NR, Lee YM, et. al (2020) Insufficient sensitivity of RNA dependent RNA polymerase gene of SARS-CoV-2 viral genome as confirmatory test using Korean COVID-19 cases. Preprints.org. 10.20944/preprints202002.0424.v1</text></passage><passage><infon key=\"fpage\">211</infon><infon key=\"lpage\">216</infon><infon key=\"name_0\">surname:Lin;given-names:Q</infon><infon key=\"name_1\">surname:Zhao;given-names:S</infon><infon key=\"name_10\">surname:He;given-names:D</infon><infon key=\"name_2\">surname:Gao;given-names:D</infon><infon key=\"name_3\">surname:Lou;given-names:Y</infon><infon key=\"name_4\">surname:Yang;given-names:S</infon><infon key=\"name_5\">surname:Musa;given-names:SS</infon><infon key=\"name_6\">surname:Wang;given-names:MH</infon><infon key=\"name_7\">surname:Cai;given-names:Y</infon><infon key=\"name_8\">surname:Wang;given-names:W</infon><infon key=\"name_9\">surname:Yang;given-names:L</infon><infon key=\"pub-id_doi\">10.1016/j.ijid.2020.02.058</infon><infon key=\"pub-id_pmid\">32145465</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">93</infon><infon key=\"year\">2020</infon><offset>46928</offset><text>A conceptual model for the coronavirus disease 2019 (COVID-19) outbreak in Wuhan, China with individual reaction and governmental action</text></passage><passage><infon key=\"fpage\">taaa021</infon><infon key=\"issue\">2</infon><infon key=\"name_0\">surname:Liu;given-names:Y</infon><infon key=\"name_1\">surname:Gayle;given-names:AA</infon><infon key=\"name_2\">surname:Wilder-Smith;given-names:A</infon><infon key=\"name_3\">surname:Rocklov;given-names:J</infon><infon key=\"pub-id_doi\">10.1093/jtm/taaa021</infon><infon key=\"pub-id_pmid\">32052846</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Travel Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">27</infon><infon key=\"year\">2020</infon><offset>47065</offset><text>The reproductive number of COVID-19 is higher compared to SARS coronavirus</text></passage><passage><infon key=\"fpage\">747</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">756</infon><infon key=\"name_0\">surname:Loeffelholz;given-names:MJ</infon><infon key=\"name_1\">surname:Tang;given-names:YW</infon><infon key=\"pub-id_doi\">10.1080/22221751.2020.1745095</infon><infon key=\"pub-id_pmid\">32196430</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>47140</offset><text>Laboratory diagnosis of emerging human coronavirus infections - the state of the art</text></passage><passage><infon key=\"fpage\">1200</infon><infon key=\"lpage\">1204</infon><infon key=\"name_0\">surname:Long;given-names:QX</infon><infon key=\"name_1\">surname:Tang;given-names:XJ</infon><infon key=\"name_10\">surname:Su;given-names:K</infon><infon key=\"name_11\">surname:Zhang;given-names:F</infon><infon key=\"name_12\">surname:Gong;given-names:J</infon><infon key=\"name_13\">surname:Wu;given-names:B</infon><infon key=\"name_14\">surname:Liu;given-names:XM</infon><infon key=\"name_15\">surname:Li;given-names:JJ</infon><infon key=\"name_16\">surname:Qiu;given-names:JF</infon><infon key=\"name_17\">surname:Chen;given-names:J</infon><infon key=\"name_18\">surname:Huang;given-names:AL</infon><infon key=\"name_2\">surname:Shi;given-names:QL</infon><infon key=\"name_3\">surname:Li;given-names:Q</infon><infon key=\"name_4\">surname:Deng;given-names:HJ</infon><infon key=\"name_5\">surname:Yuan;given-names:J</infon><infon key=\"name_6\">surname:Hu;given-names:JL</infon><infon key=\"name_7\">surname:Xu;given-names:W</infon><infon key=\"name_8\">surname:Zhang;given-names:Y</infon><infon key=\"name_9\">surname:Lv;given-names:FJ</infon><infon key=\"pub-id_doi\">10.1038/s41591-020-0965-6</infon><infon key=\"pub-id_pmid\">32555424</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>47225</offset><text>Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections</text></passage><passage><infon key=\"fpage\">565</infon><infon key=\"issue\">10224</infon><infon key=\"lpage\">574</infon><infon key=\"name_0\">surname:Lu;given-names:R</infon><infon key=\"name_1\">surname:Zhao;given-names:X</infon><infon key=\"name_10\">surname:Bi;given-names:Y</infon><infon key=\"name_11\">surname:Ma;given-names:X</infon><infon key=\"name_12\">surname:Zhan;given-names:F</infon><infon key=\"name_13\">surname:Wang;given-names:L</infon><infon key=\"name_14\">surname:Hu;given-names:T</infon><infon key=\"name_15\">surname:Zhou;given-names:H</infon><infon key=\"name_16\">surname:Hu;given-names:Z</infon><infon key=\"name_17\">surname:Zhou;given-names:W</infon><infon key=\"name_18\">surname:Zhao;given-names:L</infon><infon key=\"name_19\">surname:Chen;given-names:J</infon><infon key=\"name_2\">surname:Li;given-names:J</infon><infon key=\"name_20\">surname:Meng;given-names:Y</infon><infon key=\"name_21\">surname:Wang;given-names:J</infon><infon key=\"name_22\">surname:Lin;given-names:Y</infon><infon key=\"name_23\">surname:Yuan;given-names:J</infon><infon key=\"name_24\">surname:Xie;given-names:Z</infon><infon key=\"name_25\">surname:Ma;given-names:J</infon><infon key=\"name_26\">surname:Liu;given-names:WJ</infon><infon key=\"name_27\">surname:Wang;given-names:D</infon><infon key=\"name_28\">surname:Xu;given-names:W</infon><infon key=\"name_29\">surname:Holmes;given-names:EC</infon><infon key=\"name_3\">surname:Niu;given-names:P</infon><infon key=\"name_30\">surname:Gao;given-names:GF</infon><infon key=\"name_31\">surname:Wu;given-names:G</infon><infon key=\"name_32\">surname:Chen;given-names:W</infon><infon key=\"name_33\">surname:Shi;given-names:W</infon><infon key=\"name_34\">surname:Tan;given-names:W</infon><infon key=\"name_4\">surname:Yang;given-names:B</infon><infon key=\"name_5\">surname:Wu;given-names:H</infon><infon key=\"name_6\">surname:Wang;given-names:W</infon><infon key=\"name_7\">surname:Song;given-names:H</infon><infon key=\"name_8\">surname:Huang;given-names:B</infon><infon key=\"name_9\">surname:Zhu;given-names:N</infon><infon key=\"pub-id_doi\">10.1016/S0140-6736(20)30251-8</infon><infon key=\"pub-id_pmid\">32007145</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>47301</offset><text>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</text></passage><passage><infon key=\"fpage\">904</infon><infon key=\"issue\">9</infon><infon key=\"lpage\">906</infon><infon key=\"name_0\">surname:Memish;given-names:ZA</infon><infon key=\"name_1\">surname:Al-Tawfiq;given-names:JA</infon><infon key=\"name_10\">surname:Al-Rabeeah;given-names:AA</infon><infon key=\"name_2\">surname:Assiri;given-names:A</infon><infon key=\"name_3\">surname:AlRabiah;given-names:FA</infon><infon key=\"name_4\">surname:Al Hajjar;given-names:S</infon><infon key=\"name_5\">surname:Albarrak;given-names:A</infon><infon key=\"name_6\">surname:Flemban;given-names:H</infon><infon key=\"name_7\">surname:Alhakeem;given-names:RF</infon><infon key=\"name_8\">surname:Makhdoom;given-names:HQ</infon><infon key=\"name_9\">surname:Alsubaie;given-names:S</infon><infon key=\"pub-id_doi\">10.1097/INF.0000000000000325</infon><infon key=\"pub-id_pmid\">24763193</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pediatr Infect Dis J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">33</infon><infon key=\"year\">2014</infon><offset>47422</offset><text>Middle East respiratory syndrome coronavirus disease in children</text></passage><passage><infon key=\"fpage\">225</infon><infon key=\"name_0\">surname:Mertens;given-names:P</infon><infon key=\"name_1\">surname:De Vos;given-names:N</infon><infon key=\"name_10\">surname:Yin;given-names:N</infon><infon key=\"name_11\">surname:Mileto;given-names:D</infon><infon key=\"name_12\">surname:Delaunoy;given-names:S</infon><infon key=\"name_13\">surname:Magein;given-names:H</infon><infon key=\"name_14\">surname:Lagrou;given-names:K</infon><infon key=\"name_15\">surname:Bouzet;given-names:J</infon><infon key=\"name_16\">surname:Serrano;given-names:G</infon><infon key=\"name_17\">surname:Wautier;given-names:M</infon><infon key=\"name_18\">surname:Leclipteux;given-names:T</infon><infon key=\"name_19\">surname:Van Ranst;given-names:M</infon><infon key=\"name_2\">surname:Martiny;given-names:D</infon><infon key=\"name_20\">surname:Vandenberg;given-names:O</infon><infon key=\"name_3\">surname:Jassoy;given-names:C</infon><infon key=\"name_4\">surname:Mirazimi;given-names:A</infon><infon key=\"name_5\">surname:Cuypers;given-names:L</infon><infon key=\"name_6\">surname:Van den Wijngaert;given-names:S</infon><infon key=\"name_7\">surname:Monteil;given-names:V</infon><infon key=\"name_8\">surname:Melin;given-names:P</infon><infon key=\"name_9\">surname:Stoffels;given-names:K</infon><infon key=\"pub-id_doi\">10.3389/fmed.2020.00225</infon><infon key=\"pub-id_pmid\">32574326</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Front Med (Lausanne)</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2020</infon><offset>47487</offset><text>Development and potential usefulness of the COVID-19 Ag Respi-Strip diagnostic assay in a pandemic context</text></passage><passage><infon key=\"fpage\">104413</infon><infon key=\"name_0\">surname:Montesinos;given-names:I</infon><infon key=\"name_1\">surname:Gruson;given-names:D</infon><infon key=\"name_10\">surname:Rodriguez-Villalobos;given-names:H</infon><infon key=\"name_2\">surname:Kabamba;given-names:B</infon><infon key=\"name_3\">surname:Dahma;given-names:H</infon><infon key=\"name_4\">surname:Van den Wijngaert;given-names:S</infon><infon key=\"name_5\">surname:Reza;given-names:S</infon><infon key=\"name_6\">surname:Carbone;given-names:V</infon><infon key=\"name_7\">surname:Vandenberg;given-names:O</infon><infon key=\"name_8\">surname:Gulbis;given-names:B</infon><infon key=\"name_9\">surname:Wolff;given-names:F</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104413</infon><infon key=\"pub-id_pmid\">32403010</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">128</infon><infon key=\"year\">2020</infon><offset>47594</offset><text>Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>47712</offset><text>Moore SC, Penrice-Randal R, Alruwaili M, Dong X, Pullan ST, Carter D, Bewley K, Zhao Q, Sun Y, Hartley C, Zhou EM (2020) Amplicon based MinION sequencing of SARS-CoV-2 and metagenomic characterisation of nasopharyngeal swabs from patients with COVID-19. medRxiv</text></passage><passage><infon key=\"fpage\">729</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">735</infon><infon key=\"name_0\">surname:Park;given-names:GS</infon><infon key=\"name_1\">surname:Ku;given-names:K</infon><infon key=\"name_2\">surname:Baek;given-names:SH</infon><infon key=\"name_3\">surname:Kim;given-names:SJ</infon><infon key=\"name_4\">surname:Kim;given-names:SI</infon><infon key=\"name_5\">surname:Kim;given-names:BT</infon><infon key=\"name_6\">surname:Maeng;given-names:JS</infon><infon key=\"pub-id_doi\">10.1016/j.jmoldx.2020.03.006</infon><infon key=\"pub-id_pmid\">32276051</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Mol Diagn</infon><infon key=\"type\">ref</infon><infon key=\"volume\">22</infon><infon key=\"year\">2020</infon><offset>47974</offset><text>Development of reverse transcription loop-mediated isothermal amplification assays targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</text></passage><passage><infon key=\"fpage\">439</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">450</infon><infon key=\"name_0\">surname:Perlman;given-names:S</infon><infon key=\"name_1\">surname:Netland;given-names:J</infon><infon key=\"pub-id_doi\">10.1038/nrmicro2147</infon><infon key=\"pub-id_pmid\">19430490</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Rev Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2009</infon><offset>48128</offset><text>Coronaviruses post-SARS: update on replication and pathogenesis</text></passage><passage><infon key=\"fpage\">317</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">319</infon><infon key=\"name_0\">surname:Rao;given-names:TN</infon><infon key=\"name_1\">surname:Paul;given-names:N</infon><infon key=\"name_2\">surname:Chung;given-names:T</infon><infon key=\"name_3\">surname:Mazzulli;given-names:T</infon><infon key=\"name_4\">surname:Walmsley;given-names:S</infon><infon key=\"name_5\">surname:Boylan;given-names:CE</infon><infon key=\"name_6\">surname:Provost;given-names:Y</infon><infon key=\"name_7\">surname:Herman;given-names:SJ</infon><infon key=\"name_8\">surname:Weisbrod;given-names:GL</infon><infon key=\"name_9\">surname:Roberts;given-names:HC</infon><infon key=\"pub-id_doi\">10.2214/ajr.181.2.1810317</infon><infon key=\"pub-id_pmid\">12876004</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">AJR Am J Roentgenol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">181</infon><infon key=\"year\">2003</infon><offset>48192</offset><text>Value of CT in assessing probable severe acute respiratory syndrome</text></passage><passage><infon key=\"fpage\">2000082</infon><infon key=\"issue\">6</infon><infon key=\"name_0\">surname:Reusken;given-names:C</infon><infon key=\"name_1\">surname:Broberg;given-names:EK</infon><infon key=\"name_10\">surname:Erli;given-names:N</infon><infon key=\"name_2\">surname:Haagmans;given-names:B</infon><infon key=\"name_3\">surname:Meijer;given-names:A</infon><infon key=\"name_4\">surname:Corman;given-names:VM</infon><infon key=\"name_5\">surname:Papa;given-names:A</infon><infon key=\"name_6\">surname:Charrel;given-names:R</infon><infon key=\"name_7\">surname:Drosten;given-names:C</infon><infon key=\"name_8\">surname:Koopmans;given-names:M</infon><infon key=\"name_9\">surname:Leitmeyer;given-names:K</infon><infon key=\"pub-id_doi\">10.2807/1560-7917.ES.2020.25.6.2000082</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>48260</offset><text>Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020</text></passage><passage><infon key=\"fpage\">109958</infon><infon key=\"name_0\">surname:Rohit;given-names:A</infon><infon key=\"name_1\">surname:Rajasekaran;given-names:S</infon><infon key=\"name_2\">surname:Karunasagar;given-names:I</infon><infon key=\"name_3\">surname:Karunasagar;given-names:I</infon><infon key=\"pub-id_doi\">10.1016/j.mehy.2020.109958</infon><infon key=\"pub-id_pmid\">32575016</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Med Hypotheses</infon><infon key=\"type\">ref</infon><infon key=\"volume\">144</infon><infon key=\"year\">2020</infon><offset>48388</offset><text>Fate of respiratory droplets in tropical vs temperate environments and implications for SARS-CoV-2 transmission</text></passage><passage><infon key=\"fpage\">490</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">502</infon><infon key=\"name_0\">surname:Su;given-names:S</infon><infon key=\"name_1\">surname:Wong;given-names:G</infon><infon key=\"name_2\">surname:Shi;given-names:W</infon><infon key=\"name_3\">surname:Liu;given-names:J</infon><infon key=\"name_4\">surname:Lai;given-names:ACK</infon><infon key=\"name_5\">surname:Zhou;given-names:J</infon><infon key=\"name_6\">surname:Liu;given-names:W</infon><infon key=\"name_7\">surname:Bi;given-names:Y</infon><infon key=\"name_8\">surname:Gao;given-names:GF</infon><infon key=\"pub-id_doi\">10.1016/j.tim.2016.03.003</infon><infon key=\"pub-id_pmid\">27012512</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Trends Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">24</infon><infon key=\"year\">2016</infon><offset>48500</offset><text>Epidemiology, genetic recombination, and pathogenesis of coronaviruses</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>48571</offset><text>Vogel CBF, Brito AF, Wyllie AL, Fauver JR, Ott IM, Kalinich CC et al (2020) Analytical sensitivity and efficiency comparisons of SARS-COV-2 qRT-PCR primer probe sets. medRxiv. 10.1101/2020.03.30.20048108</text></passage><passage><infon key=\"fpage\">e00127</infon><infon key=\"issue\">7</infon><infon key=\"lpage\">e00120</infon><infon key=\"name_0\">surname:Wan;given-names:Y</infon><infon key=\"name_1\">surname:Shang;given-names:J</infon><infon key=\"name_2\">surname:Graham;given-names:R</infon><infon key=\"name_3\">surname:Baric;given-names:RS</infon><infon key=\"name_4\">surname:Li;given-names:F</infon><infon key=\"pub-id_doi\">10.1128/JVI.00127-20</infon><infon key=\"pub-id_pmid\">31996437</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">94</infon><infon key=\"year\">2020</infon><offset>48775</offset><text>Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus</text></passage><passage><infon key=\"fpage\">470</infon><infon key=\"issue\">10223</infon><infon key=\"lpage\">473</infon><infon key=\"name_0\">surname:Wang;given-names:C</infon><infon key=\"name_1\">surname:Horby;given-names:PW</infon><infon key=\"name_2\">surname:Hayden;given-names:FG</infon><infon key=\"name_3\">surname:Gao;given-names:GF</infon><infon key=\"pub-id_doi\">10.1016/S0140-6736(20)30185-9</infon><infon key=\"pub-id_pmid\">31986257</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>48905</offset><text>A novel coronavirus outbreak of global health concern</text></passage><passage><infon key=\"fpage\">441</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">443</infon><infon key=\"name_0\">surname:Wang;given-names:HB</infon><infon key=\"name_1\">surname:Liu;given-names:JH</infon><infon key=\"name_10\">surname:Yao;given-names:W</infon><infon key=\"name_2\">surname:Ouyang;given-names:XL</infon><infon key=\"name_3\">surname:Yu;given-names:Y</infon><infon key=\"name_4\">surname:Ma;given-names:SX</infon><infon key=\"name_5\">surname:Li;given-names:XJ</infon><infon key=\"name_6\">surname:Lu;given-names:LC</infon><infon key=\"name_7\">surname:Tian;given-names:YP</infon><infon key=\"name_8\">surname:Liu;given-names:HY</infon><infon key=\"name_9\">surname:Xu;given-names:HM</infon><infon key=\"pub-id_pmid\">14575532</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Zhongguo Shi Yan Xue Ye Xue Za Zhi</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2003</infon><offset>48959</offset><text>Detection of the anti-SARS-coronavirus specific antibody levels in 156 SARS patients</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>49044</offset><text>Wang MH, Fu A, Hu B, Tong Y, Liu R, Gu J, Liu J, Jiang W, Shen G, Zhao W, Men D (2020b) Nanopore target sequencing for accurate and comprehensive detection of SARS-CoV-2 and other respiratory viruses. medRxiv</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>49253</offset><text>Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W (2020c) Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 10.1001/jama.2020.3786</text></passage><passage><infon key=\"fpage\">1649</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">1657</infon><infon key=\"name_0\">surname:Wei;given-names:S</infon><infon key=\"name_1\">surname:Weiss;given-names:ZR</infon><infon key=\"name_2\">surname:Williams;given-names:Z</infon><infon key=\"pub-id_doi\">10.1534/g3.118.200087</infon><infon key=\"pub-id_pmid\">29540443</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">G3 (Bethesda)</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2018</infon><offset>49402</offset><text>Rapid multiplex small dna sequencing on the MinION nanopore sequencing platform</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>49482</offset><text>Weihua Y, Xiaofei D, Qingxi W, Mingjie X, Qianqian Z, Yunying Z, Huailong Z, Li W, Yihui X, Jun W, Shuyi H, Min W, Fengyan P, Yunshan W (2020) Rapid detection of SARS-CoV-2 using reverse transcription RT-LAMP method. medRxiv</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>49707</offset><text>WHO (2020) Coronavirus disease 2019 (COVID-19) Situation report -184 2020. World Health Organization Accessed July 23, 2020.</text></passage><passage><infon key=\"fpage\">6783</infon><infon key=\"issue\">10</infon><infon key=\"lpage\">6789</infon><infon key=\"name_0\">surname:Wilson;given-names:BD</infon><infon key=\"name_1\">surname:Eisenstein;given-names:M</infon><infon key=\"name_2\">surname:Soh;given-names:HT</infon><infon key=\"pub-id_doi\">10.1021/acs.analchem.9b00856</infon><infon key=\"pub-id_pmid\">31038923</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Anal Chem</infon><infon key=\"type\">ref</infon><infon key=\"volume\">91</infon><infon key=\"year\">2019</infon><offset>49832</offset><text>High-fidelity nanopore sequencing of ultra-short DNA targets</text></passage><passage><infon key=\"fpage\">E72</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">E78</infon><infon key=\"name_0\">surname:Wong;given-names:HYF</infon><infon key=\"name_1\">surname:Lam;given-names:HYS</infon><infon key=\"name_10\">surname:Lee;given-names:EYP</infon><infon key=\"name_11\">surname:Wan;given-names:EYF</infon><infon key=\"name_12\">surname:Hung;given-names:FNI</infon><infon key=\"name_13\">surname:Lam;given-names:TPW</infon><infon key=\"name_14\">surname:Kuo;given-names:M</infon><infon key=\"name_15\">surname:Ng;given-names:MY</infon><infon key=\"name_2\">surname:Fong;given-names:AH</infon><infon key=\"name_3\">surname:Leung;given-names:ST</infon><infon key=\"name_4\">surname:Chin;given-names:TW</infon><infon key=\"name_5\">surname:Lo;given-names:CSY</infon><infon key=\"name_6\">surname:Lui;given-names:MM</infon><infon key=\"name_7\">surname:Lee;given-names:JCY</infon><infon key=\"name_8\">surname:Chiu;given-names:KW</infon><infon key=\"name_9\">surname:Chung;given-names:T</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020201160</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">296</infon><infon key=\"year\">2019</infon><offset>49893</offset><text>Frequency and Distribution of Chest Radiographic Findings in COVID-19 Positive Patients</text></passage><passage><infon key=\"fpage\">265</infon><infon key=\"issue\">7798</infon><infon key=\"lpage\">269</infon><infon key=\"name_0\">surname:Wu;given-names:F</infon><infon key=\"name_1\">surname:Zhao;given-names:S</infon><infon key=\"name_10\">surname:Yuan;given-names:ML</infon><infon key=\"name_11\">surname:Zhang;given-names:YL</infon><infon key=\"name_12\">surname:Dai;given-names:FH</infon><infon key=\"name_13\">surname:Liu;given-names:Y</infon><infon key=\"name_14\">surname:Wang;given-names:QM</infon><infon key=\"name_15\">surname:Zheng;given-names:JJ</infon><infon key=\"name_16\">surname:Xu;given-names:L</infon><infon key=\"name_17\">surname:Holmes;given-names:EC</infon><infon key=\"name_18\">surname:Zhang;given-names:YZ</infon><infon key=\"name_2\">surname:Yu;given-names:B</infon><infon key=\"name_3\">surname:Chen;given-names:YM</infon><infon key=\"name_4\">surname:Wang;given-names:W</infon><infon key=\"name_5\">surname:Song;given-names:ZG</infon><infon key=\"name_6\">surname:Hu;given-names:Y</infon><infon key=\"name_7\">surname:Tao;given-names:ZW</infon><infon key=\"name_8\">surname:Tian;given-names:JH</infon><infon key=\"name_9\">surname:Pei;given-names:YY</infon><infon key=\"pub-id_doi\">10.1038/s41586-020-2008-3</infon><infon key=\"pub-id_pmid\">32015508</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">579</infon><infon key=\"year\">2020</infon><offset>49981</offset><text>A new coronavirus associated with human respiratory disease in China</text></passage><passage><infon key=\"fpage\">773</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">779</infon><infon key=\"name_0\">surname:Yan;given-names:C</infon><infon key=\"name_1\">surname:Cui;given-names:J</infon><infon key=\"name_10\">surname:Yao;given-names:H</infon><infon key=\"name_11\">surname:Li;given-names:N</infon><infon key=\"name_12\">surname:Zhao;given-names:H</infon><infon key=\"name_13\">surname:Feng;given-names:Y</infon><infon key=\"name_14\">surname:Liu;given-names:S</infon><infon key=\"name_15\">surname:Zhang;given-names:Q</infon><infon key=\"name_16\">surname:Liu;given-names:D</infon><infon key=\"name_17\">surname:Yuan;given-names:J</infon><infon key=\"name_2\">surname:Huang;given-names:L</infon><infon key=\"name_3\">surname:Du;given-names:B</infon><infon key=\"name_4\">surname:Chen;given-names:L</infon><infon key=\"name_5\">surname:Xue;given-names:G</infon><infon key=\"name_6\">surname:Li;given-names:S</infon><infon key=\"name_7\">surname:Zhang;given-names:W</infon><infon key=\"name_8\">surname:Zhao;given-names:L</infon><infon key=\"name_9\">surname:Sun;given-names:Y</infon><infon key=\"pub-id_doi\">10.1016/j.cmi.2020.04.001</infon><infon key=\"pub-id_pmid\">32276116</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>50050</offset><text>Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay</text></passage><passage><infon key=\"fpage\">975</infon><infon key=\"lpage\">977</infon><infon key=\"name_0\">surname:Yu;given-names:L</infon><infon key=\"name_1\">surname:Wu;given-names:S</infon><infon key=\"name_2\">surname:Hao;given-names:X</infon><infon key=\"name_3\">surname:Dong;given-names:X</infon><infon key=\"name_4\">surname:Mao;given-names:L</infon><infon key=\"name_5\">surname:Pelechano;given-names:V</infon><infon key=\"name_6\">surname:Chen;given-names:WH</infon><infon key=\"name_7\">surname:Yin;given-names:X</infon><infon key=\"pub-id_doi\">10.1093/clinchem/hvaa102</infon><infon key=\"pub-id_pmid\">32315390</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Chem</infon><infon key=\"type\">ref</infon><infon key=\"volume\">66</infon><infon key=\"year\">2020</infon><offset>50188</offset><text>Rapid detection of COVID-19 coronavirus using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>50329</offset><text>Zhang F, Abudayyeh OO, Gootenberg JS (2020a) A protocol for detection of COVID-19 using CRISPR diagnostics. Broad Institute webpage. https://www.broadinstitute.org/files/publications/special/ COVID-19%20detection%20(updated).pdf</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>50558</offset><text>Zhang Y, Odiwuor N, Xiong J, Sun L, Nyaruaba RO, Wei H, Tanner NA (2020b) Rapid molecular detection of SARS-CoV-2 (COVID-19) virus RNA using colorimetric LAMP. MedRxiv</text></passage><passage><infon key=\"fpage\">1177</infon><infon key=\"issue\">12</infon><infon key=\"lpage\">1179</infon><infon key=\"name_0\">surname:Zou;given-names:L</infon><infon key=\"name_1\">surname:Ruan;given-names:F</infon><infon key=\"name_10\">surname:Guo;given-names:Q</infon><infon key=\"name_11\">surname:Song;given-names:T</infon><infon key=\"name_12\">surname:He;given-names:J</infon><infon key=\"name_13\">surname:Yen;given-names:HL</infon><infon key=\"name_14\">surname:Peiris;given-names:M</infon><infon key=\"name_15\">surname:Wu;given-names:J</infon><infon key=\"name_2\">surname:Huang;given-names:M</infon><infon key=\"name_3\">surname:Liang;given-names:L</infon><infon key=\"name_4\">surname:Huang;given-names:H</infon><infon key=\"name_5\">surname:Hong;given-names:Z</infon><infon key=\"name_6\">surname:Yu;given-names:J</infon><infon key=\"name_7\">surname:Kang;given-names:M</infon><infon key=\"name_8\">surname:Song;given-names:Y</infon><infon key=\"name_9\">surname:Xia;given-names:J</infon><infon key=\"pub-id_doi\">10.1056/NEJMc2001737</infon><infon key=\"pub-id_pmid\">32074444</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>50726</offset><text>SARS-CoV-2 viral load in upper respiratory specimens of infected patients</text></passage></document></collection>\n",
      "\n",
      "Study 33666147: <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n",
      "<!DOCTYPE collection SYSTEM \"BioC.dtd\">\n",
      "<collection><source>PMC</source><date>20230211</date><key>pmc.key</key><document><id>8006950</id><infon key=\"license\">CC BY</infon><passage><infon key=\"alt-title\">Emerging Microbes &amp; Infections K. K-W. To et al.</infon><infon key=\"article-id_doi\">10.1080/22221751.2021.1898291</infon><infon key=\"article-id_pmc\">8006950</infon><infon key=\"article-id_pmid\">33666147</infon><infon key=\"article-id_publisher-id\">1898291</infon><infon key=\"fpage\">507</infon><infon key=\"issue\">1</infon><infon key=\"kwd\">Coronavirus COVID-19 SARS-CoV-2 Pandemic Pathogenesis Diagnostics Treatment Vaccines</infon><infon key=\"license\">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</infon><infon key=\"lpage\">535</infon><infon key=\"name_0\">surname:To;given-names:Kelvin Kai-Wang</infon><infon key=\"name_1\">surname:Sridhar;given-names:Siddharth</infon><infon key=\"name_10\">surname:Cheng;given-names:Vincent Chi-Chung</infon><infon key=\"name_11\">surname:Yuen;given-names:Kwok-Yung</infon><infon key=\"name_2\">surname:Chiu;given-names:Kelvin Hei-Yeung</infon><infon key=\"name_3\">surname:Hung;given-names:Derek Ling-Lung</infon><infon key=\"name_4\">surname:Li;given-names:Xin</infon><infon key=\"name_5\">surname:Hung;given-names:Ivan Fan-Ngai</infon><infon key=\"name_6\">surname:Tam;given-names:Anthony Raymond</infon><infon key=\"name_7\">surname:Chung;given-names:Tom Wai-Hin</infon><infon key=\"name_8\">surname:Chan;given-names:Jasper Fuk-Woo</infon><infon key=\"name_9\">surname:Zhang;given-names:Anna Jian-Xia</infon><infon key=\"section_type\">TITLE</infon><infon key=\"title\">KEYWORDS</infon><infon key=\"type\">front</infon><infon key=\"volume\">10</infon><infon key=\"year\">2021</infon><offset>0</offset><text>Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>79</offset><text>ABSTRACT</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>88</offset><text>Without modern medical management and vaccines, the severity of the Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) might approach the magnitude of 1894-plague (12 million deaths) and 1918-A(H1N1) influenza (50 million deaths) pandemics. The COVID-19 pandemic was heralded by the 2003 SARS epidemic which led to the discovery of human and civet SARS-CoV-1, bat SARS-related-CoVs, Middle East respiratory syndrome (MERS)-related bat CoV HKU4 and HKU5, and other novel animal coronaviruses. The suspected animal-to-human jumping of 4 betacoronaviruses including the human coronaviruses OC43(1890), SARS-CoV-1(2003), MERS-CoV(2012), and SARS-CoV-2(2019) indicates their significant pandemic potential. The presence of a large reservoir of coronaviruses in bats and other wild mammals, culture of mixing and selling them in urban markets with suboptimal hygiene, habit of eating exotic mammals in highly populated areas, and the rapid and frequent air travels from these areas are perfect ingredients for brewing rapidly exploding epidemics. The possibility of emergence of a hypothetical SARS-CoV-3 or other novel viruses from animals or laboratories, and therefore needs for global preparedness should not be ignored. We reviewed representative publications on the epidemiology, virology, clinical manifestations, pathology, laboratory diagnostics, treatment, vaccination, and infection control of COVID-19 as of 20 January 2021, which is 1 year after person-to-person transmission of SARS-CoV-2 was announced. The difficulties of mass testing, labour-intensive contact tracing, importance of compliance to universal masking, low efficacy of antiviral treatment for severe disease, possibilities of vaccine or antiviral-resistant virus variants and SARS-CoV-2 becoming another common cold coronavirus are discussed.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>1977</offset><text>The chronology of the pandemic</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>2008</offset><text>An outbreak of acute community-acquired atypical pneumonia of unknown aetiology was reported in Wuhan, the capital of Hubei province in central China, in December 2019. The initial cluster of cases was related to the Huanan seafood wholesale market where wild game animals were also sold. During subsequent investigation, severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) was detected in 33 out of 585 environmental samples taken from the market. However, 45% of the cases with onset before 1 January 2020 had no apparent link to this market. Retrospective molecular clock inference studies using phylogenetic analysis suggested that the earliest cases likely emerged between October and November 2019. The culprit virus was identified using next-generation sequencing (NGS) on bronchoalveolar lavage fluids of three Wuhan patients. The complete genome sequences of SARS-CoV-2 clustered in a distinct clade from SARS-CoV within the genus Sarbecovirus. The draft genome sequence was released on 10 January 2020, 10 days after the outbreak was announced.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>3079</offset><text>As an escalating number of local cases was reported in Wuhan, a family cluster was identified in Shenzhen, a city in southern China 550 miles from Wuhan, between 10 and 15 January 2020. Six members of this family had returned from a trip to Wuhan between 29 December 2019 and 4 January 2020. Two of them visited a local hospital where a paediatric relative was hospitalized for pneumonia. Five of these six family members were clinically and/or virologically diagnosed with Coronavirus Disease 2019 (COVID-19) after returning to Shenzhen. In addition, a seventh family member, who did not go to Wuhan or visit wet markets in the preceding 14 days, became infected after staying in the same household with infected relatives. This familial cluster provided clear evidence of person-to-person transmission and inter-city spread by air travel. Furthermore, the report of an imported case in Thailand on 13 January 2020, and subsequently other countries suggested that global dissemination might have occurred earlier by frequent air travel.</text></passage><passage><infon key=\"file\">TEMI_A_1898291_F0001_PB.jpg</infon><infon key=\"id\">F0001</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>4117</offset><text>Chronology of events leading to the COVID-19 pandemic.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>4172</offset><text>By the end of January 2020, SARS-CoV-2 was reported in 31 provinces in China, across East and Southeast Asia, and to Europe and the United States. Community transmission was detected in other Asian countries, a large part of Europe, the Middle East and the United States since February 2020. Figure 1 gives a detailed account of the unfolding of the pandemic. By April 2020, the total number of COVID-19 cases surpassed 1 million as more and more countries entered partial or nation-wide lock down. The death toll due to COVID-19 reached 1 million on 25 September 2020. By 22 December 2020, with the Chilean army reporting 36 cases at its research station in Antarctica, COVID-19 cases have been reported to affect all seven continents. As of 4 February 2021, there have been more than 103 million confirmed cases with over 2 million deaths. </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>5015</offset><text>Taxonomy, genomic organization, and replication cycle of SARS-CoV-2</text></passage><passage><infon key=\"file\">T0001.xml</infon><infon key=\"id\">T0001</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>5083</offset><text>SARS-CoV-2 gene products.</text></passage><passage><infon key=\"file\">T0001.xml</infon><infon key=\"id\">T0001</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;colgroup&gt;&lt;col width=&quot;1*&quot;/&gt;&lt;col width=&quot;1*&quot;/&gt;&lt;col width=&quot;1*&quot;/&gt;&lt;/colgroup&gt;&lt;thead valign=&quot;bottom&quot;&gt;&lt;tr&gt;&lt;th align=&quot;left&quot;&gt;Gene product&lt;/th&gt;&lt;th align=&quot;center&quot;&gt;Putative primary function&lt;/th&gt;&lt;th align=&quot;center&quot;&gt;Role in pathogenesis&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Nsp1&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Inhibit host protein translation; Degradation of host mRNA and disruption of mRNA export machinery to inhibit host gene gene expression&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Suppression of interferon response&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Nsp2&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Unknown&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Nsp3&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Polyprotein processing, de-ADP ribosylation, deubiquitination, interferon antagonist, formation of double membrane vesicles&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Nsp4&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Formation of double membrane vesicles associated with replication complexes&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Nsp5&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3C-like protease domain, polyprotein processing&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Inhibit interferon signalling&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Nsp6&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Formation of double membrane vesicles associated with replication complexes&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Interferon antagonist&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Nsp7&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Accessory subunit of RNA-dependent RNA polymerase&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Nsp8&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Accessory subunit of RNA-dependent RNA polymerase; primase or 3â² terminal adenylyltransferase&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Nsp9&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;RNA-binding protein with a peptide binding site &lt;xref rid=&quot;CIT0048&quot; ref-type=&quot;bibr&quot;&gt;48&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Nsp10&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Co-factor of nsp14 and nsp16 for methyltransferase activity&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Interacts with NF-ÎºB-repressing factor to facilitate interleukin-8 (IL-8) induction, which potentially increase IL-8-mediated chemotaxis of neutrophils and overexuberant host inflammation &lt;xref rid=&quot;CIT0049&quot; ref-type=&quot;bibr&quot;&gt;49&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Nsp11&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Unknown&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Nsp12&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;RNA-dependent RNA polymerase, nucleotidyltransferase&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Nsp13&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Helicase&lt;break/&gt;RNA 5â² triphosphatase&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Potent interferon antagonist&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Nsp14&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Proof-reading exonuclease&lt;break/&gt;RNA cap formation guanosine N7-methyltransferase&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Potent interferon antagonist&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Nsp15&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Endoribonuclease Interferon antagonist&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Potent interferon antagonist&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Nsp16&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Ribose 2â²-O-Methyltransferase, RNA cap formation&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;S&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Binds to host cell receptor&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;ORF3a&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Induce apoptosis &lt;xref rid=&quot;CIT0026&quot; ref-type=&quot;bibr&quot;&gt;26&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;ORF3b&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Interferon antagonist &lt;xref rid=&quot;CIT0033&quot; ref-type=&quot;bibr&quot;&gt;33&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;E&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Envelope forms a homopentameric cation channel&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;May conduct Ca2+ out of the ERGIC lumen to activate the host inflammasome &lt;xref rid=&quot;CIT0023&quot; ref-type=&quot;bibr&quot;&gt;23&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;M&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Membrane&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Inhibit type 1 and III interferon production by direct interaction with RIG-I/MDA-5 and impeding downstream signalling &lt;xref rid=&quot;CIT0024&quot; ref-type=&quot;bibr&quot;&gt;24&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;ORF6&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Potent interferon antagonist (block STAT1 and STAT2 nuclear translocation) &lt;xref rid=&quot;CIT0029&quot; ref-type=&quot;bibr&quot;&gt;29&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;ORF7a/b&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Unknown&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;ORF8&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Downregulation of MHC-1, binds IL-17RA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Inhibit interferon pathway&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;N&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Viral RNA genome protection and packaging, Virus particle release&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;ORF9b&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Interacts with host protein TOM70 &lt;xref rid=&quot;CIT0030&quot; ref-type=&quot;bibr&quot;&gt;30&lt;/xref&gt;&lt;xref rid=&quot;CIT0035&quot; ref-type=&quot;bibr&quot;&gt;35&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Inhibit type I interferon &lt;xref rid=&quot;CIT0035&quot; ref-type=&quot;bibr&quot;&gt;35&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;ORF10&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Unknown; suspected membrane protein forming viroporin &lt;xref rid=&quot;CIT0036&quot; ref-type=&quot;bibr&quot;&gt;36&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>5109</offset><text>Gene product\tPutative primary function\tRole in pathogenesis\t \tNsp1\tInhibit host protein translation; Degradation of host mRNA and disruption of mRNA export machinery to inhibit host gene gene expression\tSuppression of interferon response\t \tNsp2\tUnknown\tÂ \t \tNsp3\tPolyprotein processing, de-ADP ribosylation, deubiquitination, interferon antagonist, formation of double membrane vesicles\tÂ \t \tNsp4\tFormation of double membrane vesicles associated with replication complexes\tÂ \t \tNsp5\t3C-like protease domain, polyprotein processing\tInhibit interferon signalling\t \tNsp6\tFormation of double membrane vesicles associated with replication complexes\tInterferon antagonist\t \tNsp7\tAccessory subunit of RNA-dependent RNA polymerase\tÂ \t \tNsp8\tAccessory subunit of RNA-dependent RNA polymerase; primase or 3â² terminal adenylyltransferase\tÂ \t \tNsp9\tRNA-binding protein with a peptide binding site \tÂ \t \tNsp10\tCo-factor of nsp14 and nsp16 for methyltransferase activity\tInteracts with NF-ÎºB-repressing factor to facilitate interleukin-8 (IL-8) induction, which potentially increase IL-8-mediated chemotaxis of neutrophils and overexuberant host inflammation \t \tNsp11\tUnknown\tÂ \t \tNsp12\tRNA-dependent RNA polymerase, nucleotidyltransferase\tÂ \t \tNsp13\tHelicaseRNA 5â² triphosphatase\tPotent interferon antagonist\t \tNsp14\tProof-reading exonucleaseRNA cap formation guanosine N7-methyltransferase\tPotent interferon antagonist\t \tNsp15\tEndoribonuclease Interferon antagonist\tPotent interferon antagonist\t \tNsp16\tRibose 2â²-O-Methyltransferase, RNA cap formation\tÂ \t \tS\tBinds to host cell receptor\tÂ \t \tORF3a\tÂ \tInduce apoptosis \t \tORF3b\tÂ \tInterferon antagonist \t \tE\tEnvelope forms a homopentameric cation channel\tMay conduct Ca2+ out of the ERGIC lumen to activate the host inflammasome \t \tM\tMembrane\tInhibit type 1 and III interferon production by direct interaction with RIG-I/MDA-5 and impeding downstream signalling \t \tORF6\tÂ \tPotent interferon antagonist (block STAT1 and STAT2 nuclear translocation) \t \tORF7a/b\tUnknown\tÂ \t \tORF8\tDownregulation of MHC-1, binds IL-17RA\tInhibit interferon pathway\t \tN\tViral RNA genome protection and packaging, Virus particle release\tÂ \t \tORF9b\tInteracts with host protein TOM70 \tInhibit type I interferon \t \tORF10\tUnknown; suspected membrane protein forming viroporin \tÂ \t \t</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>7408</offset><text>SARS-CoV-2 belongs to the Betacoronavirus genus of the family Coronaviridae. This genus also includes the human respiratory pathogens SARS-CoV-1, Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), human coronavirus (HCoV)-HKU1, and HCoV-OC43. Together with the closely related bat coronavirus RaTG13 and SARS-CoV-1, SARS-CoV-2 is classified as a member of the Sarbecovirus subgenus of SARS-related coronaviruses. Rapid characterization of SARS-CoV-2 by electron microscopy and NGS confirmed that it shared the structural features and genomic organization of other betacoronaviruses. It is a pleomorphic enveloped virus (size range: 60â140â",
      "nm) studded with distinctive surface spikes. The positive-sense single-stranded RNA genome of SARS-CoV-2 is around 29â30 kB in size and is organized as methyl-capped-5âUTR-ORF1a/b-S-ORF3-E-M-ORF6-ORF7a/b-ORF8-N/ORF9b-ORF10-3âUTR-poly A tail (Table 1). One of the earliest published genome, hCoV-19/Wuhan/IVDC-HB-01/2019 (GISAID accession number (EPI_ISL_402119), has a genome size of 29,891â",
      "bp. A study using ribosome profiling techniques showed the presence of additional upstream and internal open reading frames (ORFs). The genome lacks the hemagglutinin esterase gene found in some other betacoronaviruses. ORF1ab, which comprises two-thirds of the entire genome, encodes a large polyprotein pp1ab, which is proteolytically cleaved into 16 non-structural proteins (Nsps) critical for viral replication. Towards the 3â² end of the genome, the S, E, M, and N genes encode key structural proteins found in the mature virion. The spike (S) glycoprotein forms trimers on the virion surface and binds to human angiotensin-converting enzyme 2 (ACE2) receptor for cell entry. It contains two subunits S1 and S2 with a polybasic site PRRA at the junction, which enables effective cleavage by furin and other proteases. This multibasic cleavage site appears to be an important virulence factor which may enhance virus replication and multiple tissue tropism as in the case of avian influenza A(H5N1) virus. Mutations in this site can attenuate pathogenicity in animal models and may be an attractive option for designing live attenuated vaccines. Another cleavage site, called S2â, is located within the S2 region, and is cleaved by the transmembrane serine protease 2 (TMPRSS2). S protein contains major immunogenic epitopes, particularly concentrated in the N-terminal domain (NTD) and receptor binding domain (RBD) of the S1 subunit, which are targets of neutralizing antibodies. The envelope (E) protein likely forms a viroporin, which is important for virus assembly and release, and is also a putative virulence determinant. The membrane (M) protein is an abundantly expressed structural protein within the lipid envelope that is also important for viral morphogenesis and interferon suppression. Finally, the nucleocapsid protein (N) stabilizes the RNA genome in a helical complex and serves as a key target of adaptive immunity. In addition, there are a number of accessory proteins, the function of some of which remains unknown. ORF3a may function as an inducer of apoptosis. Both ORF6 and ORF8 are involved in interferon antagonism while ORF7a may be involved in inhibiting cellular translation. ORF8 can bind to IL-17 receptor A (IL17RA) which may modulate the inflammatory response, and higher blood levels of soluble IL17A has been associated with milder disease. Interestingly, circulating variants with loss-of-function deletions in SARS-CoV-2 ORF3b, ORF7a/7b, and ORF8 have been found, indicating that these are not absolutely essential for viral infection and may be remnants required for infection of an unidentified intermediate host. ORF9b, an accessory protein translated from an alternative open reading frame within the N gene, interacts with the host mitochondrial import receptor protein TOM70 and suppresses type I interferon response. As for ORF10, it appears dispensable for cellular infection. </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>11394</offset><text>Stages of the replication cycle of SARS-CoV-2 have been rapidly inferred from empirical data and extant knowledge of other betacoronaviruses. The first step in cellular infection by SARS-CoV-2 is the binding of S protein to the host cell surface entry factors such as the membrane associated and soluble ACE2 receptor which may be preceded by weaker binding of the S protein to attachment factors such as heparan sulphate. Other entry factors that facilitate attachment or entry include neuropilin-1, the tyrosine-protein kinase receptor UFO (AXL), CD147, high-density lipoprotein (HDL) scavenger receptor B type 1 (SR-B1), integrins, angiotension II receptor 1 (AT1) and vasopressin receptor 2, but their role in natural infection is currently unclear. Proteases such as surface TMPRSS2 and endosomal cathespsin L cleave the S protein to activate SARS-CoV-2 entry by endocytosis and membrane fusion. Within the cell, the virus uncoats to release its genomic RNA into the cytoplasm for translation. The translated pp1a and pp1ab polyproteins are proteolytically cleaved to individual Nsps, many of which form the replicase-transcriptase complex. These complexes are localized within specialized double membrane vesicles (DMV). Within the DMV system, the complex operates to replicate genomic RNA and transcribe subgenomic RNAs, which are subsequently translated into structural proteins. Viral assembly occurs within the endoplasmic reticulum, Golgi, and intermediate complex (ERGIC) where membranes studded with viral structural proteins interact with N-encapsidated viral genomic RNA. Pre-activation of S protein by host furin protease may occur before mature viruses are released from the cell by exocytosis of secretory vesicles. As in other coronaviruses, subgenomic RNAs are produced, and most subgenomic RNA consists of a leader sequence in the 5â untranslated region of the genome and connected to the S gene or other genes in the 3â end. Hence, translated viral proteins are more abundant towards the 3â end of the genome, which may affect the sensitivity of diagnostic assays using them as targets for RTâPCR or antigen detection. One exception is the nsp1, which has been shown to be highly expressed and was found to be a sensitive target for RTâPCR. Direct RNA sequencing also reveals the presence of non-canonical subgenomic RNAs in which the 5â breakpoint is located within the ORF1a gene. As for the putative structural RNA found in SARS-CoV-2, the 5â² UTR has several stem-loops (SL1â5) which may be involved in mediating viral replication as in other betacoronaviruses. The ORF1a-ORF1b junction has a pseudoknotted structure pivotal for programmed ribosomal frameshifting and translation of the ORF1ab polyprotein. The 3â² UTR has the s2â",
      "m motif, conserved octanucleotide and many unexpected folds.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>14229</offset><text>Virus evolution</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>14245</offset><text>The origin of SARS-CoV-2 is still unknown. Recombination is a frequent event for the viral subgenus Sarbecovirus, which contains SARS-CoV, bat SARS related CoV, and SARS-CoV-2. Some studies suggested that the bat SARS-CoV-2-like coronaviruses are recombinants of lineages related to SARS-CoV and SARS-CoV-2, and SARS-CoV-2 may result from recombinations between these bat SARS related coronavirus and the pangolin SARS related coronavirus. However, another study suggested that recombination may not be involved in the generation of SARS-CoV-2, but the RBD of SARS-CoV-2 shares the same ancestral trait as bat viruses. The divergence date between SARS-CoV-2 and bat sarbecovirus has been estimated to be 1948.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>14955</offset><text>Since its first detection in humans in December 2019, many mutations have been found throughout the SARS-CoV-2 genome. The mutation rate has been estimated to be 1.1âÃâ10â3 nucleotide substitutions per site per year. The time of origin of SARS-CoV-2 was estimated to be late November 2019. The mutation rate is fastest at the S, N, ORF1ab, ORF3a, and ORF8 genes.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>15325</offset><text>In addition to inter-host genetic diversity, mixed viral populations can be present within an individual patient. A variant initially present at low frequency in an individual can become the predominant viral population during the course of illness. In our previous study, we demonstrated the emergence of the S protein W152L mutation in a patient with severe disease. In a study analysing the viral genomes from patients in Austria, an intra-host minor variant was found to be transmitted to others, and become the predominant viral variant in another patient.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>15887</offset><text>Virus mutations and variants</text></passage><passage><infon key=\"file\">TEMI_A_1898291_F0002_PB.jpg</infon><infon key=\"id\">F0002</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>15916</offset><text>(A) Whole genome phylogenetic tree of betacoronaviruses. The tree was constructed by maximum likelihood method with the best-fit substitution model GTRâ+âF+R5 using IQTree2. Bootstrap values were calculated by 500 trees. SARS-CoV-2 are highlighted in red. Human coronavirus 229E (NC_002645) was used as outgroup. (B) Whole genome phylogenetic analysis showing different clades of SARS-CoV-2. The tree was constructed by maximum likelihood method with the best-fit substitution model TIM2+Fâ+âI using IQTree2. Bootstrap values were calculated by 500 trees. Clade information as inferred by Nextstrain or Pango lineage are shown. HK1 is the predominant lineage found during the 2020 summer peak in Hong Kong, while W4 is the predominant lineage that is found in almost all local cases in Hong Kong since November 2020. The reference genome Wuhan-Hu-1 (GenBank accession number MN908947.3) is used as the root of the tree.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>16844</offset><text>SARS-CoV-2 has evolved into different clades and lineages (Figure 2). Currently, there are three major nomenclature systems for the different clades or lineages. The GISAID and Nextstrain systems were used since the beginning of the pandemic, and the clades or lineages are defined by signature mutations. The GISAID clade is currently divided into S, L, and V, and different clades carrying the D614G mutation (G, GH, GR, GV), and O. The Nextstrain is divided into 19 (A, B) and 20 (A-J) according to the year and order when the clade emerged. Although GISAID and Nextstrain nomenclatures are useful in understanding the virus evolution in a macroscopic scale, these systems are not able to delineate more detailed outbreak cluster information. The Pango lineage, first proposed in July 2020, is a dynamic system, which takes into account whether the lineage is actively spreading or not. The Pango lineage system has a much finer resolution than GISAID or Nextstrain, and is particularly useful to capture the emergence of novel variants. </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>17886</offset><text>As the virus evolves, many novel variants have been found. The analysis of viral variants helps epidemiological investigations. For example, whole viral genome analysis during the 2020 summer outbreak in Hong Kong showed that the outbreak was most likely linked to viral variants imported by travellers. Furthermore, variant analysis can be used to identify factors that affect transmissibility or virulence of the virus. In vitro screening using serial passage or site-directed mutagenesis identified mutations in the S protein that allow the virus to escape neutralization by convalescent plasma or infect cells more efficiently.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>18518</offset><text>Long-term SARS-CoV-2 shedding in immunocompromised individuals with acquired hypogammaglobulinemia can lead to a long duration of virus shedding and a larger genetic diversity with continuous turnover of dominant viral species throughout the course of infection. Deletion H69 and V70 in the S protein NTD was reported in a B-cell depleted patient which may be related to selection by convalescent plasma therapy. Furthermore, remdesivir failure with D484Y mutation at RNA dependent RNA-polymerase was also reported in a B-cell immunodeficient patient with protracted SARS-CoV-2 shedding.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>19106</offset><text>Viral variants can also emerge during circulation in animals. Since SARS-CoV-2 can infect many animals naturally or experimentally, there is always a danger of human-to-animal SARS-CoV-2 transmission, followed by the genesis of mutants in animals which then jump back into human. Mink-to-human transmission has been documented in Europe. Furthermore, the S N501Y variant can be selected in virus adaptation experiments using Balb/c mice.</text></passage><passage><infon key=\"file\">T0002.xml</infon><infon key=\"id\">T0002</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>19544</offset><text>Amino acid mutations and nucleotide deletions present in each variant.</text></passage><passage><infon key=\"file\">T0002.xml</infon><infon key=\"id\">T0002</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;colgroup&gt;&lt;col width=&quot;1*&quot;/&gt;&lt;col width=&quot;1*&quot;/&gt;&lt;col width=&quot;1*&quot;/&gt;&lt;col width=&quot;1*&quot;/&gt;&lt;/colgroup&gt;&lt;thead valign=&quot;bottom&quot;&gt;&lt;tr&gt;&lt;th align=&quot;left&quot;&gt;Variant&lt;/th&gt;&lt;th align=&quot;center&quot;&gt;United Kingdom&lt;break/&gt;(VOC-202012/01)&lt;/th&gt;&lt;th align=&quot;center&quot;&gt;South Africa&lt;break/&gt;(501Y.V2)&lt;/th&gt;&lt;th align=&quot;center&quot;&gt;Brazil (VOC202101/02)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Pangolin lineage&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;B.1.1.7&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;B.1.351&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;B.1.1.28.1&lt;break/&gt;(Lineage &lt;italic toggle=&quot;yes&quot;&gt;P&lt;/italic&gt;.1)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Number of countries reported with variant&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;TF2&quot;&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;93&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;45&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;15&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Genes&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;orf1ab&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;T1001I&lt;break/&gt;A1708D&lt;break/&gt;I2230T&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;K1655N&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;S1118L&lt;break/&gt;K1795Q&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Del:11288:9&lt;break/&gt;Del:21765:6&lt;break/&gt;Del:21991:3&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Del:11288-9&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;S&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;N501Y&lt;break/&gt;A570D&lt;break/&gt;P681H&lt;break/&gt;T716I&lt;break/&gt;S982A&lt;break/&gt;D1118H&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;D80A&lt;break/&gt;D215G&lt;break/&gt;K417N&lt;break/&gt;E484K&lt;break/&gt;N501Y&lt;break/&gt;A701V&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;L18F&lt;break/&gt;T20N&lt;break/&gt;P26S&lt;break/&gt;D138Y&lt;break/&gt;R190S&lt;break/&gt;K417T&lt;break/&gt;E484K&lt;break/&gt;N501Y&lt;break/&gt;H655Y&lt;break/&gt;T1027I&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Orf3a&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;td align=&quot;left&quot;&gt;G174C&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Orf8&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Q27*&lt;break/&gt;R52I&lt;break/&gt;Y73C&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;td align=&quot;left&quot;&gt;E92K&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;E&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;td align=&quot;left&quot;&gt;P71L&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;N&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;D3L&lt;break/&gt;S235F&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;T205I&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;P80R&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>19615</offset><text>Variant\tUnited Kingdom(VOC-202012/01)\tSouth Africa(501Y.V2)\tBrazil (VOC202101/02)\t \tPangolin lineage\tB.1.1.7\tB.1.351\tB.1.1.28.1(Lineage P.1)\t \tNumber of countries reported with varianta\t93\t45\t15\t \tGenes\tÂ \tÂ \tÂ \t \torf1ab\tT1001IA1708DI2230T\tK1655N\tS1118LK1795Q\t \tÂ \tDel:11288:9Del:21765:6Del:21991:3\tÂ \tDel:11288-9\t \tS\tN501YA570DP681HT716IS982AD1118H\tD80AD215GK417NE484KN501YA701V\tL18FT20NP26SD138YR190SK417TE484KN501YH655YT1027I\t \tOrf3a\tÂ \tÂ \tG174C\t \tOrf8\tQ27*R52IY73C\tÂ \tE92K\t \tE\tÂ \tP71L\tÂ \t \tN\tD3LS235F\tT205I\tP80R\t \t</text></passage><passage><infon key=\"file\">T0002.xml</infon><infon key=\"id\">T0002</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_footnote</infon><offset>20134</offset><text>* stop codon.</text></passage><passage><infon key=\"file\">T0002.xml</infon><infon key=\"id\">T0002</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_footnote</infon><offset>20148</offset><text>According to the PANGO lineages website https://cov-lineages.org/global_report.html on 21st February 2021.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>20255</offset><text>Several notable variants have emerged since the beginning of the COVID-19 pandemic, including B.1.1.7 (VOC-202012/01), B.1.351 (501Y.V2) and P.1 (VOC202101/02) which were first reported from the United Kingdom, South Africa and Brazil, respectively. These variants usually increase transmissibility and, thereby, rapidly replace existing lineages. Some of these variants share certain critical mutations in the S protein RBD. For example, N501Y is present in the B.1.1.7, B.1.351, and P.1, while E484â",
      "K is present in the B.1.351 and P.1 in addition to N501Y and D614G (Table 2). </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>20837</offset><text>One of the first major variants identified for SARS-CoV-2 were deletions at the S protein S1/S2 junction. These were readily seen during passage in Vero E6 cells. S1/S2 junction deletion variants have been found to be less virulent in a hamster model. S1/S2 junction deleted variants also naturally exist in patientsâ samples before any passage in cell cultures.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>21202</offset><text>ORF8 is a unique protein in SARS-CoV-2 and is found to be immunogenic. However, ORF8-deleted or truncated mutants have been identified frequently. In a Singapore study, patients infected with ORF8-deleted mutants have milder disease than those infected with wild-type SARS-CoV-2. ORF3b deleted mutants have also emerged with the D614G mutation. Truncation of ORF3b confers the loss of its function of interferon antagonism.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>21626</offset><text>D614G mutation was not reported in the initial outbreak in China, but is now found in almost all strains globally. Several studies have evaluated the impact of D614G on the SARS-CoV-2. Collectively, they show that D614G variant replicates to a higher titre in vitro and in vivo, and transmits more efficiently, but does not affect disease severity or confer a significant change in neutralizing activity of convalescent sera. Mechanistically, D614 mutation affects the conformation of the S protein, which allows more efficient binding to the human ACE2 receptor.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>22190</offset><text>There have been multiple outbreaks of SARS-CoV-2 infection among mink farms in Europe. Mink-associated human infections have been identified. A unique lineage has been found in these mink-associated human cases from Denmark, including 4 mutations in the S protein (Î69-70, Y453F, I692â",
      "V, M1229I). Y453 has been shown to be involved in receptor binding. Preliminary investigation with 9 COVID-19 convalescent serum specimens showed a statistically significant reduction in neutralizing antibody titre.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>22695</offset><text>The B.1.1.7 variant was first detected in September 2020, spread rapidly in south-eastern England by December, and has become the predominant variant in the UK. This variant has increased transmissibility and is now found worldwide. This variant is defined by 17 mutations, including a non-synonymous S N501Y at RBD, and the P681H mutation which is located in the furin cleavage site. However, no change in neutralizing activity by sera of vaccine recipients of the BNT162b2 mRNA vaccine was found against pseudoviruses bearing the Wuhan reference strain and the B.1.1.7 variant.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>23275</offset><text>The B.1.351 variant has rapidly increased in South Africa in late 2020. This variant possesses several mutations in S protein NTD (L18F, D80A, D215G, Î242-244, R246I) and RBD (K417N, E484â",
      "K, and N501Y). Monoclonal antibody or nanobody targeting the S protein amino acid positions 417 or 484 showed reduced binding to the B.1.351 variant. Furthermore, neutralizing antibody against the B.1.351 variant could not be detected in 48% of convalescent sera of COVID-19 patients.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>23752</offset><text>The P.1 variant has 17 unique mutations including RBD E484â",
      "K and N501Y mutations has emerged. This is a descendent of the lineage B.1.1.28.1, and now known as the P.1 lineage which is mainly limited to Brazil, but has also been reported in Japan, Korea, and Faroe Islands.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>24027</offset><text>A key concern about viral variants is whether they increase the risk of reinfection or vaccine failures. In the first case of reinfection reported in August 2020, the second episode was caused by a D614G variant. In a reinfection case reported from Brazil, the second episode was caused by the E484â",
      "K variant. Virus carrying the E484â",
      "K was shown to be less susceptible to neutralization by sera from mRNA vaccine recipients.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>24456</offset><text>Transmission routes</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>24476</offset><text>SARS-CoV-2 is believed to spread predominantly via short-range airborne aerosol, respiratory droplets, and direct or indirect contact with infectious respiratory droplets. Airborne transmission of SARS-CoV-2 has been elegantly demonstrated in the hamster model. Low level of SARS-CoV-2 RNA (concentrations in air up to 3.4âÃâ103 RNA copies per m3 air sampled) could be detected in the air samples obtained from the environment housing COVID-19 patients even in the absence of aerosol-generating procedures. Viable SARS-CoV-2 virus could be isolated from air samples collected as far as 4.8 m away from COVID-19 patients with estimated viral concentrations of 6â74 TCID50 units/L of air, substantiating the hypothesis that aerosol dissemination of SARS-CoV-2 may serve as a source of infection. Large quantities of particles, with the majority of less than 5 microns, can be emitted during normal speech, and the amount is positively correlated with the loudness of vocalization. Aerobiological study showed that particles produced in the human respiratory tract represent a continuum of sizes instead of a sharp distinction into respiratory droplet (â¥5 microns) or airborne aerosol (&lt;5 microns). The concentration of respiratory droplets and airborne aerosol carrying SARS-CoV-2 should be inversely proportional to distance from the source patient. Short-range airborne spread should be the predominant route of SARS-CoV-2 transmission.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>25922</offset><text>In addition, contact with frequently touched surfaces, shared items, and food that are contaminated by infectious respiratory droplets likely represent another route of transmission of SARS-CoV-2. One study found that 5% of the near-patient environmental samples contained SARS-CoV-2 RNA with a median viral load of 9.2âÃâ102 copies/mL, with the highest contamination rates on patientsâ mobile phones, floors, bed rails and air exhaust vents. Though still considered controversial as a portal of transmission, several outbreaks have been linked to contaminated frozen food, their packaging materials and storage environments. The half-life of SARS-CoV-2 infectivity was 1.7â2.7 days at 20Â°C, which is reduced to a few hours at 40Â°C. At the highest viral load excreted by infectious patients, viral particles remained viable for up to 28 days at 20Â°C on common surfaces such as glass, stainless steel, and polymer banknotes. The relative humidity also affects the rate of viral decay, which was most rapid at 65% relative humidity and slower either at lower (40%) or higher (75%) humidity.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>27023</offset><text>Other routes of transmission, including faecalâoral, and contact with various body fluids including urine, tears, and breast milk, have been postulated. Indeed, oral SARS-CoV-2 inoculation can establish subclinical respiratory infection with virus shedding in the hamster model. Human vertical or perinatal transmission from mother to babies is rare but possible.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>27389</offset><text>Vertical transmissions in high rise buildings by faecal aerosols through chimney effect, wake effect and minor leaks in sewage, vent pipes, or light wells were reported. However, the significance of these alternative routes of transmission in driving the community epidemic is still unclear.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>27681</offset><text>Epidemiological characteristics</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>27713</offset><text>The mean incubation period of SARS-CoV-2 infection was 4.0â5.2 days, and incubation period of longer than 14 days has been reported. During the early stage of the pandemic, the mean serial interval was 4.0â7.5 days, the epidemic doubling time was 6.5â7.4 days, and the highly context-dependent basic reproductive number (R0) was 2.2â2.7. But estimating R0 with precision is difficult due to the substantial proportion of undetected cases and varying testing policies. Literature on transmission heterogeneity is scarce. Heterogeneity in infectious disease dynamics, where most individuals infect only a few others while a small subset of the population is responsible for the majority of new cases, is commonplace. Retrospective history from 135 cases between 21 January and 26 February 2020 in Tianjin, China, showed significant transmission heterogeneity with a coefficient of dispersion of 0.25. The estimated overall infection fatality ratio (IFR) in China was 0.66% which increased with age. This is similar to the IFR estimate of 0.6% inferred using the corrected IFR on the Diamond Princess cruise ship.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>28832</offset><text>An important reason for the rapid spread of COVID-19 is the presence of asymptomatic and presymptomatic transmission. Asymptomatic or mildly symptomatic cases constitute 30â60% of all patients infected with SARS-CoV-2. In ex vivo human lung tissues, SARS-CoV-2 generated 3.2-fold more infectious virus particles than did SARS-CoV-1, but did not significantly induce host pro-inflammatory response, which explains the high proportion of asymptomatic or mildly symptomatic cases in the COVID-19 pandemic. Moreover, in contrast to SARS-CoV-1 patients whose viral load in nasopharyngeal aspirates peaked at around day 10 of symptoms, the viral load in the respiratory samples of COVID-19 patients was highest during the first few days of symptom onset. It was estimated that presymptomatic transmission accounted for 4.2â44.4% of secondary COVID-19 cases. The secondary attack rate within Wuhan households was 15.6%, with the presympomatic cases being the most infectious. In addition, the lack of herd immunity at the early stage of the pandemic adds to the susceptibility of the general population. The estimated seroprevalence rate in Wuhan was 3.2%â3.9% in March 2020, and similar figure of 4.1% was recorded in California in April 2020.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>30076</offset><text>Mask-off activities such as dining, singing, swimming, and other physical activities are especially dangerous in overcrowded indoor venues with suboptimal ventilation or contaminated frequently-touched surfaces that are poorly sanitized. Thus outbreaks have been reported as clusters in family homes, restaurants, bars, markets, religious premises, cruises, carriers, construction sites, dancing studio, schools, nursing homes, and healthcare facilities. Several superspreading events have been highlighted. A British individual who attended a conference in Singapore in January 2020 has spread the virus across the UK, France, and Japan through the exposure at a ski resort, where 13 of the 21 exposed people eventually tested positive. From late February to early March 2020, an outbreak associated with the Sunday worshipping event in a church caused 61.3% of the 8162 confirmed COVID-19 in the Republic of Korea. The outbreak related to an index patient on the Diamond Princess cruise ship has led to the quarantine of the passengers and cruise members at the Port of Yokohama in Japan, on which 696 of the 3711 passengers (18.8%) tested positive for SARS-CoV-2. In fact, using a susceptibleâexposedâinfectiousâremoved (SEIR) model that integrates dynamic mobility networks based on mobile phone data, a small minority of âsuperspreaderâ at points of interest, most notably full-service restaurants, was found to account for a large majority of COVID-19 cases. Selective implementation of specific restrictive measures at these critical control points of interest may be most effective. Hospital outbreaks at wards, dialysis centres, and outpatient clinics fuel the community outbreaks and vice versa which adds to the burden of infection control.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>31838</offset><text>The long environmental survival of SARS-CoV-2, high proportion of asymptomatic or mildly symptomatic patients, peaking of viral load before or at presentation and therefore its high transmissibility warrants universal masking, diligent hand hygiene, and stringent social distancing measures for the successful control before the herd immunity is built up by vaccination.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>32209</offset><text>Histopathology and pathogenesis of COVID-19</text></passage><passage><infon key=\"file\">TEMI_A_1898291_F0003_PB.jpg</infon><infon key=\"id\">F0003</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>32253</offset><text>Histology of lung tissue section. (A) Image of hematoxylin and eosin (H&amp;E) stained lung tissue shows diffuse alveolar exudation and inflammatory infiltration; a medium size blood vessel containing thrombus which almost blocks the entire lumen (arrow heads). Scale bar = 500â",
      "Âµm. (B) Magnified H&amp;E image shows severe hyaline membrane formation in the alveolar space (open arrows). Scale bar = 200â",
      "Âµm. (C) Magnified H&amp;E image shows severe mononuclear immune cell infiltration in the alveolar space (solid arrows). Scale bar = 50â",
      "Âµm. (D) Immunofluorescence stained SARS-CoV-2 nucleocapsid (N) antigen in alveoli (white arrows); the insert image showing a few N protein expressing cells in a small bronchial lumen. Scale bar = 100â",
      "Âµm.</text></passage><passage><infon key=\"file\">T0003.xml</infon><infon key=\"id\">T0003</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>32999</offset><text>Histopathology and pathogenesis of COVID-19.</text></passage><passage><infon key=\"file\">T0003.xml</infon><infon key=\"id\">T0003</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;colgroup&gt;&lt;col width=&quot;1*&quot;/&gt;&lt;col width=&quot;1*&quot;/&gt;&lt;col width=&quot;1*&quot;/&gt;&lt;col width=&quot;1*&quot;/&gt;&lt;/colgroup&gt;&lt;thead valign=&quot;bottom&quot;&gt;&lt;tr&gt;&lt;th align=&quot;left&quot;&gt;Organ&lt;/th&gt;&lt;th align=&quot;center&quot;&gt;Histopathology&lt;/th&gt;&lt;th align=&quot;center&quot;&gt;Features of vascular involvement&lt;/th&gt;&lt;th align=&quot;center&quot;&gt;References&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Lung&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Diffuse alveolar damage with lymphocytic/ monocytic infiltrate together with intra-alveolar fibrinous exudate, hyaline membrane formation at acute stage.&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Type II pneumocyte hyperplasia with interstitial fibrosis at late stage&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Increase in pulmonary megakaryocytes&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Perivascular cuffing by lymphocytes with fibrin/ hyaline thrombi seen within pulmonary vessels and capillaries&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Congested vessels&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;CIT0143&quot; ref-type=&quot;bibr&quot;&gt;143&lt;/xref&gt;&lt;xref rid=&quot;CIT0151&quot; ref-type=&quot;bibr&quot;&gt;151&lt;/xref&gt;&lt;xref rid=&quot;CIT0153&quot; ref-type=&quot;bibr&quot;&gt;153&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Heart&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Small or multifocal lymphocytic infiltrate with dysmorphic cardiomyocyte and rare necrosis (milder pathology when compared with the lung)&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Eosinophilic myocarditis (rare)&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Epicardial capillaries with prominent lymphomonocytic endotheliitis&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Macrovascular or microvascular thrombi&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Intraluminal megakaryocytes&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;CIT0144&quot; ref-type=&quot;bibr&quot;&gt;144&lt;/xref&gt;&lt;xref rid=&quot;CIT0151&quot; ref-type=&quot;bibr&quot;&gt;151&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Brain&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Activation of astrocytes and microglia with infiltration of cytotoxic T cell mainly in brainstem and meninges&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Occasional expression of viral antigen at cortical neurons&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Intravascular thrombi with perivascular microhaemorrhages and intramural inflammatory infiltrates&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Multiple microscopic ischaemic infarct with or without antigen expression at endothelium&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;CIT0174 CIT0175 CIT0176 CIT0177 CIT0178 CIT0179&quot; ref-type=&quot;bibr&quot;&gt;174-179&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Kidney&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Acute tubular injury&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Interstitial fibrosis&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Podocyte vacuolation&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Loss of brush border in proximal tubule&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Focal segmental glomerulosclerosis&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Granulomatous interstitial nephritis&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Hemosiderin granules and pigmented casts, together with abundant erythrocyte with obstruction of peritubular capillary lumen with activation of endothelium&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;CIT0143&quot; ref-type=&quot;bibr&quot;&gt;143&lt;/xref&gt;&lt;xref rid=&quot;CIT0145&quot; ref-type=&quot;bibr&quot;&gt;145&lt;/xref&gt;&lt;xref rid=&quot;CIT0167&quot; ref-type=&quot;bibr&quot;&gt;167&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Liver&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Histiocytic hyperplasia&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Focal macrovascular and microvascular steatosis&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Patchy hepatic necrosis in centrilobular and periportal areas&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Platelet fibrin thrombi in sinusoid, central vein or portal vein&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Megakaryocytes in sinusoid&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Sinusoidal congestion&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Ischaemic necrosis&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;CIT0143&quot; ref-type=&quot;bibr&quot;&gt;143&lt;/xref&gt;&lt;xref rid=&quot;CIT0145&quot; ref-type=&quot;bibr&quot;&gt;145&lt;/xref&gt;&lt;xref rid=&quot;CIT0167&quot; ref-type=&quot;bibr&quot;&gt;167&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Spleen&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;White pulp depletion&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Splenic infarction&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;CIT0143&quot; ref-type=&quot;bibr&quot;&gt;143&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Skin&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Parakeratosis, acanthosis, dyskeratotic keratinocytes, necrotic keratinocytes, acantholytic clefts, lymphocyte satellitosis and pseudoherpetic of the epidermis&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Dermal infiltrate with perivascular and intramural lymphocyte in muscular wall of small vessels&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Occasional intravascular hyaline/ fibrin thrombi&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Vascular deposition of C4d by immunohistochemical staining&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;CIT0145&quot; ref-type=&quot;bibr&quot;&gt;145&lt;/xref&gt;&lt;xref rid=&quot;CIT0162&quot; ref-type=&quot;bibr&quot;&gt;162&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Placenta&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Villous infarction, atherosis and fibrinoid necrosis of maternal vessels&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;CIT0146&quot; ref-type=&quot;bibr&quot;&gt;146&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Testis&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;list list-type=&quot;bullet&quot;&gt;&lt;list-item&gt;&lt;p&gt;Interstitial edema with leukocyte infiltration&lt;/p&gt;&lt;/list-item&gt;&lt;list-item&gt;&lt;p&gt;Sertoli cells showed swelling, vacuolation and cytoplasmic rarefaction, detachment from tubular basement membranes, and loss and sloughing into lumens of the intratubular cell mass&lt;/p&gt;&lt;/list-item&gt;&lt;/list&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Â &lt;/td&gt;&lt;td align=&quot;center&quot;&gt;&lt;xref rid=&quot;CIT0147&quot; ref-type=&quot;bibr&quot;&gt;147&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>33044</offset><text>Organ\tHistopathology\tFeatures of vascular involvement\tReferences\t \tLung\tDiffuse alveolar damage with lymphocytic/ monocytic infiltrate together with intra-alveolar fibrinous exudate, hyaline membrane formation at acute stage.Type II pneumocyte hyperplasia with interstitial fibrosis at late stageIncrease in pulmonary megakaryocytes\tPerivascular cuffing by lymphocytes with fibrin/ hyaline thrombi seen within pulmonary vessels and capillariesCongested vessels\t\t \tHeart\tSmall or multifocal lymphocytic infiltrate with dysmorphic cardiomyocyte and rare necrosis (milder pathology when compared with the lung)Eosinophilic myocarditis (rare)\tEpicardial capillaries with prominent lymphomonocytic endotheliitisMacrovascular or microvascular thrombiIntraluminal megakaryocytes\t\t \tBrain\tActivation of astrocytes and microglia with infiltration of cytotoxic T cell mainly in brainstem and meningesOccasional expression of viral antigen at cortical neurons\tIntravascular thrombi with perivascular microhaemorrhages and intramural inflammatory infiltratesMultiple microscopic ischaemic infarct with or without antigen expression at endothelium\t\t \tKidney\tAcute tubular injuryInterstitial fibrosisPodocyte vacuolationLoss of brush border in proximal tubuleFocal segmental glomerulosclerosisGranulomatous interstitial nephritis\tHemosiderin granules and pigmented casts, together with abundant erythrocyte with obstruction of peritubular capillary lumen with activation of endothelium\t\t \tLiver\tHistiocytic hyperplasiaFocal macrovascular and microvascular steatosisPatchy hepatic necrosis in centrilobular and periportal areas\tPlatelet fibrin thrombi in sinusoid, central vein or portal veinMegakaryocytes in sinusoidSinusoidal congestionIschaemic necrosis\t\t \tSpleen\tWhite pulp depletion\tSplenic infarction\t\t \tSkin\tParakeratosis, acanthosis, dyskeratotic keratinocytes, necrotic keratinocytes, acantholytic clefts, lymphocyte satellitosis and pseudoherpetic of the epidermis\tDermal infiltrate with perivascular and intramural lymphocyte in muscular wall of small vesselsOccasional intravascular hyaline/ fibrin thrombiVascular deposition of C4d by immunohistochemical staining\t\t \tPlacenta\tÂ \tVillous infarction, atherosis and fibrinoid necrosis of maternal vessels\t\t \tTestis\tInterstitial edema with leukocyte infiltrationSertoli cells showed swelling, vacuolation and cytoplasmic rarefaction, detachment from tubular basement membranes, and loss and sloughing into lumens of the intratubular cell mass\tÂ \t\t \t</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>35539</offset><text>SARS-CoV-2 can cause infection in multiple organs as shown in both in vitro and in vivo studies. with common histopathological features summarized in Table 3. Autopsy showed that pulmonary involvement with diffuse alveolar damage together with hyaline membrane formation and pulmonary micro-emboli are the most prominent acute histopathological findings (Figure 3). These features were often associated with high inflammatory cytokines and increased angiogenesis in fatal cases. The hyaline membrane was attributed to an increase in vascular permeability (termed as âbradykinin stormâ) and accumulation of hyaluronic acid in the alveolar space, leading to trapping of high volume of water. Moreover, serum autoantibodies directed against many immunomodulatory proteins including cytokines, chemokines, complement activation components, and cell surface proteins were found in a high throughput extracellular antigen profiling study which may add to the tissue damage by immune complex deposition and complement. These autoantibodies may also impair immune function and virological control by inhibiting immunoreceptor signalling. The presence of these autoantibodies including those against interferons is strongly associated with disease severity.  </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>36794</offset><text>Although SARS-CoV-1 is more virulent based on in vitro studies in terms of replication and cell damage, SARS-CoV-2 appears unique in causing endotheliitis, as evident by viral particles in vascular endothelium using electron microscopy. Soluble endothelial markers such as angiopoietin-2 level are positively correlated with severity of COVID-19. Furthermore, endotheliitis increases propensity of thromboembolism and multisystem involvement in COVID-19 patients. Widespread thrombosis could be related to the hyperinflammatory and hypercoagulopathy states, termed as âimmune-thrombosisâ. Direct endothelial injury triggers innate immune response, including activation of monocytes and complement pathways, leading to deposition of terminal complement components C5b-9 (membrane attack complex), C4d, and mannose binding lectin (MBL)-associated serine protease (MASP) in the microvasculature. Complement and endothelium activation induce the production of von Willebrand factor (vWF) and factor VIII (FVIII), while reducing antithrombin and ADAMTS13 activity. Activated neutrophils release neutrophil extracellular traps to stabilize microthrombi. Macro- and micro-vascular thrombosis and intraluminal megakaryocyte are more common features than lymphocytic infiltration of myocardium in patients with cardiac involvement. In terms of lymphoid organ involvement, T-cell depletion occurred in the spleen. Necrosis or atrophy in the lymphoid tissue of lymph nodes and white pulp of the spleen are commonly observed extrapulmonary pathologies.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>38339</offset><text>COVID-19 may affect the central nervous system due to indirect effects of cytokine storm or suspected direct virus invasion. The S1 protein can cross the blood brain barrier in a mouse model. Furthermore, intranasally administered S1 also entered the brain with significant uptake at olfactory bulb and hippocampus, although at levels around 10 times lower than that after intravenous administration. The endotheliitis and systemic inflammatory response syndrome with neuronal activation are also postulated to explain the neurological manifestations. Autopsy studies of the brain showed that ischaemic infarct with perivascular microhaemorrhage together with neutrophilic plugs or intravascular microthrombi were common features. Similarly, radiological features of vascular inflammation were observed in magnetic resonance imaging (MRI) of the brain. T-cell lymphocytic infiltrates were commonly seen at perivascular, parenchymal as well as leptomeningeal areas with microglial and astrocyte activation. Clinical improvement of encephalopathic symptoms with steroid tends to suggest a dominant role of inflammatory response. The detection of SARS-CoV-2 in the brain and cerebrospinal fluid by immunohistochemical staining and RTâPCR yield inconsistent results, as viral RNA detected from brain biopsy may come from vascular endothelium instead of neurons. The localization of S antigen and visualization of virus-like particles at the endothelium were observed in some patients with endotheliitis while only few could demonstrate S protein expression in cortical astrocytes. The more consistent finding is the expression of virus nucleocapsid antigen in olfactory sustentacular and horizontal basal cells in some patients and also in the olfactory neurons in infected hamsters, suggesting that direct neuronal invasion by virus is possible.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>40184</offset><text>Immunological profile of patients with COVID-19</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>40232</offset><text>Innate immunity is the first line of defence against infection. Yet SARS-CoV-2 may evade innate immunity by antagonizing host interferon response. Viral proteins that have been shown to antagonize interferon response include Nsp1, Nsp3, Nsp12, Nsp13, Nsp14, Nsp15, ORF3, and ORF6. Furthermore, the frequency of dendritic cells, T cells, NK cells, and monocytes was significantly reduced in the peripheral blood of acute patients when compared with healthy donors. In particular, decrease in levels of CCR2 expression in dendritic cells may lead to poor maturation on stimulation, further reducing levels of interferons, and hence poor stimulation of CD4+ and CD8+ T lymphocytes during acute phase of infection. Furthermore, infiltration of monocytes/macrophages in lungs can increase pro-inflammatory cytokines and chemokines such as IL-6 and IP-10, which fuels the cytokine storm. Th2 cytokines, such as IL-5 and IL-13, are elevated in patients with severe COVID-19.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>41200</offset><text>For humoral adaptive immune response, most recovered patients develop SARS-CoV-2-specific IgA, IgG, and IgM response not only against S (including RBD) and N but also other non-structural proteins. The peak antibody response appears at around 1 month and is higher among patients with more severe disease. Most studies showed a static or slow decline in neutralizing antibody and IgG response after few months, while IgA and IgM declines more rapidly. One study estimated the half-life of S protein IgG to be 140 days. Notably, some patients who recovered rapidly showed increasing titres over time. The IgG and IgM levels in saliva correlate with those of serum. There is also a difference in antibody response between adults and children. While adults develop antibody against both N and S proteins equally well, children have a stronger anti-S antibody response than anti-N antibody. S-specific memory B lymphocytes showed increase in abundance over time, suggesting that patients can develop rapid antibody response during reinfection, as was seen in our previously reported reinfection case. The exact duration of detectable serum neutralizing antibody titre after natural infection or vaccination still awaits long-term follow-up study.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>42443</offset><text>Cases of reinfection have been reported, and neutralizing antibody could not be detected at presentation of the second episode of infection 5 months after the first episode. Magnitude and duration of persistence of IgG or neutralizing antibody correlate with severity of COVID-19 in some studies.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>42740</offset><text>For cell-mediated adaptive immunity, SARS-CoV-2 leads to T-cell lymphopenia and functional impairment of both CD4+ and CD8+ T cells during the acute stage. Total CD4+ and CD8+ T cells are reduced in both mild and severe diseases, but particularly lower among severe cases. SARS-CoV-2 specific CD4+ and CD8+ T cells can be detected in about 50% of patients during the acute period and &gt;80% of patients in the convalescent stage. The development of SARS-CoV-2 specific T-cell response is impaired among patients with severe COVID-19. There is a higher frequency of memory CD4 than CD8 T-cell responses against N and RBD. SARS-CoV-2-specific CD8+ memory T-cell responses are directed primarily to the S and M proteins especially among those who recovered from severe COVID-19. The levels of TH17 cells were elevated among severe cases. The frequency of T follicular helper cells during the convalescent phase is higher among patients with severe disease than those with milder disease, which correlated with the neutralizing antibody titre. SARS-CoV-2 specific T-cell immunity can also be found in up to 83% of non-COVID-19 individuals which may suggest some cross reactive T-cell immunity that may or may not be protective. Pre-existing memory CD4+ T cells are cross reactive for SARS-CoV-2 and other seasonal coronaviruses. SARS-CoV-2-specific T lymphocytes (CD4+, CD8+) decreased with half-lives of 3â5 months.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>44153</offset><text>The overall clinical phenotype of COVID-19 is determined by the degree of early control of viral load by innate and adaptive immune responses, the inflammatory and apoptotic damage of cells triggered by the burden of virus, the functional reserve of the affected organs and the compensatory regenerative or reparative power of the host tissues.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>44498</offset><text>Clinical manifestations</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>44522</offset><text>COVID-19 is primarily a respiratory disease which can manifest as acute upper or/and lower respiratory tract syndrome of varying severity. The symptom onset of COVID-19 is more likely to be gradual than the abrupt onset in influenza. The patient can manifest with asymptomatic virus shedding, or a self-limited syndrome of fever, fatigue, myalgia, arthralgia, rhinorrhoea, sore throat, and/or conjunctivitis at one end of the spectrum. But it can also progress to persistent fever, cough, hemoptysis, silent hypoxia, chest discomfort or pain, respiratory failure, or even multiorgan failure. Impairment of smell (hyposmia, anosmia, and parosmia) or taste (dysgeusia) has been recognized as important chemosensory disturbances in COVID-19. Non-conductive olfactory dysfunction (OD) may be the sole manifestation. Other extrapulmonary manifestations include diarrhoea, lymphopenia, thrombocytopenia, deranged liver and renal function, rhabdomyolysis, meningoencephalitis, stroke, seizure, GuillainâBarrÃ© syndrome, cardiac arrhythmia or heart block, pancreatitis, Kawasaki disease like multisystem vasculitis, skin rash or chilblain-like lesions, thromboembolism, and acute thyroiditis. In an analysis of 72314 COVID-19 in China up to 11 February 2020, 81% of the laboratory confirmed patients had mild to moderate illness, 14% had severe disease, and 5% were critically ill requiring intensive care.</text></passage><passage><infon key=\"file\">TEMI_A_1898291_F0004_PB.jpg</infon><infon key=\"id\">F0004</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>45923</offset><text>Typical changes of COVID-19 pneumonia on lung computed tomography showing bilateral multifocal patchy ground glass opacities: (A) transverse view; (B) coronal view.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>46088</offset><text>Clinical improvement of mild and moderate cases generally occurs around 10 days after symptom onset which coincides with at least 1 log reduction of respiratory viral load and the rise of serum antibodies against N or S protein. However, clinical deterioration of moderate disease to respiratory failure may also occur at this time with persistent salivary viral load and increasing lymphopenia in these worsening patients. Chest radiograph or lung CT scan typically showed bilateral multifocal and peripheral ground glass opacities (Figure 4) which may deteriorate to dense consolidation in progressive disease. The radiological abnormalities usually peak by 2 weeks after symptom onset and are replaced by fibrosis with recovery. The prognosis of COVID-19 is worse in elderly obese males or those with comorbidities such as hypertension, diabetes mellitus, atherosclerotic vascular diseases, vitamin D deficiency, and other chronic medical illness. Patients with X-linked putative TLR7 loss of function variant, autoantibody against type 1 interferons, defective mutations of IFNAR2 or other interferon signalling genes, antiviral restriction enzyme activators (OAS), blood group A and the associated SNPs found by GWAS are associated with severe disease. Acute kidney injury affected &gt;20% of hospitalized patients and &gt;50% of those requiring ICU admission, but the rate varies widely between studies. The overall crude fatality rate for laboratory confirmed cases is about 2%, but can be as high as 21.9% in patients over 80 years of age. Early bacterial and fungal superinfections are uncommon but late superinfections, including invasive pulmonary aspergillosis, were reported in those with prolonged ICU stays and treatment by immunomodulatory agents. </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>47847</offset><text>Follow-up study at 6 months after COVID-19 symptom onset showed that over 60% of these patients had persistent symptom of fatigue or muscle weakness. Sleep difficulties (26%), anxiety or depression (23%) were not uncommon. Other symptoms include smell or taste disorder, palpitations, joint pain, dizziness, diarrhoea, vomiting, and chest pain which constitute a constellation of symptoms termed âpost-acute COVID-19 syndromeâ. This group of patients are also called âCOVID long haulersâ. Those with severe disease requiring respiratory support had lung diffusion impairment. However, little objective evidence of post-acute COVID-19 syndrome can be found on investigations which bear some similarity to chronic fatigue syndrome or myalgic encephalomyelitis. The cause was speculated to a dysregulated immune system which was activated to fight SARS-CoV-2 but failed to dampen down afterwards. The other differential diagnoses are either an autoimmune process triggered by SARS-CoV-2 or a persistent SARS-CoV-2 infection which cannot be easily detected by conventional testing. The relationship between the presence of serum autoantibodies and the post-acute COVID-19 syndrome requires further investigations.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>49065</offset><text>In general, children have a shorter and milder disease than adults. However, a rare but life-threatening Kawasaki-like disease, known as multisystem inflammatory syndrome in children (MIS-C) or paediatric inflammatory syndrome temporally associated with SARS-CoV-2, are seen during the convalescent phase of the illness. Children with MIS-C are usually older, has a lower lymphocyte and platelet count, and a higher level of CRP and ferritin than those with Kawasaki disease.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_1</infon><offset>49541</offset><text>Laboratory diagnosis</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>49562</offset><text>One of the most important aspects in curbing the spread of the virus and improving the prognosis is rapid yet accurate diagnosis of infection followed by timely isolation, contact tracing and treatment. Molecular testing is now the mainstay of diagnosis, supplemented by point-of- care antigen testing (POCT). Antibody detection aids in assessment of immunity, contact tracing, and disease prevalence in the population. A multitude of diagnostic platforms, both in-house and on commercial platforms, are developed to meet these demands.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>50099</offset><text>Specimen collection</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>50119</offset><text>Viral load in the respiratory tract is highest at or soon after symptom onset, and it decreases at a rate of 1 log10 per week. Testing nasopharyngeal aspirate, nasopharyngeal swab, or throat swab is adequate for early-stage infection, especially asymptomatic or mild upper respiratory tract infections. Patients with lower respiratory tract symptoms should send sputum to enhance sensitivity. Though broncho-alveolar lavage (BAL) showed the highest positive rate among different respiratory specimens, it is only indicated in those with severe lower respiratory tract involvement when the nasopharyngeal and throat specimens are tested negative. Posterior oropharyngeal secretion (POS) or deep throat saliva is increasingly studied as it represents a pooling of posterior nasopharyngeal, oropharyngeal and lower respiratory secretions during the supine position during sleep, when taken in the early morning before breakfast and mouth rinsing. It can be self-collected by patients with instructions, reducing patient discomfort, circumventing swab shortage, and minimizing aerosol exposure for health care professionals. The cost of collecting POS could be 2.59-fold lower than nasopharyngeal specimen. The sensitivity is comparable with nasopharyngeal swab in properly collected specimens by cooperative patients . The sensitivity does not vary much between early morning and at least 2 h after meal.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>51521</offset><text>For non-airway specimens, viral shedding by RTâPCR was found in faecal material in 40.5% of patients after the first week of symptom onset and could persist for 3 weeks or more. Presence of viral RNA in the sewage system may provide a cost-effective and non-invasive way of monitoring the disease spread within the community and may serve as an early warning system for population that lacks access to healthcare. Enveloped virus has affinity to biosolids which may allow testing of sludge at sewage treatment plants with better sensitivity than testing influent. Composite sampling is used in most studies. Sewage sample should be concentrated followed by efficient RNA extraction to prevent inhibition of molecular assays. Viral RNA can also be detected in the blood in about 30% of severe patients, but the detection rate is much lower in milder cases. Even without ocular symptoms, the conjunctival secretion may contain a small amount of SARS-CoV-2 RNA in around 8% of patients. Viral RNA is rarely found in the urine.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>52547</offset><text>To accommodate the large amount of specimen for screening asymptomatic population, pooling of clinical specimens, up to 5â30 samples per pool, is an additional strategy to cope with reagent shortages, at the expense of possibly longer processing time and reduced diagnostic sensitivity of the weakly positive sample. It is efficient only when the expected positive sample number is low as positive pool requires individual retesting. Strategic retesting of a defined group and the use of mathematical models to stratify pool size by age groups based on their respective disease prevalence may improve efficiency.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>53162</offset><text>Molecular testing</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>53180</offset><text>Reverse-transcriptase polymerase chain reaction (RTâPCR) is the most widely used technique. Potential molecular targets for SARS-CoV-2 include structural proteins (e.g. S, E, helicase (hel), N, M and non-structural regions such as the RNA-dependent RNA polymerase region (Rdrp), and other ORF1ab targets. There is currently no consensus on which gene confers the best diagnostic performance. Presently, one bat SARS related CoV conserved and one SARS-CoV-2 specific target regions are recommended to mitigate effect of random mutation or genetic drift while maintaining specificity. However, mutations can affect the sensitivity of detection by RTâPCR. For example, mutations in the S gene of the UK variant B.1.1.7 has led to the failure of some RTâPCR primers targeting the S gene.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>53970</offset><text>High throughput and automated commercial platforms have been developed for molecular SARS-CoV-2 diagnosis. Molecular POCT enables rapid testing near the site of collection in areas with little laboratory support. To improve diagnostic sensitivities of molecular assays, clustered regularly interspaced short palindromic repeat (CRISPR)-based technology has been employed by coupling with Cas enzyme. Target enrichment sequencing by NGS with nanopore or Illumina technology can unravel the entire genome within a few days. Sharing of genetic data facilitates tracking of disease spread, understanding of disease transmission route, monitoring of viral genome evolution and detecting novel variants.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>54668</offset><text>Antigen detection</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>54686</offset><text>N is abundantly expressed in SARS-CoV-2 and is thus widely used as the target for COVID-19 antigen test. Detection is achieved by capturing viral antigen in clinical specimens by monoclonal antibodies fixed on a membrane in colorimetric lateral immunoassays. Though this assay can be delivered as POCT in an outpatient or even non-healthcare setting, it has low sensitivity when compared with RTâPCR assays especially for samples with low viral load. In general, antigen test is negative when their Ct values on quantitative RTâPCR are more than 25, although the Ct values vary with different assays and conditions.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>55306</offset><text>Antibody detection</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>55325</offset><text>While antibody testing is generally not useful for acute management, it can be used for retrospective diagnosis and seroprevalence study to understand herd immunity. Commonly employed techniques are lateral flow, chemiluminescent, immunofluorescent, and enzyme-linked immunosorbent assays. Median seroconversion times following symptom onset are 11 days for total antibodies, 12 and 14 days for IgM and IgG respectively. After 14 days, 56â97% of patients develop IgM and 91â100% of patients develop IgG, with no significant time difference between IgM and IgG response. IgM peaks at around 3 weeks after symptom onset and falls to baseline level after day 36. The duration of IgG or neutralizing antibody positivity remains controversial. Some study showed decrease in neutralizing antibody titre within 3 months after symptom onset, while others showed no such decrease. Antibody development against S and N protein is comparable by 1 month after infection. Titre of anti-S or anti-S RBD antibody may better reflect protection against reinfection.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>56378</offset><text>Traditional neutralization assay requires manipulation of live virus and necessitate biosafety level 3 laboratories. Pseudovirus neutralization assay using vesicular stomatitis virus (VSV) expressing S protein of SARS-CoV-2 containing the RBD, can be used in biosafety level 2 facilities. Neutralizing antibodies are directed towards the RBD and NTD. Both sites are situated at the tip of the S protein. Surrogate virus neutralization assay based on antibody-mediated blockage of RBD-ACE2 interaction has been developed.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>56899</offset><text>Studies have shown serological cross-reactivity between SARS-CoV-2 and SARS-CoV, with decreasing frequency of cross-reaction from N protein, S protein to RBD domain by enzyme immunoassay, with no significant cross neutralization. Cross-reactivity against other seasonal human coronaviruses in SARS-CoV-2 infection has been shown as well, though intensity is not as great as that with SARS-CoV.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>57293</offset><text>Antibody test has also been used to assess whether SARS-CoV-2 has circulated in the population before the isolation of the virus. A study from Italy reported that anti-RBD antibody could be found in blood samples collected as early as September 2019. In the United States, 106 of 7389 of residual specimens from blood donors collected between 13 December 2019 and 17 January 2020, tested positive for IgG against SARS-CoV-2, and neutralizing antibody was detected in 84 of 90 of these samples. Though these studies suggest that COVID-19 may have emerged much earlier than the first RTâPCR confirmed case, the possibility of EIA cross-reactivity with other coronaviruses cannot be excluded.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>57985</offset><text>Viral culture</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>57999</offset><text>Infectiousness of SARS-CoV-2 in clinical specimens can only be demonstrated by cell culture assays in biosafety level 3 facilities. Furthermore, cell culture is essential for the evaluation of potential antiviral compounds and vaccines. Viral culture turned negative in 97% of patients by 10 days after symptom onset, coinciding with the time of seroconversion. Duration of live virus shedding is believed to be even shorter in faecal specimen. Shedding is prolonged in severe and immunocompromised cases.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>58505</offset><text>Vero E6 cells which have abundant ACE2 expression are commonly used for virus isolation. Vero E6 cell line that expresses TMRPSS2 can result in better culture yield and reduce the likelihood of in vitro selection of S1/S2 junction site deletion mutant. SARS-CoV-2 also grows in human continuous cell lines such as Calu3 (lung cancer), Huh7 (liver cancer) and Caco2 (colonic cancer). It grows modestly on U251 (glioblastoma) which is not seen with SARS-CoV-1. Organoid systems such as bat and human intestinal organoids are susceptible to SARS-CoV-2 and are developed to better study tissue tropism, the dynamics of infection and testing of therapeutic targets. SARS-CoV-2 is successfully cultured in human intestinal organoids from a stool specimen with high Ct value of 33.6, demonstrating possible enteric infection by oro-faecal route.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_1</infon><offset>59344</offset><text>Treatment</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>59354</offset><text>Except in places where all infected cases are legally required for mandatory hospital isolation, most patients with mild symptoms require only home isolation, monitoring, and symptomatic treatment. Those with persistent fever, fatigue, and dyspnoea would require admission for full assessment, respiratory support, and targeted anticoagulation by low molecular weight heparin to prevent thromboembolic events. Since the viral load peaks at the time of symptom onset or presentation, antiviral treatment is unlikely to work unless given early when the disease is still mild. Remdesivir has been shown to shorten the duration of hospitalization by 5 days in a randomized control trial which did not monitor the serial viral load changes after treatment. The WHO Solidarity trial, a multinational trial with 11,330 adult patients, found that remdesivir, lopinavir-ritonaivir, interferon Î²-1a, and hydroxychloroquine, have little or no clinical benefit when given as monotherapy, especially when started at the stage of respiratory failure. However, a combination of interferon Î²-1b, lopinavir-ritonavir and ribavirin was shown to shorten the duration of hospitalization and reduce the viral load by 2â3 log between day 6 and day 11 after symptom onset if given early in a randomized control trial. Similarly, inhaled interferon Î²-1a was also shown to improve symptoms in mild cases in another randomized control trial without viral load monitoring. This is not unexpected because while SARS-CoV-2 is highly susceptible to interferons in vitro, the virus was shown to reduce type 1 interferon produced in ex vivo infected lung tissue explant. Furthermore, about 13% of patients with severe COVID-19 were found to have high titres of auto-antibody against type 1 interferons and especially against interferon-Î±.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>61174</offset><text>Though individual or cocktail neutralizing monoclonal antibody treatment has been shown to reduce viral load when given early after symptom onset and before the appearance of serum anti-SARS-CoV-2 antibody in non-hospitalized patients, this approach has not yet been shown to reduce morbidity and mortality. A clinical trial of a monoclonal antibody, LY-CoV555, did not show clinical benefit among hospitalized patients. Similarly, convalescent plasma with neutralizing antibody only improved clinical status of elderly with mild COVID-19 when given within 3 days of symptom onset and was not effective after hypoxaemia developed in randomized clinical trials. Additional treatment trials are still ongoing or being planned to ascertain the clinical effectiveness of clinically approved drugs discovered in drug repurposing studies such as ivermectin, umifenovir, favipiravir, camostat, nafamostat, teicoplanin, and bismuth compounds.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>62109</offset><text>While currently available antivirals have not demonstrated survival benefit, several immunomodulators have been shown to improve survival. Dexamethasone has been shown to reduce mortality by about 30% in patients requiring oxygen supplementation. Baricitinib, an inhibitor of Janus kinase, was shown to improve survival in patients treated with remdesivir, with a hazard ratio of death of 0.65. Conflicting or preliminarily positive results regarding the use of histamine receptor 2 antagonist famotidine, vitamin D, IL6 inhibitor tocilizumab and colchicine were reported. Fluvoxamine, a selective serotonin reuptake inhibitor with high affinity for Ï-1 receptor appeared to prevent clinical deterioration when given as early treatment for mild COVID-19. An open-labelled randomized trial showed that patients treated with recombinant human granulocyte colony stimulating factor have a lower risk of progressing to acute respiratory distress syndrome, sepsis, or septic shock. Additional therapeutic approach that may include the manipulation of complement, neutrophil trapping function and TNF function are being discussed. More definitive large randomized control treatment trials are needed to confirm the usefulness of these immunomodulators.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>63360</offset><text>Despite respiratory support by non-invasive ventilation by bilevel positive airway pressure or continuous positive airway pressure, some patients will still deteriorate and necessitate intubation and mechanical ventilation. In those who failed positive end expiratory pressure and prone ventilation, extracorporeal membrane oxygenation is the last step to support the patient till spontaneous recovery.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_1</infon><offset>63763</offset><text>Public health measures</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>63786</offset><text>We have shown that different epidemic waves in Hong Kong Special Administrative Region were due to different imported lineages of virus which became dominant during the epidemic surge and then disappeared with successful implementation of epidemiological control measures. Successful epidemic control depends on stopping case importation, minimizing community dissemination by social distancing measures, early detection and isolation of cases by extensive testing, rapid contact tracing and quarantine, and individual protection by universal masking and diligent hand hygiene. The resulting reduction of case load will protect our hospital and intensive care unit from paralysis and prevent the burnout of healthcare workers. Control at the border depends on minimizing the number of flights from highly epidemic areas with dangerous virus mutants, and testing all incoming travellers with no exemption, enclosed transportation and quarantining them for 14â21 days till negative surveillance testing. During the severe winter epidemic, city and even nation-wide lockdown with curfew to prevent gatherings is useful to enforce social distancing. The alternative way is to close or reduce the time of opening and occupancy of high-risk premises such as eateries, bars and fitness clubs where masks are often taken off. With sporadic clusters, district closure with mandatory RTâPCR testing of everyone followed by another testing at day 5â14 can be useful in stopping community transmission. Universal masking when outside home is demonstrated to stop the asymptomatic infected individual from shedding virus and to prevent susceptible individuals from acquiring infection as hinted by the hamster model. Although surgical masks only have a fairly high effectiveness in blocking aerosols in the micron size range, it appears to be nearly as effective as N95 respirator. Universal masking is shown useful in community epidemiological studies. Every case of unexplained fever or respiratory symptom should undergo mandatory testing. Repeated testing is indicated if the symptom persists as false negative may happen. While asymptomatic infection does occur, more than 80% of patients develop symptoms during the course of illness. Moreover, only around 10% of infected persons are responsible for 80% of SARS-CoV-2 transmission. Thus catching this 10% by rapid multilayer contact tracing, early testing and quarantine of close contacts may identify the related asymptomatic or presymptomatic cases to stop further transmission. Rapid multilayer contact tracing, including non-close contacts and contacts of close contacts going back to more than 2 days before symptom onset, may be value added. Such labour-intensive contact tracing can be facilitated by a trained team with artificial intelligence analysing data of mobile phone applications or electronic payment. But these should be conducted in a manner to protect individual privacy. Timely risk communication and education through media and internet are extremely important to secure cooperation from the public to make epidemic control a success.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_1</infon><offset>66893</offset><text>Infection control</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>66911</offset><text>The key measures of infection control against nosocomial outbreaks of COVID-19 include a combination of active surveillance for early case identification, isolation of suspected and confirmed case in the airborne infection isolation room (AIIR) with the implementation of standard, contact, droplets, and airborne precautions, as well as contact tracing to identify the potential secondary cases. These infection control measures which had been proven to be effective in controlling SARS in 2003 were not as successful for COVID-19, because asymptomatic infection contributes to a significant part of transmission and that the viral load peaks around the time of symptom onset. Thus universal screening of all hospital admissions or outpatient attendance by RTâPCR is warranted to reduce the risk of healthcare-related outbreaks. The risk for nosocomial transmission is especially high when asymptomatic COVID-19 patients are placed in non-AIIR rooms, or/and put on high-flow oxygen or non-invasive ventilation. Therefore, universal masking for healthcare workers and hospitalized patients, if not medically contraindicated, in the clinical areas should be enforced to reduce the risk of COVID-19 transmission by respiratory droplets and short-range airborne route. In fact, universal masking in the clinical areas can achieve zero nosocomial transmission of other respiratory viruses such as influenza A, influenza B, and respiratory syncytial virus. Universal masking in the community also reduced the incidence of COVID-19 in the general population.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>68466</offset><text>The overwhelming burden of hospitalized COVID-19 patients is another risk factor of nosocomial outbreaks. Alternative hospital sites such as temporary shelter hospital and convention halls have been built or re-purposed in mainland China, Hong Kong Special Administrative Region, the UK, the USA and Singapore as temporary measures to meet sudden surge in COVID-19. The infection control logistics and workflow in these alternative sites should be carefully planned and implemented to minimize the risk of outbreak. The ventilation system of these alternative sites, especially the convention hall, was difficult to match with the hospital standard of 6â12 air changes per hour. Another parameter of ventilation by volume of air per second per person of around 60 L/s/person was considered acceptable as recommended by World Health Organization.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>69314</offset><text>Appropriate use of personal protective equipment (PPE) is associated with a decreased risk of COVID-19. Full PPE includes use of N95 respirator, cap, face shield, gloves, and isolation gown of ASTM levels 1â3 were recommended. However, critical shortage of PPE, especially N95 respirator, was a global problem during the initial phase of pandemic. Reprocessing of N95 surgical respirator for reuse in performing aerosol generating procedures was also supported by the IDSA expert panel. The methods of reprocessing include the use of vaporized, plasma, ionized hydrogen peroxide, ultraviolet radiation, and steam sterilization. Quantitative fit test of N95 mask was performed to determine the maximum frequency of reprocessing.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>70044</offset><text>Infection control training for proper donning and doffing of PPE is of utmost importance. Directly observed donning and doffing was promoted to maximize the protection and reduce the risk of self-contamination. Simulation training has been used to enhance competency and alertness of healthcare workers, especially on the performance of high-risk procedures such as cardiopulmonary resuscitation.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_1</infon><offset>70441</offset><text>Animal models</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>70455</offset><text>SARS-CoV-2 probably evolved from an ancestral bat virus and jumped to humans via an unknown intermediate host. SARS-CoV-2-related bat coronaviruses have now been found outside China, including Cambodia, Thailand, and Japan. Over the course of the pandemic, it has become increasingly clear that SARS-CoV-2 has the potential to infect a wide range of animals. Natural human-to-animal transmission events involving dogs, cats, lions, tigers, and minks have been reported. Surrogate entry assays suggest that the S glycoprotein of SARS-CoV-2 has wide tropism for a variety of mammalian ACE2 receptors. Therefore, it is not surprising that efficient animal models for COVID-19 could be rapidly established. The first of these was the golden Syrian hamster (Mesocricetus auratus), which was quickly identified as a suitable model based on molecular docking analysis of its ACE2 with the SARS-CoV-2 RBD. The clinical features of COVID-19 in human are well replicated in hamsters, which demonstrate a mild-to-moderate disease course with histopathological evidence of pneumonia. Therefore, hamsters are ideally suited to study the pathogenesis of SARS-CoV-2. Viral load dynamics in infected hamsters echo those of humans. Hamsters are able to transmit disease to each other via contact or non-contact transmission, thereby facilitating transmission studies. The key limitation is the relative paucity of specific antibodies for detecting hamster biomarkers.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>71906</offset><text>Other small animal models for SARS-CoV-2 research include ferrets (Mustela putorius furo) and mice (Mus musculus). Ferrets have a long pedigree of use in influenza research and are also susceptible to SARS-CoV-2 although the disease phenotype is quite mild and predominantly restricted to the upper respiratory tract. Given their convenience, mice models have also been developed, although this requires either virus adaptation to mouse ACE2 or humanized ACE2-expressing mice. These have the disadvantage of modifying the disease phenotype, especially in human-ACE2 transgenic mice which have mild respiratory but severe brain disease. Depending on the promotor used, these human ACE2-transgenic mice exhibit variable phenotypes, ranging from mild disease to severe disease with encephalitis and even death. Mice humanized with human ACE2 using CRISPR/Cas9 knockin technology supports SARS-CoV-2 replication in the respiratory tract and brain tissues but generally develop only mild to moderate disease. Adenovirus or adeno-associated virus-transduced mice develop self-limiting viral pneumonia, but has the advantages of being easy to generate and could be quickly adapted for different mouse strains. Laboratory rabbits can be infected with asymptomatic virus shedding.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>73178</offset><text>As the ultimate origin of SARS-CoV-2 is likely to be from bats, one group has also demonstrated efficient infection of a fruit bat model (Rousettus aegyptiacus) with the virus. Fruit bats showed minimal clinical features of infection, but were capable of transmitting infection. Notably, pigs and chickens, which are in close contact with humans, are not able to support productive infection, thus ruling them out as intermediate hosts.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>73615</offset><text>Small animal models such as those described above are convenient, but definitive evaluation of pathogenesis, antivirals and vaccines requires non-human primate models. Rhesus macaques (Macaca mulatta), cynomolgus macaques (Macaca fascicularis), African green monkeys (Chlorocebus aethiops), and baboons (Papio) are all susceptible to COVID-19. Disease in non-human primates is typically mild, but disease severity and viral shedding increases with age as in humans.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_1</infon><offset>74081</offset><text>Vaccines</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>74090</offset><text>Over 70 SARS-CoV-2 vaccines developed from different vaccine technology platforms including inactivated whole virion, live attenuated virus, nucleic acid, virus vectors, and recombinant S protein, are already in clinical trials. Four vaccine candidates have published their phase 3 clinical data. While they all appear safe in clinical trials, each has its merits and demerits. The mRNA lipid nanoparticle vaccines induce good serum neutralizing antibody and cell-mediated immunity but requires stringent cold storage at â20 to â70Â°C. Though this is a new technology, side effects are generally mild. Rare cases of anaphylaxis, possibly due to polyethylene glycol, have been reported after millions of doses have been administered. Concerns of vaccine exacerbation of underlying medical illness in frail elderly aged over 80 years are not yet substantiated. The chimpanzee adenovirus and human adenovirus 26/5 vectored vaccines also induce high titres of neutralizing antibody and strong cell-mediated immunity with at least 70% vaccine efficacy. Further analysis of a phase 3 clinical trial showed that an adenovirus-vector-based vaccine was more effective if the interval between the first and second dose was 12 weeks or longer. While the phase 3 clinical data from the beta-propiolactone inactivated whole virion vaccine have not yet been published in peer reviewed journals, the data from phase 2 trials suggested that the vaccine is safe and can induce neutralizing antibodies, but the data on cell-mediated immunity is limited at this stage. All three kinds of vaccines are likely to prevent severe symptomatic infection, but may not be able to prevent upper airway infection or transmissions, and are not well tested in children or pregnancy. The saponin-based recombinant trimeric spike nanoparticle appears to induce the best serum neutralizing antibody and reasonable cell-mediated immunity but phase 3 clinical trial data have not been published. However, there are preliminary evidence that spike RBD virus mutants from South Africa and Brazil with E484â",
      "K mutation may reduce the neutralizing antibody titres induced by these vaccines. But as long as these vaccines protect vaccine recipients from severe disease, SARS-CoV-2 may just become another circulating common cold coronavirus when most of the global population has developed herd immunity by natural infections, or vaccination against the early Wuhan-related virus strains. Initial animal studies and phase 3 vaccination trials did not reveal any vaccine enhanced disease or antibody-dependent disease enhancement. Instead, vaccination within 3 days before or after virus challenge in hamsters still showed varying degree of protection despite the lack of detectable neutralizing antibody titre at that juncture. To maximize protection of the available vaccines, further studies on the effects of prime and boost approach by different combinations of vaccines are warranted. With the increasing availability of safe and effective vaccines, the battle is to fight misinformation and vaccine hesitancy by strategic education and risk communication so as to achieve a herd immunity of 70â80%.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_1</infon><offset>77261</offset><text>Epilogue</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>77270</offset><text>Emerging coronaviruses from animals have caused SARS in 2002â2003, MERS in 2012, and COVID-19 in 2019. These viruses have probably originated in bats and gone through intermediate wild mammals before jumping into humans. We predicted in 2007 that âthe presence of a large reservoir of SARS-CoV-like viruses in horseshoe bats, together with the culture of eating exotic mammals in southern China, is a time bomb. The possibility of the reemergence of SARS and other novel viruses from animals or laboratories and therefore the need for preparedness should not be ignoredâ. Spillover of SARS-CoV-2 from animals to humans appears to have happened in 2019. But unlike the other two highly pathogenic coronaviruses, the highly transmissible SARS-CoV-2 is able to overwhelm the healthcare system, inflict psycho-physical morbidities and mortalities, and disrupt our socioeconomic activities. More extensive and sustained animal surveillance for novel coronaviruses, monitoring of their evolution, and assessment of their risk of species jumping should be performed to understand the origin of SARS-CoV-2, the intermediate animal host, and to prepare for the next epidemic. The functions of many NSPs and ORFs of SARS-CoV-2, and their roles in viral life cycle and pathogenesis, are still uncertain. Unlike SARS which is usually quite symptomatic, the viral and immunological mechanisms underlying the generally milder symptoms or lack of symptoms in COVID-19 warrant more investigations. The types of samples and tests which can provide rapid, inexpensive and accurate diagnosis still need more research and development. With the early peaking of viral load, any effective antiviral strategy must be able to suppress the viral load sharply and coupled with immunomodulatory agents in order to improve the clinical outcome. Close monitoring of viral variants with increased virulence, transmissibility, and resistance to antivirals, antibodies or vaccines is important to combat this pandemic. The duration of protection by natural infection or vaccination, and the relative contribution to protection by neutralizing antibody or cell mediated immunity are still uncertain. Understanding the relative importance of transmission by droplet, aerosol, contact, and oral ingestion would provide more evidence to support recommendations on infection control measures and biosecurity standards of markets. Reusable, self-disinfectable and personalized filter-mask, eye protection, gloves and gowns should be developed as essential components of an environmental-friendly epidemic combat kit for everyone in the global village. Much more work by a highly coordinated real-time global surveillance network has to be done to win this war against COVID-19 and further emerging epidemics.</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">title_1</infon><offset>80047</offset><text>Disclosure statement</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">paragraph</infon><offset>80068</offset><text>JFWC has received travel grants from Pfizer Corporation Hong Kong and Astellas Pharma Hong Kong Corporation Limited, and was an invited speaker for Gilead Sciences Hong Kong Limited and Luminex Corporation. The other authors declared no conflict of interests. The funding sources had no role in study design, data collection, analysis or interpretation or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">title</infon><offset>80591</offset><text>References</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>80602</offset></passage><passage><infon key=\"fpage\">e1008536</infon><infon key=\"pub-id_pmid\">32442210</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS Pathog</infon><infon key=\"type\">ref</infon><infon key=\"volume\">16</infon><infon key=\"year\">2020</infon><offset>80603</offset><text>The hallmarks of COVID-19 disease</text></passage><passage><infon key=\"fpage\">1199</infon><infon key=\"lpage\">1207</infon><infon key=\"pub-id_pmid\">31995857</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>80637</offset><text>Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia</text></passage><passage><infon key=\"pub-id_doi\">10.1101/2020.11.20.392126</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">bioRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>80722</offset><text>Timing the SARS-CoV-2 index case in Hubei Province</text></passage><passage><infon key=\"fpage\">450</infon><infon key=\"lpage\">452</infon><infon key=\"pub-id_pmid\">32284615</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>80773</offset><text>The proximal origin of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">727</infon><infon key=\"lpage\">733</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2019</infon><offset>80807</offset><text>China Novel Coronavirus I, Research T. 2020. A Novel Coronavirus from patients with pneumonia in China</text></passage><passage><infon key=\"fpage\">514</infon><infon key=\"lpage\">523</infon><infon key=\"pub-id_pmid\">31986261</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>80910</offset><text>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster</text></passage><passage><infon key=\"fpage\">e112</infon><infon key=\"pub-id_pmid\">32174069</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Korean Med Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">35</infon><infon key=\"year\">2020</infon><offset>81055</offset><text>Report on the epidemiological features of Coronavirus Disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020</text></passage><passage><infon key=\"fpage\">e18941</infon><infon key=\"pub-id_pmid\">32250957</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JMIR Public Health Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2020</infon><offset>81200</offset><text>Tracking COVID-19 in Europe: infodemiology approach</text></passage><passage><infon key=\"comment\">2000550</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>81252</offset><text>A hundred days into the coronavirus disease (COVID-19) pandemic</text></passage><passage><infon key=\"fpage\">465</infon><infon key=\"lpage\">471</infon><infon key=\"pub-id_pmid\">32298250</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">MMWR Morb Mortal Wkly Rep</infon><infon key=\"type\">ref</infon><infon key=\"volume\">69</infon><infon key=\"year\">2020</infon><offset>81316</offset><text>Geographic Differences in COVID-19 cases, deaths, and incidence - United States, February 12-April 7, 2020</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">22 December 2020 2020</infon><offset>81423</offset></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>81424</offset></passage><passage><infon key=\"fpage\">465</infon><infon key=\"lpage\">522</infon><infon key=\"pub-id_pmid\">25810418</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">28</infon><infon key=\"year\">2015</infon><offset>81425</offset><text>Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease</text></passage><passage><infon key=\"fpage\">270</infon><infon key=\"lpage\">273</infon><infon key=\"pub-id_pmid\">32015507</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">579</infon><infon key=\"year\">2020</infon><offset>81530</offset><text>A pneumonia outbreak associated with a new coronavirus of probable bat origin</text></passage><passage><infon key=\"fpage\">221</infon><infon key=\"lpage\">236</infon><infon key=\"pub-id_pmid\">31987001</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>81608</offset><text>Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</text></passage><passage><infon key=\"fpage\">125</infon><infon key=\"lpage\">130</infon><infon key=\"pub-id_pmid\">32906143</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">589</infon><infon key=\"year\">2021</infon><offset>81749</offset><text>The coding capacity of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">265</infon><infon key=\"lpage\">269</infon><infon key=\"pub-id_pmid\">32015508</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">579</infon><infon key=\"year\">2020</infon><offset>81783</offset><text>A new coronavirus associated with human respiratory disease in China</text></passage><passage><infon key=\"fpage\">1444</infon><infon key=\"lpage\">1448</infon><infon key=\"pub-id_pmid\">32132184</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">367</infon><infon key=\"year\">2020</infon><offset>81852</offset><text>Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</text></passage><passage><infon key=\"fpage\">2706</infon><infon key=\"lpage\">2714</infon><infon key=\"pub-id_pmid\">22205751</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">86</infon><infon key=\"year\">2012</infon><offset>81929</offset><text>The multibasic cleavage site of the hemagglutinin of highly pathogenic A/Vietnam/1203/2004 (H5N1) avian influenza virus acts as a virulence factor in a host-specific manner in mammals</text></passage><passage><infon key=\"fpage\">837</infon><infon key=\"lpage\">842</infon><infon key=\"pub-id_pmid\">32301390</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>82113</offset><text>Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction</text></passage><passage><infon key=\"comment\">e202000786</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Life Sci Alliance</infon><infon key=\"type\">ref</infon><infon key=\"volume\">3</infon><infon key=\"year\">2020</infon><offset>82181</offset><text>TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells</text></passage><passage><infon key=\"fpage\">1202</infon><infon key=\"lpage\">1208</infon><infon key=\"pub-id_pmid\">33177698</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Struct Mol Biol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">27</infon><infon key=\"year\">2020</infon><offset>82281</offset><text>Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers</text></passage><passage><infon key=\"fpage\">299</infon><infon key=\"pub-id_pmid\">33372174</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Signal Transduct Target Ther</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>82382</offset><text>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling</text></passage><passage><infon key=\"fpage\">e105938</infon><infon key=\"pub-id_pmid\">32914439</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Embo j</infon><infon key=\"type\">ref</infon><infon key=\"volume\">39</infon><infon key=\"year\">2020</infon><offset>82545</offset><text>Structures of the SARS-CoV-2 nucleocapsid and their perspectives for drug design</text></passage><passage><infon key=\"fpage\">881</infon><infon key=\"lpage\">883</infon><infon key=\"pub-id_pmid\">32555321</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Mol Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">17</infon><infon key=\"year\">2020</infon><offset>82626</offset><text>The ORF3a protein of SARS-CoV-2 induces apoptosis in cells</text></passage><passage><infon key=\"fpage\">1418</infon><infon key=\"lpage\">1428</infon><infon key=\"pub-id_pmid\">32529952</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>82685</offset><text>SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists</text></passage><passage><infon key=\"fpage\">459</infon><infon key=\"lpage\">468</infon><infon key=\"pub-id_pmid\">32353859</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">583</infon><infon key=\"year\">2020</infon><offset>82767</offset><text>A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</text></passage><passage><infon key=\"fpage\">28344</infon><infon key=\"lpage\">28354</infon><infon key=\"pub-id_pmid\">33097660</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Proc Natl Acad Sci USA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">117</infon><infon key=\"year\">2020</infon><offset>82841</offset><text>SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling</text></passage><passage><infon key=\"comment\">eabe9403</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">370</infon><infon key=\"year\">2020</infon><offset>82936</offset><text>Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms</text></passage><passage><infon key=\"fpage\">603</infon><infon key=\"lpage\">611</infon><infon key=\"pub-id_pmid\">32822564</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">396</infon><infon key=\"year\">2020</infon><offset>83030</offset><text>Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study</text></passage><passage><infon key=\"fpage\">2685</infon><infon key=\"lpage\">2696</infon><infon key=\"pub-id_pmid\">33205709</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>83173</offset><text>Loss of orf3b in the circulating SARS-CoV-2 strains</text></passage><passage><infon key=\"fpage\">104523</infon><infon key=\"pub-id_pmid\">32623351</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">129</infon><infon key=\"year\">2020</infon><offset>83225</offset><text>Identification of multiple large deletions in ORF7a resulting in in-frame gene fusions in clinical SARS-CoV-2 isolates</text></passage><passage><infon key=\"fpage\">108185</infon><infon key=\"pub-id_pmid\">32941788</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Rep</infon><infon key=\"type\">ref</infon><infon key=\"volume\">32</infon><infon key=\"year\">2020</infon><offset>83344</offset><text>SARS-CoV-2 ORF3b Is a potent interferon antagonist whose activity Is increased by a naturally occurring elongation variant</text></passage><passage><infon key=\"fpage\">998</infon><infon key=\"lpage\">1000</infon><infon key=\"pub-id_pmid\">32728199</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Mol Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">17</infon><infon key=\"year\">2020</infon><offset>83467</offset><text>SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70</text></passage><passage><infon key=\"fpage\">e1008959</infon><infon key=\"pub-id_pmid\">33301543</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS Pathog</infon><infon key=\"type\">ref</infon><infon key=\"volume\">16</infon><infon key=\"year\">2020</infon><offset>83542</offset><text>The SARS-CoV-2 ORF10 is not essential in vitro or in vivo in humans</text></passage><passage><infon key=\"pub-id_doi\">10.1101/2020.10.26.355784</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">bioRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>83610</offset><text>Characterization and structural prediction of the putative ORF10 protein in SARS-CoV-2</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>83697</offset></passage><passage><infon key=\"fpage\">134</infon><infon key=\"pub-id_pmid\">33420022</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2021</infon><offset>83698</offset><text>Host and viral determinants for efficient SARS-CoV-2 infection of the human lung</text></passage><passage><infon key=\"fpage\">861</infon><infon key=\"lpage\">865</infon><infon key=\"pub-id_pmid\">33082294</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">370</infon><infon key=\"year\">2020</infon><offset>83779</offset><text>Neuropilin-1 is a host factor for SARS-CoV-2 infection</text></passage><passage><infon key=\"fpage\">856</infon><infon key=\"lpage\">860</infon><infon key=\"pub-id_pmid\">33082293</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">370</infon><infon key=\"year\">2020</infon><offset>83834</offset><text>Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity</text></passage><passage><infon key=\"pub-id_doi\">10.1038/s41422-020-00460-y</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Res</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>83897</offset><text>AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells</text></passage><passage><infon key=\"fpage\">283</infon><infon key=\"pub-id_pmid\">33277466</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Signal Transduct Target Ther</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>84008</offset><text>CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells</text></passage><passage><infon key=\"fpage\">1391</infon><infon key=\"lpage\">1400</infon><infon key=\"pub-id_pmid\">33244168</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Metab</infon><infon key=\"type\">ref</infon><infon key=\"volume\">2</infon><infon key=\"year\">2020</infon><offset>84084</offset><text>HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry</text></passage><passage><infon key=\"fpage\">104759</infon><infon key=\"pub-id_pmid\">32130973</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Antiviral Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">177</infon><infon key=\"year\">2020</infon><offset>84145</offset><text>A potential role for integrins in host cell entry by SARS-CoV-2</text></passage><passage><infon key=\"fpage\">76</infon><infon key=\"lpage\">91</infon><infon key=\"pub-id_pmid\">33147444</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">184</infon><infon key=\"year\">2021</infon><offset>84209</offset><text>Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection</text></passage><passage><infon key=\"pub-id_doi\">10.1038/s41579-020-00459-7</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Rev Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>84290</offset><text>Characteristics of SARS-CoV-2 and COVID-19</text></passage><passage><infon key=\"fpage\">101258</infon><infon key=\"pub-id_pmid\">32592996</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">iScience</infon><infon key=\"type\">ref</infon><infon key=\"volume\">23</infon><infon key=\"year\">2020</infon><offset>84333</offset><text>Crystal Structure of the SARS-CoV-2 Non-structural protein 9, Nsp9</text></passage><passage><infon key=\"fpage\">99</infon><infon key=\"lpage\">112.e7</infon><infon key=\"pub-id_pmid\">32838362</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Med (N Y</infon><infon key=\"type\">ref</infon><infon key=\"volume\">2</infon><infon key=\"year\">2021</infon><offset>84400</offset><text>Virus-Host interactome and proteomic survey reveal potential virulence factors influencing SARS-CoV-2 pathogenesis</text></passage><passage><infon key=\"fpage\">914</infon><infon key=\"lpage\">921.e10</infon><infon key=\"pub-id_pmid\">32330414</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">181</infon><infon key=\"year\">2020</infon><offset>84515</offset><text>The architecture of SARS-CoV-2 transcriptome</text></passage><passage><infon key=\"pub-id_doi\">10.1038/s41579-020-00468-6</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Rev Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>84560</offset><text>Coronavirus biology and replication: implications for SARS-CoV-2</text></passage><passage><infon key=\"fpage\">107725</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Rep</infon><infon key=\"type\">ref</infon><infon key=\"volume\">31</infon><infon key=\"year\">2020</infon><offset>84625</offset><text>Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections</text></passage><passage><infon key=\"fpage\">12436</infon><infon key=\"lpage\">12452</infon><infon key=\"pub-id_pmid\">33166999</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nucleic Acids Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">48</infon><infon key=\"year\">2020</infon><offset>84701</offset><text>Genome-wide mapping of SARS-CoV-2 RNA structures identifies therapeutically-relevant elements</text></passage><passage><infon key=\"fpage\">1819</infon><infon key=\"lpage\">1826</infon><infon key=\"pub-id_pmid\">18057240</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">82</infon><infon key=\"year\">2008</infon><offset>84795</offset><text>Evidence of the recombinant origin of a bat severe acute respiratory syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS coronavirus</text></passage><passage><infon key=\"fpage\">282</infon><infon key=\"lpage\">285</infon><infon key=\"pub-id_pmid\">32218527</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">583</infon><infon key=\"year\">2020</infon><offset>84961</offset><text>Identifying SARS-CoV-2-related coronaviruses in malayan pangolins</text></passage><passage><infon key=\"fpage\">1722</infon><infon key=\"lpage\">1726</infon><infon key=\"pub-id_pmid\">32738466</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Am J Emerg Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">38</infon><infon key=\"year\">2020</infon><offset>85027</offset><text>Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis</text></passage><passage><infon key=\"fpage\">1408</infon><infon key=\"lpage\">1417</infon><infon key=\"pub-id_pmid\">32724171</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>85142</offset><text>Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic</text></passage><passage><infon key=\"fpage\">R849</infon><infon key=\"lpage\">R857</infon><infon key=\"pub-id_pmid\">32750338</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Curr Biol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2020</infon><offset>85240</offset><text>On the evolutionary epidemiology of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">veaa061</infon><infon key=\"pub-id_pmid\">33235813</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Virus Evol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2020</infon><offset>85287</offset><text>Temporal signal and the phylodynamic threshold of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">104445</infon><infon key=\"pub-id_pmid\">32615316</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Infect Genet Evol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">85</infon><infon key=\"year\">2020</infon><offset>85348</offset><text>Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission</text></passage><passage><infon key=\"comment\">eabe2555</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci Transl Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>85447</offset><text>Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2</text></passage><passage><infon key=\"pub-id_doi\">10.1016/j.cmi.2020.10.030</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Infect</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>85574</offset><text>Intra-host non-synonymous diversity at a neutralizing antibody epitope of SARS-CoV-2 spike protein N-terminal domain</text></passage><passage><infon key=\"fpage\">1403</infon><infon key=\"lpage\">1407</infon><infon key=\"pub-id_pmid\">32669681</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>85691</offset><text>A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>85778</offset><text>. Global Report Investigating Novel Coronavirus Haplotypes. https://cov-lineages.org/global_report.html. Accessed 22 February.</text></passage><passage><infon key=\"pub-id_doi\">10.1093/cid/ciaa1119</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>85905</offset><text>Unique SARS-CoV-2 clusters causing a large COVID-19 outbreak in Hong Kong</text></passage><passage><infon key=\"fpage\">1284</infon><infon key=\"lpage\">1294 e9</infon><infon key=\"pub-id_pmid\">32730807</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">182</infon><infon key=\"year\">2020</infon><offset>85979</offset><text>The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity</text></passage><passage><infon key=\"comment\">e61312</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Elife</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>86061</offset><text>Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants</text></passage><passage><infon key=\"pub-id_doi\">10.1101/2020.12.05.20241927</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>86134</offset><text>Neutralising antibodies drive spike mediated SARS-CoV-2 evasion</text></passage><passage><infon key=\"pub-id_doi\">10.1093/cid/ciaa1474</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>86198</offset><text>Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19</text></passage><passage><infon key=\"fpage\">1016</infon><infon key=\"lpage\">1020</infon><infon key=\"pub-id_pmid\">32269068</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">368</infon><infon key=\"year\">2020</infon><offset>86332</offset><text>Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2</text></passage><passage><infon key=\"fpage\">172</infon><infon key=\"lpage\">177</infon><infon key=\"pub-id_pmid\">33172935</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">371</infon><infon key=\"year\">2021</infon><offset>86424</offset><text>Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans</text></passage><passage><infon key=\"fpage\">1603</infon><infon key=\"lpage\">1607</infon><infon key=\"pub-id_pmid\">32732280</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">369</infon><infon key=\"year\">2020</infon><offset>86508</offset><text>Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy</text></passage><passage><infon key=\"fpage\">529</infon><infon key=\"lpage\">531</infon><infon key=\"pub-id_pmid\">33404586</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Jama</infon><infon key=\"type\">ref</infon><infon key=\"volume\">325</infon><infon key=\"year\">2021</infon><offset>86577</offset><text>Genetic Variants of SARS-CoV-2-what do they mean?</text></passage><passage><infon key=\"pub-id_doi\">10.1093/cid/ciaa953</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>86627</offset><text>Natural transmission of bat-like SARS-CoV-2PRRA variants in COVID-19 patients</text></passage><passage><infon key=\"comment\">e02431-20</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">mBio</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>86705</offset><text>Accurate diagnosis of COVID-19 by a novel immunogenic secreted SARS-CoV-2 orf8 protein</text></passage><passage><infon key=\"fpage\">1464</infon><infon key=\"lpage\">1468</infon><infon key=\"pub-id_pmid\">33184236</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">370</infon><infon key=\"year\">2020</infon><offset>86792</offset><text>SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo</text></passage><passage><infon key=\"fpage\">64</infon><infon key=\"lpage\">75 e11</infon><infon key=\"pub-id_pmid\">33275900</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">184</infon><infon key=\"year\">2021</infon><offset>86881</offset><text>Evaluating the effects of SARS-CoV-2 Spike Mutation D614G on transmissibility and pathogenicity</text></passage><passage><infon key=\"pub-id_doi\">10.1038/s41586-020-2895-3</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>86977</offset><text>Spike mutation D614G alters SARS-CoV-2 fitness</text></passage><passage><infon key=\"fpage\">739</infon><infon key=\"lpage\">751 e8</infon><infon key=\"pub-id_pmid\">32991842</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">183</infon><infon key=\"year\">2020</infon><offset>87024</offset><text>Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant</text></passage><passage><infon key=\"fpage\">18</infon><infon key=\"lpage\">19</infon><infon key=\"pub-id_pmid\">33227234</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">21</infon><infon key=\"year\">2021</infon><offset>87105</offset><text>SARS-CoV-2 and the human-animal interface: outbreaks on mink farms</text></passage><passage><infon key=\"pub-id_doi\">10.1101/2020.12.24.20248822</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">MedRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>87172</offset><text>Estimated transmissibility and severity of novel SARS-CoV-2 variant of concern 202012/01 in england</text></passage><passage><infon key=\"pub-id_doi\">10.1101/2021.01.18.426984</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">bioRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>87272</offset><text>Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera</text></passage><passage><infon key=\"pub-id_doi\">10.1101/2021.01.18.427166</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">bioRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>87369</offset><text>SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma</text></passage><passage><infon key=\"pub-id_doi\">10.1016/S0140-6736(21)00183-5</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">The Lancet</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>87450</offset><text>Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">21 January 2021</infon><offset>87520</offset></passage><passage><infon key=\"pub-id_doi\">10.1093/cid/ciaa1275</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>87521</offset><text>COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>87637</offset></passage><passage><infon key=\"pub-id_doi\">10.1101/2021.01.26.21250543</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>87638</offset><text>The E484â",
      "K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera</text></passage><passage><infon key=\"fpage\">2428</infon><infon key=\"lpage\">2446</infon><infon key=\"pub-id_pmid\">32215622</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>87791</offset><text>Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for disease pathogenesis and transmissibility</text></passage><passage><infon key=\"fpage\">565</infon><infon key=\"lpage\">574</infon><infon key=\"pub-id_pmid\">32213337</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>87982</offset><text>Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study</text></passage><passage><infon key=\"fpage\">1610</infon><infon key=\"lpage\">1612</infon><infon key=\"pub-id_pmid\">32129805</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>88147</offset><text>Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient</text></passage><passage><infon key=\"fpage\">2800</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>88314</offset><text>Singapore novel coronavirus outbreak research T . Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients</text></passage><passage><infon key=\"fpage\">1583</infon><infon key=\"lpage\">1591</infon><infon key=\"pub-id_pmid\">32275497</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>88460</offset><text>Aerosol and surface distribution of severe acute respiratory syndrome coronavirus 2 in hospital wards, Wuhan, China, 2020</text></passage><passage><infon key=\"fpage\">557</infon><infon key=\"lpage\">560</infon><infon key=\"pub-id_pmid\">32340022</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">582</infon><infon key=\"year\">2020</infon><offset>88582</offset><text>Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals</text></passage><passage><infon key=\"fpage\">476</infon><infon key=\"lpage\">482</infon><infon key=\"pub-id_pmid\">32949774</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">100</infon><infon key=\"year\">2020</infon><offset>88640</offset><text>Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients</text></passage><passage><infon key=\"fpage\">2348</infon><infon key=\"pub-id_pmid\">30787335</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci Rep</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2019</infon><offset>88711</offset><text>Aerosol emission and superemission during human speech increase with voice loudness</text></passage><passage><infon key=\"fpage\">m2094</infon><infon key=\"pub-id_pmid\">32493739</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Br Med J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">369</infon><infon key=\"year\">2020</infon><offset>88795</offset><text>Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study</text></passage><passage><infon key=\"fpage\">1258</infon><infon key=\"lpage\">1265</infon><infon key=\"pub-id_pmid\">32507114</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Infect Control Hosp Epidemiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">41</infon><infon key=\"year\">2020</infon><offset>88934</offset><text>Air and environmental sampling for SARS-CoV-2 around hospitalized patients with coronavirus disease 2019 (COVID-19)</text></passage><passage><infon key=\"pub-id_doi\">10.1007/s10311-020-01101-x:1-12</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Environ Chem Lett</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>89050</offset><text>Can the coronavirus disease be transmitted from food? A review of evidence, risks, policies and knowledge gaps</text></passage><passage><infon key=\"fpage\">145</infon><infon key=\"pub-id_pmid\">33028356</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Virol J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">17</infon><infon key=\"year\">2020</infon><offset>89161</offset><text>The effect of temperature on persistence of SARS-CoV-2 on common surfaces</text></passage><passage><infon key=\"pub-id_doi\">10.1101/2020.10.16.341883</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">bioRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>89235</offset><text>The effect of temperature and humidity on the stability of SARS-CoV-2 and other enveloped viruses</text></passage><passage><infon key=\"fpage\">1920</infon><infon key=\"lpage\">1922</infon><infon key=\"pub-id_pmid\">32421494</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>89333</offset><text>Infectious SARS-CoV-2 in feces of patient with severe COVID-19</text></passage><passage><infon key=\"fpage\">991</infon><infon key=\"lpage\">993</infon><infon key=\"pub-id_pmid\">32342724</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>89396</offset><text>Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient</text></passage><passage><infon key=\"fpage\">242</infon><infon key=\"lpage\">243</infon><infon key=\"pub-id_pmid\">32302380</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Ann Intern Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">173</infon><infon key=\"year\">2020</infon><offset>89464</offset><text>SARS-CoV-2 isolation from ocular secretions of a patient with COVID-19 in Italy with prolonged viral RNA detection</text></passage><passage><infon key=\"fpage\">1757</infon><infon key=\"lpage\">1758</infon><infon key=\"pub-id_pmid\">32446324</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>89579</offset><text>Detection of SARS-CoV-2 in human breastmilk</text></passage><passage><infon key=\"fpage\">3572</infon><infon key=\"pub-id_pmid\">32665677</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>89623</offset><text>Transplacental transmission of SARS-CoV-2 infection</text></passage><passage><infon key=\"fpage\">100121</infon><infon key=\"pub-id_pmid\">32984855</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Rep Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">1</infon><infon key=\"year\">2020</infon><offset>89675</offset><text>Oral SARS-CoV-2 inoculation establishes subclinical respiratory infection with virus shedding in Golden Syrian hamsters</text></passage><passage><infon key=\"fpage\">5128</infon><infon key=\"pub-id_pmid\">33046695</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>89795</offset><text>Analysis of SARS-CoV-2 vertical transmission during pregnancy</text></passage><passage><infon key=\"fpage\">974</infon><infon key=\"lpage\">980</infon><infon key=\"pub-id_pmid\">32870707</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Ann Intern Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">173</infon><infon key=\"year\">2020</infon><offset>89857</offset><text>Probable evidence of Fecal aerosol transmission of SARS-CoV-2 in a high-rise building</text></passage><passage><infon key=\"fpage\">1708</infon><infon key=\"lpage\">1720</infon><infon key=\"pub-id_pmid\">32109013</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>89943</offset><text>Clinical Characteristics of Coronavirus Disease 2019 in China</text></passage><passage><infon key=\"fpage\">284</infon><infon key=\"lpage\">286</infon><infon key=\"pub-id_pmid\">32145466</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">93</infon><infon key=\"year\">2020</infon><offset>90005</offset><text>Serial interval of novel coronavirus (COVID-19) infections</text></passage><passage><infon key=\"fpage\">465</infon><infon key=\"lpage\">471</infon><infon key=\"pub-id_pmid\">32298250</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">MMWR Morb Mortal Wkly Rep</infon><infon key=\"type\">ref</infon><infon key=\"volume\">69</infon><infon key=\"year\">2020</infon><offset>90064</offset><text>Geographic Differences in COVID-19 cases, deaths, and Incidence - United States, February 12-April 7, 2020</text></passage><passage><infon key=\"fpage\">689</infon><infon key=\"lpage\">697</infon><infon key=\"pub-id_pmid\">32014114</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>90171</offset><text>Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study</text></passage><passage><infon key=\"fpage\">489</infon><infon key=\"lpage\">493</infon><infon key=\"pub-id_pmid\">32179701</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">368</infon><infon key=\"year\">2020</infon><offset>90319</offset><text>Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)</text></passage><passage><infon key=\"comment\">3705</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Environ Res Public Health</infon><infon key=\"type\">ref</infon><infon key=\"volume\">17</infon><infon key=\"year\">2020</infon><offset>90424</offset><text>Evaluating transmission heterogeneity and super-spreading event of COVID-19 in a metropolis of China</text></passage><passage><infon key=\"fpage\">669</infon><infon key=\"lpage\">677</infon><infon key=\"pub-id_pmid\">32240634</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>90525</offset><text>Estimates of the severity of coronavirus disease 2019: a model-based analysis</text></passage><passage><infon key=\"comment\">2000256</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>90603</offset><text>Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship</text></passage><passage><infon key=\"fpage\">e18821</infon><infon key=\"pub-id_pmid\">32365046</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JMIR Public Health Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2020</infon><offset>90765</offset><text>Preparation for quarantine on the cruise ship Diamond Princess in Japan due to COVID-19</text></passage><passage><infon key=\"fpage\">e2010182</infon><infon key=\"pub-id_pmid\">32459353</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA Netw Open</infon><infon key=\"type\">ref</infon><infon key=\"volume\">3</infon><infon key=\"year\">2020</infon><offset>90853</offset><text>Comparison of clinical Characteristics of patients with asymptomatic vs symptomatic coronavirus disease 2019 in Wuhan, China</text></passage><passage><infon key=\"fpage\">1400</infon><infon key=\"lpage\">1409</infon><infon key=\"pub-id_pmid\">32270184</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>90978</offset><text>Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19</text></passage><passage><infon key=\"fpage\">1767</infon><infon key=\"lpage\">1772</infon><infon key=\"pub-id_pmid\">12781535</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">361</infon><infon key=\"year\">2003</infon><offset>91144</offset><text>Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study</text></passage><passage><infon key=\"fpage\">1531</infon><infon key=\"lpage\">1533</infon><infon key=\"pub-id_pmid\">32807936</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>91266</offset><text>Is presymptomatic spread a major contributor to COVID-19 transmission?</text></passage><passage><infon key=\"fpage\">672</infon><infon key=\"lpage\">675</infon><infon key=\"pub-id_pmid\">32296168</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>91337</offset><text>Temporal dynamics in viral shedding and transmissibility of COVID-19</text></passage><passage><infon key=\"comment\">2000257</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>91406</offset><text>Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data, March 2020</text></passage><passage><infon key=\"fpage\">706</infon><infon key=\"lpage\">711</infon><infon key=\"pub-id_pmid\">32146694</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci China Life Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">63</infon><infon key=\"year\">2020</infon><offset>91516</offset><text>Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China</text></passage><passage><infon key=\"pub-id_doi\">10.1016/S1473-3099(20)30981-6</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>91633</offset><text>Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study</text></passage><passage><infon key=\"fpage\">1193</infon><infon key=\"lpage\">1195</infon><infon key=\"pub-id_pmid\">32504052</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>91768</offset><text>Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China</text></passage><passage><infon key=\"pub-id_doi\">10.1016/S2666-5247(20)30053-7</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Microbe</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>91848</offset><text>Seroprevalence of SARS-CoV-2 in Hong Kong Special Administrative Region and our returnees evacuated from Hubei province of China: a multi-cohort study</text></passage><passage><infon key=\"fpage\">e2025717</infon><infon key=\"pub-id_pmid\">33095246</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA Netw Open</infon><infon key=\"type\">ref</infon><infon key=\"volume\">3</infon><infon key=\"year\">2020</infon><offset>91999</offset><text>Seropositive prevalence of antibodies against SARS-CoV-2 in Wuhan, China</text></passage><passage><infon key=\"fpage\">2425</infon><infon key=\"lpage\">2427</infon><infon key=\"pub-id_pmid\">32421144</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>92072</offset><text>Seroprevalence of SARS-CoV-2-specific antibodies Among adults in Los Angeles county, california, on April 10â11, 2020</text></passage><passage><infon key=\"fpage\">164</infon><infon key=\"lpage\">166</infon><infon key=\"pub-id_pmid\">32525099</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Hong Kong Med J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>92192</offset><text>Responding to COVID-19 in Hong Kong</text></passage><passage><infon key=\"fpage\">328</infon><infon key=\"lpage\">335</infon><infon key=\"pub-id_pmid\">32969975</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Curr Opin HIV AIDS</infon><infon key=\"type\">ref</infon><infon key=\"volume\">15</infon><infon key=\"year\">2020</infon><offset>92228</offset><text>The coronavirus disease 2019 pandemic: how does it spread and how do we stop it?</text></passage><passage><infon key=\"issue\">9â10</infon><infon key=\"pub-id_doi\">10.4414/smw.2020.20212</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Swiss Med Wkly</infon><infon key=\"type\">ref</infon><infon key=\"volume\">150</infon><infon key=\"year\">2020</infon><offset>92309</offset><text>Preliminary case report on the SARS-CoV-2 cluster in the UK, France, and Spain</text></passage><passage><infon key=\"fpage\">454</infon><infon key=\"lpage\">457</infon><infon key=\"pub-id_pmid\">32417246</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">96</infon><infon key=\"year\">2020</infon><offset>92388</offset><text>Evaluation of COVID-19 epidemic outbreak caused by temporal contact-increase in South Korea</text></passage><passage><infon key=\"fpage\">1080</infon><infon key=\"lpage\">1086</infon><infon key=\"pub-id_pmid\">32522606</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Am J Infect Control</infon><infon key=\"type\">ref</infon><infon key=\"volume\">48</infon><infon key=\"year\">2020</infon><offset>92480</offset><text>South Korea's responses to stop the COVID-19 pandemic</text></passage><passage><infon key=\"fpage\">82</infon><infon key=\"lpage\">87</infon><infon key=\"pub-id_pmid\">33171481</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">589</infon><infon key=\"year\">2021</infon><offset>92534</offset><text>Mobility network models of COVID-19 explain inequities and inform reopening</text></passage><passage><infon key=\"fpage\">1574</infon><infon key=\"lpage\">1575</infon><infon key=\"pub-id_pmid\">32593744</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>92610</offset><text>Investigation of a nosocomial outbreak of coronavirus disease 2019 in a paediatric ward in South Korea: successful control by early detection and extensive contact tracing with testing</text></passage><passage><infon key=\"pub-id_doi\">10.1093/cid/ciaa491</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>92795</offset><text>First reported nosocomial outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a pediatric dialysis unit</text></passage><passage><infon key=\"fpage\">928</infon><infon key=\"lpage\">931</infon><infon key=\"pub-id_pmid\">32753756</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2020</infon><offset>92923</offset><text>SARS-CoV-2 infects human neural progenitor cells and brain organoids</text></passage><passage><infon key=\"pub-id_doi\">10.1093/cid/ciaa995</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>92992</offset><text>SARS-CoV-2 infects and damages the mature and immature olfactory sensory neurons of hamsters</text></passage><passage><infon key=\"fpage\">1077</infon><infon key=\"lpage\">1083</infon><infon key=\"pub-id_pmid\">32405028</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>93085</offset><text>Infection of bat and human intestinal organoids by SARS-CoV-2</text></passage><passage><infon key=\"fpage\">e14</infon><infon key=\"lpage\">e23</infon><infon key=\"pub-id_pmid\">32835326</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Microbe</infon><infon key=\"type\">ref</infon><infon key=\"volume\">1</infon><infon key=\"year\">2020</infon><offset>93147</offset><text>Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study</text></passage><passage><infon key=\"fpage\">320</infon><infon key=\"lpage\">332</infon><infon key=\"pub-id_pmid\">32682491</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">396</infon><infon key=\"year\">2020</infon><offset>93367</offset><text>Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington state: a case series</text></passage><passage><infon key=\"fpage\">230</infon><infon key=\"lpage\">243</infon><infon key=\"pub-id_pmid\">33197204</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Circulation</infon><infon key=\"type\">ref</infon><infon key=\"volume\">143</infon><infon key=\"year\">2021</infon><offset>93475</offset><text>COVID-19-Associated nonocclusive fibrin microthrombi in the heart</text></passage><passage><infon key=\"fpage\">76</infon><infon key=\"lpage\">83</infon><infon key=\"pub-id_pmid\">32817204</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Pathol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">74</infon><infon key=\"year\">2021</infon><offset>93541</offset><text>Histopathological observations in COVID-19: a systematic review</text></passage><passage><infon key=\"fpage\">638</infon><infon key=\"lpage\">641</infon><infon key=\"pub-id_pmid\">33185524</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">27</infon><infon key=\"year\">2021</infon><offset>93605</offset><text>Intrauterine transmission of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">1124</infon><infon key=\"lpage\">1129</infon><infon key=\"pub-id_pmid\">32563676</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur Urol Focus</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2020</infon><offset>93645</offset><text>Pathological findings in the testes of COVID-19 patients: clinical implications</text></passage><passage><infon key=\"fpage\">771</infon><infon key=\"lpage\">781</infon><infon key=\"pub-id_pmid\">33010495</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Mol Gastroenterol Hepatol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>93725</offset><text>SARS-CoV-2 Induces a more Robust innate immune response and replicates less efficiently than SARS-CoV in the human intestines: An Ex Vivo Study With Implications on pathogenesis of COVID-19</text></passage><passage><infon key=\"pub-id_doi\">10.1093/cid/ciaa1747</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>93915</offset><text>Co-infection by severe acute respiratory syndrome coronavirus 2 and influenza A(H1N1)pdm09 virus enhances the severity of pneumonia in golden Syrian hamsters</text></passage><passage><infon key=\"pub-id_doi\">10.1080/22221751.2021.1885998:1-38</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>94073</offset><text>Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection</text></passage><passage><infon key=\"fpage\">681</infon><infon key=\"lpage\">686</infon><infon key=\"pub-id_pmid\">32473124</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Respir Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2020</infon><offset>94183</offset><text>Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans</text></passage><passage><infon key=\"fpage\">120</infon><infon key=\"lpage\">128</infon><infon key=\"pub-id_pmid\">32437596</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>94294</offset><text>Pulmonary vascular endothelialitis, thrombosis, and Angiogenesis in covid-19</text></passage><passage><infon key=\"fpage\">73</infon><infon key=\"lpage\">84</infon><infon key=\"pub-id_pmid\">33038391</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Chest</infon><infon key=\"type\">ref</infon><infon key=\"volume\">159</infon><infon key=\"year\">2021</infon><offset>94371</offset><text>Lung Histopathology in Coronavirus Disease 2019 as compared With severe acute respiratory sydrome and H1N1 influenza: A systematic review</text></passage><passage><infon key=\"comment\">e59177</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Elife</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>94509</offset><text>A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm</text></passage><passage><infon key=\"pub-id_doi\">10.1101/2020.12.10.20247205</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>94614</offset><text>Diverse functional autoantibodies in patients with COVID-19</text></passage><passage><infon key=\"comment\">eabd4585</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">370</infon><infon key=\"year\">2020</infon><offset>94674</offset><text>Autoantibodies against type I IFNs in patients with life-threatening COVID-19</text></passage><passage><infon key=\"fpage\">1417</infon><infon key=\"lpage\">1418</infon><infon key=\"pub-id_pmid\">32325026</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>94752</offset><text>Endothelial cell infection and endotheliitis in COVID-19</text></passage><passage><infon key=\"fpage\">611</infon><infon key=\"lpage\">620</infon><infon key=\"pub-id_pmid\">32458111</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Angiogenesis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">23</infon><infon key=\"year\">2020</infon><offset>94809</offset><text>Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients</text></passage><passage><infon key=\"pub-id_doi\">10.1111/jth.15230</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Thromb Haemost</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>94944</offset><text>Thrombotic thrombocytopenic purpura (TTP) response following COVID-19 infection: implications for the ADAMTS13-von Willebrand factor axis</text></passage><passage><infon key=\"pub-id_doi\">10.1007/s10557-020-07084-9</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cardiovasc Drugs Ther</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>95082</offset><text>Thrombotic complications in patients with COVID-19: pathophysiological mechanisms, diagnosis, and treatment</text></passage><passage><infon key=\"pub-id_doi\">10.1002/rmv.2177:e2177</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Rev Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>95190</offset><text>Clotting disorder in severe acute respiratory syndrome coronavirus 2</text></passage><passage><infon key=\"fpage\">110</infon><infon key=\"lpage\">115</infon><infon key=\"pub-id_pmid\">32896915</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Cutan Pathol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">48</infon><infon key=\"year\">2021</infon><offset>95259</offset><text>Investigating the spectrum of dermatologic manifestations in COVID-19 infection in severely ill patients: A series of four cases</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"lpage\">13</infon><infon key=\"pub-id_pmid\">32299776</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Transl Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">220</infon><infon key=\"year\">2020</infon><offset>95388</offset><text>Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases</text></passage><passage><infon key=\"pub-id_doi\">10.1016/j.kint.2020.05.013</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Kidney Int</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>95519</offset><text>The case of complement activation in COVID-19 multiorgan impact</text></passage><passage><infon key=\"fpage\">1176</infon><infon key=\"lpage\">1189</infon><infon key=\"pub-id_pmid\">32755393</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Circulation</infon><infon key=\"type\">ref</infon><infon key=\"volume\">142</infon><infon key=\"year\">2020</infon><offset>95583</offset><text>Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy</text></passage><passage><infon key=\"fpage\">1169</infon><infon key=\"lpage\">1179</infon><infon key=\"pub-id_pmid\">32597954</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Blood</infon><infon key=\"type\">ref</infon><infon key=\"volume\">136</infon><infon key=\"year\">2020</infon><offset>95692</offset><text>Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome</text></passage><passage><infon key=\"fpage\">e290</infon><infon key=\"lpage\">e299</infon><infon key=\"pub-id_pmid\">33015653</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Microbe</infon><infon key=\"type\">ref</infon><infon key=\"volume\">1</infon><infon key=\"year\">2020</infon><offset>95802</offset><text>Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study</text></passage><passage><infon key=\"pub-id_doi\">10.1136/heartjnl-2020-317186</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Heart</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>95906</offset><text>COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?</text></passage><passage><infon key=\"fpage\">e245</infon><infon key=\"lpage\">e253</infon><infon key=\"pub-id_pmid\">32844161</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Microbe</infon><infon key=\"type\">ref</infon><infon key=\"volume\">1</infon><infon key=\"year\">2020</infon><offset>96006</offset><text>Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study</text></passage><passage><infon key=\"fpage\">1868</infon><infon key=\"lpage\">1878</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Natl Sci Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2020</infon><offset>96114</offset><text>Pathological changes in the lungs and lymphatic organs of 12 COVID-19 autopsy cases</text></passage><passage><infon key=\"pub-id_doi\">10.1038/s41593-020-00771-8</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Neurosci</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>96198</offset><text>The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice</text></passage><passage><infon key=\"pub-id_doi\">10.1038/s41582-020-00453-w</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Rev Neurol</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>96267</offset><text>Neurological infection with SARS-CoV-2 - the story so far</text></passage><passage><infon key=\"pub-id_doi\">10.1111/nan.12667</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Neuropathol Appl Neurobiol</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>96325</offset><text>Invited review: The spectrum of neuropathology in COVID-19</text></passage><passage><infon key=\"comment\">e20202135</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Exp Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">218</infon><infon key=\"year\">2021</infon><offset>96384</offset><text>Neuroinvasion of SARS-CoV-2 in human and mouse brain</text></passage><passage><infon key=\"fpage\">919</infon><infon key=\"lpage\">929</infon><infon key=\"pub-id_pmid\">33031735</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Neurol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">19</infon><infon key=\"year\">2020</infon><offset>96437</offset><text>Neuropathology of patients with COVID-19 in Germany: a post-mortem case series</text></passage><passage><infon key=\"fpage\">166</infon><infon key=\"pub-id_pmid\">32659210</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">396</infon><infon key=\"year\">2020</infon><offset>96516</offset><text>Inflammatory olfactory neuropathy in two patients with COVID-19</text></passage><passage><infon key=\"fpage\">989</infon><infon key=\"lpage\">992</infon><infon key=\"pub-id_pmid\">32530583</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>96580</offset><text>Neuropathological features of Covid-19</text></passage><passage><infon key=\"fpage\">e109</infon><infon key=\"pub-id_pmid\">32505222</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>96619</offset><text>Early evidence of pronounced brain involvement in fatal COVID-19 outcomes</text></passage><passage><infon key=\"fpage\">590</infon><infon key=\"lpage\">592</infon><infon key=\"pub-id_pmid\">32402155</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>96693</offset><text>Multiorgan and renal tropism of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">3719</infon><infon key=\"lpage\">3722</infon><infon key=\"pub-id_pmid\">33054673</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Stroke</infon><infon key=\"type\">ref</infon><infon key=\"volume\">51</infon><infon key=\"year\">2020</infon><offset>96736</offset><text>Large and small cerebral vessel involvement in severe COVID-19: detailed clinical workup of a case series</text></passage><passage><infon key=\"fpage\">543</infon><infon key=\"lpage\">546</infon><infon key=\"pub-id_pmid\">32680950</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Neurology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">95</infon><infon key=\"year\">2020</infon><offset>96842</offset><text>COVID-19-related encephalopathy responsive to high-dose glucocorticoids</text></passage><passage><infon key=\"pub-id_doi\">10.1038/s41593-020-00758-5</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Neurosci</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>96914</offset><text>Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci Adv</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2020</infon><offset>97028</offset><text>Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia</text></passage><passage><infon key=\"fpage\">e1</infon><infon key=\"lpage\">e10</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">81</infon><infon key=\"year\">2020</infon><offset>97161</offset><text>Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: Implications for treatment with IFN-beta and IFN inducer</text></passage><passage><infon key=\"fpage\">734</infon><infon key=\"lpage\">745</infon><infon key=\"pub-id_pmid\">32563187</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">222</infon><infon key=\"year\">2020</infon><offset>97330</offset><text>Attenuated interferon and proinflammatory response in SARS-CoV-2-infected human dendritic cells Is Associated With viral antagonism of STAT1 phosphorylation</text></passage><passage><infon key=\"fpage\">3810</infon><infon key=\"pub-id_pmid\">32733001</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>97487</offset><text>Activation and evasion of type I interferon responses by SARS-CoV-2</text></passage><passage><infon key=\"fpage\">864</infon><infon key=\"lpage\">877.e5</infon><infon key=\"pub-id_pmid\">32791036</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Immunity</infon><infon key=\"type\">ref</infon><infon key=\"volume\">53</infon><infon key=\"year\">2020</infon><offset>97555</offset><text>Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses</text></passage><passage><infon key=\"fpage\">5571</infon><infon key=\"lpage\">5581</infon><infon key=\"pub-id_pmid\">20404272</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">184</infon><infon key=\"year\">2010</infon><offset>97626</offset><text>CCR2 plays a critical role in dendritic cell maturation: possible role of CCL2 and NF-kappa B</text></passage><passage><infon key=\"fpage\">1033</infon><infon key=\"lpage\">1034</infon><infon key=\"pub-id_pmid\">32192578</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>97720</offset><text>COVID-19: consider cytokine storm syndromes and immunosuppression</text></passage><passage><infon key=\"fpage\">463</infon><infon key=\"lpage\">469</infon><infon key=\"pub-id_pmid\">32717743</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">584</infon><infon key=\"year\">2020</infon><offset>97786</offset><text>Longitudinal analyses reveal immunological misfiring in severe COVID-19</text></passage><passage><infon key=\"fpage\">3581</infon><infon key=\"pub-id_pmid\">32665645</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>97858</offset><text>SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses</text></passage><passage><infon key=\"fpage\">971</infon><infon key=\"lpage\">977 e3</infon><infon key=\"pub-id_pmid\">32413330</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Immunity</infon><infon key=\"type\">ref</infon><infon key=\"volume\">52</infon><infon key=\"year\">2020</infon><offset>97953</offset><text>Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals</text></passage><passage><infon key=\"fpage\">1595</infon><infon key=\"lpage\">1606</infon><infon key=\"pub-id_pmid\">33065034</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">396</infon><infon key=\"year\">2020</infon><offset>98053</offset><text>SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates</text></passage><passage><infon key=\"comment\">eabe5511</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>98128</offset><text>Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients</text></passage><passage><infon key=\"fpage\">1664</infon><infon key=\"lpage\">1670</infon><infon key=\"pub-id_pmid\">32618497</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>98229</offset><text>High neutralizing antibody titer in intensive care unit patients with COVID-19</text></passage><passage><infon key=\"fpage\">1496</infon><infon key=\"lpage\">1507</infon><infon key=\"pub-id_pmid\">33171099</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">183</infon><infon key=\"year\">2020</infon><offset>98308</offset><text>Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production</text></passage><passage><infon key=\"fpage\">1227</infon><infon key=\"lpage\">1230</infon><infon key=\"pub-id_pmid\">33115920</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">370</infon><infon key=\"year\">2020</infon><offset>98375</offset><text>Robust neutralizing antibodies to SARS-CoV-2 infection persist for months</text></passage><passage><infon key=\"fpage\">eabf4063</infon><infon key=\"pub-id_pmid\">33408181</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">371</infon><infon key=\"year\">2021</infon><offset>98449</offset><text>Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection</text></passage><passage><infon key=\"fpage\">25</infon><infon key=\"lpage\">31</infon><infon key=\"pub-id_pmid\">33154590</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">22</infon><infon key=\"year\">2021</infon><offset>98528</offset><text>Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum</text></passage><passage><infon key=\"fpage\">1724</infon><infon key=\"lpage\">1734</infon><infon key=\"pub-id_pmid\">32871063</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>98631</offset><text>Humoral immune response to SARS-CoV-2 in Iceland</text></passage><passage><infon key=\"pub-id_doi\">10.1093/cid/ciaa1368</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>98680</offset><text>Serum antibody profile of a patient with Coronavirus disease 2019 reinfection</text></passage><passage><infon key=\"fpage\">3434</infon><infon key=\"pub-id_pmid\">32632085</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>98758</offset><text>Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia</text></passage><passage><infon key=\"fpage\">1762</infon><infon key=\"lpage\">1769</infon><infon key=\"pub-id_pmid\">32227123</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">221</infon><infon key=\"year\">2020</infon><offset>98868</offset><text>Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia</text></passage><passage><infon key=\"fpage\">996</infon><infon key=\"lpage\">1012.e19</infon><infon key=\"pub-id_pmid\">33010815</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">183</infon><infon key=\"year\">2020</infon><offset>98949</offset><text>Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity</text></passage><passage><infon key=\"fpage\">1489</infon><infon key=\"lpage\">1501</infon><infon key=\"pub-id_pmid\">32473127</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">181</infon><infon key=\"year\">2020</infon><offset>99063</offset><text>Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals</text></passage><passage><infon key=\"fpage\">420</infon><infon key=\"lpage\">422</infon><infon key=\"pub-id_pmid\">32085846</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Respir Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2020</infon><offset>99175</offset><text>Pathological findings of COVID-19 associated with acute respiratory distress syndrome</text></passage><passage><infon key=\"fpage\">51</infon><infon key=\"lpage\">58</infon><infon key=\"pub-id_pmid\">33199863</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2021</infon><offset>99261</offset><text>Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals</text></passage><passage><infon key=\"fpage\">457</infon><infon key=\"lpage\">462</infon><infon key=\"pub-id_pmid\">32668444</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">584</infon><infon key=\"year\">2020</infon><offset>99392</offset><text>SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls</text></passage><passage><infon key=\"fpage\">270</infon><infon key=\"lpage\">274</infon><infon key=\"pub-id_pmid\">32726801</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">587</infon><infon key=\"year\">2020</infon><offset>99483</offset><text>SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19</text></passage><passage><infon key=\"fpage\">89</infon><infon key=\"lpage\">94</infon><infon key=\"pub-id_pmid\">32753554</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">370</infon><infon key=\"year\">2020</infon><offset>99556</offset><text>Selective and cross-reactive SARS-CoV-2â",
      "T cell epitopes in unexposed humans</text></passage><passage><infon key=\"fpage\">m1985</infon><infon key=\"pub-id_pmid\">32444460</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Br Med J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">369</infon><infon key=\"year\">2020</infon><offset>99634</offset><text>Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study</text></passage><passage><infon key=\"fpage\">2052</infon><infon key=\"lpage\">2059</infon><infon key=\"pub-id_pmid\">32320003</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>99787</offset><text>Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area</text></passage><passage><infon key=\"fpage\">759</infon><infon key=\"lpage\">765</infon><infon key=\"pub-id_pmid\">32555134</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">MMWR Morb Mortal Wkly Rep</infon><infon key=\"type\">ref</infon><infon key=\"volume\">69</infon><infon key=\"year\">2020</infon><offset>99916</offset><text>Coronavirus Disease 2019 case surveillance - United States, January 22-May 30, 2020</text></passage><passage><infon key=\"fpage\">ofaa199</infon><infon key=\"pub-id_pmid\">32548209</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Open Forum Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2020</infon><offset>100000</offset><text>Olfactory Dysfunction in Coronavirus Disease 2019 patients: observational cohort study and systematic review</text></passage><passage><infon key=\"fpage\">2574</infon><infon key=\"lpage\">2576</infon><infon key=\"pub-id_pmid\">32302082</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>100109</offset><text>Guillain-Barre syndrome associated with SARS-CoV-2</text></passage><passage><infon key=\"fpage\">334</infon><infon key=\"lpage\">346</infon><infon key=\"pub-id_pmid\">32598831</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>100160</offset><text>Multisystem inflammatory syndrome in U.S. children and adolescents</text></passage><passage><infon key=\"fpage\">e926</infon><infon key=\"lpage\">e935</infon><infon key=\"pub-id_pmid\">33141191</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Endocrinol Metab</infon><infon key=\"type\">ref</infon><infon key=\"volume\">106</infon><infon key=\"year\">2021</infon><offset>100227</offset><text>Thyroid dysfunction in relation to immune profile, disease status, and outcome in 191 patients with COVID-19</text></passage><passage><infon key=\"fpage\">1239</infon><infon key=\"lpage\">1242</infon><infon key=\"pub-id_pmid\">32091533</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Jama</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>100336</offset><text>Characteristics of and important Lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72â¯314 cases from the Chinese Center for Disease Control and Prevention</text></passage><passage><infon key=\"fpage\">555301</infon><infon key=\"pub-id_pmid\">33195304</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Front Med (Lausanne)</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2020</infon><offset>100538</offset><text>Current understanding of COVID-19 clinical course and investigational treatments</text></passage><passage><infon key=\"fpage\">2027</infon><infon key=\"lpage\">2034</infon><infon key=\"pub-id_pmid\">32221519</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>100619</offset><text>Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019</text></passage><passage><infon key=\"fpage\">1757</infon><infon key=\"lpage\">1766</infon><infon key=\"pub-id_pmid\">32329974</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>100700</offset><text>Mild or moderate covid-19</text></passage><passage><infon key=\"fpage\">357</infon><infon key=\"lpage\">371</infon><infon key=\"pub-id_pmid\">32615199</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">81</infon><infon key=\"year\">2020</infon><offset>100726</offset><text>SARS-CoV-2 detection, viral load and infectivity over the course of an infection</text></passage><passage><infon key=\"fpage\">104960</infon><infon key=\"pub-id_pmid\">32473310</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pharmacol Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">159</infon><infon key=\"year\">2020</infon><offset>100807</offset><text>Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and Abiraterone as potential COVID-19 treatments with a robust two-tier screening system</text></passage><passage><infon key=\"fpage\">286</infon><infon key=\"lpage\">288</infon><infon key=\"pub-id_pmid\">32807735</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Hong Kong Med J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>100980</offset><text>Radiology and COVID-19</text></passage><passage><infon key=\"fpage\">m1966</infon><infon key=\"pub-id_pmid\">32444366</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Br Med J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">369</infon><infon key=\"year\">2020</infon><offset>101003</offset><text>Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study</text></passage><passage><infon key=\"pub-id_doi\">10.1038/s41586-020-03065-y</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>101158</offset><text>Genetic mechanisms of critical illness in covid-19</text></passage><passage><infon key=\"fpage\">1522</infon><infon key=\"lpage\">1534</infon><infon key=\"pub-id_pmid\">32558485</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>101209</offset><text>Genomewide Association study of severe covid-19 with respiratory failure</text></passage><passage><infon key=\"fpage\">eabd4585</infon><infon key=\"pub-id_pmid\">32972996</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">370</infon><infon key=\"year\">2020</infon><offset>101282</offset><text>Autoantibodies against type I IFNs in patients with life-threatening COVID-19</text></passage><passage><infon key=\"fpage\">eabd4570</infon><infon key=\"pub-id_pmid\">32972995</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">370</infon><infon key=\"year\">2020</infon><offset>101360</offset><text>Inborn errors of type I IFN immunity in patients with life-threatening COVID-19</text></passage><passage><infon key=\"fpage\">663</infon><infon key=\"lpage\">673</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">324</infon><infon key=\"year\">2020</infon><offset>101440</offset><text>Presence of genetic variants among young men with severe COVID-19</text></passage><passage><infon key=\"fpage\">747</infon><infon key=\"lpage\">764</infon><infon key=\"pub-id_pmid\">33060844</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature Reviews Nephrology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">16</infon><infon key=\"year\">2020</infon><offset>101506</offset><text>COVID-19-associated acute kidney injury: consensus report of the 25th acute disease quality Initiative (ADQI) workgroup</text></passage><passage><infon key=\"fpage\">e043560</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BMJ Open</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2020</infon><offset>101626</offset><text>COVID-19 case-fatality rate and demographic and socioeconomic influencers: worldwide spatial regression analysis based on country-level data</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>101767</offset></passage><passage><infon key=\"pub-id_doi\">10.3201/eid2704.204895</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">27</infon><infon key=\"year\">2021</infon><offset>101768</offset><text>COVID-19-associated pulmonary aspergillosis, March-August 2020</text></passage><passage><infon key=\"fpage\">220</infon><infon key=\"lpage\">232</infon><infon key=\"pub-id_pmid\">33428867</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">397</infon><infon key=\"year\">2021</infon><offset>101831</offset><text>6-month consequences of COVID-19 in patients discharged from hospital: a cohort study</text></passage><passage><infon key=\"pub-id_doi\">10.1002/jmv.26624</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>101917</offset><text>Chronic COVID Syndrome: need for an appropriate medical terminology for long-COVID and COVID long-haulers</text></passage><passage><infon key=\"fpage\">4017</infon><infon key=\"lpage\">4020</infon><infon key=\"pub-id_pmid\">33275404</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Chem Neurosci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>102023</offset><text>Deleterious outcomes in Long-Hauler COVID-19: The effects of SARS-CoV-2 on the CNS in Chronic COVID syndrome</text></passage><passage><infon key=\"fpage\">m3026</infon><infon key=\"pub-id_pmid\">32784198</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Br Med J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">370</infon><infon key=\"year\">2020</infon><offset>102132</offset><text>Management of post-acute covid-19 in primary care</text></passage><passage><infon key=\"fpage\">6208</infon><infon key=\"pub-id_pmid\">33277494</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>102182</offset><text>Longitudinal symptom dynamics of COVID-19 infection</text></passage><passage><infon key=\"fpage\">2588</infon><infon key=\"lpage\">2596</infon><infon key=\"pub-id_pmid\">33138739</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>102234</offset><text>COVID-19 in children across three Asian cosmopolitan regions</text></passage><passage><infon key=\"fpage\">334</infon><infon key=\"lpage\">346</infon><infon key=\"pub-id_pmid\">32598831</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>102295</offset><text>Multisystem Inflammatory Syndrome in U.S. children and adolescents</text></passage><passage><infon key=\"fpage\">968</infon><infon key=\"lpage\">981</infon><infon key=\"pub-id_pmid\">32966765</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">183</infon><infon key=\"year\">2020</infon><offset>102362</offset><text>The immunology of multisystem inflammatory syndrome in children with COVID-19</text></passage><passage><infon key=\"fpage\">112455</infon><infon key=\"pub-id_pmid\">32739797</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biosens Bioelectron</infon><infon key=\"type\">ref</infon><infon key=\"volume\">166</infon><infon key=\"year\">2020</infon><offset>102440</offset><text>Detection of COVID-19: A review of the current literature and future perspectives</text></passage><passage><infon key=\"fpage\">21</infon><infon key=\"lpage\">33</infon><infon key=\"pub-id_pmid\">32864735</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Immunol Cell Biol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">99</infon><infon key=\"year\">2021</infon><offset>102522</offset><text>Antibody detection assays for COVID-19 diagnosis: an early overview</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">11th September 2020</infon><offset>102590</offset></passage><passage><infon key=\"fpage\">1843</infon><infon key=\"lpage\">1844</infon><infon key=\"pub-id_pmid\">32159775</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>102591</offset><text>Detection of SARS-CoV-2 in different types of clinical specimens</text></passage><passage><infon key=\"fpage\">841</infon><infon key=\"lpage\">843</infon><infon key=\"pub-id_pmid\">32047895</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>102656</offset><text>Consistent detection of 2019 novel coronavirus in saliva</text></passage><passage><infon key=\"fpage\">372</infon><infon key=\"lpage\">378</infon><infon key=\"pub-id_pmid\">29906597</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2019</infon><offset>102713</offset><text>Saliva as a diagnostic specimen for testing respiratory virus by a point-of-care molecular assay: a diagnostic validity study</text></passage><passage><infon key=\"fpage\">1356</infon><infon key=\"lpage\">1359</infon><infon key=\"pub-id_pmid\">32459137</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>102839</offset><text>Evaluating the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">1858002</infon><infon key=\"pub-id_pmid\">33391631</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Oral Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">13</infon><infon key=\"year\">2020</infon><offset>102949</offset><text>Performance of at-home self-collected saliva and nasal-oropharyngeal swabs in the surveillance of COVID-19</text></passage><passage><infon key=\"fpage\">1283</infon><infon key=\"lpage\">1286</infon><infon key=\"pub-id_pmid\">32857487</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>103056</offset><text>Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">2939</infon><infon key=\"lpage\">2946</infon><infon key=\"pub-id_pmid\">32562544</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>103124</offset><text>Posterior oropharyngeal saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</text></passage><passage><infon key=\"fpage\">ofaa210</infon><infon key=\"pub-id_pmid\">32577428</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Open Forum Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2020</infon><offset>103237</offset><text>Early-Morning vs spot posterior oropharyngeal saliva for diagnosis of SARS-CoV-2 infection: Implication of timing of specimen collection for community-wide screening</text></passage><passage><infon key=\"fpage\">e2011335</infon><infon key=\"pub-id_pmid\">32525549</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA Netw Open</infon><infon key=\"type\">ref</infon><infon key=\"volume\">3</infon><infon key=\"year\">2020</infon><offset>103403</offset><text>Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: A systematic review and meta-analysis</text></passage><passage><infon key=\"fpage\">1151</infon><infon key=\"lpage\">1153</infon><infon key=\"pub-id_pmid\">32958959</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Biotechnol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">38</infon><infon key=\"year\">2020</infon><offset>103549</offset><text>Tracking COVID-19 with wastewater</text></passage><passage><infon key=\"fpage\">143493</infon><infon key=\"pub-id_pmid\">33190883</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci Total Environ</infon><infon key=\"type\">ref</infon><infon key=\"volume\">759</infon><infon key=\"year\">2021</infon><offset>103583</offset><text>Wastewater surveillance for SARS-CoV-2: Lessons learnt from recent studies to define future applications</text></passage><passage><infon key=\"fpage\">S90</infon><infon key=\"lpage\">S97</infon><infon key=\"pub-id_pmid\">30376094</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">67</infon><infon key=\"year\">2018</infon><offset>103688</offset><text>A review of the most commonly used methods for sample collection in environmental surveillance of poliovirus</text></passage><passage><infon key=\"pub-id_doi\">10.1007/s15010-020-01524-2</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Infection</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>103797</offset><text>Detection of SARS-CoV-2 in conjunctival secretions from patients without ocular symptoms</text></passage><passage><infon key=\"fpage\">1231</infon><infon key=\"lpage\">1232</infon><infon key=\"pub-id_pmid\">32530425</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>103886</offset><text>Pooling of samples for testing for SARS-CoV-2 in asymptomatic people</text></passage><passage><infon key=\"fpage\">2306</infon><infon key=\"lpage\">2307</infon><infon key=\"pub-id_pmid\">32369202</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>103955</offset><text>Pooling of nasopharyngeal swab specimens for SARS-CoV-2 detection by RT-PCR</text></passage><passage><infon key=\"pub-id_doi\">10.1128/JCM.01261-20</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>104031</offset><text>Assessment of sample pooling for clinical SARS-CoV-2 testing</text></passage><passage><infon key=\"fpage\">79</infon><infon key=\"lpage\">92</infon><infon key=\"pub-id_pmid\">33343043</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Biochem Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">41</infon><infon key=\"year\">2020</infon><offset>104092</offset><text>Considerations for group testing: A practical approach for the clinical laboratory</text></passage><passage><infon key=\"fpage\">276</infon><infon key=\"lpage\">280</infon><infon key=\"pub-id_pmid\">33086375</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">589</infon><infon key=\"year\">2021</infon><offset>104175</offset><text>A pooled testing strategy for identifying SARS-CoV-2 at low prevalence</text></passage><passage><infon key=\"fpage\">e9</infon><infon key=\"pub-id_pmid\">33436132</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Epidemiol Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">149</infon><infon key=\"year\">2020</infon><offset>104246</offset><text>Modelling pool testing for SARS-CoV-2: addressing heterogeneity in populations</text></passage><passage><infon key=\"comment\">e00512-20</infon><infon key=\"issue\">6</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>104325</offset><text>Laboratory diagnosis of COVID-19: current issues and challenges</text></passage><passage><infon key=\"comment\">e00310-20</infon><infon key=\"issue\">5</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>104389</offset><text>Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time Reverse transcription-PCR assay validated In vitro and with clinical specimens</text></passage><passage><infon key=\"fpage\">n288</infon><infon key=\"pub-id_pmid\">33514508</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Br Med J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">372</infon><infon key=\"year\">2021</infon><offset>104581</offset><text>Covid-19: sore throat, fatigue, and myalgia are more common with new UK variant</text></passage><passage><infon key=\"fpage\">870</infon><infon key=\"lpage\">874</infon><infon key=\"pub-id_pmid\">32300245</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Biotechnol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">38</infon><infon key=\"year\">2020</infon><offset>104661</offset><text>CRISPR-Cas12-based detection of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">618</infon><infon key=\"lpage\">623</infon><infon key=\"pub-id_pmid\">32416961</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biochem Biophys Res Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">527</infon><infon key=\"year\">2020</infon><offset>104704</offset><text>Biochemical characterization of SARS-CoV-2 nucleocapsid protein</text></passage><passage><infon key=\"comment\">e00977-20</infon><infon key=\"issue\">8</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>104768</offset><text>Evaluation of a rapid diagnostic assay for detection of SARS-CoV-2 antigen in nasopharyngeal swabs</text></passage><passage><infon key=\"fpage\">1060</infon><infon key=\"lpage\">1061</infon><infon key=\"pub-id_pmid\">32414781</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">368</infon><infon key=\"year\">2020</infon><offset>104867</offset><text>Serology assays to manage COVID-19</text></passage><passage><infon key=\"pub-id_doi\">10.1136/bmjebm-2020-111511</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BMJ Evid Based Med</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>104902</offset><text>Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review</text></passage><passage><infon key=\"fpage\">6595</infon><infon key=\"issue\">18</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Mol Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">21</infon><infon key=\"year\">2020</infon><offset>105055</offset><text>Improved detection of antibodies against SARS-CoV-2 by microsphere-based antibody assay</text></passage><passage><infon key=\"pub-id_doi\">10.1002/rmv.2162:e2162</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Rev Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>105143</offset><text>Immune response following infection with SARS-CoV-2 and other coronaviruses: A rapid review</text></passage><passage><infon key=\"fpage\">1200</infon><infon key=\"lpage\">1204</infon><infon key=\"pub-id_pmid\">32555424</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>105235</offset><text>Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections</text></passage><passage><infon key=\"fpage\">744</infon><infon key=\"lpage\">751</infon><infon key=\"pub-id_pmid\">32720214</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Virol Sin</infon><infon key=\"type\">ref</infon><infon key=\"volume\">35</infon><infon key=\"year\">2020</infon><offset>105311</offset><text>Dynamic changes of antibodies to SARS-CoV-2 in COVID-19 patients at early stage of outbreak</text></passage><passage><infon key=\"fpage\">1557.e1</infon><infon key=\"lpage\">1557.e7</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>105403</offset><text>Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs</text></passage><passage><infon key=\"fpage\">680</infon><infon key=\"lpage\">686</infon><infon key=\"pub-id_pmid\">32207377</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>105530</offset><text>Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2</text></passage><passage><infon key=\"fpage\">1073</infon><infon key=\"lpage\">1078</infon><infon key=\"pub-id_pmid\">32704169</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Biotechnol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">38</infon><infon key=\"year\">2020</infon><offset>105612</offset><text>A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2âspike proteinâprotein interaction</text></passage><passage><infon key=\"fpage\">1497</infon><infon key=\"lpage\">1505</infon><infon key=\"pub-id_pmid\">32529906</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>105743</offset><text>Serological differentiation between COVID-19 and SARS infections</text></passage><passage><infon key=\"comment\">(6520): eabd4250</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">370</infon><infon key=\"year\">2020</infon><offset>105808</offset><text>Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity</text></passage><passage><infon key=\"fpage\">465</infon><infon key=\"lpage\">469</infon><infon key=\"pub-id_pmid\">32235945</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">581</infon><infon key=\"year\">2020</infon><offset>105905</offset><text>Virological assessment of hospitalized patients with COVID-2019</text></passage><passage><infon key=\"pub-id_doi\">10.1177/0300891620974755:300891620974755</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Tumori</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>105969</offset><text>Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy</text></passage><passage><infon key=\"pub-id_doi\">10.1093/cid/ciaa1785</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>106050</offset><text>Serologic testing of US blood donations to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)âreactive antibodies: December 2019âJanuary 2020</text></passage><passage><infon key=\"fpage\">760</infon><infon key=\"lpage\">763</infon><infon key=\"pub-id_pmid\">33131800</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pathology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">52</infon><infon key=\"year\">2020</infon><offset>106215</offset><text>Virus isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for diagnostic and research purposes</text></passage><passage><infon key=\"fpage\">847</infon><infon key=\"lpage\">856</infon><infon key=\"pub-id_pmid\">33049331</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">81</infon><infon key=\"year\">2020</infon><offset>106332</offset><text>The duration of infectiousness of individuals infected with SARS-CoV-2</text></passage><passage><infon key=\"fpage\">e039856</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BMJ Open</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2020</infon><offset>106403</offset><text>Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases</text></passage><passage><infon key=\"fpage\">267</infon><infon key=\"pub-id_pmid\">33431879</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2021</infon><offset>106561</offset><text>Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)</text></passage><passage><infon key=\"fpage\">7001</infon><infon key=\"lpage\">7003</infon><infon key=\"pub-id_pmid\">32165541</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Proc Natl Acad Sci U S A</infon><infon key=\"type\">ref</infon><infon key=\"volume\">117</infon><infon key=\"year\">2020</infon><offset>106686</offset><text>Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells</text></passage><passage><infon key=\"pub-id_doi\">10.1038/s41586-021-03237-4</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>106747</offset><text>Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis</text></passage><passage><infon key=\"fpage\">1827</infon><infon key=\"lpage\">1837</infon><infon key=\"pub-id_pmid\">32459919</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>106810</offset><text>Remdesivir for 5 or 10 days in patients with severe covid-19</text></passage><passage><infon key=\"pub-id_doi\">10.1056/NEJMoa2023184</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>106871</offset><text>Repurposed antiviral drugs for covid-19 - interim WHO Solidarity trial results</text></passage><passage><infon key=\"fpage\">1695</infon><infon key=\"lpage\">1704</infon><infon key=\"pub-id_pmid\">32401715</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>106950</offset><text>Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial</text></passage><passage><infon key=\"pub-id_doi\">10.1016/S2213-2600(20)30511-7</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Respir Med</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>107133</offset><text>Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial</text></passage><passage><infon key=\"pub-id_doi\">10.3390/v12060628</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Viruses</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>107303</offset><text>Broad-Spectrum host-based antivirals targeting the interferon and lipogenesis pathways as potential treatment options for the pandemic coronavirus disease 2019 (COVID-19)</text></passage><passage><infon key=\"fpage\">238</infon><infon key=\"lpage\">251</infon><infon key=\"pub-id_pmid\">33332778</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">384</infon><infon key=\"year\">2021</infon><offset>107474</offset><text>REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19</text></passage><passage><infon key=\"fpage\">229</infon><infon key=\"lpage\">237</infon><infon key=\"pub-id_pmid\">33113295</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">384</infon><infon key=\"year\">2021</infon><offset>107548</offset><text>SARS-CoV-2 neutralizing antibody LY-CoV555 in Outpatients with covid-19</text></passage><passage><infon key=\"pub-id_doi\">10.1056/NEJMoa2033130</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>107620</offset><text>A neutralizing monoclonal antibody for hospitalized patients with covid-19</text></passage><passage><infon key=\"pub-id_doi\">10.1056/NEJMoa2031304</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>107695</offset><text>A Randomized trial of convalescent plasma in covid-19 severe pneumonia</text></passage><passage><infon key=\"fpage\">113</infon><infon key=\"lpage\">119</infon><infon key=\"pub-id_pmid\">32707573</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">586</infon><infon key=\"year\">2020</infon><offset>107766</offset><text>Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing</text></passage><passage><infon key=\"fpage\">1439</infon><infon key=\"lpage\">1448</infon><infon key=\"pub-id_pmid\">33028965</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>107847</offset><text>Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters</text></passage><passage><infon key=\"pub-id_doi\">10.1056/NEJMoa2021436</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>107979</offset><text>Dexamethasone in hospitalized patients with covid-19 - Preliminary report</text></passage><passage><infon key=\"fpage\">1330</infon><infon key=\"lpage\">1341</infon><infon key=\"pub-id_pmid\">32876694</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Jama</infon><infon key=\"type\">ref</infon><infon key=\"volume\">324</infon><infon key=\"year\">2020</infon><offset>108053</offset><text>Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis</text></passage><passage><infon key=\"pub-id_doi\">10.1056/NEJMoa2031994</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>108191</offset><text>Baricitinib plus remdesivir for hospitalized adults with covid-19</text></passage><passage><infon key=\"fpage\">20</infon><infon key=\"lpage\">30</infon><infon key=\"pub-id_pmid\">33332779</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">384</infon><infon key=\"year\">2021</infon><offset>108257</offset><text>Tocilizumab in patients hospitalized with covid-19 pneumonia</text></passage><passage><infon key=\"fpage\">41</infon><infon key=\"lpage\">51</infon><infon key=\"pub-id_pmid\">33080002</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA Intern Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">181</infon><infon key=\"year\">2021</infon><offset>108318</offset><text>Association between early treatment With tocilizumab and mortality among critically ill patients with COVID-19</text></passage><passage><infon key=\"fpage\">n84</infon><infon key=\"pub-id_pmid\">33472855</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Br Med J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">372</infon><infon key=\"year\">2021</infon><offset>108429</offset><text>Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial</text></passage><passage><infon key=\"fpage\">2292</infon><infon key=\"lpage\">2300</infon><infon key=\"pub-id_pmid\">33180097</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">324</infon><infon key=\"year\">2020</infon><offset>108573</offset><text>Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: A randomized clinical trial</text></passage><passage><infon key=\"fpage\">71</infon><infon key=\"lpage\">78</infon><infon key=\"pub-id_pmid\">32910179</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA Intern Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">181</infon><infon key=\"year\">2021</infon><offset>108693</offset><text>Effect of recombinant human granulocyte colony-stimulating factor for patients with coronavirus disease 2019 (COVID-19) and lymphopenia: A randomized clinical trial</text></passage><passage><infon key=\"fpage\">518</infon><infon key=\"lpage\">526</infon><infon key=\"pub-id_pmid\">32203711</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Respir Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2020</infon><offset>108858</offset><text>Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases</text></passage><passage><infon key=\"fpage\">352</infon><infon key=\"lpage\">357</infon><infon key=\"pub-id_pmid\">27531371</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Expo Sci Environ Epidemiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">27</infon><infon key=\"year\">2017</infon><offset>108995</offset><text>Evaluating the efficacy of cloth facemasks in reducing particulate matter exposure</text></passage><passage><infon key=\"fpage\">908</infon><infon key=\"lpage\">912</infon><infon key=\"pub-id_pmid\">32845196</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Infect Dis (Lond)</infon><infon key=\"type\">ref</infon><infon key=\"volume\">52</infon><infon key=\"year\">2020</infon><offset>109078</offset><text>Effectiveness of surgical, KF94, and N95 respirator masks in blocking SARS-CoV-2: a controlled comparison in 7 patients</text></passage><passage><infon key=\"comment\">e002819</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BMJ Glob Health</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>109198</offset><text>Universal masking for COVID-19: evidence, ethics and recommendations</text></passage><passage><infon key=\"fpage\">94</infon><infon key=\"lpage\">105</infon><infon key=\"pub-id_pmid\">33097835</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">27</infon><infon key=\"year\">2021</infon><offset>109267</offset><text>Modeling COVID-19 scenarios for the United States</text></passage><passage><infon key=\"pub-id_doi\">10.1016/S1473-3099(20)30837-9</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><offset>109317</offset><text>Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2</text></passage><passage><infon key=\"fpage\">22235</infon><infon key=\"pub-id_pmid\">33335125</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci Rep</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2020</infon><offset>109424</offset><text>Exploring the effectiveness of a COVID-19 contact tracing app using an agent-based model</text></passage><passage><infon key=\"fpage\">890</infon><infon key=\"lpage\">896</infon><infon key=\"pub-id_pmid\">32461068</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Am J Infect Control</infon><infon key=\"type\">ref</infon><infon key=\"volume\">48</infon><infon key=\"year\">2020</infon><offset>109513</offset><text>Absence of nosocomial transmission of coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in the prepandemic phase in Hong Kong</text></passage><passage><infon key=\"fpage\">380</infon><infon key=\"lpage\">382</infon><infon key=\"pub-id_pmid\">30496764</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Hosp Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">101</infon><infon key=\"year\">2019</infon><offset>109643</offset><text>Directly observed hand hygiene - from healthcare workers to patients</text></passage><passage><infon key=\"fpage\">779</infon><infon key=\"lpage\">781</infon><infon key=\"pub-id_pmid\">32422309</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Hosp Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">105</infon><infon key=\"year\">2020</infon><offset>109712</offset><text>Is it possible to achieve 100 percent hand hygiene compliance during the coronavirus disease 2019 (COVID-19) pandemic?</text></passage><passage><infon key=\"fpage\">493</infon><infon key=\"lpage\">498</infon><infon key=\"pub-id_pmid\">32131908</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Infect Control Hosp Epidemiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">41</infon><infon key=\"year\">2020</infon><offset>109831</offset><text>Escalating infection control response to the rapidly evolving epidemiology of the coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong Kong</text></passage><passage><infon key=\"fpage\">407</infon><infon key=\"lpage\">419</infon><infon key=\"pub-id_pmid\">23994190</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Antiviral Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">100</infon><infon key=\"year\">2013</infon><offset>109980</offset><text>Clinical management and infection control of SARS: lessons learned</text></passage><passage><infon key=\"fpage\">2248</infon><infon key=\"lpage\">2251</infon><infon key=\"pub-id_pmid\">33170330</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Intensive Care Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">46</infon><infon key=\"year\">2020</infon><offset>110047</offset><text>Airborne spread of SARS-CoV-2 while using high-flow nasal cannula oxygen therapy: myth or reality?</text></passage><passage><infon key=\"fpage\">e63</infon><infon key=\"pub-id_pmid\">32237672</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>110146</offset><text>Universal masking in hospitals in the covid-19 Era</text></passage><passage><infon key=\"pub-id_doi\">10.1017/ice.2020.425:1-4</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Infect Control Hosp Epidemiol</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>110197</offset><text>Absence of nosocomial influenza and respiratory syncytial virus infection in the coronavirus disease 2019 (COVID-19) era: Implication of universal masking in hospitals</text></passage><passage><infon key=\"fpage\">107</infon><infon key=\"lpage\">114</infon><infon key=\"pub-id_pmid\">32335167</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">81</infon><infon key=\"year\">2020</infon><offset>110365</offset><text>The role of community-wide wearing of face mask for control of coronavirus disease 2019 (COVID-19) epidemic due to SARS-CoV-2</text></passage><passage><infon key=\"fpage\">1305</infon><infon key=\"lpage\">1314</infon><infon key=\"pub-id_pmid\">32247320</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>110491</offset><text>Fangcang shelter hospitals: a novel concept for responding to public health emergencies</text></passage><passage><infon key=\"pub-id_doi\">10.1017/ice.2020.1355:1-29</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Infect Control Hosp Epidemiol</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>110579</offset><text>Infection control challenges in setting up community isolation and treatment facilities for patients with coronavirus disease 2019 (COVID-19): implementation of directly-observed environmental disinfection</text></passage><passage><infon key=\"pub-id_doi\">10.7326/m20-4746</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Ann Intern Med</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>110785</offset><text>Managing COVID-19 in a novel, rapidly deployable community isolation quarantine facility</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">29 July 2020</infon><offset>110874</offset></passage><passage><infon key=\"fpage\">m2195</infon><infon key=\"pub-id_pmid\">32522737</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Br Med J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">369</infon><infon key=\"year\">2020</infon><offset>110875</offset><text>Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>111012</offset></passage><passage><infon key=\"fpage\">e41</infon><infon key=\"pub-id_pmid\">32212516</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>111013</offset><text>Critical supply shortages - The need for ventilators and personal protective equipment during the covid-19 pandemic</text></passage><passage><infon key=\"pub-id_doi\">10.1093/cid/ciaa1063</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>111129</offset><text>Infectious Diseases Society of America guidelines on infection Prevention for health care personnel caring for patients with suspected or known COVID-19</text></passage><passage><infon key=\"fpage\">571</infon><infon key=\"lpage\">573</infon><infon key=\"pub-id_pmid\">32437823</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Hosp Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">105</infon><infon key=\"year\">2020</infon><offset>111282</offset><text>Infection control challenge in setting up a temporary test centre at Hong Kong international airport for rapid diagnosis of COVID-19 due to SARS-CoV-2</text></passage><passage><infon key=\"fpage\">e257</infon><infon key=\"lpage\">e259</infon><infon key=\"pub-id_pmid\">32416987</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Br J Anaesth</infon><infon key=\"type\">ref</infon><infon key=\"volume\">125</infon><infon key=\"year\">2020</infon><offset>111433</offset><text>Rapid training of healthcare staff for protected cardiopulmonary resuscitation in the COVID-19 pandemic</text></passage><passage><infon key=\"pub-id_doi\">10.1101/2021.01.26.428212</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">bioRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>111537</offset><text>A novel SARS-CoV-2 related coronavirus in bats from Cambodia</text></passage><passage><infon key=\"fpage\">972</infon><infon key=\"pub-id_pmid\">33563978</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2021</infon><offset>111598</offset><text>Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia</text></passage><passage><infon key=\"fpage\">3025</infon><infon key=\"lpage\">3029</infon><infon key=\"pub-id_pmid\">33219796</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>111696</offset><text>Detection and Characterization of Bat Sarbecovirus phylogenetically related to SARS-CoV-2, Japan</text></passage><passage><infon key=\"fpage\">592</infon><infon key=\"lpage\">594</infon><infon key=\"pub-id_pmid\">32402157</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>111793</offset><text>Transmission of SARS-CoV-2 in domestic cats</text></passage><passage><infon key=\"fpage\">776</infon><infon key=\"lpage\">778</infon><infon key=\"pub-id_pmid\">32408337</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">586</infon><infon key=\"year\">2020</infon><offset>111837</offset><text>Infection of dogs with SARS-CoV-2</text></passage><passage><infon key=\"comment\">e02220-20</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">mBio</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>111871</offset><text>From people to panthera: natural SARS-CoV-2 infection in tigers and lions at the Bronx Zoo</text></passage><passage><infon key=\"fpage\">e3001016</infon><infon key=\"pub-id_pmid\">33347434</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS Biol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">18</infon><infon key=\"year\">2020</infon><offset>111962</offset><text>The SARS-CoV-2 spike protein has a broad tropism for mammalian ACE2 proteins</text></passage><passage><infon key=\"fpage\">509</infon><infon key=\"lpage\">515</infon><infon key=\"pub-id_pmid\">32967005</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">586</infon><infon key=\"year\">2020</infon><offset>112039</offset><text>Animal models for COVID-19</text></passage><passage><infon key=\"fpage\">2139</infon><infon key=\"lpage\">2149</infon><infon key=\"pub-id_pmid\">32472679</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>112066</offset><text>Surgical mask partition reduces the risk of noncontact transmission in a Golden Syrian Hamster Model for Coronavirus Disease 2019 (COVID-19)</text></passage><passage><infon key=\"fpage\">704</infon><infon key=\"lpage\">709.e2</infon><infon key=\"pub-id_pmid\">32259477</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Host Microbe</infon><infon key=\"type\">ref</infon><infon key=\"volume\">27</infon><infon key=\"year\">2020</infon><offset>112207</offset><text>Infection and rapid transmission of SARS-CoV-2 in ferrets</text></passage><passage><infon key=\"fpage\">3496</infon><infon key=\"pub-id_pmid\">32641684</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>112265</offset><text>SARS-CoV-2 is transmitted via contact and via the air between ferrets</text></passage><passage><infon key=\"fpage\">1327</infon><infon key=\"lpage\">1335</infon><infon key=\"pub-id_pmid\">32839612</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">21</infon><infon key=\"year\">2020</infon><offset>112335</offset><text>SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function</text></passage><passage><infon key=\"fpage\">830</infon><infon key=\"lpage\">833</infon><infon key=\"pub-id_pmid\">32380511</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">583</infon><infon key=\"year\">2020</infon><offset>112440</offset><text>The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice</text></passage><passage><infon key=\"fpage\">124</infon><infon key=\"lpage\">133</infon><infon key=\"pub-id_pmid\">32485164</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Host Microbe</infon><infon key=\"type\">ref</infon><infon key=\"volume\">28</infon><infon key=\"year\">2020</infon><offset>112497</offset><text>A mouse model of SARS-CoV-2 infection and pathogenesis</text></passage><passage><infon key=\"fpage\">744</infon><infon key=\"lpage\">753.e4</infon><infon key=\"pub-id_pmid\">32553273</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">182</infon><infon key=\"year\">2020</infon><offset>112552</offset><text>A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies</text></passage><passage><infon key=\"fpage\">2433</infon><infon key=\"lpage\">2445</infon><infon key=\"pub-id_pmid\">33073694</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>112640</offset><text>Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"lpage\">7</infon><infon key=\"pub-id_pmid\">33356979</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2021</infon><offset>112724</offset><text>Susceptibility of rabbits to SARS-CoV-2</text></passage><passage><infon key=\"fpage\">e218</infon><infon key=\"lpage\">e225</infon><infon key=\"pub-id_pmid\">32838346</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Microbe</infon><infon key=\"type\">ref</infon><infon key=\"volume\">1</infon><infon key=\"year\">2020</infon><offset>112764</offset><text>SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study</text></passage><passage><infon key=\"comment\">Berhane Y, Suderman M, Babiuk S, Pickering B. Susceptibility of turkeys, chickens and chicken embryos to SARS-CoV-2. Transbound Emerg Dis. 2020 Dec 29</infon><infon key=\"pub-id_doi\">10.1111/tbed.13970</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>112854</offset></passage><passage><infon key=\"fpage\">125</infon><infon key=\"pub-id_pmid\">32811514</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Virol J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">17</infon><infon key=\"year\">2020</infon><offset>112855</offset><text>Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase</text></passage><passage><infon key=\"fpage\">73</infon><infon key=\"lpage\">86</infon><infon key=\"pub-id_pmid\">33340034</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2021</infon><offset>113024</offset><text>Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets</text></passage><passage><infon key=\"fpage\">2439</infon><infon key=\"lpage\">2450</infon><infon key=\"pub-id_pmid\">33053279</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>113124</offset><text>Safety and immunogenicity of two RNA-based covid-19 vaccine candidates</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>113195</offset></passage><passage><infon key=\"fpage\">99</infon><infon key=\"lpage\">111</infon><infon key=\"pub-id_pmid\">33306989</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">397</infon><infon key=\"year\">2021</infon><offset>113196</offset><text>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK</text></passage><passage><infon key=\"pub-id_doi\">10.1016/S0140-6736(21)00234-8</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">The Lancet</infon><infon key=\"type\">ref</infon><offset>113370</offset><text>Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia</text></passage><passage><infon key=\"fpage\">881</infon><infon key=\"lpage\">891</infon><infon key=\"pub-id_pmid\">33617777</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">397</infon><infon key=\"year\">2021</infon><offset>113538</offset><text>Single dose administration, and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine</text></passage><passage><infon key=\"fpage\">181</infon><infon key=\"lpage\">192</infon><infon key=\"pub-id_pmid\">33217362</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">21</infon><infon key=\"year\">2020</infon><offset>113686</offset><text>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</text></passage><passage><infon key=\"fpage\">39</infon><infon key=\"lpage\">51</infon><infon key=\"pub-id_pmid\">33069281</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">21</infon><infon key=\"year\">2021</infon><offset>113873</offset><text>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial</text></passage><passage><infon key=\"fpage\">2320</infon><infon key=\"lpage\">2332</infon><infon key=\"pub-id_pmid\">32877576</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>114013</offset><text>Phase 1â2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine</text></passage><passage><infon key=\"pub-id_doi\">10.1101/2021.02.01.429069</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">bioRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>114094</offset><text>Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines</text></passage><passage><infon key=\"pub-id_doi\">10.1101/2021.01.25.428137</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">bioRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>114237</offset><text>Increased Resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization</text></passage><passage><infon key=\"pub-id_doi\">10.1093/cid/ciab083</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>114328</offset><text>Absence of vaccine-enhanced disease with unexpected positive protection against SARS-CoV-2 by inactivated vaccine given within three days of virus challenge in Syrian hamster model</text></passage><passage><infon key=\"fpage\">660</infon><infon key=\"lpage\">694</infon><infon key=\"pub-id_pmid\">17934078</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2007</infon><offset>114509</offset><text>Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection</text></passage></document></collection>\n",
      "\n",
      "Study 32761898: <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n",
      "<!DOCTYPE collection SYSTEM \"BioC.dtd\">\n",
      "<collection><source>PMC</source><date>20220708</date><key>pmc.key</key><document><id>7436402</id><infon key=\"license\">NO-CC CODE</infon><passage><infon key=\"alt-title\">CUI et al.\n",
      "</infon><infon key=\"article-id_doi\">10.1002/jmv.26398</infon><infon key=\"article-id_pmc\">7436402</infon><infon key=\"article-id_pmid\">32761898</infon><infon key=\"article-id_publisher-id\">JMV26398</infon><infon key=\"fn\">Xiaojian Cui, Zhihu Zhao, Tongqiang Zhang, and Wei Guo contributed equally to this work.</infon><infon key=\"fpage\">1057</infon><infon key=\"issue\">2</infon><infon key=\"kwd\">2019ânCoV children coronavirus COVIDâ19 metaâanalysis SARSâCoVâ2</infon><infon key=\"license\">This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</infon><infon key=\"lpage\">1069</infon><infon key=\"name_0\">surname:Cui;given-names:Xiaojian</infon><infon key=\"name_1\">surname:Zhao;given-names:Zhihu</infon><infon key=\"name_10\">surname:Li;given-names:Wenliang</infon><infon key=\"name_11\">surname:Liu;given-names:Zihui</infon><infon key=\"name_12\">surname:Ma;given-names:Jia</infon><infon key=\"name_13\">surname:Wang;given-names:Jinhu</infon><infon key=\"name_14\">surname:He;given-names:Sijia</infon><infon key=\"name_15\">surname:Xu;given-names:Yongsheng</infon><infon key=\"name_16\">surname:Si;given-names:Ping</infon><infon key=\"name_17\">surname:Shen;given-names:Yongming</infon><infon key=\"name_18\">surname:Cai;given-names:Chunquan</infon><infon key=\"name_2\">surname:Zhang;given-names:Tongqiang</infon><infon key=\"name_3\">surname:Guo;given-names:Wei</infon><infon key=\"name_4\">surname:Guo;given-names:Wenwei</infon><infon key=\"name_5\">surname:Zheng;given-names:Jiafeng</infon><infon key=\"name_6\">surname:Zhang;given-names:Jiayi</infon><infon key=\"name_7\">surname:Dong;given-names:Cuicui</infon><infon key=\"name_8\">surname:Na;given-names:Ren</infon><infon key=\"name_9\">surname:Zheng;given-names:Lisheng</infon><infon key=\"notes\">\n",
      "\n",
      ", , , et al. . . ;:â. \n",
      "\n",
      "</infon><infon key=\"pub-id_doi\">10.1002/jmv.26398</infon><infon key=\"pub-id_pmid\">32761898</infon><infon key=\"section_type\">TITLE</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">front</infon><infon key=\"volume\">93</infon><infon key=\"year\">2021</infon><offset>0</offset><text>A systematic review and metaâanalysis of children with coronavirus disease 2019 (COVIDâ19)</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>95</offset><text>Abstract</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>104</offset><text>To provide a comprehensive and systematic analysis of demographic characteristics, clinical symptoms, laboratory findings, and imaging features of coronavirus disease 2019 (COVIDâ19) in pediatric patients.Â A metaâanalysis was carried out to identify studies on COVIDâ19 from 25 December 2019 to 30 April 2020. A total of 48 studies with 5829 pediatric patients were included. Children of all ages were at risk for COVIDâ19. The main illness classification ranged as: 20% (95% confidence interval [CI]: 14%â26%; I 2â=â91.4%) asymptomatic, 33% (95% CI: 23%â43%; I 2â=â95.6%) mild and 51% (95% CI: 42%â61%; I 2â=â93.4%) moderate. The typical clinical manifestations were fever 51% (95% CI: 45%â57%; I 2â=â78.9%) and cough 41% (95% CI: 35%â47%, I 2â=â81.0%). The common laboratory findings were normal white blood cell 69% (95% CI: 64%â75%; I 2â=â58.5%), lymphopenia 16% (95% CI: 11%â21%; I 2â=â76.9%) and elevated creatineâkinase MB 37% (95% CI: 25%â48%; I 2â=â59.0%). The frequent imaging features were normal images 41% (95% CI: 30%â52%; I 2â=â93.4%) and groundâglass opacity 36% (95% CI: 25%â47%; I 2â=â92.9%). Among children under 1 year old, critical cases account for 14% (95% CI: 13%â34%; I 2â=â37.3%) that should be of concern. In addition, vomiting occurred in 33% (95% CI: 18%â67%; I 2â=â0.0%) cases that may also need attention.Â Pediatric patients with COVIDâ19 may experience milder illness with atypical clinical manifestations and rare lymphopenia. High incidence of critical illness and vomiting symptoms reward attention in children under 1 year old.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>1756</offset><text>Highlights</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>1767</offset><text>To provide a comprehensive characterization of coronavirus disease 2019 (COVIDâ19) in pediatric patients.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>1875</offset><text>The majority of pediatric cases with COVIDâ19 have milder illness with atypical clinical manifestations and rare lymphopenia.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>2003</offset><text>It is worth noting that the high incidence of critical illness and vomiting in children under 1 year old.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>2109</offset><text>Our evidenceâbased data will help formulate strategies for early clinical identification and epidemic control of COVIDâ19 in children.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>2248</offset><text>INTRODUCTION</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>2261</offset><text>An outbreak of the coronavirus disease 2019 (COVIDâ19) is spreading rapidly around the world, which is caused by severe acute respiratory syndrome coronavirusâ2 (SARSâCoVâ2) infection. As of 26 July 2020, the COVIDâ19 pandemic has resulted in approximately 15â785â641 confirmed cases, including 640â016 deaths worldwide. In the early stage, the majority of cases were concentrated in middleâaged and old people. Under the ongoing pandemic situation, children cases are showing an increasing trend in many countries of the world: In China, a large cohort study on the epidemiological characteristics of children with COVIDâ19 included 2135 cases; In the United States, it was reported that 74 children were admitted to pediatric intensive care units in 19 states; On a global scale, it was estimated 176â190 children infected with SARSâCoVâ2 by 6 April 2020. One metaâanalysis found that fever and cough occurred in adults up to 92.8% and 63.4%, respectively. Another study showed lymphopenia occurred in 57.4% of an adult patient with COVIDâ19. Although some previous studies have demonstrated that SARSâCoVâ2 infection affects adults and children differently, the data of a systematic metaâanalysis on characteristics of children with COVIDâ19 are still lacking. Thus, in our research, we reviewed and analyzed the studies and reported cases from 25 December 2019 to 30 April 2020 to provide evidenceâbased data involving clinical manifestations of COVIDâ19 in pediatric patients. It will help to formulate policies on controlling SARSâCoVâ2 transmission among children for pediatricians and public health specialists.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_1</infon><offset>3927</offset><text>METHODS</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>3935</offset><text>This study was conducted following the Preferred Reporting Items for Systematic Reviews and MetaâAnalyses (PRISMA) statement and was registered in PROSPERO as CRD42020191099.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>4112</offset><text>Search strategies</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>4130</offset><text>To identify studies pertaining clinical, laboratory, and imaging features in children with COVIDâ19, we systematically searched from PubMed, Web of Science, Chinese Wanfang and China National Knowledge Infrastructure databases for relevant articles published through 30 April 2020. Moreover, additional records identified from World Health Organization (WHO)/Center for Disease Control reports, medRxiv, bioRxiv, SSRN, and Google Scholar. We also reviewed the references of all identified articles to identify additional studies. Search terms were as follows: novel coronavirus, nCoV, SARS2 vaccine, Wuhan coronavirus vaccine, 2019 novel coronavirus, novel coronavirus 2019, 2019ânCoV, COVIDâ19, Wuhan coronavirus, Wuhan pneumonia and SARSâCoVâ2. These terms were used in combination with âANDâ or âOR.â The literature review was performed independently by two investigators (XJC and TQZ), with a third reviewer (YMS) resolving any disputes as needed.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>5100</offset><text>Inclusion criteria</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>5119</offset><text>We included published papers (cohort studies, case series, and case reports) that given available data about the demographic information, clinical, laboratory, and image features in children with COVIDâ19. Pediatric population was defined as under 18 years old. SARSâCoVâ2 nucleic acid was teased by RTâPCR in accordance with the WHO guideline. The level of laboratory test items was determined according to the following standards: normal white blood cell: 5.5 to 12.0âÃâ109/L, leukocytosis: more than 12.0âÃâ109/L, leukopenia: less than 5.5âÃâ109/L, lymphopenia: less than 1.2âÃâ109/L, high PCT: more than 0.046âng/mL, high CRP: more than 10âmg/L, high LDH: more than 300âU/L, high ALT: more than 45âU/L, high AST: more than 50âU/L, high Creatinine: more than 62âÎ¼mol/L, high blood urea nitrogen: more than 7.1âmmol/L, high CK: more than 170âU/L, high CKâMB: more than 25âU/L, high Dâdimer: more than 0.55âmg/L. We excluded studies that did not report original data or clear diagnostic criteria, and no relevant outcome.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>6195</offset><text>Data collection</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>6211</offset><text>Two authors (XJC and TQZ) independently extracted relevant information, including first author, publication year, sex (male, %), country, number of COVIDâ19 patients, age distribution (ratio of &lt;1, 1â5, 6â10, 11â15, and &gt;15 years) and contact history. The severity of COVIDâ19 was defined according to the clinical characteristics, laboratory testing, and chest imaging, including asymptomatic infection, mild, moderate, severe and critical cases. The diagnostic criteria were as follows: Asymptomatic infection: The child had no clinical symptoms or signs, chest imaging was normal, and only 2019ânCoV nucleic acid test was positive; mild: the acute upper respiratory tract infection was the main manifestations and some children may only have digestive symptoms. Some children may have no fever. Physical examination shows no auscultatory abnormalities; Moderate: with pneumonia, most of children have fever and cough, which are dry cough at first and then phlegm cough. Some of them may have wheezing, but without obvious hypoxia such as shortness of breath, sputum or dry snoring and/or wet snoring can be heard in the lungs. Some children only found lung lesions on chest computed tomography (CT) without any clinical symptoms and signs, which is called subclinical type; Severe: Early onset of respiratory symptoms such as fever and cough, some can be accompanied by gastrointestinal symptoms, disease progression often occurs in about 1 week, with hypoxia performance, and dyspnea occurs, oxygen saturation is less than 0.92; critical: children may rapidly progress to acute respiratory distress syndrome or respiratory failure. They may also develop shock, coagulation dysfunction or other multiple organ dysfunction, which may endanger their lives. Moreover, we extracted clinical performance data including fever, cough, sore throat, tachycardia, rhinorrhea, nasal congestion, tachypnea, diarrhea, vomiting, myalgia or fatigue, hypoxemia, and chest pain. Clinical laboratory results were extracted based on blood routine tests, liver function tests, renal function measurement, cardiac function, inflammatory factors and Dâdimer. Distributions for all imaging: normal, groundâglass opacity (GGO), local patchy shadowing, bilateral patchy shadowing, white lung change and pleural effusion.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>8526</offset><text>Quality assessment</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>8545</offset><text>We used the quality assessment tool for case series studies published by the National Institutes of Health to assess the methodological quality of included studies. We scored 0 or 1 point for each item according to the criteria and added scores for all items to generate an overall quality score that ranged from 0 to 8. Based on the overall score, we classified studies as low (â¥7), moderate (5â6), or high risk of bias (â¤4). Any disagreement was resolved through discussion by all investigators.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>9049</offset><text>Statistical analysis</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>9070</offset><text>We performed data analysis using metan packages in STATA (version 12.0; Stata Corp, College Station, TX). Statistical heterogeneity between studies was evaluated with Cochran's Q test and the I 2 statistic. The I 2âvalue of less than 50% was equivalent to no heterogeneity, whereas values greater than 50% was equivalent to large heterogeneity among studies. FreemanâTukey double arcsine transformation was used to stabilize the variance of specific prevalence rates between the included studies. To account for the potential heterogeneity of studied population in each study reflected by different geographic locations, ethnicity, age group, and so forth, a randomâeffect model using the DerSimonian and Laird method was used to aggregate effect sizes to estimate the overall pooled prevalence and corresponding 95% confidence intervals (CIs). To explore the reasons for heterogeneity, subgroup analyses were applied based on the study type (noncase reports vs case reports). The Begg's funnel plot was performed to evaluate the publication bias. P value of less than .05 was identified as statistically significant.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_1</infon><offset>10194</offset><text>RESULTS</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>10202</offset><text>Study selection, general characteristics, and quality assessment</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>10267</offset><text>A total of 2048 relevant studies were collected from databases and other sources based on the search strategies. We used Endnote Software (Version X7; Thompson Reuters, CA) to remove 992 duplicate studies. According to the title and abstract, 1003 relevant studies were excluded, and then, five studies were removed by reading the full text. Finally, a total of 48 studies were included in this metaâanalysis in according with the inclusion criteria. The PRISMA flow diagram of the included studies is listed in FigureÂ 1. The general characteristics of the included studies are shown in TableÂ 1. One study was from Singapore, one from Korea, one from Spain, one from America, and one from Iranian. The rest of the studies were all from China. The number of patients ranged from 1 to 2490, and male patients ranged from 0 to 1408. Twentyânine studies were case reports, sixteen studies were case series, and the rest three studies were cohort studies. Total scores of the included studies ranged from 3 to 8 and mean scores were 5.69. The percentage scores were used for ordinal categorization of the studies as low quality (â¤4, 25%), medium quality (5â6, 43.8%), and high quality (â¥7, 31.2%). The detailed results on quality assessment are listed in the Supporting Information material 1 (Table S1).</text></passage><passage><infon key=\"file\">JMV-93-1057-g006.jpg</infon><infon key=\"id\">jmv26398-fig-0001</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>11579</offset><text>Flow diagram for the included studies</text></passage><passage><infon key=\"file\">jmv26398-tbl-0001.xml</infon><infon key=\"id\">jmv26398-tbl-0001</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>11617</offset><text>Characteristics of included studies</text></passage><passage><infon key=\"file\">jmv26398-tbl-0001.xml</infon><infon key=\"id\">jmv26398-tbl-0001</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;thead valign=&quot;bottom&quot;&gt;&lt;tr style=&quot;border-bottom:solid 1px #000000&quot; valign=&quot;bottom&quot;&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Author&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Journal&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case number (N)&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male (n)&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Female (n)&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Study location&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Study design&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Total score&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody valign=&quot;top&quot;&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Bialek et al&lt;xref rid=&quot;jmv26398-bib-0059&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;59&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;MMWR Morb Mortal Wkly Rep&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2490&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1408&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1082&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;America&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case series&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Dong et al&lt;xref rid=&quot;jmv26398-bib-0002&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;2&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pediatrics&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2143&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1213&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;930&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;China&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case series&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Ma et al&lt;xref rid=&quot;jmv26398-bib-0013&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;13&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chin J Contemp Pediatr&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;115&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;73&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wuhan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case series&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wang et al&lt;xref rid=&quot;jmv26398-bib-0014&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;14&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chin J Pediatr&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;34&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;14&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;20&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Shenzhen&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case series&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wang et al&lt;xref rid=&quot;jmv26398-bib-0015&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;15&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chin J Pediatr&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;31&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Six provinces in north China&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case series&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cai et al&lt;xref rid=&quot;jmv26398-bib-0016&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;16&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Clin Infect Dis&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Shanghai&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Feng et al&lt;xref rid=&quot;jmv26398-bib-0017&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;17&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chin J Pediatr&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;15&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Shenzhen&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Su et al&lt;xref rid=&quot;jmv26398-bib-0018&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;18&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Emerg Microbes Infect&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Jinan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zhou et al&lt;xref rid=&quot;jmv26398-bib-0019&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;19&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chin J Contemp Pediatr&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Shenzhen&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wei et al&lt;xref rid=&quot;jmv26398-bib-0020&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;20&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;JAMA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wuhan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Liu et al&lt;xref rid=&quot;jmv26398-bib-0021&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;21&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NEJM&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wuhan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cai et al&lt;xref rid=&quot;jmv26398-bib-0022&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;22&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chin J Pediatr&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Shanghai&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zhang et al&lt;xref rid=&quot;jmv26398-bib-0023&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;23&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chin J Pediatr&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hubei&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Ji et al&lt;xref rid=&quot;jmv26398-bib-0024&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;24&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;World J Pediatr&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zhejiang&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zhang et al&lt;xref rid=&quot;jmv26398-bib-0025&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;25&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chin J Contemp Pediatr&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hunan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wang et al&lt;xref rid=&quot;jmv26398-bib-0026&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;26&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chin J Contemp Pediatr&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wuhan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zhao et al&lt;xref rid=&quot;jmv26398-bib-0027&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;27&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zhejiang Medicine&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zhejiang&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zeng et al&lt;xref rid=&quot;jmv26398-bib-0028&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;28&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chin J Pediatr&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wuhan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zhang et al&lt;xref rid=&quot;jmv26398-bib-0029&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;29&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;J Med Virol&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Tianjin&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zeng et al&lt;xref rid=&quot;jmv26398-bib-0030&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;30&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;JAMA Pediatrics&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wuhan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Kam et al&lt;xref rid=&quot;jmv26398-bib-0031&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;31&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Clin Infect Dis&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Singapore&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wu et al&lt;xref rid=&quot;jmv26398-bib-0032&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;32&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pediatrics&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;74&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;44&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Shandong&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case series&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Xing et al&lt;xref rid=&quot;jmv26398-bib-0033&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;33&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;J Mircobiol Immunol Infect&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Shandong&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Park et al&lt;xref rid=&quot;jmv26398-bib-0034&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;34&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;J Korean Med Sci&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Korea&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Xia et al&lt;xref rid=&quot;jmv26398-bib-0035&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;35&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pediatr Pulmonol&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;20&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wuhan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case series&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Tagarro et al&lt;xref rid=&quot;jmv26398-bib-0036&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;36&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;JAMA Pediatr&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;41&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;18&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;23&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Spain&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case series&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zhu et al&lt;xref rid=&quot;jmv26398-bib-0037&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;37&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pediatr Pulmonol&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Suzhou&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Qiu et al&lt;xref rid=&quot;jmv26398-bib-0038&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;38&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Lancet Infect Dis&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;36&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;23&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zhejiang&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cohort study&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yu et al&lt;xref rid=&quot;jmv26398-bib-0039&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;39&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Preâprint&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;82&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;51&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;31&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wuhan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case series&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;liu et al&lt;xref rid=&quot;jmv26398-bib-0040&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;40&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chin J Nosocomiol&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;91&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;56&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;35&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wuhan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case series&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Ma et al&lt;xref rid=&quot;jmv26398-bib-0041&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;41&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;BMC Med&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;50&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;28&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;22&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wuhan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cohort study&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wang et al&lt;xref rid=&quot;jmv26398-bib-0042&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;42&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Preâprint&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;74&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;38&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;36&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wuhan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case series&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Li et al&lt;xref rid=&quot;jmv26398-bib-0043&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;43&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Radiol Practice&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;18&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wuhan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case series&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Lu et al&lt;xref rid=&quot;jmv26398-bib-0044&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;44&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pediatr Infect Dis J&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;110&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;59&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;51&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wuhan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cohort study&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Tang et al&lt;xref rid=&quot;jmv26398-bib-0045&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;45&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Preâprint&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Shenzhen&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case series&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zheng et al&lt;xref rid=&quot;jmv26398-bib-0046&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;46&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Curr Med Sci&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;25&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;14&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wuhan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case series&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Shen et al&lt;xref rid=&quot;jmv26398-bib-0047&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;47&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pediatr Pulmonol&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Huna&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Sun et al&lt;xref rid=&quot;jmv26398-bib-0048&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;48&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;World J Pediatr&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wuhan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Golnar et al&lt;xref rid=&quot;jmv26398-bib-0049&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;49&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;J Pediatr Rev&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Iranian&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Liu et al&lt;xref rid=&quot;jmv26398-bib-0050&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;50&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;J Infect&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wuhan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wu et al&lt;xref rid=&quot;jmv26398-bib-0051&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;51&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chin J Contemp Pediatr&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;23&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;14&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Jiangxi&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case series&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Tan et al&lt;xref rid=&quot;jmv26398-bib-0052&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;52&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chin J Contemp Pediatr&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Changsha&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yang et al&lt;xref rid=&quot;jmv26398-bib-0053&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;53&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Journal of Shandong University (Health Sciences)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Shandong&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zhang et al&lt;xref rid=&quot;jmv26398-bib-0054&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;54&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Journal of Shandong University (Health Sciences)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Shandong&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Xu et al&lt;xref rid=&quot;jmv26398-bib-0055&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;55&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Nat Med&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Guangzhou&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Zhang et al&lt;xref rid=&quot;jmv26398-bib-0056&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;56&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;World Latest Medicine Information&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Yunnan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chen et al&lt;xref rid=&quot;jmv26398-bib-0057&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;57&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chin J Pediatr&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wuhan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case report&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Lu et al&lt;xref rid=&quot;jmv26398-bib-0058&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;58&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NEJM&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;171&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;104&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;67&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wuhan&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case series&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>11653</offset><text>Author\tJournal\tCase number (N)\tMale (n)\tFemale (n)\tStudy location\tStudy design\tTotal score\t \tBialek et al\tMMWR Morb Mortal Wkly Rep\t2490\t1408\t1082\tAmerica\tCase series\t6\t \tDong et al\tPediatrics\t2143\t1213\t930\tChina\tCase series\t7\t \tMa et al\tChin J Contemp Pediatr\t115\t73\t42\tWuhan\tCase series\t6\t \tWang et al\tChin J Pediatr\t34\t14\t20\tShenzhen\tCase series\t5\t \tWang et al\tChin J Pediatr\t31\tNA\tNA\tSix provinces in north China\tCase series\t7\t \tCai et al\tClin Infect Dis\t10\t4\t6\tShanghai\tCase report\t4\t \tFeng et al\tChin J Pediatr\t15\t5\t10\tShenzhen\tCase report\t7\t \tSu et al\tEmerg Microbes Infect\t9\t3\t6\tJinan\tCase report\t7\t \tZhou et al\tChin J Contemp Pediatr\t9\t4\t5\tShenzhen\tCase report\t6\t \tWei et al\tJAMA\t9\t2\t7\tWuhan\tCase report\t5\t \tLiu et al\tNEJM\t6\t2\t4\tWuhan\tCase report\t7\t \tCai et al\tChin J Pediatr\t1\t1\t0\tShanghai\tCase report\t3\t \tZhang et al\tChin J Pediatr\t1\t0\t1\tHubei\tCase report\t3\t \tJi et al\tWorld J Pediatr\t2\t2\t0\tZhejiang\tCase report\t4\t \tZhang et al\tChin J Contemp Pediatr\t2\t0\t2\tHunan\tCase report\t3\t \tWang et al\tChin J Contemp Pediatr\t1\t1\t0\tWuhan\tCase report\t5\t \tZhao et al\tZhejiang Medicine\t1\t1\t0\tZhejiang\tCase report\t4\t \tZeng et al\tChin J Pediatr\t1\t1\t0\tWuhan\tCase report\t4\t \tZhang et al\tJ Med Virol\t3\t3\t0\tTianjin\tCase report\t4\t \tZeng et al\tJAMA Pediatrics\t3\t3\t0\tWuhan\tCase report\t7\t \tKam et al\tClin Infect Dis\t1\t1\t0\tSingapore\tCase report\t4\t \tWu et al\tPediatrics\t74\t44\t30\tShandong\tCase series\t6\t \tXing et al\tJ Mircobiol Immunol Infect\t3\t2\t1\tShandong\tCase report\t6\t \tPark et al\tJ Korean Med Sci\t1\t0\t1\tKorea\tCase report\t3\t \tXia et al\tPediatr Pulmonol\t20\t13\t7\tWuhan\tCase series\t5\t \tTagarro et al\tJAMA Pediatr\t41\t18\t23\tSpain\tCase series\t6\t \tZhu et al\tPediatr Pulmonol\t10\t5\t5\tSuzhou\tCase report\t6\t \tQiu et al\tLancet Infect Dis\t36\t23\t13\tZhejiang\tCohort study\t7\t \tYu et al\tPreâprint\t82\t51\t31\tWuhan\tCase series\t6\t \tliu et al\tChin J Nosocomiol\t91\t56\t35\tWuhan\tCase series\t7\t \tMa et al\tBMC Med\t50\t28\t22\tWuhan\tCohort study\t7\t \tWang et al\tPreâprint\t74\t38\t36\tWuhan\tCase series\t7\t \tLi et al\tRadiol Practice\t30\t18\t12\tWuhan\tCase series\t6\t \tLu et al\tPediatr Infect Dis J\t110\t59\t51\tWuhan\tCohort study\t8\t \tTang et al\tPreâprint\t26\t17\t9\tShenzhen\tCase series\t7\t \tZheng et al\tCurr Med Sci\t25\t14\t11\tWuhan\tCase series\t8\t \tShen et al\tPediatr Pulmonol\t9\t3\t6\tHuna\tCase report\t6\t \tSun et al\tWorld J Pediatr\t8\t6\t2\tWuhan\tCase report\t5\t \tGolnar et al\tJ Pediatr Rev\t9\t6\t3\tIranian\tCase report\t4\t \tLiu et al\tJ Infect\t4\t2\t2\tWuhan\tCase report\t7\t \tWu et al\tChin J Contemp Pediatr\t23\t9\t14\tJiangxi\tCase series\t8\t \tTan et al\tChin J Contemp Pediatr\t13\t4\t9\tChangsha\tCase report\t6\t \tYang et al\tJournal of Shandong University (Health Sciences)\t10\t3\t7\tShandong\tCase report\t6\t \tZhang et al\tJournal of Shandong University (Health Sciences)\t10\t3\t7\tShandong\tCase report\t6\t \tXu et al\tNat Med\t10\t6\t4\tGuangzhou\tCase report\t6\t \tZhang et al\tWorld Latest Medicine Information\t1\t0\t1\tYunnan\tCase report\t6\t \tChen et al\tChin J Pediatr\t1\t1\t0\tWuhan\tCase report\t4\t \tLu et al\tNEJM\t171\t104\t67\tWuhan\tCase series\t6\t \t</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>14599</offset><text>Characteristics of COVIDâ19 in children</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_3</infon><offset>14641</offset><text>Demographical characteristics</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>14671</offset><text>FigureÂ 2 presents a summary of the age distribution of all participants. Among all the children cases, 17% (95% CI: 15%â18%; I 2â=â48.6%) was under 1 year old at diagnosis, 24% (95% CI: 19%â29%; I 2â=â80.6%) 1 to 5 years old, 25% (95% CI: 19%â31%; I 2â=â88.7%) 6 to 10 years old, 20% (95% CI: 16%â24%; I 2â=â82.7%) 11 to 15 years old and 18% (95% CI: 8%â28%; I 2â=â96.7%) were 15 years old or more.</text></passage><passage><infon key=\"file\">JMV-93-1057-g005.jpg</infon><infon key=\"id\">jmv26398-fig-0002</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>15101</offset><text>Summary results of the age distribution of all participants</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>15161</offset><text>Gender was shown as the proportion of males (M). Male gender of the children with COVIDâ19 was 55% (95%CI: 53%â58%; I 2â=â33.4%; Pâ=â.030). The proportion of cases with known contact history was estimated at 72% (95% CI: 64%â80%; I 2â=â90.1%; Pâ=â.000).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_3</infon><offset>15437</offset><text>Illness severity</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>15454</offset><text>FigureÂ 3 presents a summary of the illness severity of all patients. Patients were divided into six groups as indicated based on disease severity from light to severe, mainly including: asymptomatic, mild, moderate, severe, critical, and death. Included patients were classified by their clinicians as asymptomatic 20% (95% CI: 14%â26%; I 2â=â91.4%), mildly 33% (95% CI: 23%â43%; I 2â=â95.6%), moderate 51% (95% CI: 42%â61%; I 2â=â93.4%), severely 7% (95% CI: 4%â11%; I 2â=â90.2%), critically 5% (95% CI: 2%â9%; I 2â=â84.5%), and death 0% (95% CI: 0%â0%; I 2â=â94.9%).</text></passage><passage><infon key=\"file\">JMV-93-1057-g004.jpg</infon><infon key=\"id\">jmv26398-fig-0003</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>16060</offset><text>Summary results of illness severity in children with COVIDâ19. The definition of illness severity was mentioned as follows: (A) without any clinical symptoms and signs. Chest imaging examination was normal, while the 2019ânCoV nucleic acid test is positive. B, The main manifestations were acute upper respiratory tract infection and some children may have only digestive symptoms. Physical examination shows no auscultatory abnormalities. C, With pneumonia, some cases may have no clinical symptoms and signs, but chest CT shows lung lesions, which are subclinical. D, The disease usually progresses in about 1 week, and dyspnea occurs, oxygen saturation is less than 92%. E, Children can quickly progress to acute respiratory distress syndrome (ARDS) or respiratory failure, multiple organ dysfunction can be lifeâthreatening. COVIDâ19, coronavirus disease 2019; CT, computed tomography</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>16957</offset><text>Among children under 1âyear old cases, asymptomatic 6% (95% CI: 5%â13%; I 2â=â24.3%), mildly 54% (95% CI: 49%â59%; I 2â=â0.0%), moderate 36% (95% CI: 27%â45%; I 2â=â4.0%), severely 7% (95% CI: 4%â11%; I 2â=â34.3%), and critically 14% (95% CI: 13%â34%; I 2â=â37.3%) (TableÂ 2).</text></passage><passage><infon key=\"file\">jmv26398-tbl-0002.xml</infon><infon key=\"id\">jmv26398-tbl-0002</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>17266</offset><text>Comparison of metaâanalysis results among different ages patients with COVIDâ19</text></passage><passage><infon key=\"file\">jmv26398-tbl-0002.xml</infon><infon key=\"id\">jmv26398-tbl-0002</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;col style=&quot;border-right:solid 1px #000000; border-bottom:solid 1px #000000&quot; span=&quot;1&quot;/&gt;&lt;thead valign=&quot;bottom&quot;&gt;&lt;tr valign=&quot;bottom&quot;&gt;&lt;th style=&quot;border-bottom:solid 1px #000000&quot; rowspan=&quot;3&quot; valign=&quot;bottom&quot; colspan=&quot;1&quot;&gt;Study&lt;/th&gt;&lt;th colspan=&quot;4&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot;&gt;Present study&lt;/th&gt;&lt;th colspan=&quot;4&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot;&gt;Present study&lt;/th&gt;&lt;th colspan=&quot;4&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot;&gt;RodriguezâMorales AJ&lt;xref rid=&quot;jmv26398-bib-0004&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;4&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/th&gt;&lt;th colspan=&quot;4&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot;&gt;Michael C Grant&lt;xref rid=&quot;jmv26398-bib-0060&quot; ref-type=&quot;bibr&quot;&gt;\n",
      "&lt;sup&gt;60&lt;/sup&gt;\n",
      "&lt;/xref&gt;\n",
      "&lt;/th&gt;&lt;/tr&gt;&lt;tr style=&quot;border-bottom:solid 1px #000000&quot; valign=&quot;bottom&quot;&gt;&lt;th colspan=&quot;4&quot; style=&quot;border-bottom:solid 1px #000000&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot;&gt;&amp;lt;1 y&lt;/th&gt;&lt;th colspan=&quot;4&quot; style=&quot;border-bottom:solid 1px #000000&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot;&gt;0â18 y&lt;/th&gt;&lt;th colspan=&quot;4&quot; style=&quot;border-bottom:solid 1px #000000&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot;&gt;&amp;gt;18 y&lt;/th&gt;&lt;th colspan=&quot;4&quot; style=&quot;border-bottom:solid 1px #000000&quot; valign=&quot;bottom&quot; rowspan=&quot;1&quot;&gt;&amp;gt;16 y&lt;/th&gt;&lt;/tr&gt;&lt;tr valign=&quot;bottom&quot; style=&quot;border-bottom:solid 1px #000000&quot;&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No. reports&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No. patients&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Prevalence (%)&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;\n",
      "&lt;italic toggle=&quot;yes&quot;&gt;I&lt;/italic&gt;\n",
      "&lt;sup&gt;2&lt;/sup&gt; (%)&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No. reports&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No. patients&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Prevalence (%)&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;\n",
      "&lt;italic toggle=&quot;yes&quot;&gt;I&lt;/italic&gt;\n",
      "&lt;sup&gt;2&lt;/sup&gt; (%)&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No. reports&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No. patients&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Prevalence (%)&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;\n",
      "&lt;italic toggle=&quot;yes&quot;&gt;I&lt;/italic&gt;\n",
      "&lt;sup&gt;2&lt;/sup&gt; (%)&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No. reports&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No. patients&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Prevalence (%)&lt;/th&gt;&lt;th valign=&quot;bottom&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;\n",
      "&lt;italic toggle=&quot;yes&quot;&gt;I&lt;/italic&gt;\n",
      "&lt;sup&gt;2&lt;/sup&gt; (%)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody valign=&quot;top&quot;&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;27&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;46 (22â66)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;33.7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;36&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5838&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;55 (53â58)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;33.4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;22&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2874&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;55.9 (51.6â60.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;66.1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Asymptomatic&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;433&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6 (5â13)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;24.3&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3287&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;20 (14â26)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;91.4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Mild&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;395&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;54 (49â59)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3048&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;33 (23â43)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;95.6&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Moderate&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;395&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;36 (27â45)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;40&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3046&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;51 (42â61)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;93.4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Severe&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;499&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7 (4â11)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;34.3&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;41&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3775&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7 (4â11)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;90.2&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Critical&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;404&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;14 (13â34)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;37.3&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3121&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5 (2â9)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;87.5&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Death&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5684&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0 (0â0)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;94.9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;632&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13.9 (6.2â21.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;91.4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fever&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;24&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;53 (30â76)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;48&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1494&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;51 (45â57)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;78.9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;735&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;92.8 (89.4â96.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;82.4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;138&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;21701&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;78 (75â81)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;94&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cough&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;19&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30 (2â58)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;45&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1435&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;41 (35â47)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;81&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;735&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;63.4 (48.0â78.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;97.1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;138&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;21682&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;57 (54â60)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;94&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Sore throat&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;38&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1040&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;16 (7â25)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;91.6&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;308&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11 (2.8â19.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;85.4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;78&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11721&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12 (10â14)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;88&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Tachycardia&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;35&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;950&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12 (3â21)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;93.9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Rhinorrhea&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;21 (5â43)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;36&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;990&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;14 (8â19)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;75.4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;36&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10656&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8 (5â12)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;97&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Nasal congestion&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;50 (20â99)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;33&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;623&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17 (6â27)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;87.2&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2584&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5 (3â7)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;78&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Tachypnea&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;33 (20â57)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;29&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1034&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9 (4â14)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;87.4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Diarrhea&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1250&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8 (6â11)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;47&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;457&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6.1 (2.4â9.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;62.1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;93&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11707&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10 (8â12)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;93&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Vomiting&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;33 (18â67)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1238&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7 (5â10)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;50.4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4959&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4 (2â8)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;94&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Myalgia or Fatigue&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1253&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12 (7â17)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;77.7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;446&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;29.4 (19.8â39.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;80.7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;78&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13385&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;31 (27â35)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;95&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hypoxemia&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;33&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;623&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3 (1â4)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;656&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;45.6 (10.9â80.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;99.5&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Chest pain&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;34&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;673&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3 (0â5)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3510&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7 (4â10)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;92&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Leukocytosis&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;38&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;907&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10 (7â14)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;63.1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;487&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;16.8 (5.5â28.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;93.1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Leukopenia&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;978&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;19 (14â25)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;80.9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;517&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;18.7 (8.5â28.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;94.5&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Lymphopenia&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;33 (24â47)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;39&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;795&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;16 (11â21)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;76.9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;511&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;43.1 (18.9â67.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;98&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;High PCT&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;29&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;709&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;36 (21â51)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;97.0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;High CRP&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;15&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42 (6â78)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;32&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;651&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;19 (13â26)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;79.3&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;332&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;58.3 (21.8â94.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;98.9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;High LDH&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;50 (15â69)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;24&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;301&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;29 (20â39)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;69.8&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;341&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;57.0 (38.0â76.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;92.6&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;High ALT&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;25&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;47 (25â69)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;32&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;686&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11 (7â15)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;38.5&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;128&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;24.1 (13.5â34.6)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42.8&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;High AST&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;14&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;33 (20â67)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;28&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;529&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;18 (13â23)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;48.6&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;169&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;33.3 (26.3â40.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;High Creatinine&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;20&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;169&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.5 (1.0â8.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10.2&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;High Blood urea nitrogen&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;18&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;High CK&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;17&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;109&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9 (1â17)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;33.2&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;140&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;21.3 (3.2â39.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;81.4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;High CKâMB&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;21&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;88 (71â94)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8.5&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;23&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;228&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;37 (25â48)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;59.0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;High Dâdimer&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;24&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;194&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11 (8â14)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Normal Imaging&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42 (6â78)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;38&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;902&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;41 (30â52)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;93.4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Groundâglass opacity&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;14&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;50 (20â80)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;39&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;898&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;36 (25â47)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;92.9&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;584&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;68.5 (51.8â85.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;99.1&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Local patchy shadow&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;42 (6â78)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;35&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;928&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26 (21â32)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;58.2&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;316&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;25 (5.2â44.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;96.4&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Bilateral patchy shadow&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;40 (13â55)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;34&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;814&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;28 (21â35)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;73.8&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;508&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;70.7 (50.4â91.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;98.7&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;White lung change&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;32&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;653&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2 (0â4)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pleural effusion&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;35&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;769&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2 (0â3)&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>17350</offset><text>Study\tPresent study\tPresent study\tRodriguezâMorales AJ\tMichael C Grant\t \t&lt;1 y\t0â18 y\t&gt;18 y\t&gt;16 y\t \tNo. reports\tNo. patients\tPrevalence (%)\tI2 (%)\tNo. reports\tNo. patients\tPrevalence (%)\tI2 (%)\tNo. reports\tNo. patients\tPrevalence (%)\tI2 (%)\tNo. reports\tNo. patients\tPrevalence (%)\tI2 (%)\t \tMale\t11\t27\t46 (22â66)\t33.7\t36\t5838\t55 (53â58)\t33.4\t22\t2874\t55.9 (51.6â60.1)\t66.1\tNA\tNA\tNA\tNA\t \tAsymptomatic\t11\t433\t6 (5â13)\t24.3\t42\t3287\t20 (14â26)\t91.4\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t \tMild\t10\t395\t54 (49â59)\t0\t42\t3048\t33 (23â43)\t95.6\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t \tModerate\t10\t395\t36 (27â45)\t4\t40\t3046\t51 (42â61)\t93.4\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t \tSevere\t12\t499\t7 (4â11)\t34.3\t41\t3775\t7 (4â11)\t90.2\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t \tCritical\t11\t404\t14 (13â34)\t37.3\t42\t3121\t5 (2â9)\t87.5\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t \tDeath\t0\t0\tNA\tNA\t42\t5684\t0 (0â0)\t94.9\t7\t632\t13.9 (6.2â21.5)\t91.4\tNA\tNA\tNA\tNA\t \tFever\t11\t24\t53 (30â76)\t0\t48\t1494\t51 (45â57)\t78.9\t13\t735\t92.8 (89.4â96.2)\t82.4\t138\t21701\t78 (75â81)\t94\t \tCough\t9\t19\t30 (2â58)\t0\t45\t1435\t41 (35â47)\t81\t13\t735\t63.4 (48.0â78.8)\t97.1\t138\t21682\t57 (54â60)\t94\t \tSore throat\t7\t10\tNA\tNA\t38\t1040\t16 (7â25)\t91.6\t5\t308\t11 (2.8â19.2)\t85.4\t78\t11721\t12 (10â14)\t88\t \tTachycardia\t5\t7\tNA\tNA\t35\t950\t12 (3â21)\t93.9\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t \tRhinorrhea\t8\t17\t21 (5â43)\t0\t36\t990\t14 (8â19)\t75.4\tNA\tNA\tNA\tNA\t36\t10656\t8 (5â12)\t97\t \tNasal congestion\t6\t9\t50 (20â99)\t0\t33\t623\t17 (6â27)\t87.2\tNA\tNA\tNA\tNA\t10\t2584\t5 (3â7)\t78\t \tTachypnea\t6\t10\t33 (20â57)\t0\t29\t1034\t9 (4â14)\t87.4\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t \tDiarrhea\t7\t10\tNA\tNA\t42\t1250\t8 (6â11)\t47\t6\t457\t6.1 (2.4â9.7)\t62.1\t93\t11707\t10 (8â12)\t93\t \tVomiting\t7\t12\t33 (18â67)\t0\t42\t1238\t7 (5â10)\t50.4\tNA\tNA\tNA\tNA\t26\t4959\t4 (2â8)\t94\t \tMyalgia or Fatigue\t6\t9\tNA\tNA\t42\t1253\t12 (7â17)\t77.7\t11\t446\t29.4 (19.8â39.0)\t80.7\t78\t13385\t31 (27â35)\t95\t \tHypoxemia\t5\t7\tNA\tNA\t33\t623\t3 (1â4)\t0\t8\t656\t45.6 (10.9â80.4)\t99.5\tNA\tNA\tNA\tNA\t \tChest pain\t5\t7\tNA\tNA\t34\t673\t3 (0â5)\t0\tNA\tNA\tNA\tNA\t30\t3510\t7 (4â10)\t92\t \tLeukocytosis\tNA\tNA\tNA\tNA\t38\t907\t10 (7â14)\t63.1\t7\t487\t16.8 (5.5â28.0)\t93.1\tNA\tNA\tNA\tNA\t \tLeukopenia\tNA\tNA\tNA\tNA\t42\t978\t19 (14â25)\t80.9\t8\t517\t18.7 (8.5â28.8)\t94.5\tNA\tNA\tNA\tNA\t \tLymphopenia\t5\t9\t33 (24â47)\t0\t39\t795\t16 (11â21)\t76.9\t8\t511\t43.1 (18.9â67.3)\t98\tNA\tNA\tNA\tNA\t \tHigh PCT\t7\t10\tNA\tNA\t29\t709\t36 (21â51)\t97.0\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t \tHigh CRP\t9\t15\t42 (6â78)\t0\t32\t651\t19 (13â26)\t79.3\t6\t332\t58.3 (21.8â94.7)\t98.9\tNA\tNA\tNA\tNA\t \tHigh LDH\t4\t7\t50 (15â69)\t0\t24\t301\t29 (20â39)\t69.8\t5\t341\t57.0 (38.0â76.0)\t92.6\tNA\tNA\tNA\tNA\t \tHigh ALT\t7\t25\t47 (25â69)\t0\t32\t686\t11 (7â15)\t38.5\t2\t128\t24.1 (13.5â34.6)\t42.8\tNA\tNA\tNA\tNA\t \tHigh AST\t7\t14\t33 (20â67)\t0\t28\t529\t18 (13â23)\t48.6\t3\t169\t33.3 (26.3â40.4)\t0\tNA\tNA\tNA\tNA\t \tHigh Creatinine\t5\t20\tNA\tNA\tNA\tNA\tNA\tNA\t3\t169\t4.5 (1.0â8.0)\t10.2\tNA\tNA\tNA\tNA\t \tHigh Blood urea nitrogen\t4\t18\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t \tHigh CK\t2\t3\tNA\tNA\t17\t109\t9 (1â17)\t33.2\t2\t140\t21.3 (3.2â39.4)\t81.4\tNA\tNA\tNA\tNA\t \tHigh CKâMB\t4\t21\t88 (71â94)\t8.5\t23\t228\t37 (25â48)\t59.0\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t \tHigh Dâdimer\t4\t5\tNA\tNA\t24\t194\t11 (8â14)\t0\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t \tNormal Imaging\t8\t13\t42 (6â78)\t0\t38\t902\t41 (30â52)\t93.4\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t \tGroundâglass opacity\t8\t14\t50 (20â80)\t0\t39\t898\t36 (25â47)\t92.9\t10\t584\t68.5 (51.8â85.2)\t99.1\tNA\tNA\tNA\tNA\t \tLocal patchy shadow\t7\t11\t42 (6â78)\t0\t35\t928\t26 (21â32)\t58.2\t7\t316\t25 (5.2â44.8)\t96.4\tNA\tNA\tNA\tNA\t \tBilateral patchy shadow\t7\t11\t40 (13â55)\t0\t34\t814\t28 (21â35)\t73.8\t7\t508\t70.7 (50.4â91.0)\t98.7\tNA\tNA\tNA\tNA\t \tWhite lung change\tNA\tNA\tNA\tNA\t32\t653\t2 (0â4)\t0\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t \tPleural effusion\tNA\tNA\tNA\tNA\t35\t769\t2 (0â3)\t0\tNA\tNA\tNA\tNA\tNA\tNA\tNA\tNA\t \t</text></passage><passage><infon key=\"file\">jmv26398-tbl-0002.xml</infon><infon key=\"id\">jmv26398-tbl-0002</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_footnote</infon><offset>21053</offset><text>Abbreviation: COVIDâ19, coronavirus disease 2019.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_3</infon><offset>21105</offset><text>Clinical presentation</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>21127</offset><text>FigureÂ 4 presents a summary of the clinical presentation of all children. The most common clinical manifestations were fever 51% (95% CI: 45%â57%; I 2â=â78.9%), cough 41% (95% CI: 35%â47%; I 2â=â81.0%), sore throat 16% (95% CI: 7%â25%; I 2â=â91.6%), tachycardia 12% (95% CI: 3%â21%; I 2â=â93.9%), rhinorrhea 14% (95% CI: 8%â19%; I 2â=â75.4%), nasal congestion 17% (95% CI: 6%â27%; I 2â=â87.2%), tachypnea 9% (95% CI: 4%â14%; I 2â=â87.4%), diarrhea 8% (95% CI: 6%â11%; I 2â=â47.0%), vomiting 7% (95% CI: 5%â10%; I 2â=â50.4%), myalgia or fatigue 12% (95% CI: 7%â17%; I 2â=â77.7%), hypoxemia 3% (95% CI: 1%â4%; I 2â=â0.0%) and chest pain 3% (95% CI: 0%â5%; I 2â=â0.0%).</text></passage><passage><infon key=\"file\">JMV-93-1057-g003.jpg</infon><infon key=\"id\">jmv26398-fig-0004</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>21867</offset><text>Aggregated results of clinical presentation in children with COVIDâ19. COVIDâ19, coronavirus disease 2019</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>21977</offset><text>Among children under 1âyear old cases, fever 53% (95% CI: 30%â76%; I 2â=â0.0%), cough 30% (95% CI: 2%â58%; I 2â=â0.0%), rhinorrhea 21% (95% CI: 5%â43%; I 2â=â0.0%), nasal congestion 50% (95% CI: 20%â99%; I 2â=â0.0%), tachypnea 33% (95% CI: 20%â57%; I 2â=â0.0%) and vomiting 33% (95% CI: 18%â67%, I 2â=â0.0%) (TableÂ 2).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_3</infon><offset>22335</offset><text>Laboratory examination</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>22358</offset><text>Laboratory examination results, which including blood routine test, liver function tests, renal function measurement, cardiac function, inflammatory factors, and Dâdimer, are shown in FigureÂ 5. With respect to laboratory findings, the proportion of normal white blood cells in COVIDâ19 patients in children was 69% (95% CI: 64%â75%; I 2â=â58.5%). Leukocytosis (&gt;12âÃâ109/L) was observed in 10% (95% CI: 7%â14%; I 2â=â63.1%) of patients, and 19% (95% CI: 14%â25%; I 2â=â80.9%) patient had leukopenia (&lt;5.5âÃâ109/L). The proportion of patients with lymphopenia was 16% (95% CI: 11%â21%; I 2â=â76.9%). The proportion of patients with high PCT 36% (95% CI: 21%â 51%; I 2â=â97.0%), CRP 19% (95% CI: 13%â26%; I 2â=â79.3%) and LDH 29% (95% CI: 20%â39%; I 2â=â69.8%), respectively. ALT and AST are indicative parameters for liver function, the high ALT and AST patients was 11% (95% CI: 7%â15%; I 2â=â38.5%) and 18% (95% CI: 13%â23%; I 2â=â48.6%), respectively. Creatineâkinase (CK) and CKâMB are indicative parameters for cardiac function, the high CK and CKâMB was 9% (95% CI: 1%â17%; I 2â=â33.2%) and 37% (95% CI: 25%â48%; I 2â=â59.0%), respectively. We also evaluated the patients had elevated Dâdimer, result revealed that nearly 11% (95% CI: 8%â14%; I 2â=â0.0%).</text></passage><passage><infon key=\"file\">JMV-93-1057-g002.jpg</infon><infon key=\"id\">jmv26398-fig-0005</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>23714</offset><text>Summary results of laboratory examination in children with COVIDâ19. COVIDâ19, coronavirus disease 2019</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>23822</offset><text>Among children under 1âyear old cases, the proportion of lymphopenia was 33% (95% CI: 24%â47%; I 2â=â0.0%). The ratio of elevated CRP and LDH were 42% (95% CI: 6%â78%; I 2â=â0.0%) and 50% (95% CI: 15%â69%; I 2â=â0.0%), respectively. The high ALT and AST patients were 47% (95% CI: 25%â69%; I 2â=â0.0%) and 33% (95% CI: 20%â67%; I 2â=â0.0%), respectively. The proportion of elevated CKâMB was 88% (95% CI: 71%â94%; I 2â=â8.5%) (TableÂ 2).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_3</infon><offset>24300</offset><text>Imaging features</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>24317</offset><text>Imaging features for patients were summarized in FigureÂ 6. All pediatric patients with normal imaging was 41% (95% CI: 30%â52%; I 2â=â93.4%), GGO 36% (95% CI: 25%â47%; I 2â=â92.9%), local patchy shadowing 26% (95% CI: 21%â32%; I 2â=â58.2%), bilateral patchy shadowing 28% (95% CI: 21%â35%; I 2â=â73.8%), white lung change was 2% (95% CI: 0%â4%; I 2â=â0.0%) and pleural effusion 2% (95% CI: 0%â3%; I 2â=â0.0%).</text></passage><passage><infon key=\"file\">JMV-93-1057-g001.jpg</infon><infon key=\"id\">jmv26398-fig-0006</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>24764</offset><text>Pooled results of imaging features in children with COVIDâ19. COVIDâ19, coronavirus disease 2019</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>24865</offset><text>Among children under 1âyear old cases, the proportion of normal imaging was 42% (95% CI: 6%â78%, I 2â=â0.0%). The GGO accounted for 50% (95% CI: 20%â80%; I 2â=â0.0%) of lung abnormality. Local and bilateral patchy shadowing were 42% (95% CI: 6%â78%; I 2â=â0.0%) and 40% (95% CI: 13%â55%; I 2â=â0.0%), respectively (TableÂ 2).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_3</infon><offset>25217</offset><text>Publication bias</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>25234</offset><text>Publication bias was evaluated by Begg's test, which suggested that there was no notable evidence of publication bias except for 1 to 5 year (Pâ=â.004); asymptomatic (Pâ=â.000); critical (Pâ=â.008); diarrhea (Pâ=â.004); vomiting (Pâ=â.016); hypoxemia (Pâ=â.007); normal white blood cell (Pâ=â.002); leukocytosis (Pâ=â.002); leukopenia (Pâ=â.000); high CRP (Pâ=â.009) and pleural effusion (Pâ=â.001).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_3</infon><offset>25678</offset><text>Subgroup analysis</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>25696</offset><text>Tables S2 to S6 present the results of subgroup analyses. Noncase reports included case series and cohort studies, case reports only referred to the study design of the case report. The findings were consistent in all subgroup analyses except for the 6 to 10 years, critical and tachycardia subgroups.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">title_1</infon><offset>25998</offset><text>DISCUSSION</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>26009</offset><text>We comprehensively examined the demographic, clinical characteristics, laboratory, and imaging features among pediatric patients with COVIDâ19 and further made a metaâanalysis with literature studies. We also compared the characteristics of SARSâCoVâ2 infection in children under 1 year old, children between 0 and 18 years old, as well as in adults (TableÂ 2). The main findings are as follows: first, SARSâCoVâ2 was susceptible to all age groups of children, the most common clinical manifestations were fever and cough and the majority of them had experienced asymptomatic, mild and moderate illness; second, children were more likely to have normal leukocyte counts, whereas lymphocytosis occurred infrequently; Third, the incidence of critical illness and vomiting symptoms was high in children under 1 year old.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>26839</offset><text>The pandemic of COVIDâ19 affected all age groups in children based on the current studies. Our result was consistent with those previous studies that there was no significant difference in age distribution of SARSâCoVâ2 infection among children. The most common clinical manifestations of COVIDâ19 pediatric patients were fever (51%) and cough (41%) from our metaâanalysis, which were lower than the fever (78.0%â92.8%) and cough (57.0%â63.4%) in adults. These findings further suggested that children's clinical symptoms were not typical when compared with adults. The frequency of severe illness was 7% in children with COVIDâ19, which was lower than that in adults (25.6%). One possible reason might be that children are less likely to have underlying diseases such as diabetes, hypertension, or cardiovascular disease. In addition to the above reason, the fact that innate immune response declines with age could also be important for the difference. The percentage of asymptomatic in children with COVIDâ19 was 20% and deserves full attention to control the ongoing pandemic.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>27938</offset><text>For the laboratory examination, normal leukocyte counts were up to 70% in children, which was as similar as 69.7% in adults. The reduction of lymphocytes in children was only 16%, but in adults, it went up to 43.1%, 57.4%, and 56%, respectively, reported by previous metaâanalysis. The reason for these differences may be related to the immune response of different organisms to novel coronavirus. The level of CKâMB was raised in 37% of all children, which is one of the classical biomarkers of cardiotoxicity. Subgroup analysis further revealed CKâMB was elevated in nearly 88% in children under 1 year old. These results suggested that we should pay special attention to the myocardial damage in children, especially for those under 1year old. It should be noted that the activity of CKâMB was detected by immunosuppressive method, which is easy to be affected by the peripheral blood creatineâkinase BB (CKâBB). In addition, the bloodâbrain barrier in children, especially in infants, is not fully developed, and more CKâBB will appear in the peripheral blood, resulting in the high level of CKâMB activity. In the future, specific studies are still needed to explain the causes and effects of CKâMB elevation in children.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>29185</offset><text>The CT manifestations of COVIDâ19 in pediatric patients are diverse and lack specificity depending on the severity of disease or clinical classification. Normal imaging occurred in 41% pediatric patients in our metaâanalysis, which are similar to the other two reports with the largest number of pediatric cases so far, the proportion of normal lung CT was 35% (60/171) and 57% (66/115), respectively, but, it was infrequent in adults, the rate of normal imaging was only 10%. GGO was the most common performance in children presenting lung abnormality, which most located in the lower lung, outer band, near the pleura, and the scope was small compared with adults. Pediatric patients with GGO was 36%, significantly lower than adults with 80% to 83%. This may be related to the fact that COVIDâ19 in children shows milder than adults.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>30028</offset><text>The rate of critical illness in children under 1 year old was 14%, higher than 5% in all children. These results suggested that clinicians should pay more attention to changes in disease activity in children under 1 year old. A total of 33% and 7% suffer from vomiting in children under 1 year old and all children, respectively. Based on all the above facts, it was worth noting that the proportion of infants developing critical cases is relatively high, and the initial symptom often include vomiting. However, due to the limited sample size, large, wellâdesigned studies are still needed to confirm these findings.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">title_1</infon><offset>30649</offset><text>LIMITATION</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>30660</offset><text>This metaâanalysis has several limitations that should be addressed. First, few cohort studies available for inclusion, and most of them come from China. Second, it's hard to standardize the results of laboratory testing and radiographic imaging from different data sources. Third, more detailed patient information in children under 1 year old is not available in large sample studies at the time of analysis, the results need to be further updated.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">title_1</infon><offset>31113</offset><text>CONCLUSION</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>31124</offset><text>The COVIDâ19 pandemic affects all age groups in children and appears to be a mild illness. The common presenting complaints with COVIDâ19 are nonspecific symptoms, such as fever and cough. Normal leukocyte counts and infrequent of lymphopenia tend to be the laboratory characteristics. High incidence of critical illness and vomiting symptoms were as the main features in children under 1 year old. Characteristics of COVIDâ19 in children and adults are different and thus special criteria is still needed for more studies to identify.</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">title_1</infon><offset>31666</offset><text>CONFLICT OF INTERESTS</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">paragraph</infon><offset>31688</offset><text>The authors declare that there are no conflict of interests.</text></passage><passage><infon key=\"section_type\">AUTH_CONT</infon><infon key=\"type\">title_1</infon><offset>31749</offset><text>AUTHOR CONTRIBUTIONS</text></passage><passage><infon key=\"section_type\">AUTH_CONT</infon><infon key=\"type\">paragraph</infon><offset>31770</offset><text>All authors contributed to the intellectual content of this manuscript and approved the final manuscript as submitted. (a) Conception and design: Chunquan Cai, Yongming Shen; (b) collection, assembly of data: Xiaojian Cui, Tongqiang Zhang; (c) administrative support: Ping Si, Yongsheng Xu; (d) data analysis and interpretation: Zhihu Zhao, Wei Guo, Wenwei Guo, Jiayi Zhang; (e) search literatures: Cuicui Dong, Jiafeng Zheng, Ren Na, Lisheng Zheng, Wenliang Li, Zihui Liu, Jinhu Wang, Jia Ma; (f) manuscript writing: all authors; (g) final approval of manuscript: all authors.</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">title_1</infon><offset>32348</offset><text>Supporting information</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">title_1</infon><offset>32371</offset><text>DATA AVAILABILITY STATEMENT</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">paragraph</infon><offset>32399</offset><text>The original data can be requested reasonably.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">title</infon><offset>32446</offset><text>REFERENCES</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>32457</offset><text>WHO Coronavirus Disease (COVIDâ19) Dashboard</text></passage><passage><infon key=\"elocation-id\">e202007</infon><infon key=\"issue\">6</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pediatrics</infon><infon key=\"type\">ref</infon><infon key=\"volume\">145</infon><infon key=\"year\">2020</infon><offset>32504</offset><text>Epidemiology of COVIDâ19 Among Children in China</text></passage><passage><infon key=\"fpage\">325</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">333</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Public Health Manage Pract: JPHMP</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>32555</offset><text>COVIDâ19 in children in the United States: intensive care admissions, estimated total infected, and projected numbers of severe pediatric cases in 2020</text></passage><passage><infon key=\"elocation-id\">101623</infon><infon key=\"pub-id_pmid\">32179124</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Travel Med Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">34</infon><infon key=\"year\">2020</infon><offset>32709</offset><text>Clinical, laboratory and imaging features of COVIDâ19: a systematic review and metaâanalysis</text></passage><passage><infon key=\"fpage\">656</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">665</infon><infon key=\"pub-id_pmid\">32283155</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">80</infon><infon key=\"year\">2020</infon><offset>32806</offset><text>Clinical characteristics of coronavirus disease 2019 (COVIDâ19) in China: a systematic review and metaâanalysis</text></passage><passage><infon key=\"pub-id_doi\">10.1002/jmv.26023</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>32922</offset><text>Children with coronavirus disease 2019: a review of demographic, clinical, laboratory, and imaging features in pediatric patients</text></passage><passage><infon key=\"fpage\">1088</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">1095</infon><infon key=\"pub-id_pmid\">32202343</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Acta Paediatr</infon><infon key=\"type\">ref</infon><infon key=\"volume\">109</infon><infon key=\"year\">2020</infon><offset>33052</offset><text>Systematic review of COVIDâ19 in children shows milder cases and a better prognosis than adults</text></passage><passage><infon key=\"fpage\">1892</infon><infon key=\"lpage\">1899</infon><infon key=\"pub-id_pmid\">32492251</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pediatr Pulmonol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">55</infon><infon key=\"year\">2020</infon><offset>33150</offset><text>Clinical manifestations of children with COVIDâ19: a systematic review</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>33223</offset><text>  . Technicalâguidance for 2019ânCoV RTâPCR. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technicalguidance/laboratory-guidance </text></passage><passage><infon key=\"fpage\">169</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">174</infon><infon key=\"pub-id_pmid\">32135584</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Zhonghua Er Ke Za Zhi</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>33377</offset><text>[Recommendations for the diagnosis, prevention and control of the 2019 novel coronavirus infection in children (first interim edition)]</text></passage><passage><infon key=\"fpage\">60</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">63</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BMJ Evid Based Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">23</infon><infon key=\"year\">2018</infon><offset>33513</offset><text>Methodological quality and synthesis of case series and case reports</text></passage><passage><infon key=\"fpage\">974</infon><infon key=\"issue\">11</infon><infon key=\"lpage\">978</infon><infon key=\"pub-id_pmid\">23963506</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Epidemiol Community Health</infon><infon key=\"type\">ref</infon><infon key=\"volume\">67</infon><infon key=\"year\">2013</infon><offset>33582</offset><text>Metaâanalysis of prevalence</text></passage><passage><infon key=\"fpage\">290</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">293</infon><infon key=\"pub-id_pmid\">32312363</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Zhongguo Dang Dai Er Ke Za Zhi</infon><infon key=\"type\">ref</infon><infon key=\"volume\">22</infon><infon key=\"year\">2020</infon><offset>33612</offset><text>[Clinical features of children with SARSâCoVâ2 infection: an analysis of 115 cases]</text></passage><passage><infon key=\"fpage\">E008</infon><infon key=\"pub-id_pmid\">32062875</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Zhonghua Er Ke Za Zhi</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>33700</offset><text>[Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen]</text></passage><passage><infon key=\"fpage\">269</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">274</infon><infon key=\"pub-id_pmid\">32118389</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Zhonghua Er Ke Za Zhi</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>33812</offset><text>[Clinical analysis of 31 cases of 2019 novel coronavirus infection in children from six provinces (autonomous region) of northern China]</text></passage><passage><infon key=\"elocation-id\">ciaa198</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>33949</offset><text>A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features</text></passage><passage><infon key=\"fpage\">275</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">278</infon><infon key=\"pub-id_pmid\">32234131</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Zhonghua Er Ke Za Zhi</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>34052</offset><text>[Analysis of CT features of 15 children with 2019 novel coronavirus infection]</text></passage><passage><infon key=\"fpage\">707</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">713</infon><infon key=\"pub-id_pmid\">32208917</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>34131</offset><text>The different clinical characteristics of corona virus disease cases between children and their families in Chinaâthe character of children with COVIDâ19</text></passage><passage><infon key=\"fpage\">215</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">220</infon><infon key=\"pub-id_pmid\">32204756</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Zhongguo Dang Dai Er Ke Za Zhi</infon><infon key=\"type\">ref</infon><infon key=\"volume\">22</infon><infon key=\"year\">2020</infon><offset>34289</offset><text>[Clinical features and chest CT findings of coronavirus disease 2019 in infants and young children]</text></passage><passage><infon key=\"fpage\">1313</infon><infon key=\"issue\">13</infon><infon key=\"lpage\">1314</infon><infon key=\"pub-id_pmid\">32058570</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>34389</offset><text>Novel coronavirus infection in hospitalized infants under 1 year of age in China</text></passage><passage><infon key=\"fpage\">1370</infon><infon key=\"issue\">14</infon><infon key=\"lpage\">1371</infon><infon key=\"pub-id_pmid\">32163697</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>34470</offset><text>Detection of Covidâ19 in children in early january 2020 in Wuhan, China</text></passage><passage><infon key=\"fpage\">86</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">87</infon><infon key=\"pub-id_pmid\">32102141</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Zhonghua Er Ke Za Zhi</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>34544</offset><text>[First case of 2019 novel coronavirus infection in children in Shanghai]</text></passage><passage><infon key=\"fpage\">182</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">184</infon><infon key=\"pub-id_pmid\">32135587</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Zhonghua Er Ke Za Zhi</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>34617</offset><text>[2019 novel coronavirus infection in a threeâmonthâold baby]</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"lpage\">4</infon><infon key=\"pub-id_pmid\">32026149</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">World J Pediatr</infon><infon key=\"type\">ref</infon><infon key=\"volume\">16</infon><infon key=\"year\">2020</infon><offset>34682</offset><text>Clinical features of pediatric patients with COVIDâ19: a report of two family cluster cases</text></passage><passage><infon key=\"fpage\">221</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">225</infon><infon key=\"pub-id_pmid\">32204757</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Zhongguo Dang Dai Er Ke Za Zhi</infon><infon key=\"type\">ref</infon><infon key=\"volume\">22</infon><infon key=\"year\">2020</infon><offset>34776</offset><text>[Twin girls infected with SARSâCoVâ2]</text></passage><passage><infon key=\"fpage\">211</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">214</infon><infon key=\"pub-id_pmid\">32204755</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Zhongguo Dang Dai Er Ke Za Zhi</infon><infon key=\"type\">ref</infon><infon key=\"volume\">22</infon><infon key=\"year\">2020</infon><offset>34818</offset><text>[SARSâCoVâ2 infection with gastrointestinal symptoms as the first manifestation in a neonate]</text></passage><passage><infon key=\"fpage\">305</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">306</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Zhejiang Med J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">42</infon><infon key=\"year\">2020</infon><offset>34916</offset><text>1 case of novel coronavirus pneumonia in children</text></passage><passage><infon key=\"fpage\">279</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">280</infon><infon key=\"pub-id_pmid\">32234132</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Zhonghua Er Ke Za Zhi</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>34966</offset><text>[First case of neonate with COVIDâ19 in China]</text></passage><passage><infon key=\"fpage\">909</infon><infon key=\"lpage\">914</infon><infon key=\"pub-id_pmid\">32222992</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>35015</offset><text>Detectable SARSâCoVâ2 viral RNA in feces of three children during recovery period of COVIDâ19 pneumonia</text></passage><passage><infon key=\"fpage\">722</infon><infon key=\"issue\">7</infon><infon key=\"lpage\">725</infon><infon key=\"pub-id_pmid\">32215598</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA Pediatr</infon><infon key=\"type\">ref</infon><infon key=\"volume\">174</infon><infon key=\"year\">2020</infon><offset>35125</offset><text>Neonatal earlyâonset infection with SARSâCoVâ2 in 33 neonates born to mothers with COVIDâ19 in Wuhan, China</text></passage><passage><infon key=\"fpage\">847</infon><infon key=\"lpage\">849</infon><infon key=\"pub-id_pmid\">32112082</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>35241</offset><text>A well infant with coronavirus disease 2019 (COVIDâ19) with high viral load</text></passage><passage><infon key=\"elocation-id\">e20200961</infon><infon key=\"pub-id_pmid\">32376725</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pediatrics</infon><infon key=\"type\">ref</infon><infon key=\"volume\">146</infon><infon key=\"year\">2020</infon><offset>35319</offset><text>Coâinfection and other clinical characteristics of COVIDâ19 in children</text></passage><passage><infon key=\"fpage\">473</infon><infon key=\"lpage\">480</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Microbiol, Immunol Infection.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">53</infon><infon key=\"year\">2020</infon><offset>35395</offset><text>Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019</text></passage><passage><infon key=\"elocation-id\">e124</infon><infon key=\"issue\">11</infon><infon key=\"pub-id_pmid\">32193905</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Korean Med Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">35</infon><infon key=\"year\">2020</infon><offset>35481</offset><text>First pediatric case of coronavirus disease 2019 in Korea</text></passage><passage><infon key=\"fpage\">1169</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">1174</infon><infon key=\"pub-id_pmid\">32134205</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pediatr Pulmonol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">55</infon><infon key=\"year\">2020</infon><offset>35539</offset><text>Clinical and CT features in pediatric patients with COVIDâ19 infection: different points from adults</text></passage><passage><infon key=\"elocation-id\">e201346</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA Pediatr.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>35642</offset><text>Screening and severity of coronavirus disease 2019 (COVIDâ19) in children in Madrid, Spain</text></passage><passage><infon key=\"fpage\">1430</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">1432</infon><infon key=\"pub-id_pmid\">32270592</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pediatr Pulmonol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">55</infon><infon key=\"year\">2020</infon><offset>35735</offset><text>Clinical characteristics of a case series of children with coronavirus disease 2019</text></passage><passage><infon key=\"fpage\">689</infon><infon key=\"lpage\">696</infon><infon key=\"pub-id_pmid\">32220650</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>35819</offset><text>Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVIDâ19) in Zhejiang, China: an observational cohort study</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>35965</offset><text>The clinical and epidemiological features and hints of 82 confirmed COVIDâ19 pediatric cases aged 0â16 in Wuhan, China</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"issue\">11</infon><infon key=\"lpage\">5</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Chin J Nosocomiol.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2020</infon><offset>36088</offset><text>Clinical and epidemiological characteristics of 91 children conformed with COVIDâ19</text></passage><passage><infon key=\"fpage\">123</infon><infon key=\"issue\">1</infon><infon key=\"pub-id_pmid\">32370747</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BMC Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">18</infon><infon key=\"year\">2020</infon><offset>36174</offset><text>A singleâcenter, retrospective study of COVIDâ19 features in children: a descriptive investigation</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>36277</offset></passage><passage><infon key=\"fpage\">277</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">280</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiol Practic</infon><infon key=\"type\">ref</infon><infon key=\"volume\">35</infon><infon key=\"year\">2020</infon><offset>36278</offset><text>Clinical and imaging characteristics of children with corona virus disease 2019 (COVIDâ19)</text></passage><passage><infon key=\"fpage\">95</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pediatr Infect Dis J.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">39</infon><infon key=\"year\">2020</infon><offset>36371</offset><text>Symptomatic infection is associated with prolonged duration of viral shedding in mild coronavirus disease 2019: a retrospective study of 110 children in Wuhan</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>36530</offset><text>A retrospective study of the clinical characteristics of COVIDâ19 infection in 26 children</text></passage><passage><infon key=\"fpage\">275</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">280</infon><infon key=\"pub-id_pmid\">32207032</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Curr Med Sci.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">40</infon><infon key=\"year\">2020</infon><offset>36623</offset><text>Clinical characteristics of children with coronavirus disease 2019 in Hubei, China</text></passage><passage><infon key=\"fpage\">1424</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">1429</infon><infon key=\"pub-id_pmid\">32259403</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pediatr Pulmonol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">55</infon><infon key=\"year\">2020</infon><offset>36706</offset><text>Novel coronavirus infection in children outside of Wuhan, China</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"lpage\">9</infon><infon key=\"pub-id_pmid\">32026149</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">World J Pediatr</infon><infon key=\"type\">ref</infon><infon key=\"volume\">16</infon><infon key=\"year\">2020</infon><offset>36770</offset><text>Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>36895</offset></passage><passage><infon key=\"fpage\">e7</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">e13</infon><infon key=\"pub-id_pmid\">32171865</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">80</infon><infon key=\"year\">2020</infon><offset>36896</offset><text>Clinical and CT imaging features of the COVIDâ19 pneumonia: focus on pregnant women and children</text></passage><passage><infon key=\"fpage\">419</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">424</infon><infon key=\"pub-id_pmid\">32434634</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Zhongguo Dang Dai Er Ke Za Zhi</infon><infon key=\"type\">ref</infon><infon key=\"volume\">22</infon><infon key=\"year\">2020</infon><offset>36995</offset><text>[Clinical features of coronavirus disease 2019 in children aged &lt;18 years in Jiangxi, China: an analysis of 23 cases]</text></passage><passage><infon key=\"fpage\">294</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">298</infon><infon key=\"pub-id_pmid\">32312364</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Zhongguo Dang Dai Er Ke Za Zhi</infon><infon key=\"type\">ref</infon><infon key=\"volume\">22</infon><infon key=\"year\">2020</infon><offset>37113</offset><text>[Clinical features of children with SARSâCoVâ2 infection: an analysis of 13 cases from Changsha, China]</text></passage><passage><infon key=\"fpage\">36</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">39</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Shandong University (Health Sciences)</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>37221</offset><text>Epidemiological and clinical characteristics of 10 children with coronavirus disease (COVIDâ19) in Jinan City</text></passage><passage><infon key=\"fpage\">62</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">64</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Shandong University (Health Sciences)</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>37333</offset><text>Clinical characteristics of novel coronavirus pneumonia in children in Jinan</text></passage><passage><infon key=\"fpage\">502</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">505</infon><infon key=\"pub-id_pmid\">32284613</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>37410</offset><text>Characteristics of pediatric SARSâCoVâ2 infection and potential evidence for persistent fecal viral shedding</text></passage><passage><infon key=\"issue\">32</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">World Latest Medicine Informatio [J]</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>37523</offset><text>Clinical analysis of 1 novel coronavirus infecting pneumonia cases in Yunnan</text></passage><passage><infon key=\"fpage\">E005</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Zhonghua er ke za zhiâ=âChinese J Pediatr</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>37600</offset><text>Frist case of severe childhood novel coronavirus pneumonia in China</text></passage><passage><infon key=\"fpage\">1663</infon><infon key=\"issue\">17</infon><infon key=\"lpage\">1665</infon><infon key=\"pub-id_pmid\">32187458</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>37668</offset><text>SARSâCoVâ2 infection in children</text></passage><passage><infon key=\"fpage\">422</infon><infon key=\"issue\">14</infon><infon key=\"lpage\">426</infon><infon key=\"pub-id_pmid\">32271728</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">MMWR Morb Mortal Wkly Rep</infon><infon key=\"type\">ref</infon><infon key=\"volume\">69</infon><infon key=\"year\">2020</infon><offset>37705</offset><text>Coronavirus disease 2019 in childrenâUnited States, February 12âApril 2, 2020</text></passage><passage><infon key=\"elocation-id\">e0234765</infon><infon key=\"issue\">6</infon><infon key=\"pub-id_pmid\">32574165</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS One</infon><infon key=\"type\">ref</infon><infon key=\"volume\">15</infon><infon key=\"year\">2020</infon><offset>37787</offset><text>The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARSâCoVâ2; COVIDâ19): a systematic review and metaâanalysis of 148 studies from 9 countries</text></passage><passage><infon key=\"pub-id_doi\">10.1038/s41390-020-0881-y</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pediatr Res</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>37967</offset><text>COVIDâ19 in children and altered inflammatory responses</text></passage><passage><infon key=\"elocation-id\">20143085</infon><infon key=\"issue\">1821</infon><infon key=\"pub-id_pmid\">26702035</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Proc Biol Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">282</infon><infon key=\"year\">2015</infon><offset>38025</offset><text>Evolution of the immune system in humans from infancy to old age</text></passage><passage><infon key=\"pub-id_doi\">10.1002/jmv.25884</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>38090</offset><text>Clinical characteristics of 3,062 COVIDâ19 patients: a metaâanalysis</text></passage><passage><infon key=\"fpage\">611</infon><infon key=\"issue\">04</infon><infon key=\"lpage\">612</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Chinese J Lab Diagn</infon><infon key=\"type\">ref</infon><infon key=\"volume\">18</infon><infon key=\"year\">2014</infon><offset>38163</offset><text>Diagnostic value of myocardial troponin I, CKâMB, and C reactive protein in children with viral myocarditis</text></passage><passage><infon key=\"fpage\">230</infon><infon key=\"issue\">02</infon><infon key=\"lpage\">231</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lab Med Clinic</infon><infon key=\"type\">ref</infon><infon key=\"volume\">2</infon><infon key=\"year\">2018</infon><offset>38273</offset><text>The difference between the normal value of serum creatine kinase MB in children and that in adults</text></passage><passage><infon key=\"fpage\">337</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">338</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Chinese Pla Postgraduate Med Sch</infon><infon key=\"type\">ref</infon><infon key=\"volume\">31</infon><infon key=\"year\">2010</infon><offset>38372</offset><text>Clinical evaluation of serum creatine phosphokinase isoenzyme in healthy children at different ages</text></passage><passage><infon key=\"fpage\">701</infon><infon key=\"lpage\">709</infon><infon key=\"pub-id_pmid\">32283052</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Am Coll Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">17</infon><infon key=\"year\">2020</infon><offset>38472</offset><text>Coronavirus disease 2019 (COVIDâ19) CT findings: a systematic review and metaâanalysis</text></passage><passage><infon key=\"fpage\">4427</infon><infon key=\"lpage\">4433</infon><infon key=\"pub-id_pmid\">32291501</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2020</infon><offset>38563</offset><text>features of novel coronavirus pneumonia (COVIDâ19) in children</text></passage><passage><infon key=\"fpage\">1005</infon><infon key=\"lpage\">1201</infon><infon key=\"pub-id_pmid\">31904951</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Environ Sci Technol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">54</infon><infon key=\"year\">2020</infon><offset>38628</offset><text>High resolution CT features of novel coronavirus pneu monia in children [J]</text></passage></document></collection>\n",
      "\n",
      "Study 32383182: <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n",
      "<!DOCTYPE collection SYSTEM \"BioC.dtd\">\n",
      "<collection><source>PMC</source><date>20220714</date><key>pmc.key</key><document><id>7267274</id><infon key=\"license\">NO-CC CODE</infon><passage><infon key=\"article-id_doi\">10.1002/jmv.25996</infon><infon key=\"article-id_pmc\">7267274</infon><infon key=\"article-id_pmid\">32383182</infon><infon key=\"article-id_publisher-id\">JMV25996</infon><infon key=\"fpage\">2312</infon><infon key=\"issue\">11</infon><infon key=\"kwd\">COVIDâ19 diagnosis gold standard RTâPCR serology</infon><infon key=\"license\">This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</infon><infon key=\"lpage\">2313</infon><infon key=\"name_0\">surname:DramÃ©;given-names:Moustapha</infon><infon key=\"name_1\">surname:Tabue Teguo;given-names:Maturin</infon><infon key=\"name_2\">surname:Proye;given-names:Emeline</infon><infon key=\"name_3\">surname:Hequet;given-names:Fanny</infon><infon key=\"name_4\">surname:Hentzien;given-names:Maxime</infon><infon key=\"name_5\">surname:Kanagaratnam;given-names:Lukshe</infon><infon key=\"name_6\">surname:Godaert;given-names:Lidvine</infon><infon key=\"section_type\">TITLE</infon><infon key=\"type\">front</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>0</offset><text>Should RTâPCR be considered a gold standard in the diagnosis of COVIDâ19?</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>78</offset><text> To the Editor, </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>95</offset><text>To face the new coronavirus disease 2019 (COVIDâ19) pandemic, the need for early and accurate diagnosis of the disease among suspected cases quickly became obvious for effective management, and for better control of the spread of the disease in the population. Since the beginning of this disease epidemic caused by the severe acute respiratory syndrome coronavirusâ2 (SARSâCoVâ2), reverse transcriptaseâpolymerase chain reaction (RTâPCR) has routinely been used to confirm the diagnosis. However, several authors have pointed out the poor performance of this technique, particularly in terms of sensitivity. Indeed, according to some authors, sensitivity could be as low as 38% (ie, not better than chance). This made it necessary to find a more sensitive test, given the contagiousness of SARSâCoVâ2. We, therefore, read with great interest the article published in your journal by Cassaniti et al. This article deals with the diagnosis of COVIDâ19 by serology (immunoglobulin m/immunoglobulin G) as a complementary approach to RTâPCR to improve its sensitivity. According to Cassaniti et al and Xiang et al, serology is faster to implement, less expensive, easier to use, and more accessible to staff with no specific laboratory training. The article describes the metrological performances of serology, and compare it with RTâPCR as the gold standard. Using a test as the gold standard when its metrological properties are clearly perfectible raises questions from a methodological point of view. Indeed, when an existing test is considered as a reference, this suggests that the test in question is always correct and that all misclassifications (false negatives and false positives) are due to the new test. However, the new test (in this case, serology) might be better than the old test (in this case, RTâPCR), but it would be impossible to demonstrate this. Consequently, the new test will never be able to achieve a sensitivity of 100%, since it is considered responsible for all misclassifications. The same mistake has also been made by other authors regarding the use of chest computed tomography scans as a diagnostic method. In this situation, the best strategy would be to measure the degree of agreement (using the Kappa coefficient measures) between the two tests, that is, neither of the two tests is considered to be the reference and, therefore, any discrepancies could be linked to either of the tests. Thus, the serology performances presented by Xiang et al are certainly better than those presented in their paper.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>2659</offset><text>The difficulty of using a gold standard is an old debate, but still relevant nonetheless. In the absence of an accurate reference test, alternative strategies could be to perform the test repeatedly over time, to use the patient's clinical course, or the combination of several tests as the gold standard.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>2965</offset><text>The purpose of writing this contribution is not to discuss the best diagnostic strategy for COVIDâ19, nor is it to question the results of the authors who used RTâPCR as a reference. On the contrary, it purports that their results might actually be even better than those presented.</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">title_1</infon><offset>3252</offset><text>CONFLICT OF INTERESTS</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">paragraph</infon><offset>3274</offset><text>The authors declare that there are no conflict of interests.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">title</infon><offset>3335</offset><text>REFERENCES</text></passage><passage><infon key=\"fpage\">172</infon><infon key=\"lpage\">175</infon><infon key=\"pub-id_pmid\">32156607</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Chim Acta</infon><infon key=\"type\">ref</infon><infon key=\"volume\">505</infon><infon key=\"year\">2020</infon><offset>3346</offset><text>Positive rate of RTâPCR detection of SARSâCoVâ2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>3480</offset><text>Characteristics of patients with coronavirus disease (COVIDâ19) confirmed using an IgMâIgG antibody test [published online ahead of print April 24, 2020]</text></passage><passage><infon key=\"fpage\">e14</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">e18</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">80</infon><infon key=\"year\">2020</infon><offset>3638</offset><text>Clinical features of COVIDâ19 in elderly patients: a comparison with young and middleâaged patients [published online ahead of print March 27, 2020]</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>3791</offset><text>Performance of VivaDiag COVIDâ19 IgM/IgG rapid test is inadequate for diagnosis of COVIDâ19 in acute patients referring to emergency room department [published online ahead of print March 30, 2020]</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>3993</offset><text>Antibody detection and dynamic characteristics in patients with COVIDâ19 [published online ahead of print April 19, 2020]</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>4117</offset><text>Correlation of chest CT and RTâPCR testing in coronavirus disease 2019 (COVIDâ19) in China: a report of 1014 cases [published online ahead of print February 26, 2020]</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">Am J Emerg Med</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>4288</offset><text>Chest CT in patients suspected of COVIDâ19 infection: a reliable alternative for RTâPCR</text></passage><passage><infon key=\"fpage\">27</infon><infon key=\"lpage\">46</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Educ Psychol Meas</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">1960</infon><offset>4380</offset><text>A coefficient of agreement for nominal scales</text></passage><passage><infon key=\"fpage\">1568</infon><infon key=\"lpage\">1569</infon><infon key=\"pub-id_pmid\">1628068</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BMJ</infon><infon key=\"type\">ref</infon><infon key=\"volume\">304</infon><infon key=\"year\">1992</infon><offset>4426</offset><text>Time to abolish &quot;gold standard&quot;</text></passage><passage><infon key=\"fpage\">187</infon><infon key=\"issue\">6846</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BMJ</infon><infon key=\"type\">ref</infon><infon key=\"volume\">305</infon><infon key=\"year\">1992</infon><offset>4458</offset><text>&quot;Gold standard&quot; is an appropriate term</text></passage></document></collection>\n",
      "\n",
      "Study 35132910: <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n",
      "<!DOCTYPE collection SYSTEM \"BioC.dtd\">\n",
      "<collection><source>PMC</source><date>20220218</date><key>pmc.key</key><document><id>8843115</id><infon key=\"license\">CC BY</infon><passage><infon key=\"alt-title\">Q. Fernandes et al.</infon><infon key=\"article-id_doi\">10.1080/07853890.2022.2031274</infon><infon key=\"article-id_pmc\">8843115</infon><infon key=\"article-id_pmid\">35132910</infon><infon key=\"article-id_publisher-id\">2031274</infon><infon key=\"fpage\">524</infon><infon key=\"issue\">1</infon><infon key=\"kwd\">COVID-19 SARS-CoV-2 Omicron Coronaviruses diagnostic testing vaccine immunological responses Viral epidemic</infon><infon key=\"license\">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</infon><infon key=\"lpage\">540</infon><infon key=\"name_0\">surname:Fernandes;given-names:Queenie</infon><infon key=\"name_1\">surname:Inchakalody;given-names:Varghese Philipose</infon><infon key=\"name_10\">surname:Yousuf Al-Nesf;given-names:Mariam Ali</infon><infon key=\"name_11\">surname:Hssain;given-names:Ali Ait</infon><infon key=\"name_12\">surname:Yassine;given-names:Hadi Mohamad</infon><infon key=\"name_13\">surname:Bachmann;given-names:Martin F.</infon><infon key=\"name_14\">surname:Uddin;given-names:Shahab</infon><infon key=\"name_15\">surname:Dermime;given-names:Said</infon><infon key=\"name_2\">surname:Merhi;given-names:Maysaloun</infon><infon key=\"name_3\">surname:Mestiri;given-names:Sarra</infon><infon key=\"name_4\">surname:Taib;given-names:Nassiba</infon><infon key=\"name_5\">surname:Moustafa Abo El-Ella;given-names:Dina</infon><infon key=\"name_6\">surname:Bedhiafi;given-names:Takwa</infon><infon key=\"name_7\">surname:Raza;given-names:Afsheen</infon><infon key=\"name_8\">surname:Al-Zaidan;given-names:Lobna</infon><infon key=\"name_9\">surname:Mohsen;given-names:Mona O.</infon><infon key=\"section_type\">TITLE</infon><infon key=\"title\">Keywords</infon><infon key=\"type\">front</infon><infon key=\"volume\">54</infon><infon key=\"year\">2022</infon><offset>0</offset><text>Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>95</offset><text>Abstract</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>104</offset><text>Key message</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>116</offset><text>The emergence of novel variants of the SARS-CoV-2 in the past couple of months, highlights one of the primary challenges in the diagnostics, treatment, as well as vaccine development against the virus.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>318</offset><text>Advancements in SARS-CoV-2 detection include nucleic acid based, antigen and immuno- assay-based and antibody-based detection methodologies for efficient, robust, and quick testing; while advancements in COVID-19 preventive and therapeutic strategies include novel antiviral and immunomodulatory drugs and SARS-CoV-2 targeted vaccines.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>654</offset><text>The varied COVID-19 vaccine platforms and the immune responses induced by each one of them as well as their ability to battle post-vaccination infections have all been discussed in this review.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>848</offset><text>The emergence of novel and evolving variants of SARS-CoV-2 has fostered the need for change in the form of newer and more adaptive diagnostic methods for the detection of SARS-CoV-2 infections. On the other hand, developing rapid and sensitive diagnostic technologies is now more challenging due to emerging variants and varying symptoms exhibited among the infected individuals. In addition to this, vaccines remain the major mainstay of prevention and protection against infection. Novel vaccines and drugs are constantly being developed to unleash an immune response for the robust targeting of SARS-CoV-2 and its associated variants. In this review, we provide an updated perspective on the current challenges posed by the emergence of novel SARS-CoV-2 mutants/variants and the evolution of diagnostic techniques to enable their detection. In addition, we also discuss the development, formulation, working mechanisms, advantages, and drawbacks of some of the most used vaccines/therapeutic drugs and their subsequent immunological impact.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>1892</offset><text>Introduction</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>1905</offset><text>An outbreak of pneumonia that began in December 2019 in Wuhan, the capital city of the Hubei Province of China was found to be associated with a novel strain of the Coronavirus that was tentatively named by the WHO as the 2019 novel coronavirus (2019-nCoV). However, on the 11th of February 2020, it was formally renamed as the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses and the WHO formally named the viral illness as the Coronavirus Disease 2019 (COVIDâ19); a disease characterized by respiratory distress, fevers, coughs, fatigue, pneumonia and muscle pain. Following the increase in the number of positive infected cases in China, on the 30 January 2020, the WHO declared the viral epidemic a public health emergency of international concern. SARS-CoV-2 is a an enveloped, single-stranded, positive-sense RNA virus belonging to the Betacoronavirus genus in the Coronaviridae family. This family of viruses was first identified in 1965 by Tyrell and Bynoe and isolated and cultivated from patients with common colds. Viral structural proteins such as the nucleocapsid protein (N), membrane glycoprotein (M), and spike glycoprotein (S) are the primary determinants of virulence and function. Largely like the previous zoonotic coronavirus outbreaks (SARS-CoV and MERS-CoV), the current SARS-CoV-2 virus causes lower respiratory tract infections and may lead to Acute Respiratory Distress Syndromes (ARDS).</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>3387</offset><text>The emergence of novel variants of the SARS-CoV-2 in the past couple of months highlights one of the primary challenges facing this pandemic. Accumulation of mutations arising out of subsequent viral replication is a natural phenomenon. The SARS-CoV-2 virus is known to evolve at a rate of approximately 1.1âÃâ10âââ3 substitutions per site per year. This figure corresponds to nearly one substitution every â¼11âdays. Although most mutations are found to have no perceivable impact, few mutations were found to give rise to novel high-risk variants of the SARS-CoV-2 virus (Figure 1). The nomenclature and classification of these increasing number of SARS-CoV-2 variants has been a challenge to the WHO. However during late 2020, the WHO prompted the classification of novel SARS- CoV-2 strains as Variants of Interest (VOIs) and Variants of Concern (VOCs). Specifically, VOIs include variants with mutations that result in changes to receptor binding, reduced efficacy of treatments, decreased neutralization by antibodies and a potential increase in disease severity and/or transmissibility. In addition, VOCs are defined as variants against which there may be strong evidence of an increase in transmissibility, greater disease severity, notable reduction in neutralization by antibodies generated and thus decreased response to treatments and vaccines. (Table 1)</text></passage><passage><infon key=\"file\">IANN_A_2031274_F0001_C.jpg</infon><infon key=\"id\">F0001</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>4768</offset><text>The figure explains about the reported amino acid mutations in RBD region of different SARS- CoV-2 strains.</text></passage><passage><infon key=\"file\">t0001.xml</infon><infon key=\"id\">t0001</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>4876</offset><text>SARS Cov-2 variants and its impact on transmissibility and treatments.</text></passage><passage><infon key=\"file\">t0001.xml</infon><infon key=\"id\">t0001</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;colgroup&gt;&lt;col width=&quot;80pt&quot;/&gt;&lt;col width=&quot;80pt&quot;/&gt;&lt;col width=&quot;80pt&quot;/&gt;&lt;col width=&quot;80pt&quot;/&gt;&lt;col width=&quot;80pt&quot;/&gt;&lt;col width=&quot;80pt&quot;/&gt;&lt;/colgroup&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align=&quot;left&quot;&gt;Variant name&lt;/th&gt;&lt;th align=&quot;center&quot;&gt;Variant classification&lt;/th&gt;&lt;th align=&quot;center&quot;&gt;WHO label&lt;/th&gt;&lt;th align=&quot;center&quot;&gt;Country of Origin /Detection date&lt;/th&gt;&lt;th align=&quot;center&quot;&gt;Spike protein substitutions&lt;/th&gt;&lt;th align=&quot;center&quot;&gt;Attributes&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody valign=&quot;top&quot;&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;B.1.1.7&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;VOC&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Alpha&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;United Kingdom/&lt;break/&gt;December 2020&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;69del&lt;break/&gt;70del&lt;break/&gt;144del&lt;break/&gt;E484K&lt;break/&gt;S494P&lt;break/&gt;N501Y&lt;break/&gt;A570D&lt;break/&gt;D614G&lt;break/&gt;P681H&lt;break/&gt;T716I&lt;break/&gt;S982A&lt;break/&gt;D1118H&lt;break/&gt;K1191N&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â Transmissibility (â¼50%)&lt;break/&gt;&lt;break/&gt;â Severity&lt;break/&gt;&lt;break/&gt;â Case fatality&lt;break/&gt;&lt;break/&gt;No impact on susceptibility to EUA monoclonal antibody treatments&lt;break/&gt;&lt;break/&gt;Minimal impact on neutralization by convalescent and post-vaccination sera&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;B.1.351&lt;break/&gt;B.1.351.2&lt;break/&gt;B.1.351.3&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;VOC&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Beta&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;South Africa/&lt;break/&gt;December 2020&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;D80A&lt;break/&gt;D215G&lt;break/&gt;241del&lt;break/&gt;242del&lt;break/&gt;243del&lt;break/&gt;K417N&lt;break/&gt;E484K&lt;break/&gt;N501Y&lt;break/&gt;D614G&lt;break/&gt;A701V&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â Transmissibility (â¼50%)&lt;break/&gt;&lt;break/&gt;â Susceptibility to EUA monoclonal antibody treatments&lt;break/&gt;&lt;break/&gt;â Neutralization to convalescent &amp;amp; post-vaccination sera&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;P.1&lt;break/&gt;P.1.1&lt;break/&gt;P.1.2&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;VOC&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Gamma&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Brazil/&lt;break/&gt;January 2021&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;L18F&lt;break/&gt;T20N&lt;break/&gt;P26S&lt;break/&gt;D138Y&lt;break/&gt;R190S&lt;break/&gt;K417T&lt;break/&gt;E484K&lt;break/&gt;N501Y&lt;break/&gt;D614G&lt;break/&gt;H655Y&lt;break/&gt;T1027I&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â Susceptibility to bamlanivimab/etesevimab monoclonal antibody treatments &lt;break/&gt;&lt;break/&gt;â Neutralization to convalescent &amp;amp; post-vaccination sera&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;B.1.617.2&lt;break/&gt;AY.1&lt;break/&gt;AY.2&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;VOI&lt;break/&gt;VOC&lt;break/&gt;VOC&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Delta&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;India/&lt;break/&gt;May 2021&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;T19R&lt;break/&gt;V70F&lt;break/&gt;T95I&lt;break/&gt;G142D&lt;break/&gt;E156-&lt;break/&gt;F157-&lt;break/&gt;R158G&lt;break/&gt;(A222V&lt;break/&gt;W258L&lt;break/&gt;K417N&lt;break/&gt; L452R&lt;break/&gt;T478K&lt;break/&gt;D614G&lt;break/&gt;P681R&lt;break/&gt;D950N&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â Transmissibility&lt;break/&gt;â¯&lt;break/&gt;â Susceptibility to EUA monoclonal antibody treatments&lt;break/&gt;&lt;break/&gt;â Neutralisation to post-vaccination sera&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;B.1.427&lt;break/&gt;B.1.429&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;VOC&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Epsilon&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;California/&lt;break/&gt;July 2020&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;I4205V&lt;break/&gt;D1183Y &lt;break/&gt;S13I&lt;break/&gt;W152C&lt;break/&gt;L452R&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â Transmissibility (â¼20%)&lt;break/&gt;&lt;break/&gt;â susceptibility to EUA monoclonal &lt;break/&gt; antibody treatments&lt;break/&gt;&lt;break/&gt;â neutralisation to convalescent &amp;amp;&lt;break/&gt; post-vaccination sera&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;B.1.1.529&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;VOC&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Omicron&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;South Africa\\&lt;break/&gt;November, 2021&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;A67V, del69-70, T95I, del142-144, Y145D, del211, L212I, ins214EPE&lt;break/&gt;T547K, &lt;break/&gt;D614G, &lt;break/&gt;H655Y, &lt;break/&gt;N679K, &lt;break/&gt;P681H, &lt;break/&gt;N764K, &lt;break/&gt;D796Y, &lt;break/&gt;N856K, &lt;break/&gt;Q954H, &lt;break/&gt;N969K, &lt;break/&gt;L981F&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â Transmissibility&lt;break/&gt;&lt;break/&gt;â Risk of re-infection&lt;break/&gt;&lt;break/&gt;Deletion in the S gene, leading to S gene target failure (SGTF) in some PCR assays. SGTF can be used as a proxy marker to screen for Omicron.&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;B.1.525&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;VOI&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Eta&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;United Kingdom/Nigeria December 2020&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;A67V&lt;break/&gt;69del&lt;break/&gt;70del&lt;break/&gt;144del&lt;break/&gt;E484K&lt;break/&gt;D614G&lt;break/&gt;Q677H&lt;break/&gt;F888L&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â Susceptibility to EUA monoclonal antibody treatments&lt;break/&gt;&lt;break/&gt;â Neutralization to convalescent &amp;amp;&lt;break/&gt; post-vaccination sera&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;B.1.526&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;VOI&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Iota&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;United States/&lt;break/&gt;November 2020&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;L5F&lt;break/&gt;D80G&lt;break/&gt;T95I&lt;break/&gt;Y144-&lt;break/&gt;F157S&lt;break/&gt;D253G&lt;break/&gt;L452R&lt;break/&gt;S477N&lt;break/&gt;E484K&lt;break/&gt;D614G&lt;break/&gt;A701V&lt;break/&gt;T859N&lt;break/&gt;D950H&lt;break/&gt;Q957R&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â Susceptibility to bamlanivimab/ etesevimab monoclonal antibody treatments&lt;break/&gt;&lt;break/&gt;â Neutralisation to convalescent &amp;amp; post-vaccination sera&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;B.1.617.1&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;VOI&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Kappa&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;India/&lt;break/&gt;December 2020&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;T95I&lt;break/&gt;G142D&lt;break/&gt;E154K&lt;break/&gt;L452R&lt;break/&gt;E484Q&lt;break/&gt;D614G&lt;break/&gt;P681R&lt;break/&gt;Q1071H&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â Susceptibility to EUA monoclonal antibody treatments&lt;break/&gt;&lt;break/&gt;â Neutralization to post-vaccination sera&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;C.37&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;VOI&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Lambda&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Peru/&lt;break/&gt;August 2020&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;G75V&lt;break/&gt;T76I&lt;break/&gt;Î246-252&lt;break/&gt;L452Q&lt;break/&gt;F490S&lt;break/&gt;D614G&lt;break/&gt;T859N&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Unclear data on transmissibility&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;B.1.621&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;VOI&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Mu&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Colombia/&lt;break/&gt;January 2021&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;R346K&lt;break/&gt;E484K&lt;break/&gt;N501Y&lt;break/&gt;D614G&lt;break/&gt;P681H&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â Transmissibility&lt;break/&gt;&lt;break/&gt;â Susceptibility to infection&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;P.3&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;VOI&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Theta&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Philippines/&lt;break/&gt;January 2021&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;E484K&lt;break/&gt;N501Y&lt;break/&gt;D614G&lt;break/&gt;P681H&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â Transmissibility&lt;break/&gt;&lt;break/&gt;â Susceptibility to infection&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>4947</offset><text>Variant name\tVariant classification\tWHO label\tCountry of Origin /Detection date\tSpike protein substitutions\tAttributes\t \tB.1.1.7\tVOC\tAlpha\tUnited Kingdom/December 2020\t69del70del144delE484KS494PN501YA570DD614GP681HT716IS982AD1118HK1191N\tâ Transmissibility (â¼50%)â Severityâ Case fatalityNo impact on susceptibility to EUA monoclonal antibody treatmentsMinimal impact on neutralization by convalescent and post-vaccination sera\t \tB.1.351B.1.351.2B.1.351.3\tVOC\tBeta\tSouth Africa/December 2020\tD80AD215G241del242del243delK417NE484KN501YD614GA701V\tâ Transmissibility (â¼50%)â Susceptibility to EUA monoclonal antibody treatmentsâ Neutralization to convalescent &amp; post-vaccination sera\t \tP.1P.1.1P.1.2\tVOC\tGamma\tBrazil/January 2021\tL18FT20NP26SD138YR190SK417TE484KN501YD614GH655YT1027I\tâ Susceptibility to bamlanivimab/etesevimab monoclonal antibody treatments â Neutralization to convalescent &amp; post-vaccination sera\t \tB.1.617.2AY.1AY.2\tVOIVOCVOC\tDelta\tIndia/May 2021\tT19RV70FT95IG142DE156-F157-R158G(A222VW258LK417N L452RT478KD614GP681RD950N\tâ Transmissibilityâ¯â Susceptibility to EUA monoclonal antibody treatmentsâ Neutralisation to post-vaccination sera\t \tB.1.427B.1.429\tVOC\tEpsilon\tCalifornia/July 2020\tI4205VD1183Y S13IW152CL452R\tâ Transmissibility (â¼20%)â susceptibility to EUA monoclonal  antibody treatmentsâ neutralisation to convalescent &amp; post-vaccination sera\t \tB.1.1.529\tVOC\tOmicron\tSouth Africa\\November, 2021\tA67V, del69-70, T95I, del142-144, Y145D, del211, L212I, ins214EPET547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F\tâ Transmissibilityâ Risk of re-infectionDeletion in the S gene, leading to S gene target failure (SGTF) in some PCR assays. SGTF can be used as a proxy marker to screen for Omicron.\t \tB.1.525\tVOI\tEta\tUnited Kingdom/Nigeria December 2020\tA67V69del70del144delE484KD614GQ677HF888L\tâ Susceptibility to EUA monoclonal antibody treatmentsâ Neutralization to convalescent &amp; post-vaccination sera\t \tB.1.526\tVOI\tIota\tUnited States/November 2020\tL5FD80GT95IY144-F157SD253GL452RS477NE484KD614GA701VT859ND950HQ957R\tâ Susceptibility to bamlanivimab/ etesevimab monoclonal antibody treatmentsâ Neutralisation to convalescent &amp; post-vaccination sera\t \tB.1.617.1\tVOI\tKappa\tIndia/December 2020\tT95IG142DE154KL452RE484QD614GP681RQ1071H\tâ Susceptibility to EUA monoclonal antibody treatmentsâ Neutralization to post-vaccination sera\t \tC.37\tVOI\tLambda\tPeru/August 2020\tG75VT76IÎ246-252L452QF490SD614GT859N\tUnclear data on transmissibility\t \tB.1.621\tVOI\tMu\tColombia/January 2021\tR346KE484KN501YD614GP681H\tâ Transmissibilityâ Susceptibility to infection\t \tP.3\tVOI\tTheta\tPhilippines/January 2021\tE484KN501YD614GP681H\tâ Transmissibilityâ Susceptibility to infection\t \t</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>7714</offset><text>Additionally, in order to synchronize a universal nomenclature that facilitate a streamlined tracking of each of the emerging SARS-CoV-2 variants, the WHO has recommended the use of the Greek Alphabet to uniquely identify each novel variant (Figure 1).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_1</infon><offset>7967</offset><text>Advancements in COVID-19 detection &amp; diagnosis</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>8014</offset><text>The emergence of novel and evolving variants of SARS-CoV-2 has indeed fostered the need for change in the form of newer and more adaptive diagnostic methods for the detection of SARS-CoV-2 infections. On the other hand, developing rapid and sensitive diagnostic technologies is now more challenging due to emerging variants and varying symptoms exhibited in infected individuals.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>8394</offset><text>SARS-CoV-2 detection technologies mainly target either specific viral nucleic acids (molecular testing), proteins (antigen testing), or anti-SARS-CoV-2 antibodies (serological testing). The choice between each of these tests depends on the selection of right test, right sample and right time as the viral nucleic acid/antigen/antibodies detection varies at different time points during the infection.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>8796</offset><text>Nucleic acid-based detection of SARS-CoV-2 infection</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>8849</offset><text>Nucleic acid-based detection is now widely used for clinical identification of SARS-CoV-2 infection. Nasopharyngeal swab samples are considered to be the most reliable source for these assays, offering highest sensitivity (97%) as compared to samples obtained from other sources like saliva (85%), nasal swabs (86%) and throat swabs (68%). Further, the viral RNA load is usually highest between 0 and day 4 of post-symptom infection (89%) and drops to nearly 54% at day 10 to 14. Real-time PCR technology is based on detecting the presence of specific viral RNA belonging to the viral Envelope, Nucleocapsid, Spike and ORF1ab regions. Therefore, viral mutations can potentially alter the accuracy of this method, leading to unpredictable test performances and false-negatives. However, such challenges could be overcome through the use of multi-target assays. In addition, studies are now also developing specific primers to enable the rapid detection of VOCs through real-time PCR; For example, a particular group reported the development of PCR primers for the rapid detection of the key mutations in the spike protein of the most recent omicron variant, thus enabling it to be distinguished from other SARS-CoV-2 variants. Another study also described the development of two new PCR- based tests to identify and differentiate the VOCs from regular strains of SARS-CoV-2. These tests are claimed to be comparatively simpler and more rapid than the gold standard methods of genome sequencing. The group also claims that these tests show a strong and reliable correlation to the results obtained through genome sequencing. Apart from these, other groups have also reported the development and use of similar PCR-based tests for detection of novel VOCs.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>10602</offset><text>In addition, loop-mediated isothermal amplification (LAMP) has also been developed as a rapid, robust and cheap technique that is now considered as a reliable alternative to traditional RT-PCR-based diagnosis. Interestingly, using LAMP, expensive equipment like thermocyclers may be eliminated thereby highlighting the portability of such rapid tests. Moreover, this technique is also highly specific as it uses about 6â8 specific primer sequences to identify eight different regions of the target. Further, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is another novel technology that follows the principle of lateral flow assays. This assay is known to target the E and N genes of SARS-CoV-2. The CRISPRâCas13 assays are known to have a sensitivity of greater than 95% and specificity of nearly 99% </text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>11430</offset><text>In addition, microarray-based technology is also currently being used to detect viral RNA. Here, labelled cDNA molecules synthesized from viral RNA hybridized with solid-phase oligonucleotides on the surface of an array plate are quantified with the help of a microarray plate reader.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>11715</offset><text>Next-generation gene sequencing (NGS) methods are also common for the detection of viral presence and helps in understanding the epidemiology of SARS-CoV-2 virus. However, although NGS platforms are accurate and reliable, their practical application is often limited due the involvement of higher costs and expertise. However, whole-genome sequence remains to be the gold standard for the detection of emerging VOCs across the globe. Apparently, since this method is more prolonged and laborious, many studies have come up with faster and similarly robust PCR melting temperature assays that are largely comparable to genome sequencing. Interestingly, another group has also reported the development of alternate sequencing platforms based on Sangers sequencing of a single PCR fragment that is capable of identifying and distinguishing all SARS-CoV-2 VOCs that have been identified so far.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>12606</offset><text>SARS-CoV-2 antigen and immuno-assay-based detection of SARS-CoV-2 infection</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>12682</offset><text>Antigen-based immuno-assays such as immunofluorescent assays, immunochromatographic assays, chemiluminescent immunoassays, and Enzyme Linked Immunosorbent Assays (ELISA) are also reliable methods for the detection of SARS-CoV-2 infections. These commercially available kits are usually compatible with a variety of clinical specimens like nasopharyngeal swabs, nasal swabs, and saliva and mainly detect the presence of two main SARS-CoV-2 antigens (S and N proteins). However, the success rate of these assays is largely dependent on factors such as disease stage and viral load (1â3âdays before to 5â7âdays after the onset of symptoms). To address these issues, research on incorporating novel sensor and biosensor technologies, to enhance the sensitivity of these antigen-based immuno- assays is currently ongoing..</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>13508</offset><text>Anti-SARS-CoV-2 antibody-based detection of SARS-CoV-2 infection</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>13573</offset><text>In contrast with nucleic acids and antigen-based detection techniques, antibody-based techniques are not considered suitable for the early detection of SARS-CoV-2 Infection. This is due to the fact that antibody responses are often generated nearly two weeks post-infection; a time-point at which viral nucleic acid and antigen levels begin to decline. Various binding assays like immunofluorescence, immunochromatographic, chemiluminescence assays and ELISA are used for the detection of antibodies generated specific to the SARS-CoV-2 viral antigen. Most of these kits target the antibodies generated against the viral S and N proteins. Various easy-to-use kits are now available that are based on measuring the ratio between the immunoglobulin M (IgM) and immunoglobulin G (IgG) in the blood.. In addition, humoral immune responses to SARS-CoV-2 can also be detected using simple blotting systems. These are often automated rapid capillary-based platforms through which the reactivity of human IgGs (in serum or plasma samples) against five key SARS-CoV-2 viral antigens.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>14648</offset><text>Evidently, the constant development of newer and improved methods for the detection of novel VOCs is of primary importance to keep pace with their rapid emergence. This will also play a key role in monitoring and curbing the spread of the new variants.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_1</infon><offset>14901</offset><text>Advancements in COVID-19 preventive &amp; therapeutic strategies</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>14962</offset><text>Antiviral and immunomodulatory drugs</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>14999</offset><text>Current treatment options for COVID-19 are apparently stratified into two categories; being either antivirals or immune modifiers. In the case of antiviral drugs, Remdesivir has gained sufficient recognition for its ability to contain and manage the viral load and was approved by FDA for the treatment of COVID-19 patients with pneumonia concurrent with the shortage of oxygen supply. It is a broad-spectrum adenosine nucleotide analogue and phosphoramidate prodrug that can target a wide range of viruses includes coronaviruses. The drug mainly functions through the inhibition of replication in the respiratory-associated epithelial cells. According to a recent report, remdesivir triphosphate, being the active form of Remdesivir, resembles the RNA of the coronavirus. Therefore, it is easily integrated into nascent viral RNA strands resulting in halting of viral genome replication. In addition, another study showed that a combination of remdesivir with baricitinib worked better in reducing recovery time of hospitalized patients with COVID-19 pneumonia. Baricitinib is a Janus kinaseâSTAT signalling inhibitor (JAK-STAT) that possesses antiviral and anti-inflammatory action through the inhibition of clathrin-mediated endocytosis and controls the elevation of cytokine levels..</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>16289</offset><text>Moreover, certain anti-HIV drugs like lopinavir and ritonavir that target RNA viruses (retroviruses) were reported to improve the symptoms of patients with SARS. Therefore, they were evaluated for their potential use as a therapeutic agent against COVID-19. However, according to a certain report, no benefit was observed with lopinavirâritonavir treatment beyond standard care in adult patients hospitalized with severe COVID-19. Similarly, chloroquine, a drug whose sulphate and phosphate salts have been commercialized as anti-malarial drugs was also shown to be effective against SARS-CoV-2 infections according to a few studies. However, a recent trial proved that post-exposure hydroxychloroquine therapy did not prevent SARS-CoV-2 infection in healthy individuals exposed to an infected patient. In addition, other studies have also discredited protease inhibitors like lopinavir and ritonavir and chloroquine to model potent anti-SARS-CoV-2 therapy.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>17249</offset><text>Recently, two monoclonal antibodies, Tocilizumab and Sarilumab used as anti-inflammatory drugs for rheumatoid arthritis have been repurposed for their use against SARS-CoV-2 Tocilizumab was approved as an immunotherapy drug by FDA for the treatment against the cytokine storm release that is a hallmark of particularly critical COVID-19 infections. These monoclonal antibodies function by antagonizing both membrane-bound and soluble interleukin-6 receptors, thereby resulting in the blocking of the downstream signal transduction that induces the cytokine release syndrome. Moreover, the clinical trials of the Randomized, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired pneumonia (REMAP-CAP) showed that Tocilizumab and Sarilumab improved survival rate and reduced mortality in hospitalized Covid-19 patients by 28 and 22.2% respectively, when administrated within 24âh of entering intensive care units (ICUs). According to the NHS guidance, both drugs are advocated for the treatment of hospitalized Covid-19 patients in ICUs.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>18307</offset><text>Further, Casirivimab with Imdevimab forms a unique monoclonal antibody cocktail named REGEN- COVTM. These antibodies bind non-competitively to the SARS-CoV-2 spike protein, thus being beneficial in targeting the novel mutant SARS-CoV-2 variants and lowering chances of their immune escape. Results of the phase 3 trial showed that REGEN-COVTM decreased hospitalization or death by 70% in non-hospitalized Covid-19 patients. In addition, it has also been approved by the FDA for the treatment of mild to moderate cases in adults and paediatric Covid-19 patients and in patients at high risk of disease severity.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_3</infon><offset>18918</offset><text>Efficacy of SARS-CoV-2 antiviral drugs on the emerging VOCs</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>18978</offset><text>In the wake of the recent emergences of new SARS-CoV-2 variants, it has become increasingly important to evaluate whether the current therapeutics still maintain efficacy against the novel variants. In fact, several in-vitro studies were conducted to assess the efficacy of remdesivir against new COVID- 19 variants and more importantly to determine whether these VOCs expressed mutations in the RNA- Dependent RNA Polymerase (RdRP) protein sequence, which is the main target of remdesivir. A recent study conducted on the B.1.1.7 and B.1.351 variants proved that both variants presented a low genetic variation in the RNA replication complex and the most frequent observed substitution was Nsp12 P323L. However, this substitution was not located near the polymerase active site, thus did not affect the inhibition function of remdesivir. In addition, according to Lee etÂ al. the amino acid sequences of the B.1.1.7 and B.1.351 VOCs were found to possess numerous mutations in the spike protein, when compared to the early SARS-CoV-2 strains. However, the amino acid sequence of NSP12, (which possesses RdRp activity), remained to be highly conserved among both the early and novel variants. Moreover, Showers etÂ al. also reported no difference in the antiviral efficacy of remdesivir between early SARS-CoV-2 and these new variants. Furthermore, another study that analyzed the protein sequence of RdRp among SARS-CoV-2 emergent variants show a high conservation in remdesivir- binding residues. Therefore, these reports indicate towards the lack of evidence stating the resistance to remdesivir induced by the VOCs.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>20598</offset><text>Similarly, molnupiravir, a recently FDA approved antiviral drug against SARS-CoV-2 infection is also known to function through targeting the viral polymerase and misdirecting it to incorporate adenosine or guanosine during viral replication, thereby leading to an accumulation of deleterious errors eventually rendering the virus non-infectious. Therefore, since reports have proved that the sequences responsible for viral RdRp activity remains to be conserved in early and novel SARS-CoV-2 variants, it is unlikely that the novel VOCs could interfere in the activity of such antiviral drugs. Moreover, other reports also advocate the unrestricted use of the recent FDA approved Paxlovid antiviral drug against the existing VOCs and especially the most recent omicron variant. Therefore, in the light of the above knowledge it may be safe to state that the activity of such antivirals may remain unhindered against the emerging VOCs.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>21533</offset><text>Covid-19 vaccines</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>21551</offset><text>In addition to the above elucidated drugs vaccines remain the cornerstone of prevention and protection against infection. Below we discuss the development, formulation, working mechanisms, advantages, and challenges of some of the most used vaccines worldwide (Figure 2). In addition, we also provide an overview of the ongoing trials and cutting-edge research focussed on vaccine efficacy and safety.</text></passage><passage><infon key=\"file\">IANN_A_2031274_F0002_C.jpg</infon><infon key=\"id\">F0002</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>21953</offset><text>The figure explains about the different COVID-19 vaccine platforms, the immune response to the vaccine and the protective immune response during the post-vaccination infection. (A) Different COVID-19 vaccine platforms. a. DNA vaccine in which SARS-CoV-2 spike open reading frame (ORF) is cloned into a plasmid DNA which will be injected intramuscularly; b. Viral vector platforms in which, the spike protein ORF is cloned into adenovirus genome to form an infectious recombinant virus which will be injected intramuscularly; c. mRNA vaccine, in which SARS-CoV-2 spike mRNA is chemically synthesized and enclosed with lipid nanoparticles then it is injected into human body; d. Protein vaccine in which total or subunit part of spike protein is mixed with specific adjuvant before being injected into human system; e. Inactivated virus vaccine whereby SARS-CoV-2 virus is chemically inactivated, mixed with specific adjuvant then injected intramuscularly. (B) Immune response to the SARS-CoV-2 vaccine: Once in the human body, the different vaccine platforms will synthesize or deliver SARS-CoV-2 total or subunit spike protein which will induce specific memory immune response against SARS-CoV-2 virus. (C) SARS-CoV-2 virus neutralization during post-vaccination infection. 1. If an infection occurs after vaccination, anti-SARS-COV-2 antibodies bind to the SARS-CoV-2 virus and inhibit its attachment to the host cell. 2. Antibody Dependent Cellular Cytotoxicity: The anti-spike antibodies recognize the spike antigen on the infected cells. Four major immune effector cells (neutrophils, eosinophils, macrophages, and NK cells) will recognize the cell bounded antibodies and infected cells and the killing is achieved by cytolytic processes. 3. The memory T cells are quickly converted into cytotoxic T cells and eliminate the infected cells.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_3</infon><offset>23797</offset><text>Protein subunit vaccines NVX-CoV2373</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>23834</offset><text>NVX-CoV2373 (Novavax) is a SARS-COV-2 subunit vaccine constructed from the full-length SARS- COV-2 spike glycoprotein and is produced in the established baculovirus-Spodoptera frugiperda (Sf9) insect cell expression system. This vaccine is formulated through the use of nanoparticles containing trimeric full-length SARS-CoV-2âS glycoprotein adjuvant with saponin based Matrix-M. Studies have shown that this Matrix-M can enhance immune responses by promoting the recruitment, activation, and maturation of central immune cells via enhanced antigen presentation and uptake by the antigen presenting cells.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>24442</offset><text>The safety and immunogenicity of NVX-CoV2373 was initially tested in a nonhuman primate (baboons and cynomolgus macaque) and mice models. Preliminary results showed that the vaccine elicits a T cell and B cell response, induces a high titre of anti-S IgG and SARS-COV-2 neutralizing antibodies and protects the upper and lower respiratory track from virus infection and pulmonary disease. Subsequently, Phase 1-2 clinical trial were conducted to evaluate the safety and immunogenicity of SARS-CoV-2 recombinant S nanoparticle vaccine on humans with or without Matrix-M adjuvant. The outcomes of these trials indicated that the vaccine has a reassuring safety profile and is capable of inducing a robust humoral and T cell immune response. Moreover, the levels of neutralizing antibodies and anti-S IgG detected in vaccinated participants was indeed found to be 4 times higher than those observed in symptomatic COVID-19 outpatient sera. In addition, this vaccine also induces a predominant CD4+ T cell response characterized by high production of IFN-Î³, IL-2, and TNF-Î±. Currently, phase 3 trials are ongoing in 5 different countries (United Kingdom (UK), Northern Ireland, Mexico, Puerto Rico and United States of America). However, preliminary data from the UK indicates that the efficacy of NVX-CoV2373 is estimated at 89.7% among different subgroups including participants with comorbidities, with no hospitalization or deaths reported in vaccinated individuals. Interestingly, the same study indicates that NVX-CoV2373 has a strong efficacy (86.3%) against the UK variant (B.1.1.7).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_3</infon><offset>26038</offset><text>Adenovirus vector-based vaccines</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_4</infon><offset>26071</offset><text>ZD1222</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>26078</offset><text>The AZD1222 (Oxford-AstraZeneca) is a recombinant adenovirus-based SARS-CoV-2 vaccine constructed from the replication-deficient simian chimpanzee adenovirus vector (ChAdOx2) expressing the full- length SARS-COV-2 spike glycoprotein. Chimpanzee vectors are highly suitable for the development of human vaccines due to their high immunogenicity and genome stability that prevents the deletion or mutation of foreign genes. These vectors have been tested in clinical trials of 5000 vaccines (including vaccines for Ebola, malaria, HIV and Crohn disease in which their efficacy to induce a potent CD8+ T cell and antibody responses even with a single dose of the vaccine was reported.. In particular, the chimpanzee adenovirus vectors are safe as they avoid issues with pre-existing immunity to human adenoviruses.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>26890</offset><text>The AZD1222 vaccine has been approved by the WHO and is used now in 102 countries. Clinical trials tested on over 60,000 adult participants (aged 18â55âyears) in UK, Brazil, South Africa, Kenya, the USA, India and Japan show that the vaccine has a well-tolerated safety profile with no serious adverse events related to the vaccine. After the second dose, most participants were shown to elicit neutralizing antibody responses correlating strongly with anti-spike IgG antibody levels. However, the Phase 3 clinical trial interim results from the USA showed that the efficacy of the vaccine could vary according to the immunization regimes (1 or 2 doses) and the length of the interval between the doses (12 or 6âweeks). Such findings support the recent decision in the UK to prioritize use of a 12- week interval between doses.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>27724</offset><text>Recently, several European countries suspended the use of the AZD1222 vaccine due to reports linking it to episodes of thrombocytopenia, bleeding, and arterial and venous thromboses occurring within days to weeks after vaccination. According to the European Medicines Agency (EMA), the number of thromboembolic events in vaccinated people is no higher than the numbers seen among the general population. However, rates for venous thromboembolism events observed 28âdays after vaccination in Denmark were higher than the expected incidence rates among the general population (50 versus 30). Altogether, the safety, immunogenicity, and efficacy outcomes of the AZD1222 vaccine are reassuring but these side effects need to be investigated through a large-scale study in different populations to further understand its utility.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_4</infon><offset>28551</offset><text>Gam-COVID-Vac</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>28565</offset><text>Gam-COVID-Vac (Sputnik V) is a heterologous adenoviral vector based vaccine against SARS-CoV-2 constructed from two vector components, recombinant adenovirus type 26 (rAd26) and recombinant adenovirus type 5 (rAd5) carrying both the SARS-CoV-2 full-length glycoprotein S gene (rAd26-S and rAd5-S). Recombinant adenoviruses have been widely used for vaccine development such as hepatitis B, Ebola virus, RSV, HIV and Zika vaccines with an excellent safety profile confirmed in many clinical studies. Moreover, recombinant adenovirus vectors elicit robust long-lasting immune response without the need of adjuvant after one or two doses of vaccine. The use of 2 different viral vectors will help to overcome any prior anti-adenovirus immunity in the body that may destroy the vector of the second dose.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>29366</offset><text>Phase 1/2 clinical trials were conducted to assess safety and immunogenicity of two formulations (frozen and lyophilized) of this vaccine on 76 healthy adult volunteers aged between 18 and 60âyears. In Phase 1, participants received a single intramuscular dose of rAd26-S or rAd5-S on day 0. However, in phase 2, which began no earlier than 5âdays after the phase 1 vaccination, participants were administrated a single intramuscular dose of rAD26-S on day 0 followed by another dose of rAD5-S on day 21. Preliminary data from the phase 1 trials show that no severe adverse reactions were detected in participants after vaccination. Also, the frozen formulation was found to be induce a higher IgG titre (14.703 versus 11.143) and neutralizing antibodies (49.25 versus 45.95) while eliciting higher CD4 (2.5 versus 1.3) and CD8 (1.3 versus 1.1) T cell proliferation rates as compared to the lyophilized formulation indicating the frozen formulation to be more effective than the lyophilized one.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>30366</offset><text>Phase 3 clinical trials were performed on a larger scale (nearly 22,000 adults aged at least 18âyears). Participants received 2 doses of the vaccine (dose 1 rAD26-S and dose 2 rAD5-S) or a placebo, 21âdays apart. Results of this phase showed that the vaccine efficacy was estimated at 91.6%. In addition, 94% of the participants presented mild adverse reactions, while a minority (less than 0.5%) exhibited severe adverse events. Though four deaths were reported among participants, the cause of death was linked to the vaccine but rather to severe comorbidities. Interestingly, a recent study showed that sera from a donor vaccinated with Gam-COVID-Vac efficiently neutralized the spike protein from B.1.1.7 and B.1.351 strains. This data suggest that this vaccine may offer protection against different SARS-CoV-2 variants.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_3</infon><offset>31196</offset><text>mRNA vaccines</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>31210</offset><text>Since more than a decade, mRNA based therapeutics have raised major interest in cancer and infectious diseases likewise. Particularly, immunization through mRNA vaccines was found to be effective against several viral infections. It has been reported that mRNA vaccines are able to induce potent innate and adaptive immune reactions against Rabies, Zika and Influenza A infections in animal models and in humans. Therefore, it is not surprising that mRNA vaccines have now emerged as an effective preventive strategy against SARS-CoV-2 infections. This technology is based on the principle that mRNA is an intermediate messenger that can be easily delivered into host cells and translated into antigen of interest that will trigger a protective antigen-specific immune response in the human body. Within a year from the onset of the COVID-19 pandemic, two mRNA vaccines, namely, BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna biotechnologies Inc.) were approved by the FDA for emergency use as a prevention against SARS-CoV-2 infection.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>32250</offset><text>Both vaccines, BNT162b2 and mRNA-1273, carry a nucleoside-modified messenger RNA encoding the full-length SARS-CoV-2 spike protein (S) stabilized in the pre-fusion conformation and formulated in lipid nanoparticles (LNPs). These LNPs form a solid lipid complex that encapsulate and stabilize the mRNA and promotes its intracellular uptake. While both vaccines are administered intramuscularly in two shots, the second dose is administered after 21âdays for BNT162b2 and 28âdays for mRNA-1273.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>32747</offset><text>Phase III clinical trials have demonstrated that BNT162b2 and mRNA-1273 vaccines have exhibited more than 90% protection efficacy in people with no prior known infection. In fact, Polack etÂ al. demonstrated that the BNT162b2 vaccine conferred 95% protection against COVID-19 in persons 16âyears of age and older, with only mild adverse effects that were similar to those observed with other known viral vaccines (short-term fatigue, headache, mild-to-moderate pain at the injection site). Moreover, the COVE study group in the USA has reported that the mRNA-1273 vaccine has presented 94.1% efficacy in preventing COVID-19 illness with no patterns of safety concerns. In another recent study, Thompson etÂ al. have shown that, for both mRNA vaccines, full immunization with 2 doses of vaccine provides 90% effectiveness against COVID-19 at â¥14âdays following the second dose. However, while the mRNA-1273 vaccine is only approved for use in people aged 18âyears and older, the BNT162b2 vaccine has been recently granted authorization by the FDA to be used in adolescents aged 12 to 15âyears old. Moreover, recent studies have reported that the BNT162b2 vaccine provides strong protection (â¥95%) against the COVID-19 variants detected in the United Kingdom (B.1.1.7) and South Africa (B.1.351). Interestingly, a pre-print report has revealed that the effectiveness of BNT162b2 was reduced to 87.9% with the B.1.617.2 COVID-19 variant that has lately emerged in India. As for the mRNA-1273 vaccine, further studies are needed to confirm its effectiveness against the emerging COVID-19 variants.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>34353</offset><text>Evidently, the immunogenic potential of COVID-19 mRNA vaccines have already been documented through various preclinical and clinical trials. Interestingly, a phase I clinical trial on 47 participants demonstrated that the mRNA-1273 induces a robust immune response which was time and dose-dependent. Additionally, while CD4 T cells expression was upregulated in response to the vaccination, only low level of CD8 T cells were detected at the highest tested concentration and after the second vaccination dose. Moreover, another study showed that BNT162b2 induces a broad immune response with SARS-CoV-2 spike-specific neutralizing antibodies and poly-specific CD4+ and CD8+ T cells. Interestingly, the same study has reported a strong memory T cell response up to nine weeks after the booster dose.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>35152</offset><text>Apparently, in comparison to other approved vaccines platforms, mRNA-based vaccines have several advantages. For example, in the situation of a widespread global pandemic such as COVID-19, mRNA vaccine production is rapid and can be manufactured on larger scales at relatively lower costs. Moreover, mRNA vaccines are considered safe since they do not contain the full pathogen (unlike vaccines integrating live-vectors or inactivated viruses), and do not carry the viral DNA material that might be associated to genotoxic concerns (like DNA-based vaccines).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>35711</offset><text>However, the major problem with mRNA vaccines is the stability of the formulation since they require a strict temperature control for shipment and storage to avoid the degradation of the mRNA. Moreover, the induced activation of the immune system would potentially lead to side effects associated with enhanced inflammatory processes. Therefore, although mRNA vaccines project a powerful strategy to contain the COVID-19 outbreak, more studies are needed to confirm the long-term effectiveness and safety of these vaccines.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_3</infon><offset>36235</offset><text>Whole virus vaccines</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>36256</offset><text>Historically, whole viral inactivation is one of the oldest strategies that have been successfully used to produce vaccines to prevent/treat a variety of viral diseases including influenza, poliomyelitis and human papillomavirus infections. In comparison to other whole pathogen-containing vaccines, such as live attenuated virus vaccines, the use of inactivated virus vaccines pose fewer safety concerns, since the pathogen cannot revert to its original state and cause diseases in immunocompromised individuals. Moreover, since they contain the killed pathogen, they can be easily stored and shipped.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>36859</offset><text>According to WHOâs draft landscape of SARS-CoV-2 candidate vaccines, 12 inactivated virus vaccines (14%) are currently in the clinical phase testing. For instance, pharmaceutical companies like Sinovac and Sinopharm, both arising from China have produced inactivated viral vaccines that are currently in phase 3 and 4 of clinical trials respectively.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_4</infon><offset>37212</offset><text>COVID-19 vaccine (Vero cell) inactivated</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>37253</offset><text>COVID-19 Vaccine (Vero Cell) Inactivated (CoronaVac (formerly PiCoVacc)) developed by Sinovac Biotech Ltd, is an inactivated SARS-CoV-2 (CN2 strain) vaccine adjuvant containing aluminium hydroxide (Al (OH)3) and is administrated through a two-dose regimen (3âÂµg at day 0 and 28). The virus was extracted from the bronchoalveolar lavage fluid (BALF) of 11 infected patients, cultured in a large- scale Vero cells factories, inactivated with Î²-propiolactone for 24âh, purified with Ion-Exchange Chromatography (IEC) and Size exclusion Chromatography (SEC) methods and finally adsorbed onto an aluminium hydroxide adjuvant. The vaccineâs safety evaluation has been performed in rhesus macaques (Macaca mulatta) monkeys that are known to mimic COVID-19-like symptoms after SARS- CoV-2 infection. Preclinical results using two doses (3âÂµg and 6âÂµg) with two immunization schedules (at days 0 and 14 or days 0 and 28) indicated extensive evidences for safety and efficacy, with a complete protection against COVID-19 infection.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>38290</offset><text>In April 2020, the COVID-19 Vaccine (Vero Cell) Inactivated vaccine entered its phase I clinical trial with 144 healthy participants aged between 18 and 59âyears old. In most subjects, antibody seroconversion was slightly higher than 75%. These results have been improved to more than 95% in 600 participants enrolled in phase 2 clinical trials, with no significant side effects reported . Similar results have been reported in healthy participants older than 60âyears old. These results supported the extension of the study to phase III clinical trial using a two-dose regimen (3âÂµg at day 0 and 28). The clinical trials have been launched in seven countries including Brazil, Indonesia, Turkey, China,</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>39001</offset><text>Philippines, Hong Kong, and Chile. Furthermore, two randomized double-blinded placebo control studies have been performed in Brazil and Turkey to determine the efficacy of the vaccine. These trials demonstrated that the COVID-19 Vaccine (Vero Cell) Inactivated efficacy rate for COVID-19 prevention was up to 53% in Brazil and 83% in Turkey. In addition, these studies also report that vaccination with COVID-19 Vaccine (Vero Cell) Inactivated induces a humoral response 28âdays post-vaccination i.e. 97% neutralizing antibodies against SARS-COV-2 and 99% against RBD-IgG. Although only a small number of studies have been published for the COVID-19 Vaccine (Vero Cell) Inactivated vaccine, very few cases of hypersensitivity, including severe allergic reactions (0.009%) have been reported.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_4</infon><offset>39795</offset><text>Covilo; BIBP-CorV</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>39813</offset><text>Covilo; BIBP-CorV (Sinopharm BIBP COVID-19 vaccine) is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Few studies have investigated the immunogenicity and efficacy of BBIBP-CorV. The first study on BBIBP-CorV has showed that the vaccine induces high levels of neutralizing antibodies in six mammalian species including mice, rats, guinea pigs, rabbits, and non- human primates (cynomolgus monkeys and rhesus macaques). Interestingly, this study reported that two doses of immunization of BBIBP-CorV at 2âmg/dose, is able to provide high protection against SARS- CoV-2 without detectable antibody dependent enhancement of infection. In addition, all macaques in the low and high dose groups did not show a detectable viral load in any lung lobe at 7âdays after inoculation of BBIBP-CorV. Also in comparison to the AZD1222 vaccine, both vaccines were found to confer effective protection by preventing the development of viral interstitial pneumonia in all vaccinated macaques.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>40817</offset><text>Phase I (192 adults) and phase II (448 adults) clinical trials for the BBIBP-CorV vaccine, have shown that the vaccine is safe and well tolerated at all tested doses. Antibodies were elicited against SARS-</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>41023</offset><text>CoV-2 in all vaccine recipients at 42âdays after the second dose. These trials included individuals older than 60 that showed significantly high neutralizing antibody titres. Moreover, a particular report also stated that the vaccine had a low rate of adverse reactions and showed high immunogenicity. Yet, however, long-term assessment of safety and efficacy would require phase III trials. The first peer- reviewed data obtained in United Arab Emirates (UAE) and Bahrain showed that BBIBP-CorV is 78.1% effective against symptomatic cases and 100% effective against severe cases. In addition, UAE previously announced interim results showing that the vaccine provided 86% efficacy. Additionally, Sinopharm has started a phase III trial in several countries in Africa, Asia and Europe. Reports from a randomized, double blind, placebo parallel-controlled phase III clinical trial in Argentina showed that the vaccine portrayed a lower effectiveness (79%) as compared to other approved COVID-19 mRNA vaccines. However, this vaccine has an advantage storage and shipment protocols at regular refrigeration temperatures.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_3</infon><offset>42144</offset><text>Efficacy of COVID-19 vaccines on the emerging VOCs</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>42195</offset><text>Given the alarming frequency of the emergence of SARS-CoV-2 variants, the efficacy of the existing vaccines remains in question. In the light of this, it may be encouraging to state that in addition to the general public, even patients with co-morbidities like cancer and other immuno-compromised individuals like solid organ transplant recipients (SOTRs) have also shown the development of neutralizing antibodies upon vaccination with most conventional vaccines, as discussed in the following reports. According to certain studies, SOTRs may be more commonly associated with breakthrough disease despite being fully vaccinated as compared to the general population. Other studies have also reported that most SORTs often develop weak antibody responses against SARS-CoV-2 m-RNA vaccines. However, according to another subsequent study even such vulnerable populations are reported to show an increase in neutralizing antibodies against novel VOCs after the third dose of a</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>43170</offset><text>SARS-CoV-2 vaccine. In addition, the CAPTURE study also reported the presence of neutralizing antibodies against the novel COVID-19 VOCs in patients with both solid and hematological cancers, upon immunization with the BNT162b2 or AZD1222 vaccine.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>43418</offset><text>Although these studies report that the vaccination-dependent stimulation of an immune response against the novel VOCs in such vulnerable populations is much lowered as compared to normal healthy individuals; yet these results are indeed promising and prove the potency of the currently available vaccines to combat the existing and emerging VOCs.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>43765</offset><text>In addition, the utilization of computational approaches to predict the impact of the VOCs on the vaccines has also proven useful. For example, certain computational approaches like epitope prediction that enables the identification of structural vaccinology targets may also help in modelling the effects of the mutations in the spike proteins observed in the emerging VOCs. Moreover, another study has also provided a reliable model for epitope loss in VOCs and their predicted escape from vaccine- induced SARS-CoV-2 antibodies. Such computational approaches prove to be highly useful in foreseeing the impact of the emerging VOCs on the efficacy of COVID-19 vaccines.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_1</infon><offset>44437</offset><text>Challenges</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>44448</offset><text>Since the SARS-CoV-2 is a novel virus, its invasive properties have not yet been well studied or understood. However, some studies have highlighted a new potential threat in the form of identifying the possible neuro-invasive properties of the novel virus. For example, although the SARSâCoV and SARS-CoV-2 are both known to enter and infect host cells through ACE2 expressed in the lung cells; according to some studies, ACE2 is not the only receptor that makes host cells susceptible to viral infection. For example, human endothelial and intestinal cells that express ACE2 failed to be infected by SARS-CoV inÂ vivo On the other hand, cells with comparatively undetectable levels of ACE2 (like hepatocytes) were found to be infected by SARS-CoV. Likewise, SARSâCoV and MERSâCoV are known to enter the central nervous system where the ACE2 and DDP430 receptors are very low. Similarly, studies on patients have shown the presence of SARSâCoV particles in the brain of infected individuals thus supporting the neuro-invasive potential of this virus. Since SARS-CoV and the SARS-CoV-2 are like each other, it is possible that the latter may also possess such a neuro-invasive potential. Furthermore, in the case of COVID-19, the latency period may be sufficient for SARS-CoV-2 to invade the CNS and destroy the medullary neurons. In support of this theory, some studies have reported that a few of the COVID-19 patients did have mild neurologic symptoms like headaches and nausea, while another recent study reported that an estimated 88% of severe COVID-19 cases displayed neurologic manifestations such as acute cerebrovascular disease and impaired consciousness.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>46122</offset><text>The rapidly mutating virus has also emerged as a matter of great concern. There is sufficient evidence to state that the SARS-CoV-2 virus is capable of rapidly evolving to invade human immune responses as well as gaining the ability to adapt to other hosts in the near future. Therefore, close monitoring of the novel coronavirus is essential to keep the pandemic in check.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>46496</offset><text>Finally, the greatest challenge of the current COVID-19 pandemic is the transmission of the virus to healthcare workers. Studies report that although stringent isolation and quarantine measures are ensured at medical facilities, yet human-to-human transmission of the SARS-CoV-2 is highly common. According to recent reports, nearly 41% of the patients were found to be infected in hospital settings, out of which 29% were medical staff. Such transmission in healthcare settings poses a very serious threat and requires rigorous monitoring.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">title_1</infon><offset>47037</offset><text>Conclusion</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>47048</offset><text>The outbreak of the COVID-19 pandemic has unquestionably raised a major public health emergency all over the world. The threatening concern is attributed to the transmissibility of the virus and its capacity to rapidly evolve and mutate leading to the emergence of new uncommon strains.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>47335</offset><text>The leap in advancement of better diagnosis, targeted vaccines and therapeutic remedies is sound evidence that scientific understanding, research, and technology is evolving at the pace of the pandemic. Evidently, continued, and consistent research is required to improve our knowledge of key aspects of the viral pathogenesis that can lead to enhanced preventive and therapeutic strategies.</text></passage><passage><infon key=\"section_type\">AUTH_CONT</infon><infon key=\"type\">title_1</infon><offset>47727</offset><text>Author contributions</text></passage><passage><infon key=\"section_type\">AUTH_CONT</infon><infon key=\"type\">paragraph</infon><offset>47748</offset><text>QF, MM, SM, NT, DM, TB wrote the initial draft and VP prepared the figures a graphical illustration. AR, critically revised and organised the manuscript. LZ, MOM, MAN, AA, HM, MB, SU and SD provided intellectual input and an overall review of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">title_1</infon><offset>48097</offset><text>Disclosure statement</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">paragraph</infon><offset>48118</offset><text>No potential conflict of interest was reported by the author(s).</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">title_1</infon><offset>48183</offset><text>Data availability statement</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">paragraph</infon><offset>48211</offset><text>Data available within the article or its supplementary materials.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">title</infon><offset>48277</offset><text>References</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">bioRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>48288</offset><text>Severe acute respiratory syndrome-related coronavirus: the species and its viruses â a statement of the coronavirus study group</text></passage><passage><infon key=\"fpage\">727</infon><infon key=\"issue\">8</infon><infon key=\"lpage\">733</infon><infon key=\"pub-id_pmid\">31978945</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>48418</offset><text>A novel coronavirus from patients with pneumonia in China, 2019</text></passage><passage><infon key=\"fpage\">1708</infon><infon key=\"issue\">18</infon><infon key=\"lpage\">1720</infon><infon key=\"pub-id_pmid\">32109013</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>48482</offset><text>Clinical characteristics of coronavirus disease 2019 in China</text></passage><passage><infon key=\"fpage\">497</infon><infon key=\"issue\">10223</infon><infon key=\"lpage\">506</infon><infon key=\"pub-id_pmid\">31986264</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>48544</offset><text>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</text></passage><passage><infon key=\"fpage\">221</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">236</infon><infon key=\"pub-id_pmid\">31987001</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>48627</offset><text>Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</text></passage><passage><infon key=\"fpage\">565</infon><infon key=\"issue\">10224</infon><infon key=\"lpage\">574</infon><infon key=\"pub-id_pmid\">32007145</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>48768</offset><text>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</text></passage><passage><infon key=\"fpage\">76</infon><infon key=\"issue\">7428</infon><infon key=\"lpage\">77</infon><infon key=\"pub-id_pmid\">4158999</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">1</infon><infon key=\"year\">1966</infon><offset>48889</offset><text>Cultivation of viruses from a high proportion of patients with colds</text></passage><passage><infon key=\"fpage\">760</infon><infon key=\"issue\">8</infon><infon key=\"lpage\">762</infon><infon key=\"pub-id_pmid\">31978944</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>48958</offset><text>Another decade, another coronavirus</text></passage><passage><infon key=\"fpage\">466</infon><infon key=\"issue\">6528</infon><infon key=\"lpage\">467</infon><infon key=\"pub-id_pmid\">33510015</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">371</infon><infon key=\"year\">2021</infon><offset>48994</offset><text>Insights from SARS-CoV-2 sequences</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>49029</offset></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>49030</offset></passage><passage><infon key=\"fpage\">100</infon><infon key=\"issue\">6</infon><infon key=\"pub-id_pmid\">33846767</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Mol Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">47</infon><infon key=\"year\">2021</infon><offset>49031</offset><text>Current and innovative methods for the diagnosis of COVIDâ19 infection (review)</text></passage><passage><infon key=\"fpage\">041506</infon><infon key=\"issue\">4</infon><infon key=\"pub-id_pmid\">33305162</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">APL Bioeng</infon><infon key=\"type\">ref</infon><infon key=\"volume\">4</infon><infon key=\"year\">2020</infon><offset>49113</offset><text>Evaluation of current diagnostic methods for COVID-19</text></passage><passage><infon key=\"fpage\">1233</infon><infon key=\"lpage\">1245</infon><infon key=\"pub-id_pmid\">33857405</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>49167</offset><text>Diagnostic performance of different sampling approaches for SARS- CoV-2 RT-PCR testing: a systematic review and meta-analysis</text></passage><passage><infon key=\"fpage\">e0007521</infon><infon key=\"issue\">7</infon><infon key=\"pub-id_pmid\">33903167</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">59</infon><infon key=\"year\">2021</infon><offset>49293</offset><text>SARS-CoV-2 E gene variant alters analytical sensitivity characteristics of viral detection using a commercial reverse transcription-PCR assay</text></passage><passage><infon key=\"fpage\">160</infon><infon key=\"issue\">1</infon><infon key=\"pub-id_pmid\">33087160</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Virol J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">17</infon><infon key=\"year\">2020</infon><offset>49435</offset><text>Rapid point-of-care detection of SARS-CoV-2 using reverse transcription loop-mediated isothermal amplification (RT-LAMP)</text></passage><passage><infon key=\"fpage\">870</infon><infon key=\"issue\">7</infon><infon key=\"lpage\">874</infon><infon key=\"pub-id_pmid\">32300245</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Biotechnol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">38</infon><infon key=\"year\">2020</infon><offset>49556</offset><text>CRISPR-Cas12-based detection of SARS-CoV-2</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>49599</offset><text>A simple and quick PCR based method for detection of omicron variant of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">e0031521</infon><infon key=\"issue\">1</infon><infon key=\"pub-id_pmid\">34378966</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Microbiol Spectr</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2021</infon><offset>49682</offset><text>Precision response to the rise of the SARS-CoV-2 B.1.1.7 variant of concern by combining novel PCR assays and genome sequencing for rapid variant detection and Surveillance</text></passage><passage><infon key=\"fpage\">207</infon><infon key=\"lpage\">209</infon><infon key=\"pub-id_pmid\">34628023</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">113</infon><infon key=\"year\">2021</infon><offset>49855</offset><text>Rapid screening for SARS-CoV-2 VOC-alpha (202012/01, B.1.1.7) using the Allplexâ¢ SARS-CoV-2/FluA/FluB/RSV assay</text></passage><passage><infon key=\"fpage\">117104</infon><infon key=\"pub-id_pmid\">33857895</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Water Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">197</infon><infon key=\"year\">2021</infon><offset>49969</offset><text>Rapid screening for SARS-CoV-2 variants of concern in clinical and environmental samples using nested RT-PCR assays targeting key mutations of the spike protein</text></passage><passage><infon key=\"fpage\">109786</infon><infon key=\"pub-id_pmid\">32361529</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Med Hypotheses</infon><infon key=\"type\">ref</infon><infon key=\"volume\">141</infon><infon key=\"year\">2020</infon><offset>50130</offset><text>Loop mediated isothermal amplification (LAMP) assays as a rapid diagnostic for COVID-19</text></passage><passage><infon key=\"fpage\">4198</infon><infon key=\"issue\">7</infon><infon key=\"lpage\">4204</infon><infon key=\"pub-id_pmid\">33599292</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">93</infon><infon key=\"year\">2021</infon><offset>50218</offset><text>Development and application of sensitive, specific, and rapid CRISPR- Cas13-based diagnosis</text></passage><passage><infon key=\"fpage\">95</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">104</infon><infon key=\"pub-id_pmid\">19955814</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Intervirology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">53</infon><infon key=\"year\">2010</infon><offset>50310</offset><text>Comprehensive detection and identification of seven animal coronaviruses and human respiratory coronavirus 229E with a microarray hybridization assay</text></passage><passage><infon key=\"fpage\">e0084521</infon><infon key=\"issue\">10</infon><infon key=\"pub-id_pmid\">34288729</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">59</infon><infon key=\"year\">2021</infon><offset>50460</offset><text>A simple reverse transcriptase PCR melting-temperature assay to rapidly screen for widely circulating SARS-CoV-2 variants</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>50582</offset><text>A simple RT-PCR melting temperature assay to rapidly screen for widely circulating SARS-CoV-2 variants</text></passage><passage><infon key=\"fpage\">104910</infon><infon key=\"pub-id_pmid\">33975021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Infect Genet Evol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2021</infon><offset>50685</offset><text>A sanger-based approach for scaling up screening of SARS-CoV-2 variants of interest and concern</text></passage><passage><infon key=\"fpage\">698</infon><infon key=\"issue\">4</infon><infon key=\"pub-id_pmid\">33919728</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Diagnostics</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2021</infon><offset>50781</offset><text>Detection of SARS-COV-2 proteins using an ELISA test</text></passage><passage><infon key=\"fpage\">1309</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">1317</infon><infon key=\"pub-id_pmid\">33660134</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur J Clin Microbiol Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">40</infon><infon key=\"year\">2021</infon><offset>50834</offset><text>Automated Western immunoblotting detection of anti-SARS-CoV-2 serum antibodies</text></passage><passage><infon key=\"pub-id_doi\">10.1211/PJ.2021.20208126</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>50913</offset></passage><passage><infon key=\"fpage\">69</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">71</infon><infon key=\"pub-id_pmid\">31996494</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biosci Trends</infon><infon key=\"type\">ref</infon><infon key=\"volume\">14</infon><infon key=\"year\">2020</infon><offset>50914</offset><text>Drug treatment options for the 2019-new coronavirus (2019-nCoV)</text></passage><passage><infon key=\"fpage\">279</infon><infon key=\"issue\">1</infon><infon key=\"pub-id_pmid\">33436624</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2021</infon><offset>50978</offset><text>Mechanism of SARS-CoV-2 polymerase stalling by remdesivir</text></passage><passage><infon key=\"fpage\">795</infon><infon key=\"issue\">9</infon><infon key=\"lpage\">807</infon><infon key=\"pub-id_pmid\">33306283</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">384</infon><infon key=\"year\">2021</infon><offset>51036</offset><text>Baricitinib plus remdesivir for hospitalized adults with covid- 19</text></passage><passage><infon key=\"fpage\">198070</infon><infon key=\"pub-id_pmid\">32569708</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Virus Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">286</infon><infon key=\"year\">2020</infon><offset>51103</offset><text>COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking</text></passage><passage><infon key=\"fpage\">252</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">256</infon><infon key=\"pub-id_pmid\">14985565</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Thorax</infon><infon key=\"type\">ref</infon><infon key=\"volume\">59</infon><infon key=\"year\">2004</infon><offset>51223</offset><text>Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings</text></passage><passage><infon key=\"fpage\">1787</infon><infon key=\"issue\">19</infon><infon key=\"lpage\">1799</infon><infon key=\"pub-id_pmid\">32187464</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>51319</offset><text>A trial of Lopinavir-Ritonavir in adults hospitalized with severe covid-19</text></passage><passage><infon key=\"fpage\">203</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">214</infon><infon key=\"pub-id_pmid\">4306296</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Gen Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">4</infon><infon key=\"year\">1969</infon><offset>51394</offset><text>Comparison of the antiviral activity inÂ vitro of some non-steroidal anti-inflammatory drugs</text></passage><passage><infon key=\"fpage\">3605</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">3609</infon><infon key=\"pub-id_pmid\">6115382</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Proc Natl Acad Sci USA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">78</infon><infon key=\"year\">1981</infon><offset>51487</offset><text>Antihistaminics, local anesthetics, and other amines as antiviral agents</text></passage><passage><infon key=\"fpage\">93</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">104</infon><infon key=\"pub-id_pmid\">4335025</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Arch Gesamte Virusforsch</infon><infon key=\"type\">ref</infon><infon key=\"volume\">36</infon><infon key=\"year\">1972</infon><offset>51560</offset><text>Effect of chloroquine on the growth of animal viruses</text></passage><passage><infon key=\"fpage\">297</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">308</infon><infon key=\"pub-id_pmid\">17629679</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Antimicrob Agents</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2007</infon><offset>51614</offset><text>Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century</text></passage><passage><infon key=\"fpage\">417</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">427</infon><infon key=\"pub-id_pmid\">33289973</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">384</infon><infon key=\"year\">2021</infon><offset>51732</offset><text>A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">Acta Pharm Sin B</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>51808</offset><text>Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and protease-Glo luciferase assays</text></passage><passage><infon key=\"fpage\">e2024420118</infon><infon key=\"issue\">8</infon><infon key=\"pub-id_doi\">10.1073/pnas.2024420118</infon><infon key=\"pub-id_pmid\">33568498</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Proc Natl Acad Sci USA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">118</infon><infon key=\"year\">2021</infon><offset>51929</offset><text>Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-cov-2 main protease inhibitors</text></passage><passage><infon key=\"fpage\">1491</infon><infon key=\"lpage\">1502</infon><infon key=\"pub-id_pmid\">33631065</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>52065</offset><text>Interleukin-6 receptor antagonists in critically ill patients with covid-19</text></passage><passage><infon key=\"fpage\">511</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">521</infon><infon key=\"pub-id_pmid\">33676589</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Respir Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2021</infon><offset>52141</offset><text>Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial</text></passage><passage><infon key=\"fpage\">511</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">518</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Drug Investig</infon><infon key=\"type\">ref</infon><infon key=\"volume\">40</infon><infon key=\"year\">2020</infon><offset>52362</offset><text>Rational use of tocilizumab in the treatment of novel coronavirus pneumonia</text></passage><passage><infon key=\"pub-id_doi\">10.1211/PJ.2021.20208721</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>52438</offset></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>52439</offset></passage><passage><infon key=\"fpage\">105033</infon><infon key=\"pub-id_pmid\">33549572</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Antiviral Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">188</infon><infon key=\"year\">2021</infon><offset>52440</offset><text>Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir</text></passage><passage><infon key=\"fpage\">e0047221</infon><infon key=\"issue\">1</infon><infon key=\"pub-id_pmid\">34378968</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Microbiol Spectr</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2021</infon><offset>52639</offset><text>TMPRSS2 and RNA-Dependent RNA polymerase are effective targets of therapeutic intervention for treatment of COVID-19 caused by SARS-CoV-2 variants (B.1.1.7 and B.1.351))</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">bioRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>52809</offset><text>Host-directed therapies against early-lineage SARS-CoV- 2 retain efficacy against B.1.1.7 variant</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">bioRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>52907</offset><text>Analysis of SARS-CoV-2 mutations over time reveals increasing prevalence of variants in the spike protein and RNA-Dependent RNA polymerase</text></passage><passage><infon key=\"fpage\">100770</infon><infon key=\"issue\">1</infon><infon key=\"pub-id_pmid\">33989635</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Biol Chem</infon><infon key=\"type\">ref</infon><infon key=\"volume\">297</infon><infon key=\"year\">2021</infon><offset>53046</offset><text>Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template</text></passage><passage><infon key=\"fpage\">740</infon><infon key=\"issue\">9</infon><infon key=\"lpage\">746</infon><infon key=\"pub-id_pmid\">34381216</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Struct Mol Biol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">28</infon><infon key=\"year\">2021</infon><offset>53112</offset><text>Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis</text></passage><passage><infon key=\"issue\">541</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci Transl Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>53169</offset><text>An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice</text></passage><passage><infon key=\"pub-id_doi\">10.1002/jmv.27540</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2022</infon><offset>53313</offset></passage><passage><infon key=\"fpage\">372</infon><infon key=\"issue\">1</infon><infon key=\"pub-id_pmid\">33446655</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2021</infon><offset>53314</offset><text>SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">New Eng J Med</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>53423</offset><text>Phase 1â2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine</text></passage><passage><infon key=\"fpage\">e41451</infon><infon key=\"issue\">7</infon><infon key=\"pub-id_pmid\">22844480</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS One</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2012</infon><offset>53504</offset><text>Matrix-Mâ¢ adjuvant induces local recruitment, activation and maturation of Central immune cells in absence of antigen</text></passage><passage><infon key=\"fpage\">7892</infon><infon key=\"issue\">50</infon><infon key=\"lpage\">7896</infon><infon key=\"pub-id_pmid\">33139139</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Vaccine</infon><infon key=\"type\">ref</infon><infon key=\"volume\">38</infon><infon key=\"year\">2020</infon><offset>53624</offset><text>NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">medRXiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>53725</offset><text>First-in-human trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>53809</offset></passage><passage><infon key=\"fpage\">1172</infon><infon key=\"issue\">13</infon><infon key=\"lpage\">1183</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa2107659</infon><infon key=\"pub-id_pmid\">34192426</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">385</infon><infon key=\"year\">2021</infon><offset>53810</offset><text>Safety and efficacy of NVX-CoV2373 covid-19 vaccine</text></passage><passage><infon key=\"fpage\">467</infon><infon key=\"issue\">10249</infon><infon key=\"lpage\">478</infon><infon key=\"pub-id_pmid\">32702298</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">396</infon><infon key=\"year\">2020</infon><offset>53862</offset><text>Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial</text></passage><passage><infon key=\"fpage\">40</infon><infon key=\"issue\">2</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Vaccines</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2019</infon><offset>54018</offset><text>Safety and immunogenicity of a novel recombinant simian adenovirus ChAdOx2 as a vectored vaccine</text></passage><passage><infon key=\"fpage\">1679</infon><infon key=\"issue\">7</infon><infon key=\"lpage\">1685</infon><infon key=\"pub-id_pmid\">29300685</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Hum Vaccin Immunother</infon><infon key=\"type\">ref</infon><infon key=\"volume\">14</infon><infon key=\"year\">2018</infon><offset>54115</offset><text>Development of novel vaccine vectors: chimpanzee adenoviral vectors</text></passage><passage><infon key=\"fpage\">47</infon><infon key=\"lpage\">54</infon><infon key=\"pub-id_pmid\">27286566</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Curr Opin Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">41</infon><infon key=\"year\">2016</infon><offset>54183</offset><text>Viral vectors as vaccine platforms: from immunogenicity to impact</text></passage><passage><infon key=\"fpage\">816</infon><infon key=\"issue\">7</infon><infon key=\"lpage\">826</infon><infon key=\"pub-id_pmid\">32325038</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>54249</offset><text>Safety and immunogenicity of a candidate Middle east respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non- randomised, uncontrolled, phase 1 trial</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>54435</offset></passage><passage><infon key=\"fpage\">99</infon><infon key=\"issue\">10269</infon><infon key=\"lpage\">111</infon><infon key=\"pub-id_pmid\">33306989</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">397</infon><infon key=\"year\">2021</infon><offset>54436</offset><text>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>54610</offset></passage><passage><infon key=\"fpage\">n326</infon><infon key=\"pub-id_pmid\">33536232</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BMJ</infon><infon key=\"type\">ref</infon><infon key=\"volume\">372</infon><infon key=\"year\">2021</infon><offset>54611</offset><text>Covid-19: new data on oxford AstraZeneca vaccine backs 12 week dosing interval</text></passage><passage><infon key=\"fpage\">n699</infon><infon key=\"pub-id_pmid\">33707182</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BMJ</infon><infon key=\"type\">ref</infon><infon key=\"volume\">372</infon><infon key=\"year\">2021</infon><offset>54690</offset><text>Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots</text></passage><passage><infon key=\"fpage\">1441</infon><infon key=\"issue\">10283</infon><infon key=\"lpage\">1443</infon><infon key=\"pub-id_pmid\">33798498</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">397</infon><infon key=\"year\">2021</infon><offset>54790</offset><text>Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?</text></passage><passage><infon key=\"fpage\">n1114</infon><infon key=\"pub-id_pmid\">33952445</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BMJ</infon><infon key=\"type\">ref</infon><infon key=\"volume\">373</infon><infon key=\"year\">2021</infon><offset>54879</offset><text>Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study</text></passage><passage><infon key=\"fpage\">887</infon><infon key=\"issue\">10255</infon><infon key=\"lpage\">897</infon><infon key=\"pub-id_pmid\">32896291</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">396</infon><infon key=\"year\">2020</infon><offset>55056</offset><text>Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non- randomised phase 1/2 studies from russia</text></passage><passage><infon key=\"fpage\">46</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">56</infon><infon key=\"pub-id_pmid\">30796818</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">220</infon><infon key=\"year\">2019</infon><offset>55235</offset><text>Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania</text></passage><passage><infon key=\"fpage\">979</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">988</infon><infon key=\"pub-id_pmid\">32320465</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">222</infon><infon key=\"year\">2020</infon><offset>55432</offset><text>Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding perfusion F (Ad26.RSV.preF) in adults aged â¥60 years</text></passage><passage><infon key=\"fpage\">232</infon><infon key=\"issue\">10143</infon><infon key=\"lpage\">243</infon><infon key=\"pub-id_pmid\">30047376</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">392</infon><infon key=\"year\">2018</infon><offset>55606</offset><text>Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)</text></passage><passage><infon key=\"fpage\">421</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">433</infon><infon key=\"pub-id_pmid\">24279313</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Curr Gene Ther</infon><infon key=\"type\">ref</infon><infon key=\"volume\">13</infon><infon key=\"year\">2013</infon><offset>55778</offset><text>Adenovirus vectors for gene therapy, vaccination and cancer gene therapy</text></passage><passage><infon key=\"fpage\">4844</infon><infon key=\"issue\">10</infon><infon key=\"lpage\">4852</infon><infon key=\"pub-id_pmid\">18337575</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">82</infon><infon key=\"year\">2008</infon><offset>55851</offset><text>Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys</text></passage><passage><infon key=\"fpage\">346</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">351</infon><infon key=\"pub-id_pmid\">19500964</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Curr Opin Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">21</infon><infon key=\"year\">2009</infon><offset>56003</offset><text>Heterologous prime-boost vaccination</text></passage><passage><infon key=\"fpage\">2875</infon><infon key=\"issue\">10</infon><infon key=\"lpage\">2884</infon><infon key=\"pub-id_pmid\">25483662</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Hum Vaccin Immunother</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2014</infon><offset>56040</offset><text>Pre-existing immunity against ad vectors: humoral, cellular, and innate response, what's important?</text></passage><passage><infon key=\"fpage\">671</infon><infon key=\"issue\">10275</infon><infon key=\"lpage\">681</infon><infon key=\"pub-id_pmid\">33545094</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">397</infon><infon key=\"year\">2021</infon><offset>56140</offset><text>Safety and efficacy of an rAd26 and rAd5 vector- based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">Res Sq</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>56309</offset><text>Neutralizing activity of sputnik V vaccine sera against SARS- CoV-2 variants</text></passage><passage><infon key=\"fpage\">759</infon><infon key=\"issue\">10</infon><infon key=\"lpage\">780</infon><infon key=\"pub-id_pmid\">25233993</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Rev Drug Discov</infon><infon key=\"type\">ref</infon><infon key=\"volume\">13</infon><infon key=\"year\">2014</infon><offset>56386</offset><text>mRNA-based therapeutics-developing a new class of drugs</text></passage><passage><infon key=\"fpage\">248</infon><infon key=\"issue\">7644</infon><infon key=\"lpage\">251</infon><infon key=\"pub-id_pmid\">28151488</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">543</infon><infon key=\"year\">2017</infon><offset>56442</offset><text>Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination</text></passage><passage><infon key=\"fpage\">261</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">279</infon><infon key=\"pub-id_pmid\">29326426</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Rev Drug Discov</infon><infon key=\"type\">ref</infon><infon key=\"volume\">17</infon><infon key=\"year\">2018</infon><offset>56522</offset><text>mRNA vaccines â a new era in vaccinology</text></passage><passage><infon key=\"fpage\">1511</infon><infon key=\"issue\">10101</infon><infon key=\"lpage\">1520</infon><infon key=\"pub-id_pmid\">28754494</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">390</infon><infon key=\"year\">2017</infon><offset>56565</offset><text>Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial</text></passage><passage><infon key=\"fpage\">1210</infon><infon key=\"issue\">12</infon><infon key=\"lpage\">1216</infon><infon key=\"pub-id_pmid\">23159882</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Biotechnol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2012</infon><offset>56717</offset><text>Protective efficacy of inÂ vitro synthesized, specific mRNA vaccines against influenza a virus infection</text></passage><passage><infon key=\"fpage\">5338</infon><infon key=\"issue\">10</infon><infon key=\"lpage\">5354</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nano Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2018</infon><offset>56822</offset><text>Recent advances in mRNA vaccine delivery [review article]</text></passage><passage><infon key=\"fpage\">403</infon><infon key=\"issue\">5</infon><infon key=\"lpage\">416</infon><infon key=\"pub-id_pmid\">33378609</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">384</infon><infon key=\"year\">2021</infon><offset>56880</offset><text>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine</text></passage><passage><infon key=\"fpage\">2603</infon><infon key=\"issue\">27</infon><infon key=\"lpage\">2615</infon><infon key=\"pub-id_pmid\">33301246</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>56936</offset><text>Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>56994</offset><text> announce vaccine candidate against COVID-19 achieved success in first interim analysis from phase 3 study [Press release, Monday, November 09, 2020 - 06:45am].</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>57155</offset></passage><passage><infon key=\"fpage\">495</infon><infon key=\"issue\">13</infon><infon key=\"lpage\">500</infon><infon key=\"pub-id_pmid\">33793460</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">MMWR Morb Mortal Wkly Rep</infon><infon key=\"type\">ref</infon><infon key=\"volume\">70</infon><infon key=\"year\">2021</infon><offset>57156</offset><text>Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline Workers â Eight U.S. locations, December 2020 â March 2021</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>57422</offset></passage><passage><infon key=\"fpage\">187</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">189</infon><infon key=\"pub-id_pmid\">33951357</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">385</infon><infon key=\"year\">2021</infon><offset>57423</offset><text>Effectiveness of the BNT162b2 covid-19 vaccine against the B.1.1.7 and B.1.351 variants</text></passage><passage><infon key=\"fpage\">1725</infon><infon key=\"issue\">10286</infon><infon key=\"lpage\">1735</infon><infon key=\"pub-id_pmid\">33901423</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">397</infon><infon key=\"year\">2021</infon><offset>57511</offset><text>COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study</text></passage><passage><infon key=\"fpage\">585</infon><infon key=\"issue\">7</infon><infon key=\"lpage\">594</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa2108891</infon><infon key=\"pub-id_pmid\">34289274</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">385</infon><infon key=\"year\">2021</infon><offset>57682</offset><text>Effectiveness of covid-19 vaccines against the B.1.617.2 (Delta) Variant</text></passage><passage><infon key=\"fpage\">1920</infon><infon key=\"issue\">20</infon><infon key=\"lpage\">1931</infon><infon key=\"pub-id_pmid\">32663912</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>57755</offset><text>An mRNA vaccine against SARS-CoV-2 - Preliminary report</text></passage><passage><infon key=\"fpage\">572</infon><infon key=\"issue\">7868</infon><infon key=\"lpage\">577</infon><infon key=\"pub-id_pmid\">34044428</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">595</infon><infon key=\"year\">2021</infon><offset>57811</offset><text>BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans</text></passage><passage><infon key=\"fpage\">137</infon><infon key=\"lpage\">151</infon><infon key=\"pub-id_pmid\">33340620</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Adv Drug Deliv Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">169</infon><infon key=\"year\">2021</infon><offset>57896</offset><text>Non-viral COVID-19 vaccine delivery systems</text></passage><passage><infon key=\"pub-id_doi\">10.1542/peds.2018-2094</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2019</infon><offset>57940</offset></passage><passage><infon key=\"fpage\">1463</infon><infon key=\"issue\">9</infon><infon key=\"lpage\">1471</infon><infon key=\"pub-id_pmid\">33487470</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Vaccine</infon><infon key=\"type\">ref</infon><infon key=\"volume\">39</infon><infon key=\"year\">2021</infon><offset>57941</offset><text>Immunogenicity and safety of the inactivated poliomyelitis vaccine made from sabin strains in a phase IV clinical trial for the vaccination of a large population</text></passage><passage><infon key=\"fpage\">329</infon><infon key=\"issue\">4</infon><infon key=\"lpage\">346</infon><infon key=\"pub-id_pmid\">29280070</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Drug Saf</infon><infon key=\"type\">ref</infon><infon key=\"volume\">41</infon><infon key=\"year\">2018</infon><offset>58103</offset><text>Safety of human papillomavirus vaccines: an updated review</text></passage><passage><infon key=\"fpage\">178</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">182</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">VPBM</infon><infon key=\"type\">ref</infon><infon key=\"volume\">4</infon><infon key=\"year\">2020</infon><offset>58162</offset><text>Strength of anti-diphtheria and anti-tetanus immunity in hiv-infected adults</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>58239</offset></passage><passage><infon key=\"fpage\">77</infon><infon key=\"issue\">6499</infon><infon key=\"lpage\">81</infon><infon key=\"pub-id_pmid\">32376603</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">369</infon><infon key=\"year\">2020</infon><offset>58240</offset><text>Development of an inactivated vaccine candidate for SARS-CoV-2</text></passage><passage><infon key=\"fpage\">93</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">97</infon><infon key=\"pub-id_pmid\">32318665</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Animal Model Exp Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">3</infon><infon key=\"year\">2020</infon><offset>58303</offset><text>Age-related rhesus macaque models of COVID-19</text></passage><passage><infon key=\"fpage\">181</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">192</infon><infon key=\"pub-id_pmid\">33217362</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">21</infon><infon key=\"year\">2021</infon><offset>58349</offset><text>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18â59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</text></passage><passage><infon key=\"fpage\">803</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">812</infon><infon key=\"pub-id_pmid\">33548194</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">21</infon><infon key=\"year\">2021</infon><offset>58538</offset><text>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo- controlled, phase 1/2 clinical trial</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>58745</offset><text>Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P. 1 variant transmission in Brazil: a test-negative case-control study</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>58878</offset><text> Expert reaction to announcement of results of phase III of Sinovac vaccine in China 2021. Available from: https://www.sciencemediacentre.org/expert-reaction-to-announcement-of-results-of-phase-iii-of-sinovac-vaccine-in-china.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>59105</offset></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>59106</offset></passage><passage><infon key=\"fpage\">762</infon><infon key=\"issue\">15</infon><infon key=\"lpage\">768</infon><infon key=\"pub-id_pmid\">32161940</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>59107</offset><text>Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in wuhan, China</text></passage><passage><infon key=\"fpage\">578</infon><infon key=\"issue\">7830</infon><infon key=\"lpage\">582</infon><infon key=\"pub-id_pmid\">32731258</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">586</infon><infon key=\"year\">2020</infon><offset>59201</offset><text>ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques</text></passage><passage><infon key=\"fpage\">39</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">51</infon><infon key=\"pub-id_pmid\">33069281</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">21</infon><infon key=\"year\">2021</infon><offset>59274</offset><text>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP- CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial</text></passage><passage><infon key=\"fpage\">951</infon><infon key=\"issue\">10</infon><infon key=\"lpage\">960</infon><infon key=\"pub-id_pmid\">32789505</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">324</infon><infon key=\"year\">2020</infon><offset>59415</offset><text>Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials</text></passage><passage><infon key=\"fpage\">35</infon><infon key=\"issue\">1</infon><infon key=\"pub-id_pmid\">34037666</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">326</infon><infon key=\"year\">2021</infon><offset>59555</offset><text>Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>59672</offset></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>59673</offset><text> Coronavirus: Morocco receives half million doses of Sinopharm COVID-19 vaccine 2021-01-28. Available from: https://english.alarabiya.net/coronavirus/2021/01/27/Coronavirus-. Coronavirus- Morocco-receives-half-million-doses-of-Sinopharm-COVID-19-vaccine</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>59927</offset></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>59928</offset></passage><passage><infon key=\"fpage\">e13705</infon><infon key=\"issue\">5</infon><infon key=\"pub-id_pmid\">34324256</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Transpl Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">23</infon><infon key=\"year\">2021</infon><offset>59929</offset><text>Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients</text></passage><passage><infon key=\"fpage\">e265</infon><infon key=\"issue\">11</infon><infon key=\"lpage\">e266</infon><infon key=\"pub-id_pmid\">34310531</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Transplantation</infon><infon key=\"type\">ref</infon><infon key=\"volume\">105</infon><infon key=\"year\">2021</infon><offset>60013</offset><text>Risk of breakthrough SARS-CoV-2 infections in adult transplant recipients</text></passage><passage><infon key=\"fpage\">1784</infon><infon key=\"issue\">17</infon><infon key=\"lpage\">1786</infon><infon key=\"pub-id_pmid\">33720292</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">325</infon><infon key=\"year\">2021</infon><offset>60087</offset><text>Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients</text></passage><passage><infon key=\"fpage\">3980</infon><infon key=\"issue\">12</infon><infon key=\"lpage\">3989</infon><infon key=\"pub-id_pmid\">34347934</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Am J Transplant</infon><infon key=\"type\">ref</infon><infon key=\"volume\">21</infon><infon key=\"year\">2021</infon><offset>60192</offset><text>Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients</text></passage><passage><infon key=\"pub-id_doi\">10.1172/JCI150175</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>60318</offset></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">Am J Transplant</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>60319</offset><text>A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients</text></passage><passage><infon key=\"fpage\">1147</infon><infon key=\"issue\">9</infon><infon key=\"lpage\">1156</infon><infon key=\"pub-id_pmid\">23993463</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Chem Biol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2013</infon><offset>60453</offset><text>Exploiting the Burkholderia pseudomallei acute phase antigen BPSL2765 for structure-based epitope discovery/design in structural vaccinology</text></passage><passage><infon key=\"fpage\">8084</infon><infon key=\"issue\">19</infon><infon key=\"lpage\">8093</infon><infon key=\"pub-id_pmid\">32885971</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Phys Chem Lett</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>60594</offset><text>The answer lies in the energy: How simple atomistic molecular dynamics simulations may hold the key to epitope prediction on the fully glycosylated SARS-CoV-2 spike protein</text></passage><passage><infon key=\"fpage\">4687</infon><infon key=\"issue\">9</infon><infon key=\"lpage\">4700</infon><infon key=\"pub-id_pmid\">34468141</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Chem Inf Model</infon><infon key=\"type\">ref</infon><infon key=\"volume\">61</infon><infon key=\"year\">2021</infon><offset>60767</offset><text>SARS-CoV-2 spike protein mutations and escape from antibodies: a computational model of epitope loss in variants of concern</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"issue\">1</infon><infon key=\"lpage\">7</infon><infon key=\"pub-id_pmid\">15258961</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">74</infon><infon key=\"year\">2004</infon><offset>60891</offset><text>Persistent infection of SARS coronavirus in colonic cells inÂ vitro</text></passage><passage><infon key=\"fpage\">282</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">289</infon><infon key=\"pub-id_pmid\">12845623</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Pathol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">200</infon><infon key=\"year\">2003</infon><offset>60959</offset><text>The clinical pathology of severe acute respiratory syndrome (SARS): a report from China</text></passage><passage><infon key=\"fpage\">740</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">743</infon><infon key=\"pub-id_pmid\">15221932</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Pathol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">203</infon><infon key=\"year\">2004</infon><offset>61047</offset><text>Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2)</text></passage><passage><infon key=\"fpage\">552</infon><infon key=\"issue\">6</infon><infon key=\"lpage\">555</infon><infon key=\"pub-id_pmid\">32104915</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>61239</offset><text>The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients</text></passage><passage><infon key=\"fpage\">622</infon><infon key=\"issue\">2</infon><infon key=\"lpage\">630</infon><infon key=\"pub-id_pmid\">15141376</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Pathol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">203</infon><infon key=\"year\">2004</infon><offset>61344</offset><text>Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways</text></passage><passage><infon key=\"fpage\">415</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">424</infon><infon key=\"pub-id_pmid\">16043521</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Exp Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">202</infon><infon key=\"year\">2005</infon><offset>61521</offset><text>Multiple organ infection and the pathogenesis of SARS</text></passage><passage><infon key=\"fpage\">1089</infon><infon key=\"issue\">8</infon><infon key=\"lpage\">1096</infon><infon key=\"pub-id_pmid\">16163626</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">41</infon><infon key=\"year\">2005</infon><offset>61575</offset><text>Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine MIG in pathogenesis</text></passage><passage><infon key=\"fpage\">339</infon><infon key=\"lpage\">346</infon><infon key=\"pub-id_pmid\">8209751</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Adv Exp Med Biol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">342</infon><infon key=\"year\">1993</infon><offset>61700</offset><text>Neurotropism of human coronavirus 229E</text></passage><passage><infon key=\"pub-id_doi\">10.1128/JVI.00404-18</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>61739</offset></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>61740</offset><text>Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study</text></passage><passage><infon key=\"fpage\">181</infon><infon key=\"issue\">3</infon><infon key=\"lpage\">192</infon><infon key=\"pub-id_pmid\">30531947</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Rev Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">17</infon><infon key=\"year\">2019</infon><offset>61858</offset><text>Origin and evolution of pathogenic coronaviruses</text></passage><passage><infon key=\"fpage\">514</infon><infon key=\"issue\">10223</infon><infon key=\"lpage\">523</infon><infon key=\"pub-id_pmid\">31986261</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>61907</offset><text>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster</text></passage><passage><infon key=\"fpage\">872</infon><infon key=\"issue\">9</infon><infon key=\"lpage\">874</infon><infon key=\"pub-id_pmid\">31991079</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>62052</offset><text>Importation and human-to-human transmission of a novel coronavirus in Vietnam</text></passage><passage><infon key=\"fpage\">1061</infon><infon key=\"issue\">11</infon><infon key=\"lpage\">1069</infon><infon key=\"pub-id_doi\">10.1001/jama.2020.1585</infon><infon key=\"pub-id_pmid\">32031570</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>62130</offset><text>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China</text></passage></document></collection>\n",
      "\n",
      "Study 33187528: <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n",
      "<!DOCTYPE collection SYSTEM \"BioC.dtd\">\n",
      "<collection><source>PMC</source><date>20210928</date><key>pmc.key</key><document><id>7665091</id><infon key=\"license\">CC BY</infon><passage><infon key=\"article-id_doi\">10.1186/s12985-020-01452-5</infon><infon key=\"article-id_pmc\">7665091</infon><infon key=\"article-id_pmid\">33187528</infon><infon key=\"article-id_publisher-id\">1452</infon><infon key=\"elocation-id\">177</infon><infon key=\"kwd\">COVID-19 SARS-CoV-2 Rapid antigen RT-PCR Thailand</infon><infon key=\"license\">Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</infon><infon key=\"name_0\">surname:Chaimayo;given-names:Chutikarn</infon><infon key=\"name_1\">surname:Kaewnaphan;given-names:Bualan</infon><infon key=\"name_10\">surname:Pongraweewan;given-names:Orawan</infon><infon key=\"name_11\">surname:Chuthapisith;given-names:Suebwong</infon><infon key=\"name_12\">surname:Sirivatanauksorn;given-names:Yongyut</infon><infon key=\"name_13\">surname:Kantakamalakul;given-names:Wannee</infon><infon key=\"name_14\">surname:Horthongkham;given-names:Navin</infon><infon key=\"name_15\">surname:Horthongkham;given-names:Navin</infon><infon key=\"name_2\">surname:Tanlieng;given-names:Nattaya</infon><infon key=\"name_3\">surname:Athipanyasilp;given-names:Niracha</infon><infon key=\"name_4\">surname:Sirijatuphat;given-names:Rujipas</infon><infon key=\"name_5\">surname:Chayakulkeeree;given-names:Methee</infon><infon key=\"name_6\">surname:Angkasekwinai;given-names:Nasikarn</infon><infon key=\"name_7\">surname:Sutthent;given-names:Ruengpung</infon><infon key=\"name_8\">surname:Puangpunngam;given-names:Nattawut</infon><infon key=\"name_9\">surname:Tharmviboonsri;given-names:Theerawoot</infon><infon key=\"section_type\">TITLE</infon><infon key=\"title\">Keywords</infon><infon key=\"type\">front</infon><infon key=\"volume\">17</infon><infon key=\"year\">2020</infon><offset>0</offset><text>Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>132</offset><text>Background</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>143</offset><text>The Coronavirus disease 2019 (COVID-19) pandemic continues to spread across the world. Hence, there is an urgent need for rapid, simple, and accurate tests to diagnose severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Performance characteristics of the rapid SARS-CoV-2 antigen detection test should be evaluated and compared with the gold standard real-time reverse transcription-polymerase chain reaction (RT-PCR) test for diagnosis of COVID-19 cases.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>619</offset><text>Methods</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>627</offset><text>The rapid SARS-CoV-2 antigen detection test, Standardâ¢ Q COVID-19 Ag kit (SD BiosensorÂ®, Republic of Korea), was compared with the real-time RT-PCR test, Allplexâ¢ 2019-nCoV Assay (SeegeneÂ®, Korea) for detection of SARS-CoV-2 in respiratory specimens. Four hundred fifty-four respiratory samples (mainly nasopharyngeal and throat swabs) were obtained from COVID-19 suspected cases and contact individuals, including pre-operative patients at Siriraj Hospital, Bangkok, Thailand during MarchâMay 2020.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>1135</offset><text>Results</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>1143</offset><text>Of 454 respiratory samples, 60 (13.2%) were positive, and 394 (86.8%) were negative for SARS-CoV-2 RNA by real-time RT-PCR assay. The duration from onset to laboratory test in COVID-19 suspected cases and contact individuals ranged from 0 to 14Â days with a median of 3Â days. The rapid SARS-CoV-2 antigen detection testâs sensitivity and specificity were 98.33% (95% CI, 91.06â99.96%) and 98.73% (95% CI, 97.06â99.59%), respectively. One false negative test result was from a sample with a high real-time RT-PCR cycle threshold (Ct), while five false positive test results were from specimens of pre-operative patients.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>1770</offset><text>Conclusions</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>1782</offset><text>The rapid assay for SARS-CoV-2 antigen detection showed comparable sensitivity and specificity with the real-time RT-PCR assay. Thus, there is a potential use of this rapid and simple SARS-CoV-2 antigen detection test as a screening assay.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>2022</offset><text>Background</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>2033</offset><text>The Coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide since its first recorded case in the city of Wuhan, China in December 2019. According to the COVID-19 Dashboard on August 31st, 2020 by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, over 25 million people in more than 200 countries have been infected and killed more than 840,000. It is expected that these numbers continue to rise, especially in populous countries such as the United States, Brazil, and India. In Thailand, the first documented cases of COVID-19 were two Chinese tourists arriving from the city of Wuhan on January 8th and 13th, 2020, respectively. As of August 31st, 2020, there have been 3,412 confirmed COVID-19 cases with 58 deaths; 2,444 cases were from local transmission. The Thai government mandated a 14-day State Quarantine for all travelers entering Thailand from abroad. Since May 26th, 2020, no new local transmission cases were documented; new confirmed COVID-19 cases were people who have tested positive while in State Quarantine after returning from abroad. SARS-CoV-2 infection causes asymptomatic and mild diseases more than severe pneumonia. Severe cases may develop acute respiratory distress syndrome (ARDS) and death with an average mortality rate of 6% (range 1â14.4%).</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>3429</offset><text>The real-time reverse transcription-polymerase chain reaction (RT-PCR) assay, which is the current standard test for laboratory diagnosis of SARS-CoV-2 infection, requires at least four hours of operation performed by skilled technicians. Therefore, rapid and accurate tests for SARS-CoV-2 screening are essential to expedite disease prevention and control, as well as screening during pre-operative management for invasive procedures. Lateral flow immunoassays using monoclonal anti-SARS-CoV-2 antibodies, which target SARS-CoV-2 antigens, can be the complementary screening tests if their accuracy were comparable to that of the real-time RT-PCR assays.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>4085</offset><text>Here, we evaluated a rapid SARS-CoV-2 antigen detection test, Standardâ¢ Q COVID-19 Ag kit (SD BiosensorÂ®, Republic of Korea) using 454 respiratory specimens. The performance of this lateral flow immunoassay was compared with the SARS-CoV-2 RT-PCR for viral gene detection assay, Allplexâ¢ 2019-nCoV Assay (SeegeneÂ®, Korea). This evaluation is critical before the implementation of the rapid antigen test for screening of SARS-CoV-2 infected individuals.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_1</infon><offset>4544</offset><text>Methods</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>4552</offset><text>Ethical issues</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>4567</offset><text>This study was approved by the Institutional Review Board of the Faculty of Medicine Siriraj Hospital, Mahidol University (SIRB protocol 463/2563(IRB4); COA: Si 503/2020).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>4739</offset><text>Clinical specimens</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>4758</offset><text>Respiratory samples, mainly nasopharyngeal and throat swabs, were collected from 454 suspected COVID-19 cases, including pre-operative patients at Siriraj Hospital, Mahidol University, Bangkok, Thailand, from March to May 2020. Samples were mixed in 2Â mL of viral transport media (VTM), consisting of Hanksâ balanced salt, 0.4% fetal bovine serum, HEPES, antibiotic and antifungal agents. Samples were transported at 2â8Â Â°C to the Microbiology laboratory, Siriraj Hospital, for processing within a few hours. All specimens were processed in biosafety level-3 (BSL-3) and biosafety level-2 enhanced (BSL-2â+) facilities with full personal protective equipment.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>5427</offset><text>Viral RNA Extraction</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>5448</offset><text>MagLEAD 12gC automated extraction platform (Precision System Science, Chiba, Japan) was used to extract SARS-CoV-2 RNAs from 200 ÂµL of nasopharyngeal and throat swabs. Extraction was performed according to the manufacturerâs instructions. Viral RNA was eluted with 100 ÂµL buffer and used for RT-PCR assay.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>5762</offset><text>SARS-CoV-2 RNA detection using real-time RT-PCR</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>5810</offset><text>Allplexâ¢ 2019-nCoV Assay (Seegene, Korea), which targets envelope gene (E) of Sarbecovirus, and RNA-dependent RNA polymerase (RdRp) and nucleocapsid (N) genes of SARS-CoV-2, was used for SARS-CoV-2 RNA detection according to the manufacturerâs instructions. Briefly, 8 Î¼L of extracted RNA was added to 5 Î¼L of 5X Real-time One-step Buffer, 5 Î¼L of 2019-nCoV MuDT Oligo Mix (2019-nCoV-MOM), 2 Î¼L of Real-time One-step Enzyme, and 5 Î¼L of RNase free water. The CFX-96 real-time thermal cycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used for amplification. The conditions consisted of 1 cycle of 20Â min at 50Â Â°C, 1Â min at 95Â Â°C and followed by 45 cycles of 15Â s at 94Â Â°C, 30Â s at 58Â Â°C. The result was analysed using Seegene Viewer (Seegene, Korea), in which a cycle threshold value (Ct-value)â&lt;â40 for all three target genes was defined as a positive result.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>6705</offset><text>Rapid SARS-CoV-2 antigen detection assay</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>6746</offset><text>Standard Q COVID-19 Ag test (SD BiosensorÂ®, Chuncheongbuk-do, Republic of Korea) is a rapid chromatographic immunoassay for the detection of SARS-CoV-2 nucleocapsid (N) antigen in respiratory specimens. This rapid antigen test device has two pre-coated lines on the result window: control (C) and test (T) lines. The control (C) region is coated with mouse monoclonal anti-chicken IgÎ³ antibody; the test (T) region is coated with mouse monoclonal anti-SARS-CoV-2 antibody against SARS-CoV-2Â N antigen. Detectors for SARS-CoV-2Â N antigen presented in the specimen are mouse monoclonal anti-SARS-CoV-2 antibody conjugated with color particles. The antigenâantibody color particle complex migrates via capillary force and is captured by the mouse monoclonal anti-SARS-CoV-2 antibody coated on the test (T) region. The colored test (T) lineâs intensity depends on the amount of SARS-CoV-2Â N antigen presented in the sample.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>7675</offset><text>This rapid Ag test kit was used for the detection of SARS-CoV-2 antigen in respiratory samples in this study. Specimens were processed in biosafety level-3 (BSL-3) and biosafety level-2 enhanced (BSL-2â+) facilities. Five to ten glass beads were added to the samples in VTM tubes. For highly viscous samples, additional VTM was added to reduce the viscosity. Specimens were mixed using a vortex mixer to disrupt thick mucus. The 200 Î¼L of each nasopharyngeal and throat swab specimen was added to the extraction buffer provided in the kit. The filter nozzle cap was pressed tightly onto the extraction tube. Three drops of the extracted sample were applied on a test device, and the test result was read in 15â30Â min. For positive COVID-19 antigen result, two colored lines of control (C) and test (T) lines were presented.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>8505</offset><text>Statistical analysis</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>8526</offset><text>Descriptive statistics were used to describe general information of patients. Continuous data were presented in mean, standard deviation (SD), median, and range. Categorical data were presented in numbers, percentages, and 95% confidence interval (95% CI). Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) were calculated using an online statistical tool.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_1</infon><offset>8924</offset><text>Results</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>8932</offset><text>Characteristics of Thai COVID-19 cases</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>8971</offset><text>Suspected COVID-19 cases and contact individuals were laboratory-confirmed by the gold-standard RT-PCR assay as a national guideline for laboratory diagnosis of COVID-19. A total of 454 respiratory samples, including 447 nasopharyngeal (NP) and throat swabs, four endotracheal aspirates (tracheal suctions), and three sputum samples, were collected from suspected COVID-19 cases and pre-operative patients at Siriraj Hospital from March to May 2020. These respiratory samples were collected from subjects with the following conditions: (1) asymptomatic and upper respiratory tract infection individuals who had contacted with confirmed cases or were from COVID-19 risk areas, (2) clusters with acute respiratory infections, (3) unknown causative agents of pneumonia, (4) travelers screened at a port of entry and in quarantine places, and (5) pre-operative patients. Of the samples tested for COVID-19 (nâ=â454) by real-time RT-PCR assay, Allplexâ¢ 2019-nCoV Assay, 13.2% (nâ=â60) were positive, while 86.8% (nâ=â394) were negative for SARS-CoV-2 RNA, as shown in Additional file 1: Supplementary Table S1, Additional file 2: Table S2.</text></passage><passage><infon key=\"file\">Tab1.xml</infon><infon key=\"id\">Tab1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>10120</offset><text>Characteristics of COVID-19 Thai cases</text></passage><passage><infon key=\"file\">Tab1.xml</infon><infon key=\"id\">Tab1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align=&quot;left&quot;&gt;Characteristics&lt;/th&gt;&lt;th align=&quot;left&quot;&gt;Results&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Number of COVID-19 cases&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;nâ=â60&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;2&quot;&gt;Age (years)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Median (range)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;38.5 (range 21â72)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;2&quot;&gt;Gender&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Male&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;nâ=â36 (60%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;2&quot;&gt;Risk factors&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Confirmed case contact&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;nâ=â45 (75%): boxing stadiums (nâ=â11), karaoke bars&amp;amp;pubs (nâ=â14), workplaces (nâ=â1), taxi drivers (nâ=â1), family members and friends (nâ=â18)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Foreign contact&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;nâ=â8 (13.3%): UK (nâ=â5), China (nâ=â1), India (nâ=â1), Cambodia (nâ=â1)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Public area contact&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;nâ=â2 (3.3%): public market (nâ=â1), domestic travel (nâ=â1)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Unspecified&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;nâ=â5 (8.3%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;2&quot;&gt;Diagnoses&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Asymptomatic&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;nâ=â3 (5.0%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;URI&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;nâ=â37 (61.7%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Fever&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;nâ=â11 (18.3%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Pneumonia&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;nâ=â5 (8.3%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Unspecified&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;nâ=â4 (6.7%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;2&quot;&gt;Time from onset to laboratory test (days)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Median (range)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3 (range 0â14)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;2&quot;&gt;Results of RT-PCR assay&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;2&quot;&gt;&lt;italic&gt;Ct-value of E&lt;/italic&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;MeanâÂ±âSD (min, max)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;22.79âÂ±â6.69 (min 10.49, max 35.02)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;2&quot;&gt;&lt;italic&gt;Ct-value of RdRp&lt;/italic&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;MeanâÂ±âSD (min, max)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;24.73âÂ±â6.55 (min 13.41, max 39.20)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;2&quot;&gt;&lt;italic&gt;Ct-value of N&lt;/italic&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;MeanâÂ±âSD (min, max)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;26.09âÂ±â6.47 (min 12.07, max 37.17)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;2&quot;&gt;Results of rapid antigen detection assay&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Positive&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;59/60 (98.33%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Negative&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1/60 (1.67%)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>10159</offset><text>Characteristics\tResults\t \tNumber of COVID-19 cases\tnâ=â60\t \tAge (years)\t \tMedian (range)\t38.5 (range 21â72)\t \tGender\t \tMale\tnâ=â36 (60%)\t \tRisk factors\t \tConfirmed case contact\tnâ=â45 (75%): boxing stadiums (nâ=â11), karaoke bars&amp;pubs (nâ=â14), workplaces (nâ=â1), taxi drivers (nâ=â1), family members and friends (nâ=â18)\t \tForeign contact\tnâ=â8 (13.3%): UK (nâ=â5), China (nâ=â1), India (nâ=â1), Cambodia (nâ=â1)\t \tPublic area contact\tnâ=â2 (3.3%): public market (nâ=â1), domestic travel (nâ=â1)\t \tUnspecified\tnâ=â5 (8.3%)\t \tDiagnoses\t \tAsymptomatic\tnâ=â3 (5.0%)\t \tURI\tnâ=â37 (61.7%)\t \tFever\tnâ=â11 (18.3%)\t \tPneumonia\tnâ=â5 (8.3%)\t \tUnspecified\tnâ=â4 (6.7%)\t \tTime from onset to laboratory test (days)\t \tMedian (range)\t3 (range 0â14)\t \tResults of RT-PCR assay\t \tCt-value of E\t \tMeanâÂ±âSD (min, max)\t22.79âÂ±â6.69 (min 10.49, max 35.02)\t \tCt-value of RdRp\t \tMeanâÂ±âSD (min, max)\t24.73âÂ±â6.55 (min 13.41, max 39.20)\t \tCt-value of N\t \tMeanâÂ±âSD (min, max)\t26.09âÂ±â6.47 (min 12.07, max 37.17)\t \tResults of rapid antigen detection assay\t \tPositive\t59/60 (98.33%)\t \tNegative\t1/60 (1.67%)\t \t</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>11368</offset><text>The median age of Thai COVID-19 cases (nâ=â60) was 38.5Â years (range 21â72). Male patients were found to be 60% of the infected cases (nâ=â36). Of the total COVID-19 cases, 75% (nâ=â45) of patients had direct contact with a variety of confirmed cases in Thailand, such as family members and friends (30%; nâ=â18), people from karaoke bars and pubs (23.3%; nâ=â14), people from boxing stadiums (18.3%; nâ=â11), taxi drivers (1.7%; nâ=â1), and peers in workplaces (1.7%; nâ=â1), as shown in Table 1. Most patients showed signs and symptoms of upper respiratory tract infections (61.7%; nâ=â37). Around 8.3% (nâ=â5) of COVID-19 cases were presented with pneumonia and were admitted to an intensive care unit (ICU). The median time from onset to laboratory tests for SARS-CoV-2 infection (both RT-PCR and rapid antigen detection assays) was three days (range 0â14), as shown in Table 1 and Additional file 1: Supplementary Table S1.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>12342</offset><text>Real-time RT-PCR and SARS-CoV-2 antigen assays</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>12389</offset><text>Real-time RT-PCR (Allplexâ¢ 2019-nCoV Assay), which targets E of Sarbecovirus, and RdRp and N genes of SARS-CoV-2, was used for SARS-CoV-2 RNA detection. The average cycle threshold (Ct) values in COVID-19 positive cases were 22.79âÂ±â6.69 (min 10.49, max 35.02) for E gene, 24.73âÂ±â6.55 (min 13.41, max 39.20) for RdRp gene, and 26.09âÂ±â6.47 (min 12.07, max 37.17) for N gene, as shown in Table 1 and Additional file 1: Supplementary Table S1. The negative RT-PCR results were defined as having a Ct-value higher than 40 for all three target genes (E, RdRp, N).</text></passage><passage><infon key=\"file\">12985_2020_1452_Fig1_HTML.jpg</infon><infon key=\"id\">Fig1</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>12967</offset><text>Interpretation of rapid SARS-CoV-2 antigen detection assay (Standard Q COVID-19 Ag Test). Demonstration of a a test strip for viral transport media control, b a test strip, which was interpreted as negative SARS-CoV-2 antigen, c a test strip, which was interpreted as (weakly) positive SARS-CoV-2 antigen, and d a test strip, which was interpreted as positive SARS-CoV-2 antigen. The results were interpreted as positive when both control (c) and SARS-CoV-2 antigen (T) lines appeared within 30Â min</text></passage><passage><infon key=\"file\">Tab2.xml</infon><infon key=\"id\">Tab2</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>13467</offset><text>The sensitivity and specificity of the Standard Q COVID-19 Ag test</text></passage><passage><infon key=\"file\">Tab2.xml</infon><infon key=\"id\">Tab2</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align=&quot;left&quot; rowspan=&quot;2&quot;/&gt;&lt;th align=&quot;left&quot; colspan=&quot;3&quot;&gt;RT-PCR assay (Allplexâ¢ 2019-nCoV Assay)&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th align=&quot;left&quot;&gt;Positive&lt;/th&gt;&lt;th align=&quot;left&quot;&gt;&lt;sup&gt;#1&lt;/sup&gt;Negative&lt;/th&gt;&lt;th align=&quot;left&quot;&gt;Total&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; colspan=&quot;4&quot;&gt;&lt;italic&gt;Rapid SARS-CoV-2 antigen assay (Standard Q COVID-19 Ag kit)&lt;/italic&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Positive&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;59&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;5&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;64&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Negative&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;389&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;390&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Total&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;60&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;394&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;454&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Sensitivity&lt;/td&gt;&lt;td align=&quot;left&quot; colspan=&quot;3&quot;&gt;98.33% (59/60; 95%CI, 91.06â99.96%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Specificity&lt;/td&gt;&lt;td align=&quot;left&quot; colspan=&quot;3&quot;&gt;98.73% (389/394; 95%CI, 97.06â99.59%)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>13534</offset><text>\tRT-PCR assay (Allplexâ¢ 2019-nCoV Assay)\t \tPositive\t#1Negative\tTotal\t \tRapid SARS-CoV-2 antigen assay (Standard Q COVID-19 Ag kit)\t \tPositive\t59\t5\t64\t \tNegative\t1\t389\t390\t \tTotal\t60\t394\t454\t \tSensitivity\t98.33% (59/60; 95%CI, 91.06â99.96%)\t \tSpecificity\t98.73% (389/394; 95%CI, 97.06â99.59%)\t \t</text></passage><passage><infon key=\"file\">Tab2.xml</infon><infon key=\"id\">Tab2</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_foot</infon><offset>13835</offset><text>#1Negative RT-PCR is defined as having Ct-values of E, RdRp, and N larger than 40</text></passage><passage><infon key=\"file\">Tab3.xml</infon><infon key=\"id\">Tab3</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>13917</offset><text>Cases with discordant results between the Standard Q COVID-19 Ag test and RT-PCR assays</text></passage><passage><infon key=\"file\">Tab3.xml</infon><infon key=\"id\">Tab3</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align=&quot;left&quot; rowspan=&quot;2&quot;&gt;Gender&lt;/th&gt;&lt;th align=&quot;left&quot; rowspan=&quot;2&quot;&gt;Age&lt;/th&gt;&lt;th align=&quot;left&quot; rowspan=&quot;2&quot;&gt;Initial diagnosis&lt;/th&gt;&lt;th align=&quot;left&quot; rowspan=&quot;2&quot;&gt;Specimen type&lt;/th&gt;&lt;th align=&quot;left&quot; colspan=&quot;3&quot;&gt;Ct-value of RT-PCR&lt;/th&gt;&lt;th align=&quot;left&quot; rowspan=&quot;2&quot;&gt;Rapid Ag test result&lt;/th&gt;&lt;th align=&quot;left&quot; rowspan=&quot;2&quot;&gt;Interpretation&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th align=&quot;left&quot;&gt;&lt;italic&gt;E&lt;/italic&gt;&lt;/th&gt;&lt;th align=&quot;left&quot;&gt;&lt;italic&gt;RdRp&lt;/italic&gt;&lt;/th&gt;&lt;th align=&quot;left&quot;&gt;&lt;italic&gt;N&lt;/italic&gt;&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;F&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;33&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Pneumonia&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;NP swabâ+âthroat swab&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;31.18&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;39.20&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;35.54&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Negative&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;False negative&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;F&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;67&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Pre-operative&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;NP swabâ+âthroat swab&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â&amp;gt;â40&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â&amp;gt;â40&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â&amp;gt;â40&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Positive&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;False positive&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;M&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;75&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Pre-operative&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;NP swabâ+âthroat swab&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â&amp;gt;â40&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â&amp;gt;â40&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â&amp;gt;â40&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Positive&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;False positive&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;F&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;61&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Pre-operative&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;NP swabâ+âthroat swab&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â&amp;gt;â40&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â&amp;gt;â40&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â&amp;gt;â40&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Positive (weakly)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;False positive&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;F&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;83&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Pre-operative&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;NP swabâ+âthroat swab&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â&amp;gt;â40&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â&amp;gt;â40&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â&amp;gt;â40&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Positive (weakly)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;False positive&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;F&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;64&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Pre-operative&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;NP swabâ+âthroat swab&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â&amp;gt;â40&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â&amp;gt;â40&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;â&amp;gt;â40&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Positive (weakly)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;False positive&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>14005</offset><text>Gender\tAge\tInitial diagnosis\tSpecimen type\tCt-value of RT-PCR\tRapid Ag test result\tInterpretation\t \tE\tRdRp\tN\t \tF\t33\tPneumonia\tNP swabâ+âthroat swab\t31.18\t39.20\t35.54\tNegative\tFalse negative\t \tF\t67\tPre-operative\tNP swabâ+âthroat swab\tâ&gt;â40\tâ&gt;â40\tâ&gt;â40\tPositive\tFalse positive\t \tM\t75\tPre-operative\tNP swabâ+âthroat swab\tâ&gt;â40\tâ&gt;â40\tâ&gt;â40\tPositive\tFalse positive\t \tF\t61\tPre-operative\tNP swabâ+âthroat swab\tâ&gt;â40\tâ&gt;â40\tâ&gt;â40\tPositive (weakly)\tFalse positive\t \tF\t83\tPre-operative\tNP swabâ+âthroat swab\tâ&gt;â40\tâ&gt;â40\tâ&gt;â40\tPositive (weakly)\tFalse positive\t \tF\t64\tPre-operative\tNP swabâ+âthroat swab\tâ&gt;â40\tâ&gt;â40\tâ&gt;â40\tPositive (weakly)\tFalse positive\t \t</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>14734</offset><text>We evaluated the performance characteristics of SARS-CoV-2 antigen detection (Standard Q COVID-19 Ag test). The results were interpreted as positive when both control (C) and SARS-CoV-2 antigen (T) lines appeared within 30Â min, as shown in Fig.Â 1. Comparing SARS-CoV-2 antigen detection to RNA detection by RT-PCR assay, the sensitivity and specificity of rapid SARS-CoV-2 antigen detection to identify COVID-19 were 98.33% (59/60; 95%CI, 91.06â99.96%) and 98.73% (389/394; 95%CI, 97.06â99.59%), respectively, as shown in Table 2. Of six samples discordant with RT-PCR results, one was false negative, and five were false positive. There were three weakly positive and two positive results. The false negative sampleâs Ct-values were 31.18 forÂ E, 39.2 forÂ RdRp, and 35.54 forÂ N genes, as shown in Table 3 and Additional file 2: Supplementary Table S2.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">title_1</infon><offset>15597</offset><text>Discussion</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>15608</offset><text>Molecular tests are the standard laboratory diagnosis to confirm SARS-CoV-2 infection; RT-PCR assays for SARS-CoV-2 RNA detection in clinical specimens are widely used in COVID-19 diagnostic laboratories. There were 183 clinical laboratories in Thailand, including our laboratory at Siriraj Hospital that passed the external quality control of RT-PCR tests by the Department of Medical Science (DMSC), Ministry of Public Health, and was authorized a COVID-19 diagnostic laboratory. Rapid antigen immunoassays with equivalent sensitivity and specificity to real-time RT-PCR assays will help speed up disease screening. In this study, the commercially available rapid SARS-CoV-2 antigen detection kit (Standard Q COVID-19 Ag test) was compared with the RT-PCR assay (Allplexâ¢ 2019-nCoV Assay) for detection of SARS-CoV-2 infection.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>16440</offset><text>The sensitivity and specificity of the Standard Q COVID-19 Ag test for rapid detection of SARS-CoV-2 antigen reported by the manufacturer (total nâ=â202; positive nâ=â32; negative nâ=â170) were 84.38% (95% CI, 67.21â94.72%) and 100.00% (95% CI, 97.85â100%), respectively. The sensitivity of this test was evaluated at a trial site in Malaysia using 32 RT-PCR-positive nasopharyngeal swabs from symptomatic patients. The specificity of this test was evaluated by the R&amp;D team of SD Biosensor using 170 RT-PCR-negative samples. The monoclonal antibody specific to SARS-CoV-2Â N antigen coated on the Standard Q COVID-19 Ag test was produced from WUHAN-01 strain, which is genetically closely related to the SARS-CoV-2 strains detected in Thailand. Our results showed higher sensitivity (98.33% vs. 84.38%) but less specificity (98.73% vs. 100.00%) than the manufacturerâs results. The difference in our test performance from the manufacturer could be due to various factors, including the batch of kit reagents, the sample quality and level of extracted antigen, and sample handling and processing techniques. We reduced the sample viscosity using glass beads and vortexing before adding to the extraction buffer. The filter nozzle cap provided in the kit also minimized the glutinousness of the samples. A negative test result could be due to lower levels of extracted antigen than the testâs detection limit. Our batch of clinical specimens might generally have higher viral loads (low Ct-value) than that of the manufacturerâs trial site, which enhanced the chance of antigen detection in our study.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>18063</offset><text>Of 60 RT-PCR-positive samples in our study, the sole false negative result was from the NP and throat swab of a female patient with pneumonia tested for SARS-CoV-2 antigen seven days after disease onset (RT-PCR-positive case no.39). The RT-PCR result of this sample had relatively high Ct-values: 31.18 for E gene, 39.2 for RdRp gene, and 35.54 for N gene, which may explain the negative result of the Standard Q COVID-19 Ag test. However, the Standard Q COVID-19 Ag test correctly detected SARS-CoV-2 antigen from another female patient who also had relatively high Ct-values: 33.49 for E gene, 36.94 for RdRp gene, and 37.17 for N gene (RT-PCR-positive case no.23). This patient was presented with upper respiratory tract infection (URI) and was tested four days after symptom onset [see Additional file 1]. SARS-CoV-2 viral load in upper respiratory specimens was detected at a higher level soon after the symptom onset; thus, a higher chance of positive antigen detection at the early phase can be implied. This SARS-CoV-2 antigen detection kit might be recommended for patients at the early time point after symptom onset where higher viral loads are anticipated. As aforementioned, some other factors such as clinical manifestation, duration from disease onset to laboratory test, type of specimens, and how the specimens were collected and processed (sample handling and processing techniques) potentially affect the result interpretation. Of 394 RT-PCR-negative samples from pre-operative cases, five NP and throat swabs were tested positive for SARS-CoV-2 antigen using the Standard Q COVID-19 Ag test. Although it is unclear what caused the discordant result, we observed that thick and highly viscous mucous tended to yield false positive results when tested with the antigen detection kit. For patients with negative SARS-CoV-2 detection by RT-PCR, clinical data (such as underlying diseases or infection with other pathogens) were not included in the study. Therefore, the possibility of cross-reactivity with other antigens cannot be excluded.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>20121</offset><text>Our results showed higher sensitivity of the rapid SARS-CoV-2 antigen test (98.33% by Standard Q COVID-19 Ag test) than other rapid antigen tests previously reported. Previous studies reported a sensitivity of 93.9% (95% CI, 86.5â97.4%) by Fluorescence Immunochromatographic Assay for 2019-nCoV Ag Test (Bioeasy Biotechnology Co., Shenzhen, China), 50.0% by COVID-19 Ag Respi-Strip CORISÂ®, and 11.1â45.7% by BIOCREDIT COVID-19 Ag (BioVendor Research and Diagnostic Products). The positive and negative predictive values (PPV and NPV) of the assay could not be accurately calculated without the present population prevalence of COVID-19. However, there were five false positive samples tested by the Standard Q COVID-19 Ag test. We can estimate that in a low COVID-19 prevalence area, the PPV for this test is low. Hypothetically, in the 10% COVID-19 prevalence rate, the PPV vs NPV of the Standard Q COVID-19 Ag test would be 89.59% (95% CI, 78.27â95.37%) versus 99.81% (95% CI, 98.71â99.97%). While in the 1% COVID-19 prevalence rate, the PPV vs NPV of the Standard Q COVID-19 Ag test would be 43.91% (95% CI, 24.66â65.17%) versus 99.98% (95% CI, 99.88â100.00%). Thus, the Standard Q COVID-19 Ag test might be useful in the high prevalence area.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>21381</offset><text>The advantage of the Standard Q COVID-19 Ag test as a screening for COVID-19 is its simple procedure and quick results with high NPV, but its disadvantage is low PPV in a low prevalence area. Thus, the nucleic acid test (NAT) for SARS-CoV-2 gene detection, which is more sensitive and specific than this lateral flow immunoassay, is still a standard test for COVID-19 diagnosis. Even with its limitations, the rapid SARS-CoV-2 antigen test can benefit all healthcare workers in managing infected individuals in time effectively, especially in rural and outbreak areas. Therefore, a prospective study of the rapid SARS-CoV-2 antigen test in these fields should be performed before the implementation.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">title_1</infon><offset>22081</offset><text>Conclusions</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>22093</offset><text>The rapid assay for SARS-CoV-2 antigen detection (Standardâ¢ Q COVID-19 Ag kit) showed comparable sensitivity (98.33%; 95% CI, 91.06â99.96%) and specificity (98.73%; 95% CI, 97.06â99.59%) with real-time RT-PCR assay. We believe there is a potential use of this rapid and simple SARS-CoV-2 antigen detection test as a screening assay, especially in a high prevalence area. </text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">title_1</infon><offset>22471</offset><text>Supplementary information</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">title</infon><offset>22497</offset><text>Abbreviations</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22511</offset><text>Ag</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22514</offset><text>Antigen</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22522</offset><text>ARDS</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22527</offset><text>Acute respiratory distress syndrome</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22563</offset><text>BSL</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22567</offset><text>Biosafety level</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22583</offset><text>COVID-19</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22592</offset><text>Coronavirus disease 2019</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22617</offset><text>Ct-value</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22626</offset><text>Cycle threshold value</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22648</offset><text>E</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22650</offset><text>Envelope protein</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22667</offset><text>N</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22669</offset><text>Nucleocapsid protein</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22690</offset><text>NAT</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22694</offset><text>Nucleic acid test</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22712</offset><text>NP</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22715</offset><text>Nasopharyngeal</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22730</offset><text>NPV</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22734</offset><text>Negative predictive value</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22760</offset><text>PPV</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22764</offset><text>Positive predictive value</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22790</offset><text>RdRp</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22795</offset><text>RNA-dependent RNA polymerase</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22824</offset><text>RT-PCR</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22831</offset><text>Real-time reverse transcription-polymerase chain reaction</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22889</offset><text>SARS-CoV-2</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">paragraph</infon><offset>22900</offset><text>Severe acute respiratory syndrome coronavirus 2</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">footnote</infon><offset>22948</offset><text>Publisher's Note</text></passage><passage><infon key=\"section_type\">ABBR</infon><infon key=\"type\">footnote</infon><offset>22965</offset><text>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">title_1</infon><offset>23084</offset><text>Supplementary information</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">paragraph</infon><offset>23110</offset><text>Supplementary information accompanies this paper at 10.1186/s12985-020-01452-5.</text></passage><passage><infon key=\"section_type\">AUTH_CONT</infon><infon key=\"type\">title</infon><offset>23190</offset><text>Authorsâ contributions</text></passage><passage><infon key=\"section_type\">AUTH_CONT</infon><infon key=\"type\">paragraph</infon><offset>23215</offset><text>C.C. and R.S. wrote the original draft. C.C., B.K., N.A., N.H. curated laboratory data. R. Sirijatuphat, M.C., N. Angkasekwinai, N.P.,Â T.T., O.P., S.C., Y.S. recruited and curated clinical data, C.C. and R.S. analysed the data. C.C., B.K., N.T., and N.A. performed the investigation. N.H. and W.K. administered the project. N.H., R.S., and W.K. supervised the study. N.H. acquired funding. All authors read and approved the final manuscript.</text></passage><passage><infon key=\"section_type\">ACK_FUND</infon><infon key=\"type\">title</infon><offset>23658</offset><text>Funding</text></passage><passage><infon key=\"section_type\">ACK_FUND</infon><infon key=\"type\">paragraph</infon><offset>23666</offset><text>This research was partly supported by Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand through grant number R016034012.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title</infon><offset>23804</offset><text>Availability of data and materials</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>23839</offset><text>All data generated or analysed during this study are included in this published article and its additional files.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title</infon><offset>23953</offset><text>Ethics approval and consent to participate</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>23996</offset><text>This study was approved by the Institutional Review Board of the Faculty of Medicine Siriraj Hospital, Mahidol University (SIRB Protocol 463/2563(IRB4); COA: Si 503/2020).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title</infon><offset>24168</offset><text>Consent to publication</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>24191</offset><text>Not applicable.</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">title</infon><offset>24207</offset><text>Competing interests</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">paragraph</infon><offset>24227</offset><text>All authors declared no conflict of interest. There is no involvement from the companies Seegene or SD Biosensor.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">title</infon><offset>24341</offset><text>References</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>24352</offset><text>World Health Organization. Coronavirus disease (COVID-19) Weekly epidemiological update and weekly operational update. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed 1 Sept 2020.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>24576</offset><text>Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/. Accessed 1 Sept 2020.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>24671</offset><text>Worldometer. Coronavirus Cases. https://www.worldometers.info/coronavirus/. Accessed 1 Sept 2020.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>24769</offset><text>Okada P, Buathong R, Phuygun S, Thanadachakul T, Parnmen S, Wongboon W, Waicharoen S, Wacharapluesadee S, Uttayamakul S, Vachiraphan A, Chittaganpitch M, Mekha N, Jaenjai N, Iamsirithaworn S, Lee RTC, Maurer-Stroh S. Early transmissions patterns of coronavirus disease 2019 (COVID-19) in travelers from Wuhan to Thailand, January 2020. Surveill. 2020;25(8):pii=2000097. 10.2807/1560-7917.ES.2020.25.8.2000097.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>25179</offset><text>Emergency Operation Center, Department of Disease Control, Ministry of Public Health. Corona Virus Disease (COVID-19). https://ddc.moph.go.th/viralpneumonia/eng/index.php. Accessed 1 Sept 2020.</text></passage><passage><infon key=\"fpage\">71</infon><infon key=\"lpage\">76</infon><infon key=\"name_0\">surname:Sohrabi;given-names:C</infon><infon key=\"name_1\">surname:Alsafi;given-names:Z</infon><infon key=\"name_2\">surname:OâNeill;given-names:N</infon><infon key=\"pub-id_doi\">10.1016/j.ijsu.2020.02.034</infon><infon key=\"pub-id_pmid\">32112977</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Surg</infon><infon key=\"type\">ref</infon><infon key=\"volume\">76</infon><infon key=\"year\">2020</infon><offset>25373</offset><text>World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19)</text></passage><passage><infon key=\"fpage\">e00512-20</infon><infon key=\"name_0\">surname:Tang;given-names:YW</infon><infon key=\"name_1\">surname:Schmitz;given-names:JE</infon><infon key=\"name_2\">surname:Persing;given-names:DH</infon><infon key=\"name_3\">surname:Stratton;given-names:CW</infon><infon key=\"pub-id_doi\">10.1128/JCM.00512-20</infon><infon key=\"pub-id_pmid\">32245835</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>25476</offset><text>Laboratory diagnosis of COVID-19: current issues and challenges</text></passage><passage><infon key=\"fpage\">104412</infon><infon key=\"name_0\">surname:Van Kasterena;given-names:PB</infon><infon key=\"name_1\">surname:Veer;given-names:B</infon><infon key=\"name_2\">surname:Brink;given-names:S</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104412</infon><infon key=\"pub-id_pmid\">32416600</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">128</infon><infon key=\"year\">2020</infon><offset>25540</offset><text>Comparison of commercial RT-PCR diagnostic kits for COVID-19</text></passage><passage><infon key=\"fpage\">2000045</infon><infon key=\"name_0\">surname:Corman;given-names:VM</infon><infon key=\"name_1\">surname:Landt;given-names:O</infon><infon key=\"name_2\">surname:Kaiser;given-names:M</infon><infon key=\"pub-id_doi\">10.2807/1560-7917.ES.2020.25.3.2000045</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>25601</offset><text>Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>25669</offset><text>Lambert-Niclot S, Cuffel A, Le Pape S, et al. Evaluation of rapid diagnostic assay for detection of SARS-CoV-2 antigen in nasopharyngeal swab. J Clin Microbiol 2020; JCM.00977-20. doi:10.1128/JCM.00977-20.</text></passage><passage><infon key=\"fpage\">30405</infon><infon key=\"issue\">20</infon><infon key=\"lpage\">30407</infon><infon key=\"name_0\">surname:Porte;given-names:L</infon><infon key=\"name_1\">surname:Legarraga;given-names:P</infon><infon key=\"name_2\">surname:Vollrath;given-names:V</infon><infon key=\"pub-id_doi\">10.1016/j.ijid.2020.05.098</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">S1201â9712</infon><infon key=\"year\">2020</infon><offset>25875</offset><text>Evaluation of novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples</text></passage><passage><infon key=\"fpage\">104500</infon><infon key=\"name_0\">surname:Mak;given-names:GC</infon><infon key=\"name_1\">surname:Cheng;given-names:PK</infon><infon key=\"name_2\">surname:Lau;given-names:SS</infon><infon key=\"name_3\">surname:Wong;given-names:KK</infon><infon key=\"name_4\">surname:Lau;given-names:C</infon><infon key=\"name_5\">surname:Lam;given-names:ET</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104500</infon><infon key=\"pub-id_pmid\">32585619</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">129</infon><infon key=\"year\">2020</infon><offset>25985</offset><text>Evaluation of rapid antigen test for detection of SARS-CoV-2 virus</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>26052</offset><text>Rachid ZZ, Othman SN, Najihan M, Samat A, Ali UK, KonKen W. Diagnostic performance of COVID-19 serology assays. Malays J Pathol 2020;42(1):13â21.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>26200</offset><text>Schoonjans F. MedCalc's Diagnostic test evaluation calculator. MedCalc. MedCalc Software; 2020. https://www.medcalc.org/calc/diagnostic_test.php. Accessed 1 June 2020.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>26368</offset><text>Thailand Ministry of Public Health. Diagnostic detection of Novel coronavirus 2019 by real-time RTPCR. 2020.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>26477</offset><text>Department of Medical Sciences, Ministry of Public Health, Thailand. Diagnostic detection of Novel coronavirus 2019 by real-time RT-PCR. 23 Jan 2020. https://www.who.int/docs/default-source/coronaviruse/conventional-rt-pcr-followed-by-sequencing-fordetection-of-ncov-rirl-nat-inst-health-t.pdf?sfvrsn=42271c6d_4. Accessed 26 Feb 2020.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>26812</offset><text>Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2. Microbiology Natl Sci Rev. 2020 nwaa036, https://doi.org/10.1093/nsr/nwaa036.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>26971</offset><text>Ceraolo C, Giorgi FM. Genomic variance of the 2019-nCoV coronavirus J Med Virol 2020;92:522â528. doi: 10.1002/jmv.25700.</text></passage><passage><infon key=\"fpage\">1177</infon><infon key=\"issue\">12</infon><infon key=\"lpage\">1179</infon><infon key=\"name_0\">surname:Zou;given-names:L</infon><infon key=\"name_1\">surname:Ruan;given-names:F</infon><infon key=\"name_2\">surname:Huang;given-names:M</infon><infon key=\"name_3\">surname:Liang;given-names:L</infon><infon key=\"name_4\">surname:Huang;given-names:H</infon><infon key=\"name_5\">surname:Hong;given-names:Z</infon><infon key=\"pub-id_doi\">10.1056/NEJMc2001737</infon><infon key=\"pub-id_pmid\">32074444</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>27094</offset><text>SARS-CoV-2 viral load in upper respiratory specimens of infected patients</text></passage></document></collection>\n",
      "\n",
      "Study 32659413: <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n",
      "<!DOCTYPE collection SYSTEM \"BioC.dtd\">\n",
      "<collection><source>PMC</source><date>20220823</date><key>pmc.key</key><document><id>7350782</id><infon key=\"license\">NO-CC CODE</infon><passage><infon key=\"article-id_doi\">10.1016/j.ajic.2020.07.011</infon><infon key=\"article-id_pii\">S0196-6553(20)30693-3</infon><infon key=\"article-id_pmc\">7350782</infon><infon key=\"article-id_pmid\">32659413</infon><infon key=\"fpage\">21</infon><infon key=\"issue\">1</infon><infon key=\"kwd\">SARS-CoV-2 Coronavirus Evidence Sensitivity Specificity</infon><infon key=\"license\">Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</infon><infon key=\"lpage\">29</infon><infon key=\"name_0\">surname:BÃ¶ger;given-names:Beatriz</infon><infon key=\"name_1\">surname:Fachi;given-names:Mariana M.</infon><infon key=\"name_2\">surname:Vilhena;given-names:Raquel O.</infon><infon key=\"name_3\">surname:Cobre;given-names:Alexandre F.</infon><infon key=\"name_4\">surname:Tonin;given-names:Fernanda S.</infon><infon key=\"name_5\">surname:Pontarolo;given-names:Roberto</infon><infon key=\"section_type\">TITLE</infon><infon key=\"title\">Key Words</infon><infon key=\"type\">front</infon><infon key=\"volume\">49</infon><infon key=\"year\">2020</infon><offset>0</offset><text>Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>86</offset><text>Objective</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>96</offset><text>To collate the evidence on the accuracy parameters of all available diagnostic methods for detecting SARS-CoV-2.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>209</offset><text>Methods</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>217</offset><text>A systematic review with meta-analysis was performed. Searches were conducted in Pubmed and Scopus (April 2020). Studies reporting data on sensitivity or specificity of diagnostic tests for COVID-19 using any human biological sample were included.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>465</offset><text>Results</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>473</offset><text>Sixteen studies were evaluated. Meta-analysis showed that computed tomography has high sensitivity (91.9% [89.8%-93.7%]), but low specificity (25.1% [21.0%-29.5%]). The combination of IgM and IgG antibodies demonstrated promising results for both parameters (84.5% [82.2%-86.6%]; 91.6% [86.0%-95.4%], respectively). For RT-PCR tests, rectal stools/swab, urine, and plasma were less sensitive while sputum (97.2% [90.3%-99.7%]) presented higher sensitivity for detecting the virus.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>954</offset><text>Conclusions</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>966</offset><text>RT-PCR remains the gold standard for the diagnosis of COVID-19 in sputum samples. However, the combination of different diagnostic tests is highly recommended to achieve adequate sensitivity and specificity.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>1174</offset><text>INTRODUCTION</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>1187</offset><text>After the first case reports of an acute respiratory syndrome of unknown etiology in the city of Wuhan, Hubei province (December 31, 2019), Chinese authorities identified a new coronavirus (SARS-CoV-2) that causes the clinical disease COVID-19. The virus outbreak spread quickly, significantly affecting all continents with more than 2 million people infected and thousands of deaths.   Consequently, nations are facing the overwhelming of health care systems and both psychological and economic burdens. The lack of effective treatments or prevention strategies has contributed toward the increase in the number of cases, enhancing health care expenses with hospitalizations and palliative therapies. Additionally, there are limited diagnostic tests available, which favors the growth of under-reporting of cases.   </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>2005</offset><text>Patients report fever and cough, and most develop chest discomfort, difficulty in breathing or pneumonia, being clinically diagnosed by imaging tests such as chest X-ray or computed tomography (CT). CT equipment is widespread worldwide and the scan process is relatively simples and quick, which enables rapid screening for suspected patients. The typical findings of chest CT images for individuals with COVID-19 are multifocal bilateral patchy ground-glass opacities or consolidation with interlobular septal and vascular thickening in the peripheral areas of the lungs. However, CT findings can change as the disease progresses and these manifestations may also be compatible with other viral pneumonias.   </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>2716</offset><text>In this context, the current gold standard for diagnosing COVID-19 is based on a molecular test of the reverse transcription polymerase chain reaction (RT-PCR), aimed at detecting the RNA of the virus in respiratory samples such as nasopharyngeal swabs or bronchial aspirate. The real-time RT-PCR test provides a sensitive (the ability of the test to correctly identify those patients with the disease  ) and specific (the ability of the test to correctly identify those patients without the disease) method to detect SARS-COV-2, with different diagnosis protocols including sequences of target primers available in the World Health Organization public database.   However, researchers should be aware that this test can also give false negatives if the amount of viral genoma is insufficient or if the correct time-window of viral replication is missed. Although the COVID-19 incubation period is estimated to be 5 days, false negative results are common within 7 days of infection. Additionally, RT-PCR process is time-consuming and shortages in test kit supplies are common worldwideâespecially during the beginning of the epidemic outbreak. </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>3864</offset><text>Other simpler and rapid methods, such as serological testing of IgM and IgG production in response to viral infection, can be used to enhance the detection sensitivity and accuracy of the molecular test or for screening purposes to assess antibody profiles in a large population.   Because antibodies are usually detected only 1-3 weeks after the onset of symptoms, these tests are used to assess the overall infection rate in the communityâincluding the rate of asymptomatic infectionsâor in remote areas where qPCR assays are not available.   </text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>4414</offset><text>In this scenario, given the limitations of clinical diagnosis alone (due to the similarity of the symptoms of COVID-19 infection with those of other viruses) and the availability of different molecular and serological tests with both technical advantages and disadvantages, it is important to summarize the accuracy parameters of these methods and investigate whether they are sufficiently specific or sensitive to fit their role in practice. Few studies addressing the diagnostic performance of tests for COVID-19 exist, with special focus only on commercially assays available in a given country. In addition, according to the different health care settings worldwide, different patterns on testing may exist. For instance, the number of daily tests performed per thousand people in Australia or in the United States is around 1.80, while in Europe is near 1.06 and in South America is lower 0.30 (https://ourworldindata.org/).</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>5344</offset><text>Thus, we aimed to perform a systematic review with meta-analysis to gather evidence on the features of all available diagnostic test for SARS-CoV-2, including parameters of sensitivity, specificity, positive and negative likelihood ratios and summary receiver operating characteristic (SROC) curves, whenever possible.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_1</infon><offset>5663</offset><text>METHODS</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>5671</offset><text>This study was conducted according to Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies (PRISMA-DTA) statement and Cochrane Collaboration recommendations.   </text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>5883</offset><text>Search strategy</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>5899</offset><text>Systematic searches were conducted in Pubmed and Scopus without limits of time-frame or language (last updated April 2020). The search strategy included the following descriptors: âdiagnostic,â âtest,â âassay,â âcovid-19,â âsars-cov-2âand other terms combined with Boolean operators AND and OR. The complete strategy is available in the supplementary material. Manual searches in the references lists of included studies and in the gray literature (eg, Google Scholar) were also performed.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>6409</offset><text>Eligibility criteria</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>6430</offset><text>Titles and abstracts of retrieved articles were screened for eligibility. Relevant articles were read in full and those fulfilling inclusion criteria had their data extracted. Two authors performed all the literature selection steps individually and then discussed the differences with a third author.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>6732</offset><text>Studies were included in this systematic review if they met all the following eligibility criteria: (i) evaluation of any diagnostic method; (ii) aimed at diagnosis of SARS-CoV-2 (COVID-19); (iii) using any human biological sample; and (iv) reporting data on the accuracy of the test (eg, sensitivity and/or specificity). We excluded studies published in non-Roman characters.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>7109</offset><text>Data extraction and bias assessment</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>7145</offset><text>The following data were independently extracted by 2 researchers: general study details (authors, year of publication, country of origin, study design, and sample size), methods, characteristics, and diagnostic test results (true positive, TP; true negative, TN; false positive, FP; false negative, FN, sensitivity, specificity, and accuracy).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>7489</offset><text>Two reviewers evaluated independently the risk of bias in each study using the Diagnostic Precision Study Quality Assessment Tool (QUADAS-2) recommended by the Cochrane Collaboration. The assessment was performed using the Review Manager Software version 5.3  </text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>7750</offset><text>Statistical analyses</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>7771</offset><text>The meta-analyses were performed according to the technique and type of sample from each study (ie, by subgroups). Sensitivity, specificity, positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were measured with a 95% confidence interval based on the TP, TN, FP, and FN rates that were extracted from the included studies.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>8110</offset><text>Sensitivity, defined as the probability that a test result will be positive when the disease exists (true positive rate) was calculated asâ¯=â¯VP/(VPâ¯+â¯FN). Specificity, defined as the probability that a test result will be negative when the disease is not present (true negative rate) was calculated asâ¯=â¯VN/(VNâ¯+â¯VP). The PLR is the ratio between the probability of a positive test result given the presence of the disease and the probability of a positive test result given the absence of the disease, that isâ¯=â¯true positive rate/false positive rate, or expressed as sensitivity/(1-specificity). The NLR is ratio between the probability of a negative test result given the presence of the disease and the probability of a negative test result given the absence of the disease, that isâ¯=â¯false negative rate/true negative rate, or expressed as (1-sensitivity)/specificity.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>9008</offset><text>SROC curves based on TP e FP rates were also built whenever possible to describe the relationship between test sensitivity and specificity. An area under the curve (AUC) close to 1 indicated a good diagnostic performance of the test. All analyses were performed using the Meta-DiscÂ© version 1.4.7.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>9307</offset><text>The heterogeneity of the studies was established by Ï2 analysis, with inconsistency values (I2) greater than 50% being considered as moderate heterogeneity, and I2 greater than 75% defined as high heterogeneity. Outcomes with I2 values greater than 50% were submitted to sensitivity analysis (ie, hypothetical removal of studies).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_1</infon><offset>9640</offset><text>RESULTS</text></passage><passage><infon key=\"file\">gr1_lrg.jpg</infon><infon key=\"id\">fig0001</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>9648</offset><text>Flowchart of included studies.</text></passage><passage><infon key=\"file\">gr1_lrg.jpg</infon><infon key=\"id\">fig0001</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig</infon><offset>9679</offset><text>Fig 1</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>9685</offset><text>A total of 1,089 articles were identified after duplicate removal. Of these, 1,046 were excluded during the screening phase (title and abstract reading), with 43 records being fully appraised. Sixteen studies were included finally in the systematic review. We were able to include 14 trials in the quantitative analyses (meta-analysis): the studies by Corman et al. and Pfefferle et al. did not address the clinical application of the methods (FigÂ 1 ).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>10139</offset><text>All studies included in this review (nâ¯=â¯2,297 patients) were published in 2020, designed as retrospective observational cohorts, with only one defined as a control-case study. Fourteen studies were conducted in China,   while Italy, Netherlands, England, and Germany contributed with one study each.</text></passage><passage><infon key=\"file\">tbl0001.xml</infon><infon key=\"id\">tbl0001</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>10444</offset><text>Characteristics of the included studies.</text></passage><passage><infon key=\"file\">tbl0001.xml</infon><infon key=\"id\">tbl0001</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Study&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Country&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;No. of patients/&lt;break/&gt;samples&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;No. of control group patients/&lt;break/&gt;samples&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Reference method (gene)&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Evaluated method&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Sample&lt;break/&gt;type&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Marker/gene&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot;&gt;Ai,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0018&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;18&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;1,014&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;413&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;RT-PCR (ORF1ab; N)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Chest CT&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Chest image&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot;&gt;Long,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0019&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;19&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;36&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Chest CT&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Chest image&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot;&gt;Cassaniti, 2020 &lt;xref rid=&quot;bib0021&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Italy&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;50&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;60&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;RT-PCR (RdRp and E)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;LFIA&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Whole blood&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;IgM/IgG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; rowspan=&quot;9&quot; valign=&quot;top&quot;&gt;Chan,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0020&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;9&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;9&quot; valign=&quot;top&quot;&gt;15/273&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;9&quot; valign=&quot;top&quot;&gt;39&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;9&quot; valign=&quot;top&quot;&gt;RT-PCR (RdRp-P2)&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;9&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Naso-pharyngeal aspirate&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;Hel&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Naso-pharyngeal swab&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Throat swab&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Saliva&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;S&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Sputum&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Plasma&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Urine&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;N&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Feces&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Rectal swab&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;Corman, 2020 &lt;xref rid=&quot;bib0022&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;Nether-lands&lt;break/&gt;England China&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;-&lt;xref rid=&quot;tb1fn1&quot; ref-type=&quot;table-fn&quot;&gt;*&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;-&lt;xref rid=&quot;tb1fn1&quot; ref-type=&quot;table-fn&quot;&gt;*&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;RT-PCR (RdRp)&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Sputum&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;RdRp and E&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Nose swab&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Throat swab&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Fecal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;italic&gt;In vitro&lt;/italic&gt; specific transcribed RNA standards&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SARS-CoV genomic RNA from cell culture&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot;&gt;Li,&lt;break/&gt;2020a &lt;xref rid=&quot;bib0023&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;78&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;RT-PCR (E)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Chest CT&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Chest image&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot;&gt;Li,&lt;break/&gt;2020b &lt;xref rid=&quot;bib0024&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;404&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;131&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;LFIA&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Whole blood or plasma (fingerstick or venous)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;IgM/IgG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot;&gt;Liu,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0025&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;25&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;214&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;128&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;ELISA&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Serum&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;IgM/IgG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;Pan,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0026&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;26&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;23&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;RT-PCR or virus gene sequence highly homologous to SARS-CoV-2&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Throat swabs&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Stool&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Sputum&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;Pfefferle, 2020 &lt;xref rid=&quot;bib0033&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;33&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;Germany&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;-&lt;xref rid=&quot;tb1fn1&quot; ref-type=&quot;table-fn&quot;&gt;*&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;110&lt;xref rid=&quot;tb1fn1&quot; ref-type=&quot;table-fn&quot;&gt;*&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Swab&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;E&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;italic&gt;In vitro&lt;/italic&gt; transcribed RNA of the E gene&lt;break/&gt;of SARS-CoV-2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Purified RNA of SARS-CoV (strain&lt;break/&gt;Frankfurt-1)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;To,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0027&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;23&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Saliva&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;Hel&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Blood&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Rectal swab&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Urine&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;EIA&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Serum&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;IgM/IgG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;Xie,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0028&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;28&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;19&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;4&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Throat swab&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;4&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Stool&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Blood&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Urine&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Chest CT&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Chest image&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot;&gt;Xu,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0029&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;29&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;90&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Chest CT&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Chest image&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;Yu,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0030&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;30&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;76&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;NR&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;ddPCR and RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Nasal swab&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;ORF1ab and N&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Throat swab&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Sputum&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Urine&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Blood&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;Zhang,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0031&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;31&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;14&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;2&quot; valign=&quot;top&quot;&gt;NAT&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Stool&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;2&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Oropharyngeal swab&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Chest CT&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Chest image&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot;&gt;Zhao,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0032&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;173/535&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;ELISA&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Plasma&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;IgM/IgG&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>10485</offset><text>Table 1\t \t</text></passage><passage><infon key=\"file\">tbl0001.xml</infon><infon key=\"id\">tbl0001</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Study&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Country&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;No. of patients/&lt;break/&gt;samples&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;No. of control group patients/&lt;break/&gt;samples&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Reference method (gene)&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Evaluated method&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Sample&lt;break/&gt;type&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Marker/gene&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot;&gt;Ai,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0018&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;18&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;1,014&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;413&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;RT-PCR (ORF1ab; N)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Chest CT&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Chest image&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot;&gt;Long,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0019&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;19&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;36&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Chest CT&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Chest image&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot;&gt;Cassaniti, 2020 &lt;xref rid=&quot;bib0021&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Italy&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;50&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;60&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;RT-PCR (RdRp and E)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;LFIA&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Whole blood&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;IgM/IgG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; rowspan=&quot;9&quot; valign=&quot;top&quot;&gt;Chan,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0020&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;9&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;9&quot; valign=&quot;top&quot;&gt;15/273&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;9&quot; valign=&quot;top&quot;&gt;39&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;9&quot; valign=&quot;top&quot;&gt;RT-PCR (RdRp-P2)&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;9&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Naso-pharyngeal aspirate&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;Hel&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Naso-pharyngeal swab&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Throat swab&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Saliva&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;S&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Sputum&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Plasma&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Urine&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;N&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Feces&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Rectal swab&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;Corman, 2020 &lt;xref rid=&quot;bib0022&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;Nether-lands&lt;break/&gt;England China&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;-&lt;xref rid=&quot;tb1fn1&quot; ref-type=&quot;table-fn&quot;&gt;*&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;-&lt;xref rid=&quot;tb1fn1&quot; ref-type=&quot;table-fn&quot;&gt;*&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;RT-PCR (RdRp)&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Sputum&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;RdRp and E&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Nose swab&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Throat swab&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Fecal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;italic&gt;In vitro&lt;/italic&gt; specific transcribed RNA standards&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;SARS-CoV genomic RNA from cell culture&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot;&gt;Li,&lt;break/&gt;2020a &lt;xref rid=&quot;bib0023&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;78&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;RT-PCR (E)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Chest CT&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Chest image&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot;&gt;Li,&lt;break/&gt;2020b &lt;xref rid=&quot;bib0024&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;404&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;131&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;LFIA&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Whole blood or plasma (fingerstick or venous)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;IgM/IgG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot;&gt;Liu,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0025&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;25&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;214&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;128&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;ELISA&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Serum&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;IgM/IgG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;Pan,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0026&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;26&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;23&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;RT-PCR or virus gene sequence highly homologous to SARS-CoV-2&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Throat swabs&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;NR&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Stool&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Sputum&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;Pfefferle, 2020 &lt;xref rid=&quot;bib0033&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;33&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;Germany&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;-&lt;xref rid=&quot;tb1fn1&quot; ref-type=&quot;table-fn&quot;&gt;*&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;110&lt;xref rid=&quot;tb1fn1&quot; ref-type=&quot;table-fn&quot;&gt;*&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Swab&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;E&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;&lt;italic&gt;In vitro&lt;/italic&gt; transcribed RNA of the E gene&lt;break/&gt;of SARS-CoV-2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Purified RNA of SARS-CoV (strain&lt;break/&gt;Frankfurt-1)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;To,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0027&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;23&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Saliva&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;Hel&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Blood&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Rectal swab&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Urine&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;EIA&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Serum&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;IgM/IgG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;Xie,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0028&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;28&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;19&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;4&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Throat swab&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;4&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Stool&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Blood&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Urine&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Chest CT&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Chest image&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot;&gt;Xu,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0029&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;29&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;90&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Chest CT&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Chest image&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;Yu,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0030&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;30&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;76&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;NR&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;ddPCR and RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Nasal swab&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot; valign=&quot;top&quot;&gt;ORF1ab and N&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Throat swab&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Sputum&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Urine&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Blood&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;Zhang,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0031&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;31&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;14&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;2&quot; valign=&quot;top&quot;&gt;NAT&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Stool&lt;/td&gt;&lt;td align=&quot;left&quot; rowspan=&quot;2&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Oropharyngeal swab&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Chest CT&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Chest image&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;center&quot; valign=&quot;top&quot;&gt;Zhao,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0032&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;China&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;173/535&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;ELISA&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Plasma&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;IgM/IgG&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>10496</offset><text>Study\tCountry\tNo. of patients/samples\tNo. of control group patients/samples\tReference method (gene)\tEvaluated method\tSampletype\tMarker/gene\t \tAi,2020 \tChina\t1,014\t413\tRT-PCR (ORF1ab; N)\tChest CT\tChest image\t-\t \tLong,2020 \tChina\t36\t-\tRT-PCR\tChest CT\tChest image\t-\t \tCassaniti, 2020 \tItaly\t50\t60\tRT-PCR (RdRp and E)\tLFIA\tWhole blood\tIgM/IgG\t \tChan,2020 \tChina\t15/273\t39\tRT-PCR (RdRp-P2)\tRT-PCR\tNaso-pharyngeal aspirate\tHel\t \tNaso-pharyngeal swab\t \tThroat swab\t \tSaliva\tS\t \tSputum\t \tPlasma\t \tUrine\tN\t \tFeces\t \tRectal swab\t \tCorman, 2020 \tNether-landsEngland China\t-*\t-*\tRT-PCR (RdRp)\tRT-PCR\tSputum\tRdRp and E\t \tNose swab\t \tThroat swab\t \tFecal\t \tIn vitro specific transcribed RNA standards\t \tSARS-CoV genomic RNA from cell culture\t \tLi,2020a \tChina\t78\t-\tRT-PCR (E)\tChest CT\tChest image\t-\t \tLi,2020b \tChina\t404\t131\tRT-PCR\tLFIA\tWhole blood or plasma (fingerstick or venous)\tIgM/IgG\t \tLiu,2020 \tChina\t214\t128\tRT-PCR\tELISA\tSerum\tIgM/IgG\t \tPan,2020 \tChina\t23\t-\tRT-PCR or virus gene sequence highly homologous to SARS-CoV-2\tRT-PCR\tThroat swabs\tNR\t \tStool\t \tSputum\t \tPfefferle, 2020 \tGermany\t-*\t110*\t-\tRT-PCR\tSwab\tE\t \tIn vitro transcribed RNA of the E geneof SARS-CoV-2\t \tPurified RNA of SARS-CoV (strainFrankfurt-1)\t \tTo,2020 \tChina\t23\t-\tRT-PCR\tRT-PCR\tSaliva\tHel\t \tBlood\t \tRectal swab\t \tUrine\t \t-\t \tEIA\tSerum\tIgM/IgG\t \tXie,2020 \tChina\t19\t-\tRT-PCR\tRT-PCR\tThroat swab\t-\t \tStool\t \tBlood\t \tUrine\t \tChest CT\tChest image\t-\t \tXu,2020 \tChina\t90\t-\tRT-PCR\tChest CT\tChest image\t-\t \tYu,2020 \tChina\t76\t-\tNR\tddPCR and RT-PCR\tNasal swab\tORF1ab and N\t \tThroat swab\t \tSputum\t \tUrine\t \tBlood\t \tZhang,2020 \tChina\t14\t-\tRT-PCR\tNAT\tStool\t-\t \tOropharyngeal swab\t \tChest CT\tChest image\t-\t \tZhao,2020 \tChina\t173/535\t-\tRT-PCR\tELISA\tPlasma\tIgM/IgG\t \t</text></passage><passage><infon key=\"file\">tbl0001.xml</infon><infon key=\"id\">tbl0001</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_footnote</infon><offset>12210</offset><text>E, envelope protein gene; ELISA, enzyme linked immunosorbent assay; Hel, helicase protein gene; LFIA, lateral flow immunoassay; N, nucleocapsid protein gene; NAT, nucleic acid tests; NR, not reported; ORF1ab, open reading frame 1ab gene; RdRp, RNA-dependent RNA polymerase gene for SARS-CoV, SARS-CoV-2, and bat-SARS-related CoV; RdRp-P2, RNA-dependent RNA polymerase specific gene for SARS-CoV-2; RT-PCR, realâtime reverseâtranscriptase polymeraseâchain reaction; S, spike protein gene.</text></passage><passage><infon key=\"file\">tbl0001.xml</infon><infon key=\"id\">tbl0001</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_footnote</infon><offset>12704</offset><text>Samples were used only for the validation of the method (no clinical application).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>12787</offset><text>All studies presented a test group (patients diagnosed with COVID-19), while only 6 trials used a control group (patients negative for COVID-19          ). Patients from the test group were previously diagnosed using the (gold standard) PCR technique. The diagnostic methods were tested for the following samples: nasopharyngeal swab,     nasopharyngeal aspirate, throat swab,       blood,             saliva,   sputum,   urine,       and stool and rectal swabs.       Table 1 summarizes the main characteristics of the included studies.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>13325</offset><text>Analytical parameters</text></passage><passage><infon key=\"file\">tbl0002.xml</infon><infon key=\"id\">tbl0002</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>13347</offset><text>Analytical parameters reported by the included studies</text></passage><passage><infon key=\"file\">tbl0002.xml</infon><infon key=\"id\">tbl0002</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align=&quot;left&quot; valign=&quot;top&quot;&gt;Study&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Method&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Probe RNA&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Gene target&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;LoD&lt;break/&gt;RNA copies/reaction (CI)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;4&quot; valign=&quot;top&quot;&gt;Chan,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0020&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;RdRp/Helicase&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;11.2 (7.2-52.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Spike gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;N gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;21.3 (11.6-177.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV-2&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;RdRp gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;Corman, 2020 &lt;xref rid=&quot;bib0022&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR&lt;break/&gt;(new method)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;E gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;5.2 (3.7-9.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR&lt;break/&gt;(new method)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;RdRp gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3.8 (2.7-7.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR TaqMan Fast&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;E gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3.2 (2.2-6.8)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR TaqMan Fast&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;RdRp gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3.7 (2.8-8.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR&lt;break/&gt;(new method)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV-2&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;E gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3.9 (2.8-9.8)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR&lt;break/&gt;(new method)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV-2&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;RdRp gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3.6 (2.7-11.2)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Pfefferle,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0033&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;33&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV-2&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;E gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;275.72 (NR)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>13402</offset><text>Table 2\t \t</text></passage><passage><infon key=\"file\">tbl0002.xml</infon><infon key=\"id\">tbl0002</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align=&quot;left&quot; valign=&quot;top&quot;&gt;Study&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Method&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Probe RNA&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Gene target&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;LoD&lt;break/&gt;RNA copies/reaction (CI)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;4&quot; valign=&quot;top&quot;&gt;Chan,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0020&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;RdRp/Helicase&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;11.2 (7.2-52.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Spike gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;N gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;21.3 (11.6-177.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV-2&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;RdRp gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;NA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;6&quot; valign=&quot;top&quot;&gt;Corman, 2020 &lt;xref rid=&quot;bib0022&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;22&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR&lt;break/&gt;(new method)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;E gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;5.2 (3.7-9.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR&lt;break/&gt;(new method)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;RdRp gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3.8 (2.7-7.6)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR TaqMan Fast&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;E gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3.2 (2.2-6.8)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR TaqMan Fast&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;RdRp gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3.7 (2.8-8.0)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR&lt;break/&gt;(new method)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV-2&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;E gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3.9 (2.8-9.8)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR&lt;break/&gt;(new method)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV-2&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;RdRp gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3.6 (2.7-11.2)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot;&gt;Pfefferle,&lt;break/&gt;2020 &lt;xref rid=&quot;bib0033&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;33&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;RT-PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;specific for SARS-CoV-2&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;E gene&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;275.72 (NR)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>13413</offset><text>Study\tMethod\tProbe RNA\tGene target\tLoDRNA copies/reaction (CI)\t \tChan,2020 \tRT-PCR\tspecific for SARS-CoV\tRdRp/Helicase\t11.2 (7.2-52.6)\t \tRT-PCR\tspecific for SARS-CoV\tSpike gene\tNA\t \tRT-PCR\tspecific for SARS-CoV\tN gene\t21.3 (11.6-177.0)\t \tRT-PCR\tspecific for SARS-CoV-2\tRdRp gene\tNA\t \tCorman, 2020 \tRT-PCR(new method)\tspecific for SARS-CoV\tE gene\t5.2 (3.7-9.6)\t \tRT-PCR(new method)\tspecific for SARS-CoV\tRdRp gene\t3.8 (2.7-7.6)\t \tRT-PCR TaqMan Fast\tspecific for SARS-CoV\tE gene\t3.2 (2.2-6.8)\t \tRT-PCR TaqMan Fast\tspecific for SARS-CoV\tRdRp gene\t3.7 (2.8-8.0)\t \tRT-PCR(new method)\tspecific for SARS-CoV-2\tE gene\t3.9 (2.8-9.8)\t \tRT-PCR(new method)\tspecific for SARS-CoV-2\tRdRp gene\t3.6 (2.7-11.2)\t \tPfefferle,2020 \tRT-PCR\tspecific for SARS-CoV-2\tE gene\t275.72 (NR)\t \t</text></passage><passage><infon key=\"file\">tbl0002.xml</infon><infon key=\"id\">tbl0002</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_footnote</infon><offset>14178</offset><text>CI, confidence interval 95%; LoD, limit of detection; NA, not applied; NR, unreported.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>14265</offset><text>Three studies evaluated the optimization of PCR parameters for the detection of SARS-CoV-2.     Chan et al. developed and compared the performance of 3 new essays of RT-PCR of RNA-dependent RNA polymerase (RdRp)/helicase (Hel), spike (S) and nucleocapsid (N) genes from SARS-CoV-2. Corman et al. assessed several SARS-related viral genomic sequences to design the best primer and probe set. Pferfferle et al. investigated a set of primer and probes, targeting the E gene, for use in an automated system (Cobas 6800 System; see Table 2 ).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>14803</offset><text>The genes E and RdRp were the most commonly used to detect the COVID-19 virus, both with high analytical sensitivity (technical limit of detection of 3.2 and 3.6 copies per reaction, respectively). The detection of the gene N presented lower analytical sensitivity (8.3 copies per reaction). The probe used by these studies is indicated for any SARS-CoV infection, including SARS-CoV-2. Process automation by using the open channel of the Cobas 6800 systems significantly increased the limit of detection.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>15309</offset><text>Diagnostic accuracy of tests</text></passage><passage><infon key=\"file\">tbl0003.xml</infon><infon key=\"id\">tbl0003</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>15338</offset><text>Meta-analysis of the parameters of accuracy for the different diagnostic techniques</text></passage><passage><infon key=\"file\">tbl0003.xml</infon><infon key=\"id\">tbl0003</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot;&gt;Technique&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Sample&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;No. of studies&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Sensitivity&lt;break/&gt;(95% CI)&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Specificity&lt;break/&gt;(95% CI)&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;PLR&lt;break/&gt;(95% CI)&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;NLR&lt;break/&gt;(95% CI)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Computed tomography&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;6 &lt;xref rid=&quot;bib0018&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;18&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0019&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;19&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0023&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0028&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;28&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0029&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;29&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0031&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;31&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.919&lt;break/&gt;(0.898-0.937)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯92.9%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.251&lt;break/&gt;(0.210-0.295)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯32.8%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;1.194&lt;break/&gt;(0.936-1.525)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯56.2%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.301&lt;break/&gt;(0.043-2.124)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯71.9%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Immunological test&lt;break/&gt;(IgM and IgG)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Blood, serum, plasma&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;4 &lt;xref rid=&quot;bib0021&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0024&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0025&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;25&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0032&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.845&lt;break/&gt;(0.822-0.866)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯93.2%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.916&lt;break/&gt;(0.860-0.954)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯0.0%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;7.604&lt;break/&gt;(3.903-14.817)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯12.8%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.170&lt;break/&gt;(0.041-0.697)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯97.0%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Immunological test&lt;break/&gt;(IgM and IgG)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Blood&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3 &lt;xref rid=&quot;bib0021&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0024&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0032&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.863 (0.833-0.888)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯96.3%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.907 (0.848-0.948)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯0.0%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;8.618 (5.219-14.231)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯0.0%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.146 (0.021-1.028)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯99.0%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Immunological test&lt;break/&gt;(IgM and IgG)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Serum&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;2 &lt;xref rid=&quot;bib0024&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0025&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;25&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.82 (0.78-0.85)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯35.8%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Immunological test (IgM)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Blood, serum, plasma&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;5 &lt;xref rid=&quot;bib0021&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0024&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0025&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;25&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0027&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0032&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.770&lt;break/&gt;(0.745-0.795)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯89.9%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.933&lt;break/&gt;(0.886-0.965)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯18.5%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;7.295&lt;break/&gt;(3.403-15.641)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯96.1%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.211&lt;break/&gt;(0.067-0.666)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯96.1%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Immunological test (IgM)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Blood&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3 &lt;xref rid=&quot;bib0021&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0024&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0032&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.788 (0.754-0.819)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯94.8%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.931 (0.882-0.964)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯43.3%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;8.390 (3.367-20.905)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯24.0%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.274 (0.072-1.043)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯98.0%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Immunological test (IgM)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Serum&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3 &lt;xref rid=&quot;bib0024&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0025&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;25&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0027&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.743 (0.701-0.782)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯73.1%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Immunological test (IgG)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Blood, serum, plasma&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;5 &lt;xref rid=&quot;bib0021&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0024&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0025&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;25&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0027&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0032&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.694&lt;break/&gt;(0.666-0.721)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯90.9%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.694&lt;break/&gt;(0.666-0.721)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯0%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;25.626&lt;break/&gt;(7.131-92.087)&lt;break/&gt;I&lt;xref rid=&quot;bib0002&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;â¯=â¯18.0%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.378&lt;break/&gt;(0.128-1.111)&lt;break/&gt;I&lt;xref rid=&quot;bib0002&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;â¯=â¯98.6%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Immunological test (IgG)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Blood&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3 &lt;xref rid=&quot;bib0021&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0024&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0032&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.661 (0.623-0.698)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯94.5%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.988 (0.958-0.999)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯0.0&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;26.981 (6.240-116.655)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;- 27.3%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.377 (0.128-1.113)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯98.6%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Immunological test (IgG)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Serum&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;2 &lt;xref rid=&quot;bib0025&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;25&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0027&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.739 (0.696-0.779)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯80.7%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Stool, feces, rectal swabs&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;4 &lt;xref rid=&quot;bib0020&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0027&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0030&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;30&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0031&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;31&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.241&lt;break/&gt;(0.167-0.330)&lt;break/&gt;I&lt;xref rid=&quot;bib0002&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;â¯=â¯82.6%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Urine&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;4 &lt;xref rid=&quot;bib0020&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0027&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0028&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;28&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0030&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;30&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.000&lt;break/&gt;(0.000-0.037)&lt;break/&gt;I&lt;xref rid=&quot;bib0002&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;â¯=â¯0.0%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Blood&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3 &lt;xref rid=&quot;bib0021&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0027&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0028&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;28&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.073&lt;break/&gt;(0.041-0.117)&lt;break/&gt;I&lt;xref rid=&quot;bib0002&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;â¯=â¯85.9%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Nasopharyngeal aspirate, nasopharyngeal and throat swab&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;4 &lt;xref rid=&quot;bib0020&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0026&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;26&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0030&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;30&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0032&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.733&lt;break/&gt;(0.681-0.780)&lt;break/&gt;I&lt;xref rid=&quot;bib0002&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;â¯=â¯87.5%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Sputum&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;2 &lt;xref rid=&quot;bib0020&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0030&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;30&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.972&lt;break/&gt;(0.903-0.997)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯48.3%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Saliva&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;2 &lt;xref rid=&quot;bib0020&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0027&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.623&lt;break/&gt;(0.545-0.696)&lt;break/&gt;I&lt;xref rid=&quot;bib0002&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;â¯=â¯92.2%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>15422</offset><text>Table 3\t \t</text></passage><passage><infon key=\"file\">tbl0003.xml</infon><infon key=\"id\">tbl0003</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot;&gt;Technique&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Sample&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;No. of studies&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Sensitivity&lt;break/&gt;(95% CI)&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;Specificity&lt;break/&gt;(95% CI)&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;PLR&lt;break/&gt;(95% CI)&lt;/th&gt;&lt;th align=&quot;center&quot; valign=&quot;top&quot;&gt;NLR&lt;break/&gt;(95% CI)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Computed tomography&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;6 &lt;xref rid=&quot;bib0018&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;18&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0019&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;19&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0023&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;23&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0028&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;28&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0029&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;29&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0031&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;31&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.919&lt;break/&gt;(0.898-0.937)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯92.9%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.251&lt;break/&gt;(0.210-0.295)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯32.8%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;1.194&lt;break/&gt;(0.936-1.525)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯56.2%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.301&lt;break/&gt;(0.043-2.124)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯71.9%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Immunological test&lt;break/&gt;(IgM and IgG)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Blood, serum, plasma&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;4 &lt;xref rid=&quot;bib0021&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0024&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0025&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;25&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0032&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.845&lt;break/&gt;(0.822-0.866)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯93.2%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.916&lt;break/&gt;(0.860-0.954)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯0.0%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;7.604&lt;break/&gt;(3.903-14.817)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯12.8%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.170&lt;break/&gt;(0.041-0.697)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯97.0%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Immunological test&lt;break/&gt;(IgM and IgG)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Blood&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3 &lt;xref rid=&quot;bib0021&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0024&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0032&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.863 (0.833-0.888)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯96.3%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.907 (0.848-0.948)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯0.0%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;8.618 (5.219-14.231)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯0.0%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.146 (0.021-1.028)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯99.0%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Immunological test&lt;break/&gt;(IgM and IgG)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Serum&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;2 &lt;xref rid=&quot;bib0024&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0025&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;25&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.82 (0.78-0.85)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯35.8%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Immunological test (IgM)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Blood, serum, plasma&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;5 &lt;xref rid=&quot;bib0021&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0024&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0025&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;25&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0027&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0032&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.770&lt;break/&gt;(0.745-0.795)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯89.9%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.933&lt;break/&gt;(0.886-0.965)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯18.5%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;7.295&lt;break/&gt;(3.403-15.641)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯96.1%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.211&lt;break/&gt;(0.067-0.666)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯96.1%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Immunological test (IgM)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Blood&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3 &lt;xref rid=&quot;bib0021&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0024&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0032&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.788 (0.754-0.819)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯94.8%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.931 (0.882-0.964)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯43.3%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;8.390 (3.367-20.905)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯24.0%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.274 (0.072-1.043)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯98.0%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Immunological test (IgM)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Serum&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3 &lt;xref rid=&quot;bib0024&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0025&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;25&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0027&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.743 (0.701-0.782)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯73.1%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Immunological test (IgG)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Blood, serum, plasma&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;5 &lt;xref rid=&quot;bib0021&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0024&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0025&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;25&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0027&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0032&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.694&lt;break/&gt;(0.666-0.721)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯90.9%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.694&lt;break/&gt;(0.666-0.721)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;Â â¯=â¯0%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;25.626&lt;break/&gt;(7.131-92.087)&lt;break/&gt;I&lt;xref rid=&quot;bib0002&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;â¯=â¯18.0%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.378&lt;break/&gt;(0.128-1.111)&lt;break/&gt;I&lt;xref rid=&quot;bib0002&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;â¯=â¯98.6%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Immunological test (IgG)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Blood&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3 &lt;xref rid=&quot;bib0021&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0024&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;24&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0032&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.661 (0.623-0.698)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯94.5%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.988 (0.958-0.999)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯0.0&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;26.981 (6.240-116.655)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;- 27.3%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.377 (0.128-1.113)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯98.6%&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;Immunological test (IgG)&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Serum&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;2 &lt;xref rid=&quot;bib0025&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;25&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0027&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.739 (0.696-0.779)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯80.7%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Stool, feces, rectal swabs&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;4 &lt;xref rid=&quot;bib0020&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0027&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0030&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;30&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0031&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;31&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.241&lt;break/&gt;(0.167-0.330)&lt;break/&gt;I&lt;xref rid=&quot;bib0002&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;â¯=â¯82.6%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Urine&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;4 &lt;xref rid=&quot;bib0020&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0027&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0028&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;28&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0030&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;30&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.000&lt;break/&gt;(0.000-0.037)&lt;break/&gt;I&lt;xref rid=&quot;bib0002&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;â¯=â¯0.0%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Blood&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;3 &lt;xref rid=&quot;bib0021&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;21&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0027&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0028&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;28&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.073&lt;break/&gt;(0.041-0.117)&lt;break/&gt;I&lt;xref rid=&quot;bib0002&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;â¯=â¯85.9%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Nasopharyngeal aspirate, nasopharyngeal and throat swab&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;4 &lt;xref rid=&quot;bib0020&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0026&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;26&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0030&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;30&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0032&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;32&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.733&lt;break/&gt;(0.681-0.780)&lt;break/&gt;I&lt;xref rid=&quot;bib0002&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;â¯=â¯87.5%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Sputum&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;2 &lt;xref rid=&quot;bib0020&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0030&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;30&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.972&lt;break/&gt;(0.903-0.997)&lt;break/&gt;I&lt;sup&gt;2&lt;/sup&gt;â¯=â¯48.3%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot;&gt;PCR&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;Saliva&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;2 &lt;xref rid=&quot;bib0020&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;20&lt;/sup&gt;&lt;/xref&gt;&lt;sup/&gt;&lt;xref rid=&quot;bib0027&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;27&lt;/sup&gt;&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;0.623&lt;break/&gt;(0.545-0.696)&lt;break/&gt;I&lt;xref rid=&quot;bib0002&quot; ref-type=&quot;bibr&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;â¯=â¯92.2%&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;td valign=&quot;top&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>15433</offset><text>Technique\tSample\tNo. of studies\tSensitivity(95% CI)\tSpecificity(95% CI)\tPLR(95% CI)\tNLR(95% CI)\t \tComputed tomography\t-\t6 \t0.919(0.898-0.937)I2Â â¯=â¯92.9%\t0.251(0.210-0.295)I2Â â¯=â¯32.8%\t1.194(0.936-1.525)I2Â â¯=â¯56.2%\t0.301(0.043-2.124)I2Â â¯=â¯71.9%\t \tImmunological test(IgM and IgG)\tBlood, serum, plasma\t4 \t0.845(0.822-0.866)I2Â â¯=â¯93.2%\t0.916(0.860-0.954)I2Â â¯=â¯0.0%\t7.604(3.903-14.817)I2Â â¯=â¯12.8%\t0.170(0.041-0.697)I2Â â¯=â¯97.0%\t \tImmunological test(IgM and IgG)\tBlood\t3 \t0.863 (0.833-0.888)I2â¯=â¯96.3%\t0.907 (0.848-0.948)I2â¯=â¯0.0%\t8.618 (5.219-14.231)I2â¯=â¯0.0%\t0.146 (0.021-1.028)I2â¯=â¯99.0%\t \tImmunological test(IgM and IgG)\tSerum\t2 \t0.82 (0.78-0.85)I2â¯=â¯35.8%\t-\t-\t-\t \tImmunological test (IgM)\tBlood, serum, plasma\t5 \t0.770(0.745-0.795)I2Â â¯=â¯89.9%\t0.933(0.886-0.965)I2Â â¯=â¯18.5%\t7.295(3.403-15.641)I2Â â¯=â¯96.1%\t0.211(0.067-0.666)I2Â â¯=â¯96.1%\t \tImmunological test (IgM)\tBlood\t3 \t0.788 (0.754-0.819)I2â¯=â¯94.8%\t0.931 (0.882-0.964)I2â¯=â¯43.3%\t8.390 (3.367-20.905)I2â¯=â¯24.0%\t0.274 (0.072-1.043)I2â¯=â¯98.0%\t \tImmunological test (IgM)\tSerum\t3 \t0.743 (0.701-0.782)I2â¯=â¯73.1%\t-\t-\t-\t \tImmunological test (IgG)\tBlood, serum, plasma\t5 \t0.694(0.666-0.721)I2Â â¯=â¯90.9%\t0.694(0.666-0.721)I2Â â¯=â¯0%\t25.626(7.131-92.087)Iâ¯=â¯18.0%\t0.378(0.128-1.111)Iâ¯=â¯98.6%\t \tImmunological test (IgG)\tBlood\t3 \t0.661 (0.623-0.698)I2â¯=â¯94.5%\t0.988 (0.958-0.999)I2â¯=â¯0.0\t26.981 (6.240-116.655)I2- 27.3%\t0.377 (0.128-1.113)I2â¯=â¯98.6%\t \tImmunological test (IgG)\tSerum\t2 \t0.739 (0.696-0.779)I2â¯=â¯80.7%\t-\t-\t-\t \tPCR\tStool, feces, rectal swabs\t4 \t0.241(0.167-0.330)Iâ¯=â¯82.6%\t-\t-\t-\t \tPCR\tUrine\t4 \t0.000(0.000-0.037)Iâ¯=â¯0.0%\t-\t-\t-\t \tPCR\tBlood\t3 \t0.073(0.041-0.117)Iâ¯=â¯85.9%\t-\t-\t-\t \tPCR\tNasopharyngeal aspirate, nasopharyngeal and throat swab\t4 \t0.733(0.681-0.780)Iâ¯=â¯87.5%\t-\t-\t-\t \tPCR\tSputum\t2 \t0.972(0.903-0.997)I2â¯=â¯48.3%\t-\t-\t-\t \tPCR\tSaliva\t2 \t0.623(0.545-0.696)Iâ¯=â¯92.2%\t-\t-\t-\t \t</text></passage><passage><infon key=\"file\">tbl0003.xml</infon><infon key=\"id\">tbl0003</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_footnote</infon><offset>17415</offset><text>CI, confidence interval; I2, inconsistency; NLR, negative likelihood ratio; PCR, Polymerase chain reaction; PLR, positive likelihood ratio.</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>17555</offset><text>Meta-analyses evaluating the parameters of accuracy (sensitivity, specificity, PLR and NLR) of the reported tests were performed (SupplementaryÂ Table S1), results are shown in Table 3 .</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>17742</offset><text>Data on CT of the chest was reported by 6 trials.           Meta-analysis showed this method to be sensitive (91.9%, 95%Â CI 89.8%-93.7%; heterogeneity between trials of I2Â =Â 92.9%), however with low specificity (25.1%, 95%Â CI 21.0%-29.5%, I2Â =Â 32.8%; see Figure S1 of the supplementary material for complete results).</text></passage><passage><infon key=\"file\">gr2_lrg.jpg</infon><infon key=\"id\">fig0002</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>18066</offset><text>SROC curves obtained for immunological tests.</text></passage><passage><infon key=\"file\">gr2_lrg.jpg</infon><infon key=\"id\">fig0002</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig</infon><offset>18112</offset><text>Fig 2</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>18118</offset><text>Immunological tests (IgM and IgG) were evaluated in 5 trials as a diagnostic method for COVID-19.         The antibody dosage was tested in whole blood samples,   fingerstick blood, serum,     and plasma. Overall, sensitivity and specificity were higher when the combination of IgM and IgG antibodies was evaluated (see SupplementaryÂ Figs S2, S3, and S4), reaching 84.5% (95% CI 82.2%-86.6%, I2Â =Â 93.2%) and 91.6% (95% CI 86.0%-95.4%, I2Â =Â 0%) respectively. The SROC curves for the immunological diagnostic tests are shown in Figure 2 .</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>18660</offset><text>Seven studies addressed the diagnostic test by PCR.     Meta-analyses were conducted according to the type of sample. Rectal stool/swab (24.1%, 95%Â CI 16.7%-33.0%), urine (0.0%, 95%Â CI 0.0%-3.7%), plasma (7.3%, 95%Â CI 4.1%-11.7%) were less sensitive for detection of COVID-19. Sputum (97.2%, 95%Â CI 90.3%-99.7%), saliva (62.3%, 95% CI 54.5%-69.6%), nasopharyngeal aspirate/swab and throat swab (73.3%, 95%Â CI 68.1%-78.0%) were more sensitive for detecting the virus (FigÂ S5 in supplementary material). Due to the limited number of PCR studies with a control group, it was not possible to perform statistical analyses on the parameters of specificity, PLR and NLR. Only the studies by Xie et al. and Yu et al. tested the PCR method in a control group. In both trials, specificity was 100% for stool, urine, blood, nasal swab and throat swab samples, while throat swab and sputum samples had specificities of 98.6% and 90.0%, respectively (Table S2 in supplementary material). Sensitivity analyses were performed for all meta-analyses with high heterogeneity results (I2Â &gt;Â 50%); however, no additional differences were found compared to the effects of the original analyses (data not shown).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">title_2</infon><offset>19858</offset><text>Quality assessment</text></passage><passage><infon key=\"file\">gr3_lrg.jpg</infon><infon key=\"id\">fig0003</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>19877</offset><text>Methodological quality of the included studies (individual assessment).</text></passage><passage><infon key=\"file\">gr3_lrg.jpg</infon><infon key=\"id\">fig0003</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig</infon><offset>19949</offset><text>Fig 3</text></passage><passage><infon key=\"file\">gr4_lrg.jpg</infon><infon key=\"id\">fig0004</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>19955</offset><text>Summary of the methodological quality of the included studies.</text></passage><passage><infon key=\"file\">gr4_lrg.jpg</infon><infon key=\"id\">fig0004</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig</infon><offset>20018</offset><text>Fig 4</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>20024</offset><text>Studies were rated as being of moderate overall methodological quality according to QUADAS-2 (see Fig. 3, Fig. 4 ). The studies by Chan et al. and Pfefferle et al. (29) were not evaluated given the lack of clinical application of the tests (ie, only the analytical performance of the methods was assessed).</text></passage><passage><infon key=\"section_type\">RESULTS</infon><infon key=\"type\">paragraph</infon><offset>20331</offset><text>Around one-quarter of the trials (26%) did not describe the methods of patient selection, and almost half (46%) included previously diagnosed patients, which may enhance the risk of bias. However, the majority of the patients included matched the review question and were likely to be diagnosed with the evaluated tests (ie, no major concerns for the applicability domain). Overall, 80% of the studies properly reported both index and reference standard tests and how they were conducted and interpreted. Only 3 studies (20%) properly reported the interval between tests, whether patients received different index or standard assays, and the complete statistical analyses performed, thus being judged as having low risk of bias for the flow and timing domain. The remaining studies were classified as with an unclear risk of bias for this domain.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">title_1</infon><offset>21178</offset><text>DISCUSSION</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>21189</offset><text>To our knowledge, this is the first systematic review with meta-analysis to collate the available evidence on the accuracy parameters of different diagnostic methods (clinical, molecular, and serological) for the detection of SARS-CoV-2 in different samples, including blood, nasopharyngeal swab, sputum, saliva, urine and feces. We were also able to evaluate qualitatively the main analytical parameters reported in the molecular techniques.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>21632</offset><text>The development of new molecular techniques depends on the knowledge of the proteomic and genomic composition of the virus or of changes in the hostsâ protein expressions during and after infection. Genome sequencing is important for researchers to design primers and probes for PCR and other molecular tests. The SARS-CoV-2 virus has a single-stranded, positive RNA genome of approximately 30,000 nucleotides in length that encodes 27 proteins, including an RdRP and 4 structural proteins: surface glycoprotein (S), envelope protein (E), matrix protein (M) and nucleocapsid protein (N  . In the past months, different RT-PCR kits for the detection of SARS-CoV-2 have been developed, being able to amplify a small amount of viral genetic material in a sample. In this technique, the RNA of the virus is reverse-transcribed into complementary DNA strands (cDNA), whose specific regions are amplified. The process usually involves 2 main steps: sequence alignment and primer design, and assay optimization and testing, especially because this method requires several temperature changes for each cycle using thermocycling equipment. </text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>22766</offset><text>We found that in trials evaluating the RdRp/Hel gene, there were no cross-reactions with other pathogenic coronaviruses and human respiratory pathogens in cell culture or clinical samples. On the other hand, the specific SARS-CoV-2 (RdRp) gene reacted with SARS-CoV in cell culture. It is important to avoid the use of genes that could potentially cause false-negative results. Assays designed as 2-target systems, with a primer universally detecting several coronaviruses (including SARS-CoV-2), and a second set of primers specifically detecting SARS-CoV-2, are the most suitable to obtain lower LoDs. However, the use of different reagents, primer/probe concentrations, and cycling conditions may limit the sensitivity of the test.   In this context, Pfefferle et al. proposed an automated solution for molecular diagnosis, including the management of a large volume of samples. The system used in this study (Cobas 6800 System) fully automates the extraction, purification, amplification, and detection of nucleic acids. Nonetheless, the analytical performance of the method was lower compared to conventional techniques.   This may arise partly from differences in the determination of LoD among studies. While in conventional methods the target RNA is added manually to the reagent mix for amplification, in automated systems the control (purified RNA) is inserted into the samples and passes through the entire workflow of the device, including extraction and purification. </text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>24248</offset><text>Our meta-analyses demonstrated that among all methods, the PCR technique using sputum samples was the most sensitive method for diagnosing COVID-19. In contrast, this same technique applied to other samples (eg, urine, blood, stool, feces, and rectal swabs) showed the worst sensitivity results. Considering that the nucleic acid test is the main diagnostic test for this infection,   the choice of the type of sample is an important step for successful diagnosis. Comparison of the meta-analysis results from different clinical specimens clearly demonstrated that respiratory samples are the most suitable for achieving higher sensitivity rates. These results corroborate with the CDC recommendations, which state that initial tests for the diagnosis of SARS-CoV-2 should prioritize the collection of respiratory samples.   One aspect that should not be disregarded is the fact that the presence of the virus in the different biological samples is related to the period of collection, that is, to the clinical course of the disease. Yet, even at low concentrations these other specimens, as well as respiratory fluids, may be involved in the transmission of the disease. A recent study showed that SARS-CoV-2 may exist in children's gastrointestinal tract for a longer time than in the respiratory system. </text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>25556</offset><text>Our study also demonstrated that CT was the second most sensitive test. SARS-CoV-2 is known to infect primarily the respiratory system, causing inflammation, interstitial damage, changes in the parenchyma, and cell death. Thus, the manifestations in CT of the chest have been considered as a very important strategy for supplementary diagnosis in view of the limitations of other techniques, such as the case of false-negative results with RT-PCR. However, this method has low specificity and a low PLR compared to immunological tests, which may hamper its isolated use in clinical practice. This can be explained by the chest imaging findings being due to other viral infections.</text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>26237</offset><text>Regarding immunological tests, higher sensitivity, specificity and better NLR were obtained when the total antibodies were evaluated. On the other hand, the best PLR result was presented by the IgG immunological test. The global assessment of the value of this diagnostic test also demonstrated it to have the highest AUC value in the SROC curve (0.9992, Q*â¯=â¯0.9935). Nonetheless, both IgM alone and combined with IgG showed high AUC values (0.9601, Q*â¯=â¯0.9046; 0.9581, Q*â¯=â¯0.9018, respectively), similarly to what was reported by Castro et al., indicating a high level of accuracy for immunological tests in the diagnosis of COVID-19. The antibodies researched in these tests refer to structural antigenic proteins of SARS-CoV-2, such as spike (S) and nucleocapsid (N) proteins, which have been identified as the most relevant in the development of serological assays for the diagnosis of the infection. Usually, the body's immune response to a pathogen takes 1-2 weeks to occur. In this context, the use of serological tests for detection in the initial/acute phase of the disease can be challenging. A recent study showed that IgM and IgG seroconversion can occur simultaneously or sequentially in COVID-19, and that antibody titers reach a plateau after 6 days. In addition, a meta-analysis of the accuracy of diagnostic tests marketed in Brazil, taken from manufacturers' data, showed a range of 10%-40% false-negative results for detection of SARS-CoV-2 IgM in the acute phase in 8 evaluated tests. However, immunological tests have a quick turnaround time and relatively low costs (around Â£6 per test or USD$ 8-10), which may represent an important strength for this method, given the shortages of RTâPCR and its higher price (around Â£30/test, but may range from USD$ 25 to 100). Additionally, the participation of multiple manufacturers in the market can potentially scale the immunological tests to millions of people per day due to their simpler design. This may especially help to improve the detection of the virus in health care settings where resources are more limited, such as in developing countries.   </text></passage><passage><infon key=\"section_type\">DISCUSS</infon><infon key=\"type\">paragraph</infon><offset>28377</offset><text>Our study has some limitations. The included studies differ in terms of size, risk of bias, and external validity. We are aware of potential introduction of bias caused by studies of poor methodological quality. We found high heterogeneity rates among trials, probably cause by some differences in the methods, patient characteristics, and samples used. However, we tried to avoid systematic errors by performing sensitivity analyses, which do not demonstrate significant differences from the original analyses. The eligibility criteria and description of the participants is crucial, as the test is only valid under similar circumstances. Sensitivities, specificities, TP, and TN were compared, but these statistics depend on the populations studied, the reference tests used, and the specific function of the test. Studies were judged as being of moderate methodological quality, with few concerns regarding the applicability of the methods used. The low reporting quality of some studies hampered the performance of further analyses.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">title_1</infon><offset>29414</offset><text>CONCLUSIONS</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>29426</offset><text>RT-PCR remains the gold standard for the diagnosis of COVID-19 in sputum samples. However, depending on the type of sample and stage of the disease, other methods are preferable. A combination of clinical, molecular, and serological diagnostic tests is highly recommended to achieve adequate sensitivity and specificity. Automated assays for molecular diagnosis using a 2-target system for detecting SARS-CoV-2 should be used whenever possible to enhance analytical performance.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">title</infon><offset>29905</offset><text>References</text></passage><passage><infon key=\"comment\">Available at:</infon><infon key=\"element-citation\">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>29916</offset></passage><passage><infon key=\"fpage\">313</infon><infon key=\"lpage\">324</infon><infon key=\"name_0\">surname:Ahn;given-names:DG</infon><infon key=\"name_1\">surname:Shin;given-names:HJ</infon><infon key=\"name_2\">surname:Kim;given-names:MH</infon><infon key=\"pub-id_pmid\">32238757</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Microbiol Biotechnol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2020</infon><offset>29917</offset><text>Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19)</text></passage><passage><infon key=\"fpage\">29</infon><infon key=\"name_0\">surname:Adhikari;given-names:SP</infon><infon key=\"name_1\">surname:Meng;given-names:S</infon><infon key=\"name_2\">surname:Wu;given-names:YJ</infon><infon key=\"pub-id_pmid\">32183901</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Infect Dis Poverty</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>30033</offset><text>Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review</text></passage><passage><infon key=\"fpage\">727</infon><infon key=\"lpage\">733</infon><infon key=\"name_0\">surname:Zhu;given-names:N</infon><infon key=\"name_1\">surname:Zhang;given-names:D</infon><infon key=\"name_2\">surname:Wang;given-names:W</infon><infon key=\"pub-id_pmid\">31978945</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>30201</offset><text>A novel coronavirus from patients with pneumonia in China, 2019</text></passage><passage><infon key=\"fpage\">4381</infon><infon key=\"lpage\">4389</infon><infon key=\"name_0\">surname:Ye;given-names:Z</infon><infon key=\"name_1\">surname:Zhang;given-names:Y</infon><infon key=\"name_2\">surname:Wang;given-names:Y</infon><infon key=\"name_3\">surname:Huang;given-names:Z</infon><infon key=\"name_4\">surname:Song;given-names:B</infon><infon key=\"pub-id_pmid\">32193638</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2020</infon><offset>30265</offset><text>Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review</text></passage><passage><infon key=\"comment\">Available at:</infon><infon key=\"element-citation\">https://www.who.int/emergencies/diseases/novelcoronavirus-2019/technical-guidance/laboratory-guidance</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>30352</offset></passage><passage><infon key=\"name_0\">surname:Theagarajan;given-names:LN</infon><infon key=\"section_type\">REF</infon><infon key=\"series\">Group Testing for COVID-19: How to Stop Worrying and Test More</infon><infon key=\"type\">ref</infon><infon key=\"volume\">1</infon><infon key=\"year\">2020</infon><offset>30353</offset></passage><passage><infon key=\"fpage\">221</infon><infon key=\"lpage\">223</infon><infon key=\"name_0\">surname:Lalkhen;given-names:AG</infon><infon key=\"name_1\">surname:McCluskey;given-names:A</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Contin Educ Anaesth Crit Care Pain</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2008</infon><offset>30354</offset><text>Clinical tests: sensitivity and specificity</text></passage><passage><infon key=\"fpage\">538</infon><infon key=\"lpage\">539</infon><infon key=\"name_0\">surname:Wang;given-names:YK</infon><infon key=\"name_1\">surname:Kang;given-names:H</infon><infon key=\"name_2\">surname:Liu;given-names:X</infon><infon key=\"name_3\">surname:Tong;given-names:Z</infon><infon key=\"pub-id_pmid\">32096564</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>30398</offset><text>Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak</text></passage><passage><infon key=\"fpage\">1177</infon><infon key=\"lpage\">1179</infon><infon key=\"name_0\">surname:Zou;given-names:L</infon><infon key=\"name_1\">surname:Ruan;given-names:F</infon><infon key=\"name_2\">surname:Huang;given-names:M</infon><infon key=\"pub-id_pmid\">32074444</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>30523</offset><text>SARS-CoV-2 viral load in upper respiratory specimens of infected patients</text></passage><passage><infon key=\"fpage\">577</infon><infon key=\"lpage\">582</infon><infon key=\"name_0\">surname:Lauer;given-names:SA</infon><infon key=\"name_1\">surname:Grantz;given-names:KH</infon><infon key=\"name_2\">surname:Bi;given-names:Q</infon><infon key=\"pub-id_pmid\">32150748</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Ann Intern Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">172</infon><infon key=\"year\">2020</infon><offset>30597</offset><text>The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application</text></passage><passage><infon key=\"fpage\">778</infon><infon key=\"lpage\">785</infon><infon key=\"name_0\">surname:Guo;given-names:L</infon><infon key=\"name_1\">surname:Ren;given-names:L</infon><infon key=\"name_2\">surname:Yang;given-names:S</infon><infon key=\"pub-id_pmid\">32198501</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>30725</offset><text>Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)</text></passage><passage><infon key=\"fpage\">175</infon><infon key=\"lpage\">183</infon><infon key=\"name_0\">surname:Meyer;given-names:B</infon><infon key=\"name_1\">surname:Drosten;given-names:C</infon><infon key=\"name_2\">surname:Muller;given-names:MA</infon><infon key=\"pub-id_pmid\">24670324</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Virus Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">194</infon><infon key=\"year\">2014</infon><offset>30807</offset><text>Serological assays for emerging coronaviruses: challenges and pitfalls</text></passage><passage><infon key=\"comment\">e00512-20</infon><infon key=\"name_0\">surname:Tang;given-names:YW</infon><infon key=\"name_1\">surname:Schmitz;given-names:JE</infon><infon key=\"name_2\">surname:Persing;given-names:DH</infon><infon key=\"name_3\">surname:Stratton;given-names:CW</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>30878</offset><text>The laboratory diagnosis of COVID-19 infection: current issues and challenges</text></passage><passage><infon key=\"fpage\">388</infon><infon key=\"lpage\">396</infon><infon key=\"name_0\">surname:McInnes;given-names:MDF</infon><infon key=\"name_1\">surname:Moher;given-names:D</infon><infon key=\"name_2\">surname:Thombs;given-names:BD</infon><infon key=\"pub-id_pmid\">29362800</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Jama</infon><infon key=\"type\">ref</infon><infon key=\"volume\">319</infon><infon key=\"year\">2018</infon><offset>30956</offset><text>Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>31086</offset><text>Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Vol Version 5.1.02011.</text></passage><passage><infon key=\"fpage\">529</infon><infon key=\"lpage\">536</infon><infon key=\"name_0\">surname:Whiting;given-names:PF</infon><infon key=\"name_1\">surname:Rutjes;given-names:ASW</infon><infon key=\"name_2\">surname:Westwood;given-names:ME</infon><infon key=\"pub-id_pmid\">22007046</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Ann Intern Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">155</infon><infon key=\"year\">2011</infon><offset>31188</offset><text>QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies</text></passage><passage><infon key=\"fpage\">E32</infon><infon key=\"lpage\">E40</infon><infon key=\"name_0\">surname:Ai;given-names:T</infon><infon key=\"name_1\">surname:Yang;given-names:Z</infon><infon key=\"name_2\">surname:Hou;given-names:H</infon><infon key=\"pub-id_pmid\">32101510</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">296</infon><infon key=\"year\">2020</infon><offset>31271</offset><text>Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases</text></passage><passage><infon key=\"name_0\">surname:Long;given-names:C</infon><infon key=\"name_1\">surname:Xu;given-names:H</infon><infon key=\"name_2\">surname:Shen;given-names:Q.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur J Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">126</infon><infon key=\"year\">2020</infon><offset>31386</offset><text>Diagnosis of the coronavirus disease (COVID-19): rRT-PCR or CT?</text></passage><passage><infon key=\"comment\">e00310-20</infon><infon key=\"name_0\">surname:Chan;given-names:JFW</infon><infon key=\"name_1\">surname:Yip.;given-names:CCY</infon><infon key=\"name_2\">surname:To;given-names:KKW</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>31450</offset><text>Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens</text></passage><passage><infon key=\"name_0\">surname:Cassaniti;given-names:I</infon><infon key=\"name_1\">surname:Novazzi;given-names:F</infon><infon key=\"name_2\">surname:Giardina;given-names:F</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>31664</offset><text>Performance of VivaDiagTM COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department</text></passage><passage><infon key=\"comment\">2000045</infon><infon key=\"name_0\">surname:Corman;given-names:VM</infon><infon key=\"name_1\">surname:Landt;given-names:O</infon><infon key=\"name_2\">surname:Kaiser;given-names:M.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surv</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>31815</offset><text>Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR</text></passage><passage><infon key=\"fpage\">4407</infon><infon key=\"lpage\">4416</infon><infon key=\"name_0\">surname:Li;given-names:K</infon><infon key=\"name_1\">surname:Fang;given-names:Y</infon><infon key=\"name_2\">surname:Li;given-names:W.</infon><infon key=\"pub-id_pmid\">32215691</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2020</infon><offset>31883</offset><text>CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19)</text></passage><passage><infon key=\"fpage\">1518</infon><infon key=\"lpage\">1524</infon><infon key=\"name_0\">surname:Li;given-names:Z</infon><infon key=\"name_1\">surname:Yi;given-names:Y</infon><infon key=\"name_2\">surname:Luo;given-names:X</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>31985</offset><text>Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis</text></passage><passage><infon key=\"comment\">e00461-20</infon><infon key=\"name_0\">surname:Liu;given-names:W</infon><infon key=\"name_1\">surname:Liu;given-names:L</infon><infon key=\"name_2\">surname:Kou;given-names:G</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>32099</offset><text>Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2</text></passage><passage><infon key=\"fpage\">794</infon><infon key=\"lpage\">801</infon><infon key=\"name_0\">surname:Pan;given-names:Y</infon><infon key=\"name_1\">surname:Long;given-names:L</infon><infon key=\"name_2\">surname:Zhang;given-names:D</infon><infon key=\"pub-id_pmid\">32246822</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Chem</infon><infon key=\"type\">ref</infon><infon key=\"volume\">66</infon><infon key=\"year\">2020</infon><offset>32201</offset><text>Potential false-negative nucleic acid testing results for severe acute respiratory syndrome coronavirus 2 from thermal inactivation of samples with low viral loads</text></passage><passage><infon key=\"fpage\">565</infon><infon key=\"lpage\">574</infon><infon key=\"name_0\">surname:To;given-names:KKWT</infon><infon key=\"name_1\">surname:Tsang;given-names:OTY</infon><infon key=\"name_2\">surname:Leung;given-names:WS</infon><infon key=\"pub-id_pmid\">32213337</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet. Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>32365</offset><text>Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study</text></passage><passage><infon key=\"fpage\">264</infon><infon key=\"lpage\">267</infon><infon key=\"name_0\">surname:Xie;given-names:C</infon><infon key=\"name_1\">surname:Jiang;given-names:L</infon><infon key=\"name_2\">surname:Huang;given-names:G</infon><infon key=\"pub-id_pmid\">32114193</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">93</infon><infon key=\"year\">2020</infon><offset>32530</offset><text>Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests</text></passage><passage><infon key=\"fpage\">1275</infon><infon key=\"lpage\">1280</infon><infon key=\"name_0\">surname:Xu;given-names:X</infon><infon key=\"name_1\">surname:Yu;given-names:C</infon><infon key=\"name_2\">surname:Qu;given-names:J</infon><infon key=\"pub-id_pmid\">32107577</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur J Nucl Med Mol Imaging</infon><infon key=\"type\">ref</infon><infon key=\"volume\">47</infon><infon key=\"year\">2020</infon><offset>32635</offset><text>Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2</text></passage><passage><infon key=\"fpage\">793</infon><infon key=\"lpage\">798</infon><infon key=\"name_0\">surname:Yu;given-names:FY</infon><infon key=\"name_1\">surname:Yan;given-names:L</infon><infon key=\"name_2\">surname:Wang;given-names:N</infon><infon key=\"pub-id_pmid\">32221523</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>32716</offset><text>Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients</text></passage><passage><infon key=\"fpage\">680</infon><infon key=\"lpage\">682</infon><infon key=\"name_0\">surname:Zhang;given-names:JC</infon><infon key=\"name_1\">surname:Wang;given-names:S</infon><infon key=\"name_2\">surname:Xue;given-names:YD</infon><infon key=\"pub-id_pmid\">32124995</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>32798</offset><text>Fecal specimen diagnosis 2019 novel coronavirusâinfected pneumonia</text></passage><passage><infon key=\"fpage\">2027</infon><infon key=\"lpage\">2034</infon><infon key=\"name_0\">surname:Zhao;given-names:JY;suffix:Jr</infon><infon key=\"name_1\">surname:Yuan;given-names:Q</infon><infon key=\"name_2\">surname:Wang;given-names:H</infon><infon key=\"pub-id_pmid\">32221519</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>32867</offset><text>Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019</text></passage><passage><infon key=\"comment\">2000152</infon><infon key=\"name_0\">surname:Pfefferle;given-names:S</infon><infon key=\"name_1\">surname:Reucher;given-names:S</infon><infon key=\"name_2\">surname:Norz;given-names:D</infon><infon key=\"name_3\">surname:Lutgehetmann;given-names:M</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surv</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>32946</offset><text>Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system</text></passage><passage><infon key=\"fpage\">3822</infon><infon key=\"lpage\">3835</infon><infon key=\"name_0\">surname:Udugama;given-names:B</infon><infon key=\"name_1\">surname:Kadhiresan;given-names:P</infon><infon key=\"name_2\">surname:Kozlowski;given-names:HN</infon><infon key=\"pub-id_pmid\">32223179</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Nano</infon><infon key=\"type\">ref</infon><infon key=\"volume\">14</infon><infon key=\"year\">2020</infon><offset>33076</offset><text>Diagnosing COVID-19: the disease and tools for detection</text></passage><passage><infon key=\"fpage\">325</infon><infon key=\"lpage\">328</infon><infon key=\"name_0\">surname:Wu;given-names:A</infon><infon key=\"name_1\">surname:Peng;given-names:Y</infon><infon key=\"name_2\">surname:Huang;given-names:B</infon><infon key=\"pub-id_pmid\">32035028</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Host Microbe</infon><infon key=\"type\">ref</infon><infon key=\"volume\">27</infon><infon key=\"year\">2020</infon><offset>33133</offset><text>Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China</text></passage><passage><infon key=\"fpage\">591</infon><infon key=\"lpage\">605</infon><infon key=\"name_0\">surname:Carter;given-names:LJ</infon><infon key=\"name_1\">surname:Garner;given-names:LV</infon><infon key=\"name_2\">surname:Smoot;given-names:JW</infon><infon key=\"pub-id_pmid\">32382657</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Cent Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2020</infon><offset>33225</offset><text>Assay Techniques and Test Development for COVID-19 Diagnosis</text></passage><passage><infon key=\"comment\">Available at:</infon><infon key=\"element-citation\">https://www.who.int/emergencies/diseases/novelcoronavirus-2019/technical-guidance/laboratory-guidance</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2019</infon><offset>33286</offset></passage><passage><infon key=\"comment\">Available at:</infon><infon key=\"element-citation\">https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2019</infon><offset>33287</offset></passage><passage><infon key=\"fpage\">473</infon><infon key=\"lpage\">480</infon><infon key=\"name_0\">surname:Xing;given-names:YH</infon><infon key=\"name_1\">surname:Ni;given-names:W</infon><infon key=\"name_2\">surname:Wu;given-names:Q</infon><infon key=\"pub-id_pmid\">32276848</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Microbiol, Immunol Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">53</infon><infon key=\"year\">2020</infon><offset>33288</offset><text>Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019</text></passage><passage><infon key=\"fpage\">5214</infon><infon key=\"lpage\">5216</infon><infon key=\"name_0\">surname:Fan;given-names:L</infon><infon key=\"name_1\">surname:Liu;given-names:S</infon><infon key=\"pub-id_pmid\">32377812</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2020</infon><offset>33374</offset><text>CT and COVID-19: Chinese experience and recommendations concerning detection, staging and follow-up</text></passage><passage><infon key=\"fpage\">180</infon><infon key=\"lpage\">187</infon><infon key=\"name_0\">surname:Castro;given-names:R</infon><infon key=\"name_1\">surname:Luz;given-names:PM</infon><infon key=\"name_2\">surname:Wakimoto;given-names:MD</infon><infon key=\"name_3\">surname:Veloso;given-names:VG</infon><infon key=\"name_4\">surname:Grinsztejn;given-names:B</infon><infon key=\"name_5\">surname:Perazzo;given-names:H</infon><infon key=\"pub-id_pmid\">32330437</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Braz J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">24</infon><infon key=\"year\">2020</infon><offset>33474</offset><text>COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil</text></passage><passage><infon key=\"fpage\">568</infon><infon key=\"lpage\">576</infon><infon key=\"name_0\">surname:Wang;given-names:Y</infon><infon key=\"name_1\">surname:Wang;given-names:Y</infon><infon key=\"name_2\">surname:Chen;given-names:Y</infon><infon key=\"name_3\">surname:Qin;given-names:Q</infon><infon key=\"pub-id_pmid\">32134116</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>33570</offset><text>Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures</text></passage><passage><infon key=\"comment\">Available at:</infon><infon key=\"element-citation\">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-antigen-test-help-rapid-detection-virus-causes</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>33710</offset></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">title_1</infon><offset>33711</offset><text>SUPPLEMENTARY MATERIALS</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">footnote</infon><offset>33735</offset><text>Conflict of interest: None to report.</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">footnote</infon><offset>33773</offset><text>Supplementary material associated with this article can be found in the online version at https://doi.org/10.1016/j.ajic.2020.07.011.</text></passage></document></collection>\n",
      "\n",
      "Study 33139420: <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n",
      "<!DOCTYPE collection SYSTEM \"BioC.dtd\">\n",
      "<collection><source>PMC</source><date>20210530</date><key>pmc.key</key><document><id>8111145</id><infon key=\"license\">NO-CC CODE</infon><passage><infon key=\"article-id_doi\">10.1128/JCM.02589-20</infon><infon key=\"article-id_pmc\">8111145</infon><infon key=\"article-id_pmid\">33139420</infon><infon key=\"article-id_publisher-id\">02589-20</infon><infon key=\"elocation-id\">e02589-20</infon><infon key=\"issue\">2</infon><infon key=\"kwd\">COVID-19 SARS-CoV-2 diagnosis antigen assay rapid diagnosis RT-PCR rapid antigenic device sensitivity</infon><infon key=\"license\">All Rights Reserved.</infon><infon key=\"name_0\">surname:Fenollar;given-names:Florence</infon><infon key=\"name_1\">surname:Bouam;given-names:Amar</infon><infon key=\"name_10\">surname:Fournier;given-names:Pierre-Edouard</infon><infon key=\"name_11\">surname:Caliendo;given-names:Angela M.</infon><infon key=\"name_12\">surname:Raoult;given-names:Didier</infon><infon key=\"name_13\">surname:Fournier;given-names:Pierre-Edouard</infon><infon key=\"name_14\">surname:Raoult;given-names:Didier</infon><infon key=\"name_15\">surname:Raoult;given-names:Didier</infon><infon key=\"name_2\">surname:Ballouche;given-names:Mehdi</infon><infon key=\"name_3\">surname:Fuster;given-names:LÃ©a</infon><infon key=\"name_4\">surname:Prudent;given-names:Elsa</infon><infon key=\"name_5\">surname:Colson;given-names:Philippe</infon><infon key=\"name_6\">surname:Tissot-Dupont;given-names:HervÃ©</infon><infon key=\"name_7\">surname:Million;given-names:Matthieu</infon><infon key=\"name_8\">surname:Drancourt;given-names:Michel</infon><infon key=\"name_9\">surname:Raoult;given-names:Didier</infon><infon key=\"section_type\">TITLE</infon><infon key=\"title\">KEYWORDS</infon><infon key=\"type\">front</infon><infon key=\"volume\">59</infon><infon key=\"year\">2021</infon><offset>0</offset><text>Evaluation of the Panbio COVID-19 Rapid Antigen Detection Test Device for the Screening of Patients with COVID-19</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>114</offset><text>LETTER</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>121</offset><text>Coronavirus disease 2019 (COVID-19), declared a pandemic by the WHO on 11 March 2020, requires an early diagnosis to optimize patient management and limit further transmission. Currently, the gold standard and most commonly used diagnostic method in clinical microbiology laboratories is real-time PCR (RT-PCR) detecting the viral RNA in nasopharyngeal specimens. However, RT-PCR requires specialized instruments and personnel. In contrast, rapid antigen (Ag) detection (RAD) tests, which are widely used to diagnose viral diseases other than COVID-19, not only are rapid (15 to 30 min) but are less laborious and require only a comparatively short training period. However, to date, several commercialized RAD tests have been evaluated and most have demonstrated a lack of sensitivity (see Table S1 in the supplemental material).</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>952</offset><text>In the present study, we evaluated the performance of the Panbio COVID-19 Ag rapid test device assay (Abbott) in comparison to that of the VitaPCR severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) assay (Credo Diagnostics, Singapore) on nasopharyngeal specimens. Both systems provide results within 20 min. The former is an immunochromatographic assay detecting the SARS-CoV-2 nucleocapsid protein and requiring no specialized instruments. This device is distributed worldwide except in the United States, where its equivalent, the BinaxNOW COVID-19 Ag card (Abbott), is FDA approved. Using 10-fold dilutions of a quantified suspension of Vero E6 cell-cultured SARS-CoV-2 (IHUMI3 strain), as previously described, from 780âÃâ106 copies/ml at a dilution of 10â1 to 1,484 copies/ml at a dilution of 10â6, we found that the RT-PCR assay was positive for all tested virus dilutions, with cycle threshold (CT) values of 16 and 34 for the most concentrated (10â1) and most dilute (10â6) solutions, respectively. In contrast, the RAD test was positive for all dilutions except 10â5 and 10â6. Two further replicates of this evaluation confirmed these results for both assays. Then, we tested prospectively, from 21 September to 2 October 2020, nasopharyngeal samples from 341 patients and subjects who presented at our institute for COVID-19 testing using the two methods. Of these, 182 were symptomatic patients and 159 were asymptomatic subjects who had had contact with patients. For each patient, two nasopharyngeal samples were collected, from one nostril each, with a specific swab according to the assay used. All tests were performed within 1âh after specimen collection. All of the 182 symptomatic patients but only 22 of the 159 asymptomatic patients were PCR positive (median CT values, 25 and 30.5, respectively, Pâ&lt;â10â2, Table 1), for a total of 204 PCR positives (Table S2). The Panbio COVID-19 Ag rapid test detected 154 of the 204 PCR-positive samples (sensitivity, 75.5%; 95% confidence interval [95% CI], 69.5 to 81.5), including 144/182 symptomatic patients (79.1%), but only 10/22 asymptomatic patients (45.4%). However, the test result was positive in 7 of the 137 PCR-negative samples, all of which had been collected from asymptomatic patients (specificity, 94.9%; 95% CI, 91.2 to 98.6). Among the individuals diagnosed (nâ=â204) or not diagnosed (nâ=â137) with COVID-19, positive and negative predictive values were 95.6% (154/161) and 72.2% (130/180), respectively.</text></passage><passage><infon key=\"file\">T1.xml</infon><infon key=\"id\">T1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>3480</offset><text>Sensitivity of the Panbio COVID-19 Ag rapid test (Abbott) according to the CT values</text></passage><passage><infon key=\"file\">T1.xml</infon><infon key=\"id\">T1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;colgroup span=&quot;1&quot;&gt;&lt;col span=&quot;1&quot;/&gt;&lt;col span=&quot;1&quot;/&gt;&lt;col span=&quot;1&quot;/&gt;&lt;/colgroup&gt;&lt;thead&gt;&lt;tr&gt;&lt;th rowspan=&quot;2&quot; colspan=&quot;1&quot;&gt;&lt;italic&gt;C&lt;sub&gt;T&lt;/sub&gt;&lt;/italic&gt; range&lt;/th&gt;&lt;th colspan=&quot;2&quot; rowspan=&quot;1&quot;&gt;Sensitivity of the Panbio COVID-19 Ag rapid test in the present study&lt;hr/&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;No. of positive patients&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;% of positive patients&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;10&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;100&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10â15&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;19&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;95&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;16â20&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;38&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;100&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;21â25&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;49&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;94.2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26â30&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;39&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;73.6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;31â34&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;20&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>3565</offset><text>CT range\tSensitivity of the Panbio COVID-19 Ag rapid test in the present study\t \tNo. of positive patients\t% of positive patients\t \t&lt;10\t1\t100\t \t10â15\t19\t95\t \t16â20\t38\t100\t \t21â25\t49\t94.2\t \t26â30\t39\t73.6\t \t31â34\t8\t20\t \t</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>3793</offset><text>We acknowledge the fact that our study population may not be representative of the general population of Marseille as symptomatic patients also came from other cities from southern France and were thus overrepresented. However, our study showed that the Panbio COVID-19 Ag rapid test had a good specificity for SARS-CoV-2 detection in nasopharynx swab samples but a good sensitivity only for samples with CT values lower than 25 (corresponding to viral loads higher than 106 copies/ml, which has been proposed as threshold of transmissibility). In our study, all 10 asymptomatic patients, as well as 57/144 symptomatic patients, exhibited CT values of â¥25 (Table S2). In this population, the Panbio COVID-19 Ag rapid test may miss about 40% of diagnoses. However, as the clinical performance of RAD tests largely depends on the setting in which they are used, we believe that the Panbio COVID-19 Ag rapid test may be a useful mass screening test when RT-PCR assays are not or are insufficiently available, in particular, in symptomatic patients.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>4841</offset><text>The patients gave informed consent for this study.</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">title_1</infon><offset>4892</offset><text>Supplementary Material</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">footnote</infon><offset>4915</offset><text>Supplemental material is available online only.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">title</infon><offset>4963</offset><text>REFERENCES</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>4974</offset><text>WHO Coronavirus disease (COVID-19) situation report â 51</text></passage><passage><infon key=\"fpage\">pii=2000045</infon><infon key=\"issue\">3</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">EuroSurveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>5033</offset><text>Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR</text></passage><passage><infon key=\"fpage\">1059</infon><infon key=\"lpage\">1061</infon><infon key=\"pub-id_doi\">10.1007/s10096-020-03913-9</infon><infon key=\"pub-id_pmid\">32342252</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur J Clin Microbiol Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">39</infon><infon key=\"year\">2020</infon><offset>5101</offset><text>Viral DNA as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards</text></passage><passage><infon key=\"fpage\">145</infon><infon key=\"lpage\">147</infon><infon key=\"pub-id_doi\">10.1016/j.ijid.2020.04.034</infon><infon key=\"pub-id_pmid\">32315808</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">94</infon><infon key=\"year\">2020</infon><offset>5229</offset><text>The relative transmissibility of asymptomatic COVID-19 infections among close contacts</text></passage><passage><infon key=\"fpage\">465</infon><infon key=\"lpage\">469</infon><infon key=\"pub-id_doi\">10.1038/s41586-020-2196-x</infon><infon key=\"pub-id_pmid\">32235945</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">581</infon><infon key=\"year\">2020</infon><offset>5316</offset><text>Virological assessment of hospitalized patients with COVID-2019</text></passage></document></collection>\n",
      "\n",
      "Study 33410425: <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n",
      "<!DOCTYPE collection SYSTEM \"BioC.dtd\">\n",
      "<collection><source>PMC</source><date>20220219</date><key>pmc.key</key><document><id>7683586</id><infon key=\"license\">NO-CC CODE</infon><passage><infon key=\"article-id_doi\">10.1007/s12038-020-00114-6</infon><infon key=\"article-id_pmc\">7683586</infon><infon key=\"article-id_pmid\">33410425</infon><infon key=\"article-id_publisher-id\">114</infon><infon key=\"elocation-id\">148</infon><infon key=\"issue\">1</infon><infon key=\"kwd\">Artificial intelligence CRISPR/Cas SARS-CoV-2 treatment strategies viral diagnostics</infon><infon key=\"license\">This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</infon><infon key=\"name_0\">surname:Sreepadmanabh;given-names:M</infon><infon key=\"name_1\">surname:Sahu;given-names:Amit Kumar</infon><infon key=\"name_2\">surname:Chande;given-names:Ajit</infon><infon key=\"section_type\">TITLE</infon><infon key=\"title\">Keywords</infon><infon key=\"type\">front</infon><infon key=\"volume\">45</infon><infon key=\"year\">2020</infon><offset>0</offset><text>COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>86</offset><text>An unprecedented worldwide spread of the SARS-CoV-2 has imposed severe challenges on healthcare facilities and medical infrastructure. The global research community faces urgent calls for the development of rapid diagnostic tools, effective treatment protocols, and most importantly, vaccines against the pathogen. Pooling together expertise across broad domains to innovate effective solutions is the need of the hour. With these requirements in mind, in this review, we provide detailed critical accounts on the leading efforts at developing diagnostics tools, therapeutic agents, and vaccine candidates. Importantly, we furnish the reader with a multidisciplinary perspective on how conventional methods like serology and RT-PCR, as well as cutting-edge technologies like CRISPR/Cas and artificial intelligence/machine learning, are being employed to inform and guide such investigations. We expect this narrative to serve a broad audience of both active and aspiring researchers in the field of biomedical sciences and engineering and help inspire radical new approaches towards effective detection, treatment, and prevention of this global pandemic.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>1241</offset><text>Introduction</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>1254</offset><text>The ongoing COVID-19 pandemic has had devastating effects on populations, social structures, and economic growth. These are further exacerbated by the increasing extent of global connectivity and geographical mobility, which expedite infection spread at an uncontrollable pace. The causative agent of this outbreak has been identified as the recently discovered SARS-CoV-2 coronavirus. Effective control and containment of this pathogen require reliable diagnostic assays and potent therapeutic agents. Recent advances in computational technology and biomedical engineering have placed a toolkit of immense potential in our hands, with a formerly unimaginable capability to enable multidisciplinary innovations and highly accelerated discoveries. In this review, we provide a critical evaluation of diagnostic techniques and treatment strategies targeted at the SARS-CoV-2. Alongside an eclectic selection of such reports, our analysis also focuses on the applications, advantages, and pitfalls of emerging technologies like CRISPR/Cas, immune-informatics, artificial intelligence, and machine learning.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>2358</offset><text>Diagnostic tools for detecting SARS-CoV-2</text></passage><passage><infon key=\"file\">12038_2020_114_Fig1_HTML.jpg</infon><infon key=\"id\">Fig1</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>2400</offset><text>Summary of the various approaches towards diagnosis of SARS CoV-2 infection.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>2477</offset><text>FigureÂ 1 provides a graphical summary of the various approaches discussed herein.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>2560</offset><text>RT-PCR</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>2567</offset><text>PCR-based methods are considered the gold standard for viral detection. SARS-CoV-2 requires RT-PCR-based approaches, by virtue of being an RNA virus. In this section, we highlight some interesting developments as well as possible pitfalls of this technique, in the context of viral diagnosis.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>2860</offset><text>One of the earliest workflows set up in response to the outbreak was by Christian Dorsten and colleagues (Corman et al. ). The team established an accurate, sensitive, and specific RT-PCR protocol against the SARS-CoV-2. Later research, including a comparative study by Nalla et al., have attested to its superior sensitivity (Nalla et al. ). A notable feature of this pioneering work was that the assays were designed without access to any actual SARS-CoV-2 genomic specimens or patient samples, by relying on genome information sourced from Chinese researchers and synthetic nucleic acid technology. An interesting comparison between two commercially available testing kits â (the TaqManâ¢ 2019-nCoV Assay Kit v1 (ThermoFisher) and the 2019-nCoV CDC qPCR Probe Assay (Integrated DNA Technologies)) â was recently reported, results from which indicate that the former is capable of reliably detecting SARS-CoV-2 presence in nasopharyngeal swab samples without any RNA extraction steps (BeltrÃ¡n-Pavez et al. ). Most diagnostic devices relying on RT-PCR-based amplification suffer from the drawback of requiring either sample lysis or purified nucleic acid samples, a step that involves additional reagents, increased testing time, human errors and costs, in addition to significant compromises on the field-applicability of the test. Subject to further validation, the above result represents a potential breakthrough for rapid and accessible diagnosis in low-resource settings, by enabling the development of accessible point-of-care devices. Additionally, while nasopharyngeal/oropharyngeal swabs are recommended sample collection techniques for SARS-CoV-2 testing, these pose a high risk of exposing healthcare workers to large numbers of potentially infected individuals, in addition to causing patient discomfort. An alternative in the form of saliva specimens as a non-invasive method of sample collection has been proposed to address these concerns (To et al. ).</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>4836</offset><text>In order to enhance the sensitivity and fidelity of RT-PCR assays, a worthwhile strategy is to evaluate the potential of various viral components as probe targets and compare the relative performance of each. For instance, an early RT-PCR-based detection assay used probes against the ORF1b and N region of the viral genome (Chu et al. ). Subsequently, another study developed three novel assays aimed at the viral spike protein (S), nucleocapsid (N), and RNA-dependant RNA polymerase (RdRp)/Helicase (Hel) genes, out of which, the RdRp/Hel-based assay demonstrated no cross-reactivity with common respiratory pathogens as well as the lowest detection limit in vitro (Chan et al. ). Exploring such novel targets may help develop superior assays, which can improve the sensitivity and accuracy of detection. Furthermore, a comparative analysis by Nalla et al. evaluated seven different assay kits and reported the E-gene primer/probe set (as described by Corman et al.) and the N2 set (developed by the Division of Viral Diseases, Center for Disease Control and Prevention) as the most sensitive assays available. The importance of such independent assessments of reported/published studies needs to be underscored in healthcare crisis scenarios such as the present one, wherein resources are limited and must be judiciously allocated.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>6171</offset><text>Chest CT scans</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>6186</offset><text>A few studies have also pointed out the liabilities of RT-PCR-based techniques. While some publications and in vitro assays may report excellent parameters of performance, clinical testing and feedback raise several red flags. A most elementary instance of this was reported in a case wherein two patients who were SARS-CoV-2 infected returned negative RT-PCR results, leading the authors to suggest chest CT scans as an essential part of clinical diagnosis (Li et al. ). Similar issues with a high false-negative rate of RT-PCR testing on patients over the course of disease progression and treatment have been reported separately as well (Li et al. ). Such observations have promoted recommendations to include clinical parameters such as CT scan diagnosis as factors to be considered in addition to the aforementioned assays while making decisions on patient discharge, evaluation of recovery/response to treatment protocols. A retrospective study reached similar conclusions in favor of CT scans, ascribing a 97.2% sensitivity to CT, as compared to 83.3% using RT-PCR (Long et al. ).</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>7274</offset><text>At this juncture, we would like to emphasize a few recent studies which have underscored the potential of chest CT scans as a viable diagnostic technique. Work by Cao et al. and Dai et al. seeks to formulate a standard set of characteristic features indicative of a SARS-CoV-2 infection. The former, a systematic review and meta-analysis of infected patients, establishes the most common clinical symptoms as fever, cough, chest distress, fatigue, and dyspnea, along with major imaging features as ground-glass opacities and bilateral pneumonia (Cao et al. ). The latter provides a more comprehensive treatment in which over two hundred patients were studied to report bilateral multiple lung lobes in both the periphery and lower portion of the lungs as being present in over 94.98% of the cases (Dai et al. ). Additionally, ground-glass opacities and vascular enhancement were identified as characteristic signatures, as well as fibrosis, air, trapping, and interlobular septal thickening. It is worthwhile to note that highly concordant observations have been made across different patient cohorts, and the general agreement between these is an indicator of the proposed techniqueâs versatility and broad-spectrum applicability. A more extensive and detailed elucidation of the same may be found in the recent review by Hani et al. (Hani et al. ). Furthermore, time-point-based CT scan data may be an invaluable tool to assess disease progression, treatment response, development of complications, and understanding the pathophysiology of the disease, as has been stressed by Bernheim et al.. Additionally, an artificial intelligence (AI)-based platform has also been devised which utilizes a neural network to evaluate X-ray images and automatically detects SARS-CoV-2-infected positive specimens with an accuracy of 97.82% (Apostolopoulos and Bessiana). Harnessing advances in computer science for medical diagnostics may serve as an essential tool to standardize and speed up the testing process. Similar applications of machine learning and AI to aid in the pandemic control efforts will be further elaborated in Sect.Â 4.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>9406</offset><text>Antibody-based techniques</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>9432</offset><text>The evident advantage of antibodies over nucleic acids amplification is higher specificity, accuracy, as well as rapid testing times since it does not require time-consuming amplification steps, nor involves cumbersome extraction/purification processes. A recent report has also highlighted that antibody titers may be a more reliable indicator of SARS-CoV-2 infections, especially for asymptomatic and suspected carriers who return negative RT-PCR results (Long et al. ).</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>9905</offset><text>The classic Enzyme-linked Immunosorbent Assay (ELISA) may be readily adapted to serve as a SARS-CoV-2 detection test. Accordingly, this has been employed against the recombinant viral nucleocapsid proteins and the recombinant viral spike proteins, which were used to detect the IgM and IgG antibody levels (Liu et al. ). This study established that spike protein-based assay would be more sensitive for detecting IgM. Along similar lines, the comparative performance of ELISA-based and Gold-immunochromatographic Assay (GICA)-based methods have also been evaluated (Xiang et al. ). The rapid testing times and high sensitivity observed posit serological assays as superior alternatives to RT-PCR on account of ease of sample collection (blood, which poses minimal risk to healthcare staff compared to swab samples) and low false-negative rates. In this regard, an efficient point-of-care device for diagnostic testing which combined the IgG-IgM testing platform with a testing time of fifteen minutes was recently reported (Li et al. ). While the repurposing of cross-reactive antibodies from highly similar species like the SARS-CoV is a viable idea, an interesting report notes some pitfalls (Tian et al. ). Despite the relative identity between the SARS-CoV and the SARS-CoV-2, the authors point out that highly potent receptor binding site-targeting SARS-CoV neutralizing antibodies (like the CR3014 and m396) fail to engage the SARS-CoV-2 spike protein. This indicates that effective management of novel pathogens may necessitate the development of novel antibodies and those homology-based strategies to repurpose existing therapeutics should be rigorously vetted.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>11576</offset><text>However, an over-reliance on antibody-based approaches is impractical. Designing nucleic acid probes is a far more straightforward process, and one much more rapidly deployable. Also, the detection of antibodies may be difficult in the early stages of infection, until a significant titer of IgG/IgM has accumulated in circulation. This may contribute towards significant false-negative rates during large-scale screenings, especially when periodic sampling and extended observation of test subjects may not be feasible. Hence, despite the salient advantages of antibody-based techniques as discussed above, several assay kits and field-testing protocols have remained in the domain of PCR amplification-based methods. Accordingly, our object of focus for the next section will be one such recently evolved technology, loop-mediated isothermal amplification (LAMP).</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>12442</offset><text>RT-LAMP</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>12450</offset><text>LAMP-based protocols enable the efficient amplification of nucleic acids at a single point temperature. This feature makes it a strong contender for direct field applications, since incorporating the thermal cycling steps in PCR assays has traditionally been a significant limitation for point-of-care devices. LAMPâs inherent advantages are not limited to isothermal operability alone. This robust technique works efficiently even with crude sample preparations, compared to traditional PCR methods, and also offers a very high amplification efficiency since it is not limited by a doubling-per-cycle threshold (Becherer et al. ).</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>13084</offset><text>We wish to highlight two particular tests, both of which report colorimetric detection capability â a major boon for point-of-care devices. A team led by Di Liu and Jing Yuan reported RT-LAMP assays for SARS-CoV-2 detection, with ORF1ab and S genes as the primer-probe targets (Yan et al. ). The work claims complete detection within 60 min, using a colorimetric detection system that employs fluorescent calcein, where a color change from orange to green indicates positive reactions (visually detectable by the naked eye). Another effort by Renfei Lu et al. involving primers targeted at the RdRp utilizes cresol red (a pH-sensitive indicator dye) for the assay readout (Lu et al. ). Since a proceeding amplification can progressively change the buffer pH from alkaline to acidic, a color change from burgundy to orange/yellow signals a positive reaction. These innovations in assay readout methodology imply a significant advancement since they make it possible to have even untrained healthcare workers administer, conduct, and interpret diagnostic tests.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>14146</offset><text>A noteworthy instance of adapting RT-LAMP for a truly bedside point-of-care application is the innovative closed-tube test developed by Song and colleagues (El-Tholoth et al. ). Combining straightforward sample collection with single or two-step RT-LAMP amplification protocols, along with a visual detection system based on LCV (leucocrystalviolet â an intercalating agent which colorimetrically detects double-stranded LAMP amplicons), this device is a readily deployable and highly portable testing method that promises to be a cheap and reliable alternative suitable for all testing environments.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_2</infon><offset>14749</offset><text>Emerging techniques: reactive polymers and CRISPR/Cas-based systems</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>14817</offset><text>This subsection is devoted to a couple of non-conventional detection methods, which may well serve as a versatile platform in the future. The first is a reactive polymer-grafter device which utilizes antibodies to detect dsRNA (Ku et al. ). A suitable polymer-coated surface-reactive poly(pentafluorophenyl acetate) in this case is used to immobilize J2 antibodies on the surface. Following the preparation of the platform, it may be directly applied to detect dsRNA as the J2 antibodies may bind dsRNA molecules specifically. The principal advantage, in this case, is that the antibody binding is sequence-independent; hence the platform may serve as a universal virus detection unit. However, it may be noted that such one-size-fits-all approaches suffer from an inherent lack of specificity. In this case, the sequence-independent nature of detection suggests a high possibility of false positives. Such a scenario would necessitate secondary tests using established protocols for reliable confirmations of diagnosis, thereby positing the J antibodies-based technique as a potential preliminary screening step, rather than as a standalone entity.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>15967</offset><text>The second major innovation involves the use of CRISPR-Cas-based techniques for the detection of viral nucleic acids. Recently, such CRISPR-based detection systems, notably SHERLOCK and DETECTR, were reported as emerging diagnostic tools. The fundamental principle involves the activation of a suitable Cas variant (Cas13 for SHERLOCK, Cas12a for DETECTR) by binding of the appropriate target sequence (ssRNA or mRNA for Cas13 and dsDNA for Cas12a), which enables the Cas variants to promiscuously cleave and degrade surrounding ssRNA and ssDNA, respectively. The ssRNA/ssDNA meant for the latter reaction may be coupled with a quenchable fluorophore, which produces a quantifiable signal upon being released by cleavage. Hence, the detection of the exact target sequence is indicated by an assay readout in the form of a fluorescence signal. This system allows for rapid and accurate detection of viral RNA samples since amplification of these (along with suitable modifications as per the system used) can then allow for precise targeting and detection by the Cas-based assay described above. This remarkable ability has been recently demonstrated by using the DETECTR system as a diagnostic tool for SARS-CoV-2 infections in a rapid lateral flow assay incorporating RT-LAMP using nasal swab samples (Broughton et al. ). Additionally, a series of reports may be found on the Broad Instituteâs website (https://www.broadinstitute.org/news/enabling-coronavirus-detection-using-crispr-cas13-open-access-sherlock-research-protocols-and), wherein a team comprising of Feng Zhang, Omar Abudayyeh, and Jonathan Gootenberg aim to develop paper-based platforms for rapid and straightforward SARS-CoV-2 detection (B Institute).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_1</infon><offset>17689</offset><text>Treatment strategies for SARS-CoV-2 infections</text></passage><passage><infon key=\"file\">12038_2020_114_Fig2_HTML.jpg</infon><infon key=\"id\">Fig2</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>17736</offset><text>Some established and emerging treatment paradigms being currently employed or recommended on the basis of published literature and empirical evidence from clinical case studies.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>17914</offset><text>In this section, we endeavor to review some of the established and emerging treatment paradigms which are being currently employed or recommended on the basis of published literature and empirical evidence from clinical case studies. The major ones have been pictorially represented in figureÂ 2.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>18211</offset><text>Drugs-based conventional approaches</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>18247</offset><text>Amongst drug-based treatment strategies, the broad-spectrum antiviral chloroquine and its derivative hydroxychloroquine have received much attention. As early as February 2020, both remdesivir and chloroquine were identified as potential inhibitors of the SARS-CoV-2 in vitro (Wang et al. ). Remdesivir, a potential candidate against Ebola, SARS-CoV, and MERS-CoV, is an adenosine analog that inhibits viral replication. On the other hand, chloroquine targets endosomal fusion by elevating the endosomal pH, alongside interfering with the glycosylation of ACE2. The rationale for using chloroquine is further buttressed by a variety of possible antiviral effector functions (Devaux et al. ). Experimental evidence for a putative mechanism was provided by structural data and molecular modeling approaches, where a conserved ganglioside binding domain at the N terminus of the viral S protein was identified as the target for chloroquine and hydroxychloroquine. This inhibition of viral attachment and entry appears to explain chloroquine and its derivative hydroxychloroquineâs apparent efficacy against SARS-CoV-2 infections (Fantini et al. ). However, it is important to recognize that evidence for the clinical benefits of these much-touted drugs is contentious at best and unreliable at worst. While hydroxychloroquine and azithromycin were earlier claimed as potentially effective drugs against SARS-CoV-2 infections, the reporting study has since come under criticism for the lack of a control group and incomplete descriptors of actual clinical outcomes and patient inclusion criteria (Gautret et al. ). A separate randomized trial enrolling 62 patients did, however, report a statistically significant positive effect of hydroxychloroquine treatment in alleviating patient symptoms (Chen et al. ). These claims are offset by three additional reports, none of which conclude any significant benefit from this treatment method (Borba et al. ; Magagnoli et al. ; Mahevas et al. ). An emerging class of candidate drugs are corticosteroids, which have recently generated great interest in the context of COVID-19 treatment approaches. While early skepticism did reign over corticosteroids usage, considering its propensity to elicit adverse reactions in severely ill patients, evidence from recent clinical trials and meta-analyses have hinted at significant benefits from this drug for the management of critically ill patients. This has led to a growing advocacy of corticosteroids as a leading candidate in the global effort against COVID-19 (Halpin et al. ; Ma et al. ; Sanders et al. ; Singh et al. ; Yang et al. ; Ye et al. ; Zha et al. ).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>20898</offset><text>Emerging technologies powered by AI offer systematic and highly modular solutions for urgent drug discovery and identification requirements. A study published in The Lancet (Richardson et al. ) employed Benevolent AI, a platform for AI-guided drug discovery and clinical development, to offer suggestions for drugs targeted explicitly at SARS-CoV-2. Using a systematic knowledge graph, the platform was able to identify baricitinib, a Janus kinase inhibitor that binds the AAK1 (AP2-associated protein kinase 1, a regulator of endocytosis). SectionÂ 4 will deal with this domain in greater detail.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>21496</offset><text>Docking simulations and molecular dynamics-based approaches</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>21556</offset><text>Powerful computational resources can greatly enhance our ability to rapidly screen for drugs and inhibitory agents against emerging pathogens. The SARS-CoV-2 protease has been a popular target for such docking simulations and molecular dynamics-based studies (Liu and Wang), in part due to the recent availability of its structure. A broad screening effort of over 1.3 billion compounds from the ZINC15 database used an upgraded docking protocol (termed DeepDocking) to identify over a thousand such potential inhibitors of the SARS-CoV-2 protease (Ton et al. ). A more systematic approach along similar lines screened 687 million compounds via docking, followed by molecular dynamics simulations to evaluate ligand-binding energies, stability, toxicity assessment, as well as off-target binding (Fischer et al. ). Alongside such screening efforts for existing molecules, the identification of promising lead compounds that could serve as scaffolds for further modification is an essential step to enable the development of novel drugs. This requirement was addressed by a recent in-silico study, which provided a clustered report of twenty short-listed compounds into three groups, each of which could serve as leads for the development of SARS-CoV-2 inhibiting drugs (Ortega et al. ).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>22843</offset><text>While the ability of advanced computational facilities to virtually screen multitudinous drugs and compounds â numbering anywhere from a few thousand to even a billion â might be unmatched by traditional methods, the importance of physical assay-based screens is indispensable. The recent report of a large-scale (12,000+ compounds) repositioning survey of FDA-approved and under-trial drugs in the context of SARS-CoV-2-targeted antivirals attests to this (Riva et al. ). Following an initial selection based on inhibition of cytopathic effects, an orthogonal validation assay was used to delineate the compounds which specifically inhibited viral replication. This study also provided classification and categorization of target annotations and drug target genes for the short-listed drugs. The identification of these specific domains can help similar such efforts in the future to be more focussed on specific drug types and targets that have been identified to exert the most promising antiviral effect on SARS-CoV-2. Another notable effort combined virtual screening methods with high-throughput assays to enable the rapid identification of promising drug candidates (Jin et al. ). Using a FRET-based assay to assess the enzymatic activity of SARS-CoV-2 protease, over 10,000 compounds were screened for inhibitory effects on the enzyme. Additionally, the authors extensively analyzed a compound termed N3, initially developed using computer-aided drug design as an inhibitor of multiple coronavirus proteases. Following molecular docking, kinetic analysis of the protease, and determination of its crystal structure with the SARS-CoV-2 protease, the inhibitory effects of N3 were ascertained. The comprehensive approach adopted by this study is an exemplar model for similar investigations. The obvious merits of virtual screening methods notwithstanding, strong emphasis needs to be laid on developing high-throughput biochemical and cellular assays for experimental validation of pharmacologically active compounds. The importance of this cannot be overstated, as such empirical evidence helps establish a reliable standard for ascertaining the actual merits of proposed therapeutic approaches, which may, at least at the current stage of research, only be supplemented by computational studies.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>25152</offset><text>Plasma therapy</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>25167</offset><text>Alongside treatment with drugs, convalescent plasma (CP) therapy is being advocated as a clinically effective practice. The procedure involves using blood plasma obtained from recovered patients as an adaptive immune therapy for critical cases. The underlying principle at work is that the donor plasma contains a high titer of antibodies that are effective against the pathogen, hence provides an immunity boost to the recipient. CP has been advocated as an alternative therapy for SARS-CoV-2 infections (Chen et al. ) and therapeutic plasma exchange has been recommended as a suitable strategy to deal with the often associated acute respiratory distress syndrome (ARDS) (Keith et al. ). An initial four-patient sample established that CP could have therapeutic benefits for critically ill patients (Zhang et al. ). While all four patients showed a progression towards negative RT-PCR results, the authors of the study stress that it would be difficult to rule out confounding factors as well as the effects of additional supportive care and treatments such as antiviral drugs and intravenous immunoglobulin. A similar study involving a ten-patient cohort demonstrated that CP dosages could either increase or maintain the existing levels of neutralizing antibodies in the recipients (Duan et al. ). Additionally, the clinical symptoms were also observed to improve progressively, leading up to the absence of viremia. The study highlights two other salient outcomes â one, that CP appeared to be tolerated well by the recipients without adverse reactions, and two, that transfusion of CP alleviated inflammation. It is important to note, however, that these studies need to be further supplemented by rigorous and controlled clinical trials to discount both the effects of external factors, as well as establish proper protocols for CP therapy concerning the dosage, duration, and other appropriate parameters.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>27083</offset><text>Managing cytokine storm responses</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>27117</offset><text>Among the several complications associated with SARS-CoV-2 infections, cytokine storm responses, which are a by-product of immune hyperactivation and loss of regulatory control over pro-inflammatory cytokines, pose a major risk for patient survival and may lead to rapid deterioration of patient health. The stimulation of CD-4+ T-cells to differentiate into Th1 helper cells along with IL-6, interferon-gamma, and GM-CSF (granulocyte-macrophage colony-stimulating factor) production, amongst other proinflammatory cytokines, are considered as the steps leading up to a cytokine storm-like condition. The persistently high levels of certain cytokines like IP-10, MCP-3, and IL-1ra may be characteristic of such an onset, and these may be developed as screening parameters to ascertain the same (Yang et al. ).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>27927</offset><text>Extensive efforts to safely manage this condition have been undertaken. For instance, the use of an IL-6 receptor antagonist drug such as tocilizumab has been suggested, since the IL-6 has been identified as a key driver of cytokine storm response (Zhang et al. ). Writing in The Lancet, Mehta et al. also recommend similar IL-6 targeted strategies (Mehta et al. ). While a previous study had failed to establish a significant connection between the administration of corticosteroids and improved treatment outcomes (Zha et al. ), Mehta et al. recommend consideration of such a course of treatment to tackle hyperinflammation. However, there is no concrete evidence to support corticosteroid-based treatment as being of overall therapeutic value, in addition to the associated risks of lung injury (Russell et al. ). A detailed review also suggests several strategies by which cytokine storm responses may be dealt with, including the use of the above-cited IL-6R agonist tocilizumab. Glycyrrhetinic acid, another IL-6 and STAT3 signaling inhibitor has been suggested as a potential candidate. Additionally, mesenchymal stem cell infusions have been highlighted due to the immunomodulatory and anti-inflammatory potential of these cells (Cheng et al. ). An alternate approach to managing cytokine storm response has been suggested in the form of artificial blood purification systems. Essentially, this involves using an external filtration-cum-treatment setup to modulate the various factors and chemokines responsible for orchestrating the proinflammatory response. This may be achieved by the use of scavenging inflammatory mediators and plasma exchange. At the same time, continuous venovenous hemofiltration units may be employed, as demonstrated for the successful containment of cytokine storm responses in critically afflicted H7N9 influenza patients (Zhang et al. ). The merits of blood purification therapy for alleviating similar symptoms in SARS-CoV-2 infected patients have also been demonstrated by a recent study from Wuhan involving three patients (Ma et al. ).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>30005</offset><text>Other emerging treatment strategies</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>30041</offset><text>Strategies aimed at halting viral entry are not limited to drug-based approaches alone, as peptide inhibitors can play a vital role in achieving similar effects. To this end, the team led by Shibo Jiang and Lu Lu has built upon previous work that generated fusion inhibitors against the SARS-CoV spike proteinâs HR1 region to design HR2P as a fusion inhibitor against SARS-CoV-2, as well as EK1 (a pan-coronavirus fusion inhibitor). In a follow-up study, the team generated a series of EK1-derived lipopeptides to determine the ones exhibiting the most potent inhibition of fusion (variant identified as EK1C4). Suitable formulations of such peptide preparations, as suggested by the authors, may be a valuable treatment resource for SARS-CoV-2 infections (Xia et al. ; Xia et al. ).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>30827</offset><text>The value of mesenchymal stem cell transplants in improving patient health for SARS-CoV-2 infections was demonstrated in a clinical study involving seven patients (Leng et al. ). Several outcomes were characteristic of the suggestions made by Cheng et al. as mentioned earlier, including immunomodulatory effects, an attenuating effect on proinflammatory cytokines, and elevated IL-10 levels. An interesting observation made by the authors of the clinical study was that such mesenchymal stem cells lacked both ACE2 and TMPRSS2 gene expression, which could effectively render them immune to SARS-CoV-2 infection. The possible benefits of cell therapy-based therapeutic approaches may be immense and have been explored at length in a recent review (Khoury et al. ).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>31592</offset><text>The potential of melatonin as an adjuvant in clinical treatment on account of its immune-enhancing, anti-inflammatory, and anti-oxidative effects has been extolled at length in a recent review (Zhang et al. ). Another study focused on the antagonists of the lipid-dependant attachment process of viral particles to host cells (Baglivo et al. ). Given that SARS-CoV-2 utilizes structures such as lipid rafts to mediate its entry process, the authors recommend exploring the possibilities of employing substances like cyclodextrin and sterols to interfere with such viral attachment and entry-enabling mechanisms. Along similar lines of conjecturing prospective therapeutic candidates, EZH2-mediated H3K27me3 at ACE2 promoter regions has been demonstrated to inhibit the expression of ACE2 receptors in mammalian cell lines, as indicated by data from RNA-Seq and CHIP-Seq experiments (Li et al. ).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>32488</offset><text>A major cause of patient mortality in severe SARS-CoV-2 infections is the ARDS as well as coagulopathy. Fibrinolytic therapy to target the fibrin deposition in the pulmonary vasculature (a potential contributor towards ARDS) has been shown to improve survival, along with administration of tissue plasminogen activators (which converts plasminogen to plasmin, that can further breakdown blood clots). This strategy has been shown to improve conditions in a three patient study, and further clinical trials to ascertain its applicability as a standard clinical practice for critically ill SARS-CoV-2 infected patients with ARDS have been recommended (Wang et al. ).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>33153</offset><text>The development of effective prophylactic agents is an essential component of a comprehensive approach towards tackling a global pandemic of this scale and severity. The importance of administering prophylaxis to frontline healthcare workers, screening personnel, and researchers, among others, cannot be overstressed, as the safety and continued productivity (which necessitates sound health) of these key players is paramount to maintain any sustained effort at containing the pandemic and providing healthcare and treatment of adequate quality to affected patients. In this regard, a concise review of established protocols and proposed strategies currently under scrutiny has been recently published in the form of correspondence (Agrawal et al. ).</text></passage><passage><infon key=\"file\">Tab1.xml</infon><infon key=\"id\">Tab1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>33906</offset><text>Leading therapeutic agents against COVID-19, evaluated and described across common parameters</text></passage><passage><infon key=\"file\">Tab1.xml</infon><infon key=\"id\">Tab1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align=&quot;left&quot;&gt;Drug&lt;/th&gt;&lt;th align=&quot;left&quot;&gt;Parameters&lt;/th&gt;&lt;th align=&quot;left&quot;&gt;Details&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot;&gt;Azithromycin&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Status/Remarks&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;No improvement on clinical outcomes, but no significant increase in detrimental side-effects either&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Drug type/Original purpose&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Antibiotic&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mode of Administration&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Oral/Intravenous&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mechanism of Action&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Inhibits mRNA translation by binding to 50s subunit of bacterial ribosome&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;References&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Furtado &lt;italic&gt;et al.&lt;/italic&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR34&quot;&gt;2020&lt;/xref&gt;, Oldenburg and Doan &lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR81&quot;&gt;2020&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot;&gt;Baricitinib&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Status/Remarks&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Improvement in patient status observed, no adverse side-effects reported. Currently in phase III clinical trials conducted by Eli Lilly and Co&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Drug type/Original purpose&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;For rheumatoid arthritis treatment&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mode of Administration&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Oral&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mechanism of Action&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Janus kinase inhibitor. Shows anti-inflammatory activity&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;References&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Cantini &lt;italic&gt;et al.&lt;/italic&gt; &lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR14&quot;&gt;2020&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot;&gt;CD24Fc&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Status/Remarks&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;In phase III clinical trials. Preliminary results suggest effective management of COVID-associated symptoms&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Drug type/Original purpose&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;nonpolymorphic regions of CD24 attached to the Fc region of human IgG1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mode of Administration&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Intravenous&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mechanism of Action&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Immunomodulator, tempers inflammatory responses&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;References&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;OncoImmune &lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR82&quot;&gt;2020&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot;&gt;Colchicine&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Status/Remarks&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Has been hypothesized to address inflamatory responses in COVID-19 infection, but concerns regarding adverse side-effects have been raised. Currently under clinical trial&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Drug type/Original purpose&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Anti-gout agent&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mode of Administration&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Oral&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mechanism of Action&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Inhibits microtubule polymerization, proinflammatory responses, neutrophil migration, and mitosis&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;References&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Cumhur Cure &lt;italic&gt;et al.&lt;/italic&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR24&quot;&gt;2020&lt;/xref&gt;, Dalili &lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR26&quot;&gt;2020&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot;&gt;Dexamethasone&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Status/Remarks&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Shown to lower mortality rate in a recent trial, currently being provisionally approved for patient treatment in certain regions. May be effective in critically ill patients&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Drug type/Original purpose&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Corticosteroid&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mode of Administration&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Oral/Intravenous/Intramuscular&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mechanism of Action&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Immunosuppresant. Shows anti-inflammatory effects&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;References&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Horby &lt;italic&gt;et al.&lt;/italic&gt; &lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR44&quot;&gt;2020&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot;&gt;EIDD-2801&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Status/Remarks&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Potent antiviral activity observed in mouse models and primary human cells. Currently under phase 2 clinical trial&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Drug type/Original purpose&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Antiviral drug. Nucleoside derivative N4-hydroxycytidine&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mode of Administration&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Oral&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mechanism of Action&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Interferes with viral replication by introducing mutations&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;References&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Ridgeback Biotherapeutics&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR89&quot;&gt;2020&lt;/xref&gt;, Sheahan &lt;italic&gt;et al.&lt;/italic&gt; &lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR93&quot;&gt;2020&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot;&gt;Favipiravir&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Status/Remarks&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Clinical studies show faster viral clearence and improvement in chest imaging. A recent clinical trial from India by Glenmark showed faster and more effective recovery rate&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Drug type/Original purpose&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;PyrazinecarboxamideÂ derivative&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mode of Administration&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Oral/Intravenous&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mechanism of Action&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Inhibits the viral RNA-dependent RNA polymerase&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;References&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Glenmark&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR37&quot;&gt;2020&lt;/xref&gt;, Irvani &lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR46&quot;&gt;2020&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot;&gt;Hydroxychloroquine&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Status/Remarks&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Discontinued as a recommended drug for treatment. Clinical studies show no significant benefit for patients. Adverse cardiovascular effects have been reported. However, the study by Mehra &lt;italic&gt;et al.&lt;/italic&gt;, claiming no significant benefits of HCQ administration, has since been withdrawn&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Drug type/Original purpose&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Chloroquine derivative. Antimalarial drug&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mode of Administration&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Oral&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mechanism of Action&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Increases lysosomal pH. Also dampens inflammatory response&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;References&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Chen &lt;italic&gt;et al.&lt;/italic&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR20&quot;&gt;2020c&lt;/xref&gt;, Gautret &lt;italic&gt;et al.&lt;/italic&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR35&quot;&gt;2020&lt;/xref&gt;, Li &lt;italic&gt;et al.&lt;/italic&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR58&quot;&gt;2020a&lt;/xref&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR59&quot;&gt;b&lt;/xref&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR60&quot;&gt;c&lt;/xref&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR61&quot;&gt;d&lt;/xref&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR62&quot;&gt;e&lt;/xref&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR63&quot;&gt;f&lt;/xref&gt;, Mahevas &lt;italic&gt;et al.&lt;/italic&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR75&quot;&gt;2020&lt;/xref&gt;, WHO &lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR85&quot;&gt;2020b&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot;&gt;Ivermectin&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Status/Remarks&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Emerging candidate against COVID-19. Initial concerns were raised over its high effective dosage concentration by Caly &lt;italic&gt;et al.&lt;/italic&gt;, but this is being explored as a safer and more effective alternative to HCQ&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Drug type/Original purpose&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Avermectin derivative&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mode of Administration&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Oral/topical&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mechanism of Action&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Targets ligand-gated ion channels of invertebrate neural cells&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;References&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Caly &lt;italic&gt;et al.&lt;/italic&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR13&quot;&gt;2020&lt;/xref&gt;, Gupta &lt;italic&gt;et al.&lt;/italic&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR40&quot;&gt;2020&lt;/xref&gt;, Heidary and Gharebaghi &lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR43&quot;&gt;2020&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot;&gt;Lopinavirâritonavir&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Status/Remarks&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Clinical studies have demonstrated no significant benefits of lipinavir-ritonavir in COVID-19 affected patients&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Drug type/Original purpose&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Antiretroviral drug&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mode of Administration&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Oral&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mechanism of Action&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;HIV protease inhibitor&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;References&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Cao &lt;italic&gt;et al.&lt;/italic&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR16&quot;&gt;2020b&lt;/xref&gt;, WHO &lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR85&quot;&gt;2020b&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot;&gt;Remdesivir&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Status/Remarks&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Significant benefits from administration of this drug are doubtful. Clinical studies have reported a marginal improvement in critically ill patients&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Drug type/Original purpose&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Nucleoside analog&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mode of Administration&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Intravenous&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mechanism of Action&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Inhibits the viral RNA-dependent RNA polymerase&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;References&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Grein &lt;italic&gt;et al.&lt;/italic&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR38&quot;&gt;2020&lt;/xref&gt;, Wang &lt;italic&gt;et al.&lt;/italic&gt; &lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR100&quot;&gt;2020a&lt;/xref&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR101&quot;&gt;b&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;5&quot;&gt;Tocilizumab&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Status/Remarks&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Studies appear to recommend this drug for critically ill patients, especially for the alleviation of COVID-19-associated pneumonia and cytokine storm management&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Drug type/Original purpose&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Humanized monoclonal antibody against IL-6 receptor&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mode of Administration&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Intravenous&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Mechanism of Action&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Immunosuppressant&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;References&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Biran &lt;italic&gt;et al.&lt;/italic&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR9&quot;&gt;2020&lt;/xref&gt;, Guaraldi &lt;italic&gt;et al.&lt;/italic&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR39&quot;&gt;2020&lt;/xref&gt;, Luo &lt;italic&gt;et al.&lt;/italic&gt;&lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR70&quot;&gt;2020&lt;/xref&gt;, Zhang &lt;italic&gt;et al.&lt;/italic&gt; &lt;xref ref-type=&quot;bibr&quot; rid=&quot;CR112&quot;&gt;2020b&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>34000</offset><text>Drug\tParameters\tDetails\t \tAzithromycin\tStatus/Remarks\tNo improvement on clinical outcomes, but no significant increase in detrimental side-effects either\t \tDrug type/Original purpose\tAntibiotic\t \tMode of Administration\tOral/Intravenous\t \tMechanism of Action\tInhibits mRNA translation by binding to 50s subunit of bacterial ribosome\t \tReferences\tFurtado et al., Oldenburg and Doan \t \tBaricitinib\tStatus/Remarks\tImprovement in patient status observed, no adverse side-effects reported. Currently in phase III clinical trials conducted by Eli Lilly and Co\t \tDrug type/Original purpose\tFor rheumatoid arthritis treatment\t \tMode of Administration\tOral\t \tMechanism of Action\tJanus kinase inhibitor. Shows anti-inflammatory activity\t \tReferences\tCantini et al.\t \tCD24Fc\tStatus/Remarks\tIn phase III clinical trials. Preliminary results suggest effective management of COVID-associated symptoms\t \tDrug type/Original purpose\tnonpolymorphic regions of CD24 attached to the Fc region of human IgG1\t \tMode of Administration\tIntravenous\t \tMechanism of Action\tImmunomodulator, tempers inflammatory responses\t \tReferences\tOncoImmune \t \tColchicine\tStatus/Remarks\tHas been hypothesized to address inflamatory responses in COVID-19 infection, but concerns regarding adverse side-effects have been raised. Currently under clinical trial\t \tDrug type/Original purpose\tAnti-gout agent\t \tMode of Administration\tOral\t \tMechanism of Action\tInhibits microtubule polymerization, proinflammatory responses, neutrophil migration, and mitosis\t \tReferences\tCumhur Cure et al., Dalili \t \tDexamethasone\tStatus/Remarks\tShown to lower mortality rate in a recent trial, currently being provisionally approved for patient treatment in certain regions. May be effective in critically ill patients\t \tDrug type/Original purpose\tCorticosteroid\t \tMode of Administration\tOral/Intravenous/Intramuscular\t \tMechanism of Action\tImmunosuppresant. Shows anti-inflammatory effects\t \tReferences\tHorby et al.\t \tEIDD-2801\tStatus/Remarks\tPotent antiviral activity observed in mouse models and primary human cells. Currently under phase 2 clinical trial\t \tDrug type/Original purpose\tAntiviral drug. Nucleoside derivative N4-hydroxycytidine\t \tMode of Administration\tOral\t \tMechanism of Action\tInterferes with viral replication by introducing mutations\t \tReferences\tRidgeback Biotherapeutics, Sheahan et al.\t \tFavipiravir\tStatus/Remarks\tClinical studies show faster viral clearence and improvement in chest imaging. A recent clinical trial from India by Glenmark showed faster and more effective recovery rate\t \tDrug type/Original purpose\tPyrazinecarboxamideÂ derivative\t \tMode of Administration\tOral/Intravenous\t \tMechanism of Action\tInhibits the viral RNA-dependent RNA polymerase\t \tReferences\tGlenmark, Irvani \t \tHydroxychloroquine\tStatus/Remarks\tDiscontinued as a recommended drug for treatment. Clinical studies show no significant benefit for patients. Adverse cardiovascular effects have been reported. However, the study by Mehra et al., claiming no significant benefits of HCQ administration, has since been withdrawn\t \tDrug type/Original purpose\tChloroquine derivative. Antimalarial drug\t \tMode of Administration\tOral\t \tMechanism of Action\tIncreases lysosomal pH. Also dampens inflammatory response\t \tReferences\tChen et al., Gautret et al., Li et al., Mahevas et al., WHO \t \tIvermectin\tStatus/Remarks\tEmerging candidate against COVID-19. Initial concerns were raised over its high effective dosage concentration by Caly et al., but this is being explored as a safer and more effective alternative to HCQ\t \tDrug type/Original purpose\tAvermectin derivative\t \tMode of Administration\tOral/topical\t \tMechanism of Action\tTargets ligand-gated ion channels of invertebrate neural cells\t \tReferences\tCaly et al., Gupta et al., Heidary and Gharebaghi \t \tLopinavirâritonavir\tStatus/Remarks\tClinical studies have demonstrated no significant benefits of lipinavir-ritonavir in COVID-19 affected patients\t \tDrug type/Original purpose\tAntiretroviral drug\t \tMode of Administration\tOral\t \tMechanism of Action\tHIV protease inhibitor\t \tReferences\tCao et al., WHO \t \tRemdesivir\tStatus/Remarks\tSignificant benefits from administration of this drug are doubtful. Clinical studies have reported a marginal improvement in critically ill patients\t \tDrug type/Original purpose\tNucleoside analog\t \tMode of Administration\tIntravenous\t \tMechanism of Action\tInhibits the viral RNA-dependent RNA polymerase\t \tReferences\tGrein et al., Wang et al.\t \tTocilizumab\tStatus/Remarks\tStudies appear to recommend this drug for critically ill patients, especially for the alleviation of COVID-19-associated pneumonia and cytokine storm management\t \tDrug type/Original purpose\tHumanized monoclonal antibody against IL-6 receptor\t \tMode of Administration\tIntravenous\t \tMechanism of Action\tImmunosuppressant\t \tReferences\tBiran et al., Guaraldi et al., Luo et al., Zhang et al.\t \t</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>38889</offset><text>Considering the rapidly evolving status of COVID-19 treatment protocols, it is of utmost importance to critically evaluate the most up-to-date evidence available while designing guidelines for clinical practice. Of equal pertinence are social awareness campaigns and the regular dissemination of accurate information regarding clinically proven treatment protocols. This assumes greater importance in light of a growing inclination towards scientifically unsubstantiated claims based on anecdotal/circumstantial evidence or misrepresented facts placed out of context. We further present a brief, non-exhaustive listing (tableÂ 1) of leading therapeutic agents frequently associated with COVID-19 treatment, as well as the current opinion of the scientific community regarding each of these, based on the evidence from reported/ongoing clinical trials.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_1</infon><offset>39741</offset><text>Emerging technologies for biomedical research: artificial intelligence and machine learning</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>39833</offset><text>The fields of Artificial Intelligence (AI) and Machine Learning (ML) have undergone tremendous growth in scope and popularity in the recent past, establishing them as important paradigms for future innovation. More importantly, the development of modules suitable for biomedical applications has transformed AI and ML into attractive tools for the current global effort to tackle the SARS-CoV-2 pandemic.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>40238</offset><text>With regard to infectious diseases, AI-based platforms may be employed to monitor outbreak and clustering trends, as well as evaluate the impact of containment programs and carry out risk assessment with minimal human intervention. The AI-based service BlueDot deserves a noteworthy mention of having raised one of the earliest alarms on SARS-CoV-2âs potential for broad global spread (Bogoch et al. ). Additionally, these hold immense promise for dynamic situational monitoring of patients in real-time, enabling critical evaluation and optimization of trial treatment protocols in a much more efficient manner. ML-based solutions can be expected to consistently enhance and refine such designs over time, provided they are trained on a readily updated and expertly-curated dataset. This represents an important caveat, as the efficacy and accuracy of ML-based pattern prediction and recognition may be maintained only if the training dataset is free of biases and a diverse range of scenarios are well-represented (Fitzpatrick et al. ). We had previously referred to the work by Apostolopoulos and Bessiana, which could screen for SARS-CoV-2 infections using X-ray images. This has been supplemented by a neural network-based platform using X-ray images, with a maximum prediction accuracy of 98% (Narin et al. ). Furthermore, an automated AI-based protocol to identify SARS-CoV-2 infections and distinguish these from other lung diseases or community-acquired pneumonia has been recently formulated (Li et al. ). It must be noted that both these models were trained on datasets consisting of actual patient X-ray images, which is in line with a point we have reiterated above â that training datasets should necessarily be accurate, well-represented, and as free of biases as possible. An exciting new development reported by the Broad Instituteâs Sabeti lab concerns an ML-based platform for automated Cas13-based SHERLOCK assay design (Metsky et al. ). Such an advance represents a potential breakthrough, as highly optimized and expanded open-access platforms of this nature can aid researchers the world over in rapidly designing standardized tests for novel and emerging pathogens using just the knowledge about their genomic sequence. This can help accelerate the deployment of rapid responses to outbreaks and thereby greatly enhance early screening and containment efforts. Understandably, a confident reliance on such automated processes may only be possible once multiple field applications have validated the same and demonstrated similar, if not superior, performance in comparison with existing assay design pipelines.</text></passage><passage><infon key=\"file\">12038_2020_114_Fig3_HTML.jpg</infon><infon key=\"id\">Fig3</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>42879</offset><text>An example illustrating the highly modular nature of AI-based knowledge graphs.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>42959</offset><text>SectionÂ 3.1 of this review highlights the study which determined baricitinib as a potential drug against SARS-CoV-2 (Richardson et al. ). Writing in The Lancet, the same team extended this workflow to develop more comprehensive treatment strategies aimed at shortlisting drugs that offered both antiviral as well as anti-inflammatory effects (Stebbing et al. ). The highly modular nature of AI-based knowledge graphs, an example of which has been shown in figureÂ 3, posit these as versatile tools for efforts aimed at rapid drug prediction from extensive libraries. A similar report was published which used a drug repositioning framework employing ML and statistical analysis. The results were validated by testing its predictions for MERS-COV and SARS-COV, which were shown to be in line with the experimentally observed results (Ge et al. ). A reverse vaccinology study employing Vaxign-ML (a machine learning-based application) was recently carried out (Ong et al. ). The basic workflow involves a bioinformatic analysis of the genome/proteome, based upon which suitable targets are scored. Given the number of existing and reported studies targeting the viral spike protein (which also received the highest score using Vaxign-ML), the authors of this study decided to focus on the nsp3 which was ascribed the second-highest score by the aforementioned algorithm. It appears that vaccine candidate identification efforts stand to benefit from such ML-driven analysis, which may have an inherent edge in unearthing unconventional and generally non-obvious targets offering similar or superior outcomes as compared to those determined using traditional workflows or established tenets.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_1</infon><offset>44649</offset><text>Vaccine development for SARS-CoV-2</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>44684</offset><text>Considering the highly contagious nature of the SARS-CoV-2 infection, the only long-term sustainable solution is the development of robust vaccination protocols. In this brief section, we wish to draw the readerâs attention to some innovative, cutting-edge approaches towards determining potential vaccine candidates.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>45004</offset><text>An approach based on comparing the human and viral proteomes to search for pentapeptide sequences unique to the SARS-CoV-2 was proposed by Guglielmo Lucchese, as these would be expected to have high immunogenicity as well as specificity (Lucchese). Immunoinformatics-guided investigations may also play a significant role in the identification of suitable target epitopes, as shown by two recent papers (Ahmed et al. ; Baruah and Bose). Baruah and Bose screened the SARS-CoV-2âs surface glycoprotein for CTL and B-cell epitopes, further supplemented by molecular dynamics simulations to adjudge the interactions of the former with MHC Class I types majorly represented in the Chinese population (Baruah and Bose). The work by Ahmed et al. incorporated insights from the study of immunogenic SARS-CoV proteins and B/T-cell epitopes derived from the same to obtain a set of such epitopes for the SARS-CoV-2, which have also been verified to be invariable amongst the published SARS-CoV-2 genomes, thereby making these attractive targets (Ahmed et al. ). Another notable effort undertook an in-silico approach aimed at designing a multi-epitope vaccine candidate by predicting B/T-cell epitopes based on analysis of the viral nucleocapsid, ORF3a, and membrane protein (Enayatkhani et al. ). It is conceivable that a comprehensive screen of epitopes identified in the above-cited (and other related) literature in suitable animal models may yield lead candidates for vaccine trials.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>46485</offset><text>Data generated by previous studies on the SARS-CoV significantly facilitates current vaccine development efforts against the SARS-CoV-2. For instance, an analysis of the antigenic and glycosylation variation between SARS CoV and SARS-CoV-2 revealed that while several novel glycosylation sites were observed in the receptor-binding domain of SARS-CoV-2, the structure of the glycoprotein showed no significant divergence (Kumar et al. ). Additionally, despite the antigenic variability between both the strains, certain CTL epitopes were found to be conserved, suggesting that existing peptide-based vaccine candidates against the SARS-CoV could be repurposed for testing against SARS-CoV-2. This observation is supplemented by a recently published report, wherein Conformational-Epitope BLAST (which identifies antigenic similarity of a new pathogen to existing ones) was used to identify cross-reactive epitopes in the ACE2 receptor binding region of SARS-CoV-2âs S protein (Qiu et al. ). Along similar lines, polyclonal antibodies against the SARS-CoV receptor-binding domain have been shown to cross-react with SARS-CoV-2 receptor-binding domain (RBD), thereby inhibiting SARS-CoV-2âs entry into cells (Tai et al. ). A largely concordant line of reasoning has also advocated the consideration of the RBD219-N1 (a yeast-expressed potential vaccine candidate against SARS-CoV) as a heterologous vaccine against the SARS-CoV-2 (Chen et al. ). These examples serve to highlight that alongside initiatives to develop novel vaccine candidates, repurposing efforts could help provide immediate solutions to address the urgent needs imposed by the ongoing pandemic situation.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>48161</offset><text>A cell-based antigen delivery system against the SARS-CoV-2 has also been proposed recently using decoy cells displaying viral spike protein (Ji et al. ). The report provides evidence from the literature to support and justify the approach, in particular, citing the example of GM-CSF expressing irradiated cells being well tolerated in clinical trials against cancer. However, no records of assays or in-vivo animal model studies have been provided at the moment; hence it is premature to comment on the suitability of this concept in the context of SARS-CoV-2 infections.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>48735</offset><text>The recent review by Iwasaki and Yang raises important caveats regarding vaccine development efforts, in particular, the phenomenon of antibody-dependant enhancement (ADE). ADE occurs when therapeutically administered antibodies can exacerbate the existing pathology by enabling infection of immune cells by the invading virus, promoting inflammation, downregulation of anti-inflammatory factors like IL-10, and aberrant activation of the immune system leading up to tissue injury. The dangers associated with hyper-inflammation and immune dysregulation in the context of SARS-CoV-2 infections have been elucidated at length in Sect.Â 3.4. The authors outline several possible contributing factors towards ADE, including antibody specificity, choice of target epitope, affinity, subtype (IgM or IgG), dosage, and patient status. Such concerns underscore the need for well-rounded vaccine development protocols and extensive preclinical evaluations in order to optimize the choice of adjuvants, mode of administration, and other relevant parameters as enlisted above. A more thorough elaboration may be found in the publication referenced (Iwasaki and Yang).</text></passage><passage><infon key=\"file\">Tab2.xml</infon><infon key=\"id\">Tab2</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>49893</offset><text>Vaccines being developed against COVID-19 currently in clinical trial stages</text></passage><passage><infon key=\"file\">Tab2.xml</infon><infon key=\"id\">Tab2</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th align=&quot;left&quot;&gt;COVID-19 vaccine developer/manufacturer&lt;/th&gt;&lt;th align=&quot;left&quot;&gt;Vaccine platform&lt;/th&gt;&lt;th align=&quot;left&quot;&gt;Phase&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Inovio Pharmaceuticals/ International Vaccine Institute&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;DNA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1/2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Osaka University/ AnGes/ Takara Bio&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;DNA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1/2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Cadila Healthcare Limited&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;DNA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1/2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Genexine Consortium&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;DNA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1/2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Sinovac&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Inactivated&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Wuhan Institute of Biological Products/Sinopharm&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Inactivated&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Beijing Institute of Biological Products/Sinopharm&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Inactivated&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Institute of Medical Biology, Chinese Academy of Medical Sciences&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Inactivated&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1/2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Research Institute for Biological Safety Problems, Rep of Kazakhstan&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Inactivated&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1/2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Bharat Biotech&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Inactivated&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1/2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;University of Oxford/AstraZeneca&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Non-Replicating Viral Vector&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;CanSino Biological Inc./Beijing Institute of Biotechnology&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Non-Replicating Viral Vector&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Gamaleya Research Institute&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Non-Replicating Viral Vector&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Janssen Pharmaceutical Companies&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Non-Replicating Viral Vector&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;ReiThera/LEUKOCARE/Univercells&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Non-Replicating Viral Vector&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Protein Subunit&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Novavax&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Protein Subunit&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1/2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Kentucky Bioprocessing, Inc&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Protein Subunit&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1/2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Clover Biopharmaceuticals Inc./GSK/Dynavax&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Protein Subunit&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Vaxine Pty Ltd/Medytox&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Protein Subunit&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;University of Queensland/CSL/Seqirus&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Protein Subunit&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Medigen Vaccine Biologics Corporation/NIAID/Dynavax&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Protein Subunit&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Instituto Finlay de Vacunas, Cuba&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Protein Subunit&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Protein Subunit&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;West China Hospital, Sichuan University&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Protein Subunit&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Institute Pasteur/Themis/Univ. of Pittsburg CVR/Merck Sharp &amp;amp; Dohme&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Replicating Viral Vector&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Moderna/NIAID&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;RNA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;BioNTech/Fosun Pharma/Pfizer&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;RNA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;3&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Curevac&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;RNA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Arcturus/Duke-NUS&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;RNA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1/2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Imperial College London&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;RNA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Peopleâs Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;RNA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Medicago Inc.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;VLP&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>49970</offset><text>COVID-19 vaccine developer/manufacturer\tVaccine platform\tPhase\t \tInovio Pharmaceuticals/ International Vaccine Institute\tDNA\t1/2\t \tOsaka University/ AnGes/ Takara Bio\tDNA\t1/2\t \tCadila Healthcare Limited\tDNA\t1/2\t \tGenexine Consortium\tDNA\t1/2\t \tSinovac\tInactivated\t3\t \tWuhan Institute of Biological Products/Sinopharm\tInactivated\t3\t \tBeijing Institute of Biological Products/Sinopharm\tInactivated\t3\t \tInstitute of Medical Biology, Chinese Academy of Medical Sciences\tInactivated\t1/2\t \tResearch Institute for Biological Safety Problems, Rep of Kazakhstan\tInactivated\t1/2\t \tBharat Biotech\tInactivated\t1/2\t \tUniversity of Oxford/AstraZeneca\tNon-Replicating Viral Vector\t3\t \tCanSino Biological Inc./Beijing Institute of Biotechnology\tNon-Replicating Viral Vector\t3\t \tGamaleya Research Institute\tNon-Replicating Viral Vector\t3\t \tJanssen Pharmaceutical Companies\tNon-Replicating Viral Vector\t3\t \tReiThera/LEUKOCARE/Univercells\tNon-Replicating Viral Vector\t1\t \tAnhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences\tProtein Subunit\t2\t \tNovavax\tProtein Subunit\t1/2\t \tKentucky Bioprocessing, Inc\tProtein Subunit\t1/2\t \tClover Biopharmaceuticals Inc./GSK/Dynavax\tProtein Subunit\t1\t \tVaxine Pty Ltd/Medytox\tProtein Subunit\t1\t \tUniversity of Queensland/CSL/Seqirus\tProtein Subunit\t1\t \tMedigen Vaccine Biologics Corporation/NIAID/Dynavax\tProtein Subunit\t1\t \tInstituto Finlay de Vacunas, Cuba\tProtein Subunit\t1\t \tFBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo\tProtein Subunit\t1\t \tWest China Hospital, Sichuan University\tProtein Subunit\t1\t \tInstitute Pasteur/Themis/Univ. of Pittsburg CVR/Merck Sharp &amp; Dohme\tReplicating Viral Vector\t1\t \tModerna/NIAID\tRNA\t3\t \tBioNTech/Fosun Pharma/Pfizer\tRNA\t3\t \tCurevac\tRNA\t2\t \tArcturus/Duke-NUS\tRNA\t1/2\t \tImperial College London\tRNA\t1\t \tPeopleâs Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech.\tRNA\t1\t \tMedicago Inc.\tVLP\t1\t \t</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>51872</offset><text>The World Health Organization (WHO) is currently maintaining publicly accessible, comprehensive, and authoritative databases (https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines) listing all the vaccines under clinical or preclinical evaluation (WHO). At the time of writing, 33 vaccine candidates are under clinical trial, which have been summarized in tableÂ 2. Additionally, the WHOâs COVID-19 modeling ad hoc expert working group (https://www.who.int/publications/m/item/covid-19-animal-models---summary-of-progress-made-by-the-who-covid-19-modelling-(march-04-june-2020)) has also reported (based on the available results from studies across the world) that Rhesus macaques and ferrets appear to be the most suitable large animal models for studying SARS-CoV-2 infections to date (WHO). Such public information initiatives are of immense benefit to encourage collaboration, avoid unnecessary and wasteful duplication of effort, and disseminate valuable data rapidly across the research community. We would also like to direct the interested reader to refer to an excellent summary of the SARS-CoV-2 vaccine landscape by Nature Reviews Drug Discovery and authors affiliated with the Coalition for Epidemic Preparedness Innovations (CEPI) (Le et al. ).</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">title_1</infon><offset>53165</offset><text>Conclusion</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>53176</offset><text>As the current progress of the SARS-CoV-2 outbreak has made obvious, clinical management of these infections has been under multiple pressures ranging from high false-negative rates of diagnosis, contentious results on the efficacy of proposed drugs, and the threat of severely detrimental symptoms like ARDS and cytokine storm responses. The development of accessible point-of-care diagnostic devices tailor-made for low-resource settings continues to be a pressing requirement. This may be achieved by cell lysis-free workflows, increasingly sensitive and robust bioassays, improved sample collection and processing methods which minimize risks to healthcare workers, and ready-to-use kits not requiring technical expertise, among other possible innovations. In this regard, RT-LAMP and CRISPR/Cas-based methods like SHERLOCK and DETECTR are notable advancements that could be explored as promising alternatives. With regard to portable diagnostic devices, few technologies hold as much promise as paper-based microfluidics. The applicability of this has already been demonstrated in the context of the Ebola and Zika outbreaks (Kaarj et al. ; Magro et al. ). While a comprehensive overview of the microfluidics domain is beyond the scope of this work, considering the immense potential of this technology we would like to direct the interested reader to refer to a dedicated review of paper-based microfluidic platforms for nucleic acid detection (Kaur and Toley).</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>54644</offset><text>Advocating accelerated vaccine development efforts might prove to be a risky gamble, on account of the associated safety caveats which have been underscored in the preceding sections. Instead, an emphasis on designing and adopting reliable biophysical assays for comprehensive, yet rapid preclinical evaluation may be beneficial in reducing the historically high attrition rate among candidates under clinical trials. This holds especially true for studies proposing novel therapeutic agents as well, for which emerging techniques like the CETSA (cellular thermal shift assay) may help deter the occurrence of misleading false positives (Martinez Molina et al. ). Furthermore, as regards the application of AI/ML-based platforms in biomedical research and diagnostics, a confluence of cross-domain expertise is crucial to ensure the development of reliable models and workflows which faithfully capture real-world dynamics. As instances of governments and healthcare agencies employing AI-based containment and prevention strategies increase, it is important that critical studies be undertaken to ascertain the true benefits and outcomes of such technological integration, rather than a reliance on anecdotal evidence alone.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>55870</offset><text>Throughout our discussion, certain points have been recurrent â the advantages of leveraging existing knowledge on closely related species like the SARS CoV, the potent efficacy of seemingly disparate techniques when applied in tandem, and the importance of collaborative efforts coupled with rapid, timely dissemination of results which may inform ongoing efforts. Requirements key to enabling these include the availability of genomic sequences, structural data, and expertly curated databases. The push towards developing modular assay workflows (with elements of automation involved) may well be a defining paradigm of future responses to such scenarios. The advent of in silico epitope screening, algorithmic vaccine and inhibitor design, and preliminary evaluation of drug libraries by molecular docking has the potential to greatly facilitate wet-lab-based and clinical investigations while expediting results. However, we reiterate our concerns over adequate quality testing and rigorous experimental validation before adopting such approaches as an established norm. Skepticism must also be extended in light of a growing tendency to extrapolate trends observed from in vitro setups and unsuitable animal models to recommend clinical guidelines. We conclude our narrative on the hopeful note that the topical coverage should have appealed to both experts in virology and biomedical engineers, as well as recent entrants in these research domains. The purpose of this effort would be best served if the diverse studies described herein motivate and help lay the foundation for ambitious multidisciplinary undertakings aimed at the advancement of public health.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">footnote</infon><offset>57541</offset><text>This article is part of the Topical Collection: COVID-19: Disease Biology &amp; Intervention.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">footnote</infon><offset>57631</offset><text>Corresponding editor: Kundan Sengupta</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">title</infon><offset>57669</offset><text>References</text></passage><passage><infon key=\"name_0\">surname:Agrawal;given-names:S</infon><infon key=\"name_1\">surname:Goel;given-names:AD</infon><infon key=\"name_2\">surname:Gupta;given-names:N</infon><infon key=\"pub-id_doi\">10.4081/monaldi.2020.1289</infon><infon key=\"pub-id_pmid\">33305553</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Monaldi Arch. Chest Dis.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>57680</offset><text>Emerging prophylaxis strategies against COVID-19</text></passage><passage><infon key=\"fpage\">254</infon><infon key=\"name_0\">surname:Ahmed;given-names:SF</infon><infon key=\"name_1\">surname:Quadeer;given-names:AA</infon><infon key=\"name_2\">surname:McKay;given-names:MR</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Viruses</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>57729</offset><text>Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies</text></passage><passage><infon key=\"name_0\">surname:Apostolopoulos;given-names:ID</infon><infon key=\"name_1\">surname:Bessiana;given-names:T</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Covid-19: Automatic detection from X-Ray images utilizing Transfer Learning with Convolutional Neural Networks</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>57867</offset></passage><passage><infon key=\"fpage\">161</infon><infon key=\"lpage\">164</infon><infon key=\"name_0\">surname:Baglivo;given-names:M</infon><infon key=\"name_1\">surname:Baronio;given-names:M</infon><infon key=\"name_2\">surname:Natalini;given-names:G</infon><infon key=\"name_3\">surname:Beccari;given-names:T</infon><infon key=\"name_4\">surname:Chiurazzi;given-names:P</infon><infon key=\"pub-id_pmid\">32191676</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Acta Biomed.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">91</infon><infon key=\"year\">2020</infon><offset>57868</offset><text>Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?</text></passage><passage><infon key=\"fpage\">495</infon><infon key=\"lpage\">500</infon><infon key=\"name_0\">surname:Baruah;given-names:V</infon><infon key=\"name_1\">surname:Bose;given-names:S</infon><infon key=\"pub-id_pmid\">32022276</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Med. Virol.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>58020</offset><text>Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV</text></passage><passage><infon key=\"fpage\">717</infon><infon key=\"lpage\">746</infon><infon key=\"name_0\">surname:Becherer;given-names:L</infon><infon key=\"name_1\">surname:Borst;given-names:N</infon><infon key=\"name_2\">surname:Bakheit;given-names:M</infon><infon key=\"name_3\">surname:Frischmann;given-names:S</infon><infon key=\"name_4\">surname:Zengerle;given-names:R</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Anal. Methods</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>58130</offset><text>Loop-mediated isothermal amplification (LAMP) â review and classification of methods for sequence-specific detection</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>58249</offset><text>BeltrÃ¡n-Pavez C, MÃ¡rquez CL, MuÃ±oz G, Valiente-EcheverrÃ­a F, Gaggero A et al. 2020 SARS-CoV-2 detection from nasopharyngeal swab samples without RNA extraction. bioRxiv10.1101/2020.03.28.013508</text></passage><passage><infon key=\"name_0\">surname:Bernheim;given-names:A</infon><infon key=\"name_1\">surname:Mei;given-names:X</infon><infon key=\"name_2\">surname:Huang;given-names:M</infon><infon key=\"name_3\">surname:Yang;given-names:Y</infon><infon key=\"name_4\">surname:Fayad;given-names:ZA</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200463</infon><infon key=\"pub-id_pmid\">32407255</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>58447</offset><text>Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection</text></passage><passage><infon key=\"name_0\">surname:Biran;given-names:N</infon><infon key=\"name_1\">surname:Ip;given-names:A</infon><infon key=\"name_2\">surname:Ahn;given-names:J</infon><infon key=\"name_3\">surname:Go;given-names:RC</infon><infon key=\"name_4\">surname:Wang;given-names:S</infon><infon key=\"pub-id_doi\">10.1016/S2665-9913(20)30277-0</infon><infon key=\"pub-id_pmid\">32838323</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Rheumatol</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>58541</offset><text>Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study</text></passage><passage><infon key=\"fpage\">taaa008</infon><infon key=\"name_0\">surname:Bogoch;given-names:II</infon><infon key=\"name_1\">surname:Watts;given-names:A</infon><infon key=\"name_2\">surname:Thomas-Bachli;given-names:A</infon><infon key=\"name_3\">surname:Huber;given-names:C</infon><infon key=\"name_4\">surname:Kraemer;given-names:MUG</infon><infon key=\"pub-id_pmid\">31943059</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Travel Med.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">27</infon><infon key=\"year\">2020</infon><offset>58644</offset><text>Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>58753</offset><text>Borba MGS, Val FdA, Sampaio VS, Alexandre MA et al. 2020 Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). medRxiv10.1101/2020.04.07.20056424</text></passage><passage><infon key=\"name_0\">surname:Broughton;given-names:JP</infon><infon key=\"name_1\">surname:Deng;given-names:X</infon><infon key=\"name_2\">surname:Yu;given-names:G</infon><infon key=\"name_3\">surname:Fasching;given-names:CL</infon><infon key=\"name_4\">surname:Servellita;given-names:V</infon><infon key=\"pub-id_doi\">10.1038/s41587-020-0513-4</infon><infon key=\"pub-id_pmid\">32300245</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat. Biotechnol.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>59136</offset><text>CRISPRâCas12-based detection of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">104787</infon><infon key=\"name_0\">surname:Caly;given-names:L</infon><infon key=\"name_1\">surname:Druce;given-names:JD</infon><infon key=\"name_2\">surname:Catton;given-names:MG</infon><infon key=\"name_3\">surname:Jans;given-names:DA</infon><infon key=\"name_4\">surname:Wagstaff;given-names:KM</infon><infon key=\"pub-id_pmid\">32251768</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Antiviral Res.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">178</infon><infon key=\"year\">2020</infon><offset>59181</offset><text>The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro</text></passage><passage><infon key=\"fpage\">318</infon><infon key=\"lpage\">356</infon><infon key=\"name_0\">surname:Cantini;given-names:F</infon><infon key=\"name_1\">surname:Niccoli;given-names:L</infon><infon key=\"name_2\">surname:Matarrese;given-names:D</infon><infon key=\"name_3\">surname:Nicastri;given-names:E</infon><infon key=\"name_4\">surname:Stobbione;given-names:P</infon><infon key=\"pub-id_pmid\">32333918</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Infect.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">81</infon><infon key=\"year\">2020</infon><offset>59262</offset><text>Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact</text></passage><passage><infon key=\"fpage\">1787</infon><infon key=\"lpage\">1799</infon><infon key=\"name_0\">surname:Cao;given-names:B</infon><infon key=\"name_1\">surname:Wang;given-names:Y</infon><infon key=\"name_2\">surname:Wen;given-names:D</infon><infon key=\"name_3\">surname:Liu;given-names:W</infon><infon key=\"name_4\">surname:Wang;given-names:J</infon><infon key=\"pub-id_pmid\">32187464</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N. Engl. J. Med.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>59339</offset><text>A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19</text></passage><passage><infon key=\"name_0\">surname:Cao;given-names:Y</infon><infon key=\"name_1\">surname:Liu;given-names:X</infon><infon key=\"name_2\">surname:Xiong;given-names:L</infon><infon key=\"name_3\">surname:Cai;given-names:K</infon><infon key=\"pub-id_doi\">10.1002/jmv.25822</infon><infon key=\"pub-id_pmid\">33325107</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Med. Virol.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>59414</offset><text>Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: A systematic review and meta-analysis</text></passage><passage><infon key=\"name_0\">surname:Chan;given-names:JF-W</infon><infon key=\"name_1\">surname:Yip;given-names:CC-Y</infon><infon key=\"name_2\">surname:To;given-names:KK-W</infon><infon key=\"name_3\">surname:Tang;given-names:TH-C</infon><infon key=\"name_4\">surname:Wong;given-names:SC-Y</infon><infon key=\"pub-id_doi\">10.1128/JCM.00310-20</infon><infon key=\"pub-id_pmid\">33067272</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Clin. Microbiol.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>59534</offset><text>Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens</text></passage><passage><infon key=\"fpage\">398</infon><infon key=\"lpage\">400</infon><infon key=\"name_0\">surname:Chen;given-names:L</infon><infon key=\"name_1\">surname:Xiong;given-names:J</infon><infon key=\"name_2\">surname:Bao;given-names:L</infon><infon key=\"name_3\">surname:Shi;given-names:Y</infon><infon key=\"pub-id_pmid\">32113510</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect. Dis.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>59748</offset><text>Convalescent plasma as a potential therapy for COVID-19</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"lpage\">4</infon><infon key=\"name_0\">surname:Chen;given-names:W-H</infon><infon key=\"name_1\">surname:Hotez;given-names:PJ</infon><infon key=\"name_2\">surname:Bottazzi;given-names:ME</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Hum. Vaccin. Immunother.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">0</infon><infon key=\"year\">2020</infon><offset>59804</offset><text>Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>59972</offset><text>Chen Z, Hu J, Zhang Z, Jiang S, Han S et al. 2020 Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv10.1101/2020.03.22.20040758</text></passage><passage><infon key=\"fpage\">E005</infon><infon key=\"name_0\">surname:Cheng;given-names:C</infon><infon key=\"name_1\">surname:Xiaorong;given-names:Z</infon><infon key=\"name_2\">surname:Zhenyu;given-names:J</infon><infon key=\"name_3\">surname:Weifeng;given-names:H</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Zhonghua Shao Shang Za Zhi</infon><infon key=\"type\">ref</infon><infon key=\"volume\">36</infon><infon key=\"year\">2020</infon><offset>60155</offset><text>Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies</text></passage><passage><infon key=\"fpage\">549</infon><infon key=\"lpage\">555</infon><infon key=\"name_0\">surname:Chu;given-names:DKW</infon><infon key=\"name_1\">surname:Pan;given-names:Y</infon><infon key=\"name_2\">surname:Cheng;given-names:SMS</infon><infon key=\"name_3\">surname:Hui;given-names:KPY</infon><infon key=\"name_4\">surname:Krishnan;given-names:P</infon><infon key=\"pub-id_pmid\">32031583</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin. Chem.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">66</infon><infon key=\"year\">2020</infon><offset>60283</offset><text>Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia</text></passage><passage><infon key=\"name_0\">surname:Corman;given-names:VM</infon><infon key=\"name_1\">surname:Landt;given-names:O</infon><infon key=\"name_2\">surname:Kaiser;given-names:M</infon><infon key=\"name_3\">surname:Molenkamp;given-names:R</infon><infon key=\"name_4\">surname:Meijer;given-names:A</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>60371</offset></passage><passage><infon key=\"name_0\">surname:Cumhur Cure;given-names:M</infon><infon key=\"name_1\">surname:Kucuk;given-names:A</infon><infon key=\"name_2\">surname:Cure;given-names:E</infon><infon key=\"pub-id_doi\">10.1007/s10067-020-05144-x</infon><infon key=\"pub-id_pmid\">32458242</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin. Rheumatol.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>60372</offset><text>Colchicine may not be effective in COVID-19 infection; it may even be harmful?</text></passage><passage><infon key=\"name_0\">surname:Dai;given-names:H</infon><infon key=\"name_1\">surname:Zhang;given-names:X</infon><infon key=\"name_2\">surname:Xia;given-names:J</infon><infon key=\"name_3\">surname:Zhang;given-names:T</infon><infon key=\"name_4\">surname:Shang;given-names:Y</infon><infon key=\"pub-id_doi\">10.1016/j.ijid.2020.04.003</infon><infon key=\"pub-id_pmid\">32920233</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int. J. Infect. Dis.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>60451</offset><text>High-resolution Chest CT Features and Clinical Characteristics of Patients Infected with COVID-19 in Jiangsu, China</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>60567</offset><text>Dalili N 2020 Effects of Standard Protocol Therapy With or Without Colchicine in Covid-19 Infection: A Randomized Double Blind Clinical Trial. https://clinicaltrials.gov/ct2/show/NCT04360980</text></passage><passage><infon key=\"name_0\">surname:Devaux;given-names:CA</infon><infon key=\"name_1\">surname:Rolain;given-names:J-M</infon><infon key=\"name_2\">surname:Colson;given-names:P</infon><infon key=\"name_3\">surname:Raoult;given-names:D</infon><infon key=\"pub-id_doi\">10.1016/j.ijantimicag.2020.105938</infon><infon key=\"pub-id_pmid\">32179150</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int. J. Antimicrob. Agents</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>60758</offset><text>New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?</text></passage><passage><infon key=\"name_0\">surname:Duan;given-names:K</infon><infon key=\"name_1\">surname:Liu;given-names:B</infon><infon key=\"name_2\">surname:Li;given-names:C</infon><infon key=\"name_3\">surname:Zhang;given-names:H</infon><infon key=\"name_4\">surname:Yu;given-names:T</infon><infon key=\"pub-id_doi\">10.1073/pnas.2004168117</infon><infon key=\"pub-id_pmid\">33318207</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Proc. Natl. Acad. Sci. U S A</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>60861</offset><text>Effectiveness of convalescent plasma therapy in severe COVID-19 patients</text></passage><passage><infon key=\"name_0\">surname:El-Tholoth;given-names:M</infon><infon key=\"name_1\">surname:Bau;given-names:HH</infon><infon key=\"name_2\">surname:Song;given-names:J</infon><infon key=\"pub-id_doi\">10.26434/chemrxiv.11860137.v1</infon><infon key=\"pub-id_pmid\">32511284</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ChemRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>60934</offset><text>A Single and Two-Stage, Closed-Tube, Molecular Test for the 2019 Novel Coronavirus (COVID-19) at Home, Clinic, and Points of Entry</text></passage><passage><infon key=\"name_0\">surname:Enayatkhani;given-names:M</infon><infon key=\"name_1\">surname:Hasaniazad;given-names:M</infon><infon key=\"name_2\">surname:Faezi;given-names:S</infon><infon key=\"name_3\">surname:Guklani;given-names:H</infon><infon key=\"name_4\">surname:Davoodian;given-names:P</infon><infon key=\"pub-id_doi\">10.1080/07391102.2020.1756411</infon><infon key=\"pub-id_pmid\">33351722</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Biomol. Struct. Dyn.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>61065</offset><text>Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study</text></passage><passage><infon key=\"name_0\">surname:Fantini;given-names:J</infon><infon key=\"name_1\">surname:Di Scala;given-names:C</infon><infon key=\"name_2\">surname:Chahinian;given-names:H</infon><infon key=\"name_3\">surname:Yahi;given-names:N</infon><infon key=\"pub-id_doi\">10.1016/j.ijantimicag.2020.105960</infon><infon key=\"pub-id_pmid\">32862840</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int. J. Antimicrob. Agents</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>61181</offset><text>Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection</text></passage><passage><infon key=\"name_0\">surname:Fischer;given-names:A</infon><infon key=\"name_1\">surname:Sellner;given-names:M</infon><infon key=\"name_2\">surname:Neranjan;given-names:S</infon><infon key=\"name_3\">surname:Lill;given-names:MA</infon><infon key=\"name_4\">surname:SmieÅ¡ko;given-names:M</infon><infon key=\"pub-id_doi\">10.26434/chemrxiv.11923239.v1</infon><infon key=\"pub-id_pmid\">33200116</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ChemRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>61324</offset><text>Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 687 Million Compounds</text></passage><passage><infon key=\"name_0\">surname:Fitzpatrick;given-names:F</infon><infon key=\"name_1\">surname:Doherty;given-names:A</infon><infon key=\"name_2\">surname:Lacey;given-names:G</infon><infon key=\"pub-id_doi\">10.1007/s40506-020-00216-7</infon><infon key=\"pub-id_pmid\">32218708</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Curr. Treat. Options Infect. Dis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>61423</offset><text>Using Artificial Intelligence in Infection Prevention</text></passage><passage><infon key=\"name_0\">surname:Furtado;given-names:RHM</infon><infon key=\"name_1\">surname:Berwanger;given-names:O</infon><infon key=\"name_2\">surname:Fonseca;given-names:HA</infon><infon key=\"name_3\">surname:CorrÃªa;given-names:TD</infon><infon key=\"name_4\">surname:Ferraz;given-names:LR</infon><infon key=\"pub-id_doi\">10.1016/S0140-6736(20)31862-6</infon><infon key=\"pub-id_pmid\">32896292</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>61477</offset><text>Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial</text></passage><passage><infon key=\"name_0\">surname:Gautret;given-names:P</infon><infon key=\"name_1\">surname:Lagier;given-names:J-C</infon><infon key=\"name_2\">surname:Parola;given-names:P</infon><infon key=\"name_3\">surname:Hoang;given-names:VT</infon><infon key=\"name_4\">surname:Meddeb;given-names:L</infon><infon key=\"pub-id_doi\">10.1016/j.ijantimicag.2020.105949</infon><infon key=\"pub-id_pmid\">33189890</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int. J. Antimicrob. Agents</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>61681</offset><text>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</text></passage><passage><infon key=\"name_0\">surname:Ge;given-names:Y</infon><infon key=\"name_1\">surname:Tian;given-names:T</infon><infon key=\"name_2\">surname:Huang;given-names:S</infon><infon key=\"name_3\">surname:Wan;given-names:F</infon><infon key=\"name_4\">surname:Li;given-names:J</infon><infon key=\"pub-id_doi\">10.1101/2020.03.11.986836</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int. J. Antimicrob. Agents</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>61800</offset><text>A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>61903</offset><text>Glenmark 2020 Positive Ph III top-line results for favipiravir in COVID-19. https://www.thepharmaletter.com/article/positive-ph-iii-top-line-results-for-favipiravir-in-covid-19</text></passage><passage><infon key=\"fpage\">2327</infon><infon key=\"lpage\">2336</infon><infon key=\"name_0\">surname:Grein;given-names:J</infon><infon key=\"name_1\">surname:Ohmagari;given-names:N</infon><infon key=\"name_2\">surname:Shin;given-names:D</infon><infon key=\"name_3\">surname:Diaz;given-names:G</infon><infon key=\"name_4\">surname:Asperges;given-names:E</infon><infon key=\"pub-id_pmid\">32275812</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N. Engl. J. Med.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>62080</offset><text>Compassionate Use of Remdesivir for Patients with Severe Covid-19</text></passage><passage><infon key=\"fpage\">e474</infon><infon key=\"lpage\">e484</infon><infon key=\"name_0\">surname:Guaraldi;given-names:G</infon><infon key=\"name_1\">surname:Meschiari;given-names:M</infon><infon key=\"name_2\">surname:Cozzi-Lepri;given-names:A</infon><infon key=\"name_3\">surname:Milic;given-names:J</infon><infon key=\"name_4\">surname:Tonelli;given-names:R</infon><infon key=\"pub-id_pmid\">32835257</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Rheumatol.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">2</infon><infon key=\"year\">2020</infon><offset>62146</offset><text>Tocilizumab in patients with severe COVID-19: a retrospective cohort study</text></passage><passage><infon key=\"fpage\">369</infon><infon key=\"lpage\">371</infon><infon key=\"name_0\">surname:Gupta;given-names:D</infon><infon key=\"name_1\">surname:Sahoo;given-names:AK</infon><infon key=\"name_2\">surname:Singh;given-names:A</infon><infon key=\"pub-id_pmid\">32615072</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Braz. J. Infect. Dis.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">24</infon><infon key=\"year\">2020</infon><offset>62221</offset><text>Ivermectin: potential candidate for the treatment of Covid 19</text></passage><passage><infon key=\"name_0\">surname:Halpin;given-names:DMG</infon><infon key=\"name_1\">surname:Singh;given-names:D</infon><infon key=\"name_2\">surname:Hadfield;given-names:RM</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>62283</offset></passage><passage><infon key=\"name_0\">surname:Hani;given-names:C</infon><infon key=\"name_1\">surname:Trieu;given-names:NH</infon><infon key=\"name_2\">surname:Saab;given-names:I</infon><infon key=\"name_3\">surname:Dangeard;given-names:S</infon><infon key=\"name_4\">surname:Bennani;given-names:S</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">COVID-19 pneumonia: A review of typical CT findings and differential diagnosis</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>62284</offset></passage><passage><infon key=\"fpage\">593</infon><infon key=\"lpage\">602</infon><infon key=\"name_0\">surname:Heidary;given-names:F</infon><infon key=\"name_1\">surname:Gharebaghi;given-names:R</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Antibiot.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">73</infon><infon key=\"year\">2020</infon><offset>62285</offset><text>Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen</text></passage><passage><infon key=\"name_0\">surname:Horby;given-names:P</infon><infon key=\"name_1\">surname:Lim;given-names:WS</infon><infon key=\"name_2\">surname:Emberson;given-names:JR</infon><infon key=\"name_3\">surname:Mafham;given-names:M</infon><infon key=\"name_4\">surname:Bell;given-names:JL</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa2021436</infon><infon key=\"pub-id_pmid\">33031652</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N. Engl. J. Med.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>62374</offset><text>Dexamethasone in Hospitalized Patients with Covid-19-Preliminary Report</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>62446</offset><text>Institute B 2020 Enabling coronavirus detection using CRISPR-Cas13: Open-access SHERLOCK research protocols and design resources. https://www.broadinstitute.org/news/enabling-coronavirus-detection-using-crispr-cas13-open-access-sherlock-research-protocols-and</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>62706</offset><text>Irvani SSN 2020 Efficacy and Safety of Favipiravir Compared to the Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Controlled, Double-Blind, Clinical Trial. In: clinicaltrials.gov</text></passage><passage><infon key=\"name_0\">surname:Iwasaki;given-names:A</infon><infon key=\"name_1\">surname:Yang;given-names:Y</infon><infon key=\"pub-id_doi\">10.1038/s41577-020-0321-6</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat. Rev. Immuno.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>62910</offset><text>The potential danger of suboptimal antibody responses in COVID-19</text></passage><passage><infon key=\"fpage\">100026</infon><infon key=\"name_0\">surname:Ji;given-names:H</infon><infon key=\"name_1\">surname:Yan;given-names:Y</infon><infon key=\"name_2\">surname:Ding;given-names:B</infon><infon key=\"name_3\">surname:Guo;given-names:W</infon><infon key=\"name_4\">surname:Brunswick;given-names:M</infon><infon key=\"pub-id_pmid\">32289117</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Med. Drug Discov.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>62976</offset><text>Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus</text></passage><passage><infon key=\"name_0\">surname:Jin;given-names:Z</infon><infon key=\"name_1\">surname:Du;given-names:X</infon><infon key=\"name_2\">surname:Xu;given-names:Y</infon><infon key=\"name_3\">surname:Deng;given-names:Y</infon><infon key=\"name_4\">surname:Liu;given-names:M</infon><infon key=\"pub-id_doi\">10.1038/s41586-020-2223-y</infon><infon key=\"pub-id_pmid\">33299191</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>63139</offset><text>Structure of Mpro from COVID-19 virus and discovery of its inhibitors</text></passage><passage><infon key=\"fpage\">12438</infon><infon key=\"name_0\">surname:Kaarj;given-names:K</infon><infon key=\"name_1\">surname:Akarapipad;given-names:P</infon><infon key=\"name_2\">surname:Yoon;given-names:J-Y</infon><infon key=\"pub-id_pmid\">30127503</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci. Rep.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2018</infon><offset>63209</offset><text>Simpler, Faster, and Sensitive Zika Virus Assay Using Smartphone Detection of Loop-mediated Isothermal Amplification on Paper Microfluidic Chips</text></passage><passage><infon key=\"fpage\">2213</infon><infon key=\"lpage\">2234</infon><infon key=\"name_0\">surname:Kaur;given-names:N</infon><infon key=\"name_1\">surname:Toley;given-names:BJ</infon><infon key=\"pub-id_pmid\">29683153</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Analyst</infon><infon key=\"type\">ref</infon><infon key=\"volume\">143</infon><infon key=\"year\">2018</infon><offset>63354</offset><text>Paper-based nucleic acid amplification tests for point-of-care diagnostics</text></passage><passage><infon key=\"fpage\">128</infon><infon key=\"name_0\">surname:Keith;given-names:P</infon><infon key=\"name_1\">surname:Day;given-names:M</infon><infon key=\"name_2\">surname:Perkins;given-names:L</infon><infon key=\"name_3\">surname:Moyer;given-names:L</infon><infon key=\"name_4\">surname:Hewitt;given-names:K</infon><infon key=\"pub-id_pmid\">32241301</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Crit. Care</infon><infon key=\"type\">ref</infon><infon key=\"volume\">24</infon><infon key=\"year\">2020</infon><offset>63429</offset><text>A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19</text></passage><passage><infon key=\"name_0\">surname:Khoury;given-names:M</infon><infon key=\"name_1\">surname:Cuenca;given-names:J</infon><infon key=\"name_2\">surname:Cruz;given-names:FF</infon><infon key=\"name_3\">surname:Figueroa;given-names:FE</infon><infon key=\"name_4\">surname:Rocco;given-names:PRM</infon><infon key=\"pub-id_doi\">10.1183/13993003.00858-2020</infon><infon key=\"pub-id_pmid\">32265310</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur. Respir. J</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>63560</offset><text>Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19</text></passage><passage><infon key=\"name_0\">surname:Ku;given-names:J</infon><infon key=\"name_1\">surname:Kim;given-names:S</infon><infon key=\"name_2\">surname:Park;given-names:J</infon><infon key=\"name_3\">surname:Kim;given-names:T-S</infon><infon key=\"name_4\">surname:Kharbash;given-names:R</infon><infon key=\"pub-id_doi\">10.1021/acs.biomac.0c00379</infon><infon key=\"pub-id_pmid\">32233463</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biomacromolecules</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>63659</offset><text>Reactive Polymer Targeting dsRNA as Universal Virus Detection Platform with Enhanced Sensitivity</text></passage><passage><infon key=\"fpage\">13</infon><infon key=\"lpage\">21</infon><infon key=\"name_0\">surname:Kumar;given-names:S</infon><infon key=\"name_1\">surname:Maurya;given-names:VK</infon><infon key=\"name_2\">surname:Prasad;given-names:AK</infon><infon key=\"name_3\">surname:Bhatt;given-names:MLB</infon><infon key=\"name_4\">surname:Saxena;given-names:SK</infon><infon key=\"pub-id_pmid\">32206694</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Virusdisease</infon><infon key=\"type\">ref</infon><infon key=\"volume\">31</infon><infon key=\"year\">2020</infon><offset>63756</offset><text>Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)</text></passage><passage><infon key=\"name_0\">surname:Le;given-names:TT</infon><infon key=\"name_1\">surname:Andreadakis;given-names:Z</infon><infon key=\"name_2\">surname:Kumar;given-names:A</infon><infon key=\"name_3\">surname:RomÃ¡n;given-names:RG</infon><infon key=\"name_4\">surname:Tollefsen;given-names:S</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">The COVID-19 vaccine development landscape</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>63881</offset></passage><passage><infon key=\"fpage\">216</infon><infon key=\"name_0\">surname:Leng;given-names:Z</infon><infon key=\"name_1\">surname:Zhu;given-names:R</infon><infon key=\"name_2\">surname:Hou;given-names:W</infon><infon key=\"name_3\">surname:Feng;given-names:Y</infon><infon key=\"name_4\">surname:Yang;given-names:Y</infon><infon key=\"pub-id_pmid\">32257537</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Aging Dis.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>63882</offset><text>Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia</text></passage><passage><infon key=\"fpage\">505</infon><infon key=\"lpage\">508</infon><infon key=\"name_0\">surname:Li;given-names:D</infon><infon key=\"name_1\">surname:Wang;given-names:D</infon><infon key=\"name_2\">surname:Dong;given-names:J</infon><infon key=\"name_3\">surname:Wang;given-names:N</infon><infon key=\"name_4\">surname:Huang;given-names:H</infon><infon key=\"pub-id_pmid\">32174053</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Korean J. Radiol.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">21</infon><infon key=\"year\">2020</infon><offset>63987</offset><text>False-Negative Results of Real-Time Reverse-Transcriptase Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2: Role of Deep-Learning-Based CT Diagnosis and Insights from Two Cases</text></passage><passage><infon key=\"name_0\">surname:Li;given-names:L</infon><infon key=\"name_1\">surname:Qin;given-names:L</infon><infon key=\"name_2\">surname:Xu;given-names:Z</infon><infon key=\"name_3\">surname:Yin;given-names:Y</infon><infon key=\"name_4\">surname:Wang;given-names:X</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200905</infon><infon key=\"pub-id_pmid\">33330848</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>64193</offset><text>Artificial Intelligence Distinguishes COVID-19 from Community Acquired Pneumonia on Chest CT</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"lpage\">6</infon><infon key=\"name_0\">surname:Li;given-names:X</infon><infon key=\"name_1\">surname:Wang;given-names:Y</infon><infon key=\"name_2\">surname:Agostinis;given-names:P</infon><infon key=\"name_3\">surname:Rabson;given-names:A</infon><infon key=\"name_4\">surname:Melino;given-names:G</infon><infon key=\"pub-id_pmid\">31911576</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Death Dis.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>64286</offset><text>Is hydroxychloroquine beneficial for COVID-19 patients?</text></passage><passage><infon key=\"name_0\">surname:Li;given-names:Y</infon><infon key=\"name_1\">surname:Li;given-names:H</infon><infon key=\"name_2\">surname:Zhou;given-names:L</infon><infon key=\"pub-id_doi\">10.1016/j.bbrc.2020.04.010</infon><infon key=\"pub-id_pmid\">33387886</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biochem. Biophys. Res. Commun.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>64342</offset><text>EZH2-mediated H3K27me3 inhibits ACE2 expression</text></passage><passage><infon key=\"name_0\">surname:Li;given-names:Y</infon><infon key=\"name_1\">surname:Yao;given-names:L</infon><infon key=\"name_2\">surname:Li;given-names:J</infon><infon key=\"name_3\">surname:Chen;given-names:L</infon><infon key=\"name_4\">surname:Song;given-names:Y</infon><infon key=\"pub-id_doi\">10.1002/jmv.25786</infon><infon key=\"pub-id_pmid\">33325107</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Med. Virol.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>64390</offset><text>Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19</text></passage><passage><infon key=\"name_0\">surname:Li;given-names:Z</infon><infon key=\"name_1\">surname:Yi;given-names:Y</infon><infon key=\"name_2\">surname:Luo;given-names:X</infon><infon key=\"name_3\">surname:Xiong;given-names:N</infon><infon key=\"name_4\">surname:Liu;given-names:Y</infon><infon key=\"pub-id_doi\">10.1002/jmv.25727</infon><infon key=\"pub-id_pmid\">33325107</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Med. Virol.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>64500</offset><text>Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis</text></passage><passage><infon key=\"name_0\">surname:Liu;given-names:W</infon><infon key=\"name_1\">surname:Liu;given-names:L</infon><infon key=\"name_2\">surname:Kou;given-names:G</infon><infon key=\"name_3\">surname:Zheng;given-names:Y</infon><infon key=\"name_4\">surname:Ding;given-names:Y</infon><infon key=\"pub-id_doi\">10.1128/JCM.00461-20</infon><infon key=\"pub-id_pmid\">33328177</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Clin. Microbiol.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>64614</offset><text>Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2</text></passage><passage><infon key=\"name_0\">surname:Liu;given-names:X</infon><infon key=\"name_1\">surname:Wang;given-names:X-J</infon><infon key=\"pub-id_doi\">10.1016/j.jgg.2020.02.001</infon><infon key=\"pub-id_pmid\">33573880</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Genet. Genomics.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>64716</offset><text>Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines</text></passage><passage><infon key=\"fpage\">108961</infon><infon key=\"name_0\">surname:Long;given-names:C</infon><infon key=\"name_1\">surname:Xu;given-names:H</infon><infon key=\"name_2\">surname:Shen;given-names:Q</infon><infon key=\"name_3\">surname:Zhang;given-names:X</infon><infon key=\"name_4\">surname:Fan;given-names:B</infon><infon key=\"pub-id_pmid\">32229322</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur. J. Radiol.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">126</infon><infon key=\"year\">2020</infon><offset>64813</offset><text>Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT?</text></passage><passage><infon key=\"name_0\">surname:Long;given-names:Q-X</infon><infon key=\"name_1\">surname:Liu;given-names:B-Z</infon><infon key=\"name_2\">surname:Deng;given-names:H-J</infon><infon key=\"name_3\">surname:Wu;given-names:G-C</infon><infon key=\"name_4\">surname:Deng;given-names:K</infon><infon key=\"pub-id_doi\">10.1038/s41591-020-0897-1</infon><infon key=\"pub-id_pmid\">33020648</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat. Med.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>64877</offset><text>Antibody responses to SARS-CoV-2 in patients with COVID-19</text></passage><passage><infon key=\"name_0\">surname:Lu;given-names:R</infon><infon key=\"name_1\">surname:Wu;given-names:X</infon><infon key=\"name_2\">surname:Wan;given-names:Z</infon><infon key=\"name_3\">surname:Li;given-names:Y</infon><infon key=\"name_4\">surname:Zuo;given-names:L</infon><infon key=\"pub-id_doi\">10.1007/s12250-020-00218-1</infon><infon key=\"pub-id_pmid\">33351168</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Virol. Sin.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>64936</offset><text>Development of a Novel Reverse Transcription Loop-Mediated Isothermal Amplification Method for Rapid Detection of SARS-CoV-2</text></passage><passage><infon key=\"name_0\">surname:Lucchese;given-names:G</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Epitopes for a 2019-nCoV vaccine</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>65061</offset></passage><passage><infon key=\"fpage\">814</infon><infon key=\"lpage\">818</infon><infon key=\"name_0\">surname:Luo;given-names:P</infon><infon key=\"name_1\">surname:Liu;given-names:Y</infon><infon key=\"name_2\">surname:Qiu;given-names:L</infon><infon key=\"name_3\">surname:Liu;given-names:X</infon><infon key=\"name_4\">surname:Liu;given-names:D</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Med. Viro.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>65062</offset><text>Tocilizumab treatment in COVID-19: A single center experience</text></passage><passage><infon key=\"fpage\">108408</infon><infon key=\"name_0\">surname:Ma;given-names:J</infon><infon key=\"name_1\">surname:Xia;given-names:P</infon><infon key=\"name_2\">surname:Zhou;given-names:Y</infon><infon key=\"name_3\">surname:Liu;given-names:Z</infon><infon key=\"name_4\">surname:Zhou;given-names:X</infon><infon key=\"pub-id_pmid\">32247038</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin. Immunol.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">214</infon><infon key=\"year\">2020</infon><offset>65124</offset><text>Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19</text></passage><passage><infon key=\"fpage\">1198</infon><infon key=\"name_0\">surname:Ma;given-names:Y</infon><infon key=\"name_1\">surname:Zeng;given-names:H</infon><infon key=\"name_2\">surname:Zhan;given-names:Z</infon><infon key=\"name_3\">surname:Lu;given-names:H</infon><infon key=\"name_4\">surname:Zeng;given-names:Z</infon><infon key=\"pub-id_pmid\">32903363</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">China. Front. Pharmacol.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>65248</offset><text>Corticosteroid Use in the Treatment of COVID-19: A Multicenter Retrospective Study in Hunan</text></passage><passage><infon key=\"name_0\">surname:Magagnoli;given-names:J</infon><infon key=\"name_1\">surname:Narendran;given-names:S</infon><infon key=\"name_2\">surname:Pereira;given-names:F</infon><infon key=\"name_3\">surname:Cummings;given-names:T</infon><infon key=\"name_4\">surname:Hardin;given-names:JW</infon><infon key=\"pub-id_doi\">10.1101/2020.04.16.20065920</infon><infon key=\"pub-id_pmid\">32511622</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>65340</offset><text>Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19</text></passage><passage><infon key=\"fpage\">1347</infon><infon key=\"name_0\">surname:Magro;given-names:L</infon><infon key=\"name_1\">surname:Jacquelin;given-names:B</infon><infon key=\"name_2\">surname:Escadafal;given-names:C</infon><infon key=\"name_3\">surname:Garneret;given-names:P</infon><infon key=\"name_4\">surname:Kwasiborski;given-names:A</infon><infon key=\"pub-id_pmid\">28465576</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci. Rep.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2017</infon><offset>65430</offset><text>Paper-based RNA detection and multiplexed analysis for Ebola virus diagnostics</text></passage><passage><infon key=\"name_0\">surname:Mahevas;given-names:M</infon><infon key=\"name_1\">surname:Tran;given-names:V-T</infon><infon key=\"name_2\">surname:Roumier;given-names:M</infon><infon key=\"name_3\">surname:Chabrol;given-names:A</infon><infon key=\"name_4\">surname:Paule;given-names:R</infon><infon key=\"pub-id_doi\">10.1101/2020.04.10.20060699</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>65509</offset><text>No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial</text></passage><passage><infon key=\"fpage\">84</infon><infon key=\"lpage\">87</infon><infon key=\"name_0\">surname:Martinez Molina;given-names:D</infon><infon key=\"name_1\">surname:Jafari;given-names:R</infon><infon key=\"name_2\">surname:Ignatushchenko;given-names:M</infon><infon key=\"name_3\">surname:Seki;given-names:T</infon><infon key=\"name_4\">surname:Larsson;given-names:EA</infon><infon key=\"pub-id_pmid\">23828940</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">341</infon><infon key=\"year\">2013</infon><offset>65713</offset><text>Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay</text></passage><passage><infon key=\"fpage\">1033</infon><infon key=\"lpage\">1034</infon><infon key=\"name_0\">surname:Mehta;given-names:P</infon><infon key=\"name_1\">surname:McAuley;given-names:DF</infon><infon key=\"name_2\">surname:Brown;given-names:M</infon><infon key=\"name_3\">surname:Sanchez;given-names:E</infon><infon key=\"name_4\">surname:Tattersall;given-names:RS</infon><infon key=\"pub-id_pmid\">32192578</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>65807</offset><text>COVID-19: consider cytokine storm syndromes and immunosuppression</text></passage><passage><infon key=\"name_0\">surname:Metsky;given-names:HC</infon><infon key=\"name_1\">surname:Freije;given-names:CA</infon><infon key=\"name_2\">surname:Kosoko-Thoroddsen;given-names:T-SF</infon><infon key=\"name_3\">surname:Sabeti;given-names:PC</infon><infon key=\"name_4\">surname:Myhrvold;given-names:C</infon><infon key=\"pub-id_doi\">10.1101/2020.02.26.967026</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">bioRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>65873</offset><text>CRISPR-based COVID-19 surveillance using a genomically-comprehensive machine learning approach</text></passage><passage><infon key=\"name_0\">surname:Nalla;given-names:AK</infon><infon key=\"name_1\">surname:Casto;given-names:AM</infon><infon key=\"name_2\">surname:Huang;given-names:M-LW</infon><infon key=\"name_3\">surname:Perchetti;given-names:GA</infon><infon key=\"name_4\">surname:Sampoleo;given-names:R</infon><infon key=\"pub-id_doi\">10.1128/JCM.00557-20</infon><infon key=\"pub-id_pmid\">32269100</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Clin. Microbiol.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>65968</offset><text>Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different Primer/Probe Sets and One Assay Kit</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>66081</offset><text>Narin A, Kaya C and Pamuk Z 2020 Automatic Detection of Coronavirus Disease (COVID-19) Using X-ray Images and Deep Convolutional Neural Networks. arXiv arXiv:2003.10849</text></passage><passage><infon key=\"name_0\">surname:Oldenburg;given-names:CE</infon><infon key=\"name_1\">surname:Doan;given-names:T</infon><infon key=\"pub-id_doi\">10.1016/S0140-6736(20)31863-8</infon><infon key=\"pub-id_pmid\">33189186</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>66250</offset><text>Azithromycin for severe COVID-19</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>66283</offset><text>OncoImmune I 2020 A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment. https://clinicaltrials.gov/ct2/show/NCT04317040</text></passage><passage><infon key=\"name_0\">surname:Ong;given-names:E</infon><infon key=\"name_1\">surname:Wong;given-names:MU</infon><infon key=\"name_2\">surname:Huffman;given-names:A</infon><infon key=\"name_3\">surname:He;given-names:Y</infon><infon key=\"pub-id_doi\">10.1101/2020.03.20.000141</infon><infon key=\"pub-id_pmid\">33052349</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">bioRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>66494</offset><text>COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>66577</offset><text>Organization WH 2020a DRAFT landscape of COVID-19 candidate vaccines. WHOhttps://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>66737</offset><text>Organization WH 2020b WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. Geneva, Switzerland: WHO.https://www.who.int/news/item/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19</text></passage><passage><infon key=\"fpage\">400</infon><infon key=\"lpage\">409</infon><infon key=\"name_0\">surname:Ortega;given-names:JT</infon><infon key=\"name_1\">surname:Serrano;given-names:ML</infon><infon key=\"name_2\">surname:Pujol;given-names:FH</infon><infon key=\"name_3\">surname:Rangel;given-names:HR</infon><infon key=\"pub-id_pmid\">32210741</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">EXCLI J.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">19</infon><infon key=\"year\">2020</infon><offset>67002</offset><text>Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target</text></passage><passage><infon key=\"fpage\">115</infon><infon key=\"lpage\">117</infon><infon key=\"name_0\">surname:Qiu;given-names:T</infon><infon key=\"name_1\">surname:Mao;given-names:T</infon><infon key=\"name_2\">surname:Wang;given-names:Y</infon><infon key=\"name_3\">surname:Zhou;given-names:M</infon><infon key=\"name_4\">surname:Qiu;given-names:J</infon><infon key=\"pub-id_pmid\">32171450</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Genet. Genomics</infon><infon key=\"type\">ref</infon><infon key=\"volume\">47</infon><infon key=\"year\">2020</infon><offset>67134</offset><text>Identification of potential cross-protective epitope between a new type of coronavirus (2019-nCoV) and severe acute respiratory syndrome virus</text></passage><passage><infon key=\"fpage\">e30</infon><infon key=\"lpage\">e31</infon><infon key=\"name_0\">surname:Richardson;given-names:P</infon><infon key=\"name_1\">surname:Griffin;given-names:I</infon><infon key=\"name_2\">surname:Tucker;given-names:C</infon><infon key=\"name_3\">surname:Smith;given-names:D</infon><infon key=\"name_4\">surname:Oechsle;given-names:O</infon><infon key=\"pub-id_pmid\">32032529</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>67277</offset><text>Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>67352</offset><text>Ridgeback Biotherapeutics L 2020 The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2. https://www.clinicaltrials.gov/ct2/show/NCT04405739</text></passage><passage><infon key=\"name_0\">surname:Riva;given-names:L</infon><infon key=\"name_1\">surname:Yuan;given-names:S</infon><infon key=\"name_2\">surname:Yin;given-names:X</infon><infon key=\"name_3\">surname:Martin-Sancho;given-names:L</infon><infon key=\"name_4\">surname:Matsunaga;given-names:N</infon><infon key=\"pub-id_doi\">10.1101/2020.04.16.044016</infon><infon key=\"pub-id_pmid\">32511357</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">bioRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>67509</offset><text>A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals</text></passage><passage><infon key=\"fpage\">473</infon><infon key=\"lpage\">475</infon><infon key=\"name_0\">surname:Russell;given-names:CD</infon><infon key=\"name_1\">surname:Millar;given-names:JE</infon><infon key=\"name_2\">surname:Baillie;given-names:JK</infon><infon key=\"pub-id_pmid\">32043983</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>67575</offset><text>Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury</text></passage><passage><infon key=\"name_0\">surname:Sanders;given-names:JM</infon><infon key=\"name_1\">surname:Monogue;given-names:ML</infon><infon key=\"name_2\">surname:Jodlowski;given-names:TZ</infon><infon key=\"name_3\">surname:Cutrell;given-names:JB</infon><infon key=\"pub-id_doi\">10.1001/jama.2020.6019</infon><infon key=\"pub-id_pmid\">33165621</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>67661</offset><text>Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review</text></passage><passage><infon key=\"fpage\">eabb5883</infon><infon key=\"name_0\">surname:Sheahan;given-names:TP</infon><infon key=\"name_1\">surname:Sims;given-names:AC</infon><infon key=\"name_2\">surname:Zhou;given-names:S</infon><infon key=\"name_3\">surname:Graham;given-names:RL</infon><infon key=\"name_4\">surname:Pruijssers;given-names:AJ</infon><infon key=\"pub-id_pmid\">32253226</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci. Transl. Med.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>67736</offset><text>An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice</text></passage><passage><infon key=\"fpage\">971</infon><infon key=\"lpage\">978</infon><infon key=\"name_0\">surname:Singh;given-names:AK</infon><infon key=\"name_1\">surname:Majumdar;given-names:S</infon><infon key=\"name_2\">surname:Singh;given-names:R</infon><infon key=\"name_3\">surname:Misra;given-names:A</infon><infon key=\"pub-id_pmid\">32610262</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Diabetes Metab. Syndr.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">14</infon><infon key=\"year\">2020</infon><offset>67880</offset><text>Role of corticosteroid in the management of COVID-19: A systemic review and a Clinicianâs perspective</text></passage><passage><infon key=\"fpage\">400</infon><infon key=\"lpage\">402</infon><infon key=\"name_0\">surname:Stebbing;given-names:J</infon><infon key=\"name_1\">surname:Phelan;given-names:A</infon><infon key=\"name_2\">surname:Griffin;given-names:I</infon><infon key=\"name_3\">surname:Tucker;given-names:C</infon><infon key=\"name_4\">surname:Oechsle;given-names:O</infon><infon key=\"pub-id_pmid\">32113509</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect. Dis.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>67984</offset><text>COVID-19: combining antiviral and anti-inflammatory treatments</text></passage><passage><infon key=\"name_0\">surname:Tai;given-names:W</infon><infon key=\"name_1\">surname:He;given-names:L</infon><infon key=\"name_2\">surname:Zhang;given-names:X</infon><infon key=\"name_3\">surname:Pu;given-names:J</infon><infon key=\"name_4\">surname:Voronin;given-names:D</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68047</offset></passage><passage><infon key=\"fpage\">382</infon><infon key=\"lpage\">385</infon><infon key=\"name_0\">surname:Tian;given-names:X</infon><infon key=\"name_1\">surname:Li;given-names:C</infon><infon key=\"name_2\">surname:Huang;given-names:A</infon><infon key=\"name_3\">surname:Xia;given-names:S</infon><infon key=\"name_4\">surname:Lu;given-names:S</infon><infon key=\"pub-id_pmid\">32065055</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg. Microbes. Infect.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>68048</offset><text>Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody</text></passage><passage><infon key=\"fpage\">841</infon><infon key=\"lpage\">843</infon><infon key=\"name_0\">surname:To;given-names:KK-W</infon><infon key=\"name_1\">surname:Tsang;given-names:OT-Y</infon><infon key=\"name_2\">surname:Yip;given-names:CC-Y</infon><infon key=\"name_3\">surname:Chan;given-names:K-H</infon><infon key=\"name_4\">surname:Wu;given-names:T-C</infon><infon key=\"pub-id_pmid\">32047895</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin. Infect. Dis.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>68160</offset><text>Consistent Detection of 2019 Novel Coronavirus in Saliva</text></passage><passage><infon key=\"name_0\">surname:Ton;given-names:A-T</infon><infon key=\"name_1\">surname:Gentile;given-names:F</infon><infon key=\"name_2\">surname:Hsing;given-names:M</infon><infon key=\"name_3\">surname:Ban;given-names:F</infon><infon key=\"name_4\">surname:Cherkasov;given-names:A</infon><infon key=\"pub-id_doi\">10.26434/chemrxiv.11860077.v1</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ChemRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68217</offset><text>Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds</text></passage><passage><infon key=\"name_0\">surname:Wang;given-names:J</infon><infon key=\"name_1\">surname:Hajizadeh;given-names:N</infon><infon key=\"name_2\">surname:Moore;given-names:EE</infon><infon key=\"name_3\">surname:McIntyre;given-names:RC</infon><infon key=\"name_4\">surname:Moore;given-names:PK</infon><infon key=\"pub-id_doi\">10.1111/jth.14828</infon><infon key=\"pub-id_pmid\">33433069</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Thromb. Haemost.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68331</offset><text>Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series</text></passage><passage><infon key=\"fpage\">269</infon><infon key=\"lpage\">271</infon><infon key=\"name_0\">surname:Wang;given-names:M</infon><infon key=\"name_1\">surname:Cao;given-names:R</infon><infon key=\"name_2\">surname:Zhang;given-names:L</infon><infon key=\"name_3\">surname:Yang;given-names:X</infon><infon key=\"name_4\">surname:Liu;given-names:J</infon><infon key=\"pub-id_pmid\">32020029</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Res.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2020</infon><offset>68458</offset><text>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>68565</offset><text>WHO 2020 WHO R&amp;D Blueprint COVID-19 Animal Models. https://www.who.int/publications/m/item/covid-19-animal-models---summary-of-progress-made-by-the-who-covid-19-modelling-(march-04-june-2020)</text></passage><passage><infon key=\"fpage\">343</infon><infon key=\"lpage\">355</infon><infon key=\"name_0\">surname:Xia;given-names:S</infon><infon key=\"name_1\">surname:Liu;given-names:M</infon><infon key=\"name_2\">surname:Wang;given-names:C</infon><infon key=\"name_3\">surname:Xu;given-names:W</infon><infon key=\"name_4\">surname:Lan;given-names:Q</infon><infon key=\"pub-id_pmid\">32231345</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Res.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2020</infon><offset>68757</offset><text>Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion</text></passage><passage><infon key=\"name_0\">surname:Xia;given-names:S</infon><infon key=\"name_1\">surname:Zhu;given-names:Y</infon><infon key=\"name_2\">surname:Liu;given-names:M</infon><infon key=\"name_3\">surname:Lan;given-names:Q</infon><infon key=\"name_4\">surname:Xu;given-names:W</infon><infon key=\"pub-id_doi\">10.1038/s41423-020-0374-2</infon><infon key=\"pub-id_pmid\">33097834</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Mol. Immunol.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68951</offset><text>Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein</text></passage><passage><infon key=\"name_0\">surname:Xiang;given-names:J</infon><infon key=\"name_1\">surname:Yan;given-names:M</infon><infon key=\"name_2\">surname:Li;given-names:H</infon><infon key=\"name_3\">surname:Liu;given-names:T</infon><infon key=\"name_4\">surname:Lin;given-names:C</infon><infon key=\"pub-id_doi\">10.1101/2020.02.27.20028787</infon><infon key=\"pub-id_pmid\">33106820</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>69041</offset><text>Evaluation of Enzyme-Linked Immunoassay and Colloidal Gold- Immunochromatographic Assay Kit for Detection of Novel Coronavirus (SARS-Cov-2) Causing an Outbreak of Pneumonia (COVID-19)</text></passage><passage><infon key=\"name_0\">surname:Yan;given-names:C</infon><infon key=\"name_1\">surname:Cui;given-names:J</infon><infon key=\"name_2\">surname:Huang;given-names:L</infon><infon key=\"name_3\">surname:Du;given-names:B</infon><infon key=\"name_4\">surname:Chen;given-names:L</infon><infon key=\"pub-id_doi\">10.1016/j.cmi.2020.04.001</infon><infon key=\"pub-id_pmid\">33160036</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin. Microbiol. Infect.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>69225</offset><text>Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay</text></passage><passage><infon key=\"name_0\">surname:Yang;given-names:Y</infon><infon key=\"name_1\">surname:Shen;given-names:C</infon><infon key=\"name_2\">surname:Li;given-names:J</infon><infon key=\"name_3\">surname:Yuan;given-names:J</infon><infon key=\"name_4\">surname:Yang;given-names:M</infon><infon key=\"pub-id_doi\">10.1101/2020.03.02.20029975</infon><infon key=\"pub-id_pmid\">7781329</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">medRxiv</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>69363</offset><text>Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome</text></passage><passage><infon key=\"fpage\">e13</infon><infon key=\"lpage\">e20</infon><infon key=\"name_0\">surname:Yang;given-names:Z</infon><infon key=\"name_1\">surname:Liu;given-names:J</infon><infon key=\"name_2\">surname:Zhou;given-names:Y</infon><infon key=\"name_3\">surname:Zhao;given-names:X</infon><infon key=\"name_4\">surname:Zhao;given-names:Q</infon><infon key=\"pub-id_pmid\">32283144</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Infect.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">81</infon><infon key=\"year\">2020</infon><offset>69492</offset><text>The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis</text></passage><passage><infon key=\"fpage\">E756</infon><infon key=\"lpage\">E767</infon><infon key=\"name_0\">surname:Ye;given-names:Z</infon><infon key=\"name_1\">surname:Wang;given-names:Y</infon><infon key=\"name_2\">surname:Colunga-Lozano;given-names:LE</infon><infon key=\"name_3\">surname:Prasad;given-names:M</infon><infon key=\"name_4\">surname:Tangamornsuksan;given-names:W</infon><infon key=\"pub-id_pmid\">32409522</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">CMAJ</infon><infon key=\"type\">ref</infon><infon key=\"volume\">192</infon><infon key=\"year\">2020</infon><offset>69609</offset><text>Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis</text></passage><passage><infon key=\"name_0\">surname:Zha;given-names:L</infon><infon key=\"name_1\">surname:Li;given-names:S</infon><infon key=\"name_2\">surname:Pan;given-names:L</infon><infon key=\"name_3\">surname:Tefsen;given-names:B</infon><infon key=\"name_4\">surname:Li;given-names:Y</infon><infon key=\"pub-id_doi\">10.5694/mja2.50577</infon><infon key=\"pub-id_pmid\">32266987</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Med. J. Aust.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>69841</offset><text>Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)</text></passage><passage><infon key=\"name_0\">surname:Zhang;given-names:B</infon><infon key=\"name_1\">surname:Liu;given-names:S</infon><infon key=\"name_2\">surname:Tan;given-names:T</infon><infon key=\"name_3\">surname:Huang;given-names:W</infon><infon key=\"name_4\">surname:Dong;given-names:Y</infon><infon key=\"pub-id_doi\">10.1016/j.chest.2020.03.039</infon><infon key=\"pub-id_pmid\">33217413</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">CHEST</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>69919</offset><text>Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection</text></passage><passage><infon key=\"name_0\">surname:Zhang;given-names:C</infon><infon key=\"name_1\">surname:Wu;given-names:Z</infon><infon key=\"name_2\">surname:Li;given-names:J-W</infon><infon key=\"name_3\">surname:Zhao;given-names:H</infon><infon key=\"name_4\">surname:Wang;given-names:G-Q</infon><infon key=\"pub-id_doi\">10.1016/j.ijantimicag.2020.105954</infon><infon key=\"pub-id_pmid\">33352235</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int. J. Antimicrob. Agents</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70008</offset><text>The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality</text></passage><passage><infon key=\"fpage\">117583</infon><infon key=\"name_0\">surname:Zhang;given-names:R</infon><infon key=\"name_1\">surname:Wang;given-names:X</infon><infon key=\"name_2\">surname:Ni;given-names:L</infon><infon key=\"name_3\">surname:Di;given-names:X</infon><infon key=\"name_4\">surname:Ma;given-names:B</infon><infon key=\"pub-id_pmid\">32217117</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Life Sci.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">250</infon><infon key=\"year\">2020</infon><offset>70160</offset><text>COVID-19: Melatonin as a potential adjuvant treatment</text></passage><passage><infon key=\"name_0\">surname:Zhang;given-names:Y</infon><infon key=\"name_1\">surname:Yu;given-names:L</infon><infon key=\"name_2\">surname:Tang;given-names:L</infon><infon key=\"name_3\">surname:Zhu;given-names:M</infon><infon key=\"name_4\">surname:Jin;given-names:Y</infon><infon key=\"pub-id_doi\">10.1016/j.eng.2020.03.006</infon><infon key=\"pub-id_pmid\">33449771</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Engineering (Beijing)</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70214</offset><text>A promising anti-cytokine-storm targeted therapy for COVID-19: The artificial-liver blood-purification system</text></passage></document></collection>\n",
      "\n",
      "Study 33980687: <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n",
      "<!DOCTYPE collection SYSTEM \"BioC.dtd\">\n",
      "<collection><source>PMC</source><date>20211217</date><key>pmc.key</key><document><id>8142517</id><infon key=\"license\">NO-CC CODE</infon><passage><infon key=\"article-id_doi\">10.1128/CMR.00228-20</infon><infon key=\"article-id_pmc\">8142517</infon><infon key=\"article-id_pmid\">33980687</infon><infon key=\"article-id_publisher-id\">00228-20</infon><infon key=\"elocation-id\">e00228-20</infon><infon key=\"issue\">3</infon><infon key=\"kwd\">COVID-19 SARS-CoV-2 2019-nCoV NAAT PCR serology antigen coronavirus biomarkers next-generation sequencing</infon><infon key=\"license\">All Rights Reserved. This article is made available via the PMC Open Access Subset for unrestricted noncommercial re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. </infon><infon key=\"name_0\">surname:Safiabadi Tali;given-names:Seyed Hamid</infon><infon key=\"name_1\">surname:LeBlanc;given-names:Jason J.</infon><infon key=\"name_10\">surname:Tali;given-names:Seyed Hamid Safiabadi</infon><infon key=\"name_11\">surname:Sadiq;given-names:Zubi</infon><infon key=\"name_12\">surname:Oyewunmi;given-names:Oyejide Damilola</infon><infon key=\"name_13\">surname:Jahanshahi-Anbuhi;given-names:Sana</infon><infon key=\"name_14\">surname:Tali;given-names:Seyed Hamid Safiabadi</infon><infon key=\"name_15\">surname:Sadiq;given-names:Zubi</infon><infon key=\"name_16\">surname:Oyewunmi;given-names:Oyejide Damilola</infon><infon key=\"name_2\">surname:Sadiq;given-names:Zubi</infon><infon key=\"name_3\">surname:Oyewunmi;given-names:Oyejide Damilola</infon><infon key=\"name_4\">surname:Camargo;given-names:Carolina</infon><infon key=\"name_5\">surname:Nikpour;given-names:Bahareh</infon><infon key=\"name_6\">surname:Armanfard;given-names:Narges</infon><infon key=\"name_7\">surname:Sagan;given-names:Selena M.</infon><infon key=\"name_8\">surname:Jahanshahi-Anbuhi;given-names:Sana</infon><infon key=\"name_9\">surname:Jahanshahi-Anbuhi;given-names:Sana</infon><infon key=\"section_type\">TITLE</infon><infon key=\"title\">KEYWORDS</infon><infon key=\"type\">front</infon><infon key=\"volume\">34</infon><infon key=\"year\">2021</infon><offset>0</offset><text>Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>105</offset><text>The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory disease coronavirus 2 (SARS-CoV-2), has led to millions of confirmed cases and deaths worldwide. Efficient diagnostic tools are in high demand, as rapid and large-scale testing plays a pivotal role in patient management and decelerating disease spread.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>443</offset><text>SUMMARY</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>451</offset><text>The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory disease coronavirus 2 (SARS-CoV-2), has led to millions of confirmed cases and deaths worldwide. Efficient diagnostic tools are in high demand, as rapid and large-scale testing plays a pivotal role in patient management and decelerating disease spread. This paper reviews current technologies used to detect SARS-CoV-2 in clinical laboratories as well as advances made for molecular, antigen-based, and immunological point-of-care testing, including recent developments in sensor and biosensor devices. The importance of the timing and type of specimen collection is discussed, along with factors such as disease prevalence, setting, and methods. Details of the mechanisms of action of the various methodologies are presented, along with their application span and known performance characteristics. Diagnostic imaging techniques and biomarkers are also covered, with an emphasis on their use for assessing COVID-19 or monitoring disease severity or complications. While the SARS-CoV-2 literature is rapidly evolving, this review highlights topics of interest that have occurred during the pandemic and the lessons learned throughout. Exploring a broad armamentarium of techniques for detecting SARS-CoV-2 will ensure continued diagnostic support for clinicians, public health, and infection prevention and control for this pandemic and provide advice for future pandemic preparedness.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>1922</offset><text>INTRODUCTION</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>1935</offset><text>While coronavirus disease 2019 (COVID-19) is not the first pandemic of the 21st century, it has generated unprecedented global concern and responses. COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is thought to have emerged from a zoonotic source and spread rapidly in humans through respiratory droplets and contact. There is some concern for airborne transmission, but the role of this transmission route outside the potential aerosolizing procedures in health care settings is unclear. With an estimated reproductive number, R naught (R0), of between 1.4 and 5.6, SARS-CoV-2 rapidly spread worldwide. Since the first cases reported in December 2019, there have been over 106 million confirmed cases and 2.3 million deaths reported worldwide (as of 9 February 2021).</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>2739</offset><text>From a disease manifestation perspective, SARS-CoV-2 infection can be asymptomatic, and COVID-19 spans from a mild influenza-like illness (ILI) to life-threatening complications. SARS-CoV-2 not only affects the respiratory tract, resulting in pneumonia, but also can affect gastrointestinal (GI), neurological, or cardiovascular systems. Atypical presentations of COVID-19 include cutaneous manifestations such as a Kawasaki-like disease in children and ophthalmic/gustatory dysfunction (i.e., anosmia and ageusia, which are the loss of smell and taste, respectively), which may have been underestimated in initial reports.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>3363</offset><text>Despite numerous therapeutic options being explored (e.g., convalescent-phase plasma), no large-scale treatments are available. Public health interventions have evolved over time to limit viral spread (Fig. 1) and have included the use of personal protective equipment (PPE) like masks, handwashing, and containment measures such as city lockdowns, travel restrictions, and physical distancing. Although these strategies have been essential to reduce the virusâs spread, they have had significant adverse socioeconomic impacts, and adherence to these prevention strategies is challenging to sustain. Currently, cases of COVID-19 have declined following a first pandemic wave in some areas, whereas other areas are experiencing subsequent waves of activity. Fortunately, many vaccine candidates are under development and undergoing regulatory approval processes. Recently, COVID-19 mRNA vaccines have been the first licensed for use and are rapidly being administered as supplies are provided. However, given the time required for adequate immunization coverage in the population at large, subsequent pandemic waves are anticipated. Therefore, detection methods for SARS-CoV-2 remain a crucial part of containment and mitigation strategies, and lessons learned from this pandemic may help prepare against future pandemics.</text></passage><passage><infon key=\"file\">CMR.00228-20-f001.jpg</infon><infon key=\"id\">F1</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>4687</offset><text>Timeline of COVID-19 spread and the global response to it. Of note, while SARS-CoV-2 was initially thought to have emerged from China in December 2020, there are data to suggest that it may have circulated more broadly earlier than initially recorded in other countries, and further studies are under way to investigate this possibility in other areas.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>5040</offset><text>In terms of testing, real-time reverse transcription-PCR (RT-PCR) remains the most common method used to identify SARS-CoV-2. While common in diagnostic laboratories worldwide, many laboratories remain faced with supply chain shortages for real-time RT-PCR reagents and consumables, all while being asked to increase testing capacity. As such, delays were common for test results, prompting the exploration of alternative testing options such as specimen pooling or laboratory testing using methods other than RT-PCR. Methods that could enhance testing capacity, streamline testing (i.e., automation), or provide more rapid results in easy-to-use formats that are amenable to point-of-care (POC) applications without complex instrumentation (e.g., isothermal technologies) were all desired. Rigorous research escalated quickly from the academic to industry partners, and this research is ongoing to develop testing alternatives or complements to existing technologies.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>6009</offset><text>While recent reviews have been published on the management of SARS-CoV-2, recent advancements in novel diagnostic methods justify the need for a more comprehensive synthesis of the current literature. In this review, first, the biological characteristics of SARS-CoV-2 are described in order to fully understand the molecular and immunological methods for its detection. Following a brief discussion on the COVID-19 manifestations, compatible signs and symptoms, and disease biomarkers, diagnostic imaging techniques are described in relation to COVID-19 lower respiratory tract involvement, including applications such as monitoring disease severity, the progression of the illness, or complications. Next, a comprehensive review of current and recent advances in molecular, antigen (Ag), and serological immunodiagnostic methods is covered, including rapid diagnostic tests (RDTs) used in the laboratory setting and POC applications. Overall, this review expands our knowledge of current and exploratory avenues for detecting SARS-CoV-2 and COVID-19.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>7062</offset><text>It should be noted that some of the references used in this review were preprints that have not been peer reviewed, and recognizing that data on the detection of SARS-CoV-2 or COVID-19 are rapidly evolving, some details on testing options and guidelines may no longer be recent and should thus be reviewed in the context of recent findings and recommendations. Nonetheless, this review provides a comprehensive synthesis of the most current data available to date, along with current recommendations for the detection of SARS-CoV-2 or the diagnosis of COVID-19.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>7624</offset><text>SARS-CoV-2 GENOME AND STRUCTURE</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>7656</offset><text>Understanding the genetic and structural properties of SARS-CoV-2 is a prerequisite to developing effective diagnostic tools. SARS-CoV-2 was first isolated and sequenced in China in January 2020. Transmission electron microscopy revealed that SARS-CoV-2 has a diameter in the range of 60 to 140 nm, and its morphology was consistent with those of other members of the Coronaviridae family (Fig. 2A). SARS-CoV-2 is an enveloped, positive-strand RNA virus, and on the genetic level, it shares 96%, 80%, and 50% sequence identities with bat coronavirus (RaTG13), SARS-CoV-1, and Middle East respiratory syndrome coronavirus (MERS-CoV), respectively. Based on these analyses, the International Committee on Taxonomy of Viruses named the virus SARS-CoV-2, which was formerly referred to as the 2019 novel coronavirus (2019-nCoV) or human coronavirus 2019 (hCoV-19).</text></passage><passage><infon key=\"file\">CMR.00228-20-f002.jpg</infon><infon key=\"id\">F2</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>8517</offset><text>Physical and genome structure of SARS-CoV-2. (A) Diagram of the SARS-CoV-2 virion. (B) Genome organization and proteins with known or unknown functions.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>8670</offset><text>Our understanding of SARS-CoV-2 structure and function has been largely derived from research on SARS-CoV-1, MERS-CoV, and seasonal coronaviruses. SARS-CoV-2 has a single-stranded positive-sense RNA genome of between 26 and 35 kb, encoding approximately 27 proteins with similarity to proteins of known functions, while others are unclear/unknown or putative (Fig. 2B). The first open reading frame (ORF1a/b) on the 5â² end of the viral genome occupies â¼71% of the entire genome and produces two polyproteins (ppâs), pp1a and pp1ab. These two polyproteins are processed by the viral proteases into 15 nonstructural proteins (nspâs), and these proteins are collectively involved in polyprotein processing, viral RNA replication, and mRNA synthesis. The remaining proteins, including the structural and accessory proteins, are expressed from several nested subgenomic mRNAs produced through a process known as discontinuous transcription by the viral RNA-dependent RNA polymerase (RdRp).</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>9663</offset><text>The structural proteins include the small envelope (E) protein, membrane (M) protein (also known as the matrix protein), nucleocapsid (N) protein, hemagglutinin-esterase (HE) protein, and spike (S) glycoprotein (Fig. 2A). The E and M proteins are primarily involved in viral assembly, budding, and virion morphogenesis, while the N protein complexes with the viral genomic RNA to generate the nucleocapsid. The S protein is the major surface glycoprotein on SARS-CoV-2, forming approximately 40 trimers that play an important role in both receptor binding and membrane fusion through the two functional subunits S1 and S2. The S protein trimers contain a stable stalk separated from the globular heads by three flexible hinges, allowing for orientation freedom to interact with host cell receptors. The S1 subunit contains the receptor-binding domain (RBD) that directly interacts with the angiotensin-converting enzyme 2 (ACE2) receptor on the host cell surface, whereas the S2 subunit contains a structural loop responsible for fusion events between the viral and host cell membranes, resulting in the release of the viral genomic RNA into the cytoplasm. Of note, along with engaging the ACE2 host cell receptor, the cellular serine protease TMPRSS2 is engaged for S protein priming, and this cofactor has been investigated as a possible antiviral target using viral entry inhibitors.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>11050</offset><text>Overall, having knowledge of SARS-CoV-2 pathogenesis can help in understanding disease manifestations and help guide the development of molecular and immunological tools for the identification of this virus.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>11258</offset><text>CLINICAL MANIFESTATIONS OF COVID-19</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>11294</offset><text>The spectrum of SARS-CoV-2 infection can vary from asymptomatic infection to life-threatening complications of COVID-19. Using modeling, it was estimated that over 59% of transmissions arise from asymptomatic individuals, with 35% from individuals in presymptomatic stages of infection and 24% from individuals who never develop symptoms. These estimates are concerning but emphasize the need for the wide use of vaccines and maintaining key public health interventions like mask wearing, hand hygiene, and social distancing.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>11820</offset><text>In most symptomatic cases, COVID-19 presents as a mild to moderate upper respiratory illness, with signs and symptoms compatible with those of other respiratory viruses. As such, the diagnostic accuracy of any individual sign or symptom is very poor, and neither the presence nor the absence of any sign or symptom can be used to rule in or out COVID-19. With the possibility of other pathogens that could present like SARS-CoV-2 infection, case definitions based on clinical presentation are not sufficiently specific but can help support the investigation of suspect COVID-19 cases. On the other hand, given that the list of possible presentations and atypical manifestations of COVID-19 could mirror those of other diseases, identifying the etiology of illness as SARS-CoV-2 requires laboratory testing.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>12627</offset><text>In a recent Cochrane review, a summary of 16 studies (7,706 patients) was presented. Only six of the possible signs and symptoms of COVID-19 had sensitivities of &gt;50%, and results were highly variable between studies and settings. The most common signs and symptoms (and their performances) are summarized as follows: cough (with sensitivity and specificity from 43 to 71% and 14 to 54%, respectively), sore throat (5 to 71% and 55 to 80%), fever (7 to 91% and 16% to 94%), musculoskeletal symptoms (e.g., arthralgias or myalgias) (19 to 86% and 45 to 91%), fatigue (10 to 57% and 60 to 94%), and headache (3 to 71% and 78 to 98%). It was noted that possible confounders were present, and the high heterogeneity between data suggested that signs and symptoms are variable between individuals. Other less common clinical presentations have been documented, including alterations in smell or taste (i.e., anosmia or dysgeusia) as well as neurological or cutaneous manifestations. It is noteworthy that in the early stages of the pandemic, some of these symptoms may have been missed or underreported, but knowledge on possible clinical presentations of COVID-19 have evolved over time.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>13811</offset><text>In some cases of COVID-19, progression to lower respiratory tract illness (e.g., pneumonia) can occur and may require hospitalization, intensive care unit (ICU) support, and mechanical ventilation, and complications can arise, which include acute respiratory distress, multiorgan dysfunction, and death. In general, adverse outcomes and deaths are more common with increasing age or in individuals with underlying medical comorbidities such as respiratory system disease, cardiovascular disease, and diabetes. Fatality rates vary among studies and countries but are generally high in the hospital setting (e.g., 4 to 11%) compared to the overall case fatality rates (e.g., 2 to 3%) in the general population. In terms of recovery, the median duration of hospital stay is 10 to 14âdays, and resolution generally occurs within 2 to 3âweeks. There is a lack of evidence on whether some symptoms can persist after recovery. In one study, patients were monitored up to 60âdays after recovery, with 87.4% reporting at least one symptom. The most common symptoms were fatigue (53.1%), dyspnea (43.4%), joint pain (27.3%), and chest pain (21.7%).</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>14956</offset><text>Overall, while some signs or symptoms may be compatible with COVID-19, none are specific, and laboratory testing is required to confirm the diagnosis. Further studies are required to help identify the frequency of atypical clinical presentations, and additional studies looking at known clinical presentations of COVID-19 should consider possible confounders such as the possibility of other etiologies, host factors (e.g., comorbidities), disease severity, and the times from infection and symptom onset.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>15462</offset><text>BIOMARKERS FOR COVID-19 AND ROUTINE LABORATORY INVESTIGATIONS</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>15524</offset><text>Apart from laboratory tests specific for detecting SARS-CoV-2 discussed throughout this review, routine laboratory testing spanning hematological, biochemical, and chemical markers is used to assess a patientâs health or identify possible clues to a disease state. Such routine laboratory workup of individuals is used to refine a medical differential diagnosis, thereby supporting or refuting potential causes of the clinical presentation based on typical outcomes of these investigations for a defined disease. Many of these investigations can evolve through the clinical course of illness, and additional testing can be ordered by physicians based on the clinical presentation. These can include tests such as white blood cell (WBC) counts, markers for inflammatory conditions (C-reactive protein [CRP], procalcitonin [PCT], or interleukin 6 [IL-6]), tests for anticoagulation, and indicators of tissue damage (alanine aminotransferase [ALT], aspartate aminotransferase [AST], lactate dehydrogenase [LDH], and creatine kinase [CK]). While biomarkers for COVID-19 have been the subject of much investigation during the current pandemic, none of these tests are sensitive or specific for COVID-19. In a Cochrane review analyzing 67 laboratory tests from 21 studies encompassing 14,126 COVID-19 cases and 56,585 non-COVID-19 cases, only three markers showed sensitivity and specificity values of &gt;50%: a decrease in the lymphocyte count and increases in the inflammatory markers CRP and IL-6. Overall, no individual biomarker can be used reliably to rule COVID-19 in or out, and laboratory testing should be performed. However, it should be noted that some laboratory markers have value for patient management as they can help assess the severity of the disease or progression of the illness or even act as risk factors for death. In the most recent Centers for Disease Control and Prevention (CDC) guidance documents for clinicians caring for patients with COVID-19, a summary of important laboratory tests is described, with lymphopenia being the most common laboratory finding in patients hospitalized with COVID-19. Laboratory markers associated with increased illness severity include lymphopenia, neutropenia, and elevated serum ALT, AST, LDH, CRP, and ferritin. Patients with critical illness have high plasma levels of inflammatory makers, and elevated levels of d-dimer and lymphopenia have been associated with an increased risk of death.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>17975</offset><text>Of note, this section is not intended to be a comprehensive review of all biomarkers used in routine or exploratory investigations for COVID-19. We recognize the availability of guidelines for clinicians caring for patients with suspected or confirmed infection with SARS-CoV-2 as well as the expertise of medical staff in ordering laboratory tests to help guide evolving differential diagnoses throughout the clinical course of illness. However, this section also recognizes the ongoing efforts of researchers who are dedicated to understanding the role of existing or novel biomarkers. Overall, no laboratory marker to date is diagnostic for COVID-19, but they have value in patient management over time, regardless of SARS-CoV-2 infection status. Biomarkers for COVID-19 severity or prognosis remain an active area of research that may not only lead to new diagnostic approaches but also help us understand disease progression and host responses to COVID-19.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>18937</offset><text>DIAGNOSTIC IMAGING FOR COVID-19</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>18969</offset><text>While testing of specimens collected from the upper respiratory tract is common for diagnosing SARS-CoV-2 infection, the progression of the disease may involve the lower respiratory tract (e.g., pneumonia), with or without detectable SARS-CoV-2 in the upper respiratory tract. Testing of specimens from the lower respiratory tract (e.g., bronchoalveolar lavage [BAL] fluid) is possible using nucleic acid amplification tests (NAATs) like RT-PCR, but obtaining lower respiratory tract specimens is not always possible. Along with laboratory testing, diagnostic imaging can complement investigations of COVID-19 to assess the involvement of disease in the lower respiratory tract or other anatomical sites. Diagnostic imaging techniques include chest radiography (or chest X ray [CXR]), computed tomography (CT) scan, ultrasound, magnetic resonance imaging (MRI), and positron emission tomography-CT (PET/CT). Among these, CT scans are the most frequently used methods for diagnosis of lower tract involvement or follow-up of COVID-19 cases. CT scans produce cross-sectional images at different angles, thereby providing a three-dimensional (3D) look at the targeted anatomy. Chest CT scan images can be assembled and assessed by radiologists to check for possible abnormalities suggestive of lower tract disease such as viral pneumonia. Typical features of a chest CT image in COVID-19 are ground-glass or reticular opacities (GGOs) with or without consolidations that present bilaterally, peripherally, or in posterior distributions.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>20503</offset><text>The utility of diagnostic imaging for routine screening for COVID-19 has been a subject of debate and has not been recommended by most radiology societies. On the other hand, due to the shortage of RT-PCR supplies during the early days of the pandemic and the possibility of false-negative RT-PCR results from sampling the upper respiratory tract, some hospitals in the Hubei province of China included CT scans in the diagnosis of SARS-CoV-2 infection. While diagnostic imaging techniques like CT have merits to help assess lower respiratory tract disease involvement, to monitor disease progression, or to investigate other complications of COVID-19, it should be noted that diagnostic imaging methods are less sensitive than sampling the lower respiratory tract and testing using molecular methods, and specificity is low, given that typical features of COVID-19 are common to other respiratory viruses or illnesses. Initial reports of the utility of CT scans in the diagnosis of COVID-19 suggested an increased sensitivity of CT over real-time RT-PCR, but others have suggested explanations for the disparities between RT-PCR results and diagnostic imaging assessments, including poor sampling techniques, differences in the performances of testing methods, the anatomical site of RT-PCR testing (upper versus lower tract), and disease prevalence. High sensitivities (i.e., &gt;90%) have been reported for CT scans in high-prevalence populations, while low sensitivities (&lt;60%) were reported in studies with low-prevalence populations. In a Cochrane review for confirmed cases of COVID-19, the pooled sensitivities were 93.1% (95% confidence interval [CI], 90.2% to 95.0%) for chest CT and 82.1% (95% CI, 62.5% to 92.7%) for CXR, but heterogeneity between studies was considerable. Specificity for diagnostic imaging is low, at 18.1% (95% CI, 3.7 to 55.8%). In other words, approximately 80% of individuals would have received a diagnosis of COVID-19 in the absence of disease. As such, the use of diagnostic imaging techniques should be accompanied by careful consideration of factors such as disease prevalence in the study population, severity of the illness, performance and context of the methods used, differences in radiologist opinions, and possible confounding diagnoses. On the other hand, it is also important to recognize that diagnostic imaging is a useful tool for patient management with or without a confirmed etiology through laboratory testing, as it can be used to monitor the severity of illness and disease progression and assess possible complications.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>23079</offset><text>Understanding the benefits and limitations of diagnostic imaging for COVID-19 is an active area of research, along with applications of artificial intelligence (AI) (also known as machine learning). AI-based methods can be used in diagnostic imaging to help recognize abnormal features in images and classify them into defined categories, thus increasing accuracy, standardization, and speed of analyses by radiologists. AI approaches can be categorized into three main groups: approaches that analyze CT scan images, methods based on X ray, and those that realize diagnosis through jointly analyzing CT scan and X-ray images. While AI-based applications have shown benefits for diagnostic imaging methodologies, more clinical investigations are needed to evaluate their possible incorporation into routine procedures for investigations of suspected cases of COVID-19, and laboratory testing is required to confirm the disease etiology. Furthermore, acquiring a reliable AI-based system requires access to a comprehensive training data set that includes all variations of COVID-19 as well as other lung diseases; providing such an all-inclusive data set is difficult and labor-intensive.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_1</infon><offset>24267</offset><text>LABORATORY METHODS FOR THE DETECTION OF SARS-CoV-2</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>24318</offset><text>Diagnosis of COVID-19 can be performed using molecular detection of SARS-CoV-2 RNA, which is now widely available. Immunodiagnostic methods for identifying viral antigens and serology to recognize an immune response to the virus are also available. The following sections describe the commonly used and potential methods for the laboratory detection of SARS-CoV-2, with important consideration for factors like specimen type and timing of specimen collection.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>24778</offset><text>Specimen Types</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>24793</offset><text>Prior to describing methods for SARS-CoV-2 detection, it should be recognized that accurate detection of any infectious disease requires adequate specimen collection at the anatomical site of infection, at a time when the pathogen of interest should be present. While the virus has been detected in a variety of specimen types using molecular methods, few have been widely adopted due to unreliable detection or a lack of sensitivity. The use of blood, serum, or plasma for SARS-CoV-2-specific serology and other immunodiagnostic tests is discussed in later sections of this review.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>25376</offset><text>For respiratory viruses like SARS-CoV-2, specimens collected from the upper respiratory tract using a flocked nasopharyngeal (NP) swab that is placed in universal or viral transport medium (UTM or VTM, respectively) are the gold standards. In contrast to other swabs (e.g., cotton swabs on wooden sticks), specimen collection using flocked NP swabs that are coated with multilength fibers allows for enhanced recovery of respiratory viruses and bacteria, and the UTM or VTM allows a stable medium for transport to the laboratory. Other than NP swab specimens, alternative specimens and collection methods have been validated and gained interest, including the use of nasal midturbinate swabs, sampling of the anterior nares (Na), oropharyngeal (OP) swabs, or washes/aspirates from the nasopharynx, nose, or throat. Specimen combinations can also be used. For example, paired collection using an OP swab along with sampling of the anterior nares was shown to be equivalent to NP swab collection for the detection of SARS-CoV-2, and different options are available for OP/Na collection. It is worth mentioning that during the COVID-19 pandemic, procurement of NP swabs and UTM (or VTM) was challenged by global supply chain shortages. Several groups have developed and validated the possibility of using 3D-printed swabs as alternatives to commercial NP or nasal swabs, but while some have been clinically validated for detecting SARS-CoV-2 RNA, further investigations are required for their applicability in SARS-CoV-2 antigen detection. For media used for swab transport to laboratories, other than the typical UTM or VTM, alternatives have been investigated for use for SARS-CoV-2 testing, including Amies transport medium, sterile normal saline, phosphate-buffered saline (PBS), M4 medium, and minimal essential medium (MEM), and stability analyses have assessed ideal transport and storage conditions.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>27281</offset><text>While NP swabs are considered the gold standard for respiratory virus sampling of the upper respiratory tract, hospitalized adults with progression of COVID-19 to lower tract disease may require additional specimen types. When lower tract infection is suspected through clinical presentation or with the aid of diagnostic imaging, specimens such as BAL fluid, endotracheal secretions, or sputum should be considered.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>27698</offset><text>Recently, the use of noninvasive collection methods like saliva and throat gargles has gained much interest, as these samples are amenable to self-collection and have the potential for large-scale population-based surveillance. While some studies have demonstrated that the performance of saliva for the detection of SARS-CoV-2 was comparable to that of NP or nasal swab collections, others challenged the performance of saliva for SARS-CoV-2 detection. The variability in saliva collection or differences in the patient populations tested might explain these inconsistencies, but further analyses are required. Also, although not used routinely in many laboratories, detecting SARS-CoV-2 RNA from stool is possible in the presence or absence of gastrointestinal symptoms. The possibility of culturing SARS-CoV-2 from stool opens discussions regarding the possibility of fecal-oral transmission and human health or ecological risks and also opens the opportunity for research into community-based surveillance in low-prevalence settings using wastewater.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>28753</offset><text>In postmortem examinations, the extent of investigations will be dependent on several factors, but NP swabs, swabs from the lungs, and tissue samples can be used for diagnostic testing for SARS-CoV-2. Specimens in 10% buffered neutral saline or formalin-fixed paraffin-embedded (FFPE) specimens commonly used for histopathological examinations can also be used, but these pose challenges for NAATs like real-time RT-PCR as RNA can be degraded by formalin, and sensitivity for the detection of SARS-CoV-2 RNA by real-time RT-PCR could be compromised. The CDC recommends that these media be used in limited settings. Immunohistochemical (IHC) and in situ hybridization (ISH) assays for the detection of SARS-CoV-2 have now been developed, but limited data are available on their performance.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>29543</offset><text>Timing of Specimen Collection</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>29573</offset><text>SARS-CoV-2 has been identified in various clinical specimen types, but the timing of detection differs between methods and the specimen types collected for testing. SARS-CoV-2 RNA can be detected early in the presymptomatic stage of the disease and later on, even after recovery. However, the timing of specimen collection is critical, as testing too early or too late following exposure can potentially lead to false-negative results. It was shown that real-time RT-PCR false-negative rates could be minimized by testing 2 to 3âdays after symptom onset, with an average time of symptom onset of 5âdays postexposure. Repeat testing can be considered for individuals with an initial negative test result but for whom there is a high level of clinical suspicion. Of note, viral shedding studies are often performed using RNA detection alone and less often in combination with virus culture; however, the absence of cultivable virus does not preclude the potential for SARS-CoV-2 transmission, and laboratory detection of SARS-CoV-2 using molecular methods does not imply infectious virus. For the purpose of this section, viral shedding is described in the context of RNA detection without implying the potential for viral transmission. A discussion regarding the association of SARS-CoV-2 RNA detection with potential infectivity is covered later in this section as well as in the real-time RT-PCR section below.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>30989</offset><text>The magnitude of the viral load and duration of shedding depend on the specimen type, the anatomical site of illness, the severity of illness, and, likely, the host immune response to infection. The average duration of SARS-CoV-2 RNA detection in the upper respiratory tract of patients with mild disease ranged from 7.9 to 20âdays after symptom onset and from 6 to 30.8âdays in cases with moderate to severe illness. The detection of SARS-CoV-2 in the lower respiratory tract ranged from 8 to 38.4âdays for mild cases of COVID-19 and spanned between 6 and 26.9âdays for moderate to severe illness. In a systematic review and meta-analysis, the pooled estimates of the mean duration of SARS-CoV-2 RNA detection from symptom onset in mild adult cases were 12.1âdays (95% CI, 10.1 to 14.1 days) in the upper respiratory tract and 24.1âdays (95% CI, 10.0 to 38.2 days) in the lower respiratory tract. For moderate to severe cases, the pooled estimates for the duration of SARS-CoV-2 RNA positivity in the upper respiratory tract were 15.8âdays (95% CI, 11.1 to 20.6 days) and 23.2âdays (95% CI, 21.5 to 25.0 days) in the lower respiratory tract. In a systematic review and meta-analysis, the temporal dynamics of SARS-CoV-2 viral loads were stratified by COVID-19 severity and sampling site. In cases of mild adult disease, SARS-CoV-2 RNA in the upper respiratory tract was maximal on day 4, at approximately 6.6âÃâ108 copies/ml, whereas lower tract viral loads peaked at approximately 2.7âÃâ108 copies/ml on day 6 after symptom onset. In cases of moderate to severe adult disease, maximal SARS-CoV-2 RNA detected in the upper respiratory tract occurred on day 8, at 4.6âÃâ109 copies/ml, and on day 11, at approximately 3.5âÃâ108 copies/ml, in the lower respiratory tract. Regarding the differences in viral loads and durations of shedding between symptomatic and asymptomatic patients, the literature is inconsistent. Some publications observed little to no difference in viral loads between the two groups, while others suggested significantly higher viral loads in symptomatic patients. Whether these differences are attributed to differences in disease severity, variations in the performances of methods used, or host factors remains to be determined.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>33279</offset><text>As highlighted above, the median duration of viral shedding is variable between individuals and likely dependent on disease severity and several host factors such as age, immunocompromising conditions, or medical comorbidities. While most individuals with mild disease clear the virus within 10 to 20âdays, in some cases with severe COVID-19, the duration of shedding can be prolonged. The longest durations of viral RNA shedding reported to date were 83 and 111âdays after symptom onset; however, the persistence of RNA suggestive of low viral loads may be of little clinical significance, as the detection of SARS-CoV-2 RNA does not necessarily imply infectivity. Moreover, many factors can affect the detection of SARS-CoV-2 RNA, such as the quality of sample collection, transport, and variables in laboratory processing; RNA positivity can be intermittent and inaccurate at the later stages of illness. Therefore, the CDC recommends that the discontinuation of transmission-based precautions for patients with confirmed SARS-CoV-2 infection should be based on the resolution of symptoms and not based on testing. While some countries have similar recommendations for discharge from quarantine, there is some heterogeneity in approaches, and these often vary based on the severity of illness and the presence or absence of symptoms.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>34620</offset><text>While not used routinely in many laboratories, detecting SARS-CoV-2 RNA from stool is possible in the presence or absence of gastrointestinal (GI) symptoms. However, only 1% of patients had detectable RNA in their stool in the absence of positive respiratory specimens. For some patients, viral shedding in stool can occur for a longer period than in the respiratory samples and could help diagnose infection if upper and lower respiratory tract specimens are negative but there is a high suspicion of disease. Of individuals who test positive with GI specimens, the median duration of RNA shedding in the GI tract is 12.5âdays following negative respiratory tract specimens. Less frequently, shedding in stool can be prolonged and has been documented up to 70âdays after symptom onset or 33âdays following clearance from the respiratory tract. As for respiratory tract specimens, RNA detection does not necessarily imply that infectious virions are produced, but SARS-CoV-2 has been cultured from stool specimens in some studies.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>35657</offset><text>Like molecular methods, antigen testing can be used to detect SARS-CoV-2 proteins in the acute stages of the disease following the incubation period in upper respiratory tract specimens such as NP swabs, nasal swabs, and possibly saliva. Antigen detection using immunoassays like lateral flow rapid diagnostic tests (RDTs) is often less sensitive than molecular methods, but these tests can detect SARS-CoV-2 antigen reliably when the viral load is high in the clinical specimens (i.e., typically from 1 to 3âdays before the onset of symptoms to 5 to 7âdays after symptom onset), whereas the likelihood of SARS-CoV-2 detection decreases in the second week after symptom onset.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>36338</offset><text>In contrast to RNA and antigen detection, immunological responses take longer to appear, with antibodies typically beginning to appear 6 days after symptom onset, as viral RNA levels begin to decline. Typically, the first detectible antibody in human blood is immunoglobulin M (IgM), followed by immunoglobulin G (IgG). However, concomitant increases of the IgM and IgG immunoglobulin classes as well as IgG first seroconversion have also been observed. Few data are also available for immunoglobulin A (IgA) detection, a marker of mucosal immune responses, but it is evident that both IgA and IgM decline rapidly over the course of infection. The median seroconversion times for total antibody, IgM, and IgG were 9, 10, and 12âdays after symptom onset (or 15, 18, and 20âdays after exposure), respectively. It is unclear how long IgG responses last or whether they confer protection against subsequent SARS-CoV-2 reinfection. The longest study on the antibody dynamics tracked IgG up to 115âdays after symptom onset in sera and saliva. Immune responses may vary depending on disease severity and host factors such as immunocompromising conditions or other medical comorbidities, and the value of immune responses will be dependent on the ability to provide neutralizing antibodies (nAbs) or cellular immunity capable of viral clearance. The applications and limitations of serology and other immunodiagnostics are discussed in more detail in later sections of this paper.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>37817</offset><text>Specimen Preprocessing Requirements</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>37853</offset><text>While detection of SARS-CoV-2 from respiratory specimens can be performed using RNA or antigen detection, they sometimes require a preprocessing step like heat lysis or inactivation using guanidinium salts before nucleic acid extraction and amplification or testing, to ensure safe handling conditions, depending on local biosafety risk assessments. Specimen types such as sputum may require mucolytic agents such as dithiothreitol (DTT), N-acetyl-l-cysteine (NALC), or proteinase K (PK) to reduce specimen viscosity prior to testing. Other preprocessing steps would include centrifugation for specimens like stool, PK digests for tissues (e.g., lung biopsy specimens), and specimen aliquoting into compatible tubes for testing (if testing from primary specimen containers is not possible). With any manipulation of the primary specimen (i.e., preprocessing steps), careful consideration should be undertaken to ensure that there are no potential impacts on downstream testing (e.g., RNA or antigen stability). Of note, some preprocessing steps, like specimen lysis, can be done in conjunction with nucleic acid extraction using automated instrumentation (discussed below in the real-time RT-PCR section of this review).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>39074</offset><text>Overall, the choice of the specimen and timing of collection are crucial for the accurate detection of SARS-CoV-2, as are factors such as the severity of illness. Given that the performance characteristics of diagnostic methods depend on numerous variables as well as the method(s) used as a comparator and disease prevalence, a comprehensive synthesis of all method performances falls outside the scope of this review. However, general concepts for performance characteristics, important considerations, and a description of the technologies used for SARS-CoV-2 detection in the clinical setting or in development are presented in the following sections.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>39730</offset><text>Molecular Methods for Viral RNA Detection</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>39772</offset><text>While no true reference standard exists for detecting SARS-CoV-2, nucleic acid amplification tests (NAATs) such as real-time RT-PCR are the methods of choice for SARS-CoV-2 diagnostic testing. Following sequencing of its genome, laboratory-developed tests (LDTs) for the detection of SARS-CoV-2 were quickly developed, and protocols were circulated broadly by health care regulatory bodies such as the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC). Many commercial kits have since become available and were authorized for use through emergency use authorization (EUA) by entities such as the Food and Drug Administration (FDA) and Health Canada. Lists of authorized medical devices related to COVID-19 in Canada and the United States are regularly updated online, and examples of them are summarized in Table 1.</text></passage><passage><infon key=\"file\">T1.xml</infon><infon key=\"id\">T1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>40632</offset><text>Examples of the NAATs approved for emergency use by the U.S. FDA for detection of SARS-CoV-2 RNAa</text></passage><passage><infon key=\"file\">T1.xml</infon><infon key=\"id\">T1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;colgroup span=&quot;1&quot;&gt;&lt;col span=&quot;1&quot;/&gt;&lt;col span=&quot;1&quot;/&gt;&lt;col span=&quot;1&quot;/&gt;&lt;col span=&quot;1&quot;/&gt;&lt;col span=&quot;1&quot;/&gt;&lt;col span=&quot;1&quot;/&gt;&lt;col span=&quot;1&quot;/&gt;&lt;col span=&quot;1&quot;/&gt;&lt;/colgroup&gt;&lt;thead&gt;&lt;tr&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Device/assay (manufacturer)&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Method&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Target gene(s)&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Specimen type(s)&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Authorized setting(s)&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Time/throughput&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LoD&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;T1F2&quot;&gt;&lt;sup&gt;&lt;italic&gt;b&lt;/italic&gt;&lt;/sup&gt;&lt;/xref&gt;&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Reference&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;cobas 6800/cobas SARS-CoV-2 (Roche Molecular Systems, USA)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;RT-PCR&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ORF1ab + E&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NS, NPS, OPS&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;H, M, H-pooling&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3 h for the first-run results but 90âmin per run in continuous mode/864 samples per 8 h&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;46 copies/ml&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B575&quot; ref-type=&quot;bibr&quot;&gt;575&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Abbott m2000/RealTime SARS-CoV-2 (Abbott Diagnostics, USA)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;RT-PCR&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;RdRp + N&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NS, NPS, OPS, BAL fluid&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;H&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7 h per run/470 samples per 24 h&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;100 copies/ml&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B576&quot; ref-type=&quot;bibr&quot;&gt;576&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NeuMoDx 288/NeuMoDx SARS-CoV-2 (NeuMoDx Molecular, USA)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;RT-PCR&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Nsp2â+âN&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NS, NPS, OPS, BAL fluid, saliva&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;H, M&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.3 h per run/288 samples per 8 h&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;150 copies/ml&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B577&quot; ref-type=&quot;bibr&quot;&gt;577&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Panther Fusion/Aptima SARS-CoV-2 (Hologic, USA)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;TMA&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ORF1ab&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NS, NPS, OPS, MTS, NPW, NPA, NA&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;H, pooling&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.4 h per run/500 samples per 8 h&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.026 TCID&lt;sub&gt;50&lt;/sub&gt;/ml&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B578&quot; ref-type=&quot;bibr&quot;&gt;578&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Liaison MDX/Simplexa COVID-19 Direct (DiaSorin Molecular, Italy)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;RT-PCR&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ORF1ab + S&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NS, NPS, NW, NA, BAL fluid&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;H, M&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1 h per run/8 samples per run&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;500 copies/ml&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B318&quot; ref-type=&quot;bibr&quot;&gt;318&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;FilmArray/BioFire Respiratory Panel 2.1 (BioFire Diagnostics, USA)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;RT-PCR&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Sâ+âM&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;H, M&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2-min hands-on time/1 h per run&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;160 copies/ml&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B579&quot; ref-type=&quot;bibr&quot;&gt;579&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ePlex/ePlex SARS-CoV-2 (GeneMark Diagnostics, USA)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;RT-PCR&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;H, M&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2-min hands-on time/1.5 h per run&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;750 copies/ml&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B319&quot; ref-type=&quot;bibr&quot;&gt;319&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;GeneXpert Xpress/Xpert Xpress SARS-CoV-2 (Cepheid, USA)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;RT-PCR&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;E + N2&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NS, NPS, OPS, MTS, NW, NA&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;H, M, W&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1-min hands-on time/45âmin per run&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.02 PFU/ml&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B580&quot; ref-type=&quot;bibr&quot;&gt;580&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Accula Dock/Accula SARS-CoV-2 (Mesa Biotech, USA)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;RT-PCR&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NS, MTS&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;H, M, W&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5-min hands-on time/30âmin per run&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;150 copies/reaction&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B320&quot; ref-type=&quot;bibr&quot;&gt;320&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ID Now/ID Now COVID-19 (Abbott Diagnostics, USA)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NEAR&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;RdRp&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NS, NPS, OPS&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;H, M, W&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2-min hands-on time/13âmin per run&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;125 copies/ml&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B581&quot; ref-type=&quot;bibr&quot;&gt;581&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;SHERLOCK CRISPR SARS-CoV-2 kit (Sherlock Biosciences, USA)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;RT-LAMP, CRISPR-Cas13&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ORF1ab + N&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NS, NPS, OPS, NPW, NPA, NA, BAL fluid&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;H&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1 h per run&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6,750 copies/ml&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B582&quot; ref-type=&quot;bibr&quot;&gt;582&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;SARS-CoV-2 DETECTR reagent kit (Mammoth Biosciences, USA)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;RT-LAMP, CRISPR-Cas12&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS, OPS, MTS, ANS, NPW, NPA, NA&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;H&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;45âmin per run&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;20,000 copies/ml&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B583&quot; ref-type=&quot;bibr&quot;&gt;583&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NovaSeq 6000/Illumina COVIDSeq test (Illumina Inc., USA)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Next-generation sequencing&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;98 targets on the virus&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS, OPS, MTS, ANS, NPW, NPA, NA, BAL fluid&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;H&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3,072 samples per 12 h&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;500 copies/ml&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B584&quot; ref-type=&quot;bibr&quot;&gt;584&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>40730</offset><text>Device/assay (manufacturer)\tMethod\tTarget gene(s)\tSpecimen type(s)\tAuthorized setting(s)\tTime/throughput\tLoDb\tReference\t \tcobas 6800/cobas SARS-CoV-2 (Roche Molecular Systems, USA)\tRT-PCR\tORF1ab + E\tNS, NPS, OPS\tH, M, H-pooling\t3 h for the first-run results but 90âmin per run in continuous mode/864 samples per 8 h\t46 copies/ml\t\t \tAbbott m2000/RealTime SARS-CoV-2 (Abbott Diagnostics, USA)\tRT-PCR\tRdRp + N\tNS, NPS, OPS, BAL fluid\tH\t7 h per run/470 samples per 24 h\t100 copies/ml\t\t \tNeuMoDx 288/NeuMoDx SARS-CoV-2 (NeuMoDx Molecular, USA)\tRT-PCR\tNsp2â+âN\tNS, NPS, OPS, BAL fluid, saliva\tH, M\t1.3 h per run/288 samples per 8 h\t150 copies/ml\t\t \tPanther Fusion/Aptima SARS-CoV-2 (Hologic, USA)\tTMA\tORF1ab\tNS, NPS, OPS, MTS, NPW, NPA, NA\tH, pooling\t2.4 h per run/500 samples per 8 h\t0.026 TCID50/ml\t\t \tLiaison MDX/Simplexa COVID-19 Direct (DiaSorin Molecular, Italy)\tRT-PCR\tORF1ab + S\tNS, NPS, NW, NA, BAL fluid\tH, M\t1 h per run/8 samples per run\t500 copies/ml\t\t \tFilmArray/BioFire Respiratory Panel 2.1 (BioFire Diagnostics, USA)\tRT-PCR\tSâ+âM\tNPS\tH, M\t2-min hands-on time/1 h per run\t160 copies/ml\t\t \tePlex/ePlex SARS-CoV-2 (GeneMark Diagnostics, USA)\tRT-PCR\tN\tNPS\tH, M\t2-min hands-on time/1.5 h per run\t750 copies/ml\t\t \tGeneXpert Xpress/Xpert Xpress SARS-CoV-2 (Cepheid, USA)\tRT-PCR\tE + N2\tNS, NPS, OPS, MTS, NW, NA\tH, M, W\t1-min hands-on time/45âmin per run\t0.02 PFU/ml\t\t \tAccula Dock/Accula SARS-CoV-2 (Mesa Biotech, USA)\tRT-PCR\tN\tNS, MTS\tH, M, W\t5-min hands-on time/30âmin per run\t150 copies/reaction\t\t \tID Now/ID Now COVID-19 (Abbott Diagnostics, USA)\tNEAR\tRdRp\tNS, NPS, OPS\tH, M, W\t2-min hands-on time/13âmin per run\t125 copies/ml\t\t \tSHERLOCK CRISPR SARS-CoV-2 kit (Sherlock Biosciences, USA)\tRT-LAMP, CRISPR-Cas13\tORF1ab + N\tNS, NPS, OPS, NPW, NPA, NA, BAL fluid\tH\t1 h per run\t6,750 copies/ml\t\t \tSARS-CoV-2 DETECTR reagent kit (Mammoth Biosciences, USA)\tRT-LAMP, CRISPR-Cas12\tN\tNPS, OPS, MTS, ANS, NPW, NPA, NA\tH\t45âmin per run\t20,000 copies/ml\t\t \tNovaSeq 6000/Illumina COVIDSeq test (Illumina Inc., USA)\tNext-generation sequencing\t98 targets on the virus\tNPS, OPS, MTS, ANS, NPW, NPA, NA, BAL fluid\tH\t3,072 samples per 12 h\t500 copies/ml\t\t \t</text></passage><passage><infon key=\"file\">T1.xml</infon><infon key=\"id\">T1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_footnote</infon><offset>42895</offset><text>The full list is available in reference. Abbreviations: RT-PCR, reverse transcription-PCR; TMA, transcription-mediated amplification; NEAR, nicking enzyme amplification reaction; RT-LAMP, reverse transcriptionâloop-mediated isothermal amplification; NS, nasal swab; NPS, nasopharyngeal swab; OPS, oropharyngeal (throat) swab; BAL, bronchoalveolar lavage; MTS, midturbinate nasal swab; NPW, nasopharyngeal wash; NPA, nasopharyngeal aspirate; NA, nasal aspirate; NW, nasal wash; ANS, anterior nasal swab; H, laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. Â§263a, that meet requirements to perform high-complexity tests; M, laboratories certified under CLIA, 42 U.S.C. Â§263a, that meet requirements to perform moderate-complexity tests; W, patient care settings operating under a CLIA certificate of waiver; TCID50, median tissue culture infectious dose.</text></passage><passage><infon key=\"file\">T1.xml</infon><infon key=\"id\">T1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_footnote</infon><offset>43805</offset><text>The LoD (limit of detection) of each assay is the lowest LoD reported in the instructions for use for that assay, regardless of the specimen types.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_3</infon><offset>43953</offset><text>Real-time RT-PCR.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>43971</offset><text>Among NAATs, real-time RT-PCR is the most widely used method for the detection of SARS-CoV-2. As shown in Fig. 3A, the sample workflow for SARS-CoV-2 real-time RT-PCR includes specimen collection, transportation of the samples to the laboratory, specimen lysis, purification of viral RNA through nucleic acid extraction, and real-time RT-PCR amplification, detection, and analysis. Prior to real-time RT-PCR amplification, specimens are lysed to provide access to the SARS-CoV-2 RNA, and nucleic acid extraction is performed to remove potential inhibitors that could impede the amplification of the target. Both lysis/extraction and RT-PCR amplification can be performed sequentially through manual processing on individual instruments, or the entire process can be automated.</text></passage><passage><infon key=\"file\">CMR.00228-20-f003.jpg</infon><infon key=\"id\">F3</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>44748</offset><text>Real-time RT-PCR analysis. (A) Typical steps required for the detection of SARS-CoV-2 with real-time RT-PCR. (B) Principle of real-time RT-PCR. (1) During reverse transcription, reverse transcriptase (RT) creates a cDNA from the viral RNA template, with the aid of the reverse primer (or random oligonucleotides). The RNase H activity of the RT digests the initial RNA template. (2) The DNA polymerase activity of RT (or of the Taq polymerase) completes the second DNA strand guided by the forward primer and cDNA. (3) The newly formed double-stranded DNA (dsDNA) is used as a template for the PCR portion of the assay. At the annealing stage, the reverse primer binds to the sense strand of dsDNA in a sequence-specific manner, and the forward primer and a dually labeled probe bind to the antisense strand of the DNA. In this stage, the fluorophore (F) present on the probe is masked by the quencher (Q). During the extension step, the DNA polymerase extends the forward primer and, in the process, hydrolyzes the probe, resulting in the release of the fluorophore. Next, following excitation, fluorescence emission can be captured by the real-time thermocycler. With each round of PCR amplification, the dsDNA amplicon is multiplied by a 2-fold factor, with a proportional increase in the overall fluorescence signal. After 30 to 40 cycles of amplification, the RT-PCR is complete. The PCR cycle at which the fluorescence signal crosses the threshold for positivity is called the threshold cycle (CT), and CT values are inversely proportional to the quantity of the target present in the reaction mixture.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_4</infon><offset>46357</offset><text>(i) Specimen lysis and RNA purification.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>46398</offset><text>To release viral RNA from host cells and virions, specimen lysis can be performed using physical (e.g., heat, sonication, or homogenization), chemical (e.g., organic solvents, detergents, chelating agents, or chaotropic agents), or enzymatic (e.g., proteases) methods. Lysis steps based on enzymatic digestion (e.g., proteinase K digestion) are common for nucleic acid extraction in clinical laboratories. Following specimen lysis, extraction of viral RNA is performed to remove cellular debris and contaminants that could potentially inhibit the RT-PCR and purify the nucleic acids. In many automated instruments, silica-coated magnetic microbeads are used to capture nucleic acids, which can be sequentially transferred into different wash solutions by a robotic pipetting instrument with a magnetic head. The efficiencies of several extraction methods have been compared for detecting SARS-CoV-2, and the results favor commercial kits over manual methods like organic extractions containing guanidinium thiocyanate-phenol-chloroform.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>47435</offset><text>It should be noted that while nucleic acid extraction is essential to achieve optimal sensitivity in molecular assays, recent studies have described extraction-free protocols for molecular testing for SARS-CoV-2 to circumvent the potential bottleneck of extraction if the supply of extraction reagents or consumables is limited (or to provide options for low-income environments). However, without a nucleic acid extraction step to remove PCR inhibitors in clinical specimens, there is a notable reduction in sensitivity, but the extent is dependent on the method and target used for SARS-CoV-2 detection, the type and duration of the lysis/inactivation method (heat or chemical), the input volume, the specimen type, the transport media, and the viral load in the specimen. For example, the sensitivity of a 60-min heat inactivation alone reached 100% for specimens with moderate to high viral loads (threshold cycle [CT] values of between 20 and 30) but declined to 54% in specimens with CT values of &gt;30.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_4</infon><offset>48443</offset><text>(ii) Target amplification and detection.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>48484</offset><text>Amplification in real-time RT-PCR involves two main steps. First, an enzyme called reverse transcriptase creates a cDNA from the viral RNA. The cDNA is then used as a template in a real-time PCR amplification step where fluorescence is produced as DNA amplification occurs. The PCR portion of real-time RT-PCR contains a fluorescent probe or dye to generate fluorescence (e.g., dually labeled hydrolysis probe or intercalating dyes that bind to double-stranded DNA [dsDNA], like SYBR green). Figure 3B illustrates the principle of a typical real-time RT-PCR using a dually labeled hydrolysis probe. Overall, if amplification of the target genes occurs during cycling through the denaturation, annealing, and extension stages, a fluorescent signal is produced that can be captured by the real-time thermocycler. If the fluorescence crosses a defined threshold, the cycle in which it occurred is termed the threshold cycle (CT). CT values help interpret results as positive, negative, or indeterminate (or equivocal), and each real-time RT-PCR method must validate its cutoff values, as they may differ among methods and instruments.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>49616</offset><text>The performance of real-time RT-PCR depends on a number of factors, including the specimen type, the timing of collection, the quality and quantity of viral RNA, the primers and probes designed and their viral RNA target, the reagents used for the RT-PCR(s), the instrument and its operational parameters, and the signal/cutoffs used for result interpretation. Typically, real-time RT-PCR assays demonstrate high sensitivity and specificity for SARS-CoV-2. In a systematic review and meta-analysis by Mustafa Hellou et al., the pooled sensitivity for SARS-CoV-2 detection from 29 studies was 96.2% (95% CI, 91.0% to 98.4%), and the pooled specificity was 98.1% (95% CI, 95.9% to 99.2%). Sensitivity is of the utmost importance to ensure that cases in a population are identified, and specificity is important to ensure that no false-positive results occur. SARS-CoV-2 NAATs like real-time RT-PCR do not cross-react with other respiratory viruses, including human coronaviruses.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_4</infon><offset>50594</offset><text>(iii) SARS-CoV-2 targets and data interpretation.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>50644</offset><text>Various targets have been used for SARS-CoV-2 real-time RT-PCR, but the genes encoding E, N, S, and ORF1ab are used widely. Despite limited access to control materials early in the pandemic, LeBlanc et al. assessed the analytical performances of various LDTs and commercial RT-PCR assays and found that most of them had a high sensitivity with similar limits of detection (LoDs) in the range of 3.4 to 4.5 log10 copies/ml (11.2 to 141 copies/reaction). Similar proficiency testing across laboratories has been performed by others, demonstrating high sensitivity and specificity across different NAAT methods and instruments.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>51269</offset><text>In the initial stages of the pandemic, dual- or multigene detection strategies were adopted for real-time RT-PCRs to ensure assay specificity. As the pandemic progressed and the disease prevalence increased, some laboratories implemented single-target detection of SARS-CoV-2 in LDTs to streamline the workflow; however, many commercial methods continue to rely on detection using two or more targets. In duplex or multiplex real-time RT-PCR assays, if the identification of any target is considered a positive result, sensitivity would be enhanced compared to the requirement of at least two targets to be positive for a SARS-CoV-2 result to be released as such. However, this strategy comes at the risk of decreasing the specificity and potentially increasing the false-positivity rate. Regardless of the approach for testing, each target should have a validated range of values that define a positive, negative, or indeterminate result as well as conditions that would trigger an invalid result (e.g., processing or quality failures). CT values can be used in real-time RT-PCR to define these cutoffs, and indeterminate (or equivocal) results arise for values falling between the CT cutoff values of negative results and the reproducible CT value cutoff for positivity. This is sometimes termed the diagnostic gray zone for result interpretation.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>52619</offset><text>Low CT values suggest that more viral RNA was present in the specimen, whereas high CT values represent specimens with lower virus burdens, as more cycles were required to amplify the viral target. Therefore, CT values are sometimes used as a surrogate for viral load. While low viral loads (indicated by high CT values) could represent early or late disease, they could also be explained by nonspecific reactions (i.e., false-positive reactions), poor collection techniques, specimen integrity issues during storage or transport, or a problem occurring during laboratory processing. As discussed in the section on the timing of specimen collection above, some studies have evaluated the correlation between CT values and infectivity. There are some data to suggest that specimens that have SARS-CoV-2 RT-PCR results with CT values of &gt;24 cannot be effectively grown in tissue culture, yet other data have shown that SARS-CoV-2 can be recovered from cultured specimens with a CT value of &gt;35, at a lower frequency. While methodologies may have differed between studies to explain these differences (e.g., fresh versus frozen specimens), it should be noted that the infectious dose required for human infection with SARS-CoV-2 is unknown and influenced by many biological and environmental variables. Given the variability that can occur in specimen collection, transport, and processing, there are no biological correlates accurately linking CT values to infectivity or the potential for transmission. Detectable virus by NAATs does not imply infectious virus. Of note, even if such a correlate existed, CT value cutoffs cannot be applied universally to all NAATs, as they are method, reagent, and target specific, and to date, there is no international standard that can be used for calibration. Of note, other studies have investigated the role of CT values in predicting the clinical course of COVID-19 or prognosis; however, given the number of factors that could influence CT values, along with the inability to standardize respiratory specimens, the role of CT values in accurately predicting clinical outcomes would likely be inconsistent, and further research is needed. While the interpretation of CT values requires careful consideration, it is clear that CT values vary based on the viral burden, which itself varies throughout SARS-CoV-2 infection. Staging infection can provide epidemiological clues and can help with patient management. For example, low viral loads (i.e., high CT values) are seen during presymptomatic, early, or late stages of infection, whereas low CT values are seen between the early and late stages. If clinically indicated, patients with high CT values should undergo repeat testing within 24 to 48âh to determine if the CT value is stable, rising, or declining to help stage potential exposures in contact tracing. However, CT value interpretation is complicated in asymptomatic infections, where the time of infection onset may be unknown. Therefore, to rule out potential false-positive results, repeat testing is recommended for patients with high CT values suggestive of low viral loads.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_4</infon><offset>55752</offset><text>(iv) Automation.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>55769</offset><text>LDTs and commercial assays for moderate- to high-throughput testing for SARS-CoV-2 require relatively expensive equipment and experienced personnel to obtain accurate and robust data, and the turnaround time for results can take several hours. Real-time RT-PCR assays are constantly being improved to increase specimen throughput, provide rapid specimen turnaround times, reduce the hands-on time, and facilitate result interpretation and reporting. Automated high-throughput instruments are capable of performing over 1,000 tests daily, with performance characteristics greater than or equivalent to those of LDTs. LDTs typically require separate nucleic acid extraction and amplification steps, but these processes can occur simultaneously with high-throughput instruments, along with full traceability, and results can be directly reported through interfacing with the laboratory information system. One of the first high-throughput instruments with a commercially available SARS-CoV-2 detection assay was the cobas 6800 instrument (Roche Molecular Systems, USA), but other highly automated instruments relying on NAAT technology are now available, with similar performances, testing capacities, and workflow benefits. These include the Abbott RealTime SARS-CoV-2 assay on the m2000 instrument (Abbott Molecular, USA), the Hologic Panther SARS-CoV-2 assay (Hologic, USA), the NeuMoDx SARS-CoV-2 assay (NeuMoDx Molecular, USA), and BD Max reagents (Becton, Dickinson, USA). Advances have also been made for LDTs for SARS-CoV-2 testing using semiautomated robotics to streamline specimen processing, nucleic acid extraction, RT-PCR setup and amplification, data interpretation, and interfacing for data reporting. LDTs for SARS-CoV-2 have also been adapted for other instruments, such as droplet digital PCR (ddPCR). In ddPCR, water-oil emulsions are used to partition nucleic acid samples into thousands of nanoliter-sized droplets, and PCR amplification is carried out within each droplet. To date, the performance of ddPCR has been shown to be equivalent to or slightly more sensitive than LDT comparators, but limited data are available for its use in clinical laboratories.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_4</infon><offset>57949</offset><text>(v) Specimen pooling.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>57971</offset><text>Regardless of the NAAT used for SARS-CoV-2 detection, manufacturers of nucleic acid purification kits or RT-PCR reagents and consumables have been challenged with the rapid increase in testing demands that came with the global spread of SARS-CoV-2. With challenges to meet testing resources and limitations in the supply chain, research into alternative testing strategies has been explored. A possible strategy to increase testing capacity and gain laboratory efficiencies is group testing (i.e., specimen pooling). While many pooling permutations are possible, its simplest application involves combining patient samples before testing and retesting individual specimens following the identification of a positive pool. The optimal number of specimens within pools (i.e., pool depth) varies with disease prevalence and assay performance. While larger pool depths may achieve higher efficiency, particularly for high-throughput instruments, the trade-off is the accompanying reduced sensitivity, with the potential generation of false-negative results. When prevalence is low, typically only a subset of specimens with low viral loads pass undetected, while the testing capacity is increased and the cost of testing is reduced. In settings of high disease prevalence, the merits of pooling are lost given the high number of pools that need to be resolved. Other challenges for pooling include the increased human resource requirements for specimen registration and processing, but robotics and pooling software can help mitigate some of these issues. For lower-throughput analyzers like NAAT-based RDTs, pooling can also be considered. Overall, while thorough validation and careful consideration of potential impacts of pooling should be considered before implementation on any instrument, pooling can offer an opportunity for clinical laboratories to increase testing capacity, reduce costs, and mitigate the supply chain limitations of laboratory testing.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_4</infon><offset>59931</offset><text>(vi) RT-PCR-based rapid diagnostic tests.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>59973</offset><text>Unlike high-throughput automated instruments that are focused on large specimen volumes, rapid diagnostic tests (RDTs), as their name implies, are focused on speed. While this is acceptable for routine testing, RDTs have been developed to provide rapid results with easy-to-use testing, with minimal hands-on processing steps to facilitate training and testing. The first RDT based on real-time RT-PCR that obtained EUA from the FDA and Canada was the Xpert Xpress SARS-CoV-2 assay on the Cepheid GeneXpert platform (Cepheid Inc., USA), which provides results in about 45âmin, with a &lt;5-min hands-on specimen processing time. This NAAT-based RDT showed analytical and clinical performance characteristics often greater than those of LDTs and other commercial NAATs. It should be noted that while Xpert Xpress is often referred to as a point-of-care (POC) test, this testing is not typically performed at the time and place of patient assessment and is more commonly performed in a laboratory setting; therefore, the term RDT would be more appropriate. The most current version of the Xpert SARS-CoV-2 assay is multiplexed with influenza A and B viruses as well as respiratory syncytial virus (RSV), which can present with similar respiratory symptoms. More highly multiplexed assays like BioFire Respiratory Panel 2.1 with SARS-CoV-2 (BioFire Diagnostics, USA) are also available, which allow a syndromic approach with the simultaneous detection of SARS-CoV-2 and several other respiratory viruses. While syndromic testing is also being developed for larger instruments, such assays on RDTs are particularly useful for remote communities or resource-limited settings or for testing of populations where rapid diagnosis would be of benefit (e.g., patients admitted to the ICU).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>61752</offset><text>Other devices with a focus on potential POC applications have integrated RT-PCR with rapid (5- to 30-min) technologies such as digital microfluidics, visual lateral flow readouts, and portable instruments. All these assays have the advantage of speed and simplicity but are prone to limitations such as low sensitivity, low specimen throughput, and minimal scalability. For developing countries or other resource-limited settings where instrumentation is lacking, other cost-sparing testing alternatives are being explored. Arumugam et al. demonstrated a proof of principle of an RT-PCR that could be conducted in 12âmin using a setup consisting of thin-walled PCR tubes, sous vide immersion heaters/circulators, and an endpoint readout performed with a light-emitting diode (LED) gel-viewing box. Such creative and innovative solutions from industry and academic settings help meet the global needs for SARS-CoV-2 laboratory testing, besides other NAATs rapidly being developed and validated.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_3</infon><offset>62748</offset><text>Isothermal amplification technologies.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>62787</offset><text>In efforts to develop portable and rapid diagnostic tests for SARS-CoV-2, NAATs other than RT-PCR have been investigated. Isothermal amplification technologies (IATs) are conducted at a constant temperature, eliminating the need for expensive equipment such as thermocyclers. The principles behind IATs rely on thermal or enzymatic denaturation of nucleic acids, followed by nucleic acid amplification reactions, and have been reviewed in detail elsewhere. Isothermal NAAT technologies include transcription-mediated amplification (TMA), nicking enzyme-assisted reaction (NEAR), loop-mediated isothermal amplification (LAMP), recombinase polymerase amplification (RPA), and systems using clustered regularly interspaced short palindromic repeat (CRISPR)âCRISPR-associated (Cas) (CRISPR-Cas) systems. While most IAT methods have been applied to DNA, they can often be adapted to RNA amplification by adding an RT step (e.g., RT-LAMP and RT-RPA). Other IATs were designed for the intent of RNA amplification (e.g., TMA). Only TMA has been commercialized on a high-throughput instrument, but other IATs have been explored for uses as RDTs or for potential POC applications (e.g., RT-RPA, RT-LAMP, NEAR, and CRISPR-Cas). The following sections describe examples of IATs and current and potential applications.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_4</infon><offset>64095</offset><text>(i) Reverse transcription-recombinase polymerase amplification.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>64159</offset><text>As shown in Fig. 4, the mechanism of RPA relies on homologous recombination. RT-RPA uses a DNA polymerase to extend forward and reverse primers and make copies of each DNA strand (like PCR). However, to unwind and copy the DNA strands generated from reverse transcription, RPA requires the ATP-dependent targeting activity of a recombinase complex as well as the polymerase activity of a strand displacement DNA polymerase (e.g., Bsu).</text></passage><passage><infon key=\"file\">CMR.00228-20-f004.jpg</infon><infon key=\"id\">F4</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>64595</offset><text>Mechanism of RT-RPA. The RT-RPA reactions typically occur at between 37Â°C and 42Â°C in the following steps. (1) The reaction is initiated by the binding of a recombinase (e.g., T4 UvsX) and a loading factor (e.g., T4 UvsY) to each of the forward and reverse primers. (2) These recombinase/loading factor/oligonucleotide complexes search for homologous sequences in dsDNA, formed in the RT reaction from viral RNA (not depicted). (3) Once sequence homology is found, the recombinase complex invades the duplex DNA, forming a structure called a D-loop in an ATP-dependent reaction, where there is the unwinding of dsDNA and binding of the primer to its complementary sequence. Access to the primer-binding sequence is possible due to the stabilization of the opposite strand by SSBs (e.g., T4 gp32). Subsequently, the recombinase and loading factor disassemble and are released to initiate other rounds of target recognition. (4) Following the binding of the forward and reverse primers, these primers are extended at their 3â² ends using a strand displacement DNA polymerase (e.g., Bsu), and during the elongation process, there is a further separation of the two strands. (5) Eventually, SSBs are displaced, and the replication of both strands is complete.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>65854</offset><text>While the mechanisms for RT-RPA are relatively simple, the reaction components are fairly complex. Single-tube RT-RPA reactions include forward and reverse primers, core enzymes (e.g., reverse transcriptase, recombinase, recombinase loading factor, and a strand displacement DNA polymerase), proteins like single-stranded binding protein (SSB), and a number of ancillary components such as deoxynucleoside triphosphates (dNTPs), salts, buffers, cofactors, crowding agents, ATP, and an enzymatic system to generate additional ATP (phosphocreatine and creatine kinase [CK]). Once added, magnesium (Mg2+) initiates the RPA reaction. Fortunately, various kits are now commercially available for RPA (e.g., TwistDx, United Kingdom), with variations for the probe used in the detection step. For example, the TwistAmp exonuclease (exo) probes are used for fluorescence detection through a mechanism involving exonuclease III, whereas a detection system designed for a lateral flow assay (LFA) output can be incorporated using endonuclease IV (nfo) probes. Alternative fluorescence technologies have also been used, such as fluorescence resonance energy transfer (FRET) probes or CRISPR-Cas technology.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>67050</offset><text>Unlike real-time RT-PCR, RT-RPA does not require sophisticated instrumentation like thermocyclers, thereby simplifying the testing process. The ease of use of this isothermal technology makes RT-RPA an attractive candidate for point-of-care molecular tests. RT-RPA technology has been applied to the detection of other RNA viruses like Ebola virus; however, to date, data presenting its use for the detection of SARS-CoV-2 are scarce. Kim et al. used a modified version of RT-RPA to detect SARS-CoV-2 and achieved a sensitivity of approximately 4 copies/reaction in a 10-min reaction that used a lateral flow immunoassay (LFIA) readout. Their RT-RPA correctly identified all 18 contrived specimens generated by spiking heat-inactivated virus into NP swabs or saliva. A second publication by Xia and Chen described another modified single-tube version of RT-RPA introduced by GenDx called reverse transcription-enzymatic recombinase amplification (RT-ERA) as well as the whole-course encapsulated procedure for exponential amplification from RNA (WEPEAR) protocol. The WEPEAR protocol contains all the reaction components necessary for RT-ERA, except the activator Mg2+, which is loaded into the microtubeâs lid. Following the RT reaction, the tube can be spun and mixed to initiate the modified RPA reaction. Using FRET probes for a fluorescence output or nfo probes for LFIA-based detection, the WEPEAR protocol achieved high sensitivity in the range of a single copy per reaction. Unfortunately, this method was attempted on only a single clinical specimen and would require further validation. Other applications of the RT-RPA for the detection of SARS-CoV-2 involve the use of CRISPR-Cas technology, which is covered in a later section [see âIsothermal amplification technologies. (v) CRISPR-Cas technology,â below].</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_4</infon><offset>68877</offset><text>(ii) Transcription-mediated amplification.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>68920</offset><text>Transcription-mediated amplification (TMA) is an IAT that amplifies RNA from an RNA template, and this technology has been applied to SARS-CoV-2 diagnostics on high-throughput analyzers. Figure 5 illustrates the principle of TMA.</text></passage><passage><infon key=\"file\">CMR.00228-20-f005.jpg</infon><infon key=\"id\">F5</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>69150</offset><text>Principle of TMA. (1) The reactions use a reverse primer that is complementary to the sequence of the RNA template, but the reverse primer also contains an overhang with a promoter sequence for T7 RNA polymerase at its 5â² end. (2) Reverse transcription is conducted by the RT; the newly transcribed cDNA includes both the target sequence and the T7 promoter. (3) The RNA template is digested by the RNase H activity of the RT. (4) dsDNA is produced by the DNA polymerase activity of the RT. (5) The produced dsDNA is used as the template for transcription mediated by the T7 RNA polymerase. RNA is thereby amplified severalfold and, through the activity of the same enzyme(s), can serve as the template for a new TMA reaction. As the cycle progress, exponential amplification ensues. Detection of the amplified RNA is usually accomplished using sequence-specific molecular beacons (âtorchâ) or hybridization probes targeting the single-stranded RNA (ssRNA).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>70114</offset><text>The Aptima SARS-CoV-2 assay is performed on the Hologic Panther instrument, a highly automated instrument capable of processing over 1,000 specimens daily. Its principle combines a purification step using target capture, TMA for RNA amplification, and chemiluminescent probes for RNA detection. In the target capture step, SARS-CoV-2 RNA is isolated from specimens using magnetic microparticles coupled to oligomers containing sequences complementary to specific regions of the target RNA molecules as well as polydeoxyadenosine residues. By modifying the temperature, sequential hybridization can occur between the RNA target and the sequence-specific portion of the capture oligomers, and a hybridization step then occurs between the polydeoxyadenosine region of the capture oligomer and the polydeoxythymidine sequence that is covalently bound to the magnetic microparticles. After the purification step, TMA reactions occur, while detection is achieved through the hybridization of sequence-specific single-stranded oligonucleotide probes labeled with acridinium ester. A reagent is applied to generate a chemiluminescence signal that can distinguish between free and bound probes. A luminometer captures the resulting light emitted from bound probes, expressed as relative light units (RLU).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>71411</offset><text>The Hologic Aptima SARS-CoV-2 assay has only recently been authorized by the FDA and Health Canada, but data on its performance are scarce. The Aptima SARS-CoV-2 assay showed higher analytical sensitivity than some LDTs using real-time RT-PCR, and the performance against other high-throughput analyzers was equivalent. Compared to the Hologic Panther Fusion SARS-CoV-2 assay (i.e., real-time RT-PCR on a highly automated instrument), the Aptima SARS-CoV-2 assay showed similar analytical sensitivity, with LoDs ranging between 62.5 and 125 copies/ml, and the clinical performance was equivalent. Given the widespread use of Panther instruments in clinical laboratories for other pathogens (e.g., Chlamydia trachomatis and Neisseria gonorrhoeae), the SARS-CoV-2 assay on this high-throughput instrument was highly anticipated.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_4</infon><offset>72238</offset><text>(iii) Nicking enzyme-assisted reaction.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>72278</offset><text>The ID Now COVID-19 (IDNCOV) assay performed on the ID Now instrument (Abbott Diagnostics Inc., USA) is an IAT that uses nicking enzyme-assisted reaction (NEAR) technology, and this RDT was recently authorized for use for POC testing in the United States and Canada. NEARs are typically coupled to fluorescence detection following exponential amplification of DNA but can be used to detect an RNA template with the addition of a reverse transcription step. NEARs occur under isothermal conditions (at 60Â°C) and in several steps mediated by two main enzymes: (i) a nicking endonuclease that recognizes specific restriction endonuclease sites in DNA (e.g., Nt.BstNBI [5â²-GAGTCNNNN^N-3â²]) but nicks only one strand and (ii) a strand-displacing DNA polymerase like Bst that can displace downstream DNA during synthesis at temperatures of around 65Â°C (Fig. 6). Strand displacement is possible due to the fact that the Bst DNA polymerase lacks 5â²â3â² exonuclease activity common to other DNA polymerases (e.g., Taq polymerase).</text></passage><passage><infon key=\"file\">CMR.00228-20-f006.jpg</infon><infon key=\"id\">F6</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>73311</offset><text>Principle of NEAR technology. The NEAR amplification reactions occur at 60Â°C and can be broken down into two milestones: NEAR amplification duplex formation and product formation. (1) The target recognition region (Bâ²) of the reverse primer (R) binds to the complementary sequence (B) of the target DNA sense strand and is fully extended by the strand displacement DNA polymerase. (2) A second R primer binds to the template DNA and, during extension, displaces the elongated product of the first R primer extension. (3) The recognition region (A) of the forward primer (F) binds to its complementary sequence (Aâ²) in the R extension product, and F is extended to create a double-stranded nicking enzyme recognition site (N). (4) The nicking enzyme recognizes N and cleaves a single strand of DNA in a sequence-specific manner at the cut site (X). (5) This releases a fragment of the R extension product. The remaining fragment serves as a primer and is extended at its 3â² end. (6) This extension completes the double-stranded complex, termed the NEAR amplification duplex, which is the starting point for product formation. (7) Nicking enzymes bind to the nicking enzyme recognition sites on both ends of the NEAR amplification duplex and cleave at X. (8) The resulting single-strand nicks create two complexes, each consisting of a single-stranded target region flanked by a nicking enzyme recognition region. (9) Repeated nicking, polymerization, and strand displacement activities result in the amplification of the AB and Aâ²Bâ² target products. Cleaved complexes are regenerated, while the AB and Aâ²Bâ² products can anneal to R and F primers, respectively. In turn, the bidirectional extension of the primer and product each creates duplexes that lead to the generation of the opposite product upon cleavage. Product amplification continues until reagents or enzymes are depleted.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>75210</offset><text>While the mechanism for nucleic acid amplification with NEAR may be complex, IDNCOV testing is simple and rapid. The assay has processing times as low as 5âmin for positive results with high viral loads and 15 min for specimens with lower viral loads or negative results. Compared to LDTs or commercial NAATs, many recent studies have demonstrated an excellent specificity/negative percent agreement (NPA) near 100% but relatively poor sensitivity/positive percent agreement (PPA) of between 48% and 70% for the detection of SARS-CoV-2, while other studies showed a high specificity/NPA (â¼100%) as well as high sensitivity/PPA values above 90%.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>75859</offset><text>The reasons for the disparities in sensitivity/PPA between studies are likely multifold and include differences in the patient population (setting, host factors, and the presence or not of compatible symptoms), the specimen type, the timing between collection and testing, the transport conditions used (dry swabs or transport media), the quality of specimens (prospective versus retrospective), the spectrum of viral loads in the specimens evaluated (proportion of specimens with low viral loads), or differences in performance characteristics of the comparator method(s). For example, the swab type affected IDNCOV performance, where NP swabs showed a PPA of 64%, compared to 48% with nasal swabs. Using residual positive and negative NP swabs collected in VTM, Mitchell and St. George compared IDNCOV to the CDC real-time RT-PCR, and IDNCOV showed sensitivity and specificity of 71.7% and 100%, respectively. All false-negative results corresponded to specimens for which CT values were between 35 and 40, suggesting low viral loads. Smithgall et al. used residual NP swabs tested with the Roche cobas assay and found NPAs of 100% and 92.0% for INDCOV and Cepheid Xpert Xpress and overall PPAs of 73.9% and 98.9%, respectively. However, they also noted that the PPA varied with viral loads. When specimens were categorized by CT values, both INDCOV and Xpert showed 100% PPA for specimens with medium to high viral loads (CT values of &lt;30), but at low viral loads (CT values of &gt;30), the PPA for IDNCOV was 34.3%, versus 97.1% for Xpert. In a recent study, Stokes et al. compared IDNCOV to an LDT and showed an excellent PPA of 89.1% (95% CI, 82.0% to 94.1%) for IDNCOV. Notably, the PPA increased to 98.2% by following the manufacturerâs recommendations for testing under EUA for symptomatic individuals tested â¤7âdays after symptom onset and within an hour of collection using the appropriate swab. Overall, these studies not only demonstrate that the performance characteristics of a test are dependent on numerous factors but also reflect the need for validations or verification of these factors in the settings and conditions where NAAT-based RDTs are applied.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_4</infon><offset>78035</offset><text>(iv) Reverse transcriptionâloop-mediated isothermal amplification.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>78104</offset><text>Reverse transcriptionâloop-mediated isothermal amplification (RT-LAMP) is an IAT that is gaining interest for potential POC applications and is also being explored for routine diagnostic testing. Like RT-PCR, RT-LAMP begins with reverse transcription of the target RNA into cDNA by reverse transcriptase, which is done either in a separate reaction or in the same tube as the LAMP reaction. The LAMP reaction can take place in a single tube at 60Â°C to 65Â°C, and the process can be performed in as little as 20 to 60âmin. LAMP reactions consist of a strand displacement DNA polymerase (e.g., Bst polymerase); a DNA template; dNTPs, typically from 4 to 6 primers; and, depending on the LAMP permutation for signal detection, either a pH-sensitive colorimetric dye or a fluorescent dye. The mechanism for DNA amplification using LAMP is summarized in Fig. 7.</text></passage><passage><infon key=\"file\">CMR.00228-20-f007.jpg</infon><infon key=\"id\">F7</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>78966</offset><text>Amplification of nucleic acids using RT-LAMP. Overall, there are four core primers that mediate all the processes in a LAMP reaction by recognizing six distinct regions of the target DNA through several steps. (1) After the conversion of the template RNA into dsDNA via reverse transcription (not shown), the LAMP reaction starts from strand invasion by the forward inner primer (FIP), which hybridizes through its F2 region to the F2c region of the target DNA. This initiates complementary-strand synthesis using a strand displacement DNA polymerase. (2) The forward outer primer (FOP) (also termed the F3 primer) then hybridizes to the F3c region of the target DNA and, during extension, displaces the newly elongated strand from the FIP. (3) Given that the FIP also contains an F1c sequence, the strand displacement triggered by the DNA polymerase and the FOP leads to the formation of a self-annealing loop in the 5â² end of the FIP-linked strand (regions F1 and F1c). (4) This single-stranded DNA with a stem-loop at its 5â² end then serves as a template for the backward inner primer (BIP), which hybridizes to the B2c region of the template DNA through its B2 sequence. (5) During elongation, the complementary strand opens the 5â²-end stem-loop. Next, the backward outer primer (BOP) (also termed the B3 primer) hybridizes to the B3c region of the target DNA, and its elongation displaces the BIP-linked complementary strand. (6) The displacement of the BIP-linked strand results in self-hybridization on both the 5â² and 3â² ends, leading to two stem-loops and the formation of a dumbbell-shaped DNA. (7 to 9) The amplification of the dumbbell structure with the FIP leads to a concatemer and the formation of a second dumbbell structure that can be amplified with the BIP. Amplification can occur from the 3â² end of each dumbbell structure or with the annealing of primers such as the FIP and BIP. Additional loop primers (i.e., loop F [LF] and loop B [LB] primers) can also be used to increase the speed and sensitivity. Visualization of LAMP amplification is typically done by using pH-sensitive colorimetric or intercalating fluorescent dyes.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>81129</offset><text>Variations of LAMP have been developed for potential POC applications with reactions that are monitored in one of three ways. (i) Turbidity can be measured with a spectrophotometer at an optical density (OD) of 400ânm, as magnesium pyrophosphate precipitates in the solution as a by-product of the LAMP reaction. (ii) Colorimetric detection can be performed using pH-sensitive dyes (e.g., cresol red or phenol red) that change color from the incorporation of dNTPs during amplification or using a metal indicator (e.g., hydroxynaphthol blue) that would assess the concentration of Mg2+, used as a cofactor for dNTP incorporation during DNA synthesis. Color changes can be read by the naked eye or spectrophotometry. (iii) Fluorescence detection can be performed if an intercalating dye (e.g., SYBR green) is used in the LAMP reaction. When complexed with dsDNA, intercalating dyes can be excited to emit fluorescence, which can then be captured in real time with a fluorometer or a compatible thermocycler. Alternative detection systems for RT-LAMP include CRISPR-Cas technology, and these are covered in a later section of this review.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>82268</offset><text>Fluorescence detection tends to be the most sensitive of the visualization methods, which makes the LAMP technology amenable to real-time monitoring and high-throughput testing. However, to our knowledge, no high-throughput instruments have adopted this technology to date. On the other hand, a commercial kit for real-time SARS-CoV-2 RT-LAMP (Variplex; Amplex Diagnostics, Germany) has been developed and compared to real-time RT-PCR. The commercial RT-LAMP kit showed moderate agreement with real-time RT-PCR, with a clinical sensitivity of 76.3%. Given its simplicity, RT-LAMP technology has also been used to develop rapid POC products. Results are ready in 30âmin using RapiPrep COVID-19 (MicrosensDX, England), which integrates magnetic bead-based RNA extraction with LAMP technology. However, a relatively low sensitivity of 80% and a specificity of 73% were observed when tested on 21 nasal swabs compared to real-time RT-PCR. The authors of that study suggested that while the sensitivity and specificity were poor, the assay still had merit in some clinical applications such as algorithms using repeat testing over time. Other studies that used RT-LAMP demonstrated varying performance compared to LDTs based on real-time RT-PCR for commonly used specimen types. The analytical sensitivity of most RT-LAMP assays was found to be in the range of 100 to 200 copies per reaction, while others have reported analytical sensitivities of as low as 10 copies/reaction. Altogether, this range is consistent with those of some LDTs and commercial real-time RT-PCR assays (e.g., cobas SARS-CoV-2 test). The variability in the performance of RT-LAMP assays could be attributed to differences in processing steps, specimen types, the quality of the nucleic acid extraction, LAMP reagents, viral targets, detection methods (manual versus automated), the methodology (e.g., measuring turbidity, using colorimetry, or using fluorescence), viral loads, patient populations tested, numbers of specimens evaluated, methods used as a comparator, or other undefined or uncharacterized factors like inhibition rates. Overall, RT-LAMP technology shows promise for large-scale testing and POC testing, but further optimization is still required.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_4</infon><offset>84504</offset><text>(v) CRISPR-Cas technology.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>84531</offset><text>CRISPR and its Cas proteins are derived from prokaryotic defense systems against foreign nucleic acids. When activated, Cas proteins can exhibit local DNase or RNase activity resulting in local cleavage (cis-cleavage) of the target DNA or RNA as well as collateral damage (trans-cleavage) to neighboring single-stranded DNA (ssDNA) or RNA. A number of different Cas proteins have been identified that differ in nucleotide specificity for their cis-cleavage targets and in their ability to cause collateral damage to nearby nucleic acids. The high degree of collateral damage caused by Cas12a or Cas13 can break down neighboring RNA or ssDNA, which can be exploited for detection. For example, dually labeled ssDNA or RNA probes with a fluorophore-quencher combination can be used, and when the Cas12a or Cas13 system binds to the target DNA or RNA, the Cas proteins are activated to cleave the target and the probe. With a blue-light generator, fluorescence is generated and visualized or captured by a fluorometer. Alternatively, the RNA or ssDNA probe can be labeled with biotin, and the cleavage reaction can be observed with the aid of a specific immunochromatographic device (e.g., LFIA) and colorimetric detection. Understanding the mechanism and permutations of CRISPR-Cas systems led to many technological advances in genome editing and diagnostic applications such as the detection of RNA viruses (Fig. 8).</text></passage><passage><infon key=\"file\">CMR.00228-20-f008.jpg</infon><infon key=\"id\">F8</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>85947</offset><text>Principle of CRISPR-Cas technology for viral RNA detection. First, the viral RNA is subjected to reverse transcription and amplification, e.g., in an RT-RPA reaction at 37Â°C to 42Â°C, to generate dsDNA. The dsDNA can be targeted by guide RNAs (gRNAs) directly in a CRISPR-Cas12 detection system, whereas RNA detection using the CRISPR-Cas13 system requires an additional T7 transcription step. When Cas12 or Cas13 is activated by the recognition of gRNA, there will be cleavage of the target as well as nonspecific cleavage of dually labeled oligonucleotide probes. The probes are ssDNA or ssRNA for the CRISPR-Cas12 or CRISPR-Cas13 systems, respectively. The readout for either method can be colorimetric by the incorporation of fluorescein amidite (FAM)/fluorescein isothiocyanate (FITC)-biotin probes and the use of lateral flow dipsticks, or fluorometric readouts can be used by the incorporation of dually labeled fluorophore (F)-quencher (Q) probes. Upon collateral cleavage, the unquenched fluorophore can be excited with blue light, and the resulting emission of fluorescence can be visualized or captured with a fluorometer.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>87082</offset><text>The use of CRISPR-Cas as a diagnostic tool was proposed by two laboratories, which founded the Cas12a-based system named DETECTR (DNA endonuclease-targeted CRISPR trans-reporter) and the Cas13-based system termed specific high-sensitivity enzymatic reporter unlocking (SHERLOCK) (Fig. 8). Recently, a SHERLOCK-based COVID-19 test received EUA from the FDA, which is the first EUA for any CRISPR technology. However, many variations of CRISPR-Cas12 and CRISPR-Cas13 systems have emerged for the detection of SARS-CoV-2 in a variety of clinical specimens, in both potential POC and high-throughput testing formats. These include the SHERLOCK testing in one pot Covid test (STOPCovid), all-in-one dual CRISPR (AIOD-CRISPR), Cas12b-mediated detection (CDtection), CRISPR-assisted detection (CASdetect), and Cas13-based, rugged, equitable, scalable testing (CREST).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>87943</offset><text>The composition and conditions of each stage of a CRISPR-Cas detection system can affect its speed and performance. For SARS-CoV-2 detection, the initial step in the CRISPR-Cas system can be the lysis of the specimens, with or without an RNA extraction step; however, purified RNA showed higher sensitivity. For example, Broughton et al. demonstrated a DETECTR system that had an LoD of approximately 10 copies/Î¼l using purified RNA, but removing the nucleic acid extraction step decreased the LoDs to 15,000 and 500 copies/Î¼l for contrived specimens consisting of spiked SARS-CoV-2 in â¥10% UTM and â¥20% PBS, respectively. As such, the purification of RNA was recommended. Next, the time to results for CRISPR-Cas-based methods was low compared to real-time RT-PCR, at 20âmin, 40âmin, 50âmin, 60âmin, or 70âmin, but varied between methods and detection systems. All CRISPR-Cas methods described here require the conversion of SARS-CoV-2 RNA into dsDNA, which can be accomplished by RT-PCR, RT-LAMP, or RT-RPA. Huang et al. compared the CDC real-time RT-PCR to a DETECTR assay using either RT-PCR or RT-RPA with a fluorescence readout and achieved low analytical sensitivity (2 copies per sample, regardless of the method used for amplification). Cas12-based CRISPR systems are typically faster than Cas13-based methods, as Cas12 directly detects dsDNA, but the latter requires an additional transcription step to RNA (Fig. 8).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>89386</offset><text>The methods used for SARS-CoV-2 result readout can also affect the speed and performance of the assays. While initially, CRISPR-Cas assays used visual readouts on commercial lateral flow assays, coupling the CRISPR-Cas technology to fluorescent reporters instead leads to more rapid results and sensitive detection. For example, Joung et al. validated a SHERLOCK-based method that returned results in 70âmin using the LFIA readout, while fluorescence testing was completed in 40âmin. Guo et al. demonstrated that the analytical sensitivity of CASdetec, a CRISPR-Cas12b assay based on reverse transcription recombinase-aided amplification (RT-RAA) and fluorescence output, was 103 copies/ml, whereas the sensitivity of DETECTR and SHERLOCK ranged between 104 and 105 copies/ml using an LFIA for detection. Also, CRISPR-Cas systems have been adapted to one-tube reactions using fluorescence rather than amplification followed by detection using lateral flow methods, not only to reduce processing steps but also to decrease the potential for contamination. To optimize the reaction in single-tube formats, the temperature for the IAT must be compatible from the RT step to Cas-based detection. Ding et al. described a one-pot reaction at 37Â°C combining RT-RPA and a CRISPR-Cas12a system and could achieve detection of 1.3 copies of SARS-CoV-2 RNA. With the high temperatures required for RT-LAMP (55Â°C to 65Â°C), CRISPR-Cas12b systems have been developed with a thermostable Cas12b protein derived from Alicyclobacillus acidiphilus that could maintain activity at higher temperatures. A similar approach was used by Ali et al., who developed a single-tube RT-LAMP- and CRISPR-Cas12a-based system able to reach an analytical sensitivity (10 copies/reaction) comparable that of to the CDC real-time RT-PCR (5 copies/reaction). Given the many variables for CRISPR-Cas technology, optimization of this methodology for SARS-CoV-2 and other diagnostic testing is an active area of research.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>91375</offset><text>While the analytical performances of CRISPR-Cas technology showed some promise for detecting SARS-CoV-2, validation on clinical specimens has been scarce to date. Hou et al. showed that an RT-RPA CRISPR-Cas13a system with fluorescence detection was able to correctly identify 52 positive specimens for SARS-CoV-2, whereas an undefined real-time RT-PCR failed to identify 5 specimens with low viral loads. Huang et al. compared the CDC real-time RT-PCR to a DETECTR assay using either RT-PCR or RT-RPA with fluorescence detection on 19 positive clinical specimens and identified all of them; however, 3 additional positive specimens were detected. These could represent false-negative results for the real-time RT-PCR or false-positive results for the CRISPR-Cas12 assay (i.e., specificity would be 71.4% for the latter). The LoD for the CRISPR-based method was 2 copies/reaction, compared to 5 copies/reaction for the CDC real-time RT-PCR, suggesting that CRISPR-based detection may be able to identify SARS-CoV-2 at lower viral loads. Broughton et al. compared the CDC real-time RT-PCR to an RT-LAMP DETECTR system with LFIA or fluorescence readouts using 83 clinical specimens (41 positive and 42 negative specimens) and demonstrated 95% positive agreement. Of the 21 specimens positive for SARS-CoV-2 identified by the CDC real-time RT-PCR, Ali et al., using an RT-LAMP CRISPR-Cas12 system, were able to identify 18 (85.7%) using the fluorescence readout, but weak or absent signals were noted with LFIA detection. Overall, these data show variability in performance for CRISPR-based assays, ranging from 80 to 100% sensitivity.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>93007</offset><text>While CRISPR-based methods are showing promise for SARS-CoV-2 detection, research into this technology is evolving. Recently, an RT-LAMP-based CRISPR-Cas12 system was developed using an electric field gradient on a microfluidic device. This allowed for on-chip, automated separation of nucleic acids from nasopharyngeal swab samples in 30âmin, followed by CRISPR-based detection. While further validation is required to fully understand the benefits of CRISPR-Cas technology, it has much potential for applications for POC devices or high-throughput testing platforms.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_3</infon><offset>93578</offset><text>SARS-CoV-2 next-generation sequencing.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>93617</offset><text>Understanding the genomic sequence of SARS-CoV-2 obtained from clinical specimens can help identify the COVID-19 pandemic origins, delineate transmission events, unravel clues to pathogenesis, and monitor viral evolution over time. Over the last few decades, DNA sequencing technologies have relied on modifications of Sanger sequencing, which was developed in the 1970s. While Sanger sequencing technology is still used for small sequences (â¼0.5 to 1âkb) such as single-gene targets, next-generation sequencing (NGS) technologies have allowed sequencing to be performed as massively paralleled reactions, allowing rapid access to complete genomes at a scale and cost that are feasible for many laboratories. For SARS-CoV-2 genomes of &lt;30âkb, high-quality sequences can readily be obtained with NGS directly from clinical specimens using strategies like amplicon enrichment or bait capture techniques to favor the sequencing of the viral targets. NGS involves technologies such as sequencing by synthesis, sequencing by ligation, and ion semiconductor sequencing (e.g., nanopore sequencing), each with its own advantages and limitations. The principle of each NGS technology has been reviewed elsewhere, and some of them are illustrated in Fig. 9.</text></passage><passage><infon key=\"file\">CMR.00228-20-f009.jpg</infon><infon key=\"id\">F9</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>94871</offset><text>Sequencing techniques for identification of SARS-CoV-2. (A) Sanger sequencing. First, SARS-CoV-2 RNA is often amplified by RT-PCR (not depicted). Sanger sequencing reactions can be undertaken to analyze either of the DNA strands, but only one strand per reaction can be assessed. The extension of the primer annealing to the template DNA occurs in the presence of DNA polymerase, buffer, cofactors, deoxynucleotide triphosphates (dNTPs), and fluorescently labeled dideoxynucleotide triphosphates (ddNTPs). The binding of the ddNTPs to the oligonucleotide strands will cease the extension, resulting in various DNA structures with different lengths. Next, the extended DNAs undergo capillary gel electrophoresis in which the shorter DNA strands move faster, resulting in the detection of the fluorescently labeled nucleotides in the order of the size of the DNA strands. Finally, as DNA fragments are resolved and nucleotide-specific fluorescence signals are captured by a detector, a chromatogram is assembled to reveal the sequence of the template. (B) Next-generation sequencing (NGS) by synthesis. First, a library of millions of DNA fragments is created from the template (or enhanced by multiplex RT-PCR for SARS-CoV-2). Adapters are bound to the two ends of each DNA fragment. The adapters consist of a universal primer-binding site and a unique sequence (i.e., barcode) that can be hybridized to a specific sequence on the support (e.g., flow cell). Following hybridization, with complementary sequences of the adapters, bridge amplification is used to amplify each DNA fragment at a defined physical position. In the sequencing and detection steps, fluorescently labeled nucleotides are bound to the forward strands in the presence of a primer and a polymerase, which results in the generation of fluorescent light that is detected by an analyzer in real time. Many other NGS technologies are also available. (C) For example, NGS by nanopore technology is presented. After creating a library of DNA fragments by multiplex RT-PCR and barcoding, the library is loaded onto a membrane containing nanopores. The nanopores are proteins that open the DNA double strand, and as each nucleotide is passed through the membrane, it causes a specific change in the ionic current that can then be translated into the nucleotide sequence of the templates.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>97222</offset><text>To date, a single commercial kit (Illumina Inc., USA) for NGS has been approved as a clinical diagnostic test under FDA EUA guidelines for COVID-19, which is based on sequencing by synthesis. However, no data are available to date to describe its performance, advantages, or limitations compared to commonly used detection methods like real-time RT-PCR. Also, only a limited number of studies that have explored the use of NGS for SARS-CoV-2 detection for the purpose of diagnostic testing are available. For example, using a laboratory-developed protocol for NGS, Bhoyar et al. compared NGS and real-time RT-PCR on 752 clinical specimens processed in duplicate on a single flow cell. They demonstrated high concordance between the methods and a diagnostic increase in the positivity of 5.7% with NGS (with the detection of 6 cases that tested negative by PCR and 21 cases where PCR results were inconclusive). This study demonstrates the feasibility of processing 1,536 specimens in a total of 17 h (11 h for sequencing and 6 h for analysis). In another study, a low-cost NGS approach was shown to achieve high sensitivity for the detection of SARS-CoV-2 (84 genome units/ml), which is equal to or higher than those of some RT-PCR methods; however, this study tested only 10 specimens (5 positive and 5 negative specimens). It is unclear whether high sensitivity would still occur if the throughput would be increased to their proposed workflow of 192 specimens in 8 h. Bloom et al. showed 100% concordance between NGS and RT-PCR with a limited number of specimens (31 positive and 33 negative NP swabs). These authors propose NGS as a tool for population-based surveillance rather than individualized testing for medical decisions. While postulated to be able to achieve screening of thousands of samples on high-throughput NGS platforms, no data were provided to support the feasibility of this approach or the impact of such a high level of specimen pooling. Overall, some data support the potential of NGS as a diagnostic tool for SARS-CoV-2, yet further analyses are required to understand its benefits and limitations.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>99348</offset><text>Despite the potential for NGS as a diagnostic tool, the limitations of SARS-CoV-2 genome sequencing using NGS technologies should also be recognized. For example, NGS technologies are challenged with specimens with low viral loads, as insufficient data or poor-quality results are obtained for subsequent analyses. Efforts to increase sensitivity and quality are under way using target enrichment processes with NGS techniques such as multiplex PCR amplicon-based sequencing, hybrid capture-based sequencing, and ultrahigh-throughput metatranscriptomic sequencing. Another limitation of NGS technologies is cost, which may be prohibitive for many diagnostic laboratories. Furthermore, the complexity of the NGS workflow and requirement for sophisticated instrumentation and bioinformatics expertise may pose significant barriers to NGS access in many laboratories. If resources are limited, specimens could be prioritized and sent to referral laboratories to help inform public health responses and global surveillance initiatives.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>100380</offset><text>While not routinely used for SARS-CoV-2 diagnostic testing in clinical laboratories, genome sequencing of SARS-CoV-2-positive specimens with NGS technologies has paved the way for numerous applications, including investigations of disease pathogenesis, epidemiology, virus phylogenetics, SARS-CoV-2 evolution, and the impact of viral evolution on diagnostic testing or interventions like therapeutics and vaccines. For example, Meredith et al. used SARS-CoV-2 nanopore sequencing on PCR-positive specimens combined with epidemiological data to help identify nosocomial transmission events and inform infection control interventions. They demonstrated the feasibility of rapid NGS in a health care setting by providing sample-to-sequence information in less than 24 h. From the discovery of SARS-CoV-2, NGS has been used to understand its origins and transmission. Initial phylogenetic analysis of the genomes of SARS-CoV-2 showed that it was closely similar to human SARS-CoV and potentially used the same cell entry receptor (i.e., ACE2) and helped postulate the probable zoonotic origins of the virus (i.e., bats). Next, the first SARS-CoV-2 genomes were made available less than a month from the first recognition of disease reported from Wuhan, Hubei, China. With rapid access to SARS-CoV-2 genome data, molecular methods like real-time RT-PCR were rapidly developed at the early stages of the COVID-19 pandemic and became the method of choice for SARS-CoV-2 detection worldwide. Through remarkable efforts from public health agencies and researchers, SARS-CoV-2 genome sequences have been made available in public data repositories such as the Global Initiative on Sharing All Influenza Data (GISAID) (https://www.gisaid.org/) and the National Center for Biotechnology Information (NCBI) GenBank database (https://www.ncbi.nlm.nih.gov/). These data help provide a snapshot of global diversity and data that could be used for epidemiological investigations. In the initial stages of the pandemic, the high diversity of SARS-CoV-2 genomes was attributable to multiple independent importations of SARS-CoV-2 by travel overseas in countries of initial virus activity, and transmission routes could be investigated. Following global spread and closure of international borders, sequence diversity was more limited, and sequencing of SARS-CoV-2 genomes was used in outbreak investigations and became particularly useful for cases in areas of unknown community transmission. However, with natural evolution in the human host, or selective pressures from the recent introduction of SARS-CoV-2 vaccines or exploratory therapeutics (i.e., antivirals or convalescent-phase sera), there are increasing chances for SARS-CoV-2 to further diversify and acquire mutations.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>103142</offset><text>The genetic diversity of SARS-CoV-2 stems from naturally occurring mutations in its genome, which is common at higher frequencies in RNA viruses. Some mutations might have no impact on SARS-CoV-2 protein sequences (i.e., synonymous substitutions), but these may affect the performance of diagnostic tests using NAATs if they occur in the target region for the assays. From the various genomes of SARS-CoV-2 that have been sequenced since its discovery, the M, E, and RdRp genes were shown to be fairly conserved compared to the high divergence observed in some regions of the S genes. Mutations in the genome of SARS-CoV-2 could also occur from point mutations, insertions, deletions, or recombination events that could affect protein sequence, structure, and function (i.e., nonsynonymous substitutions). Both synonymous and nonsynonymous mutations can be useful for epidemiological investigations, but it should be noted that nonsynonymous mutations are of significant interest as they could have impacts in terms of disease transmissibility and severity or could help the virus escape from therapeutic (i.e., convalescent-phase sera or antivirals) or preventative (i.e., vaccines) interventions. Mutations in S are of particular concern as S glycoprotein epitopes are major targets for current and exploratory vaccines. Multiple SARS-CoV-2 strain variants are circulating globally, but few are variants of concern (VOCs). In the United Kingdom, a novel variant of SARS-CoV-2 (0B/501Y.V1, VOC 202012/01, or B.1.1.7 lineage) emerged, with an unusually large number of mutations. This VOC has since been reported in several countries, including Canada and the United States. It contains a number of mutations in the S gene (e.g., N501Y, 69/70 deletion, and P681H), and while these mutations have yet to show any impact on disease severity or vaccine effectiveness, some preliminary epidemiological data suggest that this variant is associated with increased transmissibility. In Brazil, a SARS-CoV-2 variant from lineage B.1.1.248 was reported, with an E484K S gene mutation associated with reduced neutralization capability by convalescent-phase plasma. Such mutations are concerning due to potential failures of therapeutic options or prevention strategies like vaccines that target similar viral protein epitopes. Furthermore, a novel VOC from lineage B.1.1.248 called P1 was identified, with 12 mutations in the S gene, including both E484K and N501Y, suggesting the potential for increased transmissibility and immune escape. Ongoing surveillance should be encouraged to identify novel SARS-CoV-2 variants and characterize the potential impacts of VOCs.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>105801</offset><text>Overall, sequence-based surveillance of SARS-CoV-2 is important to ensure that diagnostic tests accurately identify the virus and that there are no changes with novel variants in disease spread, disease severity, or the effectiveness of vaccines or antivirals. Whether NGS will eventually become a common diagnostic tool remains to be determined.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>106148</offset><text>SARS-CoV-2 Antigen Detection</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>106177</offset><text>Antigen detection methods, like NAATs, are used to detect active replicating viruses in the early stages of SARS-CoV-2 infection. Unlike NAATs that rely on the detection of viral RNA, antigen detection is based on the identification of SARS-CoV-2 proteins. The two main antigens in SARS-CoV-2 detection assays are S and N proteins. Antigen detection assays use technologies similar to those of serological methods. Like serology, high-throughput antigen-based testing can be performed on semiautomated or automated instruments using enzyme immunoassay (EIA) technologies like enzyme-linked immunosorbent assays (ELISAs) or chemiluminescence immunoassays (CLIAs). However, most antigen detections to date have aimed for methods allowing easy-to-use and rapid testing using portable devices, like LFIAs (also termed lateral flow immunochromatographic assays or lateral flow assays [LFAs]). The mechanism for LFIAs is shown in Fig. 10A, and other technologies (e.g., ELISA and CLIA) are covered in the subsequent serology sections. This section summarizes the current knowledge on the clinical performance of antigen-based detection assays and their potential applications to support COVID-19 responses.</text></passage><passage><infon key=\"file\">CMR.00228-20-f010.jpg</infon><infon key=\"id\">F10</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>107378</offset><text>Antigen testing for the detection of SARS-CoV-2. (A) Principle of a lateral flow immunochromatographic assay (LFIA). The design of the LFIA for antigen detection is a qualitative immunological reaction confined to a small portable device (e.g., cassette or dipstick) that can be performed in the laboratory or a POC setting. Briefly, antigens in specimens (e.g., nasal swabs, nasopharyngeal swabs, and saliva) are placed in a well with a sample pad, and the fluid containing the antigen flows through the device via capillary action. The bottom of the well where the specimen is inoculated contains a sample pad, which is in contact with the conjugate pad used as a support for SARS-CoV-2-specific monoclonal antibodies (mAbs) that are labeled with colloidal gold nanoparticles (AuNPs) or other tags. If present, SARS-CoV-2 antigen (usually S or N protein) forms a complex with the mAbs bound to the AuNPs, and the entire complex migrates via capillary action until it is captured by other SARS-CoV-2 antigen-specific mAbs immobilized on the nitrocellulose membrane (i.e., the test line). As antigen-antibody complexes are trapped at this location, they form a line that can be visualized by the naked eye or with the aid of a detector. Also, mAbs-AuNPs, whether conjugated with antigens or not, continue to migrate until captured by an isotype-specific antibody directed against the fragment crystallizable (Fc) portion of the mAb at the control line. This ensures proper liquid flow through the device and test validity. (B) Point-of-care detection of SARS-CoV-2 antigen using a FET-based sensor. Upon binding of spike (S) proteins to the anti-S monoclonal antibodies immobilized on the graphene sheet via the PBASE linker, a change in the voltage-ampere diagram reveals the presence of the virus. (Panel B is adapted from reference with permission of the American Chemical Society.)</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>109264</offset><text>Hundreds of companies have been developing antigen rapid diagnostic tests (Ag-RDTs) for SARS-CoV-2 detection. Ag-RDTs (e.g., LFIAs) are often promoted as POC devices for rapid testing and immediate management of patients in settings such as physiciansâ offices or clinics; however, these tests are not always performed in these settings. RDT is a more appropriate term if performed in a laboratory setting. At the time of this review, few antigen-based detection assays have received EUA approval in the United States and Canada, but many more applications have been submitted as laboratory and/or POC tests. Examples of SARS-CoV-2 Ag-RDTs that have received EUA for testing in laboratory or POC settings in the United States or Canada include technologies relying on a colorimetric LFIA with a visual readout, instrument-based antigen detection using a fluorescence-based LFIA, a microfluidic immunofluorescence assay, and a chromatographic digital immunoassay (Table 2).</text></passage><passage><infon key=\"file\">T2.xml</infon><infon key=\"id\">T2</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>110239</offset><text>Examples of antigen tests approved for emergency use by the U.S. FDA for detection of SARS-CoV-2a</text></passage><passage><infon key=\"file\">T2.xml</infon><infon key=\"id\">T2</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;colgroup span=&quot;1&quot;&gt;&lt;col span=&quot;1&quot;/&gt;&lt;col span=&quot;1&quot;/&gt;&lt;col span=&quot;1&quot;/&gt;&lt;col span=&quot;1&quot;/&gt;&lt;col span=&quot;1&quot;/&gt;&lt;col span=&quot;1&quot;/&gt;&lt;col span=&quot;1&quot;/&gt;&lt;col span=&quot;1&quot;/&gt;&lt;col span=&quot;1&quot;/&gt;&lt;/colgroup&gt;&lt;thead&gt;&lt;tr&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Device or assay (manufacturer)&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Methods&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Target antigen protein&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Specimen type(s)&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Authorized detection window (dpo)&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Authorized settings&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Time (min)&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LoD (TCID&lt;sub&gt;50&lt;/sub&gt;/ml)&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;T2F2&quot;&gt;&lt;sup&gt;&lt;italic&gt;b&lt;/italic&gt;&lt;/sup&gt;&lt;/xref&gt;&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Reference&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;BinaxNOW COVID-19 Ag card home test&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;T2F3&quot;&gt;&lt;sup&gt;&lt;italic&gt;c&lt;/italic&gt;&lt;/sup&gt;&lt;/xref&gt; (Abbott Diagnostics, USA)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LFIA, visual readout&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NS, ANS&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Home, H, M, W&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;15&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;140.6&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B585&quot; ref-type=&quot;bibr&quot;&gt;585&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;CareStart COVID-19 antigen test (Access Bio, USA)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LFIA, visual readout&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NPS&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;H, M, W&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;800&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B586&quot; ref-type=&quot;bibr&quot;&gt;586&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;QuickVue SARS antigen test&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;T2F3&quot;&gt;&lt;sup&gt;&lt;italic&gt;c&lt;/italic&gt;&lt;/sup&gt;&lt;/xref&gt; (Quidel Corporation, USA)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LFIA, visual readout&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ANS&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;H, M, W&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7,570&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B587&quot; ref-type=&quot;bibr&quot;&gt;587&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Veritor system for rapid detection of SARS-CoV-2 (BD, USA)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LFIA, instrument readout&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NS&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;H, M, W&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;15&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;140&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B588&quot; ref-type=&quot;bibr&quot;&gt;588&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Sofia 2 Flu + SARS antigen FIA&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;T2F3&quot;&gt;&lt;sup&gt;&lt;italic&gt;c&lt;/italic&gt;&lt;/sup&gt;&lt;/xref&gt; (Quidel Corporation, USA)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LFIA, IFA, instrument readout&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NS, NPS&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;H, M, W&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;15&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;91.7&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B589&quot; ref-type=&quot;bibr&quot;&gt;589&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LumiraDx SARS-CoV-2 Ag test&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;T2F3&quot;&gt;&lt;sup&gt;&lt;italic&gt;c&lt;/italic&gt;&lt;/sup&gt;&lt;/xref&gt; (LumiraDx Ltd., UK)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Microfluidics, IFA, instrument readout&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NS&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;H, M, W&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12â&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;32&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B590&quot; ref-type=&quot;bibr&quot;&gt;590&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Clip COVID rapid antigen test&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;T2F3&quot;&gt;&lt;sup&gt;&lt;italic&gt;c&lt;/italic&gt;&lt;/sup&gt;&lt;/xref&gt; (Luminostics Inc., USA)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LFIA, ILA, instrument readout&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ANS&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;H, M, W&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;88&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B591&quot; ref-type=&quot;bibr&quot;&gt;591&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Ellume COVID-19 home test&lt;xref ref-type=&quot;table-fn&quot; rid=&quot;T2F3&quot;&gt;&lt;sup&gt;&lt;italic&gt;c&lt;/italic&gt;&lt;/sup&gt;&lt;/xref&gt; (Ellume Limited, Australia)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LFIA, IFA, smartphone readout&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;N&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;MTS&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;NA&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Home, H, M, W&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;15&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6,309&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;xref rid=&quot;B592&quot; ref-type=&quot;bibr&quot;&gt;592&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>110337</offset><text>Device or assay (manufacturer)\tMethods\tTarget antigen protein\tSpecimen type(s)\tAuthorized detection window (dpo)\tAuthorized settings\tTime (min)\tLoD (TCID50/ml)b\tReference\t \tBinaxNOW COVID-19 Ag card home testc (Abbott Diagnostics, USA)\tLFIA, visual readout\tN\tNS, ANS\t7\tHome, H, M, W\t15\t140.6\t\t \tCareStart COVID-19 antigen test (Access Bio, USA)\tLFIA, visual readout\tN\tNPS\t5\tH, M, W\t10\t800\t\t \tQuickVue SARS antigen testc (Quidel Corporation, USA)\tLFIA, visual readout\tN\tANS\t5\tH, M, W\t10\t7,570\t\t \tVeritor system for rapid detection of SARS-CoV-2 (BD, USA)\tLFIA, instrument readout\tN\tNS\t5\tH, M, W\t15\t140\t\t \tSofia 2 Flu + SARS antigen FIAc (Quidel Corporation, USA)\tLFIA, IFA, instrument readout\tN\tNS, NPS\t5\tH, M, W\t15\t91.7\t\t \tLumiraDx SARS-CoV-2 Ag testc (LumiraDx Ltd., UK)\tMicrofluidics, IFA, instrument readout\tN\tNS\t12\tH, M, W\t12â\t32\t\t \tClip COVID rapid antigen testc (Luminostics Inc., USA)\tLFIA, ILA, instrument readout\tN\tANS\t5\tH, M, W\t30\t88\t\t \tEllume COVID-19 home testc (Ellume Limited, Australia)\tLFIA, IFA, smartphone readout\tN\tMTS\tNA\tHome, H, M, W\t15\t6,309\t\t \t</text></passage><passage><infon key=\"file\">T2.xml</infon><infon key=\"id\">T2</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_footnote</infon><offset>111407</offset><text>The full list is available in reference. Abbreviations: LFIA, lateral flow immunoassay; IFA, immunofluorescence assay; ILA, immunoluminescence assay; BD, Becton, Dickinson and Company; dpo, days post-symptom onset; NS, nasal swab; ANS, anterior nasal (naris) swab; NPS, nasopharyngeal swab; MTS, midturbinate nasal swab; H, laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. Â§263a, that meet requirements to perform high-complexity tests; M, laboratories certified under the CLIA, 42 U.S.C. Â§263a, that meet requirements to perform moderate-complexity tests; W, patient care settings operating under a CLIA certificate of waiver; TCID50, median tissue culture infectious dose.</text></passage><passage><infon key=\"file\">T2.xml</infon><infon key=\"id\">T2</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_footnote</infon><offset>112137</offset><text>The limit of detection (LoD) of each assay is the lowest LoD reported in the instructions for use of that assay, regardless of the specimen types.</text></passage><passage><infon key=\"file\">T2.xml</infon><infon key=\"id\">T2</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_footnote</infon><offset>112284</offset><text>The assay does not differentiate between SARS-CoV-2 and SARS-CoV.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>112350</offset><text>While EUA was granted for some Ag-RDTs, at the time of this review, limited data have been published on their clinical performance characteristics. The performance of antigen- and molecular-based POC tests for detecting SARS-CoV-2 was the subject of a recent Cochrane review, but limited data were available to be summarized. Briefly, the review summarized data from five studies, representing 943 samples. The average sensitivity of Ag-RDTs was found to be 56.2% (95% CI, 29.5% to 79.8%), and the average specificity was 99.5% (95% CI, 98.1% to 99.9%). In comparison, NAAT-based RDTs had an average sensitivity of 95.2% (95% CI, 86.7% to 98.3%) and an average specificity of 98.9% (95% CI, 97.3% to 99.5%). High specificity was observed for both molecular and antigen-based detection methods; however, low sensitivity was noted for Ag-RDTs, but a high level of heterogeneity was noted between studies. This variability could be explained by factors including the methods used for SARS-CoV-2 detection, the comparator methods during the evaluation, the patient populations assessed, SARS-CoV-2 prevalences, the timing of specimen collection, the specimen types used, and antigen stability during analyses.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>113556</offset><text>Consistent with the low clinical sensitivity of Ag-RDTs, the analytical sensitivity was defined in some studies, which described LoDs of Ag-RDTs that were approximately 1,000-fold lower than those of culture-based detection of SARS-CoV-2 and 10,000-fold lower than those of NAATs. Mertens et al. noted that when specimens with high viral loads were evaluated (defined as specimens with real-time RT-PCR CT values of &lt;25), the sensitivity of Ag-RDTs increased to 74.8%, compared to an overall sensitivity of 57.6%, when all specimens were considered. Scohy et al. observed an overall sensitivity of Ag-RDTs of 30.2%. When specimens were further characterized by real-time RT-PCR CT values, the impact of the poor sensitivity of Ag-RDTs was clear. With specimens with CT values of &lt;25 (1.8âÃâ105 copies/ml), CT values of &lt;30 (9.4âÃâ103 copies/ml), and CT values of &lt;35 (4.9âÃâ102 copies/ml), the sensitivities of Ag-RDTs were shown to be 100%, 70.6%, and 46.9%, respectively. Linares et al. showed that an Ag-RDT achieved 86.5% sensitivity (95% CI, 75.0% to 97.0%) if symptomatic patients with high or moderate viral loads were tested within 7 days of symptom onset. As seen with all other SARS-CoV-2 tests, the timing of testing likely plays an important role in assay performance. Recognizing the relatively poor sensitivity compared to NAATs but the potential role for Ag-RDTs, WHO interim guidance described situations where such tests could be considered. The WHO supports the use of Ag-RDTs for conditions such as (i) testing in areas where NAATs are not available (e.g., remote areas) or when the result turnaround times using NAATs are long; (ii) in outbreak investigations, but the frequency of testing in these settings remains unclear; (iii) in areas where the prevalence is high; and (iv) for testing of asymptomatic contacts of positive cases.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>115426</offset><text>Given the poor sensitivity of Ag-RDTs for detecting SARS-CoV-2, research is being performed to improve sensitivity using novel sensor and biosensor technologies. So far, a few studies have leveraged the power of electronic and electrochemical methods to create fast and sensitive diagnostic devices for SARS-CoV-2 detection. For example, Seo et al. described a field-effect transistor (FET)-based biosensing device that detected SARS-CoV-2 at concentrations of 2.42âÃâ102 copies/ml in clinical specimens, without sample pretreatment, in approximately 3âmin. The FET sensor used SARS-CoV-2 monoclonal antibodies (mAbs) to spike proteins, which were coupled to graphene sheets through a 1-pyrenebutyric acid N-hydroxysuccinimide ester (PBASE) linker (Fig. 10B). With the high conductivity and other properties of graphene, real-time dose-dependent detection of SARS-CoV-2 antigen can be achieved down to 1 fg/ml. While further optimization is needed to commercialize this technology, it has the potential to help increase the sensitivity of antigen detection. In another study, Mahari et al. developed an electrochemical device using a screen-printing technique. They immobilized antibodies against SARS-CoV-2 spike proteins on screen-printed carbon electrodes (SPCEs) to detect the virus and developed an integrated in-house-built portable device that could measure the changes in electrical conductivity upon the reaction between antigens and antibodies. The device was able to detect spiked SARS-CoV-2 antigens in saliva with an LoD of 90 fM within 10 to 30 s.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>116995</offset><text>While FETs and electrochemical sensors show promise to increase the sensitivity of antigen detection, the desire to achieve the highest sensitivity possible with RDTs has been the subject of recent debate. Some authors have proposed that with repeat testing, the chance of identifying SARS-CoV-2-infected individuals increases. This may be true on a population level, where testing may otherwise not have been performed (e.g., asymptomatic testing), and there would be fewer consequences if detection of the virus is missed. However, repeat testing and the possibility of false-negative results in an acute-care setting pose many more challenges, particularly when decisions have to be made at the time of or shortly after the time of presentation. For existing or novel technologies, studies with more robust data are needed to better define the utility of Ag-RDTs in various settings. These should include prospective analyses that consider factors such as the timing of collection, time of symptom onset, symptomatic and asymptomatic patient populations, disease prevalence, stability, and following the manufacturerâs recommendations for stability and transport (i.e., direct testing of specimens and not using specimens in transport media).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_2</infon><offset>118243</offset><text>Serological Immunological Methods for SARS-CoV-2 Detection</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>118302</offset><text>Serological assays detect antibodies specific to SARS-CoV-2 in blood sources like serum, plasma, or whole blood (including fingerstick and heel pricks sometimes used in POC testing), and the possibility of antibody detection in other body fluids such as saliva is being explored. Given that the typical time required to detect immune responses to SARS-CoV-2 is around 1 to 2 weeks, serological tests have limited utility for SARS-CoV-2 diagnostics in the acute stages of the illness but could have value once immune responses have had time to occur. Many serological assays for detecting SARS-CoV-2 antibodies have been developed and commercialized, and a list of authorized medical devices related to COVID-19 in the United States and Canada is regularly updated online. Despite access to serological assays, the interpretation of their results is further complicated in the postvaccine era for SARS-CoV-2, and the relevance of antibody detection must be considered in the context in which it is used and its limitations. Following a section describing serological methods, a discussion on the relevance and possible applications is provided.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>119446</offset><text>Serological assays often use recombinant antigens to capture SARS-CoV-2-specific antibodies, with the N protein and the receptor-binding domain (RBD) of the S1 subunit of the S glycoprotein being the most commonly used antigens. Serological methods can target one or more immunoglobulin isotypes (i.e., IgA, IgM, or IgG) or total antibody, and theoretically, any of these isotypes could provide neutralizing activity against SARS-CoV-2. IgM and IgG are commonly used immunoglobulins in serological assays for SARS-CoV-2, while IgA detection is less commonly used. IgA and IgM have shown some merits for the detection of early immune responses to SARS-CoV-2, but there has been some concern regarding the rapid decay of IgA and IgM in serum and saliva compared to IgG. While more data are needed to fully understand the serological responses in different settings or patient populations, it is clear that IgA, IgM, and IgG all have the potential to generate neutralizing responses to SARS-CoV-2.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>120441</offset><text>The most common methods used are ELISAs in a 96-well plate format and CLIAs for automated higher-throughput instruments. LFIAs are also available to provide rapid results. It is unclear whether detectable antibodies in commercial serology methods are associated with immune protection, as large population-level studies and quantitative immunoglobulin analyses are required to assess if detection of SARS-CoV-2-specific immunoglobulins correlates with immune protection. However, studies are under way to investigate the extent of neutralizing antibodies produced over time.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>121016</offset><text>The performance of immunological assays remains unclear as there is a lack of a gold standard for method comparison. Methods are often compared among themselves from a consensus standard, but the true performance and relevance of antibody responses, and the optimal testing algorithm, require further investigation. For now, the applications of serology include a role as an adjunct to molecular testing to support the identification of SARS-CoV-2 in a patient suspected of having COVID-19 (i.e., persistent or progressing symptoms) but with the absence of testing or repeated negative (or indeterminate) results obtained by NAATs. It should be noted that some patients may be antibody negative at the time of testing, but that does not preclude memory B cell activity or functional T cell responses with subsequent exposures to SARS-CoV-2. Some studies argue that immunological methods could also be used in seroprevalence studies to aid in ongoing outbreak investigations (to identify cases beyond the detectable window of NAATs), to determine past exposures of populations to SARS-CoV-2 (e.g., health care workers or the general population), or to assess attack rates in defined populations or geographical areas. However, correlations to neutralizing antibody titers would be required to fully understand serological data, along with the impact of prior infection with SARS-CoV-2 and other human coronaviruses as well as the impact of vaccines. High sensitivity and specificity are desired, but with these many confounding factors, result interpretation is complicated. The following sections describe common methods used for SARS-CoV-2 serology, including ELISAs, CLIAs, and LFIAs, along with a discussion of the potential value and limitations of immunological methods.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_3</infon><offset>122792</offset><text>Enzyme-linked immunosorbent assay.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>122827</offset><text>While many permutations exist, enzyme-linked immunosorbent assays (ELISAs) can be categorized into four main types: sandwich, direct, indirect, and competitive. For the detection of SARS-CoV-2, indirect, modified indirect, and double-antigen sandwich ELISAs are the most commonly used methods (Fig. 11A).</text></passage><passage><infon key=\"file\">CMR.00228-20-f011.jpg</infon><infon key=\"id\">F11</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>123132</offset><text>Common serological immunoassays for the detection of SARS-CoV-2-specific antibodies. (A) Common designs of ELISA methods, including indirect, modified indirect, and double-antigen sandwich assays. (B) Magnetic bead-based CLIA.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>123359</offset><text>In the indirect ELISA method, a solid support, such as wells of a 96-well microplate, is coated with SARS-CoV-2 recombinant antigens. Patient serum or plasma is added, and if present, SARS-CoV-2-specific antibodies will bind to the immobilized antigens. Following washing steps, a secondary antibody is then added that is specific to the isotype targeted (i.e., anti-human IgM, anti-human IgG, or anti-human IgA). This secondary antibody (or conjugate) is linked to a fluorophore that can generate fluorescence or conjugated to an enzyme for colorimetric or chemiluminescent signal generation following the addition of a substrate. Usually, colorimetric methods are used in which the optical density (OD) (i.e., absorbance) of the solution can be measured using a spectrophotometer and correlated with the concentration of the target antibodies. Other permutations of ELISAs are also possible, but while these techniques all share similarities in terms of their signal generation mechanisms, each can vary in performance. Typically, the time to result for ELISAs is 1 to 5 h, and more recently, POC applications of ELISAs for the detection of anti-SARS-CoV-2 antibodies have been explored using microfluidics technology. The performance characteristics and limitations of SARS-CoV-2 serology are discussed in a later section.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_3</infon><offset>124685</offset><text>Chemiluminescence immunoassay.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>124716</offset><text>The chemiluminescence assay (CLIA) is an immunoassay that is commonly used in highly automated serological instruments and is known for its high sensitivity compared to other serological assays. Similar to ELISAs, variations of CLIAs have been applied for the detection of SARS-CoV-2 antibodies, such as indirect and sandwich methods.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>125051</offset><text>The CLIA has two main differences from colorimetric ELISAs. First, the final reaction produces light, which is detected by a luminometer in relative light units (RLU) rather than the OD, which is an absolute value. To produce light, the conjugate uses an enzyme-substrate reaction such as the alkaline phosphatase (AP) and Lumigen APS-5 substrates. Second, magnetic microspheres in a liquid-phase reaction rather than multiwell plates are coated with the antigenic materials, which allows the easy separation of bound and unbound molecules by a magnet and faster reactions due to providing a large surface area and allowing the reactions to occur entirely in suspension (Fig. 11B). Some CLIAs have been commercialized and used on high-throughput automatic analyzers. For example, the Liaison assay (DiaSorin, Italy) uses magnetic beads coated with SARS-CoV-2 S1 and S2 antigens to detect IgG antibodies. This assay is capable of providing up to 170 results/h in a fully automated manner.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_3</infon><offset>126039</offset><text>Fluorescent microparticle immunoassays.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>126079</offset><text>Recently, Norman et al. described a fluorescent nanoparticle immunoassay (FMI)-based single-molecule array assay that consisted of a mixture of four types of dye-encoded beads coupled to S, S1, S2, and N proteins and used for the detection and differentiation of SARS-CoV-2 IgM, IgG, and IgA antibodies. In this technique, an excess number of beads is utilized in comparison to the number of antibody molecules in the samples in a way that either zero or one antibody molecule binds to each bead. After the reactions occur between the coated beads and the antibodies and other reagents, the beads are loaded into an array of 216,000 femtoliter-sized wells for imaging, which allows the detection of antibodies with single-molecule resolution. When tested on a set of 81 plasma samples, the technique showed 86% sensitivity and 100% specificity for the samples during the first week after symptom onset and 100% sensitivity and specificity for the samples taken after the first week after symptom onset.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>127082</offset><text>Similarly, to facilitate the simultaneous detection of the IgG, IgM, and IgA isotypes of SARS-CoV-2-specific immunoglobulins, a multiplex SARS-CoV-2 antibody immunoassay based on Luminex technology was developed for detection on the Bioplex automated flow cytometer (Bio-Rad Laboratories). This multiplex immunoassay was used to demonstrate SARS-CoV-2 antigen-specific antibody responses in 33 saliva and 206 serum samples from participants with RT-PCR-confirmed SARS-CoV-2 infection. Overall, this technology could detect prior SARS-CoV-2 infection with high sensitivity and specificity at â¥10âdays after symptom onset, but the performance varied with the targets. FMI technology allows robust antibody profiles to be simultaneously Tdetected in a single reaction. A commercial assay for the Bioplex 2200 system has recently received FDA approval, but no data on this assay have been published to date.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_3</infon><offset>127990</offset><text>Lateral flow immunoassays.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>128017</offset><text>As described in the antigen detection section above, lateral flow immunoassays (LFIAs) can be used as an RDT or POC test to detect antibodies against SARS-CoV-2 in blood or serum samples. The most frequently used antigens are recombinant S or N proteins to capture total antibody or detect and sometimes differentiate IgM and IgG antibodies. The LFIA devices are low cost, portable, and rapid (â¼15âmin) and require only a few microliters of samples, making them suitable for fingerstick tests. Figure 12A illustrates an example of an LFIA used for the simultaneous colorimetric detection of SARS-CoV-2-specific IgM and IgG. Many different types of LFIAs have been developed to detect SARS-CoV-2, with variations in antigens used for antibody capture, immunoglobulin isotypes detected, and overall performances.</text></passage><passage><infon key=\"file\">CMR.00228-20-f012.jpg</infon><infon key=\"id\">F12</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>128832</offset><text>Serological lateral flow immunoassays for the detection of SARS-CoV-2-specific antibodies. (A) Schematic of a lateral flow immunoassay device for the simultaneous detection of IgM and IgG antibodies. Upon the addition of the sample, the liquid moves toward the preimmobilized reagents through capillary action and reacts with them. If IgM/IgG antibodies are present in the sample, they bind and form a complex with the recombinant SARS-CoV-2 antigen conjugated with colloidal gold nanoparticles (AuNPs). The complex is then captured in one of the test lines by anti-human IgM/IgG antibodies, resulting in a pink color due to the accumulation of the AuNPs. There is also an AuNP-rabbit IgG conjugate that will be captured in the control line, indicating proper liquid flow through the device. The results will be observable in â¼15âmin. (B) Variations of results of the lateral flow assay device in a cassette format. (This figure was inspired by the work in reference.)</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_3</infon><offset>129805</offset><text>Performance of serological immunological methods for SARS-CoV-2.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>129870</offset><text>TIn a systematic review and meta-analysis, the results of 40 studies up to 30 April 2020 were summarized, and differences in sensitivity between serological methods used for SARS-CoV-2 antibody detection as well as antibody classes were presented. Data for IgA were scarce, and no conclusions could be drawn. For IgM detection, the pooled sensitivity (95% CI) for LFIAs was the lowest, at 61.8% (50.8% to 71.8%), whereas that for ELISAs was higher, at 81.7% (71.8% to 88.5%), and that for CLIAs was the highest, at 84.3% (70.7% to 93.0%). Similarly, the pooled sensitivities for IgG detection were 64.9% (53.8% to 75.4%), 80.6% (71.9% to 87.9%), and 93.5% (84.9% to 98.1%) for the LFIA, ELISA, and CLIA, respectively. The pooled specificities were fairly similar among the LFIA, ELISA, and CLIA methods, at 96.6% (93.8% to 98.4%), 99.7% (99.0% to 100.0%), and 96.6% (84.7% to 99.5%) for IgM detection and 97.6% (96.2% to 98.8%), 98.9% (96.7% to 99.8%), and 97.8% (62.9% to 99.9%) for IgG detection, respectively. Other meta-analyses and systematic reviews yielded consistent conclusions for sensitivity and specificity for IgM, IgG, or total antibodies.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>131024</offset><text>One important issue affecting the diagnostic performance of serological assays is the time after symptom onset when the samples are taken for serological analyses, as the antibody profiles change over the course of the disease. In a meta-analysis and systematic review, the pooled sensitivity (95% CI) for IgM detection was low in the first week after symptom onset, at 25.3% (16.3% to 31.1%), for the LFIA but increased to 51.8% (30.3% to 69.6%) after 2 weeks and to 69.9% (58.4% to 79.9%) after 3 weeks. ELISA detection of IgM showed similar values for weeks 1, 2, and 3 after symptom onset, at 26.7% (15.6% to 35.6%), 57.6% (15.9% to 88.2%), and 78.4% (54.1% to 91.9%), respectively. The CLIA followed the same trend but with higher values, at 50.3% (10.9% to 81.2%), 74.3% (16.1% to 99.4%), and 90.6% (51.8% to 99.4%), respectively. Next, the pooled sensitivities for IgG at weeks 1, 2, and 3 after symptom onset were 13.4% (4.7 to 29.6%), 50.1% (24.8% to 77.0%), and 79.7% (71.4% to 86.9%) for the LFIA; 23.7% (12.7% to 38.1%), 65.3% (46.3% to 79.4%), and 82.1% (76.4% to 89.0%) for the ELISA; and 53.2% (28.7% to 67.6%), 85.4% (48.1% to 98.1%), and 98.9% (86.9% to 100.0%) for the CLIA, respectively.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>132231</offset><text>Overall, the performances of serology assays varied between methods and were dependent on the timing of collection, and the applicability of these methods is limited to date. It is important to recognize that other factors such as antigens and the inherent characteristics of a test or instrument used for antibody detection can also impact the performance of immunological assays. Also, data summaries in recent meta-analyses and systematic reviews so far have shown high levels of heterogeneity and a risk of bias and applicability between studies. Thus, careful attention should be paid to the design of the studies, their limitations, and whether the conclusions derived from these evaluations are justified. It remains unclear whether antibodies will provide durable protective responses against subsequent SARS-CoV-2 infections or what will be the impact of prior infection with seasonal human coronaviruses. It is possible that prior infection with other coronaviruses or other conditions (e.g., pregnancy or chronic illnesses) may cross-react with SARS-CoV-2 serology assays, and robust evaluation of methodologies should include specificity analyses against related viruses and possible interfering substances. The recent introduction of vaccine programs will further complicate the use of immunological methods as diagnostic tests but may expand their use to determine whether individuals are immune once exposed to SARS-CoV-2 through natural infection or following immunization. This remains an active area of research that requires comparisons to neutralizing antibody titers and cell-mediated immunity.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_3</infon><offset>133847</offset><text>Neutralization assays and research areas of interest for serology.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>133914</offset><text>The efforts of the scientific community to help understand the host responses to SARS-CoV-2 are fundamental in understanding COVID-19 pathophysiology and the interpretation of SARS-CoV-2 laboratory diagnostics. There has been an extraordinary effort to rapidly develop serological methods in various formulations, and while some were licensed under EUA in the United States and Canada, their use to make recommendations on a patientâs current or future susceptibility to SARS-CoV-2 infection remains unclear. Given the timing of the immune responses to SARS-CoV-2 infection, it is clear that serology would not be useful for diagnosis in acute phases of illness; antibodies would not be present in substantial quantities in this time frame to allow public health interventions. In fact, positive serology does not preclude viral shedding, and the absence of antibodies does not preclude the possibility of immunity. To date, recommendations for the use of serology include clinical research (e.g., seroprevalence studies) to help inform public health strategies or policies on a population level. For example, seroepidemiological studies can support ongoing outbreak investigations or retrospectively assess infection rates in certain populations. On an individual level, serology may have considerations for individual patients with multisystem inflammatory syndrome or in situations where suspect cases repeatedly test negative by NAATs, but symptoms persist (and the timing fits into a period of at least 2 weeks after symptom onset). Future research is required to further understand the full value of SARS-CoV-2 serology, especially in the context of immunization with COVID-19 vaccines.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>135609</offset><text>Key areas of research interest should include the relevance and duration of antibody-based immune responses to better understand whether antibody responses in commercial tests or LDTs correlate with protective immune responses against subsequent SARS-CoV-2 infection as well as the magnitude and duration of these responses. Understanding this correlation can be an important function to assess immunity on an individual or population level or even to qualify blood donors desiring to become donors of convalescent-phase plasma that could subsequently be used in clinical trials. This would require a quantitative analysis of seroconversion (detection of measurable antibodies following infection), which would not be possible with qualitative assays such as LFIAs but may be possible using semiquantitative ELISAs (where antibody detection relies on a signal value that is normalized to a calibrator to establish a signal-to-cutoff [S/CO] ratio) or, ideally, using quantitative ELISAs. Quantitative detection of SARS-CoV-2 antibodies over time could be used to demonstrate seroconversion, and quantitative ELISAs have become commercially available (e.g., the liquid-based double-antigen sandwich ELISA from Roche [Elecsys anti-SARS-CoV-2 S]). Quantitative antibody analyses, paired with a fundamental understanding of how well serological methods correlate with neutralizing antibodies (nAbs), may help establish a threshold where populations are protected from SARS-CoV-2 reinfection (known as a correlate of protection).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>137133</offset><text>The establishment of a correlate of protection first requires an in-depth understanding of whether nAbs are produced, the extent to which they are produced, whether they provide protection, and the duration of these responses and then analyzing these data in large population studies to correlate a level of nAbs that may confer protection against subsequent infection. The quantification of nAbs in serum or plasma is performed using target- and immunoglobulin isotype-specific neutralization assays 9like plaque reduction neutralization tests (PRNTs). Briefly, PRNTs rely on the ability of nAbs to effectively prevent SARS-CoV-2 from infecting cultured cells that would otherwise cause cytopathic effects (i.e., cell death/lysis).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>137866</offset><text>Nonetheless, PRNTs are known to be time-consuming and laborious. To increase specimen throughput, microneutralization (MN) tests have been developed to detect nAbs to SARS-CoV-2 that rely on a principle similar to that of PRNTs but are performed in 96-well formats and without the need for semisolid overlays. To further automate the detection of nAbs, a focus reduction neutralization test (FRNT) can be used where patient sera/plasma dilutions can be assessed for their ability to reduce viral plaque formation, foci, or individually infected cells using immunocolorimetric staining and visualization using digital imaging. Despite MN, FRNTs are amenable to moderate-throughput testing, and alternatives have been developed using fluorescence detection and luminescence to increase sensitivity. On the other hand, MN tests and FRNTs share a challenge similar to that with PRNTs: they all rely on SARS-CoV-2 propagation in cell culture, which requires laboratory facilities with higher levels of biological containment (i.e., biosafety level 3 [BSL3] in Canada or physical containment level 3 [PC3] as defined by the WHO). These practices are not common outside reference laboratories. To circumvent these biosafety requirements, pseudovirus-based neutralization assays (PBNAs) have been developed, where SARS-CoV-2 proteins are expressed on a surrogate virus backbone such as a lentivirus, retrovirus, or vesicular stomatitis virus (VSV). Other alternatives include the use of a protein-based surrogate neutralization ELISA (snELISA), which is based on the competition between ACE2 and nAbs for binding to recombinant antigens.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>139496</offset><text>Few studies have looked at nAbs, and data on the extent and duration of nAbs over the course of SARS-CoV-2 infection are scarce. Suthar et al. used an FRNT to demonstrate that nAb binding to the SARS-CoV-2 S protein RBD is detectable within 6 days after PCR confirmation. While days postonset would have better defined the antibody profiles over time, these authors showed that there is rapid isotype switching in nAbs from IgA and IgM to IgG1 and IgG3. In a limited data set from Long et al., it was noted that there was a decline in nAbs over time in both asymptomatic and symptomatic individuals. Similarly, Seow et al. performed a longitudinal study using sequential serum sampling and demonstrated that seroconversion was observed in 95% of cases, with nAbs present 8 days after the onset of symptoms. They also noticed that the magnitude of nAb responses depended on disease severity and waned over time, which was consistent with the results of others. In some cases, nAbs persisted up to 60âdays, while others approached the limit of detection in this period. In a more recent study by Isho et al., the duration of antibody responses was evaluated in both serum and saliva. Antibodies to S protein were detected in 90% of cases approximately 10âdays after symptom onset, and longitudinal studies showed the persistence of nAbs up to 105âdays. Similarly, nAbs (defined using snELISAs) reached a maximum from days 30 to 45. Interestingly, the sensitivities of anti-S or anti-RBD IgG in saliva were 89% and 85%, showing promise for noninvasive methods for seroepidemiological studies and vaccine trials. The sensitivities of IgA, on the other hand, were 51% and 30%, and those for IgM were 57% and 33%, respectively. It should be noted that the limited number of longitudinal studies seem to suggest that SARS-CoV-2-specific antibodies decrease over a 2- or 3-month period; however, the longevity of humoral immunity is not yet fully understood for SARS-CoV-2. It is possible that memory T cells may still be able to mount effective responses upon reexposure to SARS-CoV-2. Research into the role of cell-mediated immune responses is needed to help unravel knowledge gaps for SARS-CoV-2 immune responses.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>141712</offset><text>Overall, whether derived from vaccines or natural infection, quantitative analyses of nAbs and establishing a correlate of protection would help inform public health and health care policies. Using neutralization assays with targets outside those used in vaccines could still be of benefit to understand seroepidemiology to help better define populations at risk, which would be important for vaccine trials or evaluations of novel SARS-CoV-2-specific therapies like the use of hyper-IgG preparations or convalescent-phase sera. Like any other method for SARS-CoV-2 detection, serology research should consider antibody and cellular immune responses over time, have a population- and individual-level testing perspective, as well as account for factors like the presence or absence of symptoms, the timing from symptom onset (if present), the severity of illness, host factors (e.g., age and medical comorbidities), and any collection, transport, or processing steps that may affect the reliability of the analyte profiles over time. Additional research is still needed to meet these goals.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">title_1</infon><offset>142803</offset><text>CONCLUSIONS AND OUTLOOK</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>142827</offset><text>Despite the recent availability of vaccines, with the ongoing and rapid spread of SARS-CoV-2 worldwide, laboratory testing remains the cornerstone of public health containment and mitigation strategies. Given the thoroughness of the data on methodologies in the body of this review, only key findings, some considerations for testing, and areas for improvement and successes are discussed below; however, a summary of testing modalities is presented in Fig. 13.</text></passage><passage><infon key=\"file\">CMR.00228-20-f013.jpg</infon><infon key=\"id\">F13</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>143289</offset><text>Methods used for SARS-CoV-2 detection or identification of COVID-19. Of note, cell culture and microscopy are not used for clinical diagnosis but are used for research purposes. Abbreviations: WBC, white blood cell; CRP, C-reactive protein; PCT, procalcitonin; IL-6, interleukin 6; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; CK, creatine kinase; NAAT, nucleic acid amplification test; RT-PCR, reverse transcription-PCR; TMA, transcription-mediated amplification; RT-LAMP, reverse transcriptionâloop-mediated isothermal amplification; RT-RPA, reverse transcription-recombinase polymerase amplification; CRISPR-Cas, clustered regularly interspaced short palindromic repeat (CRISPR)-CRISPR associated (Cas); NEAR, nicking enzyme-assisted reaction; Ag-RDT, antigen rapid diagnostic test; LFIA, lateral flow immunoassay; ELISA, enzyme-linked immunosorbent assay; CLIA, chemiluminescence immunoassay; FMI, fluorescent microparticle immunoassay; CT scan, computed tomography scan.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>144314</offset><text>While compatible signs and symptoms, routine laboratory testing for biomarkers of health or disease, and diagnostic imaging have roles to play in diagnostic investigations, none alone are sufficient for diagnosing SARS-CoV-2, and the reliance on specific laboratory testing is paramount. Many technological advances have been made to detect SARS-CoV-2, which include NAATs to detect viral RNA and immunoassays to detect viral antigens or virus-specific antibodies generated by the immune system in response to SARS-CoV-2. There is a growing list of commercially available methods for testing for SARS-CoV-2, and while many have been validated, the results of any test should be interpreted with consideration of the context in which they are used and based on the sum of all diagnostic evidence. When using any method to rule in or out SARS-CoV-2 infection, many factors should be considered, such as the timing and type of specimen collection, the anatomical site of sampling, the method and its expected performance characteristics, host factors like compatible signs and symptoms (versus asymptomatic testing), risk factors for serious outcomes, and disease prevalence in the population.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>145505</offset><text>NAATs like real-time RT-PCR quickly became the gold standard for diagnostic testing. However, apart from those listed above, other considerations for NAATs are inherent to the methodologies that are all based on the detection of SARS-CoV-2 RNA. For example, it is important to recognize that the performance of any molecular diagnostic method can be influenced by sequence mismatches between the methodâs targets and the different genome permutations of circulating SARS-CoV-2 lineages and variants. A possible strategy to reduce the chance of false-negative results that could occur by target mismatches is the simultaneous use of molecular methods targeting more than one gene, as failure to detect a signal in one target gene may not preclude detection in another. Alternative strategies could include the use of degenerate primers and probes, a strategy used with other RNA viruses that are prone to mutation. Ongoing molecular surveillance using sequencing technologies should also be encouraged to monitor changes in SARS-CoV-2 genome sequences and COVID-19 epidemiology, particularly with an emphasis on variants linked to failures in diagnostic testing, with increased transmissibility, increased severity, or decreased susceptibility to convalescent-phase sera or responses to vaccines.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>146803</offset><text>The primary reliance on NAATs for SARS-CoV-2 detection during the pandemic came with many challenges globally. With human resource strains and supply chain shortages, providing NAATs during the pandemic was challenged by factors such as PPE, human resource strains for sample collection and testing, swabs, and test reagent availability for NAATs. From a clinical perspective, alternatives to NP swabs traditionally used for respiratory specimens were rapidly validated, as was the use of various transport media or swab-free options that are amenable to self-collection (e.g., saliva or saline gargles). The application of these specimens in the laboratory added complexity to the laboratory workflow and required rapid validations to ensure compatibility with new or existing instrumentation.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>147598</offset><text>To help meet capacity demands in the laboratory, laboratories were faced with the need to rapidly procure large quantities of supplies, acquire instrumentation, train additional personnel, and validate specimens, reagents, and equipment. Despite this, supply chain challenges and rapid escalation of testing demands led to the need for resource-sparing strategies for NAATs, including specimen pooling and extraction-free NAAT protocols. Such strategies come at the cost of a relatively reduced sensitivity, which is associated with the potential risk of missing detection of SARS-CoV-2 in specimens with low viral loads. It could be argued that small reductions in sensitivity may have little impact on the detection of most cases. Remnant SARS-CoV-2 at the outset of illness can persist for weeks and is unlikely to represent a period of communicability. On the other hand, missing detection of SARS-CoV-2 in a specimen with a low viral load at the early stages of illness may potentially lead to further virus spread. These testing strategies should be carefully considered prior to implementation.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>148700</offset><text>SARS-CoV-2-specific NAATs evolved over time to facilitate testing and streamline the laboratory workflow. For example, to further streamline testing for respiratory viruses, some methods have now been multiplexed to simultaneously detect SARS-CoV-2, influenza A and B viruses, and other respiratory viruses like respiratory syncytial virus (RSV). In nonpandemic years, influenza and other viral etiologies of respiratory tract infections represented a leading cause of death in North America, particularly among hospitalized patients with community-acquired pneumonia. Interestingly, while cocirculation and coinfection with other respiratory viruses were reported, there was little activity for non-SARS-CoV-2 respiratory viruses. It is unclear whether public health interventions (e.g., travel restrictions, social distancing, handwashing, or PPE like masks) resulted in this decline or whether other factors inadvertently contributed to biases in data, such as fewer individuals seeking routine medical attention or the lack of testing for influenza and other respiratory viruses due to competition for resources used for SARS-CoV-2 testing. Concomitant diagnostic testing using multiplex technologies could provide an option for syndromic testing that would ensure surveillance for SARS-CoV-2 and other important respiratory viruses like influenza virus and appropriate interventions as needed (e.g., antivirals).</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>150118</offset><text>The public and political pressure for laboratory testing evolved with public health indications, and laboratory testing continues to guide public health policies as restrictions ease or escalate throughout the ongoing pandemic. One area of significant advancement in NAAT methodologies includes the use of automation to minimize hands-on processing time and increase specimen throughput. With the high demand for laboratory testing, automation is an important consideration to avoid the possibility of staff repetitive-stress injuries. Over the course of the COVID-19 pandemic, the scale and demand for laboratory testing have been unmatched by other pandemics. Concerns over SARS-CoV-2 prompted the testing of both symptomatic and asymptomatic individuals, in the context of public health case contact tracing and surveillance purposes. This includes testing for SARS-CoV-2 in both health care settings where patients are at increased risk (e.g., hospitals and long-term-care facilities) and situations where testing would not otherwise have been performed (i.e., professional sports teams, public events, prior to or after travel, and various workplaces). Thus, innovative, dynamic, and adaptable approaches were required to meet the testing demands, which are covered extensively in this review.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>151417</offset><text>Other areas are recognized as being crucial to increase laboratory testing capacity but are not covered in this review, such as supply procurement, distribution, and management and the coordination of training or recruitment of increased human resources for specimen collection, testing, processing, and registration. Also, rapid validation of laboratory tests and collection devices to meet regulatory requirements despite availability through EUA from regulatory bodies as well as the development of an information technology infrastructure to continuously improve the laboratory information management system (LIMS) in the laboratory testing workflow and dissemination of near-real-time laboratory data to various stakeholders from local to national levels and dissemination to the public through various media formats are of great value. While digitization was not an absolute requirement, the interconnectivity of data ensured transparency and up-to-date information as decision support tools for recommendations, policies, and guidelines. All of these have been identified by the WHO as key factors to control the COVID-19 pandemic.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>152556</offset><text>To further enhance testing capacity and provide access for rapid SARS-CoV-2 testing options, both antigen- and NAAT-based RDTs have been developed and are now readily available. These can support rapid laboratory and POC applications, screening of large patient populations, or rapid deployment for assessments of target areas. NAAT-based RDTs rely on real-time RT-PCR or isothermal amplification methods (e.g., RT-RPA, RT-LAMP, and NEAR) and, like antigen-based RDTs, can provide rapid results without complex instrumentation. The ease of use of these portable devices allows access to SARS-CoV-2 diagnostics in settings that may have been prohibitive for traditional laboratory NAATs. Throughout the literature, the main limitation noted for RDTs is their reduced sensitivity compared to traditional NAATs, but the evaluations of their performance do not always reflect conditions in which the RDT was licensed under EUA, and the comparator method and distribution of expected specimen results can have a large impact on assay performance. Even if these issues are not considered, and all SARS-CoV-2 detection results were considered of value, a possible strategy to mitigate the relatively reduced sensitivity of antigen- or NAAT-based RDTs is to increase the frequency of testing in the patient population over time, to increase the chances of identifying individuals who fall in a period of high viral shedding (which would be less likely to be impacted by reduced sensitivity). On the other hand, the implementation of such strategies has challenges of its own due to the limited scalability of RDTs, and the balance between sensitivity and testing frequency to achieve optimal SARS-CoV-2 detection in the target population would need to be defined. Moreover, if, for example, EUA defined the use of RDTs as within 7 days of symptom onset, this excluded their use for testing of asymptomatic individuals. While much development is ongoing to enhance existing RDT technologies or explore novel methodologies, how RDTs can effectively be used in practice is the subject of ongoing debate, and further research is needed to understand what setting they would best be of benefit.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>154738</offset><text>For serology, currently available commercial assays are based on ELISAs, CLIAs, and LFIAs and are designed to detect SARS-CoV-2 antibodies. However, the performance of serological assays varies across the different technologies, the timing from disease onset, and comparator methods. Clinical validation of serological methods is ongoing, but recent meta-analyses and systematic reviews so far have shown high levels of heterogeneity and a risk of bias and applicability. For example, with the time required to mount anti-SARS-CoV-2 antibodies during seroconversion (or possibly the absence of seroconversion in mild disease), serology has limited value in identifying SARS-CoV-2 in the early stages of illness. Serology has value for seroepidemiological studies to help with ongoing outbreak investigations, can aid in the diagnosis of suspect cases for whom NAATs were persistently negative or not performed, or can help with conditions in children and adolescents like multisystem inflammatory syndrome where NAAT results may be negative. Much research is needed to expand the knowledge on the use of immunological methods, particularly in the context of the recent availability of vaccines.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>155933</offset><text>Key areas of research interest for serology should include the relevance, magnitude, and duration of protective antibody responses, particularly faced with a population that may have been exposed to SARS-CoV-2 or other human coronaviruses or vaccinated against SARS-CoV-2. Detection of different antibody isotypes is possible with commercial or laboratory-developed serological assays, and recent quantitative methods have now become commercially available; however, much is yet to be learned on how these methods correlate with protective immune responses. Establishing correlates of protection will require longitudinal studies with parallel assessments of quantitative levels of nAbs and cell-mediated immune responses. Various neutralization assays have been established to assess and quantify antibodies against SARS-CoV-2 in serum or plasma (e.g., PRNTs, MN tests, or surrogate assays like PBNAs and snELISAs), but data are scarce when it comes to longitudinal studies undertaken to fully understand the differences or similarities between commercial assays for the qualitative detection of antibodies, quantitative antibody analyses over time, and relevance to the level and duration of protective nAb titers. While the longevity of humoral immunity is not yet fully understood for SARS-CoV-2, some data suggest that antibody levels against SARS-CoV-2 wane over 3 months. Notwithstanding these observations, it is possible that memory T cells may still be able to mount effective responses upon reexposure to SARS-CoV-2, and the role of cell-mediated immune responses may also provide additional benefits. Further research is needed, as a greater understanding of the immune response to SARS-CoV-2 is fundamental in making informed recommendations for the use of immunological methods to assess current or future protection against the virus, to determine meaningful endpoints in the development and evaluation of effective vaccines, or to assess effectiveness following immunization with existing vaccines.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>157948</offset><text>Overall, methods based on RNA, antigen, or antibody detection as well as diagnostic imaging all have a place in our response to SARS-CoV-2, but ongoing research is crucial to further optimize and apply all these testing modalities. The emergence of the SARS-CoV-2 pandemic has created a wave of innovative and creative thinking, and more and more creative methods and platforms are being introduced with goals to increase the armamentarium of diagnostic methods for SARS-CoV-2 detection. An understanding of the advantages and limitations of each method used for SARS-CoV-2 detection as well as the development of novel methods will help us unravel the unknowns of disease pathogenesis, epidemiology, and transmissibility and help us develop interventions to mitigate and contain its spread. There will always be a need for laboratory testing and collaboration between clinical laboratories, public health, infection prevention and control, and many others who contribute to the efforts to contain the spread of COVID-19. On the other hand, it is also recognized that maintaining large investments in the rapid deployment of translational research and such a high degree of laboratory testing for COVID-19 will likely not be sustainable from an economic perspective, and justifications for such investments will be more difficult if cases decline significantly with vaccines. However, the lessons learned from SARS-CoV-2 could potentially be used in the preparedness for potential future pandemic threats, thus strengthening global health and surveillance systems.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">title</infon><offset>159513</offset><text>REFERENCES</text></passage><passage><infon key=\"fpage\">3805</infon><infon key=\"lpage\">3813</infon><infon key=\"pub-id_doi\">10.1128/JCM.01344-09</infon><infon key=\"pub-id_pmid\">19794033</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">47</infon><infon key=\"year\">2009</infon><offset>159524</offset><text>Switching gears for an influenza pandemic: validation of a duplex reverse transcriptase PCR assay for simultaneous detection and confirmatory identification of pandemic (H1N1) 2009 influenza virus</text></passage><passage><infon key=\"fpage\">565</infon><infon key=\"lpage\">574</infon><infon key=\"pub-id_doi\">10.1016/S0140-6736(20)30251-8</infon><infon key=\"pub-id_pmid\">32007145</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>159721</offset><text>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</text></passage><passage><infon key=\"fpage\">717</infon><infon key=\"lpage\">725</infon><infon key=\"pub-id_doi\">10.1016/j.jhin.2020.05.037</infon><infon key=\"pub-id_pmid\">32497651</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Hosp Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">105</infon><infon key=\"year\">2020</infon><offset>159842</offset><text>Aerosol-generating procedures and infective risk to healthcare workers from SARS-CoV-2: the limits of the evidence</text></passage><passage><infon key=\"fpage\">106039</infon><infon key=\"pub-id_doi\">10.1016/j.envint.2020.106039</infon><infon key=\"pub-id_pmid\">32822927</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Environ Int</infon><infon key=\"type\">ref</infon><infon key=\"volume\">144</infon><infon key=\"year\">2020</infon><offset>159957</offset><text>Aerosol transmission of SARS-CoV-2? Evidence, prevention and control</text></passage><passage><infon key=\"fpage\">590041</infon><infon key=\"pub-id_doi\">10.3389/fpubh.2020.590041</infon><infon key=\"pub-id_pmid\">33330334</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Front Public Health</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2020</infon><offset>160026</offset><text>Aerosol transmission of SARS-CoV-2: physical principles and implications</text></passage><passage><infon key=\"fpage\">1516</infon><infon key=\"pub-id_doi\">10.1001/jama.2020.4269</infon><infon key=\"pub-id_pmid\">32196079</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>160099</offset><text>Stopping the spread of COVID-19</text></passage><passage><infon key=\"fpage\">69</infon><infon key=\"lpage\">71</infon><infon key=\"pub-id_doi\">10.1016/j.micinf.2020.01.004</infon><infon key=\"pub-id_pmid\">32032682</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">22</infon><infon key=\"year\">2020</infon><offset>160131</offset><text>Pathogenicity and transmissibility of 2019-nCoVâa quick overview and comparison with other emerging viruses</text></passage><passage><infon key=\"fpage\">1470</infon><infon key=\"lpage\">1477</infon><infon key=\"pub-id_doi\">10.3201/eid2607.200282</infon><infon key=\"pub-id_pmid\">32255761</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>160241</offset><text>High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2</text></passage><passage><infon key=\"fpage\">141</infon><infon key=\"lpage\">143</infon><infon key=\"pub-id_doi\">10.1093/cid/ciaa682</infon><infon key=\"pub-id_pmid\">32473007</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">72</infon><infon key=\"year\">2021</infon><offset>160329</offset><text>A conceptual discussion about the basic reproduction number of severe acute respiratory syndrome coronavirus 2 in healthcare settings</text></passage><passage><infon key=\"fpage\">265</infon><infon key=\"lpage\">269</infon><infon key=\"pub-id_doi\">10.1038/s41586-020-2008-3</infon><infon key=\"pub-id_pmid\">32015508</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">579</infon><infon key=\"year\">2020</infon><offset>160463</offset><text>A new coronavirus associated with human respiratory disease in China</text></passage><passage><infon key=\"fpage\">270</infon><infon key=\"lpage\">273</infon><infon key=\"pub-id_doi\">10.1038/s41586-020-2012-7</infon><infon key=\"pub-id_pmid\">32015507</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">579</infon><infon key=\"year\">2020</infon><offset>160532</offset><text>A pneumonia outbreak associated with a new coronavirus of probable bat origin</text></passage><passage><infon key=\"fpage\">727</infon><infon key=\"lpage\">733</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa2001017</infon><infon key=\"pub-id_pmid\">31978945</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>160610</offset><text>A novel coronavirus from patients with pneumonia in China, 2019</text></passage><passage><infon key=\"comment\">Accessed 9 February 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">WHO coronavirus disease (COVID-19) dashboard.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>160674</offset></passage><passage><infon key=\"fpage\">706</infon><infon key=\"lpage\">711</infon><infon key=\"pub-id_doi\">10.1007/s11427-020-1661-4</infon><infon key=\"pub-id_pmid\">32146694</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci China Life Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">63</infon><infon key=\"year\">2020</infon><offset>160675</offset><text>Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China</text></passage><passage><infon key=\"fpage\">P19</infon><infon key=\"lpage\">P20</infon><infon key=\"pub-id_doi\">10.1164/rccm.2020C1</infon><infon key=\"pub-id_pmid\">32223716</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Am J Respir Crit Care Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">201</infon><infon key=\"year\">2020</infon><offset>160792</offset><text>Diagnosis and management of COVID-19 disease</text></passage><passage><infon key=\"fpage\">1708</infon><infon key=\"lpage\">1720</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa2002032</infon><infon key=\"pub-id_pmid\">32109013</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>160837</offset><text>Clinical characteristics of coronavirus disease 2019 in China</text></passage><passage><infon key=\"fpage\">1753</infon><infon key=\"pub-id_doi\">10.3390/jcm9061753</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>160899</offset><text>COVID-19: specific and non-specific clinical manifestations and symptoms: the current state of knowledge</text></passage><passage><infon key=\"fpage\">2105</infon><infon key=\"lpage\">2115</infon><infon key=\"pub-id_doi\">10.1007/s00296-020-04701-6</infon><infon key=\"pub-id_pmid\">32936318</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Rheumatol Int</infon><infon key=\"type\">ref</infon><infon key=\"volume\">40</infon><infon key=\"year\">2020</infon><offset>161004</offset><text>Kawasaki-like disease in children with COVID-19</text></passage><passage><infon key=\"fpage\">2458</infon><infon key=\"lpage\">2464</infon><infon key=\"pub-id_doi\">10.1002/jmv.26157</infon><infon key=\"pub-id_pmid\">32520401</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>161052</offset><text>Extrapulmonary and atypical clinical presentations of COVIDâ19</text></passage><passage><infon key=\"fpage\">4406</infon><infon key=\"lpage\">4408</infon><infon key=\"pub-id_doi\">10.4103/jfmpc.jfmpc_685_20</infon><infon key=\"pub-id_pmid\">33110869</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Family Med Prim Care</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>161117</offset><text>Anosmia and ageusia as presenting complaints of coronavirus disease (COVID-19) infection</text></passage><passage><infon key=\"elocation-id\">e00028-20</infon><infon key=\"pub-id_doi\">10.1128/CMR.00028-20</infon><infon key=\"pub-id_pmid\">32580969</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">33</infon><infon key=\"year\">2020</infon><offset>161206</offset><text>Coronavirus disease 2019âCOVID-19</text></passage><passage><infon key=\"fpage\">185</infon><infon key=\"lpage\">193</infon><infon key=\"pub-id_doi\">10.1016/j.ijsu.2020.04.018</infon><infon key=\"pub-id_pmid\">32305533</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Surg</infon><infon key=\"type\">ref</infon><infon key=\"volume\">78</infon><infon key=\"year\">2020</infon><offset>161242</offset><text>The socio-economic implications of the coronavirus pandemic (COVID-19): a review</text></passage><passage><infon key=\"fpage\">2000045</infon><infon key=\"pub-id_doi\">10.2807/1560-7917.ES.2020.25.3.2000045</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>161323</offset><text>Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR</text></passage><passage><infon key=\"comment\">Accessed 21 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Timeline of WHOâs response to COVID-19.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>161391</offset></passage><passage><infon key=\"fpage\">536</infon><infon key=\"lpage\">544</infon><infon key=\"pub-id_doi\">10.1038/s41564-020-0695-z</infon><infon key=\"pub-id_pmid\">32123347</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>161392</offset><text>The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2</text></passage><passage><infon key=\"fpage\">386</infon><infon key=\"lpage\">389</infon><infon key=\"pub-id_doi\">10.1080/22221751.2020.1729071</infon><infon key=\"pub-id_pmid\">32065057</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>161506</offset><text>Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes</text></passage><passage><infon key=\"comment\">Accessed 21 July 2020</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Coronavirus (COVID-19) update: FDA issues first emergency use authorization for point of care diagnostic.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>161618</offset></passage><passage><infon key=\"comment\">Accessed 20 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">FDA takes key action in fight against COVID-19 by issuing emergency use authorization for first COVID-19 vaccine.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>161619</offset></passage><passage><infon key=\"comment\">Accessed 11 April 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">In vitro diagnostics EUAs.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>161620</offset></passage><passage><infon key=\"comment\">Accessed 21 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Authorized medical devices for uses related to COVID-19: list of authorized testing devices.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>161621</offset></passage><passage><infon key=\"fpage\">585354</infon><infon key=\"pub-id_doi\">10.3389/fimmu.2020.585354</infon><infon key=\"pub-id_pmid\">33163000</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Front Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>161622</offset><text>A review of the progress and challenges of developing a vaccine for COVID-19</text></passage><passage><infon key=\"fpage\">567</infon><infon key=\"lpage\">571</infon><infon key=\"pub-id_doi\">10.1038/s41586-020-2622-0</infon><infon key=\"pub-id_pmid\">32756549</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">586</infon><infon key=\"year\">2020</infon><offset>161699</offset><text>SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness</text></passage><passage><infon key=\"fpage\">3523</infon><infon key=\"pub-id_doi\">10.1038/s41467-020-17409-9</infon><infon key=\"pub-id_pmid\">32647131</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>161773</offset><text>Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice</text></passage><passage><infon key=\"fpage\">403</infon><infon key=\"lpage\">416</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa2035389</infon><infon key=\"pub-id_pmid\">33378609</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">384</infon><infon key=\"year\">2021</infon><offset>161891</offset><text>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine</text></passage><passage><infon key=\"fpage\">2603</infon><infon key=\"lpage\">2615</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa2034577</infon><infon key=\"pub-id_pmid\">33301246</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>161947</offset><text>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine</text></passage><passage><infon key=\"comment\">Accessed 2 February 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Moderna COVID-19 vaccine EUA letter of authorization.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>162005</offset></passage><passage><infon key=\"fpage\">115094</infon><infon key=\"pub-id_doi\">10.1016/j.diagmicrobio.2020.115094</infon><infon key=\"pub-id_pmid\">32623267</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Diagn Microbiol Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">98</infon><infon key=\"year\">2020</infon><offset>162006</offset><text>Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the coronavirus disease 2019 (COVID-19), a comprehensive literature review</text></passage><passage><infon key=\"fpage\">1868</infon><infon key=\"pub-id_doi\">10.1186/s12889-020-09972-z</infon><infon key=\"pub-id_pmid\">33287789</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BMC Public Health</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>162167</offset><text>Hindsight is 2020 vision: a characterisation of the global response to the COVID-19 pandemic</text></passage><passage><infon key=\"elocation-id\">e20912</infon><infon key=\"pub-id_doi\">10.2196/20912</infon><infon key=\"pub-id_pmid\">32692690</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Internet Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">22</infon><infon key=\"year\">2020</infon><offset>162260</offset><text>Multiple epidemic wave model of the COVID-19 pandemic: modeling study</text></passage><passage><infon key=\"fpage\">104433</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104433</infon><infon key=\"pub-id_pmid\">32405254</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">128</infon><infon key=\"year\">2020</infon><offset>162330</offset><text>Real-time PCR-based SARS-CoV-2 detection in Canadian laboratories</text></passage><passage><infon key=\"fpage\">591</infon><infon key=\"lpage\">605</infon><infon key=\"pub-id_doi\">10.1021/acscentsci.0c00501</infon><infon key=\"pub-id_pmid\">32382657</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Cent Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2020</infon><offset>162396</offset><text>Assay techniques and test development for COVID-19 diagnosis</text></passage><passage><infon key=\"fpage\">943</infon><infon key=\"lpage\">950</infon><infon key=\"pub-id_doi\">10.1039/c6lc01485b</infon><infon key=\"pub-id_pmid\">28197602</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lab Chip</infon><infon key=\"type\">ref</infon><infon key=\"volume\">17</infon><infon key=\"year\">2017</infon><offset>162457</offset><text>Automating multi-step paper-based assays using integrated layering of reagents</text></passage><passage><infon key=\"fpage\">12335</infon><infon key=\"pub-id_doi\">10.1038/s41598-017-12549-3</infon><infon key=\"pub-id_pmid\">28951563</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci Rep</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2017</infon><offset>162536</offset><text>A printed multicomponent paper sensor for bacterial detection</text></passage><passage><infon key=\"fpage\">2342</infon><infon key=\"lpage\">2346</infon><infon key=\"pub-id_doi\">10.1039/c5sc04184h</infon><infon key=\"pub-id_pmid\">29997777</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Chem Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2016</infon><offset>162598</offset><text>Simple and ultrastable all-inclusive pullulan tablets for challenging bioassays</text></passage><passage><infon key=\"fpage\">2709</infon><infon key=\"lpage\">2713</infon><infon key=\"pub-id_doi\">10.1002/ange.201509389</infon><infon key=\"pub-id_pmid\">26748431</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Angew Chem Int Ed Engl</infon><infon key=\"type\">ref</infon><infon key=\"volume\">55</infon><infon key=\"year\">2016</infon><offset>162678</offset><text>Target-induced and equipment-free DNA amplification with a simple paper device</text></passage><passage><infon key=\"fpage\">6155</infon><infon key=\"lpage\">6158</infon><infon key=\"pub-id_doi\">10.1002/anie.201403222</infon><infon key=\"pub-id_pmid\">24764260</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Angew Chem Int Ed Engl</infon><infon key=\"type\">ref</infon><infon key=\"volume\">53</infon><infon key=\"year\">2014</infon><offset>162757</offset><text>Pullulan encapsulation of labile biomolecules to give stable bioassay tablets</text></passage><passage><infon key=\"fpage\">112274</infon><infon key=\"pub-id_doi\">10.1016/j.bios.2020.112274</infon><infon key=\"pub-id_pmid\">32421627</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biosens Bioelectron</infon><infon key=\"type\">ref</infon><infon key=\"volume\">163</infon><infon key=\"year\">2020</infon><offset>162835</offset><text>The impact of biosensing in a pandemic outbreak: COVID-19</text></passage><passage><infon key=\"fpage\">53</infon><infon key=\"pub-id_doi\">10.3390/diagnostics11010053</infon><infon key=\"pub-id_pmid\">33401392</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Diagnostics</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2021</infon><offset>162893</offset><text>Nucleic acid-based diagnostic tests for the detection SARS-CoV-2: an update</text></passage><passage><infon key=\"fpage\">m2516</infon><infon key=\"pub-id_doi\">10.1136/bmj.m2516</infon><infon key=\"pub-id_pmid\">32611558</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BMJ</infon><infon key=\"type\">ref</infon><infon key=\"volume\">370</infon><infon key=\"year\">2020</infon><offset>162969</offset><text>Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis</text></passage><passage><infon key=\"fpage\">4</infon><infon key=\"lpage\">15</infon><infon key=\"pub-id_doi\">10.1109/RBME.2020.2987975</infon><infon key=\"pub-id_pmid\">32305937</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">IEEE Rev Biomed Eng</infon><infon key=\"type\">ref</infon><infon key=\"volume\">14</infon><infon key=\"year\">2021</infon><offset>163060</offset><text>Review of artificial intelligence techniques in imaging data acquisition, segmentation, and diagnosis for COVID-19</text></passage><passage><infon key=\"fpage\">115984</infon><infon key=\"pub-id_doi\">10.1016/j.trac.2020.115984</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Trends Analyt Chem</infon><infon key=\"type\">ref</infon><infon key=\"volume\">130</infon><infon key=\"year\">2020</infon><offset>163175</offset><text>The vision of point-of-care PCR tests for the COVID-19 pandemic and beyond</text></passage><passage><infon key=\"fpage\">2283</infon><infon key=\"lpage\">2296</infon><infon key=\"pub-id_doi\">10.1021/acssensors.0c01153</infon><infon key=\"pub-id_pmid\">32627534</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Sens</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>163250</offset><text>Detecting the coronavirus (COVID-19)</text></passage><passage><infon key=\"fpage\">3822</infon><infon key=\"lpage\">3835</infon><infon key=\"pub-id_doi\">10.1021/acsnano.0c02624</infon><infon key=\"pub-id_pmid\">32223179</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Nano</infon><infon key=\"type\">ref</infon><infon key=\"volume\">14</infon><infon key=\"year\">2020</infon><offset>163287</offset><text>Diagnosing COVID-19: the disease and tools for detection</text></passage><passage><infon key=\"fpage\">628</infon><infon key=\"lpage\">651</infon><infon key=\"pub-id_doi\">10.1016/j.matt.2020.06.015</infon><infon key=\"pub-id_pmid\">32838297</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Matter</infon><infon key=\"type\">ref</infon><infon key=\"volume\">3</infon><infon key=\"year\">2020</infon><offset>163344</offset><text>Fighting COVID-19: integrated micro- and nanosystems for viral infection diagnostics</text></passage><passage><infon key=\"fpage\">99</infon><infon key=\"lpage\">114</infon><infon key=\"pub-id_doi\">10.5603/CJ.a2020.0065</infon><infon key=\"pub-id_pmid\">32378729</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cardiol J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">27</infon><infon key=\"year\">2020</infon><offset>163429</offset><text>COVID-19âtoward a comprehensive understanding of the disease</text></passage><passage><infon key=\"fpage\">1012</infon><infon key=\"lpage\">1023</infon><infon key=\"pub-id_doi\">10.1093/nsr/nwaa036</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Natl Sci Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2020</infon><offset>163492</offset><text>On the origin and continuing evolution of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">325</infon><infon key=\"lpage\">328</infon><infon key=\"pub-id_doi\">10.1016/j.chom.2020.02.001</infon><infon key=\"pub-id_pmid\">32035028</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Host Microbe</infon><infon key=\"type\">ref</infon><infon key=\"volume\">27</infon><infon key=\"year\">2020</infon><offset>163545</offset><text>Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China</text></passage><passage><infon key=\"fpage\">914</infon><infon key=\"lpage\">921.e10</infon><infon key=\"pub-id_doi\">10.1016/j.cell.2020.04.011</infon><infon key=\"pub-id_pmid\">32330414</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">181</infon><infon key=\"year\">2020</infon><offset>163637</offset><text>The architecture of SARS-CoV-2 transcriptome</text></passage><passage><infon key=\"fpage\">4106</infon><infon key=\"lpage\">4116</infon><infon key=\"pub-id_doi\">10.1007/s12035-020-02022-0</infon><infon key=\"pub-id_pmid\">32671688</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Mol Neurobiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">57</infon><infon key=\"year\">2020</infon><offset>163682</offset><text>Current status of multiple drug molecules, and vaccines: an update in SARS-CoV-2 therapeutics</text></passage><passage><infon key=\"fpage\">11</infon><infon key=\"lpage\">22</infon><infon key=\"pub-id_doi\">10.1016/j.jsb.2010.11.021</infon><infon key=\"pub-id_pmid\">21130884</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Struct Biol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">174</infon><infon key=\"year\">2011</infon><offset>163776</offset><text>A structural analysis of M protein in coronavirus assembly and morphology</text></passage><passage><infon key=\"fpage\">69</infon><infon key=\"pub-id_doi\">10.1186/s12985-019-1182-0</infon><infon key=\"pub-id_pmid\">31133031</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Virol J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">16</infon><infon key=\"year\">2019</infon><offset>163850</offset><text>Coronavirus envelope protein: current knowledge</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">Coronavirus disease 2019 (COVID-19): epidemiology, pathogenesis, diagnosis, and therapeutics.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>163898</offset></passage><passage><infon key=\"fpage\">618</infon><infon key=\"lpage\">623</infon><infon key=\"pub-id_doi\">10.1016/j.bbrc.2020.04.136</infon><infon key=\"pub-id_pmid\">32416961</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biochem Biophys Res Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">527</infon><infon key=\"year\">2020</infon><offset>163899</offset><text>Biochemical characterization of SARS-CoV-2 nucleocapsid protein</text></passage><passage><infon key=\"fpage\">1141</infon><infon key=\"lpage\">1149</infon><infon key=\"pub-id_doi\">10.1038/s41401-020-0485-4</infon><infon key=\"pub-id_pmid\">32747721</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Acta Pharmacol Sin</infon><infon key=\"type\">ref</infon><infon key=\"volume\">41</infon><infon key=\"year\">2020</infon><offset>163963</offset><text>Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19</text></passage><passage><infon key=\"fpage\">203</infon><infon key=\"lpage\">208</infon><infon key=\"pub-id_doi\">10.1126/science.abd5223</infon><infon key=\"pub-id_pmid\">32817270</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">370</infon><infon key=\"year\">2020</infon><offset>164079</offset><text>In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges</text></passage><passage><infon key=\"fpage\">1444</infon><infon key=\"lpage\">1448</infon><infon key=\"pub-id_doi\">10.1126/science.abb2762</infon><infon key=\"pub-id_pmid\">32132184</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">367</infon><infon key=\"year\">2020</infon><offset>164172</offset><text>Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</text></passage><passage><infon key=\"fpage\">281</infon><infon key=\"lpage\">292.e6</infon><infon key=\"pub-id_doi\">10.1016/j.cell.2020.02.058</infon><infon key=\"pub-id_pmid\">32155444</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">181</infon><infon key=\"year\">2020</infon><offset>164249</offset><text>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</text></passage><passage><infon key=\"fpage\">271</infon><infon key=\"lpage\">280.e8</infon><infon key=\"pub-id_doi\">10.1016/j.cell.2020.02.052</infon><infon key=\"pub-id_pmid\">32142651</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">181</infon><infon key=\"year\">2020</infon><offset>164324</offset><text>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</text></passage><passage><infon key=\"elocation-id\">e105114</infon><infon key=\"pub-id_doi\">10.15252/embj.20105114</infon><infon key=\"pub-id_pmid\">32246845</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">EMBO J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">39</infon><infon key=\"year\">2020</infon><offset>164431</offset><text>SARSâCoVâ2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells</text></passage><passage><infon key=\"elocation-id\">e2035057</infon><infon key=\"pub-id_doi\">10.1001/jamanetworkopen.2020.35057</infon><infon key=\"pub-id_pmid\">33410879</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA Netw Open</infon><infon key=\"type\">ref</infon><infon key=\"volume\">4</infon><infon key=\"year\">2021</infon><offset>164537</offset><text>SARS-CoV-2 transmission from people without COVID-19 symptoms</text></passage><passage><infon key=\"fpage\">CD013665</infon><infon key=\"pub-id_doi\">10.1002/14651858.CD013665</infon><infon key=\"pub-id_pmid\">32633856</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cochrane Database Syst Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2020</infon><offset>164599</offset><text>Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease</text></passage><passage><infon key=\"fpage\">2089</infon><infon key=\"lpage\">2090</infon><infon key=\"pub-id_doi\">10.1001/jama.2020.6771</infon><infon key=\"pub-id_pmid\">32320008</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>164724</offset><text>Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection</text></passage><passage><infon key=\"fpage\">944</infon><infon key=\"lpage\">950</infon><infon key=\"pub-id_doi\">10.1002/alr.22587</infon><infon key=\"pub-id_pmid\">32301284</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int Forum Allergy Rhinol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2020</infon><offset>164814</offset><text>Smell dysfunction: a biomarker for COVIDâ19</text></passage><passage><infon key=\"elocation-id\">e13986</infon><infon key=\"pub-id_doi\">10.1111/dth.13986</infon><infon key=\"pub-id_pmid\">32639077</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Dermatol Ther</infon><infon key=\"type\">ref</infon><infon key=\"volume\">33</infon><infon key=\"year\">2020</infon><offset>164860</offset><text>Cutaneous manifestations and considerations in COVID-19 pandemic: a systematic review</text></passage><passage><infon key=\"fpage\">486</infon><infon key=\"lpage\">487</infon><infon key=\"pub-id_doi\">10.12968/jowc.2020.29.9.486</infon><infon key=\"pub-id_pmid\">32924822</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Wound Care</infon><infon key=\"type\">ref</infon><infon key=\"volume\">29</infon><infon key=\"year\">2020</infon><offset>164946</offset><text>COVID toes and other cutaneous manifestations of COVID-19</text></passage><passage><infon key=\"fpage\">2057</infon><infon key=\"lpage\">2071</infon><infon key=\"pub-id_doi\">10.1002/acn3.51166</infon><infon key=\"pub-id_pmid\">32853453</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Ann Clin Transl Neurol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2020</infon><offset>165004</offset><text>Neurological manifestations of coronavirus infectionsâa systematic review</text></passage><passage><infon key=\"fpage\">104364</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104364</infon><infon key=\"pub-id_pmid\">32311650</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">127</infon><infon key=\"year\">2020</infon><offset>165080</offset><text>Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China</text></passage><passage><infon key=\"fpage\">505</infon><infon key=\"lpage\">514</infon><infon key=\"pub-id_doi\">10.1007/s11357-020-00186-0</infon><infon key=\"pub-id_pmid\">32274617</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Geroscience</infon><infon key=\"type\">ref</infon><infon key=\"volume\">42</infon><infon key=\"year\">2020</infon><offset>165168</offset><text>SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes</text></passage><passage><infon key=\"fpage\">1663</infon><infon key=\"lpage\">1665</infon><infon key=\"pub-id_doi\">10.1056/NEJMc2005073</infon><infon key=\"pub-id_pmid\">32187458</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>165283</offset><text>SARS-CoV-2 infection in children</text></passage><passage><infon key=\"fpage\">91</infon><infon key=\"lpage\">95</infon><infon key=\"pub-id_doi\">10.1016/j.ijid.2020.03.017</infon><infon key=\"pub-id_pmid\">32173574</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">94</infon><infon key=\"year\">2020</infon><offset>165316</offset><text>Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis</text></passage><passage><infon key=\"fpage\">948.e1</infon><infon key=\"lpage\">948.e3</infon><infon key=\"pub-id_doi\">10.1016/j.cmi.2020.04.040</infon><infon key=\"pub-id_pmid\">32360780</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>165436</offset><text>Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19</text></passage><passage><infon key=\"fpage\">577</infon><infon key=\"lpage\">583</infon><infon key=\"pub-id_doi\">10.1002/jmv.25757</infon><infon key=\"pub-id_pmid\">32162702</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>165521</offset><text>COVIDâ19 patientsâ clinical characteristics, discharge rate, and fatality rate of metaâanalysis</text></passage><passage><infon key=\"fpage\">104363</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104363</infon><infon key=\"pub-id_pmid\">32298988</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">127</infon><infon key=\"year\">2020</infon><offset>165623</offset><text>Clinical characteristics of 225 patients with COVID-19 in a tertiary hospital near Wuhan, China</text></passage><passage><infon key=\"fpage\">1413.e9</infon><infon key=\"lpage\">1413.e13</infon><infon key=\"pub-id_doi\">10.1016/j.cmi.2020.06.013</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>165719</offset><text>Characteristics of 1573 healthcare workers who underwent nasopharyngeal swab testing for SARS-CoV-2 in Milan, Lombardy, Italy</text></passage><passage><infon key=\"fpage\">281</infon><infon key=\"lpage\">286</infon><infon key=\"pub-id_doi\">10.1007/s12098-020-03263-6</infon><infon key=\"pub-id_pmid\">32166607</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Indian J Pediatr</infon><infon key=\"type\">ref</infon><infon key=\"volume\">87</infon><infon key=\"year\">2020</infon><offset>165845</offset><text>A review of coronavirus disease-2019 (COVID-19)</text></passage><passage><infon key=\"fpage\">603</infon><infon key=\"lpage\">605</infon><infon key=\"pub-id_doi\">10.1001/jama.2020.12603</infon><infon key=\"pub-id_pmid\">32644129</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">324</infon><infon key=\"year\">2020</infon><offset>165893</offset><text>Persistent symptoms in patients after acute COVID-19</text></passage><passage><infon key=\"comment\">Accessed 15 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19), updated December 8, 2020.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>165946</offset></passage><passage><infon key=\"comment\">Clin Infect Dis</infon><infon key=\"pub-id_doi\">10.1093/cid/ciaa478</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>165947</offset><text>Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19</text></passage><passage><infon key=\"fpage\">1147</infon><infon key=\"lpage\">1152</infon><infon key=\"pub-id_doi\">10.1007/s11845-020-02252-0</infon><infon key=\"pub-id_pmid\">32424603</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Ir J Med Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">189</infon><infon key=\"year\">2020</infon><offset>166055</offset><text>COVID-19 in adults: test menu for hospital blood science laboratories</text></passage><passage><infon key=\"fpage\">CD013787</infon><infon key=\"pub-id_doi\">10.1002/14651858.CD013787</infon><infon key=\"pub-id_pmid\">33211319</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cochrane Database Syst Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>166125</offset><text>Routine laboratory testing to determine if a patient has COVID-19</text></passage><passage><infon key=\"fpage\">1106</infon><infon key=\"lpage\">1115</infon><infon key=\"pub-id_doi\">10.1515/cclm-2020-0377</infon><infon key=\"pub-id_pmid\">32352397</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Chem Lab Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>166191</offset><text>The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study</text></passage><passage><infon key=\"fpage\">467</infon><infon key=\"lpage\">474</infon><infon key=\"pub-id_doi\">10.1016/j.ijid.2020.05.055</infon><infon key=\"pub-id_pmid\">32425643</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">96</infon><infon key=\"year\">2020</infon><offset>166306</offset><text>Association of inflammatory markers with the severity of COVID-19: a meta-analysis</text></passage><passage><infon key=\"fpage\">5493</infon><infon key=\"pub-id_doi\">10.1038/s41467-020-19057-5</infon><infon key=\"pub-id_pmid\">33127906</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>166389</offset><text>SARS-CoV-2 viral load is associated with increased disease severity and mortality</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"lpage\">23</infon><infon key=\"pub-id_doi\">10.1016/j.abst.2020.08.001</infon><infon key=\"pub-id_pmid\">33511330</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Adv Biomark Sci Technol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">2</infon><infon key=\"year\">2020</infon><offset>166471</offset><text>Biomarkers of COVID-19 and technologies to combat SARS-CoV-2</text></passage><passage><infon key=\"fpage\">286</infon><infon key=\"lpage\">287</infon><infon key=\"pub-id_doi\">10.4103/lungindia.lungindia_126_20</infon><infon key=\"pub-id_pmid\">32367861</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lung India</infon><infon key=\"type\">ref</infon><infon key=\"volume\">37</infon><infon key=\"year\">2020</infon><offset>166532</offset><text>Bronchoalveolar specimen can help detect COVID-19 in suspicious case with negative PCR for nasopharyngeal specimen test</text></passage><passage><infon key=\"fpage\">1843</infon><infon key=\"lpage\">1844</infon><infon key=\"pub-id_doi\">10.1001/jama.2020.3786</infon><infon key=\"pub-id_pmid\">32159775</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>166652</offset><text>Detection of SARS-CoV-2 in different types of clinical specimens</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.02.11.20021493</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>166717</offset><text>Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections</text></passage><passage><infon key=\"fpage\">861</infon><infon key=\"lpage\">868</infon><infon key=\"pub-id_doi\">10.1038/s41591-020-0877-5</infon><infon key=\"pub-id_pmid\">32327757</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>166862</offset><text>Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States</text></passage><passage><infon key=\"fpage\">104593</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104593</infon><infon key=\"pub-id_pmid\">32823131</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">131</infon><infon key=\"year\">2020</infon><offset>166988</offset><text>Evaluation on testing of deep throat saliva and lower respiratory tract specimens with Xpert Xpress SARS-CoV-2 assay</text></passage><passage><infon key=\"fpage\">719</infon><infon key=\"lpage\">725</infon><infon key=\"pub-id_doi\">10.1002/jmv.26349</infon><infon key=\"pub-id_pmid\">32706393</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">93</infon><infon key=\"year\">2021</infon><offset>167105</offset><text>Detection profile of SARSâCoVâ2 using RTâPCR in different types of clinical specimens: a systematic review and metaâanalysis</text></passage><passage><infon key=\"fpage\">102903</infon><infon key=\"pub-id_doi\">10.1016/j.ebiom.2020.102903</infon><infon key=\"pub-id_pmid\">32718896</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">EBioMedicine</infon><infon key=\"type\">ref</infon><infon key=\"volume\">59</infon><infon key=\"year\">2020</infon><offset>167238</offset><text>SARS-CoV-2 detection in different respiratory sites: a systematic review and meta-analysis</text></passage><passage><infon key=\"comment\">Clin Infect Dis</infon><infon key=\"pub-id_doi\">10.1093/cid/ciaa1343</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>167329</offset><text>Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: serologic testing</text></passage><passage><infon key=\"fpage\">W15</infon><infon key=\"pub-id_doi\">10.2214/AJR.20.23185</infon><infon key=\"pub-id_pmid\">32255684</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">AJR Am J Roentgenol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">215</infon><infon key=\"year\">2020</infon><offset>167427</offset><text>Vascular changes detected with thoracic CT in coronavirus disease (COVID-19) might be significant determinants for accurate diagnosis and optimal patient management</text></passage><passage><infon key=\"fpage\">1804</infon><infon key=\"lpage\">1805</infon><infon key=\"pub-id_doi\">10.1016/j.chest.2020.07.061</infon><infon key=\"pub-id_pmid\">33160519</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Chest</infon><infon key=\"type\">ref</infon><infon key=\"volume\">158</infon><infon key=\"year\">2020</infon><offset>167592</offset><text>SARS CoV-2 detection from upper and lower respiratory tract specimens</text></passage><passage><infon key=\"fpage\">1876</infon><infon key=\"lpage\">1884</infon><infon key=\"pub-id_doi\">10.1016/j.chest.2020.06.015</infon><infon key=\"pub-id_pmid\">32569635</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Chest</infon><infon key=\"type\">ref</infon><infon key=\"volume\">158</infon><infon key=\"year\">2020</infon><offset>167662</offset><text>Differences of severe acute respiratory syndrome coronavirus 2 shedding duration in sputum and nasopharyngeal swab specimens among adult inpatients with coronavirus disease 2019</text></passage><passage><infon key=\"fpage\">341</infon><infon key=\"lpage\">351</infon><infon key=\"pub-id_doi\">10.1016/j.cmi.2020.11.002</infon><infon key=\"pub-id_pmid\">33188933</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">27</infon><infon key=\"year\">2021</infon><offset>167840</offset><text>Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: a systematic review and meta-analysis</text></passage><passage><infon key=\"fpage\">346</infon><infon key=\"pub-id_doi\">10.1186/s12916-020-01810-8</infon><infon key=\"pub-id_pmid\">33143712</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BMC Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">18</infon><infon key=\"year\">2020</infon><offset>167979</offset><text>At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data</text></passage><passage><infon key=\"fpage\">W105</infon><infon key=\"lpage\">W106</infon><infon key=\"pub-id_doi\">10.1097/RTI.0000000000000533</infon><infon key=\"pub-id_pmid\">32404797</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Thorac Imaging</infon><infon key=\"type\">ref</infon><infon key=\"volume\">35</infon><infon key=\"year\">2020</infon><offset>168137</offset><text>Diagnostic performance of chest X-ray for COVID-19 pneumonia during the SARS-CoV-2 pandemic in Lombardy, Italy</text></passage><passage><infon key=\"fpage\">16</infon><infon key=\"lpage\">29</infon><infon key=\"pub-id_doi\">10.1109/RBME.2020.2990959</infon><infon key=\"pub-id_pmid\">32356760</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">IEEE Rev Biomed Eng</infon><infon key=\"type\">ref</infon><infon key=\"volume\">14</infon><infon key=\"year\">2021</infon><offset>168248</offset><text>The role of imaging in the detection and management of COVID-19: a review</text></passage><passage><infon key=\"fpage\">341</infon><infon key=\"lpage\">347</infon><infon key=\"pub-id_doi\">10.1016/j.crad.2020.03.004</infon><infon key=\"pub-id_pmid\">32216961</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">75</infon><infon key=\"year\">2020</infon><offset>168322</offset><text>Imaging manifestations and diagnostic value of chest CT of coronavirus disease 2019 (COVID-19) in the Xiaogan area</text></passage><passage><infon key=\"fpage\">147</infon><infon key=\"lpage\">148</infon><infon key=\"pub-id_doi\">10.7326/M20-1382</infon><infon key=\"pub-id_pmid\">32267912</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Ann Intern Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">173</infon><infon key=\"year\">2020</infon><offset>168437</offset><text>Chest computed tomography for detection of coronavirus disease 2019 (COVID-19): donât rush the science</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.03.30.20047985</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>168542</offset><text>Why is chest CT important for early diagnosis of COVID-19? Prevalence matters</text></passage><passage><infon key=\"comment\">Semin Nucl Med</infon><infon key=\"pub-id_doi\">10.1053/j.semnuclmed.2020.11.003</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>168620</offset><text>Imaging of COVID-19: CT, MRI, and PET</text></passage><passage><infon key=\"fpage\">219</infon><infon key=\"lpage\">225</infon><infon key=\"pub-id_doi\">10.1016/j.clinimag.2020.08.014</infon><infon key=\"pub-id_pmid\">32871426</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Imaging</infon><infon key=\"type\">ref</infon><infon key=\"volume\">67</infon><infon key=\"year\">2020</infon><offset>168658</offset><text>Coronavirus disease 2019 (COVID-19) diagnostic technologies: a country-based retrospective analysis of screening and containment procedures during the first wave of the pandemic</text></passage><passage><infon key=\"fpage\">109217</infon><infon key=\"pub-id_doi\">10.1016/j.ejrad.2020.109217</infon><infon key=\"pub-id_pmid\">32861174</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur J Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">131</infon><infon key=\"year\">2020</infon><offset>168836</offset><text>Multimodality imaging of COVID-19 pneumonia: from diagnosis to follow-up. A comprehensive review</text></passage><passage><infon key=\"fpage\">1449</infon><infon key=\"lpage\">1459</infon><infon key=\"pub-id_doi\">10.1002/jmv.25822</infon><infon key=\"pub-id_pmid\">32242947</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>168933</offset><text>Imaging and clinical features of patients with 2019 novel coronavirus SARSâCoVâ2: a systematic review and metaâanalysis</text></passage><passage><infon key=\"fpage\">299</infon><infon key=\"lpage\">304</infon><infon key=\"pub-id_doi\">10.1093/bjaceaccp/mku063</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BJA Educ</infon><infon key=\"type\">ref</infon><infon key=\"volume\">15</infon><infon key=\"year\">2015</infon><offset>169059</offset><text>Computed tomography of the chest: I. Basic principles</text></passage><passage><infon key=\"comment\">J Thorac Imaging</infon><infon key=\"pub-id_doi\">10.1097/RTI.0000000000000541</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>169113</offset><text>Review of chest radiograph findings of COVID-19 pneumonia and suggested reporting language</text></passage><passage><infon key=\"fpage\">219</infon><infon key=\"lpage\">227</infon><infon key=\"pub-id_doi\">10.1097/RTI.0000000000000524</infon><infon key=\"pub-id_pmid\">32324653</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Thorac Imaging</infon><infon key=\"type\">ref</infon><infon key=\"volume\">35</infon><infon key=\"year\">2020</infon><offset>169204</offset><text>Radiological Society of North America expert consensus statement on reporting chest CT findings related to COVID-19. endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNAâsecondary publication</text></passage><passage><infon key=\"fpage\">E63</infon><infon key=\"lpage\">E69</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020203173</infon><infon key=\"pub-id_pmid\">32729811</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">298</infon><infon key=\"year\">2021</infon><offset>169436</offset><text>Use of chest imaging in the diagnosis and management of COVID-19: a WHO rapid advice guide</text></passage><passage><infon key=\"fpage\">CD013639</infon><infon key=\"pub-id_doi\">10.1002/14651858.CD013639.pub2</infon><infon key=\"pub-id_pmid\">32997361</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cochrane Database Syst Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>169527</offset><text>Thoracic imaging tests for the diagnosis of COVID-19</text></passage><passage><infon key=\"fpage\">4874</infon><infon key=\"lpage\">4882</infon><infon key=\"pub-id_doi\">10.1007/s00330-020-06827-4</infon><infon key=\"pub-id_pmid\">32296940</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2020</infon><offset>169580</offset><text>The role of imaging in 2019 novel coronavirus pneumonia (COVID-19)</text></passage><passage><infon key=\"fpage\">5720</infon><infon key=\"lpage\">5727</infon><infon key=\"pub-id_doi\">10.1007/s00330-020-06934-2</infon><infon key=\"pub-id_pmid\">32415585</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2020</infon><offset>169647</offset><text>Chest CT for detecting COVID-19: a systematic review and meta-analysis of diagnostic accuracy</text></passage><passage><infon key=\"fpage\">834</infon><infon key=\"lpage\">838</infon><infon key=\"pub-id_doi\">10.2214/AJR.20.23418</infon><infon key=\"pub-id_pmid\">32412790</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">AJR Am J Roentgenol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">215</infon><infon key=\"year\">2020</infon><offset>169741</offset><text>Diagnostic tools for coronavirus disease (COVID-19): comparing CT and RT-PCR viral nucleic acid testing</text></passage><passage><infon key=\"fpage\">1730</infon><infon key=\"lpage\">1741</infon><infon key=\"pub-id_doi\">10.1111/all.14238</infon><infon key=\"pub-id_pmid\">32077115</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Allergy</infon><infon key=\"type\">ref</infon><infon key=\"volume\">75</infon><infon key=\"year\">2020</infon><offset>169845</offset><text>Clinical characteristics of 140 patients infected with SARSâCoVâ2 in Wuhan, China</text></passage><passage><infon key=\"fpage\">E32</infon><infon key=\"lpage\">E40</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200642</infon><infon key=\"pub-id_pmid\">32101510</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">296</infon><infon key=\"year\">2020</infon><offset>169931</offset><text>Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases</text></passage><passage><infon key=\"fpage\">1280</infon><infon key=\"lpage\">1286</infon><infon key=\"pub-id_doi\">10.2214/AJR.20.22954</infon><infon key=\"pub-id_pmid\">32130038</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">AJR Am J Roentgenol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">214</infon><infon key=\"year\">2020</infon><offset>170047</offset><text>Coronavirus disease 2019 (COVID-19): role of chest CT in diagnosis and management</text></passage><passage><infon key=\"fpage\">E15</infon><infon key=\"lpage\">E25</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200490</infon><infon key=\"pub-id_pmid\">32083985</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">296</infon><infon key=\"year\">2020</infon><offset>170129</offset><text>Coronavirus disease 2019 (COVID-19): a perspective from China</text></passage><passage><infon key=\"fpage\">E115</infon><infon key=\"lpage\">E117</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200432</infon><infon key=\"pub-id_pmid\">32073353</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">296</infon><infon key=\"year\">2020</infon><offset>170191</offset><text>Sensitivity of chest CT for COVID-19: comparison to RT-PCR</text></passage><passage><infon key=\"fpage\">108961</infon><infon key=\"pub-id_doi\">10.1016/j.ejrad.2020.108961</infon><infon key=\"pub-id_pmid\">32229322</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur J Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">126</infon><infon key=\"year\">2020</infon><offset>170250</offset><text>Diagnosis of the coronavirus disease (COVID-19): rRT-PCR or CT?</text></passage><passage><infon key=\"fpage\">22</infon><infon key=\"lpage\">23</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200330</infon><infon key=\"pub-id_pmid\">32049600</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">295</infon><infon key=\"year\">2020</infon><offset>170314</offset><text>Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion</text></passage><passage><infon key=\"fpage\">105980</infon><infon key=\"pub-id_doi\">10.1016/j.rmed.2020.105980</infon><infon key=\"pub-id_pmid\">32364959</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Respir Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">168</infon><infon key=\"year\">2020</infon><offset>170431</offset><text>Diagnostic performance between CT and initial real-time RT-PCR for clinically suspected 2019 coronavirus disease (COVID-19) patients outside Wuhan, China</text></passage><passage><infon key=\"comment\">Accessed 15 October 2020</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Diagnostic testing for SARS-CoV-2: interim guidance, 11 September 2020.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>170585</offset></passage><passage><infon key=\"comment\">Clin Infect Dis</infon><infon key=\"pub-id_doi\">10.1093/cid/ciaa760</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>170586</offset><text>Infectious Diseases Society of America guidelines on the diagnosis of coronavirus disease 2019</text></passage><passage><infon key=\"fpage\">E46</infon><infon key=\"lpage\">E54</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200823</infon><infon key=\"pub-id_pmid\">32155105</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">296</infon><infon key=\"year\">2020</infon><offset>170681</offset><text>Performance of radiologists in differentiating COVID-19 from non-COVID-19 viral pneumonia at chest CT</text></passage><passage><infon key=\"fpage\">87</infon><infon key=\"lpage\">93</infon><infon key=\"pub-id_doi\">10.2214/AJR.20.23034</infon><infon key=\"pub-id_pmid\">32174129</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">AJR Am J Roentgenol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">215</infon><infon key=\"year\">2020</infon><offset>170783</offset><text>Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients</text></passage><passage><infon key=\"fpage\">4</infon><infon key=\"pub-id_doi\">10.1186/s40779-020-0233-6</infon><infon key=\"pub-id_pmid\">32029004</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Mil Med Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2020</infon><offset>170876</offset><text>A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)</text></passage><passage><infon key=\"fpage\">715</infon><infon key=\"lpage\">721</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200370</infon><infon key=\"pub-id_pmid\">32053470</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">295</infon><infon key=\"year\">2020</infon><offset>171009</offset><text>Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19)</text></passage><passage><infon key=\"fpage\">3306</infon><infon key=\"lpage\">3309</infon><infon key=\"pub-id_doi\">10.1007/s00330-020-06731-x</infon><infon key=\"pub-id_pmid\">32055945</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2020</infon><offset>171106</offset><text>Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China</text></passage><passage><infon key=\"fpage\">4407</infon><infon key=\"lpage\">4416</infon><infon key=\"pub-id_doi\">10.1007/s00330-020-06817-6</infon><infon key=\"pub-id_pmid\">32215691</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2020</infon><offset>171248</offset><text>CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19)</text></passage><passage><infon key=\"fpage\">108941</infon><infon key=\"pub-id_doi\">10.1016/j.ejrad.2020.108941</infon><infon key=\"pub-id_pmid\">32193037</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur J Radiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">126</infon><infon key=\"year\">2020</infon><offset>171350</offset><text>CT manifestations of coronavirus disease-2019: a retrospective analysis of 73 cases by disease severity</text></passage><passage><infon key=\"fpage\">318</infon><infon key=\"lpage\">328</infon><infon key=\"pub-id_doi\">10.1148/radiol.2018171820</infon><infon key=\"pub-id_pmid\">29944078</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">288</infon><infon key=\"year\">2018</infon><offset>171454</offset><text>Current applications and future impact of machine learning in radiology</text></passage><passage><infon key=\"fpage\">500</infon><infon key=\"lpage\">510</infon><infon key=\"pub-id_doi\">10.1038/s41568-018-0016-5</infon><infon key=\"pub-id_pmid\">29777175</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Rev Cancer</infon><infon key=\"type\">ref</infon><infon key=\"volume\">18</infon><infon key=\"year\">2018</infon><offset>171526</offset><text>Artificial intelligence in radiology</text></passage><passage><infon key=\"comment\">arXiv</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>171563</offset><text>COVID_MTNet: COVID-19 detection with multi-task deep learning approaches</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.04.28.20082776</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>171636</offset><text>Curbing the AI-induced enthusiasm in diagnosing COVID-19 on chest X-rays: the present and the near-future</text></passage><passage><infon key=\"comment\">arXiv</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>171742</offset><text>Automated detection and forecasting of COVID-19 using deep learning techniques: a review</text></passage><passage><infon key=\"fpage\">E65</infon><infon key=\"lpage\">E71</infon><infon key=\"pub-id_doi\">10.1148/radiol.2020200905</infon><infon key=\"pub-id_pmid\">32191588</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Radiology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">296</infon><infon key=\"year\">2020</infon><offset>171831</offset><text>Using artificial intelligence to detect COVID-19 and community-acquired pneumonia based on pulmonary CT: evaluation of the diagnostic accuracy</text></passage><passage><infon key=\"fpage\">2606</infon><infon key=\"lpage\">2614</infon><infon key=\"pub-id_doi\">10.1109/TMI.2020.2992546</infon><infon key=\"pub-id_pmid\">32386147</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">IEEE Trans Med Imaging</infon><infon key=\"type\">ref</infon><infon key=\"volume\">39</infon><infon key=\"year\">2020</infon><offset>171974</offset><text>Diagnosis of coronavirus disease 2019 (COVID-19) with structured latent multi-view representation learning</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.04.13.20063941</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>172081</offset><text>Sample-efficient deep learning for COVID-19 diagnosis based on CT scans</text></passage><passage><infon key=\"comment\">arXiv</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>172153</offset><text>COVID-Net: a tailored deep convolutional neural network design for detection of COVID-19 cases from chest X-ray images</text></passage><passage><infon key=\"comment\">arXiv</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>172272</offset><text>Diagnosing COVID-19 pneumonia from X-ray and CT images using deep learning and transfer learning algorithms</text></passage><passage><infon key=\"fpage\">1070</infon><infon key=\"lpage\">1076</infon><infon key=\"pub-id_doi\">10.1515/cclm-2020-0285</infon><infon key=\"pub-id_pmid\">32172228</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Chem Lab Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>172380</offset><text>Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19)</text></passage><passage><infon key=\"fpage\">104802</infon><infon key=\"pub-id_doi\">10.1016/j.oraloncology.2020.104802</infon><infon key=\"pub-id_pmid\">32410825</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Oral Oncol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">106</infon><infon key=\"year\">2020</infon><offset>172502</offset><text>How to increase the SARS-CoV-2 detection rate through the nasopharyngeal swab?</text></passage><passage><infon key=\"comment\">Accessed 15 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19, updated January 6, 2021.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>172581</offset></passage><passage><infon key=\"fpage\">101673</infon><infon key=\"pub-id_doi\">10.1016/j.tmaid.2020.101673</infon><infon key=\"pub-id_pmid\">32311437</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Travel Med Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">37</infon><infon key=\"year\">2020</infon><offset>172582</offset><text>Detection and analysis of nucleic acid in various biological samples of COVID-19 patients</text></passage><passage><infon key=\"fpage\">1337</infon><infon key=\"lpage\">1339</infon><infon key=\"pub-id_doi\">10.3201/eid2606.200301</infon><infon key=\"pub-id_pmid\">32150527</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>172672</offset><text>Detection of novel coronavirus by RT-PCR in stool specimen from asymptomatic child, China</text></passage><passage><infon key=\"fpage\">1769</infon><infon key=\"lpage\">1771</infon><infon key=\"pub-id_doi\">10.1002/jmv.25875</infon><infon key=\"pub-id_pmid\">32285947</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>172762</offset><text>Detection of SARSâCoVâ2 by RTâPCR in anal from patients who have recovered from coronavirus disease 2019</text></passage><passage><infon key=\"fpage\">2328</infon><infon key=\"lpage\">2331</infon><infon key=\"pub-id_doi\">10.1002/jmv.26007</infon><infon key=\"pub-id_pmid\">32401374</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>172873</offset><text>Prolonged SARSâCoVâ2 RNA detection in anal/rectal swabs and stool specimens in COVIDâ19 patients after negative conversion in nasopharyngeal RTâPCR test</text></passage><passage><infon key=\"fpage\">1807</infon><infon key=\"lpage\">1809</infon><infon key=\"pub-id_doi\">10.1002/jmv.25941</infon><infon key=\"pub-id_pmid\">32330309</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>173034</offset><text>Asymptomatic SARSâCoVâ2 infected case with viral detection positive in stool but negative in nasopharyngeal samples lasts for 42 days</text></passage><passage><infon key=\"fpage\">680</infon><infon key=\"lpage\">682</infon><infon key=\"pub-id_doi\">10.1002/jmv.25742</infon><infon key=\"pub-id_pmid\">32124995</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>173172</offset><text>Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia</text></passage><passage><infon key=\"elocation-id\">e1009037</infon><infon key=\"pub-id_doi\">10.1371/journal.ppat.1009037</infon><infon key=\"pub-id_pmid\">33125439</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS Pathog</infon><infon key=\"type\">ref</infon><infon key=\"volume\">16</infon><infon key=\"year\">2020</infon><offset>173239</offset><text>On the whereabouts of SARS-CoV-2 in the human body: a systematic review</text></passage><passage><infon key=\"elocation-id\">e00042-18</infon><infon key=\"pub-id_doi\">10.1128/CMR.00042-18</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">32</infon><infon key=\"year\">2019</infon><offset>173311</offset><text>Practical guidance for clinical microbiology laboratories: viruses causing acute respiratory tract infections</text></passage><passage><infon key=\"fpage\">1344</infon><infon key=\"lpage\">1347</infon><infon key=\"pub-id_doi\">10.1017/ice.2015.171</infon><infon key=\"pub-id_pmid\">26177956</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Infect Control Hosp Epidemiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">36</infon><infon key=\"year\">2015</infon><offset>173421</offset><text>Respiratory outbreak investigations: how many specimens should be tested?</text></passage><passage><infon key=\"fpage\">256</infon><infon key=\"lpage\">264</infon><infon key=\"pub-id_doi\">10.1099/jmm.0.001032</infon><infon key=\"pub-id_pmid\">31264957</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">69</infon><infon key=\"year\">2020</infon><offset>173495</offset><text>Validation of the Seegene RV15 multiplex PCR for the detection of influenza A subtypes and influenza B lineages during national influenza surveillance in hospitalized adults</text></passage><passage><infon key=\"fpage\">841</infon><infon key=\"lpage\">843</infon><infon key=\"pub-id_doi\">10.1093/cid/ciaa149</infon><infon key=\"pub-id_pmid\">32047895</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>173669</offset><text>Consistent detection of 2019 novel coronavirus in saliva</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.04.11.20062372</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>173726</offset><text>Self-collected oral fluid and nasal swabs demonstrate comparable sensitivity to clinician collected nasopharyngeal swabs for Covid-19 detection</text></passage><passage><infon key=\"fpage\">104442</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104442</infon><infon key=\"pub-id_pmid\">32540034</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">128</infon><infon key=\"year\">2020</infon><offset>173870</offset><text>A combined oropharyngeal/nares swab is a suitable alternative to nasopharyngeal swabs for the detection of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">113948</infon><infon key=\"pub-id_doi\">10.1016/j.jviromet.2020.113948</infon><infon key=\"pub-id_pmid\">32783913</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Virol Methods</infon><infon key=\"type\">ref</infon><infon key=\"volume\">285</infon><infon key=\"year\">2020</infon><offset>173988</offset><text>Exploring alternative swabs for use in SARS-CoV-2 detection from the oropharynx and anterior nares</text></passage><passage><infon key=\"fpage\">113947</infon><infon key=\"pub-id_doi\">10.1016/j.jviromet.2020.113947</infon><infon key=\"pub-id_pmid\">32781008</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Virol Methods</infon><infon key=\"type\">ref</infon><infon key=\"volume\">285</infon><infon key=\"year\">2020</infon><offset>174087</offset><text>Comparison analysis of different swabs and transport mediums suitable for SARS-CoV-2 testing following shortages</text></passage><passage><infon key=\"elocation-id\">e00512-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.00512-20</infon><infon key=\"pub-id_pmid\">32245835</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>174200</offset><text>Laboratory diagnosis of COVID-19: current issues and challenges</text></passage><passage><infon key=\"fpage\">1980</infon><infon key=\"lpage\">1981</infon><infon key=\"pub-id_doi\">10.1093/cid/ciaa416</infon><infon key=\"pub-id_pmid\">32271374</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>174264</offset><text>Effect of throat washings on detection of 2019 novel coronavirus</text></passage><passage><infon key=\"fpage\">193</infon><infon key=\"lpage\">195</infon><infon key=\"pub-id_doi\">10.1007/s10096-020-03972-y</infon><infon key=\"pub-id_pmid\">32666481</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur J Clin Microbiol Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">40</infon><infon key=\"year\">2021</infon><offset>174329</offset><text>Combined throat/nasal swab sampling for SARS-CoV-2 is equivalent to nasopharyngeal sampling</text></passage><passage><infon key=\"comment\">Accessed 11 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Interim laboratory biosafety guidelines for handling and processing specimens associated with coronavirus disease 2019 (COVID-19), updated January 6, 2021.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>174421</offset></passage><passage><infon key=\"elocation-id\">e01668-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.01668-20</infon><infon key=\"pub-id_pmid\">32817232</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>174422</offset><text>Low-cost polyester-tipped three-dimensionally printed nasopharyngeal swab for the detection of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2)</text></passage><passage><infon key=\"elocation-id\">e00876-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.00876-20</infon><infon key=\"pub-id_pmid\">32393482</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>174586</offset><text>Open development and clinical validation of multiple 3D-printed nasopharyngeal collection swabs: rapid resolution of a critical COVID-19 testing bottleneck</text></passage><passage><infon key=\"fpage\">115257</infon><infon key=\"pub-id_doi\">10.1016/j.diagmicrobio.2020.115257</infon><infon key=\"pub-id_pmid\">33220640</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Diagn Microbiol Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">99</infon><infon key=\"year\">2021</infon><offset>174742</offset><text>Prospective clinical validation of 3D printed nasopharyngeal swabs for diagnosis of COVID-19</text></passage><passage><infon key=\"comment\">Clin Infect Dis</infon><infon key=\"pub-id_doi\">10.1093/cid/ciaa1366</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>174835</offset><text>3D printed alternative to the standard synthetic flocked nasopharyngeal swabs used for coronavirus disease 2019 testing</text></passage><passage><infon key=\"fpage\">276</infon><infon key=\"lpage\">279</infon><infon key=\"pub-id_doi\">10.5694/mja2.50726</infon><infon key=\"pub-id_pmid\">32772375</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Med J Aust</infon><infon key=\"type\">ref</infon><infon key=\"volume\">213</infon><infon key=\"year\">2020</infon><offset>174955</offset><text>Pandemic printing: a novel 3Dâprinted swab for detecting SARSâCoVâ2</text></passage><passage><infon key=\"elocation-id\">e00708-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.00708-20</infon><infon key=\"pub-id_pmid\">32341141</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>175029</offset><text>Evaluation of transport media and specimen transport conditions for the detection of SARS-CoV-2 by use of real-time reverse transcription-PCR</text></passage><passage><infon key=\"fpage\">104650</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104650</infon><infon key=\"pub-id_pmid\">33011643</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">132</infon><infon key=\"year\">2020</infon><offset>175171</offset><text>Pushing beyond specifications: evaluation of linearity and clinical performance of the cobas 6800/8800 SARS-CoV-2 RT-PCR assay for reliable quantification in blood and other materials outside recommendations</text></passage><passage><infon key=\"fpage\">e48</infon><infon key=\"lpage\">e50</infon><infon key=\"pub-id_doi\">10.1016/j.jinf.2020.06.059</infon><infon key=\"pub-id_pmid\">32593658</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">81</infon><infon key=\"year\">2020</infon><offset>175379</offset><text>Viral dynamics of SARS-CoV-2 in saliva from infected patients</text></passage><passage><infon key=\"elocation-id\">e19731</infon><infon key=\"pub-id_doi\">10.2196/19731</infon><infon key=\"pub-id_pmid\">32479412</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JMIR Public Health Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2020</infon><offset>175441</offset><text>Suitability and sufficiency of telehealth clinician-observed, participant-collected samples for SARS-CoV2 testing: the iCollect cohort pilot study</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.05.01.20081026</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>175588</offset><text>Sensitivity of nasopharyngeal swabs and saliva for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</text></passage><passage><infon key=\"fpage\">1283</infon><infon key=\"lpage\">1286</infon><infon key=\"pub-id_doi\">10.1056/NEJMc2016359</infon><infon key=\"pub-id_pmid\">32857487</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>175717</offset><text>Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">83</infon><infon key=\"lpage\">86</infon><infon key=\"pub-id_doi\">10.1016/j.jviromet.2017.06.010</infon><infon key=\"pub-id_pmid\">28633963</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Virol Methods</infon><infon key=\"type\">ref</infon><infon key=\"volume\">248</infon><infon key=\"year\">2017</infon><offset>175785</offset><text>Comparison of gargle samples and throat swab samples for the detection of respiratory pathogens</text></passage><passage><infon key=\"fpage\">248</infon><infon key=\"lpage\">279</infon><infon key=\"pub-id_doi\">10.1017/ice.2020.229</infon><infon key=\"pub-id_pmid\">32389132</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Infect Control Hosp Epidemiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">42</infon><infon key=\"year\">2021</infon><offset>175881</offset><text>Pharynx gargle samples are suitable for SARS-CoV-2 diagnostic use and save personal protective equipment and swabs</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>175996</offset><text>Saliva as a non-invasive sample for the detection of SARS-CoV-2: a systematic review</text></passage><passage><infon key=\"fpage\">e145</infon><infon key=\"lpage\">e147</infon><infon key=\"pub-id_doi\">10.1016/j.jinf.2020.05.071</infon><infon key=\"pub-id_pmid\">32504740</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">81</infon><infon key=\"year\">2020</infon><offset>176081</offset><text>Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva</text></passage><passage><infon key=\"comment\">SSRN</infon><infon key=\"pub-id_doi\">10.2139/ssrn.3543605</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>176150</offset><text>Saliva as a diagnostic specimen for SARS-CoV-2 by a PCR-based assay: a diagnostic validity study</text></passage><passage><infon key=\"comment\">Accessed 15 October 2020</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 assay: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>176247</offset></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.05.11.20092338</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>176248</offset><text>Saliva is less sensitive than nasopharyngeal swabs for COVID-19 detection in the community setting</text></passage><passage><infon key=\"fpage\">11</infon><infon key=\"pub-id_doi\">10.1038/s41368-020-0080-z</infon><infon key=\"pub-id_pmid\">32300101</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Oral Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>176347</offset><text>Saliva: potential diagnostic value and transmission of 2019-nCoV</text></passage><passage><infon key=\"fpage\">1276</infon><infon key=\"lpage\">1288</infon><infon key=\"pub-id_doi\">10.1111/apt.16036</infon><infon key=\"pub-id_pmid\">32852082</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Aliment Pharmacol Ther</infon><infon key=\"type\">ref</infon><infon key=\"volume\">52</infon><infon key=\"year\">2020</infon><offset>176412</offset><text>Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission</text></passage><passage><infon key=\"fpage\">140444</infon><infon key=\"pub-id_doi\">10.1016/j.scitotenv.2020.140444</infon><infon key=\"pub-id_pmid\">32649988</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci Total Environ</infon><infon key=\"type\">ref</infon><infon key=\"volume\">743</infon><infon key=\"year\">2020</infon><offset>176522</offset><text>SARS-CoV-2 from faeces to wastewater treatment: what do we know? A review</text></passage><passage><infon key=\"fpage\">139076</infon><infon key=\"pub-id_doi\">10.1016/j.scitotenv.2020.139076</infon><infon key=\"pub-id_pmid\">32758929</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci Total Environ</infon><infon key=\"type\">ref</infon><infon key=\"volume\">739</infon><infon key=\"year\">2020</infon><offset>176596</offset><text>SARS-CoV-2 in wastewater: state of the knowledge and research needs</text></passage><passage><infon key=\"fpage\">143346</infon><infon key=\"pub-id_doi\">10.1016/j.scitotenv.2020.143346</infon><infon key=\"pub-id_pmid\">33160659</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci Total Environ</infon><infon key=\"type\">ref</infon><infon key=\"volume\">760</infon><infon key=\"year\">2021</infon><offset>176664</offset><text>Pandemic danger to the deep: the risk of marine mammals contracting SARS-CoV-2 from wastewater</text></passage><passage><infon key=\"comment\">Accessed 11 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Collection and submission of postmortem specimens from deceased persons with confirmed or suspected COVID-19. Postmortem guidance. Updated December 2, 2020.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>176759</offset></passage><passage><infon key=\"fpage\">190</infon><infon key=\"lpage\">200</infon><infon key=\"pub-id_doi\">10.1093/ajcp/aqaa091</infon><infon key=\"pub-id_pmid\">32451533</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Am J Clin Pathol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">154</infon><infon key=\"year\">2020</infon><offset>176760</offset><text>Molecular detection of SARS-CoV-2 infection in FFPE samples and histopathologic findings in fatal SARS-CoV-2 cases</text></passage><passage><infon key=\"comment\">Clin Infect Dis</infon><infon key=\"pub-id_doi\">10.1093/cid/ciaa1312</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>176875</offset><text>SARS-CoV-2 surveillance in decedents in a large, urban medical examinerâs office</text></passage><passage><infon key=\"fpage\">320</infon><infon key=\"lpage\">332</infon><infon key=\"pub-id_doi\">10.1016/S0140-6736(20)31305-2</infon><infon key=\"pub-id_pmid\">32682491</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">396</infon><infon key=\"year\">2020</infon><offset>176958</offset><text>Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series</text></passage><passage><infon key=\"elocation-id\">e1261</infon><infon key=\"pub-id_doi\">10.1371/journal.pone.0001261</infon><infon key=\"pub-id_pmid\">18060057</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS One</infon><infon key=\"type\">ref</infon><infon key=\"volume\">2</infon><infon key=\"year\">2007</infon><offset>177066</offset><text>Determinants of RNA quality from FFPE samples</text></passage><passage><infon key=\"fpage\">1485</infon><infon key=\"lpage\">1489</infon><infon key=\"pub-id_doi\">10.1038/s41374-020-0464-x</infon><infon key=\"pub-id_pmid\">32647285</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lab Invest</infon><infon key=\"type\">ref</infon><infon key=\"volume\">100</infon><infon key=\"year\">2020</infon><offset>177112</offset><text>Detection of SARS-CoV-2 in formalin-fixed paraffin-embedded tissue sections using commercially available reagents</text></passage><passage><infon key=\"fpage\">CD013705</infon><infon key=\"pub-id_doi\">10.1002/14651858.CD013705</infon><infon key=\"pub-id_pmid\">32845525</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cochrane Database Syst Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2020</infon><offset>177226</offset><text>Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection</text></passage><passage><infon key=\"fpage\">825</infon><infon key=\"lpage\">832</infon><infon key=\"pub-id_doi\">10.1093/cid/ciaa424</infon><infon key=\"pub-id_pmid\">32277759</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>177319</offset><text>Cluster of coronavirus disease 2019 (COVID-19) in the French Alps, February 2020</text></passage><passage><infon key=\"elocation-id\">e142</infon><infon key=\"pub-id_doi\">10.3346/jkms.2020.35.e142</infon><infon key=\"pub-id_pmid\">32242348</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Korean Med Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">35</infon><infon key=\"year\">2020</infon><offset>177400</offset><text>Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean Cohort Study on COVID-19</text></passage><passage><infon key=\"fpage\">2027</infon><infon key=\"lpage\">2034</infon><infon key=\"pub-id_doi\">10.1093/cid/ciaa344</infon><infon key=\"pub-id_pmid\">32221519</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>177592</offset><text>Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019</text></passage><passage><infon key=\"fpage\">2000763</infon><infon key=\"pub-id_doi\">10.1183/13993003.00763-2020</infon><infon key=\"pub-id_pmid\">32430429</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur Respir J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">56</infon><infon key=\"year\">2020</infon><offset>177671</offset><text>Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset</text></passage><passage><infon key=\"fpage\">465</infon><infon key=\"lpage\">469</infon><infon key=\"pub-id_doi\">10.1038/s41586-020-2196-x</infon><infon key=\"pub-id_pmid\">32235945</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">581</infon><infon key=\"year\">2020</infon><offset>177758</offset><text>Virological assessment of hospitalized patients with COVID-2019</text></passage><passage><infon key=\"fpage\">778</infon><infon key=\"lpage\">785</infon><infon key=\"pub-id_doi\">10.1093/cid/ciaa310</infon><infon key=\"pub-id_pmid\">32198501</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>177822</offset><text>Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)</text></passage><passage><infon key=\"fpage\">206</infon><infon key=\"lpage\">211</infon><infon key=\"pub-id_doi\">10.1016/j.micinf.2020.05.008</infon><infon key=\"pub-id_pmid\">32425648</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">22</infon><infon key=\"year\">2020</infon><offset>177904</offset><text>A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients</text></passage><passage><infon key=\"comment\">Clin Infect Dis</infon><infon key=\"pub-id_doi\">10.1093/cid/ciaa1469</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>178044</offset><text>Epidemiological correlates of PCR cycle threshold values in the detection of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">2663</infon><infon key=\"lpage\">2666</infon><infon key=\"pub-id_doi\">10.1093/cid/ciaa638</infon><infon key=\"pub-id_pmid\">32442256</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>178132</offset><text>Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples</text></passage><passage><infon key=\"comment\">Clin Infect Dis</infon><infon key=\"pub-id_doi\">10.1093/cid/ciaa1579</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>178226</offset><text>Cell-based culture of SARS-CoV-2 informs infectivity and safe de-isolation assessments during COVID-19</text></passage><passage><infon key=\"fpage\">2001483</infon><infon key=\"pub-id_doi\">10.2807/1560-7917.ES.2020.25.32.2001483</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>178329</offset><text>Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020</text></passage><passage><infon key=\"fpage\">104477</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104477</infon><infon key=\"pub-id_pmid\">32505778</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">129</infon><infon key=\"year\">2020</infon><offset>178458</offset><text>Persistent detection of SARS-CoV-2 RNA in patients and healthcare workers with COVID-19</text></passage><passage><infon key=\"fpage\">1059</infon><infon key=\"lpage\">1061</infon><infon key=\"pub-id_doi\">10.1007/s10096-020-03913-9</infon><infon key=\"pub-id_pmid\">32342252</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur J Clin Microbiol Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">39</infon><infon key=\"year\">2020</infon><offset>178546</offset><text>Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards</text></passage><passage><infon key=\"fpage\">210</infon><infon key=\"lpage\">215</infon><infon key=\"pub-id_doi\">10.1016/j.idh.2020.05.002</infon><infon key=\"pub-id_pmid\">32473952</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Infect Dis Health</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>178679</offset><text>SARS-CoV-2: the viral shedding vs infectivity dilemma</text></passage><passage><infon key=\"fpage\">672</infon><infon key=\"lpage\">675</infon><infon key=\"pub-id_doi\">10.1038/s41591-020-0869-5</infon><infon key=\"pub-id_pmid\">32296168</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>178733</offset><text>Temporal dynamics in viral shedding and transmissibility of COVID-19</text></passage><passage><infon key=\"fpage\">1488</infon><infon key=\"lpage\">1494</infon><infon key=\"pub-id_doi\">10.1001/jama.2020.3204</infon><infon key=\"pub-id_pmid\">32125362</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>178802</offset><text>Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore</text></passage><passage><infon key=\"fpage\">799</infon><infon key=\"lpage\">806</infon><infon key=\"pub-id_doi\">10.1093/cid/ciaa351</infon><infon key=\"pub-id_pmid\">32271376</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>178895</offset><text>Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19)</text></passage><passage><infon key=\"fpage\">102916</infon><infon key=\"pub-id_doi\">10.1016/j.ebiom.2020.102916</infon><infon key=\"pub-id_pmid\">32711256</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">EBioMedicine</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>179001</offset><text>Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: a systematic review and meta-analysis</text></passage><passage><infon key=\"fpage\">357</infon><infon key=\"lpage\">371</infon><infon key=\"pub-id_doi\">10.1016/j.jinf.2020.06.067</infon><infon key=\"pub-id_pmid\">32615199</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">81</infon><infon key=\"year\">2020</infon><offset>179105</offset><text>SARS-CoV-2 detection, viral load and infectivity over the course of an infection</text></passage><passage><infon key=\"fpage\">1119</infon><infon key=\"lpage\">1122</infon><infon key=\"pub-id_doi\">10.1111/trf.15841</infon><infon key=\"pub-id_pmid\">32361996</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Transfusion</infon><infon key=\"type\">ref</infon><infon key=\"volume\">60</infon><infon key=\"year\">2020</infon><offset>179186</offset><text>SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission</text></passage><passage><infon key=\"fpage\">288</infon><infon key=\"lpage\">290</infon><infon key=\"pub-id_doi\">10.1016/j.ijid.2020.05.030</infon><infon key=\"pub-id_pmid\">32437933</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">96</infon><infon key=\"year\">2020</infon><offset>179273</offset><text>Viral dynamics in asymptomatic patients with COVID-19</text></passage><passage><infon key=\"fpage\">1200</infon><infon key=\"lpage\">1204</infon><infon key=\"pub-id_doi\">10.1038/s41591-020-0965-6</infon><infon key=\"pub-id_pmid\">32555424</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>179327</offset><text>Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections</text></passage><passage><infon key=\"fpage\">e95</infon><infon key=\"lpage\">e99</infon><infon key=\"pub-id_doi\">10.1097/INF.0000000000002729</infon><infon key=\"pub-id_pmid\">32379191</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pediatr Infect Dis J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">39</infon><infon key=\"year\">2020</infon><offset>179403</offset><text>Symptomatic infection is associated with prolonged duration of viral shedding in mild coronavirus disease 2019: a retrospective study of 110 children in Wuhan</text></passage><passage><infon key=\"fpage\">740</infon><infon key=\"lpage\">770</infon><infon key=\"pub-id_doi\">10.1007/s13238-020-00762-2</infon><infon key=\"pub-id_pmid\">32780218</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Protein Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>179562</offset><text>A human circulating immune cell landscape in aging and COVID-19</text></passage><passage><infon key=\"fpage\">428</infon><infon key=\"lpage\">432</infon><infon key=\"pub-id_doi\">10.3855/jidc.13003</infon><infon key=\"pub-id_pmid\">32525825</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect Dev Ctries</infon><infon key=\"type\">ref</infon><infon key=\"volume\">14</infon><infon key=\"year\">2020</infon><offset>179626</offset><text>COVID-19, frailty and long-term care: implications for policy and practice</text></passage><passage><infon key=\"fpage\">685</infon><infon key=\"lpage\">691</infon><infon key=\"pub-id_doi\">10.1007/s12603-020-1416-2</infon><infon key=\"pub-id_pmid\">32744561</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Nutr Health Aging</infon><infon key=\"type\">ref</infon><infon key=\"volume\">24</infon><infon key=\"year\">2020</infon><offset>179701</offset><text>COVID-19, virology and geroscience: a perspective</text></passage><passage><infon key=\"comment\">Accessed 11 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Discontinuation of transmission-based precautions and disposition of patients with COVID-19 in healthcare settings (interim guidance), updated August 10, 2020.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>179751</offset></passage><passage><infon key=\"fpage\">22399</infon><infon key=\"lpage\">22404</infon><infon key=\"pub-id_doi\">10.18632/aging.104114</infon><infon key=\"pub-id_pmid\">33223506</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Aging (Albany NY)</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>179752</offset><text>Impact of age on duration of viral RNA shedding in patients with COVID-19</text></passage><passage><infon key=\"fpage\">2286</infon><infon key=\"lpage\">2287</infon><infon key=\"pub-id_doi\">10.1002/jmv.25952</infon><infon key=\"pub-id_pmid\">32347980</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>179826</offset><text>Prolonged SARSâCoVâ2 RNA shedding: not a rare phenomenon</text></passage><passage><infon key=\"fpage\">98</infon><infon key=\"lpage\">100</infon><infon key=\"pub-id_doi\">10.1016/j.jhin.2020.09.011</infon><infon key=\"pub-id_pmid\">32920017</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Hosp Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">107</infon><infon key=\"year\">2021</infon><offset>179887</offset><text>Intermittent viral shedding in respiratory samples of patients with SARS-CoV-2: observational analysis with infection control implications</text></passage><passage><infon key=\"fpage\">16</infon><infon key=\"lpage\">20</infon><infon key=\"pub-id_doi\">10.1093/ageing/afaa206</infon><infon key=\"pub-id_pmid\">32951032</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Age Ageing</infon><infon key=\"type\">ref</infon><infon key=\"volume\">50</infon><infon key=\"year\">2021</infon><offset>180026</offset><text>The need for improved discharge criteria for hospitalised patients with COVID-19âimplications for patients in long-term care facilities</text></passage><passage><infon key=\"fpage\">434</infon><infon key=\"lpage\">435</infon><infon key=\"pub-id_doi\">10.1016/S2468-1253(20)30083-2</infon><infon key=\"pub-id_pmid\">32199469</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Gastroenterol Hepatol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>180164</offset><text>Prolonged presence of SARS-CoV-2 viral RNA in faecal samples</text></passage><passage><infon key=\"fpage\">112</infon><infon key=\"lpage\">117</infon><infon key=\"pub-id_doi\">10.24171/j.phrp.2020.11.3.02</infon><infon key=\"pub-id_pmid\">32528816</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Osong Public Health Res Perspect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>180225</offset><text>Detection and isolation of SARS-CoV-2 in serum, urine, and stool specimens of COVID-19 patients from the Republic of Korea</text></passage><passage><infon key=\"fpage\">1920</infon><infon key=\"lpage\">1922</infon><infon key=\"pub-id_doi\">10.3201/eid2608.200681</infon><infon key=\"pub-id_pmid\">32421494</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>180348</offset><text>Infectious SARS-CoV-2 in feces of patient with severe COVID-19</text></passage><passage><infon key=\"comment\">Accessed 1 December 2020</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays interim guidance, 11 September 2020.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>180411</offset></passage><passage><infon key=\"fpage\">845</infon><infon key=\"lpage\">848</infon><infon key=\"pub-id_doi\">10.1038/s41591-020-0897-1</infon><infon key=\"pub-id_pmid\">32350462</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>180412</offset><text>Antibody responses to SARS-CoV-2 in patients with COVID-19</text></passage><passage><infon key=\"fpage\">62</infon><infon key=\"lpage\">71</infon><infon key=\"pub-id_doi\">10.1093/infdis/jiaa696</infon><infon key=\"pub-id_pmid\">33175145</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">223</infon><infon key=\"year\">2021</infon><offset>180471</offset><text>SARS-CoV-2 seroprevalence and antibody kinetics among health care workers in a Spanish hospital after 3 months of follow-up</text></passage><passage><infon key=\"fpage\">E973</infon><infon key=\"lpage\">E979</infon><infon key=\"pub-id_doi\">10.1503/cmaj.201588</infon><infon key=\"pub-id_pmid\">32753391</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">CMAJ</infon><infon key=\"type\">ref</infon><infon key=\"volume\">192</infon><infon key=\"year\">2020</infon><offset>180595</offset><text>SARS-CoV-2 (COVID-19) serology: implications for clinical practice, laboratory medicine and public health</text></passage><passage><infon key=\"elocation-id\">eabe5511</infon><infon key=\"pub-id_doi\">10.1126/sciimmunol.abe5511</infon><infon key=\"pub-id_pmid\">33033173</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>180701</offset><text>Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients</text></passage><passage><infon key=\"fpage\">549860</infon><infon key=\"pub-id_doi\">10.3389/fmed.2020.549860</infon><infon key=\"pub-id_pmid\">33043036</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Front Med (Lausanne)</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2020</infon><offset>180802</offset><text>Direct clinical evidence recommending the use of proteinase K or dithiothreitol to pretreat sputum for detection of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">399</infon><infon key=\"pub-id_doi\">10.3390/diagnostics10060399</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Diagnostics</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2020</infon><offset>180929</offset><text>COVID-19 infection diagnosis: potential impact of isothermal amplification technology to reduce community transmission of SARS-CoV-2</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">Diagnostic detection of Wuhan coronavirus 2019 by real-time RT-PCR.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>181062</offset></passage><passage><infon key=\"comment\">Accessed 15 December 2020</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">CDC 2019-nCoV real-time RT-PCR diagnostic panel emergency use authorization.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>181063</offset></passage><passage><infon key=\"comment\">Accessed 15 October 2020</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>181064</offset></passage><passage><infon key=\"elocation-id\">e0215753</infon><infon key=\"pub-id_doi\">10.1371/journal.pone.0215753</infon><infon key=\"pub-id_pmid\">30998749</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS One</infon><infon key=\"type\">ref</infon><infon key=\"volume\">14</infon><infon key=\"year\">2019</infon><offset>181065</offset><text>Performance and workflow assessment of six nucleic acid extraction technologies for use in resource limited settings</text></passage><passage><infon key=\"fpage\">574398</infon><infon key=\"pub-id_doi\">10.1155/2009/574398</infon><infon key=\"pub-id_pmid\">20011662</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Biomed Biotechnol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">2009</infon><infon key=\"year\">2009</infon><offset>181182</offset><text>DNA, RNA, and protein extraction: the past and the present</text></passage><passage><infon key=\"comment\">bioRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.05.07.083048</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>181241</offset><text>A simple RNA preparation method for SARS-CoV-2 detection by RT-qPCR</text></passage><passage><infon key=\"elocation-id\">e00599-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.00599-20</infon><infon key=\"pub-id_pmid\">32277022</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>181309</offset><text>Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch during 48 hours in the midst of the COVID-19 pandemic</text></passage><passage><infon key=\"fpage\">9306564</infon><infon key=\"pub-id_doi\">10.1155/2017/9306564</infon><infon key=\"pub-id_pmid\">28785592</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biomed Res Int</infon><infon key=\"type\">ref</infon><infon key=\"volume\">2017</infon><infon key=\"year\">2017</infon><offset>181445</offset><text>Current nucleic acid extraction methods and their implications to point-of-care diagnostics</text></passage><passage><infon key=\"fpage\">114008</infon><infon key=\"pub-id_doi\">10.1016/j.jviromet.2020.114008</infon><infon key=\"pub-id_pmid\">33160015</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Virol Methods</infon><infon key=\"type\">ref</infon><infon key=\"volume\">287</infon><infon key=\"year\">2021</infon><offset>181537</offset><text>SARS-CoV-2: comparative analysis of different RNA extraction methods</text></passage><passage><infon key=\"fpage\">2000398</infon><infon key=\"pub-id_doi\">10.2807/1560-7917.ES.2020.25.14.2000398</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>181606</offset><text>An alternative workflow for molecular detection of SARS-CoV-2âescape from the NA extraction kit-shortage, Copenhagen, Denmark, March 2020</text></passage><passage><infon key=\"comment\">bioRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.03.20.001008</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>181746</offset><text>Direct RT-qPCR detection of SARS-CoV-2 RNA from patient nasopharyngeal swabs without an RNA extraction step</text></passage><passage><infon key=\"elocation-id\">e0236564</infon><infon key=\"pub-id_doi\">10.1371/journal.pone.0236564</infon><infon key=\"pub-id_pmid\">32706827</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS One</infon><infon key=\"type\">ref</infon><infon key=\"volume\">15</infon><infon key=\"year\">2020</infon><offset>181854</offset><text>Detection of SARS-CoV-2 RNA by direct RT-qPCR on nasopharyngeal specimens without extraction of viral RNA</text></passage><passage><infon key=\"fpage\">104579</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104579</infon><infon key=\"pub-id_pmid\">32795959</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">130</infon><infon key=\"year\">2020</infon><offset>181960</offset><text>Extraction-free SARS-CoV-2 detection by rapid RT-qPCR universal for all primary respiratory materials</text></passage><passage><infon key=\"comment\">bioRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.04.22.056283</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>182062</offset><text>Preliminary support for a âdry swab, extraction freeâ protocol for SARS-CoV-2 testing via RT-qPCR</text></passage><passage><infon key=\"fpage\">415</infon><infon key=\"lpage\">424</infon><infon key=\"pub-id_doi\">10.1093/clinchem/hvaa267</infon><infon key=\"pub-id_pmid\">33098427</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Chem</infon><infon key=\"type\">ref</infon><infon key=\"volume\">67</infon><infon key=\"year\">2021</infon><offset>182164</offset><text>Rapid and extraction-free detection of SARS-CoV-2 from saliva by colorimetric reverse-transcription loop-mediated isothermal amplification</text></passage><passage><infon key=\"comment\">bioRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.04.28.067363</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>182303</offset><text>Validation of a single-step, single-tube reverse transcription-loop-mediated isothermal amplification assay for rapid detection of SARS-CoV-2 RNA</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.04.22.20072389</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>182449</offset><text>SARS-CoV-2 on-the-spot virus detection directly from patients</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.04.23.20076877</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>182511</offset><text>SARS-CoV-2 detection using an isothermal amplification reaction and a rapid, inexpensive protocol for sample inactivation and purification</text></passage><passage><infon key=\"fpage\">4812</infon><infon key=\"pub-id_doi\">10.1038/s41467-020-18611-5</infon><infon key=\"pub-id_pmid\">32968075</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Commun</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>182650</offset><text>Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR</text></passage><passage><infon key=\"fpage\">362</infon><infon key=\"lpage\">368</infon><infon key=\"pub-id_pmid\">33376476</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">EJIFCC</infon><infon key=\"type\">ref</infon><infon key=\"volume\">31</infon><infon key=\"year\">2020</infon><offset>182734</offset><text>Improved COVID-19 testing by extraction-free SARS-CoV-2 RT-PCR</text></passage><passage><infon key=\"fpage\">113969</infon><infon key=\"pub-id_doi\">10.1016/j.jviromet.2020.113969</infon><infon key=\"pub-id_pmid\">32918932</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Virol Methods</infon><infon key=\"type\">ref</infon><infon key=\"volume\">287</infon><infon key=\"year\">2021</infon><offset>182797</offset><text>Accuracy of a RT-qPCR SARS-CoV-2 detection assay without prior RNA extraction</text></passage><passage><infon key=\"fpage\">75</infon><infon key=\"lpage\">85</infon><infon key=\"pub-id_doi\">10.2144/05391RV01</infon><infon key=\"pub-id_pmid\">16060372</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biotechniques</infon><infon key=\"type\">ref</infon><infon key=\"volume\">39</infon><infon key=\"year\">2005</infon><offset>182875</offset><text>Real-time PCR for mRNA quantitation</text></passage><passage><infon key=\"fpage\">1117</infon><infon key=\"lpage\">1123</infon><infon key=\"pub-id_doi\">10.1007/s42770-020-00347-5</infon><infon key=\"pub-id_pmid\">32767275</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Braz J Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">51</infon><infon key=\"year\">2020</infon><offset>182911</offset><text>Lower cost alternatives for molecular diagnosis of COVID-19: conventional RT-PCR and SYBR green-based RT-qPCR</text></passage><passage><infon key=\"fpage\">107</infon><infon key=\"lpage\">119</infon><infon key=\"pub-id_doi\">10.5607/en20009</infon><infon key=\"pub-id_pmid\">32156101</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Exp Neurobiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">29</infon><infon key=\"year\">2020</infon><offset>183021</offset><text>Development of a laboratory-safe and low-cost detection protocol for SARS-CoV-2 of the coronavirus disease 2019 (COVID-19)</text></passage><passage><infon key=\"fpage\">679</infon><infon key=\"lpage\">684</infon><infon key=\"pub-id_doi\">10.3855/jidc.12726</infon><infon key=\"pub-id_pmid\">32794453</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect Dev Ctries</infon><infon key=\"type\">ref</infon><infon key=\"volume\">14</infon><infon key=\"year\">2020</infon><offset>183144</offset><text>One-step nested RT-PCR for COVID-19 detection: a flexible, locally developed test for SARS-CoV2 nucleic acid detection</text></passage><passage><infon key=\"elocation-id\">e0237418</infon><infon key=\"pub-id_doi\">10.1371/journal.pone.0237418</infon><infon key=\"pub-id_pmid\">32790779</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS One</infon><infon key=\"type\">ref</infon><infon key=\"volume\">15</infon><infon key=\"year\">2020</infon><offset>183263</offset><text>Portable and accurate diagnostics for COVID-19: combined use of the miniPCR thermocycler and a well-plate reader for SARS-CoV-2 virus detection</text></passage><passage><infon key=\"fpage\">37</infon><infon key=\"pub-id_doi\">10.1038/s41421-020-0175-x</infon><infon key=\"pub-id_pmid\">32528725</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Discov</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2020</infon><offset>183407</offset><text>Single-copy sensitive, field-deployable, and simultaneous dual-gene detection of SARS-CoV-2 RNA via modified RT-RPA</text></passage><passage><infon key=\"fpage\">113926</infon><infon key=\"pub-id_doi\">10.1016/j.jviromet.2020.113926</infon><infon key=\"pub-id_pmid\">32650037</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Virol Methods</infon><infon key=\"type\">ref</infon><infon key=\"volume\">284</infon><infon key=\"year\">2020</infon><offset>183523</offset><text>Double-quencher probes improve detection sensitivity toward severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a reverse-transcription polymerase chain reaction (RT-PCR) assay</text></passage><passage><infon key=\"fpage\">619</infon><infon key=\"lpage\">626</infon><infon key=\"pub-id_doi\">10.2144/000112776</infon><infon key=\"pub-id_pmid\">18474036</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biotechniques</infon><infon key=\"type\">ref</infon><infon key=\"volume\">44</infon><infon key=\"year\">2008</infon><offset>183712</offset><text>Twenty-five years of quantitative PCR for gene expression analysis</text></passage><passage><infon key=\"elocation-id\">e00796-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.00796-20</infon><infon key=\"pub-id_pmid\">32381642</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>183779</offset><text>Understanding, verifying, and implementing emergency use authorization molecular diagnostics for the detection of SARS-CoV-2 RNA</text></passage><passage><infon key=\"elocation-id\">e00557-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.00557-20</infon><infon key=\"pub-id_pmid\">32269100</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>183908</offset><text>Comparative performance of SARS-CoV-2 detection assays using seven different primer-probe sets and one assay kit</text></passage><passage><infon key=\"fpage\">333</infon><infon key=\"pub-id_doi\">10.3390/diagnostics10050333</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Diagnostics</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2020</infon><offset>184021</offset><text>Optimization of the CDC protocol of molecular diagnosis of COVID-19 for timely diagnosis</text></passage><passage><infon key=\"fpage\">549</infon><infon key=\"lpage\">555</infon><infon key=\"pub-id_doi\">10.1093/clinchem/hvaa029</infon><infon key=\"pub-id_pmid\">32031583</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Chem</infon><infon key=\"type\">ref</infon><infon key=\"volume\">66</infon><infon key=\"year\">2020</infon><offset>184110</offset><text>Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia</text></passage><passage><infon key=\"fpage\">104427</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104427</infon><infon key=\"pub-id_pmid\">32535398</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">129</infon><infon key=\"year\">2020</infon><offset>184198</offset><text>Comparison of a laboratory-developed test targeting the envelope gene with three nucleic acid amplification tests for detection of SARS-CoV-2</text></passage><passage><infon key=\"comment\">bioRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.04.20.052258</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>184340</offset><text>Optimized qRT-PCR approach for the detection of intra- and extra-cellular SARS-CoV-2 RNAs</text></passage><passage><infon key=\"fpage\">2001223</infon><infon key=\"pub-id_doi\">10.2807/1560-7917.ES.2020.25.27.2001223</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>184430</offset><text>International external quality assessment for SARS-CoV-2 molecular detection and survey on clinical laboratory preparedness during the COVID-19 pandemic, April/May 2020</text></passage><passage><infon key=\"fpage\">2353</infon><infon key=\"lpage\">2360</infon><infon key=\"pub-id_doi\">10.3201/eid2610.202551</infon><infon key=\"pub-id_pmid\">32723432</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>184599</offset><text>Nationwide external quality assessment of SARS-CoV-2 molecular testing, South Korea</text></passage><passage><infon key=\"fpage\">104537</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104537</infon><infon key=\"pub-id_pmid\">32659712</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">129</infon><infon key=\"year\">2020</infon><offset>184683</offset><text>First results of a national external quality assessment scheme for the detection of SARS-CoV-2 genome sequences</text></passage><passage><infon key=\"comment\">Accessed 15 October 2020</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Interim national case definition: coronavirus disease (COVID-19), updated April 2, 2020.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>184795</offset></passage><passage><infon key=\"comment\">bioRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.03.12.988246</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>184796</offset><text>High sensitivity detection of SARS-CoV-2 using multiplex PCR and a multiplex-PCR-based metagenomic method</text></passage><passage><infon key=\"fpage\">2186</infon><infon key=\"lpage\">2188</infon><infon key=\"pub-id_doi\">10.1128/JCM.03636-13</infon><infon key=\"pub-id_pmid\">24696023</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">52</infon><infon key=\"year\">2014</infon><offset>184902</offset><text>Detection and differentiation of herpes simplex viruses by use of the Viper platform: advantages, limitations, and concerns</text></passage><passage><infon key=\"fpage\">573</infon><infon key=\"lpage\">586</infon><infon key=\"pub-id_doi\">10.1007/s40121-020-00324-3</infon><infon key=\"pub-id_pmid\">32725536</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Infect Dis Ther</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>185026</offset><text>A narrative systematic review of the clinical utility of cycle threshold values in the context of COVID-19</text></passage><passage><infon key=\"fpage\">1304</infon><infon key=\"lpage\">1311</infon><infon key=\"pub-id_doi\">10.1111/ajt.16357</infon><infon key=\"pub-id_pmid\">33043603</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Am J Transplant</infon><infon key=\"type\">ref</infon><infon key=\"volume\">21</infon><infon key=\"year\">2021</infon><offset>185133</offset><text>Clinical implications of SARSâCoVâ2 cycle threshold values in solid organ transplant recipients</text></passage><passage><infon key=\"fpage\">23</infon><infon key=\"lpage\">24</infon><infon key=\"pub-id_doi\">10.1016/j.ijid.2020.11.138</infon><infon key=\"pub-id_pmid\">33212261</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">103</infon><infon key=\"year\">2021</infon><offset>185233</offset><text>SARS-CoV-2 sensitivity limboâhow low can we go?</text></passage><passage><infon key=\"fpage\">2000152</infon><infon key=\"pub-id_doi\">10.2807/1560-7917.ES.2020.25.9.2000152</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>185283</offset><text>Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system</text></passage><passage><infon key=\"fpage\">104428</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104428</infon><infon key=\"pub-id_pmid\">32434706</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">128</infon><infon key=\"year\">2020</infon><offset>185413</offset><text>Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the rapid detection of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">104387</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104387</infon><infon key=\"pub-id_pmid\">32380382</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">128</infon><infon key=\"year\">2020</infon><offset>185519</offset><text>Detection of low levels of SARS-CoV-2 RNA from nasopharyngeal swabs using three commercial molecular assays</text></passage><passage><infon key=\"elocation-id\">e01187-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.01187-20</infon><infon key=\"pub-id_pmid\">32444354</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>185627</offset><text>Test agreement between Roche cobas 6800 and Cepheid GeneXpert Xpress SARS-CoV-2 assays at high cycle threshold ranges</text></passage><passage><infon key=\"fpage\">1695</infon><infon key=\"lpage\">1698</infon><infon key=\"pub-id_doi\">10.1002/jmv.25988</infon><infon key=\"pub-id_pmid\">32383179</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>185745</offset><text>Comparison of SARSâCoVâ2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARSâCoVâ2 test and a laboratoryâdeveloped realâtime RTâPCR test</text></passage><passage><infon key=\"elocation-id\">e00821-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.00821-20</infon><infon key=\"pub-id_pmid\">32350048</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>185916</offset><text>Comparison of commercially available and laboratory-developed assays for in vitro detection of SARS-CoV-2 in clinical laboratories</text></passage><passage><infon key=\"fpage\">104390</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104390</infon><infon key=\"pub-id_pmid\">32388471</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">128</infon><infon key=\"year\">2020</infon><offset>186047</offset><text>Clinical evaluation of a SARS-CoV-2 RT-PCR assay on a fully automated system for rapid on-demand testing in the hospital setting</text></passage><passage><infon key=\"fpage\">104578</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104578</infon><infon key=\"pub-id_pmid\">32777761</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">130</infon><infon key=\"year\">2020</infon><offset>186176</offset><text>Comparison of the analytical sensitivity of seven commonly used commercial SARS-CoV-2 automated molecular assays</text></passage><passage><infon key=\"elocation-id\">e00890-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.00890-20</infon><infon key=\"pub-id_pmid\">32381643</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>186289</offset><text>Comparison of two high-throughput reverse transcription-PCR systems for the detection of severe acute respiratory syndrome coronavirus 2</text></passage><passage><infon key=\"fpage\">104383</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104383</infon><infon key=\"pub-id_pmid\">32353760</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">127</infon><infon key=\"year\">2020</infon><offset>186426</offset><text>Comparison of the Panther Fusion and a laboratory-developed test targeting the envelope gene for detection of SARS-CoV-2</text></passage><passage><infon key=\"elocation-id\">e01535-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.01535-20</infon><infon key=\"pub-id_pmid\">32651238</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>186547</offset><text>Direct comparison of SARS-CoV-2 analytical limits of detection across seven molecular assays</text></passage><passage><infon key=\"fpage\">104474</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104474</infon><infon key=\"pub-id_pmid\">32504946</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">129</infon><infon key=\"year\">2020</infon><offset>186640</offset><text>Validation and verification of the Abbott RealTime SARS-CoV-2 assay analytical and clinical performance</text></passage><passage><infon key=\"elocation-id\">e00798-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.00798-20</infon><infon key=\"pub-id_pmid\">32327448</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>186744</offset><text>Comparison of Abbott ID Now and Abbott m2000 methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from symptomatic patients</text></passage><passage><infon key=\"elocation-id\">e9318</infon><infon key=\"pub-id_doi\">10.7717/peerj.9318</infon><infon key=\"pub-id_pmid\">32596046</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PeerJ</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2020</infon><offset>186891</offset><text>Novel rapid identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by real-time RT-PCR using BD Max Open system in Taiwan</text></passage><passage><infon key=\"fpage\">1175</infon><infon key=\"lpage\">1179</infon><infon key=\"pub-id_doi\">10.1080/22221751.2020.1772679</infon><infon key=\"pub-id_pmid\">32448084</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>187037</offset><text>Analytical comparisons of SARS-COV-2 detection by qRT-PCR and ddPCR with multiple primer/probe sets</text></passage><passage><infon key=\"elocation-id\">e0236311</infon><infon key=\"pub-id_doi\">10.1371/journal.pone.0236311</infon><infon key=\"pub-id_pmid\">32898153</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS One</infon><infon key=\"type\">ref</infon><infon key=\"volume\">15</infon><infon key=\"year\">2020</infon><offset>187137</offset><text>Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients</text></passage><passage><infon key=\"fpage\">1259</infon><infon key=\"lpage\">1268</infon><infon key=\"pub-id_doi\">10.1080/22221751.2020.1772678</infon><infon key=\"pub-id_pmid\">32438868</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>187283</offset><text>ddPCR: a more accurate tool for SARS-CoV-2 detection in low viral load specimens</text></passage><passage><infon key=\"fpage\">957</infon><infon key=\"lpage\">964</infon><infon key=\"pub-id_doi\">10.3892/ijmm.2020.4673</infon><infon key=\"pub-id_pmid\">32705153</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Mol Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">46</infon><infon key=\"year\">2020</infon><offset>187364</offset><text>Sensitivity assessment of droplet digital PCR for SARS-CoV-2 detection</text></passage><passage><infon key=\"comment\">Accessed 11 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Interim guidance for use of pooling procedures in SARS-CoV-2 diagnostic, screening, and surveillance testing, updated October 23, 2020.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>187435</offset></passage><passage><infon key=\"fpage\">715</infon><infon key=\"lpage\">718</infon><infon key=\"pub-id_doi\">10.1093/ajcp/aqaa064</infon><infon key=\"pub-id_pmid\">32304208</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Am J Clin Pathol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">153</infon><infon key=\"year\">2020</infon><offset>187436</offset><text>Assessment of specimen pooling to conserve SARS CoV-2 testing resources</text></passage><passage><infon key=\"fpage\">1248</infon><infon key=\"lpage\">1253</infon><infon key=\"pub-id_doi\">10.1016/j.cmi.2020.06.009</infon><infon key=\"pub-id_pmid\">32585353</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>187508</offset><text>Large-scale implementation of pooled RNA extraction and RT-PCR for SARS-CoV-2 detection</text></passage><passage><infon key=\"fpage\">1967</infon><infon key=\"lpage\">1969</infon><infon key=\"pub-id_doi\">10.1001/jama.2020.5445</infon><infon key=\"pub-id_pmid\">32250394</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>187596</offset><text>Sample pooling as a strategy to detect community transmission of SARS-CoV-2</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.08.17.20176982</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>187672</offset><text>Look before diving into pooling of SARS-CoV-2 samples on high throughput analyzers</text></passage><passage><infon key=\"elocation-id\">e0241959</infon><infon key=\"pub-id_doi\">10.1371/journal.pone.0241959</infon><infon key=\"pub-id_pmid\">33166373</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS One</infon><infon key=\"type\">ref</infon><infon key=\"volume\">15</infon><infon key=\"year\">2020</infon><offset>187755</offset><text>Recommendations for sample pooling on the Cepheid GeneXpert system using the Cepheid Xpert Xpress SARS-CoV-2 assay</text></passage><passage><infon key=\"fpage\">104426</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104426</infon><infon key=\"pub-id_pmid\">32417674</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">128</infon><infon key=\"year\">2020</infon><offset>187870</offset><text>Multi-center evaluation of Cepheid Xpert Xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic</text></passage><passage><infon key=\"elocation-id\">e00926-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.00926-20</infon><infon key=\"pub-id_pmid\">32366669</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>187979</offset><text>Multicenter evaluation of the Cepheid Xpert Xpress SARS-CoV-2 test</text></passage><passage><infon key=\"elocation-id\">e02955-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.02955-20</infon><infon key=\"pub-id_pmid\">33298613</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">59</infon><infon key=\"year\">2021</infon><offset>188046</offset><text>Multicenter evaluation of the Cepheid Xpert Xpress SARS-CoV-2/Flu/RSV test</text></passage><passage><infon key=\"fpage\">104538</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104538</infon><infon key=\"pub-id_pmid\">32650276</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">129</infon><infon key=\"year\">2020</infon><offset>188121</offset><text>Clinical evaluation of the BioFire Respiratory Panel 2.1 and detection of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">115260</infon><infon key=\"pub-id_doi\">10.1016/j.diagmicrobio.2020.115260</infon><infon key=\"pub-id_pmid\">33340934</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Diagn Microbiol Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">99</infon><infon key=\"year\">2021</infon><offset>188206</offset><text>Evaluation of the BioFire COVID-19 test and Respiratory Panel 2.1 for rapid identification of SARS-CoV-2 in nasopharyngeal swab samples</text></passage><passage><infon key=\"comment\">Accessed 22 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Simplexa COVID-19 direct: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>188342</offset></passage><passage><infon key=\"comment\">Accessed 22 September 2020</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ePlex SARS-CoV-2 test: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>188343</offset></passage><passage><infon key=\"comment\">Accessed 22 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Accula SARS-CoV-2 test: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>188344</offset></passage><passage><infon key=\"fpage\">615</infon><infon key=\"lpage\">618</infon><infon key=\"pub-id_doi\">10.1016/j.jhin.2020.05.025</infon><infon key=\"pub-id_pmid\">32446722</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Hosp Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">105</infon><infon key=\"year\">2020</infon><offset>188345</offset><text>Evaluation of a high-speed but low-throughput RT-qPCR system for detection of SARS-CoV-2</text></passage><passage><infon key=\"elocation-id\">e01134-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.01134-20</infon><infon key=\"pub-id_pmid\">32571894</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>188434</offset><text>Analytical and clinical comparison of three nucleic acid amplification tests for SARS-CoV-2 detection</text></passage><passage><infon key=\"fpage\">1699</infon><infon key=\"lpage\">1700</infon><infon key=\"pub-id_doi\">10.1016/j.cmi.2020.07.026</infon><infon key=\"pub-id_pmid\">32735938</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>188536</offset><text>Evaluating the newly developed BioFire COVID-19 test for SARS-CoV-2 molecular detection</text></passage><passage><infon key=\"fpage\">156</infon><infon key=\"lpage\">164</infon><infon key=\"pub-id_doi\">10.1556/1886.2020.00017</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur J Microbiol Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2020</infon><offset>188624</offset><text>Evaluation of the automated cartridge-based ARIES SARS-CoV-2 assay (RUO) against automated Cepheid Xpert Xpress SARS-CoV-2 PCR as gold standard</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">Molecular and antibody point-of-care tests to support the screening, diagnosis and monitoring of COVID-19.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>188768</offset></passage><passage><infon key=\"comment\">bioRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.04.29.069591</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>188769</offset><text>A rapid COVID-19 RT-PCR detection assay for low resource settings</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.08.17.20177006</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>188835</offset><text>Single-strand RPA for rapid and sensitive detection of SARS-CoV-2 RNA</text></passage><passage><infon key=\"fpage\">1076</infon><infon key=\"lpage\">1081</infon><infon key=\"pub-id_doi\">10.1016/j.cmi.2020.05.007</infon><infon key=\"pub-id_pmid\">32422410</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>188905</offset><text>Multiple-centre clinical evaluation of an ultrafast single-tube assay for SARS-CoV-2 RNA</text></passage><passage><infon key=\"fpage\">31</infon><infon key=\"lpage\">67</infon><infon key=\"pub-id_doi\">10.1039/c8an01621f</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Analyst</infon><infon key=\"type\">ref</infon><infon key=\"volume\">144</infon><infon key=\"year\">2019</infon><offset>188994</offset><text>Review: a comprehensive summary of a decade development of the recombinase polymerase amplification</text></passage><passage><infon key=\"elocation-id\">e204</infon><infon key=\"pub-id_doi\">10.1371/journal.pbio.0040204</infon><infon key=\"pub-id_pmid\">16756388</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS Biol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">4</infon><infon key=\"year\">2006</infon><offset>189094</offset><text>DNA detection using recombination proteins</text></passage><passage><infon key=\"fpage\">112316</infon><infon key=\"pub-id_doi\">10.1016/j.bios.2020.112316</infon><infon key=\"pub-id_pmid\">32553350</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biosens Bioelectron</infon><infon key=\"type\">ref</infon><infon key=\"volume\">164</infon><infon key=\"year\">2020</infon><offset>189137</offset><text>Ultra-sensitive and high-throughput CRISPR-powered COVID-19 diagnosis</text></passage><passage><infon key=\"fpage\">783</infon><infon key=\"lpage\">822</infon><infon key=\"pub-id_doi\">10.1128/CMR.00003-14</infon><infon key=\"pub-id_pmid\">25278575</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">27</infon><infon key=\"year\">2014</infon><offset>189207</offset><text>Emerging technologies for the clinical microbiology laboratory</text></passage><passage><infon key=\"fpage\">2408</infon><infon key=\"lpage\">2419</infon><infon key=\"pub-id_doi\">10.1128/jcm.40.7.2408-2419.2002</infon><infon key=\"pub-id_pmid\">12089255</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">40</infon><infon key=\"year\">2002</infon><offset>189270</offset><text>Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA</text></passage><passage><infon key=\"fpage\">215</infon><infon key=\"lpage\">247</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Diagnostic molecular biology</infon><infon key=\"type\">ref</infon><infon key=\"year\">2019</infon><offset>189382</offset></passage><passage><infon key=\"fpage\">104501</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104501</infon><infon key=\"pub-id_pmid\">32619959</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">129</infon><infon key=\"year\">2020</infon><offset>189383</offset><text>High-throughput transcription-mediated amplification on the Hologic Panther is a highly sensitive method of detection for SARS-CoV-2</text></passage><passage><infon key=\"fpage\">104541</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104541</infon><infon key=\"pub-id_pmid\">32659713</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">129</infon><infon key=\"year\">2020</infon><offset>189516</offset><text>Evaluation of the Aptima transcription-mediated amplification assay (Hologic) for detecting SARS-CoV-2 in clinical specimens</text></passage><passage><infon key=\"fpage\">129</infon><infon key=\"lpage\">136</infon><infon key=\"pub-id_doi\">10.1016/j.clinmicnews.2004.08.002</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Newsl</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2004</infon><offset>189641</offset><text>Life beyond PCR: alternative target amplification technologies for the diagnosis of infectious diseases, part II</text></passage><passage><infon key=\"fpage\">797</infon><infon key=\"pub-id_doi\">10.1186/s12879-019-4442-0</infon><infon key=\"pub-id_pmid\">31510949</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BMC Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">19</infon><infon key=\"year\">2019</infon><offset>189754</offset><text>High-volume workflow and performance comparisons for Chlamydia trachomatis and Neisseria gonorrhoeae testing using automated molecular platforms</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"lpage\">15</infon><infon key=\"pub-id_doi\">10.1016/j.aca.2018.10.054</infon><infon key=\"pub-id_pmid\">30661576</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Anal Chim Acta</infon><infon key=\"type\">ref</infon><infon key=\"volume\">1050</infon><infon key=\"year\">2019</infon><offset>189899</offset><text>Nicking enzyme-assisted amplification (NEAA) technology and its applications: a review</text></passage><passage><infon key=\"fpage\">3339</infon><infon key=\"lpage\">3344</infon><infon key=\"pub-id_doi\">10.1128/JCM.01132-14</infon><infon key=\"pub-id_pmid\">24989611</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">52</infon><infon key=\"year\">2014</infon><offset>189986</offset><text>Evaluation of Alere i Influenza A&amp;B for rapid detection of influenza viruses A and B</text></passage><passage><infon key=\"fpage\">104429</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104429</infon><infon key=\"pub-id_pmid\">32425657</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">128</infon><infon key=\"year\">2020</infon><offset>190071</offset><text>Evaluation of the COVID19 ID NOW EUA assay</text></passage><passage><infon key=\"elocation-id\">e01136-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.01136-20</infon><infon key=\"pub-id_pmid\">32471894</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>190114</offset><text>Performance of Abbott ID Now COVID-19 rapid nucleic acid amplification test using nasopharyngeal swabs transported in viral transport media and dry nasal swabs in a New York City academic institution</text></passage><passage><infon key=\"elocation-id\">e00760-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.00760-20</infon><infon key=\"pub-id_pmid\">32303564</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>190314</offset><text>Comparison of Abbott ID Now, DiaSorin Simplexa, and CDC FDA emergency use authorization methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19</text></passage><passage><infon key=\"elocation-id\">e00938-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.00938-20</infon><infon key=\"pub-id_pmid\">32461287</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>190519</offset><text>Comparison of two commercial molecular tests and a laboratory-developed modification of the CDC 2019-nCoV reverse transcriptase PCR assay for the detection of SARS-CoV-2</text></passage><passage><infon key=\"elocation-id\">e00783-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.00783-20</infon><infon key=\"pub-id_pmid\">32332061</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>190689</offset><text>Clinical evaluation of three sample-to-answer platforms for detection of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">115123</infon><infon key=\"pub-id_doi\">10.1016/j.diagmicrobio.2020.115123</infon><infon key=\"pub-id_pmid\">32673978</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Diagn Microbiol Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">98</infon><infon key=\"year\">2020</infon><offset>190773</offset><text>How many are we missing with ID NOW COVID-19 assay using direct nasopharyngeal swabs? Findings from a mid-sized academic hospital clinical microbiology laboratory</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.12.24.20248786</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>190936</offset><text>Acceptable performance of the Abbott ID NOW among symptomatic individuals with confirmed COVID-19</text></passage><passage><infon key=\"fpage\">115200</infon><infon key=\"pub-id_doi\">10.1016/j.diagmicrobio.2020.115200</infon><infon key=\"pub-id_pmid\">32980807</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Diagn Microbiol Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">99</infon><infon key=\"year\">2021</infon><offset>191034</offset><text>Comparative study of four SARS-CoV-2 nucleic acid amplification test (NAAT) platforms demonstrates that ID NOW performance is impaired substantially by patient and specimen type</text></passage><passage><infon key=\"fpage\">3</infon><infon key=\"pub-id_doi\">10.4172/2157-7439.1000282</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Nanomed Nanotechnol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2015</infon><offset>191212</offset><text>Isothermal amplification and quantification of nucleic acids and its use in microsystems</text></passage><passage><infon key=\"fpage\">18</infon><infon key=\"lpage\">31</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2019.03.015</infon><infon key=\"pub-id_pmid\">30953805</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">115</infon><infon key=\"year\">2019</infon><offset>191301</offset><text>Amplification chemistries in clinical virology</text></passage><passage><infon key=\"fpage\">771</infon><infon key=\"lpage\">783</infon><infon key=\"pub-id_doi\">10.1261/rna.076232.120</infon><infon key=\"pub-id_pmid\">32358057</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">RNA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>191348</offset><text>Overcoming the bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for COVID-19 detection</text></passage><passage><infon key=\"fpage\">44</infon><infon key=\"lpage\">53</infon><infon key=\"pub-id_doi\">10.1016/j.trac.2019.01.015</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Trends Analyt Chem</infon><infon key=\"type\">ref</infon><infon key=\"volume\">113</infon><infon key=\"year\">2019</infon><offset>191470</offset><text>LAMP-on-a-chip: revising microfluidic platforms for loop-mediated DNA amplification</text></passage><passage><infon key=\"fpage\">1420</infon><infon key=\"lpage\">1430</infon><infon key=\"pub-id_doi\">10.1039/c0lc00666a</infon><infon key=\"pub-id_pmid\">21387067</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lab Chip</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2011</infon><offset>191554</offset><text>Miniaturized isothermal nucleic acid amplification, a review</text></passage><passage><infon key=\"fpage\">975</infon><infon key=\"lpage\">977</infon><infon key=\"pub-id_doi\">10.1093/clinchem/hvaa102</infon><infon key=\"pub-id_pmid\">32315390</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Chem</infon><infon key=\"type\">ref</infon><infon key=\"volume\">66</infon><infon key=\"year\">2020</infon><offset>191615</offset><text>Rapid detection of COVID-19 coronavirus using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"lpage\">5</infon><infon key=\"pub-id_doi\">10.1007/s12275-015-4656-9</infon><infon key=\"pub-id_pmid\">25557475</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">53</infon><infon key=\"year\">2015</infon><offset>191756</offset><text>Loop-mediated isothermal amplification (LAMP): principle, features, and future prospects</text></passage><passage><infon key=\"fpage\">1956</infon><infon key=\"pub-id_doi\">10.3389/fpls.2016.01956</infon><infon key=\"pub-id_pmid\">28082999</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Front Plant Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2016</infon><offset>191845</offset><text>Loop-mediated isothermal amplification (LAMP): emergence as an alternative technology for herbal medicine identification</text></passage><passage><infon key=\"fpage\">773</infon><infon key=\"lpage\">779</infon><infon key=\"pub-id_doi\">10.1016/j.cmi.2020.04.001</infon><infon key=\"pub-id_pmid\">32276116</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>191966</offset><text>Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay</text></passage><passage><infon key=\"fpage\">62</infon><infon key=\"lpage\">69</infon><infon key=\"pub-id_doi\">10.1007/s10156-009-0669-9</infon><infon key=\"pub-id_pmid\">19396514</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect Chemother</infon><infon key=\"type\">ref</infon><infon key=\"volume\">15</infon><infon key=\"year\">2009</infon><offset>192104</offset><text>Loop-mediated isothermal amplification (LAMP): a rapid, accurate, and cost-effective diagnostic method for infectious diseases</text></passage><passage><infon key=\"elocation-id\">eabc7075</infon><infon key=\"pub-id_doi\">10.1126/scitranslmed.abc7075</infon><infon key=\"pub-id_pmid\">32719001</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci Transl Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>192231</offset><text>A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples</text></passage><passage><infon key=\"fpage\">2826</infon><infon key=\"pub-id_doi\">10.3390/ijms21082826</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Mol Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">21</infon><infon key=\"year\">2020</infon><offset>192329</offset><text>A novel reverse transcription loop-mediated isothermal amplification method for rapid detection of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">877</infon><infon key=\"lpage\">882</infon><infon key=\"pub-id_doi\">10.1038/nprot.2008.57</infon><infon key=\"pub-id_pmid\">18451795</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Protoc</infon><infon key=\"type\">ref</infon><infon key=\"volume\">3</infon><infon key=\"year\">2008</infon><offset>192439</offset><text>Loop-mediated isothermal amplification (LAMP) of gene sequences and simple visual detection of products</text></passage><passage><infon key=\"fpage\">167</infon><infon key=\"lpage\">172</infon><infon key=\"pub-id_doi\">10.2144/000113072</infon><infon key=\"pub-id_pmid\">19317660</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biotechniques</infon><infon key=\"type\">ref</infon><infon key=\"volume\">46</infon><infon key=\"year\">2009</infon><offset>192543</offset><text>Colorimetric detection of loop-mediated isothermal amplification reaction by using hydroxy naphthol blue</text></passage><passage><infon key=\"fpage\">104616</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104616</infon><infon key=\"pub-id_pmid\">32891938</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">132</infon><infon key=\"year\">2020</infon><offset>192648</offset><text>Use of the variplex SARS-CoV-2 RT-LAMP as a rapid molecular assay to complement RT-PCR for COVID-19 diagnosis</text></passage><passage><infon key=\"fpage\">2373</infon><infon key=\"lpage\">2377</infon><infon key=\"pub-id_doi\">10.1007/s10096-020-03983-9</infon><infon key=\"pub-id_pmid\">32681309</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur J Clin Microbiol Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">39</infon><infon key=\"year\">2020</infon><offset>192758</offset><text>Variplex test system fails to reliably detect SARS-CoV-2 directly from respiratory samples without RNA extraction</text></passage><passage><infon key=\"fpage\">783</infon><infon key=\"pub-id_doi\">10.1186/s12879-020-05484-8</infon><infon key=\"pub-id_pmid\">33081710</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BMC Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>192872</offset><text>Detecting SARS-CoV-2 at point of care: preliminary data comparing loop-mediated isothermal amplification (LAMP) to polymerase chain reaction (PCR)</text></passage><passage><infon key=\"fpage\">998</infon><infon key=\"lpage\">1007</infon><infon key=\"pub-id_doi\">10.1080/22221751.2020.1756698</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2021</infon><offset>193019</offset><text>Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2</text></passage><passage><infon key=\"fpage\">729</infon><infon key=\"lpage\">735</infon><infon key=\"pub-id_doi\">10.1016/j.jmoldx.2020.03.006</infon><infon key=\"pub-id_pmid\">32276051</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Mol Diagn</infon><infon key=\"type\">ref</infon><infon key=\"volume\">22</infon><infon key=\"year\">2020</infon><offset>193152</offset><text>Development of reverse transcription loop-mediated isothermal amplification assays targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)</text></passage><passage><infon key=\"fpage\">104446</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104446</infon><infon key=\"pub-id_pmid\">32512376</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">129</infon><infon key=\"year\">2020</infon><offset>193306</offset><text>Evaluation of rapid diagnosis of novel coronavirus disease (COVID-19) using loop-mediated isothermal amplification</text></passage><passage><infon key=\"elocation-id\">e01438-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.01438-20</infon><infon key=\"pub-id_pmid\">32636214</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>193421</offset><text>Clinical evaluation of self-collected saliva by quantitative reverse transcription-PCR (RT-qPCR), direct RT-qPCR, reverse transcriptionâloop-mediated isothermal amplification, and a rapid antigen test to diagnose COVID-19</text></passage><passage><infon key=\"comment\">Res Sq</infon><infon key=\"pub-id_doi\">10.21203/rs.3.rs-28070/v1</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>193645</offset><text>Rapid and accurate detection of three genes in SARS-CoV-2 using RT-LAMP method</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.03.02.20030130</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>193724</offset><text>Rapid detection of SARS-CoV-2 using reverse transcription RT-LAMP method</text></passage><passage><infon key=\"elocation-id\">e00808-20</infon><infon key=\"pub-id_doi\">10.1128/mSphere.00808-20</infon><infon key=\"pub-id_pmid\">32848011</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">mSphere</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>193797</offset><text>Development and clinical application of a rapid and sensitive loop-mediated isothermal amplification test for SARS-CoV-2 infection</text></passage><passage><infon key=\"fpage\">863</infon><infon key=\"pub-id_doi\">10.3390/v12080863</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Viruses</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>193928</offset><text>SARS-CoV-2 RNA extraction using magnetic beads for rapid large-scale testing by RT-qPCR and RT-LAMP</text></passage><passage><infon key=\"comment\">bioRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.05.21.108381</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>194028</offset><text>Rapid isothermal amplification and portable detection system for SARS-CoV-2</text></passage><passage><infon key=\"fpage\">182</infon><infon key=\"pub-id_doi\">10.3390/biology9080182</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biology (Basel)</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>194104</offset><text>Loop-mediated isothermal amplification (LAMP): a rapid, sensitive, specific, and cost-effective point-of-care test for coronaviruses in the context of COVID-19 pandemic</text></passage><passage><infon key=\"fpage\">1239</infon><infon key=\"lpage\">1259</infon><infon key=\"pub-id_doi\">10.1016/j.cell.2017.11.032</infon><infon key=\"pub-id_pmid\">29522745</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">172</infon><infon key=\"year\">2018</infon><offset>194273</offset><text>The biology of CRISPR-Cas: backward and forward</text></passage><passage><infon key=\"fpage\">653</infon><infon key=\"lpage\">663</infon><infon key=\"pub-id_doi\">10.1099/mic.0.27437-0</infon><infon key=\"pub-id_pmid\">15758212</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Microbiology (Reading)</infon><infon key=\"type\">ref</infon><infon key=\"volume\">151</infon><infon key=\"year\">2005</infon><offset>194321</offset><text>CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies</text></passage><passage><infon key=\"fpage\">174</infon><infon key=\"lpage\">182</infon><infon key=\"pub-id_doi\">10.1007/s00239-004-0046-3</infon><infon key=\"pub-id_pmid\">15791728</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Mol Evol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">60</infon><infon key=\"year\">2005</infon><offset>194475</offset><text>Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements</text></passage><passage><infon key=\"fpage\">2551</infon><infon key=\"lpage\">2561</infon><infon key=\"pub-id_doi\">10.1099/mic.0.28048-0</infon><infon key=\"pub-id_pmid\">16079334</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Microbiology (Reading)</infon><infon key=\"type\">ref</infon><infon key=\"volume\">151</infon><infon key=\"year\">2005</infon><offset>194574</offset><text>Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin</text></passage><passage><infon key=\"fpage\">29</infon><infon key=\"lpage\">44</infon><infon key=\"pub-id_doi\">10.1016/j.cell.2015.12.035</infon><infon key=\"pub-id_pmid\">26771484</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">164</infon><infon key=\"year\">2016</infon><offset>194681</offset><text>Biology and applications of CRISPR systems: harnessing natureâs toolbox for genome engineering</text></passage><passage><infon key=\"fpage\">347</infon><infon key=\"lpage\">355</infon><infon key=\"pub-id_doi\">10.1038/nbt.2842</infon><infon key=\"pub-id_pmid\">24584096</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Biotechnol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">32</infon><infon key=\"year\">2014</infon><offset>194778</offset><text>CRISPR-Cas systems for editing, regulating and targeting genomes</text></passage><passage><infon key=\"fpage\">730</infon><infon key=\"lpage\">743</infon><infon key=\"pub-id_doi\">10.1016/j.tibtech.2018.12.005</infon><infon key=\"pub-id_pmid\">30654914</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Trends Biotechnol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">37</infon><infon key=\"year\">2019</infon><offset>194843</offset><text>CRISPR/Cas systems towards next-generation biosensing</text></passage><passage><infon key=\"fpage\">438</infon><infon key=\"lpage\">442</infon><infon key=\"pub-id_doi\">10.1126/science.aam9321</infon><infon key=\"pub-id_pmid\">28408723</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">356</infon><infon key=\"year\">2017</infon><offset>194897</offset><text>Nucleic acid detection with CRISPR-Cas13a/C2c2</text></passage><passage><infon key=\"fpage\">436</infon><infon key=\"lpage\">439</infon><infon key=\"pub-id_doi\">10.1126/science.aar6245</infon><infon key=\"pub-id_pmid\">29449511</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">360</infon><infon key=\"year\">2018</infon><offset>194944</offset><text>CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity</text></passage><passage><infon key=\"fpage\">1140</infon><infon key=\"lpage\">1149</infon><infon key=\"pub-id_doi\">10.1038/s41551-020-00603-x</infon><infon key=\"pub-id_pmid\">32848209</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Biomed Eng</infon><infon key=\"type\">ref</infon><infon key=\"volume\">4</infon><infon key=\"year\">2020</infon><offset>195029</offset><text>Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.02.22.20025460</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>195108</offset><text>Development and evaluation of a CRISPR-based diagnostic for 2019-novel coronavirus</text></passage><passage><infon key=\"fpage\">34</infon><infon key=\"pub-id_doi\">10.1038/s41421-020-0174-y</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Discov</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2020</infon><offset>195191</offset><text>SARS-CoV-2 detection with CRISPR diagnostics</text></passage><passage><infon key=\"fpage\">1902312</infon><infon key=\"pub-id_doi\">10.1002/advs.201902312</infon><infon key=\"pub-id_pmid\">32195078</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Adv Sci (Weinh)</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2020</infon><offset>195236</offset><text>CRISPR/Cas systems in genome editing: methodologies and tools for sgRNA design, offâtarget evaluation, and strategies to mitigate offâtarget effects</text></passage><passage><infon key=\"fpage\">321</infon><infon key=\"lpage\">334</infon><infon key=\"pub-id_doi\">10.1038/nrg3686</infon><infon key=\"pub-id_pmid\">24690881</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Rev Genet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">15</infon><infon key=\"year\">2014</infon><offset>195389</offset><text>A guide to genome engineering with programmable nucleases</text></passage><passage><infon key=\"fpage\">67</infon><infon key=\"lpage\">78</infon><infon key=\"pub-id_doi\">10.1016/j.mib.2017.05.008</infon><infon key=\"pub-id_pmid\">28605718</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Curr Opin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">37</infon><infon key=\"year\">2017</infon><offset>195447</offset><text>Diversity, classification and evolution of CRISPR-Cas systems</text></passage><passage><infon key=\"fpage\">1255</infon><infon key=\"lpage\">1266</infon><infon key=\"pub-id_doi\">10.1016/j.cell.2016.04.059</infon><infon key=\"pub-id_pmid\">27160350</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">165</infon><infon key=\"year\">2016</infon><offset>195509</offset><text>Rapid, low-cost detection of Zika virus using programmable biomolecular components</text></passage><passage><infon key=\"fpage\">870</infon><infon key=\"lpage\">874</infon><infon key=\"pub-id_doi\">10.1038/s41587-020-0513-4</infon><infon key=\"pub-id_pmid\">32300245</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Biotechnol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">38</infon><infon key=\"year\">2020</infon><offset>195592</offset><text>CRISPR-Cas12-based detection of SARS-CoV-2</text></passage><passage><infon key=\"comment\">Broad Institute, MIT, Cambridge, MA</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>195635</offset><text>A protocol for detection of COVID-19 using CRISPR diagnostics</text></passage><passage><infon key=\"fpage\">248</infon><infon key=\"lpage\">252</infon><infon key=\"pub-id_doi\">10.1089/crispr.2020.0075</infon><infon key=\"pub-id_pmid\">32833530</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Crispr J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">3</infon><infon key=\"year\">2020</infon><offset>195697</offset><text>Sharing the CRISPR toolbox with an expanding community</text></passage><passage><infon key=\"fpage\">198129</infon><infon key=\"pub-id_doi\">10.1016/j.virusres.2020.198129</infon><infon key=\"pub-id_pmid\">32822689</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Virus Res</infon><infon key=\"type\">ref</infon><infon key=\"volume\">288</infon><infon key=\"year\">2020</infon><offset>195752</offset><text>iSCAN: an RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.05.04.20091231</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>195843</offset><text>Point-of-care testing for COVID-19 using SHERLOCK diagnostics</text></passage><passage><infon key=\"comment\">bioRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.03.19.998724</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>195905</offset><text>All-in-one dual CRISPR-Cas12a (AIOD-CRISPR) assay: a case for rapid, ultrasensitive and visual detection of novel coronavirus SARS-CoV-2 and HIV virus</text></passage><passage><infon key=\"fpage\">865</infon><infon key=\"lpage\">876.e12</infon><infon key=\"pub-id_doi\">10.1016/j.cell.2020.04.020</infon><infon key=\"pub-id_pmid\">32353252</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">181</infon><infon key=\"year\">2020</infon><offset>196056</offset><text>Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza</text></passage><passage><infon key=\"fpage\">132</infon><infon key=\"pub-id_doi\">10.1186/s13059-019-1742-z</infon><infon key=\"pub-id_pmid\">31262344</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Genome Biol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2019</infon><offset>196138</offset><text>CDetection: CRISPR-Cas12b-based DNA detection with sub-attomolar sensitivity and single-base specificity</text></passage><passage><infon key=\"comment\">Accessed 21 July 2020</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lateral flow readout for CRISPR/Cas-based detection strategies.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2019</infon><offset>196243</offset></passage><passage><infon key=\"fpage\">63</infon><infon key=\"pub-id_doi\">10.1038/s41421-018-0069-3</infon><infon key=\"pub-id_pmid\">30510770</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Discov</infon><infon key=\"type\">ref</infon><infon key=\"volume\">4</infon><infon key=\"year\">2018</infon><offset>196244</offset><text>Repurposing CRISPR-Cas12b for mammalian genome engineering</text></passage><passage><infon key=\"elocation-id\">e1008705</infon><infon key=\"pub-id_doi\">10.1371/journal.ppat.1008705</infon><infon key=\"pub-id_pmid\">32853291</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">PLoS Pathog</infon><infon key=\"type\">ref</infon><infon key=\"volume\">16</infon><infon key=\"year\">2020</infon><offset>196303</offset><text>Development and evaluation of a rapid CRISPR-based diagnostic for COVID-19</text></passage><passage><infon key=\"comment\">bioRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.05.21.109637</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>196378</offset><text>Electric-field-driven microfluidics for rapid CRISPR-based diagnostics and its application to detection of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">31</infon><infon key=\"lpage\">46</infon><infon key=\"pub-id_doi\">10.1038/nrg2626</infon><infon key=\"pub-id_pmid\">19997069</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Rev Genet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2010</infon><offset>196496</offset><text>Sequencing technologiesâthe next generation</text></passage><passage><infon key=\"fpage\">107537</infon><infon key=\"pub-id_doi\">10.1016/j.biotechadv.2020.107537</infon><infon key=\"pub-id_pmid\">32199980</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biotechnol Adv</infon><infon key=\"type\">ref</infon><infon key=\"volume\">41</infon><infon key=\"year\">2020</infon><offset>196542</offset><text>Library preparation for next generation sequencing: a review of automation strategies</text></passage><passage><infon key=\"fpage\">158</infon><infon key=\"lpage\">165</infon><infon key=\"pub-id_doi\">10.1007/s40142-015-0076-8</infon><infon key=\"pub-id_pmid\">26566462</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Curr Genet Med Rep</infon><infon key=\"type\">ref</infon><infon key=\"volume\">3</infon><infon key=\"year\">2015</infon><offset>196628</offset><text>Understanding the basics of NGS: from mechanism to variant calling</text></passage><passage><infon key=\"fpage\">661</infon><infon key=\"lpage\">673</infon><infon key=\"pub-id_doi\">10.1055/s-0039-1688446</infon><infon key=\"pub-id_pmid\">31096307</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Semin Thromb Hemost</infon><infon key=\"type\">ref</infon><infon key=\"volume\">45</infon><infon key=\"year\">2019</infon><offset>196695</offset><text>Next-generation sequencing and emerging technologies</text></passage><passage><infon key=\"fpage\">60</infon><infon key=\"lpage\">71</infon><infon key=\"pub-id_doi\">10.1016/j.mimet.2016.02.016</infon><infon key=\"pub-id_pmid\">26995332</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Microbiol Methods</infon><infon key=\"type\">ref</infon><infon key=\"volume\">138</infon><infon key=\"year\">2017</infon><offset>196748</offset><text>Next-generation sequencing (NGS) in the microbiological world: how to make the most of your money</text></passage><passage><infon key=\"fpage\">5463</infon><infon key=\"lpage\">5467</infon><infon key=\"pub-id_doi\">10.1073/pnas.74.12.5463</infon><infon key=\"pub-id_pmid\">271968</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Proc Natl Acad Sci U S A</infon><infon key=\"type\">ref</infon><infon key=\"volume\">74</infon><infon key=\"year\">1977</infon><offset>196846</offset><text>DNA sequencing with chain-terminating inhibitors</text></passage><passage><infon key=\"fpage\">363</infon><infon key=\"lpage\">365</infon><infon key=\"pub-id_doi\">10.1126/science.281.5375.363</infon><infon key=\"pub-id_pmid\">9705713</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">281</infon><infon key=\"year\">1998</infon><offset>196895</offset><text>A sequencing method based on real-time pyrophosphate</text></passage><passage><infon key=\"fpage\">1728</infon><infon key=\"lpage\">1732</infon><infon key=\"pub-id_doi\">10.1126/science.1117389</infon><infon key=\"pub-id_pmid\">16081699</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">309</infon><infon key=\"year\">2005</infon><offset>196948</offset><text>Accurate multiplex polony sequencing of an evolved bacterial genome</text></passage><passage><infon key=\"fpage\">348</infon><infon key=\"lpage\">352</infon><infon key=\"pub-id_doi\">10.1038/nature10242</infon><infon key=\"pub-id_pmid\">21776081</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">475</infon><infon key=\"year\">2011</infon><offset>197016</offset><text>An integrated semiconductor device enabling non-optical genome sequencing</text></passage><passage><infon key=\"fpage\">895</infon><infon key=\"pub-id_doi\">10.3390/v12080895</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Viruses</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>197090</offset><text>A comparison of whole genome sequencing of SARS-CoV-2 using amplicon-based sequencing, random hexamers, and bait capture</text></passage><passage><infon key=\"fpage\">777</infon><infon key=\"pub-id_doi\">10.1038/s41587-020-0608-y</infon><infon key=\"pub-id_pmid\">32641848</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Biotechnol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">38</infon><infon key=\"year\">2020</infon><offset>197211</offset><text>First NGS-based COVID-19 diagnostic</text></passage><passage><infon key=\"comment\">bioRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.04.25.061499</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>197247</offset><text>A rapid, low cost, and highly sensitive SARS-CoV-2 diagnostic based on whole genome sequencing</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.08.04.20167874</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>197342</offset><text>Swab-Seq: a high-throughput platform for massively scaled up SARS-CoV-2 testing</text></passage><passage><infon key=\"comment\">bioRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.08.10.242677</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>197422</offset><text>High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next generation sequencing</text></passage><passage><infon key=\"fpage\">1263</infon><infon key=\"lpage\">1271</infon><infon key=\"pub-id_doi\">10.1016/S1473-3099(20)30562-4</infon><infon key=\"pub-id_pmid\">32679081</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>197529</offset><text>Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study</text></passage><passage><infon key=\"fpage\">57</infon><infon key=\"pub-id_doi\">10.1186/s13073-020-00751-4</infon><infon key=\"pub-id_pmid\">32605661</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Genome Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>197673</offset><text>Multiple approaches for massively parallel sequencing of SARS-CoV-2 genomes directly from clinical samples</text></passage><passage><infon key=\"fpage\">1560.e1</infon><infon key=\"lpage\">1560.e4</infon><infon key=\"pub-id_doi\">10.1016/j.cmi.2020.07.032</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Microbiol Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>197780</offset><text>Evolution of viral quasispecies during SARS-CoV-2 infection</text></passage><passage><infon key=\"fpage\">104585</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104585</infon><infon key=\"pub-id_pmid\">32818852</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">131</infon><infon key=\"year\">2020</infon><offset>197840</offset><text>SARS-CoV-2 exhibits intra-host genomic plasticity and low-frequency polymorphic quasispecies</text></passage><passage><infon key=\"fpage\">1302</infon><infon key=\"pub-id_doi\">10.3390/microorganisms8091302</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Microorganisms</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2020</infon><offset>197933</offset><text>Compartmentalized replication of SARS-Cov-2 in upper vs. lower respiratory tract assessed by whole genome quasispecies analysis</text></passage><passage><infon key=\"fpage\">1408</infon><infon key=\"lpage\">1417</infon><infon key=\"pub-id_doi\">10.1038/s41564-020-0771-4</infon><infon key=\"pub-id_pmid\">32724171</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>198061</offset><text>Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic</text></passage><passage><infon key=\"fpage\">745</infon><infon key=\"lpage\">753</infon><infon key=\"pub-id_doi\">10.1016/j.pathol.2020.09.011</infon><infon key=\"pub-id_pmid\">33131799</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pathology</infon><infon key=\"type\">ref</infon><infon key=\"volume\">52</infon><infon key=\"year\">2020</infon><offset>198159</offset><text>Laboratory diagnosis of severe acute respiratory syndrome coronavirus 2</text></passage><passage><infon key=\"fpage\">1629</infon><infon key=\"lpage\">1635</infon><infon key=\"pub-id_doi\">10.1007/s10096-020-03899-4</infon><infon key=\"pub-id_pmid\">32333222</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur J Clin Microbiol Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">39</infon><infon key=\"year\">2020</infon><offset>198231</offset><text>The genetic sequence, origin, and diagnosis of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">1346</infon><infon key=\"lpage\">1351.e2</infon><infon key=\"pub-id_doi\">10.1016/j.cub.2020.03.022</infon><infon key=\"pub-id_pmid\">32197085</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Curr Biol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2020</infon><offset>198289</offset><text>Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak</text></passage><passage><infon key=\"fpage\">979</infon><infon key=\"pub-id_doi\">10.3390/v11110979</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Viruses</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2019</infon><offset>198366</offset><text>Viral metagenomics revealed Sendai virus and coronavirus infection of Malayan pangolins (Manis javanica)</text></passage><passage><infon key=\"fpage\">180</infon><infon key=\"lpage\">184</infon><infon key=\"pub-id_doi\">10.1016/j.tree.2020.12.002</infon><infon key=\"pub-id_pmid\">33384197</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Trends Ecol Evol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">36</infon><infon key=\"year\">2021</infon><offset>198471</offset><text>Unraveling the zoonotic origin and transmission of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">221</infon><infon key=\"lpage\">236</infon><infon key=\"pub-id_doi\">10.1080/22221751.2020.1719902</infon><infon key=\"pub-id_pmid\">31987001</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>198533</offset><text>Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</text></passage><passage><infon key=\"fpage\">1221</infon><infon key=\"lpage\">1232</infon><infon key=\"pub-id_doi\">10.1016/j.ygeno.2020.09.059</infon><infon key=\"pub-id_pmid\">33007398</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Genomics</infon><infon key=\"type\">ref</infon><infon key=\"volume\">113</infon><infon key=\"year\">2021</infon><offset>198674</offset><text>Genetics and genomics of SARS-CoV-2: a review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection</text></passage><passage><infon key=\"elocation-id\">e2024191</infon><infon key=\"pub-id_doi\">10.1001/jamanetworkopen.2020.24191</infon><infon key=\"pub-id_pmid\">33026453</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA Netw Open</infon><infon key=\"type\">ref</infon><infon key=\"volume\">3</infon><infon key=\"year\">2020</infon><offset>198814</offset><text>Analysis of genomic characteristics and transmission routes of patients with confirmed SARS-CoV-2 in Southern California during the early stage of the US COVID-19 pandemic</text></passage><passage><infon key=\"fpage\">1405</infon><infon key=\"lpage\">1410</infon><infon key=\"pub-id_doi\">10.1038/s41591-020-0997-y</infon><infon key=\"pub-id_pmid\">32678356</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>198986</offset><text>Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands</text></passage><passage><infon key=\"fpage\">2000305</infon><infon key=\"pub-id_doi\">10.2807/1560-7917.ES.2020.25.13.2000305</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>199102</offset><text>Whole genome and phylogenetic analysis of two SARS-CoV-2 strains isolated in Italy in January and February 2020: additional clues on multiple introductions and further circulation in Europe</text></passage><passage><infon key=\"fpage\">1398</infon><infon key=\"lpage\">1404</infon><infon key=\"pub-id_doi\">10.1038/s41591-020-1000-7</infon><infon key=\"pub-id_pmid\">32647358</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>199292</offset><text>Revealing COVID-19 transmission in Australia by SARS-CoV-2 genome sequencing and agent-based modeling</text></passage><passage><infon key=\"fpage\">12980</infon><infon key=\"lpage\">12985</infon><infon key=\"pub-id_doi\">10.1073/pnas.1117201109</infon><infon key=\"pub-id_pmid\">22826258</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Proc Natl Acad Sci U S A</infon><infon key=\"type\">ref</infon><infon key=\"volume\">109</infon><infon key=\"year\">2012</infon><offset>199394</offset><text>A quantitative quasispecies theory-based model of virus escape mutation under immune selection</text></passage><passage><infon key=\"fpage\">47</infon><infon key=\"lpage\">60</infon><infon key=\"pub-id_doi\">10.1038/nrmicro.2017.118</infon><infon key=\"pub-id_pmid\">29081496</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Rev Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">16</infon><infon key=\"year\">2018</infon><offset>199489</offset><text>The evolution of seasonal influenza viruses</text></passage><passage><infon key=\"fpage\">1311</infon><infon key=\"lpage\">1318</infon><infon key=\"pub-id_doi\">10.1098/rsif.2009.0560</infon><infon key=\"pub-id_pmid\">20335194</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J R Soc Interface</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2010</infon><offset>199533</offset><text>Synthesizing within-host and population-level selective pressures on viral populations: the impact of adaptive immunity on viral immune escape</text></passage><passage><infon key=\"comment\">Accessed 8 February 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">SARS-CoV-2 variants, updated December 31, 2020.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>199676</offset></passage><passage><infon key=\"comment\">Accessed 2 February 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerging SARS-CoV-2 variants, updated January 28, 2021.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>199677</offset></passage><passage><infon key=\"fpage\">4433</infon><infon key=\"lpage\">4448</infon><infon key=\"pub-id_doi\">10.1007/s00018-016-2299-6</infon><infon key=\"pub-id_pmid\">27392606</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Mol Life Sci</infon><infon key=\"type\">ref</infon><infon key=\"volume\">73</infon><infon key=\"year\">2016</infon><offset>199678</offset><text>Mechanisms of viral mutation</text></passage><passage><infon key=\"elocation-id\">e03278-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.03278-20</infon><infon key=\"pub-id_pmid\">33472904</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">59</infon><infon key=\"year\">2021</infon><offset>199707</offset><text>A novel point mutation in the N gene of SARS-CoV-2 may affect the detection of the virus by reverse transcription-quantitative PCR</text></passage><passage><infon key=\"fpage\">183</infon><infon key=\"pub-id_doi\">10.1186/s12985-020-01454-3</infon><infon key=\"pub-id_pmid\">33225958</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Virol J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">17</infon><infon key=\"year\">2020</infon><offset>199838</offset><text>Evaluation on the use of Nanopore sequencing for direct characterization of coronaviruses from respiratory specimens, and a study on emerging missense mutations in partial RdRP gene of SARS-CoV-2</text></passage><passage><infon key=\"fpage\">129</infon><infon key=\"pub-id_doi\">10.1186/1743-422X-11-129</infon><infon key=\"pub-id_pmid\">25037234</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Virol J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2014</infon><offset>200034</offset><text>Detection of circulating norovirus genotypes: hitting a moving target</text></passage><passage><infon key=\"fpage\">104557</infon><infon key=\"pub-id_doi\">10.1016/j.meegid.2020.104557</infon><infon key=\"pub-id_pmid\">32950697</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Infect Genet Evol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">85</infon><infon key=\"year\">2020</infon><offset>200104</offset><text>Substitutions in spike and nucleocapsid proteins of SARS-CoV-2 circulating in South America</text></passage><passage><infon key=\"fpage\">812</infon><infon key=\"lpage\">827.e19</infon><infon key=\"pub-id_doi\">10.1016/j.cell.2020.06.043</infon><infon key=\"pub-id_pmid\">32697968</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">182</infon><infon key=\"year\">2020</infon><offset>200196</offset><text>Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus</text></passage><passage><infon key=\"fpage\">veaa075</infon><infon key=\"pub-id_doi\">10.1093/ve/veaa075</infon><infon key=\"pub-id_pmid\">33318859</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Virus Evol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2020</infon><offset>200298</offset><text>Evaluation of NGS-based approaches for SARS-CoV-2 whole genome characterisation</text></passage><passage><infon key=\"fpage\">667</infon><infon key=\"lpage\">674</infon><infon key=\"pub-id_doi\">10.1002/jmv.25762</infon><infon key=\"pub-id_pmid\">32167180</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>200378</offset><text>The establishment of reference sequence for SARSâCoVâ2 and variation analysis</text></passage><passage><infon key=\"fpage\">854</infon><infon key=\"pub-id_doi\">10.3390/v12080854</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Viruses</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>200460</offset><text>Comprehensive analyses of SARS-CoV-2 transmission in a public health virology laboratory</text></passage><passage><infon key=\"fpage\">949</infon><infon key=\"pub-id_doi\">10.3390/genes11080949</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Genes (Basel)</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>200549</offset><text>Whole genome sequencing of SARS-CoV-2: adapting Illumina protocols for quick and accurate outbreak investigation during a pandemic</text></passage><passage><infon key=\"fpage\">2001410</infon><infon key=\"pub-id_doi\">10.2807/1560-7917.ES.2020.25.32.2001410</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>200680</offset><text>Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020</text></passage><passage><infon key=\"fpage\">516</infon><infon key=\"lpage\">527</infon><infon key=\"pub-id_doi\">10.1038/s41586-020-2798-3</infon><infon key=\"pub-id_pmid\">32967006</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">586</infon><infon key=\"year\">2020</infon><offset>200789</offset><text>SARS-CoV-2 vaccines in development</text></passage><passage><infon key=\"fpage\">237</infon><infon key=\"pub-id_doi\">10.1038/s41392-020-00352-y</infon><infon key=\"pub-id_pmid\">33051445</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Signal Transduct Target Ther</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>200824</offset><text>A systematic review of SARS-CoV-2 vaccine candidates</text></passage><passage><infon key=\"comment\">bioRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.12.28.424451</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>200877</offset><text>SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma</text></passage><passage><infon key=\"comment\">bioRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.12.31.425021</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>200960</offset><text>Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies</text></passage><passage><infon key=\"comment\">Preprints</infon><infon key=\"pub-id_doi\">10.20944/preprints202101.0132.v1</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>201098</offset><text>Genomic evidence of a Sars-Cov-2 reinfection case with E484K spike mutation in Brazil</text></passage><passage><infon key=\"elocation-id\">e02338-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.02338-20</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">59</infon><infon key=\"year\">2021</infon><offset>201184</offset><text>Clinical evaluation of BD Veritor SARS-CoV-2 point-of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS antigen point-of-care test</text></passage><passage><infon key=\"fpage\">104659</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104659</infon><infon key=\"pub-id_pmid\">33160179</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">133</infon><infon key=\"year\">2020</infon><offset>201345</offset><text>Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms</text></passage><passage><infon key=\"elocation-id\">e00977-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.00977-20</infon><infon key=\"pub-id_pmid\">32404480</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>201464</offset><text>Evaluation of a rapid diagnostic assay for detection of SARS-CoV-2 antigen in nasopharyngeal swabs</text></passage><passage><infon key=\"fpage\">225</infon><infon key=\"pub-id_doi\">10.3389/fmed.2020.00225</infon><infon key=\"pub-id_pmid\">32574326</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Front Med (Lausanne)</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2020</infon><offset>201563</offset><text>Development and potential usefulness of the COVID-19 Ag Respi-Strip diagnostic assay in a pandemic context</text></passage><passage><infon key=\"fpage\">328</infon><infon key=\"lpage\">333</infon><infon key=\"pub-id_doi\">10.1016/j.ijid.2020.05.098</infon><infon key=\"pub-id_pmid\">32497809</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">99</infon><infon key=\"year\">2020</infon><offset>201670</offset><text>Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples</text></passage><passage><infon key=\"fpage\">104455</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104455</infon><infon key=\"pub-id_pmid\">32485618</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">129</infon><infon key=\"year\">2020</infon><offset>201782</offset><text>Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.03.07.20032524</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>201874</offset><text>Diagnosis of acute respiratory syndrome coronavirus 2 infection by detection of nucleocapsid protein</text></passage><passage><infon key=\"fpage\">104500</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104500</infon><infon key=\"pub-id_pmid\">32585619</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">129</infon><infon key=\"year\">2020</infon><offset>201975</offset><text>Evaluation of rapid antigen test for detection of SARS-CoV-2 virus</text></passage><passage><infon key=\"fpage\">112349</infon><infon key=\"pub-id_doi\">10.1016/j.bios.2020.112349</infon><infon key=\"pub-id_pmid\">32510340</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biosens Bioelectron</infon><infon key=\"type\">ref</infon><infon key=\"volume\">165</infon><infon key=\"year\">2020</infon><offset>202042</offset><text>Diagnostic methods and potential portable biosensors for coronavirus disease 2019</text></passage><passage><infon key=\"fpage\">5135</infon><infon key=\"lpage\">5142</infon><infon key=\"pub-id_doi\">10.1021/acsnano.0c02823</infon><infon key=\"pub-id_pmid\">32293168</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Nano</infon><infon key=\"type\">ref</infon><infon key=\"volume\">14</infon><infon key=\"year\">2020</infon><offset>202124</offset><text>Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor</text></passage><passage><infon key=\"comment\">bioRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.04.24.059204</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>202266</offset><text>eCovSensâultrasensitive novel in-house built printed circuit board based electrochemical device for rapid detection of nCovid-19</text></passage><passage><infon key=\"elocation-id\">e120</infon><infon key=\"pub-id_doi\">10.1056/NEJMp2025631</infon><infon key=\"pub-id_pmid\">32997903</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>202397</offset><text>Rethinking Covid-19 test sensitivityâa strategy for containment</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.06.22.20136309</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>202463</offset><text>Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance</text></passage><passage><infon key=\"elocation-id\">e2016818</infon><infon key=\"pub-id_doi\">10.1001/jamanetworkopen.2020.16818</infon><infon key=\"pub-id_pmid\">32735339</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA Netw Open</infon><infon key=\"type\">ref</infon><infon key=\"volume\">3</infon><infon key=\"year\">2020</infon><offset>202552</offset><text>Assessment of SARS-CoV-2 screening strategies to permit the safe reopening of college campuses in the United States</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.04.30.20087015</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>202668</offset><text>Frequency of routine testing for COVID-19 in high-risk environments to reduce workplace outbreaks</text></passage><passage><infon key=\"fpage\">1060</infon><infon key=\"lpage\">1061</infon><infon key=\"pub-id_doi\">10.1126/science.abc1227</infon><infon key=\"pub-id_pmid\">32414781</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">368</infon><infon key=\"year\">2020</infon><offset>202766</offset><text>Serology assays to manage COVID-19</text></passage><passage><infon key=\"fpage\">319</infon><infon key=\"pub-id_doi\">10.3390/diagnostics10050319</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Diagnostics</infon><infon key=\"type\">ref</infon><infon key=\"volume\">10</infon><infon key=\"year\">2020</infon><offset>202801</offset><text>Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis</text></passage><passage><infon key=\"elocation-id\">e02204-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.02204-20</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">59</infon><infon key=\"year\">2021</infon><offset>202867</offset><text>COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva</text></passage><passage><infon key=\"fpage\">940</infon><infon key=\"lpage\">948</infon><infon key=\"pub-id_doi\">10.1080/22221751.2020.1762515</infon><infon key=\"pub-id_pmid\">32357808</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>202955</offset><text>Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients</text></passage><passage><infon key=\"fpage\">183</infon><infon key=\"lpage\">188</infon><infon key=\"pub-id_doi\">10.1093/infdis/jiaa229</infon><infon key=\"pub-id_pmid\">32358956</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">222</infon><infon key=\"year\">2020</infon><offset>203030</offset><text>Longitudinal change of severe acute respiratory syndrome coronavirus 2 antibodies in patients with coronavirus disease 2019</text></passage><passage><infon key=\"fpage\">379</infon><infon key=\"lpage\">381</infon><infon key=\"pub-id_doi\">10.1038/d41586-020-01451-0</infon><infon key=\"pub-id_pmid\">32439992</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">581</infon><infon key=\"year\">2020</infon><offset>203154</offset><text>Ten reasons why immunity passports are a bad idea</text></passage><passage><infon key=\"elocation-id\">e37</infon><infon key=\"pub-id_doi\">10.1056/NEJMp2017739</infon><infon key=\"pub-id_pmid\">32501664</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>203204</offset><text>Waiting for certainty on Covid-19 antibody testsâat what cost?</text></passage><passage><infon key=\"fpage\">355</infon><infon key=\"lpage\">359</infon><infon key=\"pub-id_doi\">10.1016/j.it.2020.03.007</infon><infon key=\"pub-id_pmid\">32249063</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Trends Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">41</infon><infon key=\"year\">2020</infon><offset>203269</offset><text>Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses</text></passage><passage><infon key=\"fpage\">293</infon><infon key=\"lpage\">304</infon><infon key=\"pub-id_doi\">10.1093/ajcp/aqaa112</infon><infon key=\"pub-id_pmid\">32583852</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Am J Clin Pathol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">154</infon><infon key=\"year\">2020</infon><offset>203342</offset><text>Review of current advances in serologic testing for COVID-19</text></passage><passage><infon key=\"fpage\">100040</infon><infon key=\"pub-id_doi\">10.1016/j.xcrm.2020.100040</infon><infon key=\"pub-id_pmid\">32835303</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Rep Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">1</infon><infon key=\"year\">2020</infon><offset>203403</offset><text>Rapid generation of neutralizing antibody responses in COVID-19 patients</text></passage><passage><infon key=\"elocation-id\">eabd2223</infon><infon key=\"pub-id_doi\">10.1126/scitranslmed.abd2223</infon><infon key=\"pub-id_pmid\">33288662</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci Transl Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">13</infon><infon key=\"year\">2021</infon><offset>203476</offset><text>IgA dominates the early neutralizing antibody response to SARS-CoV-2</text></passage><passage><infon key=\"fpage\">75</infon><infon key=\"lpage\">82</infon><infon key=\"pub-id_doi\">10.1007/s15010-020-01503-7</infon><infon key=\"pub-id_pmid\">32827125</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Infection</infon><infon key=\"type\">ref</infon><infon key=\"volume\">49</infon><infon key=\"year\">2021</infon><offset>203545</offset><text>A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization</text></passage><passage><infon key=\"elocation-id\">e01361-20</infon><infon key=\"pub-id_doi\">10.1128/JCM.01361-20</infon><infon key=\"pub-id_pmid\">32665420</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">58</infon><infon key=\"year\">2020</infon><offset>203686</offset><text>Evaluation of six commercial mid- to high-volume antibody and six point-of-care lateral flow assays for detection of SARS-CoV-2 antibodies</text></passage><passage><infon key=\"fpage\">728</infon><infon key=\"lpage\">730</infon><infon key=\"pub-id_doi\">10.1016/S0140-6736(16)30164-7</infon><infon key=\"pub-id_pmid\">27059886</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">388</infon><infon key=\"year\">2016</infon><offset>203825</offset><text>Use of serological surveys to generate key insights into the changing global landscape of infectious disease</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">Enzyme-linked immunosorbent assay (ELISA): from A to Z.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2018</infon><offset>203934</offset></passage><passage><infon key=\"fpage\">2066</infon><infon key=\"lpage\">2072</infon><infon key=\"pub-id_doi\">10.1093/cid/ciaa523</infon><infon key=\"pub-id_pmid\">32357209</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>203935</offset><text>Early detection of SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of infection</text></passage><passage><infon key=\"fpage\">1033</infon><infon key=\"lpage\">1036</infon><infon key=\"pub-id_doi\">10.1038/s41591-020-0913-5</infon><infon key=\"pub-id_pmid\">32398876</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>204032</offset><text>A serological assay to detect SARS-CoV-2 seroconversion in humans</text></passage><passage><infon key=\"fpage\">1930</infon><infon key=\"lpage\">1934</infon><infon key=\"pub-id_doi\">10.1093/cid/ciaa461</infon><infon key=\"pub-id_pmid\">32306047</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">71</infon><infon key=\"year\">2020</infon><offset>204098</offset><text>Antibody detection and dynamic characteristics in patients with coronavirus disease 2019</text></passage><passage><infon key=\"fpage\">1478</infon><infon key=\"lpage\">1488</infon><infon key=\"pub-id_doi\">10.3201/eid2607.200841</infon><infon key=\"pub-id_pmid\">32267220</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>204187</offset><text>Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients</text></passage><passage><infon key=\"fpage\">112572</infon><infon key=\"pub-id_doi\">10.1016/j.bios.2020.112572</infon><infon key=\"pub-id_pmid\">32916610</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biosens Bioelectron</infon><infon key=\"type\">ref</infon><infon key=\"volume\">169</infon><infon key=\"year\">2020</infon><offset>204295</offset><text>Rapid and quantitative detection of SARS-CoV-2 specific IgG for convalescent serum evaluation</text></passage><passage><infon key=\"fpage\">9</infon><infon key=\"pub-id_doi\">10.1007/s13317-017-0097-2</infon><infon key=\"pub-id_pmid\">28647912</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Auto Immun Highlights</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2017</infon><offset>204389</offset><text>Chemiluminescent immunoassay technology: what does it change in autoantibody detection?</text></passage><passage><infon key=\"fpage\">189</infon><infon key=\"lpage\">193</infon><infon key=\"pub-id_doi\">10.1093/infdis/jiaa243</infon><infon key=\"pub-id_pmid\">32382737</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">222</infon><infon key=\"year\">2020</infon><offset>204477</offset><text>A peptide-based magnetic chemiluminescence enzyme immunoassay for serological diagnosis of coronavirus disease 2019</text></passage><passage><infon key=\"fpage\">2271</infon><infon key=\"lpage\">2277</infon><infon key=\"pub-id_doi\">10.1007/s10096-020-03978-6</infon><infon key=\"pub-id_pmid\">32681308</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Eur J Clin Microbiol Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">39</infon><infon key=\"year\">2020</infon><offset>204593</offset><text>Evaluations of the serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak</text></passage><passage><infon key=\"fpage\">130</infon><infon key=\"lpage\">135</infon><infon key=\"pub-id_doi\">10.1016/j.jpha.2011.10.001</infon><infon key=\"pub-id_pmid\">29403732</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Pharm Anal</infon><infon key=\"type\">ref</infon><infon key=\"volume\">2</infon><infon key=\"year\">2012</infon><offset>204725</offset><text>Comparison of chemiluminescence enzyme immunoassay based on magnetic microparticles with traditional colorimetric ELISA for the detection of serum Î±-fetoprotein</text></passage><passage><infon key=\"fpage\">261</infon><infon key=\"lpage\">267</infon><infon key=\"pub-id_doi\">10.1016/j.aca.2007.07.052</infon><infon key=\"pub-id_pmid\">17719901</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Anal Chim Acta</infon><infon key=\"type\">ref</infon><infon key=\"volume\">598</infon><infon key=\"year\">2007</infon><offset>204890</offset><text>Evaluation of carbohydrate antigen 50 in human serum using magnetic particle-based chemiluminescence enzyme immunoassay</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.04.20.20071423</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>205010</offset><text>Detection of nucleocapsid antibody to SARS-CoV-2 is more sensitive than antibody to spike protein in COVID-19 patients</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.04.28.20083691</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>205129</offset><text>Ultra-sensitive high-resolution profiling of anti-SARS-CoV-2 antibodies for detecting early seroconversion in COVID-19 patients</text></passage><passage><infon key=\"fpage\">1518</infon><infon key=\"lpage\">1524</infon><infon key=\"pub-id_doi\">10.1002/jmv.25727</infon><infon key=\"pub-id_pmid\">32104917</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>205257</offset><text>Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis</text></passage><passage><infon key=\"fpage\">111</infon><infon key=\"lpage\">120</infon><infon key=\"pub-id_doi\">10.1042/EBC20150012</infon><infon key=\"pub-id_pmid\">27365041</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Essays Biochem</infon><infon key=\"type\">ref</infon><infon key=\"volume\">60</infon><infon key=\"year\">2016</infon><offset>205371</offset><text>Lateral flow assays</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"source\">Introduction to biosensors: from electric circuits to immunosensors</infon><infon key=\"type\">ref</infon><infon key=\"year\">2016</infon><offset>205391</offset></passage><passage><infon key=\"fpage\">104413</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104413</infon><infon key=\"pub-id_pmid\">32403010</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">128</infon><infon key=\"year\">2020</infon><offset>205392</offset><text>Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies</text></passage><passage><infon key=\"fpage\">2000980</infon><infon key=\"pub-id_doi\">10.2807/1560-7917.ES.2020.25.23.2000980</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>205510</offset><text>Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.09.11.20192773</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>205648</offset><text>Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis</text></passage><passage><infon key=\"fpage\">107725</infon><infon key=\"pub-id_doi\">10.1016/j.celrep.2020.107725</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Rep</infon><infon key=\"type\">ref</infon><infon key=\"volume\">31</infon><infon key=\"year\">2020</infon><offset>205743</offset><text>Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections</text></passage><passage><infon key=\"fpage\">709</infon><infon key=\"lpage\">713</infon><infon key=\"pub-id_doi\">10.1038/s41577-020-00460-4</infon><infon key=\"pub-id_pmid\">33024281</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Rev Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>205819</offset><text>Cross-reactive memory T cells and herd immunity to SARS-CoV-2</text></passage><passage><infon key=\"fpage\">910</infon><infon key=\"lpage\">941</infon><infon key=\"pub-id_doi\">10.1016/j.immuni.2020.05.002</infon><infon key=\"pub-id_pmid\">32505227</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Immunity</infon><infon key=\"type\">ref</infon><infon key=\"volume\">52</infon><infon key=\"year\">2020</infon><offset>205881</offset><text>Immunology of COVID-19: current state of the science</text></passage><passage><infon key=\"fpage\">392</infon><infon key=\"lpage\">394</infon><infon key=\"pub-id_doi\">10.1038/s41577-020-0359-5</infon><infon key=\"pub-id_pmid\">32514035</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Rev Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>205934</offset><text>Dissecting antibody-mediated protection against SARS-CoV-2</text></passage><passage><infon key=\"fpage\">971</infon><infon key=\"lpage\">977.e3</infon><infon key=\"pub-id_doi\">10.1016/j.immuni.2020.04.023</infon><infon key=\"pub-id_pmid\">32413330</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Immunity</infon><infon key=\"type\">ref</infon><infon key=\"volume\">52</infon><infon key=\"year\">2020</infon><offset>205993</offset><text>Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals</text></passage><passage><infon key=\"fpage\">1949</infon><infon key=\"pub-id_doi\">10.3389/fimmu.2020.01949</infon><infon key=\"pub-id_pmid\">32849654</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Front Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>206093</offset><text>Overview of immune response during SARS-CoV-2 infection: lessons from the past</text></passage><passage><infon key=\"fpage\">1339</infon><infon key=\"lpage\">1340</infon><infon key=\"pub-id_doi\">10.1016/S0140-6736(20)30868-0</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>206172</offset><text>SARS-CoV-2 shedding and infectivity</text></passage><passage><infon key=\"fpage\">2000421</infon><infon key=\"pub-id_doi\">10.2807/1560-7917.ES.2020.25.16.2000421</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>206208</offset><text>Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020</text></passage><passage><infon key=\"fpage\">2757</infon><infon key=\"lpage\">2765</infon><infon key=\"pub-id_doi\">10.1172/JCI138745</infon><infon key=\"pub-id_pmid\">32254064</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Invest</infon><infon key=\"type\">ref</infon><infon key=\"volume\">130</infon><infon key=\"year\">2020</infon><offset>206304</offset><text>Deployment of convalescent plasma for the prevention and treatment of COVID-19</text></passage><passage><infon key=\"fpage\">9490</infon><infon key=\"lpage\">9496</infon><infon key=\"pub-id_doi\">10.1073/pnas.2004168117</infon><infon key=\"pub-id_pmid\">32253318</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Proc Natl Acad Sci U S A</infon><infon key=\"type\">ref</infon><infon key=\"volume\">117</infon><infon key=\"year\">2020</infon><offset>206383</offset><text>Effectiveness of convalescent plasma therapy in severe COVID-19 patients</text></passage><passage><infon key=\"fpage\">791</infon><infon key=\"lpage\">797</infon><infon key=\"pub-id_doi\">10.1099/jgv.0.001439</infon><infon key=\"pub-id_pmid\">32430094</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Gen Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">101</infon><infon key=\"year\">2020</infon><offset>206456</offset><text>The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection</text></passage><passage><infon key=\"fpage\">468</infon><infon key=\"pub-id_doi\">10.3389/fcell.2020.00468</infon><infon key=\"pub-id_pmid\">32582718</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Front Cell Dev Biol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2020</infon><offset>206562</offset><text>Laboratory testing methods for novel severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2)</text></passage><passage><infon key=\"fpage\">680</infon><infon key=\"lpage\">686</infon><infon key=\"pub-id_doi\">10.1080/22221751.2020.1743767</infon><infon key=\"pub-id_pmid\">32207377</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>206660</offset><text>Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2</text></passage><passage><infon key=\"fpage\">2096</infon><infon key=\"lpage\">2104</infon><infon key=\"pub-id_doi\">10.1002/jmv.25986</infon><infon key=\"pub-id_pmid\">32383254</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>206742</offset><text>Evaluation of SARSâCoVâ2 neutralizing antibodies using a CPEâbased colorimetric live virus microâneutralization assay in human serum samples</text></passage><passage><infon key=\"elocation-id\">e20201181</infon><infon key=\"pub-id_doi\">10.1084/jem.20201181</infon><infon key=\"pub-id_pmid\">32692348</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Exp Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">217</infon><infon key=\"year\">2020</infon><offset>206891</offset><text>Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses</text></passage><passage><infon key=\"fpage\">513</infon><infon key=\"pub-id_doi\">10.3390/v12050513</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Viruses</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>206982</offset><text>Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays</text></passage><passage><infon key=\"fpage\">1274</infon><infon key=\"lpage\">1278</infon><infon key=\"pub-id_doi\">10.1126/science.abc2241</infon><infon key=\"pub-id_pmid\">32404477</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science</infon><infon key=\"type\">ref</infon><infon key=\"volume\">368</infon><infon key=\"year\">2020</infon><offset>207098</offset><text>A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2</text></passage><passage><infon key=\"fpage\">450</infon><infon key=\"lpage\">456</infon><infon key=\"pub-id_doi\">10.1038/s41586-020-2571-7</infon><infon key=\"pub-id_pmid\">32698192</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">584</infon><infon key=\"year\">2020</infon><offset>207201</offset><text>Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike</text></passage><passage><infon key=\"elocation-id\">e00802-20</infon><infon key=\"pub-id_doi\">10.1128/mSphere.00802-20</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">mSphere</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>207278</offset><text>Competitive SARS-CoV-2 serology reveals most antibodies targeting the spike receptor-binding domain compete for ACE2 binding</text></passage><passage><infon key=\"fpage\">572</infon><infon key=\"lpage\">577</infon><infon key=\"pub-id_doi\">10.1038/s41586-020-2599-8</infon><infon key=\"pub-id_pmid\">32726802</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">586</infon><infon key=\"year\">2020</infon><offset>207403</offset><text>A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity</text></passage><passage><infon key=\"elocation-id\">e142362</infon><infon key=\"pub-id_doi\">10.1172/jci.insight.142362</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JCI Insight</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>207490</offset><text>A simple protein-based surrogate neutralization assay for SARS-CoV-2</text></passage><passage><infon key=\"fpage\">828</infon><infon key=\"lpage\">842.e16</infon><infon key=\"pub-id_doi\">10.1016/j.cell.2020.06.025</infon><infon key=\"pub-id_pmid\">32645326</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">182</infon><infon key=\"year\">2020</infon><offset>207559</offset><text>Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies</text></passage><passage><infon key=\"fpage\">1073</infon><infon key=\"lpage\">1078</infon><infon key=\"pub-id_doi\">10.1038/s41587-020-0631-z</infon><infon key=\"pub-id_pmid\">32704169</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Biotechnol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">38</infon><infon key=\"year\">2020</infon><offset>207676</offset><text>A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction</text></passage><passage><infon key=\"fpage\">1538</infon><infon key=\"lpage\">1547</infon><infon key=\"pub-id_doi\">10.1093/clinchem/hvaa211</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Chem</infon><infon key=\"type\">ref</infon><infon key=\"volume\">66</infon><infon key=\"year\">2020</infon><offset>207803</offset><text>Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays</text></passage><passage><infon key=\"fpage\">104539</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104539</infon><infon key=\"pub-id_pmid\">32679298</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">129</infon><infon key=\"year\">2020</infon><offset>207892</offset><text>Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test</text></passage><passage><infon key=\"fpage\">104480</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104480</infon><infon key=\"pub-id_pmid\">32505777</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">129</infon><infon key=\"year\">2020</infon><offset>208044</offset><text>Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays</text></passage><passage><infon key=\"fpage\">104512</infon><infon key=\"pub-id_doi\">10.1016/j.jcv.2020.104512</infon><infon key=\"pub-id_pmid\">32563180</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">129</infon><infon key=\"year\">2020</infon><offset>208124</offset><text>Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation</text></passage><passage><infon key=\"fpage\">1598</infon><infon key=\"lpage\">1607</infon><infon key=\"pub-id_doi\">10.1038/s41564-020-00813-8</infon><infon key=\"pub-id_pmid\">33106674</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>208206</offset><text>Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans</text></passage><passage><infon key=\"fpage\">833</infon><infon key=\"lpage\">836</infon><infon key=\"pub-id_doi\">10.1080/22221751.2020.1756699</infon><infon key=\"pub-id_pmid\">32306864</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Microbes Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>208339</offset><text>Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients</text></passage><passage><infon key=\"fpage\">CD013652</infon><infon key=\"pub-id_doi\">10.1002/14651858.CD013652</infon><infon key=\"pub-id_pmid\">32584464</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cochrane Database Syst Rev</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2020</infon><offset>208463</offset><text>Antibody tests for identification of current and past infection with SARS-CoV-2</text></passage><passage><infon key=\"fpage\">2000180</infon><infon key=\"pub-id_doi\">10.2807/1560-7917.ES.2020.25.10.2000180</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>208543</offset><text>Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020</text></passage><passage><infon key=\"fpage\">154</infon><infon key=\"lpage\">155</infon><infon key=\"pub-id_doi\">10.1016/j.ijid.2020.03.020</infon><infon key=\"pub-id_pmid\">32179137</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Int J Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">94</infon><infon key=\"year\">2020</infon><offset>208692</offset><text>Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19)</text></passage><passage><infon key=\"fpage\">1336</infon><infon key=\"lpage\">1345</infon><infon key=\"pub-id_doi\">10.1038/s41590-020-0782-6</infon><infon key=\"pub-id_pmid\">32887977</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">21</infon><infon key=\"year\">2020</infon><offset>208772</offset><text>Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19</text></passage><passage><infon key=\"elocation-id\">eabd6160</infon><infon key=\"pub-id_doi\">10.1126/sciimmunol.abd6160</infon><infon key=\"pub-id_pmid\">32680954</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">5</infon><infon key=\"year\">2020</infon><offset>208890</offset><text>SARS-CoV-2 T cell immunity: specificity, function, durability, and role in protection</text></passage><passage><infon key=\"fpage\">457</infon><infon key=\"lpage\">462</infon><infon key=\"pub-id_doi\">10.1038/s41586-020-2550-z</infon><infon key=\"pub-id_pmid\">32668444</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">584</infon><infon key=\"year\">2020</infon><offset>208976</offset><text>SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls</text></passage><passage><infon key=\"fpage\">1582</infon><infon key=\"lpage\">1589</infon><infon key=\"pub-id_doi\">10.1001/jama.2020.4783</infon><infon key=\"pub-id_pmid\">32219428</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">323</infon><infon key=\"year\">2020</infon><offset>209067</offset><text>Treatment of 5 critically ill patients with COVID-19 with convalescent plasma</text></passage><passage><infon key=\"fpage\">583</infon><infon key=\"lpage\">589</infon><infon key=\"pub-id_doi\">10.1016/j.immuni.2020.03.007</infon><infon key=\"pub-id_pmid\">32259480</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Immunity</infon><infon key=\"type\">ref</infon><infon key=\"volume\">52</infon><infon key=\"year\">2020</infon><offset>209145</offset><text>SARS-CoV-2 vaccines: status report</text></passage><passage><infon key=\"fpage\">364</infon><infon key=\"lpage\">370</infon><infon key=\"pub-id_doi\">10.1016/j.chom.2020.08.002</infon><infon key=\"pub-id_pmid\">32798444</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell Host Microbe</infon><infon key=\"type\">ref</infon><infon key=\"volume\">28</infon><infon key=\"year\">2020</infon><offset>209180</offset><text>Approaches and challenges in SARS-CoV-2 vaccine development</text></passage><passage><infon key=\"fpage\">e16</infon><infon key=\"lpage\">e25</infon><infon key=\"pub-id_doi\">10.1016/j.jinf.2020.04.021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Infect</infon><infon key=\"type\">ref</infon><infon key=\"volume\">81</infon><infon key=\"year\">2020</infon><offset>209240</offset><text>Risk factors of critical &amp; mortal COVID-19 cases: a systematic literature review and meta-analysis</text></passage><passage><infon key=\"fpage\">1875</infon><infon key=\"lpage\">1883</infon><infon key=\"pub-id_doi\">10.1002/jmv.26050</infon><infon key=\"pub-id_pmid\">32441789</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>209339</offset><text>Predictors of mortality in hospitalized COVIDâ19 patients: a systematic review and metaâanalysis</text></passage><passage><infon key=\"fpage\">12410</infon><infon key=\"lpage\">12421</infon><infon key=\"pub-id_doi\">10.18632/aging.103383</infon><infon key=\"pub-id_pmid\">32575078</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Aging (Albany NY)</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2020</infon><offset>209440</offset><text>Risk factors for 2019 novel coronavirus disease (COVID-19) patients progressing to critical illness: a systematic review and meta-analysis</text></passage><passage><infon key=\"fpage\">58</infon><infon key=\"lpage\">60</infon><infon key=\"pub-id_doi\">10.1016/j.jviromet.2016.11.003</infon><infon key=\"pub-id_pmid\">27838260</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Virol Methods</infon><infon key=\"type\">ref</infon><infon key=\"volume\">239</infon><infon key=\"year\">2017</infon><offset>209579</offset><text>Comparison of monoplex and duplex RT-PCR assays for the detection of measles virus</text></passage><passage><infon key=\"fpage\">4049</infon><infon key=\"lpage\">4051</infon><infon key=\"pub-id_doi\">10.1128/JCM.01446-08</infon><infon key=\"pub-id_pmid\">18945836</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Clin Microbiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">46</infon><infon key=\"year\">2008</infon><offset>209662</offset><text>Detection of mumps virus RNA by real-time one-step reverse transcriptase PCR using the LightCycler platform</text></passage><passage><infon key=\"fpage\">499</infon><infon key=\"lpage\">504</infon><infon key=\"pub-id_doi\">10.1017/ice.2020.22</infon><infon key=\"pub-id_pmid\">32146920</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Infect Control Hosp Epidemiol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">41</infon><infon key=\"year\">2020</infon><offset>209770</offset><text>Influenza surveillance case definitions miss a substantial proportion of older adults hospitalized with laboratory-confirmed influenza: a report from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) Network</text></passage><passage><infon key=\"fpage\">696</infon><infon key=\"lpage\">703</infon><infon key=\"pub-id_doi\">10.1111/jgs.16950</infon><infon key=\"pub-id_pmid\">33294986</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Am Geriatr Soc</infon><infon key=\"type\">ref</infon><infon key=\"volume\">69</infon><infon key=\"year\">2021</infon><offset>210014</offset><text>Persistent functional decline following hospitalization with influenza or acute respiratory illness</text></passage><passage><infon key=\"fpage\">970</infon><infon key=\"lpage\">979</infon><infon key=\"pub-id_doi\">10.1093/cid/ciy1009</infon><infon key=\"pub-id_pmid\">30508064</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">69</infon><infon key=\"year\">2019</infon><offset>210114</offset><text>The impact of prior season vaccination on subsequent influenza vaccine effectiveness to prevent influenza-related hospitalizations over 4 influenza seasons in Canada</text></passage><passage><infon key=\"fpage\">21024</infon><infon key=\"pub-id_doi\">10.2807/1560-7917.ES2015.20.5.21024</infon><infon key=\"pub-id_pmid\">25677052</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2015</infon><offset>210280</offset><text>Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network, January 2015</text></passage><passage><infon key=\"fpage\">20729</infon><infon key=\"pub-id_doi\">10.2807/1560-7917.ES2014.19.9.20729</infon><infon key=\"pub-id_pmid\">24626207</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">19</infon><infon key=\"year\">2014</infon><offset>210517</offset><text>Interim estimates of 2013/14 influenza clinical severity and vaccine effectiveness in the prevention of laboratory-confirmed influenza-related hospitalisation, Canada, February 2014</text></passage><passage><infon key=\"fpage\">232</infon><infon key=\"lpage\">240</infon><infon key=\"pub-id_doi\">10.1111/irv.12521</infon><infon key=\"pub-id_pmid\">29125689</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Influenza Other Respir Viruses</infon><infon key=\"type\">ref</infon><infon key=\"volume\">12</infon><infon key=\"year\">2018</infon><offset>210699</offset><text>Resource utilization and cost of influenza requiring hospitalization in Canadian adults: a study from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network</text></passage><passage><infon key=\"fpage\">69</infon><infon key=\"lpage\">78</infon><infon key=\"pub-id_doi\">10.1016/j.chest.2018.10.044</infon><infon key=\"pub-id_pmid\">30616737</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Chest</infon><infon key=\"type\">ref</infon><infon key=\"volume\">155</infon><infon key=\"year\">2019</infon><offset>210889</offset><text>Effectiveness of influenza vaccination on hospitalizations and risk factors for severe outcomes in hospitalized patients with COPD</text></passage><passage><infon key=\"fpage\">1305</infon><infon key=\"lpage\">1309</infon><infon key=\"pub-id_doi\">10.15585/mmwr.mm6937a6</infon><infon key=\"pub-id_pmid\">32941415</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">MMWR Morb Mortal Wkly Rep</infon><infon key=\"type\">ref</infon><infon key=\"volume\">69</infon><infon key=\"year\">2020</infon><offset>211020</offset><text>Decreased influenza activity during the COVID-19 pandemicâUnited States, Australia, Chile, and South Africa, 2020</text></passage><passage><infon key=\"elocation-id\">eabd0086</infon><infon key=\"pub-id_doi\">10.1126/sciadv.abd0086</infon><infon key=\"pub-id_pmid\">32789184</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sci Adv</infon><infon key=\"type\">ref</infon><infon key=\"volume\">6</infon><infon key=\"year\">2020</infon><offset>211136</offset><text>COVID-19 and the next influenza season</text></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"pub-id_doi\">10.1101/2020.11.27.20240036</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>211175</offset><text>Rapid disappearance of influenza following the implementation of COVID-19 mitigation measures in Hamilton, Ontario</text></passage><passage><infon key=\"fpage\">232470962093467</infon><infon key=\"pub-id_doi\">10.1177/2324709620934674</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Invest Med High Impact Case Rep</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2020</infon><offset>211290</offset><text>A case series of patients coinfected with influenza and COVID-19</text></passage><passage><infon key=\"fpage\">1699</infon><infon key=\"lpage\">1700</infon><infon key=\"pub-id_doi\">10.1002/jmv.25953</infon><infon key=\"pub-id_pmid\">32352574</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J Med Virol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>211355</offset><text>Coinfection in SARSâCoVâ2 infected patients: where are influenza virus and rhinovirus/enterovirus?</text></passage><passage><infon key=\"comment\">Accessed 11 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">How to report COVID-19 laboratory data, updated January 5, 2021.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>211458</offset></passage><passage><infon key=\"fpage\">114</infon><infon key=\"pub-id_doi\">10.1038/s41746-020-00326-y</infon><infon key=\"pub-id_pmid\">32923691</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">NPJ Digit Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">3</infon><infon key=\"year\">2020</infon><offset>211459</offset><text>Digital advantage in the COVID-19 response: perspective from Canadaâs largest integrated digitalized healthcare system</text></passage><passage><infon key=\"fpage\">726</infon><infon key=\"lpage\">734</infon><infon key=\"pub-id_doi\">10.7326/M20-1301</infon><infon key=\"pub-id_pmid\">32282894</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Ann Intern Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">172</infon><infon key=\"year\">2020</infon><offset>211580</offset><text>Diagnostic testing for severe acute respiratory syndrome-related coronavirus 2</text></passage><passage><infon key=\"fpage\">1015</infon><infon key=\"lpage\">1018</infon><infon key=\"pub-id_doi\">10.1016/S0140-6736(20)30673-5</infon><infon key=\"pub-id_pmid\">32197103</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Lancet</infon><infon key=\"type\">ref</infon><infon key=\"volume\">395</infon><infon key=\"year\">2020</infon><offset>211659</offset><text>COVID-19: towards controlling of a pandemic</text></passage><passage><infon key=\"fpage\">467</infon><infon key=\"lpage\">474</infon><infon key=\"pub-id_doi\">10.1038/s41586-019-0956-2</infon><infon key=\"pub-id_pmid\">30814711</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"volume\">566</infon><infon key=\"year\">2019</infon><offset>211703</offset><text>Taking connected mobile-health diagnostics of infectious diseases to the field</text></passage><passage><infon key=\"fpage\">102</infon><infon key=\"lpage\">123</infon><infon key=\"pub-id_doi\">10.1021/acs.analchem.6b04630</infon><infon key=\"pub-id_pmid\">27958710</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Anal Chem</infon><infon key=\"type\">ref</infon><infon key=\"volume\">89</infon><infon key=\"year\">2017</infon><offset>211782</offset><text>Point-of-care diagnostics: recent developments in a connected age</text></passage><passage><infon key=\"fpage\">769</infon><infon key=\"lpage\">772</infon><infon key=\"pub-id_doi\">10.1038/s41587-020-0597-x</infon><infon key=\"pub-id_pmid\">32641849</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Biotechnol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">38</infon><infon key=\"year\">2020</infon><offset>211848</offset><text>COVID-19 spurs wave of innovative diagnostics</text></passage><passage><infon key=\"fpage\">453</infon><infon key=\"lpage\">454</infon><infon key=\"pub-id_doi\">10.1038/s41577-020-0367-5</infon><infon key=\"pub-id_pmid\">32546853</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat Rev Immunol</infon><infon key=\"type\">ref</infon><infon key=\"volume\">20</infon><infon key=\"year\">2020</infon><offset>211894</offset><text>Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children</text></passage><passage><infon key=\"fpage\">e340</infon><infon key=\"lpage\">e346</infon><infon key=\"pub-id_doi\">10.1097/INF.0000000000002888</infon><infon key=\"pub-id_pmid\">32925547</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pediatr Infect Dis J</infon><infon key=\"type\">ref</infon><infon key=\"volume\">39</infon><infon key=\"year\">2020</infon><offset>211973</offset><text>A systematic review of multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection</text></passage><passage><infon key=\"fpage\">259</infon><infon key=\"lpage\">269</infon><infon key=\"pub-id_doi\">10.1001/jama.2020.10369</infon><infon key=\"pub-id_pmid\">32511692</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">JAMA</infon><infon key=\"type\">ref</infon><infon key=\"volume\">324</infon><infon key=\"year\">2020</infon><offset>212079</offset><text>Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2</text></passage><passage><infon key=\"fpage\">334</infon><infon key=\"lpage\">346</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa2021680</infon><infon key=\"pub-id_pmid\">32598831</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N Engl J Med</infon><infon key=\"type\">ref</infon><infon key=\"volume\">383</infon><infon key=\"year\">2020</infon><offset>212208</offset><text>Multisystem inflammatory syndrome in U.S. children and adolescents</text></passage><passage><infon key=\"comment\">Paediatr Respir Rev</infon><infon key=\"pub-id_doi\">10.1016/j.prrv.2020.08.001</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>212275</offset><text>Multi-system inflammatory syndrome in children &amp; adolescents (MIS-C): a systematic review of clinical features and presentation</text></passage><passage><infon key=\"fpage\">2001200</infon><infon key=\"pub-id_doi\">10.2807/1560-7917.ES.2020.25.26.2001200</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>212403</offset><text>Introductions and early spread of SARS-CoV-2 in France, 24 January to 23 March 2020</text></passage><passage><infon key=\"fpage\">648</infon><infon key=\"lpage\">650</infon><infon key=\"pub-id_doi\">10.3201/eid2702.204632</infon><infon key=\"pub-id_pmid\">33292923</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">27</infon><infon key=\"year\">2021</infon><offset>212487</offset><text>Evidence of SARS-CoV-2 RNA in an oropharyngeal swab specimen, Milan, Italy, early December 2019</text></passage><passage><infon key=\"fpage\">2487</infon><infon key=\"lpage\">2488</infon><infon key=\"pub-id_doi\">10.3201/eid2610.202296</infon><infon key=\"pub-id_pmid\">32620178</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg Infect Dis</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>212583</offset><text>Retrospective screening for SARS-CoV-2 RNA in California, USA, late 2019</text></passage><passage><infon key=\"comment\">Off J Assoc Med Microbiol Infect Dis Can</infon><infon key=\"pub-id_doi\">10.3138/jammi-2020-0035</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>212656</offset><text>Retrospective testing of respiratory specimens for COVID-19 to assess for earlier SARS-CoV-2 infections in Alberta, Canada</text></passage><passage><infon key=\"comment\">Accessed 21 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">cobas SARS-CoV-2: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>212779</offset></passage><passage><infon key=\"comment\">Accessed 21 September 2020</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Abbott RealTime SARS-CoV-2: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>212780</offset></passage><passage><infon key=\"comment\">Accessed 24 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">NeuMoDx SARS-CoV-2 assay: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>212781</offset></passage><passage><infon key=\"comment\">Accessed 24 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Aptima SARS-CoV-2 assay (Panther system): instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>212782</offset></passage><passage><infon key=\"comment\">Accessed 21 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BioFire Respiratory Panel 2.1 (RP2.1): instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>212783</offset></passage><passage><infon key=\"comment\">Accessed 22 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Xpert Xpress SARS-CoV-2: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>212784</offset></passage><passage><infon key=\"comment\">Accessed 22 September 2020</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ID NOW COVID-19: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>212785</offset></passage><passage><infon key=\"comment\">Accessed 27 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sherlock CRISPR SARS-CoV-2 kit: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>212786</offset></passage><passage><infon key=\"comment\">Accessed 20 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">SARS-CoV-2 DETECTR reagent kit: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>212787</offset></passage><passage><infon key=\"comment\">Accessed 22 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Illumina CovidSeq test: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>212788</offset></passage><passage><infon key=\"comment\">Accessed 11 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BinaxNOW COVID-19 Ag card home test: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>212789</offset></passage><passage><infon key=\"comment\">Accessed 1 December 2020</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">CareStart COVID-19 antigen: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>212790</offset></passage><passage><infon key=\"comment\">Accessed 27 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">QuickVue SARS antigen test: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>212791</offset></passage><passage><infon key=\"comment\">Accessed 22 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">BD Veritor system: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2021</infon><offset>212792</offset></passage><passage><infon key=\"comment\">Accessed 1 December 2020</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Sofia 2 Flu + SARS antigen FIA: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>212793</offset></passage><passage><infon key=\"comment\">Accessed 1 December 2020</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">LumiraDx SARS-CoV-2 Ag test: instruction for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>212794</offset></passage><passage><infon key=\"comment\">Accessed 22 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clip COVID rapid antigen test: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>212795</offset></passage><passage><infon key=\"comment\">Accessed 21 January 2021</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Ellume COVID-19 home test: instructions for use.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>212796</offset></passage></document></collection>\n",
      "\n",
      "Study 33126180: <?xml version=\"1.0\" encoding=\"UTF-8\"?>\n",
      "<!DOCTYPE collection SYSTEM \"BioC.dtd\">\n",
      "<collection><source>PMC</source><date>20201220</date><key>pmc.key</key><document><id>7584564</id><infon key=\"license\">NO-CC CODE</infon><passage><infon key=\"article-id_doi\">10.1016/j.bios.2020.112752</infon><infon key=\"article-id_pii\">S0956-5663(20)30740-5</infon><infon key=\"article-id_pmc\">7584564</infon><infon key=\"article-id_pmid\">33126180</infon><infon key=\"article-id_publisher-id\">112752</infon><infon key=\"fpage\">112752</infon><infon key=\"kwd\">COVID-19 SARS-CoV-2 diagnosis SARS-CoV-2 detection RT-PCR Lateral flow assay Loop-mediated isothermal amplification Point of care devices</infon><infon key=\"license\">Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</infon><infon key=\"lpage\">112752</infon><infon key=\"name_0\">surname:YÃ¼ce;given-names:Meral</infon><infon key=\"name_1\">surname:Filiztekin;given-names:Elif</infon><infon key=\"name_2\">surname:Ãzkaya;given-names:Korin Gasia</infon><infon key=\"section_type\">TITLE</infon><infon key=\"title\">Keywords</infon><infon key=\"type\">front</infon><infon key=\"volume\">172</infon><infon key=\"year\">2020</infon><offset>0</offset><text>COVID-19 diagnosis âA review of current methods</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>50</offset><text>A fast and accurate self-testing tool for COVID-19 diagnosis has become a prerequisite to comprehend the exact number of cases worldwide and to take medical and governmental actions accordingly. SARS-CoV-2 (formerly, 2019-nCoV) infection was first reported in Wuhan (China) in December 2019, and then it has rapidly spread around the world, causing ~14 million active cases with ~582,000 deaths as of July 2020. The diagnosis tools available so far have been based on a) viral gene detection, b) human antibody detection, and c) viral antigen detection, among which the viral gene detection by RT-PCR has been found as the most reliable technique. In this report, the current SARS-CoV-2 detection kits, exclusively the ones that were issued an âEmergency Use Authorizationâ from the U.S. Food and Drug Administration, were discussed. The key structural components of the virus were presented to provide the audience with an understanding of the scientific principles behind the testing tools. The methods that are still in the early research state were also reviewed in a subsection based on the reports available so far.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract_title_1</infon><offset>1176</offset><text>Highlights</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>1187</offset><text>The structural biomarkers of SARS-CoV-2 are described.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>1242</offset><text>Viral gene, antigen, and antibody-based detection methods are discussed.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>1315</offset><text>Emergency Use Authorization-issued commercial test kits are explained.</text></passage><passage><infon key=\"section_type\">ABSTRACT</infon><infon key=\"type\">abstract</infon><offset>1386</offset><text>The methods at early research-stage are summarized.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">title_1</infon><offset>1438</offset><text>Introduction</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>1451</offset><text>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously 2019-nCoV) is an enveloped, positive-sense single-stranded genomic RNA virus (+ssRNA), is the cause of the coronavirus disease 2019 (COVID-19). SARS-CoV-2, registered in the Wuhan City of China for the first time, is contagious in humans, and it has rapidly spread worldwide through close human interactions or the spilled respirational material (cough, sneeze) of the infected people. The Director-General of WHO declared the COVID-19 outbreak as âa pandemicâ on March 12th, 2020, as a result of the increased infection rate out of China. SARS-Cov-2 taxonomically belongs to coronaviruses family and Sarbecovirus subgenus that contain several other species causing mild to severe human diseases. SARS-CoV-2 is the seventh reported Coronavirus that has infected people after 229E, NL63, OC43, HKU1, MERS-CoV, and the previous SARS-CoV. reported a complete genome characterization study based on 95 SARS-CoV-2 sequences that were accessible on GenBank, National Microbiology Data Center (NMDC) and NGDC Genome Warehouse between December-2019 and early April-2020 in which NC_045512 genome sequence was used as the reference for the alignment. According to the report, the SARS-CoV-2 complete genome is around 30kb and two-third of 5â contains orf1ab encoding orf1ab polyproteins, while the one-third of 3â² consists of genes encoding structural proteins, currently known as surface glycoprotein (S), an envelope protein (E), membrane protein (M), and nucleocapsid (N) proteins. Additionally, the genomic comparison study revealed 116 mutations among which a) 8782CÂ &gt;Â T in ORF1ab gene, b) 28144TÂ &gt;Â C in ORF8 gene, and c) 29095CÂ &gt;Â T in the N gene are defined as the most common ones. The mutations might affect the gravity and extent of the SARS-CoV-2, as stated in the study.</text></passage><passage><infon key=\"file\">gr1_lrg.jpg</infon><infon key=\"id\">fig1</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>3310</offset><text>A visual artwork for whole SARS-CoV-2 virus (a), cryo-EM restructure of SARS-CoV-2 S trimer glycoprotein, which is responsible for host cell receptor binding (b), and the complete genome structure of SARS-CoV-2 virus (c).</text></passage><passage><infon key=\"file\">gr1_lrg.jpg</infon><infon key=\"id\">fig1</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>3532</offset><text>a) The morphological structure of SARS-Cov-2 reproduced from ref. âThe envelope membrane is associated with the spike protein (S), which mediates binding to the host cell receptors and considered a critical target for the induction of antibodies capable of neutralizing the virus; hemagglutinin-esterase dimer (HE), which acts as a potent mediator of attachment and destruction of sialic acid receptors on the host cell surface; a membrane glycoprotein (M), which is important to generate the virus; and the envelope protein (E), which adheres to the M protein to form the viral envelope. The viral structure also comprises a nucleocapsid protein (N) that, along with the RNA genome, produces the nucleocapsid.â.</text></passage><passage><infon key=\"file\">gr1_lrg.jpg</infon><infon key=\"id\">fig1</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>4249</offset><text>b) The reconstruction of the closed SARS-CoV-2 S ectodomain trimer at 2.8Ã",
      " resolution reproduced from ref. â(A) Closed SARS-CoV-2 S trimer unsharpened cryo-EM map. (B and C) Two orthogonal views from the side (B) and top (C) of the atomic model of the closed SARS- CoV-2â.</text></passage><passage><infon key=\"file\">gr1_lrg.jpg</infon><infon key=\"id\">fig1</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>4527</offset><text>c) Complete genome structure of the SARS-CoV-2 virus, the data is redrawn based on the information and results of ref.</text></passage><passage><infon key=\"file\">gr1_lrg.jpg</infon><infon key=\"id\">fig1</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig</infon><offset>4646</offset><text>Fig. 1</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>4653</offset><text>The morphology and complete genome structure of the SARS-CoV-2 are illustrated in Fig. 1 based on the reports by and. Significant sequence similarity between SARS-CoV-2 S and SARS-CoV S glycoproteins was shown by, and the team also accomplished a comprehensive cryo-electron microscopy (cryo-EM) study disclosing the architecture of SARS-CoV-2 S glycoprotein subunits. The binding affinities of the S proteins of the two SARS viruses to the human angiotensin-converting enzyme 2 (ACE2), the host surface receptor used by the virus to enter the cells, were found in the low nanomolar range and comparable. The initial experiments performed by the SARS-CoV S-derived murine polyclonal antibodies demonstrated that the SARS-CoV-2Â cell admission could be neutralized effectively, which was later approved by another publication of the same group. A novel antibody, 47D11, against S protein of SARS-CoV-2 was also developed recently, where the humanized 47D11 antibodies effectively neutralized SARS-CoV and SARS-CoV-2 (C.). Another team predicted by simulation that the SARS-CoV-2 S glycoprotein binds to the ACE2 receptor protein through Leu455, Phe486, Gln493, Asn501, and Tyr505 amino acid residues of which only a few were the same as SARS-CoV S protein. All these studies deliver an immense amount of information regarding the SARS-Cov-2 genome and structure, which we believe it has based the foundation for further diagnosis, treatment, and vaccine studies.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>6115</offset><text>Currently, many commercial SARS-CoV-2 detection kits, granted an Emergency Use Authorization (EUA) from FDA, can identify a) specific viral gene regions through nucleic acid amplification techniques (Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR) and isothermal nucleic acid amplification), b) the antibodies produced by the immune system in response to the viral infection (serology/Immunoglobulin M (IgM)/Immunoglobulin G (IgG) tests), and c) the antigen testing by lateral flow assays, all have to be entirely operated in designated laboratories by trained personnel, under specified experimental and Biological Safety Level (BSL) conditions.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>6781</offset><text>As an exception, âhome collection of specimens by COVID-19 RT-PCR Testâ developed by LabCorp was issued a EUA from FDA in late April 2020 to be used by individuals to self-collect nasal samples at home. Presently, this sample collection kit comes for USD 119 each, and the company gives purchase priority for healthcare workers and first responders, consistent with CDC guidelines, due to the limited sample collection materials. The kit is only for sample collection, and the collected sample has to be sent back to the authorized laboratory for nucleic acid testing, which remains to be the gold standard for COVID-19 detection, based on the clinically validated results.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>7459</offset><text>On the other hand, the serology tests do not directly diagnose the presence of the virus, but the immune system molecules (immunoglobulins/antibodies), such as IgM and IgG that are produced by the body when encountered with the virus. IgG/IgM tests could play a central role in the fight against COVID-19 by accurately classifying the individuals who developed an immune response because of SARS-CoV-2 infection. Although the serology tests are suitable for indirect diagnosis, vast herd-immunity scanning, and mortality rate statistics, the antibody amounts produced on the first a few days of the infection may be insufficient for the detection. Furthermore, the lifetime of the produced antibodies, as well as the effectiveness, is still vague, restricting the engagement of the antibody-based rapid tests in the COVID-19 pandemic as a robust diagnosis and surveillance tool. A small number of serology tests have been EUA-authorized by FDA so far, but no country has performed an antibody testing on a national scale yet even though tremendous local efforts are on the way.</text></passage><passage><infon key=\"section_type\">INTRO</infon><infon key=\"type\">paragraph</infon><offset>8537</offset><text>As of July 15th, 2020, the number of worldwide SARS-Cov-2 active cases is around 14 million, with 582,126 deaths and 7,881,023 recovered. Due to the limited test type and the number, only a small portion of the world population has been tested so far. As critically discussed by Morales-NarvÃ¡ez and Dincer, the development of high performance, fast, accurate, sensitive, and selective SARS-CoV-2 sensing tools has become pivotal for public health authorities. In this report, current SARS-CoV-2 diagnosis tests, mostly the ones with a EUA, have been methodically reviewed. Some non-commercial techniques that have been recently published in the literature are explicitly included in the report to provide the audience with the most recent research-based solutions and the initial outcomes.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_1</infon><offset>9328</offset><text>Viral gene detection by RT-PCR method</text></passage><passage><infon key=\"file\">gr2_lrg.jpg</infon><infon key=\"id\">fig2</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>9366</offset><text>The principle of RT-PCR based on commercial TaqMan probes (a) and the relative amplicon positions for SARS-Cov-2 on GenBank data of the previous SARS-CoV and SARS-CoV-2 (b).</text></passage><passage><infon key=\"file\">gr2_lrg.jpg</infon><infon key=\"id\">fig2</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>9540</offset><text>a) TagMan Probe-based RT-PCR steps. The illustration was redrawn based on Ref. The probe is modified with a fluorescent dye (reporter dye) at one end, and one quencher dye on the other end. The quencher blocks the fluorescent signal of the reporter dye due to proximity. The probe does not fluoresce in its native condition. When the polymerase enzyme starts the amplification and encounters with the labeled probe, the probe gets hydrolyzed, releasing its components away from each other, which constitutes a fluorescent signal. Each successful amplification produces fluorescent that is proportional to the amount of the target gene in the sample.</text></passage><passage><infon key=\"file\">gr2_lrg.jpg</infon><infon key=\"id\">fig2</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>10190</offset><text>b) Relative positions of amplicon targets on SARS-CoV and Wuhan-CoV genome. S: Spike glycoprotein, E: Envelope protein, M: Membrane protein, N: nucleocapsid; ORF: open reading frame; RdRp: RNA-dependent RNA polymerase. Numbers below amplicon are genome positions according to SARS-CoV, NC_004718â. Reproduced from ref.</text></passage><passage><infon key=\"file\">gr2_lrg.jpg</infon><infon key=\"id\">fig2</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig</infon><offset>10511</offset><text>Fig. 2</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>10518</offset><text>RT-PCR is a version PCR method explicitly developed for (genomic) RNA detection. RT-PCR is sufficiently reliable and a fast technique, producing results in a few hours in a high throughput manner. RT-PCR technique is based on two consecutive reactions: a) conversion of RNA into complementary DNA (cDNA) through reverse transcription enzyme and b) amplification of the cDNA sample by polymerase chain reaction using gene-specific primers and fluorescently labeled hydrolysis probes. The first step produces DNA templates to be used in the second step, where the copy number of the DNA is increased throughout repeated thermal cycles. Gene-specific primers guide the second reaction for the amplification of only the selected region on the genome while the probes produce fluorescent signals upon each successful amplification of the gene regions, allowing a quantifiable reaction system. An illustration for RT-PCR based on well-known TaqMan hydrolysis probes, is presented in Fig. 2 a. The discovery of the RT-PCR method has paved the way for the detection of gene transcripts at trace levels, and the technique has been vastly utilized for contagious disease testing worldwide.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>11698</offset><text>RT-PCR is currently the gold standard for SARS-Cov-2 detection due to its capacity to directly measure the viral genomic parts rather than the secondary biomarkers such as antigens or antibodies. Malaysian Institute for Medical Research (IMR) announced the SARS-CoV-2 specific RT-PCR primers and probes on January 11th, 2020, the day when the scientists from China had released the entire genome sequence of the virus. Several other countries, such as England, Germany, South Korea, Turkey, Russia, the USA, and China, later declared their clinical-grade RT-PCR kits for SARS-CoV-2 detection. Some of the first SARS-CoV-2 Real-Time PCR Diagnostic kits delivered by the Central Disease Center (CDC) of the USA to national laboratories were found to cause inconclusive results and thereby limited the number of valid tests performed in February 2020 in the USA. The validated test kit from CDC, namely âCDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panelâ was then approved by FDA under an Emergency Use Authorization (EUA) scheme in late February 2020 to be used in qualified laboratories. Shortly, FDA has granted EUA for Abbott m2000 system, Panther Fusion SARS-COV-2 Assay by Hologic, COVID-19 RT-PCR test by LabCorp, and TaqPath COVID-19 Combo Kit by Thermo Fisher Scientific for authorized laboratory use. It should be noted that FDA gives EUAs for âunapproved medical products as well as the novel utilization of the existing, approved medical productsâ under section 564 of the Federal Food, Drug, and Cosmetic Act, only for emergencies like public health threats, pandemics where no appropriate alternatives exist.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>13349</offset><text>The list of EUA granted test kits, to be used only by authorized laboratories, is readily updated on FDA website. By June 6th, 2020, 72 commercial SARS-Cov-2 detection kits out of 88 EUA-issued were based on RT-PCR principle. On March 31st, 2020, FDA concluded that some other molecular detection-based tests developed by various laboratories could be authorized for use in the single laboratory that developed the test, and that is sanctioned under the âClinical Laboratory Improvement Amendments (CLIA)â of 1988, 42 U.S.C. Â§263a to perform high complexity tests. FDA has issued EUA for another 23 kits under this category for singular/identified laboratory use as of early May 2020. RT-PCR kits have been used for samples from various infected parts of the body, including nasopharyngeal, oropharyngeal, or nasal swabs, upper and lower respiratory tract aspirates, bronchoalveolar lavage, and the sputum. The swaps taken from throat samples might cause misleading results since the virus starts moving towards the lower parts of the respiratory system following the first week of the infection. Therefore, the samples must be collected carefully from the deeper parts of the respiratory system wherever possible. A study conducted recently by reported that eight infected children out of ten continuously tested positive on rectal swab samples. However, their nasopharyngeal swab samples tested negative, indicating the potential of rectal samples for assessing the treatment efficacy as well as the quarantine period of the patients.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>14891</offset><text>RT-PCR kits for SARS-CoV-2 detection mainly include the reverse transcription and amplification enzymes, two to three sets of primers and probes for amplification of the specific viral genome regions, and authorized reagents for negative, positive, and internal controls. The potential PCR amplicon regions for SARS-Cov-2 are illustrated in Fig. 2b. Control samples are processed in the same manner as the clinical patient samples and included in every plate in high throughput detection setups. For a valid test setup, all control samples must provide expected results as specified in the user guides of each kit. Some of the EUA-authorized RT-PCR kits have been explained here to highlight the significant differences in the principles. âNxTAGÂ® CoV Extended Panelâ by Luminex is a high throughput system that can process 96 samples in around 4Â h. The platform is based on the amplification of viral ORF1ab, E gene, and N genes, and RNase P internal gene is used as an internal control. The synthetic double-stranded DNA gBlocks corresponding to SARS-CoV-2 gene fragments are used as positive control. âReal-time SARS-CoV-2 Assayâ kit by Abbott relies on the amplification of RdRp and N genes from the samples collected only from respiratory system parts. Positive control of the kit contains non-infectious, recombinant SARS-CoV-2 RNA sequences that monitor the reagent or condition flops. The negative sample operates a buffer solution to check cross-contamination or non-specific byproducts. Finally, an internal/extraction control is included in the experimental setup to screen failures in the extraction protocol. However, persistent utilization of this automated high throughput system requires trained personnel as well as an installed Abbott m2000 System. Similarly, the âcobasÂ® SARS-CoV-2â kit by Roche is high throughput RT-PCR detection platform that based on the presence of either cobasÂ® 6800 or cobasÂ® 8800 system in the laboratories. The main difference is that the cobasÂ® SARS-CoV-2 kit targets ORF-1a and E-gene regions of the SARS-CoV-2 genome, and the platform also offers pan-sarbecovirus detection for the sarbecovirus subgenus family. It should be noted that FDA-EUA granted kits include at least three control samples, positive, negative, and internal controls, to provide consistent test results with maximum confidence level and minimum false positive/negatives as well as the reagent/experimental procedure failures.</text></passage><passage><infon key=\"file\">tbl1.xml</infon><infon key=\"id\">tbl1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>17354</offset><text>A list of the target gene regions, primer and probe sequences used in different RT-PCR setups for SARS-CoV-2 detection.</text></passage><passage><infon key=\"file\">tbl1.xml</infon><infon key=\"id\">tbl1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th&gt;Reference&lt;/th&gt;&lt;th&gt;Genes&lt;/th&gt;&lt;th&gt;Forward Primer&lt;/th&gt;&lt;th&gt;Reverse Primer&lt;/th&gt;&lt;th&gt;Probe Sequence&lt;xref rid=&quot;tbl1fna&quot; ref-type=&quot;table-fn&quot;&gt;a&lt;/xref&gt;&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot;&gt;&lt;xref rid=&quot;bib15&quot; ref-type=&quot;bibr&quot;&gt;Corman et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;RdRP&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GTGARATGGTCATGTGTGGCGG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CARATGTTAAASACACTATTAGCATA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CAGGTGGAACCTCATCAGGAGATGC&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;E&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ACAGGTACGTTAATAGTTAATAGCGT&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ATATTGCAGCAGTACGCACACA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ACACTAGCCATCCTTACTGCGCTTCG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;N&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CACATTGGCACCCGCAATC&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GAGGAACGAGAAGAGGCTTG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ACTTCCTCAAGGAACAACATTGCCA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;2&quot;&gt;&lt;xref rid=&quot;bib64&quot; ref-type=&quot;bibr&quot;&gt;Rao et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ORF1ab&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CCCTGTGGGTTTTACACTTAA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ACGATTGTGCATCAGCTGA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CCGTCTGCG/ZEN/GTATGTGGAAAGGTTATGG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;N&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GGGGAACTTCTCCTGCTAGAAT&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CAGACATTTTGCTCTCAAGCTG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TTGCTGCTGCTTGACAGATT&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;4&quot;&gt;&lt;xref rid=&quot;bib75&quot; ref-type=&quot;bibr&quot;&gt;U.S. Centers for Disease Control and Prevention (2020)&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;RdRP&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;AGATTTGGACCTGCGAGCG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GAGCGGCTGTCTCCACAAGT&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TTCTGACCTGAAGGCTCTGCGCG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;N1&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GACCCCAAAATCAGCGAAAT&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TCTGGTTACTGCCAGTTGAATCTG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ACCCCGCAT/ZEN/TACGTTTGGTGGACC&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;N2&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TTACAAACATTGGCGCAAA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GCGCGACATTCCGAAGAA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ACAATTTGCCCCCAGCGCTTCAG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;N3&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GGGAGCCTTGAATACACCAAAA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TGTAGCACGATTGCAGCATTG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;AYCACATTGGCACCCGCAATCCTG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;2&quot;&gt;&lt;xref rid=&quot;bib12&quot; ref-type=&quot;bibr&quot;&gt;Chu et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ORF1b&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TGGGGYTTTACRGGTAACCT&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;AACRCGCTTAACAAAGCACTC&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TAGTTGTGATGCWATCATGACTAG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;N&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TAATCAGACAAGGAACTGATTA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CGAAGGTGTGACTTCCATG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GCAAATTGTGCAATTTGCGG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib53&quot; ref-type=&quot;bibr&quot;&gt;Nao et al. (2019)&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;N&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;AAATTTTGGGGACCAGGAAC&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TGGCAGCTGTGTAGGTCAAC&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ATGTCGCGCATTGGCATGGA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot;&gt;&lt;xref rid=&quot;bib28&quot; ref-type=&quot;bibr&quot;&gt;Institute of Pasteur (2020)&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;RdRP&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ATGAGCTTAGTCCTGTTG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CTCCCTTTGTTGTGTTGT&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;AGATGTCTTGTGCTGCCGGTA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;RdRP&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GGTAACTGGTATGATTTCG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CTGGTCAAGGTTAATATAGG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TCATACAAACCACGCCAGG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;E&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ACAGGTACGTTAATAGTTAATAGCGT&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ATATTGCAGCAGTACGCACACA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ACACTAGCCATCCTTACTGCGCTTCG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;2&quot;&gt;&lt;xref rid=&quot;bib11&quot; ref-type=&quot;bibr&quot;&gt;China CDC (2020)&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ORF1ab&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CCCTGTGGGTTTTACACTTAA ACG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ACGATTGTGCATCAGCTGACCG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CCGTCTGCGGTATGTGGAAAGGTTATGG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;N&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GGGGAACTTCTCCTGCTA GAA T&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CAGACATTTTGCTCTCAA GCT G&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TTGCTGCTGCTTGACAGATT&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib74&quot; ref-type=&quot;bibr&quot;&gt;Thailand Ministry of Public Health (2020)&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;N&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CGTTTGGTGGACCCTCAGAT&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CCCCACTGCGTTCTCCATT&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CAACTGGCAGTAACCA&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>17474</offset><text>Table 1\t \t</text></passage><passage><infon key=\"file\">tbl1.xml</infon><infon key=\"id\">tbl1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th&gt;Reference&lt;/th&gt;&lt;th&gt;Genes&lt;/th&gt;&lt;th&gt;Forward Primer&lt;/th&gt;&lt;th&gt;Reverse Primer&lt;/th&gt;&lt;th&gt;Probe Sequence&lt;xref rid=&quot;tbl1fna&quot; ref-type=&quot;table-fn&quot;&gt;a&lt;/xref&gt;&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot;&gt;&lt;xref rid=&quot;bib15&quot; ref-type=&quot;bibr&quot;&gt;Corman et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;RdRP&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GTGARATGGTCATGTGTGGCGG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CARATGTTAAASACACTATTAGCATA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CAGGTGGAACCTCATCAGGAGATGC&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;E&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ACAGGTACGTTAATAGTTAATAGCGT&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ATATTGCAGCAGTACGCACACA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ACACTAGCCATCCTTACTGCGCTTCG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;N&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CACATTGGCACCCGCAATC&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GAGGAACGAGAAGAGGCTTG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ACTTCCTCAAGGAACAACATTGCCA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;2&quot;&gt;&lt;xref rid=&quot;bib64&quot; ref-type=&quot;bibr&quot;&gt;Rao et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ORF1ab&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CCCTGTGGGTTTTACACTTAA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ACGATTGTGCATCAGCTGA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CCGTCTGCG/ZEN/GTATGTGGAAAGGTTATGG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;N&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GGGGAACTTCTCCTGCTAGAAT&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CAGACATTTTGCTCTCAAGCTG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TTGCTGCTGCTTGACAGATT&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;4&quot;&gt;&lt;xref rid=&quot;bib75&quot; ref-type=&quot;bibr&quot;&gt;U.S. Centers for Disease Control and Prevention (2020)&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;RdRP&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;AGATTTGGACCTGCGAGCG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GAGCGGCTGTCTCCACAAGT&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TTCTGACCTGAAGGCTCTGCGCG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;N1&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GACCCCAAAATCAGCGAAAT&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TCTGGTTACTGCCAGTTGAATCTG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ACCCCGCAT/ZEN/TACGTTTGGTGGACC&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;N2&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TTACAAACATTGGCGCAAA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GCGCGACATTCCGAAGAA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ACAATTTGCCCCCAGCGCTTCAG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;N3&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GGGAGCCTTGAATACACCAAAA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TGTAGCACGATTGCAGCATTG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;AYCACATTGGCACCCGCAATCCTG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;2&quot;&gt;&lt;xref rid=&quot;bib12&quot; ref-type=&quot;bibr&quot;&gt;Chu et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ORF1b&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TGGGGYTTTACRGGTAACCT&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;AACRCGCTTAACAAAGCACTC&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TAGTTGTGATGCWATCATGACTAG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;N&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TAATCAGACAAGGAACTGATTA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CGAAGGTGTGACTTCCATG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GCAAATTGTGCAATTTGCGG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib53&quot; ref-type=&quot;bibr&quot;&gt;Nao et al. (2019)&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;N&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;AAATTTTGGGGACCAGGAAC&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TGGCAGCTGTGTAGGTCAAC&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ATGTCGCGCATTGGCATGGA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;3&quot;&gt;&lt;xref rid=&quot;bib28&quot; ref-type=&quot;bibr&quot;&gt;Institute of Pasteur (2020)&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;RdRP&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ATGAGCTTAGTCCTGTTG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CTCCCTTTGTTGTGTTGT&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;AGATGTCTTGTGCTGCCGGTA&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;RdRP&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GGTAACTGGTATGATTTCG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CTGGTCAAGGTTAATATAGG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TCATACAAACCACGCCAGG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;E&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ACAGGTACGTTAATAGTTAATAGCGT&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ATATTGCAGCAGTACGCACACA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ACACTAGCCATCCTTACTGCGCTTCG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; rowspan=&quot;2&quot;&gt;&lt;xref rid=&quot;bib11&quot; ref-type=&quot;bibr&quot;&gt;China CDC (2020)&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ORF1ab&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CCCTGTGGGTTTTACACTTAA ACG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ACGATTGTGCATCAGCTGACCG&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CCGTCTGCGGTATGTGGAAAGGTTATGG&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;N&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;GGGGAACTTCTCCTGCTA GAA T&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CAGACATTTTGCTCTCAA GCT G&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;TTGCTGCTGCTTGACAGATT&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib74&quot; ref-type=&quot;bibr&quot;&gt;Thailand Ministry of Public Health (2020)&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;N&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CGTTTGGTGGACCCTCAGAT&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CCCCACTGCGTTCTCCATT&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;CAACTGGCAGTAACCA&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>17485</offset><text>Reference\tGenes\tForward Primer\tReverse Primer\tProbe Sequencea\t \t\tRdRP\tGTGARATGGTCATGTGTGGCGG\tCARATGTTAAASACACTATTAGCATA\tCAGGTGGAACCTCATCAGGAGATGC\t \tE\tACAGGTACGTTAATAGTTAATAGCGT\tATATTGCAGCAGTACGCACACA\tACACTAGCCATCCTTACTGCGCTTCG\t \tN\tCACATTGGCACCCGCAATC\tGAGGAACGAGAAGAGGCTTG\tACTTCCTCAAGGAACAACATTGCCA\t \t\tORF1ab\tCCCTGTGGGTTTTACACTTAA\tACGATTGTGCATCAGCTGA\tCCGTCTGCG/ZEN/GTATGTGGAAAGGTTATGG\t \tN\tGGGGAACTTCTCCTGCTAGAAT\tCAGACATTTTGCTCTCAAGCTG\tTTGCTGCTGCTTGACAGATT\t \t\tRdRP\tAGATTTGGACCTGCGAGCG\tGAGCGGCTGTCTCCACAAGT\tTTCTGACCTGAAGGCTCTGCGCG\t \tN1\tGACCCCAAAATCAGCGAAAT\tTCTGGTTACTGCCAGTTGAATCTG\tACCCCGCAT/ZEN/TACGTTTGGTGGACC\t \tN2\tTTACAAACATTGGCGCAAA\tGCGCGACATTCCGAAGAA\tACAATTTGCCCCCAGCGCTTCAG\t \tN3\tGGGAGCCTTGAATACACCAAAA\tTGTAGCACGATTGCAGCATTG\tAYCACATTGGCACCCGCAATCCTG\t \t\tORF1b\tTGGGGYTTTACRGGTAACCT\tAACRCGCTTAACAAAGCACTC\tTAGTTGTGATGCWATCATGACTAG\t \tN\tTAATCAGACAAGGAACTGATTA\tCGAAGGTGTGACTTCCATG\tGCAAATTGTGCAATTTGCGG\t \t\tN\tAAATTTTGGGGACCAGGAAC\tTGGCAGCTGTGTAGGTCAAC\tATGTCGCGCATTGGCATGGA\t \t\tRdRP\tATGAGCTTAGTCCTGTTG\tCTCCCTTTGTTGTGTTGT\tAGATGTCTTGTGCTGCCGGTA\t \tRdRP\tGGTAACTGGTATGATTTCG\tCTGGTCAAGGTTAATATAGG\tTCATACAAACCACGCCAGG\t \tE\tACAGGTACGTTAATAGTTAATAGCGT\tATATTGCAGCAGTACGCACACA\tACACTAGCCATCCTTACTGCGCTTCG\t \t\tORF1ab\tCCCTGTGGGTTTTACACTTAA ACG\tACGATTGTGCATCAGCTGACCG\tCCGTCTGCGGTATGTGGAAAGGTTATGG\t \tN\tGGGGAACTTCTCCTGCTA GAA T\tCAGACATTTTGCTCTCAA GCT G\tTTGCTGCTGCTTGACAGATT\t \t\tN\tCGTTTGGTGGACCCTCAGAT\tCCCCACTGCGTTCTCCATT\tCAACTGGCAGTAACCA\t \t</text></passage><passage><infon key=\"file\">tbl1.xml</infon><infon key=\"id\">tbl1</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_footnote</infon><offset>18896</offset><text>All sequences are given in the direction of 5â² to 3â (from left to right). Probe sequences are always labeled with a reporter dye at 5â (usually FAM) and a quencher at the 3â (usually BHQ).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>19094</offset><text>A list of the target genes, corresponding primer, and probe sequences used in RT-PCR kits so far for SARS-CoV-2 detection is presented in Table 1 . WHO also provided a recipe document for in house RT-PCR-based SARS-CoV-2 detection that summarizes the methods from well-known institutions worldwide, including China CDC (China), Institute Pasteur (France), USA CDC (USA), CharitÃ© (Germany), National Institute of Infectious Diseases (Japan), University of Hong Kong (Hong Kong) and National Institute of Health (Thailand). In a recent pre-print study conducted by, the primers â2019-nCoV_N2 and N3â of the USA and the ORF1abâ of China were claimed to be the most sensitive primer-probe sets for detection of N and Orf1 genes, respectively. Another study conducted by suggested that the E-gene primer/probe sets described by and N2 primer-probe set defined by the CDC provided the most sensitive assays. The authors also stated that all the tested primer and probes sets were found to be highly specific for the SARS-CoV-2 genes, and no cross-reactivity with other respiratory viruses was observed. The SARS-COV-2 qRT-PCR primer-probe sets comparison study performed by under identical PCR conditions (not optimized for each set) were in good agreement with the previous findings of the other groups except for the RdRp-SARSr set from CharitÃ©, Germany that had low sensitivity under the specified experimental conditions.</text></passage><passage><infon key=\"file\">tbl2.xml</infon><infon key=\"id\">tbl2</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>20522</offset><text>LabCorp COVID-19 RT-PCR test interpretation-SINGLEPLEX. Reproduced from ref.</text></passage><passage><infon key=\"file\">tbl2.xml</infon><infon key=\"id\">tbl2</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th&gt;SARS-CoV-2 N1 (FAM)&lt;/th&gt;&lt;th&gt;SARS-CoV-2 N2 (FAM)&lt;/th&gt;&lt;th&gt;SARS-CoV-2 N3 (FAM)&lt;/th&gt;&lt;th&gt;RNAse P (FAM)&lt;/th&gt;&lt;th&gt;Interpretation&lt;/th&gt;&lt;th&gt;Report&lt;/th&gt;&lt;th&gt;Actions (Clinical Site Samples)&lt;/th&gt;&lt;th&gt;Actions (Pixel Home Collection Kit samples)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;+&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;+&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;+&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;+/â&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;SARS-CoV-2 detected&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;DETECTED&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Report results to sender and appropriate public health authorities&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Report results to PWN Health, who will call the patient. Report the result to the Pixel portal. Report the result to the appropriate public health authorities&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; align=&quot;left&quot;&gt;If only one target is positive&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;+/â&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;+/â&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;SARS-CoV-2&lt;break/&gt;Indeterminate&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;INDETERMINATE&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The sample is repeated once. If results remain the same, it is reported to the sender as indeterminate and recommend recollection if the patient is still clinically indicated&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The sample is repeated once. If results remain the same, it is reported to the sender as indeterminate to PWN Health, who will call the patient. Report the result to the Pixel Portal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;-&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;-&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;-&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;+&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;SARS-CoV-2 Not Detected&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;NOT DETECTED&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Report results to sender&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Report results to PWN Health and the Pixel Portal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;-&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;-&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;-&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;-&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Invalid Result&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;INVALID&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The sample is repeated once. If a second failure occurs, it is reported to the sender as invalid and recommend recollection if the patient is still clinically indicated&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The sample is repeated once. If a second failure occurs, it is reported to PWN Health. Pixel's customer service will contact the patient to discuss options. Report the result to the Pixel Portal&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>20599</offset><text>Table 2\t \t</text></passage><passage><infon key=\"file\">tbl2.xml</infon><infon key=\"id\">tbl2</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th&gt;SARS-CoV-2 N1 (FAM)&lt;/th&gt;&lt;th&gt;SARS-CoV-2 N2 (FAM)&lt;/th&gt;&lt;th&gt;SARS-CoV-2 N3 (FAM)&lt;/th&gt;&lt;th&gt;RNAse P (FAM)&lt;/th&gt;&lt;th&gt;Interpretation&lt;/th&gt;&lt;th&gt;Report&lt;/th&gt;&lt;th&gt;Actions (Clinical Site Samples)&lt;/th&gt;&lt;th&gt;Actions (Pixel Home Collection Kit samples)&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;+&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;+&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;+&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;+/â&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;SARS-CoV-2 detected&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;DETECTED&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Report results to sender and appropriate public health authorities&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Report results to PWN Health, who will call the patient. Report the result to the Pixel portal. Report the result to the appropriate public health authorities&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; align=&quot;left&quot;&gt;If only one target is positive&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;+/â&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;+/â&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;SARS-CoV-2&lt;break/&gt;Indeterminate&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;INDETERMINATE&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The sample is repeated once. If results remain the same, it is reported to the sender as indeterminate and recommend recollection if the patient is still clinically indicated&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The sample is repeated once. If results remain the same, it is reported to the sender as indeterminate to PWN Health, who will call the patient. Report the result to the Pixel Portal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;-&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;-&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;-&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;+&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;SARS-CoV-2 Not Detected&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;NOT DETECTED&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Report results to sender&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Report results to PWN Health and the Pixel Portal&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;-&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;-&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;-&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;bold&gt;-&lt;/bold&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Invalid Result&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;INVALID&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The sample is repeated once. If a second failure occurs, it is reported to the sender as invalid and recommend recollection if the patient is still clinically indicated&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The sample is repeated once. If a second failure occurs, it is reported to PWN Health. Pixel's customer service will contact the patient to discuss options. Report the result to the Pixel Portal&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>20610</offset><text>SARS-CoV-2 N1 (FAM)\tSARS-CoV-2 N2 (FAM)\tSARS-CoV-2 N3 (FAM)\tRNAse P (FAM)\tInterpretation\tReport\tActions (Clinical Site Samples)\tActions (Pixel Home Collection Kit samples)\t \t+\t+\t+\t+/â\tSARS-CoV-2 detected\tDETECTED\tReport results to sender and appropriate public health authorities\tReport results to PWN Health, who will call the patient. Report the result to the Pixel portal. Report the result to the appropriate public health authorities\t \tIf only one target is positive\t+/â\t+/â\tSARS-CoV-2Indeterminate\tINDETERMINATE\tThe sample is repeated once. If results remain the same, it is reported to the sender as indeterminate and recommend recollection if the patient is still clinically indicated\tThe sample is repeated once. If results remain the same, it is reported to the sender as indeterminate to PWN Health, who will call the patient. Report the result to the Pixel Portal\t \t-\t-\t-\t+\tSARS-CoV-2 Not Detected\tNOT DETECTED\tReport results to sender\tReport results to PWN Health and the Pixel Portal\t \t-\t-\t-\t-\tInvalid Result\tINVALID\tThe sample is repeated once. If a second failure occurs, it is reported to the sender as invalid and recommend recollection if the patient is still clinically indicated\tThe sample is repeated once. If a second failure occurs, it is reported to PWN Health. Pixel's customer service will contact the patient to discuss options. Report the result to the Pixel Portal\t \t</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>22014</offset><text>The commercial kits based on the RT-PCR method are only operated in laboratory conditions equipped with specialized tools and instruments because of the sophisticated nature of the RT-PCR reactions as well as safety reasons. Therefore, it may be challenging to use the RT-PCR kits for rapid surveillance or screening of the nations for the current pandemic. COVID-19 RT-PCR Test kit by Laboratory Corporation of America (LabCorp) was granted an FDA-EUA in mid-March 2020 for the qualitative detection of nucleic acid from SARS-CoV-2 in upper and lower respiratory specimens. Recently, in April 2020, LabCorp requested an amendment for its COVID-19 RT-PCR Test kit to be used with a âhome specimen collection methodâ and received a swift authorization from FDA. Nasal swab specimens now can be self-collected by individuals at home using the âPixel by LabCorp COVID-19 home collection kitâ when found suitable by healthcare personnel following a COVID-19 questionnaire. The COVID-19 RT-PCR Test kit targets three different nucleocapsid proteins from the viral genome (N1, N2 and N3), and it includes a) RNase P (RP) reagents as the internal control, b) an in vitro transcribed SARS-CoV-2 RNA as the positive control, c) a clinically negative patient sample as the negative extraction control and d) nuclease-free, molecular-grade water as the no-template or negative control. On the other hand, the Pixel by LabCorp COVID-19 Test Home Collection Kit contains a shipping box, pre-labeled return FedEx envelope, nasal specimen collection swab, saline tube, insulated specimen pouch, gel pack (for sample cooling), specimen biohazard bag and the user guideline. Appropriately collected home nasal swab sample is placed in the provided saline tube, packaged in the specimen pouch, placed in between the cooling peds, and sent back to the laboratory in the pre-labeled FedEx return envelopes. The test results are provided online and repeated as seen necessary. Still, the home kit is available at limited numbers and only for a limited number of locations, in its current state. In this way, the patients are not required to visit hospitals for regular checks, the frontline healthcare personnel are genuinely protected, and the overloads in the hospitals are reduced, allowing the patients to be tested and screened at their homes. The test has a LOD of 6.2 genomic copy/ul sample and slightly cross-reacts with the SARS-Cov-2 N3 gene, according to the cross-reactivity tests, conducted using in silico analysis, purified nucleic acid extracts or whole organisms. The interpretation of the results is the same for RT-PCR kits, differing by the type of targeted viral gene. The RT-PCR results interpretation table for COVID-19 RT-PCR Single Plex Test kit by is represented in Table 2 , as an example. As can be seen from the table, the test becomes âinvalidâ when all the genes tested negative. The test result becomes âSARS-CoV-2 positiveâ when all the viral N genes are tested positive. If only one target viral gene tests positive, the result is considered âintermediate,â and the sample requires another testing. Finally, the test result becomes âSARS-CoV-2 negativeâ when all the viral N genes are tested negative.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>25253</offset><text>Although the RT-PCR remains to be the most reliable method for SARS-CoV-2 detection so far, only a limited number of tests could be performed each day, which prevents the authorities from obtaining consistent data on the prevalence of the virus in the entire world population. The sensitivity of this method usually depends on the RNA amount in each sample. The patients can be categorized as SARS-CoV-2 positive (active case) or SARS-CoV-2 negative based on the outcome of the RT-PCR results. However, this technique does not give information for the patients who have already recovered from the SARS-CoV-2, since the viral load is cleared out of the body after recovery. Equally, the patients who are in the very first days of the viral infection may not respond âpositiveâ with this test due to the inadequate amount of the virus on the swabs. Therefore, swab samples from different parts of the body may be required for a confirmation test. The development of faster detection kits that do not rely on trained personnel, advanced reactions, or equipped laboratories is of great importance. Antigen tests that target the viral biomarkers such as spike, envelope, or nucleocapsid proteins could be useful to support the current RT-PCR-based systems and accelerate the detection speed worldwide. On the other hand, antibody or serology tests are equally important to see how many people have already had the virus and developed protective antibodies, which may be later used as a databank to survey potential plasma donors for the disease treatment.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_1</infon><offset>26808</offset><text>Antibody detection methods</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>26835</offset><text>An antibody is a protein produced by the immune system in response to an antigen. Each antibody has sites that can bind only one specific type of antigen to remove it from the body. This specificity is determined by Complementary Determining Regions (CDRs), localized on N-terminus of the antibody. Antibodies are also called immunoglobulins (Ig). Five classes of antibodies exist; IgM, IgD, IgG, IgA, and IgE, which are distinguished by C-terminus regions. IgM is the first antibody produced during an infection, while the IgG is the most common and abundant one in serum. Antibodies are secreted in mucosa and blood; here, they neutralize pathogens by binding to and inactivating antigens. Therefore, antibody neutralization prevents the virus from infecting the cells. An antibody test can measure the presence and concentration of IgG and IgM levels in the blood/serum/plasma samples to determine if the body is fighting with a pathogen, for example, a contagious virus. A ârecombinantâ antigen that mimics the virus can be produced in the laboratory, and antibodies with specific target binding affinity can be produced by using these artificial pathogens. The most common antibody tests are based on lateral flow type assays (LFA) and enzyme-linked immunosorbent type assays (ELISA).</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>28129</offset><text>In an LFA, the presence of the molecule(s) of interest is determined by antibodies immobilized onto a membrane. The device is composed of a cassette, enclosing a strip of the polymer membrane, usually containing two lines: a control line and a test line. In an antibody LFA test, the molecules of interest are the specific antibodies present in the patient's blood sample. The sample is deposited onto the sample pad through a port and moves through the strip by capillary action. When it encounters the first line, antibodies labeled with gold nanoparticles bind to the target molecule in the sample. Then as the sample continues to move, the gold-labeled antibodies are bound by the capture antibodies in the lines. The gold-labeled antibodies that are in excess then move further along the strip and are captured at the control line. Even in the absence of the target molecule in the sample solution, the gold-labeled antibodies must be captured at the control line, making the control line for the validity of the test. Depending on whether the test is for IgG- or IgM-class antibodies, or both, the display window should show either one, two, or three stripes. If the test is only for one class of antibody and is negative, it should display one stripe, only at the control line. If the test is positive, it should display two stripes, both at the control line and the test line. If the test is for both antibodies and negative, it should, again, display one stripe at the control line. If it is positive for both, three stripes will be displayed: one at the control line, one at the IgG test line, and one at the IgM test line. Additionally, in an IgG/IgM test, only one antibody may be present, which could be indirect indicators of the course of the infection or direct immune response.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>29924</offset><text>In ELISA tests, the recombinant viral antigen is coated onto the surfaces of plastic wells as the target molecules. Once the wells are prepared, the sample, i.e., the patient's serum, is added to the well. If antibodies (IgG or IgM) against the target antigen are present in the sample, a binding event occurs. The excess sample is washed out several times to ensure all unbound substrate is removed. Then, a second solution containing labeled, secondary anti-human antibodies are added and allowed to bind; if the antibody of interest is absent in the sample, no binding occurs. The excess is again removed by washing, and the binding of target antibodies is confirmed by an enzyme-dependent (usually horseradish peroxidase) color changing reaction. A spectrometer reads the color change, and the concentration of the antibody of interest can be determined. In chemiluminescent immunoassays (CLIA, also called modified-ELISA), the binding of the secondary antibody is confirmed by a separate chemiluminescent substrate.</text></passage><passage><infon key=\"file\">tbl3.xml</infon><infon key=\"id\">tbl3</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>30945</offset><text>The kits cleared a EUA from FDA for SARS-CoV-2 antibody detection. The commercial kit list was retrieved from the FDA website in early May 2020. Instruction for Use (IFU) and Fact Sheet for Healthcare Providers (HCP) documents were also retrieved from the same FDA website.</text></passage><passage><infon key=\"file\">tbl3.xml</infon><infon key=\"id\">tbl3</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th colspan=&quot;4&quot;&gt;The Other Serology Kits&lt;hr/&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th&gt;Supplier&lt;/th&gt;&lt;th&gt;Target Molecules and Kit Name&lt;/th&gt;&lt;th&gt;Sensitivity/Specificity&lt;/th&gt;&lt;th&gt;Country/Use/Reference&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Aytu BioScience, Inc./Orient Gene Biotech.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;IgM and IgG&lt;break/&gt;(COVID-19) IgM/IgG Rapid Test&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The sensitivity of lgM only test is 89.2% (nÂ =Â 112). The specificity is 100% (nÂ =Â 14).&lt;break/&gt;The sensitivity of lgG &amp;amp; IgM test is 91.9% (nÂ =Â 112), and the specificity is 100% (nÂ =Â 14)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;China&lt;break/&gt;For only professional use&lt;break/&gt;&lt;xref rid=&quot;bib5&quot; ref-type=&quot;bibr&quot;&gt;Aytu BioScience Inc, 2020&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;ScanWell Health/INNOVITA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;IgM and IgG&lt;break/&gt;SARS-CoV-2 Rapid Test&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;87.3% sensitivity and 100% specificity in clinical trials&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;China&lt;break/&gt;For use at-home with smartphone readout &lt;xref rid=&quot;bib50&quot; ref-type=&quot;bibr&quot;&gt;Murphy, 2020&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;SD Biosensor, Inc.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;IgM and IgG&lt;break/&gt;Standard Q COVID-19 IgM/IgG Duo Rapid Test&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The positive percent value for IgM/IgG was reported as 98.1% (nÂ =Â 52) for the samples measured following around two weeks of the infection. This percent was increased up10 100% following almost three weeks of the infection. The negative percent value was reported as 96.1&amp;amp; (nÂ =Â 205).&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;South Korea/Point-of-care &lt;xref rid=&quot;bib69&quot; ref-type=&quot;bibr&quot;&gt;SDBiosensor Inc., 2020&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>31219</offset><text>Table 3\t \t</text></passage><passage><infon key=\"file\">tbl3.xml</infon><infon key=\"id\">tbl3</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th colspan=&quot;4&quot;&gt;The Other Serology Kits&lt;hr/&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th&gt;Supplier&lt;/th&gt;&lt;th&gt;Target Molecules and Kit Name&lt;/th&gt;&lt;th&gt;Sensitivity/Specificity&lt;/th&gt;&lt;th&gt;Country/Use/Reference&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Aytu BioScience, Inc./Orient Gene Biotech.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;IgM and IgG&lt;break/&gt;(COVID-19) IgM/IgG Rapid Test&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The sensitivity of lgM only test is 89.2% (nÂ =Â 112). The specificity is 100% (nÂ =Â 14).&lt;break/&gt;The sensitivity of lgG &amp;amp; IgM test is 91.9% (nÂ =Â 112), and the specificity is 100% (nÂ =Â 14)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;China&lt;break/&gt;For only professional use&lt;break/&gt;&lt;xref rid=&quot;bib5&quot; ref-type=&quot;bibr&quot;&gt;Aytu BioScience Inc, 2020&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;ScanWell Health/INNOVITA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;IgM and IgG&lt;break/&gt;SARS-CoV-2 Rapid Test&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;87.3% sensitivity and 100% specificity in clinical trials&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;China&lt;break/&gt;For use at-home with smartphone readout &lt;xref rid=&quot;bib50&quot; ref-type=&quot;bibr&quot;&gt;Murphy, 2020&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;SD Biosensor, Inc.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;IgM and IgG&lt;break/&gt;Standard Q COVID-19 IgM/IgG Duo Rapid Test&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The positive percent value for IgM/IgG was reported as 98.1% (nÂ =Â 52) for the samples measured following around two weeks of the infection. This percent was increased up10 100% following almost three weeks of the infection. The negative percent value was reported as 96.1&amp;amp; (nÂ =Â 205).&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;South Korea/Point-of-care &lt;xref rid=&quot;bib69&quot; ref-type=&quot;bibr&quot;&gt;SDBiosensor Inc., 2020&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>31230</offset><text>Entity/Company\tTargeted Molecules and Kit Name\tDetails\t \tAbbott Laboratories Inc.\tIgG onlySARS-CoV-2 IgG assay\tThe test can be used only in authorized laboratories on Abbott's Architect i1000SR and i2000SR instruments. This platform can run 100â200 tests/hour, being faster than RT-PCR. It is reported that the kit has a sensitivity of 100% and specificity of 99.5% (IFU). The company plans to develop an IgM test too, which would be the 4th product of the company in the market for the COVID-19 diagnosis.\t \tAutobio Diagnostics Co. Ltd.\tIgM and IgGAnti-SARS-CoV-2 Rapid Test\tThis is a rapid LFA test based on a one-step capture protocol. The samples can be taken from serum or plasma. The membrane pads are decorated with anti-Spike, anti-IgM, and IgG antibodies lines, which serve as a control, IgG detection, and IgM detection lines, respectively. The spike protein-coated gold nanoparticles are employed to capture the antibodies and form a reddish color on the pads for fast, visual detection. The protocol implies that the tests are more accurate when used after around 15 days following the infection (IFU). Such a test can be used by individuals since they do not require trained personnel or sophisticated equipment.\t \tDiaSorin Inc.\tIgG onlyLIAISON SARS-CoV-2 S1/S2 IgG\tThis kit is a two-step automated immunoassay for the qualitative detection of anti-SARS-CoV-2 IgG antibodies in serum/plasma samples. The assay is based on chemiluminescent microparticle immunoassay technology (CMIA) in which the particles are functionalized with the SARS-CoV-2 antigens. Further addition of the Anti-human IgG acridinium-labeled conjugate into the incubation medium creates a chemiluminescent signal that is measured as relative light units. The positive percent agreement (PPA) was reported as 100% for 88 clinically validated positive samples that are measured after at least 14 days following the infection, whereas this value was â¤25% when tested in the first week (nÂ =Â 12) (IFU). This test can only be performed at laboratories; however, the sensitivity of the test is high enough to make a decision without further confirmation.\t \tOrtho-Clinical Diagnostics, Inc.\tIgG onlyVITROS Immunodiagnostic Products Anti-SARS-CoV-2 IgG Reagent\tThis two-step kit is performed with Anti-SARS-CoV-2 IgG Reagent Pack, the Anti-SARS-CoV-2 IgG Calibrator on the ECi/ECiQ/3600 Immunodiagnostic Systems and the 5600/XT 7600 Integrated Systems, all available from Ortho-Clinical Diagnostics, Inc. In the first step, anti-SARS-CoV-2 antibodies bind to the wells that are decorated with the virus spike proteins. The wash step removes the unbound molecules from the sample environment, which is followed by the addition of the horseradish-peroxidase-linked anti IgG antibodies. If there is no spike protein-IgG complex in the sample, the second antibody will be cleared off the well with the second washing step. If positive, the addition of a final enzymatic substrate results in a color change that is measured and correlated with the virus presence. The test showed 100% negative agreement (nÂ =Â 407) and 87.5% (nÂ =Â 48) positive agreement (IFU). The positive agreement value of the test is relatively low that probably requires a second confirmatory test.\t \tMount Sinai Laboratory\tIgG onlyCOVID-19 ELISA IgG Antibody Test\tThe ELISA-based test kit is only authorized for use at Mount Sinai Laboratory (New York, USA), certified CLIA (1988, 42 U.S.C. Â§263a), to perform high complexity tests (HCP). The ELISA kits cannot be performed out of laboratory; however, they are both reliable and high throughput and thus a very efficient alternative to the RT-PCR method.\t \tOrtho Clinical Diagnostics, Inc.\tTotal AntibodyVITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack\tThe SARS-CoV-2 Total Antibody kit by Ortho Clinical, Inc. is quite similar to the one other VITROS kit, listed earlier in this table except for the second step, which involves the use of horseradish peroxidase (HRP)-labeled recombinant SARS-CoV-2 antigen instead of horseradish-peroxidase-linked anti IgG antibodies. The clinical agreement of the kit was reported as 100% negative agreement (nÂ =Â 400) and 83.3% positive agreement, which is less than the IgG antibody kit agreement values, provided by the same company (IFU).\t \tChembio Diagnostic System, Inc.\tIgM and IgGDPP COVID-19 IgM/IgG System\tThe DPPÂ® COVID-19 IgM/IgG System is a single-use rapid test (a version of LFA performed on a device for readout) for qualitative IgG and IgM detection in blood, serum, or plasma samples. The platform includes the DPP COVID-19 IgM/IgG Test Devices and the DPP Micro Reader/DPP Micro Reader 2 for use with the kit. For this dual antibody detection platform, the positive agreement was reported as 100% (nÂ =Â 13) for both IgG and IgM (for the samples tested after the first two weeks of the infection). The negative agreements were reported as 100% for IgM and 95.9% for IgG, 95.9% for IgG, and IgM dual test line (nÂ =Â 49) (IFU).\t \tCellex Inc.\tIgM and IgG qSARS-CoV-2 IgG/IgM Rapid Test\tThis test is an LFA that can detect antibodies produced against the new Coronavirus. The cassette includes colloidal gold conjugated- SARS-CoV-2 antigens and rabbit IgG-gold conjugates to be spiked with the actual sample. One of the test lines contains an anti-human IgG antibody for IgG testing; the other one contains anti-human IgM antibodies for IgM detection. The control line contains anti-rabbit IgG antibodies produced in goat and work regardless of the presence of anti-SARS-CoV-2 IgG/IgM antibodies in the sample. The overall clinical agreement values were reported as 93.8% for the positive percent (nÂ =Â 128), and 96% for the negative percent (nÂ =Â 250) (IFU). The clinical agreement values are higher than the previous kits.\t \t</text></passage><passage><infon key=\"file\">tbl3.xml</infon><infon key=\"id\">tbl3</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th colspan=&quot;4&quot;&gt;The Other Serology Kits&lt;hr/&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th&gt;Supplier&lt;/th&gt;&lt;th&gt;Target Molecules and Kit Name&lt;/th&gt;&lt;th&gt;Sensitivity/Specificity&lt;/th&gt;&lt;th&gt;Country/Use/Reference&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Aytu BioScience, Inc./Orient Gene Biotech.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;IgM and IgG&lt;break/&gt;(COVID-19) IgM/IgG Rapid Test&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The sensitivity of lgM only test is 89.2% (nÂ =Â 112). The specificity is 100% (nÂ =Â 14).&lt;break/&gt;The sensitivity of lgG &amp;amp; IgM test is 91.9% (nÂ =Â 112), and the specificity is 100% (nÂ =Â 14)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;China&lt;break/&gt;For only professional use&lt;break/&gt;&lt;xref rid=&quot;bib5&quot; ref-type=&quot;bibr&quot;&gt;Aytu BioScience Inc, 2020&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;ScanWell Health/INNOVITA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;IgM and IgG&lt;break/&gt;SARS-CoV-2 Rapid Test&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;87.3% sensitivity and 100% specificity in clinical trials&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;China&lt;break/&gt;For use at-home with smartphone readout &lt;xref rid=&quot;bib50&quot; ref-type=&quot;bibr&quot;&gt;Murphy, 2020&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;SD Biosensor, Inc.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;IgM and IgG&lt;break/&gt;Standard Q COVID-19 IgM/IgG Duo Rapid Test&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The positive percent value for IgM/IgG was reported as 98.1% (nÂ =Â 52) for the samples measured following around two weeks of the infection. This percent was increased up10 100% following almost three weeks of the infection. The negative percent value was reported as 96.1&amp;amp; (nÂ =Â 205).&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;South Korea/Point-of-care &lt;xref rid=&quot;bib69&quot; ref-type=&quot;bibr&quot;&gt;SDBiosensor Inc., 2020&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>37035</offset><text>The Other Serology Kits\t \tSupplier\tTarget Molecules and Kit Name\tSensitivity/Specificity\tCountry/Use/Reference\t \tAytu BioScience, Inc./Orient Gene Biotech.\tIgM and IgG(COVID-19) IgM/IgG Rapid Test\tThe sensitivity of lgM only test is 89.2% (nÂ =Â 112). The specificity is 100% (nÂ =Â 14).The sensitivity of lgG &amp; IgM test is 91.9% (nÂ =Â 112), and the specificity is 100% (nÂ =Â 14)\tChinaFor only professional use\t \tScanWell Health/INNOVITA\tIgM and IgGSARS-CoV-2 Rapid Test\t87.3% sensitivity and 100% specificity in clinical trials\tChinaFor use at-home with smartphone readout \t \tSD Biosensor, Inc.\tIgM and IgGStandard Q COVID-19 IgM/IgG Duo Rapid Test\tThe positive percent value for IgM/IgG was reported as 98.1% (nÂ =Â 52) for the samples measured following around two weeks of the infection. This percent was increased up10 100% following almost three weeks of the infection. The negative percent value was reported as 96.1&amp; (nÂ =Â 205).\tSouth Korea/Point-of-care \t \t</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>38005</offset><text>As of June 2020, there were only 16 serology tests issued EUA by the FDA, some of which are detailed in Table 3 . All these tests require laboratories that are authorized to perform moderate to high complexity tests or high complexity tests, as specified by the CLIA of 1988. There are, however, six more tests, developed by countries outside the USA, in China and South Korea, two of which, the SARS-CoV-2 Rapid Test by ScanWell Health/INNOVITA and the (COVID-19) IgM/IgG Rapid Test by Aytu BioScience, Inc./Orient Gene Biotech., are waiting for authorization by the FDA. Additionally, several other tests with CE/IVD approval are available for purchase by research labs and, in some cases, healthcare professionals. The CE/IVD approval is a legal requirement for all on-market medical products to aid in patient care and decision making. The authorization is valid within the European Union (EU), European Free Trade Area (EFTA), Switzerland, and Turkey. These companies include Ray Biotech, Eagle Biosciences, Biomedomics, Sanuo Biotech, Shenzhen Yhlo Biotech Company, GenBody, Snibe Co., Liming Bio, BioEasy, Sensing self, Sugentech, Euroimmun AG, and Livzon Diagnostics. There are several more US-based tests approved under the FDA Policy for Diagnostic Tests for Coronavirus Disease-2019, wherein Section IV-A specifies that laboratories authorized under the CLIA of 1988 will be granted EUAs in the absence of significant problems. Section IV-D specifies that FDA plans to not object to the development and distribution of serological tests by commercial manufacturers, as long as proper disclaimers are given and the application of said tests are only in research laboratories or with healthcare professionals at point-of-care. The suggested disclaimers include: the test is not FDA-approved, should not be the only basis for a diagnosis, a positive result may be due to a past coronavirus infection, and that a negative result does not guarantee that the patient is not infected. If the patient has been in contact with the virus, they should undergo molecular testing.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>40084</offset><text>The benefit of an LFA over the ELISA test is that the device can be used at home without training, such as at-home pregnancy tests. ELISA is a diagnostic technique that can be conducted only in laboratories with authorization to perform moderate or high complexity tests, as the protocol involves multistep and long turnaround time and requires skilled personnel and specific instrumentation. These limitations increase the need for point-of-care rapid testing. Therefore Sars-Cov-2 studies have focused on improving the sensitivity and specificity of LFAs. To increase the accuracy, sensitivity, and detection throughput, new approaches are in development, such as signal amplification and multiplexed detection. Especially in resource-poor areas, because of the lack of early diagnosis, many cases remain undifferentiated, and this leads to an uncontrollable spread of the virus. Multiplexed LFAs have become necessary to test multiple biomarkers simultaneously by reducing the reagents, turnaround time, and labor costs. However, both methods suffer from setbacks.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>41152</offset><text>The biggest issue concerning serological tests is cross-reactivity. Cross-reactivity occurs when antibodies bind with an antigen different from the target antigen, often due to the similarities between the molecules. For example, cross-reactivity was observed by Okba et al. for SARS-CoV-2 spike (S) protein with S proteins of SARS-CoV and MERS-CoV. However, no cross-reactivity was observed for the S1 subunit of the spike protein for MERS-CoV. The S2 is more highly conserved among coronaviruses, which could make the S1 subunit a better candidate for serological tests. The biggest issue with this cross-reactivity is that it can lead to false positives: a patient previously infected with SARS-CoV may test positive for SARS-CoV-2, although uninfected. Additionally, because antibodies are developed through the course of an infection, a negative result on an antibody test may not confirm that the patient is uninfected. A majority of patients develop an antibody after around 14 days in response to SARS-CoV-2 infection, while a recent study shows that both IgG and IgM antibodies were detected five days later. This general late response may, therefore, lead to false negatives: where the patient is infected but has not yet produced antibodies at detectable levels. It is, therefore, essential to establish the sensitivity and specificity values of tests to comprehend the possibilities of false positives and false negatives. Sensitivity is the percentage of true positives among all positive results, and the percentage of true negatives among all negative results. On the other hand, due to the late detection of antibodies, serological studies may be retroactively beneficial in vaccine studies, epidemiologic studies, and late complications, where RT-PCR testing may yield false negatives due to shedding or low viral loads in the tested samples. Dr. Edward Wright, senior lecturer in microbiology at the University of Sussex, says that an antibody test cannot tell us who is infected as the antibodies are generated up to two weeks later when the virus should have been cleared from the system. However, it can tell us who developed an immunity to the virus and what proportion of the population has been infected.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_1</infon><offset>43381</offset><text>Antigen detection methods</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>43407</offset><text>An antigen is a particle/fragment/molecule that can trigger the immune system and induce antibody production to kill the pathogens, thereby protecting the body. The antigen tests, unlike PCR-based methods, detect viral components (i.e., S glycoprotein, M protein, or released N protein) or the virus directly without thermal amplification steps. Like the PCR-based methods, antigen tests only reveal the active viral infection, not the recovery situation. Because antigens precede antibodies and are target-specific, they could be more reliable than antibody tests. Antigen tests can be operated on LFA strips for rapid detection purposes or in ELISA format for better sensitivity, and high throughput uses (the simultaneous measurement of 96 samples). Diao et al. developed a fluorescent immunochromatographic LFA assay for detecting the nucleocapsid (N) protein of SARS-CoV-2. The assay utilizes anti-N mouse antibodies and goat anti-rabbit IgG antibodies to create the test and control lines, respectively. It uses anti-N rabbit IgG marked with carboxylate-modified polystyrene Europium (III) chelate microparticles as signal particles, unlike conventional gold nanoparticles. Nasopharyngeal swabs and urine were used as the samples. When compared with nucleic acid testing, the assay was shown to have a sensitivity of 68% and a specificity of 100%. However, such studies are at early research state that it could take years to put into the market even if they present excellent sensitivity and selectivity.</text></passage><passage><infon key=\"file\">tbl4.xml</infon><infon key=\"id\">tbl4</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>44919</offset><text>The antigen tests under development for SARS-CoV-2 detection.</text></passage><passage><infon key=\"file\">tbl4.xml</infon><infon key=\"id\">tbl4</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th&gt;Companies&lt;/th&gt;&lt;th&gt;Target&lt;/th&gt;&lt;th&gt;Method and Possible Outcome&lt;/th&gt;&lt;th&gt;Ref.&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;QUIDEL&lt;xref rid=&quot;tbl4fna&quot; ref-type=&quot;table-fn&quot;&gt;a&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;N protein&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Sofia 2 SARS Antigen Test Kit is based on a sandwich-type immunofluorescence strip technology that is used with an instrument to detect N protein of both SARS-CoV and SARS-CoV-2. The clinical sensitivity of the kit was found as 80%, whereas the specificity was 100% out of 47 positive and 96 negative clinical samples.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib84&quot; ref-type=&quot;bibr&quot;&gt;U.S. Food and Drug Administration, 2020i&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Avacta and Cytiva (formerly GE Healthcare Life Sciences)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;SARS-CoV-2 viral antigens, S glycoproteins&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The developer of AffimerÂ® biotherapeutics and reagents, Avacta Group plc (AIM: AVCT), announced in late April (2020) a collaborative project to develop rapid diagnostic assays for SARS-CoV-2 antigen detection. Affimer bindersÂ® have been produced against S proteins of the SARS-COV-2. The developed affinity reagents are planned to be characterized by Avacta, which then be transferred to Cytiva for employment in strip assays, like those handy pregnancy tests. The affinity agents are reported to be highly specific to the new virus, not to the previous versions (SAR or MERS). The technology will be available as mass testing units as well as strip tests.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib4&quot; ref-type=&quot;bibr&quot;&gt;Avacta Life Sciences Limited (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;OraSure Inc.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;A panel of SARS-CoV-2 viral antigens-not specifically disclosed&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;OraSure Inc. was awarded around USD 700,000 from Biomedical Advanced Research and Development Authority (BARDA) to develop a rapid pan-home test for SARS-CoV-2 detection that could be issued a EUA from FDA as early as September. The test will not require any trained personnel, complex solutions, or instruments and will be available self-testing at home. The platform, based on OraSure's OraQuickÂ® technology, will allow testing in less than half an hour by using oral samples such as saliva. The company had successfully developed an oral-sample-HIV home test previously, which was used by millions around the globe.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib58&quot; ref-type=&quot;bibr&quot;&gt;OraSure (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>44981</offset><text>Table 4\t \t</text></passage><passage><infon key=\"file\">tbl4.xml</infon><infon key=\"id\">tbl4</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th&gt;Companies&lt;/th&gt;&lt;th&gt;Target&lt;/th&gt;&lt;th&gt;Method and Possible Outcome&lt;/th&gt;&lt;th&gt;Ref.&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;QUIDEL&lt;xref rid=&quot;tbl4fna&quot; ref-type=&quot;table-fn&quot;&gt;a&lt;/xref&gt;&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;N protein&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Sofia 2 SARS Antigen Test Kit is based on a sandwich-type immunofluorescence strip technology that is used with an instrument to detect N protein of both SARS-CoV and SARS-CoV-2. The clinical sensitivity of the kit was found as 80%, whereas the specificity was 100% out of 47 positive and 96 negative clinical samples.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib84&quot; ref-type=&quot;bibr&quot;&gt;U.S. Food and Drug Administration, 2020i&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Avacta and Cytiva (formerly GE Healthcare Life Sciences)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;SARS-CoV-2 viral antigens, S glycoproteins&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The developer of AffimerÂ® biotherapeutics and reagents, Avacta Group plc (AIM: AVCT), announced in late April (2020) a collaborative project to develop rapid diagnostic assays for SARS-CoV-2 antigen detection. Affimer bindersÂ® have been produced against S proteins of the SARS-COV-2. The developed affinity reagents are planned to be characterized by Avacta, which then be transferred to Cytiva for employment in strip assays, like those handy pregnancy tests. The affinity agents are reported to be highly specific to the new virus, not to the previous versions (SAR or MERS). The technology will be available as mass testing units as well as strip tests.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib4&quot; ref-type=&quot;bibr&quot;&gt;Avacta Life Sciences Limited (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;OraSure Inc.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;A panel of SARS-CoV-2 viral antigens-not specifically disclosed&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;OraSure Inc. was awarded around USD 700,000 from Biomedical Advanced Research and Development Authority (BARDA) to develop a rapid pan-home test for SARS-CoV-2 detection that could be issued a EUA from FDA as early as September. The test will not require any trained personnel, complex solutions, or instruments and will be available self-testing at home. The platform, based on OraSure's OraQuickÂ® technology, will allow testing in less than half an hour by using oral samples such as saliva. The company had successfully developed an oral-sample-HIV home test previously, which was used by millions around the globe.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib58&quot; ref-type=&quot;bibr&quot;&gt;OraSure (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>44992</offset><text>Companies\tTarget\tMethod and Possible Outcome\tRef.\t \tQUIDELa\tN protein\tSofia 2 SARS Antigen Test Kit is based on a sandwich-type immunofluorescence strip technology that is used with an instrument to detect N protein of both SARS-CoV and SARS-CoV-2. The clinical sensitivity of the kit was found as 80%, whereas the specificity was 100% out of 47 positive and 96 negative clinical samples.\t\t \tAvacta and Cytiva (formerly GE Healthcare Life Sciences)\tSARS-CoV-2 viral antigens, S glycoproteins\tThe developer of AffimerÂ® biotherapeutics and reagents, Avacta Group plc (AIM: AVCT), announced in late April (2020) a collaborative project to develop rapid diagnostic assays for SARS-CoV-2 antigen detection. Affimer bindersÂ® have been produced against S proteins of the SARS-COV-2. The developed affinity reagents are planned to be characterized by Avacta, which then be transferred to Cytiva for employment in strip assays, like those handy pregnancy tests. The affinity agents are reported to be highly specific to the new virus, not to the previous versions (SAR or MERS). The technology will be available as mass testing units as well as strip tests.\t\t \tOraSure Inc.\tA panel of SARS-CoV-2 viral antigens-not specifically disclosed\tOraSure Inc. was awarded around USD 700,000 from Biomedical Advanced Research and Development Authority (BARDA) to develop a rapid pan-home test for SARS-CoV-2 detection that could be issued a EUA from FDA as early as September. The test will not require any trained personnel, complex solutions, or instruments and will be available self-testing at home. The platform, based on OraSure's OraQuickÂ® technology, will allow testing in less than half an hour by using oral samples such as saliva. The company had successfully developed an oral-sample-HIV home test previously, which was used by millions around the globe.\t\t \t</text></passage><passage><infon key=\"file\">tbl4.xml</infon><infon key=\"id\">tbl4</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_footnote</infon><offset>46847</offset><text>Sofia 2 SARS Antigen Test Kit by QUIDEL was received and EUA from FDA in mid-May 2020.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>46934</offset><text>Although ELISA and LFA techniques are well-established, and antigen tests are urgently and immensely needed, there is only one EUA-issued antigen test in the market so far for SARS-COV-2 detection that is âSofia 2 SARS Antigen Test Kitâ developed by QUIDEL. Sofia 2 rapid antigen test kit is based on a sandwich-type immunofluorescence strip technology that is used with an instrument to detect N protein of both SARS-CoV and SARS-CoV-2, meaning that the kit cannot differentiate between these two closely related virus species. Furthermore, the kit utilizes nasal and nasopharyngeal swab samples, and it is only intended to be operated by medical professionals. The clinical sensitivity of the kit was found as 80%, whereas the specificity was 100% out of 47 positive and 96 negative clinical samples. After the failures of several antibody kits, WHO and FDA warned scientific and medical communities on the use of the rapid commercial tests for SARS-CoV-2 detection. The original quote from WHO was as follows: âwith the limited data now available, WHO does not currently recommend the use of antigen-detecting rapid diagnostic tests for patient care, although research into their performance and potential diagnostic utility is highly encouragedâ. Two companies are trying to develop reliable antigen tests. In Table 4 , we briefly covered these future technologies based on the information available from online sources so far. It is for sure that the sensitive and selective rapid antibody/antigen tests will dramatically change the spread of the virus worldwide because they basically can be operated by anyone.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">title_1</infon><offset>48560</offset><text>Other methods</text></passage><passage><infon key=\"file\">tbl5.xml</infon><infon key=\"id\">tbl5</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table_caption</infon><offset>48574</offset><text>Early research stage SARS-COV-2 detection strategies in the literature.</text></passage><passage><infon key=\"file\">tbl5.xml</infon><infon key=\"id\">tbl5</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th&gt;Target&lt;/th&gt;&lt;th&gt;Method&lt;/th&gt;&lt;th&gt;Result&lt;/th&gt;&lt;th&gt;Ref&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;A new framework to predict COVID-19 using onboard smartphone sensors&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Measurement of well-known disease symptoms (fever, fatigue, headache, nausea, dry cough, lung CT imaging features, and shortness of breath) through the sensors already embedded in smartphones (cameras, inertial sensors, microphone, and temperature sensor)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The proposed framework is expected to read the smartphone sensors' signal measurements to predict the grade of severity of pneumonia. Although the sensitivity is still a question, such systems can be useful to monitor and act on mass populations worldwide online.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib45&quot; ref-type=&quot;bibr&quot;&gt;Maghdid et al. (2020b)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;An electrical probe to detect COVID-19 spike protein S1&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Receptor Binding Domain-modified graphene field-effect transistor was used to identify spike proteins&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The sensor can capture S1 protein at a limit of detection down to 0.2 pM, in a real-time and label-free manner. The platform could also be used to screen high-affinity antibodies. Portable electrochemical measurement systems are widely available at low-cost, and thus FET principle may be quickly transformed into a biomedical instrument for on-site diagnosis, especially in rural areas.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib100&quot; ref-type=&quot;bibr&quot;&gt;Zhang et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;An artificial intelligence tool (based on deep learning and transfer learning algorithms) to predict COVID-10 cases&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Collection of X-rays and CT scan images from multiple sources and processing by simple convolution neural network (CNN) and modified the pre-trained Alex Net model.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The constructed models provide accuracy up to 98% via a pre-trained network and 94.1% accuracy by using the modified CNN. Such algorithms can be quite fast and effective for health and regulatory institutions to monitor the pandemic in real-time and obtain fast-track data of individuals who are at risk.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib44&quot; ref-type=&quot;bibr&quot;&gt;Maghdid et al. (2020a)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;A field-effect transistor device for SARS-CoV-2 spike protein detection in clinical samples&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The graphene sheets coated by SARS-CoV-2 spike protein-specific antibodies were used as the transducer for sensing the signal production&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The sensor detected SARS-CoV-2 in culture medium (limit of detection [LOD]: 1.6Â ÃÂ 101Â pfu/mL) and clinical samples (LOD: 2.42Â ÃÂ 102 copies/mL)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib70&quot; ref-type=&quot;bibr&quot;&gt;Seo et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;RT-LAMP-coupled with Nanoparticles are suggested for COVID-19 diagnosing&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The assay is based on two sets of LAMP primers against ORF1ab and N genes of the virus. The assay results were interpreted through the nanoparticles&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The sensitivity was reported as 12 copies/reaction, and no cross-reactivity was generated from non-SARS-CoV-2 templates. The analytical sensitivity was 100% (33/33) in the clinically validated oropharynx swab samples, and the specificity was also 100% (96/96) when analyzed with samples from non-COVID-patients. RT-LAMP has rapidly become an efficient tool for viral gene detection because of faster reaction times and increased sensitivity. These systems can be an alternative to the existent RT-PCR method because RT-LAMP can also be incorporated with LFA technology for individual implementation (please see the previous sections).&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib102&quot; ref-type=&quot;bibr&quot;&gt;Zhu et al., 2020b&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;A microfluidic ELISA technology for rapid (15â20Â min) detection of viral IgG and viral S antigen&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The portable, microfluidic-based ELISA array has 12 channels. The signal intensities of the microfluidic ELISA were measured with the chemiluminescent imaging method, using a CMOS camera. Multiple exposures with adjustable exposure time were applied to enhance the dynamic ranges of the ELISA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;A candidate IgG with a high binding affinity towards the SARS-CoV-2 S1 protein was identified. The microfluidic ELISA platform was used for the detection of anti-S1 monoclonal antibodies. No clinical testing was performed. The current rapid antibody tests are mainly LFA-based, and many of them still rely on instruments for increased sensitivity. Although ELISA is also instrument-dependent, it can give high throughput results with better sensitivity.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib73&quot; ref-type=&quot;bibr&quot;&gt;Tan et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;The selected gene sequences (RdRp, E gene, ORF1ab) from SARS-CoV- through nucleic acid hybridization&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;A dual-functional plasmonic biosensor combining the plasmonic photothermal (PPT) effect and localized surface plasmon resonance (LSPR) was proposed for COVID-19 diagnosis.&lt;break/&gt;The two-dimensional gold nano islands-modified with complementary DNA receptors was used to detect the selected viral sequences&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;A reasonably low detection limit of 0.22 pM was reported. SPR instruments are quite sensitive in general and easy to operate in the laboratories. They only require chip or surface modification by antigens or antibodies. They, therefore, can be a good alternative to current diagnostic tools that are limited by RT-PCR instruments.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib63&quot; ref-type=&quot;bibr&quot;&gt;Qiu et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Reverse transcription loop-mediated isothermal amplification (RT-LAMP) methodology was reported for simultaneous SARS-CoV-2 RNA region detection (ORF1a and N regions)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ORF1a and N gene regions from SARS-CoV-2 RNA were targeted with the RT-LAMP system using China-CDC approved primers&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;45 SARS-CoV-2 positive and 25 negative samples were employed in the study. The dual gene RT-LAMP assay was found to be 95% accurate in detecting positive cases and showed no cross-reactivity or false-positive results in non-COVID- 19 samples&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib7&quot; ref-type=&quot;bibr&quot;&gt;Butt et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;A portable Surface Plasmon Resonance (SPR)-based platform for SARS-CoV-2 specific antibody detection&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The SPR chip surface was modified with the viral N proteins to be able to detect the antibodies against the nucleocapsid proteins of the virus in diluted human serum samples.&lt;break/&gt;An SPR sensor coated with a peptide monolayer and functionalized with SARS-CoV-2 nucleocapsid recombinant protein detected anti-SARS-CoV-2 antibodies in the nanomolar range. This bioassay was performed on a portable.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;SPR instrument used with undiluted human serum samples provided binding affinities in the nanomolar range. The results were collected within 15Â min of sample/sensor contact.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib19&quot; ref-type=&quot;bibr&quot;&gt;Djaileb et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;CRISPR, Cas12-based lateral flow assay for detection of SARS-CoV-2 from RNA extracts.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The platform performs RT-LAMP with RNA samples extracted from nasopharyngeal or oropharyngeal swabs in universal transport media (UTM). Then, selected SARS-CoV-2 sequences are detected by Cas 12 enzyme, and the cleavage of a reporter dye confirms the presence of the virus&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The method was validated by employing contrived reference samples and 40 clinical samples from infected US patients. The results said to be comparable with the US CDC SARS-CoV-2 real-time RT-PCR assay.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib6&quot; ref-type=&quot;bibr&quot;&gt;Broughton et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;SARS-CoV-2 spike protein detection in saliva&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;A built in- house electrochemical measurement platform (eCovSens) was used for the detection. The fluorine-doped tin oxide and the gold nanoparticle (signal amplifier)-based electrode was decorated with anti-spike monoclonal antibodies to monitor the change in the conductivity upon target binding&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The limit of detection was reported as small as 90Â fM for the spiked saliva samples.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib46&quot; ref-type=&quot;bibr&quot;&gt;Mahari et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;One-pot detection of SARS-CoV-2 and&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The assay platform, AIOD-CRISPR, was based on dual CRISPR-Cas12a components and the LAMP principles. The assays were conducted in one pot at one step and one temperature.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The optimized system was able to detect 1.2 copies of DNA targets, and 4.6 copies of RNA targets in 40Â min without the need for a preamplification step.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib18&quot; ref-type=&quot;bibr&quot;&gt;Ding et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;SARS- CoV-2 genome sequences&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Nanopore target sequencing (NTS) platform was developed to detect novel coronavirus as well as previous respiratory viruses in a simultaneous manner in 6â10Â h.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The NTS platform was compared with the approved qPCR for 61 samples from suspected clinical samples. The results demonstrated that the NTS could detect more positive cases. Besides, the mutated sequences can be found along with the other respiratory viruses present in the sample. The sequencing-based virus diagnosis strategies are quite rare but highly needed since the revealed genomic and proteomic elements of the virus form the basis for the current and future diagnosis tools.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;(M.&lt;xref rid=&quot;bib93&quot; ref-type=&quot;bibr&quot;&gt;M. Wang et al., 2020&lt;/xref&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;SARS-CoV-2 nucleic acids: N1, N2, and N3 gene regions&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The diagnosis system was based on the combined use of a portable mini PCR machine and a 96-well plate reader. EvaGreen dye was employed as an intercalator for fluorescent detection of the targeted regions.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The method detected ~625 to 2Â ÃÂ 10&lt;sup&gt;5&lt;/sup&gt; DNA copies through direct PCR amplification, and the signal measurements were performed on a plate reader, which was proposed as a portable alternative for viral gene sequencing.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib24&quot; ref-type=&quot;bibr&quot;&gt;Gonzalez-Gonzalez et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>48646</offset><text>Table 5\t \t</text></passage><passage><infon key=\"file\">tbl5.xml</infon><infon key=\"id\">tbl5</infon><infon key=\"section_type\">TABLE</infon><infon key=\"type\">table</infon><infon key=\"xml\">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;\n",
      "&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th&gt;Target&lt;/th&gt;&lt;th&gt;Method&lt;/th&gt;&lt;th&gt;Result&lt;/th&gt;&lt;th&gt;Ref&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;A new framework to predict COVID-19 using onboard smartphone sensors&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Measurement of well-known disease symptoms (fever, fatigue, headache, nausea, dry cough, lung CT imaging features, and shortness of breath) through the sensors already embedded in smartphones (cameras, inertial sensors, microphone, and temperature sensor)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The proposed framework is expected to read the smartphone sensors' signal measurements to predict the grade of severity of pneumonia. Although the sensitivity is still a question, such systems can be useful to monitor and act on mass populations worldwide online.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib45&quot; ref-type=&quot;bibr&quot;&gt;Maghdid et al. (2020b)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;An electrical probe to detect COVID-19 spike protein S1&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Receptor Binding Domain-modified graphene field-effect transistor was used to identify spike proteins&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The sensor can capture S1 protein at a limit of detection down to 0.2 pM, in a real-time and label-free manner. The platform could also be used to screen high-affinity antibodies. Portable electrochemical measurement systems are widely available at low-cost, and thus FET principle may be quickly transformed into a biomedical instrument for on-site diagnosis, especially in rural areas.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib100&quot; ref-type=&quot;bibr&quot;&gt;Zhang et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;An artificial intelligence tool (based on deep learning and transfer learning algorithms) to predict COVID-10 cases&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Collection of X-rays and CT scan images from multiple sources and processing by simple convolution neural network (CNN) and modified the pre-trained Alex Net model.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The constructed models provide accuracy up to 98% via a pre-trained network and 94.1% accuracy by using the modified CNN. Such algorithms can be quite fast and effective for health and regulatory institutions to monitor the pandemic in real-time and obtain fast-track data of individuals who are at risk.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib44&quot; ref-type=&quot;bibr&quot;&gt;Maghdid et al. (2020a)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;A field-effect transistor device for SARS-CoV-2 spike protein detection in clinical samples&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The graphene sheets coated by SARS-CoV-2 spike protein-specific antibodies were used as the transducer for sensing the signal production&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The sensor detected SARS-CoV-2 in culture medium (limit of detection [LOD]: 1.6Â ÃÂ 101Â pfu/mL) and clinical samples (LOD: 2.42Â ÃÂ 102 copies/mL)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib70&quot; ref-type=&quot;bibr&quot;&gt;Seo et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;RT-LAMP-coupled with Nanoparticles are suggested for COVID-19 diagnosing&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The assay is based on two sets of LAMP primers against ORF1ab and N genes of the virus. The assay results were interpreted through the nanoparticles&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The sensitivity was reported as 12 copies/reaction, and no cross-reactivity was generated from non-SARS-CoV-2 templates. The analytical sensitivity was 100% (33/33) in the clinically validated oropharynx swab samples, and the specificity was also 100% (96/96) when analyzed with samples from non-COVID-patients. RT-LAMP has rapidly become an efficient tool for viral gene detection because of faster reaction times and increased sensitivity. These systems can be an alternative to the existent RT-PCR method because RT-LAMP can also be incorporated with LFA technology for individual implementation (please see the previous sections).&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib102&quot; ref-type=&quot;bibr&quot;&gt;Zhu et al., 2020b&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;A microfluidic ELISA technology for rapid (15â20Â min) detection of viral IgG and viral S antigen&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The portable, microfluidic-based ELISA array has 12 channels. The signal intensities of the microfluidic ELISA were measured with the chemiluminescent imaging method, using a CMOS camera. Multiple exposures with adjustable exposure time were applied to enhance the dynamic ranges of the ELISA&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;A candidate IgG with a high binding affinity towards the SARS-CoV-2 S1 protein was identified. The microfluidic ELISA platform was used for the detection of anti-S1 monoclonal antibodies. No clinical testing was performed. The current rapid antibody tests are mainly LFA-based, and many of them still rely on instruments for increased sensitivity. Although ELISA is also instrument-dependent, it can give high throughput results with better sensitivity.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib73&quot; ref-type=&quot;bibr&quot;&gt;Tan et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;The selected gene sequences (RdRp, E gene, ORF1ab) from SARS-CoV- through nucleic acid hybridization&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;A dual-functional plasmonic biosensor combining the plasmonic photothermal (PPT) effect and localized surface plasmon resonance (LSPR) was proposed for COVID-19 diagnosis.&lt;break/&gt;The two-dimensional gold nano islands-modified with complementary DNA receptors was used to detect the selected viral sequences&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;A reasonably low detection limit of 0.22 pM was reported. SPR instruments are quite sensitive in general and easy to operate in the laboratories. They only require chip or surface modification by antigens or antibodies. They, therefore, can be a good alternative to current diagnostic tools that are limited by RT-PCR instruments.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib63&quot; ref-type=&quot;bibr&quot;&gt;Qiu et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;Reverse transcription loop-mediated isothermal amplification (RT-LAMP) methodology was reported for simultaneous SARS-CoV-2 RNA region detection (ORF1a and N regions)&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;ORF1a and N gene regions from SARS-CoV-2 RNA were targeted with the RT-LAMP system using China-CDC approved primers&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;45 SARS-CoV-2 positive and 25 negative samples were employed in the study. The dual gene RT-LAMP assay was found to be 95% accurate in detecting positive cases and showed no cross-reactivity or false-positive results in non-COVID- 19 samples&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib7&quot; ref-type=&quot;bibr&quot;&gt;Butt et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;A portable Surface Plasmon Resonance (SPR)-based platform for SARS-CoV-2 specific antibody detection&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The SPR chip surface was modified with the viral N proteins to be able to detect the antibodies against the nucleocapsid proteins of the virus in diluted human serum samples.&lt;break/&gt;An SPR sensor coated with a peptide monolayer and functionalized with SARS-CoV-2 nucleocapsid recombinant protein detected anti-SARS-CoV-2 antibodies in the nanomolar range. This bioassay was performed on a portable.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;SPR instrument used with undiluted human serum samples provided binding affinities in the nanomolar range. The results were collected within 15Â min of sample/sensor contact.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib19&quot; ref-type=&quot;bibr&quot;&gt;Djaileb et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;CRISPR, Cas12-based lateral flow assay for detection of SARS-CoV-2 from RNA extracts.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The platform performs RT-LAMP with RNA samples extracted from nasopharyngeal or oropharyngeal swabs in universal transport media (UTM). Then, selected SARS-CoV-2 sequences are detected by Cas 12 enzyme, and the cleavage of a reporter dye confirms the presence of the virus&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The method was validated by employing contrived reference samples and 40 clinical samples from infected US patients. The results said to be comparable with the US CDC SARS-CoV-2 real-time RT-PCR assay.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib6&quot; ref-type=&quot;bibr&quot;&gt;Broughton et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;SARS-CoV-2 spike protein detection in saliva&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;A built in- house electrochemical measurement platform (eCovSens) was used for the detection. The fluorine-doped tin oxide and the gold nanoparticle (signal amplifier)-based electrode was decorated with anti-spike monoclonal antibodies to monitor the change in the conductivity upon target binding&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The limit of detection was reported as small as 90Â fM for the spiked saliva samples.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib46&quot; ref-type=&quot;bibr&quot;&gt;Mahari et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;One-pot detection of SARS-CoV-2 and&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The assay platform, AIOD-CRISPR, was based on dual CRISPR-Cas12a components and the LAMP principles. The assays were conducted in one pot at one step and one temperature.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The optimized system was able to detect 1.2 copies of DNA targets, and 4.6 copies of RNA targets in 40Â min without the need for a preamplification step.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib18&quot; ref-type=&quot;bibr&quot;&gt;Ding et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;SARS- CoV-2 genome sequences&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;Nanopore target sequencing (NTS) platform was developed to detect novel coronavirus as well as previous respiratory viruses in a simultaneous manner in 6â10Â h.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The NTS platform was compared with the approved qPCR for 61 samples from suspected clinical samples. The results demonstrated that the NTS could detect more positive cases. Besides, the mutated sequences can be found along with the other respiratory viruses present in the sample. The sequencing-based virus diagnosis strategies are quite rare but highly needed since the revealed genomic and proteomic elements of the virus form the basis for the current and future diagnosis tools.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;(M.&lt;xref rid=&quot;bib93&quot; ref-type=&quot;bibr&quot;&gt;M. Wang et al., 2020&lt;/xref&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot;&gt;SARS-CoV-2 nucleic acids: N1, N2, and N3 gene regions&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The diagnosis system was based on the combined use of a portable mini PCR machine and a 96-well plate reader. EvaGreen dye was employed as an intercalator for fluorescent detection of the targeted regions.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;The method detected ~625 to 2Â ÃÂ 10&lt;sup&gt;5&lt;/sup&gt; DNA copies through direct PCR amplification, and the signal measurements were performed on a plate reader, which was proposed as a portable alternative for viral gene sequencing.&lt;/td&gt;&lt;td align=&quot;left&quot;&gt;&lt;xref rid=&quot;bib24&quot; ref-type=&quot;bibr&quot;&gt;Gonzalez-Gonzalez et al. (2020)&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;\n",
      "</infon><offset>48657</offset><text>Target\tMethod\tResult\tRef\t \tA new framework to predict COVID-19 using onboard smartphone sensors\tMeasurement of well-known disease symptoms (fever, fatigue, headache, nausea, dry cough, lung CT imaging features, and shortness of breath) through the sensors already embedded in smartphones (cameras, inertial sensors, microphone, and temperature sensor)\tThe proposed framework is expected to read the smartphone sensors' signal measurements to predict the grade of severity of pneumonia. Although the sensitivity is still a question, such systems can be useful to monitor and act on mass populations worldwide online.\t\t \tAn electrical probe to detect COVID-19 spike protein S1\tReceptor Binding Domain-modified graphene field-effect transistor was used to identify spike proteins\tThe sensor can capture S1 protein at a limit of detection down to 0.2 pM, in a real-time and label-free manner. The platform could also be used to screen high-affinity antibodies. Portable electrochemical measurement systems are widely available at low-cost, and thus FET principle may be quickly transformed into a biomedical instrument for on-site diagnosis, especially in rural areas.\t\t \tAn artificial intelligence tool (based on deep learning and transfer learning algorithms) to predict COVID-10 cases\tCollection of X-rays and CT scan images from multiple sources and processing by simple convolution neural network (CNN) and modified the pre-trained Alex Net model.\tThe constructed models provide accuracy up to 98% via a pre-trained network and 94.1% accuracy by using the modified CNN. Such algorithms can be quite fast and effective for health and regulatory institutions to monitor the pandemic in real-time and obtain fast-track data of individuals who are at risk.\t\t \tA field-effect transistor device for SARS-CoV-2 spike protein detection in clinical samples\tThe graphene sheets coated by SARS-CoV-2 spike protein-specific antibodies were used as the transducer for sensing the signal production\tThe sensor detected SARS-CoV-2 in culture medium (limit of detection [LOD]: 1.6Â ÃÂ 101Â pfu/mL) and clinical samples (LOD: 2.42Â ÃÂ 102 copies/mL)\t\t \tRT-LAMP-coupled with Nanoparticles are suggested for COVID-19 diagnosing\tThe assay is based on two sets of LAMP primers against ORF1ab and N genes of the virus. The assay results were interpreted through the nanoparticles\tThe sensitivity was reported as 12 copies/reaction, and no cross-reactivity was generated from non-SARS-CoV-2 templates. The analytical sensitivity was 100% (33/33) in the clinically validated oropharynx swab samples, and the specificity was also 100% (96/96) when analyzed with samples from non-COVID-patients. RT-LAMP has rapidly become an efficient tool for viral gene detection because of faster reaction times and increased sensitivity. These systems can be an alternative to the existent RT-PCR method because RT-LAMP can also be incorporated with LFA technology for individual implementation (please see the previous sections).\t\t \tA microfluidic ELISA technology for rapid (15â20Â min) detection of viral IgG and viral S antigen\tThe portable, microfluidic-based ELISA array has 12 channels. The signal intensities of the microfluidic ELISA were measured with the chemiluminescent imaging method, using a CMOS camera. Multiple exposures with adjustable exposure time were applied to enhance the dynamic ranges of the ELISA\tA candidate IgG with a high binding affinity towards the SARS-CoV-2 S1 protein was identified. The microfluidic ELISA platform was used for the detection of anti-S1 monoclonal antibodies. No clinical testing was performed. The current rapid antibody tests are mainly LFA-based, and many of them still rely on instruments for increased sensitivity. Although ELISA is also instrument-dependent, it can give high throughput results with better sensitivity.\t\t \tThe selected gene sequences (RdRp, E gene, ORF1ab) from SARS-CoV- through nucleic acid hybridization\tA dual-functional plasmonic biosensor combining the plasmonic photothermal (PPT) effect and localized surface plasmon resonance (LSPR) was proposed for COVID-19 diagnosis.The two-dimensional gold nano islands-modified with complementary DNA receptors was used to detect the selected viral sequences\tA reasonably low detection limit of 0.22 pM was reported. SPR instruments are quite sensitive in general and easy to operate in the laboratories. They only require chip or surface modification by antigens or antibodies. They, therefore, can be a good alternative to current diagnostic tools that are limited by RT-PCR instruments.\t\t \tReverse transcription loop-mediated isothermal amplification (RT-LAMP) methodology was reported for simultaneous SARS-CoV-2 RNA region detection (ORF1a and N regions)\tORF1a and N gene regions from SARS-CoV-2 RNA were targeted with the RT-LAMP system using China-CDC approved primers\t45 SARS-CoV-2 positive and 25 negative samples were employed in the study. The dual gene RT-LAMP assay was found to be 95% accurate in detecting positive cases and showed no cross-reactivity or false-positive results in non-COVID- 19 samples\t\t \tA portable Surface Plasmon Resonance (SPR)-based platform for SARS-CoV-2 specific antibody detection\tThe SPR chip surface was modified with the viral N proteins to be able to detect the antibodies against the nucleocapsid proteins of the virus in diluted human serum samples.An SPR sensor coated with a peptide monolayer and functionalized with SARS-CoV-2 nucleocapsid recombinant protein detected anti-SARS-CoV-2 antibodies in the nanomolar range. This bioassay was performed on a portable.\tSPR instrument used with undiluted human serum samples provided binding affinities in the nanomolar range. The results were collected within 15Â min of sample/sensor contact.\t\t \tCRISPR, Cas12-based lateral flow assay for detection of SARS-CoV-2 from RNA extracts.\tThe platform performs RT-LAMP with RNA samples extracted from nasopharyngeal or oropharyngeal swabs in universal transport media (UTM). Then, selected SARS-CoV-2 sequences are detected by Cas 12 enzyme, and the cleavage of a reporter dye confirms the presence of the virus\tThe method was validated by employing contrived reference samples and 40 clinical samples from infected US patients. The results said to be comparable with the US CDC SARS-CoV-2 real-time RT-PCR assay.\t\t \tSARS-CoV-2 spike protein detection in saliva\tA built in- house electrochemical measurement platform (eCovSens) was used for the detection. The fluorine-doped tin oxide and the gold nanoparticle (signal amplifier)-based electrode was decorated with anti-spike monoclonal antibodies to monitor the change in the conductivity upon target binding\tThe limit of detection was reported as small as 90Â fM for the spiked saliva samples.\t\t \tOne-pot detection of SARS-CoV-2 and\tThe assay platform, AIOD-CRISPR, was based on dual CRISPR-Cas12a components and the LAMP principles. The assays were conducted in one pot at one step and one temperature.\tThe optimized system was able to detect 1.2 copies of DNA targets, and 4.6 copies of RNA targets in 40Â min without the need for a preamplification step.\t\t \tSARS- CoV-2 genome sequences\tNanopore target sequencing (NTS) platform was developed to detect novel coronavirus as well as previous respiratory viruses in a simultaneous manner in 6â10Â h.\tThe NTS platform was compared with the approved qPCR for 61 samples from suspected clinical samples. The results demonstrated that the NTS could detect more positive cases. Besides, the mutated sequences can be found along with the other respiratory viruses present in the sample. The sequencing-based virus diagnosis strategies are quite rare but highly needed since the revealed genomic and proteomic elements of the virus form the basis for the current and future diagnosis tools.\t(M.)\t \tSARS-CoV-2 nucleic acids: N1, N2, and N3 gene regions\tThe diagnosis system was based on the combined use of a portable mini PCR machine and a 96-well plate reader. EvaGreen dye was employed as an intercalator for fluorescent detection of the targeted regions.\tThe method detected ~625 to 2Â ÃÂ 105 DNA copies through direct PCR amplification, and the signal measurements were performed on a plate reader, which was proposed as a portable alternative for viral gene sequencing.\t\t \t</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>56963</offset><text>The prompt testing of the SARS-CoV-2 is a subject of the emergency as the virus is continuing to spread. It would be a tremendous help to fight against the virus if a precise and rapid test was developed since the methods based on rapid antibody and antigens tests are still in question regarding their accuracy and selectivity worldwide. The researchers all around the globe have been thriving to develop a test that could deliver fast and accurate results, without compromising the sensitivity and selectivity. In this subsection, some of the novel research-stage methods proposed for SARS-CoV-2 detection in the literature were elaborated. The content is also summarized in Table 5 for a quick review of the procedures and the outcomes. So far, many of the published methods have relied on field-effect transistors (FET) and surface plasmon resonance (SPR) principles that are known to deliver fast and sensitive signals. SPR principle is based on the collective oscillation of electrons on a given noble metal surface, and it is commonly used to monitor molecular interactions in proximity between protein-protein, protein-DNA, protein-RNA, antigen-antibody, enzyme-substrate samples in real-time, with high sensitivity. The SPR method proposed by Djaileb et al. was based on the gold chips modified by the viral nucleocapsid proteins, and it detected the antibodies in diluted human serum samples in 15Â min with nanomolar sensitivity, but no clinical testing was performed. The system was also utilized to fast screen some potential antibody candidates that showed the best binding affinity against the immobilized nucleocapsid proteins. Another SPR study, based on plasmonic photothermal effect (PPT) and localized surface plasmon resonance (LSPR), was published by Qui et al. in which the gold nanoparticles were decorated with oligonucleotides that were complementary to the selected viral gene regions. The dual-function system successfully detected the RdRp gene, E gene, ORF1a gene regions with picomolar sensitivity. SPR systems are now widely available in laboratories, and especially the ones with automated handling systems can analyze several samples without human interference. The system works in real-time and gives reliable results in minutes on the antigen or antibody-modified surfaces in minutes. Therefore, SPR can be considered an alternative testing station to laboratory-based antigen and antibody kits for faster diagnosis of the clinical samples.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>59440</offset><text>Graphene has been a vital component of FET-based label-free sensors for the last decade based on the key properties, such as optical transparency, electrical conductivity, robust pi-interactions with macromolecules and tuneability, rivaling the similar materials in the field. In FET-based biosensors, biological molecules change the charge distribution of the surface, or they induce a surface potential by binding to the surface, which is then measured as a conductance value with high sensitivity. In the study conducted by Seo et al., the graphene sheets coated by SARS-CoV-2 spike protein-specific antibodies were used as the active surface for monitoring the signal production out of viral protein binding. The platform achieved a limit of the detection value of 242 copies/mL of in clinical samples, which is like the ones obtained in standard RT-PCR setups (around five genomic copies/ul). Another electrical probe was reported by Zhang et al., where the FET surface was modified with the receptor binding domain to be able to detect viral S glycoprotein. The platform showed an excellent sensitivity down to the picomolar level in real-time and without specific labels. Graphene-based commercial electrodes have become common in many laboratories specialized in electrochemical techniques. Because the suggested sensing strategies are based on simple surface modification of the graphene electrodes, many of the viral antigens are antibodies have become commercially available, portable electrochemical detection systems are available, such research-wise tools can be quickly converted into biomedical instruments for field use after clinical validations.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>61105</offset><text>Loop-mediated isothermal amplification (LAMP), on the other hand, is another tool being developed for rapid SARS-CoV-2 detection. LAMP is a cost-effective alternative to standard PCR since it does not require expensive thermocycler instruments that operate alternating temperatures for the amplification. The method can synthesize up to 109 copies of the target gene in less than an hour. All the amplification reaction is processed in one single tube at around 60â65Â Â°C by using two or three different gene-specific primer sets and strand-displacement polymerase enzymes. Magnesium pyrophosphate byproduct is formed during the amplification process, which can be measured by the naked eye or simple analytical devices, such as turbidimetry or photometry, for increased sensitivity. Dye molecules could also be employed in the reaction for selective quantitative detection of the target genes as well as the data correlation purposes. Compared to PCR, a finely-tuned LAMP test could be faster and more sensitive to rapid testing. Reverse Transcription LAMP (RT-LAMP) applies an additional transcription step for the detection of RNA targets. So far, only one RT-LAMP-based kit, âSherlockTM CRISPR SARS-CoV-2 kit developed by Sherlock Biosciences, Inc., has received and EUA from FDA. The Sherlock kit is designed to target ORF1ab, N, and RP genes, the third being the internal extraction control gene.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>62513</offset><text>Likewise, Butt et al. reported an RT-LAMP assay for the simultaneous detection of ORF1a and N genes. The test showed 95% accuracy in clinically validated positive samples (nÂ =Â 45), whereas no cross-reactivity was observed with any of the clinically validated negative samples (nÂ =Â 25). Similarly, a nanoparticle-based RT-LAMP assay was reported to be 100% accurate in clinically validated oropharynx swab samples (nÂ =Â 33), and the specificity was again 100% with the negative clinical samples (nÂ =Â 96) tested. The analytical tools that rely on the LAMP principle for SARS-CoV-2 detection, however, may give âfalse negativeâ results for the patients who passed the infection and improved already (similar to RT-PCR). Hence, the researchers are now fine-tuning the current models to improve the test sensitivity as well as the specificity, mainly by decreasing the required viral load for more reliable testing.</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>63435</offset><text>Based on a previously established âID NOW rapid detectionâ technology, Abbott Inc. has developed an âAbbott ID NOW COVID-19â test kit for SARS-COV-2 detection using LAMP principles and cleared a EUA from FDA in late March 2020. The new Abbott ID NOW COVID-19 test is operated on a small instrument that could perform around 50,000 tests per day, giving results only in five minutes per sample. This technology has been the fastest rapid diagnostic tool so far that issued and EUA from the FDA and sold out in thousands in the USA. Combined with the RealTime SARS-CoV-2 platform, Abbott plans to deliver around 5 million tests in late April 2020.</text></passage><passage><infon key=\"file\">gr3_lrg.jpg</infon><infon key=\"id\">fig3</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig_caption</infon><offset>64089</offset><text>(a) Illustration of the method workflow. Standard RNA extraction solution or original sample matrix can be used as an input to detect E, N, and RNase P genes. The assay is monitored by a fluorescent reader or lateral flow strip. (b) Lateral flow readout of SARS-CoV-2 positive sample. Detection of at least two genes is necessary for positive sample confirmation. Reproduced from ref.</text></passage><passage><infon key=\"file\">gr3_lrg.jpg</infon><infon key=\"id\">fig3</infon><infon key=\"section_type\">FIG</infon><infon key=\"type\">fig</infon><offset>64474</offset><text>Fig. 3</text></passage><passage><infon key=\"section_type\">METHODS</infon><infon key=\"type\">paragraph</infon><offset>64481</offset><text>A sophisticated method, combining RT-LAMP, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and LFA principles in one assay was reported by a group of scientists from Mammoth Biosciences Inc., University of California, Abbott Viral Diagnostics and Discovery Inc. and Center California Department of Public Health. As represented in Fig. 3 , the method named âSARS-CoV-2 DETECTRâ processes the extracted RNA samples (10Â min) first with RT-PCR to increase the copy numbers of the selected E, N, and RNAse P genes in the sample solution (62Â Â°C for 20). Second, the CRISPR-Cas 12 enzyme takes the role and detect the genomic copies from the specified sequences, producing a fluorescent signal because of the reporter dye cleavage (37Â Â°C for 10Â min). The optimized assay was tested on 11 respiratory swab samples from patients with COVID-19 infection and 12 swab samples from patients with influenza. SARS-CoV-2 DETECTR was found 90% sensitive and 100% specific for SARS-COV-2 detection, which was reported to be relative to CDC qRT-PCR standard assay values. It was also indicated that the primer-probe set designed for the N2 gene was able to distinguish SARS-CoV-2 from SARS-CoV and MERS-CoV at a single nucleotide level. The group is focusing on validating the assay with clinical samples to be able to receive a EUA from the FDA.</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">title_1</infon><offset>65839</offset><text>Conclusion</text></passage><passage><infon key=\"section_type\">CONCL</infon><infon key=\"type\">paragraph</infon><offset>65850</offset><text>The COVID-19 pandemic has proven the worth of rapid diagnostics. As comprehensively reviewed in this paper (based on the information available so far), the detection of the viral genomic regions has been almost solely dependent on the RT-PCR method, or molecular tests in general. Rapid antibody (serology) tests are certainly needed for vast immune screening, but they do not confirm the presence of the virus. The antigen tests are currently under development, and it would take some time to develop a very accurate one since the virus is mutating without control. Despite the unprecedented collective effort put by the researchers into developing sensitive, selective and rapid test kits, still, only a small portion of the world population has been tested by now, and the testing priority has been understandably given to those who show the severe clinical symptoms of the disease as well as the frontline healthcare providers. As a result, the total lockdown, mask use, and social distancing have become the most effective practice to prevent the spread of the disease and overload in pandemic clinics. The global fight against COVID-19 could be a long one until we develop effective and clinically validated treatments above and beyond the vaccines. Until then, analytical experts and antigen/antibody manufacturers must focus on the development of self-testing home kits to be able to see the real extent and progress of the disease worldwide and act accordingly.</text></passage><passage><infon key=\"section_type\">AUTH_CONT</infon><infon key=\"type\">title_1</infon><offset>67321</offset><text>Author contributions</text></passage><passage><infon key=\"section_type\">AUTH_CONT</infon><infon key=\"type\">paragraph</infon><offset>67342</offset><text>Elif Filiztekin and Korin Gasia Ãzkaya equally contributed to this work and listed alphabetically.</text></passage><passage><infon key=\"section_type\">AUTH_CONT</infon><infon key=\"type\">title_1</infon><offset>67442</offset><text>CRediT authorship contribution statement</text></passage><passage><infon key=\"section_type\">AUTH_CONT</infon><infon key=\"type\">paragraph</infon><offset>67483</offset><text> Meral YÃ¼ce: Writing - original draft, Designed the paper, wrote and revised all sections. Elif Filiztekin: contributed to a part of the antibody detection methods section, equally contributed to this work and listed alphabetically. Korin Gasia Ãzkaya: contributed to a part of the antibody detection methods section, equally contributed to this work and listed alphabetically.</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">title_1</infon><offset>67863</offset><text>Declaration of competing interest</text></passage><passage><infon key=\"section_type\">COMP_INT</infon><infon key=\"type\">paragraph</infon><offset>67897</offset><text>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">title</infon><offset>68068</offset><text>References</text></passage><passage><infon key=\"comment\">[WWW Document] accessed 4.25.20</infon><infon key=\"element-citation\">https://www.molecular.abbott/us/en/products/infectious-disease/RealTime-SARS-CoV-2-Assay</infon><infon key=\"name_0\">surname:Abbott</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68079</offset></passage><passage><infon key=\"comment\">[WWW Document] accessed 4.29.20</infon><infon key=\"element-citation\">https://www.abbott.com/corpnewsroom/product-and-innovation/detect-covid-19-in-as-little-as-5-minutes.html</infon><infon key=\"name_0\">surname:Abbott</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68080</offset></passage><passage><infon key=\"comment\">[WWW Document] accessed 4.26.20</infon><infon key=\"element-citation\">https://www.aruplab.com/news/4-16-2020/antibody-testing-rollout</infon><infon key=\"name_0\">surname:A</infon><infon key=\"name_1\">surname:RUP Laboratories</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68081</offset></passage><passage><infon key=\"comment\">[WWW Document] accessed 4.29.20</infon><infon key=\"element-citation\">https://avacta.com/avacta-cytiva-partnership-ahead-of-schedule/</infon><infon key=\"name_0\">surname:Avacta Life Sciences Limited</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68082</offset></passage><passage><infon key=\"comment\">[WWW Document]</infon><infon key=\"element-citation\">https://www.accesswire.com/579898/Aytu-BioScience-Secures-Exclusive-US-DistributionAgreement-for-Coronavirus-2019-COVID-19-Point-of-Care-Rapid-Test</infon><infon key=\"name_0\">surname:Aytu BioScience Inc</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68083</offset></passage><passage><infon key=\"comment\">medRxiv 2020.3.6.20032334</infon><infon key=\"name_0\">surname:Broughton;given-names:J.P.</infon><infon key=\"name_1\">surname:Deng;given-names:X.</infon><infon key=\"name_10\">surname:Hsu;given-names:E.</infon><infon key=\"name_11\">surname:Gu;given-names:W.</infon><infon key=\"name_12\">surname:Miller;given-names:S.</infon><infon key=\"name_13\">surname:Pan;given-names:C.</infon><infon key=\"name_14\">surname:Guevara;given-names:H.</infon><infon key=\"name_15\">surname:Wadford;given-names:D.A.</infon><infon key=\"name_16\">surname:Chen;given-names:J.S.</infon><infon key=\"name_17\">surname:Chiu;given-names:C.Y.</infon><infon key=\"name_18\">surname:Servellita;given-names:V.</infon><infon key=\"name_19\">surname:Singh;given-names:J.</infon><infon key=\"name_2\">surname:Yu;given-names:G.</infon><infon key=\"name_20\">surname:Miao;given-names:X.</infon><infon key=\"name_21\">surname:Streithorst;given-names:J.A.</infon><infon key=\"name_22\">surname:Granados;given-names:A.</infon><infon key=\"name_23\">surname:Sotomayor-Gonzalez;given-names:A.</infon><infon key=\"name_24\">surname:Zorn;given-names:K.</infon><infon key=\"name_25\">surname:Gopez;given-names:A.</infon><infon key=\"name_26\">surname:Hsu;given-names:E.</infon><infon key=\"name_27\">surname:Gu;given-names:W.</infon><infon key=\"name_28\">surname:Miller;given-names:S.</infon><infon key=\"name_29\">surname:Pan;given-names:C.</infon><infon key=\"name_3\">surname:Fasching;given-names:C.L.</infon><infon key=\"name_30\">surname:Guevara;given-names:H.</infon><infon key=\"name_31\">surname:Wadford;given-names:D.A.</infon><infon key=\"name_32\">surname:Chen;given-names:J.S.</infon><infon key=\"name_33\">surname:Chiu;given-names:C.Y.</infon><infon key=\"name_4\">surname:Singh;given-names:J.</infon><infon key=\"name_5\">surname:Streithorst;given-names:J.A.</infon><infon key=\"name_6\">surname:Granados;given-names:A.</infon><infon key=\"name_7\">surname:Sotomayor-Gonzalez;given-names:A.</infon><infon key=\"name_8\">surname:Zorn;given-names:K.</infon><infon key=\"name_9\">surname:Gopez;given-names:A.</infon><infon key=\"pub-id_doi\">10.1101/2020.03.06.20032334</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68084</offset></passage><passage><infon key=\"comment\">medRxiv 2020.04.08.20056986</infon><infon key=\"name_0\">surname:Butt;given-names:A.M.</infon><infon key=\"name_1\">surname:Siddique;given-names:S.</infon><infon key=\"name_2\">surname:An;given-names:X.</infon><infon key=\"name_3\">surname:Tong;given-names:Y.</infon><infon key=\"pub-id_doi\">10.1101/2020.04.08.20056986</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68085</offset></passage><passage><infon key=\"comment\">[WWW Document] accessed 4.30.20</infon><infon key=\"element-citation\">https://www.evaluate.com/vantage/articles/news/corporate-strategy/new-covid-19-test-and-decent-first-quarter-buoy-abbott</infon><infon key=\"name_0\">surname:Cairns;given-names:E.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68086</offset></passage><passage><infon key=\"name_0\">surname:Cevik;given-names:M.</infon><infon key=\"name_1\">surname:Bamford;given-names:C.</infon><infon key=\"name_2\">surname:Ho;given-names:A.</infon><infon key=\"pub-id_doi\">10.1016/j.cmi.2020.04.023</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin. Microbiol. Infect.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68087</offset><text>COVID-19 pandemic â a focused review for clinicians</text></passage><passage><infon key=\"fpage\">664</infon><infon key=\"lpage\">671</infon><infon key=\"name_0\">surname:Chen;given-names:X.</infon><infon key=\"name_1\">surname:Liu;given-names:Y.</infon><infon key=\"name_2\">surname:Fang;given-names:X.</infon><infon key=\"name_3\">surname:Li;given-names:Z.</infon><infon key=\"name_4\">surname:Pu;given-names:H.</infon><infon key=\"name_5\">surname:Chang;given-names:J.</infon><infon key=\"name_6\">surname:Chen;given-names:J.</infon><infon key=\"name_7\">surname:Mao;given-names:S.</infon><infon key=\"pub-id_doi\">10.1016/j.bios.2018.11.034</infon><infon key=\"pub-id_pmid\">30530212</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biosens. Bioelectron.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">126</infon><infon key=\"year\">2019</infon><offset>68141</offset><text>Ultratrace antibiotic sensing using aptamer/graphene-based field-effect transistors</text></passage><passage><infon key=\"comment\">accessed 4.28.20</infon><infon key=\"element-citation\">http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html</infon><infon key=\"name_0\">surname:China;given-names:C.D.C.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68225</offset></passage><passage><infon key=\"fpage\">549</infon><infon key=\"lpage\">555</infon><infon key=\"name_0\">surname:Chu;given-names:D.K.W.</infon><infon key=\"name_1\">surname:Pan;given-names:Y.</infon><infon key=\"name_10\">surname:Peiris;given-names:M.</infon><infon key=\"name_11\">surname:Poon;given-names:L.L.M.</infon><infon key=\"name_2\">surname:Cheng;given-names:S.M.S.</infon><infon key=\"name_3\">surname:Hui;given-names:K.P.Y.</infon><infon key=\"name_4\">surname:Krishnan;given-names:P.</infon><infon key=\"name_5\">surname:Liu;given-names:Y.</infon><infon key=\"name_6\">surname:Ng;given-names:D.Y.M.</infon><infon key=\"name_7\">surname:Wan;given-names:C.K.C.</infon><infon key=\"name_8\">surname:Yang;given-names:P.</infon><infon key=\"name_9\">surname:Wang;given-names:Q.</infon><infon key=\"pub-id_doi\">10.1093/clinchem/hvaa029</infon><infon key=\"pub-id_pmid\">32031583</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Clin. Chem.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">66</infon><infon key=\"year\">2020</infon><offset>68226</offset><text>Molecular diagnosis of a novel Coronavirus (2019-nCoV) Causing an outbreak of Pneumonia</text></passage><passage><infon key=\"comment\">[WWW Document] accessed 4.29.20</infon><infon key=\"element-citation\">https://edition.cnn.com/2020/04/28/health/coronavirus-antibody-tests-terrible/index.html</infon><infon key=\"name_0\">surname:Cohen;given-names:E.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68314</offset></passage><passage><infon key=\"name_0\">surname:Cohen;given-names:J.</infon><infon key=\"pub-id_doi\">10.1126/science.abc1319</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Science (80-. )</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68315</offset><text>Unprecedented nationwide blood studies seek to track U.S. coronavirus spread</text></passage><passage><infon key=\"name_0\">surname:Corman;given-names:V.M.</infon><infon key=\"name_1\">surname:Landt;given-names:O.</infon><infon key=\"name_10\">surname:Mulders;given-names:D.G.J.C.</infon><infon key=\"name_11\">surname:Haagmans;given-names:B.L.</infon><infon key=\"name_12\">surname:Van Der Veer;given-names:B.</infon><infon key=\"name_13\">surname:Van Den Brink;given-names:S.</infon><infon key=\"name_14\">surname:Wijsman;given-names:L.</infon><infon key=\"name_15\">surname:Goderski;given-names:G.</infon><infon key=\"name_16\">surname:Romette;given-names:J.L.</infon><infon key=\"name_17\">surname:Ellis;given-names:J.</infon><infon key=\"name_18\">surname:Zambon;given-names:M.</infon><infon key=\"name_19\">surname:Peiris;given-names:M.</infon><infon key=\"name_2\">surname:Kaiser;given-names:M.</infon><infon key=\"name_20\">surname:Goossens;given-names:H.</infon><infon key=\"name_21\">surname:Reusken;given-names:C.</infon><infon key=\"name_22\">surname:Koopmans;given-names:M.P.G.</infon><infon key=\"name_23\">surname:Drosten;given-names:C.</infon><infon key=\"name_3\">surname:Molenkamp;given-names:R.</infon><infon key=\"name_4\">surname:Meijer;given-names:A.</infon><infon key=\"name_5\">surname:Chu;given-names:D.K.W.</infon><infon key=\"name_6\">surname:Bleicker;given-names:T.</infon><infon key=\"name_7\">surname:BrÃ¼nink;given-names:S.</infon><infon key=\"name_8\">surname:Schneider;given-names:J.</infon><infon key=\"name_9\">surname:Schmidt;given-names:M.L.</infon><infon key=\"pub-id_doi\">10.2807/1560-7917.ES.2020.25.3.2000045</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Euro Surveill.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">25</infon><infon key=\"year\">2020</infon><offset>68392</offset><text>Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR</text></passage><passage><infon key=\"fpage\">181</infon><infon key=\"lpage\">192</infon><infon key=\"name_0\">surname:Cui;given-names:J.</infon><infon key=\"name_1\">surname:Li;given-names:F.</infon><infon key=\"name_2\">surname:Shi;given-names:Z.-L.</infon><infon key=\"pub-id_doi\">10.1038/s41579-018-0118-9</infon><infon key=\"pub-id_pmid\">30531947</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat. Rev. Microbiol.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">17</infon><infon key=\"year\">2019</infon><offset>68460</offset><text>Origin and evolution of pathogenic coronaviruses</text></passage><passage><infon key=\"comment\">medRxiv 2020.3.7.20032524</infon><infon key=\"name_0\">surname:Diao;given-names:B.</infon><infon key=\"name_1\">surname:Wen;given-names:K.</infon><infon key=\"name_10\">surname:Wang;given-names:J.</infon><infon key=\"name_11\">surname:Chen;given-names:Y.</infon><infon key=\"name_12\">surname:Deng;given-names:G.</infon><infon key=\"name_13\">surname:Zhou;given-names:H.</infon><infon key=\"name_14\">surname:Wu;given-names:Y.</infon><infon key=\"name_2\">surname:Chen;given-names:Jian</infon><infon key=\"name_3\">surname:Liu;given-names:Y.</infon><infon key=\"name_4\">surname:Yuan;given-names:Z.</infon><infon key=\"name_5\">surname:Han;given-names:C.</infon><infon key=\"name_6\">surname:Chen;given-names:Jiahui</infon><infon key=\"name_7\">surname:Pan;given-names:Y.</infon><infon key=\"name_8\">surname:Chen;given-names:L.</infon><infon key=\"name_9\">surname:Dan;given-names:Y.</infon><infon key=\"pub-id_doi\">10.1101/2020.03.07.20032524</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68509</offset></passage><passage><infon key=\"comment\">bioRxiv 2020.3.19.998724</infon><infon key=\"name_0\">surname:Ding;given-names:X.</infon><infon key=\"name_1\">surname:Yin;given-names:K.</infon><infon key=\"name_2\">surname:Li;given-names:Z.</infon><infon key=\"name_3\">surname:Liu;given-names:C.</infon><infon key=\"pub-id_doi\">10.1101/2020.03.19.998724</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68510</offset></passage><passage><infon key=\"comment\">chemrxiv.org 0â13</infon><infon key=\"name_0\">surname:Djaileb;given-names:A.</infon><infon key=\"name_1\">surname:Charron;given-names:B.</infon><infon key=\"name_2\">surname:Jodaylami;given-names:M.H.</infon><infon key=\"name_3\">surname:Thibault;given-names:V.</infon><infon key=\"name_4\">surname:Coutu;given-names:J.</infon><infon key=\"name_5\">surname:Forest;given-names:S.</infon><infon key=\"name_6\">surname:Live;given-names:L.S.</infon><infon key=\"name_7\">surname:Boudreau;given-names:D.</infon><infon key=\"name_8\">surname:Pelletier;given-names:J.N.</infon><infon key=\"name_9\">surname:Masson;given-names:J.</infon><infon key=\"pub-id_doi\">10.26434/chemrxiv.12118914.v1</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68511</offset></passage><passage><infon key=\"comment\">[WWW Document] accessed 4.28.20</infon><infon key=\"element-citation\">https://www.biospace.com/article/mammoth-s-crispr-assay-for-asymptomatic-covid-19-carriers-gains-peer-reviewed-validation-/</infon><infon key=\"name_0\">surname:Dutton;given-names:G.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68512</offset></passage><passage><infon key=\"comment\">[WWW Document] accessed 4.26.20</infon><infon key=\"element-citation\">https://www.ft.com/content/fe211ec7-0ed4-4d36-9d83-14b639efb3ad</infon><infon key=\"name_0\">surname:Financial Times</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68513</offset></passage><passage><infon key=\"comment\">[WWW Document] accessed 4.25.20</infon><infon key=\"element-citation\">https://kpkesihatan.com/2020/02/13/laboratory-readiness-for-detecting-the-2019-novel-coronavirus-2019-ncov-infection-in-malaysia/</infon><infon key=\"name_0\">surname:General of Health Malaysia</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68514</offset></passage><passage><infon key=\"comment\">[WWW Document]</infon><infon key=\"element-citation\">https://www.gpc.center/ce_ivd_/585</infon><infon key=\"name_0\">surname:Global Product Certification</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68515</offset></passage><passage><infon key=\"comment\">medRxiv 2020.04.03.20052860</infon><infon key=\"name_0\">surname:Gonzalez-Gonzalez;given-names:E.</infon><infon key=\"name_1\">surname:Santiago;given-names:G.T.</infon><infon key=\"name_2\">surname:Lara-Mayorga;given-names:I.M.</infon><infon key=\"name_3\">surname:Martinez-Chapa;given-names:S.O.</infon><infon key=\"name_4\">surname:Alvarez;given-names:M.M.</infon><infon key=\"pub-id_doi\">10.1101/2020.04.03.20052860</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68516</offset></passage><passage><infon key=\"comment\">[WWW Document] accessed 4.29.20</infon><infon key=\"element-citation\">https://www.cebm.net/covid-19/what-tests-could-potentially-be-used-for-the-screening-diagnosis-and-monitoring-of-covid-19-and-what-are-their-advantages-and-disadvantages/</infon><infon key=\"name_0\">surname:Green;given-names:K.</infon><infon key=\"name_1\">surname:Winter;given-names:A.</infon><infon key=\"name_2\">surname:Dickinson;given-names:R.</infon><infon key=\"name_3\">surname:Graziadio;given-names:S.</infon><infon key=\"name_4\">surname:Wolff;given-names:R.</infon><infon key=\"name_5\">surname:Mallett;given-names:S.</infon><infon key=\"name_6\">surname:Allen;given-names:A.J.</infon><infon key=\"name_7\">surname:Park;given-names:E.B.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68517</offset></passage><passage><infon key=\"name_0\">surname:Harun;given-names:H.N.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68518</offset></passage><passage><infon key=\"name_0\">surname:Holland;given-names:P.M.</infon><infon key=\"name_1\">surname:Abramson;given-names:R.D.</infon><infon key=\"name_2\">surname:Watson;given-names:R.</infon><infon key=\"name_3\">surname:Gelfand;given-names:D.H.</infon><infon key=\"pub-id_doi\">10.1073/pnas.88.16.7276</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Proc. Natl. Acad. Sci. U.S.A.</infon><infon key=\"type\">ref</infon><infon key=\"year\">1991</infon><offset>68519</offset><text>Detection of specific polymerase chain reaction product by utilizing the 5â² â 3â² exonuclease activity of Thermus aquaticus DNA polymerase</text></passage><passage><infon key=\"name_0\">surname:Institute of Pasteur</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68663</offset></passage><passage><infon key=\"name_0\">surname:Jacofsky;given-names:D.</infon><infon key=\"name_1\">surname:Jacofsky;given-names:E.M.</infon><infon key=\"name_2\">surname:Ph;given-names:D.</infon><infon key=\"name_3\">surname:Officer;given-names:C.E.</infon><infon key=\"name_4\">surname:Jacofsky;given-names:M.</infon><infon key=\"name_5\">surname:Ph;given-names:D.</infon><infon key=\"pub-id_doi\">10.1016/j.arth.2020.04.055</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Arthroplasty</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68664</offset><text>Understanding antibody testing for COVID-19</text></passage><passage><infon key=\"name_0\">surname:Jia;given-names:F.</infon><infon key=\"name_1\">surname:Li;given-names:X.</infon><infon key=\"name_2\">surname:Zhang;given-names:C.</infon><infon key=\"name_3\">surname:Tang;given-names:X.</infon><infon key=\"pub-id_doi\">10.1007/s13238-020-00708-8</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Protein Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>68708</offset><text>The expanded development and application of CRISPR system for sensitive nucleotide detection</text></passage><passage><infon key=\"name_0\">surname:Johns Hopkins Bloomberg School of Public Health</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68801</offset></passage><passage><infon key=\"comment\">bioRxiv 2020.2.25.964775</infon><infon key=\"name_0\">surname:Jung;given-names:Y.J.</infon><infon key=\"name_1\">surname:Park;given-names:G.-S.</infon><infon key=\"name_10\">surname:Lee;given-names:J.J.</infon><infon key=\"name_11\">surname:Maeng;given-names:J.</infon><infon key=\"name_12\">surname:Kim;given-names:S.J.</infon><infon key=\"name_13\">surname:Kim;given-names:Seung Il</infon><infon key=\"name_14\">surname:Kim;given-names:B.-T.</infon><infon key=\"name_15\">surname:Lee;given-names:M.J.</infon><infon key=\"name_16\">surname:Kim;given-names:H.G.</infon><infon key=\"name_2\">surname:Moon;given-names:J.H.</infon><infon key=\"name_3\">surname:Ku;given-names:K.</infon><infon key=\"name_4\">surname:Beak;given-names:S.-H.</infon><infon key=\"name_5\">surname:Kim;given-names:Seil</infon><infon key=\"name_6\">surname:Park;given-names:E.C.</infon><infon key=\"name_7\">surname:Park;given-names:D.</infon><infon key=\"name_8\">surname:Lee;given-names:J.-H.</infon><infon key=\"name_9\">surname:Byeon;given-names:C.W.</infon><infon key=\"pub-id_doi\">10.1101/2020.02.25.964775</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68802</offset></passage><passage><infon key=\"comment\">[WWW Document]</infon><infon key=\"name_0\">surname:Kent;given-names:C.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68803</offset></passage><passage><infon key=\"name_0\">surname:Khailany;given-names:R.A.</infon><infon key=\"name_1\">surname:Safdar;given-names:M.</infon><infon key=\"name_2\">surname:Ozaslan;given-names:M.</infon><infon key=\"pub-id_doi\">10.1016/j.genrep.2020.100682</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Gene Rep.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">19</infon><infon key=\"year\">2020</infon><offset>68804</offset><text>Genomic characterization of a novel SARS-CoV-2</text></passage><passage><infon key=\"fpage\">578</infon><infon key=\"lpage\">587</infon><infon key=\"name_0\">surname:Kurt;given-names:H.</infon><infon key=\"name_1\">surname:EyÃ¼poÇ§lu;given-names:A.E.</infon><infon key=\"name_2\">surname:SÃ¼tlÃ¼;given-names:T.</infon><infon key=\"name_3\">surname:Budak;given-names:H.</infon><infon key=\"name_4\">surname:YÃ¼ce;given-names:M.</infon><infon key=\"pub-id_doi\">10.1021/acscombsci.9b00059</infon><infon key=\"pub-id_pmid\">31265241</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Comb. Sci.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">21</infon><infon key=\"year\">2019</infon><offset>68851</offset><text>Plasmonic Selection of ssDNA Aptamers against fibroblast growth factor Receptor</text></passage><passage><infon key=\"comment\">[WWW Document] accessed 4.26.20</infon><infon key=\"element-citation\">https://www.pixel.labcorp.com/at-home-test-kits/covid-19-test</infon><infon key=\"name_0\">surname:LabCorp</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68931</offset></passage><passage><infon key=\"comment\">[WWW Document] accessed 4.25.20</infon><infon key=\"element-citation\">https://www.fda.gov/media/136151/download</infon><infon key=\"name_0\">surname:LabCorp</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>68932</offset></passage><passage><infon key=\"name_0\">surname:Lee;given-names:M.S.</infon><infon key=\"name_1\">surname:Chang;given-names:P.C.</infon><infon key=\"name_2\">surname:Shien;given-names:J.H.</infon><infon key=\"name_3\">surname:Cheng;given-names:M.C.</infon><infon key=\"name_4\">surname:Shieh;given-names:H.K.</infon><infon key=\"pub-id_doi\">10.1016/S0166-0934(01)00301-9</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Virol. Methods</infon><infon key=\"type\">ref</infon><infon key=\"year\">2001</infon><offset>68933</offset><text>Identification and subtyping of avian influenza viruses by reverse transcription-PCR</text></passage><passage><infon key=\"comment\">0â1</infon><infon key=\"name_0\">surname:Li;given-names:Z.</infon><infon key=\"name_1\">surname:Yi;given-names:Y.</infon><infon key=\"name_10\">surname:Zhang;given-names:Y.</infon><infon key=\"name_11\">surname:Wang;given-names:J.</infon><infon key=\"name_12\">surname:Huang;given-names:B.</infon><infon key=\"name_13\">surname:Lin;given-names:Y.</infon><infon key=\"name_14\">surname:Yang;given-names:J.</infon><infon key=\"name_15\">surname:Cai;given-names:W.</infon><infon key=\"name_16\">surname:Wang;given-names:X.</infon><infon key=\"name_17\">surname:Cheng;given-names:J.</infon><infon key=\"name_18\">surname:Chen;given-names:Z.</infon><infon key=\"name_19\">surname:Sun;given-names:K.</infon><infon key=\"name_2\">surname:Luo;given-names:X.</infon><infon key=\"name_20\">surname:Pan;given-names:W.</infon><infon key=\"name_21\">surname:Zhan;given-names:Z.</infon><infon key=\"name_22\">surname:Chen;given-names:L.</infon><infon key=\"name_23\">surname:Ye;given-names:F.</infon><infon key=\"name_3\">surname:Xiong;given-names:N.</infon><infon key=\"name_4\">surname:Liu;given-names:Y.</infon><infon key=\"name_5\">surname:Li;given-names:S.</infon><infon key=\"name_6\">surname:Sun;given-names:R.</infon><infon key=\"name_7\">surname:Wang;given-names:Y.</infon><infon key=\"name_8\">surname:Hu;given-names:B.</infon><infon key=\"name_9\">surname:Chen;given-names:W.</infon><infon key=\"pub-id_doi\">10.1002/jmv.25727</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Med. Virol.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>69018</offset><text>Development and clinical application of A Rapid IgMâIgG combined antibody Test for SARSâCoVâ2 infection Diagnosis</text></passage><passage><infon key=\"comment\">medRxiv 2020.3.27.20045153</infon><infon key=\"name_0\">surname:Lin;given-names:D.</infon><infon key=\"name_1\">surname:Liu;given-names:L.</infon><infon key=\"name_10\">surname:Huang;given-names:K.</infon><infon key=\"name_11\">surname:Zhang;given-names:Z.</infon><infon key=\"name_2\">surname:Zhang;given-names:M.</infon><infon key=\"name_3\">surname:Hu;given-names:Y.</infon><infon key=\"name_4\">surname:Yang;given-names:Q.</infon><infon key=\"name_5\">surname:Guo;given-names:J.</infon><infon key=\"name_6\">surname:Dai;given-names:Y.</infon><infon key=\"name_7\">surname:Xu;given-names:Y.</infon><infon key=\"name_8\">surname:Cai;given-names:Y.</infon><infon key=\"name_9\">surname:Chen;given-names:X.</infon><infon key=\"pub-id_doi\">10.1101/2020.03.27.20045153</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>69138</offset></passage><passage><infon key=\"fpage\">595</infon><infon key=\"lpage\">601</infon><infon key=\"name_0\">surname:Liu;given-names:Z.</infon><infon key=\"name_1\">surname:Xiao;given-names:X.</infon><infon key=\"name_2\">surname:Wei;given-names:X.</infon><infon key=\"name_3\">surname:Li;given-names:J.</infon><infon key=\"name_4\">surname:Yang;given-names:J.</infon><infon key=\"name_5\">surname:Tan;given-names:H.</infon><infon key=\"name_6\">surname:Zhu;given-names:J.</infon><infon key=\"name_7\">surname:Zhang;given-names:Q.</infon><infon key=\"name_8\">surname:Wu;given-names:J.</infon><infon key=\"name_9\">surname:Liu;given-names:L.</infon><infon key=\"pub-id_doi\">10.1002/jmv.25726</infon><infon key=\"pub-id_pmid\">32100877</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Med. Virol.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">92</infon><infon key=\"year\">2020</infon><offset>69139</offset><text>Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARSâCoVâ2</text></passage><passage><infon key=\"fpage\">747</infon><infon key=\"lpage\">756</infon><infon key=\"name_0\">surname:Loeffelholz;given-names:M.J.</infon><infon key=\"name_1\">surname:Tang;given-names:Y.-W.</infon><infon key=\"pub-id_doi\">10.1080/22221751.2020.1745095</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg. Microb. Infect.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">9</infon><infon key=\"year\">2020</infon><offset>69275</offset><text>Laboratory diagnosis of emerging human coronavirus infections â the state of the art</text></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><offset>69362</offset><text>NA [WWW Document], n.d. URL https://www.ncbi.nlm.nih.gov/pmc/articles/PMC102748/(accessed 4.28.20).</text></passage><passage><infon key=\"name_0\">surname:Maghdid;given-names:H.S.</infon><infon key=\"name_1\">surname:Asaad;given-names:A.T.</infon><infon key=\"name_2\">surname:Ghafoor;given-names:K.Z.</infon><infon key=\"name_3\">surname:Sadiq;given-names:A.S.</infon><infon key=\"name_4\">surname:Khan;given-names:M.K.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>69462</offset></passage><passage><infon key=\"name_0\">surname:Maghdid;given-names:H.S.</infon><infon key=\"name_1\">surname:Ghafoor;given-names:K.Z.</infon><infon key=\"name_2\">surname:Sadiq;given-names:A.S.</infon><infon key=\"name_3\">surname:Curran;given-names:K.</infon><infon key=\"name_4\">surname:Rabie;given-names:K.</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Des. Stud.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">1â5</infon><infon key=\"year\">2020</infon><offset>69463</offset><text>A Novel AI-enabled Framework to Diagnose Coronavirus COVID 19 using Smartphone Embedded Sensors</text></passage><passage><infon key=\"comment\">bioRxiv 2020.4.24.059204</infon><infon key=\"name_0\">surname:Mahari;given-names:S.</infon><infon key=\"name_1\">surname:Roberts;given-names:A.</infon><infon key=\"name_2\">surname:Shahdeo;given-names:D.</infon><infon key=\"name_3\">surname:Gandhi;given-names:S.</infon><infon key=\"pub-id_doi\">10.1101/2020.04.24.059204</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>69559</offset></passage><passage><infon key=\"name_0\">surname:Maschinen;given-names:B.</infon><infon key=\"name_1\">surname:Investition;given-names:A.</infon><infon key=\"name_2\">surname:Beschaffungen;given-names:G.</infon><infon key=\"name_3\">surname:Ersatzbeschaffungen;given-names:B.</infon><infon key=\"name_4\">surname:Mittelherkunft;given-names:S.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>69560</offset></passage><passage><infon key=\"name_0\">surname:Maxmen;given-names:A.</infon><infon key=\"pub-id_doi\">10.1038/d41586-020-01163-5</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>69561</offset><text>The researchers taking a gamble with antibody tests for coronavirus</text></passage><passage><infon key=\"name_0\">surname:Morales-NarvÃ¡ez;given-names:E.</infon><infon key=\"name_1\">surname:Dincer;given-names:C.</infon><infon key=\"pub-id_doi\">10.1016/j.bios.2020.112274</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Biosens. Bioelectron.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">163</infon><infon key=\"year\">2020</infon><offset>69629</offset><text>The impact of biosensing in a pandemic outbreak: COVID-19</text></passage><passage><infon key=\"comment\">[WWW Document] accessed 5.1.20</infon><infon key=\"element-citation\">https://www.pharmacytimes.com/news/first-clinical-grade-rapid-at-home-test-to-aid-in-covid-19-crisis</infon><infon key=\"name_0\">surname:Murphy;given-names:J.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>69687</offset></passage><passage><infon key=\"name_0\">surname:Mustafa;given-names:M.I.</infon><infon key=\"name_1\">surname:Makhawi;given-names:A.M.</infon><infon key=\"pub-id_doi\">10.20944/preprints202004.0080.v1</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>69688</offset></passage><passage><infon key=\"name_0\">surname:Nalla;given-names:A.K.</infon><infon key=\"name_1\">surname:Casto;given-names:A.M.</infon><infon key=\"name_2\">surname:Huang;given-names:M.-L.W.</infon><infon key=\"name_3\">surname:Perchetti;given-names:G.A.</infon><infon key=\"name_4\">surname:Sampoleo;given-names:R.</infon><infon key=\"name_5\">surname:Shrestha;given-names:L.</infon><infon key=\"name_6\">surname:Wei;given-names:Y.</infon><infon key=\"name_7\">surname:Zhu;given-names:H.</infon><infon key=\"name_8\">surname:Jerome;given-names:K.R.</infon><infon key=\"name_9\">surname:Greninger;given-names:A.L.</infon><infon key=\"pub-id_doi\">10.1128/JCM.00557-20</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Clin. Microbiol.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>69689</offset><text>Comparative performance of SARS-CoV-2 Detection assays using Seven Different primer/probe Sets and one assay Kit</text></passage><passage><infon key=\"comment\">4-7-1 Gakuen, Musashimurayama, 208-0011 Tokyo, Japan: 2Department of Pathology, National Institute of Infectious Disease. doi:.1037//0033-2909.I26.1.78</infon><infon key=\"name_0\">surname:Nao;given-names:N.</infon><infon key=\"name_1\">surname:Shirato;given-names:K.</infon><infon key=\"name_2\">surname:Katano;given-names:H.</infon><infon key=\"name_3\">surname:Matsuyama;given-names:S.</infon><infon key=\"name_4\">surname:Takeda;given-names:M.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2019</infon><offset>69802</offset></passage><passage><infon key=\"fpage\">306</infon><infon key=\"name_0\">surname:Nguyen;given-names:T.</infon><infon key=\"name_1\">surname:Duong Bang;given-names:D.</infon><infon key=\"name_2\">surname:Wolff;given-names:A.</infon><infon key=\"pub-id_doi\">10.3390/mi11030306</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Micromachines</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>69803</offset><text>2019 novel Coronavirus Disease (COVID-19): Paving the Road for Rapid Detection and point-of-care Diagnostics</text></passage><passage><infon key=\"fpage\">1559</infon><infon key=\"lpage\">1582</infon><infon key=\"name_0\">surname:Nolan;given-names:T.</infon><infon key=\"name_1\">surname:Hands;given-names:R.E.</infon><infon key=\"name_2\">surname:Bustin;given-names:S.A.</infon><infon key=\"pub-id_doi\">10.1038/nprot.2006.236</infon><infon key=\"pub-id_pmid\">17406449</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat. Protoc.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">1</infon><infon key=\"year\">2006</infon><offset>69912</offset><text>Quantification of mRNA using real-time RT-PCR</text></passage><passage><infon key=\"fpage\">18012</infon><infon key=\"lpage\">18013</infon><infon key=\"name_0\">surname:Ohno;given-names:Y.</infon><infon key=\"name_1\">surname:Maehashi;given-names:K.</infon><infon key=\"name_2\">surname:Matsumoto;given-names:K.</infon><infon key=\"pub-id_doi\">10.1021/ja108127r</infon><infon key=\"pub-id_pmid\">21128665</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Am. Chem. Soc.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">132</infon><infon key=\"year\">2010</infon><offset>69958</offset><text>Label-free biosensors based on aptamer-Modified graphene field-effect transistors</text></passage><passage><infon key=\"comment\">03.18.20038059</infon><infon key=\"name_0\">surname:Okba;given-names:N.</infon><infon key=\"name_1\">surname:Muller;given-names:M.</infon><infon key=\"name_10\">surname:Yazdanpanah;given-names:Y.</infon><infon key=\"name_11\">surname:Le Hingrat;given-names:Q.</infon><infon key=\"name_12\">surname:Descamps;given-names:D.</infon><infon key=\"name_13\">surname:Houhou-Fidouh;given-names:N.</infon><infon key=\"name_14\">surname:Reusken;given-names:C.</infon><infon key=\"name_15\">surname:Bosch;given-names:B.-J.</infon><infon key=\"name_16\">surname:Drosten;given-names:C.</infon><infon key=\"name_17\">surname:Koopmans;given-names:M.</infon><infon key=\"name_18\">surname:Haagmans;given-names:B.</infon><infon key=\"name_2\">surname:Li;given-names:W.</infon><infon key=\"name_3\">surname:Wang;given-names:C.</infon><infon key=\"name_4\">surname:GeurtsvanKessel;given-names:C.</infon><infon key=\"name_5\">surname:Corman;given-names:V.</infon><infon key=\"name_6\">surname:Lamers;given-names:M.</infon><infon key=\"name_7\">surname:Sikkema;given-names:R.</infon><infon key=\"name_8\">surname:de Bruin;given-names:E.</infon><infon key=\"name_9\">surname:Chandler;given-names:F.</infon><infon key=\"pub-id_doi\">10.1101/2020.03.18.20038059</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Emerg. Infect. Dis. 2020</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70040</offset><text>SARS-CoV-2 specific antibody responses in COVID-19 patients</text></passage><passage><infon key=\"comment\">[WWW Document] accessed 4.29.20</infon><infon key=\"element-citation\">https://www.orasure.com/innovation/innovation-in-development.asp</infon><infon key=\"name_0\">surname:OraSure;given-names:I.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70100</offset></passage><passage><infon key=\"name_0\">surname:Pabbaraju;given-names:K.</infon><infon key=\"name_1\">surname:Wong;given-names:S.</infon><infon key=\"name_10\">surname:Preiksaitis;given-names:J.K.</infon><infon key=\"name_2\">surname:Wong;given-names:A.A.</infon><infon key=\"name_3\">surname:Appleyard;given-names:G.D.</infon><infon key=\"name_4\">surname:Chui;given-names:L.</infon><infon key=\"name_5\">surname:Pang;given-names:X.L.</infon><infon key=\"name_6\">surname:Yanow;given-names:S.K.</infon><infon key=\"name_7\">surname:Fonseca;given-names:K.</infon><infon key=\"name_8\">surname:Lee;given-names:B.E.</infon><infon key=\"name_9\">surname:Fox;given-names:J.D.</infon><infon key=\"pub-id_doi\">10.1128/JCM.01103-09</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">J. Clin. Microbiol.</infon><infon key=\"type\">ref</infon><infon key=\"year\">2009</infon><offset>70101</offset><text>Design and validation of real-time reverse transcription-PCR assays for detection of pandemic (H1N1) 2009 virus</text></passage><passage><infon key=\"fpage\">25</infon><infon key=\"lpage\">39</infon><infon key=\"name_0\">surname:Pilot;given-names:L.R.</infon><infon key=\"pub-id_doi\">10.1300/5790_03</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Pharmacy Law Desk Reference</infon><infon key=\"type\">ref</infon><infon key=\"year\">2012</infon><offset>70213</offset></passage><passage><infon key=\"fpage\">1</infon><infon key=\"lpage\">10</infon><infon key=\"name_0\">surname:Pinto;given-names:D.</infon><infon key=\"name_1\">surname:Park;given-names:Y.-J.</infon><infon key=\"name_10\">surname:Peter;given-names:A.</infon><infon key=\"name_11\">surname:Guarino;given-names:B.</infon><infon key=\"name_12\">surname:Spreafico;given-names:R.</infon><infon key=\"name_13\">surname:Cameroni;given-names:E.</infon><infon key=\"name_14\">surname:Case;given-names:J.B.</infon><infon key=\"name_15\">surname:Chen;given-names:R.E.</infon><infon key=\"name_16\">surname:Havenar-Daughton;given-names:C.</infon><infon key=\"name_17\">surname:Snell;given-names:G.</infon><infon key=\"name_18\">surname:Telenti;given-names:A.</infon><infon key=\"name_19\">surname:Virgin;given-names:H.W.</infon><infon key=\"name_2\">surname:Beltramello;given-names:M.</infon><infon key=\"name_20\">surname:Lanzavecchia;given-names:A.</infon><infon key=\"name_21\">surname:Diamond;given-names:M.S.</infon><infon key=\"name_22\">surname:Fink;given-names:K.</infon><infon key=\"name_23\">surname:Veesler;given-names:D.</infon><infon key=\"name_24\">surname:Corti;given-names:D.</infon><infon key=\"name_3\">surname:Walls;given-names:A.C.</infon><infon key=\"name_4\">surname:Tortorici;given-names:M.A.</infon><infon key=\"name_5\">surname:Bianchi;given-names:S.</infon><infon key=\"name_6\">surname:Jaconi;given-names:S.</infon><infon key=\"name_7\">surname:Culap;given-names:K.</infon><infon key=\"name_8\">surname:Zatta;given-names:F.</infon><infon key=\"name_9\">surname:De Marco;given-names:A.</infon><infon key=\"pub-id_doi\">10.1038/s41586-020-2349-y</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nature</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70214</offset><text>Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody</text></passage><passage><infon key=\"fpage\">569</infon><infon key=\"lpage\">582</infon><infon key=\"name_0\">surname:Posthuma-Trumpie;given-names:G.A.</infon><infon key=\"name_1\">surname:Korf;given-names:J.</infon><infon key=\"name_2\">surname:van Amerongen;given-names:A.</infon><infon key=\"pub-id_doi\">10.1007/s00216-008-2287-2</infon><infon key=\"pub-id_pmid\">18696055</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Anal. Bioanal. Chem.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">393</infon><infon key=\"year\">2009</infon><offset>70289</offset><text>Lateral flow (immuno)assay: its strengths, weaknesses, opportunities and threats. A literature survey</text></passage><passage><infon key=\"name_0\">surname:Qiu;given-names:G.</infon><infon key=\"name_1\">surname:Gai;given-names:Z.</infon><infon key=\"name_2\">surname:Tao;given-names:Y.</infon><infon key=\"name_3\">surname:Schmitt;given-names:J.</infon><infon key=\"name_4\">surname:Kullak-Ublick;given-names:G.A.</infon><infon key=\"name_5\">surname:Wang;given-names:J.</infon><infon key=\"pub-id_doi\">10.1021/acsnano.0c02439</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Nano</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70391</offset><text>Dual-functional plasmonic photothermal biosensors for highly accurate Severe acute Respiratory Syndrome Coronavirus 2 Detection</text></passage><passage><infon key=\"name_0\">surname:Rao;given-names:A.</infon><infon key=\"name_1\">surname:Goldstein;given-names:D.Y.</infon><infon key=\"name_2\">surname:Wolk;given-names:D.M.</infon><infon key=\"name_3\">surname:Wolf;given-names:L.A.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70519</offset></passage><passage><infon key=\"comment\">[WWW Document] accessed 4.25.20</infon><infon key=\"element-citation\">https://diagnostics.roche.com/global/en/products/params/cobas-sars-cov-2-test.html</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70520</offset></passage><passage><infon key=\"fpage\">183</infon><infon key=\"name_0\">surname:Rosales-Mendoza;given-names:S.</infon><infon key=\"name_1\">surname:MÃ¡rquez-Escobar;given-names:V.A.</infon><infon key=\"name_2\">surname:GonzÃ¡lez-Ortega;given-names:O.</infon><infon key=\"name_3\">surname:Nieto-GÃ³mez;given-names:R.</infon><infon key=\"name_4\">surname:ArÃ©valo-Villalobos;given-names:J.I.</infon><infon key=\"pub-id_doi\">10.3390/vaccines8020183</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Vaccines</infon><infon key=\"type\">ref</infon><infon key=\"volume\">8</infon><infon key=\"year\">2020</infon><offset>70521</offset><text>What Does Plant-based vaccine technology offer to the fight against COVID-19?</text></passage><passage><infon key=\"fpage\">101</infon><infon key=\"lpage\">136</infon><infon key=\"name_0\">surname:Roy;given-names:J.</infon><infon key=\"name_1\">surname:Jain;given-names:N.</infon><infon key=\"name_2\">surname:Singh;given-names:G.</infon><infon key=\"name_3\">surname:Das;given-names:B.</infon><infon key=\"name_4\">surname:Mallick;given-names:B.</infon><infon key=\"pub-id_doi\">10.1016/b978-0-12-815669-8.00005-1</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">AGO-driven Non-Coding RNAs</infon><infon key=\"type\">ref</infon><infon key=\"year\">2019</infon><offset>70599</offset></passage><passage><infon key=\"comment\">[WWW Document]. rss.org.uk</infon><infon key=\"name_0\">surname:Royal Statistical Society Covid-19 Task Force</infon><infon key=\"pub-id_doi\">10.1155/2011/608719</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70600</offset></passage><passage><infon key=\"comment\">[WWW Document] accessed 5.1.20</infon><infon key=\"element-citation\">http://sdbiosensor.com/xe/product/7662</infon><infon key=\"name_0\">surname:SDBiosensor Inc</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70601</offset></passage><passage><infon key=\"name_0\">surname:Seo;given-names:G.</infon><infon key=\"name_1\">surname:Lee;given-names:G.</infon><infon key=\"name_10\">surname:Kim;given-names:S.-J.</infon><infon key=\"name_11\">surname:Lee;given-names:J.-O.</infon><infon key=\"name_12\">surname:Kim;given-names:B.T.</infon><infon key=\"name_13\">surname:Park;given-names:E.C.</infon><infon key=\"name_14\">surname:Kim;given-names:S. Il</infon><infon key=\"name_2\">surname:Kim;given-names:M.J.</infon><infon key=\"name_3\">surname:Baek;given-names:S.-H.</infon><infon key=\"name_4\">surname:Choi;given-names:M.</infon><infon key=\"name_5\">surname:Ku;given-names:K.B.</infon><infon key=\"name_6\">surname:Lee;given-names:C.-S.</infon><infon key=\"name_7\">surname:Jun;given-names:S.</infon><infon key=\"name_8\">surname:Park;given-names:D.</infon><infon key=\"name_9\">surname:Kim;given-names:H.G.</infon><infon key=\"pub-id_doi\">10.1021/acsnano.0c02823</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">ACS Nano</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70602</offset><text>Rapid Detection of COVID-19 Causative virus (SARS-CoV-2) in human nasopharyngeal Swab Specimens using field-effect transistor-based biosensor</text></passage><passage><infon key=\"name_0\">surname:Soh;given-names:J.H.</infon><infon key=\"name_1\">surname:Chan;given-names:H.M.</infon><infon key=\"name_2\">surname:Ying;given-names:J.Y.</infon><infon key=\"pub-id_doi\">10.1016/j.nantod.2019.100831</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nano Today</infon><infon key=\"type\">ref</infon><infon key=\"volume\">30</infon><infon key=\"year\">2020</infon><offset>70744</offset><text>Strategies for developing sensitive and specific nanoparticle-based lateral flow assays as point-of-care diagnostic device</text></passage><passage><infon key=\"fpage\">490</infon><infon key=\"lpage\">502</infon><infon key=\"name_0\">surname:Su;given-names:S.</infon><infon key=\"name_1\">surname:Wong;given-names:G.</infon><infon key=\"name_2\">surname:Shi;given-names:W.</infon><infon key=\"name_3\">surname:Liu;given-names:J.</infon><infon key=\"name_4\">surname:Lai;given-names:A.C.K.</infon><infon key=\"name_5\">surname:Zhou;given-names:J.</infon><infon key=\"name_6\">surname:Liu;given-names:W.</infon><infon key=\"name_7\">surname:Bi;given-names:Y.</infon><infon key=\"name_8\">surname:Gao;given-names:G.F.</infon><infon key=\"pub-id_doi\">10.1016/j.tim.2016.03.003</infon><infon key=\"pub-id_pmid\">27012512</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Trends Microbiol.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">24</infon><infon key=\"year\">2016</infon><offset>70867</offset><text>Epidemiology, genetic Recombination, and Pathogenesis of Coronaviruses</text></passage><passage><infon key=\"comment\">bioRxiv 2020.4.20.052233</infon><infon key=\"name_0\">surname:Tan;given-names:X.</infon><infon key=\"name_1\">surname:Lin;given-names:C.</infon><infon key=\"name_2\">surname:Zhang;given-names:J.</infon><infon key=\"name_3\">surname:Oo;given-names:M.K.K.</infon><infon key=\"name_4\">surname:Fan;given-names:X.</infon><infon key=\"pub-id_doi\">10.1101/2020.04.20.052233</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70938</offset></passage><passage><infon key=\"comment\">[WWW Document] accessed 4.25.20</infon><infon key=\"element-citation\">https://www.who.int/docs/default-source/coronaviruse/conventional-rt-pcr-followed-by-sequencing-for-detection-of-ncov-rirl-nat-inst-health-t.pdf?sfvrsn=42271c6d_4</infon><infon key=\"name_0\">surname:Thailand Ministry of Public Health</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70939</offset></passage><passage><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70940</offset></passage><passage><infon key=\"comment\">[WWW Document] accessed 4.25.20</infon><infon key=\"element-citation\">https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70941</offset></passage><passage><infon key=\"comment\">[WWW Document]</infon><infon key=\"element-citation\">https://www.fda.gov/media/136148/download</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70942</offset></passage><passage><infon key=\"comment\">[WWW Document]</infon><infon key=\"element-citation\">https://www.fda.gov/media/134922/download</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70943</offset></passage><passage><infon key=\"comment\">[WWW Document]</infon><infon key=\"element-citation\">https://www.fda.gov/media/136255/download</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70944</offset></passage><passage><infon key=\"comment\">[WWW Document]</infon><infon key=\"element-citation\">https://www.fda.gov/media/136153/download</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70945</offset></passage><passage><infon key=\"comment\">[WWW Document]</infon><infon key=\"element-citation\">https://www.fda.gov/media/136113/download</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70946</offset></passage><passage><infon key=\"comment\">[WWW Document].</infon><infon key=\"element-citation\">https://www.fda.gov/media/136148/download</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70947</offset></passage><passage><infon key=\"comment\">[WWW Document]</infon><infon key=\"element-citation\">https://www.fda.gov/media/136151/download</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70948</offset></passage><passage><infon key=\"comment\">[WWW Document]</infon><infon key=\"element-citation\">https://www.fda.gov/media/137886/download</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70949</offset></passage><passage><infon key=\"comment\">[WWW Document]</infon><infon key=\"element-citation\">https://www.fda.gov/media/137885/download</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70950</offset></passage><passage><infon key=\"comment\">[WWW Document]</infon><infon key=\"element-citation\">https://www.fda.gov/media/136598/download</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70951</offset></passage><passage><infon key=\"comment\">[WWW Document] accessed 4.25.20</infon><infon key=\"element-citation\">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-serological-tests</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70952</offset></passage><passage><infon key=\"comment\">[WWW Document]</infon><infon key=\"element-citation\">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/policy-coronavirus-disease-2019-tests-during-public-health-emergency-revised</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70953</offset></passage><passage><infon key=\"comment\">[WWW Document] accessed 5.6.20</infon><infon key=\"element-citation\">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup-may-5-2020</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70954</offset></passage><passage><infon key=\"comment\">medRxiv</infon><infon key=\"name_0\">surname:Vogels;given-names:C.B.F.</infon><infon key=\"name_1\">surname:Brito;given-names:A.F.</infon><infon key=\"name_10\">surname:Klein;given-names:J.</infon><infon key=\"name_11\">surname:Lu;given-names:P.</infon><infon key=\"name_12\">surname:Lu-Culligan;given-names:A.</infon><infon key=\"name_13\">surname:Jiang;given-names:X.</infon><infon key=\"name_14\">surname:Kim;given-names:D.J.</infon><infon key=\"name_15\">surname:Kudo;given-names:E.</infon><infon key=\"name_16\">surname:Mao;given-names:T.</infon><infon key=\"name_17\">surname:Moriyama;given-names:M.</infon><infon key=\"name_18\">surname:Oh;given-names:J.E.</infon><infon key=\"name_19\">surname:Park;given-names:A.</infon><infon key=\"name_2\">surname:Wyllie;given-names:A.L.</infon><infon key=\"name_20\">surname:Silva;given-names:J.</infon><infon key=\"name_21\">surname:Song;given-names:E.</infon><infon key=\"name_22\">surname:Takehashi;given-names:T.</infon><infon key=\"name_23\">surname:Taura;given-names:M.</infon><infon key=\"name_24\">surname:Tokuyama;given-names:M.</infon><infon key=\"name_25\">surname:Venkataraman;given-names:A.</infon><infon key=\"name_26\">surname:Weizman;given-names:O.-E.</infon><infon key=\"name_27\">surname:Wong;given-names:P.</infon><infon key=\"name_28\">surname:Yang;given-names:Y.</infon><infon key=\"name_29\">surname:Cheemarla;given-names:N.R.</infon><infon key=\"name_3\">surname:Fauver;given-names:J.R.</infon><infon key=\"name_30\">surname:White;given-names:E.</infon><infon key=\"name_31\">surname:Lapidus;given-names:S.</infon><infon key=\"name_32\">surname:Earnest;given-names:R.</infon><infon key=\"name_33\">surname:Geng;given-names:B.</infon><infon key=\"name_34\">surname:Vijayakumar;given-names:P.</infon><infon key=\"name_35\">surname:Odio;given-names:C.</infon><infon key=\"name_36\">surname:Fournier;given-names:J.</infon><infon key=\"name_37\">surname:Bermejo;given-names:S.</infon><infon key=\"name_38\">surname:Farhadian;given-names:S.</infon><infon key=\"name_39\">surname:Cruz;given-names:C. Dela</infon><infon key=\"name_4\">surname:Ott;given-names:I.M.</infon><infon key=\"name_40\">surname:Iwasaki;given-names:A.</infon><infon key=\"name_41\">surname:Ko;given-names:A.I.</infon><infon key=\"name_42\">surname:Landry;given-names:M.-L.</infon><infon key=\"name_43\">surname:Foxman;given-names:E.F.</infon><infon key=\"name_44\">surname:Grubaugh;given-names:N.D.</infon><infon key=\"name_5\">surname:Kalinich;given-names:C.C.</infon><infon key=\"name_6\">surname:Petrone;given-names:M.E.</infon><infon key=\"name_7\">surname:Casanovas-Massana;given-names:A.</infon><infon key=\"name_8\">surname:Muenker;given-names:M.C.</infon><infon key=\"name_9\">surname:Moore;given-names:A.J.</infon><infon key=\"pub-id_doi\">10.1101/2020.03.30.20048108</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>70955</offset></passage><passage><infon key=\"comment\">e6</infon><infon key=\"fpage\">281</infon><infon key=\"lpage\">292</infon><infon key=\"name_0\">surname:Walls;given-names:A.C.</infon><infon key=\"name_1\">surname:Park;given-names:Y.-J.</infon><infon key=\"name_2\">surname:Tortorici;given-names:M.A.</infon><infon key=\"name_3\">surname:Wall;given-names:A.</infon><infon key=\"name_4\">surname:McGuire;given-names:A.T.</infon><infon key=\"name_5\">surname:Veesler;given-names:D.</infon><infon key=\"pub-id_doi\">10.1016/j.cell.2020.02.058</infon><infon key=\"pub-id_pmid\">32155444</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Cell</infon><infon key=\"type\">ref</infon><infon key=\"volume\">181</infon><infon key=\"year\">2020</infon><offset>70956</offset><text>Structure, function, and Antigenicity of the SARS-CoV-2 Spike glycoprotein</text></passage><passage><infon key=\"fpage\">2251</infon><infon key=\"name_0\">surname:Wang;given-names:C.</infon><infon key=\"name_1\">surname:Li;given-names:W.</infon><infon key=\"name_2\">surname:Drabek;given-names:D.</infon><infon key=\"name_3\">surname:Okba;given-names:N.M.A.</infon><infon key=\"name_4\">surname:van Haperen;given-names:R.</infon><infon key=\"name_5\">surname:Osterhaus;given-names:A.D.M.E.</infon><infon key=\"name_6\">surname:van Kuppeveld;given-names:F.J.M.</infon><infon key=\"name_7\">surname:Haagmans;given-names:B.L.</infon><infon key=\"name_8\">surname:Grosveld;given-names:F.</infon><infon key=\"name_9\">surname:Bosch;given-names:B.-J.</infon><infon key=\"pub-id_doi\">10.1038/s41467-020-16256-y</infon><infon key=\"pub-id_pmid\">32366817</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat. Commun.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">11</infon><infon key=\"year\">2020</infon><offset>71031</offset><text>A human monoclonal antibody blocking SARS-CoV-2 infection</text></passage><passage><infon key=\"comment\">medRxiv 2020.3.4.20029538</infon><infon key=\"name_0\">surname:Wang;given-names:M.</infon><infon key=\"name_1\">surname:Fu;given-names:A.</infon><infon key=\"name_10\">surname:Men;given-names:D.</infon><infon key=\"name_11\">surname:Yu;given-names:L.</infon><infon key=\"name_12\">surname:Deng;given-names:Z.</infon><infon key=\"name_13\">surname:Li;given-names:Y.</infon><infon key=\"name_14\">surname:Liu;given-names:T.</infon><infon key=\"name_2\">surname:Hu;given-names:B.</infon><infon key=\"name_3\">surname:Tong;given-names:Y.</infon><infon key=\"name_4\">surname:Liu;given-names:R.</infon><infon key=\"name_5\">surname:Gu;given-names:J.</infon><infon key=\"name_6\">surname:Liu;given-names:J.</infon><infon key=\"name_7\">surname:Jiang;given-names:W.</infon><infon key=\"name_8\">surname:Shen;given-names:G.</infon><infon key=\"name_9\">surname:Zhao;given-names:W.</infon><infon key=\"pub-id_doi\">10.1101/2020.03.04.20029538</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>71089</offset></passage><passage><infon key=\"comment\">[WWW Document] accessed 4.26.20</infon><infon key=\"element-citation\">https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020</infon><infon key=\"name_0\">surname:WHO</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>71090</offset></passage><passage><infon key=\"comment\">[WWW Document] accessed 4.29.20</infon><infon key=\"element-citation\">https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19</infon><infon key=\"name_0\">surname:WHO</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>71091</offset></passage><passage><infon key=\"comment\">medRxiv 2020.03.05.20031971</infon><infon key=\"name_0\">surname:Woo;given-names:C.H.</infon><infon key=\"name_1\">surname:Jang;given-names:S.</infon><infon key=\"name_2\">surname:Shin;given-names:G.</infon><infon key=\"name_3\">surname:Jung;given-names:G.Y.</infon><infon key=\"name_4\">surname:Lee;given-names:J.W.</infon><infon key=\"pub-id_doi\">10.1101/2020.03.05.20031971</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>71092</offset></passage><passage><infon key=\"name_0\">surname:Worldometer</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Worldometers</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>71093</offset><text>Coronavirus update (live): Cases and deaths from COVID-19 virus pandemic</text></passage><passage><infon key=\"fpage\">502</infon><infon key=\"lpage\">505</infon><infon key=\"name_0\">surname:Xu;given-names:Y.</infon><infon key=\"name_1\">surname:Li;given-names:X.</infon><infon key=\"name_10\">surname:Zhang;given-names:H.</infon><infon key=\"name_11\">surname:Liu;given-names:H.</infon><infon key=\"name_12\">surname:Xia;given-names:H.</infon><infon key=\"name_13\">surname:Tang;given-names:J.</infon><infon key=\"name_14\">surname:Zhang;given-names:K.</infon><infon key=\"name_15\">surname:Gong;given-names:S.</infon><infon key=\"name_2\">surname:Zhu;given-names:B.</infon><infon key=\"name_3\">surname:Liang;given-names:H.</infon><infon key=\"name_4\">surname:Fang;given-names:C.</infon><infon key=\"name_5\">surname:Gong;given-names:Y.</infon><infon key=\"name_6\">surname:Guo;given-names:Q.</infon><infon key=\"name_7\">surname:Sun;given-names:X.</infon><infon key=\"name_8\">surname:Zhao;given-names:D.</infon><infon key=\"name_9\">surname:Shen;given-names:J.</infon><infon key=\"pub-id_doi\">10.1038/s41591-020-0817-4</infon><infon key=\"pub-id_pmid\">32284613</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">Nat. Med.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">26</infon><infon key=\"year\">2020</infon><offset>71166</offset><text>Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding</text></passage><passage><infon key=\"fpage\">49386</infon><infon key=\"lpage\">49403</infon><infon key=\"name_0\">surname:YÃ¼ce;given-names:M.</infon><infon key=\"name_1\">surname:Kurt;given-names:H.</infon><infon key=\"pub-id_doi\">10.1039/C7RA10479K</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">RSC Adv.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">7</infon><infon key=\"year\">2017</infon><offset>71275</offset><text>How to make nanobiosensors: surface modification and characterisation of nanomaterials for biosensing applications</text></passage><passage><infon key=\"fpage\">1</infon><infon key=\"lpage\">20</infon><infon key=\"name_0\">surname:Zhang;given-names:X.</infon><infon key=\"name_1\">surname:Qi;given-names:Q.</infon><infon key=\"name_10\">surname:Zhang;given-names:Zhengjun</infon><infon key=\"name_11\">surname:Fu;given-names:W.</infon><infon key=\"name_2\">surname:Jing;given-names:Q.</infon><infon key=\"name_3\">surname:Ao;given-names:S.</infon><infon key=\"name_4\">surname:Zhang;given-names:Zhihong</infon><infon key=\"name_5\">surname:Ding;given-names:M.</infon><infon key=\"name_6\">surname:Wu;given-names:M.</infon><infon key=\"name_7\">surname:Liu;given-names:K.</infon><infon key=\"name_8\">surname:Wang;given-names:W.</infon><infon key=\"name_9\">surname:Ling;given-names:Y.</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>71390</offset></passage><passage><infon key=\"fpage\">727</infon><infon key=\"lpage\">733</infon><infon key=\"name_0\">surname:Zhu;given-names:N.</infon><infon key=\"name_1\">surname:Zhang;given-names:D.</infon><infon key=\"name_10\">surname:Niu;given-names:P.</infon><infon key=\"name_11\">surname:Zhan;given-names:F.</infon><infon key=\"name_12\">surname:Ma;given-names:X.</infon><infon key=\"name_13\">surname:Wang;given-names:D.</infon><infon key=\"name_14\">surname:Xu;given-names:W.</infon><infon key=\"name_15\">surname:Wu;given-names:G.</infon><infon key=\"name_16\">surname:Gao;given-names:G.F.</infon><infon key=\"name_17\">surname:Tan;given-names:W.</infon><infon key=\"name_2\">surname:Wang;given-names:W.</infon><infon key=\"name_3\">surname:Li;given-names:X.</infon><infon key=\"name_4\">surname:Yang;given-names:B.</infon><infon key=\"name_5\">surname:Song;given-names:J.</infon><infon key=\"name_6\">surname:Zhao;given-names:X.</infon><infon key=\"name_7\">surname:Huang;given-names:B.</infon><infon key=\"name_8\">surname:Shi;given-names:W.</infon><infon key=\"name_9\">surname:Lu;given-names:R.</infon><infon key=\"pub-id_doi\">10.1056/NEJMoa2001017</infon><infon key=\"pub-id_pmid\">31978945</infon><infon key=\"section_type\">REF</infon><infon key=\"source\">N. Engl. J. Med.</infon><infon key=\"type\">ref</infon><infon key=\"volume\">382</infon><infon key=\"year\">2020</infon><offset>71391</offset><text>A novel Coronavirus from patients with Pneumonia in China, 2019</text></passage><passage><infon key=\"comment\">medRxiv 2020.3.17.20037796</infon><infon key=\"name_0\">surname:Zhu;given-names:X.</infon><infon key=\"name_1\">surname:Wang;given-names:X.</infon><infon key=\"name_10\">surname:Mei;given-names:X.</infon><infon key=\"name_11\">surname:Chen;given-names:H.</infon><infon key=\"name_12\">surname:Wang;given-names:Y.</infon><infon key=\"name_2\">surname:Han;given-names:L.</infon><infon key=\"name_3\">surname:Chen;given-names:T.</infon><infon key=\"name_4\">surname:Wang;given-names:L.</infon><infon key=\"name_5\">surname:Li;given-names:H.</infon><infon key=\"name_6\">surname:Li;given-names:S.</infon><infon key=\"name_7\">surname:He;given-names:L.</infon><infon key=\"name_8\">surname:Fu;given-names:X.</infon><infon key=\"name_9\">surname:Chen;given-names:S.</infon><infon key=\"pub-id_doi\">10.1101/2020.03.17.20037796</infon><infon key=\"section_type\">REF</infon><infon key=\"type\">ref</infon><infon key=\"year\">2020</infon><offset>71455</offset></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">title_1</infon><offset>71456</offset><text>Supplementary data</text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">paragraph</infon><offset>71475</offset><text>The following is the Supplementary data to this article: </text></passage><passage><infon key=\"section_type\">SUPPL</infon><infon key=\"type\">footnote</infon><offset>71533</offset><text>Supplementary data to this article can be found online at https://doi.org/10.1016/j.bios.2020.112752.</text></passage></document></collection>\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "import torch\n",
    "import transformers\n",
    "import urllib\n",
    "import time\n",
    "\n",
    "\n",
    "def get_literature(query, api_key):\n",
    "    \"\"\"Fetches relevant clinical trial literature from PubMed.\"\"\"\n",
    "    query = urllib.parse.quote(query)\n",
    "    url = f\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&retmode=json&retmax=20&sort=relevance&term={query}&api_key={api_key}\"\n",
    "    response = make_request_with_retry(url)\n",
    "\n",
    "    if response.status_code == 200:\n",
    "        literature = response.json()\n",
    "        return literature\n",
    "    else:\n",
    "        raise Exception(f\"Error fetching literature: {response.status_code}\")\n",
    "\n",
    "\n",
    "def get_full_text(pmid):\n",
    "    \"\"\"Fetches the full text of an article using the BioC-PMC API.\"\"\"\n",
    "    url = f\"https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/{pmid}/unicode\"\n",
    "    response = make_request_with_retry(url)\n",
    "\n",
    "    if response and response.status_code == 200:\n",
    "        return response.text\n",
    "    else:\n",
    "        print(f\"Failed to retrieve full text for PMID: {pmid}\")\n",
    "        return \"\"\n",
    "\n",
    "\n",
    "def preprocess_literature(literature):\n",
    "    \"\"\"Converts the collected data into a format suitable for the LLM.\"\"\"\n",
    "    processed_literature = []\n",
    "    for study_id in literature[\"esearchresult\"][\"idlist\"]:\n",
    "        study = get_study_details(study_id)\n",
    "        study[\"full_text\"] = get_full_text(study_id)  # Retrieve the full text\n",
    "        study[\"text\"] = study.get(\"abstract\", \"\")\n",
    "        study[\"label\"] = 1  # Assign a label of 1\n",
    "        processed_literature.append(study)\n",
    "    return processed_literature\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "def get_study_details(study_id):\n",
    "    \"\"\"Fetches detailed information for a specific study from PubMed.\"\"\"\n",
    "    url = f\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id={study_id}\"\n",
    "    response = make_request_with_retry(url)\n",
    "\n",
    "    if response.status_code == 200:\n",
    "        study = response.json()\n",
    "        study_details = study[\"result\"][study_id]\n",
    "        study_details[\"id\"] = study_id\n",
    "        study_details[\"review\"] = study_details.get(\"abstract\", \"\")\n",
    "        return study_details\n",
    "    else:\n",
    "        raise Exception(f\"Error fetching study details: {response.status_code}\")\n",
    "\n",
    "\n",
    "def make_request_with_retry(url, max_retries=3):\n",
    "    \"\"\"Makes a request with retry and exponential backoff.\"\"\"\n",
    "    retry_delay = 1\n",
    "    for attempt in range(1, max_retries + 1):\n",
    "        try:\n",
    "            response = requests.get(url)\n",
    "            if response.status_code == 200:\n",
    "                return response\n",
    "            elif response.status_code == 429:\n",
    "                print(f\"Rate limit exceeded. Retrying in {retry_delay} seconds...\")\n",
    "                time.sleep(retry_delay)\n",
    "                retry_delay *= 2\n",
    "                continue\n",
    "            else:\n",
    "                response.raise_for_status()\n",
    "        except Exception as e:\n",
    "            print(f\"Request failed. Retrying in {retry_delay} seconds...\")\n",
    "            time.sleep(retry_delay)\n",
    "            retry_delay *= 2\n",
    "    # Return an empty response if retries exceeded\n",
    "    return None\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "def train_llm(literature):\n",
    "    \"\"\"Fine-tunes a pre-trained LLM on a specialized corpus of clinical trial literature.\"\"\"\n",
    "    train_texts = [study[\"full_text\"] for study in literature]\n",
    "    train_labels = [study[\"label\"] for study in literature]\n",
    "\n",
    "    tokenizer = transformers.AutoTokenizer.from_pretrained(\"bert-base-uncased\")\n",
    "    model = transformers.AutoModelForSequenceClassification.from_pretrained(\"bert-base-uncased\")\n",
    "\n",
    "    # Tokenize and encode the training texts\n",
    "    train_encodings = tokenizer(train_texts, truncation=True, padding=True, return_tensors=\"pt\")\n",
    "\n",
    "    # Convert the labels to tensors\n",
    "    train_labels = torch.tensor(train_labels)\n",
    "\n",
    "    # Create a Dataset object\n",
    "    train_dataset = torch.utils.data.TensorDataset(train_encodings[\"input_ids\"], train_encodings[\"attention_mask\"], train_labels)\n",
    "\n",
    "    # Create a DataLoader for training\n",
    "    train_loader = torch.utils.data.DataLoader(train_dataset, batch_size=4, shuffle=True)\n",
    "\n",
    "    # Training loop\n",
    "    optimizer = torch.optim.AdamW(model.parameters(), lr=1e-5)\n",
    "    device = torch.device(\"cuda\" if torch.cuda.is_available() else \"cpu\")\n",
    "    model.to(device)\n",
    "\n",
    "    for epoch in range(3):\n",
    "        model.train()\n",
    "        for batch in train_loader:\n",
    "            batch = tuple(t.to(device) for t in batch)\n",
    "            input_ids, attention_mask, labels = batch\n",
    "\n",
    "            optimizer.zero_grad()\n",
    "            outputs = model(input_ids, attention_mask=attention_mask, labels=labels)\n",
    "            loss = outputs.loss\n",
    "            logits = outputs.logits\n",
    "            loss.backward()\n",
    "            optimizer.step()\n",
    "\n",
    "    return model\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "\n",
    "def extract_data(llm, literature, tokenizer):\n",
    "    \"\"\"Uses the trained LLM to extract relevant data from the literature.\"\"\"\n",
    "    for study in literature:\n",
    "        inputs = tokenizer.encode_plus(\n",
    "            study[\"full_text\"],  # Use the full text instead of the abstract\n",
    "            add_special_tokens=True,\n",
    "            truncation=True,\n",
    "            max_length=512,\n",
    "            padding=\"max_length\",\n",
    "            return_tensors=\"pt\"\n",
    "        )\n",
    "        outputs = llm(**inputs)\n",
    "        logits = outputs.logits\n",
    "        predicted_label = torch.argmax(logits, dim=1)\n",
    "\n",
    "        study[\"study_design\"] = predicted_label.item()\n",
    "        study[\"sample_size\"] = int(study[\"study_design\"])\n",
    "        study[\"interventions\"] = study.get(\"interventions\", [])\n",
    "        study[\"outcome_measures\"] = study.get(\"outcome_measures\", [])\n",
    "        study[\"main_findings\"] = study.get(\"main_findings\", \"\")\n",
    "    return literature\n",
    "\n",
    "\n",
    "def generate_report(literature):\n",
    "    \"\"\"Generates a comprehensive review report.\"\"\"\n",
    "    report = \"\"\n",
    "    for study in literature:\n",
    "        study_id = study.get(\"id\")\n",
    "        full_text = study.get(\"full_text\")\n",
    "        if study_id and full_text:\n",
    "            report += f\"Study {study_id}: {full_text}\\n\"\n",
    "    return report\n",
    "\n",
    "\n",
    "if __name__ == \"__main__\":\n",
    "    query = input(\"Enter a search query for clinical trial literature: \")\n",
    "    api_key = 'dcbe9b28ab11329579a3694164c127836807'\n",
    "    literature = get_literature(query, api_key)\n",
    "    processed_literature = preprocess_literature(literature)\n",
    "    llm = train_llm(processed_literature)\n",
    "    tokenizer = transformers.AutoTokenizer.from_pretrained(\"bert-base-uncased\")\n",
    "    literature = extract_data(llm, processed_literature, tokenizer)\n",
    "    report = generate_report(literature)\n",
    "    print(report)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "90939a43",
   "metadata": {},
   "source": [
    "## LLM interface - working V3"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "id": "bdca91e9",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Enter a search query for clinical trial literature: covid 19\n",
      "Request failed. Retrying in 1 seconds...\n",
      "Request failed. Retrying in 2 seconds...\n",
      "Request failed. Retrying in 4 seconds...\n",
      "Failed to retrieve full text for PMID: 33664170\n",
      "Request failed. Retrying in 1 seconds...\n",
      "Request failed. Retrying in 2 seconds...\n",
      "Request failed. Retrying in 4 seconds...\n",
      "Failed to retrieve full text for PMID: 34355645\n",
      "Request failed. Retrying in 1 seconds...\n",
      "Request failed. Retrying in 2 seconds...\n",
      "Request failed. Retrying in 4 seconds...\n",
      "Failed to retrieve full text for PMID: 32749914\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Some weights of the model checkpoint at bert-base-uncased were not used when initializing BertForSequenceClassification: ['cls.seq_relationship.weight', 'cls.predictions.transform.LayerNorm.weight', 'cls.predictions.transform.dense.weight', 'cls.seq_relationship.bias', 'cls.predictions.bias', 'cls.predictions.transform.LayerNorm.bias', 'cls.predictions.transform.dense.bias']\n",
      "- This IS expected if you are initializing BertForSequenceClassification from the checkpoint of a model trained on another task or with another architecture (e.g. initializing a BertForSequenceClassification model from a BertForPreTraining model).\n",
      "- This IS NOT expected if you are initializing BertForSequenceClassification from the checkpoint of a model that you expect to be exactly identical (initializing a BertForSequenceClassification model from a BertForSequenceClassification model).\n",
      "Some weights of BertForSequenceClassification were not initialized from the model checkpoint at bert-base-uncased and are newly initialized: ['classifier.bias', 'classifier.weight']\n",
      "You should probably TRAIN this model on a down-stream task to be able to use it for predictions and inference.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Ask a clinical question (type 'exit' to quit): How many clinical trials were phase 2?\n",
      "Answer: 1\n",
      "Ask a clinical question (type 'exit' to quit): how many trials occurred in 2020\n",
      "Answer: 1\n",
      "Ask a clinical question (type 'exit' to quit): how many total trials occurred\n",
      "Answer: 0\n",
      "Ask a clinical question (type 'exit' to quit): what was the most popular trial protocol\n",
      "Answer: 1\n",
      "Ask a clinical question (type 'exit' to quit): exit\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "import torch\n",
    "import transformers\n",
    "import urllib\n",
    "import time\n",
    "\n",
    "\n",
    "def get_literature(query, api_key):\n",
    "    \"\"\"Fetches relevant clinical trial literature from PubMed.\"\"\"\n",
    "    query = urllib.parse.quote(query)\n",
    "    url = f\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&retmode=json&retmax=20&sort=relevance&term={query}&api_key={api_key}\"\n",
    "    response = make_request_with_retry(url)\n",
    "\n",
    "    if response.status_code == 200:\n",
    "        literature = response.json()\n",
    "        return literature\n",
    "    else:\n",
    "        raise Exception(f\"Error fetching literature: {response.status_code}\")\n",
    "\n",
    "\n",
    "def get_full_text(pmid):\n",
    "    \"\"\"Fetches the full text of an article using the BioC-PMC API.\"\"\"\n",
    "    url = f\"https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_xml/{pmid}/unicode\"\n",
    "    response = make_request_with_retry(url)\n",
    "\n",
    "    if response is not None and response.status_code == 200:\n",
    "        return response.text\n",
    "    else:\n",
    "        print(f\"Failed to retrieve full text for PMID: {pmid}\")\n",
    "        return \"\"\n",
    "\n",
    "\n",
    "def preprocess_literature(literature):\n",
    "    \"\"\"Converts the collected data into a format suitable for the LLM.\"\"\"\n",
    "    processed_literature = []\n",
    "    for study_id in literature[\"esearchresult\"][\"idlist\"]:\n",
    "        study = get_study_details(study_id)\n",
    "        study[\"full_text\"] = get_full_text(study_id)  # Retrieve the full text\n",
    "        study[\"text\"] = study.get(\"abstract\", \"\")\n",
    "        study[\"label\"] = 1  # Assign a default label value\n",
    "        processed_literature.append(study)\n",
    "    return processed_literature\n",
    "\n",
    "\n",
    "def get_study_details(study_id):\n",
    "    \"\"\"Fetches detailed information for a specific study from PubMed.\"\"\"\n",
    "    url = f\"https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id={study_id}\"\n",
    "    response = make_request_with_retry(url)\n",
    "\n",
    "    if response.status_code == 200:\n",
    "        study = response.json()\n",
    "        study_details = study[\"result\"][study_id]\n",
    "        study_details[\"id\"] = study_id\n",
    "        study_details[\"review\"] = study_details.get(\"abstract\", \"\")\n",
    "        return study_details\n",
    "    else:\n",
    "        raise Exception(f\"Error fetching study details: {response.status_code}\")\n",
    "\n",
    "\n",
    "def make_request_with_retry(url, max_retries=3):\n",
    "    \"\"\"Makes a request with retry and exponential backoff.\"\"\"\n",
    "    retry_delay = 1\n",
    "    for attempt in range(1, max_retries + 1):\n",
    "        try:\n",
    "            response = requests.get(url)\n",
    "            if response.status_code == 200:\n",
    "                return response\n",
    "            elif response.status_code == 429:\n",
    "                print(f\"Rate limit exceeded. Retrying in {retry_delay} seconds...\")\n",
    "                time.sleep(retry_delay)\n",
    "                retry_delay *= 2\n",
    "                continue\n",
    "            else:\n",
    "                response.raise_for_status()\n",
    "        except Exception as e:\n",
    "            print(f\"Request failed. Retrying in {retry_delay} seconds...\")\n",
    "            time.sleep(retry_delay)\n",
    "            retry_delay *= 2\n",
    "    # Return an empty response if retries exceeded\n",
    "    return None\n",
    "\n",
    "\n",
    "def train_llm(literature):\n",
    "    \"\"\"Fine-tunes a pre-trained LLM on a specialized corpus of clinical trial literature.\"\"\"\n",
    "    train_texts = [study[\"full_text\"] for study in literature]\n",
    "    train_labels = [study[\"label\"] for study in literature]\n",
    "\n",
    "    tokenizer = transformers.AutoTokenizer.from_pretrained(\"bert-base-uncased\")\n",
    "    model = transformers.AutoModelForSequenceClassification.from_pretrained(\"bert-base-uncased\")\n",
    "\n",
    "    # Tokenize and encode the training texts\n",
    "    train_encodings = tokenizer(train_texts, truncation=True, padding=True, return_tensors=\"pt\")\n",
    "\n",
    "    # Convert the labels to tensors\n",
    "    train_labels = torch.tensor(train_labels)\n",
    "\n",
    "    # Create a Dataset object\n",
    "    train_dataset = torch.utils.data.TensorDataset(train_encodings[\"input_ids\"], train_encodings[\"attention_mask\"], train_labels)\n",
    "\n",
    "    # Create a DataLoader for training\n",
    "    train_loader = torch.utils.data.DataLoader(train_dataset, batch_size=4, shuffle=True)\n",
    "\n",
    "    # Training loop\n",
    "    optimizer = torch.optim.AdamW(model.parameters(), lr=1e-5)\n",
    "    device = torch.device(\"cuda\" if torch.cuda.is_available() else \"cpu\")\n",
    "    model.to(device)\n",
    "\n",
    "    for epoch in range(3):\n",
    "        model.train()\n",
    "        for batch in train_loader:\n",
    "            batch = tuple(t.to(device) for t in batch)\n",
    "            input_ids, attention_mask, labels = batch\n",
    "\n",
    "            optimizer.zero_grad()\n",
    "            outputs = model(input_ids, attention_mask=attention_mask, labels=labels)\n",
    "            loss = outputs.loss\n",
    "            logits = outputs.logits\n",
    "            loss.backward()\n",
    "            optimizer.step()\n",
    "\n",
    "    return model\n",
    "\n",
    "\n",
    "def ask_clinical_question(question, llm, tokenizer):\n",
    "    \"\"\"Uses the trained LLM to generate an answer for a clinical question.\"\"\"\n",
    "    inputs = tokenizer.encode_plus(\n",
    "        question,\n",
    "        add_special_tokens=True,\n",
    "        truncation=True,\n",
    "        max_length=512,\n",
    "        padding=\"max_length\",\n",
    "        return_tensors=\"pt\"\n",
    "    )\n",
    "\n",
    "    inputs = {k: v.to(llm.device) for k, v in inputs.items()}\n",
    "    outputs = llm(**inputs)\n",
    "    logits = outputs.logits\n",
    "    predicted_label = torch.argmax(logits, dim=1)\n",
    "\n",
    "    answer = predicted_label.item()\n",
    "    return answer\n",
    "\n",
    "\n",
    "if __name__ == \"__main__\":\n",
    "    query = input(\"Enter a search query for clinical trial literature: \")\n",
    "    api_key = 'dcbe9b28ab11329579a3694164c127836807'\n",
    "    literature = get_literature(query, api_key)\n",
    "    processed_literature = preprocess_literature(literature)\n",
    "    llm = train_llm(processed_literature)\n",
    "    tokenizer = transformers.AutoTokenizer.from_pretrained(\"bert-base-uncased\")\n",
    "\n",
    "    while True:\n",
    "        question = input(\"Ask a clinical question (type 'exit' to quit): \")\n",
    "        if question.lower() == \"exit\":\n",
    "            break\n",
    "\n",
    "        answer = ask_clinical_question(question, llm, tokenizer)\n",
    "        print(f\"Answer: {answer}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "5efb4409",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'clinical_trial_code.pdf'"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import graphviz\n",
    "\n",
    "# Create a new graph\n",
    "graph = graphviz.Digraph()\n",
    "\n",
    "# Add nodes to the graph\n",
    "graph.node(\"Get Literature (PubMed API)\")\n",
    "graph.node(\"Fetch Full Text (BioC-PMC API)\")\n",
    "graph.node(\"Preprocess Literature\")\n",
    "graph.node(\"Get Study Details (PubMed API)\")\n",
    "graph.node(\"Make Request with Retry\")\n",
    "graph.node(\"Train LLM\")\n",
    "graph.node(\"Ask Clinical Question\")\n",
    "\n",
    "# Add edges between nodes\n",
    "graph.edge(\"Get Literature (PubMed API)\", \"Fetch Full Text (BioC-PMC API)\")\n",
    "graph.edge(\"Fetch Full Text (BioC-PMC API)\", \"Preprocess Literature\")\n",
    "graph.edge(\"Preprocess Literature\", \"Get Study Details (PubMed API)\")\n",
    "graph.edge(\"Get Study Details (PubMed API)\", \"Make Request with Retry\")\n",
    "graph.edge(\"Make Request with Retry\", \"Train LLM\")\n",
    "graph.edge(\"Train LLM\", \"Ask Clinical Question\")\n",
    "\n",
    "# Render and save the graph as a PDF file\n",
    "graph.render(\"clinical_trial_code\", format=\"pdf\", view=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a8397e6e",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
